Annual Meeting Program - Society of Toxicology

Program 

49 

th 

Annual Meeting 

49 th and ToxExpo TM 

Salt Lake City, Utah 

and ToxExpo TM 


March 7–11, 2010 

www.toxicology.org


2010 

Awards Ceremony 

Sunday, March 7 

5:15 PM–6:30 PM 

Ballroom J 

Welcoming 

Reception 


6:30 PM–7:30 PM 

Hall E 

25-Year (or More) 

Member Reception 


7:00 PM–8:00 PM 

Ballroom A 

SOT Annual Business 

Meeting 

Tuesday, March 9 

4:30 PM–6:00 PM 

Ballroom A 

The above events take 

place in the Salt Palace 

Convention Center. 

Dear Colleagues, 

I am cordially inviting you to attend the Society of Toxicology’s 49 th Annual Meeting 

and ToxExpo, March 7–11 in Salt Lake City, Utah. Among the many highlights, 

this year’s program will feature sessions grouped around the scientific themes of Cell 

Signaling, Gene-Environment Interactions, Metabolic Disease, Mitochondrial Basis of 

Disease, Toxicity Testing in the 21 st Century, and Translational Toxicology. The five-day 

event promises to provide scientists with countless opportunities to explore the depth 

and breadth of the field of toxicology. This year’s Regional Interest Session, Signaling 

Mechanisms for Metabolic Dysfunction Following Low-Level Arsenic Exposures: 

From Mouse to Man, will address an issue of relevance to mining states such as Utah. 

Featured scientific programs include the symposia, workshops, roundtables, historical 

highlights, and platform and poster sessions. These will address an array of topics that 

clearly demonstrate how the science of toxicology contributes to a safer and healthier 

world. 

In addition to the scientific program, the Annual Meeting affords every attendee 

the opportunity to come together to learn about the latest scientific achievements 

from experts in a myriad of fields, including the keynote speakers and other featured 

lecturers. This year’s Plenary Lecture will be given by Dr. Ferid Murad. Dr. Murad was 

one of three recipients to receive the 1998 Nobel Prize in Physiology or Medicine for 

his work on nitric oxide and its role in cell signaling. Continuing Education courses, 

as always, will offer both introductory and advanced topics, and will be targeting 

biologicals and cytokine biology in the course material. 

The Annual Meeting in Salt Lake City also provides an important networking 

opportunity for the exchange of ideas and solutions to many issues that toxicologists 

face in their professional careers. In addition to affording attendees the chance to 

renew and foster relationships with their colleagues, the meeting also provides an 

opportunity to see the latest products, services, and technologies at the ToxExpo, 

the largest toxicology trade show of its kind anywhere. 

We look forward to seeing you in Salt Lake City. Help us make this 

49 th Annual Meeting an event to remember. 

Sincerely, 

Cheryl Lyn Walker, Ph.D. 

2009–2010 SOT President 

49 th Annual Meeting and ToxExpo

Scientific Program 

Overview 

A page reference follows the session information. 


CE Target Areas 

Course titles related to each theme are color coded in this 

Program Overview. 

Biologicals—This topic provides an integrated discussion of the 

regulatory and risk assessment processes for the development of 

human monoclonal antibodies, siRNA molecules, vaccines, and 

other biological materials to be used as new disease modifying 

therapies, including the evolving and emerging regulations for 

FDA approval and regulatory aspects of biologicals vs. small 

molecules. 

Cytokine Biology—Cytokines, molecules important in mediating 

toxicant-induced responses, emanate from multiple sources. 

Their release is in response to different stimuli and they interact to 

produce distinct and defined cellular and organismic responses. 

These responses are deterministic in autoimmune diseases and 

in response to toxicant exposure. This theme includes elucidation 

of their roles in diseases (including cancer), response to injury 

from exposure to chemical or biological agents (including 

infections), analytical approaches for quantification of cytokine 

release, presentation of examples of cytokine involvement in 

toxic responses, cytokine effects on xenobiotic metabolism, and 

emerging issues in the area. 

7:00 AM–7:45 AM 

ConTinuing EduCATion SunriSE Mini-CourSE 

1. Biological Pathway Analysis: An Introduction to the 

Pathway Knowledge Bases for Toxicological Research 

(p86) 

8:15 AM–12:00 noon 

ConTinuing EduCATion Morning CourSES 

2. Biologicals: Introduction to Drug Development (p86) 

3. Comparative Biology of the Lung (p87) 

4. Cytokines: Balancing Therapeutic Utility and Immune 

System-Mediated Toxicities (p87) 

5. Nuclear Receptors: Role in Chemical Mode of Action 

and Targets for Toxicity Testing (p88) 

6. Predictive Power of Novel Technologies (Cells to ‘Omics): 

Promises, Pitfalls, and Potential Applications (p88) 

7. Reproduction and Regulatory Impact (p89) 

1:15 PM–5:00 PM 

ConTinuing EduCATion AfTErnoon CourSES 

8. Assessment of Ocular Toxicity in Toxicology Studies 

Conducted for Regulatory Purposes (p89) 

9. Gene-Environment Interactions Influence Cytokine 

Biology in Immunotoxicity and Disease: Genomic, 

Genetic, and Epigenetic Perspectives (p90) 

10. Mitochondrial Toxicity: Animal Models and Screening 

Methods in Drug Development (p90) 

11. ICH Initiatives for Conducting Pharmaceutical Preclinical 

Safety Studies: New and Revised Guidelines and 

Challenges (p91) 

12. Segment-Specific Renal Pathology for the Non- 

Pathologist (p91) 

13. Technologies and Tools for Toxicity Testing in the 

21 st Century (p92) 

Thematic Approach 

Session titles related to each theme are color coded in the 

Program overview. 

Cell Signaling—Cell signaling encompasses the broad range of 

pathways involved in how cells detect and respond to external 

stimuli and communicate with other cells. Key cellular responses 

regulated by cell signaling include cell death, differentiation, 

and cell motility. Understanding the contribution of cell signaling 

pathways to toxicity is often key to determining mechanisms of 

toxicity or the pathogenesis of biological responses elicited by 

chemicals or pharmaceuticals. Sessions in this theme highlight 

mechanistic roles for cell signaling pathways in toxic responses 

and disease pathogenesis. 

Gene-Environment Interactions—It is clear that disease 

susceptibility cannot be attributed only to variations in the 

human genome. The environment is major among the additional 

variables that define individual susceptibility to disease. A 

more precise determination of the influence of environmental 

exposures within a given genetic background on disease 

processes will be required to significantly improve the ability 

to predict, detect, treat, and monitor disease progression and 

disease response. The Gene-Environment Interaction theme has 

been selected to highlight recent advances in this field that are 

relevant to the toxicological sciences. 

Metabolic Disease—Metabolic dysfunction, either acquired or 

inherited, affects biochemical reactions resulting in metabolic 

diseases. The incidence of acquired metabolic diseases is rising 

at an alarming rate. Perturbation of lipid and glucose metabolic 

pathways increases the risk of developing a number of chronic 

conditions such as obesity, diabetes, fatty liver disease, and 

cardiovascular disease. While genetic variability plays a role in 

individual susceptibility, there is evidence that environmental 

agents, drugs, and other toxicants are contributing factors. This 

theme will focus on the mechanistic changes in glucose and 

lipid metabolism induced by toxicants and the relationship to 

disease progression. 

Mitochondrial Basis of Disease—Mitochondrial dysfunction has 

been found to be an important component in the progression of 

numerous human disease states. In addition, the mitochondrial 

genome is susceptible to oxidative stress and mutation due 

to the high percentage of coding DNA and its small size. 

Therefore, the mitochondria are a suspected target organelle of 

xenobiotics in different model organisms. This thematic area will 

highlight studies that evaluate the effect of xenobiotic exposure 

on mitochondrial function and the connection to the progression 

of disease. 

Toxicity Testing in the 21 st Century—The NRC’s 2007 report 

“Toxicity Testing in the Twenty-first Century: A Vision and a 

Strategy” articulated the critical need for development and 

validation of predictive high-throughput assays to replace 

current expensive and time-consuming animal tests. This theme 

includes applications of genomics and in vitro tests to identify 

pathways of toxicity and methods for using advanced computer 

power that make it feasible to analyze large volumes of complex 

data and use common data platforms to link existing and new 

exposure and effects databases. 

Translational Toxicology—In most settings, translational science 

is described by the term “Bench to Bedside.” Translational 

Toxicology can be described as the transition of basic toxicology 

related-research into strategies to improve the performance 

of the science of toxicology. Thus, translational toxicology may 

be best described by the term “discovery to application.” 

Sessions involving the translation of fundamental mechanistic 

observations into bioassays, biological models and other novel 

approaches that can be applied to toxicology research, and 

studies that describe the supporting biologic or mechanistic 

qualification of endpoints and detailed assay validation are 

highlighted in this theme.

8:00 AM–9:00 AM 

Monday, March 8 

PLENARY OPENING LECTURE 

Discovery of Nitric Oxide and Cyclic GMP Cell 

Signaling and Their Role in Drug Development— 

Lecturer: Nobel Laureate Ferid Murad (p102) 

9:15 AM–12:00 noon 

SYMPoSiuM SESSionS 

• Mechanistic Role of Reactive Intermediate Protein 

Covalent Binding in Target Organ Toxicity: Past, 

Present, and Future (p103) 

• Neurological Responses after Exposure to Inhaled 

Metal Particles (p103) 

• Ovarian Toxicity: Current Concepts in Toxicology, 

Pathology, and Mechanisms (p104) 

• Silica and Asbestos Immunotoxicity: Mechanisms 

to Fibrosis, Autoimmunity, and Modified Tumor 

Resistance (p104) 

workSHoP SESSionS 

• Does Background Disease Lead to Low Dose 

Linearity? (p105) 

• Heart Smart: Innovative Approaches for Improving 

Cardiovascular Safety through Collaboration (p105) 

• Toxicology in the 21 st Century: Stem Cells in Drug 

Discovery and Development (p106) 

PlATforM SESSionS 

• Biomarkers of Target-Organ Toxicity (p107) 

• Chemical and Biological Weapons—Sulfur Mustard 

(p107) 

• Immunopharmacogenomics and Immune 

Regulation (p108) 

• Mitochondrial-Mediated Mechanisms of Toxicity of 

Xenobiotics (p109) 

9:30 AM–12:30 PM 

PoSTEr SESSionS 

• Carcinogenesis I (p112) 

• Epigenetics (p114) 

• Hypersensitivity, Autoimmunity, and Idiosyncratic 

Drug Reactions (p126) 

• Investigations of Chemical Mixtures (p122) 

• Mechanistic Aspects of Persistent Organic 

Chemical Toxicity (p120) 

• Nanotoxicology I (p123) 

• Neurodevelopmental Toxicity: General (p115) 

• Screening and Predicting Toxicity: Computational 

Approaches to Identify Targets (p117) 

• Toxicity Testing—Alternative Models I (p110) 

12:10 PM–1:30 PM 

roundTABlE SESSionS 

• Combination Toxicology Studies for Pharmaceutical 

Agents: Design Considerations and Impact on 

Clinical Development (p130) 

• Melamine Contamination of Infant Formulas: 

Lessons Learned (p130) 

HiSToriCAl HigHligHTS SESSion 

• Translating Toxicology to Public Health Protection: 

Lessons Learned from Superfund (p131) 

12:30 PM–1:20 PM 

LEADING EDGE IN BASIC SCIENCE 

AWARD LECTURE 

Toxicogenomics at NIEHS: How Genomics Is 

Impacting the Science of Toxicology— 

Lecturer: Richard S. Paules (p131) 

1:00 PM–4:30 PM 


• Advances in Dermal Toxicology (p145) 

• Biotransformation I (p141) 

• Carcinogenesis II (p146) 

• Chemical and Biological Weapons (p131) 

• Environmental Impact of Xenobiotics (p139) 

• Genetic Diversity and Response to Xenobiotics 

(p134) 

• Nanotoxicology II (p135) 

• Reproductive Toxicology (p136) 

• Toxicity Testing—Alternative Models II (p142) 

1:40 PM–4:25 PM 


• Alterations in Regulatory T Cells: Novel Pathways to 

Immunotoxicology (p148) 

• Faster Science for Better Decisions: Characterizing 

Environmental Contaminant Risk from High- 

Throughput Data (p149) 

• Genotoxic Impurities in Drugs and Drug Products: 

What Is the Right Way to Deal with Impurities in R&D 

versus Regulatory Guidance? (p149) 

• Metabolic Syndrome and Increased Sensitivity to 

Drug-Induced Liver Injury (DILI): Nonclinical Models 

and Clinical Implications (p150) 

• Phthalate Reproductive and Developmental 

Toxicity: Implications for Cumulative Risk Assessment 

(p151) 

workSHoP SESSion 

• Determination of the Contribution of Individual 

Stressors in Cumulative Risk Assessments (p151) 

rEgionAl inTErEST SESSion 

• Signaling Mechanisms for Metabolic Dysfunction 

Following Low-Level Arsenic Exposures: From Mouse 

to Man (p152) 


• Advances in Biomarkers of Renal Injury (p153) 

• Animal Models in the 21 st Century (p153) 

• Lipid Metabolism and Apoptosis (p154) 

• Methods and Animal Models in Cardiovascular 

Safety Pharmacology (p154) 

4:35 PM–5:55 PM 

SOT/EUROTOX DEBATE 

Threshold of Toxicological Concern (TTC): 

Is It Based on Science or Politics? (p156) 


• Inhaled Particles: From the Nose to the Brain? (p156) 

• Safety of Vitamins and Minerals: Controversies and 

Perspectives (p157) 

• The Evolution of the Extended One-Generation 

Study Design for Agricultural and Industrial 

Chemical Hazard Identification (p157) 

7:30 AM–8:50 AM 



• Can Animal Neurotoxicity Predict Human 

Dysfunction? (p158) 

• Weighing Complex Data in Risk Decisions: Concepts 

of Evidence-Based Toxicology (p159) 

inforMATionAl SESSionS 

• Human Hepatocytes Derived from Embryonic Stem 

Cells: A New Tool for In Vitro Toxicity Testing (p159) 

• Recent Advances in Pulmonary Surfactant 

Toxicological Assessment and Therapeutics (p160) 

8:00 AM–8:50 AM 

TRANSLATIONAL IMPACT AWARD LECTURE 

Translating Mechanism-Based Research into 

Antidotes: Trials, Tribulations, and Triumphs 

Lecturer: Kenneth E. McMartin (p160) 

9:00 AM–11:45 AM 


• Anti-Drug Antibody-Mediated Toxicity in 

Nonclinical Toxicity Studies: Impact and Relevance 

to Human Safety (p161) 

• Bile Salt Transport and Liver Injury (p161) 

• MAP Kinase Signaling: A Common Target Eliciting 

Unique Tissue Responses (p162) 

• Molecular Determinants of Mitochondrial Disease 

(p163) 

• POPs: What’s New and Why Should We Care? (p163) 


• Opportunities to Modify Current Regulatory Testing 

Guidelines and Advance the Assessment of 

Carcinogenicity Risk in the 21 st Century (p164) 

• Research Advances and Enduring Needs in 

Children’s Environmental Health Protection (p164) 

EduCATion-CArEEr dEvEloPMEnT SESSion 

• Where Do I Go Now? Rational Career Development 

Planning for Early-Career Scientists (p165) 


• Epidemiological Insights: Effects of Environmental 

and Occupational Exposures (p166) 

• Gene Environmental Interactions in Carcinogenesis 

(p166) 

• Reproductive and Developmental Effects Using Fish 

Models (p167) 

9:00 AM–12:30 PM 


• Animal Models—Emerging Methods (p185) 

• Arsenic I (p188) 

• Biological Modeling: Multiple Scales of Parameters, 

Structures, and Applications (p182) 

• Developmental Toxicology (p179) 

• DNA Damage and Repair (p169) 

• Education (p187) 

• Inflammation and the Pathogenesis of Toxicity 

(p171) 

• Kidney I (p177) 

• Metal Neurotoxicity: General (p190) 

• Mutagenicity (p168) 

• Nanotoxicology—Carbon Nanostructures (p175) 

• Oxidative Injury and Redox Biology (p173) 

• Pharmaceutical Toxicology I (p170) 

12:00 noon–1:20 PM 


• The Ying and Yang of Immunomodulatory 

Biopharmaceuticals: What Have We Learned since 

MABEL and How Close Are We to the Clinical Dose? 

(p193) 

• Women’s Health: Toxicology and Safety of 

Complementary and Alternative Medicine (p194) 

EduCATion—CArEEr dEvEloPMEnT SESSion 

• Science Communication in 2010: A New Decade 

in Toxicology and Need for Better Communication 

(p194) 

12:30 PM–1:20 PM 

DISTINGUISHED TOXICOLOGY SCHOLAR 

AWARD LECTURE 

Toxic Injury: Initiation, Expansion, and Repair— 

Lecturer: Harihara M. Mehendale (p195) 

Name: 

If found please return to: 

Contact Telephone:

1:00 PM–4:30 PM 


• Ah Receptor Biology and Toxicology (p209) 

• Apoptosis/Cell Death (p211) 

• Biomarkers (p217) 

• Biotransformation II (p201) 

• Genotoxicity (p203) 

• Neurodegenerative Disease (p215) 

• Neurotoxicity of Pesticides (p212) 

• Pharmaceutical Toxicology II (p198) 

• Risk Assessment I: New Data and Derivations across 

Chemicals from A to V (p195) 

• Safety Assessment: Commercial and Consumer 

Products (p207) 

• Safety Concerns of Food and Natural Products 

(p205) 

1:30 PM–4:15 PM 


• Genetics: The Link between Exposures, Gene x 

Environment Interaction, and Toxicity (p220) 

• It’s Not Your Father’s Aryl Hydrocarbon Receptor: 

New Biological Roles for a Misunderstood Receptor 

(p220) 

• Mechanisms of Chemical-Induced Liver Cancer: 

Putting the Pieces Together (p221) 

• New Strategies for the Use of Genetic Toxicology 

Data in Human Risk Assessment (p222) 

• Recent Knowledge on Critical Regulators of Lipid 

Homeostasis in Metabolic Disease (p222) 

• Zinc, Copper, and Their Metabolic Effect: Myths 

and Musts (p223) 


• Immunotoxicity and Other Safety Considerations in 

the Development of Therapeutic Vaccines (p223) 

• Widely Varying Strategies Implemented in 

Discovery to Reduce the Failure Rate of Clinical 

Lead Candidates in Development (p224) 


• Emphasis on the Embryo: HTS, PBPK, and Virtual 

Tissue Technologies (p225) 

• Model Systems in Neurodevelopmental Toxicity 

(p225) 

• Nanotoxicology—Pulmonary Effects (p226) 

• Toxicity Detection—Alternatives to Animal Models 

(p227) 

wednesday, March 10 

7:30 AM–8:50 AM 


• Impact of Tungsten and Tungsten Alloys on Health 

Risk (p229) 

• The 2009 Tennessee Fly Ash Spill—An Environmental 

Emergency Case Study (p229) 

EduCATion—CArEEr dEvEloPMEnT SESSion 

• Career Alternatives in Toxicology: Lessons Learned 

(p230) 

8:00 AM–9:00 AM 

KEYNOTE MEDICAL RESEARCH COUNCIL 

(MRC) LECTURE 

The Interplay between Phosphorylation and 

Ubiquitination in Regulating the Innate Immune 

System—Lecturer: Sir Philip Cohen (p230) 

9:00 AM–11:45 AM 


• Gender Divergent Xenobiotic Responses (p231) 

• Mitochondrial Toxicity in Disease and Death (p231) 

• The Fetal Basis of Adult Disease (p232) 

9:00 AM–11:45 AM 


• Current Thinking and Experiences Related 

to Developmental and Reproductive Safety 

Assessment of Biotherapeutics (p233) 

• Novel Research Approaches and Animal Models in 

Translational Toxicology (p233) 

• Toxicity Testing in the 21 st Century for Ecotoxicology 

(p234) 

• Understanding Nonlinearities at the Low-End of 

the Dose-Response Curve: Insights from Molecular 

Network Analysis (p235) 


• Advances in Mycotoxin Toxicity (p235) 

• Impact of Receptors and Gene Regulation in 

Toxicological Response (p236) 

• Inhalation Toxicology of Ultrafine or Nanoparticles 

(p236) 

• Reproductive and Developmental Toxicity of 

Phthalates (p237) 

9:00 AM–12:30 PM 


• Causes and Progression of Hepatic Metabolic 

Dysfunction (p248) 

• Gene Regulation (p255) 

• Hepatotoxicity: Role of Bile Acid Metabolism and 

Homeostasis (p247) 

• Immunotoxicology: Mechanisms (p240) 

• Inhalation Toxicology (p237) 

• Nanotoxicology—Gold or Silver Nanoparticles 

(p254) 

• Neurodevelopmental Toxicity of Metals (p246) 

• Signal Transduction (p251) 

• Stem Cell Toxicology (p253) 

• Studies in Pharmacokinetics and Disposition (p243) 

• Toxicogenomics—Continuing Advances in 

Molecular Toxicology (p249) 

12:00 noon–1:20 PM 


• Life-Stage Adjustment Five Years Later— 

Experiences from the Cancer Risk Assessment Field 

(p256) 

• Measuring Immune Responses in Monkeys for Drug 

Development: Opportunities and Challenges for 

Predicting Human Efficacy and Immunotoxicity 

(p257) 

• The Tox21 st Community and the Future of Toxicology 

Testing (p258) 

12:30 PM–1:20 PM 

MERIT AWARD LECTURE 

Living with Passion—Opening Doors in Research, 

Teaching, and Service—Lecturer: Marion Ehrich 

(p258) 

1:00 PM–4:30 PM 


• Beneficial Effects of Natural Products (p261) 

• Carcinogenesis: Breast and Reproductive (p279) 

• Cardiovascular Toxicology (p259) 

• Exposure Assessment and Emerging Biomonitoring 

Applications (p268) 

• Fetal Basis of Adult Disease (p277) 

• Immunotoxicology: Methods and Models (p278) 

• Metals I (p265) 

• Models and Mechanisms of Hepatotoxicity (p275) 

• Pesticides: General (p271) 

• Regulations and Policy in Toxicology (p263) 

• Risk Assessment II: Methodological Challenges and 

Metals (p272) 

1:15 PM–2:15 PM 

FEATURED SESSION 

A Conversation with the EPA Office of Research and 

Development Director: Paul Anastas (p280) 

1:30 PM–4:15 PM 


• Aging As a Determinant of Xenobiotic Toxicity 

(p280) 

• TRPing the Sensor: The Role of TRP Channel 

Signaling in Cardiopulmonary Toxicity (p281) 

• Zebrafish Models for Developmental 

Neurobehavioral Toxicology (p282) 


• High-Throughput Electrophysiology—21 st Century 

Toxicity Testing Approaches with Functional 

Outcomes (p282) 

• Minerals and Metals: Pros and Cons of Deliberate 

Exposure (p283) 

• ‘Omics Profiling of Cell and Tissue Interactions of 

Nanomaterials: Insight into Mechanisms of Action 

(p283) 

• The Process of Defining Risk for Environmental 

Chemicals Having Significant Skin Exposure and 

Absorption Potential (p284) 

• Translation of Nonclinical Models to Clinical Risk 

Management Strategies of Severe Infectious 

Diseases with Immunomodulatory Drugs (p285) 


• Insights into Polyaromatic Hydrocarbon-Induced 

Toxicities (p285) 

• Nanotoxicology—Metals and Metal Oxide Particles 

(p286) 

• Predicting Hepatotoxicity: Computational 

Approaches to a Critical Target (p287) 

2:30 PM–3:30 PM 


A Conversation with the NIEHS Director: 

Linda Birnbaum (p288) 

3:45 PM–4:45 PM 


A Conversation with the U.S. FDA National Center 

for Toxicological Research: William Slikker, Jr. (p288) 

4:30 PM–5:50 PM 

roundTABlE SESSion 

• Overview of Current Regulatory Expectations for 

Oligonucleotide-Based Therapeutics: Case Studies 

for Different Classes of ODNs (p288) 

inforMATionAl SESSion 

• Seeking Funding for Undergraduate Research 

(p289) 

7:30 AM–8:50 AM 

ISSUES SESSION 

Thursday, March 11 

National Academy of Sciences Vision for Toxicity 

Testing in the 21 st Century (p289) 

8:30 AM–12:00 noon 


• Drug-Induced Liver Injury (p293) 

• Endocrine Toxicology (p289) 

• Immune System Safety Evaluation/Developmental 

Immunotoxicology (p297) 

• Juvenile Toxicity (p292) 

• Metals II (p296) 

• Receptors (p294) 

9:00 AM–11:45 AM 


• Blood-Based Genomic Profiles As Biomarkers of 

Exposure and Effect (p299) 

• Humanized Models in Toxicology and Their 

Application to Hazard Characterization and Risk 

Assessment (p299) 

• Systems Biology Approaches to Understanding Cell 

Signaling in Dermal and Ocular Toxicology (p300) 

• Toxicological Challenges in Green Product 

Development (p301)

50 

th Anniversary 


and ToxExpo 

2011 

Washington, D.C. 

March 6–10, 2011 

Walter E. Washington Convention Center 

Watch for: 

• Anniversary Book 

• Anniversary Brochure 

• Celebration Evening 

• Commemorative Posters 

• Exhibits 

• History of Toxicology Session 

• Scientific Presentations 

• Special Activities 

See you there!

49 th Annual Meeting and ToxExpo 

Annual Meeting and ToxExpo 

March 7–11, 2010 

Society of Toxicology 2010 

Program Contents 

President’s Letter ......................................................... Inside Front Cover 

Scientific Program Overview ..........................................Front Fold-Out 

How to Use this Program ..............................................................................2 

Sponsorship 

Sponsorship Opportunities ....................................................................376 

2010 Annual Meeting Sponsors 

and The Toxicologist on CD-ROM ....................Inside Back Cover 

2010 Annual Meeting Diamond Sponsors .........................Back Cover 

Events and Maps 

Daily Pocket Calendar....................................................................................3 

Schedule by Event Name .......................................................................... 13 

Salt Palace Convention Center Maps ....................................................22 

Salt Lake City Hotel Accommodations ................................................. 24 

Map of Salt Lake City Hotel Locations .................................................. 26 

Hilton Salt Lake City Center Hotel Map ................................................ 27 

Marriott Downtown Hotel Map ..............................................................28 

Salt Lake City Restaurant Listings ..........................................................30 

Poster Session Schedule and Board Surface Maps .......................... 33 

2010 ToxExpo 

ToxExpo Information ............................................................................... 39 

ToxExpo Floor Plan ...................................................................................40 

ToxExpo 2010 Exhibitors ......................................................................... 42 

Exhibitor Hosted Session Index .............................................................. 45 

Registration 

Registration Information ...........................................................................48 

General Information 

Accessibility for Persons with Disabilities ........................................... 49 

Attire ................................................................................................................. 49 

Badges .............................................................................................................. 49 

Business Center ............................................................................................. 49 

Career Resources and Development Services................................... 49 

Climate ............................................................................................................. 49 

Coat/Luggage Check .................................................................................. 50 

Exhibitor Information .................................................................................50 

Exhibit Hall (Hours/Location)...................................................................50 

First Aid and Emergency Services 

at the Convention Center ................................................................50 

Food Services ................................................................................................50 

Green in Salt Lake City ............................................................................... 51 

Guest/Spouse Hospitality Center .......................................................... 51 

Housing Information and Reservations ............................................... 52 

Internet Access .............................................................................................. 52 

Letter of Attendance ................................................................................... 53 

Lost and Found ............................................................................................. 53 

Lunch with an Expert Information Board ........................................... 53 

Media Support Services ............................................................................. 53 

Meet Me at the Meeting Place ................................................................ 53 

Message Boards ............................................................................................ 53 

Parking Information .................................................................................... 53 

up-to-date information at www.toxicology.org 1 

Photography Policy and Session Etiquette for Attendees ...........54 

Registration Desk Hours ............................................................................54 

Safety and Security......................................................................................54 

Salt Lake City Information Desks ............................................................54 

SOT Headquarters Office ........................................................................... 55 

SOT Resource Pavilion ................................................................................ 55 

Speaker Ready Room .................................................................................. 55 

Sponsorship ................................................................................................... 55 

Tour Information .......................................................................................... 55 

The Toxicologist (Print and CD-ROM)/Itinerary Planner 

and the Program .................................................................................56 

Transportation ...............................................................................................56 

Career Resources and Development 

Career Resources and Development Services...................................60 

Education and Outreach Activities 

Undergraduate Education ........................................................................64 

Social Functions 

Social Events .................................................................................................. 67 

Award and Honor Recipients 

2010 Award Recipients ...............................................................................72 

2010 Honorary Memberships .................................................................. 81 

SOT Endowment 2009 Award Recipients ........................................... 82 

Continuing Education 

Continuing Education Courses ............................................................... 85 

Sessions Index 

Scientific Session Index .............................................................................. 93 


Program Description.................................................................................100 

Author Index ............................................................................................... 304 

Abstract Key Word Index .........................................................................327 

SOT Leadership 

2009–2010 Council ................................................................................... 340 

Officers and Councilors ............................................................................342 

Past Presidents ............................................................................................342 

Elected Committees ..................................................................................343 

Appointed Committees ...........................................................................343 

Officers—Regional Chapters .................................................................347 

Officers—Specialty Sections..................................................................349 

Officers—Special Interest Groups .......................................................352 

SOT References 

SOT Awards and Honors (Descriptions and History) ....................353 

Sponsored Award Descriptions ............................................................361 

Endowment Fund (Donor Contribution Form) ...............................365 

SOT Affiliates ................................................................................................373 

Headquarters Staff ....................................................................................374 

All text and graphics are ©2010 by the Society of Toxicology unless noted. Some Salt Lake 

City photos are courtesy of the Salt Lake Convention and Visitor’s Bureau unless otherwise 

noted. Photographed by Richard Cheski and Eric Schramm. For promotional use only. No 

advertising use is permitted.

How to Use this Program 

The Society of Toxicology’s (SOT) Annual Meeting is always an exciting opportunity to highlight advancements in the science of 

toxicology. In order to maximize the value of your Annual Meeting attendance, we offer this Program Publication Layout Overview, the 

Scientific Session Reference, and Scientific Session Type Legend to assist you. We hope that you find this information useful and welcome 

your comments. 

Program Publication Layout Overview 

Section 

Front Fold-Out 

Cover —Scientific 

Program Overview 

Daily Pocket 

Calendar 

(pages 3–11) 

Schedule by Event 

Name 

(pages 13–21) 

Poster Session 

Schedule and Board 

Surface Maps 

(pages 33–37) 

Scientific Session 

Index 

(pages 93–99) 

Author Index 

(pages 304–326) 

Abstract Key Word 

Index 

(pages 327–338) 

Description 

This quick reference guide lists the Annual Meeting scientific sessions with corresponding page numbers in the Program Description 

section. Color-coded presentation titles assist you in identifying sessions within each theme. A brief description for each theme is 

available as well. 

This at-a-glance calendar is your guide to the daily activities of the Annual Meeting including special sessions; Specialty Section, 

Regional Chapter, Special Interest Group, and ancillary functions; and SOT committee meetings. We encourage you to tear out the daily 

guide for easy reference. Please note that the scientific session details are included at the end of each day’s guide. 

This is an alphabetical listing of all the functions held during the Annual Meeting. You may use this easy-to-read schedule to quickly 

locate an event. Please note that for the scientific sessions detail, you must refer to the Scientific Program Overview on the front fold-out 

cover or Daily Pocket Calendar on pages 3–11. 

The Poster Session Schedule and Poster Board Surface Maps are displayed with a mock layout of the ToxExpo Exhibit Hall to assist 

you in finding poster sessions. Each poster schedule and surface map shows the poster session abstract numbers and the poster surface 

locations for each poster session time. Posters are displayed in the Exhibit Hall Monday–Wednesday and Exhibit Hall E on Thursday. 

This index lists the scientific sessions by type, date, and time. In addition, this information includes the session titles with abstract 

numbers, poster boards, session locations, and corresponding page numbers in the Program Description section. 

The numerals following the author’s names refer to the abstract numbers referenced in this Program and The Toxicologist. 

The asterisk after the abstract number indicates the author is the first presenter. 

This index provides a listing of key words by subject or chemical and the relevant abstract(s) referenced in this Program and 

The Toxicologist. 

Program Description Scientific Session Reference (pages 100–301) 

The Program Description layout is ordered by date and start time. Please refer to the description below. Each scientific session listing includes a session abstract 

and list of speakers or the featured presenters. 

Listing 

Session Type and 

Title 

Sponsors or 

Endorsers 

Abstract Number or 

Presentation Time 

Poster Sessions 

Description 

Session type and title display in bold type. A brief description for each scientific session type is listed below. 

This section lists the sponsors and endorsers from SOT Special Interest Groups, Specialty Sections, Regional Chapters, or 

SOT Committees. For each scientific session, the sponsor, the group that developed the session, is listed first and followed 

by the endorsers. The list of endorsers, groups that support the session, is sorted alphabetically. 

The first number listed is the abstract number, or the SOT final identifying number. For scientific sessions (but not Continuing Education 

Courses or Poster Presentations), the second number is the presentation time. Individual abstracts can be found on The Toxicologist 

CD-ROM (free to all attendees), The Toxicologist publication (available for purchase on-site for $20), and on the SOT Web site. 

The poster board surface number is listed above the title of each individual poster presentation for easy reference. 

Scientific Session Type Legend 

CE Target Areas (45 or 225 minutes)—Continuing Education courses 

highlighting specialized areas of interest 

Education-Career Development Sessions (80 minutes)—Sessions that provide 

the tools and resources to toxicologists that will enhance their professional 

and scientific development 

Exhibitor Hosted Sessions (60 minutes)—Informative sessions developed by 

an exhibiting company 

Featured Sessions (50–60 minutes)—Keynote and other special lectures 

Historical Highlights (80 minutes)—Review of a historical body of science 

that has impacted toxicology 

Informational Sessions (80 minutes)—Scientific planning or membership 

development 

Platform Sessions (165 minutes)—Oral presentations that cover new areas, 

concepts, or data 

Poster Sessions (180–210 minutes)—Topic specific presentations that cover 

new areas, concepts, or data 

Regional Interest Session (165 minutes)—Central topics of relevance that 

describe public health and/or ecological problems of a particular region 

Roundtable Sessions (80 minutes)—Controversial subjects 

Symposium Sessions (80 or 165 minutes)—Cutting-edge science; new areas, 

concepts, or data 

Thematic Sessions (80–210 minutes)—Timely topics of relevance to 

toxicology 

Workshop Sessions (165 minutes)—State-of-the-art knowledge in toxicology 

2 

SOT 49 th Annual Meeting

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page for a convenient daily calendar _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 

Daily Pocket Calendar 

Events names are listed alphabetically by 

the event start time. 

Events at the Salt Palace Convention 

Center are noted as CC. 

Events are listed alphabetically by the event 

start time. 



8:00 AM to 1:30 PM 

Council Meeting 

Marriott Downtown Solitude 

8:00 AM to 5:00 PM 

IUTOX Meetings 

Shilo Inn Wasatch and Alta 

8:00 AM to 5:00 PM 

ToxExpo Set Up 

CC Exhibit Hall 

11:30 AM to 6:00 PM 

Johnson & Johnson Toxicology Interest 

Group Meeting 

Marriott Downtown Deer Valley 1 


start time. 



7:00 AM to 8:30 PM 

Coat/Luggage Check 

CC North Foyer 

7:00 AM to 7:45 AM 

Continuing Education Sunrise Mini-Course 

(Ticket Required) 

CC Lower Concourse 

(See Signage for Room Location) 

7:00 AM to 6:00 PM 

E-mail Center/Message Boards 


7:00 AM to 8:00 PM 

Registration 

CC South Foyer 

7:00 AM to 5:30 PM 

SOT Office 

CC Room 254 B 

7:00 AM to 5:30 PM 

Speaker Ready Room 

CC Room 252 

7:30 AM to 9:30 AM 

Career Resource and Development 

Committee Meeting I 

CC Room 258 

7:30 AM to 2:30 PM 

Concession Stands 

CC Lower and Upper Concourses 

8:00 AM to 5:00 PM 

Guest/Spouse Hospitality Center 

Marriott Downtown Park City 

8:00 AM to 5:00 PM 

Housing Desk 


4:00 PM to 7:00 PM 

Council Orientation Meeting 


1:00 PM to 6:00 PM 

American Board of Toxicology 

Board of Directors Meeting 


4:00 PM to 7:00 PM 



4:00 PM to 7:00 PM 

Housing Desk 


4:00 PM to 7:00 PM 

Registration 


4:00 PM to 7:00 PM 

SOT Office 

CC Room 254 B 

4:00 PM to 7:00 PM 


CC Room 252 

8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Tour Desk 


8:00 AM to 12:00 NOON 

Toxicology Education Foundation 

Board Meeting 

Marriott Downtown Cottonwood 

8:00 AM to 5:00 PM 

ToxExpo Set Up 


8:00 AM to 11:30 AM 

Undergraduate Education Program: 

Toxicology Lectures 

CC Room 255 B 

8:15 AM to 12:00 NOON 

Continuing Education Morning Courses 



(See Signage for Room Locations) 

10:00 AM to 12:00 NOON 

Endowment Fund Board Meeting 

CC Room 254 A 

10:00 AM to 4:30 PM 

Job Bank Center 

CC Room 155 A 

11:30 AM to 12:45 PM 


Lunch and Networking 

(By Invitation Only) 

CC Room 255 C 

11:45 AM to 1:15 PM 

Continuing Education Luncheon 

for Speakers, Committee, and 

Student Volunteers 


CC Ballroom A 



For your convenience, please tear out and carry with you. 

Friday March 5 

7:00 PM to 10:00 PM 

Council Orientation Reception/Dinner 


Saturday March 6 

4:00 PM to 7:00 PM 

Tour Desk 


4:15 PM to 5:45 PM 


Orientation for SOT Hosts, Peer Mentors, 

and Advisors 

CC Room 258 

5:00 PM to 5:45 PM 

Continuing Education Committee 

Walk-Through 

CC Ballroom F 

5:30 PM to 7:00 PM 

Graduate Fellowship Interviews 

by Awards Committee 

CC Room 259 

5:45 PM to 9:00 PM 


Opening Event 

CC Room 255 C 

12:00 NOON to 3:30 PM 

Toxicological Sciences Associate Editors 



12:45 PM to 1:45 PM 

Undergraduate Education Program— 

Advisors: Tips for Advising Prospective 

Graduate Students 

CC Room 258 

12:45 PM to 1:45 PM 

Undergraduate Education Program— 

Students: Planning for Graduate School 

CC Rooms 259, 260 A, 260 B 

(Concurrent Sessions) 

1:00 PM to 3:00 PM 

SOT Committee/Task Force Chair 

Orientation 

CC Room 255 A 

1:15 PM to 5:00 PM 

Continuing Education Afternoon Courses 



(See Signage for Room Locations) 

2:00 PM to 3:00 PM 


Career Panel Discussion 

CC Room 255 C 

3:00 PM to 5:00 PM 


Academic Toxicology Programs 

and Internships 

CC Room 255 F 

3:00 PM to 3:30 PM 

Undergraduate Education Program: Host 

Mentor and Peer Mentoring Meeting 

CC Room 258 

4:00 PM to 5:15 PM 

Awards Recipients Photographed 

CC Ballroom I 

8:00 PM to 9:00 PM 

CDI Reunion (Networking and Dessert) 

CC Room 255 C 

(Invited: Anyone involved with the SOT 

Undergraduate Education Program through 

the years) 

Sunday March 7 

4:45 PM to 5:15 PM 

Awards Ceremony Music—Performed by 

Michael Lucarelli, Classical Guitarist 

CC Ballroom J 

5:15 PM to 6:30 PM 


(All Attendees Welcome) 

CC Ballroom J 

6:30 PM to 7:30 PM 

Welcoming Reception 


CC Exhibit Hall E 

7:00 PM to 8:00 PM 

25-Year (or More) Member Reception 


CC Ballroom A 

7:30 PM to 10:00 PM 

Arizona Night 

Hilton Topaz 

7:30 PM to 10:30 PM 

Lovelace Respiratory Research 

Institute Reception 

Marriott Downtown 

Grand Ballroom A 

7:30 PM to 8:30 PM 

Student/Postdoctoral Fellow Mixer 


CC Room 355 

8:00 PM to 10:00 PM 

IUTOX Executive Committee Dinner 

J. Wong’s Restaurant 

EvEnt CalEndar

EvEnt CalEndar 


7:00 AM–7:45 AM 

COnTInuInG EDuCATIOn SunRISE 

MInI-COuRSE 

1. Biological Pathway Analysis: An Introduction to 

the Pathway Knowledge Bases for Toxicological 

Research 

CE courses held in the Upper and Lower Concourses. 

(Pick up a flyer upon entrance of the Convention 

Center or see signage at the CE booths for room 

assignments.) 

49 th Annual Meeting and ToxExpo 

Scientific Program Overview by day & time 

Sunday March 7 

8:15 AM–12:00 nOOn 

COnTInuInG EDuCATIOn MORnInG COuRSES 

2. Biologicals: Introduction to Drug Development 

3. Comparative Biology of the Lung 

4. Cytokines: Balancing Therapeutic Utility and 

Immune System-Mediated Toxicities 

5. Nuclear Receptors: Role in Chemical Mode of 

Action and Targets for Toxicity Testing 

6. Predictive Power of Novel Technologies (Cells 

to ‘Omics): Promises, Pitfalls, and Potential 

Applications 

7. Reproduction and Regulatory Impact 

Introducing a new on-line SOT member resource 

created entirely with YOU in mind… 

4 


YOUr network. 

1:15 PM–5:00 PM 

COnTInuInG EDuCATIOn AFTERnOOn 

COuRSES 

8. Assessment of Ocular Toxicity in Toxicology 

Studies Conducted for Regulatory Purposes 

9. Gene-Environment Interactions Influence 

Cytokine Biology in Immunotoxicity and 

Disease: Genomic, Genetic, and Epigenetic 

Perspectives 

10. Mitochondrial Toxicity: Animal Models and 

Screening Methods in Drug Development 

11. ICH Initiatives for Conducting Pharmaceutical 

Preclinical Safety Studies: New and Revised 

Guidelines and Challenges 

12. Segment-Specific Renal Pathology for the 

Non-Pathologist 

13. Technologies and Tools for Toxicity Testing in 

the 21 st Century 

at the heart of toXchange is an enhanced SOt membership directory 

that allows you to: 

• Create a customized, SOt member profile you can update on-line 24/7 

• Search for and find other SOt members based on their profile information 

• Be found by other SOt members based on YOUr profile information 

• Communicate with your SOt peers with easy-to-use, secure networking 

tools 

Plus, you can pull in content from other social networking systems, making toXchange 

your one-stop professional on-line resource. 

Hosted on a safe-and-secure network platform, toXchange is specifically designed for SOt members. 

Be sure to visit the SOT Resource Pavilion, Booth #1901 in the Exhibit Hall, for on-site information on 

how to get started—and have YOUr profile picture taken and uploaded. 

It’s YOUR Network. Go ahead. Be a part of it. 

Go to the SOt resource Pavilion for on-site information. 

For on-line information, go to www.toXchange.org. 

SOT 49 th Annual Meeting 

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page for a convenient daily calendar _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _




start time. 



6:30 AM to 7:30 AM 

Academy of Toxicological Sciences 

Board Meeting 

Hilton Executive Boardroom 

6:30 AM to 8:00 AM 

Medical Device Specialty Section 

Officers Meeting 

CC Room 255 F 

6:30 AM to 8:00 AM 

Metals Specialty Section Officers Meeting 

CC Room 255 D 

6:30 AM to 8:00 AM 

Past Presidents Breakfast 

CC Boardroom 

6:45 AM to 7:45 AM 

Postdoctoral Assembly Board Meeting 

CC Room 259 

7:00 AM to 8:30 PM 



7:00 AM to 8:00 AM 

Continuing Education Committee Meeting 

CC Room 258 

7:00 AM to 9:00 AM 

Dermal Toxicology Specialty Section 


CC Room 355 A 

7:00 AM to 6:00 PM 



7:00 AM to 5:00 PM 

Housing Desk 


7:00 AM to 9:00 AM 

In Vitro and Alternative Methods 

Specialty Section Officers Meeting 

CC Room 260 B 

7:00 AM to 8:00 AM 

Molecular Biology Specialty Section 


CC Room 355 D 

7:00 AM to 8:00 AM 

MPI RESEARCH: Non-Invasive Assays in 

Ophthalmic Toxicology 


7:00 AM to 8:00 AM 

Neurotoxicology Specialty Section 


CC Room 254 A 

7:00 AM to 8:30 AM 

Regional Chapter/Special Interest Group 

Graduate Committee Meeting 

CC Room 255 A 

7:00 AM to 5:00 PM 

Registration 


7:00 AM to 8:00 AM 

Regulatory and Safety Evaluation 


CC Room 355 B 

7:00 AM to 9:00 AM 

Risk Assessment Specialty Section 


CC Room 355 E 

7:00 AM to 8:00 AM 

Scientific Program Committee 

Walk-Through 

CC Ballroom J 

7:00 AM to 5:00 PM 

SOT Office 

CC Room 254 B 

7:00 AM to 8:00 AM 

Southeastern Regional Chapter 

Business Meeting 


7:00 AM to 5:00 PM 


CC Room 252 

7:30 AM to 7:50 AM 

Undergraduate Education Program 

CC Room 255 C 

7:30 AM to 9:30 AM 


CC Upper and Lower Concourses 

7:30 AM to 9:30 AM 

Poster Set Up (See Poster Board Surface 

Maps on Pages 33–37) 


7:30 AM to 9:00 AM 

Toxicologic and Exploratory Pathology 


CC Room 260 A 

8:00 AM to 5:00 PM 



8:00 AM to 5:00 PM 



8:00 AM to 9:00 AM 

Plenary Opening Lecture: Discovery 

of Nitric Oxide and Cyclic GMP Cell 

Signaling and Their Role in Drug 

Development—Lecturer: Nobel Laureate 

Ferid Murad 


8:00 AM to 4:00 PM 

Tour Desk 


9:00 AM to 10:00 AM 

Complimentary Coffee 


9:00 AM to 3:00 PM 



9:00 AM to 4:30 PM 

Hot Zones (Wireless Internet Access) 


9:00 AM to 4:30 PM 


CC Room 155 A 

9:00 AM to 4:30 PM 

SOT Resource Pavilion 

CC Exhibit Hall, Booth 1901 

9:00 AM to 4:30 PM 

ToxExpo Exhibits Open 


9:15 AM to 10:15 AM 

Exhibitor Hosted Sessions: Analytical 

Bio-Chemistry Labs, Inc.; Biological Test 

Center; and Charles River 

CC (See Program Description for 

Room Locations) 

9:15 AM to 12:00 NOON 

Scientific Sessions 



9:30 AM to 12:30 PM 



9:30 AM to 10:50 AM 


Poster Session for Visiting Students 





Monday March 8 

10:30 AM to 11:30 AM 

Exhibitor Hosted Sessions: 

CANTEST Ltd.; Research Diets, Inc.; 

and TSE Systems Inc. 



11:00 AM to 11:50 AM 


Wrap Up 

CC Room 255 C 

11:30 AM to 2:30 PM 

Communications Committee Meeting 

CC Room 258 

11:45 AM to 12:45 PM 

Exhibitor Hosted Sessions: Roche Applied 

Science and STEMCELL Technologies Inc. 

CC (See Program Description for Room 

Locations) 

12:00 NOON to 1:00 PM 

AACT Distinguished Chinese 

Toxicologist Lectureship 

CC Room 355 D 

12:00 NOON to 1:30 PM 

Cardiovascular Toxicology 

Specialty Section Meeting/Luncheon 

CC Room 355 B 

12:00 NOON to 1:30 PM 

Central States Regional Chapter 

Meeting/Luncheon 

CC Room 355 A 

12:00 NOON to 1:30 PM 

Food Safety Specialty Section 


CC Room 259 

12:00 NOON to 1:20 PM 

In Vitro Toxicology Lecture 

and Luncheon for Students 


CC Room 255 E 

12:00 NOON to 1:30 PM 

Mid-Atlantic Regional Chapter 

Luncheon 

(Members Only, RSVP Required) 

Tucanos Restaurant 

12:00 NOON to 1:30 PM 

Northeast Regional Chapter Student 

and Poster Travel Award Luncheon 

Marriott Downtown Brighton 

12:00 NOON to 1:30 PM 

Occupational and Public Health 


CC Room 255 B 

12:00 NOON to 1:30 PM 

Scientific Liaison Task Force Meeting 

CC Room 260 A 

12:00 NOON to 1:00 PM 

Special Interest Group Presidents and 


CC Room 255 A 

12:00 NOON to 1:30 PM 

Toxicology and Applied Pharmacology 

Associate Editors Meeting 


12:10 PM to 1:30 PM 




12:30 PM to 1:20 PM 

Leading Edge in Basic Science Award 

Lecture: Toxicogenomics at NIEHS: 

How Genomics Is Impacting the Science of 

Toxicology—Lecturer: Richard S. Paules 

CC Room 251 A 

12:30 PM to 1:00 PM 




1:00 PM to 2:00 PM 

Exhibitor Hosted Sessions: ReachBio LLC; 

SNBL USA, Ltd.; and Trevigen, Inc. 



1:00 PM to 4:30 PM 



1:30 PM to 2:30 PM 

VIP ToxExpo Exhibit Hall 

Walk-Through 

CC SOT Resource Pavilion Exhibit Hall 

1:40 PM to 4:25 PM 




2:15 PM to 3:15 PM 

Exhibitor Hosted Sessions: Covance Inc.; 

Huntingdon Life Sciences; and 

LAB Research Inc. 



4:30 PM to 6:00 PM 

American Board of Toxicology 

Open Mixer Meeting 


4:30 PM to 6:30 PM 

Roundtable of Toxicology Consultants 

Business Meeting/Reception 

Hilton Canyons C 

4:30 PM to 6:00 PM 

Specialty Section Presidents and 


CC Room 255 A 

4:35 PM to 5:55 PM 

Scientific Sessions (Sunset) 



4:35 PM to 5:55 PM 

SOT/Eurotox Debate: Threshold of 

Toxicological Concern (TTC): Is It Based 

on Science or Politics? 

CC Ballroom A 

5:00 PM to 7:00 PM 

Gulf Coast and South Central Regional 

Chapters Joint Mixer 

Lumpy's Downtown 

5:00 PM to 7:00 PM 

Mountain West and Southern California 

Regional Chapters Joint Reception 

Squatters Pub Brewery 

5:00 PM to 7:00 PM 

MPI RESEARCH: Molecular Imaging in 

Preclinical Research 


5:00 PM to 8:00 PM 

Pacific Northwest Regional 

Chapter Reception 


5:00 PM to 7:00 PM 

Toxicology and Applied Pharmacology 

50 th Anniversary Reception 

Marriott City Center Capitol Ballroom A 

6:00 PM to 8:00 PM 

American Association of Chinese in 

Toxicology Special Interest Group 

Meeting/Reception 

Hilton Grand Ballroom A 

Continued on next page 

EvEnt CalEndar



6:00 PM to 7:30 PM 

Association of Scientists of Indian Origin 

in America Special Interest Group 


CC Room 355 D 

6:00 PM to 7:30 PM 

Carcinogenesis Specialty Section 


CC Room 355 B 

6:00 PM to 7:30 PM 



CC Room 355 A 

6:00 PM to 7:30 PM 



CC Room 255 D 

8:00 AM–9:00 AM 

PLEnARy OPEnInG LECTuRE 

Discovery of Nitric Oxide and Cyclic GMP 

Cell Signaling and Their Role in Drug 

Development—Lecturer: Nobel Laureate 

Ferid Murad (Exhibit Hall E) 

9:15 AM–12:00 nOOn 

SyMPOSIuM SESSIOnS 

• Mechanistic Role of Reactive Intermediate 

Protein Covalent Binding in Target Organ 

Toxicity: Past, Present, and Future (Ballroom A) 

• Neurological Responses after Exposure to 

Inhaled Metal Particles (Room 150) 

• Ovarian Toxicity: Current Concepts in 

Toxicology, Pathology, and Mechanisms 

(Ballroom B) 

• Silica and Asbestos Immunotoxicity: 

Mechanisms to Fibrosis, Autoimmunity, and 

Modified Tumor Resistance (Ballroom G) 

wORkSHOP SESSIOnS 

• Does Background Disease Lead to Low Dose 

Linearity? (Room 151) 

• Heart Smart: Innovative Approaches for 

Improving Cardiovascular Safety through 

Collaboration (Ballroom J) 

• Toxicology in the 21 st Century: Stem Cells in 

Drug Discovery and Development (Room 250) 

PLATFORM SESSIOnS 

• Biomarkers of Target-Organ Toxicity 

(Ballroom F) 

• Chemical and Biological Weapons—Sulfur 

Mustard (Ballroom I) 

• Immunopharmacogenomics and Immune 

Regulation (Ballroom D) 

• Mitochondrial-Mediated Mechanisms of Toxicity 

of Xenobiotics (Room 251 A) 

9:30 AM–12:30 PM 

POSTER SESSIOnS 

(Exhibit Hall—See Poster Board Surface Maps on 

Pages 33–37) 

• Carcinogenesis I 

• Epigenetics 

• Hypersensitivity, Autoimmunity, and 

Idiosyncratic Drug Reactions 

• Investigations of Chemical Mixtures 

6:00 PM to 7:30 PM 

Korean Toxicologists Association in 

America Special Interest Group 


CC Room 260 

6:00 PM to 7:30 PM 

Medical Device Specialty Section 


CC Room 258 

6:00 PM to 7:30 PM 

Metals Specialty Section 


CC Room 255 C 

6:00 PM to 7:30 PM 

Molecular Biology Specialty 

Section Meeting/Reception 

CC Room 255 B 


6 

6:00 PM to 7:30 PM 

Nanotoxicology Specialty Section 


CC Room 255 E 

6:00 PM to 7:30 PM 

Ocular Toxicology Specialty Section 


CC Room 259 

6:00 PM to 7:30 PM 



CC Room 355 E 

6:00 PM to 7:30 PM 

Southeastern Regional Chapter Reception 

Hilton Canyons B 

• Mechanistic Aspects of Persistent Organic 

Chemical Toxicity 

• Nanotoxicology I 

• Neurodevelopmental Toxicity: General 

• Screening and Predicting Toxicity: 

Computational Approaches to Identify Targets 

• Toxicity Testing—Alternative Models I 

12:10 PM–1:30 PM 

ROunDTABLE SESSIOnS 

• Combination Toxicology Studies for 

Pharmaceutical Agents: Design Considerations 

and Impact on Clinical Development 

(Ballroom D) 

• Melamine Contamination of Infant Formulas: 

Lessons Learned (Ballroom F) 

HISTORICAL HIGHLIGHTS SESSIOn 

• Translating Toxicology to Public Health 

Protection: Lessons Learned from Superfund 

(Room Ballroom I) 

12:30 PM–1:20 PM 

LEADInG EDGE In BASIC SCIEnCE 

AwARD LECTuRE 


Impacting the Science of Toxicology— 

Lecturer: Richard S. Paules (Room 251 A) 

1:00 PM–4:30 PM 



Pages 33–37) 

• Advances in Dermal Toxicology 

• Biotransformation I 

• Carcinogenesis II 

• Chemical and Biological Weapons 

• Environmental Impact of Xenobiotics 

• Genetic Diversity and Response to Xenobiotics 

• Nanotoxicology II 

• Reproductive Toxicology 

• Toxicity Testing—Alternative Models II 


Monday (Continued) March 8 

6:00 PM to 8:00 PM 

St. John’s University 8 th Annual 

Toxicology Alumni Dinner 

Hilton Topaz 

6:00 PM to 8:00 PM 

Toxicologists of African Origin Special 

Interest Group Meeting/Reception 

Salt Lake Plaza Hotel Salt Room 

7:00 PM to 9:00 PM 

Toxicological Sciences/Oxford Journals 

Appreciation Dinner (By Invitation Only) 

Hotel Monaco Bombay 

7:30 PM to 9:00 PM 

North Carolina State University 

Alumni Reception 



Monday March 8 

1:40 PM–4:25 PM 


• Alterations in Regulatory T Cells: Novel 

Pathways to Immunotoxicology (Room 151) 

• Faster Science for Better Decisions: 

Characterizing Environmental Contaminant Risk 

from High-Throughput Data (Ballroom B) 

• Genotoxic Impurities in Drugs and Drug 

Products: What Is the Right Way to Deal with 

Impurities in R&D versus Regulatory Guidance? 

(Room 250) 

• Metabolic Syndrome and Increased Sensitivity to 

Drug-Induced Liver Injury (DILI): Nonclinical 

Models and Clinical Implications (Ballroom A) 

• Phthalate Reproductive and Developmental 

Toxicity: Implications for Cumulative Risk 

Assessment (Ballroom D) 

wORkSHOP SESSIOn 

• Determination of the Contribution of Individual 

Stressors in Cumulative Risk Assessments 

(Room 150) 

REGIOnAL InTEREST SESSIOn 

• Signaling Mechanisms for Metabolic 

Dysfunction Following Low-Level Arsenic 

Exposures: From Mouse to Man (Ballroom G) 


• Advances in Biomarkers of Renal Injury 

(Ballroom I) 

• Animal Models in the 21 st Century (Ballroom J) 

• Lipid Metabolism and Apoptosis (Ballroom F) 

• Methods and Animal Models in Cardiovascular 

Safety Pharmacology (Room 251 A) 

4:35 PM–5:55 PM 

SOT/EuROTOx DEBATE 

Threshold of Toxicological Concern (TTC): 

Is It Based on Science or Politics? (Ballroom A) 


• Inhaled Particles: From the Nose to the Brain? 

(Ballroom B) 

• Safety of Vitamins and Minerals: Controversies 

and Perspectives (Ballroom D) 

• The Evolution of the Extended One-Generation 

Study Design for Agricultural and Industrial 

Chemical Hazard Identification (Ballroom F) 







Tuesday March 9 


start time. 



6:30 AM to 8:00 AM 

AstraZeneca GRC 2011 Mechanisms of 

Toxicity Steering Group Meeting 

Marriott Downtown Grand Ballroom I 

6:45 AM to 7:45 AM 

American Board of Veterinary Toxicology 

Diplomate Meeting 

Marriott Downtown Grand Ballroom A 

7:00 AM to 9:00 AM 

50 th Year Anniversary SOT Task Force 


CC Room 260 A 

7:00 AM to 8:30 AM 



CC Room 258 

7:00 AM to 8:00 PM 



7:00 AM to 8:30 AM 

Comparative and Veterinary 


CC Room 255 D 

7:00 AM to 8:30 AM 

Education Committee Meeting 

CC Room 260 B 

7:00 AM to 8:45 AM 

Food and Chemical Toxicology 

Editorial Board Meeting 

Marriott Downtown Grand Ballroom B 

7:00 AM to 8:30 AM 

Immunotoxicology 


Marriott Downtown, Elevations Restaurant 

7:00 AM to 8:00 AM 

Inhalation and Respiratory 


CC Room 255 B 

7:00 AM to 8:30 AM 

Mechanisms Specialty Section 


CC Room 255 E 

7:00 AM to 8:30 AM 

Mixtures Specialty Section 


CC Room 255 F 

7:00 AM to 8:30 AM 



CC Room 355 A 

7:00 AM to 8:30 AM 

Regional Chapter Presidents and 


CC Room 255 A 

7:00 AM to 8:30 AM 

Reproductive and Developmental 

Toxicology Specialty Section 


CC Room 255 C 

7:00 AM to 4:30 PM 

SOT Office 

CC Room 254 B 

7:00 AM to 4:30 PM 


CC Room 252 

7:00 AM to 8:30 AM 

Specialty Section Graduate 

Committee Meeting 

CC Room 259 

7:30 AM to 9:30 AM 



7:30 AM to 8:50 AM 

Scientific Sessions (Sunrise) 



8:00 AM to 6:00 PM 



8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Housing Desk 


8:00 AM to 4:00 PM 

Registration 


8:00 AM to 4:00 PM 

Tour Desk 


8:00 AM to 8:50 AM 

Translational Impact Award Lecture: 

Translating Mechanism-Based Research 

into Antidotes: Trials, Tribulations, and 

Triumphs—Lecturer: Kenneth E. McMartin 

CC Room 251 A 

8:30 AM to 9:30 AM 



8:30 AM to 3:00 PM 



8:30 AM to 9:30 AM 

Exhibitor Hosted Session: Charles River 


Room Location) 

8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 


CC Room 155 A 

8:30 AM to 9:00 AM 




8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 



9:00 AM to 10:30 AM 

Audit Committee Meeting 

CC Boardroom 

9:00 AM to 4:30 PM 

NIH Resource Room 


CC Room 254 A 

9:00 AM to 12:30 PM 



9:00 AM to 11:45 AM 





9:45 AM to 10:45 AM 

Exhibitor Hosted Sessions: Accelera Srl; 

Huntingdon Life Sciences; and 

Transparent Inc. 



10:30 AM to 11:45 AM 

ToxLearn Work Group 

CC Room 258 

11:00 AM to 12:00 NOON 

Exhibitor Hosted Sessions: Ingenuity 

Systems; Promega Corporation; and 

SkinEthic Laboratories 



11:45 AM to 1:30 PM 

Toxicology Letters Editorial Board Meeting 


12:00 NOON to 1:30 PM 

ASIO Lunch and Learn Program 


12:00 NOON to 1:30 PM 

Awards Committee Meeting 

CC Room 260 B 

12:00 NOON to 1:30 PM 

Global Strategy Task Force Meeting 

CC Room 259 

12:00 NOON to 1:30 PM 

ILSI-HESI Seminar: Human Pluripotent 

Stem Cells—Prof. James Thomson, 

University of Wisconsin 

Marriott Downtown Grand Ballroom D 

12:00 NOON to 1:30 PM 

In Vitro and Alternative Methods Specialty 

Section Meeting/Luncheon 

CC Room 255 C 

12:00 NOON to 1:15 PM 

NIH Brown Bag Lunch 

CC Room 255 B 

12:00 NOON to 1:15 PM 

Postdoctoral Assembly Luncheon 


CC Room 255 E 

12:00 NOON to 1:20 PM 




12:15 PM to 1:15 PM 

Exhibitor Hosted Sessions: ADMET Group; 

GeneGo, Inc; and LAB Research Inc. 



12:30 PM to 1:00 PM 




12:30 PM to 1:20 PM 

Distinguished Toxicology Scholar Award 

Lecture: Toxic Injury: Initiation, Expansion, 

and Repair— 

Lecturer: Harihara M. Mehendale 

CC Room 251 A 

1:00 PM to 4:30 PM 



1:30 PM to 2:30 PM 

Exhibitor Hosted Sessions: emka 

TECHNOLOGIES; Quertle, LLC; and 

Science/AAAS 



1:30 PM to 4:15 PM 




2:45 PM to 3:45 PM 

Exhibitor Hosted Sessions: Aperio; 

Covance Inc.; and Ellegaard Göttingen 

Minipigs A/S 


Locations) 

3:30 PM to 4:30 PM 

Undergraduate Faculty Meeting 

CC Room 355 A 

4:30 PM to 6:00 PM 

Annual Business Meeting of the Society 

of Toxicology (SOT Members Only; Full, 

Associate, Postdoctoral, and Student 

Members Invited) 

CC Ballroom A 

4:45 PM to 6:00 PM 

ToxExpo 2011 Exhibit Space 

Selection Meeting 

CC Room 155 B 

6:00 PM to 7:30 PM 

Biological Modeling Specialty 


CC Room 260 B 

6:00 PM to 7:30 PM 

Comparative and Veterinary Specialty 


CC Room 258 

6:00 PM to 7:30 PM 

Drug Discovery Toxicology Specialty 


CC Room 355 D 

6:00 PM to 8:00 PM 

Immunotoxicology Specialty Section 

Meeting/Reception 25 th Anniversary 

Celebration 

CC Room 355 E 

6:00 PM to 7:30 PM 

Inhalation and Respiratory Specialty 


CC Room 255 B 

6:00 PM to 7:30 PM 



CC Room 255 E 

6:00 PM to 7:30 PM 



CC Room 259 

6:00 PM to 9:00 PM 

Northern California Regional Chapter 

Reception 


6:00 PM to 7:30 PM 

Regulatory and Safety Evaluation 

Specialty Section Meeting/Reception 

CC Room 355 B 

6:30 PM to 8:30 PM 

Hispanic Organization for Toxicologists 

Special Interest Group Meeting/Reception 


6:30 PM to 8:00 PM 

Kettering Reception— 

University of Cincinnati 


7:00 PM to 10:00 PM 

University of Rochester Alumni Reception 


9:00 PM to 11:00 PM 

Michigan State University Environmental 

Toxicology Reception 

Marriott Downtown Grand Ballroom G 

9:00 PM to 11:00 PM 

Rutgers University Joint Graduate Program 

in Toxicology Annual Dessert Reception 



EvEnt CalEndar



7:30 AM–8:50 AM 


• Can Animal Neurotoxicity Predict Human 

Dysfunction? (Ballroom D) 

• Weighing Complex Data in Risk Decisions: 

Concepts of Evidence-Based Toxicology 

(Ballroom B) 

InFORMATIOnAL SESSIOnS 

• Human Hepatocytes Derived from Embryonic 

Stem Cells: A New Tool for In Vitro Toxicity 

Testing (Ballroom G) 

• Recent Advances in Pulmonary Surfactant 

Toxicological Assessment and Therapeutics 

(Ballroom F) 

8:00 AM–8:50 AM 

TRAnSLATIOnAL IMPACT AwARD LECTuRE 



Lecturer: Kenneth E. McMartin (Room 251 A) 

9:00 AM–11:45 AM 


• Anti-Drug Antibody-Mediated Toxicity in 

Nonclinical Toxicity Studies: Impact and 

Relevance to Human Safety (Ballroom J) 

• Bile Salt Transport and Liver Injury 

(Ballroom F) 

• MAP Kinase Signaling: A Common Target 

Eliciting Unique Tissue Responses (Ballroom A) 

• Molecular Determinants of Mitochondrial 

Disease (Ballroom D) 

• POPs: What’s New and Why Should We Care? 

(Ballroom I) 


• Opportunities to Modify Current Regulatory 

Testing Guidelines and Advance the Assessment 

of Carcinogenicity Risk in the 21 st Century 

(Room 151) 

• Research Advances and Enduring Needs in 

Children’s Environmental Health Protection 

(Ballroom B) 

EDuCATIOn-CAREER DEvELOPMEnT SESSIOn 

• Where Do I Go Now? Rational Career 

Development Planning for Early-Career 

Scientists (Ballroom G) 


• Epidemiological Insights: Effects of 

Environmental and Occupational Exposures 

(Room 250) 

• Gene Environmental Interactions in 

Carcinogenesis (Room 150) 

• Reproductive and Developmental Effects Using 

Fish Models (Room 251 A) 


9:00 AM–12:30 PM 



Pages 33–37) 

• Animal Models—Emerging Methods 

• Arsenic I 

• Biological Modeling: Multiple Scales of 

Parameters, Structures, and Applications 

• Developmental Toxicology 

• DNA Damage and Repair 

• Education 

• Inflammation and the Pathogenesis of Toxicity 

• Kidney I 

• Metal Neurotoxicity: General 

• Mutagenicity 

• Nanotoxicology—Carbon Nanostructures 

• Oxidative Injury and Redox Biology 

• Pharmaceutical Toxicology I 

12:00 nOOn–1:20 PM 


• The Ying and Yang of Immunomodulatory 

Biopharmaceuticals: What Have We Learned 

since MABEL and How Close Are We to the 

Clinical Dose? (Room 150) 

• Women’s Health: Toxicology and Safety of 

Complementary and Alternative Medicine 

(Ballroom D) 

EDuCATIOn—CAREER DEvELOPMEnT SESSIOn 

• Science Communication in 2010: A New 

Decade in Toxicology and Need for Better 

Communication (Ballroom F) 

12:30 PM–1:20 pM 

DISTInGuISHED TOxICOLOGy SCHOLAR 

AwARD LECTuRE 


Lecturer: Harihara M. Mehendale (Room 251 A) 

1:00 PM–4:30 PM 



Pages 33–37) 

• Ah Receptor Biology and Toxicology 

• Apoptosis/Cell Death 

• Biomarkers 

• Biotransformation II 

• Genotoxicity 

• Neurodegenerative Disease 

• Neurotoxicity of Pesticides 

• Risk Assessment I: New Data and Derivations 

across Chemicals from A to V 

• Safety Assessment: Commercial and Consumer 

Products 

• Pharmaceutical Toxicology II 

• Safety Concerns of Food and Natural Products 

8 



Tuesday March 9 

1:30 PM–4:15 PM 


• Genetics: The Link between Exposures, Gene x 

Environment Interaction, and Toxicity 

(Ballroom A) 

• It’s Not Your Father’s Aryl Hydrocarbon 

Receptor: New Biological Roles for a 

Misunderstood Receptor (Ballroom F) 

• Mechanisms of Chemical-Induced Liver Cancer: 

Putting the Pieces Together (Ballroom J) 

• New Strategies for the Use of Genetic Toxicology 

Data in Human Risk Assessment (Room 151) 

• Recent Knowledge on Critical Regulators of 

Lipid Homeostasis in Metabolic Disease 

(Ballroom D) 

• Zinc, Copper, and Their Metabolic Effect: 

Myths and Musts (Room 250) 


• Immunotoxicity and Other Safety Considerations 

in the Development of Therapeutic Vaccines 

(Ballroom B) 

• Widely Varying Strategies Implemented in 

Discovery to Reduce the Failure Rate of Clinical 

Lead Candidates in Development (Room 150) 


• Emphasis on the Embryo: HTS, PBPK, and 

Virtual Tissue Technologies (Ballroom G) 

• Model Systems in Neurodevelopmental Toxicity 

(Ballroom I) 

• Nanotoxicology—Pulmonary Effects 

(Room 251 A) 

• Toxicity Detection—Alternatives to Animal 

Models (251 D) 






start time. 



7:00 AM to 8:00 PM 



7:00 AM to 8:30 AM 

Committee on Diversity Initiatives Meeting 

CC Room 258 

7:00 AM to 4:30 PM 

SOT Office 

CC Room 254 B 

7:00 AM to 4:30 PM 


CC Room 252 

7:00 AM to 8:00 AM 

Student Advisory Council 


CC Room 255 A 

7:00 AM to 8:45 AM 

Toxicology In Vitro Editorial Board Meeting 


7:30 AM to 9:30 AM 



7:30 AM to 8:30 AM 

Contemporary Concepts in Toxicology 

Conference Committee 

CC Room 260 A 

7:30 AM to 8:50 AM 




8:00 AM to 6:00 PM 



8:00 AM to 5:00 PM 



8:00 AM to 4:00 PM 

Housing Desk 


8:00 AM to 9:00 AM 

Keynote Medical Research Council 

(MRC) Lecture: The Interplay between 

Phosphorylation and Ubiquitination in 

Regulating the Innate Immune System— 

Lecturer: Sir Philip Cohen 

CC Ballroom A 

8:00 AM to 4:00 PM 

Registration 


8:00 AM to 2:00 PM 

Tour Desk 


8:30 AM to 9:30 AM 



8:30 AM to 3:00 PM 



8:30 AM to 9:30 AM 

Disease Prevention Task Force Meeting 

CC Room 260 A 

8:30 AM to 9:30 AM 

Exhibitor Hosted Session: Charles River 



8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 


CC Room 155 A 

8:30 AM to 9:00 AM 




8:30 AM to 4:30 PM 



8:30 AM to 4:30 PM 



9:00 AM to 4:30 PM 



CC Room 254 A 

9:00 AM to 12:30 PM 



9:00 AM to 11:45 AM 




9:45 AM to 10:45 AM 

Exhibitor Hosted Session: Huntingdon 

Life Sciences 



11:30 AM to 1:30 PM 

Finance Committee Meeting 

CC Room 259 

11:30 AM to 1:00 PM 

Membership Committee Meeting 

CC Room 258 

11:45 AM to 1:30 PM 

Toxicology Editorial Board Meeting 





wednesday March 10 

Introducing a new on-line SOT member resource 

created entirely with YOU in mind… 

12:00 NOON to 1:30 PM 

Professional Needs Assessment 

Task Force Meeting 

CC Room 260 B 

12:00 NOON to 1:30 PM 

Regional Chapter Governance Committee 

CC Room 260 A 

12:00 NOON to 1:20 PM 




12:00 NOON to 1:30 PM 

Toxicologic and Exploratory Pathology 


CC Room 255 E 

12:15 PM to 1:15 PM 

Exhibitor Hosted Sessions: Data Sciences 

International; and Gentronix Limited and 

Apredica LLC 



12:30 PM to 1:20 PM 

Merit Award Lecture: Living with 

Passion—Opening Doors in Research, 

Teaching, and Service— 

Lecturer: Marion Ehrich 

CC Room 251 A 

12:30 PM to 1:00 PM 




12:30 PM to 1:25 PM 

Toxicological Sciences Focus Group A 

CC Room 257 B (By Invitation Only) 

1:00 PM to 4:30 PM 



1:15 PM to 2:15 PM 

Featured Session: A Conversation with the 

EPA Office of Research and Development 

Director: Paul Anastas 

CC Room 251 D 

1:30 PM to 2:30 PM 

Exhibitor Hosted Session: Metabolon, Inc. 



1:30 PM to 4:15 PM 




2:00 PM to 4:00 PM 

Exhibitor Liaison Working Group 

CC Room 260 A 

2:30 PM to 3:30 PM 


NIEHS Director: Linda Birnbaum 

CC Room 251 D 

3:15 PM to 4:15 PM 

Toxicological Sciences Focus Group B 

CC Room 257 B (By Invitation Only) 

3:45 PM to 4:45 PM 

Featured Session: A Conversation 

with the U.S. FDA National Center for 

Toxicological Research: William Slikker, Jr. 

CC Room 251 D 

4:30 PM to 6:00 PM 

Board of Publications Meeting 

CC Room 260 B 

4:30 PM to 5:50 PM 

Scientific Sessions (Sunset) 



4:30 PM to 6:00 PM 

Women in Toxicology Special Interest 

Group Meeting/Reception 


4:45 PM to 12:00 MIDNIGHT 

ToxExpo Tear Down 


5:00 PM to 6:00 PM 

International Neurotoxicology Association 



5:00 PM to 6:30 PM 

Michigan Regional Chapter Happy Hour 

TBD 

6:00 PM to 7:30 PM 

Biotechnology Specialty Section 


CC Room 355 A 

6:00 PM to 7:30 PM 

Ethical, Legal, and Social Issues 

Specialty Section Meeting/Reception 

CC Room 258 

6:00 PM to 7:30 PM 



CC Room 255 E 

6:00 PM to 7:30 PM 

Reproductive and Developmental 

Toxicology Specialty Section 


CC Room 255 B 

7:00 PM to 8:30 PM 

President’s Reception 


Hilton Grand Ballroom 

8:00 PM to 10:00 PM 

Academy of Toxicological 

Sciences Reception 

Hilton Alpine Ballroom East 





EvEnt CalEndar



7:30 AM–8:50 AM 


• Impact of Tungsten and Tungsten Alloys on 

Health Risk (Ballroom F) 

• The 2009 Tennessee Fly Ash Spill— 

An Environmental Emergency Case Study 

(Ballroom D) 

EDuCATIOn—CAREER DEvELOPMEnT SESSIOn 

• Career Alternatives in Toxicology: Lessons 

Learned (Ballroom B) 

8:00 AM–9:00 AM 

kEynOTE MEDICAL RESEARCH COunCIL 

(MRC) LECTuRE 

The Interplay between Phosphorylation and 

Ubiquitination in Regulating the Innate Immune 

System—Lecturer: Sir Philip Cohen 

(Ballroom A) 

9:00 AM–11:45 AM 


• Gender Divergent Xenobiotic Responses 

(Room 150) 

• Mitochondrial Toxicity in Disease and Death 

(Ballroom J) 

• The Fetal Basis of Adult Disease (Room 250) 

9:00 AM–11:45 AM 


• Current Thinking and Experiences Related 

to Developmental and Reproductive Safety 

Assessment of Biotherapeutics (Room 151) 

• Novel Research Approaches and Animal Models 

in Translational Toxicology (Ballroom G) 

• Toxicity Testing in the 21 st Century for 

Ecotoxicology (Ballroom F) 

• Understanding Nonlinearities at the Low-End 

of the Dose-Response Curve: Insights from 

Molecular Network Analysis (Ballroom D) 


• Advances in Mycotoxin Toxicity (Ballroom I) 

• Impact of Receptors and Gene Regulation in 

Toxicological Response (Room 251 D) 

• Inhalation Toxicology of Ultrafine or 

Nanoparticles (Ballroom B) 

• Reproductive and Developmental Toxicity of 

Phthalates (Room 251 A) 


9:00 AM–12:30 PM 



Pages 33–37) 

• Causes and Progression of Hepatic Metabolic 

Dysfunction 

• Gene Regulation 

• Hepatotoxicity: Role of Bile Acid Metabolism 

and Homeostasis 

• Immunotoxicology: Mechanisms 

• Inhalation Toxicology 

• Nanotoxicology—Gold or Silver Nanoparticles 

• Neurodevelopmental Toxicity of Metals 

• Signal Transduction 

• Stem Cell Toxicology 

• Studies in Pharmacokinetics and Disposition 

• Toxicogenomics—Continuing Advances in 

Molecular Toxicology 

12:00 nOOn–1:20 PM 


• Life-Stage Adjustment Five Years Later— 

Experiences from the Cancer Risk Assessment 

Field (Ballroom B) 

• Measuring Immune Responses in Monkeys 

for Drug Development: Opportunities and 

Challenges for Predicting Human Efficacy and 

Immunotoxicity (Ballroom D) 

• The Tox21 st Community and the Future of 

Toxicology Testing (Ballroom F) 

12:30 PM–1:20 PM 

MERIT AwARD LECTuRE 

Living with Passion—Opening Doors in 

Research, Teaching, and Service— 

Lecturer: Marion Ehrich (Room 251 A) 

1:00 PM–4:30 PM 



Pages 33–37) 

• Beneficial Effects of Natural Products 

• Carcinogenesis: Breast and Reproductive 

• Cardiovascular Toxicology 

• Exposure Assessment and Emerging 

Biomonitoring Applications 

• Fetal Basis of Adult Disease 

• Immunotoxicology: Methods and Models 

• Metals I 

• Models and Mechanisms of Hepatotoxicity 

• Pesticides: General 

• Regulations and Policy in Toxicology 

• Risk Assessment II: Methodological Challenges 

and Metals 

10 



wednesday March 10 

1:15 PM–2:15 PM 

FEATuRED SESSIOn 

A Conversation with the EPA Office of Research 

and Development Director: Paul Anastas 

(Room 251 D) 

1:30 PM–4:15 PM 


• Aging As a Determinant of Xenobiotic Toxicity 

(Ballroom A) 

• TRPing the Sensor: The Role of TRP Channel 

Signaling in Cardiopulmonary Toxicity 

(Ballroom B) 

• Zebrafish Models for Developmental 

Neurobehavioral Toxicology (Ballroom D) 


• High-Throughput Electrophysiology— 

21 st Century Toxicity Testing Approaches with 

Functional Outcomes (Room 150) 

• Minerals and Metals: Pros and Cons of 

Deliberate Exposure (Ballroom I) 

• ‘Omics Profiling of Cell and Tissue Interactions 

of Nanomaterials: Insight into Mechanisms of 

Action (Ballroom J) 

• The Process of Defining Risk for Environmental 

Chemicals Having Significant Skin Exposure and 

Absorption Potential (Ballroom G) 

• Translation of Nonclinical Models to Clinical 

Risk Management Strategies of Severe Infectious 

Diseases with Immunomodulatory Drugs 

(Room 151) 


• Insights into Polyaromatic Hydrocarbon-Induced 

Toxicities (Ballroom F) 

• Nanotoxicology—Metals and Metal Oxide 

Particles (Room 251 A) 

• Predicting Hepatotoxicity: Computational 

Approaches to a Critical Target (Room 250) 

2:30 PM–3:30 PM 


A Conversation with the NIEHS Director: 

Linda Birnbaum (Room 251 D) 

3:45 PM–4:45 PM 


A Conversation with the U.S. FDA 

National Center for Toxicological Research: 

William Slikker, Jr. (Room 251 D) 

4:30 PM–5:50 PM 

ROunDTABLE SESSIOn 

• Overview of Current Regulatory Expectations 

for Oligonucleotide-Based Therapeutics: Case 

Studies for Different Classes of ODNs 

(Room 150) 


• Seeking Funding for Undergraduate Research 

(Ballroom D) 






start time. 



7:00 AM to 1:00 PM 



7:00 AM to 11:30 AM 

SOT Office 

CC Room 254 B 

7:00 AM to 11:30 AM 


CC Room 252 

7:30 AM–8:50 AM 

ISSuES SESSIOn 

National Academy of Sciences Vision for 

Toxicity Testing in the 21 st Century (Ballroom I) 

8:30 AM–12:00 nOOn 


(Exhibit Hall E—See Poster Board Surface Maps on 

Pages 33–37) 

• Drug-Induced Liver Injury 

• Endocrine Toxicology 

• Immune System Safety Evaluation/ 

Developmental Immunotoxicology 

• Juvenile Toxicity 

• Metals II 

• Receptors 

7:30 AM to 12:00 NOON 



7:30 AM to 8:50 AM 

Issues Session: National Academy 

of Science Vision for Toxicity Testing 

in the 21 st Century 

CC Ballroom I 

7:30 AM to 8:50 AM 




8:00 AM to 11:30 AM 



9:00 AM–11:45 AM 


• Blood-Based Genomic Profiles As Biomarkers of 

Exposure and Effect (Ballroom I) 

• Humanized Models in Toxicology and Their 

Application to Hazard Characterization and Risk 

Assessment (Ballroom F) 

• Systems Biology Approaches to Understanding 

Cell Signaling in Dermal and Ocular Toxicology 

(Ballroom B) 

• Toxicological Challenges in Green Product 

Development (Ballroom D) 




Thursday March 11 


8:00 AM to 11:30 AM 



8:00 AM to 8:30 AM 




8:00 AM to 11:30 AM 

Registration 


8:00 AM to 12:00 NOON 

ToxExpo Tear Down 


8:30 AM to 12:00 NOON 



9:00 AM to 11:45 AM 



Locations) 

10:00 AM to 1:00 PM 

Research Funding Committee Meeting 

CC Room 254 A 

12:00 NOON to 1:00 PM 

Scientific Program Committee Meeting 

CC Room 258 

Thursday March 11 

EvEnt CalEndar


Stop by the SOt resource Pavilion toxExpo Booth #1901 

• Obtain Information about SOt Membership 

• Support the SOt Endowment 

• Connect with SOt volunteers 

• learn More about SOt regional Chapters, 

Specialty Sections, and Special Interest Groups 

• Share and discuss Communication tips 

• Select Material about 

animals in research 

K–12 Education 

Public Outreach 

regulatory and legislative Initiatives 

• visit High School research Posters 

The Resource Pavilion is your connection to key resources 

and people in toxicology. 

At the SOT Resource Pavilion find out all you need to know 

about a new on-line SOT member resource … 

YOUr network. 

visit the SOt resource Pavilion, Booth #1901 in the Exhibit Hall… 

and have a photo taken to post as YOUr profile picture. 

learn all about this exciting new SOt member resource and how you can— 

• Create a customized, SOt member profile you can update on-line 24/7 

• Search for and find other SOt members based on their profile information 

• Be found by other SOt members based on YOUr profile information 

• Communicate with YOUr SOt peers with easy-to-use, secure networking tools 




12 



Schedule by Event Name 



Event: Date: Time: Location: Room: 

25-Year (or More) Member Reception (By Invitation Only) Sunday, Mar 7 7:00 PM to 8:00 PM Convention Center Ballroom A 

50 th Year Anniversary SOT Task Force Meeting Tuesday, Mar 9 7:00 AM to 9:00 AM Convention Center Room 260 A 

AACT Distinguished Chinese Toxicologist Lectureship Monday, Mar 8 12:00 to 1:00 PM Convention Center Room 355 D 

Academy of Toxicological Sciences Board Meeting Monday, Mar 8 6:30 AM to 7:30 AM Hilton Executive 

Boardroom 

Academy of Toxicological Sciences Reception Wednesday, Mar 10 8:00 PM to 10:00 PM Hilton Alpine Ballroom 

East 

American Association of Chinese in Toxicology Special Interest 


Monday, Mar 8 6:00 PM to 8:00 PM Hilton Grand 

Ballroom A 

American Board of Toxicology Board of Directors Meeting Saturday, Mar 6 1:00 PM to 6:00 PM Marriott Downtown Deer Valley 3 

American Board of Toxicology Open Mixer Meeting Monday, Mar 8 4:30 PM to 6:00 PM Marriott Downtown Deer Valley 1 

American Board of Veterinary Toxicology Diplomate Meeting Tuesday, Mar 9 6:45 AM to 7:45 AM Marriott Downtown Grand 

Ballroom A 

Annual Business Meeting of the Society of Toxicology 

(SOT Members Only; Full, Associates, Postdoctoral, and 

Student Members Invited) 

Tuesday, Mar 9 4:30 PM to 6:00 PM Convention Center Ballroom A 

Arizona Night Sunday, Mar 7 7:30 PM to 10:00 PM Hilton Topaz 

ASIO Lunch and Learn Program Tuesday, Mar 9 12:00 NOON to 1:30 PM Marriott Downtown Grand 

Ballroom A 

Association of Scientists of Indian Origin in America 


AstraZeneca GRC 2011 Mechanisms of Toxicity Steering 

Group Meeting 

Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 D 

Tuesday, Mar 9 6:30 AM to 8:00 AM Marriott Downtown Grand 

Ballroom I 

Audit Committee Meeting Tuesday, Mar 9 9:00 AM to 10:30 AM Convention Center Boardroom 

Awards Ceremony (All Attendees Welcome) Sunday, Mar 7 5:15 PM to 6:30 PM Convention Center Ballroom J 

Awards Ceremony Music—Performed by Michael Lucarelli, 

Classical Guitarist 

Sunday, Mar 7 4:45 PM to 5:15 PM Convention Center Ballroom J 

Awards Committee Meeting Tuesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 260 B 

Awards Recipients Photographed Sunday, Mar 7 4:00 PM to 5:15 PM Convention Center Ballroom I 

Biological Modeling Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 260 B 

Biotechnology Specialty Section Meeting/Reception Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 355 A 

Board of Publications Meeting Wednesday, Mar 10 4:30 PM to 6:00 PM Convention Center Room 260 B 

Carcinogenesis Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 B 

Carcinogenesis Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 258 

Cardiovascular Toxicology Specialty Section Meeting/Luncheon Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 355 B 

Career Resource and Development Committee Meeting I Sunday, Mar 7 7:30 AM to 9:30 AM Convention Center Room 258 

CDI Reunion (Networking and Dessert—Invited: Anyone involved 

with the SOT Undergraduate Education Program through the years) 

Saturday, Mar 6 8:00 PM to 9:00 PM Convention Center Room 255 C 

Central States Regional Chapter Meeting/Luncheon Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 355 A 

Coat/Luggage Check Sunday, Mar 7 7:00 AM to 8:30 PM Convention Center North Foyer 

Coat/Luggage Check Monday, Mar 8 7:00 AM to 8:30 PM Convention Center North Foyer 

Coat/Luggage Check Tuesday, Mar 9 7:00 AM to 8:00 PM Convention Center North Foyer 

Coat/Luggage Check Wednesday, Mar 10 7:00 AM to 8:00 PM Convention Center North Foyer 

Coat/Luggage Check Thursday, Mar 11 7:00 AM to 1:00 PM Convention Center North Foyer 

Committee on Diversity Initiatives Meeting Wednesday, Mar 10 7:00 AM to 8:30 AM Convention Center Room 258 

Communications Committee Meeting Monday, Mar 8 11:30 AM to 2:30 PM Convention Center Room 258 

EvEnt CalEndar


Schedule by Event Name (Continued) 



Comparative and Veterinary Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 258 

Comparative and Veterinary Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 D 

Complimentary Coffee Monday, Mar 8 9:00 AM to 10:00 AM Convention Center Exhibit Hall 

Complimentary Coffee Tuesday, Mar 9 8:30 AM to 9:30 AM Convention Center Exhibit Hall 

Complimentary Coffee Wednesday, Mar 10 8:30 AM to 9:30 AM Convention Center Exhibit Hall 

Concession Stands Sunday, Mar 7 7:30 AM to 2:30 PM Convention Center Lower and Upper 

Concourses 

Concession Stands Monday, Mar 8 7:30 AM to 9:30 AM Convention Center Lower and Upper 

Concourses 

Concession Stands Monday, Mar 8 9:00 AM to 3:00 PM Convention Center Exhibit Hall 

Concession Stands Tuesday, Mar 9 7:30 AM to 9:30 AM Convention Center Lower and Upper 

Concourses 

Concession Stands Tuesday, Mar 9 8:30 AM to 3:00 PM Convention Center Exhibit Hall 

Concession Stands Wednesday, Mar 10 7:30 AM to 9:30 AM Convention Center Lower and Upper 

Concourses 

Concession Stands Wednesday, Mar 10 8:30 AM to 3:00 PM Convention Center Exhibit Hall 

Concession Stands Thursday, Mar 11 7:30 AM to 12:00 NOON Convention Center Lower and Upper 

Concourses 

Contemporary Concepts in Toxicology Conference Committee Wednesday, Mar 10 7:30 AM to 8:30 AM Convention Center Room 260 A 

Continuing Education Committee Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 258 

Continuing Education Committee Walk-Through Saturday, Mar 6 5:00 PM to 5:45 PM Convention Center Ballroom F 

Continuing Education Luncheon for Speakers, Committee, 

and Student Volunteers (By Invitation Only) 

Sunday, Mar 7 11:45 AM to 1:15 PM Convention Center Ballroom A 

Continuing Education Sunrise Mini-Course (Ticket Required) Sunday, Mar 7 7:00 AM to 7:45 AM Convention Center Lower Concourse 

(See Signage for 


Continuing Education Morning Courses (Ticket Required) Sunday, Mar 7 8:15 AM to 12:00 NOON Convention Center Lower and Upper 

Concourses 



Continuing Education Afternoon Courses (Ticket Required) Sunday, Mar 7 1:15 PM to 5:00 PM Convention Center Lower and Upper 

Concourses 



Council Meeting Saturday, Mar 6 8:00 AM to 1:30 PM Marriott Downtown Solitude 

Council Orientation Meeting Friday, Mar 5 4:00 PM to 7:00 PM Marriott Downtown Deer Valley 2 

Council Orientation Reception/Dinner Friday, Mar 5 7:00 PM to 10:00 PM Marriott Downtown Deer Valley 3 

Dermal Toxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 A 

Dermal Toxicology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 355 A 

Disease Prevention Task Force Meeting Wednesday, Mar 10 8:30 AM to 9:30 AM Convention Center Room 260 A 

Distinguished Toxicology Scholar Award Lecture: 


Lecturer: Harihara M. Mehendale 

Tuesday, Mar 9 12:30 PM to 1:20 PM Convention Center Room 251 A 

Drug Discovery Toxicology Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 355 D 

Education Committee Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 260 B 

E-mail Center/Message Boards Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center North Foyer 

E-mail Center/Message Boards Sunday, Mar 7 7:00 AM to 6:00 PM Convention Center North Foyer 

E-mail Center/Message Boards Monday, Mar 8 7:00 AM to 6:00 PM Convention Center North Foyer 

E-mail Center/Message Boards Tuesday, Mar 9 8:00 AM to 6:00 PM Convention Center North Foyer 

14 








E-mail Center/Message Boards Wednesday, Mar 10 8:00 AM to 6:00 PM Convention Center North Foyer 

E-mail Center/Message Boards Thursday, Mar 11 8:00 AM to 11:30 AM Convention Center North Foyer 

Endowment Fund Board Meeting Sunday, Mar 7 10:00 AM to 12:00 NOON Convention Center Room 254 A 

Ethical, Legal, and Social Issues Specialty Section 


Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 258 

Exhibitor Hosted Session: Accelera Srl Tuesday, Mar 9 9:45 AM to 10:45 AM Convention Center Room 155 C 

Exhibitor Hosted Session: ADMET Group Tuesday, Mar 9 12:15 PM to 1:15 PM Convention Center Room 155 C 

Exhibitor Hosted Session: Analytical Bio-Chemistry Labs, Inc. Monday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 155 F 

Exhibitor Hosted Session: Aperio Tuesday, Mar 9 2:45 PM to 3:45 PM Convention Center Room 155 B 

Exhibitor Hosted Session: Biological Test Center Monday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 155 C 

Exhibitor Hosted Session: CANTEST Ltd. Monday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Charles River Monday, Mar 8 9:15 AM to 10:15 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Charles River Tuesday, Mar 9 8:30 AM to 9:30 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Charles River Wednesday, Mar 10 8:30 AM to 9:30 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Covance Inc. Monday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 155 C 

Exhibitor Hosted Session: Covance Inc. Tuesday, Mar 9 2:45 PM to 3:45 PM Convention Center Room 155 C 

Exhibitor Hosted Session: Data Sciences International Wednesday, Mar 10 12:15 PM to 1:15 PM Convention Center Room 155 C 

Exhibitor Hosted Session: Ellegaard Göttingen Minipigs A/S Tuesday, Mar 9 2:45 PM to 3:45 PM Convention Center Room 155 F 

Exhibitor Hosted Session: emka TECHNOLOGIES Tuesday, Mar 9 1:30 PM to 2:30 PM Convention Center Room 155 F 

Exhibitor Hosted Session: GeneGo, Inc. Tuesday, Mar 9 12:15 PM to 1:15 PM Convention Center Room 155 F 

Exhibitor Hosted Session: Gentronix Limited and Apredica LLC Wednesday, Mar 10 12:15 PM to 1:15 PM Convention Center Room 155 B 

Exhibitor Hosted Session: Huntingdon Life Sciences Monday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 155 B 

Exhibitor Hosted Session: Huntingdon Life Sciences Tuesday, Mar 9 9:45 AM to 10:45 AM Convention Center Room 155 F 

Exhibitor Hosted Session: Huntingdon Life Sciences Wednesday, Mar 10 9:45 AM to 10:45 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Ingenuity Systems Tuesday, Mar 9 11:00 AM to 12:00 NOON Convention Center Room 155 F 

Exhibitor Hosted Session: LAB Research Inc. Monday, Mar 8 2:15 PM to 3:15 PM Convention Center Room 155 F 

Exhibitor Hosted Session: LAB Research Inc. Tuesday, Mar 9 12:15 PM to 1:15 PM Convention Center Room 155 B 

Exhibitor Hosted Session: Metabolon, Inc. Wednesday, Mar 10 1:30 PM to 2:30 PM Convention Center Room 155 B 

Exhibitor Hosted Session: Promega Corporation Tuesday, Mar 9 11:00 AM to 12:00 NOON Convention Center Room 155 B 

Exhibitor Hosted Session: Quertle, LLC Tuesday, Mar 9 1:30 PM to 2:30 PM Convention Center Room 155 C 

Exhibitor Hosted Session: ReachBio LLC Monday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 155 F 

Exhibitor Hosted Session: Research Diets, Inc. Monday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 155 C 

Exhibitor Hosted Session: Roche Applied Science Monday, Mar 8 11:45 AM to 12:45 PM Convention Center Room 155 C 

Exhibitor Hosted Session: Science/AAAS Tuesday, Mar 9 1:30 PM to 2:30 PM Convention Center Room 155 B 

Exhibitor Hosted Session: SkinEthic Laboratories Tuesday, Mar 9 11:00 AM to 12:00 NOON Convention Center Room 155 C 

Exhibitor Hosted Session: SNBL USA, Ltd. Monday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 155 B 

Exhibitor Hosted Session: STEMCELL Technologies Inc. Monday, Mar 8 11:45 AM to 12:45 PM Convention Center Room 155 F 

Exhibitor Hosted Session: Transparent Inc. Tuesday, Mar 9 9:45 AM to 10:45 AM Convention Center Room 155 B 

Exhibitor Hosted Session: Trevigen, Inc. Monday, Mar 8 1:00 PM to 2:00 PM Convention Center Room 155 C 

Exhibitor Hosted Session: TSE Systems Inc. Monday, Mar 8 10:30 AM to 11:30 AM Convention Center Room 155 F 

Exhibitor Liaison Working Group Wednesday, Mar 10 2:00 PM to 4:00 PM Convention Center Room 260 A 

Featured Session: A Conversation with the EPA Office of 

Research and Development Director: Paul Anastas 

Wednesday, Mar 10 1:15 PM to 2:15 PM Convention Center Room 251 D 

EvEnt CalEndar





Featured Session: A Conversation with the NIEHS 


Director: Linda Birnbaum 

Featured Session: A Conversation with the U.S. FDA National Center 

for Toxicological Research: William Slikker, Jr. 


Finance Committee Meeting Wednesday, Mar 10 11:30 AM to 1:30 PM Convention Center Room 259 

Food and Chemical Toxicology Editorial Board Meeting Tuesday, Mar 9 7:00 AM to 8:45 AM Marriott Downtown Grand 

Ballroom B 

Food Safety Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 D 

Food Safety Specialty Section Officers Meeting Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 259 

Global Strategy Task Force Meeting Tuesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 259 

Graduate Fellowship Interviews by Awards Committee Saturday, Mar 6 5:30 PM to 7:00 PM Convention Center Room 259 

Guest/Spouse Hospitality Center Sunday, Mar 7 8:00 AM to 5:00 PM Marriott Downtown Park City 

Guest/Spouse Hospitality Center Monday, Mar 8 8:00 AM to 5:00 PM Marriott Downtown Park City 

Guest/Spouse Hospitality Center Tuesday, Mar 9 8:00 AM to 5:00 PM Marriott Downtown Park City 

Guest/Spouse Hospitality Center Wednesday, Mar 10 8:00 AM to 5:00 PM Marriott Downtown Park City 

Guest/Spouse Hospitality Center Thursday, Mar 11 8:00 AM to 11:30 AM Marriott Downtown Park City 

Gulf Coast and South Central Regional Chapters Joint Mixer Monday, Mar 8 5:00 PM to 7:00 PM Lumpy's Downtown 

Hispanic Organization for Toxicologists Special Interest Group Tuesday, Mar 9 6:30 PM to 8:30 PM Marriott Downtown Brighton 


Hot Zones (Wireless Internet Access) Monday, Mar 8 9:00 AM to 4:30 PM Convention Center Exhibit Hall 

Hot Zones (Wireless Internet Access) Tuesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Hot Zones (Wireless Internet Access) Wednesday, Mar 10 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

Housing Desk Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center South Foyer 

Housing Desk Sunday, Mar 7 8:00 AM to 5:00 PM Convention Center South Foyer 

Housing Desk Monday, Mar 8 7:00 AM to 5:00 PM Convention Center South Foyer 

Housing Desk Tuesday, Mar 9 8:00 AM to 4:00 PM Convention Center South Foyer 

Housing Desk Wednesday, Mar 10 8:00 AM to 4:00 PM Convention Center South Foyer 

ILSI-HESI Seminar: Human Pluripotent Stem Cells— 

Prof. James Thomson, University of Wisconsin 

Immunotoxicology Specialty Section Meeting/Reception 

25 th Anniversary Celebration 

Tuesday, Mar 9 12:00 NOON to 1:30 PM Marriott Downtown Grand 

Ballroom D 

Tuesday, Mar 9 6:00 PM to 8:00 PM Convention Center Room 355 E 

Immunotoxicology Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Marriott Downtown Elevations 

Restaurant 

In Vitro and Alternative Methods Specialty Section Meeting/ 

Luncheon 

Tuesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 255C 

In Vitro and Alternative Methods Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 260 B 

In Vitro Toxicology Lecture and Luncheon for Students 


Monday, Mar 8 12:00 NOON to 1:20 PM Convention Center Room 255 E 

Inhalation and Respiratory Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 255 B 

Inhalation and Respiratory Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:00 AM Convention Center Room 255 B 

International Neurotoxicology Association Business Meeting Wednesday, Mar 10 5:00 PM to 6:00 PM Marriott Downtown Grand 

Ballroom A 

Issues Session: National Academy of Sciences Vision for Toxicity 

Testing in the 21 st Century 

Thursday, Mar 11 7:30 AM to 8:50 AM Convention Center Ballroom I 

IUTOX Meetings Saturday, Mar 6 8:00 AM to 5:00 PM Shilo Inn Wasatch and Alta 

IUTOX Meetings Saturday, Mar 6 8:00 AM to 5:00 PM Shilo Inn Wasatch and Alta 

IUTOX Meetings Monday, Mar 8 8:00 AM to 5:00 PM Shilo Inn Wasatch and Alta 

IUTOX Executive Committee Dinner Sunday, Mar 7 8:00 PM to 10:00 PM J. Wong’s Restaurant 

16 








Job Bank Center Sunday, Mar 7 10:00 AM to 4:30 PM Convention Center Room 155 A&D 

Job Bank Center Monday, Mar 8 9:00 AM to 4:30 PM Convention Center Room 155 A&D 

Job Bank Center Tuesday, Mar 9 8:30 AM to 4:30 PM Convention Center Room 155 A&D 

Job Bank Center Wednesday, Mar 10 8:30 AM to 4:30 PM Convention Center Room 155 A&D 

Johnson & Johnson Toxicology Interest Group Meeting Saturday, Mar 6 11:30 AM to 6:00 PM Marriott Downtown Deer Valley 1 

Kettering Reception—University of Cincinnati Tuesday, Mar 9 6:30 PM to 8:00 PM Marriott Downtown Solitude 

Keynote Medical Research Council (MRC) Lecture: The Interplay 

between Phosphorylation and Ubiquitination in Regulating the Innate 

Immune System—Lecturer: Sir Philip Cohen 

Korean Toxicologists Association in America Special Interest Group 


Leading Edge in Basic Science Award Lecture: Toxicogenomics at 

NIEHS: How Genomics Is Impacting the Science of Toxicology— 

Lecturer: Richard S. Paules 

Wednesday, Mar 10 8:00 AM to 9:00 AM Convention Center Ballroom A 

Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 260 

Monday, Mar 8 12:30 PM to 1:20 PM Convention Center Room 251 A 

Lovelace Respiratory Research Institute Reception Sunday, Mar 7 7:30 PM to 10:30 PM Marriott Downtown Grand 

Ballroom A 

Mechanisms Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 255 E 

Mechanisms Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 E 

Medical Device Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 258 

Medical Device Specialty Section Officers Meeting Monday, Mar 8 6:30 AM to 8:00 AM Convention Center Room 255 F 

Membership Committee Meeting Wednesday, Mar 10 11:30 AM to 1:00 PM Convention Center Room 258 

Merit Award Lecture: Living with Passion—Opening Doors in 

Research, Teaching, and Service—Lecturer: Marion Ehrich 

Wednesday, Mar 10 12:30 PM to 1:20 PM Convention Center Room 251 A 

Metals Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 C 

Metals Specialty Section Officers Meeting Monday, Mar 8 6:30 AM to 8:00 AM Convention Center Room 255 D 

Michigan Regional Chapter Happy Hour Wednesday, Mar 10 5:00 PM to 6:30 PM TBD 

Michigan State University Environmental Toxicology Reception Tuesday, Mar 9 9:00 PM to 11:00 PM Marriott Downtown Grand 

Ballroom G 

Mid-Atlantic Regional Chapter Luncheon 


Monday, Mar 8 12:00 NOON to 1:30 PM Tucanos Restaurant 

Mixtures Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 259 

Mixtures Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 F 

Molecular Biology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 B 

Molecular Biology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 355 D 

Mountain West and Southern California Regional Chapters 

Joint Reception 

Monday, Mar 8 5:00 PM to 7:00 PM Squatters Pub 

Brewery 

MPI RESEARCH: Molecular Imaging in Preclinical Research Monday, Mar 8 5:00 PM to 7:00 PM Marriott Downtown Brighton 

MPI RESEARCH: Non-Invasive Assays in Ophthalmic Toxicology Monday, Mar 8 7:00 AM to 8:00 AM Marriott Downtown Deer Valley 1 

Nanotoxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 E 

Nanotoxicology Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 355 A 

National Capital Area Regional Chapter Reception TBD TBD Red Rock Brewing 

Company 

Neurotoxicology Specialty Section Meeting/Reception Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 255 E 

Neurotoxicology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 254 A 

NIH Brown Bag Lunch Tuesday, Mar 9 12:00 NOON to 1:15 PM Convention Center Room 255 B 

NIH Resource Room (All Attendees Welcome) Tuesday, Mar 9 9:00 AM to 4:30 PM Convention Center Room 254 A 

NIH Resource Room (All Attendees Welcome) Wednesday, Mar 10 9:00 AM to 4:30 PM Convention Center Room 254 A 

EvEnt CalEndar



Northeast Regional Chapter Student and Poster Travel Award 

Luncheon 



Monday, Mar 8 12:00 NOON to 1:30 PM Marriott Downtown Brighton 

Northern California Regional Chapter Reception Tuesday, Mar 9 6:00 PM to 9:00 PM Squatters Pub 

Brewery 

North Carolina State University Alumni Reception Monday, Mar 8 7:30 PM to 9:00 PM Marriott Downtown Deer Valley 2 

Occupational and Public Health Specialty Section Meeting/Luncheon Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 255 B 

Ocular Toxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 259 

Pacific Northwest Regional Chapter Reception Monday, Mar 8 5:00 PM to 8:00 PM Squatters Pub 

Brewery 

Past Presidents Breakfast Monday, Mar 8 6:30 AM to 8:00 AM Convention Center Boardroom 

Plenary Opening Lecture: Discovery of Nitric Oxide and Cyclic 

GMP Cell Signaling and Their Role in Drug Development 

Lecturer: Nobel Laureate Ferid Murad 

Monday, Mar 8 8:00 AM to 9:00 AM Convention Center Exhibit Hall E 

Postdoctoral Assembly Board Meeting Monday, Mar 8 6:45 AM to 7:45 AM Convention Center Room 259 

Postdoctoral Assembly Luncheon (Ticket Required) Tuesday, Mar 9 12:00 NOON to 1:15 PM Convention Center Room 255 E 

Poster Sessions Monday, Mar 8 9:30 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Monday, Mar 8 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 9 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Tuesday, Mar 9 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 10 9:00 AM to 12:30 PM Convention Center Exhibit Hall 

Poster Sessions Wednesday, Mar 10 1:00 PM to 4:30 PM Convention Center Exhibit Hall 

Poster Sessions Thursday, Mar 11 8:30 AM to 12:00 NOON Convention Center Exhibit Hall E 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Monday, Mar 8 7:30 AM to 9:30 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Monday, Mar 8 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Tuesday, Mar 9 8:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Tuesday, Mar 9 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Wednesday, Mar 10 8:30 AM to 9:00 AM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Wednesday, Mar 10 12:30 PM to 1:00 PM Convention Center Exhibit Hall 

Poster Set Up (See Poster Board Surface Maps on Pages 33–37) Thursday, Mar 11 8:00 AM to 8:30 AM Convention Center Exhibit Hall E 

President’s Reception (By Invitation Only) Wednesday, Mar 10 7:00 PM to 8:30 PM Hilton Grand Ballroom 

Professional Needs Assessment Task Force Meeting Wednesday, Mar 10 12:00 NOON to 1:30 PM Convention Center Room 260 B 

Regional Chapter Governance Committee Wednesday, Mar 10 12:00 NOON to 1:30 PM Convention Center Room 260 A 

Regional Chapter Presidents and Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 A 

Regional Chapter/Special Interest Group 

Graduate Committee Meeting 

Monday, Mar 8 7:00 AM to 8:30 AM Convention Center Room 255 A 

Registration Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center South Foyer 

Registration Sunday, Mar 7 7:00 AM to 8:00 PM Convention Center South Foyer 

Registration Monday, Mar 8 7:00 AM to 5:00 PM Convention Center South Foyer 

Registration Tuesday, Mar 9 8:00 AM to 4:00 PM Convention Center South Foyer 

Registration Wednesday, Mar 10 8:00 AM to 4:00 PM Convention Center South Foyer 

Registration Thursday, Mar 11 8:00 AM to 11:30 AM Convention Center South Foyer 

Regulatory and Safety Evaluation Specialty Section 


Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 355 B 

Regulatory and Safety Evaluation Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 355 B 

Reproductive and Developmental Toxicology Specialty Section Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 255 B 


18 








Reproductive and Developmental Toxicology Specialty Section 


Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 C 

Research Funding Committee Meeting Thursday, Mar 11 10:00 AM to 1:00 PM Convention Center Room 254 A 

Risk Assessment Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 E 

Risk Assessment Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 355 E 

Roundtable of Toxicology Consultants Business Meeting/Reception Monday, Mar 8 4:30 PM to 6:30 PM Hilton Canyons C 

Rutgers University Joint Graduate Program in Toxicology Annual 

Dessert Reception 

Tuesday, Mar 9 9:00 PM to 11:00 PM Marriott Downtown Deer Valley 1 

Scientific Liaison Task Force Meeting Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 260 A 

Scientific Program Committee Meeting Thursday, Mar 11 12:00 NOON to 1:00 PM Convention Center Room 258 

Scientific Program Committee Walk-Through Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Ballroom J 

Scientific Sessions Monday, Mar 8 9:15 AM to 12:00 NOON Convention Center (See Program 

Description for 


Scientific Sessions Monday, Mar 8 12:10 PM to 1:30 PM Convention Center (See Program 



Scientific Sessions Monday, Mar 8 1:40 PM to 4:25 PM Convention Center (See Program 



Scientific Sessions (Sunset) Monday, Mar 8 4:35 PM to 5:55 PM Convention Center (See Program 



Scientific Sessions (Sunrise) Tuesday, Mar 9 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Tuesday, Mar 9 9:00 AM to 11:45 AM Convention Center (See Program 



Scientific Sessions Tuesday, Mar 9 12:00 NOON to 1:20 PM Convention Center (See Program 



Scientific Sessions Tuesday, Mar 9 1:30 PM to 4:15 PM Convention Center (See Program 



Scientific Sessions (Sunrise) Wednesday, Mar 10 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 10 9:00 AM to 11:45 AM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 10 12:00 NOON to 1:20 PM Convention Center (See Program 



Scientific Sessions Wednesday, Mar 10 1:30 PM to 4:15 PM Convention Center (See Program 



Scientific Sessions (Sunset) Wednesday, Mar 10 4:35 PM to 5:50 PM Convention Center (See Program 



Scientific Sessions (Sunrise) Thursday, Mar 11 7:30 AM to 8:50 AM Convention Center (See Program 



Scientific Sessions Thursday, Mar 11 9:00 AM to 11:45 AM Convention Center (See Program 



EvEnt CalEndar





SOT Committee/Task Force Chair Orientation Sunday, Mar 7 1:00 PM to 3:00 PM Convention Center Room 255 A 

SOT Office Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center Room 254 B 

SOT Office Sunday, Mar 7 7:00 AM to 5:30 PM Convention Center Room 254 B 

SOT Office Monday, Mar 8 7:00 AM to 5:00 PM Convention Center Room 254 B 

SOT Office Tuesday, Mar 9 7:00 AM to 4:30 PM Convention Center Room 254 B 

SOT Office Wednesday, Mar 10 7:00 AM to 4:30 PM Convention Center Room 254 B 

SOT Office Thursday, Mar 11 7:00 AM to 11:30 AM Convention Center Room 254 B 

SOT Resource Pavilion, Booth 1901 Monday, Mar 8 9:00 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 1901 

SOT Resource Pavilion, Booth 1901 Tuesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 1901 

SOT Resource Pavilion, Booth 1901 Wednesday, Mar 10 8:30 AM to 4:30 PM Convention Center Exhibit Hall, 

Booth 1901 

SOT/Eurotox Debate: Threshold of Toxicological Concern (TTC): 

Is It Based on Science or Politics? 

Monday, Mar 8 4:35 PM to 5:55 PM Convention Center Ballroom A 

Southeastern Regional Chapter Business Meeting Monday, Mar 8 7:00 AM to 8:00 AM Marriott Downtown Cottonwood 

Southeastern Regional Chapter Reception Monday, Mar 8 6:00 PM to 7:30 PM Hilton Canyons B 

Speaker Ready Room Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center Room 252 

Speaker Ready Room Sunday, Mar 7 7:00 AM to 5:30 PM Convention Center Room 252 

Speaker Ready Room Monday, Mar 8 7:00 AM to 5:00 PM Convention Center Room 252 

Speaker Ready Room Tuesday, Mar 9 7:00 AM to 4:30 PM Convention Center Room 252 

Speaker Ready Room Wednesday, Mar 10 7:00 AM to 4:30 PM Convention Center Room 252 

Speaker Ready Room Thursday, Mar 11 7:00 AM to 11:30 AM Convention Center Room 252 

Special Interest Group Presidents and Officers Meeting Monday, Mar 8 12:00 NOON to 1:00 PM Convention Center Room 255 A 

Specialty Section Graduate Committee Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 259 

Specialty Section Presidents and Officers Meeting Monday, Mar 8 4:30 PM to 6:00 PM Convention Center Room 255 A 

St. John’s University 8 th Annual Toxicology Alumni Dinner Monday, Mar 8 6:00 PM to 8:00 PM Hilton Topaz 

Student Advisory Council Business Meeting Wednesday, Mar 10 7:00 AM to 8:00 AM Convention Center Room 255 A 

Student/Postdoctoral Fellow Mixer (Ticket Required) Sunday, Mar 7 7:30 PM to 8:30 PM Convention Center Room 355 

Tour Desk Saturday, Mar 6 4:00 PM to 7:00 PM Convention Center South Foyer 

Tour Desk Sunday, Mar 7 8:00 AM to 4:00 PM Convention Center South Foyer 

Tour Desk Monday, Mar 8 8:00 AM to 4:00 PM Convention Center South Foyer 

Tour Desk Tuesday, Mar 9 8:00 AM to 4:00 PM Convention Center South Foyer 

Tour Desk Wednesday, Mar 10 8:00 AM to 2:00 PM Convention Center South Foyer 

ToxExpo 2011 Exhibit Space Selection Meeting Tuesday, Mar 9 4:45 PM to 6:00 PM Convention Center Room 155 B 

ToxExpo Exhibits Open Monday, Mar 8 9:00 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Tuesday, Mar 9 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Exhibits Open Wednesday, Mar 10 8:30 AM to 4:30 PM Convention Center Exhibit Hall 

ToxExpo Set Up Saturday, Mar 6 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

ToxExpo Set Up Sunday, Mar 7 8:00 AM to 5:00 PM Convention Center Exhibit Hall 

ToxExpo Tear Down Wednesday, Mar 10 4:45 PM to 

12:00 MIDNIGHT 

20 

Convention Center 

Exhibit Hall 

ToxExpo Tear Down Thursday, Mar 11 8:00 AM to 12:00 NOON Convention Center Exhibit Hall 

Toxicologic and Exploratory Pathology Specialty Section Meeting/ 

Luncheon 

Wednesday, Mar 10 12:00 NOON to 1:30 PM Convention Center Room 255 E 





Toxicologic and Exploratory Pathology Specialty Section 


Toxicological Sciences/Oxford Journals Appreciation Dinner 






Monday, Mar 8 7:00 PM to 9:00 PM Hotel Monaco Bombay 

Toxicological Sciences Associate Editors Meeting Sunday, Mar 7 12:00 NOON to 3:30 PM Marriott Downtown Solitude 

Toxicological Sciences Focus Group A (By Invitation Only) Wednesday, Mar 10 12:30 PM to 1:25 PM Convention Center Room 257 B 

Toxicological Sciences Focus Group B (By Invitation Only) Wednesday, Mar 10 3:15 PM to 4:15 PM Convention Center Room 257 B 

Toxicologists of African Origin Special Interest Group 


Monday, Mar 8 6:00 PM to 8:00 PM Salt Lake Plaza Hotel Salt Room 

Toxicology and Applied Pharmacology Associate Editors Meeting Monday, Mar 8 12:00 NOON to 1:30 PM Marriott Downtown Deer Valley 1 

Toxicology and Applied Pharmacology 50 th Anniversary Reception Monday, Mar 8 5:00 PM to 7:00 PM Marriott City Center Capitol 

Ballroom A 

Toxicology Editorial Board Meeting Wednesday, Mar 10 11:45 AM to 1:30 PM Marriott Downtown Deer Valley 1 

Toxicology Education Foundation Board Meeting Sunday, Mar 7 8:00 AM to 12:00 NOON Marriott Downtown Cottonwood 

Toxicology In Vitro Editorial Board Meeting Wednesday, Mar 10 7:00 AM to 8:45 AM Marriott Downtown Deer Valley 1 

Toxicology Letters Editorial Board Meeting Tuesday, Mar 9 11:45 AM to 1:30 PM Marriott Downtown Deer Valley 1 

ToxLearn Work Group Tuesday, Mar 9 10:30 AM to 11:45 AM Convention Center Room 258 

Translational Impact Award Lecture: Translating Mechanism-Based 

Research into Antidotes: Trials, Tribulations, and Triumphs— 

Lecturer: Kenneth E. McMartin 

Undergraduate Education Program: Orientation for SOT Hosts, Peer 

Mentors, and Advisors 

Tuesday, Mar 9 8:00 AM to 8:50 AM Convention Center Room 251 A 

Saturday, Mar 6 4:15 PM to 5:45 PM Convention Center Room 258 

Undergraduate Education Program: Opening Event Saturday, Mar 6 5:45 PM to 9:00 PM Convention Center Room 255 C 

Undergraduate Education Program: Toxicology Lectures Sunday, Mar 7 8:00 AM to 11:30 AM Convention Center Room 255 B 

Undergraduate Education Program: Lunch and Networking 


Undergraduate Education Program—Advisors: Tips for Advising 

Prospective Graduate Students 

Undergraduate Education Program—Students: Planning for 

Graduate School (Concurrent Sessions) 

Sunday, Mar 7 11:30 AM to 12:45 PM Convention Center Room 255 C 

Sunday, Mar 7 12:45 PM to 1:45 PM Convention Center Room 258 

Sunday, Mar 7 12:45 PM to 1:45 PM Convention Center Rooms 259, 

260 A, 260 B 

Undergraduate Education Program: Career Panel Discussion Sunday, Mar 7 2:00 PM to 3:00 PM Convention Center Room 255 C 

Undergraduate Education Program: Host Mentor and Peer Mentoring Sunday, Mar 7 3:00 PM to 3:30 PM Convention Center Room 258 


Undergraduate Education Program: Academic Toxicology Programs 

and Internships 

Sunday, Mar 7 3:00 PM to 5:00 PM Convention Center Room 255 F 

Undergraduate Education Program Monday, Mar 8 7:30 AM to 7:50 AM Convention Center Room 255 C 

Undergraduate Education Program: Poster Session for Visiting 

Students 

Monday, Mar 8 9:30 AM to 10:50 AM Convention Center Exhibit Hall 

Undergraduate Education Program Wrap Up Monday, Mar 8 11:00 AM to 11:50 AM Convention Center Room 255 C 

Undergraduate Faculty Meeting Tuesday, Mar 9 3:30 PM to 4:30 PM Convention Center Room 355 A 

University of Rochester Alumni Reception Tuesday, Mar 9 7:00 PM to 10:00 PM Marriott Downtown Grand 

Ballroom A 

VIP ToxExpo Exhibit Hall Walk-Through Monday, Mar 8 1:30 PM to 2:30 PM Convention Center SOT Resource 

Pavilion 

Exhibit Hall 



Sunday, Mar 7 6:30 PM to 7:30 PM Convention Center Exhibit Hall E 

Women in Toxicology Special Interest Group Meeting/Reception Wednesday, Mar 10 4:30 PM to 6:00 PM Marriott Downtown Grand 

Ballroom D 

EvEnt CalEndar

Upper Mezzanine 

D 

255 

A 


Upper A 

A 

Salt Palace Convention Center Maps 

Concourse 

First Level 

A 

B 

260 

259 

258 

A 

B 

Exhibitor Hosted 

Sessions 

Job Bank 

Center 

257 

F 

E 

D 

155 

C 

B 

A 

254 

C 

B 

D E F 

251 

A B C 

—Escalators/Elevators/Stairs 

ESC 

252 

B 

—Exhibit D EHall 

F 

ESC 

A 

250 

253 

B 

A B C 

—Ballroom and Meeting 

rooms 

—Public areas 

—Parking 

—Concessions 

—restrooms 

MaPS 

To 

Exhibitor 

Hosted 

Sessions 

—loading docks 

Escalators up to 

CE Courses, 

Scientific Sessions, 

(East lobby) 

SOT 

RESOURCE 

PAVILION 

Security 

D E F 

151 G 

ABC 

CE Course 

rooms 

200 West 

ToxExpo 

Exhibition 

EnTRAnCE 

EXHIBIT HALL E 

welcoming Reception 

(Sunday) and 

Plenary Opening 

Lecture (Monday) 

Lower Concourse 

South Foyer 

South 

Entrance 

D E F 

150 G 

ABC 

First 

Aid 

North Foyer 

B 

D 

GRAND 

BALLROOM 

CE Information Booth 

E-mail Center 

Message Boards 


25-Year (or More) 

Member Reception 

A 

C 

CE Course 

rooms 

EF 

GH 


IJ 

South Plaza 

Lunch with an Expert 

Information Board 

registration 

Housing/Tour 

Desk 

Visitors 

Center 

West temple 

P 

SOUTH 

Parking 

Entrance 

Tour Departures 

200 South 

22 

MAIn 

EnTRAnCE 

Hilton Salt lake 

City Center 



Salt Palace Convention Center Maps (Continued) 

Third Level 

South temple 

Specialty Section Events 

Student/Postdoctoral 

Fellow Mixer 

F 

E 

D 

355 

C 

B 

A 

F 

E 

D 

255 

C 

B 

A 


MaPS 

Second Level 

300 West 

F 

E 

D 

West 

Lobby 

355 

C 

B 

A 

A 

to 

B 

West lobby and 260 

West Parking Entrance 

—Escalators/Elevators/Stairs 

—Exhibit Hall 

—Ballroom and Meeting 

rooms 

—Public areas 

—loading docks 

Specialty Section Events 

Exit to the radisson Hotel 

Entrance only with Badge 



259 

258 

A 

B 

257 

F 

E 

D 

F 

E 

D 

—Parking 

255 

200 West 

155 

—Concessions 

—restrooms 

C 

B 

A 

254 

SOT 

Office 

A 

B 

260 

Business 

Center 

C 

B 

A 

Elevator to 


and Exhibitor 

CHosted Sessions 

B(First level) 

A 

CE Information Booth 

259 

252 

B 

Upper A 

Concourse 

ESC 

258 

Boardroom 

ourse 

A 

B 

D E F 

251 

A B C 

D E F 

250 

A B C 

ESC 

A 

253 

151 G 

ABC 

D E F 

150 G 

ABC 

First 

Aid 

257 

Seating Available E 

B 

Speaker Ready 

155Room 

D 

A 

B 

F 

Elevator 

Escalators 

down to Ballroom, 

Scientific Sessions, 

Welcoming reception, 

Exhibit Hall, 

Security 

and 

registration 

(First level) 

D E F 

North Foyer 

C 

254 

West temple 

C 

B 

A 

CE Course rooms 

and Scientific 

Session rooms 

Seating Available 

Marriott 

downtown 

200 South 

East lobby 


Place 

Upper 

Concours 

ESC 

Security 


2 

D 

1 

A 

D 

1 

D 

A 

D 

A 

A 

F 

A


Salt Lake City Hotel Accommodations 

1) Courtyard by Marriott Downtown 

4) Hilton Salt Lake City Center 

7) Little America Hotel 

SOT Co-Headquarters Hotel 

MaPS 

$139 Single/Double 

130 West 400 South 

Salt Lake City, UT 84101 

Tel: (801) 531-6000 

Fax: (801) 531-1273 

Web site: www.marriott.com/slccy 

Club: Marriott Rewards 

Check in: 3:00 PM 

Check out: 12:00 NOON 

2 blocks from Convention Center 

Complimentary self parking 

Complimentary wireless Internet access in 

guest room and throughout hotel 

2) Crystal Inn Downtown 

$163 Single/$178 Double 

255 South West Temple 


Tel: (801) 328-2000 

Fax: (801) 238-4888 

Web site: www.saltlakecitycenter.hilton. 

com 

Club: Hilton HHonors 



½ block from Convention Center 

$13/day self and $16/day valet parking 



5) Hotel Monaco 

$139 Garden/$159 Tower 

500 South Main Street 


Tel: (801) 596-5700 

Fax: (801) 596-5911 

Web site: www.littleamerica.com 

Club: N/A 




Complimentary self parking and $7/day 

valet parking 



8) Marriott City Center 

$102 Government Rate or 




Tel: (801) 328-4466 

Fax: (801) 328-5653 

Web site: www.crystalinnsaltlake.com 




Tel: (801) 595-0000 

Fax: (801) 532-8500 

Web site: www.monaco-saltlakecity.com 


220 South State Street 


Tel: (801) 961-8700 

Fax: (801) 961-8704 

Web site: www.marriott.com/slccc 

Club: N/A 


Check out: 11:00 AM 





Complimentary breakfast 

Complimentary airport shuttle 

Club: Kimpton InTouch Loyalty Members 



1 block from Convention Center 

$15.50/day valet parking 








Complimentary wired Internet access in guest 

room—complimentary wireless Internet 

access in lobby 

3) Grand America 

6) Hyatt Place Salt Lake City 

Downtown 

9) Marriott Downtown 

SOT Headquarters Hotel 


555 South Main Street 


Tel: (801) 258-6000 

Fax: (801) 258-6911 

Web site: www.grandamerica.com 


55 North 400 West 


Tel: (801) 456-6300 

Fax: (801) 456-6301 

Web site: 

www.hyattplacesaltlakecitydowntown.com 




Tel: (801) 531-0800 

Fax: (801) 532-4127 

Web site: www.marriott.com/slcut 

Club: N/A 







Club: Hyatt Gold Passport 




$10/day self parking 







Across the street from Convention Center 


Wired Internet access in guest room at 

$12.95/day—wireless Internet in lobby 

as part of $12.95 

24 



Salt Lake City Hotel Accommodations (Continued) 

10) Radisson Hotel Downtown 

13) Sheraton Salt Lake City Hotel 

Legend: 

$102 Government Rate or 


215 West South Temple 


Tel: (801) 531-7500 

Fax: (801) 328-1289 

Web site: www.radisson.com 




Tel: (801) 401-2000 

Fax: (801) 534-3450 

Web site: www.sheraton.com/saltlakecity 

Valet Parking 

Self Parking 

Fitness Center 

Club: Goldpoints Plus 



1 block from Convention Center 




11) Residence Inn by Marriott City 

Center 

Club: Starwood Preferred Guest 




Complimentary self parking and $10/day 

valet Parking 




14) Shilo Inn Hotel 

Swimming Pool 

Business Center 

In-Room Wireless 

In-Room Safe 

Gift Shop 

MaPS 


285 West Broadway 


Tel: (801) 355-3300 

Fax: (801) 355-0440 

Web site: www.marriott.com/slcri 




Tel: (801) 521-9500 

Fax: (801) 359-6527 

Web site: www.shiloinns.com 

Complimentary Breakfast 

Restaurant 








12) Salt Lake Plaza at Temple 

Square 

Club: Star Rewards 



Across the street from Convention Center 






All hotels have Internet access. 

Hotel sales tax is currently 12.71% 

Internet access and parking pricing 

are subject to change. 

Please note that the discounted room rates 

within the SOT Room Block include a 10% 

commission and $3 room rebate payable to the 

Society to offset the expenses associated with 

the Annual Meeting. 


122 West South Temple 


Tel: (801) 521-0130 

Fax: (801) 322-5057 

Web site: www.plaza-hotel.com 

Club: N/A 


Check out: 11:00 AM 

½ block from Convention Center 

$5/day self parking 




up-to-date information at www.toxicology.org 25


Map of Salt Lake City Hotel Locations 

MaPS 

T HE 

GATEWAY 

Olympic 

Legacy 

Plaza 

6 

Discovery 

Gateway 

Clark 

Planetarium 

Rio Grande Depot 

& Utah State 

Historical Museum 

400 South 

400 West 

Union Pacific 

Depot 

EnergySolutions 

Arena 

100 South 

200 South 

300 South 

PIONEER 

PARK 

300 West 

11 

N 

South Temple 

Holy Trinity 

Greek Orthodox 

Church 

2 

10 

Museum of Church 

History & Art 

Family History 

Library 

Maurice 

Abravanel 

Hall 

200 West 

13 

1 

12 

Salt Lake 

Art Center 

Salt Lake To Go 

Visitor Information 

Center 

Salt Palace 

Convention 

Center 

14 

The Rose Wagner 

Performing Arts 

Center 

TEMPLE SQUARE 

Tabernacle Joseph Smith Memorial 

Building 

9 

4 

LDS Temple 

Future City Creek 

Center Site 

Capitol 

Theatre 

5 

TRAX LIGHT RAIL 

TRAX / UTA Free Fare Zone 

Museum of Utah 

Art History 

Gallivan 

Center 

Beehive 

House 

Lion 

House 

8 

KUTV2 Main Street 

News Studio 

TRAX— University Line 

Salt Lake 

City & County 

Building 

Brigham Young 

Historic Park 

1st Ave. 

First 

Mormon Pioneer 

Presbyterian 

1Memorial Courtyard Monument by Marriott Downtown Church 

South 2 Temple Crystal Inn Downtown 

3 Grand America 

Cathedral 

of the 

Madeleine 

Hilton Salt Lake Cathedral City Center 

4 

Social Hall (SOT Co-Headquarters Church of Hotel) 

Heritage 

St. Mark 

Exhibit 5 Hotel Monaco 

100 South 

6 Hyatt Place Salt Lake City Downtown 

7 Little America Hotel 

8 Marriott City Center 

9 

Marriott Downtown 

(SOT Headquarters Hotel) 

200 South 

10 Radisson Hotel Downtown 

11 Residence Inn by Marriott City Center 

TRAX / UTA Free Fare Zone 

12 Salt Lake Plaza at Temple Square 

13 Sheraton Salt Lake City Hotel 300 South 

14 Shilo Inn Hotel 

WASHINGTON 

SQUARE 

Salt Palace Convention Center 

LIBRARY 

SQUARE 

400 South 

to Foothill Cultural District 

and University of Utah 

500 South 

500 West 

500 South 

TRAX Light Rail Lines 

TRAX Light Rail Stops 

West Temple 

7 

Main St. 

3 

State St. 

200 East 

300 East 

400 East 

TRAX Light Rail/ 

600 South Utah Transit Authority (UTA) 

Free Fare Zone 

(See description on page 58) 

600 South 

700 South 

26 



Hilton Salt Lake City Center Hotel Map 

Second Floor 

Exercise Room 

Grand Ballroom 

C 

M 

W 

Lockers 

M 

Lockers 

W 

Jacuzzi 

Pool 

Sun Deck 

A 

B 

Business 

Center 

MaPS 

East 

Alpine 

Ballroom 

West 

Coatroom 

Topaz 

Elevators 

Seminar 

Theater 

A 

Canyons 

B 

C 

lobby level 

Salon 

II 

Salon 

III 

Executive 

Boardroom 

W 

M 

Salon 

I 

Granite 

Conference Center 

Elevators 

Gift 

Shop 

MW 

lobby 

Main Entrance 

Front Desk 

300 South 

to Convention Center 

West temple 



Marriott Downtown Hotel Map 

MaPS 

SECOND FLOOR MEETING SPACE 

West temple 

MAIN FLOOR MEETING SPACE 

100 South 

to Convention Center 

28 


The Official Journal of the 

Society of Toxicology 

toxicological 

sciences 

Impact Factor 

of 4.443!* 

Ranked in the top 5 most-cited 

journals in Toxicology! 

www.toxsci.oxfordjournals.org 

visit our booth at toxexpo 2010 

for a free sample copy 

*ISI Journal Citation Reports 2008 Edition, published in 2009 



Salt Lake City Restaurant Listings 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

MaPS 

Acme Burger 275 South 200 West (801) 257-5700 L D $$ 

Bambara (Hotel Monaco) 202 South Main Street (801) 363-5454 B L D $$ 

The Bayou 645 South State Street (801) 961-8400 L D $$ 

Beehive Tea Room 12 West Broadway (3 rd South) (801) 328-4700 L $ 

Benihana 165 South West Temple (801) 322-2421 L D $$$ 

Biaggi’s Ristorante Italiano 194 South 400 West (801) 596-7222 L D $$ 

Blue Iguana 165 South West Temple (801) 533-8900 L D $$ 

Buca di Beppo 202 West 300 South (801) 575-6262 L D $$ 

Café Olympus (Red Lion Hotel) 161 West 600 South (801) 521-7373 B L D $$ 

Café Trang 307 West 200 South (801) 539-1638 L D $$ 

Caffe Molise 55 East 100 South (801) 364-8833 L D $$ 

California Pizza Kitchen 156 South 490 West, The Gateway (801) 456-0075 L D $$ 

Cedars of Lebanon 152 East 200 South (801) 364-4096 L D $$ 

Christopher’s Seafood & Steakhouse 110 West Broadway (300 South) (801) 519-8515 L D $$$ 

The Copper Canyon (Radisson Hotel) 215 West South Temple (801) 933-8008 B L D $$$ 

Costa Vida Fresh Mexican Grill 169 South Rio Grande Street (801) 456-8432 L D $ 

Cucina Toscana 307 West Pierpont Avenue (801) 328-3463 D $$$ 

Donovan’s 134 West Pierpont Avenue (801) 359-4464 D $$$ 

Elevations (Marriott Downtown) 75 South West Temple (801) 537-6019 B L D $$ 

Faustina 454 East 300 South (801) 746-4441 L D $ 

Fleming’s Prime Steakhouse 20 South 400 West, The Gateway (801) 355-3704 D $$$ 

The Garden Café (Grand America) 555 South Main Street (801) 258-6708 B L D $ 

The Garden Restaurant 15 East South Temple, 10th Floor (801) 539-3170 L D $$ 

Ginza 209 West 200 South (801) 322-2224 L D $$ 

Gracie’s 326 West Temple (801) 819-7563 L D $ 

Happy Sumo at Gateway 153 South Rio Grand Street (801) 456-7866 L D $ 

Himalayan Kitchen 73 East 400 South (801) 328-2077 L D $$ 

Ichiban Sushi & Japanese 336 South 400 East (801) 532-7522 D $$ 

Iggy’s 300 South 400 West (801) 532-9999 L D $ 

J. Wong’s Asian Bistro 163 West 200 South (801) 350-0888 L D $ 

Jason’s Deli 178 South Rio Grande, Gateway (801) 456-8989 L D $$ 

JB’s Restaurant 102 West South Temple (801) 328-8344 B L D $ 

Krewson’s (Shilo Inn Hotel) 206 South West Temple (801) 521-9500 B L D $ 

Lamb’s Grill 169 South Main Street (801) 364-7166 B L D $$ 

The Last Samurai 214 West 600 South (801) 596-2293 L D $$ 

Les Madeleines 216 East 500 South (801) 355-2294 B L $ 

Lion House 73 East South Temple (801) 539-3257 L D $ 

B=Breakfast, L=Lunch, D=Dinner 

30 



Salt Lake City Restaurant Listings (Continued) 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically (continued) 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

Little America Hotel Coffee Shop 500 South Main Street (801) 596-5700 B L D $$ 

Little America Hotel Steak House 500 South Main Street (801) 596-5700 B L D $$ 

Lumpy’s Downtown 145 West Pierpont Avenue (801) 938-3070 L D $ 

Market Street Grill/Oyster Bar 48 West Market Street (801) 322-4668 L D $$ 

Martine 22 East 100 South (801) 363-9328 L D $$ 

McDonald’s 210 West 500 South (801) 364-1614 B L D $ 

McGrath’s Fish House 190 South 400 West, (801) 456-7890 L D $$ 

The Melting Pot 340 South Main Street (801) 521-6358 D $$$ 

The Metropolitan 173 West Broadway (300 South) (801) 364-3472 L D $$$ 

Naked Fish 67 West 100 South (801) 595-8888 L D $$ 

Navoo Café 15 East South Temple (801) 539-3346 B L D $ 

New Yorker 60 West Market Street (801) 363-0166 L D $$$ 

Oasis 151 South 500 East (801) 322-0404 B L D $$ 

Olio’s (Sheraton City Centre) 150 West 500 South (801) 323-7575 B L D $$ 

Olive Garden 77 West 200 South (801) 537-6202 L D $$ 

One World Everybody Eats 41 South 300 East (801) 519-2002 L D $$ 

P.F. Chang’s 174 West 300 South (801) 539-0500 L D $$ 

Piastra (Marriott City Center) 220 South State Street (801) 961-8700 B L D $$ 

Pier 49 Pizza 238 South Main Street (801) 364-2974 L D $ 

The Plum (Embassy Suites) 110 West 600 South (801) 359-7800 L D $$ 

Red Iguana 736 West North Temple (801) 322-1489 L D $ 

Red Rock Brewing Company 254 South 200 West (801) 521-7446 L D $$ 

Rio Grande Café 270 South Rio Grande (801) 364-3302 L D $$ 

Romano’s Macaroni Grill 110 West 300 South (801) 521-3133 L D $ 

The Roof Restaurant 15 East South Temple, 10 th Floor (801) 539-1911 D $$$ 

Royal Eatery 379 South Main Street (801) 532-4301 B L $ 

Sage’s Café 473 East Broadway (300 South) (801) 322-3790 B L D $$ 

Sandbar & Grill 122 West Pierpont Avenue (801) 819-7575 L D $ 

Settebello Pizzeria Napoletana 260 South 200 West (801) 322-3556 L D $$ 

Siegfried’s Delicatessen 20 West 200 South (801) 355-3891 L D $ 

SkyBox 4 South Rio Grand Street (801) 456-1200 L D $$ 

Spencer’s (Hilton Hotel) 255 South West Temple (801) 238-4748 L D $$$ 

Squatters Pub Brewery 147 West Broadway (801) 363-2739 L D $ 

Star of India 55 East 400 South (801) 363-7555 L D $$ 

Takashi 18 West Market Street (801) 519-9595 L D $$ 

Thaifoon 7 North 400 West (801) 456-8424 L D $$ 

Thai Lotus 212 East 500 South (801) 328-4401 L D $$ 


MaPS 



Salt Lake City Restaurant Listings (Continued) 

Restaurants within Seven Blocks of the Convention Center, Listed Alphabetically 

$ = Under $12 $$ = $12–$18 $$$ = $18-$30 $$$$ = over $30 

MaPS 

The Tin Angel Café 365 West 400 South (801) 328-4155 L D $$ 

Tipica 314 West 300 South (801) 328-0222 D $$ 

Toaster’s 151 West 200 South (801) 328-2928 B L $ 

Tony Caputo’s 308 West Broadway (801) 531-8669 L $ 

Trofi (Hilton Hotel) 255 South West Temple (801) 238-4877 B $ 

Tucanos Brazilian Grill 162 South 400 West (801) 456-2550 L D $$ 

Vienna Bistro 132 South Main Street (801) 322-0334 L D $$ 

Vosen’s Bread Paradise 249 West 200 South (801) 322-2424 B $ 

ZTejas 191 South Rio Grand (801) 456-0450 L D $$ 


L’Astelier 

Raw Bean 

Salt Lake Roasting Company 

Starbucks Marriott Downtown 

Starbucks Marriott City Center 

Starbucks Sheraton SLC Hotel 

Toasters 



320 East 4th South 

75 S. West Temple 

220 S. Main Street 



Coffee Nearby 

Dairy Queen 

Edo Japan 

Hot Dog on a Stick 

McDonald’s 

Orange Julius 

Food Court—Gateway—3 Blocks from SPCC 

Panda Express 

Sbarro 

Subway 

Taco Time 

Mall open Sunday 12:00 nOOn–6:00 PM 

32 



Poster Session Schedule and Board Surface Maps 

Monday Morning, March 8—9:30 aM to 12:30 PM—Exhibit Hall—Poster Set Up 7:30 aM to 9:30 aM 

SESSIOn TITLE ABSTRACT nuMBERS POSTER BOARD nuMBERS 

Toxicity Testing—Alternative Models I 85–118 101–134 

Carcinogenesis I 119–144 201–226 

Epigenetics 145–154 231–240 

*Late Breaking Abstracts TBD 243–248 and 301–318 

Neurodevelopmental Toxicity: General 155–184 319–348 

Screening and Predicting Toxicity: Computational Approaches to Identify Targets 185–125 401–431 


Mechanistic Aspects of Persistent Organic Chemical Toxicity 216–241 513–538 

Investigations of Chemical Mixtures 242–254 543–548 and 601–607 

Nanotoxicology I 255–292 611–648 

Hypersensitivity, Autoimmunity, and Idiosyncratic Drug Reactions 293–317 701–725 

Visiting Student Poster Session By InvITATIOn OnLy 801–830 

MaPS 

Monday afternoon, March 8—1:00 PM to 4:30 PM—Exhibit Hall—Poster Set Up 12:30 PM to 1:00 PM 


Chemical and Biological Weapons 321–354 101–134 

*Late Breaking Abstracts TBD 201–224 

Genetic Diversity and Response to Xenobiotics 355–366 225–236 

Nanotoxicology II 367–375 237–245 

Reproductive Toxicology 376–422 302–348 


Environmental Impact of Xenobiotics 423–441 425–443 


Biotransformation I 442–459 525–542 

Toxicity Testing—Alternative Models II 460–492 601–633 

Advances in Dermal Toxicology 493–505 701–713 

Carcinogenesis II 506–535 801–830 

*All accepted Late Breaking and Grace Period Abstracts will be available on-line through the Itinerary Planner. 

However, a printed supplemental list of the abstract titles will be available on-site in the Registration area. 

Photography in the Exhibit Hall is prohibited without the consent of exhibitors or poster presenter(s)/authors(s). 

Please respect your colleagues’ right to privacy. 



Poster Session Schedule and Board Surface Maps (Continued) 

tuesday Morning, March 9—9:00 aM to 12:30 PM—Exhibit Hall—Poster Set Up 8:30 aM to 9:00 aM 

MaPS 


Mutagenicity 688–701 101–114 

DNA Damage and Repair 702–718 120–136 

Pharmaceutical Toxicology I 719–729 201–211 

Inflammation and the Pathogenesis of Toxicity 730–761 217–248 

Oxidative Injury and Redox Biology 762–787 301–326 

Nanotoxicology—Carbon Nanostructures 788–805 331–348 

Kidney I 806–828 401–423 

Developmental Toxicology 829–867 425–448 and 501–515 

Biological Modeling: Multiple Scales of Parameters, Structures, and Applications 868–902 519–548 and 601–605 

Animal Models—Emerging Methods 903–940 607–644 

Education 941–944 645–648 

Arsenic I 945–974 701–730 

Metal Neurotoxicity: General 975–1002 801–828 

tuesday afternoon, March 9—1:00 PM to 4:30 PM—Exhibit Hall—Poster Set Up 12:30 PM to 1:00 PM 


Risk Assessment I: New Data and Derivations across Chemicals from A to V 1006–1041 101–136 

Pharmaceutical Toxicology II 1042–1085 201–244 

Biotransformation II 1086–1105 301–320 

Genotoxicity 1106–1130 324–348 

Safety Concerns of Food and Natural Products 1131–1167 401–437 

Safety Assessment: Commercial and Consumer Products 1168–1193 440–448 and 501–517 

Ah Receptor Biology and Toxicology 1194–1210 519–535 

Apoptosis/Cell Death 1211–1229 537–548 and 601–607 

Neurotoxicity of Pesticides 1230–1264 610–644 

Neurodegenerative Disease 1265–1297 645–648 and 701–729 

Biomarkers 1298–1331 731–748 and 801–828 



34 




Wednesday Morning, March 10—9:00 aM to 12:30 PM—Exhibit Hall—Poster Set Up 8:30 aM to 9:00 aM 


Inhalation Toxicology 1490–1524 101–135 

Immunotoxicology: Mechanisms 1525–1562 201–238 

Studies in Pharmacokinetics and Disposition 1563–1599 243–248 and 301–331 

Neurodevelopmental Toxicity of Metals 1600–1615 333–348 

Hepatotoxicity: Role of Bile Acid Metabolism and Homeostasis 1616–1624 401–409 

Causes and Progression of Hepatic Metabolic Dysfunction 1625–1636 413–424 

Toxicogenomics—Continuing Advances in Molecular Toxicology 1637–1662 425–448 and 501–502 

Signal Transduction 1663–1677 507–521 

Stem Cell Toxicology 1678–1691 525–538 

Nanotoxicology—Gold or Silver Nanoparticles 1692–1707 543–548 and 601–610 

Gene Regulation 1708–1720 613–625 


MaPS 

Wednesday afternoon, March 10—1:00 PM to 4:30 PM—Exhibit Hall—Poster Set Up 12:30 PM to 1:00 PM 


Cardiovascular Toxicology 1724–1757 101–134 

Beneficial Effects of Natural Products 1758–1786 201–229 

Regulations and Policy in Toxicology 1787–1810 231–248 and 301–306 

Metals I 1811–1845 314–348 

Exposure Assessment and Emerging Biomonitoring Applications 1846–1886 401–441 

Pesticides: General 1887–1905 443–448 and 501–513 

Risk Assessment II: Methodological Challenges and Metals 1906–1947 516–548 and 601–609 

Models and Mechanisms of Hepatotoxicity 1948–1969 613–634 

Fetal Basis of Adult Disease 1970–1977 637–644 

Immunotoxicology: Methods and Models 1978–1997 701–720 

Carcinogenesis: Breast and Reproductive 1998–2009 725–736 


thursday Morning, March 11—8:30 aM to 12:00 nOOn—Exhibit Hall E—Poster Set Up 8:00 aM to 8:30 aM 


Endocrine Toxicology 2084–2113 101–130 

Juvenile Toxicity 2114–2121 133–140 

*Grace Period Abstracts TBD 201–220 

Drug-Induced Liver Injury 2122–2139 221–238 

Receptors 2140–2157 321–338 

*Grace Period Abstracts TBD 401–420 

Metals II 2158–2178 421–440 and 501 

Immune System Safety Evaluation/Developmental Immunotoxicology 2179–2197 506–524 

*Grace Period Abstracts TBD 531–540 and 601–640 

*All accepted Late Breaking and Grace Period Abstracts will be available on-line through the Itinerary Planner. 

However, a printed supplemental list of the abstract titles will be available on-site in the Registration area. 






Monday, March 8–wednesday, March 10—Exhibit Hall—First Level 

MOndaY 

Morning, March 8—9:30 aM to 12:30 PM—Poster Set Up—7:30 aM to 9:30 aM 

afternoon, March 8—1:00 PM to 4:30 PM—Poster Set Up—12:30 PM to 1:00 PM 

MaPS 

tUESdaY 



WEdnESdaY 



100’s 200’s 

300’s 

101–112 113–124 125–136 201–212 213–224 225–236 237–248 301–312 313–334 325–336 337–348 

106 107 118 119 130 131 206 207 218 219 230 231 242 243 306 307 318 319 330 331 342 343 

105 108 117 120 129 132 205 208 217 220 229 232 241 244 305 308 317 320 329 332 341 344 

104 109 116 121 128 133 204 209 216 221 228 233 240 245 304 309 316 321 328 333 340 345 

103 110 115 122 127 134 203 210 215 222 227 234 239 246 303 310 315 322 327 334 339 346 

102 111 114 123 126 135 202 211 214 223 226 235 238 247 302 311 314 323 326 335 338 347 

101 112 113 124 125 136 201 212 213 224 225 236 237 248 301 312 313 324 325 336 337 348 

400’s 

401–412 413–424 425–436 437–448 

501–512 5 

406 407 418 419 430 431 442 443 506 507 5 

405 408 417 420 429 432 441 444 505 508 5 

404 409 416 421 428 433 440 445 504 509 5 

403 410 415 422 427 434 439 446 503 510 5 

402 411 414 423 426 435 438 447 502 511 5 

401 412 413 424 425 436 437 448 501 512 5 

Thursday, March 11—Exhibit Hall E—First Level 

tHUrSdaY 

Morning, March 11—8:30 aM to 12:00 nOOn—Poster Set Up—8:00 aM to 8:30 aM 

100’s 

200’s 

300’s 

400’s 

500’s 

600’s 

101–120 121–140 201–220 221–240 301–320 321–340 401–420 421–440 501–520 521–540 601–620 621–640 

110 111 130 131 210 211 230 231 310 311 330 331 410 411 430 431 510 511 530 531 610 611 630 631 

109 112 129 132 209 212 229 232 309 312 329 332 409 412 429 432 509 512 529 532 609 612 629 632 

108 113 128 133 208 213 228 233 308 313 328 333 408 413 428 433 508 513 528 533 608 613 628 633 

107 114 127 134 207 214 227 234 307 314 327 334 407 414 427 434 507 514 527 534 607 614 627 634 

106 115 126 135 206 215 226 235 306 315 326 335 406 415 426 435 506 515 526 535 606 615 626 635 

105 116 125 136 205 216 225 236 305 316 325 336 405 416 425 436 505 516 525 536 605 616 625 636 

104 117 124 137 204 217 224 237 304 317 324 337 404 417 424 437 504 517 524 537 604 617 624 637 

103 118 123 138 203 218 223 238 303 318 323 338 403 418 423 438 503 518 523 538 603 618 623 638 

102 119 122 139 202 219 222 239 302 319 322 339 402 419 422 439 502 519 522 539 602 619 622 639 

101 120 121 140 201 220 221 240 301 320 321 340 401 420 421 440 501 520 521 540 601 620 621 640 

36 




Photography in the Exhibit Hall is prohibited without the consent 

of exhibitors or poster presenter(s)/authors(s). Please respect 

your colleagues’ right to privacy. 

The numbers listed refer to the poster location that does not change 

throughout the week. Presenters ONLY should display posters on 

the date and time communicated in your acceptance notice. A list of 

poster session dates and times with abstract numbers can be found on 

pages 33–35. The ToxExpo Exhibit floor plan with a mock layout of 

the Poster Board Surface Maps can be found on pages 40–41 to assist 

you in finding poster sessions. 

MaPS 

15' aisle space indicated here. 

500’s 600’s 

436 437–448 501–512 513–524 525–536 537–548 601–612 613–624 625–636 637–648 

431 442 443 506 507 518 519 530 531 542 543 606 607 618 619 630 631 642 643 

432 441 444 505 508 517 520 529 532 541 544 605 608 617 620 629 632 641 644 

433 440 445 504 509 516 521 528 533 540 545 604 609 616 621 628 633 640 645 

434 439 446 503 510 515 522 527 534 539 546 603 610 615 622 627 634 639 646 

435 438 447 502 511 514 523 526 535 538 547 602 611 614 623 626 635 638 647 

436 437 448 501 512 513 524 525 536 537 548 601 612 613 624 625 636 637 648 

700’s 

800’s 

701–712 713–724 725–736 801–810 811–820 821–830 

706 707 718 719 730 731 805 806 815 816 825 826 

705 708 717 720 729 732 804 807 814 817 824 827 

704 709 716 721 728 733 803 808 813 818 823 828 

703 710 715 722 727 734 802 809 812 819 822 829 

702 711 714 723 726 735 801 810 811 820 821 830 

701 712 713 724 725 736 



Notes 

38 



you probably know ToxExpo as the exhibition associated with the Society of Toxicology’s 

Annual Meeting—it’s that—but it’s also a great deal more. ToxExpo.com is also a 24/7 comprehensive 

on-line resource, searchable by company name or by product or service. 

www.toxexpo.com 

• A unIquE EnVIRonMEnT to research products 

and services of exhibiting companies and keep 

you informed of new cutting-edge science and 

technology. 

• A CoMPREHEnSIVE APPRoACH to organizing the 

wealth of ideas and insights in cross-disciplinary areas 

of toxicology. 

toxExpo Prize drawing $500! 

drawings to take place on Monday, tuesday, and Wednesday 

in the Exhibit Hall 

$500 american Express Gift card awarded each day 

drop your business cards in the toxExpo prize drawing boxes found 

in all diamond level Sponsor booths 

Exhibit Hall Photography Policy and Protocols for Attendees 

Out of courtesy for the scientific presenters and exhibitors, we appreciate 

your compliance with the following policies: 

• Cell phones and other electronic devices should be set on mute. 

• Photography of poster presentations is prohibited without the specific consent 

of the presenter(s)/author(s). 

• Photography of exhibitor booths and/or equipment is prohibited without 

the specific consent of the exhibitor. 

• Children under the age of 15 are prohibited from accessing 

the Exhibit Hall at any time. 

If you have any questions regarding these polices, please contact 

the SOT Headquarter staff at the Registration Desk. 

• THE ToxICoLoGy MARkET PLACE—your source for 

product information and resources to keep your lab 

competitive. 

• THE PLACE WHERE PRoFESSIonALS WILL LEARn 

how to explore a rapidly changing science. 

• A CHAnCE To THInk ouTSIDE THE Box—find out 

how your work relates to research in other disciplines. 

• uP-To-DATE InFoRMATIon on state-of-the-art 

research equipment, technology, and the latest 

publications. 

Exhibit Hours: 

Monday, March 8 

9:00 AM–4:30 PM 


8:30 AM–4:30 PM 

Wednesday, March 10 

8:30 AM–4:30 PM 

tOXEXPO 

ToxExpo Directories are available at Registration and just inside each entrance of the Exhibit Hall. 

ToxExpo—24/7 up-to-date www.toxexpo.com information throughout at www.toxicology.org the year 

39 

at www.toxexpo.com


ToxExpo Floor Plan 

Exhibit Hall First Level 

Exhibit Hours: 

Monday 

9:00 AM–4:30 PM 

Concession Stand Hours: 

Monday ......................................................9:00 AM–3:00 PM 

Tuesday ...................................................... 8:30 AM–3:00 PM 

Wednesday ................................................. 8:30 AM–3:00 PM 

Tuesday 

8:30 AM–4:30 PM 

wednesday 

8:30 AM–4:30 PM 

Popcorn and 

Refreshments 

147 

246 

247 

346 

447 

546 

547 

646 

647 

746 

747 

846 

947 

1046 

1047 

1146 

1147 

1246 

1 


(Sunday) and 

142 

140 

145 

143 

242 

245 

243 

344 

342 

CONCESSION 

SEATING 

139 238 

239 338 

339 

439 

539 638 639 738 

136 436 536 

737 

137 236 

237 336 

337 

437 

537 636 637 736 

445 

443 

544 

542 

545 

543 

644 

642 

645 

643 

742 

745 

743 

842 

836 

839 

837 

HOT 

ZONE 

WI-FI 

936 

943 

939 

937 

1044 

1042 

1038 

1036 

1045 

1043 

1039 

1037 

1144 

1142 

1138 

1136 

1145 

1143 

1137 

1244 

1242 

CONCESSION 

SEATING 

1 

1 

tOXEXPO 

Plenary Opening Lecture 

(Monday) 

Exhibit Hall E 

130 

128 

126 

HOT 

ZONE 

WI-FI 

131 

230 

129 228 

231 

227 

223 

221 

330 

328 

326 

320 

Poster 

Board 

100’s 

419 

519 

618 

Poster 

Board 

200’s 

718 

719 

818 

Poster 

Board 

300’s 

919 

Poster 

Board 

400’s 

1318 

217 

316 317 416 

516 617 

817 

916 

1016 

1217 1 

117 

417 

517 

616 

716 

717 

816 

917 

1017 

1316 

113 

212 

413 512 

713 

813 912 

211 

310 

610 

810 

1011 1110 

110 

111 

509 

611 710 

711 

1010 

108 

109 

208 

209 

308 

307 

406 

608 

808 

909 

1008 

CHARL 

RIVER 

106 

806 

905 

1207 

104 

105 

204 

205 

305 

505 

604 

701 

802 

1000 

102 

103 

203 

300 

303 

400 

503 

200 

600 

901 

1 

200 South 

HOUSING 

TOURS 

WASHINGTON, 

DC 

South Foyer 

100 

101 

201 

301 

401 

Entrance 

ESCALATORS 

501 

800 

601 

801 

1001 


ToxExpo Entrance 

1201 

Registration 

REGISTRATION 


SCIENTIFIC SESSIONS 

Ballroom Sections A–I 

BALLROOM SECTIONS A–I 

West temple 


SPS 10Annivlogo _PMS293solidsA 

40 

ToxExpo—24/7 SOT throughout 49 Annual the Meeting year


ToxExpo Floor Plan (Continued) 

Exhibit Hall First Level 

toxExpo 2011 Exhibit Space Meeting 

Exhibiting companies should plan on attending 

the ToxExpo 2011 Space Selection Meeting 

on Tuesday, March 9 at 4:45 PM in Room 155 B 

on First Level. 

SOT Show 

Management 

Office 

Exhibitor 

Service Center 

947 

1046 

1047 

1146 

1147 

1246 

1347 

1446 

1447 

1546 

1547 

1646 

1647 

1746 

1847 

1946 

1947 

2046 

2047 

2146 2147 

I 

36 

CONCESSION 

1044 1045 1144 1145 1244 SEATING 

1444 

943 1343 

1443 

939 

937 

1042 

1038 

1036 

1043 

1039 

1037 

1142 

1138 

1136 

1143 

1137 

1242 

1337 

Poster 

Board 

500’s 

1442 

1438 

1436 

1544 

1542 

1545 

1543 

1644 

1642 

1645 

1643 

CONCESSION 

SEATING 

1538 

1639 1738 1739 

1839 

1939 2038 2039 

1437 1836 1936 2136 

1536 

1637 1736 1737 

1837 

1937 2036 2037 

1537 

Poster 

Board 

600’s 

1744 

1742 

Poster 

Board 

700’s 

1845 

1843 

1944 

1942 

1945 

1943 

2044 

2042 

Poster 

Board 

800’s 

2045 

2043 

2142 

2145 

2143 

2141 

2139 

2137 

2135 

Exit Only 

ExIT TO SOT JOB BAnk 

CEnTER, ExHIBITOR 

HOSTED SESSIOnS, 

AnD SCIEnTIFIC 

SESSIOnS 

tOXEXPO 

919 

1318 

1419 1518 

1818 

1919 2018 

2118 

16 

1016 

1217 1317 1416 1517 1616 

1717 1817 1916 2017 

2117 

917 

1017 

1316 

1417 1516 

1617 

1816 

1917 2016 

2116 

12 

909 

905 

901 

1010 

1008 

1000 

1011 1110 

1001 

1207 

1201 

CHARLES 

RIVER 

ToxExpo Entrance 

East 

Lobby 

1506 

1301 1400 1401 1500 

1511 

1507 

1501 


1608 

1606 

1602 

1600 

1611 

1601 

SCIENTIFIC 

SESSIONS 

ROOM 150 A–F 

1711 

1705 

1701 

1806 

1804 

1800 

Scientific 

Sessions 

Room 150 A–F 

West temple 

1811 

1807 

1805 

1803 

1801 

1910 

1906 

1904 

1900 

Entrance 

1913 

1909 

1901 

2012 

2010 

2008 

SOT 

PAVILION 

2013 

2009 

2112 

2110 

2108 

SCIENTIFIC 

SESSIONS 

ROOMS 151 A– F 

Scientific 

Sessions 

Room 151 A–F 

Elevator 

ToxExpo Prize Drawing 

Win $500! 

drawings to take place on 

Monday, tuesday, and 

Wednesday in the Exhibit Hall 

$500 american Express Gift card 

awarded each day 

drop your business cards 

in the toxExpo prize 

drawing boxes found 

in all diamond level 

Sponsor booths 


up-to-date www.toxexpo.com information at www.toxicology.org 41


ToxExpo 2010 Exhibitors 

ToxExpo Directories are available at 

Registration and just inside each entrance of 

the Exhibit Hall. 

tOXEXPO 

(As of January 4, 2010) 

Please visit www.ToxExpo.com or the ToxExpo Directory 

for product/service descriptions, a map of booth locations, and 

other information. 

2010 Annual Meeting sponsors are in bold. 

See listing of complete sponsors on Inside Back Cover 

and Back Cover. 

Company name 

Booth number 

Absorption Systems ........................................................................... 1444 

Accelera ...............................................................................................509 

ACGIH ® ............................................................................................... 245 

ADMET Group .................................................................................... 919 

Advanced Chemistry Development, Inc. ........................................... 743 

Advinus Therapeutics, Pvt. Ltd. ........................................................ 738 

AEgis Technologies Group ................................................................. 303 

ALA Scientific Instruments ................................................................ 131 

Alabama Research & Development ....................................................308 

AllCells, LLC .................................................................................... 1804 

Allentown Inc. ....................................................................................808 

Almac Group Ltd................................................................................. 101 

ALPCO Diagnostics ............................................................................ 642 

Alpha Genesis, Inc. (AGI) ................................................................... 943 

Alturas Analytics Inc ........................................................................ 1038 

American Board of Toxicology (ABT) ............................................. 1442 

American College of Toxicology ........................................................ 128 

American Preclinical Services ............................................................344 

American Society for Pharmacology and Experimental 

Therapeutics (ASPET) ..................................................................... 745 

Americans for Medical Progress .......................................................2044 

Analytical Bio-Chemistry Labs, Inc. .................................................608 

AnaSpec, Inc. ...................................................................................... 147 

Ani Lytics, Inc. .................................................................................. 912 

Aniara Diagnostica/Xenometrix AG ................................................ 1046 

AniClin Preclinical Services ............................................................. 2136 

Anilab, Inc. ......................................................................................... 201 

Animal Identification and Marking System (AIMS) .........................1318 

Antech Diagnostics .............................................................................. 305 

Aperio .................................................................................................. 536 

Applied BioPhysics, Inc. .................................................................. 1047 

Apredica ............................................................................................. 2018 

Aptuit Ltd........................................................................................... 1400 

Aurigene Discovery Technologies Ltd. ..............................................646 

Aurigon Life Science GmbH ............................................................. 1343 

AVA Biomedical, Inc. ........................................................................2116 

AVANZA Laboratories LLC ................................................................416 

Avogadro .............................................................................................. 647 

BASF SE .............................................................................................. 542 

BASi (Bioanalytical Systems, Inc) .....................................................1416 

Battelle .............................................................................................. 1017 

Bio Medic Data Systems, Inc. ..........................................................1000 

BioAgilytix Labs ............................................................................... 1746 

Bioagri Pharma .................................................................................... 736 

Bioculture Mauritius Ltd ................................................................... 1446 

BioFocus .............................................................................................. 145 

Biological Test Center ......................................................................... 718 

Bionas .................................................................................................. 243 

Biopredic International ...................................................................... 1538 

Company name 

Booth number 

Biopta Ltd .......................................................................................... 1436 

BioReliance ® ..................................................................................... 1110 

Bio-Serv, Inc. .................................................................................... 1036 

BioScience Laboratories .................................................................... 1847 

BioStat Consultants, Inc. ...................................................................1818 

BioStorage Technologies ................................................................... 2017 

BioTox Sciences ................................................................................... 338 

Biotoxtech Co., Ltd. ...........................................................................2112 

BioVendor Research & Diagnostic Products .....................................1811 

BRI Biopharmaceutical Research, Inc. ............................................ 1639 

Bridge Laboratories ..............................................................................317 

Bristol-Myers Squibb Company ...................................................... 336 

Burdock Group ...................................................................................1816 

Buxco Research Systems ................................................................... 1037 

Caliper Life Sciences, Inc. .................................................................644 

Calvert Laboratories, Inc. ............................................................. 1616 

CANTEST Ltd. .................................................................................. 437 

Cayman Chemical .............................................................................2036 

Cedarlane .............................................................................................204 

CEDRA Corporation ........................................................................... 747 

CeeTox, Inc. ........................................................................................200 

Cellular Dynamics International, Inc. (CDI) .................................... 1913 

Cellumen Inc. .................................................................................... 1936 

Celsis In Vitro Technologies..............................................................1500 

Center for Environmental Medicine ................................................. 1945 

Center for Toxicology & Environmental 

Health LLC(CTEH) ......................................................................... 105 

Centers for Disease Control & Prevention and 

Agency for Toxic Substances and Disease Registry ....................... 108 

Cerep .................................................................................................. 1736 

CH Technologies ................................................................................1518 

ChanTest Corp. ..................................................................................1817 

Charles River ................................................................................... 1207 

Charter Preclinical Services ............................................................. 1843 

Chemical Solutions Ltd. ..................................................................... 236 

ChemRisk ® , Inc. ............................................................................... 1801 

CIRION.............................................................................................. 1543 

ClearH20, Inc. ...................................................................................1918 

Colonial Medical Supply ......................................................................517 

Colorado Histo-Prep ............................................................................ 519 

Comparative Biosciences .................................................................. 1138 

Comparative Ophthalmic Research Laboratories (CORL) ................406 

CompuCyte Corporation ..................................................................... 447 

CorDynamics ..................................................................................... 1737 

Covance Inc. ...................................................................................... 401 

Covance Research Products, Inc. .......................................................400 

Cultex Laboratories ........................................................................... 1744 

CXR Biosciences Limited ................................................................... 445 

CytoViva, Inc. ................................................................................... 1146 

Data Integrated Scientific Systems (D.I.S.S.) ..................................... 719 

Data Sciences International (DSI) ................................................. 1517 

Data Unlimited International, Inc. ..................................................... 129 

Detroit R & D, Inc. ............................................................................. 330 

Development Center for Biotechnology .............................................1145 

DiLab ® , Inc. ........................................................................................ 539 

Dojindo Molecular Technologies, Inc. .............................................1544 

42 



ToxExpo 2010 Exhibitors (Continued) 




Company name Booth number Company name Booth number 

DTRA Chemical and Biological 

Technologies (DTRA RD-CB) .......................................................2117 

Elan Drug Technologies .................................................................... 2039 

Ellegaard Göttingen Minipigs A/S ..................................................... 816 

Elm Hill Labs ....................................................................................1246 

Elsevier ................................................................................................300 

EMD Chemicals Inc. .......................................................................... 842 

emka TECHNOLOGIES, INC. ........................................................ 1437 

Entelos ............................................................................................... 2135 

Enthalpy Analytical, Inc. ................................................................... 436 

Environ International ........................................................................ 1839 

Environmental Health Perspectives (EHP) ...................................... 1602 

Enzo Life Sciences, Inc. ...................................................................2043 

Epithelix ............................................................................................. 1647 

EPL Archives, Inc. ............................................................................ 1447 

EPL, Inc. (Experimental Pathology Laboratories) ..................... 1443 

Eurofins | Product Safety Labs (EPSL) ............................................... 501 

Experimur .......................................................................................... 1042 

Expert Publishing, LLC .................................................................... 2037 

Exponent, Inc. .....................................................................................604 

Fraunhofer ITEM ................................................................................ 516 

Frontier BioSciences, Inc. ................................................................2009 

Fulcrum Pharma Developments, Inc. .................................................203 

Genedata (USA), Inc. ....................................................................... 1837 

GeneGo, Inc. ..................................................................................... 1937 

Gentronix, Limited .............................................................................1919 

Global Preclinical Training ............................................................... 1043 

GlobalTox ............................................................................................. 326 

Hamilton Company ............................................................................. 139 

Hamilton Thorne, Inc. ........................................................................ 713 

Harlan Laboratories, Inc. ................................................................. 1137 

HCT Co., Ltd. ................................................................................... 1845 

HemoGenix Inc. .................................................................................307 

Hilltop Lab Animals, Inc. .................................................................. 947 

HistoTox Labs, Inc. ......................................................................... 1142 

HSRL Archives, LLC ........................................................................ 2016 

Huntingdon Life Sciences ............................................................... 1001 

ICDD-sas ............................................................................................. 939 

ICF International ................................................................................. 238 

Idaho Technology, Inc. ..................................................................... 1643 

IDEXX Preclinical Research Services ...............................................806 

IIBAT ................................................................................................... 543 

IIT Research Institute ...........................................................................617 

Ina Research, Inc. ............................................................................... 305 

INDIGO Biosciences, Inc. ................................................................2008 

Informa Healthcare............................................................................ 2010 

Ingenuity Systems ...............................................................................1316 

Instech Solomon ................................................................................ 1506 

Instem ................................................................................................ 1201 

Institute for In Vitro Sciences, Inc. (IIVS) .......................................... 717 

Integrated Laboratory Systems, Inc. (ILS) ........................................2118 

IntelliCyt Corporation ..........................................................................111 

International Congress of Toxicology XII .......................................... 104 

Intertek Pharmaceutical Services ......................................................1916 

Invitrogen/CellzDirect ........................................................................ 742 

IPS Therapeutique ............................................................................. 1606 

ITOCHU/InfiniteBio .........................................................................2042 

ITR Laboratories Canada, Inc. ......................................................... 1337 

IUTOX ................................................................................................. 102 

Jackson Laboratory, The ................................................................... 1645 

Jai Research Foundation (JRF - America) .......................................... 710 

Joinn Laboratories ..............................................................................1011 

Kinder Scientific Company ................................................................. 503 

KINOMEscan .................................................................................... 1347 

Korea Environment and Merchandise 

Testing Institute (KEMTI) ............................................................. 2013 

Korea Institute of Toxicology ............................................................ 1705 

Kubtec X-Ray ...................................................................................... 142 

Lab Products, Inc. ..........................................................................1217 

LAB Research Inc. ........................................................................... 601 

Lablogic Systems, Ltd. ....................................................................... 328 

Leadscope, Inc. ................................................................................... 239 

Leyden Group, The .............................................................................. 212 

Lhasa, Limited ..................................................................................... 140 

Litron Laboratories .............................................................................1147 

Lomir Biomedical, Inc. ......................................................................905 

Lonza Bioscience ................................................................................. 937 

Lovelace Respiratory Research Institute ...........................................1717 

Maccine Pte Ltd ..................................................................................1701 

Marshall BioResources ....................................................................... 817 

MB Research Labs Inc ........................................................................ 711 

MDS Pharma Services ...................................................................... 1537 

Med Associates Inc. ............................................................................ 547 

Merck & Co., Inc (Publishing Group) .............................................. 2012 

Meso Scale Discovery ..........................................................................117 

Metabolon, Inc. ...................................................................................209 

metanomics Health ..............................................................................544 

MetaSystems Group, Inc. ................................................................... 109 

METTLER TOLEDO ......................................................................... 746 

MicroConstants ................................................................................... 221 

Midwest Research Institute ................................................................. 419 

Millipore ............................................................................................ 1805 

MitoSciences Inc. ...............................................................................208 

Moltox ................................................................................................ 1939 

MPI RESEARCH .............................................................................. 801 

MultiCase ............................................................................................1917 

National Institute of Environmental Health Sciences ...................... 1600 

National Library of Medicine ............................................................. 637 

National Research Center for New Drug 

Safety Evaluation (Shenyang) .........................................................1143 

National Shanghai Center for New Drug Safety 

Evaluation and Research ................................................................ 1800 

National Toxicology Program (NTP) ............................................ 1501 

NeuroScience Associates, Inc. ......................................................... 1536 

NEUROSERVICE ............................................................................... 413 

Nexcelom Bioscience ........................................................................... 110 

NextGen Pharma Technologies, Inc .................................................. 1739 

Noesys Data ....................................................................................... 1943 

NOTOCORD Systems ......................................................................... 837 

Noveprim Ltd. .....................................................................................846 

Nucro-Technics Incorporated .............................................................1010 

Numira Biosciences ........................................................................... 1608 

tOXEXPO 



ToxExpo 2010 Exhibitors (Continued) 




tOXEXPO 

Company name 

Booth number 

Olympus America Inc. ..................................................................... 1803 

Oxford University Press .................................................................... 1545 

Pacific BioLabs .....................................................................................611 

PDS Preclinical Data Systems, Inc. ................................................. 1401 

Perceptive Instruments Ltd. ............................................................. 1242 

Pfizer Global Research and Development ...................................... 936 

Pharmatek Laboratories, Inc. ............................................................. 839 

PhoenixBio ........................................................................................ 1542 

Phylonix Pharmaceuticals Inc .............................................................205 

Pinnacle Technology Inc. ................................................................. 1642 

PointCross ............................................................................................ 130 

Porsolt & Partners Pharmacology ..................................................... 1546 

PreLabs ................................................................................................ 716 

Primate Products, Inc. .......................................................................1419 

Promega Corp .......................................................................................316 

Purina Mills LabDiet ® ....................................................................... 1301 

PWG Genetics .................................................................................... 1144 

QTest Labs ........................................................................................... 638 

Quertle ............................................................................................... 1807 

Quotient Bioresearch ........................................................................... 337 

Razel Scientific Instruments ...............................................................546 

ReachBio .............................................................................................. 237 

Redshift Technologies, Inc. ................................................................ 636 

Regenemed ......................................................................................... 2137 

Regulatory Science Associates (RSA) ................................................ 813 

Research Diets, Inc. .......................................................................... 1942 

Ricerca Biosciences ............................................................................1611 

Ridglan Farms, Inc ...............................................................................417 

Roche ................................................................................................. 1511 

Roche Applied Science ...................................................................... 1507 

RTC - Research Toxicology Centre S.p.A. ...................................... 1909 

RTI International .................................................................................600 

Rules-Based Medicine, Inc ............................................................. 1904 

SABiosciences ..................................................................................... 512 

SAGE ................................................................................................. 1806 

San Diego Instruments, Inc. ..............................................................1417 

Sarstedt, Inc. ..................................................................................... 1045 

Science/AAAS ................................................................................... 1438 

SCIREQ, Inc. (Scientific Respiratory Equipment) ............................. 836 

Seahorse Bioscience ............................................................................246 

Sequani Limited .................................................................................1317 

Seventh Wave ....................................................................................... 443 

Sibata Scientific Technology Ltd. .....................................................1742 

Siemens Medical Solutions USA....................................................... 1039 

Sigma Life Science ............................................................................ 2039 

Simulations Plus, Inc. ....................................................................... 1836 

Sinclair Research Center, Inc. (SRC) .................................................. 610 

SkinEthic Laboratories........................................................................ 227 

SNBL USA, Ltd. ............................................................................... 1601 

Society of Quality Assurance (SQA) ................................................ 1644 

SOT Resource Pavilion ................................................................... 1901 

• Animals in Research 

• Endowment Opportunities 

• K–12 Outreach 

• Member Services, RC, SIG, and SS Activities 

Company name 

Booth number 

Southern Research ..............................................................................1617 

Southwest Research Institute (SwRI)................................................ 2038 

Spring Valley Laboratories, Inc. ........................................................ 231 

Springborn ........................................................................................... 137 

SRC, Inc. ............................................................................................. 143 

SRI International ................................................................................1016 

STEMCELL Technologies Inc ............................................................ 537 

Stemina Biomarker Discovery, Inc. ....................................................618 

STILLMEADOW, Inc. ..................................................................... 1136 

Stratatech Corporation ........................................................................ 545 

Stratedigm Inc. ................................................................................... 247 

Strategic Applications, Inc. (SAI) ....................................................... 810 

SUBURBAN SURGICAL COMPANY .............................................800 

Suven Life Sciences Limited ............................................................. 1906 

Sysmex America, Inc. ......................................................................... 643 

Taconic ................................................................................................. 916 

Tandem Labs ........................................................................................ 439 

Telemetry Research ............................................................................1910 

Thermo Fisher Scientific ...................................................................320 

Thermo Scientific ................................................................................ 228 

TNO ..................................................................................................... 737 

Toxicology Education Foundation (TEF) ........................................... 106 

Toxicology Excellence for Risk Assessment (TERA) ................... 1944 

Toxicology Forum, The ....................................................................... 103 

Toxicology Regulatory Services ......................................................... 301 

Toxicology Research Laboratory ...................................................... 1637 

Toxikon Corporation ........................................................................... 901 

ToxServices LLC ............................................................................... 223 

Transformational Medical Technologies 

Initiatives (TMTI) ............................................................................ 126 

Transparent Inc. ................................................................................ 2108 

Trevigen Inc. ....................................................................................... 339 

TSE Systems, Inc. ............................................................................... 310 

Veritox, Inc. .........................................................................................616 

Vet Path Services ................................................................................. 211 

VisualSonics ........................................................................................ 230 

VITROCELL Systems GmbH ...........................................................1516 

Vitron, Inc. .......................................................................................... 818 

VRL Laboratories ................................................................................ 113 

WIL Research Laboratories, LLC .................................................. 701 

Wildlife International Ltd. ................................................................. 917 

Wiley-Blackwell ................................................................................ 1008 

World Precision Instruments ...............................................................346 

Worldwide Primates, Inc. ................................................................... 639 

Write Science Right ............................................................................. 342 

WuXi AppTec .....................................................................................1711 

XenoBiotic Laboratories, Inc. .......................................................... 1738 

XenoTech, LLC .................................................................................... 505 

Xybion Medical Systems .....................................................................802 

ZenBio, Inc ........................................................................................1244 

Zenith Biotech ..................................................................................... 136 

Zoologix, Inc. ................................................................................... 1044 

44 



Exhibitor Hosted Session Index 

EXHIBITOR HOSTED SESSIONS 

(listed by date and time, then alphabetically by presenter) 

Time: 2:15 PM–3:15 PM 

Presented by Topic Room Page 

Exhibitor Hosted Sessions are informative sessions developed by 

an exhibiting company. 

Monday 

Time: 9:15 AM–10:15 AM 


Analytical 

Bio-Chemistry 

Labs, Inc. 

Biological Test 

Center 

Charles River 

In Vivo Ecotoxicity Tests: 

Responding to U.S. EPA Endocrine 

Disruptor Screening Program 

Biological Test Center Capabilities 

Overview 

Digital Pathology in the 21 st 

Century 

155 F 109 

155 C 109 

155 B 109 

Time: 10:30 AM–11:30 AM 


CANTEST Ltd. An In Vitro Method for Measuring 

Metabolic Stability of Chemicals 

in Fish 

155 B 128 

Research Diets, 

Inc. 

TSE Systems 

Inc. 

Choose the Diet Wisely: Purified 

Diets vs. Chow in Lab Animal 

Research 

Demonstration of a Cigarette 

Smoke Generator in Combination 

with a Novel Cell Culture Exposure 

System 

155 C 128 

155 F 128 

Time: 11:45 AM–12:45 PM 


Roche Applied 

Science 

STEMCELL 

Technologies 

Inc. 

Analyzing Cells in Real Time: 

xCELLigence Technology Use in 

Pharma Research 

Cytokines and Lineage Choice in 

Stem Cell Differentiation 

155 C 128 

155 F 128 

Time: 1:00 PM–2:00 PM 


ReachBio LLC Predictive In Vitro Model 

for Determining Additive 

or Synergistic Toxicity of 

Combinations of New Small 

Molecule Compounds and 

Standard Treatments 

155 F 148 

Covance Inc. 

Huntingdon 

Life Sciences 

LAB Research 

Inc. 

The Scientific Quest for a New 

Millennium of Drug Discovery and 

Development 

Therapeutic Monoclonal 

Antibodies—Predicting Antibody- 

Mediated Cytokine Release 

The Usefulness of the Minipig in 

Regulatory Toxicology 

tuesday 

155 C 155 

155 B 155 

155 F 155 

Time: 8:30 AM–9:30 AM 


Charles River Obese Animal Models of 

155 B 160 

Metabolic Disease 

Time: 9:45 AM–10:45 AM 


Accelera Srl Preclinical Anticancer Drug 

Development: Shifting Challenges 

155 C 192 

Huntingdon 

Life Sciences 

Transparent Inc. 

Functional Biomarkers of Renal 

Injury—Optimizing Interpretive 

Value in Renal Pharmacology 

Studies 

Introduction to the Development 

and Validation Study of the New 

Technology “Cell able” for New 

Drug Discovery 

155 F 192 

155 B 192 

Time: 11:00 AM–12:00 NOON 


Ingenuity 

Systems 

Promega 

Corporation 

SkinEthic 

Laboratories 

A System’s Toxicology Approach 

for Drug Discovery and 

Development 

Predictive Multiparametric 

In Vitro Assay Combinations 

for Cytotoxicity, Viability, 

Apoptosis, and ADME 

Applications with Hepatocytes 

and Human Stem-Cell Derived 

Cardiomyocytes 

SkinEthic Laboratories— 

Providing You Available, 

Predictive, User-Friendly, and 

Sustainable In Vitro Solutions 

155 F 192 

155 B 192 

155 C 193 

tOXEXPO 

SNBL USA, Ltd. 

Trevigen, Inc. 

Interests and Limitations of New 

In Vivo Methodologies to Assess 

the Potential Cardiovascular 

Effects of NCEs and Biologics in 

Large Animal Models 

DNA Damage, PARP, and the 

Comet Assay® 

155 B 148 

155 C 148 




Exhibitor Hosted Session Index (Continued) 

tOXEXPO 

Time: 12:15 PM–1:15 PM 


ADMET Group Higher Throughput In Vitro 

Screening Assays for Drug-Drug 

Interactions and Organ- 

Specific Toxicity Using Human 

Hepatocytes and IdMOC 

155 C 195 

GeneGo, Inc. 

LAB Research 

Inc. 

Systems Toxicology Data Analysis 

with GeneGo 

How to Screen for Arrhythmias in 

Safety Pharmacology When More 

Than 86,400 Beats Are Recorded 

in One Dog over 24 Hours 

155 F 195 

155 B 195 

Time: 1:30 PM–2:30 PM 


emka 

TECHNOLOGIES 

Quertle, LLC 

Science/AAAS 

Noninvasive Blood Pressure and 

Respiration Measurements on 

Large Animals 

Tips and Tricks to Maximize Your 

Literature Search Results 

Making New Connections: 

Networking Strategically 

155 F 227 

155 C 227 

155 B 227 

Time: 2:45 PM–3:45 PM 


Aperio 

Quantitative Tissue Analysis: 

How to Get the Most from Your 

Pathologist 

155 B 228 

Covance Inc. 

Ellegaard 

Göttingen 

Minipigs A/S 

Lead Optimization—What Does 

the Future Look Like? 

The Minipig—A Non-Rodent 

Species in Regulatory Toxicity 

Testing 

155 C 228 

155 F 228 

Wednesday 

Time: 8:30 AM–9:30 AM 


Charles River Innovative Safety Studies and 

Successful Strategies for an 

Efficient IND-Enabling Program 

155 B 230 

Time: 9:45 AM–10:45 AM 


Huntingdon 

Life Sciences 

Inhalation Study Test Article 

Consumption—Ensuring 

Preclinical Inhalation Toxicology 

Programs Don’t Break the Bank 

155 B 256 

Time: 12:15 PM–1:15 PM 


Data Sciences 

International 

Gentronix 

Limited and 

Apredica LLC 

New Applications of the 

Latest Telemetry Technology 

in Toxicology and Safety 

Pharmacology 

Mechanisms of Toxicity and 

Prediction of Whole-Organ 

Toxicity: In Vitro Assays and Their 

Validation—What Can We Predict 

Early on to Avoid Costly Mistakes 

Later? 

155 C 258 

155 B 258 

Time: 1:30 PM–2:30 PM 


Metabolon, Inc. Determining Mechanisms of 155 B 287 

Action in Toxicology Using 

Metabolomics 

Additional sessions may be scheduled after print deadline. Please see 

ToxExpo Directory for the most current schedule. 

toxExpo Prize drawing $500! 

your 24/7 source for 

the latest developments 

in equipment, technology, 

toxicology services, and 

publications 

drawings to take place on Monday, tuesday, 

and Wednesday in the Exhibit Hall 

$500 american Express Gift card 

awarded each day 

drop your business cards 

in the toxExpo prize 

drawing boxes found in all 

diamond level Sponsor booths 


46 


Be a member of the premier group that is creating 

a safer and healthier world by advancing the 

science of toxicology 

As an SoT member you can . . . 

Stay connected at www.toxicology.org 

access member-restricted information 

Use the on-line Member directory 

Pay Reduced Registration Fees 

for SOt meetings 

Receive SOT Publications 

The Toxicologist (Cd-rom) 

Toxicological Sciences 

Communiqué 

Others 

Communicate the Importance of Our Discipline 

utilize Career Resources 

Register for Mentor Match 

nominate for Awards 

volunteer and Demonstrate your Leadership Skills 

Find Products and Services Easily at ToxExpo 

Membership Fees: 

Full Membership ........................................... $135 

associate Membership ................................ $135 

Postdoctoral Membership............................. $35 

Student Membership ..................................... $20 

retired Membership..........................................$0 

Easy on-line membership application takes 

approximately 15 minutes to complete. 

Participate in Your regional SOt Chapter 

Join one of 18 Regional Chapters that foster scientific exchange 

at a local level, organize regular meetings throughout the year, 

and sponsor awards. 

Join a Specialty Section 

Choose from 25 SOT Specialty Sections that provide forums 

for networking and exchanging information with peers who 

share an interest in your area of toxicology. The annual 

receptions and meetings of the Specialty Sections at the Annual 

Meeting are ideal opportunities to network with colleagues. 

Each Specialty Section membership is $15. Student and 

postdoctoral members receive the first Specialty Section at 

no cost. 

Choose a Special Interest Group 

SOT is committed to increasing the diversity and 

inclusiveness of the Society. Join one of six established 

groups that provide forums for networking, education, and 

recognition of achievement. Each Special Interest Group 

is $15. Student and postdoctoral members receive the first 

Special Interest Group at no cost. 

www.toxicology.org 

For complete information about membership 

in the Society of Toxicology, visit the 

SOT Web site at www.toxicology.org 

and select Member Information. 

March 7–11, 2010 

Special offer to non-member 2010 Annual 

Meeting attendees: apply for membership by 

May 1, 2010, and if accepted, SOT will waive 

your 2010 dues. 



Registration 

rEGIStratIOn 

Annual Meeting Registration Fees 

On-Site 

SOT Member .......................................................$395 

Non-Member ........................................................$690 

SOT Retired Member ...........................................$145 

Postdoctoral SOT Member ..................................$160 

Postdoctoral Non-Member ...................................$240 

Graduate Student SOT Member ..........................$140 

Graduate Student Non-Member ...........................$200 

Undergraduate Student.............................................$0 

SOT Affiliate ............................................................$0 

Press .........................................................................$0 

Guest (Non-Scientist) ..........................................$100 

(Guests do not have access to the Scientific Sessions or 

the Exhibit Hall.) 

Continuing Education Sunrise 

Mini-Course Fees 

(includes continental breakfast) 

(Only Annual Meeting Registrants may enroll in 

CE Courses.) 

On-Site 

SOT Member/SOT Affiliate .................................$105 

Retired ..................................................................$105 

Non-Member ........................................................$125 

Postdoctoral (SOT Member or Non-Member) .....$105 

Graduate or Undergraduate Student ......................$75 

Press .........................................................................$0 

Continuing Education Course Fees 

(per morning or afternoon course) 

(Only Annual Meeting Registrants may enroll in 

CE Courses.) 

On-Site 

SOT Member/SOT Affiliate .................................$200 

Retired ..................................................................$160 

Non-Member ........................................................$350 

Postdoctoral (SOT Member or Non-Member) ..........$140 

Graduate or Undergraduate Student 

(SOT Member or Non-Member)..................................$95 

Press .........................................................................$0 

Annual Meeting Registration Includes: 

• Awards Ceremony, Sunday, March 7 from 

5:15 PM–6:30 PM. 

• Welcoming Reception, Sunday, March 7 from 

6:30 PM–7:30 PM. 

• Plenary Opening Lecture, Monday, March 8 from 

8:00 AM–9:00 AM. 

• All Scientific Sessions (see program descriptions 

beginning on page 100) 9:15 AM, Monday, March 8 

through 12:00 NOON, Thursday, March 11. 

• ToxExpo Exhibit Hall, 9:00 AM–4:30 PM Monday, 

March 8; 8:30 AM–4:30 PM Tuesday, March 9 and 

Wednesday, March 10. 

Participants are also encouraged to register for the 

Continuing Education Courses. These are available during 

three time intervals on Sunday, March 7: the Sunrise Mini- 

Course is from 7:00 AM–7:45 AM, morning courses are 

8:15 AM–12:00 NOON, and afternoon courses are from 

1:15 PM–5:00 PM. 

Registration Desk 

The Registration Desk is located in the South Foyer of the Salt 

Palace Convention Center. 

Registration Desk hours: 

Saturday ......................................................4:00 PM–7:00 PM 

Sunday ........................................................7:00 AM–8:00 PM 

Monday ......................................................7:00 AM–5:00 PM 

Tuesday ..................................................... 8:00 AM–4:00 PM 

Wednesday ................................................ 8:00 AM–4:00 PM 

Thursday ..................................................8:00 AM–11:30 AM 

Registration Materials 

For those of you who registered before January 22, 2010, your 

badge, Program, and The Toxicologist on CD-ROM will be 

sent to you prior to the Annual Meeting. If you have registered 

and have NOT received your badge by mail or need a replacement 

badge, go to the “Badge Pick Up Only” registration 

counter located in the South Foyer. Your 2010 Annual Meeting 

Registration badge must be presented to obtain access to SOT 

functions. 

When you arrive at the Salt Palace Convention Center, you 

will need to pick up your ToxExpo Directory and badge 

holder. If you have not already registered, please go to 

the registration counter in the South Foyer to obtain these 

materials. If you already have your registration badge and 

event/CE course tickets, simply stop by a handout table in 

the South Foyer and present your badge to obtain the other 

registration materials (i.e., The Toxicologist on CD-ROM, the 

48 



General Information 

ToxExpo Directory, and other supplementary materials). 

The printed version of The Toxicologist will be available to 

purchase in the South Foyer next to the registration desk. 

Registration Confirmation 

You should receive a registration confirmation/receipt via 

e-mail whether you register directly on-line or if you have sent 

your registration form to SOT Headquarters via the mail or 

by fax. If you don’t receive your confirmation within 2 weeks, 

please contact SOT Headquarters at sothq@toxicology.org or 

call (703) 438-3115. 

Accessibility for Persons with Disabilities 

The Salt Palace Convention Center (SPCC) and most of the 

SOT hotels are accessible to persons with disabilities. If you 

require special services, please mark the appropriate box 

on the Annual Meeting Registration Form. The Salt Palace 

Business Center rents scooters and wheelchairs on a daily or 

weekly basis. For pricing and availability, call (801) 534-6301 

or e-mail businesscenter@saltpalace.com. 

Scooters can also be rented from Scoot Around. For more 

information, please go to www.scootaround.com or call 

(888) 441-7575. They will deliver to your hotel. If you require 

a sign language interpreter, please contact the American Sign 

Language Communication at www.aslcomm.com or call 

(801) 403-6606. 

If you require more information about accessibility, please 

contact Heidi Prange at SOT Headquarters: (703) 438-3115 

ext. 1424. 

Attire 

The official attire for the Annual Meeting is business casual. No 

coat or tie is required! We encourage you to bring comfortable 

clothing and shoes. Because meeting rooms may seem cold, 

please bring a sweater or jacket and/or dress in layers. 

Badges 

Those who registered before January 22, 2010, will receive 

badges and registration materials in the mail. If you already 

have your 2010 Annual Meeting badge you do not need to wait 

in a registration line. If you have registered and have NOT 

received your badge by mail or need a replacement badge, go 

to the “Badge Pick Up Only” registration counter located in 

the South Foyer to pick up your badge. 

If you have not registered for the meeting, please complete the 

On-Site Registration Form found at the kiosks in the registration 

area in South Foyer and proceed to the appropriate 

registration line. 

Business Center 

The Salt Palace Business Center is conveniently located inside 

the Convention Center offering UPS, FedEx, and USPS shipping, 

small package receiving, office equipment rentals, 

common office supplies, Internet access and wireless daily rates, 

and a place to copy, fax, scan, and print business materials. You 

may also e-mail your files to businesscenter@saltpalace.com 

before arrival and have your documents ready for you at the 

start of the convention. The Business Center is located on the 

Second Level, close to Room 254. Telephone: (801) 534-6301. 

Incoming fax number: (801) 534-6305 ($1.00 per page). 

Cost per copy: $0.14 per black and white copy and $0.75 per 

color copy. Contact: Heidi Baird (Facility Services Manager). 

Web: www.visitsaltlake.com/saltpalace/facility/businesscenter 

Business Center hours: 

Friday .........................................................9:00 AM–4:30 PM 

Saturday .....................................................9:00 AM–1:00 PM 

Sunday ........................................................9:00 AM–1:00 PM 

Monday ...................................................... 7:30 AM–4:30 PM 

Tuesday ......................................................8:30 AM–4:30 PM 

Wednesday .................................................8:30 AM–4:30 PM 

Thursday ............................................ 8:30 AM–12:00 NOON 

Career Resources and Development Services 

As part of the Career Resources and Development (CRAD) 

Services, and opportunities at the meeting, the on-site Job 

Bank Center is located in the Salt Palace Convention Center in 

Rooms 155 A&D on the First Level. 

The Job Bank Center hours: 

Sunday ......................................................10:00 AM–4:30 PM 

Monday ......................................................9:00 AM–4:30 PM 

Tuesday ......................................................8:30 AM–4:30 PM 


Full CRAD details may be found on page 60. 

Climate 

Salt Lake City weather is widely variable. The city lies 

in a semi-arid region in the Salt Lake Valley, surrounded 

by mountains and the Great Salt Lake, and receives little 

precipitation. During spring, temperatures warm steadily 

and rapidly. Wintry weather is usually last experienced by 

early-to-mid March. The average temperature for March 

is 43.1 F/6.2 C. For an up-to-date, detailed weather forecast, 

visit the National Weather Service Forecast Office at 

www.wrh.noaa.gov/slc. 

GEnEral InFO 



General Information (Continued) 


For your convenience, a coat/luggage check will be available 

in the Salt Palace Convention Center near the North Foyer 

of the Grand Ballroom (near Ballroom A) on the Lower 

Concourse. The coat/luggage check will be open Sunday, 

March 7 through Thursday, March 11. There will be a fee 

of $2 per item checked and laptop computers will not be 

accepted. 

Hours of operation: 

Sunday ........................................................7:00 AM–8:30 PM 

Monday ......................................................7:00 AM–8:30 PM 

Tuesday ......................................................7:00 AM–8:00 PM 


Thursday .................................................... 7:00 AM–1:00 PM 

Coat/Luggage check hours are subject to change. 

First Aid and Emergency Services at the 

Convention Center 

If an emergency should occur while at the Salt Palace 

Convention Center, proceed directly to the nearest pay phone, 

located throughout the facilities, and press the security button 

on the bottom of the phone. You will be connected directly 

to the 24-hour manned security department at the Convention 

Center. From any phone that is not a Convention Center pay 

phone, dial (801) 534-6320, which will connect directly to 

security. 

The First Aid room is located across from Meeting Room 150 A. 

The First Aid Administrator will be on duty 7:00 AM–8:00 PM 

Sunday through Wednesday, and 7:00 AM–12:00 NOON on 

Thursday. In accordance with the State of Utah and Salt Lake 

City regulations, the First Aid Administrator is not permitted 

to dispense any medication. 

GEnEral InFO 

Exhibitor Information 

Full exhibit information details may be found on 

pages 39–46. 

Exhibit Hall (Hours/Location) 

Exhibit hours at the Convention Center: 

Monday ............................................. 9:00 AM–4:30 PM 

Tuesday ..............................................8:30 AM–4:30 PM 

Wednesday .........................................8:30 AM–4:30 PM 

The ToxExpo Exhibition is located on the First Level. 

A map of the Exhibit Hall is located on pages 40–41. 

Exhibitor personnel may enter the hall one hour before 

the Exhibit Hall opens with appropriate identification. 

Poster presenters may enter the hall at the poster set 

up times specified in the Event Calendar. ToxExpo 

Directories are available at Registration and just inside 

each entrance of the Exhibit Hall. 

2011 Exhibit Space Selection Meeting 

Exhibiting companies should plan on attending the 

2011 Space Selection Meeting on Tuesday, March 9, at 

4:45 PM in Room 155 B on the First Level of the 


Food Services 

Coffee Breaks 

The exhibiting companies are pleased to sponsor complimentary 

coffee in the Exhibit Hall between 9:00 AM–10:00 AM, 

Monday, and 8:30 AM–9:30 AM, Tuesday–Wednesday. See 

Exhibit Hall signage for locations. 

Concessions 

Concession stands are available in the Exhibit Hall Monday 

9:00 AM–3:00 PM, and Tuesday and Wednesday from 

8:30 AM–3:00 PM. Breakfast and lunch items will be available, 

as well as coffee, soda, bottled water, and snacks for 

purchase. Seating is available in the Concession areas in the 

Exhibit Hall located at the top of aisles 300, 1200, and 1700. 

take a Break! 

Grab a bite! Check e-mail! Plenty of seating is available in 

the Hot Zones in the Exhibit Hall where wireless Internet 

access is available. 

50 




Green in Salt Lake City 

Salt Lake City is surrounded by incredible natural beauty. The 

Salt Lake Convention & Visitors Bureau is proud to be part of 

a destination that is actively engaged in the journey to make the 

community an environmentally sustainable host for conventions, 

meetings, and visitors. The Salt Palace Convention 

Center strives to reduce, reuse, and recycle and believes that 

by carefully considering the environmental impact of all business 

decisions before they make them, they have been able to 

shrink the ecological footprint and will continue to do so. The 

following lists some of the ways the Center is going green: 

• The 2006 expansion of the SPCC was awarded the U.S. 

Green Building Council’s Silver LEED Certification for 

being designed and constructed utilizing environmentally 

responsible methods and materials. 

• Bike racks are available in the parking structure to 

promote the use of alternative transportation. 

• Preferred parking stalls are offered for all carpooling 

attendees/employees at SPCC. 

• Utah Foods (caterer for the Convention Center) recycles 

all aluminum and cardboard products. In addition to the 

single source recycling program at the SPCC, recycling 

programs for grease and fry oil are in place. 

• The Center provides weekly food donations to The Road 

Home Homeless Shelter, the Salt Lake Mission, and Utah 

Food Bank. 

• 100% renewable Greenware products are available in the 

Center. 

• 100% recycled paper napkins and compostable paper 

plates are used. 

• The Center uses local food sources when possible, and 

uses organic food sources upon request. 

Learn how you can offset your travel to Salt Lake City 

through their carbon offset program www.visitsaltlake.com/ 

carbon_offset. 

the Cost of Big Gatherings 

Meetings can have a tremendous impact on the environment 

in ways you can’t imagine. For example, during a five-day 

conference, 2,500 attendees will use 62,500 plates, 87,500 

napkins, 75,000 cups/glasses and 90,000 cans/bottles! 

This year, SOT has instituted the following environmentally 

friendly practices designed to keep us growing greener: 

• On-line registration is being promoted to reduce the use of 

paper registration. 

• Presenter and speaker requests are being handled 

electronically. 

• The final Program is printed on post consumer recycled 

paper that meets FSC requirements for well-managed 

forests (see back cover for details). 

• Signage is made of 100% biodegradable materials. 

• Meeting surveys will be conducted electronically. 

• The E-mail Center offers electronic messaging. 

• Exhibit sales and the management of the ToxExpo 

exhibit floor plan were done electronically. 

• Plastic name badge holders will be collected and recycled. 

• Exhibitor kits are available on-line and include 

electrical, decorating, shipping/drayage, and AV forms. 

• Registration bags are made of certified recycled material. 


The SOT Guest/Spouse Hospitality Center provides guest 

participants (non-scientists) with a place to meet and socialize 

with other guests. To visit the Hospitality Center, guests must 

register for the Annual Meeting with the person they are 

accompanying. Guests are welcome to attend the Welcoming 

Reception, but will not have access to the scientific sessions 

or the Exhibit Hall. Please remember to wear your badge to all 

SOT events. 

The Guest/Spouse Hospitality Center will be located in the 

Marriott Downtown hotel. 

Guest/Spouse Hospitality Center hours: 

Sunday ........................................................8:00 AM–5:00 PM 

Monday ......................................................8:00 AM–5:00 PM 

Tuesday ......................................................8:00 AM–5:00 PM 


Thursday ..................................................8:00 AM–11:30 AM 

GEnEral InFO 




GEnEral InFO 

Housing 

Housing Connection desk 

The deadline date for new housing reservations is 

February 11, 2010. Continue to make any requests through 

The Housing Connection through February 25. Beginning 

February 26, you may call the hotels directly for any housing 

requests. For information regarding your hotel room reservation 

on-site, please visit the SOT Housing Desk located in the 

South Foyer of the Salt Palace Convention Center. 

Housing Desk hours: 

Saturday ......................................................4:00 PM–7:00 PM 

Sunday ........................................................8:00 AM–5:00 PM 

Monday ......................................................7:00 AM–5:00 PM 

Tuesday ..................................................... 8:00 AM–4:00 PM 


Housing desk hours are subject to change. 

Housing Information 

The Society of Toxicology has reserved and made arrangements 

for SOT Annual Meeting attendee discounted room 

rates at various Salt Lake City hotels—known as the SOT 

hotel block. This block includes discounted room rates at 

many premier hotel chains and details can be found on 

pages 24–25. 

The Room Sharing program is available for 2010 SOT Annual 

Meeting Registrants. Access this option from the Annual 

Meeting section of the SOT Web site. 

Did you know that your choice of hotel for the SOT Annual 

Meeting has direct impact on Society’s strategic initiatives? 

Although we understand that making your reservations outside 

of the SOT hotel block can sometimes be more economical, it 

decreases the money available to the Society to carry out its 

strategic goals and may cause the Society to have to pay attrition 

fees for unutilized hotel rooms. In addition, the Society is 

unable to assist you if you have any difficulties with your room 

reservation, such as the hotel over-booking or misplacing your 

reservation. 

SOT depends on the Annual Meeting revenue (hotel room 

commissions and rebates) to fund other programs throughout 

the year and to keep future registration fees low. Please assist 

the Society by making your hotel room reservation through 

the Salt Lake City Housing Connection. 

Please understand that it will take the Housing Connection 

a few days to process your reservation into the hotel system. 

Rest assured that if you have received a confirmation number 

from the Housing Connection, the hotel will honor your 

booking. Please do not call your hotel “to be sure” until Friday, 

February 26, 2010. Thank you for your consideration. 

Methods for Making Housing Reservations 

On-Line: www.toxicology.org 

Telephone: 

Toll-Free (USA and Canada): (888) 206-8717 

International: (801) 214-7282 

Hours of Operation: 7:00 AM–6:00 PM (MST) 

Monday–Friday 

Fax: (801) 355-0250 (International and Domestic) 

Mail: 

The Housing Connection 

175 S. West Temple, Suite 140 


United States 

Internet Access 

SOT knows the importance of staying connected to your daily 

activities while attending the Annual Meeting and provides 

you several ways to access the Internet. 

Free wireless Internet access is available through “Hot Zones,” 

which are designated areas in the Exhibit Hall that are clearly 

marked for laptop and handheld users. To access the Internet 

in the Hot Zones connect to the SOT2010 wireless network, no 

password is required and you will be immediately connected 

and on-line. 

Computers available at the Convention Center 

SOT will provide computers you can use to access the Internet. 

These computers are available to attendees in the E-mail 

Center, located in the North Foyer of the Grand Ballroom on 

the lower concourse of the Convention Center. 

Wireless Internet access in the Salt Palace 

Meeting rooms 

Salt Palace Wi-Fi is a self-service wireless network that is 

available to all event attendees. The cost is $14.95 per day, 

based on a 24-hour time frame, and can be purchased directly 

from any wireless capable computer. 

To access the Internet, connect to the “Salt Palace Wi-Fi” 

wireless network. Open the Internet browser, and you will be 

automatically directed to a screen where you can set up your 

user name, password, and pay for the service. 

Please stop by the Business Center if you need assistance 

connecting to the Salt Palace Wi-Fi. 

52 




E-mail Center 

The SOT Annual Meeting E-mail Center is provided to help 

you stay connected to your colleagues during the Annual 

Meeting. SOT members, 2010 Annual Meeting attendees 

including exhibitors, and Job Bank registrants can access 

the E-mail Center on the SOT Web site to send and receive 

e-mail messages during the 2010 Annual Meeting—just like 

a standard e-mail application. The difference? The 2010 SOT 

Annual Meeting E-mail Center gives you a unique mailbox 

without having to provide your personal e-mail address to 

correspondents. 

The service will send an e-mail alert to you when you receive a 

message. Use the communication preference option to forward 

your incoming messages to your primary e-mail address or 

PDA. 

Available 24/7, access to the E-mail Center is available any 

time of day and from any computer with an Internet connection, 

before, during, and after the 2010 Annual Meeting. 

Simply visit the SOT Web site and follow the E-mail Center 

link from the navigation. 

To log into your mailbox, use your e-mail address and password 

or Annual Meeting badge number. If you do not know 

your login, you can use the SOT password retrieval request 

from the login on the SOT Web site or ask the Annual Meeting 

registration staff or E-mail Center attendant for assistance. 

Job Bank users will have the option to send messages to the 

Annual Meeting E-mail Center mailboxes. E-mail Center 

users will have the option to send messages to Job Bank 

registrant mailboxes by name or Job Bank ID. Additionally, 

the E-mail Center provides extended communication permitting 

members and Job Bank registrants who do not attend the 

meeting to communicate with attendees. Even colleagues and 

family members can e-mail messages into the Center. 

Letter of Attendance 

Please stop by the SOT Annual Meeting Registration after 

Tuesday morning if you would like a letter of attendance for 

your participation in the 2010 SOT Annual Meeting and/or the 

Continuing Education Course(s). 

Lost and Found 

Lost and found articles may be taken to the SOT Headquarters 

Office, Room 254 B, of the Salt Palace Convention Center. 

Any items left in the SOT Headquarters Office after 

11:30 AM, Thursday, March 11 will be deposited in the 

Security Office at the Convention Center. 

Lunch with an Expert Information Board 

The Lunch with an Expert (LWAE) events are informal gatherings 

of small groups of students and a Toxicology Expert over 

a meal or social hour. The Student Advisory Council sponsors 

these events to provide students an opportunity to network 

with well-established toxicologists while obtaining career 

advice and meeting new colleagues. The groups are matched 

by research interests and the Expert for each group identifies a 

time and place to assemble. The LWAE Information Bulletin 

Board provides all the details for the group meetings and is 

located in the South Foyer near Registration. Groups meet at 

the board before proceeding to their meal. 

Media Support Services 

The Society of Toxicology welcomes accredited representatives 

of media organizations. Journalists may receive 

complimentary credentials for all meeting sessions, as well as 

a media kit, by contacting Martha Lindauer, Media Contact 

at SOT Headquarters: (703) 438-3115 or e-mail martha@toxicology.org. 

Speakers interviews can be arranged on-site and 

media kits can be picked up at the SOT Headquarters Office, 

Room 254 B, in the Salt Palace Convention Center. 

Meet Me at the Meeting Place 

Looking for a convenient place to meet friends or new 

acquaintances? This centralized Meeting Place has been 

designated near the East Entrance of the Convention Center, 

which is across the street from the Marriott Downtown. The 

Meeting Place makes it convenient to meet colleagues and is 

the ideal location for a photo opportunity! Look for the Mt. 

SOT tower just inside the East Entrance. 

Message Boards 

Leave a quick note on the message boards. Note pads and push 

pins will be available to post messages on the message boards, 

which are near the E-mail Center located in the North Foyer 

of the Grand Ballroom of the Salt Palace Convention Center. 

Parking Information 

The Salt Palace Convention Center has two covered parking 

areas, available seven days a week from 6:00 AM–9:00 PM. 

One garage is located at 200 South 185 West (south end has 

600 stalls) and the other garage is located at 50 South 300 

West (north west end has 400 stalls). The current parking rate 

per entrance is $7 (subject to change) and does not include in/ 

out privileges or overnight parking. 

GEnEral InFO 




GEnEral InFO 

Photography Policy and Session Etiquette 

for Attendees 

Out of courtesy for the scientific presenters, we appreciate 

your compliance with the following policies: 

• Cell phones and other electronic devices should be set 

on mute. 

• Electronic capture of scientific sessions by any method is 

prohibited. 

• Children under the age of 15 are not allowed in scientific 

sessions unless the session chair gives consent. 

Session chairs are asked to enforce these policies and individuals 

who do not comply will be asked to leave the session. 

• Photography of poster presentations is prohibited without 

the specific consent of the presenter(s)/author(s). 

• Children under the age of 15 are prohibited from 

accessing the Exhibit Hall at any time. 

If you have any questions regarding these polices, please 

contact the SOT Headquarter staff at the Registration Desk. 

Registration Desk Hours 

The Annual Meeting Registration Desk is located in the Salt 

Palace Convention Center, South Foyer. 

Registration Desk hours: 

Saturday ......................................................4:00 PM–7:00 PM 

Sunday ........................................................7:00 AM–8:00 PM 

Monday ......................................................7:00 AM–5:00 PM 

Tuesday ..................................................... 8:00 AM–4:00 PM 


Thursday ..................................................8:00 AM–11:30 AM 

Full registration details may be found on page 48. 

Safety and Security 

The possibility of demonstrators is very real given the nature 

of our conference. Events of this nature range from verbal 

confrontations, protests, strikes, to riots. We recommend the 

following procedures in the event of demonstrations: 

• Have your name badge available upon entering the 

Convention Center. Wear your name badge in the 

Convention Center. When leaving the facility, remove it so 

as to blend with other people. 

• If you see a demonstration or protest beginning, please 

contact any member of the SOT Annual Meeting staff and 

they will initiate an SOT response. If you see actions that 

appear threatening, notify the nearest security officer. 

• Do not engage, defend either side, or subdue person(s) in 

any type of disturbance. Demonstrators are usually trying 

to attract media attention. Don’t help them! 

• SOT representatives will respond to media inquires. Do 

not participate in interviews or other media responses. 

• In the unlikely event that outsiders disrupt a scientific 

session or other event, SOT security officials have developed 

a contingency plan. Please follow directions from the 

chairperson and avoid becoming involved in the situation. 

Safety Tips 

Walk “smart” when you leave the Convention Center: 

• Know your destination and the best way to reach it. 

• Travel along sidewalks in lighted areas at night, and don’t 

walk alone. 

• Establish a “buddy” system with another attendee to walk 

to the Convention Center. 

• Share schedules and check up on each other periodically. 

• Build your awareness of unknown surroundings by 

reviewing local information. 

• Laptop computers are attractive, easy targets for thieves. 

Be sure your laptop is in a secure place. 

• Jackets with pockets provide a convenient alternative to 

reduce the chance for lost or stolen handbags. 

Our first priority is safety. The best way to stay safe is to be 

aware of your surroundings and to avoid situations where you 

feel uncomfortable. 

Salt Lake City Information Desks 

The Salt Lake Convention and Visitors Bureau will run 

an information booth located in the South Foyer near the 

SOT Registration Desk. They can assist you with everything 

from attraction tickets and dining reservations to sightseeing 

suggestions and local travel information. There is also a 

Salt Lake Visitor Information Center located in the Salt Palace 

where qualified visitor information specialists and volunteers 

are on hand to assist you. They are staffed Monday–Friday 

9:00 AM–5:00 PM and Saturday and Sunday 9:00 AM–5:00 

PM. The Connect Pass (attraction ticket) can be purchased in 

the Gift Shop which is located next to the Visitors Center. 

A full listing of restaurants begins on page 30. 

54 




SOT Headquarters Office 

The SOT Headquarters Office is located in the Salt Palace 

Convention Center Room 254 B on Second Level. 

SOT Headquarters Office hours: 

Saturday ......................................................4:00 PM–7:00 PM 

Sunday ........................................................ 7:00 AM–5:30 PM 

Monday ......................................................7:00 AM–5:00 PM 

Tuesday ......................................................7:00 AM–4:30 PM 


Thursday ..................................................7:00 AM–11:30 AM 


Do you know all the resources available through SOT and 

where to find them? Stop by the SOT Resource Pavilion— 

Booth #1901—in the Exhibit Hall and learn about SOT 

services and membership benefits. Members of SOT Regional 

Chapters, Specialty Sections, and the Special Interest Groups 

will be on hand to discuss their programs and there will be 

handouts about component group activities and benefits 

of joining. You will also find Endowment information, 

toxicology-related materials that can be used for target audiences 

as well as education materials for K–12. The Pavilion is 

the One-Stop Shop for all of your questions and membership 

needs. 

Pavilion hours: 

Monday ......................................................9:00 AM–4:30 PM 

Tuesday ......................................................8:30 AM–4:30 PM 



The Speaker Ready Room will be located in Room 252 and 

is available during the SOT Headquarters Office hours listed 

above. SOT HQ will provide all confirmed presenters in 

scientific sessions log-in credentials to access the submission 

site to preload your presentations. All presentations should 

be preloaded in advance of the meeting, but not less than 

30 minutes prior to the start of the sessions in the Speaker 

Ready Room only. Presenters will not be able to upload a 

presentation in the session room. 

Sponsorship 

The SOT Annual Meeting is the largest scientific gathering of 

toxicologists in the world, and our Annual Meeting Sponsors 

play an integral role in the success of this important event. 

Becoming an Annual Meeting Sponsor demonstrates your 

organization’s commitment to SOT’s vision of “creating a safer 

and healthier world by advancing the science of toxicology.” 

Sponsorship also provides an opportunity for better name 

recognition of your company among SOT members and the 

Annual Meeting attendees. In addition, your support allows 

the Society to keep registration fees low, thereby enabling us 

to attract nearly 6,500 attendees to the Annual Meeting. 

There are four levels of sponsorship available: 

Diamond ($10,000 or more), Platinum ($5,000–$9,999), 

Gold ($2,500–$4,999), and Silver ($1,000–$2,499). 

You will find a complete menu of sponsorships designed to 

assist your organization in establishing a leadership position 

at the SOT 2010 Annual Meeting on the Web site at 

www.toxicology.org. 

Sponsor names are prominently displayed on the Annual 

Meeting Web site, as well as in print materials that are distributed 

before and during the Annual Meeting. Sponsorship 

is also recognized through signage displayed around the 

Convention Center during the Annual Meeting. 

Annual Meeting sponsorship contributions are tax deductible 

per IRS regulations. For detailed information about 

SOT sponsorship opportunities, please contact Liz 

Kasabian at SOT Headquarters: (703) 438-3115 or e-mail: 

liz@toxicology.org. 

For a complete list of our 2010 Annual Meeting Sponsors (as 

of press time), please see the back cover and inside-back cover. 

Tour Information 

For tour information, visit the Tour Desk located in the 

Registration area, South Foyer of the First Level. 

Tour Desk hours: 

Saturday, March 6 .......................................4:00 PM–7:00 PM 

Sunday, March 7 ...................................... 8:00 AM–4:00 PM 

Monday, March 8 ..................................... 8:00 AM–4:00 PM 

Tuesday, March 9 ...................................... 8:00 AM–4:00 PM 

Wednesday, March 10 ................................8:00 AM–2:00 PM 

Tour desk hours are subject to change. 

tour tickets 

Pre-purchased tickets will be mailed to registrants 

approximately 2 weeks prior to the Annual Meeting. After 

February 28, please call Western Leisure for availability of 

tickets, and tickets may be picked up at the convention tour 

desk located in the South Foyer in the Salt Palace Convention 

Center. Tickets are also sold on-site on a first-come, firstserved 

basis at the convention tour desk or from the tour guide 

on the bus at the time of the tour. No refunds will be made 

after February 28, 2010. 

GEnEral InFO 

tour departures 

Tour departure information will be available at the Tour Desk 

located in the South Foyer. All tours will leave from the south 




entrance of the Salt Palace Convention Center. Please arrive at 

least 15 minutes prior to your scheduled tour departure time. 

The Toxicologist (Print and CD-ROM)/ 

Itinerary Planner and the Program 

All Annual Meeting registrants receive a copy of this 

Program and The Toxicologist on CD-ROM, a special issue of 

Toxicological Sciences that includes all meeting abstracts and 

SOT Annual Meeting events. Special software on the CD, the 

Itinerary Planner, allows the meeting attendee to search the 

meeting abstracts, events, and create a personalized schedule 

for the meeting. (See grey box below) 

The 2010 Itinerary Planner has several new options that allow 

attendees to add committee meetings, special events, and 

exhibitor hosted sessions to their itinerary. 

• SOT members in the U.S. and Canada will receive 

the Program and The Toxicologist on CD-ROM (with 

Itinerary Planner) prior to the meeting, as will U.S. and 

Canadian non-members who pre-register by January 

22, 2010. A printed version of The Toxicologist will be 

available on-site in the registration area for a fee of $20. 

Registrants may reserve a copy by signing up on the 

Registration form or may purchase a copy on-site, while 

supplies last. 

• Non-member registrants in the U.S. who register after 

January 22 will receive the printed Program and The 

Toxicologist on CD-ROM (with Itinerary Planner) at the 

registration area on-site. 

• The Annual Meeting Itinerary Planner will be available 

on the SOT Web site January–April. 

• International members who do not attend the Annual 

Meeting may contact the SOT Headquarters office to 

request a copy of the printed 2010 Program and The 

Toxicologist on CD-ROM. These items will be mailed 

following the Annual Meeting. 

• The Toxicologist will be available on the SOT Web site 

after March 1, 2010. 

NOTE: Please bring your copy of the Program with you to the 

Annual Meeting. 

Transportation 

air transportation 

Salt Lake City International Airport is located five miles 

northwest of downtown Salt Lake City or about a 10-minute 

drive. It serves more than 20 million passengers annually 

and ranks as the 23 rd largest airport in the United States. 

The airport ranks as one of the most cost-effective, large hub 

airports in the nation and is situated within a two and a half 

hour flight from half of the United States population. 

Airlines serving Salt Lake City operate over 300 daily departures 

to 71 nonstop destinations throughout the U.S. and 

Canada. The U.S. Department of Transportation typically 

ranks Salt Lake City International Airport in the top 10 U.S. 

airports for on-time performance. 

Nine airlines and their affiliates serve Salt Lake City 

International Airport and include American, Continental, 

Delta, Frontier, JetBlue, Southwest, United and US Airways. 

It is Delta’s third largest hub. For more information, call (801) 

575-2400 or (800) 595-2442, or visit www.slcairport.com. 

GEnEral InFO 

On-Line Itinerary Planning Tool Enhancements 

New Features for 2010 

SOT is excited about the improved functionality of the on-line customizable Itinerary Planner. 

We invite you to use this tool to plan your Annual Meeting experience. 

Choose the presentations, featured lectures, meetings, or special event functions you wish to add to your personal 

itinerary. After you’ve selected your schedule of sessions, you’ll be able to export this information 

to your default calendar program for reference using iCal, a calendar software application that functions 

with Windows on the PC (www.brownbearsw.com), the Mac (www.apple.com), and most mobile 

devices. The downloaded information will contain specific details for these sessions or events such 

as date, time, and the location. Additionally, each presentation downloaded provides you with 

access to detailed abstract information including authors, institutions, and the full abstract. 

MAR 

Look for more information to be made 

available soon on the SOT Web site. 

SOT Annual Meeting Begins 

56 




Special Airfare Discounts 

SOT has established discounted rates through American, 

Delta, and JetBlue Airlines originating in the United States 

and Canada. Be sure to use the discounted reference numbers 

when making your reservations. You may purchase your ticket 

on-line, call the airline directly using the toll-free numbers, or 

provide your travel agent with the reference/discount numbers 

listed below to receive the discount. 

American Airlines 

(800) 433-1790 

www.aa.com 

Discount Code: 5130AC 

American Airlines is offering a 5% discount off the lowest 

applicable fare. The discount is valid March 4–14, 2010, for 

travel to Salt Lake City. You may make reservations by calling 

the Meeting Services Desk at (800) 433-1790 from anywhere 

in the United States or Canada and refer to discount code 

5130AC. A $20 service fee per ticket will apply for each ticket 

booked over the phone. You may also book your ticket on-line 

at www.aa.com (no service fee applies) and under the promotion 

code section, type 5130AC to receive the SOT discount. 

Delta Airlines 

(800) 328-1111 

www.nwa.com 

Discount Code: NY299 

Delta Airlines is offering up to a 5% discount off full/nonrestricted 

fares to Salt Lake City. The discount is valid March 

2–17, 2010, applicable to U.S./Canada originating passengers. 

You may make reservations by calling (800) 328-1111 

from anywhere in the United States or Canada and refer to 

file number NY299. The $20 service fee per ticket has been 

waived for SOT. You may also book your ticket on-line at 

www.nwa.com (no service fee applies) and under the promotion 

code section, type NY299 to receive the SOT discount. 

JetBlue 

(800) 328-1111 

www.jetblue.com/promo 

Discount Code: SOT2010 

JetBlue is offering a 5% discount off the lowest available 

fare. The discount is valid March 5–13 for travel to Salt 

Lake City. To use the discount, book your flight on-line 

at www.jetblue.com/promo and use the discount code 

SOT2010. 

SOT Travel Agent—Carlson Wagonlit 

Carlson Wagonlit is the official travel management firm 

for SOT’s 49 th Annual Meeting. To take advantage of their 

services and savings, call toll-free (800) 535-9117 Monday 

through Friday, 9:00 AM–5:30 PM (Eastern Standard Time) 

and ask to speak to anyone on our SOT dedicated team or 

e-mail: washington.remote@carlsonwagonlit.com. To obtain 

the maximum discounted fares, call at least 60 days prior to 

departure. Lower fares are still obtainable up to 14 days in 

advance. Please note that Carlson Wagonlit charges a $42 

service fee per ticket. 

Before calling Carlson Wagonlit, please gather the following 

information: 

• The desired dates of arrival to and departure from Salt 

Lake City. 

• Your home city or originating airport. 

• Your approximate time of departure from the originating 

airport. 

• The number of persons traveling (adults/children). 

• Your method of payment, either credit card or check. 

• Your airline frequent flyer number(s). 

Identify yourself as a Society of Toxicology attendee. Carlson 

Wagonlit will find the best fare for you and e-mail an itinerary 

to you. 

Ground transportation 

Arrive at the Salt Lake City International Airport and be 

downtown in minutes! Taxis, limos, buses, car rentals, and 

shuttles supply service to downtown and the ski resorts. For 

more information on ground transportation from the airport 

visit www.slcairport.com, or call the Ground Transportation 

Desk at (801) 575-2477. 

Car Rental 

Avis Rent A Car Systems, Inc. 

(800) 331-1600 

www.avis.com 

Discount Number: T534999 

Avis Rent A Car Systems is the official car rental company 

for the 49 th Annual Meeting. SOT discounted rates, including 

unlimited mileage, begin at $43.99 per day. These special 

group rates are good one week before and after the SOT 

Annual Meeting, so you can take in the sights and explore the 

surroundings at your own pace. To reserve your car on-line go 

to www.avis.com. 

You may also call Avis directly at (800) 331-1600 to reserve 

your car. Be sure to mention the SOT Avis Worldwide 

Discount Number (AWD) T534999. 

GEnEral InFO 




GEnEral InFO 

Express Shuttle Utah 

The Express Shuttle Utah will transport you from Salt Lake 

City Airport to your downtown hotel for a discounted price of 

$7 per person one way (prices subject to change). Reservations 

are not required for transfers from the airport. Upon arrival 

at the airport, proceed to one of two Express Shuttle desks, 

located in the baggage claim areas of both terminals. Let 

the desk agent know you are with the Society of Toxicology 

Annual Meeting. 

Reservations are required for transfers to the airport and must 

be made at least 24 hours in advance. You must mention that 

you are with the SOT Annual Meeting conference in order to 

receive the $7 rate. 

You may make your reservations by calling (800) 397-0773 or 

you may make them on-line at www.xpressshuttleutah.com. 

If you would like to make reservations on-line, please type the 

name of our meeting in the comments sections, and they will 

adjust the price. 

Taxi Service 

There are three main taxi companies in Salt Lake City, and 

each offers 24-hour service: 

• City Cab (801) 363-5550 

• Yellow Cab (801) 521-2100 

• Ute Cab (801) 359-7788 

You can call for service or hail them in the street, but they 

are not as plentiful as in other major cities. Some downtown 

hotels like the Salt Lake Hilton have taxi stands. A one-way 

taxi from the airport to downtown is usually around $10–$15. 

Taxi service booths are located in the baggage claim areas 

outside of door #7 in Terminal One and door #11 in Terminal 

Two. 

Utah Transit Administration (UTA) 

UTA provides more than 100 bus routes throughout a 1,800 

square mile area. UTA also provides light-rail service 

(TRAX), airport transportation, service to ski resorts in 

winter, and door-to-door transportation for disabled passengers. 

Fares are approximately $2 one-way or $5 for an 

all-day pass. A free fare zone allows passengers to navigate 

easily downtown. The closest TRAX stop to the South Foyer 

entrance of the Salt Palace Convention Center is Gallivan 

Plaza at 239 South Main Street. 

A UTA bus leaves the airport for the City Center Station every 

30 minutes during the day and every 60 minutes after 7:00 

PM. Bus stops are located in the parking structure between 

Terminal One and Terminal Two. Limited service is available 

on weekends and holidays. 

Call (801) 743-3882 for more information, or visit 

www.rideuta.com. 

Amtrak 

340 South 600 West 


There is currently one Amtrak train route that runs through 

Salt Lake City. This route, California Zephyr, runs from the 

San Francisco area to Chicago and is believed to be one of 

the most scenic train rides in all of North America. The train 

station is located downtown and is approximately one mile 

from the Salt Palace Convention Center. For more information, 

visit www.amtrak.com or call (800) 872-7245. 

driving 

Driving to Salt Lake is a breeze on Interstate 15, recently 

rebuilt, making it easier to go anywhere. In Salt Lake City, 

wide streets are laid out in a grid system, starting downtown 

at the intersection of Main Street and South Temple. From 

there the streets are numbered in increments of 100. If you go 

4 blocks south, you are on 400 South. If you then turn left and 

go 4 blocks, you are on 400 South and 400 East, called 4 th 

South and 4 th East. If you end up at 3900 South and 2700 East, 

you are 39 blocks South and 27 blocks East of the downtown 

marker. 

SOt ride Share 

SOT is offering a Ride Share Program in conjunction with 

the Annual Meeting. For those who live close enough to the 

Salt Lake area or those who do not wish to fly, you may want 

to consider the Ride Share Program. Avoid airport hassles 

by driving and make it easier for other scientists to attend by 

sharing rides. Students especially appreciate ways to make the 

meeting even more economical. 

Once you have registered for the Annual Meeting, you can 

access the Ride Share Program from the Annual Meeting 

section of the Web site. You can indicate whether you want 

to drive or be a passenger, and then see a list of others who 

have registered. It will be up to you to match your plans with 

someone else who is registered. Please remember to remove 

your name when your travel plans are in place. 

58 


SOT Job Bank 

The UlTimaTe RecRUiTmenT and employmenT ResoURce 

Job Seekers—Your dream Job awaits You in the SOt Job Bank!!! 

• all SOt Members can utilize the SOt Job Bank 

as a job seeker free-of-charge. 

• register and enter your candidate profile; 

it only takes 15 minutes to complete. 

• Post your resume. 

Employers are looking for Candidates through this Service 

and You don’t Want to Be left Out 

• review the positions posted by major 

corporations, academic institutions, 

government agencies, and private research 

organizations; positions range from junior- to 

senior-level. 

• Search by geographic location, employer name, 

salary, and other criteria. 

• Search from a pool of distinguished candidates. 

• Join the many employers who rely on this cost 

effective and efficient database to assist with 

their employment needs. 

• Find the right candidate from among scientists 

trained in toxicology and the biological sciences 

with the expertise and right work experience for 

your position. 

• Find potential matches to your skills and 

training at any stage of your career. 

• apply for positions. 

• Gain access to information that will help you 

plan your near-term and long-term goals and 

objectives. 

• See which sectors are hiring. 

• Stay abreast of new and emerging areas. 

Employers—recruit Highly Qualified Candidates 

through the SOt Job Bank!!! 

the SOt Job Bank is the Ideal Place to Streamline Your recruitment Process and 

Provides Your Organization with a valuable tool 

• Schedule interviews to hold during the SOt 

annual Meeting at the on-site Job Bank Center. 

• reserve interview rooms in advance or on-site. 

• SOt affiliates receive a reduced registration rate 

in appreciation for supporting the Society in 

achieving its objectives. 

The On-Line SOT Job Bank Is Available Any Time, from Any Place 

at www.toxicology.org. 



Career Resources and Development Services 

The Society of Toxicology’s Career Resource and Development 

(CRAD) services include the on-line Job Bank, special Job 

Bank activities at the Annual Meeting, career development 

seminars and resources, and employer ads in SOT’s newsletter, 

the Communiqué, which reaches the entire SOT membership 

and beyond. 

On-Line Mentor Match Program 

Career Planning is never Over: lend a Hand or 

receive One at Mentor Match! 

The Society of Toxicology recognizes the importance of 

mentoring in the scientific and professional development 

of its members. The objective of the new on-line mentoring 

program, Mentor Match, is to provide a service that matches 

mentees with potential mentors from the SOT membership 

to provide advice on career path selection, professional 

development, and life/work balance issues. SOT members are 

encouraged to share their professional knowledge and experience 

by serving as mentors for colleagues and for the next 

generation of toxicologists. The SOT Annual Meeting provides 

a great opportunity for the mentor and mentee to meet in 

person. We strongly encourage members of the Society to visit 

the Mentor Match site and register on-line as mentors and/or 

mentees. The Mentor Match program will develop as individuals 

register, allowing the quantity of profiles to increase to a 

robust combination of both mentors and mentees. The Mentor 

Match program is accessible to all active SOT members by 

visiting www.toxicology.org/ai/newcrad/mentormatch.asp. 

SOT On-Line Job Bank and On-Site Job Bank 

Center 

to provide them with a robust database of candidates available 

for career opportunities, ranging from junior- to senior-level 

positions. 

The Job Bank helps streamline the process for candidates and 

employers. Candidates can gain access to a variety of positions 

suited to their experience, areas of expertise, and desired 

geographical location. In addition, job seekers can see which 

sectors are hiring and stay abreast of new and emerging areas. 

Employers can attract potential candidates in a targeted and 

cost-effective manner through this SOT service. By having 

access to detailed candidate resumes, employers can determine 

the right match for a specific position and expedite the recruitment 

process. SOT Corporate Affiliates receive a reduced 

rate for position posting in appreciation for supporting the 

Society in achieving its objectives. 

Job Seeker Registration 

for SOT On-Line Job Bank 

Candidate Types 

Fees 

SOT Member $ 0 

Non-SOT Member $80 

Non-SOT Member—Postdoctoral $45 

Non-SOT Member—Student $30 

Employer Registration 

for SOT On-Line Job Bank 

CarEEr SErvICES 

take advantage of this Free Member Benefit 

SOT Members can register as a job seeker and access the positions 

posted on the Job Bank at no charge. 

The Society’s on-line SOT Job Bank makes it easy for 

candidates and employers alike to access this resource 

year-round, any time, any place via the SOT Web site at 


This forum links job candidates with employment positions in 

toxicology and related biological sciences. The SOT Job Bank 

allows you to: 

• Register as an employer or candidate 

• Post employment positions 

• Search the Job Bank database 

• Contact candidates or employers 

The on-line Job Bank lists positions available at corporations, 

academic institutions, government agencies, and private 

research organizations. Employers rely on this on-line service 

Employer Types 

Fees 

SOT Affiliate $200 

Corporation $400 

University or Government $110 

Nonprofit Organization $110 

60 



Career Resources and Development Services (Continued) 

Annual Meeting On-Site Job Bank Center 

Located in the Salt Palace Convention Center, the on-site Job 

Bank Center provides Annual Meeting attendees with access 

to the SOT Job Bank system as well as assistance in facilitating 

interviews at the SOT Annual Meeting. All users with 

current registrations at the time of the Annual Meeting 

will be permitted to use this service. 

A bank of computers will be available in the SOT Job Bank 

Center for last minute updates to your account information or 

posting, as well as printers for producing paper copies of candidate 

profiles and position descriptions. If you are a candidate 

attending the Annual Meeting, you should bring multiple 

copies of your personal resume for interested interviewers. 

All candidates and positions will be sought on-line. 

Employers recognize and appreciate that the Annual Meeting 

On-Site Job Bank Center provides a cost-effective and efficient 

way to interview a distinguished pool of candidates. 

Employers and candidates may take advantage of the multiple 

spaces available in Rooms 155 A&D to hold interviews. Some 

rooms were available to be scheduled in advance, others 

are on a first-come, first-served basis. To ensure privacy for 

candidates, the SOT Job Bank Center is located away from the 

scientific sessions. Also, the Job Bank interview rooms will 

be fitted with modular hard walls to increase privacy when 

interviews are conducted. 

It is up to the registrants of this service to exercise the confidentiality 

options that are offered. SOT is not responsible 

if any information contained in the Job Bank database is 

released. 

Although you are encouraged to pre-register before entering 

the Job Bank Center, you can register on-site in Rooms 155 

A&D. 

The Center is available during the following 

hours of operation: 

Sunday, March 7 ......................................10:00 AM–4:30 PM 

Monday, March 8 .......................................9:00 AM–4:30 PM 

Tuesday, March 9 .......................................8:30 AM–4:30 PM 

Wednesday, March 10 ................................8:30 AM–4:30 PM 

On-line Job Bank access will be available—as always— 

through your personal computer and at the Annual Meeting 

E-mail Center. Access to the on-line Job Bank in the Center is 

limited to short searches for updates or new information. 

For additional information, contact Kristen Meletti at 

SOT Headquarters: (703) 483-3115 ext. 1660 or e-mail: 

kristen@toxicology.org. 

Employer Ads in SOT Communiqué 

The Society’s newsletter, the Communiqué, is published four 

times annually. It includes career opportunity advertisements 

for employers from corporate, university, governmental, 

and nonprofit organizations wishing to reach the entire SOT 

membership and beyond. For more information, contact 

Marcia Lawson at SOT Headquarters: (703) 438-3115 ext. 

1446 or e-mail: marcia@toxicology.org. 

SOT’s Career Development Program Track 

To help you develop your near-term and long-term career 

pathway, plan on attending the Education-Career Development 

Sessions scheduled this year that will be of special interest to 

you. Sessions include the following: 

• Where Do I Go Now? Rational Career Development 

Planning for Early-Career Scientists— 

Tuesday, March 9, 9:00 AM–11:45 AM, Ballroom G 

• Science Communication in 2010: A New Decade in 

Toxicology and Need for Better Communication— 

Tuesday, March 9, 12:00 NOON–1:20 PM, Ballroom F 

• Career Alternatives in Toxicology: Lessons Learned— 

Wednesday, March 10, 7:30 AM–8:50 AM, Ballroom B 




Career Resources and Development Services (Continued) 


Directions to the On-Site Job Bank Center 

The SOT Annual Meeting On-Site Job Bank Center is located 

in Rooms 155 A&D of the Salt Palace Convention Center. 

Please see page 22 for a map of Salt Palace Convention Center. 

Directional signs will be placed throughout the Center to 

guide you. 

From the South Foyer (registration area) 

• Take the escalator to the second level and continue to the 

end of the corridor (550 ft.). 

• Turn left and continue down the long curved hallway (300 

ft.); at the end of the curved hallway, turn left. 

• Go (200 ft.) through the bank of doors; take the elevator, 

escalator, or stairs down one level. 

• If you have taken the elevator, exit the elevator and turn 

right and go to the end of the hall (120 ft.) and then turn 

left and go (40 ft.) into Room 155. 

• At the bottom of the escalator or stairs you will go left (30 

ft.) then turn left and go (60 ft.) to the end of the hall. 

• Turn right and go to the end of the hall (140 ft.) and then 

turn left and go (40 ft.) to Room 155. 

• Room 155 A is the first room on the right and Room 155 

D is the first room on the left. 

From the East Entrance (large tower on West 

temple Street) 

• Go up the ramp (180 ft.) and turn right and go down the 

hall (300 ft.). 

• Turn left and continue down the long curved hallway (300 

ft.); at the end of the curved hallway, turn left. 

• Go (200 ft.) through the bank of doors; take the elevator, 

escalator, or stairs down one level. 

• If you have taken the elevator, exit the elevator and turn 

right and go to the end of the hall (120 ft.) and then turn 

left and go (40 ft.) into Room 155. 

• At the bottom of the escalator or stairs you will go left (30 

ft.) then turn left and go (60 ft.) to the end of the hall. 

• Turn right and go to the end of the hall (140 ft.) and then 

turn left and go (40 ft.) to Room 155. 

• Room 155 A is the first room on the right and Room 155 

D is the first room on the left. 

From Inside the Exhibit Hall 

• Go to the north end of the Exhibit Hall (far right) to Hall 

1; there you will see a hallway. 

• Go (80 ft.) into Room 155. 

Room 155 A is the first room on the right and Room 155 D is 

the first room on the left. 

nIH Brown Bag Lunch 

Tuesday, March 9, 12:00 nOOn–1:15 PM 

Chairperson(s): Joel G. Pounds, Pacific Northwest National 

Laboratory, Richland, WA 

Sponsored by: 

Research Funding Committee 

Join staff from the NIH Center for Scientific Review (CSR) 

and the NIEHS program officers for lunch and informal 

discussions about review and grant opportunities at NIEHS. 

There will be an overview of NIH grantsmanship and then 

time for questions and discussion. You can make arrangements 

to meet these representatives later in the NIH Resource Room. 

Bag lunches will be available for the first 75 participants. 

nIH Resource Room 

Tuesday, March 9, 9:00 AM–4:30 PM 

wednesday, March 10, 9:00 AM–4:30 PM 


Laboratory, Richland, WA 

Sponsored by: 


All meeting attendees interested in National Institute of 

Health (NIH) funding are encouraged to take advantage 

of this opportunity to meet with staff from NIH Center for 

Scientific Review and NIEHS who will be available in the 

NIH Resource Room for individual conversations. Learn 

about the match of research interests to grant programs, check 

the ins and outs of the new application guidelines, and discuss 

in depth the specifics of proposals. Drop in, attend the NIH 

Brown Bag Lunch on Tuesday to make an appointment, or 

check the posted schedule to meet with the relevant NIH staff 

member. New investigators are especially encouraged to meet 

with program staff. Handouts will be available. 

62 


SOT Encourages the Recruitment of Undergraduates to Toxicology 

Undergraduates can register on the SOT Web site for special status 

as Undergraduate Student Affiliates 

Special Programs for Undergraduates at the SOT Annual Meeting 

These are coordinated by the SOT Education Committee and 

Committee on Diversity Initiatives. 

• Undergraduate Education Program for students from groups 

underrepresented in the sciences and their advisors 

• Undergraduate Education Program for students at institutions that 

receive low federal funding in science, math, engineering, and technology 

• Pfizer Undergraduate Student travel award for outstanding students 

presenting abstracts 

Support for toxicology career presentations through the ToxScholar 

and Guest Lecturer Programs 

Toxicologists receive travel support for visits to campuses to present seminars 

and meet informally with students to introduce toxicology and 

discuss career pathways. 

Find more information at 



EdUCatIOn & OUtrEaCH 

Education and Outreach Activities (Continued) 


Do you know all the resources available through SOT and 

where to find them? Stop by the SOT Resource Pavilion— 

Booth #1901—in the Exhibit Hall and learn about SOT 

services and membership benefits. Members of SOT Regional 

Chapters, Specialty Sections, and the Special Interest Groups 

will be on hand to discuss their programs and there will be 

handouts about component group activities and benefits 

of joining. You will also find Endowment information, 

toxicology-related materials that can be used for target audiences, 

as well as education materials for K–12. The Pavilion is 

the One-Stop Shop for all of your questions and membership 

needs. 

undergraduate Education Program 

Saturday, March 6, 4:15 PM–9:00 PM 

Chairperson(s): Adrian Nanez, Amgen, Thousand Oaks, CA. 

Sponsor: 

Committee for Diversity Initiatives 

This evening event is for undergraduate students and advisors 

receiving 2010 MARC and SOT Travel funding and 

SOT program volunteers. All activities are in the Salt Palace 


4:15 PM–5:45 PM Orientation for SOT Hosts, Peer 

Mentors, and Advisors (Room 258) 

Jennifer Rayner, Oak Ridge National 

Laboratory, Oak Ridge, TN. 

5:15 PM–5:45 PM Registration for Students 

5:45 PM–6:00 PM Opening Event (Room 255 C) 

Convener: Adrian Nanez, Amgen, 

Thousand Oaks, CA. 

6:15 PM–6:45 PM Lecture: Introduction to Toxicology 

Jose Manautou, University of 

Connecticut, Storrs, CT. 

6:45 PM–7:15 PM Dinner 

7:30 PM–8:00 PM Lecture: Absorption, Distribution, 

Metabolism, and Excretion 

Principles in Toxicology 

Nathan Cherrington, University of 

Arizona, Tucson, AZ. 

8:00 PM–9:00 PM CDI Reunion 

(Anyone involved with the SOT 

Undergraduate Program through the 

years is invited) 


8:00 PM–8:10 PM Recognition of the 2010 Perry J. 

Gehring Diversity Student Travel 

Award Recipient 

Nygerma L. Dangleben, University of 

California, Berkeley, Berkeley, CA. 

8:10 PM–8:20 PM Overview for Sunday 

8:20 PM–9:00 PM Dessert and Networking 


Sunday, March 7, 8:00 AM–8:30 PM 


Sponsor: 


The Sunday program is open to undergraduate students who 

register for this event using the Annual Meeting Registration 

Form, the undergraduate students receiving MARC, SOT, and 

Pfizer travel funding, and the SOT program volunteers. All 

activities are in the Salt Palace Convention Center. 

All Participants—Room 255 B 

8:00 AM–8:15 AM Welcome: Cheryl Lyn Walker, SOT 

President, University of Texas MD 

Anderson Cancer Center, Smithville, TX 

Chairs: Adrian Nanez, Amgen, 

Thousand Oaks, CA, and Nathan 

Cherrington, University of Arizona, 

Tucson, AZ. 

8:15 AM–8:55 AM Exposure to Cigarette Smoke 

In Utero: Fetal Injury and Life Long 

Consequences 

Judith Zelikoff, New York University 

School of Medicine, Tuxedo Park, NY. 

9:00 AM–9:45 AM Metals, Biocides, and the Environment 

Louis Trombetta, St. John’s University, 

Jamaica, NY. 

9:45 AM–10:00 AM Break 

10:00 AM–10:40 AM Optical Nanotechnologies for 

Imaging of Cellular Processes and 

Neurosurgery 

Martin Philbert, University of Michigan, 

Ann Arbor, MI. 

10:45 AM–11:30 AM Interactive Presentation: Exploring 

Contemporary Biomedical Problems: 

Case Studies in Toxicology 

Lauren Aleksunes, Rutgers University, 

Piscataway, NJ. 

11:30 AM–12:45 PM Lunch and Networking (Room 255 C) 

64 



Breakout Sessions for Students— 

Concurrent Sessions in Rooms 259, 260 A, 260 B 

12:45 PM–1:45 PM What Is Graduate School and 

What Can I Expect? 

How to Get into Graduate School: 

An Academic Advisor’s Perspective 

Graduate Student Facilitators: 

Michael Coronado, Johns Hopkins 

University, Baltimore, MD, 

Vanessa De La Rosa, University of 

California,Berkeley, Berkeley, CA, and 

Natalie Johnson, Texas A&M, College 

Station, TX. 

Breakout Session for Advisors—Room 258 

12:45 PM–1:45 PM Tips for Advising Prospective 

Graduate Students or How to Get 

Your Students Accepted to Graduate 

School!! 

William D. Atchison, Michigan State 

University, East Lansing, Michigan and 

Mary Ann Smith, University of Texas 

at Houston School of Public Health, 

Houston, TX, and Yolanda Banks 

Anderson, North Carolina Central 

University, Durham, NC. 

All Participants Room 255 C 

2:00 PM–2:45 PM Career Opportunities in Toxicology— 

Panel Discussion 

2:45 PM–3:00 PM Break 

For Host Mentors and Peer Mentors—Room 258 

3:00 PM–3:30 PM Host Mentor and Peer Mentor 


Chairs: Jennifer Rayner, Oak Ridge 

National Laboratory, Oak Ridge, TN, 

and Adrian Nanez, Amgen, Thousand 

Oaks, CA. 

For Students and Advisors—Room 255 F 

3:00 PM–5:00 PM Students and Advisors: Open Time 

with Academic Toxicology Program 

Directors and Internship Sponsors 

Chair: Kim Daniel, Texas A&M, College 

Station, TX. 

SOT Annual Meeting Events 

6:30 PM–7:30 PM SOT Welcoming Reception 

(Exhibit Hall E) 

7:30 PM–8:30 PM Student/Postdoctoral Fellow Mixer 

(Room 355) 



Monday, March 8, 8:00 AM–1:30 PM 


Sponsor: 


This event is for undergraduate students and advisors receiving 

2010 MARC and SOT travel funding and SOT program volunteers. 

All activities are in the Salt Palace Convention Center. 

7:30 AM–7:50 AM Meeting for Students, Advisors, 

Peer Mentors, and SOT Hosts 

(Room 255 C) 

Chair: Adrian Nanez, Amgen, Thousand 

Oaks, CA. 

8:00 AM–9:00 AM Plenary Lecture (Exhibit Hall E) 

Discovery of Nitric Oxide and Cyclic 

GMP Cell Signaling and Their Role in 

Drug Development 

Ferid Murad, Nobel Laureate, John 

S. Dunn, Sr., Distinguished Chair, 

University of Texas Health Science 

Center at Houston, Houston, TX. 

9:00 AM–9:30 AM Mystery Scientist Instructions 

9:30 AM–10:50 AM Poster Session for Visiting Students 

(Exhibit Hall) 

Chair: Julio Davila, Pfizer, Inc., 

Saint Louis, MO. 

11:00 AM–11:50 AM Program Wrap Up (Room 255 C) 

Chair: Adrian Nanez, Amgen, Thousand 

Oaks, CA. 

12:00 NOON–1:20 PM In Vitro Toxicology Lecture and 

Luncheon for Students (Room 255 E) 

Toxicity Testing in the 21 st Century: 

The Vision and Some Questions 

Kim Boekelheide, Brown University, 

Providence, RI. 

undergraduate Faculty Meeting 

Tuesday, March 9, 3:30 PM–4:30 PM 

Room 355 A 


The Education Committee is hosting the Undergraduate 

Toxicology Faculty Meeting for all faculty involved in the 

teaching of toxicology to undergraduates, or for those interested 

in including toxicology at the undergraduate level. Hear 

an update on initiatives for undergraduate faculty, provide 

your input, and network. 





In Vitro Toxicology Lecture and Luncheon for 

Students 

Monday, March 8, 12:00 nOOn–1:20 PM 

Room 255 E 



Sponsor: 

Colgate-Palmolive 

Toxicity Testing in the 21 st Century: 


Lecturer: Kim Boekelheide, M.D., Ph.D., Brown 

University, Providence, RI. 

Chairperson(s): David Allen, President, In Vitro 

and Alternative Methods Specialty Section, and 

Integrated Laboratory Systems, Inc., Research 

Triangle Park, NC. 

Endorsed by: 

Education Committee 

This purpose of this event for postdoctoral scholars, graduate 

students, undergraduate students, and invited guests is to focus 

on the importance of animal research to biomedical sciences 

and toxicology and the ethical obligations of the scientific 

community to follow the “3R’s” of animal testing (refine, 

reduce, replace) whenever it is feasible. 

In the future, toxicity testing will utilize emerging technologies 

from the ongoing revolution in understanding 

biological processes to identify the effects of chemicals on 

toxicity pathways, using in vitro approaches. The interpretation 

of chemically-induced alterations in toxicity pathways 

will depend upon sophisticated modeling that extrapolates 

from the measured dose-response in cell-based systems to 

human exposure. 

After providing an overview of the National Academy of 

Sciences report entitled “Toxicity Testing in the 21 st Century–A 

Vision and a Strategy,” this presentation will turn to a discussion 

of issues raised by this new approach. The audience will 

be asked to think about and respond to the following questions: 

• What are the limitations of the current testing approach that 

relies on animals? 

• What are the advantages of the current testing approach? 

• How long will it take to implement this new toxicity testing 

paradigm? 

• Is the focus on “toxicity pathways” useful or distracting? 

• Does a test for neurodevelopmental effects have to look at 

neurons? 

• How do we distinguish adaptive versus adverse (toxic) 

responses? 

• Is this a screening tool or a stand-alone system? 

• How is the new paradigm validated? 


• What about epigenetics and other new biology? 

• What are the limitations of the proposed new testing 

paradigm? 

• What are the advantages of the proposed new testing 

paradigm? 

Seeking Funding for undergraduate 

Research 

wednesday, March 10, 4:30 PM–5:50 PM 

Ballroom D 


Chairperson(s): Joan B. Tarloff, University of the Sciences in 

Philadelphia, Philadelphia, PA, and Vanessa Fitsanakis, King 

College, Bristol, TN. 

Sponsor: 


Endorsed by: 

Postdoctoral Assembly 


It is often difficult for undergraduate professors to readily 

know where to go for research funding. Both the National 

Institutes of Health (NIH) and National Science Foundation 

(NSF) have grants specifically tailored to the needs of undergraduate 

students and faculty in the form of classroom and 

teaching enhancement, professional development, or research 

opportunities for faculty and students. This session will provide 

undergraduate faculty with the opportunity to hear presentations 

from representatives from NIH and NSF and to ask questions of 

each. 

• Seeking Funding for Undergraduate Research, Joan Tarloff, 

University of the Sciences in Philadelphia, Philadelphia, PA. 

• Academic Research Enhancement Awards (AREA) through 

NIH, Michael Humble, NIEHS, Durham, NC. 

• Research Experiences for Undergraduates (REU) Awards 

through NSF, Sally O’Connor, NSF, Arlington, VA. 

• Experiences with the AREA Program, Eli Hestermann, Furman 

University, Greenville, SC. 

66 



Social Events (Continued) 

Awards Ceremony Music 

Performed by Michael Lucarelli 

Sunday, March 7, 4:45 PM–5:15 PM 

Ballroom J 


Michael Lucarelli received his Bachelor 

of Music degree from the University of 

Utah and his Master of Music from the 

University of Arizona in Guitar performance. 

Since 1985 Michael has 

performed extensively for concerts, festivals, 

and private events throughout Utah and the U.S. During 

the 2002 Winter Olympics, Michael performed for the athletes 

at the Olympic Village. He has appeared on several radio and 

television programs including the TV series “Touched by an 

Angel.” Michael has received numerous awards and grants and 

has had over three million views on YouTube. Aside from being 

a critically acclaimed solo artist, Michael’s seven CDs have 

received enthusiastic reviews worldwide. More information 

about Micheal Lucarelli can be found at www.lucarelli.com. 



Ballroom J 


(Open to all attendees) 

Join us as SOT honors our prestigious award winners at 

the SOT Awards Ceremony. Those honored are listed on 

pages 72–81. Please refer to the Awards and Fellowships 

section of the SOT Web site for complete details about awards 

and the application details for next year. 



Hall E 


Continue the celebration by attending the Welcoming 

Reception following the Awards Ceremony. The Welcoming 

Reception is a great opportunity to renew old friendships and 

to make new acquaintances. Please join the Society in this 

kick-off of the Annual Meeting. 

25–year (or More) Member Reception 


Ballroom A 


Have you been a member of the Society of Toxicology for 25 

years (or more)? If so, please join your colleagues in celebration 

and recognition of the scientists who established the 

Society. Note that this year some of your colleagues will be 

sporting 45-year member pins. 



Room 355 



Sponsor: 


All students and postdoctoral fellows are invited to attend this 

reception. Refreshments will be provided by SOT and sponsors. 

A cash bar will also be available. Ticket and Meeting 

Badge are required. 


Tuesday, March 9, 12:00 nOOn–1:15 PM 

Room 255 E 



Chairperson(s): Betina Lew, University of Rochester, Rochester, 

NY. 

Sponsor: 


Amidst scrambling to attend all of the events at the meeting, 

this will be time for postdocs to kick back and relax! All postdoctoral 

fellows are invited to a casual luncheon organized 

by the Postdoctoral Assembly (PDA). We will recognize the 

recipients of the Best Postdoctoral Publication Awards and 

acknowledge the postdocs who received awards this year 

from Specialty Sections and Regional Chapters. The PDA 

Board members will present an overview of accomplishments 

and future directions for the PDA and will introduce the new 

board members for 2010–2011. There will be a drawing for 

door prizes. Postdocs can reserve a ticket when registering 

for the Annual Meeting. Lunch is served at the beginning of 

the event and service concludes before the talk/main program 

begins. Meal service may not be available to guests who arrive 

after 12:30 PM. 

SOCIal EvEntS 




SOCIal EvEntS 

Regional Chapter Receptions 

Monday, March 8 through wednesday, March 10, 

various Times 

(Refer to the chart on the following page for more details.) 

Many of the SOT Regional Chapters meet during the SOT 

Annual Meeting. All current and prospective Regional 

Chapter members are encourage to attend. 

Special Interest Group Receptions 


various Times 

(Refer to the chart on the following page for more details.) 

Each of the 6 Special Interest Groups will hold a meeting/ 

reception during the 2010 SOT Annual Meeting. All current 

and prospective SOT Special Interest Group members are 

encouraged to attend. 

Specialty Section Receptions 


various Times 

(Refer to the chart on the following pages for more details.) 

Each of the 25 SOT Specialty Sections will hold either a 

luncheon or early evening meeting/reception during the 

SOT 2010 Annual Meeting. All current and prospective SOT 

Specialty Section members are encouraged to attend. 

68 




Regional Chapter Meetings/Luncheons or Receptions 

Event Date Time Location Room 

Central States Regional Chapter Meeting/Luncheon Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 355 A 

Gulf Coast and South Central Regional Chapters 

Joint Mixer 

Monday, Mar 8 5:00 PM to 7:00 PM Lumpy's Downtown 

Michigan Regional Chapter Happy Hour Wednesday, Mar 10 5:00 PM to 6:30 PM TBD 

Mid-Atlantic Regional Chapter Luncheon 


Mountain West and Southern California 

Regional Chapters Joint Reception 

Monday, Mar 8 12:00 NOON to 1:30 PM Tucanos Restaurant 

Monday, Mar 8 5:00 PM to 7:00 PM Squatters Pub Brewery 

SOCIal EvEntS 

National Capital Area Regional Chapter Reception TBD TBD Red Rock Brewing 

Company 

Northeast Regional Chapter Student and Poster Travel 

Award Luncheon 

Monday, Mar 8 12:00 NOON to 1:30 PM Marriott Downtown Brighton 

Northern California Regional Chapter Reception Tuesday, Mar 9 6:00 PM to 9:00 PM Squatters Pub Brewery 

Pacific Northwest Regional Chapter Reception Monday, Mar 8 5:00 PM to 8:00 PM Squatters Pub Brewery 

Regional Chapter Presidents and Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 A 

Southeastern Regional Chapter Business Meeting Monday, Mar 8 7:00 AM to 8:00 AM Marriott Downtown Cottonwood 

Southeastern Regional Chapter Reception Monday, Mar 8 6:00 PM to 7:30 PM Hilton Canyons B 

Special Interest Groups Meetings and/or Receptions 


AACT Distinguished Chinese Toxicologist Lectureship Monday, Mar 8 12:00 NOON to 1:00 PM Convention Center Room 355 D 

American Association of Chinese in Toxicology 


Monday, Mar 8 6:00 PM to 8:00 PM Hilton Grand 

Ballroom A 

ASIO Lunch and Learn Program Tuesday, Mar 9 12:00 NOON to 1:30 PM Marriott Downtown Grand 

Ballroom A 

Association of Scientists of Indian Origin in America 


Hispanic Organization for Toxicologists Special Interest 


Korean Toxicologists Association in America Special Interest 


Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 D 

Tuesday, Mar 9 6:30 PM to 8:30 PM Marriott Downtown Brighton 

Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 260 

Special Interest Group Presidents and Officers Meeting Monday, Mar 8 12:00 NOON to 1:00 PM Convention Center Room 255 A 

Toxicologists of African Origin Special Interest Group 


Women in Toxicology Special Interest Group 


Monday, Mar 8 6:00 PM to 8:00 PM Salt Lake Plaza Hotel Salt Room 

Wednesday, Mar 10 4:30 PM to 6:00 PM Marriott Downtown Grand 

Ballroom D 

(continued to next page) 




Specialty Section Meetings/Luncheons or Receptions 


Biological Modeling Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 260 B 

Biotechnology Specialty Section Meeting/Reception Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 355 A 

SOCIal EvEntS 

Carcinogenesis Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 B 

Carcinogenesis Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 258 

Cardiovascular Toxicology Specialty Section 


Comparative and Veterinary Specialty Section 


Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 355 B 

Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 D 



Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 258 

Dermal Toxicology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 355 A 

Dermal Toxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 A 

Drug Discovery Toxicology Specialty Section 




Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 355 D 

Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 258 

Food Safety Specialty Section Officers Meeting Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 259 

Food Safety Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 D 

Immunotoxicology Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Marriott Downtown Elevations 

Restaurant 

Immunotoxicology Specialty Section Meeting/Reception 

25 th Anniversary Celebration 

In Vitro and Alternative Methods Specialty Section Officers 


In Vitro and Alternative Methods Specialty Section 


Inhalation and Respiratory Specialty Section 




Tuesday, Mar 9 6:00 PM to 8:00 PM Convention Center Room 355 E 

Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 260 B 

Tuesday, Mar 9 12:00 NOON to 1:30 PM Convention Center Room 255 C 

Tuesday, Mar 9 7:00 AM to 8:00 AM Convention Center Room 255 B 


Mechanisms Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 E 

Mechanisms Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 255 E 

(continued to next page) 

70 




Specialty Section Meetings/Luncheons or Receptions 


Medical Device Specialty Section Officers Meeting Monday, Mar 8 6:30 AM to 8:00 AM Convention Center Room 255 F 

Medical Device Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 258 

Metals Specialty Section Officers Meeting Monday, Mar 8 6:30 AM to 8:00 AM Convention Center Room 255 D 

Metals Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 C 

Mixtures Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 F 

Mixtures Specialty Section Meeting/Reception Tuesday, Mar 9 6:00 PM to 7:30 PM Convention Center Room 259 

SOCIal EvEntS 

Molecular Biology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 355 D 

Molecular Biology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 B 

Nanotoxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 255 E 

Nanotoxicology Specialty Section Officers Meeting Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 355 A 

Neurotoxicology Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 254 A 

Neurotoxicology Specialty Section Meeting/Reception Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 255 E 

Occupational and Public Health Specialty Section 


Monday, Mar 8 12:00 NOON to 1:30 PM Convention Center Room 255 B 

Ocular Toxicology Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 259 





Reproductive and Developmental Toxicology Specialty 

Section Officers Meeting 

Reproductive and Developmental Toxicology Specialty 


Monday, Mar 8 7:00 AM to 8:00 AM Convention Center Room 355 B 


Tuesday, Mar 9 7:00 AM to 8:30 AM Convention Center Room 255 C 

Wednesday, Mar 10 6:00 PM to 7:30 PM Convention Center Room 255 B 

Risk Assessment Specialty Section Officers Meeting Monday, Mar 8 7:00 AM to 9:00 AM Convention Center Room 355 E 

Risk Assessment Specialty Section Meeting/Reception Monday, Mar 8 6:00 PM to 7:30 PM Convention Center Room 355 E 

Specialty Section Presidents and Officers Meeting Monday, Mar 8 4:30 PM to 6:00 PM Convention Center Room 255 A 






Wednesday, Mar 10 12:00 NOON to 1:30 PM Convention Center Room 255 E 



SOT 2010 Award Recipients 

Achievement Award 

Arnold J. Lehman Award 

aWardS & HOnOrS 

Gary W. Miller, Ph.D., Professor of 

Environmental and Occupational 

Health and Associate Dean for 

Research, Rollins School of Public 

Health, Emory University, is the recipient 

of the SOT 2010 Achievement 

Award for his significant early career 

contributions to toxicology. 

Dr. Miller’s research focuses on 

toxicology and environmental and 

Gary W. Miller genetic factors involved in neurological 

disease, particularly the role 

of pesticides in the development of Parkinson’s disease. By 

performing top-notch toxicological research in the field of 

neuroscience, Dr. Miller has attracted considerable attention 

to the field and served as an example of the key role of toxicology 

in elucidation of pathogenesis of neuronal disease. 

He has been continuously funded throughout his career 

starting with a Society of Toxicology pre-doctoral fellowship 

all the way to an NIEHS-funded P01 Center that was 

awarded in 2008. 

He is Chair of Emory’s Institutional Health and Biosafety 

Committee, Director of Emory Parkinson’s Disease 

Collaborative Environmental Research Center, Director 

of the Emory NIEHS-funded Toxicology Training Grant, 

and holds additional appointments in Neurology and 

Pharmacology. In addition to serving as President of the 

SOT Southeastern Regional Chapter and Vice President of 

the Neurotoxicology Specialty Section, he was a member 

of the Neurotoxicology and Alcohol Study Section and has 

served on numerous other NIH and international review 

panels and editorial boards. 

Dr. Miller earned an M.S. (1992) from Old Dominion 

University, a Ph.D. (1995) from the University of Georgia, 

and completed postdoctoral fellowships at Emory 

University (1997) and Duke University (1998). He was 

recruited to Emory from the University at Texas at Austin 

as an Associate Professor in 2002 and awarded tenure in 

2004. For the significant contributions to toxicology that he 

has made in the early stages of his career, the Society of 

Toxicology is pleased to present the SOT 2010 Achievement 

Award to Dr. Gary Miller. 

Edward V. 

ohanian 

Edward V. Ohanian, Ph.D., is recognized 

as the 2010 Arnold J. Lehman 

Award recipient for his contributions to 

risk assessment and regulation of 

chemical agents. He is the Director of 

the Health and Ecological Criteria 

Division at U.S. Environmental 

Protection Agency’s (EPA) Office of 

Water (OW), and is responsible for 

conducting human and ecological risk 

assessments of national and international 

importance. His expertise, 

experience, and broad knowledge have 

helped to shape science policy in EPA’s OW and across the 

Agency at large. He serves as mediator and the voice of 

reason in resolving contentious issues of scientific interpretation. 

Dr. Ohanian demonstrates superior scientific judgment in 

addressing critical areas of water contamination. He helped 

to guide EPA through the highly contentious and sometime 

vitriolic debates on a veritable who’s who of drinking water 

contaminants and issues including lead, fluoride, chromium, 

arsenic, and perchlorate to name just a few. His judgment 

and calm, reasoned advice have been instrumental in 

guiding senior managers, including the Administrators, on 

these and other issues throughout the years. 

His influence is also evident outside of EPA. His input 

is valued on the world stage in WHO Drinking-Water 

Guidelines Committees. His conclusions and advice are 

accepted as authoritative EPA positions. He chairs the EPA 

Risk Assessment Forum, where difficult risk assessments 

and toxicology problems are addressed, and science policy is 

formulated. As co-founder of the Federal-State Toxicology 

and Risk Analysis Committee, he has been instrumental in 

fostering partnership to improve risk analysis methods. He 

also chairs the Health Advisory Board of NSF International, 

which is responsible for setting safe levels for direct and 

indirect drinking water additives. 

Dr. Ohanian is well published, credible in his work, forceful 

yet polite in his arguments, and reasoned and patient in his 

leadership. He is also purposeful, determined, and untiring 

in his efforts to incorporate the best toxicology into risk 

assessments. He has advanced the field of risk assessment 

though innovative thinking and principled risk assessment 

practice. The SOT Awards Committee is pleased to 

announce, Dr. Ohanian as the recipient of the 2010 Arnold 

J. Lehman Award. 

72 



SOT 2010 Award Recipients (Continued) 

Best Postdoctoral Publication Awards 

The Postdoctoral Assembly recognizes these three recipients 

of their 2010 awards: 

Bret F. Bessac 

Manabu 

nukaya 

nicholas Radio 

Bret F. Bessac, Ph.D., Yale University 

School of Medicine, New Haven, CT 

Transient Receptor Potential 

Ankyrin 1 Antagonists Block the 

Noxious Effects of Toxic Industrial 

Isocyanates and Tear Gases 

The FASEB Journal 2009, Vol. 23 

1102–1114 

Manabu Nukaya, Ph.D., University of 

Wisconsin-Madison, Madison, WI 

The Role of the Dioxin Responsive 

Elements Cluster Between Cyp1a1 

and Cyp1a2 Loci in Aryl Hydrocarbon 

Receptor Biology 

Proceedings of the National 

Academy of Sciences USA 2009, 106, 

4923–4928 

Nicholas Radio, Ph.D., Cellumen, 

Pittsburgh, PA 

Assessment of Chemical Effects on 

Neurite Outgrowth in PC12 Cells 

Using High Content Screening 

Toxicological Sciences 2008, 105(1), 

106–118 

Board of Publications Award for the Best 

Paper in Toxicological Sciences 

The Board of Publications has selected 

the paper entitled “Identification and 

Characterization of Toxicity of 

Contaminants in Pet Food Leading to 

an Outbreak of Renal Toxicity in Cats 

and Dogs” as the best paper published 

in Toxicological Sciences in the past 

year (Toxicological Sciences 2008, 106: 

251–262). The authors of the paper are 

Roy L.M. Dobson, Safa Motlagh, Mike Quijano, 

R. Thomas Cambron, Timothy R. Baker, Aletha M. 

Pullen, Brian T. Regg, Adrienne S. Bigalow-Kern, 

Thomas Vennard, Andrew Fix, Ranate Reimschuessel, 

Gary Overmann, Yuching Shan, and George P. Daston. 

The work described in the paper was conducted after the 

observation of acute renal failure in cats and dogs led to a 

major recall of pet food in 2007. The authors carried out an 

extensive analytical effort to identify possible contaminants 

in wheat gluten and ultimately discovered numerous small 

molecule contaminants including melamine and several 

other triazines (ammeline, ammelide, ureidomelamine, 

N-methylmelamine, and cyanuric acid). These compounds 

were not cytotoxic when tested individually in cultured 

kidney cells or in vivo in rats, but mixtures of the triazines 

caused renal failure associated with crystalline deposits in 

the medullary region. The authors subsequently correlated 

these findings in rats to post-mortem analysis of crystals 

obtained from cats and confirmed the presence of high levels 

of melamine and cyanuric acid in the crystals. Collectively, 

the results established a causal link between the contaminated 

gluten and renal toxicity and demonstrated that 

although relatively innocuous in isolation, the combination 

of melamine and cyanuric acid formed insoluble precipitates 

that damaged the renal tubules leading to renal failure 

and death. 

This paper is being recognized because it is an outstanding 

example of the integration of analytical chemistry, in vitro 

and in vivo studies, and histopathology to identify molecular 

mechanisms of toxicity. In addition, the research was 

highlighted in a press release by the Society and Oxford 

University Press because it provided important insight to 

the general public regarding the analysis and toxicity of 

contaminated pet food (and subsequently infant formula 

as well). In this way, it also brought public visibility to 

the collective efforts of toxicologists to create a safer and 

healthier world. 


SOT Sponsored Awards 





Education Award 


Harihara M. 

Mehendale 

Harihara M. Mehendale, Ph.D., 

ATS, the Kitty Degree Endowed Chair 

of Toxicology, College of Pharmacy at 

University of Louisiana at Monroe, 

Monroe, Louisiana, is the recipient of 

the 2010 Distinguished Toxicology 

Scholar Award. 

After several years at the National 

Institute of Environmental Health 

Sciences as a visiting fellow then staff 

fellow, Dr. Mehendale began a career 

spanning 35 years as an independent 

investigator. Seminal contributions in pulmonary, hepatic, 

and renal toxicology are hallmarks of his achievements in 

biomedical research. Perhaps Dr. Mehendale’s most novel 

insight is the key role of stimulation of tissue repair in the 

ultimate outcome in diverse models of organ damage. Initial 

observations of remarkable potentiation of halomethane 

hepatoxicity in rats previously exposed to an organochlorine 

insecticide lead to a series of studies to elucidate this 

novel mechanism. Stimulation of tissue repair in response to 

injury is essential for prevention of organ failure and death 

in multiple model systems. Chemicals and other metabolic 

disturbances (such as diabetes) that interfere with stimulation 

of tissue repair therefore presents a novel mechanism 

for potentiation of toxicity. Identification of candidate genes 

for regulation of stimulated tissue repair by Dr. Mehendale’s 

group promises new therapeutic or preventative approaches 

for organ injury. In large part due to remarkable success 

with competitive grants, Dr. Mehendale consistently 

provided opportunity for education and training for graduate 

students and postdoctoral researchers. The National 

Institutes of Health and Agency for Toxic Substances and 

Disease Registry are examples of long-term sponsors 

of this research. His commitment to quality, continuous 

adoption of new technologies, and enthusiasm for refining 

understanding of mechanisms of toxicity define him as an 

outstanding mentor. Dr. Harihara Mehendale’s record of 

achievement in independent investigator-initiated research, 

and success as a mentor, make him a highly deserving 

recipient of the SOT 2010 Distinguished Toxicology Scholar 

Award. 


Toxic Injury: Initiation, Expansion, and Repair 

Tuesday, March 9, 12:30 PM–1:20 PM, Room 251 A 

Tetsuo Satoh, Ph.D., has had a prestigious 

career as one of the leaders of 

education in the science of toxicology 

and thus is recognized with the 2010 

Education Award. In addition to the 

international recognition he has 

received for his scientific contributions 

to the toxicologic aspects of drug 

metabolism, Dr. Satoh is recognized 

for his exceptional efforts in support of 

Tetsuo Satoh education in toxicology. Dr. Satoh 

joined the Chiba University, Chiba, 

Japan in 1966 where he directed toxicology teaching and 

research for 30 years until leaving the Chiba University in 

1996 as Emeritus Professor of Toxicology. More than two 

hundred students have graduated from his laboratory and 

they are currently working as leaders in toxicology for 

academia, government, and companies in Japan and in other 

countries. Dr. Satoh has served the Japanese Society of 

Toxicology (JST) in numerous positions including the 

Executive Committee. He established the Toxicology 

Education Program in the JST, which later developed into 

the Certification Program for Toxicologists in Japan. Dr. 

Satoh was the Founding President of the International 

Assembly for the Recognition of Toxicologists (IART), a 

group whose focus was on accreditation and certification of 

toxicologists worldwide. Dr. Satoh was one of the founders 

of the Asian Society of Toxicology (ASIATOX), and 

currently is the Senior Advisor to ASIATOX. He has been 

invited to a number of international meetings to give 

lectures concerning education and training of toxicologists. 

Dr. Satoh joined the Society of Toxicology in 1974 and he 

was the first recipient of the Colgate-Palmolive Traveling 

Lectureship in Alternative Methods in Toxicology Award in 

1996. In addition, he served as an Associate Editor of the 

journal Toxicological Sciences. Dr. Satoh has served the 

International Union of Toxicology (IUTOX) in numerous 

positions including Vice President, and he was awarded the 

2007 IUTOX Merit Award for his outstanding work and 

significant contributions to the filed of toxicology. He is 

an eminent toxicologist and a marvelous teacher who has 

contributed significantly over 30 years to education and 

training of graduate students and young toxicologists at 

the national, regional, and international levels. The Society 

of Toxicology recognizes Dr. Tetsuo Satoh with the 2010 

Education Award. 

74 




Enhancement of Animal welfare Award 

Founders Award 

Leonard M. 

Schechtman 

Leonard M. Schechtman, Ph.D., is 

presented the SOT 2010 Enhancement 

of Animal Welfare Aware in recognition 

of the outstanding contributions he 

has made to the advancement of toxicological 

science through the development 

and application of methods that replace, 

refine, and reduce experimental animal 

use in research, education, and regulatory 

safety testing. 

Dr. Schechtman was the U.S. Food 

and Drug Administration’s Principal 

Agency Representative to the 

Interagency Coordinating Committee on the Validation of 

Alternative Methods from 1999 through 2006 and served 

as Chairman of ICCVAM from 2001 through 2006. Under 

his leadership, ICCVAM developed guidelines for nomination 

and submission of alternative test methods, defined 

and implemented test method performance standards to 

expedite validation, enhanced international cooperation with 

the ECVAM and JaCVAM, and successfully evaluated and 

transmitted formal recommendations to U.S. federal agencies 

on the scientific validity of several new alternative methods 

in accordance with the 2000 ICCVAM Authorization Act. 

These alternative safety testing methods were subsequently 

adopted by U.S. regulatory agencies and international organizations 

such as the OECD and its 30 member countries. 

The methods now allow for required regulatory safety testing 

for dermal corrosion, acute systemic toxicity, ocular toxicity, 

and pyrogenicity testing to be conducted more humanely and 

with fewer or no animals. 

Dr. Schechtman also has contributed significantly to the 

development and adoption of internationally harmonized 

guidance on the validation and use of novel in vitro and 

in vivo safety evaluation methods. As president of Innovative 

Toxicology Consulting, he is further contributing to the 

development, scientific validation, and advancement of alternative 

methods for regulatory safety testing. The Society of 

Toxicology is pleased and honored to award Dr. Schechtman 

the SOT 2010 Enhancement of Animal Welfare Award. 

James S. Bus, Ph.D., recipient of the 

SOT 2010 Founders Award, is Director 

of External Technology, Toxicology 

and Environmental Research and 

Consulting at The Dow Chemical 

Company. He has worked tirelessly and 

vocally on the very issues that describe 

the Founders award, demonstrating 

“outstanding leadership in fostering the 

role of toxicological sciences in safety 

James S. Bus decision-making through the development 

and/or application of 

state-of-the-art approaches that elucidate, 

with a high degree of confidence, the distinctions for 

humans between safe and unsafe levels of exposures to 

chemical and physical agents.” 

Dr. Bus has truly distinguished himself over the years in 

toxicology research and its application in safety assessment. 

His leadership is demonstrated through his positions 

on such boards as the National Academy of Sciences Board 

of Environmental Sciences and Toxicology, the ILSI Health 

and Environmental Sciences Institute, the U.S. EPA Science 

Advisory Board, and the Toxicology Forum, to name a few. 

He has served as President of the Society of Toxicology and 

the American Board of Toxicology. Among his awards is the 

Society of Toxicology Achievement Award (1987) for his 

outstanding contributions to the science of toxicology. His 

research interests include mechanisms of oxidant toxicity, 

defense mechanisms to chemical toxicity, relationships of 

pharmacokinetics to expression of chemical toxicity, and 

general pesticide and industrial chemical toxicology. 

Dr. Bus has constantly pushed the science of toxicology to 

improve and expand the application of the best toxicological 

data into regulatory decisions. He is driven by a passion and 

contagious enthusiasm for improving the toxicological basis 

for regulatory decisions. Dr. Bus has worked to ensure that 

state-of-the-art approaches are applied to regulatory decisions. 

He is determined to work to improve the quality of our 

regulatory system to better protect human health and more 

capably set safe levels for chemical agents. We congratulate 

and recognize Dr. James Bus as the recipient of the SOT 

2010 Founders Award. 






Merit Award 


Richard S. 

Paules 

Richard S. Paules, Ph.D., Senior 

Scientist and Head, Environmental 

Stress and Cancer Group, Laboratory 

of Molecular Toxicology, Division of 

Intramural Research, NIEHS, and 

Director, NIEHS Microarray Group, is 

awarded the Leading Edge in Basic 

Science Award for his recent and 

seminal scientific contribution to 

understanding fundamental mechanisms 


A respected leader and strong force in 

the field of toxicogenomics, Dr. Paules proved to be a true 

visionary who early on captured the essence of the field and 

the power of the technology and has diligently positioned 

NIEHS at the forefront of the field. He has been a major 

contributor to the development of the National Center for 

Toxicogenomics (NCT) research infrastructure and the 

development of strong partnerships between the Institute, 

academia and the corporate sector. Dr. Paules led a large 

research effort in which proof-of-concept toxicogenomics 

studies were performed to demonstrate the utility of 

bringing together genomic approaches with more traditional 

approaches of biology, molecular biology, physiology, 

pathology, and toxicology in order to gain insight into the 

molecular mechanisms involved in the etiology and progression 

of injury and disease processes. An additional goal 

was to develop predictive biomarkers of the initiation and 

progression of those processes. In addition to his studies 

incorporating genomics into studies of xenobiotic-induced 

liver injury, Dr. Paules has successfully integrated genomics 

into his studies of a mechanistic understanding of how 

errors in DNA damage responses can contribute to diseases 

including cancer. 

Dr. Paules continually displays the attributes expected of 

the best scientists and his record of scientific achievements 

suggests that he will continue to excel as a leader in environmental 

health research and toxicology. For his work in 

the integration of genomics into the investigation of the 

molecular basis of injury and disease processes, the Society 

of Toxicology recognizes Dr. Richard Paules with the SOT 

2010 Leading Edge in Basic Science Award. 

Leading Edge in Basic Science Award Lecture: 

Toxicogenomics at NIEHS: How Genomics Is Impacting 

the Science of Toxicology 

Monday, March 8, 12:30 PM–1:20 PM, Room 251 A 

Marion F. Ehrich, Ph.D., receives the 

2010 Merit Award. She is a tenured 

professor of pharmacology and toxicology 

and the co-director of the 

Laboratory for Neurotoxicity Studies 

at the Virginia-Maryland Regional 

College of Veterinary Medicine 

(VMRCVM) on the campus of 

Virginia Tech. Her research interests 

include biochemical neurotoxicology, 

Marion F. Ehrich particularly neurotoxicity of organophosphates. 

Dr. Ehrich is nationally 

known and her accomplishments in 

neurotoxicology and in vitro toxicology are most notable. 

She has been a leading investigator in determining the 

mechanisms and pathogenesis of organophosphate esterinduced 

neurotoxicity (OPIDN) and other pesticide-induced 

injuries to the nervous system. An expert in the assessment 

and role of neurotoxic esterase in OPIDN, she is often called 

upon by both government and industry for her expertise. 

She has been a pioneer in the use of in vitro systems for 

mechanistic studies and safety assessment in neurotoxicology, 

with potential contribution to a diminished need for 

animal use in chemical safety assessments. 

Dr. Ehrich is a practicing registered pharmacist and 

pharmacy consultant to the VMRCVM, served as SOT 

President 2003–2004, and American Veterinary Medical 

Association, and is also a member of the Academy of 

Toxicological Sciences, and American Academy of 

Veterinary Pharmacology and Therapeutics. She has 

mentored more than 35 masters and doctoral level students. 

Dr. Ehrich's publications span 38 years, including 300 book 

chapters, reviews, research and educational publications. 

Her grant funding sources have included NIH, USDA, EPA, 

the Department of Defense and others. Her distinguished 

contributions to toxicology over 30 years encompass 

research, teaching, consulting, and mentoring as well as an 

unbridled dedication to the Society. It is a true pleasure to 

honor and recognize Dr. Marion Ehrich with the SOT 2010 

Merit Award. 

Merit Award Lecture: Living with Passion— 

Opening Doors in Research, Teaching, and Service 

Wednesday, March 10, 12:30 PM–1:20 PM, Room 251 A 

76 




nygerma L. 

Dangleben 

Perry J. Gehring 

Diversity Student Travel Award 

Nygerma L. Dangleben, B.S., 

University of California Berkeley, 

Berkely, CA 

Abstract Number: 952 

Poster Board Number: 708 

Abstract Title: Investigating Beta- 

Defensin-1 Down-Regulation in 

Arsenic Toxicity 

Public Communications Award 

Philip Wexler’s extensive career at the 

U.S. National Library of Medicine’s 

(NLM) Toxicology and Environmental 

Health Information Program, coupled 

with his other professional affiliations, 

collaborations, and independent projects, 

designed to make toxicology 

more accessible to the public, uniquely 

qualify him for the SOT Public 

Communications Award. 

Philip Wexler Serving as Editor-in-Chief of 

Elsevier’s Information Resources in 

Toxicology (4 th ed., 2009) and the 4-volume Encyclopedia 

of Toxicology (2 nd ed., 2005), he has managed the fine 

balance of communicating with both scientific audiences 

and the public. An author of numerous papers, Mr. Wexler is 

currently preparing “Toxicology: An Evolving Informatics 

Framework” for Critical Reviews in Toxicology. His public 

policy orientation will be featured in another book he is 

co-editing, Chemicals, Environment, Health: A Global 

Management Perspective, for Taylor and Francis. 

He served for two terms as Chair of the SOT’s World Wide 

Web Advisory Committee and is 2010 President of SOT’s 

Ethical, Legal, and Social Issues Specialty Section. With 

Steve Gilbert, he assembled the Toxicology History Room 

at SOT’s 2009 Annual Meeting. He is Vice President of 

the Toxicology Education Foundation, which promotes the 

public understanding of toxicology. 

Mr. Wexler is a member of the recently assembled 

Education and Communications Work Group of the CDC/ 

ATSDR’s National Conversation on Public Health and 

Chemical Exposure project. At NLM, he has been instrumental 

in developing and enhancing the TOXNET system 

and its components, serves as file manager for the LactMed, 

IRIS and ITER databases, and heads the Risk Assessment 

Information Team. He spearheaded the development of the 

multi-stakeholder produced World Library of Toxicology, 

Chemical Safety, and Environmental Health, an on-line 

global collaborative and network. 

Mr. Wexler oversees the NLM-SOT joint project ToxLearn, 

a multi-module tutorial covering the basic principles of 

toxicology for general audiences. He has taught countless 

medical librarians and others the use of toxicology information 

systems, at NLM and other venues, and made numerous 

presentations and conducted continuing education courses 

at meetings throughout the world. 

Mr. Wexler’s contributions have had and continue to have 

an enormous impact on how scientists, other professionals, 

and the public at large accesses toxicological information. 

We congratulate and recognize Philip Wexler, M.L.S., with 

the SOT 2010 Public Communications Award. 

SOT AstraZeneca IuTOx Fellowship 

Asongalem Emmanuel Acha, Ph.D., University of Buea, 

Buea, Cameroon 

Ayse Basak Engin, Ph.D., Gazi University, Ankara, Turkey 

Ronnie A. D. Frazer-Williams, Ph.D., Fourah Bay College, 

Freetown, Sierra Leone 

Yan Li, B.S., Chinese Academy of Sciences, Shanghai, 

China 

Jesus T. Olivero-Verbel, Ph.D., Universidad de Cartagena, 

Cartagena, Colombia 

Suresh V.S. Rana, Ph.D., C.C.S. University, Meerut, India 

Ganna Shayakhmetova, Ph.D., Institute of Pharmacology 

and Toxicology AMS of Ukraine, Kyiv, Ukraine 

Vanessa Steenkamp, Ph.D., University of Pretoria, 

Pretoria, South Africa 

Marcelo J. Wolansky, Ph.D., University of Buenos Aires, 

Buenos Aires, Argentina 

Motao Zhu, Ph.D., National Center for Nanoscience and 

Technology, Beijing, China 





Translational Impact Award 


kenneth E. 

McMartin 

Kenneth E. McMartin, Ph.D., is the 

2010 Translational Impact award 

recipient. He is Professor in the 

Department of Pharmacology, 

Toxicology and Neuroscience at the 

LSU Health Sciences Center— 

Shreveport, Director of the LSUHSC-S 

interdisciplinary graduate program in 

toxicology, and Co-Director of the 

Pharmacokinetics Core for the Center 

for Experimental Cancer Therapeutics. 

Dr. McMartin’s early studies showed 

that, in experimental methanol poisonings, formic acid was 

the proximate toxicant and had a causative role in the severe 

metabolic acidosis observed for these intoxications. He 

worked with collaborating laboratories to develop treatment 

modalities. This effort culminated in the commercialization 

of the antidote 4-methylpyrazole, now called fomepizole. 

The ensuing product development progressed through 

animal experimentation and then phase I-phase III clinical 

trials. Importantly, fomepizole is now utilized worldwide 

and has become the standard of care for both ethylene glycol 

and methanol poisonings. 

In recent years, Dr. McMartin has conducted mechanistic 

experimental studies on the pathogenesis of the renal 

toxicity of ethylene glycol, demonstrating that the precipitation 

of calcium oxalate crystals in the kidneys was a 

causative factor in the observed renal tubular toxicity. He 

is currently investigating mechanisms of toxicity for diethylene 

glycol poisonings, an important problem evident by 

recent and past epidemic intoxications worldwide. Thus, 

Dr. McMartin has had a significant impact on clinical toxicology, 

dedicating his career to the study of mechanisms of 

action of toxicants important in common poisonings and 

in the development of antidotes for their therapy. We are 

delighted to recognize Dr. Kenneth McMartin as the SOT 

2010 Translational Impact awardee. 


Translating Mechanism-Based Research into Antidotes: 

Trials, Tribulations, and Triumphs 

Tuesday, March 9, 8:00 AM–8:50 AM, Room 251 A 

Creating a Safer and Healthier World 

by Advancing the Science of Toxicology 

Do you know a toxicologist 

who deserves to be recognized? 

SOT recognizes distinguished 

toxicologists and students with many 

prestigious awards each year. 

In addition to receiving the specific award, 

recipients are honored at a special 

Awards Ceremony at the 

SOT Annual Meeting and their names are 

listed in SOT publications. 

Most award nominations and applications 

are submitted through a quick on-line 

process. 

Applications for 2011 national 

SOT awards are due October 9, 2010. 

Regional Chapter Awards, 

Special Interest Group Awards, and 

Specialty Section Awards have various 

deadlines throughout the year. 

Visit the Awards and Fellowships section 

of the Web site for award descriptions, 

additional information, and 

to make nominations. 


78 



2010 Award Recipients (Continued) 

AstraZeneca Traveling Lectureship Award 

J. Chris Corton, Ph.D., is the 2010 

AstraZeneca Traveling Lectureship 

Award winner. The award recognizes 

excellence in research and service in 

toxicology and enables a lecture tour 

of Europe to promote collaborations 

between European and North 

American toxicologists. Dr. Corton is 

a Senior Research Biologist in the 

Integrated Systems Toxicology 

J. Chris Corton Division at the National Health and 

Environmental Effects Research 

Laboratory of the U.S. Environmental 

Protection Agency in Research Triangle Park, NC. For 

more than two decades, Dr. Corton has studied the mode of 

action and human relevance of hepatotoxicants. His group 

has successfully used a multi-pronged strategy dominated 

by toxicogenomics and nullizygous mouse models to 

uncover chemical mode of action useful for risk assessment. 

More recently, his group is evaluating and implementing the 

use of high-throughput in vitro methods as first-tier 

screening for hepatotoxicity and mode of action categorization. 

He is on the editorial boards of 6 journals and has 

served as member and chair on numerous NIH study 

sections. He has also served in many capacities in SOT 

including member and chair of the Continuing Education 

Committee. Dr. Corton will focus his lecture tour to 

European scientists who are part of the REACH chemical 

testing program and who are part of the HepatoSys collaborative 

network of scientists directed toward building 

predictive computational models of the liver. Dr. Corton 

will conduct a lecture series at both industrial and academic 

institutions in Europe with the objective to establish productive 

relationships and collaborations with European 

colleagues, gain an understanding of approaches and 

methods in in vitro hepatotoxicology in Europe, and to gain 

a better understanding of the European viewpoints on in 

vitro testing, risk assessment and science policy of chemicals 

in general and hepatotoxicants in particular. We 

recognize Dr. Chris Corton with the 2010 AstraZeneca 

Traveling Lectureship Award. 

Colgate-Palmolive Awards for Student Research 

Training in Alternative Methods 

Maxwell C. K. Leung, M.Sc., 

Duke University, Durham, NC 

Project Title: Physiological and 

Developmental Effects of Persistent 

Mitochondrial DNA Damage in 

Caenorhabditis elegans 

Host Institution: Vanderbilt University, 

Nashville, TN 

David T. Szabo, M.S., University of North 

Carolina at Chapel Hill, Chapel Hill, NC 

Project Title: From Mice to Men: 

Generation of a Stereoisomer Specific 

Physiological Based Pharmacokinetic 

(PBPK) Model of the Flame Retardant 

Hexabromocyclododecane (HBCD) 

Host Institution: University of Montréal, 

Québec, Canada 

Natalia M. VanDuyn, B.S., Indiana 

University, Indianapolis, IN 

Project Title: Evaluating the Role of 

Intracellular Calcium and Mitochondrial 

Membrane Potential in a Novel C. 

elegans Model of Methylmercury 

Toxicity 

Host Institution: Michigan State 

University, East Lansing, MI 

Colgate-Palmolive Grants for Alternative Research 

Patrick Allard, Ph.D., Harvard School 

of Public Health, Boston, MA 

Project Title: High-Throughput 

Strategy for the Study of Environmental 

Disruption of Reproductive Health Using 


Duncan C. Ferguson, D.V.M., Ph.D., 

University of Illinois at Urbana- 

Champaign, Urbana, IL 

Project Title: Human Neural Stem Cell 

Line in Defined Medium As a Screen for 

Neurodevelopmental Toxins 

(Part II: Applications) 

Mehmet Uzumcu, D.V.M., Ph.D., 

Rutgers, The State University of New 

Jersey, New Brunswick, NJ 

Project Title: Monitoring 

Folliculogenesis in Ovary Organ 

Culture by Multiphoton Fluorescence 

Microscopy: An In Vitro Alternative for 

Testing Epigenetic Effects of Endocrine- 

Disrupting Chemicals 






Pfizer undergraduate Student Travel Award 

Annie L. Carlton, Bates College, 

Lewiston, ME 



Abstract Title: Developmental Arsenic 

Exposure Causes Obesity, Hyperglycemia 

and Liver Disease in Male Mice in 

Adulthood 

Alisha Chitrakar, Saint Peter’s College, 

Jersey City, NJ 



Abstract Title: Chronic Methylmercury 

Exposure Potentiates [ZN 2+ ] i 

in Motor 

Neurons of HSOD1 Mice 

Megan E. Culbreth, North Carolina State 

University, Raleigh, NC 



Abstract Title: Rodent and Human 

Neuroprogenitor Cells for High-Content 

Screens of Chemical Effects on 

Proliferation and Apoptosis 

Chang Woo Lee, University of Texas MD 

Anderson Cancer Center, Houston, TX 



Abstract Title: Phytotoxicity of Metal 

Oxide Nanoparticles to Arabidopsis 

thaliana 

Syngenta Fellowship Award in Human Health 

Applications of new Technologies 

Haitian Lu, M.S., Michigan State 


Project Title: Characterization of 

2,3,7,8-Tetrachlorodibenzo-p-dioxin 

(TCDD)-Mediated Effect and 

Mechanism of Action on the Humoral 

Immunity Using Primary Human and 

Mouse B Lymphocytes 

The following scientists were selected for fellowships 

at the 2009 SoT Annual Meeting. 

2009 Colgate-Palmolive Postdoctoral Fellowship 

Award in In Vitro Toxicology 

Ankur Dnyanmote, Ph.D., University of 

California, San Diego, CA 

2009 novartis Graduate Fellowship 

Yue Cui, Ph.D., University of Kansas 

Medical Center, Kansas City, KS 



Abstract Title: ChIPing the Cistrome of 

PXR in Mouse Liver 

Sharon Ochs, Wright State University, 

Dayton, OH 



Abstract Title: Role of Specific Binding 

Motifs in TCDD-induced Activation of 

the Human Polymorphic hs1,2 Enhancer 

80 



SOT 2010 Honorary Memberships 

Honorary membership is awarded by the Society of Toxicology to persons who are not members of the Society in 

recognition of outstanding and sustained contributions to advancing the science and field of toxicology. The 2010 

Honorary Member recipients are Drs. Sir Philip Cohen and Ferid Murad, who are the Keynote Medical Research 

Council (MRC) Lecturer and 2010 Plenary Opening Lecturer, respectively. 

Professor Sir Philip Cohen is the 

founder and Co-Director of the Division 

of Signal Transduction Therapy 

(DSTT), the UK’s largest collaboration 

between a basic research institution and 

the pharmaceutical industry. It is widely 

regarded as a model for how industry 

and academia should interact, for which 

it received a Queen’s Anniversary 

Award for Higher Education in 2006. 

Philip Cohen For the past 40 years, Dr. Cohen’s 

research has been devoted to studying 

the role of protein phosphorylation in cell regulation and 

human disease, a process that controls almost all aspects of 

cell life. His contributions to this area include working out 

over a 25-year period how calmodulin, the calcium-binding 

protein, is involved in the insulin-induced stimulation of 

glycogen metabolism in muscle. Currently, his laboratory 

is investigating the signaling pathways that regulate the 

production of pro-inflammatory cytokines and interferons 

during bacterial and viral infection, research that is aimed 

at understanding how the uncontrolled production of these 

substances causes chronic inflammatory diseases, such as 

rheumatoid arthritis, asthma, and septic shock. 

Dr. Cohen was born on July 22, 1945, in Edgware, Middlesex, 

England, and received his B.Sc. (1966) and Ph.D. (1969) 

from University College London. He then spent two years 

as a postdoctoral fellow at the University of Washington 

(Seattle, WA) with Dr. Edmond Fischer (the 1992 Nobel 

Laureate for Medicine or Physiology). 

In 1971, Dr. Cohen returned to the UK to become a faculty 

member at the University of Dundee, Scotland, where he has 

worked ever since. He has been a Royal Society Research 

Professor since 1984, Director of the Medical Research 

Council (MRC) Protein Phosphorylation Unit since its inception 

in 1990, and was the Honorary President of the British 

Biochemical Society from 2006–2008. He was knighted in 

1998. 

Nobel Laureate Ferid Murad is being 

recognized by SOT for his contributions 

to public health and medicine. He 

is the Director of the Institute of 

Molecular Medicine and holds the John 

S. Dunn Distinguished Chair in 

Physiology and Medicine at the 

University of Texas. 

His key research demonstrated that 

nitroglycerin and related drugs work 

Ferid Murad by releasing nitric oxide into the body, 

which acts as a signaling molecule 

in the cardiovascular system, making blood vessels dilate. 

The missing steps in the signaling process were filled in by 

Robert F. Furchgott and Louis J. Ignarro. The three received 

the 1998 Nobel Prize in Physiology or Medicine for this 

work. Drs. Murad and Furchgott received the Albert Lasker 

Award for Basic Medical Research in 1996. 

Dr. Murad is an Albanian-American physician and pharmacologist, 

who was born September 14, 1936, in Whiting, 

Indiana. He received his undergraduate degree in chemistry 

from the pre-med program at DePauw University in 1958. 

An early graduate of the first Medical Scientist Training 

Program to be developed, he recieved an M.D. and Ph.D. 

in pharmacology from Case Western Reserve University in 

1965. He then joined the faculty of University of Virginia, 

where he was made professor in 1970, before moving to 

Stanford University in 1981. Dr. Murad left Stanford in 1988 

for a position at Abbott Laboratories, where he served as a 

vice president until starting his own biotechnology company, 

the Molecular Geriatrics Corporation, in 1993. Dr. Murad 

relocated to the University of Texas in 1997 to create a new 

department of integrative biology, pharmacology, and physiology. 




SOT Endowment 2009 Award Recipients 

Mary Amdur 

Student Award Fund 

J. Grace 

Wallenborn, M.S., 

University of 

North Carolina, 

Chapel Hill, NC 

Perry J. Gehring Biological 

Modeling Student Award Fund 

Marc-André Verner, 

Université du 

Québec, Montréal, 


Perry J. Gehring Risk Assessment 


Mathieu Valcke, 

Universite de 

Montréal, Montréal, 


Founders Fund 

Roger O. McClellan, 

D.V.M., Toxicology 

& Human Health 

Risk Analysis, 

Albuquerque, NM 

Perry J. Gehring Diversity 

Student Travel Award Fund 

Vanessa De 

La Rosa, B.S., 

University of Texas, 

El Paso, TX 

Scott Auerbach, 

Ph.D., National 

Institute of 

Environmental 

Health Sciences, 

Research Triangle 

Park, NC 


vera w. Hudson and Elizabeth k. 

weisburger Scholarship Fund 

Courtney Kozul, 

B.A., Dartmouth 

Medical School, 

Hanover, NH 

Join us for the Announcement of 2010 Endowment Fund Award Recipients 

2010 Endowment Fund Awards .............................................................................................................. Awarded by 

Founders Fund ......................................................................................................................................Awards Committee at Awards Ceremony 

Perry J. Gehring Diversity Student Travel Award Fund ....................................Committee on Diversity Initiatives at Undergraduate Program 

Perry J. Gehring Biological Modeling Student Award Fund ...........................................................................................Biological Modeling SS 

Dharm V. Singh Carcinogenesis Award Fund ......................................................................................................................... Carcinogenesis SS 

Roger O. McClellan Student Award Fund ...........................................................................................................Comparative and Veterinary SS 

Emil A. Pfitzer Drug Discovery Student Award Fund .........................................................................................Drug Discovery Toxicology SS 

Frank C. Lu Food Safety Student Award Fund ............................................................................................................................. Food Safety SS 

Health and Environmental Science Institute Immunotoxicology Young Investigator Student Award Fund ...................Immunotoxicology SS 

Mary Amdur Student Award Fund ........................................................................................................................ Inhalation and Respiratory SS 

Renal Toxicology Fellowship Award Fund, Robert J. Rubin Student Travel Award Fund, and 

Carl C. Smith Student Mechanisms Award Fund .................................................................................................................... Mechanisms SS 

Molecular Biology Student Award Fund .............................................................................................................................Molecular Biology SS 

Perry J. Gehring Risk Assessment Student Award Fund and Robert J. Rubin Student Travel Award Fund ....................... Risk Assessment SS 

Roger O. McClellan Student Award Fund ......................................................................................... Toxicologic and Exploratory Pathology SS 

Jean Lu Student Scholarship Award Fund ........................................................................American Association of Chinese in Toxicology SIG 

Laxman S. Desai ASIO Student Award Fund, Harihara Mehendale ASIO 

Student Award Fund, and Dharm V. Singh ASIO Student Award Fund .................................Association of Scientists of Indian Origin SIG 

Young Soo Choi Student Scholarship Award Fund .............................................................. Korean Toxicologists Association in America SIG 

Vera W. Hudson & Elizabeth K. Weisburger Scholarship Fund ................................................................................ Women in Toxicology SIG 

Please refer to the 2010 Program for date, time, and location of the Committee on Diversity Undergraduate Education Program, 

Regional Chapter, Special Interest Group, and Specialty Section receptions on pages 13–21. 

82 



SOT Endowment 2009 Award Recipients (Continued) 

Frank C. Lu Food Safety 

Students Award Fund 

Natalie Johnson, 

B.S., Texas A&M 

University, College 

Station, TX 

Harihara Mehendale and 

Dharm v. Singh ASIO Student 

Award Funds 

Mamta Behl, Ph.D., 

Purdue University, 

West Lafayett, IN 

Carl C. Smith Student 

Mechanisms Award Fund 

Jingui Fu, B.S., 

Hamner Institutes 

for Health Sciences, 


Park, NC 

Roger O. McClellan 


Chidozie Amuzie, 

Michigan State 

University, East 

Lansing, MI 

Yogesh Saini, M.S., 



Lansing, MI 

Liang Chen, 


Cincinnati, 

Cincinnati, OH 

Emil A. Pfitzer Drug Discovery 


Jamie O’Brien- 

Barnard, University 

of Rochester, 

Rochester, NY 

Jennifer Cohen, 

B.S., University of 

Arizona, Tucson, AZ 

Arunkumar 

Asaithambi, 

B.S., Iowa State 

University, Ames, IA 

Smita Salian, 

National Institute 

for Research on 

Reproductive Health, 

Denver, CO 

Raja Settivari, 

Indiana School 

of Medicine, 

Indianapolis, IN 

(not pictured) 

Gayathri 

Chadalapaka, 

B.V.Sc., 

Texas A&M 


Station, TX 

Karen Thomas, 

Pharm.D., 

University of Utah, 

Salt Lake City, UT 


Hongfei Zhou, 

M.S., University of 

Colorado, Denver, 

CO, and Sanjeeva 

Wijeyesakere, 

Ph.D., University 

of Michigan, Ann 

Arbor, MI 



50 Endowment Awardees for 

SOT’s 50 th Anniversary 

Your Contribution This Year Will Help Us Reach Our Goal! 

Make a Contribution Now. 

In 2009, there were 22 Endowment Award Recipients. 

We anticipate 35+ Recipients in 2010 

Our Goal is 50+ Recipients in 2011! 

Your Contribution is important in establishing our priorities. 

Help exhaust the SOT Council Approved $750,000 50 th Anniversary Match. 

Your contributions can have twice the IMPACT. 

In 2010, matches will focus on the four SOT General Purpose Funds: 

• Educational Activities Fund 

• International Activities Fund 

• SOT Priorities Fund 

• Student Travel Fund 

For a full listing of all the Funds and to make a contribution 

to the SOT Endowment Fund of your choice today, 

please visit: 

www.toxicology.org/ai/csot/contribute.asp. 

INdIvIdUAl CONTRIbUTIONS 

Recognition 

level 

Paracelsus Circle 

Contribution 

in a Fiscal Year 

$500 or more 

Gold $250–$499 

Silver $100–$249 

bronze $40–$99 

84 



SOT 2010 Award Recipients 



AwArds & Honors 

Gary W. Miller, Ph.D., Professor of 

Environmental and Occupational 

Health and Associate Dean for 

Research, Rollins School of Public 

Health, Emory University, is the recipient 

of the SOT 2010 Achievement 

Award for his significant early career 

contributions to toxicology. 

Dr. Miller’s research focuses on 

toxicology and environmental and 

Gary W. Miller genetic factors involved in neurological 

disease, particularly the role 

of pesticides in the development of Parkinson’s disease. By 

performing top-notch toxicological research in the field of 

neuroscience, Dr. Miller has attracted considerable attention 

to the field and served as an example of the key role of toxicology 

in elucidation of pathogenesis of neuronal disease. 

He has been continuously funded throughout his career 

starting with a Society of Toxicology pre-doctoral fellowship 

all the way to an NIEHS-funded P01 Center that was 

awarded in 2008. 

He is Chair of Emory’s Institutional Health and Biosafety 

Committee, Director of Emory Parkinson’s Disease 

Collaborative Environmental Research Center, Director 

of the Emory NIEHS-funded Toxicology Training Grant, 

and holds additional appointments in Neurology and 

Pharmacology. In addition to serving as President of the 

SOT Southeastern Regional Chapter and Vice President of 

the Neurotoxicology Specialty Section, he was a member 

of the Neurotoxicology and Alcohol Study Section and has 

served on numerous other NIH and international review 

panels and editorial boards. 

Dr. Miller earned an M.S. (1992) from Old Dominion 

University, a Ph.D. (1995) from the University of Georgia, 

and completed postdoctoral fellowships at Emory 

University (1997) and Duke University (1998). He was 

recruited to Emory from the University at Texas at Austin 

as an Associate Professor in 2002 and awarded tenure in 

2004. For the significant contributions to toxicology that he 

has made in the early stages of his career, the Society of 

Toxicology is pleased to present the SOT 2010 Achievement 

Award to Dr. Gary Miller. 

Edward V. 

Ohanian 

Edward V. Ohanian, Ph.D., is recognized 

as the 2010 Arnold J. Lehman 

Award recipient for his contributions to 

risk assessment and regulation of 

chemical agents. He is the Director of 

the Health and Ecological Criteria 

Division at U.S. Environmental 

Protection Agency’s (EPA) Office of 

Water (OW), and is responsible for 

conducting human and ecological risk 

assessments of national and international 

importance. His expertise, 

experience, and broad knowledge have 

helped to shape science policy in EPA’s OW and across the 

Agency at large. He serves as mediator and the voice of 

reason in resolving contentious issues of scientific interpretation. 

Dr. Ohanian demonstrates superior scientific judgment in 

addressing critical areas of water contamination. He helped 

to guide EPA through the highly contentious and sometime 

vitriolic debates on a veritable who’s who of drinking water 

contaminants and issues including lead, fluoride, chromium, 

arsenic, and perchlorate to name just a few. His judgment 

and calm, reasoned advice have been instrumental in 

guiding senior managers, including the Administrators, on 

these and other issues throughout the years. 

His influence is also evident outside of EPA. His input 

is valued on the world stage in WHO Drinking-Water 

Guidelines Committees. His conclusions and advice are 

accepted as authoritative EPA positions. He chairs the EPA 

Risk Assessment Forum, where difficult risk assessments 

and toxicology problems are addressed, and science policy is 

formulated. As co-founder of the Federal-State Toxicology 

and Risk Analysis Committee, he has been instrumental in 

fostering partnership to improve risk analysis methods. He 

also chairs the Health Advisory Board of NSF International, 

which is responsible for setting safe levels for direct and 

indirect drinking water additives. 

Dr. Ohanian is well published, credible in his work, forceful 

yet polite in his arguments, and reasoned and patient in his 

leadership. He is also purposeful, determined, and untiring 

in his efforts to incorporate the best toxicology into risk 

assessments. He has advanced the field of risk assessment 

though innovative thinking and principled risk assessment 

practice. The SOT Awards Committee is pleased to 

announce, Dr. Ohanian as the recipient of the 2010 Arnold 

J. Lehman Award. 

72 




Best Postdoctoral Publication Awards 

The Postdoctoral Assembly recognizes these three recipients 

of their 2010 awards: 

Bret F. Bessac 

Manabu 

Nukaya 

Nicholas Radio 

Bret F. Bessac, Ph.D., Yale University 

School of Medicine, New Haven, CT 

Transient Receptor Potential 

Ankyrin 1 Antagonists Block the 

Noxious Effects of Toxic Industrial 

Isocyanates and Tear Gases 

The FASEB Journal 2009, Vol. 23 

1102–1114 

Manabu Nukaya, Ph.D., University of 

Wisconsin-Madison, Madison, WI 

The Role of the Dioxin Responsive 

Elements Cluster Between Cyp1a1 

and Cyp1a2 Loci in Aryl Hydrocarbon 

Receptor Biology 

Proceedings of the National 

Academy of Sciences USA 2009, 106, 

4923–4928 

Nicholas Radio, Ph.D., Cellumen, 

Pittsburgh, PA 

Assessment of Chemical Effects on 

Neurite Outgrowth in PC12 Cells 

Using High Content Screening 

Toxicological Sciences 2008, 105(1), 

106–118 

Board of Publications Award for the Best 

Paper in Toxicological Sciences 

The Board of Publications has selected 

the paper entitled “Identification and 

Characterization of Toxicity of 

Contaminants in Pet Food Leading to 

an Outbreak of Renal Toxicity in Cats 

and Dogs” as the best paper published 

in Toxicological Sciences in the past 

year (Toxicological Sciences 2008, 106: 

251–262). The authors of the paper are 

Roy L.M. Dobson, Safa Motlagh, Mike Quijano, 

R. Thomas Cambron, Timothy R. Baker, Aletha M. 

Pullen, Brian T. Regg, Adrienne S. Bigalow-Kern, 

Thomas Vennard, Andrew Fix, Ranate Reimschuessel, 

Gary Overmann, Yuching Shan, and George P. Daston. 

The work described in the paper was conducted after the 

observation of acute renal failure in cats and dogs led to a 

major recall of pet food in 2007. The authors carried out an 

extensive analytical effort to identify possible contaminants 

in wheat gluten and ultimately discovered numerous small 

molecule contaminants including melamine and several 

other triazines (ammeline, ammelide, ureidomelamine, 

N-methylmelamine, and cyanuric acid). These compounds 

were not cytotoxic when tested individually in cultured 

kidney cells or in vivo in rats, but mixtures of the triazines 

caused renal failure associated with crystalline deposits in 

the medullary region. The authors subsequently correlated 

these findings in rats to post-mortem analysis of crystals 

obtained from cats and confirmed the presence of high levels 

of melamine and cyanuric acid in the crystals. Collectively, 

the results established a causal link between the contaminated 

gluten and renal toxicity and demonstrated that 

although relatively innocuous in isolation, the combination 

of melamine and cyanuric acid formed insoluble precipitates 

that damaged the renal tubules leading to renal failure 

and death. 

This paper is being recognized because it is an outstanding 

example of the integration of analytical chemistry, in vitro 

and in vivo studies, and histopathology to identify molecular 

mechanisms of toxicity. In addition, the research was 

highlighted in a press release by the Society and Oxford 

University Press because it provided important insight to 

the general public regarding the analysis and toxicity of 

contaminated pet food (and subsequently infant formula 

as well). In this way, it also brought public visibility to 

the collective efforts of toxicologists to create a safer and 

healthier world. 


SOT Sponsored Awards 







Harihara M. 

Mehendale 

Harihara M. Mehendale, Ph.D., 

ATS, the Kitty Degree Endowed Chair 

of Toxicology, College of Pharmacy at 

University of Louisiana at Monroe, 

Monroe, Louisiana, is the recipient of 

the 2010 Distinguished Toxicology 

Scholar Award. 

After several years at the National 

Institute of Environmental Health 

Sciences as a visiting fellow then staff 

fellow, Dr. Mehendale began a career 

spanning 35 years as an independent 

investigator. Seminal contributions in pulmonary, hepatic, 

and renal toxicology are hallmarks of his achievements in 

biomedical research. Perhaps Dr. Mehendale’s most novel 

insight is the key role of stimulation of tissue repair in the 

ultimate outcome in diverse models of organ damage. Initial 

observations of remarkable potentiation of halomethane 

hepatoxicity in rats previously exposed to an organochlorine 

insecticide lead to a series of studies to elucidate this 

novel mechanism. Stimulation of tissue repair in response to 

injury is essential for prevention of organ failure and death 

in multiple model systems. Chemicals and other metabolic 

disturbances (such as diabetes) that interfere with stimulation 

of tissue repair therefore presents a novel mechanism 

for potentiation of toxicity. Identification of candidate genes 

for regulation of stimulated tissue repair by Dr. Mehendale’s 

group promises new therapeutic or preventative approaches 

for organ injury. In large part due to remarkable success 

with competitive grants, Dr. Mehendale consistently 

provided opportunity for education and training for graduate 

students and postdoctoral researchers. The National 

Institutes of Health and Agency for Toxic Substances and 

Disease Registry are examples of long-term sponsors 

of this research. His commitment to quality, continuous 

adoption of new technologies, and enthusiasm for refining 

understanding of mechanisms of toxicity define him as an 

outstanding mentor. Dr. Harihara Mehendale’s record of 

achievement in independent investigator-initiated research, 

and success as a mentor, make him a highly deserving 

recipient of the SOT 2010 Distinguished Toxicology Scholar 

Award. 


Toxic Injury: Initiation, Expansion, and Repair 

Tuesday, March 9, 12:30 PM–1:20 PM, Room 251 A 

Tetsuo Satoh, Ph.D., has had a prestigious 

career as one of the leaders of 

education in the science of toxicology 

and thus is recognized with the 2010 

Education Award. In addition to the 

international recognition he has 

received for his scientific contributions 

to the toxicologic aspects of drug 

metabolism, Dr. Satoh is recognized 

for his exceptional efforts in support of 

Tetsuo Satoh education in toxicology. Dr. Satoh 

joined the Chiba University, Chiba, 

Japan in 1966 where he directed toxicology teaching and 

research for 30 years until leaving the Chiba University in 

1996 as Emeritus Professor of Toxicology. More than two 

hundred students have graduated from his laboratory and 

they are currently working as leaders in toxicology for 

academia, government, and companies in Japan and in other 

countries. Dr. Satoh has served the Japanese Society of 

Toxicology (JST) in numerous positions including the 

Executive Committee. He established the Toxicology 

Education Program in the JST, which later developed into 

the Certification Program for Toxicologists in Japan. Dr. 

Satoh was the Founding President of the International 

Assembly for the Recognition of Toxicologists (IART), a 

group whose focus was on accreditation and certification of 

toxicologists worldwide. Dr. Satoh was one of the founders 

of the Asian Society of Toxicology (ASIATOX), and 

currently is the Senior Advisor to ASIATOX. He has been 

invited to a number of international meetings to give 

lectures concerning education and training of toxicologists. 

Dr. Satoh joined the Society of Toxicology in 1974 and he 

was the first recipient of the Colgate-Palmolive Traveling 

Lectureship in Alternative Methods in Toxicology Award in 

1996. In addition, he served as an Associate Editor of the 

journal Toxicological Sciences. Dr. Satoh has served the 

International Union of Toxicology (IUTOX) in numerous 

positions including Vice President, and he was awarded the 

2007 IUTOX Merit Award for his outstanding work and 

significant contributions to the filed of toxicology. He is 

an eminent toxicologist and a marvelous teacher who has 

contributed significantly over 30 years to education and 

training of graduate students and young toxicologists at 

the national, regional, and international levels. The Society 

of Toxicology recognizes Dr. Tetsuo Satoh with the 2010 

Education Award. 

74 




Enhancement of Animal Welfare Award 


Leonard M. 

Schechtman 

Leonard M. Schechtman, Ph.D., is 

presented the SOT 2010 Enhancement 

of Animal Welfare Aware in recognition 

of the outstanding contributions he 

has made to the advancement of toxicological 

science through the development 

and application of methods that replace, 

refine, and reduce experimental animal 

use in research, education, and regulatory 

safety testing. 

Dr. Schechtman was the U.S. Food 

and Drug Administration’s Principal 

Agency Representative to the 

Interagency Coordinating Committee on the Validation of 

Alternative Methods from 1999 through 2006 and served 

as Chairman of ICCVAM from 2001 through 2006. Under 

his leadership, ICCVAM developed guidelines for nomination 

and submission of alternative test methods, defined 

and implemented test method performance standards to 

expedite validation, enhanced international cooperation with 

the ECVAM and JaCVAM, and successfully evaluated and 

transmitted formal recommendations to U.S. federal agencies 

on the scientific validity of several new alternative methods 

in accordance with the 2000 ICCVAM Authorization Act. 

These alternative safety testing methods were subsequently 

adopted by U.S. regulatory agencies and international organizations 

such as the OECD and its 30 member countries. 

The methods now allow for required regulatory safety testing 

for dermal corrosion, acute systemic toxicity, ocular toxicity, 

and pyrogenicity testing to be conducted more humanely and 

with fewer or no animals. 

Dr. Schechtman also has contributed significantly to the 

development and adoption of internationally harmonized 

guidance on the validation and use of novel in vitro and 

in vivo safety evaluation methods. As president of Innovative 

Toxicology Consulting, he is further contributing to the 

development, scientific validation, and advancement of alternative 

methods for regulatory safety testing. The Society of 

Toxicology is pleased and honored to award Dr. Schechtman 

the SOT 2010 Enhancement of Animal Welfare Award. 

James S. Bus, Ph.D., recipient of the 

SOT 2010 Founders Award, is Director 

of External Technology, Toxicology 

and Environmental Research and 

Consulting at The Dow Chemical 

Company. He has worked tirelessly and 

vocally on the very issues that describe 

the Founders award, demonstrating 

“outstanding leadership in fostering the 

role of toxicological sciences in safety 

James S. Bus decision-making through the development 

and/or application of 

state-of-the-art approaches that elucidate, 

with a high degree of confidence, the distinctions for 

humans between safe and unsafe levels of exposures to 

chemical and physical agents.” 

Dr. Bus has truly distinguished himself over the years in 

toxicology research and its application in safety assessment. 

His leadership is demonstrated through his positions 

on such boards as the National Academy of Sciences Board 

of Environmental Sciences and Toxicology, the ILSI Health 

and Environmental Sciences Institute, the U.S. EPA Science 

Advisory Board, and the Toxicology Forum, to name a few. 

He has served as President of the Society of Toxicology and 

the American Board of Toxicology. Among his awards is the 

Society of Toxicology Achievement Award (1987) for his 

outstanding contributions to the science of toxicology. His 

research interests include mechanisms of oxidant toxicity, 

defense mechanisms to chemical toxicity, relationships of 

pharmacokinetics to expression of chemical toxicity, and 

general pesticide and industrial chemical toxicology. 

Dr. Bus has constantly pushed the science of toxicology to 

improve and expand the application of the best toxicological 

data into regulatory decisions. He is driven by a passion and 

contagious enthusiasm for improving the toxicological basis 

for regulatory decisions. Dr. Bus has worked to ensure that 

state-of-the-art approaches are applied to regulatory decisions. 

He is determined to work to improve the quality of our 

regulatory system to better protect human health and more 

capably set safe levels for chemical agents. We congratulate 

and recognize Dr. James Bus as the recipient of the SOT 

2010 Founders Award. 






Merit Award 


Richard S. 

Paules 

Richard S. Paules, Ph.D., Senior 

Scientist and Head, Environmental 

Stress and Cancer Group, Laboratory 

of Molecular Toxicology, Division of 

Intramural Research, NIEHS, and 

Director, NIEHS Microarray Group, is 

awarded the Leading Edge in Basic 

Science Award for his recent and 

seminal scientific contribution to 

understanding fundamental mechanisms 


A respected leader and strong force in 

the field of toxicogenomics, Dr. Paules proved to be a true 

visionary who early on captured the essence of the field and 

the power of the technology and has diligently positioned 

NIEHS at the forefront of the field. He has been a major 

contributor to the development of the National Center for 

Toxicogenomics (NCT) research infrastructure and the 

development of strong partnerships between the Institute, 

academia and the corporate sector. Dr. Paules led a large 

research effort in which proof-of-concept toxicogenomics 

studies were performed to demonstrate the utility of 

bringing together genomic approaches with more traditional 

approaches of biology, molecular biology, physiology, 

pathology, and toxicology in order to gain insight into the 

molecular mechanisms involved in the etiology and progression 

of injury and disease processes. An additional goal 

was to develop predictive biomarkers of the initiation and 

progression of those processes. In addition to his studies 

incorporating genomics into studies of xenobiotic-induced 

liver injury, Dr. Paules has successfully integrated genomics 

into his studies of a mechanistic understanding of how 

errors in DNA damage responses can contribute to diseases 

including cancer. 

Dr. Paules continually displays the attributes expected of 

the best scientists and his record of scientific achievements 

suggests that he will continue to excel as a leader in environmental 

health research and toxicology. For his work in 

the integration of genomics into the investigation of the 

molecular basis of injury and disease processes, the Society 

of Toxicology recognizes Dr. Richard Paules with the SOT 

2010 Leading Edge in Basic Science Award. 


Toxicogenomics at NIEHS: How Genomics Is Impacting 

the Science of Toxicology 

Monday, March 8, 12:30 PM–1:20 PM, Room 251 A 

Marion F. Ehrich, Ph.D., receives the 

2010 Merit Award. She is a tenured 

professor of pharmacology and toxicology 

and the co-director of the 

Laboratory for Neurotoxicity Studies 

at the Virginia-Maryland Regional 

College of Veterinary Medicine 

(VMRCVM) on the campus of 

Virginia Tech. Her research interests 

include biochemical neurotoxicology, 

Marion F. Ehrich particularly neurotoxicity of organophosphates. 

Dr. Ehrich is nationally 

known and her accomplishments in 

neurotoxicology and in vitro toxicology are most notable. 

She has been a leading investigator in determining the 

mechanisms and pathogenesis of organophosphate esterinduced 

neurotoxicity (OPIDN) and other pesticide-induced 

injuries to the nervous system. An expert in the assessment 

and role of neurotoxic esterase in OPIDN, she is often called 

upon by both government and industry for her expertise. 

She has been a pioneer in the use of in vitro systems for 

mechanistic studies and safety assessment in neurotoxicology, 

with potential contribution to a diminished need for 

animal use in chemical safety assessments. 

Dr. Ehrich is a practicing registered pharmacist and 

pharmacy consultant to the VMRCVM, served as SOT 

President 2003–2004, and American Veterinary Medical 

Association, and is also a member of the Academy of 

Toxicological Sciences, and American Academy of 

Veterinary Pharmacology and Therapeutics. She has 

mentored more than 35 masters and doctoral level students. 

Dr. Ehrich's publications span 38 years, including 300 book 

chapters, reviews, research and educational publications. 

Her grant funding sources have included NIH, USDA, EPA, 

the Department of Defense and others. Her distinguished 

contributions to toxicology over 30 years encompass 

research, teaching, consulting, and mentoring as well as an 

unbridled dedication to the Society. It is a true pleasure to 

honor and recognize Dr. Marion Ehrich with the SOT 2010 

Merit Award. 


Opening Doors in Research, Teaching, and Service 

Wednesday, March 10, 12:30 PM–1:20 PM, Room 251 A 

76 




Nygerma L. 

Dangleben 



Nygerma L. Dangleben, B.S., 

University of California Berkeley, 

Berkely, CA 



Abstract Title: Investigating Beta- 

Defensin-1 Down-Regulation in 

Arsenic Toxicity 


Philip Wexler’s extensive career at the 

U.S. National Library of Medicine’s 

(NLM) Toxicology and Environmental 

Health Information Program, coupled 

with his other professional affiliations, 

collaborations, and independent projects, 

designed to make toxicology 

more accessible to the public, uniquely 

qualify him for the SOT Public 

Communications Award. 

Philip Wexler Serving as Editor-in-Chief of 

Elsevier’s Information Resources in 

Toxicology (4 th ed., 2009) and the 4-volume Encyclopedia 

of Toxicology (2 nd ed., 2005), he has managed the fine 

balance of communicating with both scientific audiences 

and the public. An author of numerous papers, Mr. Wexler is 

currently preparing “Toxicology: An Evolving Informatics 

Framework” for Critical Reviews in Toxicology. His public 

policy orientation will be featured in another book he is 

co-editing, Chemicals, Environment, Health: A Global 

Management Perspective, for Taylor and Francis. 

He served for two terms as Chair of the SOT’s World Wide 

Web Advisory Committee and is 2010 President of SOT’s 

Ethical, Legal, and Social Issues Specialty Section. With 

Steve Gilbert, he assembled the Toxicology History Room 

at SOT’s 2009 Annual Meeting. He is Vice President of 

the Toxicology Education Foundation, which promotes the 

public understanding of toxicology. 

Mr. Wexler is a member of the recently assembled 

Education and Communications Work Group of the CDC/ 

ATSDR’s National Conversation on Public Health and 

Chemical Exposure project. At NLM, he has been instrumental 

in developing and enhancing the TOXNET system 

and its components, serves as file manager for the LactMed, 

IRIS and ITER databases, and heads the Risk Assessment 

Information Team. He spearheaded the development of the 

multi-stakeholder produced World Library of Toxicology, 

Chemical Safety, and Environmental Health, an on-line 

global collaborative and network. 

Mr. Wexler oversees the NLM-SOT joint project ToxLearn, 

a multi-module tutorial covering the basic principles of 

toxicology for general audiences. He has taught countless 

medical librarians and others the use of toxicology information 

systems, at NLM and other venues, and made numerous 

presentations and conducted continuing education courses 

at meetings throughout the world. 

Mr. Wexler’s contributions have had and continue to have 

an enormous impact on how scientists, other professionals, 

and the public at large accesses toxicological information. 

We congratulate and recognize Philip Wexler, M.L.S., with 

the SOT 2010 Public Communications Award. 

SOT AstraZeneca IUTOX Fellowship 

Asongalem Emmanuel Acha, Ph.D., University of Buea, 

Buea, Cameroon 

Ayse Basak Engin, Ph.D., Gazi University, Ankara, Turkey 

Ronnie A. D. Frazer-Williams, Ph.D., Fourah Bay College, 

Freetown, Sierra Leone 

Yan Li, B.S., Chinese Academy of Sciences, Shanghai, 

China 

Jesus T. Olivero-Verbel, Ph.D., Universidad de Cartagena, 

Cartagena, Colombia 

Suresh V.S. Rana, Ph.D., C.C.S. University, Meerut, India 

Ganna Shayakhmetova, Ph.D., Institute of Pharmacology 

and Toxicology AMS of Ukraine, Kyiv, Ukraine 

Vanessa Steenkamp, Ph.D., University of Pretoria, 

Pretoria, South Africa 

Marcelo J. Wolansky, Ph.D., University of Buenos Aires, 

Buenos Aires, Argentina 

Motao Zhu, Ph.D., National Center for Nanoscience and 

Technology, Beijing, China 







Kenneth E. 

McMartin 

Kenneth E. McMartin, Ph.D., is the 

2010 Translational Impact award 

recipient. He is Professor in the 

Department of Pharmacology, 

Toxicology and Neuroscience at the 

LSU Health Sciences Center— 

Shreveport, Director of the LSUHSC-S 

interdisciplinary graduate program in 

toxicology, and Co-Director of the 

Pharmacokinetics Core for the Center 

for Experimental Cancer Therapeutics. 

Dr. McMartin’s early studies showed 

that, in experimental methanol poisonings, formic acid was 

the proximate toxicant and had a causative role in the severe 

metabolic acidosis observed for these intoxications. He 

worked with collaborating laboratories to develop treatment 

modalities. This effort culminated in the commercialization 

of the antidote 4-methylpyrazole, now called fomepizole. 

The ensuing product development progressed through 

animal experimentation and then phase I-phase III clinical 

trials. Importantly, fomepizole is now utilized worldwide 

and has become the standard of care for both ethylene glycol 

and methanol poisonings. 

In recent years, Dr. McMartin has conducted mechanistic 

experimental studies on the pathogenesis of the renal 

toxicity of ethylene glycol, demonstrating that the precipitation 

of calcium oxalate crystals in the kidneys was a 

causative factor in the observed renal tubular toxicity. He 

is currently investigating mechanisms of toxicity for diethylene 

glycol poisonings, an important problem evident by 

recent and past epidemic intoxications worldwide. Thus, 

Dr. McMartin has had a significant impact on clinical toxicology, 

dedicating his career to the study of mechanisms of 

action of toxicants important in common poisonings and 

in the development of antidotes for their therapy. We are 

delighted to recognize Dr. Kenneth McMartin as the SOT 

2010 Translational Impact awardee. 


Translating Mechanism-Based Research into Antidotes: 

Trials, Tribulations, and Triumphs 

Tuesday, March 9, 8:00 AM–8:50 AM, Room 251 A 

Creating a Safer and Healthier World 

by Advancing the Science of Toxicology 

Do you know a toxicologist 

who deserves to be recognized? 

SOT recognizes distinguished 

toxicologists and students with many 

prestigious awards each year. 

In addition to receiving the specific award, 

recipients are honored at a special 

Awards Ceremony at the 

SOT Annual Meeting and their names are 

listed in SOT publications. 

Most award nominations and applications 

are submitted through a quick on-line 

process. 

Applications for 2011 national 

SOT awards are due October 9, 2010. 

Regional Chapter Awards, 

Special Interest Group Awards, and 

Specialty Section Awards have various 

deadlines throughout the year. 

Visit the Awards and Fellowships section 

of the Web site for award descriptions, 

additional information, and 

to make nominations. 


78 




AstraZeneca Traveling Lectureship Award 

J. Chris Corton, Ph.D., is the 2010 

AstraZeneca Traveling Lectureship 

Award winner. The award recognizes 

excellence in research and service in 

toxicology and enables a lecture tour 

of Europe to promote collaborations 

between European and North 

American toxicologists. Dr. Corton is 

a Senior Research Biologist in the 

Integrated Systems Toxicology 

J. Chris Corton Division at the National Health and 

Environmental Effects Research 

Laboratory of the U.S. Environmental 

Protection Agency in Research Triangle Park, NC. For 

more than two decades, Dr. Corton has studied the mode of 

action and human relevance of hepatotoxicants. His group 

has successfully used a multi-pronged strategy dominated 

by toxicogenomics and nullizygous mouse models to 

uncover chemical mode of action useful for risk assessment. 

More recently, his group is evaluating and implementing the 

use of high-throughput in vitro methods as first-tier 

screening for hepatotoxicity and mode of action categorization. 

He is on the editorial boards of 6 journals and has 

served as member and chair on numerous NIH study 

sections. He has also served in many capacities in SOT 

including member and chair of the Continuing Education 

Committee. Dr. Corton will focus his lecture tour to 

European scientists who are part of the REACH chemical 

testing program and who are part of the HepatoSys collaborative 

network of scientists directed toward building 

predictive computational models of the liver. Dr. Corton 

will conduct a lecture series at both industrial and academic 

institutions in Europe with the objective to establish productive 

relationships and collaborations with European 

colleagues, gain an understanding of approaches and 

methods in in vitro hepatotoxicology in Europe, and to gain 

a better understanding of the European viewpoints on in 

vitro testing, risk assessment and science policy of chemicals 

in general and hepatotoxicants in particular. We 

recognize Dr. Chris Corton with the 2010 AstraZeneca 

Traveling Lectureship Award. 

Colgate-Palmolive Awards for Student Research 

Training in Alternative Methods 

Maxwell C. K. Leung, M.Sc., 

Duke University, Durham, NC 

Project Title: Physiological and 

Developmental Effects of Persistent 

Mitochondrial DNA Damage in 


Host Institution: Vanderbilt University, 

Nashville, TN 

David T. Szabo, M.S., University of North 

Carolina at Chapel Hill, Chapel Hill, NC 

Project Title: From Mice to Men: 

Generation of a Stereoisomer Specific 

Physiological Based Pharmacokinetic 

(PBPK) Model of the Flame Retardant 

Hexabromocyclododecane (HBCD) 

Host Institution: University of Montréal, 


Natalia M. VanDuyn, B.S., Indiana 

University, Indianapolis, IN 

Project Title: Evaluating the Role of 

Intracellular Calcium and Mitochondrial 

Membrane Potential in a Novel C. 

elegans Model of Methylmercury 

Toxicity 

Host Institution: Michigan State 


Colgate-Palmolive Grants for Alternative Research 

Patrick Allard, Ph.D., Harvard School 

of Public Health, Boston, MA 

Project Title: High-Throughput 

Strategy for the Study of Environmental 

Disruption of Reproductive Health Using 


Duncan C. Ferguson, D.V.M., Ph.D., 

University of Illinois at Urbana- 

Champaign, Urbana, IL 

Project Title: Human Neural Stem Cell 

Line in Defined Medium As a Screen for 

Neurodevelopmental Toxins 

(Part II: Applications) 

Mehmet Uzumcu, D.V.M., Ph.D., 

Rutgers, The State University of New 

Jersey, New Brunswick, NJ 

Project Title: Monitoring 

Folliculogenesis in Ovary Organ 

Culture by Multiphoton Fluorescence 

Microscopy: An In Vitro Alternative for 

Testing Epigenetic Effects of Endocrine- 

Disrupting Chemicals 






Pfizer Undergraduate Student Travel Award 

Annie L. Carlton, Bates College, 

Lewiston, ME 



Abstract Title: Developmental Arsenic 

Exposure Causes Obesity, Hyperglycemia 

and Liver Disease in Male Mice in 

Adulthood 

Alisha Chitrakar, Saint Peter’s College, 

Jersey City, NJ 



Abstract Title: Chronic Methylmercury 

Exposure Potentiates [ZN 2+ ] i 

in Motor 

Neurons of HSOD1 Mice 

Megan E. Culbreth, North Carolina State 

University, Raleigh, NC 



Abstract Title: Rodent and Human 

Neuroprogenitor Cells for High-Content 

Screens of Chemical Effects on 

Proliferation and Apoptosis 

Chang Woo Lee, University of Texas MD 

Anderson Cancer Center, Houston, TX 



Abstract Title: Phytotoxicity of Metal 

Oxide Nanoparticles to Arabidopsis 

thaliana 


Applications of New Technologies 

Haitian Lu, M.S., Michigan State 


Project Title: Characterization of 

2,3,7,8-Tetrachlorodibenzo-p-dioxin 

(TCDD)-Mediated Effect and 

Mechanism of Action on the Humoral 

Immunity Using Primary Human and 

Mouse B Lymphocytes 

The following scientists were selected for fellowships 

at the 2009 SOT Annual Meeting. 

2009 Colgate-Palmolive Postdoctoral Fellowship 


Ankur Dnyanmote, Ph.D., University of 

California, San Diego, CA 

2009 Novartis Graduate Fellowship 

Yue Cui, Ph.D., University of Kansas 

Medical Center, Kansas City, KS 



Abstract Title: ChIPing the Cistrome of 

PXR in Mouse Liver 

Sharon Ochs, Wright State University, 

Dayton, OH 



Abstract Title: Role of Specific Binding 

Motifs in TCDD-induced Activation of 

the Human Polymorphic hs1,2 Enhancer 

80 



SOT 2010 Honorary Memberships 

Honorary membership is awarded by the Society of Toxicology to persons who are not members of the Society in 

recognition of outstanding and sustained contributions to advancing the science and field of toxicology. The 2010 

Honorary Member recipients are Drs. Sir Philip Cohen and Ferid Murad, who are the Keynote Medical Research 

Council (MRC) Lecturer and 2010 Plenary Opening Lecturer, respectively. 

Professor Sir Philip Cohen is the 

founder and Co-Director of the Division 

of Signal Transduction Therapy 

(DSTT), the UK’s largest collaboration 

between a basic research institution and 

the pharmaceutical industry. It is widely 

regarded as a model for how industry 

and academia should interact, for which 

it received a Queen’s Anniversary 

Award for Higher Education in 2006. 

Philip Cohen For the past 40 years, Dr. Cohen’s 

research has been devoted to studying 

the role of protein phosphorylation in cell regulation and 

human disease, a process that controls almost all aspects of 

cell life. His contributions to this area include working out 

over a 25-year period how calmodulin, the calcium-binding 

protein, is involved in the insulin-induced stimulation of 

glycogen metabolism in muscle. Currently, his laboratory 

is investigating the signaling pathways that regulate the 

production of pro-inflammatory cytokines and interferons 

during bacterial and viral infection, research that is aimed 

at understanding how the uncontrolled production of these 

substances causes chronic inflammatory diseases, such as 

rheumatoid arthritis, asthma, and septic shock. 

Dr. Cohen was born on July 22, 1945, in Edgware, Middlesex, 

England, and received his B.Sc. (1966) and Ph.D. (1969) 

from University College London. He then spent two years 

as a postdoctoral fellow at the University of Washington 

(Seattle, WA) with Dr. Edmond Fischer (the 1992 Nobel 

Laureate for Medicine or Physiology). 

In 1971, Dr. Cohen returned to the UK to become a faculty 

member at the University of Dundee, Scotland, where he has 

worked ever since. He has been a Royal Society Research 

Professor since 1984, Director of the Medical Research 

Council (MRC) Protein Phosphorylation Unit since its inception 

in 1990, and was the Honorary President of the British 

Biochemical Society from 2006–2008. He was knighted in 

1998. 

Nobel Laureate Ferid Murad is being 

recognized by SOT for his contributions 

to public health and medicine. He 

is the Director of the Institute of 

Molecular Medicine and holds the John 

S. Dunn Distinguished Chair in 

Physiology and Medicine at the 

University of Texas. 

His key research demonstrated that 

nitroglycerin and related drugs work 

Ferid Murad by releasing nitric oxide into the body, 

which acts as a signaling molecule 

in the cardiovascular system, making blood vessels dilate. 

The missing steps in the signaling process were filled in by 

Robert F. Furchgott and Louis J. Ignarro. The three received 

the 1998 Nobel Prize in Physiology or Medicine for this 

work. Drs. Murad and Furchgott received the Albert Lasker 

Award for Basic Medical Research in 1996. 

Dr. Murad is an Albanian-American physician and pharmacologist, 

who was born September 14, 1936, in Whiting, 

Indiana. He received his undergraduate degree in chemistry 

from the pre-med program at DePauw University in 1958. 

An early graduate of the first Medical Scientist Training 

Program to be developed, he recieved an M.D. and Ph.D. 

in pharmacology from Case Western Reserve University in 

1965. He then joined the faculty of University of Virginia, 

where he was made professor in 1970, before moving to 

Stanford University in 1981. Dr. Murad left Stanford in 1988 

for a position at Abbott Laboratories, where he served as a 

vice president until starting his own biotechnology company, 

the Molecular Geriatrics Corporation, in 1993. Dr. Murad 

relocated to the University of Texas in 1997 to create a new 

department of integrative biology, pharmacology, and physiology. 




SOT Endowment 2009 Award Recipients 

Mary Amdur 


J. Grace 

Wallenborn, M.S., 


North Carolina, 

Chapel Hill, NC 

Perry J. Gehring Biological 

Modeling Student Award Fund 

Marc-André Verner, 

Université du 

Québec, Montréal, 


Perry J. Gehring Risk Assessment 


Mathieu Valcke, 

Universite de 

Montréal, Montréal, 


Founders Fund 

Roger O. McClellan, 

D.V.M., Toxicology 

& Human Health 

Risk Analysis, 

Albuquerque, NM 

Perry J. Gehring Diversity 

Student Travel Award Fund 

Vanessa De 

La Rosa, B.S., 

University of Texas, 

El Paso, TX 

Scott Auerbach, 

Ph.D., National 

Institute of 

Environmental 

Health Sciences, 


Park, NC 


Vera W. Hudson and Elizabeth K. 

Weisburger Scholarship Fund 

Courtney Kozul, 

B.A., Dartmouth 

Medical School, 

Hanover, NH 

Join Us for the Announcement of 2010 Endowment Fund Award Recipients 

2010 Endowment Fund Awards .............................................................................................................. Awarded by 

Founders Fund ......................................................................................................................................Awards Committee at Awards Ceremony 

Perry J. Gehring Diversity Student Travel Award Fund ....................................Committee on Diversity Initiatives at Undergraduate Program 

Perry J. Gehring Biological Modeling Student Award Fund ...........................................................................................Biological Modeling SS 

Dharm V. Singh Carcinogenesis Award Fund ......................................................................................................................... Carcinogenesis SS 

Roger O. McClellan Student Award Fund ...........................................................................................................Comparative and Veterinary SS 

Emil A. Pfitzer Drug Discovery Student Award Fund .........................................................................................Drug Discovery Toxicology SS 

Frank C. Lu Food Safety Student Award Fund ............................................................................................................................. Food Safety SS 

Health and Environmental Science Institute Immunotoxicology Young Investigator Student Award Fund ...................Immunotoxicology SS 

Mary Amdur Student Award Fund ........................................................................................................................ Inhalation and Respiratory SS 

Renal Toxicology Fellowship Award Fund, Robert J. Rubin Student Travel Award Fund, and 

Carl C. Smith Student Mechanisms Award Fund .................................................................................................................... Mechanisms SS 

Molecular Biology Student Award Fund .............................................................................................................................Molecular Biology SS 

Perry J. Gehring Risk Assessment Student Award Fund and Robert J. Rubin Student Travel Award Fund ....................... Risk Assessment SS 

Roger O. McClellan Student Award Fund ......................................................................................... Toxicologic and Exploratory Pathology SS 

Jean Lu Student Scholarship Award Fund ........................................................................American Association of Chinese in Toxicology SIG 

Laxman S. Desai ASIO Student Award Fund, Harihara Mehendale ASIO 

Student Award Fund, and Dharm V. Singh ASIO Student Award Fund .................................Association of Scientists of Indian Origin SIG 

Young Soo Choi Student Scholarship Award Fund .............................................................. Korean Toxicologists Association in America SIG 

Vera W. Hudson & Elizabeth K. Weisburger Scholarship Fund ................................................................................ Women in Toxicology SIG 

Please refer to the 2010 Program for date, time, and location of the Committee on Diversity Undergraduate Education Program, 

Regional Chapter, Special Interest Group, and Specialty Section receptions on pages 13–21. 

82 



SOT Endowment 2009 Award Recipients (Continued) 

Frank C. Lu Food Safety 

Students Award Fund 

Natalie Johnson, 

B.S., Texas A&M 


Station, TX 

Harihara Mehendale and 

Dharm V. Singh ASIO Student 

Award Funds 

Mamta Behl, Ph.D., 

Purdue University, 

West Lafayett, IN 

Carl C. Smith Student 

Mechanisms Award Fund 

Jingui Fu, B.S., 

Hamner Institutes 

for Health Sciences, 


Park, NC 



Chidozie Amuzie, 



Lansing, MI 

Yogesh Saini, M.S., 



Lansing, MI 

Liang Chen, 


Cincinnati, 

Cincinnati, OH 

Emil A. Pfitzer Drug Discovery 


Jamie O’Brien- 

Barnard, University 

of Rochester, 

Rochester, NY 

Jennifer Cohen, 

B.S., University of 

Arizona, Tucson, AZ 

Arunkumar 

Asaithambi, 

B.S., Iowa State 

University, Ames, IA 

Smita Salian, 

National Institute 

for Research on 

Reproductive Health, 

Denver, CO 

Raja Settivari, 

Indiana School 

of Medicine, 

Indianapolis, IN 


Gayathri 

Chadalapaka, 

B.V.Sc., 

Texas A&M 


Station, TX 

Karen Thomas, 

Pharm.D., 

University of Utah, 

Salt Lake City, UT 


Hongfei Zhou, 

M.S., University of 

Colorado, Denver, 

CO, and Sanjeeva 

Wijeyesakere, 

Ph.D., University 

of Michigan, Ann 

Arbor, MI 




Continuing Education (Continued) 

Continuing Education Courses 

The Continuing Education Program offers a wide range of courses that 

cover established knowledge in toxicology, as well as new developments 

in toxicology and related disciplines. Courses can be applied toward 

certifying and licensing board requirements and may also be used for 

recertification with the American Board of Toxicology (ABT). Both basic 

and advanced course topics are offered. The basic course is intended to 

provide a broad overview of an area or to assist individuals in learning 

new techniques or approaches. The advanced course is intended to be of 

interest to individuals with previous knowledge of the subject or already 

working in the field. 

All courses will be held on Sunday, March 7, 2010, at the Salt Palace 

Convention Center. Please check the signage in the registration area and 

at the CE Booths for room assignments. Note: Your course materials 

will be available in the room immediately prior to the course (they will 

not be available at the registration area). If you have your course ticket, 

go directly to the assigned course room. If you have not received your 

course ticket or have not registered, please go to the registration area on 

Saturday afternoon/evening or on Sunday morning. If you have misplaced 

your ticket, please go to a Continuing Education Booth at the Convention 

Center on Sunday. The booths will be open from 6:30 AM–5:30 PM. 

7:00 AM–7:45 AM Continuing Education Sunrise Mini-Course: 

1. Biological Pathway Analysis: An Introduction to the Pathway 

Knowledge Bases for Toxicological Research 

Continuing Education Target Areas 

In addition to the thematic approach topics selected by the Scientific 

Program Committee, the Continuing Education Committee has chosen 

two specific target areas to highlight in the courses offered this year. 

Application to a target area is noted by the icon on the following page. 

Biologicals 

This topic provides an integrated discussion of the regulatory and risk 

assessment processes for the development of human monoclonal antibodies, 

siRNA molecules, vaccines, and other biological materials to 

be used as new disease modifying therapies, including the evolving and 

emerging regulations for FDA approval and regulatory aspects of biologicals 

versus small molecules. 

Cytokine Biology 

Cytokines, molecules important in mediating toxicant-induced responses, 

emanate from multiple sources. Their release is in response to different 

stimuli and they interact to produce distinct and defined cellular and 

organismic responses. These responses are deterministic in autoimmune 

diseases and in response to toxicant exposure. This theme includes elucidation 

of their roles in diseases (including cancer), response to injury 

from exposure to chemical or biological agents (including infections), 

analytical approaches for quantification of cytokine release, presentation 

of examples of cytokine involvement in toxic responses, cytokine effects 

on xenobiotic metabolism, and emerging issues in the area. 

8:15 AM–12:00 NOON Continuing Education Morning 

(AM) Courses: 

2. Biologicals: Introduction to Drug Development 

3. Comparative Biology of the Lung 

4. Cytokines: Balancing Therapeutic Utility and Immune System- 

Mediated Toxicities 

Did You Miss Out on the Baltimore Meeting? 

Were You Unable to Attend All the Courses 

That Interested You? 

SOT Now Offers Courses On-Line! 

5. Nuclear Receptors: Role in Chemical Mode of Action and Targets 

for Toxicity Testing 

6. Predictive Power of Novel Technologies (Cells to ‘Omics): 

Promises, Pitfalls, and Potential Applications 

7. Reproduction and Regulatory Impact 

1:15 PM–5:00 PM Continuing Education Afternoon (PM) 

Courses: 

8. Assessment of Ocular Toxicity in Toxicology Studies Conducted 

for Regulatory Purposes 

9. Gene-Environment Interactions Influence Cytokine Biology in 

Immunotoxicity and Disease: Genomic, Genetic, and Epigenetic 

Perspectives 

10. Mitochondrial Toxicity: Animal Models and Screening Methods in 

Drug Development 

11. ICH Initiatives for Conducting Pharmaceutical Preclinical Safety 

Studies: New and Revised Guidelines and Challenges 

12. Segment-Specific Renal Pathology for the Non-Pathologist 

13. Technologies and Tools for Toxicity Testing in the 21 st Century 

Registration for the Annual Meeting and a separate CE course ticket are 

required. 

Continuing Education 

Courses On-Line 

With the changing economy, it is more important 

than ever to keep your skills sharp, learn new 

techniques, and stay competitive in your field. 

SOT is dedicated to providing such opportunities 

and resources to the scientific community. 

In order to facilitate professional development 

beyond the Annual Meeting, as well as a low-cost 

alternative to those who are unable to attend, 

the Continuing Education Committee is proud to 

introduce a pilot program to release on-line CE 

courses through the SOT Web site. Select courses 

are available from the 48 th Annual Meeting in 

Baltimore, 2009, and plans are in place to release 

several more from Salt Lake City. 

Visit the SOT Web site 

for more information! 

CE 




CE 


7:00 AM–7:45 AM 


(See signage at CE Booth for room location) 

Biological Pathway Analysis: An Introduction to the Pathway 

Knowledge Bases for Toxicological Research 

SR01 

CE SUNRISE 

Chairperson(s): Marc E. Gillespie, St. John’s University, Queens, NY. 

Sponsor: 


Genomic and proteomic datasets are a complex and information rich 

resource. Toxicology is expanding to new omics-based technologies to 

identify important gene and protein expression changes. A critical step 

in such studies is the analysis of the data set to derive reasonable mechanistic 

meaning and testable hypothesis. Additionally, the use of genomic 

and proteomic approaches to identify new lead molecules for biologically 

relevant targets is rapidly expanding. A challenge for scientists is how 

to properly and effectively incorporate high-throughput omics technologies 

into their research programs. This course will present practical cases 

demonstrating how the Reactome pathway analysis tools can be used 

to identify relevant biological pathways within large and immensely 

complex data sets derived from multiple high-throughput technology 

platforms. The course will begin with an overview of how genomic and 

proteomic data sets are generated including, but not limited to, microarray 

gene expression data, mass-spectrometry data, protein interaction data, 

and RNAi screening. All of these methods share a common endpoint, the 

generation of large datasets that the toxicologist must analyze without 

prior knowledge of a reasonable mechanistic basis or outcome. Often 

the analysis of such data can be biased by focusing on known genes and 

pathways. The creation of new knowledge bases, often called pathway 

databases, incorporates information on protein, gene, and literature 

databases to facilitate the identification of relevant schemes using combinations 

of data, resulting in predictions that more closely approximate 

biological networks. The course will review how available knowledge 

bases such as Reactome and PharmGKB can be used to interrogate large 

and complex datasets to identify the contributions of specific pathways in 

a given biological response to toxicant exposure. 

• Biological Pathway Analysis: An Introduction to the Pathway 

Knowledge Bases for Toxicological Research, Marc E. Gillespie, 

St. John’s University, Queens, NY. 


8:15 AM–12:00 NOON 

Lower and Upper Concourses (See signage at CE Booths 

for room locations) 

Biologicals 

Biologicals: Introduction to Drug Development 

AM02 

CE BASIC 

Chairperson(s): James D. Green, Biogen Idec, Inc., Cambridge, MA, and 

Laura Andrews, Genzyme Corporation, Framingham, MA. 

Sponsor: 


Endorsed by: 




Toxicologists and other preclinical scientists have developed an extensive 

experience base with a wide range of product classes of biologics over 

the last two decades. These product classes include proteins, monoclonal 

antibodies, vaccines, cell therapies, gene therapy products, peptides, 

and oligonucleotides. These product classes are diverse in origin and are 

manufactured by a variety of production methods. For example, host cells 

(e.g., E. coli, yeast, CHO cells) are used in the production of antibodies 

and proteins; various solid and liquid state chemical syntheses have been 

used for the production of peptides, siRNA’s and oligonucleotides, and a 

variety of vectors (e.g., retrovirus, AAV) have been used to produce gene 

therapy products. The historical information that has set the ground work 

for current practices will be reviewed and important global regulatory 

requirements will be identified that should be considered collectively 

when designing the battery of nonclinical safety studies. Unique considerations 

for each of these product classes will be highlighted as well as 

the timing of the considerations. Emphasis will be placed on two distinct 

phases; in particular, those that occur prior to the conduct of human 

clinical trials and those that occur during clinical development. The 

course will be an integrated discussion of the scientific, risk/benefit, and 

regulatory considerations that should be considered for the development 

and human testing of biotherapeutics. We intend to address evolving 

regulatory requirements in each specific product area and, as appropriate, 

discuss important differences from the development of small molecule 

drugs. Students with little or no experience in this area, as well as toxicologists 

working in pharmaceutical drug development will benefit from 

taking this course. 

• Introduction, James D. Green, Biogen Idec, Inc., Cambridge, MA. 

• Principles for Development of Proteins, Shawn M. Heidel, Eli Lilly 

& Company, Indianapolis, IN. 

• Principles for Development of Monoclonal Antibodies and Related 

Forms, Randy Soltys, Genentech Inc., South San Francisco, CA. 

• Principles for Development of Novel Biologics: siRNA, 

Oligonucleotides, Anti-Sense, and Aptamers, Arthur A. Levin, 

Santaris Pharma A/S, San Diego, CA. 

• Principles for Development of Vaccines, Cell and Gene 

Therapies, and Blood Products (CBER-Regulated Products), 

Timothy MacLachlan, Genzyme Corporation, Framingham, MA. 

86 





8:15 AM–12:00 NOON 



Comparative Biology of the Lung 

AM03 

CE BASIC 

Chairperson(s): Richard Parent, Consultox Ltd., Damariscotta, ME, and 

Daniel Costa, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




All mammals have evolved respiratory structures to ensure that the 

principal function of the lung, gas exchange, is met under varying physiological 

conditions. However, this essential function is achieved despite 

significant differences in the structural organization, cellular composition, 

and related functions mediated through the respiratory system and across 

mammalian species. Translational toxicology requires that one understand 

these innate differences in fundamental respiratory biology if one 

is to appropriately interpret and extrapolate findings in animal models. 

On a gross level, the nasal passages, pleural thickness, vascularity, and 

connective tissue structure vary between species. Quantitative evaluation 

of the tracheobronchial airway tree demonstrates few consistent features 

between species. The epithelial cell populations lining the lung differ in 

cell type, location, and abundance. The metabolic enzymes, cytokines, 

chemokines, protease, and anti-oxidant potential, although showing some 

similarities, also demonstrate vast differences. Similarly, basic immunological 

functions in laboratory animals must be understood and related 

to those in humans to enable appropriate species translation. We will 

illustrate many of these fundamental differences, describe methods for 

making measurements in different species, and most importantly, focus 

on the fundamentals of appropriate interpretation of study data derived in 

animals for human use. Attendees will gain a basic understanding of the 

value and pitfalls extending from these species differences, which will 

enable improved study design and extrapolation of research data for efficacy, 

safety pharmacology, and toxicology studies. This course is intended 

to provide attendees with a basic understanding of lung structure-function 

relationships and associated immunological and metabolic functions in 

laboratory animals that will aid in the extrapolation of inhalation or respiratory 

data to humans. 

• Introduction, Richard Parent, Consultox Ltd., Damariscotta, ME, and 

Daniel Costa, U.S. EPA, Research Triangle Park, NC. 

• Comparative Anatomy of Mammalian Respiratory Systems, Kent 

Pinkerton, University of California, Davis, CA. 

• Interpretation and Limitations in the Assessment of Lung Function in 

Laboratory Mammals, Jeffrey Tepper, Tepper Nonclinical Consulting, 

San Carlos, CA. 

• Metabolism and Enzymatic Balance in the Respiratory Tract, Laura 

Van Winkle, University of California, Davis, CA. 

• Pulmonary Immune Functions Important for Translational Toxicology 

and Predictive of Risk in Humans, Gary R. Burleson, BRT—Burleson 

Research Technologies, Inc., Morrisville, NC. 

• Concluding Remarks, Daniel Costa, U.S. EPA, Research Triangle 

Park, NC. 


8:15 AM–12:00 NOON 




Cytokines: Balancing Therapeutic Utility and Immune 

System-Mediated Toxicities 

AM04 

CE BASIC 

Chairperson(s): Lynne A. LeSauteur, Charles River, Montréal, Québec, 

Canada, and Rafael Ponce, Amgen, Inc., Seattle, WA. 

Sponsor: 


Direct and indirect modulation of cytokines via therapeutics, either 

increasing or decreasing cytokines, is a central factor in the success of 

current therapies targeting cancer, autoimmunity, inflammation, and 

infection. However, nonclinical and clinical data demonstrate that these 

therapies can overwhelm compensatory mechanisms designed to protect 

the host, resulting in toxicity. The therapeutic benefits and potential 

toxicities can be best understood through an understanding of the central 

role of cytokines in modulating cellular function. To address these 

specific issues, we will define the central toxicities and syndromes that 

have been identified as arising from cytokine-mediated immunomodulation; 

establish the immunological basis for these toxicities using in-depth 

exploration where possible, including useful biological markers that can 

inform clinicians and toxicologists; develop an understanding of cytokine 

modulation in the treatment of cancer, autoimmunity, inflammation, and 

infection; and identify deficiencies in current toxicological practice for 

predicting certain immune system-mediated risks arising from cytokinemediated 

immunomodulation in humans. Finally, we will explore specific 

case studies where these principles have been applied to reinforce these 

central concepts. 

• Introduction, Lynne A. LeSauteur, Charles River, Montréal, Québec, 

Canada. 

• Cytokine Modulation: The Yin and the Yang, Rafael Ponce, Amgen, 

Inc., Seattle, WA. 

• Immunomodulators That Inhibit Cytokines, Theodora W. Salcedo, 

Bristol-Myers Squibb, Syracuse, NY. 

• Immunomodulators That Are Pro-Inflammatory Cytokines, Dennis M. 

Miller, ZymoGenetics, Inc., Seattle, WA. 

• Cytokine Storms: It’s Not Nice to Fool with Mother Nature, 

Christopher Horvath, Taligen Therapeutics, Cambridge, MA. 

CE 




CE 


8:15 AM–12:00 NOON 



Cell Signaling 

Nuclear Receptors: Role in Chemical Mode of Action and 

Targets for Toxicity Testing 

AM05 

CE BASIC 

Chairperson(s): Chris Corton, U.S. EPA, Research Triangle Park, NC, 

and Jack Vanden Heuvel, Pennsylvania State University, University Park, 

PA. 

Sponsor: 


Endorsed by: 


Nuclear receptors (NR) are one of the most abundant classes of transcriptional 

regulators in animals and function as ligand-activated transcription 

factors. They provide a direct link between signaling molecules and 

transcriptional responses that impact diverse functions including development, 

metabolic homeostasis, and reproduction. NR are not only 

promising pharmacological targets but can be activated inappropriately 

by environmentally relevant chemicals leading to a broad spectrum 

of adverse effects. Thus the intent of this basic course is to provide an 

overview of the biology of nuclear receptors, the pathways and modes 

of action of a subset of nuclear receptors involved in chemical toxicity, 

and strategies for screening chemicals for nuclear receptor interactions 

as well as placement in mode-of-action categories. To begin with, we 

will cover the structure, function and general mechanisms of activation 

as well as basic biological roles of NR that are targets of xenobiotics in 

different tissues and cell types. We will then explore the role of nuclear 

receptors in both augmenting and suppressing chemical carcinogenesis, 

which will include a summary of mode of action and human relevance 

of those NR (CAR, PPAR, PXR, RXR) commonly associated with liver 

cancer. Following this summary, the adverse effects of xenobiotics on the 

endocrine system associated with activation or modulation of estrogen, 

androgen, and thyroid hormone receptors will be addressed. Finally, 

both the primary and secondary screening strategies to define effects of 

chemicals on NRs and the pathways that mediate their adverse effects 

will conclude this course. The intended audience for this course includes 

those who desire a basic knowledge of the state of the science of nuclear 

receptors in chemical mode of action and strategies for accelerating the 

placement of chemicals into mode-of-action pathways. The course will be 

of interest to many who are engaged in wider aspects of carcinogenesis, 

reproductive biology and risk assessment. 

• Introduction, Chris Corton, U.S. EPA, Research Triangle Park, NC, 

and Jack Vanden Heuvel, Pennsylvania State University, University 

Park, PA. 

• The Structure and Function of Nuclear Receptors, Jack Vanden 

Heuvel, Pennsylvania State University, University Park, PA. 

• Role of Nuclear Receptors in Chemical Carcinogenesis, 

Chris Corton, U.S. EPA, Research Triangle Park, NC. 

• Role of Nuclear Receptors in Endocrine Disruption, Stephen Safe, 

Texas A&M University, College Station, TX. 

• Nuclear Receptors and High-Throughput Screening, Keith Houck, 

U.S. EPA, Research Triangle Park, NC. 


8:15 AM–12:00 NOON 



Predictive Power of Novel Technologies (Cells to ‘Omics): 

Promises, Pitfalls, and Potential Applications 

AM06 

CE BASIC 

Chairperson(s): Srikanth S. Nadadur, NIEHS, Research Triangle Park, 

NC, and Mary Jane Cunningham, Nanomics Biosciences, Inc., Cary, NC. 

Sponsor: 


Endorsed by: 



Advances in the disciplines of cell and molecular biology have led to 

the development of novel biotechnologies capable of generating “global 

molecular profiles” for in situ toxicological assessment. These technologies 

should accelerate our understanding of the molecular basis for 

susceptibility to toxicants and provide new insights into mechanisms 

of action. Both theoretical and practical information on these emerging 

high-throughput technologies and their applicability, interpretation, and 

integration will present a more comprehensive understanding of cellular 

responses to chemical/toxicant stress. To begin, the course will highlight 

the utility of laser capture microdissection in isolating specific cell populations 

for toxicological assessment at the level of RNA and proteins. An 

overview of proteomic technologies in protein interaction studies and 

their relevance to changes in downstream signaling mediators involved 

in toxic response pathways will be presented, followed by an update of 

gene expression profiling approaches in toxicogenomics and systems 

biology research. Focus will be placed on the examination of the capabilities 

of high-throughput technologies for identifying single nucleotide 

polymorphisms (SNPs) and their value for identifying and characterizing 

underlying genetic susceptibilities to toxicants. Finally, high-throughput 

technologies available to identify genome-wide epigenetic alterations 

will be presented, including their role in epigenetic alterations in health, 

disease, and toxicant-induced biological outcomes. The goal of this 

course is to educate toxicologists on the array of ever-growing technologies 

available to gain a comprehensive understanding of the underlying 

mechanisms mediating complex biological responses. Using these technologies, 

investigators can move towards a better and more reliable 

prediction and extrapolation of toxic responses. This course is relevant 

to scientific technical and regulatory staff involved in various stages of 

compound development. 

• ‘Omics to Predict Specific Interaction(s) in Complexity, 

Srikanth S. Nadadur, NIEHS, Research Triangle Park, NC. 

• Integrating Transgenic Animal Models and Laser Capture 

Microdissection Applications with Micro-‘Omic Based Analyses for 

In Vivo Toxicological Assessments, Kevin L. Dreher, U.S. EPA, 

Research Triangle Park, NC. 

• Clinical Proteomics: Mapping Molecular Networks in Clinical 

Specimens Using Reverse Phase Protein Microarrays, Emanuel F. 

Petricoin, George Mason University, Manassas, VA. 

• Gene Expression Profiling for Toxicity Assessment Using Systems 

Biology, Mary Jane Cunningham, Nanomics Biosciences, Inc., Cary, 

NC. 

• The Role of DNA Variation in Human Drug Response, 

Steven P. Hamilton, University of California, San Francisco, CA. 

• Epigenome Profiling: Mapping Epigenetic Alterations in Health and 

Disease, Steven A. Belinsky, Lovelace Respiratory Research Institute, 

Albuquerque, NM. 

88 





8:15 AM–12:00 NOON 



Reproduction and Regulatory Impact 

AM07 

CE BASIC 

Chairperson(s): Robert E. Chapin, Pfizer Global Research & 

Development, Groton, CT, and Jeffrey S. Moffit, Boehringer Ingelheim 

Pharmaceuticals, Inc., Ridgefield, CT. 

Sponsor: 


Endorsed by: 


Most new compounds destined for commerce, and all compounds 

intended for human consumption, need to be assessed for developmental 

and reproductive toxicity (DART). However, the underlying biology can 

be confusing because the jargon employed by the cognoscenti can be 

impenetrable and the implications of findings in these studies are often 

difficult to appreciate quickly. Our panel will begin this course with an 

open dialogue designed to lift the veil of uncertainty around many of 

these issues. After a quick review of some of the key biology, we will 

touch on the characteristic study designs which generate the necessary 

data. A point of focus will have the panel examine the typical effects seen 

in adults and juveniles, and what impact these can have on the registration 

and use of the compound in Europe and the U.S., respectively. Although 

the focal point for this course will be on environmental compounds, the 

final presentation will highlight drug candidates and how reproductive 

or developmental findings affect their journey to the marketplace. It is 

our goal to leave students with a better understanding of the impacts that 

reproductive or developmental findings have on the registration and use 

of environmental and pharma compounds. 

• Basic Biology and Study Designs, Chad Blystone, NIEHS/NTP, 


• The Regulatory Impact of Effects on Reproduction and 

Development, Aldert Piersma, RIVM, Bilthoven, Netherlands. 

• The Impact of DART Findings on Regulating Environmental and 

Occupational Exposures in the U.S., Vicki Dellarco, U.S. EPA, 

Washington, DC. 

• The Impact of DART Findings on Drug Development and Approval in 

the U.S., Tracey Zoetis, Scilucent, Herndon, VA. 


1:15 PM–5:00 PM 



Assessment of Ocular Toxicity in Toxicology Studies 

Conducted for Regulatory Purposes 

PM08 

CE BASIC 

Chairperson(s): Margaret Collins, Charles River Laboratories, Reno, NV, 

and Andrea Weir, Charles River Laboratories, Reno, NV. 

Sponsor: 


Endorsed by: 



Ocular toxicity is known to occur following intended or unintended 

exposure of ocular tissues to xenobiotics. It can occur following local 

exposure of the eye to an agent or after exposure via oral or other routes 

of administration. In order to define the risks that pharmaceuticals, pesticides, 

and other toxic substances pose to the eye, an assessment of ocular 

toxicity is routinely included in general toxicology studies conducted for 

regulatory purposes. Because anatomical and physiological differences 

between species can impact the nature of the ocular effects observed, 

understanding species differences is important. Although it is possible 

to detect some ocular effects, such as conjunctivitis, with the naked eye, 

more sensitive techniques are routinely used to assess ocular toxicity. Slit 

lamp biomicroscopy and indirect ophthalmoscopy are routinely utilized 

to more closely evaluate the anterior and posterior chambers of the eye, 

respectively, during the course of toxicology studies. At the time of 

necropsy, ocular tissues are collected and processed for histopathological 

evaluation. More specialized endpoints, such as electroretinography, 

can be incorporated, as needed. Ocular anatomy and physiology and the 

assessment of ocular toxicity can be challenging to scientists involved in 

the safety assessment of pharmaceuticals, pesticides, and other agents. 

This basic course will cover ocular anatomy and physiology in laboratory 

animals, established methods used to assess ocular toxicity, as well 

as more novel techniques for toxicity assessment. Examples of ocular 

toxicity that can occur following different routes of exposure will be 

discussed. 

• Introduction and Overview, Margaret Collins, Charles River 

Laboratories, Reno, NV. 

• Comparative Ocular Anatomy and Physiology in Laboratory Animals, 

Mark Vezina, Charles River Laboratories, Montréal, Québec, Canada. 

• Diagnostics in Ocular Toxicology, Robert Munger, Animal 

Ophthalmology Clinic, Dallas, TX. 

• Diagnostics and Ocular Imaging in the 21 st Century, Christopher 

Murphy, University of California, Davis, CA. 

• Ocular Pathology: Looking at the Eye, Ken Schafer, Vet Path Services, 

Inc., Greenfield, IN. 

CE 




CE 


1:15 PM–5:00 PM 



Gene-Environment Interactions 


Gene-Environment Interactions Influence Cytokine Biology 

in Immunotoxicity and Disease: Genomic, Genetic, and 

Epigenetic Perspectives 

PM09 

CE ADVANCED 

Chairperson(s): Berran Yucesoy, CDC/NIOSH, Morgantown WV, and 

Victor J. Johnson, CDC/NIOSH, Morgantown WV. 

Sponsor: 


Endorsed by: 



Cytokines are key signaling and effector molecules that regulate many 

aspects of host response to exogenous stressors. To date, animal and 

human studies have identified individual and interacting effects of cytokines 

at different stages in the pathogenesis of chronic inflammatory 

and immune-mediated diseases. Animal studies utilizing gene knockout 

and transgenic animals and expression microarrays have identified 

disease-related cytokine networks. Human studies using various genome 

screening efforts have also uncovered potential candidate genes for 

disease development and progression. Cytokine genes and their receptors 

are highly polymorphic and variations in these genes have been associated 

with the course of and susceptibility to a variety of diseases including 

infectious, inflammatory, and autoimmune. In addition, epigenetic 

changes including altered DNA methylation and histone acetylation can 

control cytokine gene expression by changing the transcription-permissive 

nature of chromatin structure. Environmental factors are known to modify 

the direction and magnitude of disease risk in an environment-specific 

manner. In this respect, genetic association studies have identified interactions 

between cytokine gene variations and environmental/occupational 

exposures as shown in the case of silicosis and asthma. In addition, 

recent studies demonstrated that environmental exposures might alter 

methylation states of key cytokines genes supporting an epigenetic geneenvironment 

interaction. This course will address aspects of the current 

state of knowledge with respect to genomic, genetic, and epigenetic 

approaches in the investigation of cytokine genes associated with occupational 

and environmental-related diseases. 

• Exploring Gene-Environment Interactions and the Role of 

Cytokines in Occupational Allergic Respiratory Disease: Whole- 

Genome Expression and Beyond, Victor J. Johnson, CDC/NIOSH, 

Morgantown, WV. 

• Influence of Cytokine Gene Variations on Chronic Inflammatory/ 

Immune Diseases: Importance of Gene-Environment Interactions, 

Berran Yucesoy, CDC/NIOSH, Morgantown, WV. 

• Genetic Regulation of Cytokines in Risk of Beryllium Sensitization 

and CBD: A Model for Gene-Environment Interaction, 

Lisa A. Maier, National Jewish Health, Denver, CO. 

• Environmental Epigenomics and Disease Susceptibility, 

Randy L. Jirtle, Duke University Medical Center, Durham, NC. 


1:15 PM–5:00 PM 



Mitochondrial Basis of Disease 

Mitochondrial Toxicity: Animal Models and Screening 

Methods in Drug Development 

PM10 

CE BASIC 

Chairperson(s): Yvonne Will, Pfizer Global Research & Development, 

Groton, CT, and Carlos Palmeira, University of Coimbra, Coimbra, 

Portugal. 

Sponsor: 


Endorsed by: 


Mitochondria produce almost all the energy in cells, but also chronically 

expose the cell to cytotoxic free radicals. Mitochondrial disease and 

toxicity is a rapidly advancing field and the consequences of mitochondrial 

impairment should be appreciated by scientists in all disciplines. 

It is estimated that more than 75 diseases and metabolic disorders are 

attributable, at least in part, to mitochondrial dysfunction. Mitochondrial 

dysfunction can lead to many different pathologies of the liver, 

heart, muscle, kidney, and CNS through diverse mechanisms. Numerous 

widely prescribed therapeutics can undermine mitochondrial function 

by interfering with DNA replication or expression, and more acutely, 

by uncoupling or inhibiting oxidative phosphorylation, leading to organ 

dysfunction and damage. In addition, numerous environmental agents can 

contribute to diseases and toxicity through modifications of mitochondrial 

function, leading for example to Parkinson’s Disease and Autism. This 

course will review fundamental concepts of mitochondrial biology and 

the many different mechanisms by which xenobiotics interfere with mitochondrial 

function. Both common and novel in vitro screening approaches 

will be described, as well as in vivo animal models used to study mitochondrial-mediated 

toxicities and pathologies, with an emphasis on both 

their utility and limitations. The course will also introduce Structure- 

Activity Relationship and systems biology approaches to reveal common 

factors and novel mechanisms of mitochondrial toxicity. Upon completion 

of this course, participants will have a deeper understanding of how xenobiotics 

can alter the basic biochemistry and physiology of mitochondria, 

how minute changes in mitochondrial processes translate into complex 

toxicities, organ pathologies, and diseases, as well as a basic understanding 

of how to study mitochondria and mitochondrial dysfunction. 

• Mitochondrial Function and Dysfunction in Disease and Drug- 

Induced Toxicity, James Dykens, Pfizer Global Research & 

Development, Sandwich, United Kingdom. 

• Animal Models of Mitochondria-Mediated Drug Toxicity, Urs A. 

Boelsterli, University of Connecticut School of Pharmacy, Storrs, CT. 

• In Vitro Approaches to Assess Mitochondria-Mediated Drug 

Toxicity and Possible Biomarker Development: Advantages and 

Limitations, Yvonne Will, Pfizer Global Research & Development, 

Groton, CT. 

• Integrated Mitochondrial and Nuclear Genomic Regulation of 

Oxidative Phosphorylation in the Study of Mitochondrial Toxicity 

and Function, Toshimori Kitami, Broad Institute of MIT and Harvard 

University, Cambridge, MA. 

90 





1:15 PM–5:00 PM 



ICH Initiatives for Conducting Pharmaceutical Preclinical 

Safety Studies: New and Revised Guidelines and Challenges 

PM11 

CE ADVANCED 

Chairperson(s): Tao Wang, Novartis Pharmaceuticals Corporation, 

Emeryville, CA, and David McGuinn, U.S. FDA, Silver Spring, MD. 

Sponsor: 


Endorsed by: 




In recent years, the International Conference of Harmonization (ICH) 

Expert Working Groups have been developing new guidelines and 

revising some of the existing guidelines on preclinical safety requirements. 

Some of the important recent initiatives include new guidance, 

ICH S9, for preclinical evaluation of anticancer pharmaceuticals, revision 

of ICH M3 guidance that addresses the timing of preclinical studies in 

relation to various stages of clinical development, and new guidelines 

on genotoxicity testing (ICH S2) that replaces and combines the ICH 

S2A and S2B guidelines. Over the past decade, substantial experience 

regarding preclinical safety evaluation of biologics (ICH S6) has been 

gained and based on this experience revision of S6 is underway. The 

latest rationale behind the new initiatives at ICH will be discussed, while 

a panel of experts will present new developments and key challenges in 

each of the areas mentioned above and will provide expert commentary 

and perspective on the potential impact on preclinical safety evaluation 

programs these guidelines may have. Case studies will be used to 

highlight detailed examples, experience in conducting non-clinical ICH 

safety studies, and the acceptance of the ICH guidelines by the practicing 

regulatory organizations and reviewers. Our panel experts have years of 

experience in preclinical toxicology testing from either an industry or 

regulatory perspective. In addition, several have represented the United 

States on the ICH Expert Working Groups, and participated in writing 

or revising these ICH guidelines. This panel will be available to answer 

questions that will allow participants to obtain valuable information on 

this topic. 

• Introduction, Tao Wang, Novartis Pharmaceuticals Corporation, 

Emeryville, CA. 

• Fundamentals of Nonclinical Drug Development, David McGuinn, 

U.S. FDA, Silver Spring, MD. 

• Preclinical Development of Oncology Therapeutics: An Industry 

Perspective, Daniel Lapadula, Novartis Pharmaceuticals Corporation, 

East Hanover, NJ. 

• Use of Genotoxicity and Carcinogenicity Data in U.S. FDA Center 

for Drug Evaluation and Research, David Jacobson-Kram, U.S. FDA, 

Silver Spring, MD. 

• Nonclinical Safety Evaluation of Biotechnology-Derived 

Pharmaceuticals: FDA Regulatory Perspective on the ICH S6 

Guidance and Updates, Anne M. Pilaro, U.S. FDA, Silver Spring, 

MD. 


1:15 PM–5:00 PM 



Segment-Specific Renal Pathology for the Non-Pathologist 

PM12 

CE BASIC 

Chairperson(s): Debie Hoivik, Boehringer Ingelheim Pharmaceuticals, 

Inc., Ridgefield, CT, and Susan G. Emeigh Hart, Auxilium 

Pharmaceuticals, Inc., Malvern, PA. 

Sponsor: 


Endorsed by: 


The structural and functional complexity of the kidney uniquely predisposes 

it to be a sensitive target organ for a number of toxicants. By 

taking a segment-specific approach to the kidney, participants will gain 

a broad understanding of structure and function, spontaneous changes, 

the utility of biomarkers for injury, and morphological changes associated 

with injury. The different segments of the nephron will be reviewed. 

Species and gender-related differences in renal structure and function 

will be emphasized, especially where these contribute to differences in 

nephrotoxic responses. These differences need to be considered when 

determining the relevance of findings seen in animal studies to humans. 

We will review some of the more commonly noted spontaneous lesions 

and their overall incidences, variance by strain (rodents) and age, all of 

which can impact study outcome. Lesions such as renal amyloidosis in the 

mouse and chronic progressive nephropathy in the rat are just two examples 

of spontaneous lesions which may adversely impact the outcome of a 

study or may be enhanced by chemical administration, often complicating 

findings and interpretation. Representative examples of segment-specific 

morphological changes that occur as a direct response to toxicant exposure 

will be provided, focusing on those changes evident in laboratory 

animals used for regulatory testing of new chemical entities. For each 

morphological change, a corresponding control will be provided to clearly 

depict the nature of the change. Finally, when choosing a biomarker 

to monitor for kidney effects, it is critical to understand the utility and 

limitations of traditional and novel serum and urinary markers of renal 

injury. Participants will gain a broader perspective on selection and implementation 

of biomarkers, particularly of the newer urinary markers which 

provide insight into segment specificity or mechanisms of nephrotoxic 

injury. Moreover, the participants will understand the specificity of each 

biomarker as a predictor of injury for specific parts of the nephron. 

• The Kidney: Anatomic and Physiologic Features of Mechanistic 

Relevance, Susan G. Emeigh Hart, Auxilium Pharmaceuticals, Inc., 

Malvern, PA. 

• Spontaneous and Background Changes in Laboratory Animals, John 

Seely, Experimental Pathology Laboratories, Inc., Research Triangle 

Park, NC. 

• Renal Toxicant Induced Lesions by Nephron Segment, Jim Stoltz, 

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. 

• Biomarkers of Renal Injury, Daniela Ennulat, GlaxoSmithKline, King 

of Prussia, PA. 

CE 





1:15 PM–5:00 PM 



Toxicity Testing in the 21 st Century 

Technologies and Tools for Toxicity Testing in the 21 st Century 

PM13 

CE BASIC 

Chairperson(s): Robert Kavlock, U.S. EPA, Research Triangle Park, NC, 

and Dan Wilson, Dow Chemical Company, Midland, MI. 

Sponsor: 


Endorsed by: 


Toxicology testing has traditionally been associated with defined and 

tiered testing around dedicated endpoints (i.e., acute, reproductive and 

developmental, chronic and cancer, etc.). Over time, validated surrogates 

or refined alternatives for some of the end-points have come into acceptance 

for screening and international regulatory use. Coinciding with the 

release of the NAS report on Toxicity Testing in the 21 st Century: A Vision 

and a Strategy, a dedicated and rapid shift towards use of more non-whole 

animal testing is underway. Also, in vitro methods are expected to play a 

major role under REACH and to address the European Union-wide ban on 

animal use in cosmetics development. Inherent in this shift is a necessary 

understanding of the critical aspects of cellular, metabolic, and genetic 

functions effected in response to chemical and drug-induced toxicity 

as well the dose-response attributes of the responses. Towards this end, 

elaboration of predictive toxicity pathways by integration of information 

from in vitro assays, surrogate organisms, ‘omics technologies, in silico 

approaches, and bioinformatics is ongoing. A review of how the classic 

approaches for toxicity testing are evolving into sophisticated molecular/ 

mechanistic based approaches and the nature and implementation of 

in vitro high-throughput screening assays, with some mention of implementation 

of informatics approaches will be addressed. Further insight 

into how the information will be considered in the context of animal use, 

testing prioritization, dose-response considerations, and human health 

risks will be explored. This basic course should be of interest to classically 

trained toxicologists and investigators and regulators wanting to 

understand the latest technologies and tools that will be the necessary 

repertoire for card-carrying mammalian toxicologists. 

Thank You 

Speakers 

On behalf of the SOT Council and the 

entire membership of the Society of 

Toxicology (SOT), thank you to all of 

the speakers who graciously agreed to 

come to Salt Lake City to participate 

in the 2010 Annual Meeting. SOT’s 

Annual Meeting is the largest international 

forum to highlight novel 

discoveries and emerging fields and 

how they apply to toxicology. You 

played an important role in helping 

SOT showcase this year’s achievements 

in research and education and your 

time, efforts, and expertise are truly 

appreciated. 

CE 

• From Classical Mammalian Toxicology and Pathology to the Land 

of In Vitro, Molecular, Genomics, and Other Tools, Kevin Morgan, 

sanofi-aventis, Research Triangle Park, NC. 

• Whole Genome Technologies: Integrating Human Genetic Variability 

into Toxicology, Douglas A. Bell, NIEHS-NIH, Research Triangle 

Park, NC. 

• Considerations When Utilizing High-Throughput Technologies and 

Cells of Different Target Organs to Evaluate Toxicity Endpoints of 

Large Sets of Chemicals, Jon Inglefield, Emergent Biosolutions, 

Gaithersburg, MD. 

• New Tools—How Do They Affect the Bottom Line Decisions? 

Paul Price, Dow Chemical Company, Midland, MI. 

92 



Scientific Session Index (Continued) 

All sessions will be held at the Salt Palace Convention Center. 

General Scientific Sessions 

(Listed by type, then date and time) 

Education-Career 

Development Sessions 


an exhibiting company. The Exhibitor Hosted Session Index is located on 

pages 45–46. 

SYMPOSIUM SESSIONS 

Monday 

Date/Time Topic/Abstract # Room Page 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

WORKSHOP SESSIONS 

Mechanistic Role of Reactive 

Intermediate Protein Covalent 

Binding in Target Organ 

Toxicity: Past, Present, and 

Future #14–18 and 18A 

Neurological Responses after 

Exposure to Inhaled Metal 

Particles #19–24 

Ovarian Toxicity: Current 

Concepts in Toxicology, 

Pathology, and Mechanisms 

#25–29 

Silica and Asbestos 

Immunotoxicity: Mechanisms 

to Fibrosis, Autoimmunity, and 

Modified Tumor Resistance 

#30–35 

Ballroom A 103 

Room 150 103 

Ballroom B 104 

Ballroom G 104 


Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Featured Sessions 

Historical Highlights 

Informational Sessions 

Platform Sessions 


Does Background Disease Lead 

to Low Dose Linearity? #36–40 

Heart Smart: Innovative 

Approaches for Improving 

Cardiovascular Safety through 

Collaboration #41–46 

Toxicology in the 21 st Century: 

Stem Cells in Drug Discovery 

and Development #47–52 

Regional Interest Session 

Roundtable Sessions 

Symposium Sessions 

Thematic Sessions 

Workshop Sessions 

Room 151 105 

Ballroom J 105 

Room 250 106 

PLATFORM SESSIONS 


Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

POSTER SESSIONS 

Biomarkers of Target-Organ 

Toxicity #53–60 

Chemical and Biological 

Weapons—Sulfur Mustard 

#61–69 

Immunopharmacogenomics 

and Immune Regulation 

#70–78 

Mitochondrial-Mediated 

Mechanisms of Toxicity of 

Xenobiotics #79–84 

Ballroom F 107 

Ballroom I 107 

Ballroom D 108 

Room 

251 A 

109 

*Author attended 9:30 AM–11:00 AM; otherwise author attended 

11:00 AM–12:30 PM. Poster Board Surface Maps are on pages 33–37. 


Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

* Toxicity Testing—Alternative 

Models I #85–118 

Poster Boards 101–134 

Carcinogenesis I #119–144 


* Epigenetics #145–154 


Neurodevelopmental Toxicity: 

General #155–184 


* Screening and Predicting 

Toxicity: Computational 

Approaches to Identify Targets 

#185–215 


Mechanistic Aspects of 

Persistent Organic Chemical 



* Investigations of Chemical 

Mixtures #242–254 

Poster Boards 543–548 and 

601–607 

Nanotoxicology I #255–292 


* Hypersensitivity, Autoimmunity, 

and Idiosyncratic Drug 

Reactions #293–317 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

110 

112 

114 

115 

117 

120 

122 

123 

126 

SESSION INDEX 




SESSION INDEX 

ROUNDTABLE SESSIONS 


Monday 

12:10 PM 

Monday 

12:10 PM 

Combination Toxicology 

Studies for Pharmaceutical 

Agents: Design Considerations 

and Impact on Clinical 

Development #318 

Melamine Contamination 

of Infant Formulas: Lessons 

Learned #319 

HISTORICAL HIGHLIGHTS SESSION 




Monday 

12:10 PM 


Translating Toxicology to Public 

Health Protection: Lessons 

Learned from Superfund #320 


*Author attended 1:00 PM–2:45 PM; otherwise author attended 

2:45 PM–4:30 PM. Poster Board Surface Maps are on pages 33–37. 


Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

* Chemical and Biological 

Weapons #321–354 


Genetic Diversity and Response 

to Xenobiotics #355–366 


* Nanotoxicology II #367–375 


Reproductive Toxicology 

#376–422 


* Environmental Impact of 



Biotransformation I #442–459 



Models II #460–492 


Advances in Dermal Toxicology 

#493–505 


* Carcinogenesis II #506–535 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

131 

134 

135 

136 

139 

141 

142 

145 

146 



Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

WORKSHOP SESSION 

Alterations in Regulatory 

T Cells: Novel Pathways to 

Immunotoxicology #536–540 

Faster Science for Better 

Decisions: Characterizing 

Environmental Contaminant 

Risk from High–Throughput 

Data #541–546 

Genotoxic Impurities in 

Drugs and Drug Products: 

What Is the Right Way to 

Deal with Impurities in R&D 

versus Regulatory Guidance? 

#547–552 

Metabolic Syndrome and 

Increased Sensitivity to Drug– 

Induced Liver Injury (DILI): 

Nonclinical Models and Clinical 

Implications #553–558 

Phthalate Reproductive and 

Developmental Toxicity: 

Implications for Cumulative Risk 

Assessment #559–564 

Room 151 148 


Room 250 149 




Monday 

1:40 PM 

Determination of the 

Contribution of Individual 

Stressors in Cumulative Risk 

Assessments #565–570 

REGIONAL INTEREST SESSION 

Room 150 151 


Monday 

1:40 PM 


Signaling Mechanisms for 

Metabolic Dysfunction 

Following Low-Level Arsenic 

Exposures: From Mouse to Man 

#571–576 



Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Advances in Biomarkers of 

Renal Injury #577–582 

Animal Models in the 21 st 

Century #583–591 

Lipid Metabolism and 

Apoptosis #592–599 

Methods and Animal Models 

in Cardiovascular Safety 

Pharmacology #600–607 




Room 

251 A 

154 

94 






Monday 

4:35 PM 

Monday 

4:35 PM 

Monday 

4:35 PM 

Inhaled Particles: From the 

Nose to the Brain? #608 


Safety of Vitamins and Minerals: 

Controversies and Perspectives 

#609 

The Evolution of the Extended 

One-Generation Study Design 

for Agricultural and Industrial 

Chemical Hazard Identification 

#610 

Tuesday 





Tuesday 

7:30 AM 

Tuesday 

7:30 AM 

Can Animal Neurotoxicity 

Predict Human Dysfunction? 

#611 

Weighing Complex Data in 

Risk Decisions: Concepts of 

Evidence-Based Toxicology 

#612 

INFORMATIONAL SESSIONS 




Tuesday 

7:30 AM 

Tuesday 

7:30 AM 

Human Hepatocytes Derived 

from Embryonic Stem Cells: 

A New Tool for In Vitro Toxicity 

Testing #613 

Recent Advances in Pulmonary 

Surfactant Toxicological 

Assessment and Therapeutics 

#614 





Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 


Anti-Drug Antibody-Mediated 

Toxicity In Nonclinical Toxicity 

Studies: Impact and Relevance 

to Human Safety #615–620 

Bile Salt Transport and Liver 

Injury #621–626 

MAP Kinase Signaling: A 

Common Target Eliciting 

Unique Tissue Responses 

#627–632 

Molecular Determinants 

of Mitochondrial Disease 

#633–637 

POPs: What’s New and Why 

Should We Care? #638–644 







Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Opportunities to Modify 

Current Regulatory Testing 

Guidelines and Advance the 

Assessment of Carcinogenicity 

Risk in the 21 st Century 

#645–650 

Research Advances and 

Enduring Needs in Children’s 

Environmental Health 

Protection #651–656 

Room 151 164 


EDUCATION-CAREER DEVELOPMENT SESSION 


Tuesday 

9:00 AM 

Where Do I Go Now? Rational 

Career Development Planning 

for Early-Career Scientists 

#657–662 




Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Epidemiological Insights: 

Effects of Environmental 

and Occupational Exposures 

#663–670 

Gene Environmental 

Interactions in Cacinogenesis 

#671–679 

Reproductive and 

Developmental Effects Using 

Fish Models #680–687 

Room 250 166 

Room 150 166 

Room 

251 A 

167 

SESSION INDEX 




SESSION INDEX 





Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

* Mutagenicity #688–701 


DNA Damage and Repair 

#702–718 


* Pharmaceutical Toxicology I 

#719–729 


Inflammation and the 

Pathogenesis of Toxicity 

#730–761 


* Oxidative Injury and Redox 

Biology #762–787 


Nanotoxicology—Carbon 

Nanostructures #788–805 


* Kidney I #806–828 


Developmental Toxicology 

#829–867 


501–515 

* Biological Modeling: Multiple 

Scales of Parameters, 

Structures, and Applications 

#868–902 


601–605 

Animal Models—Emerging 

Methods #903–940 


* Education #941–944 


Arsenic I #945–974 


* Metal Neurotoxicity: General 

#975–1002 



Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

168 

169 

170 

171 

173 

175 

177 

179 

182 

185 

187 

188 

190 


Tuesday 

12:00 

NOON 

Tuesday 

12:00 

NOON 

The Ying and Yang of 

Immunomodulatory 

Biopharmaceuticals: What 

Have We Learned since MABEL 

and How Close Are We to the 

Clinical Dose ? #1003 

Women’s Health: Toxicology 

and Safety of Complementary 

and Alternative Medicine #1004 

Room 150 193 


96 



Tuesday 

12:00 

NOON 


Science Communication 

in 2010: A New Decade in 

Toxicology and Need for Better 

Communication #1005 





Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

* Risk Assessment I: New 

Data and Derivations across 

Chemicals from A to V 

#1006–1041 


Pharmaceutical Toxicology II 

#1043–1085 


* Biotransformation II 

#1086–1105 


Genotoxicity #1106–1130 


* Safety Concerns of Food and 

Natural Products #1131–1167 


Safety Assessment: Commercial 

and Consumer Products 

#1168–1193 


501–517 

* Ah Receptor Biology and 

Toxicology #1194–1210 


Apoptosis/Cell Death 

#1211–1229 


607–607 

* Neurotoxicity of Pesticides 

#1230–1264 


Neurodegenerative Disease 

#1265–1297 


701–729 

* Biomarkers #1298–1331 


828–828 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

195 

198 

201 

203 

205 

207 

209 

211 

212 

215 

217 






Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Genetics: The Link between 

Exposures, Gene x Environment 

Interaction, and Toxicity 

#1332–1336 

It’s Not Your Father’s Aryl 

Hydrocarbon Receptor: 

New Biological Roles for a 

Misunderstood Receptor 

#1337–1342 

Mechanisms of Chemical- 

Induced Liver Cancer: Putting 

the Pieces Together 

#1343–1348 

New Strategies for the Use 

of Genetic Toxicology Data 

in Human Risk Assessment 

#1349–1355 

Recent Knowledge on 

Critical Regulators of Lipid 

Homeostasis in Metabolic 

Disease #1356–1361 

Zinc, Copper, and Their 

Metabolic Effect: Myths and 

Musts #1362–1367 




Room 151 222 


Room 250 223 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Immunotoxicity and Other 

Safety Considerations in the 

Development of Therapeutic 

Vaccines #1368–1373 

Widely Varying Strategies 

Implemented in Discovery 

to Reduce the Failure Rate of 

Clinical Lead Candidates in 

Development #1374–1379 


Room 150 224 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Emphasis on the Embryo: 

HTS, PBPK, and Virtual Tissue 

Technologies #1380–1387 

Model Systems in 

Neurodevelopmental Toxicity 

#1388–1394 

Nanotoxicology—Pulmonary 

Effects #1395–1403 

Toxicity Detection— 

Alternatives to Animal Models 

#1404–1412 



Room 

251 A 

Room 

251 D 

226 

227 

Wednesday 



Wednesday 

7:30 AM 

Wednesday 

7:30 AM 

Impact of Tungsten and 

Tungsten Alloys on Health Risk 

#1413 

The 2009 Tennessee Fly Ash 

Spill—An Environmental 

Emergency Case Study #1414 





Wednesday 

7:30 AM 


Career Alternatives in 

Toxicology: Lessons Learned 

#1415 



Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 


Gender Divergent Xenobiotic 

Responses #1416–1420 

Mitochondrial Toxicity in 

Disease and Death #1421–1426 

The Fetal Basis of Adult Disease 

#1427–1433 

Room 150 231 


Room 250 232 


Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Current Thinking and 

Experiences Related 

to Developmental and 

Reproductive Safety 

Assessment of Biotherapeutics 

#1434–1439 

Novel Research Approaches 

and Animal Models in 

Translational Toxicology 

#1440–1444 

Toxicity Testing in the 21 st 

Century for Ecotoxicology 

#1445–1451 

Understanding Nonlinearities 

at the Low-End of the 

Dose-Response Curve: Insights 

from Molecular Network 

Analysis #1452–1455 

Room 151 233 




SESSION INDEX 






Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Advances in Mycotoxin Toxicity 

#1456–1464 

Impact of Receptors and Gene 

Regulation in Toxicological 

Response #1465–1472 

Inhalation Toxicology of 

Ultrafine or Nanoparticles 

#1473–1480 


Developmental Toxicity of 

Phthlates #1481–1489 


Room 

251 D 

236 


Room 

251 A 

237 



Wednesday 

12:00 

NOON 

Wednesday 

12:00 

NOON 

Wednesday 

12:00 

NOON 

Life-Stage Adjustment Five 

Years Later—Experiences from 

the Cancer Risk Assessment 

Field #1721 

Measuring Immune Responses 

in Monkeys for Drug 

Development: Opportunities 

and Challenges for Predicting 

Human Efficacy and 

Immunotoxicity #1722 

The Tox21 st Community and 

the Future of Toxicology Testing 

#1723 




SESSION INDEX 





Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

* Inhalation Toxicology 

#1490–1524 


Immunotoxicology: 

Mechanisms #1525–1562 


* Studies in Pharmacokinetics 

and Disposition #1563–1599 


301–331 

Neurodevelopmental Toxicity of 

Metals #1600–1615 


* Hepatotoxicity: Role of Bile Acid 

Metabolism and Homeostasis 

#1616–1624 


Causes and Progression of 

Hepatic Metabolic Dysfunction 

#1625–1636 


* Toxicogenomics—Continuing 

Advances in Molecular 



501–502 

Signal Transduction 

#1663–1677 


* Stem Cell Toxicology 

#1678–1691 


Nanotoxicology—Gold or Silver 

Nanoparticles #1692–1707 


601–610 

* Gene Regulation #1708–1720 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

237 

240 

243 

246 

247 

248 

249 

251 

253 

254 

255 





Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

* Cardiovascular Toxicology 

#1724–1757 


Beneficial Effects of Natural 

Products #1758–1786 


* Regulations and Policy in 



301–306 

Metals I #1811–1845 


* Exposure Assessment and 

Emerging Biomonitoring 

Applications #1846–1886 


Pesticides: General #1887–1905 


501–513 

* Risk Assessment II: 

Methodological Challenges and 

Metals #1906–1947 


601–609 

Models and Mechanisms of 

Hepatotoxicity #1948–1969 


* Fetal Basis of Adult Disease 

#1970–1977 


Immunotoxicology: Methods 

and Models #1978–1997 


* Carcinogenesis: Breast and 

Reproductive #1998–2009 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

259 

261 

263 

265 

268 

271 

272 

275 

277 

278 

279 

98 






Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Aging As a Determinant of 

Xenobiotic Toxicity #2010–2015 

TRPing the Sensor: The Role 

of TRP Channel Signaling in 

Cardiopulmonary Toxicity 

#2016–2022 

Zebrafish Models 

for Developmental 

Neurobehavioral Toxicology 

#2023–2028 





Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

High-Throughput 

Electrophysiology—21 st 

Century Toxicity Testing 

Approaches with Functional 

Outcomes #2029–2033 

Minerals and Metals: Pros and 

Cons of Deliberate Exposure 

#2034–2038 

‘Omics Profiling of Cell 

and Tissue Interactions of 

Nanomaterials: Insight into 

Mechanisms of Action 

#2039–2044 

The Process of Defining Risk 

for Environmental Chemicals 

Having Significant Skin 

Exposure and Absorption 

Potential #2045–2051 

Translation of Nonclinical 

Models to Clinical Risk 

Management Strategies of 

Severe Infectious Diseases with 

Immunomodulatory Drugs 

#2052–2057 

Room 150 282 




Room 151 285 

ROUNDTABLE SESSION 


Wednesday 

4:30 PM 

Overview of Current 

Regulatory Expectations 

for Oligonucleotide-Based 

Therapeutics: Case Studies for 

Different Classes of ODNs #2082 

INFORMATIONAL SESSION 

Room 150 288 


Wednesday 

4:30 PM 


Seeking Funding for 

Undergraduate Research #2083 

Thursday 



10:15 AM–12:00 NOON. Poster Board Surface Maps are on pages 33–37. 


Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

* Endocrine Toxicology 

#2084–2113 


Juvenile Toxicity #2114–2121 


* Drug-Induced Liver Injury 

#2122–2139 


Receptors #2140–2157 


* Metals II #2158–2178 

Poster Boards 421–440 and 501 

Immune System Safety 

Evaluation/Developmental 



Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

289 

292 

293 

294 

296 

297 



Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Insights into Polyaromatic 

Hydrocarbon-Induced Toxicities 

#2058–2064 

Nanotoxicology—Metals and 

Metal Oxide Particles 

#2065–2073 

Predicting Hepatotoxicity: 

Computational Approaches to a 

Critical Target #2074–2081 


Room 

251 A 

286 

Room 250 287 



Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Blood-Based Genomic Profiles 

As Biomarkers of Exposure and 

Effect #2198–2202 

Humanized Models in 

Toxicology and Their 

Application to Hazard 

Characterization and Risk 


Systems Biology Approaches to 

Understanding Cell Signaling in 

Dermal and Ocular Toxicology 

#2209–2214 

Toxicological Challenges in 

Green Product Development 

#2215–2220 





SESSION INDEX 


Saturday/Sunday 

Program Description 

The Program Description layout is ordered by date and start time. 

All scientific sessions and special events will be held in the Salt Palace 

Convention Center unless otherwise noted. 

SOT general events and functions are displayed with a grey background. 

Scientific Session Types 



Exhibitor Hosted Sessions 





Exhibitor Hosted Sessions are informative sessions developed by an exhibiting 

company. See page 45 for Exhibitor Hosted Session Index. 

Saturday Afternoon, March 6 

4:15 PM to 5:45 PM 

Room 258 

SATURDAY 

Undergraduate Education Program: Orientation for SOT 

Hosts, Peer Mentors, and Advisors 


Sponsor: Committee for Diversity Initiatives 

This event is for advisors, peer mentors, and mentors assisting with the 

Undergraduate Program. Full Undergraduate Education details may be 

found on pages 64–66. 

Saturday Afternoon, March 6 

5:15 PM to 9:00 PM 

Room 255 C 




This event is for undergraduate students and advisors receiving 2010 

MARC and SOT travel funding, and SOT program volunteers assisting 

with the Undergraduate Program. Full program details are found pages 

64–66. 

Saturday Evening, March 6 

8:00 PM to 9:00 PM 

Room 255 C 


SATURDAY EvEning 






CDI Reunion (Dessert and Networking) 

Invited: Anyone involved with the SOT Undergraduate Education Program 

through the years. 


SUnDAY MORning 

Sunday Morning, March 7 

7:00 AM to 7:45 AM 


(See signage at CE Booth for room information) 

Continuing Education Sunrise Mini-Course 

Full Continuing Education Course details may be found on pages 85–92. 

Sunday Morning and Afternoon, March 7 

8:00 AM to 5:00 PM 

(see pages 64–66 for room information) 




The Sunday program is open to undergraduate students who register for 

this event using the Annual Meeting Registration Form, the undergraduate 

students and advisors receiving MARC, SOT, and Pfizer travel funding, 

and SOT program volunteers. Full program details are found page 64–66. 

Sunday Morning, March 7 

8:15 AM to 12:00 NOON 

Lower and Upper Concourses 


Continuing Education Morning Courses 

Full Continuing Education details may be found on pages 85–92. 

Sunday Afternoon, March 7 

1:00 PM to 3:00 PM 

Room 255 A 

SUnDAY AfTERnOOn 

SOT Committee/Task Force Chair Orientation 

If you will be a Committee/Task Force Chairperson in 2010–2011, please 

make plans to attend the Committee/Task Force Chair Meeting scheduled 

from 1:00 PM–3:00 PM, on Sunday, March, 7. With new assignments 

taking effect on May 1, 2010, the meeting is intended to provide new 

chairpersons with a jump start on operating a committee or task force 

to achieve SOT strategic goals. 2009–2010 Chairpersons are invited 

to provide input on current and planned activities. The agenda for the 

meeting will be sent to your attention in the near future. 


1:15 PM to 5:00 PM 

Lower and Upper Concourses 


Continuing Education Afternoon Courses 

Full Continuing Education Course details may be found on pages 85–92. 

100 



Program Description 

Sunday 


3:00 PM to 5:00 PM 

Room 255 F 

Undergraduate Education Program: Open Time with 

Academic Toxicology Program Directors and Internship 

Sponsors 



The Sunday program is open to undergraduate students who register for 

this event using the Annual Meeting Registration Form, the undergraduate 

students and advisors receiving MARC, SOT, and Pfizer travel funding, 

and SOT program volunteers. Full program details are found page 64–66. 


4:45 PM to 5:15 PM 

Ballroom J 

Awards Ceremony Music—Preformed by Michael Lucarelli, 

Classical Guitarist 


5:15 PM to 6:30 PM 

Ballroom J 

(Open to All Attendees) 


Join us as SOT honors our prestigious award winners at the SOT Awards 

Ceremony. Please refer to the Awards and Fellowships section of the SOT 

Web site for complete details and the nominating information for next 

year. 

SUnDAY EvEning 

Sunday Evening, March 7 

6:30 PM to 7:30 PM 


(All Attendees and Registered Guests Welcome) 


Continue the celebration by attending the Welcome Reception following 

the Awards Ceremony. The Welcoming Reception is a great opportunity 

to renew old friendships and to make new acquaintances. Please join the 

Society in this kick-off of the Annual Meeting. 


7:00 PM to 8:00 PM 

Ballroom A 


25-Year (or More) Member Reception 

Have you been a member of the Society of Toxicology for 25 years (or 

more)? If so, please join you colleagues in celebration and recognition of 

the scientists who established the Society. 


7:30 PM to 8:30 PM 

Room 355 

(Ticket and Meeting Badge Required) 


Sponsor: Student Advisory Council 

The Student Advisory Council and Graduate Committees host this 

opportunity for students and postdoctoral fellows to gather, meet new 

colleagues, and reestablish relationships in an informal atmosphere at the 

beginning of the meeting. Tickets are obtained at no cost by registering for 

this event on the Annual Meeting Registration Form. Ticket and meeting 

badge are required. Complimentary refreshments and a cash bar will be 

available. 

Opportunities to Explore 

Research Funding 

All meeting attendees invited 

Meet with NIH and 

CSR Program Officers 


9:00 AM–4:30 PM Tuesday and Wednesday 

Room 254 A 

Make appointments or drop by 

Brown Bag Lunch 

12:00 NOON–1:15 PM Tuesday 

Room 255 B 

Grantsmanship 

Informal conversation with NIH staff 

See page 62 for more information 



MOnday 

Program Description (Continued) 

Abstract # Abstract # 

Monday Morning, March 8 

6:30 AM to 8:00 AM 

See room listing below. 

MOnDAY MORning 

Specialty Section Officers Meetings: Medical Device Officers 

(Room 255 F), Metals Officers (Room 255 D) 


7:00 AM to 8:00 AM 


Regional Chapter Meeting: Southeastern Regional Chapter 



7:00 AM to 8:00 AM 


Specialty Section Officers Meetings: Molecular Biology 

Officers (Room 355 D), Neurotoxicology Officers 

(Room 254 A), Regulatory and Safety Evaluation Officers 

(Room 355 B) 


8:00 AM to 9:00 AM 


Plenary Opening Lecture: Discovery of Nitric 

Oxide and Cyclic GMP Cell Signaling and 

Their Role in Drug Development 

Lecturer: Nobel Laureate Ferid Murad, John S. Dunn, 

Sr., Distinguished Chair, University of Texas Health 

Science Center at Houston, Houston, TX. 

The role of nitric oxide in cellular signaling in the past three decades has 

become one of the most rapidly growing areas in biology. Nitric oxide 

is a gas and a free radical with an unshared electron that can regulate an 

ever-growing list of biological processes. Nitric oxide is formed from 

L-arginine by a family of enzymes called nitric oxide synthases. These 

enzymes have a complex requirement for a number of cofactors and 

regulators including NADPH, tetrahydrobioterin, flavins, calmodulin, 

and heme. The enzymes are present in most cells and tissues. 

In many instances, nitric oxide mediates its biological effects by activating 

the soluble isoform of guanylyl cyclase and increasing cyclic 

GMP synthesis from GTP. Cyclic GMP, in turn, can activate cyclic 

GMP-dependent protein kinase (PKG) and can cause smooth muscles 

and blood vessels to relax, decrease platelet aggregation, alter neuron 

function, etc. These effects can decrease blood pressure, increase blood 

flow to tissues, alter memory and behavior, decrease blood clotting, etc. 


7:00 AM to 9:00 AM 


Specialty Section Officers Meetings: Dermal Toxicology 

Officers (Room 355 A), In Vitro and Alternative Methods 

Officers (Room 260 B), Risk Assessment Officers 

(Room 355 E) 

Monday Morning and Afternoon, March 8 

7:30 AM to 1:30 PM 

(See pages 64–66 for room information.) 





MARC and SOT travel funding and SOT program volunteers assisting 

with the Undergraduate Program. Full program details are found page 

64–66. 


7:30 AM to 9:00 AM 

Room 260 A 

Specialty Section Officers Meeting: Toxicological and 

Exploratory Pathology Officers 

The list of effects of nitric oxide that are independent of cyclic GMP 

formation is also growing at a rapid rate. For example, nitric oxide can 

interact with transition metals such as iron, thiol groups, other free radicals, 

oxygen, superoxide anion, unsaturated fatty acids, and other molecules. 

Some of these reactions result in the oxidation of nitric oxide to nitrite 

and nitrate to terminate the effect, while other reactions can lead to altered 

protein structure function and/or catalytic capacity. These effects probably 

regulate bacterial infections, inflammation of tissues, tumor growth, 

and other disorders. These diverse effects of nitric oxide that are cyclic 

GMP dependent or independent can alter and regulate numerous important 

physiological events in cell regulation and function. Nitric oxide can 

function as an intracellular messenger, an antacoid, a paracrine substance, 

a neurotransmitter, or as a hormone that can be carried to distant sites for 

effects. Thus, it is a unique molecule with an array of signaling functions. 

However, with any messenger molecule, there can be too little or too 

much of the substance, resulting in pathological events. Some of the 

methods to regulate either nitric oxide formation, metabolism, or function 

have been in clinical use for more than a century, as with the use of 

organic nitrates and nitroglycerin in angina pectoris that was initiated in 

the 1870s. Inhalation of low concentrations of nitric oxide can be beneficial 

in premature infants with pulmonary hypertension and increase 

survival rates. Ongoing clinical trials with nitric oxide synthase inhibitors 

and nitric oxide scavengers are examining the effects of these agents in 

septic shock, hypotension with dialysis, inflammatory disorders, cancer 

therapy, etc. Recognition of additional molecular targets in the areas 

of nitric oxide and cyclic GMP research will continue to promote drug 

discovery and development programs in this field. Current and future 

research will undoubtedly expand the clinician’s therapeutic armamentarium 

to manage a number of important diseases by perturbing nitric 

oxide formation and metabolism. Such promise and expectations have 

obviously fueled the interests in nitric oxide research for a growing list 

of potential therapeutic applications. There have been and will continue 

to be many opportunities from nitric oxide and cyclic GMP research to 

develop novel and important therapeutic agents. There are presently more 

than 80,000 publications in the area of nitric oxide research. 

The lecture will discuss our discovery of the first biological effects of 

nitric oxide and how the field has evolved since our original reports in 

1977. The possible utility of this signaling pathway to facilitate novel 

drug development and the creation of numerous projects in the pharmaceutical 

and biotechnology industrials will also be discussed. (Dr. Murad 

is an SOT 2010 Honorary Member, see p.81) 

102 

Education-Career Development Sessions 





Platform Sessions



Abstract # 


9:15 AM to 12:00 NOON 

Ballroom A 

Symposium Session: Mechanistic Role of Reactive 

Intermediate Protein Covalent Binding in Target Organ 

Toxicity: Past, Present, and Future 

Chairperson(s): Jose E. Manautou, University of Connecticut, Storrs, CT, 

and George B. Corcoran, Wayne State University, Detroit, MI. 

Sponsor: 


Endorsed by: 



The pioneering work of Brodie and co-workers in the early 1970’s 

demonstrated that protein covalent binding of a reactive metabolite of acetaminophen, 

N-acetyl-p-benzoquinoneimine, was strongly associated with 

hepatotoxicity. Over the last three decades, immunological, biochemical, 

molecular biological, and proteomic approaches have been used to identify 

specific proteins adducted by reactive electrophilic metabolites. Although 

the identity of a number of protein targets, and the effects of covalent 

adduction on protein structure and function are known, the precise role of 

protein covalent binding in chemical-induced toxicities remains a subject of 

contention. Indeed, the importance of reactive intermediate protein binding 

has been challenged by multiple studies employing experimental manipulations 

that reduce toxicity in the absence of an effect on protein binding. 

To adequately address these findings state-of-the-knowledge of reactive 

intermediate protein binding and its toxicological consequences will be 

presented. The specific topics to be discussed include current views on the 

importance of protein covalent binding, latest in vivo and in vitro approaches 

to study covalent binding, the pharmaceutical industry’s perspective on 

the role of reactive intermediate binding in toxicity and the current safety 

assessment guidelines for drug candidates with covalent binding liability. 

Finally, current and future tools and technologies for studying reactive intermediate 

biology will be highlighted. 

#14 9:15 MECHANISTIC ROLE OF REACTIVE 

INTERMEDIATE PROTEIN COVALENT 

BINDING IN TARGET ORGAN TOXICITY: 

PAST, PRESENT, AND FUTURE. J. E. 

Manautou 1 and G. B. Corcoran 2 . 1 Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT and 

2 

Pharmaceutical Sciences, Wayne State University, 

Detroit, MI. 

#15 9:20 REACTIVE INTERMEDIATES AND 

THEIR INTERACTION WITH CELLULAR 

PROTEINS: HISTORICAL PERSPECTIVE. 

P. Moldeus. Safety Assessment, AstraZeneca, 

Södertälje, Sweden. 

#16 10:00 THE ENIGMA OF REACTIVE 

METABOLITES. J. Uetrecht. Faculty of 

Pharmacy, University of Toronto, Toronto, ON, 

Canada. 

#17 10:40 BIOACTIVATION AND COVALENT BINDING 

APPLIED IN A DRUG RESEARCH SETTING. 

R. Obach. Pfizer Inc., Groton, CT. Sponsor: J. 

Manatou. 

#18 11:20 KNOWNS AND KNOWN UNKNOWNS 

IN PROTEIN COVALENT BINDING AND 

TOXICITY. R. P. Hanzlik. Department of 

Medicinal Chemistry, University of Kansas, 

Lawrence, KS. 

Abstract # 

#18A 11:28 Drug Hypersensitivity: Molecular Aspects from 

Molecule to Man. K. Park, MRC Centre for Drug 

Safety Science, University of Liverpool, United 

Kingdom. Sponsor: J. Manatou. 


9:15 AM to 12:00 NOON 

Room 150 

Symposium Session: Neurological Responses after Exposure 

to Inhaled Metal Particles 

Chairperson(s): James Antonini, CDC-NIOSH, Morgantown, WV, and 

Lung-Chi Chen, New York University School of Medicine, Tuxedo Park, 

NY. 

Sponsor: 


Endorsed by: 



Most studies examining the toxicology of inhaled metal particles have 

focused on responses in the target organ, the respiratory system. Less 

information exists regarding the effects associated with the inhalation of 

metals in extrapulmonary organs, specifically the central nervous system. 

There is increasing interest in the health effects of airborne incidental and 

manufactured metal nanoparticles (particles with one dimension


MOnday 



#23 10:56 NEUROBEHAVIORAL EFFECTS IN 

ADOLESCENTS EXPOSED TO METALS. 

R. Lucchini 1 , N. J. Zimmerman 3 , E. Albini 1 , S. 

Micheletti 1 , S. Zoni 1 , F. Tagliani 1 , C. Nardoni 1 , 

G. Parrinello 4 , F. Donna 1 , R. Ferri 1 , Z. Annalisa 2 , 

B. Laura 2 and E. Bontempi 2 . 1 Occupational 

Health, University of Brescia, Italy, Brescia, Italy, 

2 

Chemistry Laboratory for Technologies, University 

of Brescia, Brescia, Italy, 3 School of Health 

Sciences, Purdue University, West Lafayette, IN 

and 4 Statistics and Biometry, University of Brescia, 

Brescia, Italy. 

#24 11:28 NEUROINFLAMMATION, SEVERE AIR 

POLLUTION AND CHILDREN. L. Calderon- 

Garciduenas 1,3 , L. Gonzalez-Gonzalez 3 , A. 

D’Angiulli 2 and H. Medina-Cortina 3 . 1 The University 

of Montana, Missoula, MT, 2 Psychology Carleton 

University, Ottawa, ON, Canada and 3 Instituto 

Nacional de Pediatria, Mexico City, Mexico. 

Sponsor: J. Antonini. 


9:15 AM to 12:00 NOON 

Ballroom B 

Symposium Session: Ovarian Toxicity: Current Concepts in 

Toxicology, Pathology, and Mechanisms 

Chairperson(s): William J. Brock, Brock Scientific Consulting, LLC, 

Montgomery Village, MD, and Ali Faqi, MPI Research, Mattawan, MI. 

Sponsor: 


Endorsed by: 




The ovary is responsible for the differentiation and release of a mature 

oocyte for fertilization and for synthesizing and secreting hormones that 

are essential for follicle development, estrous cyclicity, and maintenance 

of the reproductive tract and its function. Reproductive toxicity studies 

are important components of the regulatory approval of drugs and chemicals. 

The identification of ovarian toxicity and determination of its cause 

requires familiarity with ovarian anatomy, physiology, relationships with 

other components of the female reproductive tract, and the neuroendocrine 

regulation of the estrous cycle. A mechanistic approach at the morphologic, 

biochemical, and molecular level demonstrate that various factors 

are involved in ovarian toxicity. Therefore, our focus will be on the basic 

concepts of ovarian anatomy, histopathology, and potential mechanisms of 

toxicity. We will begin by discussing the importance of assessing fertility 

that utilizes a combination of methods including evaluation of estrous cycle 

length, fertility endpoints, and ovarian weights. Recent collaborative work 

suggests a 2-week rodent study may be sufficient to elucidate the effect of 

pharmaceuticals on ovarian function and its impact on the revised ICH M3 

will be presented. Better interpretation of drug induced ovarian toxicity will 

be highlighted as fertility effects in rodents, especially when both sexes are 

treated do not often distinguish between male or female mediated effects. 

A mechanistic model of ovarian toxicity of 4-vinylcyclohexene diepoxide 

provides an understanding of the potential risk of human exposure to environmental 

ovarian toxicants and greater insight of toxicants on reproductive 

health in women will also be discussed. 

#25 9:15 OVARIAN TOXICITY: CURRENT 

CONCEPTS IN TOXICOLOGY, PATHOLOGY, 

AND MECHANISMS. W. J. Brock 1 , A. Faqi 2 , 

M. Mirsky 3 , P. Hoyer 4 and A. Sanbuissho 5 . 1 Brock 

Scientific Consulting, Montgomery Village, MD, 

2 

MPI Research, Mattawan, MI, 3 Pfizer, Groton, CT, 

4 

University of Arizona, Tucson, AZ and 5 Daiichi- 

Sankyo, Fukuroi Shizuoka, Japan. 

#26 9:20 OVARIAN TOXICITY—ANATOMY, 

PATHOPHYSIOLOGY, AND THE ILLUSION 

OF SIMPLICITY. M. Mirsky. Pfizer, Groton, CT. 

#27 10:00 OVARIAN TOXICITY INDUCED BY 

PHARMACEUTICALS AND CHEMICALS. A. 

S. Faqi. Toxicology, MPI Research, Mattawan, MI. 

#28 10:40 OVOTOXICITY CAUSED BY 

4-VINYLCYCLOHEXENE DIEPOXIDE: 

MECHANISTIC INSIGHTS. P. Hoyer. 

University of Arizona, Tucson, AZ. 

#29 11:20 COLLABORATIVE WORK ON EVALUATION 

OF OVARIAN TOXICITY BY REPEATED- 

DOSE AND FERTILITY STUDIES IN 

FEMALE RATS. A. Sambuissho. DAIICHI 

SANKYO CO., LTD., Fukuroi, Shizuoka, Japan. 

Sponsor: W. Brock. 


9:15 AM to 12:00 NOON 

Ballroom G 

Symposium Session: Silica and Asbestos Immunotoxicity: 

Mechanisms to Fibrosis, Autoimmunity, and Modified Tumor 

Resistance 

Chairperson(s): Andrij Holian, University of Montana, Missoula, MT, 

and Takemi Otsuki, Kawasaki Medical School, Kurashiki, Japan. 

Sponsor: 


Endorsed by: 




Effects of silica/asbestos on local and systemic immune system components 

are very important in the cascade of events in a host that evolve over the 

course of time from the point of initial exposure to the ultimate onset of lung 

fibrosis (i.e., silicosis, asbestosis), malignant tumors (i.e., lung cancer, mesothelioma), 

or autoimmune disorders (e.g., systemic sclerosis, rheumatoid 

arthritis—Caplan syndrome). In particular, mechanisms used by immune 

competent cells to process the entrained silica or asbestos may affect induction 

of these pathologies. With regard to asbestos specifically, there may also 

be a reduction in local/general anti-tumor immune responses that serves to 

amplify its own carcinogenic potential in situ. We will begin with an up-todate 

overview of emerging topics in the field of silica/asbestos toxicology 

that can, in turn, serve as a basis to understand mechanistic interpretations 

that link development of pneumoconioses to fibrotic diseases, autoimmunity, 

and cancer. To better understand these issues the latest findings on the 

roles that particle recognition, inflammasome formation, cytokine-driven 

inflammation, or immune dysfunction have in eventual induction of fibrosis, 

altered autoimmunity, and/or modified tumor resistance in silica/asbestosexposed 

hosts. It is anticipated that with an enhanced understanding of the 

molecular pathological mechanisms underlying the immunotoxicologic 

effects of silica/asbestos, researchers in many fields (including immunology, 

immunotoxicology, pulmonary biology and medicine, occupational medicine) 

will be better able to develop therapeutic tools for the prevention, 

mitigation, or treatment of debilitating diseases induced by these agents. 

#30 9:15 SILICA AND ASBESTOS 

IMMUNOTOXICITY: MECHANISMS 

TO FIBROSIS, AUTOIMMUNITY, AND 

MODIFIED TUMOR RESISTANCE. A. Holian. 

University of Montana, Missoula, MT. 

104 






Platform Sessions



Abstract # 

#31 9:20 TUMOR NECROSIS FACTOR (TNF) 

PROTECTS MACROPHAGES FROM SILICA- 

INDUCED APOPTOSIS. L. Ortiz. Graduate 

School of Public Health, University of Pittsburgh, 

Pittsburgh, PA. Sponsor: A. Holian. 

#32 9:52 SCAVENGER RECEPTORS AND 

MACROPHAGE SUBPOPULATIONS IN THE 

DEVELOPMENT OF SILICOSIS. A. Holian, 

S. Thakur, C. Beamer, C. Migliaccio and R. F. 

Hamilton. University of Montana, Missoula, MT. 

#33 10:24 SENSING OF CELL STRESS AND 

CYTOPLASMIC DNA BY THE NLRP3 AND 

AIM2 INFLAMMASOMES. E. Latz. Division 

of Infectious Diseases and Immunology, University 

of Massachusetts Medical School, Worcester, MA. 

Sponsor: A. Holian. 

#34 10:56 ASBESTOS-INDUCED AUTOIMMUNITY: 

THE POSSIBLE ROLE OF SYSTEM XC- IN 

MACROPHAGE SIGNALING. J. C. Pfau 1 , 

J. Overocker 1 , A. Ferro 1 and T. Seib 2 . 1 Biological 

Sciences, Idaho State University, Pocatello, ID and 

2 

Biomedical & Pharmaceutical Sciences, University 

of Montana, Missoula, MT. 

#35 11:28 EFFECTS OF ASBESTOS ON 

T-LYMPHOCYTES AND NK CELLS IN THE 

ALTERATION OF TUMOR IMMUNITY. 

T. Otsuki, Y. Miura, M. Maeda, N. Kumagai, H. 

Hayashi and Y. Nishimura. Hygiene, Kawasaki 

Medical School, Kurashiki, Okayama, Japan. 


9:15 AM to 12:00 NOON 

Room 151 


Workshop Session: Does Background Disease Lead to Low 

Dose Linearity? 

Chairperson(s): Lorenz Rhomberg, Gradient Corporation, Cambridge, 

MA, and Rory Conolly, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 

Biological Modeling Specialty Section 

The additivity-to-background argument was first applied to genotoxic 

carcinogens by Crump et al. (Cancer Res 36:2973, 1976), but application 

to noncancer toxicity has recently been advocated in a report by White et 

al. (2009, Environ Health Perspect 117:283) and by the National Research 

Council (Science and Decisions: Advancing Risk Assessment, NRC Press 

2009). Adoption of this approach would suggest the lack of thresholds for 

noncancer toxicity, in contrast to longstanding practice and established 

tenets. Proponents of additivity-to-background for such endpoints argue that 

heterogeneity in the human population leads some individuals to be at the 

margins of acceptable levels of such underlying physiological variables, and 

that the background rates of disease are explicable, at least in part, by individuals 

who, even without chemical stressors, have values of the underlying 

variables that are insufficient to maintain health. The emerging application 

of systems biology to characterizing normal control processes and their 

alteration by chemical stressors may provide an avenue for investigating 

these hypotheses. A deeper discussion of the issues and identification of 

research approaches to help resolve them is warranted. Our panel of experts, 

each with their own perspectives, will begin the dialogue aimed at producing 

theoretical arguments that additivity produces low dose linearity to reflect 

our understanding of the relevant biology on background disease, population 

heterogeneity, and the incremental effects of toxicants. We will examine 

Abstract # 

prospects for new research to illuminate and perhaps resolve, what, are at 

times, contentious issues with large impacts on the use of toxicological data 

in regulation and public health protection. 

#36 9:15 DOES BACKGROUND DISEASE LEAD TO 

LOW DOSE LINEARITY? L. R. Rhomberg 1 and 

R. B. Conolly 2 . 1 Gradient Corporation, Cambridge, 

MA and 2 National Center for Computational 

Toxicology, U.S. EPA, Research Triangle Park, NC. 

#37 9:20 THE ADDITIVITY TO BACKGROUND 

ARGUMENT FOR LOW-DOSE LINEARITY— 

IS IT VIABLE? K. S. Crump. Mathematics and 

Statistics, Louisiana Tech University, Ruston, LA. 

Sponsor: R. Conolly. 

#38 9:52 LINEARITY AND NON-LINEARITY IN 

INDIVIDUAL AND POPULATION DOSE- 

RESPONSE RELATIONSHIPS. L. Zeise 1 , 

G. Ginsberg 2 and M. Sandy 1 . 1 Cal/EPA Office of 

Environmental Health Hazard Assessment, Oakland, 

CA and 2 Connecticut Department of Public Health, 

Hartford, CT. 

#39 10:24 EMPIRICAL APPROACHES AND KEY 

EVENTS ANALYSIS TO UNDERSTAND THE 

RELEVANCE OF BACKGROUND IN DOSE- 

RESPONSE. G. Daston. Miami Valley Labs, 

Procter & Gamble, Cincinnati, OH. 

#40 10:56 NONCANCER TOXICITY POTENTIAL AT 

LOW DOSES: BACKGROUND PROCESSES 

CONSIDERED STATISTICALLY AND 

BIOLOGICALLY. L. R. Rhomberg. Gradient, 

Cambridge, MA. 

11:28 PANEL DISCUSSION/Q&A. 


9:15 AM to 12:00 NOON 

Ballroom J 

Workshop Session: Heart Smart: Innovative Approaches for 

Improving Cardiovascular Safety through Collaboration 

Chairperson(s): Syril D. Pettit, HESI, Washington, DC, and Jean-Pierre 

Valentin, AstraZeneca UK, Macclesfield, United Kingdom. 

Sponsor: 


Endorsed by: 


Nonclinical and clinical safety is a major cause of drug attrition. A recent 

Association of the British Pharmaceutical Industry (ABPI) review of more 

than 225 drugs revealed that cardiovascular toxicities account for at least 

28% of compound discontinuation. Although research and development 

expenditure continues to rise, the number of new drug applications is still 

declining. A strategy is therefore required to detect drugs with potential 

liabilities earlier in drug discovery in order to progress only the real winners. 

Pharmaceutical companies and regulatory bodies alike have recognized this 

challenge and have realized the need for scientists from different institutions—industry, 

academia, and government—to share their proprietary data 

more widely. This session will highlight collaborative projects that have 

been initiated to tackle various aspects of cardiovascular toxicities. We 

will begin with an introduction of the role of collaborations within translational 

toxicology, highlighting the benefit gained from large, diverse data 

sets. Further information will be provided as we progress in describing an 

ABPI program—the animal model framework—utilizing hemodynamic 

and ECG data from conscious telemetered dogs in addition to in vitro 

human ion channel data, in line with ICH S7B guidelines to predict Phase I 

clinical trial outcome. Participants will be provided an overview of the FDA- 

HESI seminar that was designed to assess in more detail predictability of 

MOnday 







105


MOnday 



nonclinical cardiac repolarization data for assessing QT liability in the clinic 

through retrospective analysis of data from the FDA, contributing companies, 

and the literature. We will move on to explore what more can be done 

to understand cardiac toxicities by reviewing a HESI initiative that aims to 

integrate structure and function relationships. Finally, participants will be 

asked what additional data can be exploited from the animal model framework 

to address compound attrition due to non-cardiovascular toxicities. 

#41 9:15 HEART SMART: INNOVATIVE 

APPROACHES FOR IMPROVING 

CARDIOVASCULAR SAFETY THROUGH 

COLLABORATION. S. D. Pettit 1 and J. Valentin 2 . 

1 

HESI, Washington, DC and 2 AstraZeneca, 

Macclesfield, United Kingdom. 

#42 9:20 USING THE ANIMAL MODEL 

FRAMEWORK TO PREDICT NON- 

CARDIOVASCULAR TOXICITIES—AN 

ABPI PROGRAM. L. Ewart 1 , R. Bialecki 1 , C. 

Draper 1 , T. Hammond 1 , P. Jarvis 1 , D. Leishman 3 , S. 

Lindgren 1 , C. Pollard 1 , W. Redfern 1 , J. Scatchard 2 , J. 

Sherington 2 , J. Valentin 1 and R. Wallis 2 . 1 AstraZeneca 

Pharmaceuticals, Macclesfield, Cheshire, United 

Kingdom, 2 Pfizer, Sandwich, United Kingdom and 

3 

Lilly, Indianapolis, IN. Sponsor: J. Dean. 

#43 9:52 ANIMAL MODEL FRAMEWORK: 

TRANSLATION OF NONCLINICAL 

FUNCTIONAL CARDIOVASCULAR DATA 

TO HUMAN—AN ABPI PROGRAM. R. 

Wallis 2 , R. Bialecki 1 , L. Ewart 1 , T. Hammond 1 , P. 

Jarvis 1 , D. Leishman 3 , S. Lindgren 1 , C. Pollard 1 , 

W. Redfern 1 , J. Scatchard 2 , J. Sherington 2 and J. 

Valentin 1 . 1 AstraZeneca, Maccelsfield, United 

Kingdom, 2 Pfizer, sandwich, United Kingdom and 

3 

Lilly, Indianapolis, IN. Sponsor: S. Pettit. 

#44 10:24 PREDICTIVITY OF NONCLINICAL DATA 

FOR ASSESSING QT LIABILITY IN THE 

CLINIC—AN FDA-HESI JOINT PROGRAM. 

J. Koerner 4 , J. Valentin 2 , E. Trepakova 3 and S. D. 

Pettit 1 . 1 HESI, Washington, DC, 2 AstraZeneca, 

Macclesfield, United Kingdom, 3 Merck, West Point, 

PA and 4 U.S. FDA, Silver Spring, MD. 

#45 10:56 CURRENT PRACTICES AND NEW 

OPPORTUNITIES IN ASSESSING 

STRUCTURAL-FUNCTIONAL 

CARDIOVASCULAR TOXICITIES—A HESI 

INITIATIVE. D. Sarazan 2 , S. D. Pettit 1 and B. 

Berridge 3 . 1 HESI, Washington, DC, 2 Covance, 

Madison, WI and 3 GlaxoSmithKline, Research 


#46 11:28 THE CARDIAC SAFETY RESEARCH 

CONSORTIUM (CSRC): A CRITICAL 

PATH INITIATIVE FOR CARDIAC 

SAFETY EVALUATION THROUGH A 

NEW PARADIGM OF PRE-COMPETITIVE 

PUBLIC-PRIVATE PARTNERING. M. W. 

Krucoff. Duke University Medical Center, Duke 

University, Durhma, NC. Sponsor: S. Pettit. 


9:15 AM to 12:00 NOON 

Room 250 


Workshop Session: Toxicology in the 21 st Century: Stem Cells 

in Drug Discovery and Development 

Chairperson(s): Kyle Kolaja, Hoffmann-LaRoche, Inc., Nutley, NJ, and 

Chris Kendrick-Parker, Cellular Dynamics International, Madison, WI. 

Sponsor: 


Endorsed by: 



Pluripotent stem cells have the potential to differentiate into any cell type 

in the body. This biological paradigm is being leveraged to change the way 

drugs are discovered, assessed, designed, and delivered. Stem cell derived 

models of various tissues including inflammatory cells, cardiomyocytes, 

neurons, beta-islet cells, etc., have demonstrated utility in understanding 

disease processes as well as predicting toxicological outcomes. As our 

understanding of genetic reprogramming into a stem cell and subsequent 

differentiation into terminal cell types increases, it will enable a variety of 

applications in the pharmaceutical and chemical industries. In vitro models 

will be followed by individual understanding of biology through inducible 

pluripotent (iPS) technology and ultimately cellular therapies will be 

brought to the clinic. In this session, we will cover a series of presentations 

that will expound upon our understanding of pluripotent cells and their 

utility in providing cellular models, how they are being used to understand 

pharmaceutical mechanisms of efficacy and toxicity, and the practical issues 

and obstacles that will need to be addressed to make regenerative, cellular 

therapy a reality. 

#47 9:15 THE PRESENT AND FUTURE OF STEM 

CELLS IN DRUG DEVELOPMENT. K. L. 

Kolaja 1 , C. K. Parker 2 , R. McKernan 4 , D. Fink 3 

and J. Thomson 5 . 1 Nonclinical Safety, Hoffmann- 

LaRoche, Nutley, NJ, 2 Cellular Dynamics, Madison, 

WI, 3 CBER, Food and Drug Administration, 

Gaithersburg, MD, 4 Regenerative Medicine, 

Pfizer, Groton, CT and 5 Regenerative Biology at 

the Morgridge Institute for Research and School 

of Medicine and Public Health, Univerisity of 

Wisconsin, Madison, WI. 

#48 9:20 HUMAN INDUCIBLE PLURIPOTENT STEM 

CELL DERIVED IN VITRO MODELS—THE 

PATH TO A BETTER UNDERSTANDING 

OF INDIVIDUAL BIOLOGY AND THEIR 

UTILITY IN DRUG DISCOVERY AND 

DEVELOPMENT. C. Parker. Cellular Dynamics, 

Madison, WI. 

#49 9:52 APPLICATION OF STEM CELL-DERIVED 

CARDIOMYOCYTES IN TOXICOLOGY AND 

SAFETY PHARMACOLOGY. K. L. Kolaja. 

Nonclinical Safety, Hoffmann-LaRoche, Nutley, NJ. 

#50 10:24 PHARMACEUTICAL PERSPECTIVES ON 

INTRODUCTION OF REGENERATIVE 

MEDICINE CONCEPTS INTO THE 

EXISTING PHARMACEUTICAL 

PARADIGM. R. McKernan and J. D. McNeish. 

Regenerative Medicine, Pfizer, Groton, CT. 

106 






Platform Sessions



Abstract # 

#51 10:56 DEVELOPING STEM CELL-BASED 

THERAPIES: CBER PRECLINICAL 

REGULATORY CONSIDERATIONS. 

M. Serbian. CBER, Food and Drug Administration, 


#52 11:28 HOW THE UNDERSTANDING OF THE 

BIOLOGY OF INDUCIBLE PLURIPOTENT 

STEM CELLS WILL EVOLVE: 

PREDICTIONS ON METHODS OF STEM 

CELL INDUCTION AND THE IMPACT 

ON CELL-BASED THERAPY. J. Thomson. 

Regenerative Biology at the Morgridge Institute for 

Research and School of Medicine and Public Health, 

University of Wisconsin, Madison, WI. Sponsor: K. 

Kolaja. 


9:15 AM to 12:00 NOON 

Ballroom F 


Platform Session: Biomarkers of Target-Organ Toxicity 

Chairperson(s): Bruce Fowler, ATSDR/CDC, Atlanta, GA, and Vikrant 

Vijay, North Carolina State University, Raleigh, NC. 

#53 9:15 MICRORNAS AS POTENTIAL 

CIRCULATING BIOMARKERS FOR 

TESTICULAR TOXICITY SCREENING. H. 

Lin, J. Milano, M. Mukhamedova and D. Yvonne. 

Safety Assessment, AstraZeneca Pharmaceuticals, 

Wilmington, DE. 

#54 9:36 EARLY DETECTION BIOMARKERS OF 

GASTROINTESTINAL TOXICITY IN RATS. 

A. John-Baptiste 1 , W. Scott 1 , A. Yang 1 , E. Kindt 3 , A. 

Wu 3 , W. T. Schaiff 2 , R. Denlinger 1 and W. Huang 1 . 

1 

Drug Safety, Pfizer Inc., San Diego, CA, 2 Drug 

Safety, Pfizer Inc., Chesterfield, MO and 3 PDM, 

Pfizer Inc., San Diego, CA. 

#55 9:57 DEVELOPMENT OF EXHALED 

BIOMARKERS FOR AIRWAY DISEASE AND 

EXPOSURE. K. Bloemen 1 , R. Van Den Heuvel 1 , 

E. Govarts 1 , G. Koppen 1 , E. Witters 1,2 , K. Desager 3 

and G. Schoeters 1,4 . 1 Environmental Risk and Health, 

VITO, Mol, Belgium, 2 Center for Proteome Analysis 

and Mass Spectrometry, University of Antwerp, 

Antwerp, Belgium, 3 Department of Pediatrics, 

University Hospital Antwerp, Antwerp, Belgium and 

4 

Department of Biomedical Sciences, University of 

Antwerp, Antwerp, Belgium. Sponsor: B. De Wever. 

#56 10:17 PROFILING OF MICRORNA EXPRESSION 

IN THE LIVERS OF RATS ADMINISTRATED 

WITH CARCINOGENIC DOSE OF 

COMFREY. Z. Li and T. Chen. Division of Genetic 

and Reproductive Toxicology, National Center for 

Toxicological Research, Jefferson, AR. 

#57 10:38 BILE ACIDS AS POTENTIAL BIOMARKERS 

FOR DIFFERENT TYPES OF LIVER 

DAMAGE—A TARGETED METABONOMICS 

LC-MS APPROACH. A. Amberg 1 , F. Durrieu 1 , M. 

Sieber 2 , M. Raschke 3 , B. Riefke 3 and H. Ellinger 3 . 

1 

Sanofi-Aventis, Frankfurt, Germany, 2 University 

Wüerzburg, Wüerzburg, Germany and 3 Bayer 

Schering, Berlin/Wuppertal, Germany. Sponsor: M. 

Bonnefoi. 

Abstract # 

#58 10:58 THE UTILITY OF EMERGING 

BIOMARKERS OF LIVER INJURY FOR 

AGENTS AFFECTING ALT ENZYMATIC 

ACTIVITY IN PRECLINICAL DRUG 

DEVELOPMENT. S. J. Schomaker 1 , C. Houle 2 and 

J. Aubrecht 1 . 1 Safety Sciences, Pfizer Inc., Groton, 

CT and 2 Toxicologic Pathology, Pfizer Inc., Groton, 

CT. 

#59 11:19 IDENTIFICATION OF MODIFIED 

HUMAN PLASMA PROTEIN PEPTIDES AS 

BIOMARKERS OF SYSTEMIC CHRONIC 

INFLAMMATORY AND OXIDATIVE 

STRESS. D. J. Bigelow 1 , X. Zhang 1 , S. M. 

Varnum 1 , J. M. Jacobs 1 , B. M. Webb-Robertson 1 , 

K. M. Waters 1 , R. C. Zangar 1 , M. Scholand 2 , J. 

R. Hoidal 2 and J. G. Pounds 1 . 1 Pacific Northwest 

National Labortory, Richland, WA and 2 University of 

Utah Medical School, Salt Lake City, UT. 

#60 11:39 REGULATION OF MUCO-ACTIVE 

RIBOTOXIC STRESS-EXPORTED ELAVL1 

RNA BINDING PROTEIN BY PEROXISOME 

PROLIFERATOR-ACTIVATED RECEPTOR 

(Ppar) g. S. Park and Y. Moon. Department of 

Microbiology and Immunology, Pusan National 

University School of Medicine and Medical Research 

Institute, Yangsan, Republic of Korea. 


9:15 AM to 12:00 NOON 

Ballroom I 

Platform Session: Chemical and Biological Weapons— 

Sulfur Mustard 

Chairperson(s): Josh Gray, U.S. Coast Guard Academy, New London, CT. 

#61 9:15 P38 MAP KINASE REGULATES 

CAVEOLIN-1 AND HSP27-MEDIATED 

ACTIN REORGANIZATION IN MOUSE 

KERATINOCYTES FOLLOWING 

EXPOSURE TO 2-CHLOROETHYL ETHYL 

SULFIDE (CEES). J. D. Laskin 1 , A. T. Black 2 , 

L. B. Joseph 2 , C. R. Gardner 2 , J. P. Gray 3 , R. P. 

Casillas 4 , D. E. Heck 5 , D. R. Gerecke 2 and D. L. 

Laskin 2 . 1 UMDNJ-RWJ Medical School, Piscatway, 

NJ, 2 Rutgers University, Piscataway, NJ, 3 U.S. 

Coast Guard Academy, New London, CT, 4 Batelle 

Biomedical Research Center, Columbus, OH and 

5 

New York Medical College, Valhalla, NY. 

#62 9:34 THE VESICANT 2-CHLOROETHYL ETHYL 

SULFIDE (CEES) INDUCES EXPRESSION 

OF PROLIFERATIVE MARKERS IN A FULL- 

THICKNESS HUMAN SKIN EQUIVALENT. 

A. T. Black 1 , P. J. Hayden 2 , A. M. Vetrano 3 , J. P. 

Gray 4 , R. P. Casillas 5 , D. E. Heck 6 , D. R. Gerecke 1 , 

D. L. Laskin 1 and J. D. Laskin 3 . 1 Rutgers University, 

Piscataway, NJ, 2 MatTek Corporation, Ashland, 

MA, 3 UMDNJ-RWJ Medical School, Piscataway, 

NJ, 4 U.S. Coast Guard Academy, New London, CT, 

5 

Batelle Biomedical Research Center, Columbus, OH 

and 6 New York Medical College, Valhalla, NY. 

#63 9:52 LATE PHASE BIOMARKERS OF SULFUR 

MUSTARD-INDUCED INJURY. J. Seagrave, 

L. Blair, G. Grotendorst, L. Herrera, M. Lehman, T. 

March and W. Weber. Lovelace Respiratory Research 

Institute, Albuquerque, NM. 

MOnday 







107


MOnday 



#64 10:10 LONG-TERM CHARACTERIZATION OF 

A SUPERFICIAL DERMAL SKIN INJURY 

FOLLOWING EXPOSURE OF HAIRLESS 

GUINEA PIGS TO HD VAPOR. S. Dachir, M. 

Cohen, L. Tverya, R. Sahar, H. Gutman, V. Horwitz 

and T. Kadar. Pharmacology, Israel Institute for 

Biological Research, Ness Ziona, Israel. Sponsor: J. 

Dillman. 

#65 10:29 SELECTIVE CROSS-LINKING OF 

THIOREDOXIN REDUCTASE IN LUNG 

EPITHELIAL CELLS BY NITROGEN 

MUSTARD, A MODEL SULFUR MUSTARD 

VESICANT. Y. Jan 1 , D. E. Heck 2 , R. P. Casillas 3 , 

D. L. Laskin 4 and J. D. Laskin 1 . 1 Environmental 

& Occupational Medicine, UMDNJ-Robert 

Wood Johnson Medical School, Piscataway, NJ, 

2 

Environmental Health, New York Medical College, 

Valhalla, NY, 3 Biomedical Science & Technology, 

Battelle Biomedical Research Center, Columbus, 

OH and 4 Pharmacology & Toxicology, Rutgers 

University, Piscataway, NJ. 

#66 10:47 DIFFERENT METHODS TO STUDY 

THE GENOTOXIC MARKER g-H2AX 

FOLLOWING SULFUR MUSTARD 

EXPOSURE IN CULTURED HUMAN SKIN 

CELLS AND A SKIN TISSUE CONSTRUCT. 

A. Miller, C. Gross, E. Nealley, O. Clark, N. Waraich, 

K. Rodgers and W. Smith. USAMRICD, Aberdeen 

Proving Ground, MD. 

#67 11:05 PLASMA MEMBRANE-BOUND 

OXIDOREDUCTASES ARE AN IMMEDIATE 

TARGET OF NITROGEN MUSTARD IN 

PULMONARY EPITHELIAL CELLS. P. 

Collins 1 , E. Heart 2 , D. R. Gerecke 4 , D. L. Laskin 4 , J. 

D. Laskin 3 and J. P. Gray 1,4 . 1 Science - Chemistry, 

United States Coast Guard Academy, New London, 

CT, 2 Biocurrents Research Center, Marine Biological 

Laboratory, Wodos Hole, MA, 3 Environmental 

& Occupational Medicine, UMDNJ-RWJMS, 

Piscataway, NJ and 4 Pharmacology & Toxicology, 

Rutgers University, Piscataway, NJ. 

#68 11:23 SULFUR MUSTARD VAPOR DEPOSITION, 

TISSUE DISTRIBUTION AND CLEARANCE 

IN THE HAIRLESS GUINEA PIG. B. 

Tibbetts, W. Weber, T. March, D. C. Santistevan, G. 

Grotendorst and J. Benson. Lovelace Respiratory 

Research Institute, Albuquerque, NM. 

#69 11:41 THERAPEUTIC EFFICACY OF SILIBININ, 

A NATURAL FLAVANONE, IN SULFUR 

MUSTARD ANALOG INDUCED SKIN 

TOXICITY. N. Tewari-Singh 1 , A. K. Jain 1 , 

S. Inturi 1 , C. W. White 2 and R. Agarwal 1 . 

1 

Pharmaceutical Sciences, University of Colorado 

Denver, Aurora, CO and 2 Pediatrics, National Jewish 

Health, Denver, CO. 


9:15 AM to 12:00 NOON 

Ballroom D 

Platform Session: Immunopharmacogenomics and Immune 

Regulation 

Chairperson(s): Dori Germolec, NIEHS Research Triangle Park, NC, and 

Enrique Fuentes-Mattei,University of Puerto Rico, San Juan, PR. 

#70 9:15 GENE EXPRESSION ALTERATIONS 

IN IMMUNE SYSTEM PATHWAYS 

FOLLOWING EXPOSURE TO 

IMMUNOSUPPRESSIVE CHEMICALS. R. 

P. Frawley 1 , K. L. White, Jr 2 , D. Musgrove 2 , R. 

Brown 2 , N. J. Walker 1 and D. R. Germolec 1 . 1 National 

Toxicology Program, NIEHS, Research Triangle 

Park, NC and 2 Virginia Commonwealth University, 

Richmond, VA. 

#71 9:34 TCDD-INDUCED MODULATION OF THE 

HUMAN POLYMORPHIC HS1, 2 ENHANCER 

WITHIN THE 3’IgH REGULATORY 

REGION. C. E. Sulentic, T. M. Fernando and S. 

Ochs. Pharmacology & Toxicology, Wright State 

University, Dayton, OH. 

#72 9:53 THE ROLE OF AHR IN MATURATION OF 

DENDRITIC CELLS. C. F. Vogel 1 , S. R. Goth 2 , 

D. Wu 1 , B. Yuen 2 , I. Pessah 2 and F. Matsumura 1 . 

1 

CHE, University of California Davis, Davis, CA 

and 2 Molecular Biosciences, University of California 

Davis, Davis, CA. 

#73 10:11 DIRECT REGULATION OF BACH2 BY 2, 3, 

7, 8-TETRACHLORODIBENZO-P-DIOXIN IN 

MURINE B LYMPHOMA CH12.LX CELLS. 

A. S. Phadnis 1,2 , M. A. Manzan 2 , R. A. Thomas 4 and 

N. E. Kaminski 2,3 . 1 Genetics Program, Michigan State 

University, East Lansing, MI, 2 Center for Integrative 

Toxicology, Michigan State University, East Lansing, 

MI, 3 Pharmacology and Toxicology, Michigan State 

University, East Lansing, MI and 4 Hamner Institutes 

for Health Sciences, Research Triangle Park, NC. 

#74 10:29 ALLERGEN-INDUCED CHANGES IN 

INTERLEUKIN-17 EXPRESSION IN MICE. 

M. Hayes, I. Kimber and R. J. Dearman. Faculty of 

Life Sciences, Manchester University, Manchester, 

United Kingdom. 

#75 10:47 SKIN TYPE 2 CYTOKINES AND SERUM IGE 

ANTIBODY LEVELS ARE INCREASED BY 

ALLERGEN IN AGING MICE. R. J. Dearman 

and I. Kimber. Faculty of Life Sciences, Manchester 

University, Manchester, Greater Manchester, United 

Kingdom. 

#76 11:05 AHR ACTIVATION BY INDOLES LEADS 

TO AMELIORATION OF EXPERIMENTAL 

AUTOIMMUNE ENCEPHALOMYELITIS 

THROUGH RECIPROCAL REGULATION 

OF FOXP3+ T REGS AND TH17 CELLS. M. 

Rouse, M. Nagarkatti and P. Nagarkatti. Pathology, 

Microbiology, and Immunology, University of South 

Carolina, Columbia, SC. 

#77 11:23 INVOLVEMENT OF INTERLEUKIN-17 IN 

DRUG-INDUCED LIVER INJURY IN MICE. 

T. Yokoi, E. Kobayashi, M. Kobayashi, T. Fukami and 

M. Nakajima. Graduate School of Medical Science, 

Kanazawa University, Kanazawa, Ishikawa, Japan. 

108 






Platform Sessions



Abstract # 

#78 11:41 PERINATAL BISPHENOL A EXPOSURE 

ALTERS B LYMPHOPOIESIS AND 

CYTOKINE/CHEMOKINE PRODUCTION 

IN ADULT C57B6/129 MALE MICE. S. D. 

Holladay 1 , S. Xiao 2 , H. Diao 2 , J. Barber 3 , T. Nagy 4 , 

X. Ye 2 and R. M. Gogal 1 . 1 Department of Anatomy 

and Radiology, University of Georgia, Athens, 

GA, 2 Physiology and Pharmacology, University 

of Georgia, Athens, GA, 3 Infectious Diseases, 

University of Georgia, Athens, GA and 4 Pathology, 

University of Georgia, Athens, GA. 


9:15 AM to 12:00 NOON 

Room 251 A 


Platform Session: Mitochondrial-Mediated Mechanisms of 

Toxicity of Xenobiotics 

Chairperson(s): Yvonne Will, Pfizer Global Research & Development, 

Groton, CT, and Jianling Wang, University of Texas Medical Branch, 

Galveston, TX. 

#79 9:15 EVALUATING THE EFFECT OF 

TYROSINE KINASE INHIBITORS ON 

MITOCHONDRIAL FUNCTION IN RAT 

PRIMARY CARDIOMYOCYTES. K. M. 

Goldstein 1 , C. E. Thomas 1 , G. H. Searfoss 1 , S. T. 

Estrem 1 , T. K. Baker 1 , K. Giuliano 2 , K. Johnston 2 , 

B. W. Halstead 1 , K. Gardinier 1 , P. Spinazze 1 and 

R. A. Jolly 1 . 1 Eli Lilly & Co., Indianapolis, IN and 

2 

Cellumen, Inc., Pittsburgh, PA. 

#80 9:43 XANTHINE OXIDASE AND NADPH 

OXIDASE CONTRIBUTE TO 

MITOCHONDRIAL IMPAIRMENT 

INVOLVED IN COCAINE-INDUCED LV 

DIASTOLIC DYSFUNCTION. A. Vergeade 1 , 

P. Mulder 1 , C. Dehaudt 1 , D. Fortin 2 , R. Ventura- 

Clapier 2 , C. Thuillez 1 and C. Monteil 1 . 1 INSERM 

U644, Rouen, France and 2 INSERM U769, 

Chatenay-Malabry, France. Sponsor: R. Forster. 

#81 10:10 A REAL-TIME NON-INVASIVE 96-WELL 

PLATFORM FOR INVESTIGATING THE 

EFFECTS OF DRUGS ON MITOCHONDRIAL 

RESPIRATION AND GLYCOLYTIC RATES 

OF INTACT CELLS. P. Rana 1 , S. Nadanaciva 1 , 

D. Svancara 1 , D. Ferrick 2 and Y. Will 1 . 1 Compound 

Safety Prediction, Pfizer Inc., Groton, CT and 

2 

Seahorse Bioscience, Billerica, MA. 

#82 10:38 MITOCHONDRIAL FUSION AND 

AUTOPHAGY AID IN REMOVAL OF 

PERSISTENT MITOCHONDRIAL DNA 

DAMAGE. A. M. Smith, T. L. Crocker, M. C. 

Leung and J. N. Meyer. Nicholas School of the 

Environment, Duke University, Durham, NC. 

#83 11:05 CELLULAR SYSTEMS BIOLOGY 

MODELS REVEAL THE MECHANISMS 

OF ANTIBIOTIC TOXICITY. K. Johnston 2 , 

B. Gough 2 , L. Vernetti 2 , N. Radio 2 and Y. Will 1 . 

1 

Compound Safety Prediction, Pfizer Global 

Research & Development, Groton, CT and 

2 

Cellumen, Pittsburgh, PA. 

Abstract # 

#84 11:33 TCDD-MEDIATED GENE EXPRESSION 

PROFILING OF NUCLEAR ENCODED 

MITOCHONDRIAL GENES INVOLVED 

IN OXIDATIVE PHOSPHORYLATION. A. 

Forgacs 1,2 , L. D. Burgoon 1,2 , S. G. Lynn 1,2 , J. J. 

LaPres 1,2 and T. R. Zacharewski 1,2 . 1 Biochemistry & 

Molecular Biology, Michigan State University, East 

Lansing, MI and 2 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI. 


9:15 AM to 10:15 AM 

Room 155 F 

Exhibitor Hosted Session: In Vivo Ecotoxicity Tests: 

Responding to U.S. EPA Endocrine Disruptor Screening 


Presented by: Analytical Bio-Chemistry Labs, Inc. 

The U.S. EPA recently initiated a program to screen chemicals that may 

disrupt an animal’s endocrine system. This session will focus on two 

in vivo ecotoxicity tests, one with fish and a second with amphibians. 

It will include background information, and an overview of the testing and 

data analysis methods. 


9:15 AM to 10:15 AM 

Room 155 C 

Exhibitor Hosted Session: Biological Test Center Capabilities 

Overview 

Presented by: Biological Test Center 

The Biological Test Center has been providing pharmaceutical, biotechnology, 

and medical device industries with preclinical contract laboratory 

services since 1980. Our GLP, AAALAC-accredited facility is located in 

Irvine, CA. The Center performs a wide range of biocompatibility, toxicology, 

pharmacology, pharmacokinetics, ocular, and surgical studies, 

including innovative ophthalmological and surgical models. 


9:15 AM to 10:15 AM 

Room 155 B 

Exhibitor Hosted Session: Digital Pathology in the 21 st 

Century 

Presented by: Charles River 

Digital pathology is an emerging technology that affords many benefits to 

pathologists. While pathologists in the clinical area have made good use of 

this technology, pathologists in the preclinical area have not moved forward 

as rapidly. The use of digital pathology today and in the future in support of 

preclinical studies will be reviewed and discussed. 

MOnday 







109


MOnday 




9:30 AM to 10:50 AM 

Exhibit Hall 

Undergraduate Education Program: Poster Session for 

Visiting Students 

Chairperson(s): Julio Davila, Pfizer, Inc., Saint Louis, MO. 

Sponsor: Committee on Diversity Initiatives 


MARC and SOT travel funding and SOT program volunteers assisting 

with the Undergraduate Program. Full program details are found pages 

64–66. 


9:30 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Toxicity Testing—Alternative Models I 

Chairperson(s): Richard Judson, U.S. EPA, Research Triangle Park, NC. 

Displayed: 9:30 AM–12:30 PM 

Author Attended: 9:30 AM–11:00 AM 

#85 Poster Board Number .....................................101 

BLINDED ASSESSMENT OF HEPATOTOXIC 

PHARMACEUTICALS USING ZEBRAFISH. 

M. D. Aleo 1 , C. M. Doshna 1 , M. Jones 2 and A. Hill 2 . 

1 

Drug Safety R&D, Pfizer Global R&D, Groton, 

CT and 2 Evotec (UK) Ltd., Abingdon, Oxfordshire, 



A COMMON ROLE FOR MEGALIN 

IN THE OTOTOXIC POTENTIAL OF 

NEPHROTOXICANTS IN THE ZEBRAFISH. 

C. Doshna 1 , S. Fritz 2 , L. Fasulo 1 , P. Burch 1 and M. 

Aleo 1 . 1 Pfizer, Groton, CT and 2 Gettysburg College, 

Gettysburg, PA. 


DEVELOPMENT OF A SCREENING 

ASSAY TO IDENTIFY TERATOGENIC AND 

EMBRYOTOXIC CHEMICALS OR DRUGS 

USING THE ZEBRAFISH EMBRYO. H. 

Witters and I. Selderslaghs. Toxicology, VITO NV - 

Flemish Institute for Technological Research, Mol, 

Belgium. Sponsor: B. De Wever. 


THE EFFECT OF MEDICAL DEVICE 

COMPOSITION ON RESULTS OF 

CYTOTOXICITY EVALUATED BY THE 

DIRECT CONTACT AND ELUTION 

COLONY ASSAYS. S. Kostrubsky, K. L. Bullard 

and J. Wegrzyn. Vistakon, Division of J&J Vision 

Care, Jacksonville, FL. 


PROTECTIVE RESPONSE OF THE AH 

RECEPTOR TO ANIT-INDUCED BILIARY 

EPITHELIAL CELL TOXICITY IN SEE- 

THROUGH MEDAKA. D. Volz 1 , S. Kullman 2 , D. 

Howarth 3 , R. Hardman 4 and D. Hinton 5 . 1 University 

of South Carolina, Columbia, SC, 2 North Carolina 

State University, Raleigh, NC, 3 Mount Sinai 

School of Medicine, New York, 4 U.S. Food and 

Drug Administration, Silver Spring, MD and 5 Duke 



BIOMARKER FINGERPRINTING OF 

HEAVY METAL TOXICITY. N. Hussainzada 1 , 

C. E. Baer 2 , J. A. Lewis 1 and D. A. Jackson 1 . 1 U.S. 

Army Center for Environmental Health Research, 

Fort Detrick, MD and 2 Excet, Inc., Fort Detrick, MD. 


DEVELOPMENT OF AN IN VITRO 

ASSAY FOR THE ASSESSMENT OF 

PHOTOSENSITIZERS. A. G. Schepky, N. 

Karschuk, Y. Tepe, J. Spieker, S. Gerlach, W. W. 

Pape, W. Diembeck, H. Wenck, R. Schmucker, K. 

Wittern and H. Reuter. 4228-Toxicology In Vitro, 

Beiersdorf AG, Hamburg, Germany. Sponsor: R. 

Fautz. 


ASSESSMENT OF A WHOLE SMOKE IN 

VITRO EXPOSURE SYSTEM. M. D. Gaça, 

C. Meredith, K. Scott, D. Azzopardi, J. Perkins, 

J. McAughey and J. Adamson. Group Research 

& Development, British American Tobacco, 

Southampton, United Kingdom. 


NNK-INDUCED ACUTE TOXICITY AND 

CYTOKINE ALTERATIONS IN A LUNG 

SLICE MODEL. T. Liberati, M. Randle and 

R. Trammell. Internal Medicine, SIU School of 

Medicine, Springfield, IL. 


THE EFFECT OF NON-STEROIDAL 

ANTI-INFLAMMATORY DRUGS ON THE 

RESPIRATION OF INTACT HEPG2 CELLS 

AND ISOLATED MITOCHONDRIA. S. 

Nadanaciva, D. Svancara and Y. Will. Compound 

Safety Prediction, Pfizer Inc., Groton, CT. 


REAL-TIME CELL-ELECTRONIC SENSING 

FOR MONITORING THE EFFECTS 

OF ANTIBACTERIALS AND ANTI- 

RETROVIRALS IN EUKARYOTIC CELLS. 

Y. Will, K. Dillman and S. Nadanaciva. Compound 

Safety Prediction, Pfizer Inc., Groton, CT. 


PREDICTIVE SIGNATURES FROM 

TOXCAST DATA FOR CHRONIC, 

DEVELOPMENTAL, AND REPRODUCTIVE 

TOXICITY ENDPOINTS. R. Judson, D. Dix, K. 

Houck, M. Martin, T. Knudsen and R. Kavlock. U.S. 

EPA, Research Triangle Park, NC. 


PRE-VALIDATION OF MOLECULAR 

FINGERPRINT FOR ESTROGENS IN THE 

ISHIKAWA CELL LINE. J. M. Naciff, G. J. 

Overmann, T. D. Reichling, G. J. Carr, J. P. Tiesman 

and G. P. Daston. Procter & Gamble, Cincinnati, OH. 

110 






Platform Sessions



Abstract # 


DERIVING SIGNATURES OF IN VIVO 

TOXICITY USING BOTH EFFICACY AND 

POTENCY INFORMATION FROM IN 

VITRO ASSAYS: EVALUATING MODEL 

PERFORMANCE AS A FUNCTION 

OF INCREASING VARIABILITY IN 

EXPERIMENTAL DATA. A. Beam 2,1 , M. 

Martin 1 , D. Reif 1 , D. Dix 1 and R. Judson 1 . 1 U.S. EPA, 

Research Triangle Park, NC and 2 Department of 

Statistics, North Carolina State University, Raleigh, 

NC. 


IN VITRO SCREENING OF 

NANOPARTICULATES FOR SKIN AND EYE 

IRRITATION EFFECTS: RESULTS FROM 

EPIDERM AND BCOP ASSAYS. C. Carpenter, 

D. B. Warheit and S. E. Loveless. DuPont Haskell 

Laboratory, Newark, DE. 


ICCVAM RECOMMENDATIONS FOR 

USING IN VITRO OCULAR TOXICITY TEST 

METHODS TO IDENTIFY SUBSTANCES 

NOT LABELED AS IRRITANTS: A BOTTOM- 

UP APPROACH. M. Wind 1 , M. Cesta 2 , A. Jacobs 3 , 

J. Merrill 3 , D. McCall 4 , J. Redden 4 and W. Stokes 5 . 

1 

CPSC, Bethesda, MD, 2 NIEHS, Research Triangle 

Park, NC, 3 FDA, Silver Spring, MD, 4 EPA, 

Washington, DC and 5 NICEATM, NIEHS, Research 

Triangle Park, NC . 


TESTING OF CODED SUBSTANCES IN THE 

NICEATM/ECVAM/JACVAM LUMI-CELL ® 

STTA MULTIPHASE INTERNATIONAL 

VALIDATION STUDY. P. Ceger 1 , F. Deal 1 , 

D. Allen 1 , G. Clark 2 , P. Pazos 3 , J. de Lange 3 , S. 

Bremer 3 , M. Nakamura 4 , H. Kojima 5 , A. Ono 5 , R. 

Tice 6 and W. Stokes 7 . 1 NICEATM-ILS, Inc., NIEHS, 

Research Triangle Park, NC, 2 XDS, Inc., Durham, 

NC, 3 IVM/ECVAM, IHCP, Ispra, Italy, 4 Hiyoshi 

Corp., Omihachiman, Japan, 5 JaCVAM, Tokyo, 

Japan, 6 NIEHS, Research Triangle Park, NC and 

7 

NICEATM, NIEHS, Research Triangle Park, NC . 


SUPPLEMENTATION OF THE VALIDATION 

DATABASE FOR THE ISOLATED RABBIT 

EYE (IRE) ASSAY. C. Seaman 1 , F. Guerriero 2 , 

A. Whittingham 4 , M. Olson 3 and R. Guest 4 . 1 HS&P, 

GlaxoSmithKline, Ware, United Kingdom, 2 HS&P, 

GSK, Philadelphia, PA, 3 HS&P, GSK, Research 

Triangle Park, NC and 4 Harlan Laboratories, Ltd., 

Shardlow, United Kingdom. 


IN VITRO PREDICTION MODEL AS AN 

ALTERNATIVE METHOD FOR EYE 

IRRITATION TEST. Y. Xing Fen, Y. Ying and Z. 

Wen Gai. Center for Disease Control and Prevention 

of Guangdong Province, P.R. China, Institution 

of Toxicology, Guangzhou, Guangdong, China. 

Sponsor: A. Fan. 


MEDIA REFINEMENT FOR A LONG TERM 

CORNEAL CULTURE MODEL OF EYE 

IRRITATION AND POST-TREATMENT 

RECOVERY. J. R. Nash, N. Wilt, A. Kong, H. 

Raabe and G. Costin. Institute for In Vitro Sciences, 

Inc. (IIVS), Gaithersburg, MD. 

Abstract # 


A NEW IN VITRO METHOD FOR 

IDENTIFYING CHEMICAL MEDIATED 

RESPIRATORY TOXICITY USING 

MULTIPLE ENDPOINT ANALYSIS AND THE 

EPI-AIRWAY TM MODEL. J. A. Willoughby, Sr. 

and J. M. McKim, Jr. CeeTox, Kalamazoo, MI. 


HISTORICAL DATA ON PERSONAL 

CARE PRODUCTS OVER FOURTEEN 

YEARS USING THE CHORIOALLANTOIC 

MEMBRANE VASCULAR ASSAY (CAMVA) 

AND BOVINE CORNEAL OPACITY AND 

PERMEABILITY ASSAY (BCOP). D. A. 

Donahue 1 , W. Newhard 2 , L. Kaufman 3 , J. Avalos 1 

and D. Cerven 2 . 1 Research and Development, Kao 

Brands Company, Cincinnati, OH, 2 MB Research 

Laboratories, Spinnerstown, PA and 3 Scripterra 

Scientific, Wooster, OH. 


ASSESSMENT OF CHEMICAL SKIN 

SENSITIZING POTENCY BY AN IN VITRO 

ASSAY BASED ON HUMAN DENDRITIC 

CELLS. N. Lambrechts, J. Hooyberghs, H. Witters, 

R. Van Den Heuvel, I. Nelissen and G. Schoeters. 

Unit of Environmental Risk and Health, VITO, Mol, 



DEVELOPMENT OF A HIGH- 

THROUGHPUT KERATINOCYTE-BASED 

STANDARD ASSAY TO DETECT SKIN 

SENSITIZERS BASED ON ARE-DEPENDENT 

GENE ACTIVITY. A. Natsch 1 , R. Emter 1 , G. 

Ellis 2 and G. Adamson 3 . 1 Bioscience, Givaudan 

Schweiz AG, Duebendorf, Switzerland, 2 Regulatory 

affairs, Givaudan Suisse SA, Vernier, Switzerland 

and 3 Global Regulatory affairs, Givaudan USA, East 

Hannover Ridgedale, NJ. 


IN VITRO ASSESSMENT OF PERSONAL 

CARE PRODUCTS FOR VAGINAL 

IRRITATION USING 3D TISSUE 

CONSTRUCTS. E. Evans 1 , R. Priston 1 , H. Inglis 2 , 

N. Barnes 2 , H. Raabe 2 and G. Costin 2 . 1 Kimberly- 

Clark Corporation, Roswell, GA and 2 Institute for In 

Vitro Sciences, Inc. (IIVS), Gaithersburg, MD. 


DIRECT PEPTIDE REACTIVITY 

ASSAY (DPRA) FOR SCREENING SKIN 

SENSITIZATION POTENTIAL OF 

CHEMICALS. L. Foertsch 1 , B. Price 1 , J. Chaney 1 , 

J. Lepoittevin 2 and F. Gerberick 1 . 1 Procter & 

Gamble Company, Cincinnati, OH and 2 Laboratoire 

de Dermatochimie, University of Strasbourg, 

Strasbourg, France. 


A NEW IN VITRO METHOD FOR THE 

DETECTION OF CHEMICAL SENSITIZERS: 

COMBINES PEPTIDE BINDING WITH ARE/ 

EPRE-LINKED GENE EXPRESSION. D. 

J. Keller 1 , M. E. Steffey 1 , J. R. Gorski 2 and J. M. 

McKim, Jr. 1 . 1 CeeTox, Kalamazoo, MI and 2 NAMSA, 

Northwood, OH. 

MOnday 







111


MOnday 




USE OF THE STRATATEST ® HUMAN 

SKIN MODEL IN EVALUATING 

ENVIRONMENTAL INSULT-MEDIATED 

DAMAGE. C. Rasmussen 1 , F. Liebel 2 , M. Southall 2 , 

K. Gratz 1 , N. Simon 1 , A. Comer 1 and L. Allen- 

Hoffmann 1 . 1 Stratatech Corporation, Madison, WI 

and 2 Johnson & Johnson Consumer & Personal 

Products Worldwide, Skillman, NJ. 


METHODS FOR IMPROVING THE 

INTERPRETATION OF IN VITRO 

ENDOCRINE SCREENING DATA: 

REDUCING FALSE NEGATIVE AND 

FALSE POSITIVE RESULTS. J. P. Pregenzer, 

D. P. Blakeman and J. M. McKim, Jr.. CeeTox, 

Kalamazoo, MI. 


PREDICTIVE CAPACITY OF THE 3T3 

NEUTRAL RED UPTAKE ASSAY TO 

IDENTIFY SUBSTANCES WITH ACUTE 

ORAL LD 50 

S>2000 MG/KG. P. Prieto 1 , R. 

Curren 2 , H. Raabe 2 , A. Hilberer 2 , M. Whelan 3 , S. 

Coecke 1 , R. Gibson 4 , A. Compagnoni 3 , T. Hartung 5 

and A. Kinsner-Ovaskainen 1 . 1 In Vitro Methods 

Unit/ECVAM, IHCP, EC Joint Research Centre, 

Ispra, Italy, 2 Institute for In Vitro Sciences, Inc., 

Gaithersburg, MD, 3 Systems Toxicology Unit, IHCP, 

EC Joint Research Centre, Ispra, Italy, 4 Health and 

Safety Laboratory, Buxton, United Kingdom and 

5 

Bloomberg School of Public Health, Johns Hopkins 

University, Baltimore, MD. 


THE YEAST RESPONSE TO A BROMINATED 

FLAME RETARDANT. B. Gaytan, M. North 

and C. Vulpe. University of California at Berkeley, 

Berkeley, CA. 


TOWARDS AN AUTOMATED SCORING 

SYSTEM FOR THE SYRIAN HAMSTER 

EMBRYO ASSAY. S. Emery 1 , G. Ouédraogo 1 , 

E. Tatarinova 2 , J. Sallette 2 , F. Soussaline 2 and J. 

Meunier 1 . 1 International Safety Research, L’Oréal, 

Aulnay sous bois, France and 2 IMSTAR S.A, Paris, 

France. Sponsor: G. Nohynek. 


MONKEY GALL BLADDER EPITHELIAL 

CELLS: ISOLATION, CULTURE, 

CHARACTERIZATION AND APPLICATION 

IN TOXICITY EVALUATION. Y. Wu 1 , D. Averill- 

Garafolo 2 , J. Megill 3 , V. Bhaskaran 4 , D. Bigwarfe 2 , 

U. Hanumegowda 1 and S. Adams 1 . 1 Discovery 

Toxicology, BMS, Wallingford, CT, 2 Drug Safety 

Evaluation, BMS, Syracuse, NY, 3 Discovery 

Toxicology, BMS, Hopewell, NJ and 4 Discovery 

Toxicology, BMS, Lawrenceville, NJ. 


MICROFLUIDIC HEPATOCYTE ARRAY 

FOR LONG TERM DRUG EXPOSURE 

SCREENING. P. Lee and P. Hung. CellASIC 

Corporation, San Leandro, CA. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Carcinogenesis I 

Chairperson(s): David Geter, Dow Chemical Company, Midland, MI, and 

Eias Zahalka, BioReliance Corporation, Rockville, MD. 


Author Attended: 11:00 AM–12:30 PM 


ARSENIC REGULATION OF MIRNAS IN 

HUMAN CARCINOGENESIS. K. Beezhold 1,2 , 

H. Kan 2 , T. Meighan 2 , V. Castranova 2 and F. Chen 1,2 . 

1 

Cancer Cell Biology Program, West Virginia 

University, Morgantown, WV and 2 Pathology and 

Physiology Research Branch, NIOSH, Morgantown, 

WV. 


EFFECTS OF MIXED TOCOPHEROLS 

ON ESTROGEN RECEPTOR POSITIVE 

BREAST CANCER. A. K. Smolarek 1,2,3 , P. E. 

Thomas 1,2,3 , H. Lee 2 , J. So 2 , S. Paul 2 , M. Lee 2 , C. S. 

Yang 2,3 , K. Reuhl 1,2 and N. Suh 2,3,4 . 1 Pharmacology 

and Toxicology, Rutgers University, Piscataway, NJ, 

2 

Chemical Biology, Rutgers University, Piscataway, 

NJ, 3 Joint Graduate Program in Toxicology, Rutgers 

University, Piscataway, NJ and 4 The Cancer Institute 

of New Jersey, New Brunswick, NJ. 


POTENT MUTAGENICITY OF 

3-METHYLINDOLE REQUIRES 

PULMONARY CYTOCHROME P450- 

MEDIATED BIOACTIVATION: A 

COMPARISON TO THE PROTOTYPE 

CIGARETTE SMOKE MUTAGENS B(A)P 

AND NNK. J. M. Weems, J. G. Lamb and G. S. 

Yost. Department of Pharmacology and Toxicology, 

University of Utah, Salt Lake City, UT. 


LUNG CANCER RISKS FROM ASBESTOS 

EXPOSURE, ASBESTOSIS, AND OTHER 

FIBROTIC LUNG DISEASES: CASE 

EXAMPLES OF DISTINGUISHING FACTORS 

FOR DISEASE CAUSATION ANALYSIS. R. C. 

James 2 , B. D. Kerger 1 and D. H. Garabrant 3 . 1 HSRI, 

Tallahassee, FL, 2 TERRA Inc., Tallahassee, FL and 

3 

University of Michigan, Ann Arbor, MI. 


NUMERICAL CHROMOSOME 

ABERRATIONS IN THE PERIPHERAL 

LYMPHOCYTES OF WORKERS EXPOSED 

TO LOW LEVELS OF BENZENE. Z. Ji 1,4 , L. 

Zhang 1 , N. Rothman 2 , S. M. Rappaport 1 , M. Shen 2 , 

R. Vermeulen 3 , S. Yin 4 , M. T. Smith 1 , G. Li 4 and Q. 

Lan 2 . 1 University of California at Berkeley, Berkeley, 

CA, 2 National Cancer Institute, NIH, Bethesda, MD, 

3 

Institute of Risk Assessment Sciences, Utrecht, 

Netherlands and 4 Chinese Center for Disease Control 

and Prevention, Beijing, China. 


GASOLINE: UNAPPRECIATED VILLAIN 

OR UNWARRANTED SUSPECT. J. J. Keenan, 

S. H. Gaffney, D. Galbraith, P. Beatty and D. J. 

Paustenbach. ChemRisk, San Francisco, CA. 

112 






Platform Sessions



Abstract # 


INDUCTION OF DNA DAMAGE BY 2, 2-BIS 

(BROMOMETHYL)-1, 3-PROPANEDIOL IN 

HUMAN URINARY BLADDER EPITHELIUM 

CELLS. W. Kong, R. Kuester, A. Gallegos and I. 

Sipes. Pharmacology, University of Arizona, Tucson, 

AZ. 


IN VITRO CYTOTOXICITY AND 

GENOTOXICITY OF SMOKELESS 

TOBACCO PRODUCTS. S. M. Barnard, D. B. 

Muldoon, M. L. Pauley, D. C. During, T. Oshunwusi 

and F. Z. Sheabar. Toxicology, Arista Laboratories, 

Richmond, VA. 


SYSTEMS BIOLOGY OF HUMAN BENZENE 

EXPOSURE. L. Zhang 1 , C. McHale 1 , N. Rothman 2 , 

G. Li 3 , Z. Ji 1 , R. Vermeulen 2 , A. Hubbard 1 , X. 

Ren 1 , M. Shen 2 , S. M. Rappaport 1 , M. North 1 , C. 

F. Skibola 1 , S. Yin 3 , C. Vulpe 1 , S. Chanock 2 , M. 

T. Smith 1 and Q. Lan 2 . 1 University of California, 

Berkeley, CA, 2 EGRP, NCI, NIH, Bethesda, MD and 

3 

China CDC, Beijing, China. 


DIINDOLYLMETHANE (DIM) REDUCES 

SURVIVAL OF HUMAN ACUTE T-CELL 

LYMPHOBLASTIC LEUKEMIA (T-ALL) 

CELLS IN VITRO. L. E. Shorey, A. D. Benninghoff 

and D. E. Williams. Environmental and Molecular 

Toxicology and The Linus Pauling Institute, Oregon 

State University, Corvallis, OR. 


THE ALTERATIONS OF P53 PROTEIN 

PHOSPHORYLATION AND RIBOSYLATION 

IN HUMAN BRONCHIAL EPITHELIAL 

CELLS EXPOSED TO 4-(METHYLNITRO- 

SAMINO)-1-(3-PYRIDYL)-1-BUTANONE. L. 

Chen 1 , C. Shao 1 , E. Cobos 2 , J. Wang 3 and W. Gao 1,2 . 

1 

The Institute of Environmental and Human Health 

(TIEHH), Lubbock, TX, 2 Texas Tech University 

Health Sciences Center, Lubbock, TX and 3 The 



MECHANISM AND BIOLOGICAL 

SIGNIFICANCE OF INFLAMMATION 

MEDIATORS IN CADMIUM INDUCED 

ONCOGENESIS IN PROSTATE EPITHELIAL 

CELLS. R. K. Singh and B. L. Lokeshwar. Urology, 

Univ of Miami, Miami, FL. 


DNA ADDUCT FORMATION IN DNA 

REPAIR DEFICIENT (XPA-/-, P53+/-) MICE 

FED BENZO[A]PYRENE (BP): A MODEL 

FOR ESOPHAGEAL CANCER. K. John 1 , 

M. M. Pratt 1 , M. I. Churchwel 2 , F. A. Beland 2 , 

G. McMullen 1 and M. C. Poirier 1 . 1 Carcinogen- 

DNA Interactions Section, LCBG, CCR, NCI, 

NIH, Bethesda, MD and 2 Division of Biochemical 

Toxicology, NCTR, Jefferson, AR. 


CYTOCHROME P450 2S1 INFLUENCES 

CELLULAR PROLIFERATION IN HUMAN 

PULMONARY CELLS. L. A. Montoya, T. 

P. Fidler and A. M. Rowland. Chemistry and 

Biochemistry, New Mexico State University, Las 

Cruces, NM. 

Abstract # 


CURCUMIN REGULATES CELL CYCLE 

PROGRESSION IN A P53-DEPENDENT 

MANNER IN RESPONSE TO BPDE- 

INDUCED DAMAGE. E. N. Rogers 1 and J. 

States 1,2,3 . 1 Pharamcology and Toxicology, University 

of Louisville, Louisville, KY, 2 Center for Genetics 

and Molecular Medicine, Louisville, KY and 3 Center 

for Environmental Genomics and Integrative Biology, 

Louisville, KY. 


EFFECT OF DIETHYL NITROSAMINE ON 

CYCLIN D1 AND PCNA EXPRESSION—AN 

IMMUNOHISTOCHEMICAL PERSPECTIVE. 

A. Sobhakumari 1 , C. Allamargot 1 , W. Xie 1 , L. W. 

Robertson 1 and H. P. Glauert 2 . 1 Human Toxicology 

program, The University of Iowa, Iowa City, IA and 

2 

Graduate Center for Nutritional Sciences, University 

of Kentucky, Lexington, KY. 


THE XRCC1 L360R POINT MUTATION 

SUPPRESSES PROGRESSION OF 

CARCINOGEN-INDUCED COLON CANCER. 

C. Pettan-Brewer, J. Goh, R. Coil, J. Morton and 

W. Ladiges. Comparative Medicine, University of 

Washington, Seattle, WA. 


DIFFERENTIAL DNA REPAIR IN 

HEMATOPOIETIC STEM AND 

PROGENITOR CELLS FOLLOWING 

GENOTOXIC DAMAGE BY BENZENE 

METABOLITES. D. Alexander 1 , M. Zimmer 3 , 

M. T. Smith 2 , E. C. Forsberg 3 and M. Camps 1 . 

1 

Microbiology and Environmental Toxicology, 

University of California Santa Cruz, Santa Cruz, CA, 

2 

Public Health, University of California Berkeley, 

Berkeley, CA and 3 School of Engineering, University 

of California Santa Cruz, Santa Cruz, CA. 


POTENTIATING EFFECT OF DIETARY 

FAT ON BENZO(A)PYRENE (BAP) 

BIOTRANSFORMATION AND COLON 

TUMORS IN APC MIN MICE. D. L. Harris 1 , D. B. 

Hood 2 , L. J. Roberts 3 and A. Ramesh 1 . 1 Biochemistry 

& Cancer Biology, Meharry Medical College, 

Nashville, TN, 2 Neuroscience & Pharmacology, 

Meharry Medical College, Nashville, TN and 

3 

Pharmacology, Vanderbilt University, Nashville, TN. 


THE ROLES OF CR(VI) AND ITS 

REDUCTIVE INTERMEDIATES 

IN APOPTOSIS THROUGH THE 

MITOCHONDRIAL INTRINSIC PATHWAY. 

A. O. Chiu 1 , R. Hill 2 , P. W. Lee 2 , N. H. Chiu 3 and J. 

D. Robertson 4 . 1 NCEADC, U.S. EPA, Washington, 

DC, 2 Microbiology/Immunology, Dalhousie 

University, Halifax, NS, Canada, 3 Office of 

Science & Technology, Office of Water, U.S. EPA, 

Washington, DC and 4 Pharmacology, Toxicology, 

Therapeutics, University of Kansas Medical Center, 

Kansas City, KS. Sponsor: J. Landolph. 

MOnday 







113


MOnday 




PROFILING THE MODE OF ACTION FOR 

LIVER TUMORS IN B6C3F1 MICE EXPOSED 

TO METHYL ISOBUTYL KETONE (MIBK). 

D. Geter 1 , N. A. Berdasco 1 , W. Gulledge 2 , R. Gingell 3 

and S. Green 4 . 1 The Dow Chemical Company, 

Midland, MI, 2 American Chemistry Council, 

Arlington, VA, 3 Shell Oil Company, Houston, TX 

and 4 Eastman Chemical Company, Kingsport, TN. 


CANNABINOIDS DECREASE CANCER 

CELL GROWTH AND INHIBIT SP 

TRANSCRIPTION FACTORS. S. Sreevalsan 1 , S. 

Safe 1,2 and N. E. Kaminski 3 . 1 Veterinary Physiology 

and Pharmacology, Texas A & M University, College 

Station, TX, 2 Center for Environmental and Genetic 

Medicine, Institute of Biosciences and Technology, 

Texas A & M Health Science Center, Houston, TX 

and 3 Center for Integrative Toxicology, Michigan 

State University, East Lansing, MI. 


THE URINARY BLADDER CARCINOGEN 

PROPOXUR DOES NOT INDUCE 

GENOTOXIC EFFECTS IN THE URINARY 

BLADDER OF WISTAR MALE RATS. A. 

M. Jeffrey 1 , G. M. Williams 1 , M. J. Iatropoulos 1 , 

J. Duan 1 and G. Schmuck 2 . 1 Pathology, New York 

Medical College, Valhalla, NY and 2 Bayer Schering 

Pharmacology AG, Wuppertal, Germany. 


OXIDATIVE DNA DAMAGE AND HUMAN 

ESOPHAGEAL CANCER RISK IN HUAIAN, 

CHINA. L. Xu 1 , L. Tang 1 , X. Wang 2 , Z. Wang 3 , 

G. Sun 4 , S. Wang 4 , X. Hu 5 and J. S. Wang 1 . 

1 

Environmental Health Science, University of 

Georgia, Athens, GA, 2 University of Iowa, Iowa 

City, IA, 3 Indiana University, Indianapolis, IN, 

4 

Southeast University, Nanjing, China and 5 Chuzhou 

CDC, Huaian, China. 


DISTRIBUTION AND MOLECULAR 

DOSE OF INHALATION-DERIVED AND 

ENDOGENOUS FORMALDEHYDE 

DNA ADDUCTS SUPPORT CAUSATION 

OF NASAL CARCINOMA, BUT NOT 

LEUKEMIA. K. Lu 1 , L. B. Collins 1 , H. Ru 2 , E. 

Bermudez 3 and J. A. Swenberg 1 . 1 Environmental 

Sciences and Engineering, University of North 

Carolina, Chapel Hill, NC, 2 Department of 

Statistics and Operation Research, University of 

North Carolina, Chapel Hill, NC and 3 The Hamner 

Institutes for Health Sciences, Research Triangle 

Park, NC. 


RESVERATROL-MEDIATED 

CHEMOPREVENTION OF TCDD-INDUCED 

SKIN CARCINOGENESIS. N. P. Singh, 

M. Nagarkatti and P. Nagarkatti. Pathology, 

Microbiology, and Immunology, University of South 

Carolina School of Medicine, Columbia, SC. 


9:30 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Epigenetics 

Chairperson(s): Diego Montoya-Durango, University of Louisville, 

Louisville, KY, and Alvaro Puga, University of Cincinnati, Cincinnati, 

OH. 




CHANGES IN DNA METHYLATION 

AND GENE EXPRESSION DURING 

TCDD-INDUCED INHIBITION OF 

LIPOPOLYSACCHARIDE (LPS)- 

STIMULATED B-CELL DIFFERENTIATION 

IN SPLENOCYTES. E. A. McClure 1,2,3 , C. M. 

North 2,3 , N. E. Kaminski 2,3 and J. I. Goodman 2,3 . 

1 

MMG, Michigan State University, East Lansing, MI, 

2 

PHM/Toxicology Michigan State University, East 

Lansing, MI and 3 CIT, Michigan State University, 

East Lansing, MI. 


EPIGENETIC MODIFICATIONS OF 

METALLOTHIONEIN GENE IN MOUSE 

LIVER INDUCED BY INSUFFICIENT ZINC 

STATUS IN UTERO. H. Kurita 1 , S. Ohsako 1 , 

J. Yoshinaga 2 and C. Tohyama 1 . 1 Laboratory of 

Environmental Health Sciences, Center for Disease 

Biology and Integrative Medicine, Graduate School 

of Medicine, The University of Tokyo, Tokyo, Japan 

and 2 Department of Environmental Studies, Graduate 

School of Frontier Sciences, The University of 

Tokyo, Tokyo, Japan. 


LOW LEVEL CHILDHOOD LEAD 

EXPOSURE RESULTS IN A DIVERSE 

PATTERN OF DNA METHYLATION. J. S. 

Schneider 1 , J. Chen 3 , C. Szeto 3 , D. W. Anderson 1 , B. 

P. Lanphear 2 and S. Ho 3 . 1 Pathol., Anat. & Cell Biol., 

Thomas Jefferson University, Phila., PA, 2 Child & 

Family Res. Inst., BC Children’s Hosp. & Simon 

Fraser University, Vancouver, BC, Canada and 

3 

Environment Hlth. & Ctr. for Environment Genetics, 

University Cin. Med. Ctr., Cin., OH. 


DNA METHYLATION AFFECTS STRAIN- 

DEPENDENT SUSCEPTIBILITY TO 

NONALCOHOLIC STEATOHEPATITIS 

(NASH)-INDUCED LIVER INJURY IN MICE. 

V. Tryndyak 1 , D. M. Gatti 2 , I. Rusyn 2 , F. A. Beland 1 

and I. P. Pogribny 1 . 1 Biochemical Toxicology, 

FDA-National Center for Toxicological Research, 

Jefferson, AR and 2 Environmental Sciences and 

Engineering, University of North Carolina at Chapel 

Hill, Chapel Hill, NC. 


HISTONE MODIFICATION IN ARSENITE- 

MEDIATED ANTIOXIDANT GENE 

REGULATION. P. D. Ray and Y. Tsuji. 

Environmental and Molecular Toxicology, North 

Carolina State University, Raleigh, NC. Sponsor: J. 

Ninomiya-Tsuji. 

114 






Platform Sessions



Abstract # 


REACTIVATION OF L1 

RETROTRANSPOSON BY BENZO(A) 

PYRENE INVOLVES EPIGENETIC 

MECHANISMS. D. E. Montoya-Durango 1,2 , I. 

Teneng 1,2 , J. L. Quertermous 1,2 , V. Stribinskis 1,2 and K. 

S. Ramos 1,2 . 1 Biochemistry and Molecular Biology, 

University of Louisville, Louisville, KY and 2 Center 

for Genetics and Molecular Medicine, University of 

Louisville, Louisville, KY. 


BISPHENOL A UNLOCKS THE RAT PDE4D4 

PROMOTER VIA EPIGENETICS. W. Tang 

and S. Ho. Environmental Health, University of 

Cincinnati College of Medicine, Cincinnati, OH. 


REACTIVATION OF THE EPIGENETICALLY 

SILENCED TUMOR SUPPRESSOR GENE - 

TISSUE FACTOR PATHWAY INHIBITOR-2 

(TFPI-2) BY CURCUMIN CAUSES 

CELL DEATH IN HEPATOCELLULAR 

CARCINOMA CELLS. A. Moghe 1 , A. S. Barve 3 , 

S. Ghare 2 , L. Gobejishvili 2 , S. Joshi-Barve 2 , C. 

J. McClain 2,1 and S. Barve 2,1 . 1 Pharmacology and 

Toxicology, University of Louisville, Louisville, 

KY, 2 Internal Medicine, University of Louisville, 

Louisville, KY and 3 University of Louisville, 



HYPOXIA INDUCES TRI-METHYLATED 

H3 LYSINE 4 BY INHIBITION OF JARID1A 

DEMETHYLASE. X. Zhou 1 , H. Sun 1 , H. Chen 1 , 

J. Zavadil 2 , T. Kluz 1 and M. Costa 1 . 1 Department 

of Environmental Medicine, Nelson Institute of 

Environmental Medicine, New York University 

School of Medicine, Tuxedo, NY and 2 Department of 

Pathology, New York University Cancer Institute and 

Center for Health Informatics and Bioinformatics, 

New York University Langone Medical Center, New 

York. 


ROLE OF EPIGENETIC MECHANISMS IN 

DIFFERENTIAL REGULATION OF THE 

DIOXIN-INDUCED HUMAN CYP1A1 AND 

CYP1B1 GENES. S. R. Beedanagari and O. 

Hankinson. Molecular Toxicology, UCLA, Los 

Angeles, CA. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Neurodevelopmental Toxicity: General 

Chairperson(s): Tamara Tal, Oregon State University, Corvallis, OR, and 

Stephan Carey, Michigan State University, East Lansing, MI. 




THE EFFECTS OF DEVELOPMENTAL 

EXPOSURE TO PCBS AND/OR PBDES 

ON AUDITORY FUNCTION. E. Poon 1 , B. 

E. Powers 2 , R. M. McAlonan 1 and S. L. Schantz 1 . 

1 

Univerisity of Illinois, Urbana, IL and 2 Cornell 

University, Ithaca, NY. 

Abstract # 


RODENT AND HUMAN 

NEUROPROGENITOR CELLS FOR HIGH- 

CONTENT SCREENS OF CHEMICAL 

EFFECTS ON PROLIFERATION AND 

APOPTOSIS. M. E. Culbreth 2 , T. M. Freudenrich 1 , 

B. Robinette 1 , J. A. Harrill 1 , W. R. Mundy 1 and T. J. 

Shafer 1 . 1 ISTD, U.S. EPA, Research Triangle Park, 

NC and 2 Biochemistry, NC State University Raleigh, 

NC. 


MARBLE-BURYING BEHAVIOR IN PCB- 

EXPOSED MICE DIFFERING AT THE 

CYP1A2 LOCUS. B. Hays, R. Floyd, E. 

Altenhofen, C. Kamau-cheggeh, S. Kraemer and C. 

Curran. Biological Sciences, Northern Kentucky 

University, Highland Heights, KY. 


DEVELOPMENTAL THYROID HORMONE 

INSUFFICIENCY IMPAIRS VISUAL 

CONTRAST SENSITIVITY IN ADULT MALE 

OFFSPRING. M. E. Gilbert, L. Degn and W. 

Boyes. Toxicity Assessment Division, U.S. EPA, 

Research Triangle Pk, NC. 


PREDICTING THE ACUTE BEHAVIORAL 

EFFECTS IN RATS INHALING TOLUENE 

FOR UP TO 24 HRS: INHALED VS. 

INTERNAL DOSE METRICS. W. M. Oshiro, 

Q. T. Krantz, C. J. Gordon, E. M. Kenyon and P. 

J. Bushnell. Office of Research and Development, 

National Health Effects and Environmental Research 

Laboratory, U.S. EPA, Research Triangle Park, NC. 


DEVELOPMENTAL HYPOTHYROIDISM 

ALTERS BRAIN-DERIVED NEUROTROPHIC 

FACTOR (BDNF) EXPRESSION IN 

ADULTHOOD. S. M. Lasley 1 and M. E. Gilbert 2 . 

1 

Cancer Biology & Pharmacology, University of 

Illinois College of Medicine, Peoria, IL and 2 Toxicity 

Assessment Division, U. S. EPA, Research Triangle 

Park, NC. 


VALPROATE-INDUCED ABNORMAL 

DEVELOPMENT NEUROTOXICITY: FETAL 

BRAIN OBSERVATION VERSUS POSTNATAL 

BRAIN OBSERVATION. M. Kuwagata 1,3 , T. 

Ogawa 2,3 , S. Shioda 3 and T. Nagata 1 . 1 Lab. Pathology, 

Toxicology, Hatano Research Institute, FDSC, 

Kanagawa, Japan, 2 Anti-aging Medicine Funded 

Research Labs, Show University Schoo of Medicine, 

Tokyo, Japan and 3 Anatomy I, Show University 

Schoo of Medicine, Tokyo, Japan. 


DEVELOPMENTAL EXPOSURE TO 

PURITY CONTROLLED PCB52 AND 

PCB180 IN RATS: DIFFERENT PROFILES 

OF NEUROTOXICITY. H. H. Lilienthal 1 , P. 

Heikkinen 2 , C. Danielsson 3 , P. Andersson 3 and M. 

Viluksela 2 . 1 Center of Toxicology, Research Institute 

for Occupational Medicine, Ruhr University of 

Bochum, Bochum, Germany, 2 Department of 

Environmental Health, THL - National Institute 

for Health and Welfare, Kuopio, Finland and 

3 

Department of Chemistry, Umea University, Umea, 

Sweden. 

MOnday 







115


MOnday 




MICROPET IMAGING OF [18F]-DFNSH 

IN RAT BRAIN: A RADIOLIGAND FOR 

KETAMINE-INDUCED NEURONAL DEATH. 

X. Zhang 1 , M. G. Paule 1 , G. D. Newport 1 , X. Zou 1 , 

N. Sadovova 2 , M. S. Berridge 3 , S. M. Apana 3 , G. 

Kabalka 4 , W. Slikker 1 and C. Wang 1 . 1 Division of 

Neurotoxicology, NCTR/FDA, Jefferson, AR, 

2 

Toxicologic Pathology Associates, Jefferson, 

AR, 3 3D Imaging, LLC, Little Rock, AR and 4 The 

University of Tennessee, Knoxville, TN. 


IN VITRO ASSESSMENT OF 

DEVELOPMENTAL NEUROTOXICITY: 

USE OF MICROELECTRODE ARRAYS TO 

MEASURE FUNCTIONAL CHANGES IN 

NEURONAL NETWORK ONTOGENY. B. 

Robinette, W. R. Mundy and T. J. Shafer. ISTD, U.S. 

EPA, Research Triangle Park, NC . 


EVALUATING ALTERATIONS IN 

ZEBRAFISH RETINO-TECTAL 

PROJECTIONS AS AN INDICATION OF 

DEVELOPMENTAL NEUROTOXICITY. 

J. Cowden 1,2 , C. Fan 1,3 , D. Hunter 1 , B. Padnos 1 , 

K. Jensen 1 , R. Ramabhadran 1 and S. Padilla 1 . 

1 

Integrated Systems Toxicology Division, U.S. EPA, 

Durham, NC, 2 National Center for Environmental 

Assessment, U.S. EPA, Durham, NC and 3 Syngenta 

Biotechnology Inc., Durham, NC. 


METHYLPHENIDATE: A THREE-YEAR 

ASSESSMENT ON COMPLEX BRAIN 

FUNCTION IN JUVENILE RHESUS 

MONKEYS. T. A. Patterson 1 , M. Li 1 , S. M. 

Morris 1 , N. C. Twaddle 1 , D. R. Doerge 1 , W. Slikker 1 , 

D. R. Mattison 2 and M. G. Paule 1 . 1 NCTR/FDA, 

Jefferson, AR and 2 NICHD, Rockville, MD. 


STUDIES OF LONG-TERM PROTEIN 

CHANGES IN RATS NEONATALLY 

TREATED WITH THE CYANOBACTERIAL 

TOXIN b-N-METHYLAMINO-L-ALANINE 

(BMAA) USING MALDI IMAGING MASS 

SPECTROMETRY. O. Karlsson, E. Roman, 

E. Brittebo and M. Andersson. Pharmaceutical 

Biosciences, Uppsala University, Uppsala, Sweden. 

Sponsor: M. Stigson. 


EFFECT OF DEVELOPMENTAL 

CHLORPYRIFOS EXPOSURE ON 

ENDOCANNABINOID METABOLIZING 

ENZYMES IN THE BRAIN OF JUVENILE 

RATS. R. L. Carr and M. K. Ross. Center for 

Environmental Health Sciences, Mississippi State 

University, Mississippi State, MS. 


PHENCYCLIDINE (PCP) INDUCED 

CELL DEATH AND CHANGES IN GENE 

EXPRESSION. F. Liu 1 , N. Sadovova 3 , X. Zou 1 , 

X. Zhang 1 , L. Shi 2 , L. Guo 2 , F. Qian 4 , Z. Wen 4 , T. 

Patterson 1 , J. Hanig 5 , M. Paule 1 , W. Slikker 1 and 

C. Wang 1 . 1 Division of Neurotoxicology, National 

Center for Toxicological Research, Jefferson, AR, 

2 

Division of Systems Toxicology, National Center 

for Toxicological Research/U.S. FDA, Jefferson, AR, 

3 

Toxicologic Pathology Associates, Jefferson, AR, 

4 

Z-Tech, an ICF International Company at NCTR, 

Jefferson, AR and 5 Center for Drug Evaluation and 

Research/U.S. FDA, Silver Spring, MD. 


RECOMMENDATIONS FOR DEVELOPING 

ALTERNATIVE TEST METHODS FOR 

DEVELOPMENTAL NEUROTOXICITY. 

K. Crofton 1 , L. Buzanska 2 , S. Coecke 2 , H. Knaut 3 , 

P. Lein 4 , W. Mundy 1 , A. Price 2 , A. Seiler 5 and 

A. Goldberg 6 . 1 Integrated Systems Toxicology, 

U.S. EPA, Research Triangle Park, NC, 2 Joint 

Research Council, Ispra, Italy, 3 Skirball Institute, 

New York University School of Medicine, NYC, 

NY, 4 Molecular Biosciences, U.S. Davis, Davis, 

CA, 5 ZEBET, Berlin, Germany and 6 CAAT, Johns 

Hopkins University, Baltimore, MD. 


ASSESSING LATER-LIFE BEHAVIORAL 

PHENOTYPES IN RESPONSE TO PRENATAL 

EXPOSURE TO BENZOPYRENE. M. 

McCallister 1 , M. Maguire 1 , A. Ramesh 3 and D. 

B. Hood 1,2 . 1 Center for Molecular and Behavioral 

Neuroscience, Meharry Medical College, Nashville, 

TN, 2 Department of Pharmacology and The Brain 

Institute, Vanderbilt University School of Medicine, 

Nashville, TN and 3 Department of Biochemistry 

and Cancer Biology, Meharry Medical College, 

Nashville, TN. 


THE DEVELOPMENTAL NEUROTOXICITY 

OF MICRORNAS: NICOTINE-INDUCED 

DEFECTS IN MOTOR NEURON AXON 

GUIDANCE AND BEHAVIOR. T. Tal 1 , J. 

A. Franzosa 1 , E. Menelaou 2 , K. Svoboda 2 and 

R. L. Tanguay 1 . 1 Environmental and Molecular 

Toxicology, Oregon State University, Corvallis, OR 

and 2 Biological Sciences, Louisiana State University, 

Baton Rouge, LA. 


GENETIC SUSCEPTIBILITY TO PCB- 

INDUCED MOTOR DYSFUNCTION. E. 

Altenhofen, R. Floyd, A. Mynhier, S. Kraemer, 

B. Hays, C. Kamau-cheggeh and C. P. Curran. 

Biological Sciences, Northern Kentucky University, 

Highland Heights, KY. 


PERINATAL DIOXIN EXPOSURE INDUCES 

LOW-DOSE SPECIFIC EFFECTS ON 

LEARNING AND AFFECTIVE FUNCTION IN 

ADULT MALE MICE. T. Endo, C. Tohyama and 

M. Kakeyama. Laboratory of Environmental Health 

Sciences, Center for Disease Biology and Integrative 

Medicine (CDBIM), Faculty and Graduate School of 

Medicine, The University of Tokyo, Tokyo, Japan. 

116 






Platform Sessions



Abstract # 


GENETIC SUSCEPTIBILITY TO 

PCB-INDUCED DEVELOPMENTAL 

NEUROTOXICITY. R. Floyd 1 , A. Mynhier 2,1 , 

E. Altenhofen 1 , S. Kraemer 1 , B. Hays 1 , C. Kamaucheggeh 

1 and C. P. Curran 1 . 1 Biological Sciences, 

Northern Kentucky University, Highland Heights, 

KY and 2 Eastern Kentucky University, Richmond, 

KY. 


NEONATAL LOW DOSE EXPOSURE 

OF FEMALE MICE TO NICOTINE 

ALTERS ADULT SUSCEPTABILITY TO 

PARAOXON MANIFESTED AS PERSISTENT 

NEUROBEHAVIORAL DEFECTS AND 

INCREASED LEVELS OF PROTEIN TAU. 

P. Eriksson, H. Viberg, N. Johansson, F. Luo and 

A. Fredriksson. Department of Environmental 

Toxicology, Uppsala University, Uppsala, Sweden. 


NON-COPLANAR PCBS INCREASE 

SPONTANEOUS SYNCHRONIZED 

CALCIUM OSCILLATIONS IN PRIMARY 

HIPPOCAMPAL NEURONS. D. D. Bose, E. 

S. Kaplan, P. J. Lein and I. N. Pessah. Veterinary 

Molecular Biosciences, University of California, 



DETECTION OF BRDU-INDUCED 

DEVELOPMENTAL NEUROTOXICITY BY 

IMMUNOHISTOCHEMICAL OBSERVATION 

OF PARVALBUMIN. T. Ogawa 1 , M. Kuwagata 2,3 , 

T. Nagata 3 and S. Shioda 2 . 1 Antiaging Medicine, 

Showa University School of Medicine, Shinagawaku, 

Japan, 2 Anatomy, Showa University School 

of Medicine, Tokyo, Japan and 3 Laboratory of 

Pathology, Division of Toxicology, Hatano Research 

Institute, FDSC, Kanagawa, Japan. 


GENE EXPRESSION PROFILING IN THE 

DEVELOPING RAT BRAIN EXPOSED 

TO KETAMINE. N. V. Sadovova 1 , Q. Shi 2 , L. 

Guo 2 , T. Patterson 3 , Q. Li 4 , J. Hanig 5 , M. Paule 3 , 

W. Slikker 3 and C. Wang 3 . 1 TPA, Jefferson, AR, 

2 

Systems Toxicology, NCTR/FDA, Jefferson, AR, 

3 

Neurotoxicology, NCTR/FDA, Jefferson, AR, 

4 

Microarray Core Facility, UTSW Medical Center, 

Dallas, TX and 5 CDER/FDA, Silver Spring, MD. 


PRENATAL INHALED B(A)P EFFECTS ON 

REVERSAL BEHAVIORAL LEARNING IN 

A CPR MOUSE MODEL. R. Rhoades 2 , M. 

Maguire 1 , A. Ramesh 3 , M. McCallister 1 and D. 

B. Hood 1,2 . 1 Center for Molecular and Behavioral 

Neuroscience, Meharry Medical College, Nashville, 

TN, 2 Department of Pharmacology and The Brain 

Institute, Vanderbilt University School of Medicine, 

Nashville, TN and 3 Department of Biochemistry 

and Cancer Biology, Meharry Medical College, 


Abstract # 


DESIGN OF AN IN VITRO 

DEVELOPMENTAL NEUROTOXICITY 

(VITDNT) SCREENING ASSAY FOR 

NEURONAL DIFFERENTIATION USING 

HUMAN NT2/D1 CELLS. M. Taylor, L. Kan 

and S. Marty. TERC, The Dow Chemical Company, 

Midland, MI. 


STATISTICAL POWER IN THE ANALYSES 

OF BRAIN WEIGHT MEASURES IN 

PESTICIDE NEUROTOXICITY TESTING 

AND THE RELATIONSHIP BETWEEN 

BRAIN AND BODY WEIGHT. S. Weichenthal 1 , 

S. Hancock 1 and K. Raffaele 2 . 1 Health Canada, 

Ottawa, ON, Canada and 2 U.S. EPA, Washington, 

DC. 


C6 GLIOMA CELL VIABILITY AFTER 

DNB EXPOSURE IS INCREASED BY 

PRETREATMENT WITH N-ACETYL-L- 

CYSTEINE. B. Rivera and R. T. Miller. Biological 

Sciences, University of Texas at El Paso, El Paso, 

TX. 


MITOCHONDRIAL GENOTOXICITY 

DURING DEVELOPMENT LEADS TO 

DOPAMINERGIC NEURODEGENERATION 

IN ADULT CAENORHABDITIS ELEGANS. 

M. C. Leung 1 , A. E. Arrant 2 , A. M. Smith 1 , M. 

McKeever 1 , K. M. Margillo 1 , T. L. Crocker 1 and J. 

N. Meyer 1 . 1 Nicholas School of the Environment, 

Duke University, Durham, NC and 2 Department of 

Pharmacology and Cancer Biology, Duke University, 

Durham, NC. 


9:30 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Screening and Predicting Toxicity: 

Computational Approaches to Identify Targets 

Chairperson(s): George Acquaah-Mensah, Massachusetts College of 

Pharmacy & Health Sciences, Worcester, MA. 




USING IN VITRO DOSE-RESPONSE 

PROFILES TO ENHANCE QSAR MODELING 

OF IN VIVO TOXICITY. A. Sedykh 1 , H. Zhu 1 , 

H. Tang 1 , L. Zhang 1 , A. Richard 2 , I. Rusyn 1 and A. 

Tropsha 1 . 1 University of North Carolina, Chapel Hill, 

NC and 2 NCCT, U.S. EPA, Research Triangle Park, 

NC . 


STRUCTURE-ACTIVITY RELATIONSHIPS 

OF MITOCHONDRIAL UNCOUPLERS. R. 

T. Naven and Y. Will. Compound Safety Prediction, 

Pfizer Inc., Groton, CT. 

MOnday 







117


MOnday 




USING KINASE SELECTIVITY PROFILES 

TO IDENTIFY KINASES THAT CORRELATE 

AND PREDICT BONE MARROW TOXICITY. 

A. J. Olaharski 1 , H. Bitter 3 , N. Gonzaludo 2 , D. 

Goldstein 2 and K. Kolaja 1 . 1 Non Clinical Safety, 

Hoffmann-La Roche, Nutley, NJ, 2 Roche, Palo Alto, 

NJ and 3 Informatics, Hoffmann-La Roche, Nutley, 

NJ. 


STRUCTURE-ACTIVITY RELATIONSHIP 

ANALYSIS OF MAMMARY CARCINOGENS: 

USING CHEMICAL-PROTEIN BINDING 

POTENTIALS AS NOVEL AND 

BIOLOGICALLY RELEVANT MODEL 

DESCRIPTORS. A. R. Cunningham 1,2 , S. Qamar 1 , 

C. Carrasquer 1 , P. A. Holt 1 , J. M. Maquire 1 , S. L. 

Cunningham 2 and J. O. Trent 1 . 1 James Graham 

Brown Cancer Center, University of Louisville, 

Louisville, KY and 2 Gnarus System, Inc., Louisville, 

KY. 


MOLECULAR DESCRIPTORS, 

PHYSICOCHEMICAL, AND 

EXPERIMENTAL PARAMETERS THAT 

ARE INDICATIVE/PREDICTIVE FOR A 

PHOTOTOXIC POTENTIAL. A. Czich 1 , A. 

Amberg 1 , H. P. Spirkl 1 , A. Mann 1 , I. Stammberger 1 , 

G. Troschau 1 , H. Donaubauer 1 , K. Lindauer 1 , A. 

Evers 1 , F. Schmidt 1 , B. Molinier 2 and C. Robles 2 . 

1 

R&D, sanofi aventis, Frankfurt, Germany and 

2 

R&D, sanofi aventis, Montpellier, France. Sponsor: 

M. Bonnefoi. 


CHALLENGES IN APPLYING 

COMPUTATIONAL STRUCTURE-ACTIVITY 

RELATIONSHIP (SAR) MODELING 

FOR PREDICTING TOXICOLOGICAL 

ENDPOINTS FOR RISK ASSESSMENT. A. J. 

Duggan 2 and L. J. McIntosh 1 . 1 Exponent, Inc., Menlo 

Park, CA and 2 Exponent, Inc., Philadelphia, PA. 


THE COMPARISON OF TOXICOGENOMICS 

DATA USING THE GENE SET ENRICHMENT 

ANALYSIS FOR BRIDGING BETWEEN IN 

VIVO AND IN VITRO. Y. Igarashi 1 , Y. Okuno 2 , 

Y. Minowa 1 , N. Nakatsu 1 , A. Ono 3 , H. Yamada 1 , Y. 

Ohno 3 and T. Urushidani 4,1 . 1 National Institute for 

Biomedical Innovation, Ibaraki-City, Osaka, Japan, 

2 

Kyoto University, Kyoto, Japan, 3 National Institute 

of Health Sciences, Tokyo, Japan and 4 Doshisha 

Women’s College, Kyoto, Japan. 


USING TOXCAST IN VITRO ASSAYS IN 

THE HIERARCHICAL QUANTITATIVE 

STRUCTURE-ACTIVITY RELATIONSHIP 

(QSAR) MODELING FOR PREDICTING IN 

VIVO TOXICITY OF CHEMICALS. L. Zhang 1 , 

H. Zhu 1 , A. Sedykh 1 , H. Tang 1 , A. M. Richard 2 , I. 

Rusyn 1 and A. Tropsha 1 . 1 UNC, Chapel Hill, NC and 

2 

NCCT, U.S. EPA, Research Triangle Park, NC . 


COPD: TRANSCRIPTIONAL REGULATORY 

RELATIONSHIPS IMPACTING THE 

GENETIC SUSCEPTIBILITY GENE 

PRODUCT, COL4A3. G. Acquaah-Mensah 1 , D. 

Maholtra 2 and S. Biswal 2 . 1 Pharmaceutical Sciences, 

Massachusetts College of Pharmacy & Health 

Sciences, Worcester, MA and 2 Bloomberg School of 

Public Health, Johns Hopkins University, Baltimore, 

MD. 


A CONSTRAINT-BASED STOICHIOMETRIC 

MODEL OF THE STEROIDOGENIC 

NETWORK OF ZEBRAFISH (DANIO 

RERIO). D. Hala and D. B. Huggett. Biology, 

University of North Texas, Denton, TX. Sponsor: J. 

Harbell. 


PREDICTING THE DEVELOPMENTAL 

TOXICITY OF FOOD ADDITIVES AND 

RELATED COMPOUNDS USING EXPERT 

RULE AND QSAR PROGRAMS. J. Mayer. Food 

and Drug Administration (FDA), Center for Food 

Safety and Applied Nutrition (CFSAN), College 

Park, MD. Sponsor: W. Roth. 


A STATISTICAL FRAMEWORK FOR 

ANALYZING QUANTITATIVE HIGH- 

THROUGHPUT SCREENING DATA (QHTS). 

K. Shockley 1 , G. Kissling 1 , R. Huang 2 , M. Xia 2 , C. 

Austin 2 and R. Tice 1 . 1 National Toxicology Program/ 

National Inistitute of Environmental Health Sciences, 

Research Triangle Park, NC and 2 NIH Chemical 

Genomics Center, Bethesda, MD. 


DATA ANALYSIS STRATEGIES FOR LARGE- 

SCALE SYSTEMS TOXICOLOGY. A. 

Brandenburg and H. Gmuender. Genedata AG, Basel, 

Switzerland. Sponsor: F. Pfannkuch. 


HIGH-THROUGHPUT PRIORITIZATION 

FOR INTEGRATED TOXICITY TESTING 

BASED ON TOXCAST CHEMICAL 

PROFILING. D. M. Reif 1 , K. A. Houck 1 , R. 

S. Judson 1 , R. J. Kavlock 1 , T. B. Knudsen 1 , M. T. 

Matthew 1 , A. M. Richard 1 , I. Shah 1 , T. Carpenter 2 and 

D. J. Dix 1 . 1 ORD, U.S. EPA, Research Triangle Park, 

NC and 2 OW, U.S. EPA, Washington, DC. 


DEVELOPMENT OF A MULTIPARAMETER, 

CELL-BASED IN VITRO MODEL FOR THE 

PREDICTION OF SYSTEMIC TOXICITY. R. 

R. Note 1 , H. Nocairi 1 , M. Thomas 1 , L. Bourouf 1 , J. 

M. McKim 2 , G. Ouédraogo 1 and J. Meunier 1 . 1 Safety 

Research, L’Oréal, Aulnay Sous Bois, France and 

2 

Ceetox, Kalamazoo, MI. Sponsor: G. Nohynek. 


TOWARDS IN VITRO SUBCELLULAR 

TOXICOLOGY SCREENING, 

IMPLEMENTING NOVEL ORGANELLE 

ACTIVITY ASSAYS FOR ENVIRONMENTAL 

CONTAMINANT TESTING. W. F. Patton, J. 

Coleman, N. Kelkar, Y. Xiang, Z. Li, P. Pande and D. 

Shen. R&D, Enzo Life Sciences, Farmingdale, NY. 

Sponsor: C. Corton. 

118 






Platform Sessions



Abstract # 


IN VITRO SCREENING FOR POPULATION 

VARIABILITY IN CHEMICAL TOXICITY. S. 

H. O’Shea 1 , J. Schwarz 2 , O. Kosyk 1 , R. K. Pamela 1 , 

F. A. Wright 2 and I. Rusyn 1 . 1 Environmental Sciences 

and Engineering, UNC Gillings School of Global 

Public Health, Chapel Hill, NC and 2 Biostatistics, 

UNC Gillings School of Global Public Health, 

Chapel Hill, NC. 


PREDICTING ACTIVATION ENTHALPIES 

OF CYTOCHROME-P450-MEDIATED 

HYDROGEN ABSTRACTIONS: 

COMPARISON OF SEMI-EMPIRICAL 

PM3, SAM1, AND AM1 WITH A DENSITY 

FUNCTIONAL THEORY METHOD. J. L. 

Robinson 1,2 , B. Reisfeld 2,1 and A. N. Mayeno 1 . 

1 

Environmental & Radiological Health Sciences, 

Colorado State University, Fort Collins, CO and 

2 

Chemical & Biological Engineering, Colorado State 

University, Fort Collins, CO. 


THE TOXICANT-TARGET PARADIGM 

FOR TOXICITY SCREENING— 

PHARMACOPHORE BASED CONSTRAINTS. 

J. Rabinowitz 1 , S. Little 1 , T. Transue 2 and M. 

Goldsmith 3 . 1 NCCT/ORD/EPA, Research Triangle 

Park, NC, 2 Lockheed-Martin, Research Triangle 

Park, NC and 3 NERL/ORD/EPA, Research Triangle 

Park, NC . 


EXPANSION OF A PHOSPHOLIPIDOSIS 

DATABASE FOR QSAR MODELING WITH 

MULTIPLE SOFTWARE PLATFORMS. A. 

M. Orogo 1,2 , S. S. Choi 1 , B. L. Minnier 1,2 and N. 

L. Kruhlak 1 . 1 Office of Pharmaceutical Science, 

CDER, U.S. FDA, Silver Spring, MD and 2 GlobalNet 

Services, Inc., Rockville, MD. Sponsor: L. Valerio. 


DECISION TREES FOR THE OECD 

TOOLBOX, A PRIMARY LOCAL 

QSAR MODEL BUILDER FOR GREEN 

CHEMISTRY INITIATIVES. S. Maxey, G. Mao, 

J. Chan, H. W. Kim and D. E. Johnson. Nutr Sciences 

& Toxicology, Univ Calif, Berkeley, Berkeley, CA. 


COMPUTATIONAL ASSESSMENT OF 

PATHWAYS UNDERLYING DRUG INDUCED 

CARDIAC TOXICITY. A. Enayetallah and N. 

Greene. Compound Safety Prediction (CSP) - PGRD, 

Pfizer Inc., Groton, CT. 


TOWARDS A CELLULAR METABOLISM 

BASED PREDICATIVE MODEL 

OF CARDIOMYOPATHY USING 

HUMAN EMBRYONIC STEM CELL 

DERIVED CARDIOMYOCYTES AND 

METABOLOMICS. A. Smith 1 , A. M. Weir 1 , P. R. 

West 1 , J. T. Davis 1 , E. R. Donley 1 and G. G. Cezar 2 . 

1 

Stemina Biomarker Discovery, Inc., Madison, WI 

and 2 Animal Sciences, University of Wisconsin, 

Madison, WI. 

Abstract # 


HIGH-THROUGHPUT SCREENING ASSAY 

FOR ASSESSING PHOSPHOLIPIDOSIS 

INDUCING POTENTIAL OF DRUGS. C. 

Haber 1 , J. Mole 1 , K. Box 1 , P. Vitovic 2 , P. Kinnunen 2 

and J. Alakoskela 2 . 1 Sirius Analytical, Beverly, 

MA and 2 Institute of Biomedicine/Biochemistry, 

University of Helsinki, Helsinki, Finland. 


PERSISTENT ORGANIC POLLUTANTS, 

CYTOCHROME P450 INTERACTIONS, AND 

METABOLIC DISEASES: QUANTITATIVE 

STRUCTURE ACTIVITY RELATIONSHIP 

(QSAR) ANALYSIS. P. Ruiz, O. Faroon, 

B. A. Fowler, H. Hansen and M. M. Mumtaz. 

Computational Toxicology and Methods 

Development Lab, ATSDR, Atlanta, GA. 


SCIENTIFIC RECONSTRUCTION OF 

PROFILES OF GENE EXPRESSION IN 

RATS EXPOSED TO FORMALDEHYDE. L. 

Kopylev 2 , T. Kachanova 1 , B. Fomin 1 , V. Ageev 1 , K. 

Turalchuk 1 , O. Fomin 1 , S. Shirshov 1 and C. Chen 2 . 

1 

St. Petersburg State Polytechnical University, St. 

Petersburg, Russian Federation and 2 U.S. EPA, 

Washington, DC. Sponsor: K. Guyton. 


INFORMATICS APPROACH USING 

METABOLIC REACTIVITY CLASSIFIERS 

TO LINK IN VITRO TO IN VIVO DATA IN 

APPLICATION TO THE TOXCAST PHASE 

I DATASET. C. Yang 1 , A. M. Richard 2 , J. F. 

Rathman 3 , S. Ringeissen 4 , A. Tarkhov 5 , L. Terfloth 5 

and J. Gasteiger 5 . 1 OFAS (HFS-275), U.S. FDA 

CFSAN, College Park, MD, 2 NCCT (D343-03), U.S. 

EPA ORD, Research Triangle Park, NC, 3 ChBE, The 

Ohio State University, Columbus, OH, 4 Recherche, 

L’Oréal, Aulnay-sous-Bois, 93600, France and 

5 

Molecular Networks GmbH, Erlangen, Germany. 


IDENTIFYING FUNCTIONALLY LINKED 

GENE MODULES WITHIN BIOLOGICAL 

PATHWAYS ASSESSED BY TOXCAST IN 

VITRO ASSAYS. H. Mortensen, D. Reif, D. Dix, 

T. Knudsen, K. Houck and R. Kavlock. U.S. EPA, 



A DETAILED DESCRIPTION OF A FOOD 

ADDITIVES KNOWLEDGEBASE AND 

APPLICATION TO TOXICITY ENDPOINTS: 

DATABASE, ALERTS, AND QSAR MODELS 

IN THRESHOLD OF TOXICOLOGICAL 

CONCERN APPROACH. K. B. Arvidson, R. 

Brown, B. Emily, Z. Luo, B. Mugabe, A. McCarthy 

and C. Yang. OFAS (HFS-275), U.S. FDA CFSAN, 

College Park, MD. 


WWW.ALDH.ORG, A WEB DATABASE 

FOR THE CHARACTERIZATION AND 

REPORTING OF GENE SUPERFAMILIES. W. 

Black 1 and V. Vasiliou 2 . 1 Hugh E Black & Associates, 

Inc., Sparta, NJ and 2 Molecular Toxicology, 

University of Colorado, Denver, CO. 

MOnday 







119


MOnday 




CHEMINFORMATIC ANALYSIS OF THE 

U.S. EPA TOXCAST CHEMICAL LIBRARY. 

S. Little 1 , C. Yang 2 , D. Reif 1 , R. Judson 1 and A. 

Richard 1 . 1 U.S. EPA, Research Triangle Park, NC and 

2 

CFSAN, U.S. FDA, Bethesda, MD. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Mechanistic Aspects of Persistent Organic 

Chemical Toxicity 

Chairperson(s): Larry W. Robertson, University of Iowa, Iowa City, IA. 




RDX BINDS TO THE CONVULSANT 

SITE OF THE GABAA RECEPTOR AND 

INCREASES SPONTANEOUS FIRING RATES 

OF CORTICAL NEURONS IN VITRO. L. 

R. Williams 1 , A. F. Johnstone 2 , D. I. Bannon 1 and 

T. J. Shafer 2 . 1 Directorate of Toxicology, U.S. 

Army Center for Health Promotion and Preventive 

Medicine, Aberdeen Proving Ground, MD and 

2 

Integrated Systems Toxicology Division, NHEERL, 



RELEASE OF CALCIUM FROM 

INTRACELLULAR STORES IN PC12 CELLS 

BY HYDROXYLATED METABOLITES OF 

BDE-47 IS STRUCTURE-DEPENDENT. M. M. 

Dingemans 1 , H. J. Heusinkveld 1 , . Bergman 2 , M. van 

den Berg 1 and R. H. Westerink 1 . 1 Neurotoxicology 

Research Group, Institute for Risk Assessment 

Sciences, Utrecht University, Utrecht, Netherlands 

and 2 Department of Environmental Chemistry, 

Stockholm University, Stockholm, Sweden. 


PHARMACOKINETIC PROFILES OF 

PERFLUOROOCTANOIC ACID IN MICE 

AFTER CHRONIC EXPOSURE. K. P. Das 1 , 

D. Zehr 1 , M. Strynar 2 , A. Lindstrom 2 , J. Wambaugh 3 

and C. Lau 1 . 1 Toxicity Assessment Division/ 

NHEERL/ORD, U.S. EPA, Research Triangle Park, 

NC, 2 Human Exposure and Atmospheric Science 

Division/NERL/ORD, U.S. EPA, Research Triangle 

Park, NC and 3 National Center for Computational 

Toxicology/ORD, U.S. EPA, Research Triangle Park, 

NC. 


TOXICOGENOMIC PROFILING OF 

PERFLUORONONANOIC ACID IN WILD- 

TYPE AND PPARa-NULL MICE. M. B. Rosen 1 , 

J. R. Schmid 2 , R. D. Zehr 3 , K. P. Das 3 , H. Ren 4 , B. D. 

Abbott 3 and C. Lau 3 . 1 Integrated Systems Biology, 

U.S. EPA, Research Triangle Park, NC, 2 Biostatistics 

and Bioinformatics, U.S. EPA, Research Triangle 

Park, NC, 3 Toxicology Assessment, U.S. EPA, 

Research Triangle Park, NC and 4 Toxicogenomics, 



EFFECT OF ORGANOCHLORINE 

COMPOUND EXPOSURE ON 

ADIPOGENESIS AND ADIPOKINE 

PRODUCTION IN NIH3T3-L1 CELLS. G. 

Howell. Center for Environmental Health Sciences, 

Mississippi State University, Mississippi State, MS. 

Sponsor: J. Chambers. 


DOWN-REGULATION OF UREA CYCLE 

GENE EXPRESSION BY PFOA IN RATS. M. 

Walters and K. B. Wallace. Biochemistry, Molecular 

Biology, and Biophysics, University of Minnesota 

Medical School-Duluth, Duluth, MN. 


COMPARATIVE NEUROTOXICITY AND 

INTRA-CELLULAR ACCUMULATION OF 

FIVE POLYBROMINATED DIPHENYL 

ETHER (PBDE) CONGENERS IN MOUSE 

CEREBELLAR GRANULE NEURONS. 

G. Giordano 1 , S. C. Huang 1 and L. G. Costa 1,2 . 

1 

Department Env Occ Health Sciences, University of 

Washington, Seattle, WA and 2 Department of Human 

Anatomy, Pharmacology and Forensic Science, 

University of Parma Medical School., Parma, Italy. 


INVOLVEMENT OF CALCIUM-RELATED 

PROCESSES IN THE INHIBITION OF 

DEPOLARIZATION-EVOKED CALCIUM 

INCREASE BY HYDROXYLATED PBDES IN 

PC12 CELLS. R. H. Westerink 1 , H. J. Heusinkveld 1 , 

Bergman 2 , M. van den Berg 1 and M. M. Dingemans 1 . 

1 

Neurotoxicology Research Group, Institute for Risk 

Assessment Sciences, Utrecht University, Utrecht, 

Netherlands and 2 Department of Environmental 

Chemistry, Stockholm University, Stockholm, 

Sweden. 


ELUCIDATING THE MECHANISMS OF 

TOXICITY OF TRICHLOROETHYLENE 

METABOLITES. V. De La Rosa and C. Vulpe. 

Nutritional Sciences and Toxicology, University of 

California Berkeley, Berkeley, CA. 


PFOA AND PFOS-INDUCED OXIDATIVE 

STRESS RESPONSE IN HUMAN 

MICROVASCULAR ENDOTHELIAL CELLS. 

Y. Qian 1 , A. Ducatman 2 , S. Leonard 1 , R. Ward 1 , V. 

Vallyathan 1 and V. Castranova 1 . 1 PPRB, NIOSH, 

Morgantown, WV and 2 Community Medicine, West 

Virginia University, Morgantown, WV. 


THE ROLES OF ORGANIC ANION 

TRANSPORTERS IN RENAL ELIMINATION 

OF BRANCHED AND LINEAR 

PERFLUOROBUTYRATE IN RATS. Y. M. 

Weaver 1 , D. J. Ehresman 2 , S. C. Chang 2 , J. L. 

Butenhoff 2 and B. Hagenbuch 1 . 1 Pharmacology, 

Toxicology and Therapeutics, KU Medical Center, 

Kansas City, KS and 2 Medical Department, 3M 

Center, St. Paul, MN. 

120 






Platform Sessions



Abstract # 


TENUOUS DOSE-RESPONSE 

CORRELATIONS FOR COMMON DISEASE 

STATES: CASE STUDY OF CHOLESTEROL 

AND PERFLUOROOCTANOATE/ 

SULFONATE (PFOA/PFOS) IN THE C8 

HEALTH PROJECT. B. D. Kerger 1 , T. L. 

Copeland 2 and A. DeCaprio 3 . 1 Health Science 

Resource Integration Inc., Tallahassee, FL, 

2 

Consultant, Agoura Hills, CA and 3 Florida 

International University, Miami, FL. 


INHIBITION OF GAP JUNCTION 

INTERCELLULAR COMMUNICATION 

(GJIC) IN MOUSE LIVER CELLS 

BY TECHNICAL TOXAPHENE AND 

TOXAPHENE CONGENERS. J. C. Lamb 1 , C. 

L. Walker 2 , B. H. Neal 1 and J. E. Klaunig 2 . 1 Center 

for Toxicology and Mechanistic Biology, Exponent, 

Alexandria, VA and 2 Indiana University School of 

Medicine, Indianapolis, IN. 


SPECIES-SPECIFIC MULTIPLICITY OF 

NUCLEAR RECEPTOR ACTIVATION 

AND METABOLIC REGULATION BY 

PERFLUOROOCTANOATE (PFOA) AND 

PERFLUOROOCTANE SULFONATE 

(PFOS) IN CELL CULTURE. J. A. Bjork and 

K. B. Wallace. Biochemistry & Molecular Biology, 

University of Minesota Medical School, Duluth, MN. 


QUANTITATIVE ASSESSMENT OF 

AEROSOLIZED CYANOBACTERIAL 

TOXINS IN TWO NEW ZEALAND LAKES. 

S. A. Wood 1 and D. R. Dietrich 2 . 1 Aquatic 

Biotechnologies, The Cawthron Institute, Nelson, 

New Zealand and 2 Human and Environmental 

Toxicology, University of Konstanz, Konstanz, 

Germany. 


GENOME SCANS IN NATURAL 

POPULATIONS FOR SELECTIVELY 

IMPORTANT SNPS USING HIGH- 

THROUGHPUT TECHNOLOGY. L. Williams 1 

and M. F. Oleksiak 2 . 1 Environmental and Molecular 

Toxicology, North Carolina State University, Raleigh, 

NC and 2 Marine Biology and Fisheries, University of 

Miami, Miami, FL. 


INFLUENCE OF METABOLIC 

TRANSFORMATION IN THE GILL 

AND LIVER OF RAINBOW TROUT 

(ONCORHYNCHUS MYKISS) AND CHANNEL 

CATFISH (ICTALURUS PUNCTATUS) ON 

BIOCONCENTRATION. C. F. Gomez 1 , M. A. 

Moen 2 , L. Constantine 2 and D. B. Huggett 1 . 1 Biology, 

University of North Texas, Rowlett, TX and 2 Pfizer 

Global Research & Development, Groton, CT. 

Sponsor: J. Harbell. 

Abstract # 


POLYCHLORINATED BIPHENYLS DISRUPT 

INTESTINAL INTEGRITY VIA NADPH 

OXIDASE-INDUCED ALTERATIONS OF 

TIGHT JUNCTION PROTEIN EXPRESSION. 

Y. Choi 1,2 , M. J. Seelbach 2 , H. Pu 2 , S. Eum 2 , L. Chen 2 , 

B. Zhang 3,2 , B. Hennig 1,3 and M. Toborek 2,3 . 1 College 

of Agriculture, University of Kentucky, Lexington, 

KY, 2 Neurosurgery, University of Kentucky, 

Lexington, KY and 3 Graduate Center for Nutritional 

Sciences, University of Kentucky, Lexington, KY. 


SILICA NANOPARTICLES COATED WITH 

PCB153 ALTER THE BLOOD-BRAIN 

BARRIER INTEGRITY AND INDUCE 

NEUROINFLAMMATORY RESPONSES. 

B. Zhang 1,2 , L. Chen 2 , Y. Choi 2 , B. Hennig 1,3 and 

M. Toborek 1,2 . 1 Graduate Center For Nutritional 

Sciences, University of Kentucky, Lexington, 

KY, 2 Department of Neurosurgery, University 

of Kentucky, Lexington, KY and 3 College of 

Agriculture, University of Kentucky, Lexington, KY. 


MISEXPRESSION OF FGF17B AND 

NOTCH1B ARE ASSOCIATED WITH 

IMPAIRED HEART REGENERATION IN 

ZEBRAFISH (DANIO RERIO) EXPOSED 

TO 2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN (TCDD). M. Kim, W. Heideman and R. 

E. Peterson. Pharmacy, University of Wisconsin, 

Madison, WI. 


CYTOTOXICITY AND ESTROGENIC 

POTENTIAL OF PCB11 AND ITS 

METABOLITE 4-OH-PCB11. S. Flor, L. 

W. Robertson, H. Lehmler and G. Ludewig. of 

Occupational and Environmental Health, University 

of Iowa, Iowa City, IA. 


INHALATION EXPOSURE OF RATS TO 

A PCB MIXTURE RESEMBLING THE 

CHICAGO AMBIENT AIR CONGENER 

PROFILE. X. Hu 1 , A. Adam čáková-Dodd 2 , P. 

Thorne 1,2 , I. Korwel 2 , H. Lehmler 2,1 , D. Hu 3 and K. C. 

Hornbuckle 3 . 1 Human Toxicology Graduate Program, 

University of Iowa, Iowa City, IA, 2 Department of 


of Iowa, Iowa City, IA and 3 Department of Civil 

and Environmental Engineering, University of Iowa, 

Iowa City, IA. 


OXIDATIVE DNA ADDUCTS IN THE 

LIVERS OF FEMALE SPRAGUE-DAWLEY 

RATS CHRONICALLY EXPOSED TO 

POLYHALOGENATED AROMATIC 

HYDROCARBONS (PHAHS). L. Gao 1 , E. 

Multu 1 , P. Upton 1 , L. Collins 1 , N. Walker 2 , J. Olson 3 

and J. Swenberg 1 . 1 Environmental Sciences and 

Engineering, University of North Carolina Chapel 

Hill, Chapel Hill, NC, 2 National Institute of 

Environmental Sciences, Research Triangle Park, NC 

and 3 The State University of New York at Buffalo, 

Buffalo, NY. 

MOnday 







121


MOnday 




DIOXIN-LIKE PCB126 (3, 3’, 4, 4’, 

5-PENTACHLOROBIPHENYL) INCREASES 

RAT PON1 (PARAOXONASE 1) ACTIVITY: 

AN AHR (ARYL HYDROCARBON 

RECEPTOR)—MEDIATED PATHWAY? 

H. Shen 1 , B. Wang 1 , I. Lai 1 , G. Ludewig 1,2 and L. W. 

Robertson 1,2 . 1 Interdisciplinary Graduate Program 

in Human Toxicology, University of Iowa, Iowa 

City, IA and 2 Department of Occupational & 

Environmental Health, University of Iowa, Iowa City, 

IA. 


MODULATION OF MNSOD EXPRESSION 

BY PCB126 OCCURS AT MULTIPLE 

LEVELS. B. Wang 1 , I. K. Lai 1 , Y. Chai 3 , L. W. 

Robertson 1,2 and G. Ludewig 1,2 . 1 Human Toxicology, 

University of Iowa, Iowa City, IA, 2 OEH, University 

of Iowa, Iowa City, IA and 3 Iowa Hygienic 

Laboratory, Iowa City, IA. 


UV-INDUCED TOXIC EFFECTS OF 

A BROMINATED DIPHENYL ETHER 

(DECA-BDE) AND A HYDROXYLATED 

CHLORINATED DIPHENYL ETHER 

(TRICLOSAN) IN HUMAN SKIN CELLS. 

Y. Suh and G. Ludewig. Occupational and 

Environmental Health, University of Iowa, Iowa City, 

IA. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Investigations of Chemical Mixtures 

Chairperson(s): Jane Simmons, U.S. EPA, Cincinnati, OH. 




CHOLINESTERASE INHIBITION AND 

URINARY METABOLITE LEVELS FROM 

REPEATED EXPOSURES TO A MIXTURE 

OF TWO ORGANOPHOSPHORUS 

INSECTICIDES IN RATS. E. C. Meek 1 , A. 

Coban 1 , M. Davis 1 , B. Reisfeld 2 , S. Guo-Ross 1 and 

J. E. Chambers 1 . 1 Center for Environmental Health 

Sciences, Mississippi State University, Mississippi 

State, MS and 2 Colorado State Unviersity, Fort 

Collins, CO. 


DRUGS POTENTIALLY AFFECTING 

TRICHLOROETHYLENE METABOLISM. 

M. Cheikh Rouhou and S. Haddad. Sciences 

Biologiques, Toxen, Université du Québec à 

Montréal, Montréal, QC, Canada. 


NON-ADDITIVE EFFECTS OF PCB153 AND 

TCDD ON HEPATOTOXICITY IN C57BL/6 

MICE. A. K. Kopec 1,2 , L. D. Burgoon 1,2 , B. D. 

Mets 1,2 , J. R. Harkema 2,3 , C. Tashiro 4 , D. Potter 4 , B. 

Chittim 4 and T. Zacharewski 1,2 . 1 Biochemistry & 


Lansing, MI, 2 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI, 

3 

Pathobiology & Diagnostic Investigations, Michigan 

State University, East Lansing, MI and 4 Wellington 

Laboratories Inc., Guelph, ON, Canada. 


PRELIMINARY EVALUATION OF 

POTENTIAL LEAD-MERCURY 

TOXICOLOGICAL INTERACTION IN AN 

IN VITRO MODEL. K. Rahmani 1,4 , W. W. Neely 3 

and T. A. Lewandowski 1,2 . 1 Brooklyn College/CUNY, 

Brooklyn, NY, 2 Gradient Corporation, Seattle, WA, 

3 

Department of Statistics, University of Washington, 

Seattle, WA and 4 Biological Sciences, Columbia 

University, New York. 


CHEMICAL MIXTURES JOINT TOXICITY 

ASSESSMENT AT HAZARDOUS WASTE 

SITES. M. Mumtaz, M. Johnson and D. Mellard. 

ATSDR, Atlanta, GA. 


NINE AND TEN CHEMICAL 

HALOACETIC ACID MIXTURES EXHIBIT 

CONCENTRATION-DEPENDENT 

DEPARTURE FROM DOSE ADDITIVITY. 

J. Simmons 1 , C. Dingus 2 , E. D. Wagner 3 , L. K. 

Teuschler 4 , G. E. Rice 4 and M. J. Plewa 3 . 1 ORD/ 

NHEERL, U.S. EPA, Research Triangle Park, NC, 

2 

Batelle, Columbus, OH, 3 University of Illinois, 

Urbana, IL and 4 ORD/NCEA, U.S. EPA, Cincinnati, 

OH. 


EFFECTS OF CHEMICAL REACTIVITY 

AND TIME-DEPENDENT TOXICITY 

ON MIXTURE TOXICITY OF SOFT 

ELECTROPHILES: AN OVERVIEW OF 

RESULTS FROM MICROTOX. D. A. Dawson 1 , 

G. Pöch 2 and T. W. Schultz 3 . 1 Biology/Toxicology, 

Ashland University, Ashland, OH, 2 Pharmacology 

and Toxicology, University of Graz, Graz, Austria 

and 3 Comparative Medicine, The University of 

Tennessee, Knoxville, TN. Sponsor: D. Fort. 


MODELING THE INTERACTION OF 

BINARY AND TERNARY MIXTURES OF 

ESTRADIOL AND BISPHENOL A OR ITS 

ANALOGUES IN AN IN VITRO ESTROGEN 

MEDIATED TRANSCRIPTIONAL 

ACTIVATION ASSAY (T47D-KBLUC). D. S. 

Bermudez 1,2 , L. Gray 1 and V. S. Wilson 1 . 1 U.S. EPA, 

Research Triangle Park, NC and 2 NCSU, Raleigh, 

NC. 


IN VITRO-IN VIVO EXTRAPOLATION 

OF THE HUMAN DOSE-RESPONSE 

RELATIONSHIP FOR CELLULAR 

PERTURBATIONS BY A BINARY MIXTURE 

OF TOLUENE (TOL) AND N-HEXANE (HEX). 

K. Krishnan and T. Peyret. DSEST, Université de 


122 






Platform Sessions



Abstract # 


COMBINED EFFECTS OF DIRECT-ACTING 

MICHAEL ACCEPTOR COMBINATIONS 

VARY DEPENDING ON REACTIVITY RATES 

AND TIME-DEPENDENT TOXICITY OF 

THE AGENTS. Z. Il’Giovine 1 , N. Genco 1 , G. 

Pöch 2 , T. W. Schultz 3 and D. A. Dawson 1 . 1 Biology/ 

Toxicology, Ashland University, Ashland, OH, 

2 

Pharmacology and Toxicology, University of Graz, 

Graz, Austria and 3 Comparative Medicine, University 

of Tennessee, Knoxville, TN. Sponsor: D. Fort. 


MIXTURE TOXICITY AND MULTIPLE 

MODES OF TOXIC ACTION: DIRECT- 

ACTING MICHAEL ACCEPTORS WITH 

A NON-POLAR NARCOTIC. N. Genco 1 , Z. 

Il’Giovine 1 , T. W. Schultz 2 , G. Pöch 3 and D. A. 

Dawson 1 . 1 Biology/Toxicology, Ashland University, 

Ashland, OH, 2 Comparative Medicine, University 

of Tennessee, Knoxville, TN and 3 Pharmacology 

and Toxicology, University of Graz, Graz, Austria. 

Sponsor: D. Fort. 


COMPARISON OF MIXTURE TOXICITY 

FOR MONO-, DI-, AND TRI-HALOGENATED 

ACETONITRILE COMBINATIONS. D. 

Guinn 1 , D. A. Dawson 1 , T. W. Schultz 2 and G. 

Pöch 3 . 1 Biology/Toxicology, Ashland University, 

Ashland, OH, 2 Comparative Medicine, University 

of Tennessee, Knoxville, TN and 3 Pharmacology 

and Toxicology, University of Graz, Graz, Austria. 

Sponsor: D. Fort. 


HEATH-TREATED PM10 RETAIN A NON- 

VOLATILE COMPONENT RELATED 

PRO-OXIDATIVE POTENTIAL. R. O. Quintana 

Belmares 1 , V. Gomez Vidales 2 , I. Vazquez Lopez 1 , 

N. Manzano Leon 1 , L. Sevilla Tapia 1 , L. T. Molina 3 

and A. R. Osornio Vargas 1 . 1 Investigacion Basica, 

Instituto Nacional de Cancerologia, Mexico City, 

DF, Mexico, 2 Instituto de Quimica, UNAM, Mexico 

City, DF, Mexico and 3 MCE2, San Diego, CA. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology I 

Chairperson(s): Ofek Bar-Ilan, University of Wisconsin, Madison, WI. 




PHYTOTOXICITY OF METAL OXIDE 

NANOPARTICLES TO ARABIDOPSIS 

THALIANA. C. Lee 1 , S. Mahendra 2 , K. Zodrow 3 , 

D. Li 4 , Y. Tsai 5 and P. J. Alvarez 4 . 1 School of 

Health Professions, University of Texas at MD 

Anderson Cancer Center, Houston, TX, 2 Civil and 

Environmental Engineering, University of California, 

Los Angeles, Los Angeles, CA, 3 Environmental 

Engineering, Yale University, New Haven, CT, 4 Civil 

and Environmental Engineering, Rice University, 

Houston, TX and 5 Plant Science, Rice University, 

Houston, TX. Sponsor: B. Moorthy. 

Abstract # 


INDUCTION OF ENDOTHELIAL 

DYSFUNCTION BY IRON OXIDE 

NANOPARTICLE EXPOSURE. M. Zhu 1,2 , W. 

Feng 2 , G. Nie 1 and Y. Zhao 2,1 . 1 CAS Key Laboratory 

for Biomedical Effects of Nanomaterials and 

Nanosafety, National Center for Nanoscience and 

Technology, China, Beijing, China and 2 CAS Key 

Laboratory for Biomedical Effects of Nanomaterials 

and Nanosafety and CAS Key Laboratory of Nuclear 

Analytical Techniques, Institute of High Energy 

Physics, Chinese Academy of Sciences, Beijing, 

China. Sponsor: W. Zheng. 


CERIUM OXIDE, A DIESEL FUEL 

CATALYST, INDUCES PULMONARY 

FIBROSIS. J. Y. Ma 1 , R. R. Mercer 1 , M. Rao 1 , 

M. Barger 1 , T. Meighan 1 and J. K. Ma 2 . 1 NIOSH, 

Morgantown, WV and 2 WVU, Morgantown, WV. 


DETECTION OF NANOPARTICLES IN THE 

PERFUSATE OF FLOW-THROUGH SKIN 

DIFFUSION CELLS. K. E. Wiench 2 , S. Schulte 2 , 

S. Champ 2 , G. Cox 2 , N. Monteiro Riviere 1 , R. 

Landsiedel 2 and W. Wohlleben 2 . 1 Center for Chemical 

Toxicology Research and Pharmacokinetics, Raleigh, 

NC and 2 BASF SE, Ludwigshafen, Germany. 


LECTINS MODULATE MULTI-WALLED 

CARBON NANOTUBES CELLULAR 

UPTAKE IN HUMAN EPIDERMAL 

KERATINOCYTES. L. W. Zhang and N. A. 

Monteiro-Riviere. Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina State 

University, Raleigh, NC. 


TITANIUM DIOXIDE EXPOSURE INHIBITS 

ALLERGIC ASTHMA RESPONSE. K. 

Savolainen, L. Pylkkänen, E. Rossi, H. Wolff and 

A. Harri. Finnish Institute of Occupational Health, 

Helsinki, Finland. 


ACELLULAR ASSESSMENTS OF 

ENGINEERED-MANUFACTURED 

NANOPARTICLE BIOLOGICAL SURFACE 

REACTIVITY. K. Dreher 1 , D. Dunlap 2 and T. 

R. Nurkiewicz 3 . 1 NHEERL, U.S. EPA, Research 

Triangle Park, NC, 2 North Carolina State University, 

Raleigh, NC and 3 Center for Cardiovascular and 

Respiratory Sciences, West Virginia University, 



TITANIUM DIOXIDE NANOPARTICLES 

CAUSE GENOTOXICITY IN HUMAN 

LUNG EPITHELIAL CELLS. R. Y. Prasad 1 , 

K. Wallace 2 , A. H. Tennant 2 , K. T. Kitchin 2 , A. D. 

Kligerman 2 , J. G. Muñiz Ortiz 2 and C. F. Blackman 2 . 

1 

Student Contractor, Integrated Systems Toxicology 

Division, U.S. EPA, Research Triangle Park, NC and 

2 

Integrated Systems Toxicology Division, U.S. EPA, 


MOnday 







123


MOnday 




NANO TIO2: AN ASSESSMENT OF 

POTENTIAL PHOTOTOXICITY IN RETINAL 

PIGMENT EPITHELIAL CELLS IN VITRO. 

W. K. Boyes 1 , K. Sanders 1 , L. L. Degn 1 , W. R. 

Mundy 1 , R. Zucker 1 , B. Zhao 2 and J. Roberts 3,2 . 

1 

U.S. EPA, Research Triangle Park, NC, 2 NIEHS, 

Research Triangle Park, NC and 3 Fordham 

University, New York. 


COMPARATIVE RESPONSE OF PRIMARY 

MOUSE HEPATOCYTES CULTURED FOR 

1 DAY AND THREE WEEKS TO QUANTUM 

DOT EXPOSURE. K. A. Fay 1 , C. C. White 1 , X. 

Hu 2 , X. Gao 2 and T. J. Kavanagh 1 . 1 Environmental 

and Occupational Health, University of WA, Seattle, 

WA and 2 Department of Bioengineering, University 

of Washington, Seattle, WA. 


TRANSCRIPTIONAL AND CYTOTOXIC 

DIFFERENCES OF NANO-ZINC OXIDE AND 

NANO-TITANIUM DIOXIDE IN COLON AND 

SKIN-DERIVED CELL LINES. P. J. Moos 1 , 

J. Griggs 1 , S. Leachman 2 , P. Cassidy 2 and J. M. 

Veranth 1 . 1 Pharmacology & Toxicology, University 

of Utah, Salt Lake City, UT and 2 Dematology, 



IN VITRO GENOTOXICITY OF FIVE 

TITANIUM DIOXIDES. H. Norppa 1 , K. 

Savolainen 1 , G. C. Falck 1 , H. K. Lindberg 1 , S. 

Suhonen 1 , H. Järventaus 1 , J. Catalán 1,2 , M. Vippola 1,3 

and E. Vanhala 1 . 1 New Technologies and Risks, 

Finnish Institute of Occupational Health, Helsinki, 

Finland, 2 University of Zaragoza, Zaragoza, Spain 

and 3 Tampere University of Technology, Tampere, 

Finland. 


DIFFERENTIAL CYTOKINE RESPONSES 

INDUCED BY PLAIN AND RHODAMINE- 

MODIFIED SILICA-NANOPARTICLES IN 

EPITHELIAL LUNG CELLS. M. Refsnes 1 , T. 

Skuland 1 , M. Låg 1 , T. Iversen 2 , P. Schwarze 1 and M. 

Gualtieri 1 . 1 Department of Air Pollution and Noise, 

Norwegian Institute of Public Health, Oslo, Norway 

and 2 Centre for Cancer Biomedicine, National 

Hospital, Oslo, Norway. Sponsor: M. Løvik. 


OXIDATIVE STRESS OF AMORPHOUS 

MONODISPERSE SILICA NANOPARTICLES 

IN HUMAN ENDOTHELIAL CELLS. D. 

H. Napierska 1 , L. Thomassen 2 , L. Gonzalez 3 , V. 

Rabolli 4 , D. Lison 4 , M. Kirsch-Volders 3 , J. Martens 2 , 

B. Nemery 1 and P. H. Hoet 1 . 1 Research Unit for Lung 

Toxicology, K.U. Leuven, Leuven, Belgium, 2 Centre 

for Surface Chemistry and Catalysis, K.U.Leuven, 

Leuven, Belgium, 3 Free University of Brussels, 

Brussels, Belgium and 4 Catholic University of 

Louvain, Brussels, Belgium. 


HEPATIC GRANULOMATOUS FORMATION 

IN NANOCERIA INFUSED RATS, 

IMPLICATION FOR NANOPARTICLE 

SAFETY. M. T. Tseng 1 , X. Lu 1 , S. S. Hardas 2 , R. 

Sultana 2 , D. A. Butterfield 2 , M. Dan 2 , J. M. Unrine 2 , 

G. M. Uschi 2 , P. Wu 2 , E. A. Grulke 2 and R. A. 

Yokel 2 . 1 University of Louisville, Louisville, KY and 

2 

University of Kentucky, Lexington, KY. 


TOXIC EFFECTS OF METAL/METAL OXIDE 

NANOPARTICLES IN SKIN MODEL. A. R. 

Murray 1,2 , E. Kisin 1 , S. S. Leonard 1 , S. H. Young 1 , 

D. Schwegler-Berry 1 , V. Castranova 1 , B. Fadeel 3 , V. 

E. Kagan 4 and A. A. Shvedova 1,2 . 1 PPRB, NIOSH, 

Morgantown, WV, 2 WVU, Morgantown, WV, 

3 

Karolinska Institutet, Stockholm, Sweden and 

4 

University of Pittsburgh, Pittsburgh, PA. 


SIZE-DEPENDENT EFFECTS OF 

TUNGSTEN CARBIDE-COBALT PARTICLES 

ON INDUCTION OF OXIDATIVE STRESS 

AND ACTIVATION OF CELL SIGNALING 

PATHWAYS IN VITRO. A. A. Shvedova 1,3 , E. 

R. Kisin 1 , A. R. Murray 1,3 , J. Zhao 1 , L. Bowman 1 , 

Y. Lu 1 , B. Jiang 2 , S. S. Leonard 1 , V. Vallyathan 1 , 

V. Castranova 1 , B. Fadeel 4 and M. Ding 1 . 1 PPRB, 

NIOSH, Morgantown, WV, 2 Department of 

Microbiology, Immunology, and Cell Biology, WVU, 

Morgantown, WV, 3 Department of Physiology/ 

Pharmacology, WVU, Morgantown, WV and 

4 

Institute of Environmental Medicine, Karolinska 

Institutet, Stockholm, Sweden. 


MANGANESE NANOPARTICLE 

CHARACTERIZATION AND POSSIBLE 

NEUROTOXIC MECHANISMS IN A 

DOPAMINERGIC NEURONAL MODEL. H. 

Afeseh Ngwa 1 , A. Kanthasamy 1 , V. Anantharam 1 , 

Y. Gu 2 , N. Fang 2 and A. G. Kanthasamy 1 . 

1 

Biomedical Sciences, Iowa Center for Advanced 

Neurotoxicology, Iowa State University, Ames, IA 

and 2 Chemistry, Iowa State University, Ames, IA. 


PULMONARY TOXICITY OF INSTILLED 

METAL NANOPARTICLES IN THE RAT. M. 

S. Horsmon 1 , R. Kristovich 1 , T. Taylor 2 , T. Moran 1 

and S. Thomson 1 . 1 U.S. Army ECBC, Gunpowder, 

MD and 2 SAIC Inc., Gunpowder, MD. 


MODULATION OF IL-8 ACTIVITY UPON 

CHOLESTEROL DEPLETION AND 

NANOPARTICLE EXPOSURE. C. Thach and J. 

N. Finkelstein. University of Rochester, Rochester, 

NY. 


CELLULAR RECOGNITION AND 

TRAFFICKING OF ANIONIC 

NANOPARTICLES BY MACROPHAGE 

SCAVENGER RECEPTOR A. G. A. Orr 1 , W. B. 

Chrisler 2 , K. J. Cassens 1 , R. Tan 2 , B. J. Tarasevich 3 , 

L. M. Markillie 2 , R. C. Zangar 2 and B. Thrall 2 . 

1 

Chemical Physics & Analysis, Pacific Northwest 

National Laboratory, Richland, WA, 2 Cell Biology 

& Biochemistry, Pacific Northwest National 

Laboratory, Richland, WA and 3 Materials Chemistry 

Groups, Pacific Northwest National Laboratory, 

Richland, WA. 


EVALUATION OF TOPO-PMAT MODIFIED 

QUANTUM DOT UPTAKE AND TOXICITY 

IN A549 HUMAN LUNG EPITHELIAL 

CELLS. M. Zadworny, C. C. White, D. Botta and 

T. J. Kavanagh. DEOHS, University of Washington, 

Seattle, WA. 

124 






Platform Sessions



Abstract # 


SHORT- AND LONG-TERM 

BIODISTRIBUTION AND OXIDATIVE 

STRESS EFFECTS OF A SYSTEMICALLY- 

INTRODUCED 5NM CERIA ENGINEERED 

NANOMATERIAL. M. Dan 1 , M. T. Tseng 2 , R. L. 

Florence 1 , G. Tiu 1 , J. M. Unrine 1 , U. M. Graham 1 , R. 

Sultana 1 , S. S. Hardas 1 , M. Helm 1 , D. Butterfield 1 , 

P. Wu 1 , E. A. Grulke 1 and R. A. Yokel 1 . 1 University 

of Kentucky, Lexington, KY and 2 University of 



EFFECTS OF PARTICLE SIZE AND ROUTE 

OF EXPOSURE ON THE BIOAVAILABILITY 

OF ZINC FROM NANO-SIZED ZINC OXIDE 

PARTICLES. T. M. Sager 1,2 , R. Molina 2 , T. 

Donaghey 2 , J. Brain 2 and V. Castranova 1 . 1 NIOSH, 

Morgantown, WV and 2 Department of Environmental 

Health, Harvard School of Public Health, Boston, 

MA. 


AGGLOMERATION STATUS OF NANO- AND 

SUBMICRON-SIZED PARTICLES AND THE 

EFFECT ON PULMONARY TOXICITY. I. 

Gosens 1 , D. Leseman 1 , J. Boere 1 , D. Lankveld 2 , 

L. de la Fonteyne 2 , F. Cassee 1 and W. de Jong 2 . 

1 

MGO, National Institute for Public Health and the 

Environment (RIVM), Bilthoven, Netherlands and 

2 

GBO, National Institute for Public Health and the 

Environment (RIVM), Bilthoven, Netherlands. 


THE PARTICOKINETIC AND 

PHYSIOLOGICAL BASIS FOR IN VITRO 

-IN VIVO EXTRAPOLATION OF 

NANOMATERIAL TOXICITY STUDIES. J. 

G. Teeguarden, P. Hinderliter, B. Thrall, G. Orr, K. 

Waters, R. Corley and J. Pounds. Pacific Northwest 

National Laboratory, Richland, WA. 


THE ROLE OF BRAIN MICROVESSEL 

ENDOTHELIAL CELLS IN THE 

NEUROTOXICITY OF SILVER OR GOLD 

NANOPARTICLES. W. J. Trickler 1 , S. M. Lantz 1 , 

B. L. Robinson 1 , G. D. Newport 1 , J. J. Schlager 2 , 

S. J. Oldenburg 3 , M. G. Paule 1 , S. M. Hussain 2 and 

S. F. Ali 1 . 1 Neurochem. Lab., Division of Neurotox, 

NCTR/FDA, Jefferson, AR, 2 Applied Biotechnology 

Branch, Human Effectiveness Directorate, Air Force 

Research Laboratory, Wright-Patterson AFB, Dayton, 

OH and 3 NanoComposix, Inc., San Diego, CA. 


INTERNALIZATION OF SIO2 

NANOPARTICLES: THE INFLUENCE OF 

SIZE ON METAL OXIDE NANOPARTICLE 

ENDOCYTOSIS. J. M. Berg 1 , R. Payne 2 , 

R. Taylor 2 and C. M. Sayes 1 . 1 Physiology and 

Pharmacology, Texas A&M University, College 

Station, TX and 2 Veterinary Integrative Biosciences, 



COMPARATIVE TOXICOLOGICAL 

ANALYSIS OF QUANTUM DOTS AND 

WIRES ON HUMAN SKIN TISSUE. R. Iyer, J. 

Gao and J. Hollingsworth. LANL, Los Alamos, NM. 

Abstract # 


BIOLOGICAL SURFACE ACTIVITY INDEX: 

A NOVEL METRIC TO CHARACTERIZE 

NANOMATERIAL INTERACTIONS 

IN BIOLOGICAL SYSTEMS. X. Xia, 

N. A. Monteiro-Riviere and J. E. Riviere. 

Center for Chemical Toxicology Research and 

Pharmacokinetics, North Carolina State University, 

Raleigh, NC. 


UNDERSTANDING THE EFFECTS OF 

MICROENCAPSULATION AND TEMPORAL 

INTRACELLULAR RESPONSE. A. Romoser 1 , 

D. Ritter 2 , R. Majithia 3 , M. McShane 3,2 , K. Meissner 2,3 

and C. Sayes 1,2,3 . 1 Veterinary Physiology and 


Station, TX, 2 Biomedical Engineering, Texas A&M 

University, College Station, TX and 3 Materials 

Science and Engineering, Texas A&M University, 

College Station, TX. 


NICKEL NANOPARTICLES 

SYNERGISTICALLY ENHANCE PDGF- 

INDUCED CHEMOKINE PRODUCTION BY 

RAT PLEURAL MESOTHELIAL CELLS. A. 

J. Taylor, E. E. Glista, B. C. Sayers and J. C. Bonner. 


NC. 


HUMAN ENDOTHELIAL CELLS DISPLAY 

INFLAMMATORY MARKERS TO CACHE 

VALLEY PARTICULATE POLLUTION. C. 

Deering-Rice 1 , R. Coulombe 2 , R. Martin 3 and G. 

Yost 1 . 1 Pharmacology and Toxicology, University 

of Utah, Salt Lake City, UT, 2 Graduate Program 

in Toxicology, Department of Veterinary Sciences, 

Utah State University, Logan, UT and 3 Department 

of Civil and Environmental Engineering, Utah State 

University, Logan, UT. 


ZNO NANOPARTICLES ALTER 

MUSCARINIC RECEPTOR LIGAND 

BINDING AND ACTIVATION OF STORE 

OPERATED CALCIUM ENTRY IN CHO 

CELLS. H. Wang 1 , T. Tang 1 , A. C. Growcock 1 , 

J. O’Hara 1 , A. Martin 1,2 , Y. Huang 1 and R. S. 

Aronstam 1,2 . 1 Biological Sciences, Missouri S & T, 

Rolla, MO and 2 cDNA Center, Missouri University 

of Science & Technology, Rolla, MO. 


MALE REPRODUCTIVE TOXICITY STUDY 

OF QUANTUM DOT NANOPARTICLES IN 

MICE. G. Wang 1 , P. Diagaradjane 2 , C. C. Weng 2 , 

S. Krishnan 2 , S. H. Shao 2 and M. L. Meistrich 2 . 

1 

Applied Life Sciences and Toxicology, Lovelace 

Respiratory Research Institute, Albuquerque, NM 

and 2 Experimental Radiation Oncology, UTMD 

Anderson Cancer Center, Houston, TX. 

MOnday 







125


MOnday 




INFLAMMATORY RESPONSES OF 

TITANIUM DIOXIDE WITH DIFFERENT 

SIZE AND PROPERTIES. Y. Yoshioka 1,2,3 , 

T. Morishige 2 , H. Inakura 2 , S. Tsunoda 3,4,1 , 

Y. Tsutsumi 4,3,1 , Y. Mukai 2 , N. Okada 2 and S. 

Nakagawa 2,1 . 1 The Center for Advanced Medical 

Engineering and Informatics, Osaka University, 

Osaka, Japan, 2 Department of Biotechnology and 

Therapeutics, Osaka University, Osaka, Japan, 

3 

Laboratory of Pharmaceutical Proteomics, National 

Institute of Biomedical Innovation, Osaka, Japan 

and 4 Department of Toxicology, Graduate School of 

Pharmaceutical Sciences, Osaka, Japan. 


TUNABLE SUPERPARAMAGNETIC FE3O4- 

SIO2 CORE-SHELL NANOPARTICLES: 

SYNTHESIS, CHARACTERIZATION, 

AND IN VITRO COMPATIBILITY WITH 

IMMUNE-COMPETENT CELLS. B. Fadeel 1 , 

A. Kunzmann 1 , N. Feliu 1 , C. Vogt 2 , J. Shi 1 , B. 

Andersson 3 , S. Gabrielsson 3 , T. Thurnherr 4 , P. Wick 4 , 

S. Laurent 5 , R. Müller 5 , H. F. Krug 4 , A. Scheynius 3 , 

M. S. Toprak 2 and M. Muhammed 2 . 1 Institute of 

Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden, 2 Division of Functional 

Materials, Royal Institute of Technology, Stockholm, 

Sweden, 3 Department of Medicine, Karolinska 

University Hospital, Stockholm, Sweden, 4 Materials- 

Biology Interactions, Swiss Federal Laboratories 

for Materials Testing and Research, St. Gallen, 

Switzerland and 5 Department of General, Organic, 

and Biomedical Chemistry, University of Mons- 

Hainaut, Mons, Belgium. 


COMPARATIVE TOXICITY OF SHORT- 

TERM AND CHRONIC EXPOSURE TO 

LUNAR DUST AND ITS COMPONENT 

PARTICLES IN HUMAN SKIN FIBROBLAST 

CELLS. R. Duffy 1 , J. Wise 1 , H. Xie 1 , C. LaCerte 1 , M. 

Mason 2 , A. Jeevaragen 3 , W. Wallace 3 , D. Hammond 3 , 

T. Shehata 4 and J. P. Wise 1 . 1 Department of Applied 

Medical Science, University of Southern Maine, 

Portland, ME, 2 Department of Chemical and 

Biological Engineering, University of Maine, Orono, 

ME, 3 NASA Johnson Space Center, Houston, TX 

and 4 Maine Space Grant Consortium, Augusta, ME. 


9:30 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Hypersensitivity, Autoimmunity, and 

Idiosyncratic Drug Reactions 

Chairperson(s): Lynne A. LeSauteur, Charles River Laboratories, 

Montreal, QC, Canada. 




A FUNCTIONAL REGULATORY ROLE OF 

INTESTINAL GAMMADELTA T CELLS 

DURING ESTABLISHMENT OF ALLERGIC 

SENSITIZATION. M. Bol-Schoenmakers 1 , M. 

Marcondes Rezende 1,2 , R. Bleumink 1 , I. Hassing 1 , 

D. Fiechter 1 , S. Man 3 , L. Boon 3 , R. Pieters 1 and J. 

Smit 1,2 . 1 Institute for Risk Assessment Sciences, 

Utrecht University, Utrecht, Netherlands, 2 Utrecht 

Center for Food Allergy, Utrecht University, Utrecht, 

Netherlands and 3 Bioceros BV, Utrecht, Netherlands. 


DICLOFENAC ENHANCES ALLERGIC 

RESPONSES IN A MOUSE PEANUT 

ALLERGY MODEL. R. Pieters 1 , M. Bol- 

Schoenmakers 1 , R. Bleumink 1 , M. Marcondes 

Rezende 1,2 , E. Mouser 1 , I. Hassing 1 , I. Ludwig 1,3 and 

J. Smit 1,2 . 1 Institute for Risk Assessment Sciences, 

Utrecht University, Utrecht, Netherlands, 2 Utrecht 

Center for Food Allergy, Utrecht University, Utrecht, 

Netherlands and 3 TIPharma, Leiden, Netherlands. 


INHIBITION OF FOOD ALLERGY 

THROUGH THE ARYL HYDROCARBON 

RECEPTOR. V. J. Schulz 1 , J. Smit 1,2 , I. Hassing 1 , 

D. Fiechter 1 , R. Bleumink 1 , S. Save 3 , M. van 

Duursen 1 , M. van den Berg 1 and R. Pieters 1,2 . 

1 

Immunotoxicology, Institute of Risk Assessment 

Sciences, Utrecht University, Utrecht, Netherlands, 

2 

Utrecht Center for Food Allergy, Utrecht University, 

Utrecht, Netherlands and 3 College of Veterinary 

Medicine, Texas A&M University, College Station, 

TX. 


DIFFERENTIAL ALLERGENICITY 

OF NATIVE AND RECOMBINANT 

LACTOFERRIN: ROLE OF LEWIS (LE) X 

SUGARS. R. Almond 1,2 , B. F. Flanagan 2 , I. Kimber 1 

and R. J. Dearman 1 . 1 Faculty of Life Sciences, 

Manchester University, Manchester, Greater 

Manchester, United Kingdom and 2 University of 

Liverpool, Liverpool, United Kingdom. 


AN EVALUATION OF 1-BUTYL-3- 

METHYLIMIDAZOLIUM CHLORIDE (EMI) 

AND 1-ETHYL-3-METHYLIMIDAZOLIUM 

CHLORIDE (BMI): TWO IONIC LIQUIDS 

WITH DIFFERING EFFECTS ON CONTACT 

HYPERSENSITIVITY IN FEMALE BALB/C 

MICE. W. Auttachoat 1 , D. R. Germolec 2 , M. 

J. Smith 1 , T. L. Guo 1 , M. J. Hooth 2 and K. L. 

White 1 . 1 Pharmacology & Toxicology, Virginia 

Commonwealth University, Richmond, VA and 

2 

NIEHS, Research Triangle Park, NC. 

126 






Platform Sessions



Abstract # 


THE ALLERGENIC POTENTIAL OF MOLDS 

FOUND IN WATER-DAMAGED HOMES. 

M. D. Ward 1 , Y. Chung 1 , L. B. Copeland 1 , C. 

Pucheu-Haston 2 and S. Vesper 3 . 1 NHEERL, U.S. 

EPA, Research Triangle Park, NC, 2 Curriculum in 

Toxicology, University of North Carolina, Chapel 

Hill, NC and 3 NHERL, U.S. EPA, Cincinnati, OH. 


THE INFLUENCE OF GENETIC 

BACKGROUND IN A MOUSE MODEL OF 

CHEMICAL-INDUCED OCCUPATIONAL 

ASTHMA. K. Luyts, V. De Vooght, B. Nemery, 

P. H. Hoet and J. A. Vanoirbeek. Research Unit for 

Lung Toxicology, K.U. Leuven, Leuven, Belgium. 


COMPARISON OF LLNA RESPONSES 

BETWEEN CBA AND BALB/C MOUSE 

STRAINS. T. Burns 1 , J. Strickland 1 , E. Salicru 1 , D. 

Allen 1 and W. Stokes 2 . 1 ILS, Inc./NICEATM, NIEHS, 

Research Triangle Park, NC and 2 NICEATM, 



PREDICTION OF SKIN SENSITIZATION 

POTENTIAL OF CHEMICALS BY HUMAN 

CELL LINE ACTIVATION TEST (H-CLAT) 

AND AN ATTEMPT OF CLASSIFICATION 

OF SKIN SENSITIZATION POTENCY. Y. 

Nukada 1 , T. Ashikaga 2 , T. Abo 1 , S. Sono 2 , H. 

Sakaguchi 1 , H. Itagaki 2 and N. Nishiyama 1 . 1 Kao 

Corporation, Tochigi, Japan and 2 Shiseido Co., Ltd., 

Kanagawa, Japan. 


ESTABLISHMENT OF AN EX VIVO METHOD 

TO DETECT ALLERGEN SPECIFIC 

IGE MEDIATED HISTAMINE RELEASE 

IN BASOPHILS FROM CYNOMOLGUS 

MONKEY WHOLE BLOOD. P. Skov 2 , A. 

Lucock 1 , S. Kirk 1 and D. Everett 1 . 1 Covance 

Laboratories Ltd., Harrogate, North Yorkshire, 

United Kingdom and 2 RefLab ApS, Copenhagen, 

Denmark. 


EVALUATION OF PLASMACYTOID 

DENDRITIC CELL-BASED ASSAY TO 

DETERMINE CHEMICAL ALLERGENICITY. 

S. Ayehunie, M. Klausner, M. Snell, M. Child and P. 

J. Hayden. MatTek Corp, Ashland, MA. 


THE SENSITIZATION POTENTIAL OF 

FURFURYL ALCOHOL. J. L. Franko, B. 

Meade, L. G. Jackson and S. E. Anderson. NIOSH, 



IS ORTHO-PHTHALALDEHYDE A SAFE 

ALTERNATIVE TO GLUTARALDEHYDE? 

S. E. Anderson, C. Umbright, R. Sellamuthu, K. 

Fluharty, J. Franko, L. Jackson, M. Kashon, V. 

Johnson and P. Joseph. CDC/NIOSH, Morgantown, 

WV. 

Abstract # 


COMPARISON OF CONTACT ALLERGEN- 

INDUCED GENE EXPRESSION CHANGES 

IN HUMAN PERIPHERAL BLOOD 

MONONUCLEAR CELL-DERIVED 

DENDRITIC CELLS AND THE DENDRITIC 

CELL SURROGATE CELL LINE MUTZ-3. C. 

Ryan and F. Gerberick. Procter & Gamble Company, 

Cincinnati, OH. 


RECONSTRUCTED HUMAN EPIDERMIS 

INTEGRATING LANGERHANS CELLS 

(RHE-LC) RESPONSE TO CONTACT 

SENSITIZERS. S. Martinozzi Teissier 1 , A. Del 

Bufalo 1 , F. Tourneix 1 , F. Sahuc 2 , B. Bertino 2 , A. de 

Brugerolle de Fraissinette 2 and J. Meunier 1 . 1 L’Oréal 

Recherche, Aulnay sous Bois, France and 2 SkinEthic 

Laboratories, Nice, France. Sponsor: G. Nohynek. 


PEPTIDE REACTIVITY PROFILES 

OF REFERENCE CONTACT AND 

RESPIRATORY LOW MOLECULAR 

WEIGHT CHEMICAL ALLERGENS. J. 

Lalko 1,3 , I. Kimber 1 , R. J. Dearman 1 , G. Gerberick 2 , 

K. Sarlo 2 , A. Api 3 and L. W. Smith 3 . 1 The University 

of Manchester, Manchester, United Kingdom, 

2 

Procter & Gamble Company Co., Cincinnati, OH 

and 3 Research Institute for Fragrance Materials Inc., 

Woodcliff Lake, NJ. 


TRICHLOROETHENE INDUCES 

APOPTOSIS IN HEPG2 CELLS AND 

IMPAIRS CLEARANCE OF APOPTOTIC 

CELLS BY RAW CELLS. S. Kondraganti 1 , 

S. Khan 2 , P. J. Boor 2 , M. Khan 2 , R. Konig 3 , B. S. 

Kaphalia 2 and G. Ansari 1,2 . 1 BMB, The University of 

Texas Medical Branch, Galveston, TX, 2 Pathology, 

The University of Texas Medical Branch, Galveston, 

TX and 3 Microbiology and Immunology, The 

University of Texas Medical Branch, Galveston, TX. 


MICE EXPOSED TO A BINARY MIXTURE 

OF IMMUNOTOXICANTS DEVELOPED 

UNIQUE AUTOIMMUNE EFFECTS NOT 

INDUCED BY SINGLE EXPOSURE. K. 

Gilbert 1 , B. Rowley 3 , L. Hennings 4 and S. Blossom 2 . 

1 

Microbiology and Immunology, University of 

Arkansas for Medical Sciences/Arkansas Children’s 

Hospital Research Institute, Little Rock, AR, 

2 

UAMS/ACHRI, Little Rock, AR, 3 University of 

Central Arkansas, Little Rock, AR and 4 UAMS, Little 

Rock, AR. 


N-ACETYLCYSTEINE 

SUPPLEMENTATION PROTECTS 

AGAINST TRICHLOROETHENE-INDUCED 

AUTOIMMUNITY: ROLE OF OXIDATIVE 

STRESS. G. Wang, H. Ma, X. Fan, J. Wang and 

M. Khan. Pathology, University of Texas Medical 

Branch, Galveston, TX. 


DIRECT ACTIVATION OF B1A B CELLS 

VIA ASBESTOS EXPOSURE. D. Rasmussen, L. 

Coker, C. Fowers and J. Pfau. Biological Sciences, 

Idaho State University, Pocatello, ID. 

MOnday 







127


MOnday 




SERUM CYTOKINE/CHEMOKINE 

PROFILE IN PENICILLAMINE-INDUCED 

AUTOIMMUNITY. X. Zhu 1 , J. Li 1,3 and J. 

Uetrecht 1,2 . 1 Faculty of Pharmacy, University 

of Toronto, Toronto, ON, Canada, 2 Faculty of 

Medicine, University of Toronto, Toronto, ON, 

Canada and 3 DMPK, Hoffmann-La Roche Inc., 

Nutley, NJ. 


INVESTIGATION OF THE DANGER 

HYPOTHESIS IN AROMATIC AMINE 

DRUGS. W. Ng and J. Uetrecht. Faculty of 


Canada. 


COVALENT BINDING OF NEVIRAPINE IN 

VIVO AND IN VITRO. A. Sharma, Y. Li and J. 

Uetrecht. Pharmaceutical Sciences, University of 

Toronto, Toronto, ON, Canada. 


DANGER SIGNALS IN NEVIRAPINE- 

INDUCED SKIN RASH. X. Zhang and J. 

Uetrecht. Pharmaceutical Science, University of 



VALIDATION OF AN ORAL EXPOSURE 

MOUSE MODEL FOR THE PREDICTION OF 

DRUG HYPERSENSITIVITY REACTIONS 

USING A REPORTER ANTIGEN. L. Kwast, 

D. Fiechter, I. Ludwig and R. Pieters. Toxicology, 

Institute for Risk Assessment Sciences, Utrecht 

University, Utrecht, Netherlands. 


10:30 AM to 11:30 AM 

Room 155 B 

Exhibitor Hosted Session: An In Vitro Method for Measuring 

Metabolic Stability of Chemicals in Fish 

Presented by: CANTEST Ltd. 

In vitro biotransformation rates were measured using an S9 fraction from 

rainbow trout incubated with pyrene. Metabolic rates obtained from this 

study were extrapolated to whole-fish biotransformation rates and used 

to refine BCF computer model predictions. Our results suggest that this 

approach can be a potential replacement for in vivo measurements of BCF. 


10:30 AM to 11:30 AM 

Room 155 C 

Exhibitor Hosted Session: Choose the Diet Wisely: Purified 

Diets vs. Chow in Lab Animal Research 

Presented by: Research Diets, Inc. 

Grain-based laboratory animal ‘chow’ diets contain measurable and variable 

levels of toxic heavy metals and bioactive compounds such as phytoestrogens. 

These can affect the animal’s phenotype. Purified ingredient diets are 

free of these compounds and can be used to reduce data varability and influence 

outcome. 


10:30 AM to 11:30 AM 

Room 155 F 

Exhibitor Hosted Session: Demonstration of a Cigarette 

Smoke Generator in Combination with a Novel Cell Culture 

Exposure System 

Presented by: TSE Systems Inc. 

Classic submerged cultures (covered by medium) do not mimic the in-vivo 

situation. Lung cells for example are directly exposed to the air. Therefore, 

dry-wet cultures in combination with cigarette smoke have been chosen to 

validate our cell culture exposure system. 


11:00 AM to 11:50 AM 

Room 255 C 

Undergraduate Education Program Wrap Up 



The Monday Undergraduate Education Program events are for those 

undergraduate students and advisors receiving MARC and SOT funds 

and for SOT program volunteers. Full Undergraduate Education Program 

details may be found on pages 64–66. 


11:45 AM to 12:45 PM 

Room 155 C 

Exhibitor Hosted Session: Analyzing Cells in Real Time: 

xCELLigence Technology Use in Pharma Research 

Presented by: Roche Applied Science 

The xCELLigence Real-Time Cell Analyzer (RTCA) System allows the 

label-free, noninvasive dynamic monitoring of cell proliferation and viability 

in real time by utilizing an impedance read-out. Several cell-based applications 

have been developed for the system so far. Among them are cellular 

quality controls, detection of cell proliferation or cytoxicity. 


11:45 AM to 12:45 PM 

Room 155 F 

Exhibitor Hosted Session: Cytokines and Lineage Choice in 

Stem Cell Differentiation 

Presented by: STEMCELL Technologies Inc. 

A key feature of hematopoietic stem cells and their progeny is that their 

proliferation and differentiation is regulated by, and dependent on, external 

stimulation from cytokines. This session will discuss various assays that 

offer more biologically relevant screening to determine the mechanism of 

action on target cells of various pharmaceuticals. 

128 






Platform Sessions



Abstract # 

Monday Afternoon, March 8 

12:00 NOON to 1:20 PM 

Room 255 E 


MOnDAY AfTERnOOn 

In Vitro Toxicology Lecture and Luncheon for 

Students: Toxicity Testing in the 21 st Century: 


Lecturer: Kim Boekelheide, M.D., Ph.D., Brown 


Chairperson(s): David Allen, President, In Vitro and 

Alternative Methods Specialty Section, and Integrated 

Laboratory Systems, Inc., Research Triangle Park, NC. 

Sponsor: 

Colgate-Palmolive Company 

Endorsed by: 


This purpose of this event for postdoctoral scholars, graduate students, 

undergraduate students, and other invited guests is to focus on the importance 

of animal research to biomedical sciences and toxicology and the 

ethical obligations of the scientific community to follow the “3R’s” of 

animal testing (refine, reduce, replace) whenever it is feasible. 

In the future, toxicity testing will utilize emerging technologies from the 

ongoing revolution in understanding biological processes to identify the 

effects of chemicals on toxicity pathways, using in vitro approaches. The 

interpretation of chemically-induced alterations in toxicity pathways will 

depend upon sophisticated modeling that extrapolates from the measured 

dose-response in cell-based systems to human exposure. 

After providing an overview of the National Academy of Sciences report 

entitled “Toxicity Testing in the 21 st Century—A Vision and a Strategy,” 

this presentation will turn to a discussion of issues raised by this new 

approach. The audience will be asked to think about and respond to the 

following questions: 

• What are the limitations of the current testing approach that relies on 

animals? 

• What are the advantages of the current testing approach? 

• How long will it take to implement this new toxicity testing paradigm? 

• Is the focus on “toxicity pathways” useful or distracting? 

• Does a test for neurodevelopmental effects have to look at neurons? 

• How do we distinguish adaptive versus adverse (toxic) responses? 

• Is this a screening tool or a stand-alone system? 

• How is the new paradigm validated? 

• What about epigenetics and other new biology? 

• What are the limitations of the proposed new testing paradigm? 

• What are the advantages of the proposed new testing paradigm? 

Students and postdocs can reserve a ticket for the luncheon with a 

$5 deposit when they register for the SOT Annual Meeting. Lunch service 

may not be available for ticket holders who arrive after 12:15 PM. 

Abstract # 


12:00 NOON to 1:30 PM 

See room listings below. 

Regional Chapter Meetings/Luncheons: Central States 

(Room 355 A), Mid-Atlantic (Members Only, RSVP Required) 

(Tucanos Restaurant), Northeast Regional Chapter Student 

and Poster Travel Award (Marriott Downtown Brighton) 


12:00 NOON to 1:00 PM 

Room 355 D 

Special Interest Groups Meeting: AACT Distinguished 

Chinese Toxicologist Lectureship 


12:00 NOON to 1:00 PM 

Room 255 A 

Special Interest Groups Presidents and Officers Meeting 

If you will be a President or a Vice President of a Special Interest Group 

in 2010–2011, please make plans to attend the Special Interest Groups 

Presidents meeting scheduled for 12:00 NOON–1:00 PM. The agenda for 

the meeting will include an overview of the SOT Long-Range Plan. If you 

have long-range planning ideas that you would like to add to the agenda, 

please send a message to Kim von Brook at kimberly@toxicology.org. 


12:00 NOON to 1:30 PM 


Specialty Section Meetings/Luncheons: Cardiovascular 

Toxicology (Room 355 B), Occupational and Public Health 

(Room 255 B) 


12:00 NOON to 1:30 PM 

Room 259 

Specialty Section Officers Meeting: Food Safety Officers 

MOnday 







129


MOnday 




12:10 PM to 1:30 PM 

Ballroom D 

Roundtable Session: Combination Toxicology Studies for 

Pharmaceutical Agents: Design Considerations and Impact on 

Clinical Development 

Chairperson(s): Sushmita M. Chanda, Roche Palo Alto, Palo Alto, CA, 

and Hanan N. Ghantous, U.S. FDA, Silver Spring, MD. 

Sponsor: 


Endorsed by: 


Drugs or biotherapeutics are often combined in the clinic to maximize efficacy. 

The impact of such combination therapies are well known in the field 

of oncology and viral therapy, specifically HIV. The benefits of combination 

therapies have influenced pharmaceutical industries to explore development 

of new molecular entities (NME) with either NMEs or marketed 

products, or the combination of marketed products. In 2006, the Committee 

for Medicinal Products for Human Use (CHMP) and the U.S. FDA issued 

guidelines for nonclinical safety evaluation for combination products. The 

need for combination toxicity studies are dependent on the existing clinical 

and nonclinical data for each individual compound that is used to support 

the proposed dose and duration in patients. Nonclinical combination toxicity 

studies are generally conducted to evaluate whether combination of two or 

more agents cause a potentiation, synergistic, or additive effects on target 

organ toxicities that were identified for individual compounds. Design 

of such studies is critical in hazard identification as it impacts clinical 

monitoring. Usually the most sensitive species is used. Dose selection for 

individual compounds should consider levels that have some minimal effect 

so that exacerbation or additive effects can be clearly evaluated. Usually 

establishment of a NOAEL is not necessary, unless it is being developed as 

a co-formulation and there is lack of clinical/nonclinical data on individual 

compounds. Duration of studies depends on the type of toxicity profile that 

is seen with individual compounds and usually does not exceed more than 

90 days of dosing. Integration of data from ADME, PK, and clinical studies 

for individual compounds is important for designing successful combination 

toxicity studies. The roundtable will discuss general considerations for 

when and how to conduct combination toxicity studies with special focus 

on design considerations and challenges. Case examples and shared learning 

from combination toxicity studies and the impact on clinical monitoring will 

be discussed. 

#318 12:10 COMBINATION TOXICITY STUDIES FOR 

PHARMACEUTICAL AGENTS: DESIGN 

CONSIDERATIONS AND IMPACT ON 

CLINICAL DEVELOPMENT. S. M. Chanda 1 

and H. N. Ghantous 2 . 1 Roche Palo Alto, Palo Alto, 

CA and 2 U.S. FDA, Silver Spring, MD. 

12:10 REGULATORY PERSPECTIVE ON 

COMBINATION TOXICITY STUDIES. Hanan 

N. Ghantous 

12:20 POINTS TO CONSIDER IN DESIGNING 

COMBINATION TOXICITY STUDIES. 

Sushmita M. Chanda 

12:30 CASE STUDIES: SELECTION OF 

DOSES, SPECIES AND DURATION FOR 

COMBINATION TOXICITY STUDIES. 

Lorrene A. Buckley 

12:40 IMPACT OF COMBINATION TOXICITY 

FINDINGS ON CLINICAL MONITORING. 

Leigh Ann Burns Naas 



12:10 PM to 1:30 PM 

Ballroom F 

Roundtable Session: Melamine Contamination of Infant 

Formulas: Lessons Learned 

Chairperson(s): Wilson K. Rumbeiha, Michigan State University, 

Lansing, MI, and Madhu G. Soni, Vero Beach Hematology & Oncology, 

Vero Beach, FL. 

Sponsor: 


Endorsed by: 



In September 2008, officials in China acknowledged that illegal use of 

a fraudulent protein substitute, melamine, for months had contaminated 

powdered infant formula that was sold throughout the country. The tainted 

formulas also entered the market in several countries, in South East Asia 

and Africa. In the Peoples Republic of China alone at least 51,900 children 

are believed to have been affected by tainted food products, of whom 6 

died. Some milk products contained > 2000 ppm melamine. In 2007 pet 

food contaminated with melamine, cyanuric acid, ammelide, and ammeline 

affected thousands of cats and dogs in North America. In the pet food 

outbreak, the pathogenesis involved co-precipitation of melamine and 

cyanuric acid in renal distal tubules and collecting ducts, causing acute renal 

failure. In the infant formula outbreak, the cardinal toxic effect of melamine 

in these children was the presence of kidney calculi, leading to acute 

kidney injury. Unlike in pets where melamine-cyanurate interaction was a 

significant phenomenon in pathogenesis of acute renal failure, in infants the 

crystals consisted of melamine alone. The mechanism of melamine-induced 

nephrotoxicity in infants remains unknown. This emerging disease is likely 

to occur again because of the widespread use and availability of melamine 

and its analogues in the environment. The objectives of this session are to 

offer the current scientific status of this tragedy arising from the unscrupulous 

use of melamine in infant formula and how to use this knowledge to 

develop better public health and safety policies. Presentations will cover 

comparison between renal failure in pet food and infant formula outbreaks, 

dose-response, and risk assessment considerations of melamine in infants, 

the chemistry and analysis of melamine and analogues in food for risk 

assessment purposes, guidance on levels of health concern in foods, and 

regulatory aspects. 

#319 12:10 MELAMINE CONTAMINATION OF INFANT 

FORMULAS: LESSONS LEARNED. W. 

K. Rumbeiha 1 and M. Soni 2 . 1 Pathobiology and 

Diagnostic Investigation, Michigan State University, 

Lansing, MI and 2 Soni & Associates, Vero Beach, 

FL. 

12:15 A COMPARISON BETWEEN PET FOOD 

RECALL AND INFANT FORMULA 

INCIDENCE IN CHINA. Renate Reimschuessel 

12:30 DOSE-RESPONSE AND RISK ASSESSMENT 

CONSIDERATIONS OF MELAMINE IN 

INFANTS. Christopher Portier 

12:45 RISK/SAFETY ASSESSMENT OF 

MELAMINE AND ITS CONGENERS IN 

FOOD PRODUCTS. David Hattan 

1:00 ANALYSIS OF MELAMINE AND 

ANALOGUES IN FOOD FOR EXPOSURE 

AND RISK ASSESSMENT. Sheryl Tittlemier 


130 






Platform Sessions



Abstract # 


12:10 PM to 1:30 PM 

Ballroom I 


Historical Highlights Session: Translating Toxicology to 

Public Health Protection: Lessons Learned from Superfund 

Chairperson(s): Michele La Merrill, Mount Sinai School of Medicine, 

New York, NY, and Claudia Thompson, NIEHS, Research Triangle Park, 

NC. 

Sponsor: 


Endorsed by: 



The NIEHS strives to improve human health through the translation of 

scientific discoveries from bench to policy and bench to public health. The 

Comprehensive Environmental Response, Compensation, and Liability 

Act (CERCLA) defined and refined how toxicology can translate to public 

health benefits. This includes using the best available science to make 

health protective decisions at Superfund sites and conversely adapting 

what is learned at sites to inform new research directions. This two-way 

communication is exemplified by the NIEHS Superfund Research Program 

(SRP). The SRP, mandated by Congress to complement the applied nature 

of the national Superfund program, supports teams of scientists from the 

biomedical, engineering, environmental, and ecological disciplines to 

provide fundamental knowledge that could be used by decision-makers. To 

accelerate the timeframe whereby science is used by decision-makers, each 

SRP must include translational activities which include technology transfer, 

community outreach, and partnership with governmental agencies. Superfund 

responses need to act on the best available science, and not be halted by 

knowledge gaps in toxicology. This session will examine what lessons have 

been learned from the SRP; how toxicological research can be translated 

to remediation decisions; how biomarkers can inform risk assessment; how 

biomonitoring can reduce exposure at contaminated sites; and how SRP 

innovation can benefit the multi-agency work at Superfund sites. 

#320 12:10 TRANSLATING TOXICOLOGY TO PUBLIC 

HEALTH PROTECTION: LESSONS 

LEARNED FROM SUPERFUND. M. La Merrill 1 

and C. Thompson 2 . 1 Community and Preventive 

Medicine, Mount Sinai School of Medicine, New 

York and 2 Susceptibility and Population Health 

Branch, National Institute of Environmental Health 

Sciences, Research Triangle Park, NC. 

12:10 THE NIEHS SUPERFUND RESEARCH: 

TRANSLATING BASIC SCIENCE TO 

HUMAN HEALTH AND ENVIRONMENTAL 

RISK ASSESSMENT. William Suk 

12:25 THE USE AND DEVELOPMENT OF 

BIOMARKERS IN SUPERFUND RISK 

ASSESSMENT. James Swenberg 

12:40 TRANSLATION OF TOXICOLOGICAL 

MECHANISMS INTO BIOASSAYS FOR 

CHEMICAL DETECTION AND SITE 

CHARACTERIZATION. Michael S. Denison 

12:55 INTEGRATING HEALTH PROMOTION 

INTO BIOMARKER STUDIES. Thomas 

McDonald 

1:10 TRANSLATING INNOVATIONS OF THE 

SUPERFUND RESEARCH PROGRAM INTO 

THE FUTURE. Linda Birnbaum 


Abstract # 


12:30 PM to 1:20 PM 

Room 251 A 



Impacting the Science of Toxicology 

Lecturer: Richard S. Paules, National Institute of 

Environmental Health Sciences, NIH, Research 


The application of emerging ‘omics’ technologies to issues of adverse 

health effects from exposures to chemical, physical and pharmacological 

agents in our environment has given rise to the new area of 

toxicology referred to as “toxicogenomics.” At NIEHS, toxicogenomics 

technologies, and in particular genome-wide gene expression analyses 

or transcriptomics technologies, have been developed for application 

to environmental health studies and have provided new insights into 

adverse health events. Initially, many issues needed to be addressed 

and many obstacles overcome, including technical problems associated 

with gene annotation and platform development, detection of true 

signals, bioinformatic determination of significant changes, and reliability 

across different platforms and different users. Once those issues 

were addressed, the more complex and significant issues of appropriate 

experimental design and interpreting the vast amounts of information 

produced in toxicogenomics studies needed to be addressed in order 

to provide mechanistic insight into injury and disease processes and to 

develop biomarkers of gene expression signatures for safety evaluation 

and risk assessment. We developed a team that worked within NIEHS 

and with numerous collaborators and consortia to utilize toxicogenomics 

to classify exposures and chemicals, to identify changes that were early 

indicators of adverse effects, to phenotypic anchor genomic responses to 

a particular pathophysiology, and to begin to develop signatures to utilize 

as clinical biomarkers of specific adverse effects. While the challenges 

are great, the prospects have never been brighter. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Chemical and Biological Weapons 

Chairperson(s): Gunda Reddy U.S. Army-CHPPM, Aberdeen Proving 

Ground, MD. 

Displayed: 1:00 PM–4:30 PM 

Author Attended: 1:00 PM–2:45 PM 


PROTECTIVE EFFECTS OF 

PHENCYNONATE HYDROCHLORIDE 

AGAINST NERVE AGENT-INDUCED 

SEIZURE ACTIVITY. T. Shih, J. Koenig, K. 

Tarzia, A. Smelley, J. Skovira, J. Guarisco and J. 

McDonough. U.S. Army Med Res Inst Chem Defn, 

Aberdeen Proving Ground, MD. 


CYTOTOXICITY OF 

CYCLOTRIMETHYLENETRINITRAMINE 

(RDX) IN PRIMARY HUMAN CELL 

CULTURES. G. Reddy 2 , C. J. Cao 2 and A. P. 

Li 1 . 1 In Vitro ADMET Laboratories, Advanced 

Pharmaceutical Sciences, Columbia, MD and 

2 

Health Effects Research Program, U.S. Army Center 

for Health Promotion and Preventive Medicine, 


MOnday 







131


MOnday 




COMPARISON OF EFFECT UPON AND 

RECOVERY OF CHOLINESTERASE 

(CHE) ACTIVITY IN TISSUE AND BLOOD 

AFTER REPEATED INHALATION OR 

SUBCUTANEOUS SARIN (GB) EXPOSURES. 

C. E. Whalley 1 , L. Lumley 2 , J. O’Donnell 2 , D. 

Miller 1 , W. Muse 1 , J. Kraft 2 and T. Shih 2 . 1 ECBC, 

Aberdeen Proving Ground, MD and 2 USAMRICD, 

Aberdeen Proving Ground, MD . 


REACTIVATION OF PHOSPHORYLATED 

ACETYLCHOLINESTERASE IN THE 

CENTRAL NERVOUS SYSTEM USING 

NOVEL PYRIDINIUM OXIMES. R. Pringle 1 , 

A. Harmon 1 , E. Meek 1 , H. Chambers 2 , J. Gearhart 3 

and J. Chambers 1 . 1 College of Veterinary Medicine, 

Mississippi State University, Mississippi State, MS, 

2 

Department of Entomology and Plant Pathology, 

Mississippi State University, Mississippi State, MS 

and 3 AFRL, Wright-Patterson AFB, OH. 


APPLICATION OF A PBPK/PD 

MATHEMATICAL MODEL FOR THE OXIME 

HI-6 TO RELATED COUNTERMEASURES: 

HLo7, MMB-4, TMB-4 AND OBIDOXIME. T. 

R. Sterner 1 , C. D. Ruark 1 , K. O. Yu 2 , P. J. Robinson 1 , 

C. E. Hack 1 and J. M. Gearhart 1 . 1 HJF, Wright- 

Patterson AFB, OH and 2 AFRL 711 HPW/RHPB, 

Wright-Patterson AFB, OH. 


EVALUATION OF OPTIMIZED 

MONOCLONAL ANTIBODIES AGAINST 

STAPHYLOCOCCAL ENTEROTOXIN B BY 

IN VITRO PROLIFERATION AND MURINE 

SHOCK MODELS. A. Nallapaneni 1 , S. K. 

Sivasubramani 1 , S. Z. Killeen 1 , L. A. Morici 2 , K. J. 

Whaley 3 , L. Zeitlin 3 and C. J. Roy 1,2 . 1 Microbiology, 

Tulane National Primate Research Center, 

Covington, LA, 2 Microbiology and Immunology, 

Tulane School of Medicine, New Orleans, LA and 

3 

Mapp Biopharmaceutical, Inc., San Diego, CA. 


MECHANISTICALLY-BASED IN SILICO 

SIMULATION OF PATHOGEN-HOST 

IMMUNE RESPONSE DYNAMICS. C. Hack, 

E. Fleming, M. Makley, P. Robinson and J. Gearhart. 

RHPB, Wright-Patterson AFB, OH. 


TUNGSTATE EXPOSURE REDUCES THE 

QUANTITY OF CYTOTOXIC AND HELPER 

T-CELLS IN C57BL6 MICE AFTER IMMUNE 

CHALLENGE. A. Osterburg 2,1 , A. Olabisi 2 , V. 

Mokashi 2 , M. Stockelman 2 , G. Chapman 3 and G. 

Babcock 1 . 1 Shriners Hospitals for Children and the 

University of Cincinnati, Cincinnati, OH, 2 Naval 

Health Research Center Detachment / Environmental 

Health Effects Laboratory, Dayton, OH and 3 U.S. 

Army Medical Research & Material Command, 

MIDRP, Fort Detrick, MD. 


A MULTI-SPECIES MATHEMATICAL 

MODEL OF THE REGIONAL DEPOSITION 

AND CLEARANCE OF CHEMICAL AND 

BIOLOGICAL AGENTS IN THE LUNG. C. 

Hack and J. Gearhart. RHPB, 711HPW/AFRL, 

Wright-Patterson AFB, OH. 


RADIOPROTECTIVE EFFECTS AND 

MECHANISMS OF ACTION OF GENISTEIN. 

M. R. Landauer 1 , T. A. Davis 2 and R. M. Day 3 . 

1 

Armed Forces Radiobiology Research Institute, 

Bethesda, MD, 2 Naval Medical Research Center, 

Silver Spring, MD and 3 Uniformed Services 

University, Bethesda, MD. 


ALLELE COMPETITIVE BLOCKERS 

FOR IMPROVING QUANTITATIVE REAL- 

TIME PCR DETECTION OF SINGLE-BASE 

SUBSTITUTIONS. W. B. Melchior and W. H. 

Tolleson. Division of Biochemical Toxicology, 

NCTR, Jefferson, AR. 


DETECTING THE ADENOSINE 

N-GLYCOSIDASE ENZYME ACTIVITY 

OF RIBOSOME-INACTIVATING PROTEIN 

TOXINS USING A QUANTITATIVE PCR 

ASSAY METHOD WITH A SYNTHETIC 

OLIGO-2’-DEOXYRIBONUCLEOTIDE 

SUBSTRATE. K. T. Nguyen, W. B. Melchior and 

W. H. Tolleson. Division of Biochemical Toxicology, 

National Center for Toxicological Research, 

Jefferson, AR. 


ADJUNCTS FOR THE DELAYED 

TREATMENT OF NERVE AGENT-INDUCED 

STATUS EPILEPTICUS SEIZURES. J. H. 

McDonough, K. Van Shura, M. Lyman, C. Eisner, 

A. Mazza, R. Kan and T. Shih. Research Division 

USAMRICD, Aberdeen Proving Ground, MD . 


DOSE-DEPENDENT REVERSAL OF 

PARAOXON-INDUCED RESPIRATORY 

TOXICITY BY PRALIDOXIME IN MICE. 

F. Baud, M. Arnaud and P. Houze. Toxicology 

Laboratory, University Paris Descartes, Assistance 

Publique-Hôpitaux de Paris, Paris, France. 


A NON-OXIME IMPROVES SURVIVAL IN 

CHEMICAL WARFARE AGENT EXPOSED 

MICE. T. L. Garrett 1 , J. B. Lucot 1 , C. R. Rapp 1 , B. 

Sims 1 , D. G. Watson 2 , D. B. Fick 3 and D. R. Helton 3 . 

1 

Department of Pharmacology and Toxicology, 

Wright State University, Dayton, OH, 2 Air Force 

Research Laboratory, Wright Patterson Air Force 

Base, Dayton, OH and 3 Cenomed Research, LLC, 

Laguna Hills, CA. 


ROLE OF REACTIVE NITROGEN SPECIES 

IN VESICANT-INDUCED LUNG INJURY 

AND ALTERED LUNG FUNCTIONING. V. 

Sunil 1 , K. Patel 1 , J. Shen 1 , D. Reimer 1 , A. Gow 1 , 

J. Laskin 2 and D. Laskin 1 . 1 Rutgers University, 

Piscataway, NJ and 2 UMDNJ-RWJ Medical School, 


132 






Platform Sessions



Abstract # 


ANALYTICAL METHOD DEVELOPMENT 

FOR DETERMINING THE 

BIOMARKER CYANIDE METABOLITE 

2-AMINOTHIAZOLINE-4-CARBOXYLIC 

ACID IN MICE LIVER AFTER CYANIDE 

EXPOSURE. J. C. Yu 1 , I. Petrikovics 2 , R. Jackson 1 

and K. Stafford 2 . 1 Forensic Science, SHSU, 

Huntsville, TX and 2 Chemistry, SHSU, Huntsville, 

TX. 


IN VITRO AND IN VIVO EFFICACY OF 

TWO NEW SULFUR DONORS COMBINED 

WITH ENCAPSULATED RHODANESE. I. 

Petrikovics 1,2 , J. Childress 1 , G. Kuzmitcheva 1 , D. 

Tompson 1 , A. Manage 3 , M. Zottola 2 , S. Baskin 2 and 

G. A. Rockwood 2 . 1 Chemistry, SHSU, Huntsville, TX, 

2 

Analytical Toxicology, U.S. Army Medical Research 

Institute of Chemical Defense, Aberdeen Proving 

Ground, MD and 3 Mathematics and Statistics, SHSU, 

Huntsville, TX. 


BRAIN MITOCHONDRIAL CYTOCHROME 

C OXIDASE ACTIVITY AS A MARKER 

FOR CYANIDE INTOXICATION AND 

PROPHYLAXIS. D. Haines, I. Petrikovics, K. 

Jansky and R. Ruiz. Chemistry, SHSU, Huntsville, 

TX. 


SHORT-TERM AND LONG-TERM DIETARY 

RESTRICTION MODIFY SOMAN TOXICITY 

IN MALE GUINEA PIGS OF DIFFERENT 

AGES. T. M. Myers, J. L. Langston and J. 

H. McDonough. Neurobehavioral Toxicology, 

USAMRICD, Aberdeen Proving Ground, MD. 


RICIN TOXICITY IN BALB/C 3T3 

CELLS: CORRELATION OF TOTAL 

PROTEINS WITH DOSE LEVEL BY MASS 

SPECTROMETRY BASED PROTEOMICS. V. 

Bevilacqua 1 , R. Jabbour 2 , J. S. Madren-Whalley 3 , L. 

M. Reilly 4 and J. S. Rice 5 . 1 Point Detection Branch, 

Edgewood Chemical Biological Center, Aberdeen 

Proving Ground, MD, 2 SAIC, Gunpowder, MD, 

3 

Molecular Engineering Branch, Edgewood Chemical 

Biological Center, Aberdeen Proving Ground, MD, 

4 

Physical Science Department, Bethany College, 

Bethany, WV and 5 Elona Biotechnologies, Inc., 

Greenwood, IN. Sponsor: J. Sekowski. 


SOLVENT EFFECTS ON THE 

PERCUTANEOUS TOXICITY OF V AGENTS. 

E. D. Clarkson 1 , S. M. Schulz 2 , S. P. Robinson 1 and 

T. M. Ferrara 2 . 1 Analytical Toxicology Division 

U.S. Army Medical Research Institute of Chemical 

Defense, Aberdeen Proving Grounds, MD and 

2 

Research Division U.S. Army Medical Research 


Ground, MD. 


EXPRESSION OF PROLIFERATION AND 

SENESCENCE MARKERS IN SULFUR 

MUSTARD EXPOSED MOUSE SKIN. D. 

R. Gerecke, M. Soriano, J. Wang, M. Gordon and 

Y. Chang. Pharmacology & Toxicology, Rutgers 


Abstract # 


A TOXICOLOGICAL, BIOCHEMICAL, AND 

PHYSIOLOGICAL ASSESSMENT OF LUNG 

AND SYSTEMIC INJURY IN RATS EXPOSED 

TO INHALED SULFUR MUSTARD ACROSS 

DOSE AND TIME. D. S. Olivera, R. K. Kan, L. 

W. Mitcheltree, J. L. Collins, A. M. Witriol and A. M. 

Sciuto. USAMRICD, Gunpowder, MD. 


IDENTIFICATION OF POTENTIAL 

MOLECULAR TARGETS FOR 

THERAPEUTIC COUNTERMEASURES TO 

NERVE AGENT TOXICITY. K. D. Spradling 1 , 

L. A. Lumley 2 , C. L. Robison 2 , J. L. Meyerhoff 3 and 

J. F. Dillman 1 . 1 Cell and Molecular Biology Branch, 

USAMRICD, Aberdeen Proving Ground, MD, 

2 

Neurobehavioral Toxicology Branch, USAMRICD, 

Aberdeen Proving Ground, MD and 3 WRAIR, Silver 

Spring, MD. 


EVALUATION OF A NEW ANTIDOTE TO 

CHEMICAL WARFARE AGENTS IN MICE. 

J. B. Lucot 1 , T. L. Garrett 1 , C. R. Rapp 1 , B. Sims 1 , D. 

G. Watson 2 , D. B. Fick 3 , S. Mexal 3 and D. R. Helton 3 . 

1 


Wright State University, Dayton, OH, 2 Air Force 

Research Laboratory, Wright Patterson Air Force 

Base, Dayton, OH and 3 Cenomed Research LLC, 

Laguna Hills, CA. 


THE COSMECEUTICAL AMINO-PLEX 

AMELIORATES MUSTARD-INDUCED 

CORNEAL INJURY. A. S. DeSantis 1 , J. Beloni 1 , 

R. A. Hahn 1 , D. R. Gerecke 1 , M. Babin 2 and M. K. 

Gordon 1 . 1 Pharmacology and Toxicology, Rutgers 

University, Piscataway, NJ and 2 Battelle Biomedical 

Research Center, Columbus, OH. 


USE OF TOXICOGENOMICS AND 

NETWORK MODELING TO IDENTIFY THE 

NRF2-MEDIATED OXIDATIVE STRESS 

RESPONSE PATHWAY AS A MECHANISM 

OF ACTION FOR NITROAROMATIC 

EXPLOSIVES AND PROPELLANTS. M. S. 

Wilbanks 1 , Y. Deng 2 , L. Escalon 2 , X. Guan 2 , S. A. 

Meyer 3 and P. Edward 1 . 1 Engineer Research and 

Development Center, U.S. Army Corps of Engineers, 

Vicksburg, MS, 2 SpecPro, Inc., Vicksburg, MS and 

3 

Toxicology, University of Louisiana at Monroe, 

Monroe, LA. 


MODELING ORAL ADMINISTRATION OF 

ORGANOPHOSPHORUS HYDROLYZING 

ENZYME (OPH) AGAINST PARAOXON 

INTOXICATION. G. Kuzmitcheva 1 , I. 

Petrikovics 1 , S. Martin 1 , M. Wales 2 and M. Budai 3 . 

1 

Chemistry, SHSU, Huntsville, TX, 2 Department 

of Biochemistry and Biophysics, TAMU, College 

Station, TX and 3 Department of Pharmaceutics, 

Semmelweis Medical School, Budapest, Hungary. 

MOnday 







133


MOnday 




EXPOSURE TO SULFUR MUSTARD 

INDUCES THE EXPRESSION OF 

INFLAMMATORY PROTEINS IN RAT 

LUNGS. R. Malaviya 1 , V. R. Sunil 1 , L. B. Joseph 1 , 

K. J. Patel 1 , D. Anderson 2 , W. Holmes 2 , M. Conti 2 , 

J. D. Laskin 1 and D. L. Laskin 1 . 1 Pharmacology and 

Toxicology, Rutgers University/UMDNJ-Robert 

Wood Johnson Medical School, Piscataway, NJ and 

2 

U.S. Army Medical Research Institute of Chemical 

Defense, Aberdeen, MD. 


DRUG EFFICACY EVALUATIONS FOR 

TREATMENT OF SULFUR MUSTARD 

OCULAR AND DERMAL INJURY. J. Benson 1 , 

S. Lopez 1 , D. C. Santistevan 1 , W. Weber 1 , T. March 1 , 

J. Seagrave 1 , G. Schultz 2 , S. Tuli 2 , J. Talton 3 and 

G. Grotendorst 1 . 1 Lovelace Respiratory Research 

Institute, Albuquerque, NM, 2 University of Florida, 

Gainesville, FL and 3 Nanotherapeutics, Inc., 

Gainesville, FL. 


OXIDATIVE DNA DAMAGING EFFECTS 

OF SULFUR MUSTARD ANALOG CEES 

ON MOUSE SKIN CELLS. S. Inturi 1 , N. 

Tewari-Singh 1 , C. W. White 2 and R. Agarwal 1 . 

1 





DEVELOPMENT OF EFFICIENT AND 

APPLICABLE MALE SKH-1 HAIRLESS 

MOUSE SKIN TOXICITY MODEL WITH 

SULFUR MUSTARD ANALOG. A. K. Jain 1 , 

N. Tewari-Singh 1 , C. W. White 2 and R. Agarwal 1 . 

1 





COMET ANALYSIS OF GENOTOXICITY IN 

CULTURED HUMAN CELLS FOLLOWING 

EXPOSURE TO THE NERVE AGENTS VX 

AND GD. C. Gross, E. Nealley, A. Miller, M. 

Nipwoda and W. Smith. USAMRICD, Aberdeen 

Proving Ground, MD. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Genetic Diversity and Response to Xenobiotics 

Chairperson(s): Robert Kuester, University of Arizona, Tucson, AZ. 




POLYMORPHISMS OF GENES INVOLVED 

IN THE METABOLIC ACTIVATION 

OF POLYCYCLIC AROMATIC 

HYDROCARBONS (PAHS) CYP1A1, 

CYP1B1, AKR1A1, AKR1C1 AND GSTM1 IN 

A MEXICANS POPULATION. B. S. Barrón- 

Vivanco 1,3 , F. Castorena-Torres 1 , I. M. Medina-Díaz 3 , 

A. E. Rojas-García 3 , M. Robledo-Marenco 3 , G. 

Elizondo-Azuela 2 and A. Albores 1 . 1 Toxicology, 

Cinvestav, Meixco City, DF, Mexico, 2 Cell Biology, 

Cinvestav, Mexico City, DF, Mexico and 3 Laboratorio 

de Contaminación y Toxicología Ambiental, 

Universidad Autonoma de Nayarit, Tepic, Nayarit, 

Mexico. 


CYP1 POLYMORPHISMS, RESPONSE 

TO CHEMOTHERAPY, AND SURVIVAL 

IN LUNG CANCER. M. Iscan 1 , A. O. Ada 1 , S. 

Bilgen 1 , F. Hnacer 1 , S. C. Kunak 2 , S. H. Suzen 1 , 

S. Alper 3 , M. Gulhan 3 and B. Kurt 3 . 1 Toxicology, 

Ankara University, Faculty of Pharmacy, Ankara, 

Turkey, 2 Pharmacology, Giresun University, Faculty 

of Medicine, Giresun, Turkey and 3 Pulmonary 

Diseases, Ataturk Pulmonary Diseases and Thorax 

Surgery Hospital, Ankara, Turkey. 


GENETIC COMPONENTS OF PREDICTING 

DRUG ADVERSE REACTIONS IN THE 

CONFEDERATED SALISH & KOOTENAI 

TRIBAL (CSKT) POPULATION. M. A. 

Pershouse 1,3 , E. Eickholt 1 , J. Valentine 1 , L. I. 

Muzquiz 2 , K. Howlett 2 , J. S. Barnholtz-Sloan 4 , 

P. Beatty 3,1 , E. L. Woodahl 1 , H. D. Beall 1 , E. A. 

Putnam 1 , M. M. Ames 5 , S. L. Safgren 5 , C. Cable 1 , 

H. Harby 1 , M. J. Kuffel 5 and R. Molm 1 . 1 Biomed 

Pharm Sci-CEHS, University of Montana, Missoula, 

MT, 2 Tribal Health and Human Services, CSKT, St. 

Ignatius, MT, 3 Montana Cancer Institute Foundation, 

Missoula, MT, 4 Case Comprehensive Cancer Center, 

Cleveland, OH and 5 College of Medicine, Mayo 

Clinic, Rochester, MN. 


GENETIC VARIATION IN ABCB1 AND 

THE SUSCEPTIBILITY TO PARKINSON’S 

DISEASE. S. Lacher, I. M. Stone, F. Cardozo- 

Pelaez and E. L. Woodahl. University of Montana, 

Missoula, MT. Sponsor: A. Holian. 

134 






Platform Sessions



Abstract # 


STYRENE INDUCED HEALTH EFFECTS 

RELATED TO ALDH2 POLYMORPHISMS 

IN CHINESE WORKERS. Z. Weng 1 , P. Zhao 2 , 

Y. Zheng 3 and R. Wang 1 . 1 Japan National Institute 

of Occupational Safety and Health, Kawasaki, 

Japan, 2 Beijing Center of Diseases Control and 

Prevention, Beijing, China and 3 National Institute of 

Occupational Health and Poison Control, Chinese 

Center for Disease Control and Prevention, Beijing, 

China. Sponsor: N. Mei. 


INDIVIDUAL VARIATION IN 

PARAOXONASE 1 ACTIVITY IN HUMAN 

SERUM OVER TIME. L. Badtke 1 , A. Stromquist 2 , 

J. Merchant 2 and G. Ludewig 1,2 . 1 Grad. Program in 

Human Toxicology, The University of Iowa, Iowa 

City, IA and 2 Department Occup. & Environment 

Health, The University of Iowa, Iowa City, IA. 


MODULATION OF GENETIC DAMAGE 

AND DNA REPAIR CAPACITY BY GENETIC 

VARIATIONS IN THE NUCLEOTIDE 

EXCISION REPAIR GENE XPC. C. M. 

Rondelli 1 , J. K. Wickliffe 3 , R. A. El-Zein 4 , C. 

Etzel 4 and S. Z. Abdel-Rahman 1,2 . 1 Cell Biology 

& Environmental Toxicology, University of Texas 

Medical Branch, Galveston, TX, 2 Obstetrics 

& Gynecology, University of Texas Medical 

Branch, Galveston, TX, 3 Environmental Health 

Sciences, Tulane University, New Orleans, LA 

and 4 Epidemiology, MD Anderson Cancer Center, 

Houston, TX. 


GENETIC VARIATION IN ISOGENIC 

STRAINS OF FEMALE MICE ALTERS THE 

DISPOSITION AFTER ACUTE EXPOSURE 

TO [14C] BENZENE. R. Kuester 1 , G. A. Knudsen 1 , 

L. M. Jacobs 1 , M. L. Cunningham 2 and G. Sipes 1 . 

1 

Department of Pharmacology, University of Arizona, 

Tucson, AZ and 2 National Toxicology Program, 



GENETIC VARIATION IN ISOGENIC 

MURINE STRAINS ALTERS LEVELS OF 

[14C]BENZENE IN BONE MARROW AFTER 

ACUTE EXPOSURE. G. A. Knudsen 1 , R. K. 

Kuester 1 , M. L. Cunningham 2 , A. C. Gallegos 1 and I. 

G. Sipes 1 . 1 Department of Pharmacology, University 

of Arizona, Tucson, AZ and 2 National Toxicology 

Program, NIEHS, Research Triangle Park, NC. 


NMR AND MICROARRAY BASED 

ANALYSIS OF MOUSE LIVER FOLLOWING 

EXPOSURE TO TRICHLOROETHYLENE. 

B. U. Bradford 1 , S. Kim 1 , O. Kosyk 1 , J. H. Grimes 2,3 , 

T. M. O’Connell 2,3 and I. Rusyn 1 . 1 Environmental 

Sciences and Engineering, University of 

North Carolina, Chapel Hill, NC, 2 Division of 

Pharmacotherapy & Experimental Therapeutics, 

University of North Carolina, Chapel Hill, NC and 

3 

Hamner-UNC Institute for Drug Safety Sciences, 


Abstract # 


IDIOSYNCRATIC ADVERSE DRUG 

REACTIONS MODELED USING A MOUSE 

DIVERSITY PANEL MAY FACILITATE 

PHARMACOGENOMICS. A. H. Harrill 1 , M. 

T. Pletcher 2 , M. Lawton 2 and P. B. Watkins 1,3 . 1 The 

Hamner Institutes, Research Triangle Park, NC, 

2 

Pfizer, Inc., Groton, CT and University of North 

Carolina-Chapel Hill, Chapel Hill, NC. 


USE OF A GENETICALLY DIVERSE PANEL 

OF CELL LINES TO IMPROVE PREDICTIVE 

POWER OF IN VITRO SAFETY SCREENS. X. 

Zhang 1 , P. Mathew 1 , T. Wiltshire 2 and R. Thomas 3 . 

1 

Pfizer, Inc., Groton, CT, University of North 

Carolina-Chapel Hill, Chapel Hill, NC and 3 The 

Hamner Institutes, Research Triangle Park, NC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology II 

Chairperson(s): Lisa Truong, Oregon State University, Corvallis, OR. 




EFFECTS OF INSTILLATION VERSUS 

INHALATION OF NANO-SIZED SILICON 

DIOXIDE PARTICLES ON THE RAT LUNG. 

H. Muijser, J. Van Triel, E. Duistermaat, M. Mulderij, 

F. Kuper and Y. Staal. Quality of Life, TNO, Zeist, 

Netherlands. Sponsor: R. Woutersen. 


THE ROLE OF HYPOXIA-INDUCIBLE 

FACTOR IN MMP-2 AND MMP-9 

PRODUCTION BY HUMAN MONOCYTES 

EXPOSED TO NICKEL NANOPARTICLES. 

Y. Mo, R. Wan, D. J. Tollerud and Q. Zhang. 

Environmental and Occupational Health Sciences, 

University of Louisville, Louisville, KY. 


C 60 HAS OPPOSING DOSE-DEPENDENT 

EFFECTS ON ELECTRON TRANSPORT 

CHAIN FUNCTION AND OXIDATIVE 

STRESS IN ISOLATED BOVINE HEART 

MITOCHONDRIA. S. Rosario and C. Thomas. 

Chemistry, Central Washington University, 

Ellensburg, WA. 


SUB-ACUTE INHALATION EXPOSURE 

STUDY OF COPPER NANOPARTICLES 

IN MICE. J. Kim 1 , A. Adamcakova-Dodd 2 , P. T. 

O’Shaughnessy 2 , V. H. Grassian 3 and P. S. Thorne 1,2 . 

1 

Interdisciplinary Graduate Program in Human 

Toxicology, The University of Iowa, Iowa City, IA, 

2 

Department of Occupational and Environmental 

Health, The University of Iowa, Iowa City, IA and 

3 

Department of Chemistry, The University of Iowa, 

Iowa City, IA. 

MOnday 







135


MOnday 





THROUGHPUT ASSAY TO ASSESS THE 

IMMUNOMODULATORY POTENTIAL 

OF ENGINEERED NANOPARTICLES. L. 

Brusch-Richardson 1 , M. Ariza 1 , N. B. Saleh 2 and T. 

Sabo-Attwood 1,3 . 1 Environmental Health Sciences, 

University of South Carolina, Columbia, SC, 2 Civil 

and Environmental Engineering, University of South 

Carolina, Columbia, SC and 3 NanoCenter, University 

of South Carolina, Columbia, SC. Sponsor: D. Volz. 


EVALUATING THE BIOLOGICAL 

INTERACTIONS OF NANOMATERIALS 

USING FLUORESCENCE BASED 

TECHNOLOGY. L. Braydich-Stolle, A. Castle, E. 

Maurer and S. Hussain. RHPB, Air Force Research 

Labs, Wright Patterson, OH. 


METAL OXIDES INFLUENCE CELLULAR 

HOMEOSTASIS VIA MULTIPLE 

INTERCONNECTED SIGNALING 

PATHWAYS. Y. Huang, C. Huang, Y. Xu and R. S. 

Aronstam. Biological Sciences, Missouri University 

of Science and Technology, Rolla, MO. 


EFFECTS OF QUANTUM DOTS ON 

CELLULAR STRESS MARKERS IN HEPG2 

CELLS. W. E. Smith 1,3 , J. H. Tracy 1,3 , T. Lin 1,3 , 

C. C. White 1,3 , X. Hu 2 , X. Gao 2 , D. L. Eaton 1,3 and 

T. J. Kavanagh 1,3 . 1 Departments of Environmental 

and Occupational Health Sciences, University 

of Washington, Seattle, WA, 2 Department of 

Bioengineering, University of Washington, Seattle, 

WA and 3 Center for Ecogenetics and Environmental 

Health, University of Washington, Seattle, WA. 


COMPARATIVE TOXICITY OF LUNAR, 

MARTIAN, AND EARTH DUSTS IN HUMAN 

SKIN FIBROBLAST CELLS. J. Wise 1 , R. Duffy 1 , 

H. Xie 1 , C. LaCerte 1 , M. Mason 2 , A. Jeevaragen 3 , W. 

Wallace 3 , D. Hammond 3 , T. Shehata 4 and J. P. Wise 1 . 

1 

Department of Applied Medical Science, University 

of Southern Maine, Portland, ME, 2 Department of 

Chemical and Biological Engineering, University of 

Maine, Orono, ME, 3 NASA Johnson Space Center, 

Houston, TX and 4 Maine Space Grant Consortium, 

Augusta, ME. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Reproductive Toxicology 

Chairperson(s): Kembra L. Howdeshell, NIEHS, Research Triangle Park, 

NC. 




EFFECTS OF FENTANYL CITRATE ON 

FERTILITY AND EARLY EMBRYONIC 

DEVELOPMENT TO IMPLANTATION IN 

RATS. K. H. Denny 2 and A. S. Faqi 1 . 1 Toxicology, 

MPI Research, Mattawan, MI and 2 Drug Safety and 

Disposition, Cephalon, Inc., West Chester, PA. 


EVALUATION FOR OVARIAN TOXICITY 

OF SODIUM VALPROATE USING RAT 

CULTURED OVARIAN FOLLICLES. H. Inada, 

K. Chihara, C. Fukuda, A. Yamashita, Y. Tateishi, 

T. Yamada, J. Kimura, H. Funabashi and T. Seki. 

Safety Research Laboratories, Dainippon Sumitomo 

Pharmacology Co., Ltd., Osaka, Japan. 


PLACENTAL AND FETAL DISPOSITION 

OF MERCURIC IONS FOLLOWING 

TREATMENT WITH DMPS OR DMSA. C. 

Bridges, L. Joshee and R. K. Zalups. Division of 

Basic Medical Sciences, Mercer University School of 

Medicine, Macon, GA. 


INFANT DATA FROM PRE AND 

POSTNATAL DEVELOPMENT STUDIES IN 

CYNOMOLGUS MONKEYS OF DIFFERENT 

ORIGIN. S. Oneda 1 , N. Lalayeva 1 , T. Matsuyama 1 , 

J. Kenfield 1 , S. Herrin 1 , L. Lennox 1 , J. Reynolds 1 , 

A. MacIntyre 1 , N. Makori 1 , R. Eyre 1 , J. Klaassen 1 , 

S. Meyer 1 and R. Nagata 2 . 1 Safety Assessment, 

SNBL USA, Ltd., Everett, WA and 2 Shin Nippon 

Biomedical Laboratories, Ltd., Tokyo, Japan. 


EVALUATION OF TWO HIGH THROUGH- 

PUT (HTP) ANDROGEN RECEPTOR 

BASED ASSAYS: UTILITY OF DATA FOR 

PRIORITIZATION FOR FURTHER TESTING 

VERSUS PREDICTION OF ADVERSE 

EFFECTS. V. S. Wilson 1 , J. F. Pregenzer 2 and L. E. 

Gray 1 . 1 Reproductive Toxicology Branch, U.S. EPA, 

ORD, NHEERL, TAD, Research Triangle Park, NC 

and 2 CeeTox Inc., Kalamazoo, MI. 


TERATOGENIC AND TESTICULAR 

CHANGES INDUCED BY DI-N-BUTYL 

PHTHALATE ADMINISTERED ORALLY TO 

RATS. A. A. Abou-Hadeed 1 , K. A. Abdo 2 and S. 

R. El-Sayed 3 . 1 Toxicology and Forensic Medicine, 

Zagazig University, College of Veterinary Medicine, 

Zagazig, Egypt, 2 Toxicology and Forensic Medicine, 

College of Veterinary Medicine, Beni-Sueif 

University, Beni-Sueif, Egypt and 3 Toxicology and 

Forensic Medicine, Zagazig University, College of 

Veterinary Medicine, Zagazig, Egypt. 


KNOCKOUT OF THE TRANSCRIPTION 

FACTOR NRF2 DISRUPTS 

SPERMATOGENESIS IN AN AGE- 

DEPENDENT MANNER. B. N. Nakamura 1 , G. 

Lawson 3 , J. Y. Chan 2 , M. M. Cortes 4 , Y. D. Hoang 1 , 

L. Ortiz 1 and U. Luderer 1,4 . 1 Medicine, University 

of California Irvine, Irvine, CA, 2 Pathology and 

Laboratory Medicine, University of California 

Irvine, Irvine, CA, 3 Laboratory Animal Medicine, 

University of California Los Angeles, Los Angeles, 

CA and 4 Developmental and Cell Biology, University 

of California Irvine, Irvine, CA. 


EXPOSURE TO BISPHENOL A INHIBITS 

STEROID HORMONE BIOSYNTHESIS IN 

MOUSE OVARIAN FOLLICLES. J. Peretz, 

I. Hernández-Ochoa and J. A. Flaws. Veterinary 

Biosciences, University of Illinois, Urbana, IL. 

136 






Platform Sessions



Abstract # 


THE EFFECTS OF IN UTERO AND 

LACTATIONAL EXPOSURE TO 2, 3, 7, 

8 TETRACHLORODIBENZO-P-DIOXIN 

ON OVARIAN ARYL HYDROCARBON 

RECEPTOR LEVELS, AROMATASE 

ACTIVITY, AND STEROID BIOSYNTHESIS 

BY EXPLANTED OVARIAN FOLLICLES. 

T. B. Salisbury 1 and J. L. Marcinkiewicz 2 . 

1 

Pharmacology, Physiology, and Toxicology, Joan C. 

Edwards School of Medicine, Marshall University, 

Huntington, WV and 2 Biological Sciences, Kent 

State University, Kent, OH. Sponsor: M. Valentovic. 


IN UTERO EXPOSURE TO 

ENVIRONMENTAL TOBACCO SMOKE 

AND OXIDATIVE STRESS. S. T. Omaye 1 and 

S. T. Todd 2 . 1 Nutrition, University of Nevada, Reno, 

Reno, NV and 2 Operation Tobacco-Free Nevada, The 

Pregnancy Center, Reno, NV. 


IMPAIRMENT OF FETAL MOUSE 

PROSTATE DEVELOPMENT BY 2, 3, 7, 

8 TETRACHLORODIBENZO-P-DIOXIN 

(TCDD) IS LINKED TO A DEFECT IN 

b-CATENIN SIGNALING. C. M. Vezina 1,2 , H. 

A. Hardin 3 and R. E. Peterson 2,3 . 1 Comparative 

Biosciences, University of Wisconsin-Madison, 

Madison, WI, 2 Molecular and Environmental 

Toxicology Center, University of Wisconsin- 

Madison, Madison, WI and 3 School of Pharmacy, 

University of Wisconsin-Madison, Madison, WI. 


EFFECT OF ANTI-MÜLLERIAN HORMONE 

ON 4-VINYLCYCLOHEXENE DIEPOXIDE- 

INDUCED OVOTOXICITY IN CULTURED 

PND4 RAT OVARIES. C. J. Kappeler 1 , N. Sen 1 , 

I. Sipes 2 and P. B. Hoyer 1 . 1 Physiology, University of 

Arizona, Tucson, AZ and 2 Pharmacology, University 

of Arizona, Tucson, AZ. 


THE ARYL HYDROCARBON RECEPTOR 

MAY REGULATE GENES INVOLVED IN 

PROLIFERATION AND CELL DEATH IN 

THE NEONATAL MOUSE OVARY. B. N. 

Karman and J. A. Flaws. Veterinary Biosciences, 

University of Illinois, Urbana, IL. 


THE REAL-TIME CELL ELECTRONIC 

SENSOR AND ITS APPLICATIONS IN 

ENVIRONMENTAL TOXICOLOGY. D. Y. 

Huang 1 , S. Gabos 2 and D. W. Kinniburgh 1 . 1 Alberta 

Centre for Toxicology, Calgary, AB, Canada and 

2 

Alberta Health and Wellness, Edmonton, AB, 

Canada. Sponsor: M. Neuman. 


RELATIONSHIP BETWEEN URINARY 

PHYTOESTROGENS AND IDIOPATHIC 

MALE INFERTILITY. Y. Xia, P. Zhu, M. Chen, 

C. Lu, S. Wang, A. Gu and X. Wang. Key Laboratory 

of Reproductive Medicine, Institute of Toxicology, 

Nanjing Medical University, Nanjing, Jiangsu, China. 

Abstract # 


REPRODUCTIVE AND DEVELOPMENTAL 

TOXICITY OF DEGRADATION PRODUCTS 

OF REFRIGERANTS. M. Ema, M. Naya, K. 

Yoshida and R. Nagaosa. Research Institute of 

Science for Safety and Sustainability, National 

Institute of Advanced Science and Technology 

(AIST), Tsukuba, Ibaraki, Japan. 


DETERMINANTS OF PREGNANCY 

SUCCESS IN THE CYNOMOLGUS MONKEY. 

C. M. Luetjens and G. F. Weinbauer. Covance 

Laboratories GmbH, Muenster, Germany. 


GENE ALTERATIONS UNDERLYING 

2, 5-HEXANEDIONE-MEDIATED 

SUPPRESSION OF RADIATION-INDUCED 

GERM CELL APOPTOSIS. S. N. Campion 1 , 

M. A. Sandrof 1 , E. Houseman 2 , J. Hensley 3 , Y. 

Sui 2 , K. W. Gaido 3 , Z. Wu 2 and K. Boekelheide 1 . 

1 

Pathology and Laboratory Medicine, Brown 

University, Providence, RI, 2 Community Health, 

Brown University, Providence, RI and 3 The Hamner 


Park, NC. 


GENE EXPRESSION CHANGES IN THE 

TESTIS FOLLOWING X-RADIATION 

EXPOSURE. N. Catlin, S. N. Campion, M. A. 

Sandrof, S. J. Hall and K. Boekelheide. Pathology 

and Laboratory Medicine, Brown University, 



EFFECT OF METHOXYCHLOR ON 

OVARIAN ANTRAL FOLLICLES FROM 

ESTROGEN RECEPTOR ALPHA (ESR1) 

OVEREXPRESSING MICE. T. Paulose, I. 

Hernández-Ochoa and J. A. Flaws. Veterinary 

Biosciences, University of Illinois Urbana- 

Champaign, Urbana, IL. 


DEVELOPMENTAL TOXICITY 

EVALUATION OF 3, 3’, 4, 

4’-TETRACHLOROAZOBENZENE (TCAB) 

IN SPRAGUE-DAWLEY RATS. M. Mercado 

Feliciano 1 , C. J. Price 2 , M. C. Marr 2 , C. B. 

Myers 2 , M. K. Vallant 1 and M. J. Hooth 1 . 1 National 


Park, NC and 2 RTI International, Research Triangle 

Park, NC. 



TOXICITY STUDIES ON BRONOPOL. R. 

Ellis-Hutchings 1 , E. Carney 1 , C. Zablotny 1 , K. 

Brooks 1 , K. Stebbins 1 , J. Thomas 1 , R. Rasoulpour 1 , 

A. Poole 2 , N. Moore 2 and P. Spencer 1 . 1 The Dow 

Chemical Company, Midland, MI and 2 Dow Europe 

GmBH, Horgen, Switzerland. 


THE ABILITY OF THE ARYL 

HYDROCARBON RECEPTOR TO 

REGULATE OVARIAN FOLLICLE 

GROWTH IS INFLUENCED BY 

FOLLICLE-STIMULATING HORMONE. I. 

Hernández-Ochoa, M. S. Basavarajappa, J. Peretz 

and J. A. Flaws. Veterinary Bisociences, University 

of Illinois, Urbana, IL. 

MOnday 







137


MOnday 




METHOXYCHLOR MAY CAUSE TOXICITY 

THROUGH THE ARYL HYDROCARBON 

RECEPTOR PATHWAY. M. Basavarajappa, 

I. Hernández-Ochoa and J. Flaws. Veterinary 



DECREASED REPRODUCTIVE INDICES 

IN H-NAG-1 (GDF-15) MICE CORRELATED 

TO ALTERATIONS IN SERUM LEPTIN 

LEVELS. G. J. Moser 1 , J. Kosak 2 , M. A. Streicker 1 , 

M. Ehinger 1 , M. Brown 1 and T. E. Eling 2 . 1 Integrated 

Laboratory Systems Inc., Research Triangle Park, 

NC and 2 National Institute of Environmental Health 



TREATMENT OF LACTATING DAMS 

WITH HMPCC CAUSES REVERSIBLE 

SKIN PEELING IN RAT OFFSPRING. V. T. 

Politano and A. Api. Research Institute for Fragrance 

Materials, Inc., Woodcliff Lake, NJ. 


GSTPI AND PHOSPHO-C- 

JUN INTERACTIONS IN 

4-VINYLCYCLOHEXENE DIEPOXIDE- 

INDUCED OVOTOXICITY IN THE RAT 

OVARY. A. F. Keating 1 , N. Sen 1 , I. Sipes 2 and P. 

B. Hoyer 1 . 1 Department of Physiology, University 

of Arizona, Tucson, AZ and 2 Department of 

Pharmacology, University of Arizona, Tucson, AZ. 


EFFECT OF MATERNAL EXPOSURE 

TO THIAMAZOLE ON BEHAVIORAL 

DEVELOPMENT AND LEARNING AND 

MEMORY IN INFANT CYNOMOLGUS 

MONKEY. A. Inoue 1 , A. Arima 1 , Y. Nishida 1 , M. 

Wakishita 1 , M. Sugimoto 1 , Y. Ooshima 1 , R. Nagata 1 

and S. Ebihara 2 . 1 Drug Safety Research Laboratories, 

Shin Nippon Biomedical Laboratories Ltd., (SNBL), 

Kagoshima, Japan and 2 Division of Biomodeling, 

Graduate School of Bioagricultural Sciences, Nagoya 

University, Nagoya, Japan. 


IN VITRO EMBRYOTOXIC POTENTIAL 

OF ALBENDAZOLE AND ALBENDAZOLE 

SULFOXID ON RAT EMBRYOS IN 

CULTURE. C. Hofbeck, K. Eckardt and R. 

Stahlmann. Inst. for Clinical Pharmacology and 

Toxicology, Charite - Universitätsmedizin Berlin, 

Berlin, Germany. 


EMBRYOTOXIC POTENTIAL OF 

MYCOPHENOLIC ACID IN TWO IN VITRO 

TESTS. K. Eckardt, A. Felies and R. Stahlmann. 

Inst. for Clinical Pharmacology and Toxicology, 

Charite - Universitätsmedizin Berlin, Berlin, 

Germany. 


KISSPEPTIN: A NEW PATHWAY TO 

IDENTIFY AND CLASSIFY ENDOCRINE 

DISRUPTING COMPOUNDS? S. Losa, H. B. 

Adewale, A. W. Sullivan, J. A. Mickens, K. L. Todd 

and H. B. Patisaul. Biology, North Carolina State 

University, Raleigh, NC. Sponsor: G. LeBlanc. 


MALE REPRODUCTIVE PARAMETERS 

IN A RAT TWO-GENERATION 

REPRODUCTION STUDY OF AMMONIUM 

PERFLUOROOCTANOATE. R. G. York 1 , G. L. 

Kennedy 2 , G. W. Olsen 3 and J. L. Butenhoff 4 . 1 WIL 

Research Laboratories, LLC, Manlius, NY, 2 DuPont 

Company, Newark, DE, 3 Medical Department, 3M 

Company, St. Paul, MN and 4 Medical Department, 

3M Company, St. Paul, MN. 


ESTROGEN LIKE EFFECTS OF CADMIUM 

IN MICE: ARE THEY MEDIATED VIA 

NUCLEAR ESTROGEN RECEPTOR 

SIGNALING? I. Ali 1 , P. E. Penttinen 

Damdimopoulou 2 , S. I. Mäkelä 2,3 , M. Berglund 1 , 

U. Stanius 1 , A. Åkesson 1 , H. Håkansson 1 and K. 

Halldin 1 . 1 Institute of Environmental Medicine, 

Karolinska institute, Stockholm, Sweden, 

2 

Functional Food Forum, University of Turku, Turku, 

Finland and 3 Department of Biochemistry and Food 

Chemistry, University of Turku, Turku, Finland. 


BACKGROUND DATA FROM 

DEVELOPMENTAL TOXICITY STUDIES 

IN THE RABBIT. P. C. Barrow, J. Briffaux, L. 

Allais, M. Leroy and J. Guyot. MDS Pharmacology 

Services, Saint-Germain sur l’Arbresle, France. 


TESTICULAR GENE EXPRESSION 

PROFILING FOLLOWING LACTATIONAL 

EXPOSURE TO 6-N-PROPYLTHIOURACIL 

(PTU), A NEONATAL GOITROGEN. M. L. 

Hixon 1 , J. Santos Ahmed 1 , A. DeLong 2 , C. Brown 1 , 

S. Duncan Smith 1 , T. Rasoulpour 1 , C. Schorl 3 and Z. 

Wu 2 . 1 Department of Pathology, Brown University, 

Providence, RI, 2 Department of Community Health, 

Brown University, Providence, RI and 3 Center 

for Genomics and Proteomics, Brown University, 



CHARACTERIZATION OF 

P-GLYCOPROTEIN (ABCB1) ORTHOLOGS 

IN THE RAT EPIDIDYMIS: UNIQUE 

DISTRIBUTION AND UP-REGULATION 

BY XENOBIOTICS. S. R. Jones and D. Cyr. 

Institut Armand-Frappier, INRS, Laval, QC, Canada. 

Sponsor: B. Hales. 


ASSESSMENT OF ORGANOTYPIC 

EPIVAGINAL TM TISSUE MODEL TO SCREEN 

IRRITATION POTENTIAL OF CHEMICALS. 

C. Cannon, S. Ayehunie, K. LaRosa and M. 

Klausner. MatTek Corp, Ashland, MA. 


AKT/FOXO1 PATHWAY, BUT NOT 

ESTROGEN RECEPTOR ALPHA (ERa) 

OR BETA (ERb) IS ASSOCIATED WITH 

FENVALERATE (FEN)-INDUCED 

PROLIFERATION OF HUMAN UTERINE 

LEIOMYOMA (UTLM) CELLS AND 

UTERINE SMOOTH MUSCLE CELLS 

(UTSMC). X. Gao, L. Yu, L. Castro, A. B. Moore 

and D. Dixon. NIEHS, Research Triangle Park, NC. 

138 






Platform Sessions



Abstract # 


ATRAZINE EXPOSURE DOES NOT 

IMPACT SEXUAL DEVELOPMENT AND 

DIFFERENTIATION IN ZEBRAFISH. K. 

A. Stanley 1,2 , M. L. Kent 2,3 , T. Peterson 2,3 and R. 

L. Tanguay 1,2 . 1 Department of Environmental & 

Molecular Toxicology, Oregon State University, 

Corvallis, OR, 2 Environmental Health Sciences 

Center, Oregon State University, Corvallis, OR 

and 3 Department of Microbiology, Oregon State 

University, Corvallis, OR. 


N-ACETYL-L-CYSTEINE 

PREVENTS THE TOXIC EFFECTS 

OF HYPERPHOSPHATEMIA AND 

HYPOZINCEMIA ON THE TESTICULAR 

FUNCTION IN WKY, BUT NOT IN SHR/ 

NDMCR-CP, A MODEL OF METABOLIC 

SYNDROME. Y. Suzuki 1 , S. Ichihara 1 , A. Kato 1 , 

T. Yamaguchi 1 , Y. Yamada 1 and G. Ichihara 2 . 1 Life 

Science Research Center, Mie University, Tsu, 

Japan and 2 Social Life Science, Nagoya University 

Graduate School of Medicine, Nagoya, Japan. 


BISPHENOL-A AFFECTS UTERINE GENE 

EXPRESSION BUT HAS NO ADVERSE 

EFFECT ON UTERINE RECEPTIVITY IN 

MICE. S. Xiao 1,2 , H. Diao 1 and X. Ye 1,2 . 1 Physiology 

and Pharmacology, University of Georgia, Athens, 

GA and 2 Interdisciplinary Toxicology Program, 



REPRODUCTIVE TOXICOLOGY 

ASSESSMENT WITH A MURINE ANTIBODY 

AGAINST THE IL-1 RECEPTOR. S. Wild 1 , A. 

Nguyen 1 , C. Vezina 1 , Y. Sun 1 , R. Melara 1 , A. Ndifor 2 

and E. Lewis 3 . 1 Amgen Inc., Thousand Oaks, CA, 

2 

J&J Pharmacology R&D Companies, San Diego, 

CA and 3 Charles River Laboratories Preclinical, 

Horsham, PA. 


THE USE OF A COMBINED 2-GENERATION 

REPRODUCTION AND DEVELOPMENTAL 

NEUROTOXICITY TEST TO EXAMINE A 

PLASTICIZER FOR POSSIBLE HORMONE 

DISRUPTING EFFECTS. E. Wood 1 , A. Permin 2 , 

B. S. Neilsen 2 , U. Aunskjar 3 , T. F. Jensen 3 , J. S. 

Dunster 1 and S. M. Fulcher 1 . 1 Toxicology, Harlan 

Laboratories Ltd., Derby, United Kingdom, 2 DHI 

A/S, Horsholm, Denmark and 3 Danisco A/S, 

Brabrand, Denmark. Sponsor: S. Corney. 


2, 4-DICHLOROPHENOXYACETIC ACID 

(2, 4-D): EVALUATION OF SYSTEMIC 

TOXICITY IN A DIETARY EXTENDED ONE- 

GENERATION STUDY IN CRL:CD(SD) RATS. 

J. S. Bus 1 , B. H. Neal 2 , C. L. Zablotny 1 , B. L. Yano 1 , 

S. Saghir 1 and M. S. Marty 1 . 1 The Dow Chemical Co., 

Midland, MI and 2 Exponent, Alexandria, VA. 

Abstract # 


2, 4-DICHLOROPHENOXYACETIC ACID (2, 

4-D): EVALUATION OF REPRODUCTIVE/ 

ENDOCRINE ENDPOINTS IN A DIETARY 

EXTENDED ONE-GENERATION STUDY 

IN CRL:CD(SD)RATS. B. H. Neal 2 , J. S. Bus 1 , 

C. L. Zablotny 1 , B. L. Yano 1 , S. Saghir 1 and M. S. 

Marty 1 . 1 The Dow Chemical Co., Midland, MI and 

2 

Exponent, Alexandria, VA. 


2, 4-DICHLOROPHENOXYACETIC ACID (2, 

4-D): EVALUATION OF DEVELOPMENTAL 

NEUROTOXICITY (DNT) AND 

DEVELOPMENTAL IMMUNOTOXICITY 

(DIT) IN A DIETARY EXTENDED ONE- 

GENERATION STUDY IN CRL:CD(SD) 

RATS. A. K. Andrus 1 , C. L. Zablotny 1 , B. L. 

Yano 1 , J. S. Bus 1 , B. H. Neal 2 and M. S. Marty 1 . 1 The 

Dow Chemical Co., Midland, MI and 2 Exponent, 

Alexandria, VA. 


CHARACTERIZATION OF A NOVEL 

SERIES OF ENDOTHELIN-A RECEPTOR 

ANTAGONISTS IN THE SETTING OF 

INFECTION-ASSOCIATED PRETERM 

BIRTH. N. S. Olgun, H. J. Patel, R. Stephani and 

S. E. Reznik. Pharmaceutical Science, St. John’s 

University, Jamaica, NY. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Environmental Impact of Xenobiotics 

Chairperson(s): Michael R. Garry, Exponent, Inc., Seattle, WA. 




ACUTE TOXICITY OF PISCICIDAL PLANT 

EXTRACTS (ADENIA CISSAMPELOIDES) 

ON TILAPIA (SAROTHERODON 

GALILAEUS) JUVENILES. S. O. Ayoola 1 and 

E. K. Ajani 2 . 1 Marine Sciences, University of Lagos, 

Lagos State, Lagos States, Nigeria and 2 Wildlife and 

Fisheries Management, University of Ibadan, Ibadan, 

Oyo State, Nigeria. Sponsor: S. Ayoola. 


EFFECTS OF CADMIUM ON THE 

BIOENERGETIC BUDGET AND 

POPULATION GROWTH OF THE GRASS 

SHRIMP, PALAEMONETES PUGIO. T. 

Manyin 1,2 and C. Rowe 2 . 1 Environmental Science, 

SRC (formerly Syracuse Research Corporation), 

Arlington, VA and 2 Chesapeake Biological 

Laboratory, University of Maryland Center for 

Environmental Science, Solomons, MD. Sponsor: J. 

Garey. 


ELUCIDATING THE MECHANISM 

OF ACTION OF TRIBUYLTIN (TBT) 

INDUCED ZEBRAFISH (DANIO RERIO) 

MASCULINIZATION. C. McGinnis and J. F. 

Crivello. Physiology and Neurobiology, University of 


MOnday 







139


MOnday 




POLYBROMINATED DIPHENYLETHER 

(DE-71) EFFECTS ON THYROID 

HORMONE FUNCTION DURING ANURAN 

METAMORPHOSIS: EVALUATING 

PERIPHERAL MODES OF ACTION. D. J. 

Fort 1 , R. L. Rogers 1 , P. D. Guiney 2 and J. A. Weeks 2 . 

1 

Fort Environmental Laboratories, Stillwater, OK and 

2 

SC Johnson & Son, Racine, WI. 


THE EFFECT OF SODIUM TUNGSTATE AND 

TUNGSTEN ALLOYS ON THE GROWTH 

OF SELECTED MICROORGANISMS 

WITH ENVIRONMENTAL AND CLINICAL 

SIGNIFICANCE. T. L. Doyle and K. L. Mumy. 

Naval Health Research Center Detachment / 

Environmental Health Effects Laboratory, Dayton, 

OH. Sponsor: P. Gunasekar. 


PROTEOMIC SCREENING OF 

PERFLUOROALKYL ACIDS FOR 

ESTROGENIC ACTIVITY USING MASS 

SPECTROMETRY. M. J. Hemmer 1 , A. D. 

Benninghoff 2 , K. A. Salinas 1 and D. E. Williams 2 . 

1 

Gulf Ecology Division, U.S. EPA, Gulf Breeze, FL 

and 2 Department of Environmental and Molecular 

Toxicology, Oregon State University, Corvallis, OR. 


EFFECTS OF FLUOXETINE (PROZAC) 

ON AGGRESSIVE BEHAVIOR IN NILE 

TILAPIA (OREOCHROMIS NILOTICUS). 

J. L. Jamrogowicz, K. M. Harbom and M. A. 

Connaughton. Biology, Washington College, 

Chestertown, MD. Sponsor: M. Reynolds. 


A ONE-GENERATION MINK STUDY WITH 

THREE DIFFERENT DIOXIN AND FURAN 

CONGENERS. R. Rasoulpour 1 , C. Rowlands 1 , M. 

Zwiernik 3 , J. Moore 3 , S. Bursian 3 , D. Kay 2 and R. 

Budinsky 1 . 1 The Dow Chemical Company, Midland, 

MI, 2 Entrix Inc., Okemos, MI and 3 Michigan State 

University, East Lansing, MI. 


EFFECTS OF TWO ENDOCRINE-ACTIVE 

PHARMACEUTICALS, TAMOXIFEN AND 

ANASTROZOLE, ON REPRODUCTION 

IN A MARINE FISH, TAUTOGOLABRUS 

ADSPERSUS. L. J. Mills, R. Gutjahr-Gobell, 

D. Borsay Horowitz and G. Zaroogian. U.S. EPA, 

NHEERL, Atlantic Ecology Division, Narragansett, 

RI. 


AN INTEGRATED LABORATORY AND 

FIELD ASSESSMENT OF SELECT 

ENDOCRINE DISRUPTORS IN THE PUGET 

SOUND REGION. I. Schultz. Battelle PND-MSL, 

Sequim, WA. 


ENDOCRINE DISRUPTION IN A 

CALIFORNIA ESTUARY: LINKING 

RECEPTOR BINDING TO POPULATION 

LEVEL EFFECTS. S. M. Brander and G. N. 

Cherr. Environmental Toxicology, University of 

California Davis, Bodega Marine Lab, Bodega Bay, 

CA. 


ACETYLCHOLINESTERASE AND 

METALLOTHIONEIN IN OYSTERS 

(CRASSOSTREA CORTEZIENSIS) FROM A 

SUBTROPICAL MEXICAN PACIFIC. Y. Y. 

Bernal-Hernández, M. Medina-Díaz, L. Robledo- 

Marenco, J. B. Velázquez-Fernández, I. Girón-Pérez, 

L. Ortega-Cervantes, W. Maldonado-Vázquez, C. A. 

González-Arias and E. Rojas-García. Universidad 

Autónoma de Nayarit, Tepic, Mexico. Sponsor: B. 

Quintanilla-Vega. 


APPLICATION OF HIGH ENERGY 

ELECTRON BEAM AND CHEMICAL 

OXIDANTS TO DESTROY ESTROGENIC 

ACTIVITY IN WASTEWATER EFFLUENT 

AND BIOSOLIDS. C. Rambo 1,2 , L. Xiangrong 1,3 , 

P. Srisawat 4 , K. Brady 4 , P. R. Jesudhasan 2 , S. Safe 1,3 , 

R. Reimers 4 and S. D. Pillai 2,1 . 1 Interdisciplinary 

Faculty of Toxicology, Texas A&M University, 

College Station, TX, 2 Food Safety & Environmental 

Microbiology Program, Texas A&M University, 

College Station, TX, 3 Veterinary Physiology & 


Station, TX and 4 Environmental Health Sciences, 

Tulane University, New Orleans, LA. 


THE RELATIONSHIP BETWEEN 

MASCULINIZED FEMALE QUEEN CONCH 

(STROMBUS GIGAS) AND TRIBUTYLTIN- 

BASED ANTIFOULING PAINTS IN 

COASTAL WATERS OF THE BRITISH 

VIRGIN ISLANDS. O. S. Phillip 1 , C. O’Neal 1 

and K. Thomas 2 . 1 Marine Biology, H. Lavity Stoutt 

Community College, Road Town, Tortola, BVI, 

United Kingdom and 2 Environment, Fisheries and 

Aquaculture Science, Burnham on Crouch, Essex, 

United Kingdom. Sponsor: D. Hood. 


LEVERAGING MAMMALIAN 

PHARMACEUTICAL DATA TO PREDICT 

CHRONIC FISH RESPONSES TO 

PHARMACEUTICALS. J. P. Berninger 2,1 and B. 

Brooks 1,2 . 1 Environmental Science, Baylor University, 

Waco, TX and 2 Institute of Biomedical Studies, 

Baylor University, Waco, TX. 


ASSESSMENT OF METALS 

CONCENTRATIONS MONITORED IN 

CARIBOU COLLECTED NEAR A MINING 

TRANSPORT ROAD IN NORTHWEST 

ALASKA. M. R. Garry and S. S. Shock. Exponent, 

Bellevue, WA. 


ACUTE ORAL LEAD PELLET EXPOSURE 

IN NORTHERN BOBWHITE QUAIL. R. M. 

Gogal 1 , R. Kerr 1 , J. Holladay 1 , T. Jarrett 1 , S. D. 

Holladay 1 , B. A. Selcer 1 , B. Meldrum 2 , S. Williams 3 

and L. Tannenbaum 4 . 1 Department of Anatomy and 

Radiology, University of Georgia, Athens, GA, 

2 

Biomedical Sciences and Pathobiology, Virginia 

Tech, Blacksburg, VA, 3 Poultry Diagnostic and 

Research Center, University of Georgia, Athens, GA 

and 4 U.S. Army Center for Health Promotion and 

Preventative Medicine, Aberdeen, MD. 

140 






Platform Sessions



Abstract # 


2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN INHIBITS HEART REGENERATION 

IN ADULT ZEBRAFISH FOLLOWING 

VENTRICULAR RESECTION. V. Mehta 1 , P. 

Hofsteen 2 , R. E. Peterson 1,2 and W. Heideman 1,2 . 

1 

Molecular and Environmental Toxicology Center, 

University of Wisconsin-Madison, Madison, WI and 

2 

Pharmaceutical Sciences Division, University of 

Wisconsin, Madison, Madison, WI. 


NICKEL IS A MAJOR COMPONENT 

RESPONSIBLE FOR PM2.5 ASSOCIATED 

CARDIOVASCULAR DISEASES. Q. Qu 1 , J. 

Niu 2 , S. Qu 1 , X. Li 1 , X. Guo 3 , B. Luo 2 , J. Chao 2 , K. 

Ito 1 , R. Wildman 4 , L. Zhang 2 , H. Liu 3 , M. Zhong 1 

and L. Chen 1 . 1 NYUSOM, Tuxedo, NY, 2 Lanzhou 

University School of Public Health, Lanzhou, China, 

3 

Peking University School of Public Health, Beijing, 

China and 4 Albert Einstein College of Medicine, 

Bronx, NY. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Biotransformation I 

Chairperson(s): Monica Valentovic, Mashall University School of 

Medicine, Huntington, WV. 




BIOACTIVATION AND DETOXIFICATION 

PATHWAYS OF EUGENOL AND 

METHYLEUGENOL IN HUMAN LUNG AND 

LIVER MICROSOMES. C. Meredith, E. Massey 

and E. Minet. Group Research & Development, 

British American Tobacco, Southampton, United 

Kingdom. 


FORMATION OF PHENOL AND 

HYDROQUINONE METABOLITES OF 

STYRENE IN MOUSE MICROSOMES. S. 

Shen 1 , F. Zhang 1 , L. Gao 2 , S. Zeng 2 and J. Zheng 1,3 . 

1 

Center for Developmental Therapeutics, Seattle 

Children’s Hospital Research Institute, Seattle, 

WA, 2 Department of Pharmaceutical Analysis 

and Drug Metabolism, College of Pharmaceutical 

Sciences, Zhejiang University, Hangzhou, Zhejiang, 

China and 3 Department of Pediatrics, University of 

Washingtong, Seattle, WA. 


SPECIES COMPARISON OF IN VITRO 

METABOLIC CONVERSION OF AFLATOXIN 

B2 TO AFLATOXIN B1. A. Poapolathep 1 , S. 

Poapolathep 1,2 , S. Isariyodom 4 , K. Imsilp 1 , N. 

Klangkaew 1 , Y. Sugita-Konishi 3 and S. Kumagai 2 . 

1 

Department of Pharmacology, Faculty of Veterinary 

Medicine, Kasetsart University, Bangkok, Thailand, 

2 

Department of Veterinary Public Health, Graduate 

School of Agricultural and Life Sciences, University 

of Tokyo, Tokyo, Japan, 3 Division of Microbiology, 

National Institute of Health Sciences, Tokyo, Japan 

and 4 Department of Animal Husbandry, Faculty 

of Agriculture, Kasetsart University, Bangkok, 

Thailand. 

Abstract # 


THE EFFECT OF NEONATAL GENISTEIN 

EXPOSURE ON AFLATOXIN B1 

METABOLISM AND TOXICITY IN RATS. 

S. Poapolathep 1 , A. Poapolathep 2 , K. Machii 3 , H. 

Nakayama 4 , Y. Sugita-konishi 3 and S. Kumagai 1,5 . 

1 

Department of Veterinary Public Health, Graduate 

School of Agricultural and Life Sciences, The 

University of Tokyo, Tokyo, Japan, 2 Department 

of Pharmacology, Faculty of Veterinary Medicine, 

Kasetsart University, Bangkok, Thailand, 3 The 

National Institute of Health Sciences, Tokyo, Japan, 

4 

Department of Veterinary Pathology, Graduate 

School of Agricultural and Life Sciences, The 

University of Tokyo, Tokyo, Japan and 5 Research 

Center for Food Safety, The University of Tokyo, 

Tokyo, Japan. 


MOLECULAR CLONING AND 

CHARACTERIZATION OF HEPATIC 

ALPHA-CLASS GLUTATHIONE 

S-TRANSFERASES FROM TURKEYS 

AND THEIR ROLE IN AFLATOXIN B1 

SUSCEPTIBILITY. J. Kim, B. Bunderson, A. 

Croasdell and R. A. Coulombe. Department of 

Veterinary Sciences, Utah State University, Logan, 

UT. 


METABOLIC INTERACTION OF MENTHOL 

WITH NICOTINE IN IN VITRO AND IN VIVO 

TEST SYSTEMS. W. Pace 1 , D. Hala 1 , M. Hagan- 

Hughes 2 , B. J. Venables 1 and D. B. Huggett 1 . 1 IAS, 

University of North Texas, Denton, TX and 2 Lorillard 

Tobacco Company, Greensboro, NC. Sponsor: J. 

Harbell. 


BIOACTIVATION OF ISONIAZID BY 

HEPATIC MICROSOMES. T. Nakagawa, 

Y. Choi, I. Metushi and J. Uetrecht. Faculty of 


Canada. 


INVESTIGATION OF THE ROLE OF 

SULFOCONJUGATION IN NEVIRAPINE- 

INDUCED SKIN RASH. M. Novalen and J. P. 

Uetrecht. Pharmaceutical Science, University of 



IN VITRO METABOLISM OF 

6-2FLUOROTELOMER ALCOHOL IN RAT, 

MOUSE, AND HUMAN HEPATOCYTES. S. 

Gannon 1 , D. L. Nabb 1 , T. A. Snow 1 , M. P. Mawn 1 , T. 

L. Serex 1 , R. C. Buck 2 and S. E. Loveless 1 . 1 Dupont 

Haskell Global Centers, Newark, DE and 2 DuPont 

Chemical Solutions Enterprise, Wilmington, DE. 


HUMAN CYTOCHROME P450 2S1 IS 

ENABLE TO UTILIZE FATTY ACID 

HYDROPEROXIDES TO SUPPORT 

BENZO[A]PYRENE-7, 8-DIHYDRODIOL’S 

BIOACTIVATION. P. H. Bui 1 , E. Hsu 2 and O. 

Hankinson 1 . 1 Pathology of Laboratory Medicine, 

University of California, Los Angeles, Los Angeles, 

CA and 2 Feinberg School of Medicine, Northwestern 

University, Chicago, IL. 

MOnday 







141


MOnday 




BEAS2B CELLS AS A MODEL OF 

BENZO[A]PYRENE METABOLISM IN 

NONCANCEROUS HUMAN LUNG: A 

FUNCTIONAL GENOMICS APPROACH 

TOWARD UNDERSTANDING METABOLIC 

CONSEQUENCES OF GENE EXPRESSION. 

M. E. Kushman and T. M. Penning. Pharmacology 

and Center of Excellence in Environmental 

Toxicology, University of Pennsylvania, 

Philadelphia, PA. 


O-METHYLATION OF PAH CATECHOLS 

AS A DETOXIFICATION ROUTE FOR PAH 

O-QUINONES. L. Zhang 1 , S. Gelhaus 2 , I. A. 

Blair 2 and T. M. Penning 1 . 1 Centers of Excellence 

in Environmental Toxicology, Department of 

Pharmacology, University of Pennsylvania, 

Philadelphia, PA and 2 Cancer Pharmacology, 

Department of Pharmacology, University of 

Pennsylvania, Philadelphia, PA. 


GREATER INDUCTION OF SELECT 

CYTOCHROME P450 ACTIVITIES BY 

AROCLOR 1254 IN CYP1A2(-/-) AS 

COMPARED TO WILD-TYPE MICE. M. 

R. Franklin 1 , M. L. Barker 1 , D. D. Arch 1 , L. B. 

Hathaway 1 , M. L. Westbroek 1 , J. P. Kushner 2 and 

J. D. Phillips 2 . 1 Pharmacology and Toxicology, 

University of Utah, Salt Lake City, UT and 2 Internal 

Medicine, University of Utah, Salt Lake City, UT. 


DETOXIFICATION OF ARISTOLOCHIC 

ACID I BY HUMAN CYP1A2: EVIDENCE 

FROM HUMAN LIVER MICROSOMES. E. 

C. Peck, C. C. White, D. P. Cox and D. L. Eaton. 

Environmental and Occupational Health Sciences, 

University of Washington, Seattle, WA. 


TAMOXIFEN-INDUCED ADDUCT 

FORMATION AND CELL STRESS IN 

HUMAN ENDOMETRIAL GLANDS. H. 

Andersson 1 , M. Helmestam 2 , A. Zebrowska 1 , 

M. Olovsson 2 and E. Brittebo 1 . 1 Department of 

Pharmaceutical Biosciences, Uppsala University, 

Uppsala, Sweden and 2 Department of Women’s and 

Children’s Health, Uppsala University, Uppsala, 

Sweden. Sponsor: M. Stigson. 


MICE DEFICIENT IN THE GENE FOR 

CYTOCHROME P450 (CYP)1B1 ARE LESS 

SUSCEPTIBLE TO HYPEROXIC LUNG 

INJURY. B. Moorthy, B. A. Bou Aram, L. Wang, X. 

I. Couroucli and W. Jiang. Pediatrics, Baylor College 

of Medicine, Houston, TX. 


IMPROVEMENT OF EXTRACTION 

EFFICIENCY OF UNBOUND 

RADIOLABELED COMPOUNDS IN 

MICROSOMAL BIOACTIVATION AND 

BINDING STUDIES. H. Chen 1 , H. Webb 1 , R. 

Ulrich 1 , X. Teng 2 , D. Kwok 2 , A. Li 2 , C. Zhang 2 and E. 

Leung 2 . 1 Calistoga Pharmaceuticals, Inc., Seattle, WA 

and 2 BRI, Vancouver, BC, Canada. 


IN VITRO METABOLISM OF SELECT 

PHARMACEUTICALS IN THE INTESTINE 

OF RAINBOW TROUT (ONCORHYNCHUS 

MYKISS). C. Overturf, C. Gomez and D. Huggett. 

Institute of Applied Science, University of North 

Texas, Denton, TX. Sponsor: J. Harbell. 


1:00 PM to 4:30 PM 

Exhibit Hall 


Poster Session: Toxicity Testing—Alternative Models II 

Chairperson(s): Nandita Shagari, Novartis Institutes for Bio Medical 

Research, East Hanover, NJ. 




C. ELEGANS AS A MODEL SYSTEM 

TO UNDERSTAND ENVIRONMENTAL 

INFLUENCE ON GERMLINE HEALTH. 

P. Allard and M. Colaiacovo. Genetics, Harvard 

Medical School, Boston, MA. 


ANALYSIS OF THE TOXCAST 320 

PESTICIDE LIBRARY USING A 

CAENORHABDITIS ELEGANS GROWTH 

ASSAY. W. A. Boyd 1 , M. V. Smith 2 and J. H. 

Freedman 3 . 1 NTP, NIEHS, Research Triangle Park, 

NC, 2 SRA International, Research Triangle Park, NC 

and 3 LMT, NIEHS, Research Triangle Park, NC. 


C. ELEGANS REPLICATE MOUSE MODEL 

OF COLD SENSITIVITY. D. Avila 1 , V. Exil 1 , 

A. Benedetto 2 , C. Au 1 and M. Aschner 1 . 1 Pediatrics/ 

Toxicology, Vanderbilt University, Nashville, TN and 

2 

London Center for Nanotechnology, London, United 

Kingdom. 


DOSE-RESPONSE SCREENING OF THE 

TOXCAST CHEMICAL LIBRARY USING A 

ZEBRAFISH DEVELOPMENTAL ASSAY. S. 

Padilla 1 , B. Padnos 1 , D. L. Hunter 1 , D. Corum 2 , D. 

M. Reif 2 , K. A. Houck 2 , T. B. Knudsen 2 , M. T. Martin 2 

and D. J. Dix 2 . 1 ISTD/NHEERL, U.S. EPA, Research 

Triangle Park, NC and 2 NCCT, U.S. EPA, Research 



TOXIC EFFECTS OF AFLATOXIN B1 TO 

THE DEVELOPMENT, REPRODUCTION, 

AND BEHAVIOR OF THE NEMATODE 

CAENORHABDITIS ELEGANS. H. Ma, L. Tang, 

P. L. Williams and J. S. Wang. The University of 

Georgia, Athens, GA. 


ZEBRAFISH MAZE BEHAVIORAL ASSAYS. 

G. G. Gould 1 and B. W. Brooks 2 . 1 Physiology, 

University of Texas Health Science Center at San 

Antonio, San Antonio, TX and 2 Environmental 

Science, Baylor University, Waco, TX. 

142 






Platform Sessions



Abstract # 


METABOLIC DEACTIVATION OF 

ALBENDAZOLE IN THE ZEBRAFISH 

EMBRYO TOXICITY TEST COMBINED 

WITH AN EXOGENOUS MAMMALIAN 

METABOLIZING SYSTEM. A. Mattsson, E. 

Ullerås, G. Carlsson and A. Oskarsson. Biomedical 

Sciences and Veterinary Public Health, Swedish 

University of Agricultural Sciences, Uppsala, 

Sweden. 


ZEBRAFISH: A PREDICTIVE MODEL 

FOR ASSESSING COMPOUND INDUCED 

NEUROTOXICITY. P. McGrath, W. Seng and C. 

Li. Phylonix, Cambridge, MA. 


HIGH-THROUGHPUT GENE 

TRANSFECTION AND RNA INTERFERENCE 

ON A THREE-DIMENSIONAL (3D) 

CELL MICROARRAY PLATFORM FOR 

TOXICOLOGY SCREENING. M. Lee 1 , H. 

Zhang 2 , S. Kwon 2 , M. G. Hogg 1 , S. T. Sharfstein 2 , J. 

S. Dordick 2 and D. Rozzell 1 . 1 Solidus Biosciences, 

Inc., San Francisco, CA and 2 Chemical and 

Biological Engineering, Rensselaer Polytechnic 

Institute, Troy, NY. 


THE USE OF LENS EXPLANT CULTURES 

TO STUDY THE MECHANISMS OF DRUG- 

INDUCED CATARACTOGENESIS. N. 

Shangari 1 , S. Sampath 1 , L. McLean 1 , C. Buono- 

Dalton 2 , M. Gurnani 1 , V. Richard 2 , E. Cruz 1 , P. Patel 1 , 

A. Reising 1 , D. Hordych 5 , J. Schiner 4 , K. Wagner 4 , 

D. Schiavo 5 , F. Pognan 3 and A. Wolf 3 . 1 Investigative 

Toxicology, NIBR, East Hanover, NJ, 2 Investigative 

Toxicology, NIBR, Cambridge, NJ, 3 Investigative 

Toxicology, NIBR, Basel, Switzerland, 4 Pathology, 

NIBR, East Hanover, NJ and 5 Preclinical Safety, 

NIBR, East Hanover, NJ. 


DEVELOPMENT OF A VAPOR CUP 

DOSING METHOD FOR EVALUATION 

OF CHEMICAL TOXICITY IN THE 

EPIAIRWAY ORGANOTYPIC IN VITRO 

HUMAN AIRWAY MODEL. G. R. Jackson, 

J. Bolmarcich, D. Booth, M. Klausner and P. J. 

Hayden. MatTek Corporation, Ashland, MA. 


DEVELOPMENT OF A BARRIER- 

COMPROMISED HUMAN SKIN MODEL 

FOR IN VITRO PERCUTANEOUS 

PENETRATION STUDIES. J. Demetrulias 1 , K. 

Acuff 2 , L. Aust 3 , J. Avalos 4 , J. Burdick 5 , K. Cater 3 , 

C. Eisenmann 6 , R. Foxenberg 7 , E. Gilberti 8 , L. 

Loretz 6 , T. McCarthy 9 , J. Nash 11 , K. Ruble 10 and H. A. 

Raabe 11 . 1 Technikos Research Associates, Scottsdale, 

AZ, 2 Procter & Gamble Co., Cincinnati, OH, 3 Dial/ 

Henkel Corp., Scottsdale, AZ, 4 KAO Brands Co., 

Cincinnati, OH, 5 Beauty Avenues, Reynoldsburg, 

OH, 6 Personal Care Products Council, Washington, 

DC, 7 Kimberly-Clark Corp., Neenah, WI, 8 Avon 

Products, Inc., Suffern, NY, 9 Johnson & Johnson 

Consumer Products Worldwide, Skillman, NJ, 

10 

Schering-Plough Healthcare, Memphis, TN and 

11 

Institute for In Vitro Sciences, Inc., Gaithersburg, 

MD. 

Abstract # 


INCORPORATING FLOW CYTOMETRY 

BASED AUTOMATED SCORING INTO THE 

RECONSTRUCTED SKIN MICRONUCLEUS 

ASSAY. S. Bryce 2 , E. L. Dahl 1 , G. Mun 1 , S. 

Avlasevich 2 , S. Dertinger 2 and R. Curren 1 . 1 IIVS, 

Gaithersburg, MD and 2 Litron Laboratories, 

Rochester, NY. 


BOVINE CORNEAL OPACITY AND 

PERMEABILITY ASSAY—RESULTS OF A 

TWO LABORATORY REPRODUCIBILITY 

STUDY. K. Cater 1 , D. Cerven 2 , R. Curren 3 , N. 

Wilt 3 and H. A. Raabe 3 . 1 The Dial Corporation, A 

Henkel Company, Scottsdale, AZ, 2 MB Research 

Laboratories, Spinnerstown, PA and 3 Institute for In 

Vitro Sciences, Inc., Gaithersburg, MD. 


EVALUATING PORCORA FOR USE IN 

CONSUMER PRODUCTS TO ACCURATELY 

PREDICT OCULAR INJURY AND 

REVERSIBILITY. K. E. Eblin 1 , F. A. Jones 1 , 

C. L. Steele 1 and M. Piehl 2 . 1 GSARA, SC Johnson 

and Son, Inc., Racine, WI and 2 MB Research Labs, 

Spinnerstown, PA. 


IS IT POSSIBLE TO EXTEND STORAGE 

OF CORNEAS FOR USE IN THE BCOP 

ASSAY? L. C. Akhurst, J. O. Hubbard and J. 

N. Carter. Huntingdon Life Sciences, Alconbury, 

Cambridgeshire, United Kingdom. Sponsor: E. 

Moore. 


IMPACT OF EXTRACELLULAR MATRIX 

(ECM) ON CELLULAR RESPONSES TO 

CONTACT SENSITIZERS. C. Portsmouth 1 , 

G. Maxwell 2 , R. Pendlington 2 , I. Kimber 2 and R. J. 

Dearman 1 . 1 Faculty of Life Sciences, Manchester 

University, Manchester, United Kingdom and 

2 

Unilever Safety & Environmental Assurance Centre, 

Bedford, United Kingdom. 


EVALUATION OF IN VITRO MODELS 

FOR REACH TOXICITY TESTING: 

INDUCIBILITY OF XENOBIOTIC 

METABOLIZING ENZYME (XME) 

ACTIVITY IN IN VITRO HUMAN AIRWAY 

(EPIAIRWAY) AND EPIDERMAL 

(EPIDERM) MODELS. J. Bolmarcich 1 , G. 

Zhao 2 , L. Morgan 2 , G. R. Jackson 1 , M. Klausner 1 , T. 

Falzareno 2 and P. J. Hayden 1 . 1 MatTek Corporation, 

Ashland, MA and 2 Tandem Labs, Woburn, MA. 


FURTHER DEVELOPMENT OF AN 

EPIDERM IN VITRO SKIN IRRITATION 

TEST FOR THE GLOBALLY HARMONIZED 

SYSTEM OF CLASSIFICATION AND 

LABELING OF CHEMICALS. A. Armento 1 , 

H. Kandarova 2,1 , M. Klausner 1 and P. J. Hayden 1 . 

1 

MatTek Corporation, Ashland, MA and 2 MatTek 

In Vitro Life Sciences Laboratories, Bratislava, 

Slovakia. 

MOnday 







143


MOnday 




PORCINE CORNEAL OCULAR 

REVERSIBILITY ASSAY (PORCORA) 

PREDICTS EU R41 AND GHS CATEGORY 

1. M. Piehl, R. Soda, M. Carathers, G. L. DeGeorge 

and D. R. Cerven. MB Research Laboratories, 

Spinnerstown, PA. 


ESR EVIDENCES OF NO2 DERIVED 

PEROXYNITRITE AS TRIGGERING 

NEWER DIESEL ENGINE EMISSION 

LUNG OXIDANT INJURY—OXIDATION 

CATALYSIS RESPONSIBILITY. J. Morin 1 , V. 

Hasson 1 , D. Preterre 2 , V. Keravec 2 and F. Dionnet 2 . 

1 

U644, Inserm, Rouen, France and 2 Certam, Saint 

Etienne Du Rouvray, France. Sponsor: R. Forster. 


THE INFLUENCE OF PHORTRESS 

ON CYTOKINE LEVELS AND TISSUE 

VIABILITY IN PRECISION-CUT RAT LUNG 

TISSUE. M. J. Furniss 1 , R. E. Parchment 1 , J. E. 

Tomaszewski 2 and H. P. Behrsing 1 . 1 Predictive 

Toxicology Section, Laboratory of Human 

Toxicology and Pharmacology, SAIC-Frederick/NCI- 

Frederick, Frederick, MD and 2 Division of Cancer 

Treatment & Diagnosis, National Cancer Institute, 

Bethesda, MD. 


TYPE III DEIODINASE (D3) IS PROTECTIVE 

AGAINST THYROTOXICOSIS DURING 

HUMAN IN VITRO NEUROGENESIS. M. 

Vieira, T. Patel, A. Nuth, R. Brockman and D. C. 

Ferguson. Veterinary Biosciences, University of 

Illinois at Urbana-Champaign, Urbana, IL. 


EPIDERM FULL THICKNESS SKIN 

CULTURES (EFT) AS AN IN VITRO MODEL 

FOR WOUND HEALING. M. Sachdeva 1 , U. S. 

Desai 1 , R. R. Patlolla 1 , R. Mallampati 1 , M. Klausner 2 

and P. J. Hayden 2 . 1 Pharmacy, Florida A&M 

University, Tallahassee, FL and 2 MatTek Corporation, 

Ashland, MA. 


ACTIVATION OF PROTEASE-ACTIVATED 

RECEPTOR-2 BY SERINE PROTEASE 

ENZYMES STIMULATES MCSF 

RELEASE FROM HUMAN RESPIRATORY 

EPITHELIAL CELLS. T. Hu 1 , M. Baccam 1 , E. 

Roggen 2 , N. Berg 2 and K. Sarlo 1 . 1 Central Product 

Safety, Procter & Gamble, Cincinnati, OH and 

2 

Novozymes, Bagsvaerd, Denmark. 


PORCORA OCULAR REVERSIBILITY 

ASSAY TESTING WITH PERSONAL CARE 

PRODUCTS. D. R. Cerven 1 , M. Piehl 1 , G. L. 

DeGeorge 1 , D. A. Donahue 2 and J. Avalos 2 . 1 MB 

Research Laboratories, Spinnerstown, PA and 2 Kao 

Brands Company, Cincinnati, OH. 


CHARACTERIZATION OF N-ACETYL 

AND GLUTATHIONE S-TRANSFERASE 

ACTIVITIES IN SKIN AND 

RECONSTRUCTED HUMAN SKIN MODELS. 

J. Eilstein, G. Léreaux, E. Daronnat, J. Meunier, J. 

Leclaire and D. Duché. Safety Research Department 

- Life Sciences Research, L’Oréal, Paris, France. 

Sponsor: G. Nohynek. 


CULTURE OF ORGANOTYPIC, 

3-DIMENSIONAL TISSUE MODELS— 

IMPORTANCE OF SUBSTRATE 

PROPERTIES. J. E. Sheasgreen, J. Kubilus, M. 

Klausner, H. Kandarova and P. J. Hayden. MatTek 

Corp, Ashland, MA. 


IN VITRO EYE IRRITATION ASSESSMENT 

OF COLORED SUBSTANCES BY USING 

THE SKINETHICTM HCE OCULAR TEST 

METHOD. F. Amaral, M. Grandidier, D. Lelièvre 

and J. Cotovio. L’Oréal, Aulnay Sous Bois, France. 



AN EVALUATION OF THE EPIDERM 

CORROSIVITY AND CORROSITEX ® ASSAYS 

FOR PREDICTING SKIN CORROSIVITY OF 

CHEMICAL PRODUCTS WITH EXTREME 

ALKALINE PH. A. M. Burrows 1 , S. S. Willems 1 , 

F. Heitfeld 1 , J. L. Treichel 1 , H. Raabe 2 and R. 

Curren 2 . 1 Global Product Safety, JohnsonDiversey, 

Inc., Sturtevant, WI and 2 Institute for In Vitro 

Sciences, Gaithersburg, MD. 


A SIMPLE AND FAST KINETICS 

SCREENING ASSAY FOR ELECTROPHILIC 

DERMAL SENSITIZERS USING 

NITROBENZENETHIOL. T. B. Ruwona 1,2 , I. 

Chipinda 1 , R. Ajibola 2 , M. K. Morakinyo 2 , R. H. 

Simoyi 2 and P. D. Siegel 1 . 1 ACIB, NIOSH/CDC, 

Morgantown, WV and 2 Chemistry Department, 

Portland State University, Oregon. 


INTEGRATED IN VITRO VAGINAL 

SAFETY SCREENING APPROACH FOR 

BATH AND BODY WASH PRODUCTS 

UTILIZING SKINETHIC HUMAN VAGINAL 

EPITHELIUM (HVE) MODEL. V. Srinivasan 1 , 

T. Re 1 , A. Alonso 2 , B. Bertino 2 , G. Costin 3 , A. de 

Brugerolle de Fraissinette 2 , D. Orak 1 , H. Inglis 3 , 

P. Kazmi 1 and H. Raabe 3 . 1 L’Oréal USA Products, 

Clark, NJ, 2 Skinethic Laboratories, Nice, France 

and 3 Institute for In Vitro Sciences, Inc. (IIVS), 



DEVELOPMENT AND 

CHARACTERIZATION OF HUMAN AND 

MOUSE PRIMARY EPITHELIAL CELL 

CULTURES FOR ASSESSING ARSENIC 

TOXICITY. P. C. Wilga 1 , J. W. Yager 2 , H. Clewell 3 , 

R. Thomas 3 , G. Gill 4 , R. Gentry 5 and J. M. McKim, 

Jr. 1 . 1 CeeTox, Kalamazoo, MI, 2 University of New 

Mexico, Albuquerque, NM, 3 Hamner Institute, 

Research Triangle Park, NC, 4 Battelle Marine 

Sciences Lab, Sequim, WA and 5 EPRI-Environment 

Monroe, LA. 

144 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Advances in Dermal Toxicology 

Chairperson(s): Lauren Markell, The Pennsylvania State University, 

University Park, PA. 




DERMAL ABSORPTION IN RATS EXPOSED 

BODY-ONLY AND NOSE-ONLY TO 

CHEMICAL VAPORS. A. J. O’Neill, L. Crouse 

and M. A. Bazar. Directorate of Toxicology, U.S. 


Medicine, Aberdeen Proving Ground, MD. 


FROM TOPICAL ANTIDOTE AGAINST 

SKIN IRRITANTS TO A NOVEL COUNTER- 

IRRITATING AND ANTI-INFLAMMATORY 

PEPTIDE. U. Wormser 1 , M. Aschner 2 , Y. 

Schussheim 1 , A. Rosengarten 1 , E. Proscura 1 , E. 

Shapira 1 and B. Brodsky 1 . 1 The Hebrew University, 

Jerusalem, Israel and 2 Vanderbilt University Medical 

Center, Nashville, TN. 


PREDICTING SKIN PERMEABILITY: 

INCORPORATION OF CHEMICAL 

MIXTURE EFFECTS INTO SIMPLE 

QUANTITATIVE STRUCTURE 

PERMEATION RELATIONSHIPS (QSPER). 

J. E. Riviere and J. D. Brooks. Center for Chemical 

Toxicology Research and Pharmacokinetics, North 

Carolina State University, Raleigh, NC. 


DEVELOPMENT OF QUANTITATIVE 

METHODS FOR ASSESSING SOLAR 

UV-INDUCED GENOTOXICITY ON 

RECONSTRUCTED SKIN: DNA DAMAGE, 

P53 STATUS, AND APOPTOSIS. E. Planel, L. 

Marrot, J. Belaidi, C. Jones, P. Perez and J. Meunier. 

L’Oréal, Aulnay, France. Sponsor: G. Nohynek. 


MST2000 - A NEW RECONSTRUCTED 

HUMAN EPIDERMIS WITH INTEGRATED 

FUNCTIONAL PRIMARY MELANOCYTES. 

J. J. Hoffmann 1 , B. Becker 1 , A. Thiemann 2 , S. 

Weimans 2 , E. Heisler 2 and H. W. Fuchs 1 . 1 R & 

D, CellSystems Biotechnologie Vertrieb GmbH, 

St. Katharinen, Germany and 2 Laboratorium für 

Toxikologie und Ökologie, Evonik Stockhausen 

GmbH, Krefeld, NRW, Germany. Sponsor: B. De 

Wever. 


IN VITRO PREDICTION OF THE VALIDATED 

SKINETHIC RHE “42 BIS” SKIN 

IRRITATION TEST METHOD FOR THE 

GLOBALLY HARMONIZED SYSTEM (GHS) 

OF CLASSIFICATION AND LABELLING OF 

CHEMICALS. A. de Brugerolle de Fraissinette 1 , 

C. Tornier 1 , J. Cotovio 2 , J. Meunier 2 and N. Alépée 2 . 

1 

SkinEthic Laboratories, Nice, France and 2 L’Oréal, 

Aulnay sous Bois, France. Sponsor: G. Nohynek. 

Abstract # 


MEETING REQUIREMENTS OF THE 

NEW OECD TG 404 FOR IN VITRO SKIN 

IRRITATION TESTING: REPRODUCIBILITY 

OF THE EPIDERM SKIN IRRITATION 

TEST (EPIDERM-SIT) FOLLOWING THE 

ECVAM VALIDATION AND ACCEPTANCE 

AS A FULL REPLACEMENT METHOD. M. 

Klausner, H. Kandarova, P. J. Hayden, J. Kubilus and 

J. E. Sheasgreen. MatTek Corp, Ashland, MA. 


USE OF THE STRATATEST ® FULL- 

THICKNESS HUMAN SKIN MODEL FOR 

IRRITANCY AND CORROSIVITY TESTING. 

K. R. Gratz, C. A. Rasmussen, S. C. Pirnstill, P. 

Nataraj, N. J. Simon, M. C. Vander Zanden and L. 

Allen-Hoffmann. Stratatech Corporation, Madison, 

WI. 


CHARACTERIZATION OF ESTERASE, 

GLUCURONYL, AND SULFO 

TRANSFERASE ACTIVITIES IN SKIN AND 

RECONSTRUCTED HUMAN SKIN MODELS. 

D. Duche, G. Lereaux, J. Eilstein, J. Meunier and J. 

Leclaire. Life Sciences, L’Oréal Research, Aulnay 

Sous Bois, France. Sponsor: G. Nohynek. 


TRANSCRIPTIONAL CHANGES IN 

PORCINE SKIN EXPOSED TO BROMINE 

VAPOR. J. Price 1 , J. Rogers 1 , M. Wendling 1 , M. 

Perry 1 , R. Kiser 1 , F. Reid 1 and J. Graham 2 . 1 Battelle, 

Columbus, OH and 2 USAMRICD, Aberdeen Proving 

Ground, MD . 


DETERMINATION OF A WIDER CHEMICAL 

SPACE CAN IMPROVE ESTIMATES OF 

SKIN PERMEABILITY. R. E. Baynes, V. Vijay 

and J. E. Riviere. Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina State 



IN VITRO ACUTE SKIN IRRITATION 

ASSESSMENT OF COLORED / COLORING 

TEST SUBSTANCES BY USING VALIDATED 

EPISKIN TM AND SKINETHIC TM RHE “42 

BIS” TEST METHODS. C. Tornier 2 , F. Amaral 1 , 

B. Bertino 2 , A. De Brugerolle de Fraissinette 2 , N. 

Alépée 1 , J. Meunier 1 and J. Cotovio 1 . 1 L’Oréal, 

Aulnay Sous Bois, France and 2 SkinEthic 

Laboratories, Nice, France. Sponsor: G. Nohynek. 


IN VITRO ASSESSMENT OF SKIN 

IRRITATION USING THE VALIDATED 

EPISKIN TM TEST METHOD: GLOBAL 

PERFORMANCES ACCORDING TO THE 

GSH-EU CLASSIFICATION. J. Cotovio, D. 

Lelièvre, M. Grandidier, R. Roguet and J. Leclaire. 

L’Oréal, Aulnay Sous Bois, France. Sponsor: G. 

Nohynek. 

MOnday 







145


MOnday 




1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Carcinogenesis II 

Chairperson(s): Joseph Landolph, University of Southern California, 

Los Angeles, CA, and Rhonda Rosengren, University of Otago, Dunedin, 

New Zealand. 




DEER VELVET EXTRACT DECREASES 

THE GRADE AND METASTASIS OF AOM- 

INDUCED COLON CANCER IN THE MALE 

WISTAR RAT. R. J. Rosengren 1 , A. Frasier 3 , E. 

C. Stuart 1 , M. J. Scandlyn 1 , T. J. Somers-Edgar 1 , 

A. Alexander 1 and S. R. Haines 2 . 1 Pharmacology 

& Toxicology, Univeristy of Otago, Dunedin, 

New Zealand, 2 Invermay Agricultural Centre, 

AgResearch, Mosgiel, New Zealand and 3 Gribbles 

Veterinary Diagnostic Laboratory, Palmerston North, 

New Zealand. 


TRANSCRIPTIONAL PROFILE OF DIURON- 

INDUCED TOXICITY ON THE URINARY 

BLADDER OF MALE WISTAR RATS TO 

INFORM MODE OF ACTION. S. M. Ihlaseh 1 , 

K. Bailey 2 , S. Hester 2 , A. F. Cardoso 1 , M. Rosen 2 , C. 

Jones 2 , H. Ren 2 , M. C. Oliveira 1 , D. Wolf 2 and J. V. 

Camargo 1 . 1 Pathology, São Paulo State University 

- Botucatu Medical School, Botucatu, São Paulo, 

Brazil and 2 NHEERL, ORD, U.S. EPA, Research 

Triangl Park, NC. 


DERMAL CARCINOGENICITY 

EVALUATION OF ASPHALT (BITUMEN) 

FUME CONDENSATES. C. R. Clark 1 , D. M. 

Burnett 2 , C. M. Parker 3 , E. Arp 4 , M. S. Swanson 3 , 

G. D. Minsavage 5 , A. J. Kriech 6 , L. V. Osborn 6 , J. 

J. Freeman 5 , R. A. Barter 5 , C. W. Stewart 7 and P. E. 

Newton 7 . 1 ConocoPhillips, Bartlesville, OK, 2 BP 

Corporation, Naperville, IL, 3 Marathon Petroleum, 

Findlay, OH, 4 Asphalt Institute, Lexington, KY, 

5 

ExxonMobil Biomedical Sciences, Inc., Annandale, 

NJ, 6 Heritage Research Group, Indianapolis, IN and 

7 

MPI Research, Mattawan, MI. 


CONSENSUS DIAGNOSES AND MODE- 

OF-ACTION (MOA) FRAMEWORK 

FOR THE FORMATION OF GASTRIC 

NEUROENDOCRINE CELL TUMORS 

IN RATS TREATED WITH THE 

CHLOROACETANILIDE HERBICIDES 

ALACHLOR AND BUTACHLOR. J. H. 

Sherman 1 , S. Furukawa 2 , M. Iatropoulos 3 , D. Thake 4 

and T. Harada 5 . 1 Monsanto Company, St. Louis, 

MO, 2 Nissan Chemical Industries, Tokyo, Japan, 

3 

New York Medical College, Valhalla, NY, 4 Midwest 

ToxPath Sciences, St. Louis, MO and 5 Institute of 

Environmental Toxicology, Tokyo, Japan. 


REDOX CYCLING BY ENDOGENOUS 2- 

AND 4-HYDROXYESTROGEN CATECHOL 

METABOLITES IS ASSOCIATED WITH 

OXIDATIVE STRESS IN HUMAN BREAST 

EPITHELIAL CELL LINES. K. C. Fussell 1 , 

R. G. Udasin 1 , P. J. Smith 3 , M. A. Gallo 1,2 and J. D. 

Laskin 1,2 . 1 Joint Graduate Program in Toxicology, 

Rutgers University/UMDNJ, Piscataway, NJ, 

2 

Environmental & Occupational Medicine, UMDNJ- 

Robert Wood Johnson Medical School, Piscataway, 

NJ and 3 BioCurrents Research Center, Marine 

Biological Laboratory, Woods Hole, MA. 


CIGARETTE-SMOKE-INDUCED CELLULAR 

TRANSFORMATION IN VITRO USING THE 

BHAS 42 CELL TRANSFORMATION ASSAY. 

D. Weisensee and J. Schueller. Philip Morris 

International, Philip Morris Research Laboratories 

GmbH, Cologne, Germany. Sponsor: E. Roemer. 


THE HYPOXIA INDUCIBLE 

TRANSCRIPTION FACTOR HIF IS 

STABILIZED IN MICE TREATED WITH 

2-BUTOXYETHANOL. C. Somps 1 , K. Miller 2 , 

D. Robert 3 and S. Christopher 3 . 1 Drug Safety, Pfizer 

Global R&D, Groton, CT, 2 GeMM CoE, Pfizer 

Global R&D, Groton, CT and 3 Obesity Translational 

Pharmacology, Pfizer Global R&D, Groton, CT. 


MOUSE ENDOTHELIAL CELL SURVIVAL 

AND PROLIFERATION REQUIRE 

UPREGULATED ANGIOPOIETIN-2 UNDER 

HYPOXIA. C. Somps and S. Xia. Drug Safety, 

Pfizer Global R&D, Groton, CT. 


WEIGHT-OF-EVIDENCE ANALYSIS OF 

HYDROQUINONE AND LEUKEMIA. D. G. 

Dodge 1 , J. E. Goodman 2 and B. D. Beck 2 . 1 Gradient, 

Seattle, WA and 2 Gradient, Cambridge, MA. 


ASCORBIC ACID INHIBITS COLON 

CANCER CELL GROWTH BY INDUCING 

ROS-DEPENDENT DOWNREGULATION 

OF SPECIFICITY PROTEIN (SP) 

TRANSCRIPTION FACTORS. S. Pathi 1 and S. 

Safe 1,2 . 1 Veterinary Physiology and Pharmacology, 

Texas A&M University, College Station, TX and 

2 

Center for Environmental and Genetic Medicine, 

Institute of Biosciences and Technology, Houston, 

TX. 


EFFECTS OF PEROXISOME 


GAMMA (PPARg) AGONISTS ON 

ENDOTHELIAL CELLS: DIFFERENCES 

BETWEEN SARCOMAGENIC 

TROGLITAZONE AND NON- 

SARCOMAGENIC PIOGLITAZONE. S. 

Kakiuchi-Kiyota 1 , M. Yokohira 1 , S. Suzuki 2 , L. L. 

Arnold 1 , K. L. Pennington 1 , R. K. Singh 1 and S. M. 

Cohen 1 . 1 Pathology and Microbiology, University 

of Nebraska Medical Center, Omaha, NE and 

2 

Experimental Pathology and Tumor Biology, 

Nagoya City University Graduate School of Medical 

Sciences, Nagoya, Japan. 

146 






Platform Sessions



Abstract # 


GLOBAL GENE EXPRESSION ANALYSIS 

REVEALS DIFFERENCES IN CELLULAR 

RESPONSES TO HYDROXYL- AND 

SUPEROXIDE ANION RADICAL-INDUCED 

OXIDATIVE STRESS IN CACO-2 CELLS. J. 

J. Briede, J. M. van Delft, T. M. de Kok, M. H. van 

Herwijnen, L. M. Maas, R. W. Gottschalk and J. C. 

Kleinjans. Health Risk Analysis and Toxicology, 

Maastricht University, Maastricht, Netherlands. 

Sponsor: H. van Loveren. 


CAMP-DEPENDENT PATHWAY(S) DIRECTS 

THE RAP-GTP/B-RAF MAPK-MEDIATED 

CYTOSOLIC MISLOCALIZATION OF 

P27KIP-CYCLIN D1 IN RENAL CANCER. 

J. D. Cohen, K. Y. Tham, T. J. Monks and S. S. 

Lau. Pharmacology and Toxicology, University of 



CYTOTOXICITY AND ANTI-CANCER 

ACTIVITY OF NOVEL BROMOENOL 

LACTONE-BASED CA 2+ -INDEPENDENT 

PHOSPHOLIPASE A 2 

INHIBITORS. J. 

N. Mock, S. Patel, X. Lu, T. E. Long and B. S. 

Cummings. Pharmaceutical and Biomedical Science, 



EVIDENCE FOR FORMALDEHYDE- 

INDUCED LEUKEMIA AND LYMPHOMA 

IN LONG-TERM RODENT BIOASSAYS. D. 

DeVoney, J. Whalan and B. Sonawane. National 

Center for Environmental Assessment, U.S. EPA, 

Washington, DC. Sponsor: S. Vulimiri. 


EVALUATION OF THE MODE-OF-ACTION 

(MOA) FOR LIVER AND THYROID TUMORS 

IN MALE F344/DUCRL RATS WITH 

BENFLURALIN. N. J. Stagg 1 , D. R. Geter 2 , A. 

Wood 2 , M. J. Kan 2 , M. J. LeBaron 2 and R. Billington 1 . 

1 

Human Health Assessment, Dow AgroSciences, 

Indianapolis, IN and 2 Toxicology and Environmental 

Research Consulting, The Dow Chemical Company, 

Midland, MI. 


ARYL HYDROCARBON RECEPTOR (AHR) 

ACTIVATION DELAYS DMBA-INDUCED 

MAMMARY TUMOR FORMATION 

WITHOUT AFFECTING TUMOR 

INITIATION. T. Wang 1 , V. M. Arlt 2 and B. A. 

Vorderstrasse 1 . 1 Washington State University, 

Pullman, WA and 2 Institute of Cancer Research, 

Sutton, United Kingdom. 


DOSE-DEPENDENT INDUCTION OF 

HEPATIC PRENEOPLASTIC LESIONS 

BY DIETHYLNITROSAMINE IN C57BL/6 

MICE. M. Kushida 1,2 , S. M. Corthals 1 , T. J. Peat 1 , 

T. D. Baird 1 and J. E. Klaunig 1 . 1 Department of 

Parmacology and Toxicology, Indiana University 

School of Medicine, Indianapolis, IN and 

2 

Environmental Health Science Laboratory, 

Sumitomo Chemical Co., Ltd., Osaka, Japan. 

Abstract # 


KUPFFER CELLS PARTICIPATE IN 

BIS(2-ETHYLHEXYL)PHTHALATE AND 

PHENOBARBITAL-INDUCED HEPATIC 

TUMOR PROMOTION. T. J. Peat, M. Kushida, 

L. M. Kamendulis and J. E. Klaunig. Pharmacology 

and Toxicology, Indiana University, Indianapolis, IN. 


ALTERED DISTRIBUTIONS OF 

CALCIUM(+2) IONS IN NICKEL AND MCA- 

TRANSFORMED 10T1/2 MOUSE EMBRYO 

CELL LINES. J. R. Landolph 1,2,3 , D. Mai 1 , A. R. 

Harrison 2 , N. Garg 1 , E. Chang 1 , J. K. Lin 1 , J. Zheng 4 

and A. T. DeSilva 2 . 1 Molecular Microbiology and 

Immunology, University of Southern California, 

Los Angeles, CA, 2 Pathology, University of 

Southern California, Los Angeles, CA, 3 Molecular 

Pharmacology and Pharmaceutical Sciences, 

University of Southern California, Los Angeles, CA 

and 4 USC/Norris Comprehensive Cancer Center, 

University of Southern California, Los Angeles, CA. 


EFFECTS OF ANTIOXIDANTS ON 

ACRYLONITRILE-INDUCED OXIDATIVE 

STRESS IN FEMALE F344 RATS. X. Pu, 

Z. Wang, B. A. Hocevar, L. M. Kamendulis and 

J. E. Klaunig. Department of Pharmacology and 

Toxicology, Center for Environmental Health, 

Indiana University, Indianapolis, IN. 


SILENCING BENZENE-INDUCIBLE 

CYP4F3 GENE MODULATES HL-60 CELL 

PROLIFERATION. Y. Bi, Y. H. Li, M. M. Kong, 

H. You and H. Wang. Wuhan University School of 

Public Health, Wuhan, China. 


METALLIC NICKEL NANOPARTICLES 

MAY EXHIBIT HIGHER CARCINOGENIC 

POTENTIAL THAN FINE PARTICLES IN JB6 

CELLS. J. Zhao, L. Bowman, V. Castranova and M. 

Ding. NIOSH, Morgantown, WV. 


OXIDATIVE STRESS AND XRCC1 

ARG399GLN AND XPC LYS939GLN 

POLYMORPHISMS IN A TURKISH 

POPULATION WITH GASTRIC CANCER. B. 

A. Engin 1 , B. Karahalil 1 , A. Engin 2 and A. Karakaya 1 . 

1 

Department of Toxicology, Gazi University, Faculty 

of Pharmacy, Ankara, Turkey and 2 Department 

of General Surgery, Gazi University, Faculty of 

Medicine, Ankara, Turkey. 


EFFECT OF SULINDAC DERIVATIVES ON 

SPECIFICITY PROTEIN TRANSCRIPTION 

FACTORS IN COLON CANCER CELLS. 

X. Li 1 and S. Safe 2,3 . 1 College of Medicine, Texas 

A&M Health Science Center, College Station, TX, 

2 

Veterinary Physiology & Pharmacology, Texas 

A&M University, College Station, TX and 3 Institute 

of Biosciences & Technolgoy, Texas A&M Health 

Science Center, Houston, TX. 

MOnday 







147


MOnday 




ARSENIC TRIOXIDE DOWNREGULATION 

OF SPECIFICITY PROTEIN (SP) 

TRANSCRIPTION FACTORS IN BLADDER 

CANCER CELLS IS DEPENDENT ON 

REACTIVE OXYGEN SPECIES (ROS). I. 

D. Jutooru 1 , G. Chadalapaka 1 , S. Sreevalsan 1 , P. 

Lei 2 , R. Barhoumi 3 , R. Burghardt 3 and S. H. Safe 1,2 . 

1 

Veterinary Physiology and Pharmacology, Texas 

A&M University, College Station, TX, 2 Institute 

of Biosciences & Technology, Houston, TX and 

3 

Veterinary Integrative Biosciences, College Station, 

TX. 


SYNTHETIC OLEANOLIC ACID-DERIVED 

TRITERPENOIDS INHIBIT BLADDER 

CANCER CELL GROWTH AND SURIVIVAL 

AND DOWNREGULATE SPECIFICITY 

PROTEIN (SP) TRANSCRIPTION FACTORS. 

G. Chadalapaka 1 , I. D. Jutooru 1 and S. H. Safe 1,2 . 

1 



of Biosciences & Technology, Houston, TX. 


HEPATOCARCINOGENIC 

PHENOBARBITAL TREATMENTS ARE 

ASSOCIATED WITH EARLY, PERSISTENT 

ALTERATIONS IN THE EXPRESSION OF 

THE MIR-200 FAMILY IN THE LIVER OF 

MALE RAT. C. Koufaris 1 , J. Wright 2 , R. Currie 2 

and N. Gooderham 1 . 1 Biomolecular Medicine, 

Inperial College London, London, United Kingdom 

and 2 Syngenta, Bracknell, United Kingdom. Sponsor: 

P. Botham. 


IDENTIFICATION OF NON-GENOTOXIC 

CARCINOGENS USING NMR-BASED 

METABOLIC PROFILES AND BAYESIAN 

SIGNAL PROCESSING. D. Rubtsov 1 , D. 

Salazar 2 , J. Wright 2 , R. Currie 2 and J. Griffin 1 . 

1 

Cambridge University, Cambridge, United Kingdom 

and 2 Syngenta, Bracknell, United Kingdom. Sponsor: 

P. Botham. 


TIMING MATTERS IN PREVENTION OF 

BENZO(A)PYRENE (BAP)-INDUCED APC MIN 

MICE COLON TUMORS BY RESVERATROL 

(RVT). A. C. Huderson 1 , M. S. Niaz 1 , M. K. 

Washington 2 and A. Ramesh 1 . 1 Biochemistry 

& Cancer Biology, Meharry Medical College, 

Nashville, TN and 2 Pathology, Vanderbilt University, 



1:00 PM to 2:00 PM 

Room 155 F 

Exhibitor Hosted Session: Predictive In Vitro Model for 

Determining Additive or Synergistic Toxicity of Combinations 

of New Small Molecule Compounds and Standard Treatments 

Presented by: ReachBio LLC 

Although certain compounds alone may not exhibit myelotoxicity, they may 

cause unexpected neutropenia when given to specific patient populations in 

combination with other drugs. The talk will focus on in vitro CFC model for 

predicting clinical neutropenia of intentional or coincidental combination 

therapies. 


1:00 PM to 2:00 PM 

Room 155 B 

Exhibitor Hosted Session: Interests and Limitations of New 

In Vivo Methodologies to Assess the Potential Cardiovascular 

Effects of NCEs and Biologics in Large Animal Models 

Presented by: SNBL USA, Ltd. 

In NHPs, stress induced by manual restraint, complications of anesthesia, 

and limited data collection can confound Arterial blood pressure and ECG 

data and interpretation in Safety Pharmacology/Toxicology studies. The 

physiological and pharmacological validation of the new Jacketed External 

Telemetry (JET-BP System) will reveal the advantages and limitations of 

such methodology. 


1:00 PM to 2:00 PM 

Room 155 C 

Exhibitor Hosted Session: DNA Damage, PARP, and the 

CometAssay ® 

Presented by: Trevigen, Inc. 

The CometAssay ® is a valuable tool for monitoring strand breaks in DNA 

that result from exposure to genotoxic agents. Such exposure may initiate 

PARP 1 mediated DNA repair and mask DNA strand breaks. Conditions for 

optimal detection of both double and single strand breaks will be discussed. 


1:40 PM to 4:25 PM 

Room 151 


Symposium Session: Alterations in Regulatory T Cells: Novel 

Pathways to Immunotoxicology 

Chairperson(s): Emanuela Corsini, University of Milan, Milan, Italy, and 

Dori Germolec, NIEHS, Research Triangle Park, NC. 

Sponsor: 


Regulatory T cells (T(Regs)) have been shown to be critical in the maintenance 

of immune responses and T cell homeostasis. For example, depletion 

of CD4(+)CD25(+) T(Regs) from mice resulted in the development of 

multiorgan autoimmune diseases. CD4(+)CD25(+) T(Regs) and/or IL-10- 

producing Tr-1 cells are capable of modulating cell signaling thereby 

suppressing or attenuating Th2 responses to allergens. Moreover, adoptive 

transfer of CD4(+)CD25(+) T(Regs) from healthy to diseased animals 

resulted in the prevention or cure of certain autoimmune diseases, and was 

able to induce transplantation tolerance. Clinical improvement seen after 

allergen immunotherapy for allergic diseases such as rhinitis and asthma 

is associated with the induction of IL-10 and TGF-beta producing Tr-1 

cells as well as Foxp3 expressing IL-10 T cells, with resulting suppression 

of the Th2 cytokine signaling pathways and products. Activation, expansion 

or suppression of CD4(+)CD25(+) T(Regs) in vivo by xenobiotics, 

including drugs, may therefore represent a relevant mechanism underlying 

immunotoxicity, including allergic asthma, autoimmune disease, and immunosuppression. 

148 






Platform Sessions



Abstract # 

#536 1:40 ALTERATIONS IN REGULATORY 

T CELLS: NOVEL PATHWAYS TO 

IMMUNOTOXICOLOGY. E. Corsini 2 and D. 

Germolec 1 . 1 Toxicology Branch, National Toxicology 

Program, NIEHS, Research Triangle Park, NC 

and 2 Laboratory of Toxicology, Department of 

Pharmacological Sciences, University of Milan, 

Milan, Italy. 

#537 1:45 INTRODUCTION TO THE ROLE OF 

TREGS IN IMMUNITY. M. Oukka. Neurology, 

HARVARD, Cambridge, MA. Sponsor: D. Germolec. 

#538 2:25 ROLE OF IMMUNOREGULATORY CELLS 

IN CHEMICAL AND PROTEIN ALLERGY. 

R. Pieters 1,2 , M. Bol 1 , M. Marcondez Rezende 1 , I. 

Ludwig 1 and J. Smit 1 . 1 Institute for Risk Assessment 


and 2 Research Center for Life Sciences and 

Chemistry, University of Applied Sciences, Utrecht, 

Netherlands. 

#539 3:05 INDUCTION OF AHR-DEPENDENT 

TREGS: A NOVEL PATHWAY FOR TCDD 

IMMUNOTOXICITY. N. Kerkvliet and D. 

Rohlman. Environment & Molec. Toxicology, 

Oregon State University, Corvallis, OR. 

#540 3:45 SAFETY ASSESSMENT OF 

IMMUNOMODULATORY BIOLOGICS: 

THE PROMISE AND CHALLENGES OF 

REGULATORY T CELL MODULATION. R. 

Ponce. Comparative Biology and Safety Sciences, 

Amgen, Seattle, WA. 


1:40 PM to 4:25 PM 

Ballroom B 

Symposium Session: Faster Science for Better Decisions: 

Characterizing Environmental Contaminant Risk from 

High-Throughput Data 

Chairperson(s): David Dix, U.S. EPA, Research Triangle Park, NC, and 

Russell S. Thomas, The Hamner Institutes for Health Sciences, Research 


Sponsor: 


Endorsed by: 




Tens of thousands of chemicals and other man-made contaminants exist in 

our environment, but only a fraction of these have been characterized for 

their potential risk to humans and there is widespread interest in closing 

this data gap in order to better manage contaminant risk. Current practice 

of exposure estimation, toxicity testing, and risk characterization for environmental 

contaminants is too slow to support high quality science-based 

regulatory decisions for thousands of contaminants. We will address the 

various components required for performing rapid, quantitative, and highquality 

risk characterizations on thousands of contaminants. Approaches 

and technologies well suited to address specific aspects of this process 

include high-throughput hazard assessments addressing the complex biology 

associated with environmental toxicity; using reverse dosimetry, pharmacokinetics, 

and biomonitoring equivalents to account for dose and exposure in 

evaluating high-throughput screening results; defining and quantifying the 

uncertainty associated with high-throughput data; and finally, breaking from 

the current paradigm and using high-throughput chemical risk characterization 

for screening, prioritization, and other regulatory applications. 

Abstract # 

#541 1:40 FASTER SCIENCE FOR BETTER 

DECISIONS: CHARACTERIZING 

ENVIRONMENTAL CONTAMINANT RISK 

FROM HIGH-THROUGHPUT DATA. D. J. 

Dix 1 and R. Thomas 2 . 1 U.S. EPA, Research Triangle 

Park, NC and 2 The Hamner Institutes for Health 


#542 1:45 HIGH-THROUGHPUT SCREENING FOR 

HAZARD AND RISK OF ENVIRONMENTAL 

CONTAMINANTS. D. J. Dix. U.S. EPA, Research 


#543 2:17 DEFINING THE EXPOSURE-DOSE- 

TOXICITY RELATIONSHIPS IN 

HIGH-THROUGHPUT SCREENS USING IN 

VITRO PHARMACOKINETIC ASSAYS AND 

REVERSE DOSIMETRY. R. S. Thomas. The 

Hamner Institutes for Health Sciences, Research 


#544 2:49 CONSIDERATION OF “DOSE” IN 

EVALUATION OF TOXCAST DATA: 

USE OF BIOMONITORING AND 

PHARMACOKINETIC DATA. S. M. Hays 1 and 

L. L. Aylward 2 . 1 Summit Toxicology, L.L.P., Lyons, 

CO and 2 Summit Toxicology, L.L.P., Falls Church, 

VA. 

#545 3:21 ACCOUNTING FOR UNCERTAINTY IN THE 

APPLICATION OF HIGH-THROUGHPUT 

DATASETS. R. W. Setzer. National Center for 

Computational Toxicology, U.S. EPA, Research 

Triangle Park, NC. Sponsor: D. Dix. 

#546 3:53 PUTTING HIGH-THROUGHPUT 

CHEMICAL RISK CHARACTERIZATION 

INTO REAL-WORLD PRACTICE. S. Barone. 

NCEA, U.S. EPA, Washington, DC. 


1:40 PM to 4:25 PM 

Room 250 

Symposium Session: Genotoxic Impurities in Drugs and Drug 

Products: What Is the Right Way to Deal with Impurities in 

R&D versus Regulatory Guidance? 

Chairperson(s): Saryu Goel, Supernus Pharmaceuticals Inc, Rockville, 

MD, and Lutz Mueller, Hoffmann La Roche, Inc., Basel, Switzerland. 

Sponsor: 


Endorsed by: 




The process of chemical drug synthesis necessitates the use of highly 

reactive starting materials and/or intermediates that have the potential to 

be present as low level residues within the final drug/drug product. These 

materials often have the potential to react with DNA (genotoxic), with 

adverse health consequences to humans. Additionally, the quality of starting 

materials used in drug manufacture is not regulated and may inadvertently 

introduce genotoxic contaminants in final product. To minimize inadvertent 

health risks, the European Medicines Agency (EMEA) issued guidance in 

June 2006 and subsequently the U.S. Food and Drug Administration (FDA) 

issued draft guidance in December 2008 mandating pharmaceutical companies 

to closely monitor, evaluate, and mitigate risks associated with potential 

genotoxic impurities in drugs and drug products. The new genotoxic impurity 

guidance’s interject stringent requirements to Q3A, B, and C guidances. 

As with all guidances the burden of developing appropriate strategies to 

MOnday 







149


MOnday 



implement such guidances remains with the scientists at pharmaceutical 

companies with practical considerations. To better understand this new 

guidance, attendees will be provided with current state of the science 

and regulations and approaches to identify potential impurities in drug/ 

drug products; an overview of evolving strategies to determine genotoxic 

potential of identified impurities during product development cycle; and, an 

opportunity to discuss strategies to mitigate risks using case studies. To gain 

a balanced perspective, representatives from industry, regulatory agencies, 

and others from the expert scientific community will address these issues as 

outlined. To begin, a brief preview of the genotoxic impurities issue in drugs 

will be provided and followed by presentations on the historical development 

and implementation of this guidance around the globe. Finally, the 

panelists will discuss lessons learned from previously approved drugs, a now 

well known case of contamination of an approved drug, review of SAR software’s 

available to aid initial assessment, and the impact of regulation on the 

future of the drug development research and development process. 

#547 1:40 GENOTOXIC IMPURITIES IN DRUGS AND 

DRUG PRODUCTS: WHAT IS THE RIGHT 

WAY TO DEAL WITH IMPURITIES IN R&D 

VERSUS REGULATORY GUIDANCE? S. 

Goel. Preclinical Candidate Evaluation, Supernus 

Pharmaceuticals, Inc., Rockville, MD. 

#548 1:45 SCIENCE AND REGULATION OF 

GENOTOXIC IMPURITIES IN DRUG 

SUBSTANCES AND PRODUCTS. D. Jacobson- 

Kram. Office of New Drugs, Center for Drug 

Evaluation and Research, U.S. Food and Drug 

Administration, Silver Springs, MD. 

#549 2:17 REGULATION OF GENOTOXIC 

IMPURITIES IDENTIFIED DURING 

CLINICAL DEVELOPMENT: A 

REGULATOR’S EXPERIENCE. R. Froetschl. 

Federal Institute for Drugs and Medical Devices, 

BfArM, Bonn, Germany. Sponsor: G. Krishna. 

#550 2:49 QUALIFICATION STRATEGIES- 

GENOTOXICITY STUDY DESIGNS AND 

EVALUATION OF DATA FOR REGULATORY 

SUBMISSION: A CASE STUDY. G. Krishna. 

Preclinical Toxicology and Pharmacokinetics, Enzon 

Pharmaceuticals, Inc., Piscataway, NJ. 

#551 3:21 MOVING GENOTOXIC COMPOUNDS FROM 

TTC CONSIDERATIONS TO A PERMITTED 

DAILY INTAKE CALCULATION—HOW 

TO DO AND WHAT INFORMATION DO 

YOU NEED? E. Gocke and L. Mueller. PRNOBT, 

Genotoxicology Bldg 73/215, F. Hoffmann La Roche 

Ltd., CH 4070 BASEL, Switzerland. 

#552 3:53 THE ROLE OF DATA SHARING IN 

DEVELOPING (Q)SAR MODELS FOR 

THE EVALUATION OF GENOTOXIC 

IMPURITIES. S. McDonald. Lhasa Ltd., Leeds, 

West Yorkshire, United Kingdom. Sponsor: S. Goel. 


1:40 PM to 4:25 PM 

Ballroom A 


Symposium Session: Metabolic Syndrome and Increased 

Sensitivity to Drug-Induced Liver Injury (DILI): Nonclinical 

Models and Clinical Implications 

Chairperson(s): John W. Davis II, Pfizer Global Research & 

Development, Chesterfield, MO, and George B. Corcoran, Wayne State 

University, Detroit, MI. 

Sponsor: 


Endorsed by: 




Metabolic Syndrome can be described as a constellation of interrelated 

factors that increase the risk for cardiovascular disease. These factors, 

which include central obesity/elevated body mass index, hyperinsulinemia 

and/or insulin resistance (Type-2 diabetes), hyperlipidemia (elevated triacylglycerols 

+/- low high-density lipoprotein), hypertension and hepatic 

steatosis (non-alcoholic fatty liver disease/NAFLD) may also place humans 

at a higher level of risk for developing DILI. It is estimated that 76%–100% 

of obese individuals (30% of general population) have hepatic steatosis. 

Although hepatic steatosis is considered to be a reversible form of cell 

injury, the hepatocytes are more prone to irreversible cell injury and ultimately, 

cell death. Therefore, hepatic steatosis, and the hyperinsulinemia 

which is believed to be the catalyst for its development, is not considered a 

toxic endpoint, but rather, a first hit. Patients with steatosis may also present 

with an inflammatory response to the injury (non-alcoholic steatohepatitis/ 

NASH), and if allowed to progress unchecked, additional hepatocellular 

damage/cell loss may outpace the liver’s ability to repopulate itself and 

fibrous connective tissue may be laid down (hepatic fibrosis). Given that 

subjects with a first hit are presumably allowed to enroll in clinical trials, the 

need for developing both in vivo and in vitro models for studying the safety 

of compounds in an environment relevant to the obese state prior to clinical 

trials is critical. We will begin by providing an overview of metabolic 

syndrome, followed by discussions regarding the development of both in 

vivo and in vitro testing systems that may help both scientists and clinicians 

better understand the relevance of this clinical scenario to DILI. Finally, 

a discussion of the clinical implications of patients with symptoms of this 

syndrome will provide the perspective necessary for tackling this significant 

issue. 

#553 1:40 METABOLIC SYNDROME AND INCREASED 

SENSITIVITY TO DRUG-INDUCED LIVER 

INJURY (DILI): NONCLINICAL MODELS 

AND CLINICAL IMPLICATIONS. J. W. Davis 1 

and G. B. Corcoran 2 . 1 Drug Safety R&D, PGRD, 

Chesterfield, MO and 2 Pharmaceutical Sciences, 

Eugene Applebaum College of Pharmacy/Health 

Sciences, Wayne State University, Detroit, MI. 

#554 1:45 METABOLIC SYNDROME AND INCREASED 

SENSITIVITY TO DRUG-INDUCED LIVER 

INJURY (DILI): HISTORIC PERSPECTIVE. 

G. B. Corcoran. Pharmaceutical Sciences, Eugene 

Applebaum College of Pharmacy/Health Sciences, 

Wayne State University, Detroit, MI. 

#555 2:17 IN VIVO MODELING OF NON-ALCOHOLIC 

FATTY LIVER DISEASE (NAFLD) IN 

ZUCKER RATS FOR THE PURPOSE OF 

PREDICTING DRUG-INDUCED LIVER 

INJURY. T. P. LaBranche. Drug Safety R&D, 

PGRD, Chesterfield, MO. 

150 






Platform Sessions



Abstract # 

#556 2:49 DEVELOPMENT OF A HEPATOCYTE 

CULTURE MODEL OF NON-ALCOHOLIC 

FATTY LIVER DISEASE (NAFLD) FOR 

PREDICTING DRUG-INDUCED LIVER 

INJURY (DILI) USING ZUCKER RATS. J. C. 

Davila. Drug Safety R&D, PGRD, Chesterfield, MO. 

#557 3:21 ADME IN METABOLIC SYNDROME: 

INCREASED RISK OF DRUG-INDUCED 

TOXICITY. N. J. Cherrington. Pharmacology 

and Toxicology, College of Pharmacy, University of 

Arizona, Tuscon, AZ. 

#558 3:53 A PROSPECTIVE STUDY OF ACUTE DRUG- 

INDUCED LIVER INJURY IN PATIENTS 

SUFFERING FROM NON-ALCOHOLIC 

FATTY LIVER DISEASE. G. Tarantino. Clinical 

and Experimental Medicine, Federico II University 

Medical School of Naples, Naples, Italy. Sponsor: J. 

Davis. 


1:40 PM to 4:25 PM 

Ballroom D 

Symposium Session: Phthalate Reproductive and 

Developmental Toxicity: Implications for Cumulative Risk 

Assessment 

Chairperson(s): Susan Makris, U.S. EPA, Washington, DC, and Paul 

Foster, National Institute of Environmental Health Sciences, Research 


Sponsor: 


Endorsed by: 



Phthalates, a group of chemicals with many commercial uses (e.g., solvents, 

additives, plasticizers), have been associated with effects on the male 

reproductive system of laboratory animals following exposures during 

development and in adults. Studies have shown widespread human exposure 

to phthalates, and there are concerns for phthalate-related reproductive and 

developmental toxicity to humans. Since humans are generally exposed to 

mixtures of phthalates, rather than to single chemical entities, the importance 

of conducting a cumulative human health risk assessment has been 

recognized. We will highlight important reviews relative to the effects 

of phthalate exposures in laboratory animals and humans, and the use of 

biomarkers to quantify human exposure to phthalates, including for susceptible 

populations. The ground-breaking 2008 National Research Council 

(NRC) recommendations regarding the assessment of cumulative risk of 

human exposures to phthalates, and other chemicals, will be discussed. 

Finally, an overview will be provided that will address the conduct and 

status of phthalate risk assessment at the U.S. EPA including the consideration 

of cumulative risk in response to the NRC report. 

#559 1:40 PHTHALATE REPRODUCTIVE 

AND DEVELOPMENTAL TOXICITY: 

IMPLICATIONS FOR CUMULATIVE RISK 

ASSESSMENT. S. Makris. ORD, NCEA, U.S. 

EPA, Washington, DC. 

#560 1:45 BIOMONITORING FOR EXPOSURE 

ASSESSMENT TO PHTHALATES. A. Calafat, 

M. Silva, E. Samandar, J. Preau and L. Needham. 

Centers for Disease Control and Prevention, Atlanta, 

GA. Sponsor: S. Makris. 

Abstract # 

#561 2:17 PHTHALATE EXPOSURES AND POTENTIAL 

IMPACT ON HUMAN REPRODUCTIVE 

HEALTH. R. Hauser. Department of Environmental 

Health, Harvard School of Public Health, Boston, 

MA. Sponsor: S. Makris. 

#562 2:49 EFFECTS OF MIXTURES OF PHTHALATES 

AND OTHER TOXICANTS ON SEXUAL 

DIFFERENTIATON IN RATS: A RISK 

FRAMEWORK BASED UPON DISRUPTION 

OF COMMON DEVELOPING SYSTEMS. L. 

E. Gray 1 , C. Rider 2,1 , K. Howdeshell 1 , A. Hotchkiss 1 , 

J. Furr 1 , C. Lambright 1 , P. Foster 3 and V. Wilson 1 . 

1 

U.S. EPA, Research Triangle Park, NC, 2 Duke 

University, Durham, NC and 3 NIEHS, Research 


#563 3:21 THE NRC REPORT ON PHTHALATES AND 

CUMULATIVE RISK ASSESSMENT: FOCUS 

ON CUMULATIVE RISK AND COMMON 

ADVERSE OUTCOMES. D. A. Cory-Slechta. 

Department of Environmental Medicine, University 

of Rochester Medical Center, Rochester, NY. 

#564 3:53 U.S. ENVIRONMENTAL PROTECTION 

AGENCY’S (EPA) CUMULATIVE RISK 

ASSESSMENT OF THE PHTHALATES. J. B. 

Strong. U.S. EPA, ORD/NCEA, Washington, DC. 


1:40 PM to 4:25 PM 

Room 150 

Workshop Session: Determination of the Contribution of 

Individual Stressors in Cumulative Risk Assessments 

Chairperson(s): Michael L. Dourson, Toxicology Excellence for Risk 

Assessment, Cincinnati, OH, and Paul Price, Dow Chemical Company, 

Midland, MI. 

Sponsor: 


Endorsed by: 


In the NRC reports Science and Decisions: Advancing Risk Assessment and 

Phthalates and Cumulative Risk Assessment: The Task Ahead the U.S. EPA 

is challenged to move towards cumulative risk assessment and away from 

chemical-by-chemical approaches to determining public health. The U.S. 

EPA has more than decade of experience in assessing cumulative risks and 

has recently release a significant resource documents on cumulative risk 

assessment. Despite the importance of cumulative risk assessments, there 

are major challenges that have limited the number of cumulative assessments 

performed. Cumulative risk assessments are population based, thus 

separate assessments are required for different populations. Site-specific 

information will play a critical role in such assessments. In any population 

the combination of exposures to chemical and non-chemical stressors varies 

from person-to-person and from moment-to-moment. These complexities 

affect both the determination of the cumulating risks and the contributions 

of any one stressor. Simulation modeling is expected to play a major part in 

the assessment of cumulative risks. Modeling provides an effective means 

of tracking and combining the impacts of exposures to stressors that occur 

by multiple routes and sources. These models include exposure, PBPK, 

and biologically-based dose-response models (BBDR) which become more 

effective when they are linked so that data and assumptions in exposure 

models are passed on to PBPK and BBDR models. This session will present 

a review of the technical issues for each step of the cumulative risk assessment 

process. Therefore it is important that we begin with an overview 

from an NRC committee member who authored the report and follow up 

with presentations from leading speakers on the various phases of the dose- 

MOnday 







151


MOnday 



to-response modeling process—exposure, kinetics, and dose-response. 

Finally, we will present a statistical model for the evaluation of the impact 

of cumulative risks that can assist in ranking or screening cumulative risks. 

#565 1:40 ASSESSING THE CONTRIBUTION 

OF INDIVIDUAL STRESSORS IN 

ASSESSMENTS OF CUMULATIVE RISKS 

FROM CHEMICAL AND NON-CHEMICAL 

STRESSORS. P. S. Price 1 and D. L. Michael 2 . 

1 

Toxicology & Environmental Research & 

Consulting, The Dow Chemical Company, Midland, 

MI and 2 TERA, Cincinnati, OH. 

#566 1:45 ADVANCING CUMULATIVE RISK 

ASSESSMENT AND IMPACT EVALUATION. 

L. Zeise 1 , A. D. Kyle 2 , J. Faust 1 and G. V. Alexeeff 1 . 

1 

Cal/EPA Office of Environmental Health Hazard 

Assessment, Oakland, CA and 2 School of Public 

Health, University of California at Berkeley, 

Berkeley, CA. 

#567 2:17 KEY CHARACTERISTICS OF A 

CUMULATIVE EXPOSURE ASSESSMENT. 

C. A. Franklin 1 , C. F. Chaisson 2 and M. A. Jayjock 3 . 

1 

The LifeLine Group, Ottawa, ON, Canada, 2 The 

Annandale Office, The LifeLine Group, Annandale, 

VA and 3 The Langhorne Office, The LifeLine Group, 

Langhorne, PA. Sponsor: P. Price. 

#568 2:49 USE OF PBPK MODELS TO ASSESS THE 

CUMULATIVE EFFECTS OF CHEMICAL 

MIXTURES AND NON-CHEMICAL 

STRESSORS. K. Krishnan. University of 


#569 3:21 DEVELOPING MODELS OF CUMULATIVE 

RESPONSE TO MULTIPLE CHEMICAL 

STRESSORS AND THE DETERMINATION 

OF THE CONTRIBUTIONS OF INDIVIDUAL 

STRESSORS. J. C. Lambert. National Center for 

Environmental Assessment, U.S. EPA, Cincinnati, 

OH. 

#570 3:53 PREDICTING THE MAGNITUDE OF 

CUMULATIVE CHEMICAL EXPOSURES 

FROM SOURCE-SPECIFIC DATA. P. S. 

Price. Toxicology & Environmental Research & 


MI. 


1:40 PM to 4:25 PM 

Ballroom G 


Regional Interest Session: Signaling Mechanisms for 

Metabolic Dysfunction Following Low-Level Arsenic 


Chairperson(s): Aaron Barchowsky, University of Pittsburgh, Pittsburgh, 

PA, and Richard Vaillancourt, Univestity of Arizona, Tucson, AZ. 

Sponsor: 


Endorsed by: 



#571 1:40 SIGNALING MECHANISMS FOR 

METABOLIC DYSFUNCTION FOLLOWING 

LOW-LEVEL ARSENIC EXPOSURES: FROM 

MOUSE TO MAN. A. Barchowsky. Environmental 

and Occupational Health, Universtity of Pittsburgh, 

Pittsburgh, PA. 

#572 1:45 LOW-CHRONIC ARSENIC EXPOSURE: 

EPIDEMIOLOGIC EVIDENCE FOR 

CARDIOVASCULAR DISEASE AND 

DIABETES. A. Navas-Acien. Environmental 

Health Sciences, Johns Hopkins Bloomberg School 

of Public Health, Baltimore, MD. Sponsor: A. 

Barchowsky. 

#573 2:17 ANTIOXIDANT RESPONSE AND ROS 

SIGNALING IN ARSENIC-INDUCED 

IMPAIRMENT OF PANCREATIC BETA- 

CELL FUNCTION. J. Pi 1 , J. Fu 1 , Q. Zhang 2 , 

C. G. Woods 2 , S. Collins 1 and M. E. Andersen 2 . 

1 

Translational Biology, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC and 

2 

Computational Biology, The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC. 

#574 2:49 REGULATION OF GLUCOSE TRANSPORT 

MECHANISMS BY ARSENIC. R. R. 

Vaillancourt and I. L. Druwe. Pharmacology & 

Toxicology, University of Arizona College of 

Pharmacy, Tucson, AZ. 

#575 3:21 ARSENIC AS A PRO-ATHEROGEN: LOW 

DOSE EFFECTS ON NUCLEAR RECEPTORS 

AND INFLAMMATORY SIGNALING. K. 

K. Mann and M. Lemaire. Oncology, Lady Davis 

Institute for Medical Research, McGill University, 

Montréal, QC, Canada. 

#576 3:53 ARSENIC SIGNALING FOR LIVER 

VASCULATURE REMODELING IMPACTS 

PROTEIN AND LIPID METABOLISM. A. 

Barchowsky 1 , A. C. Straub 1 , L. R. Klei 1 , K. K. Mann 3 

and D. B. Stolz 2 . 1 Environmental and Occupational 

Health, Universtity of Pittsburgh, Pittsburgh, 

PA, 2 Cell Biology and Physiology, University of 

Pittsburgh, Pittsburgh, PA and 3 McGill University, 


152 






Platform Sessions



Abstract # 


1:40 PM to 4:25 PM 

Ballroom I 

Abstract # 


1:40 PM to 4:25 PM 

Ballroom J 


Platform Session: Advances in Biomarkers of Renal Injury 

Chairperson(s): Anne Gilson, Forest Research Institute, Jersey City, NJ, 

and Zahir Shaikh, University of Rhode Island,Kingston, RI. 

#577 1:40 URANYL NITRATE INHIBITS LACTATE 

GLUCONEOGENESIS IN ISOLATED 

HUMAN AND MOUSE RENAL PROXIMAL 

TUBULES: A CELLULAR METABOLOMIC 

STUDY. A. Conjard-Duplany 1,2 , S. Renault 1 , H. 

Faiz 1 , R. Gadet 1 , B. Ferrier 1,2 , G. Martin 1,2 and G. 

Baverel 2 . 1 Metabolomics and Metabolic Diseases, 

Inserm U820, Lyon Cedex 08, France and 2 Metabolys 

Inc., Lyon, Rhône-Alpes, France. 

#578 2:08 GENDER SPECIFIC DIFFERENCES IN THE 

EXPRESSION OF URINARY MARKERS OF 

INFLAMMATION AND OXIDATIVE STRESS. 

I. S. Richards and M. M. Bourgeois. EOH, University 

of South Florida COPH, Tampa, FL. 

#579 2:35 URINARY KIDNEY INJURY MOLECULE-1 

(KIM-1) AS A RENAL BIOMARKER IN 

GENTAMICIN (GEN)-INDUCED RENAL 

INJURY AND RECOVERY. R. Rouse 1 , L. 

Zhang 2 , P. Harlow 3 , J. Zhang 1 , P. Espandiari 4 , S. 

Stewart 1 , B. Rosenzweig 1 , K. Thompson 1 and 

N. Sadrieh 5 . 1 Division of Applied Pharmacology 

Research, U.S. FDA, CDER, Silver Spring, MD, 

2 

Office of Clinical Pharmacology, U.S. FDA, CDER, 

Silver Spring, MD, 3 Division of Cardiovascular and 

Renal Products, U.S. FDA, CDER, Silver Spring, 

MD, 4 Division of Metabolism and Endocrinology 

Products, U.S. FDA, CDER, Silver Spring, MD and 

5 

Science and Research Staff, U.S. FDA, CDER, 

Silver Spring, MD. 

#580 3:02 METABOLOMIC ANALYSIS OF RAT URINE 

FOLLOWING ACUTE EXPOSURE TO 

PERFLUORINATED CHEMICALS. W. M. 

Henderson 1 , T. W. Collette 1 , D. J. Dix 2 and D. R. 

Ekman 1 . 1 National Exposure Research Laboratory, 

U.S. EPA, Athens, GA and 2 National Center for 

Computational Toxicology, U.S. EPA, Research 


#581 3:30 ROADMAP FOR NOVEL BIOMARKER 

CANDIDATE NOMINATION FOR 

PREDICTIVE SAFETY TESTING 

CONSORTIUM (PSTC) HEPATOTOXICITY 

WORKING GROUP. W. J. Bailey. Analytical & 

Systems Toxicology, Merck & Co., Inc., West Point, 

PA. 

#582 3:57 IDENTIFICATION OF SENSITIVE 

URINARY BIOMARKERS FOR MULTI- 

TARGETED RECEPTOR TYROSINE KINASE 

INHIBITOR-INDUCED GLOMERULAR 

CHANGES. Y. Yang, K. L. Kowalkowski, R. 

Ciurlionis, J. A. Fagerland, G. D. Gagne, A. R. 

Lisowski, E. A. Blomme and W. R. Buck. R463, 

Abbott Laboratories, Abbott Park, IL. 


Platform Session: Animal Models in the 21 st Century 

Chairperson(s): Mark Carfagna, Eli Lilly Inc., Indianapolis, IN, and 

Stanley Benkovic, CDC, Morgantown, WV. 

#583 1:40 THE ROLE OF IGF-1 IN THE MURINE 

SILICOSIS MODEL. C. T. Migliaccio, V. Porter, 

F. Jessop and A. Holian. Center for Environmental 

Health Sciences, University of Montana, Missoula, 

MT. 

#584 1:59 GLUCOSE AND INSULIN RESPONSE OF 

SUBCHRONIC DOSING OF ATYPICAL 

ANTIPSYCHOTICS IN RATS. J. Saye, P. 

Campbell, M. Diamond, A. Zuvich, D. Brott, J. Fikes, 

P. Bentley and L. Kegelman. Safety Assessment, 

Astra Zeneca, Wilmington, DE. 

#585 2:17 EPIDERMAL GROWTH FACTOR 

RECEPTOR SIGNALING REGULATES 

ADIPOSE MASS BY AFFECTING FOOD 

INTAKE. M. B. Weed 1 and D. W. Threadgill 2,1 . 

1 

Toxicology, University of North Carolina, Chapel 

Hill, NC and 2 Genetics, University of North Carolina, 


#586 2:35 CROSS-SPECIES TRANSLATION OF 

SEIZURE POTENTIAL WITH AN MGLU2/3 

AGONIST PRODRUG (LY2140023). M. 

A. Carfagna 1 , M. P. Sgro 1 , J. C. Arezzo 2 and M. 

Kallman 1 . 1 Eli Lilly and Company, Indianapolis, IN 

and 2 Albert Einstein College of Medicine, Bronx, 

NY. 

#587 2:53 DECREASED NEURONAL DAMAGE AND 

GLIAL REACTIVITY IN AN ANIMAL 

MODEL OF STRESS. S. A. Benkovic, J. P. 

O’Callaghan and D. B. Miller. TMBB, CDC- 

NIOSH, Morgantown, WV. 

#588 3:12 PROTEIN ARRAY METHODOLOGY 

IMPROVES THE DETECTION OF IMMUNE 

RESPONSE AGAINST PATHOGENS 

IN ANIMALS USED IN TOXICOLOGY 

STUDIES. A. Leon and T. Quinn. LAHS, 

BioReliance, Rockville, MD. Sponsor: E. Zahalka. 

#589 3:30 EXPRESSION OF PHASE-I ENZYMES 

IN 17 MOUSE STRAINS—A TOOL FOR 

TOXICOLOGICAL RESEARCH. I. L. Csanaky 

and C. D. Klaassen. Department of Pharmacology, 

Toxicology & Therapeutics, University of Kansas 

Medical Center, Kansas City, KS. 

#590 3:48 A MOUSE MODEL OF SEVERE 

HALOTHANE HEPATITIS BASED ON 

HUMAN RISK FACTORS. C. M. Dugan 1,3 , R. A. 

Roth 1,2,3 and P. E. Ganey 1,2,3 . 1 Cellular and Molecular 

Biology Program, Michigan State University, East 

Lansing, MI, 2 Department of Pharmacology and 

Toxicology, Michigan State University, Lansing, MI 

and 3 Center for Integrative Toxicology, Michigan 

State University, Lansing, MI. 

MOnday 







153


MOnday 



#591 4:06 EVALUATING THE SENSITIVITY OF 

6 DIFFERENT F1 HYBRID MICE FOR 

GENETIC SUSCEPTIBILITY TO IONIZING 

RADIATION. S. J. Borghoff 1 , M. A. Streicker 1 , J. 

Painter 1 and J. E. French 2 . 1 Integrated Laboratory 

Systems, Inc., Research Triangle Park, NC and 

2 

National Institute of Environmental Health Sciences, 



1:40 PM to 4:25 PM 

Ballroom F 

Platform Session: Lipid Metabolism and Apoptosis 

Chairperson(s): Rick G. Schnellmann, Medical University of South 

Carolina, Charleston, SC, and Martin Ronis, University of Arkansas 

Medical Sciences, Little Rock, AR. 

#592 1:40 OXIDATIVE STRESS STATUS AND 

RELATED MAPK SIGNALING IN H9C2 

CARDIOMYOBLASTS EXPOSED TO 

CHOLESTEROL SECOALDEHYDE. L. 

Laynes, A. C. Raghavamenon, V. Achuthan and 

R. M. Uppu. Environmental Toxicology, Southern 

University and A&M College, Baton Rouge, LA. 

#593 2:01 INHIBITION OF CALCIUM-INDEPENDENT 

PHOSPHOLIPASE A 2 ALTERS 

PHOSPHOLIPID PROFILES DURING 

CYTOSTASIS IN PROSTATE CANCER 

CELLS. B. Sun, X. Zhang and B. Cummings. 

Pharmaceutical and Biomedical Sciences, University 

of Georgia, Athens, GA. 

#594 2:22 ER-IPLA 2g MEDIATES OXIDANT-INDUCED 

RELEASE OF FATTY ACIDS, PREVENTING 

ER LIPID PEROXIDATION AND CA 2+ 

RELEASE. A. C. Eaddy 1 , B. S. Cummings 2 and R. 

G. Schnellmann 1 . 1 Pharmaceutical and Biomedical 

Sciences, Medical University of South Carolina, 

Charleston, SC and 2 Pharmaceutical and Biomedical 

Sciences, University of Georgia, Athens, GA. 

#595 2:42 ALDEHYDE DEHYDROGENASE 7A1 

(ALDH7A1) IS A NOVEL ENZYME 

INVOLVED IN CELLULAR DEFENSE 

AGAINST HYPEROSMOTIC STRESS. 

C. Brocker 1 , N. Lassen 1 , T. Estey 1 , A. Pappa 1 , 

M. Cantore 1 , V. V. Orlova 2 , T. Chavakis 2 , K. L. 

Kavanagh 3 , U. Oppermann 3,4 and V. Vasiliou 1 . 

1 


Denver, Aurora, Co., 2 National Cancer Institute, 

National Institutes of Health, Bethesda, MD, 

3 

Structural Genomics Consortium, University 

of Oxford, Headington, United Kingdom and 

4 

Department of Orthopedic Surgery, Rheumatology, 

and Musculoskeletal Sciences, University of Oxford, 

Oxford, United Kingdom. 

#596 3:02 AHR-DEPENDENT LIPID MEMBRANE 

REMODELING: AN EARLY STEP 

FACILITATING BENZO[A]PYRENE- 

INDUCED APOPTOSIS. J. A. Holme 1 , X. Tekpli 2 , 

B. Dendelé 2 , L. Debure 2 , O. Sergent 2 , M. Rissel 2 , 

L. Huc 2 , D. Catheline 3 , V. Rioux 3 , P. Legrand 3 , M. 

Dimanche-Boitrel 2 and D. Lagadic-Gossmann 2 . 

1 

Division of Environmental Medicine, Norwegian 

Institute of Public Health, Oslo, Norway, 2 2EA 

4427 SeRAIC, Equipe labellisée Ligue contre le 

Cancer, Université de Rennes 1, Rennes, France 

and 3 Laboratoire de Biochimie, INRA–Agrocampus 

Rennes, Rennes, France. Sponsor: M. Løvik. 

#597 3:23 OXIDATIVE LIPIDOMICS OF GAMMA- 

RADIATION INDUCED LUNG INJURY. 

Y. Tyurina 1,3 , V. Tyurin 1,3 , V. Kapralova 1,3 , K. 

Wasserloos 1 , M. Mosher 1 , M. Epperly 2 , J. 

Greenberger 2 , B. Pitt 1 and V. Kagan 1,3 . 1 EOH, 

University of Pittsburgh, Pittsburgh, PA, 2 Radiation 

Oncology, University of Pittsburgh, Pittsburgh, PA 

and 3 CFRAH, University of Pittsburgh, Pittsburgh, 

PA. 

#598 3:44 OXIDATIVE LIPIDOMICS OF HYPEROXIA- 

INDUCED ACUTE LUNG INJURY. V. 

Kagan 1,2 , V. Tyurin 1,2 , V. Kapralova 1,2 , A. Kaynar 1 , 

K. Wasserloos 1 , M. Mosher 1 , P. Wipf 3 , B. Pitt 1 

and Y. Tyurina 1,2 . 1 EOH, University of Pittsburgh, 

Pittsburgh, PA, 2 CFRAH, University of Pittsburgh, 

Pittsburgh, PA and 3 Chemistry, University of 

Pittsburgh, Pittsburgh, PA. 

#599 4:04 PHOSPHOLIPID (PL) OXIDATIVE 

METABOLISM DURING MACROPHAGE 

RESPONSE TO ENVIRONMENTAL AGENTS. 

V. A. Tyurin 1,2 , D. Winnica 1 , F. Fazzi 1 , W. Feng 1,2 , 

Y. Tyurina 1,2 , N. Stewart 3 , E. Kisin 4 , A. Murray 4 , 

A. Shvedova 4 , B. Pitt 1 , V. Kagan 1,2 and L. Ortiz 1 . 

1 

EOH, University of Pittsburgh, Pittsburgh, PA, 

2 

CFRAH, University of Pittsburgh, Pittsburgh, PA, 

3 

Medicine, University of Pittsburgh, Pittsburgh, PA 

and 4 Physiology/Pathology Research Branch, Health 

Effects Laboratory Division, NIOSH, Morgantown, 

WV. 


1:40 PM to 4:25 PM 

Room 251 A 

Platform Session: Methods and Animal Models in 

Cardiovascular Safety Pharmacology 

Chairperson(s): Jill Fogleman, Calvert Laboratories, Inc., Scott 

Township, PA, and William M. Baird, Oregon State University, Corvallis, 

OR. 

#600 1:40 VALIDATION OF A NON-HUMAN PRIMATE 

TELEMETRY MODEL FOR ASSESSMENT 

OF CONTRACTILITY PARAMETERS. A. 

Simonnard, G. Froget, A. Bétat and R. Forster. CIT, 

Evreux, France. 

#601 2:01 COMBINED CARDIOVASCULAR 

AND RESPIRATION ASSESSMENT 

IN THE CONSCIOUS GÖTTINGEN 

MINI-PIG FOLLOWING INHALATION 

ADMINISTRATION OF ALBUTEROL. S. 

Purbrick, S. A. Moore, E. Peake, V. Milner, H. 

Brown, D. Butler, A. French, K. Melliti, G. Peake, D. 

Cameron, K. Meecham and C. J. Hardy. Respiratory 

Safety Assessment, Huntingdon Life Sciences, 

Huntingdon, United Kingdom. 

#602 2:21 ECG RECORDING METHODS IN DOG 

TOXICOLOGY STUDIES: WHAT IS 

THE REAL BENEFIT OF EXTERNAL 

TELEMETRY? P. Lainee, J. Schofield, C. Draper, 

K. Elliott, C. Barnard and J. Valentin. Global 

Safety Assessment, AstraZeneca, Alderley Park, 

Macclesfield, Cheshire, United Kingdom. 

154 






Platform Sessions



Abstract # 

#603 2:41 ASSESSMENT OF PULMONARY ARTERY 

HYPERTENSION BY COLOR FLOW 

DOPPLER ECHOCARDIOGRAPHY IN 

THE ANESTHETIZED MINI-PIG AND 

MONKEY. S. Baudet 1 , J. Briffaux 1 , O. Boucheix 1 , 

G. Haroutunian 2 , S. Milano 1 , E. Chalencon 1 , 

P. Lege 1 and C. Dupuis 1 . 1 MDS Pharmacology 

Services, Saint-Germain sur l’Arbresle, France and 

2 

Cardiology and Echography Center, Marseille, 

France. 

#604 3:02 ECG ACQUISITION BY EXTERNAL 

TELEMETRY FOR TOXICOLOGY (ET 2 ) 

IN FREELY-MOVING CYNOMOLGUS 

MONKEYS—COMPARISON WITH 

CONVENTIONAL, “SNAPSHOT” ECG 

IN CHAIR-RESTRAINED ANIMALS AND 

VALIDATION WITH DOFETILIDE, A QT 

INTERVAL PROLONGING DRUG. J. Briffaux, 

E. Chalencon, C. Bory, P. Lege, S. Baudet and 

S. Milano. MDS Pharmacology Services, Saint- 

Germain sur l’Arbresle, France. 

#605 3:23 EVALUATION STUDY OF BLOOD 

PRESSURE MEASUREMENTS USING AN 

IMPLANTED PA-C10-TOX TRANSMITTER 

IN CONJUNCTION WITH JACKETED 

EXTERNAL TELEMETRY IN CONSCIOUS 

UNRESTRAINED CYNOMOLGUS 

MONKEYS. C. McMahon, J. Klein, A. C. Jenkins, 

A. Mitchell and R. Sarazan. Covance Laboratories, 

Madison, WI. Sponsor: J. Kremer. 

#606 3:44 THE RELEVANCE OF CARDIOVASCULAR 

SAFETY ASSESSMENTS IN JUVENILE 

DOGS. D. Salvail 1 , A. Bouchard 1 , K. Norton 2 

and M. Vézina 2 . 1 Safety Pharmacology, IPS 

Therapeutique, Sherbrooke, QC, Canada and 

2 

Safety Pharmacology, Charles River Laboratories, 

Preclinical Services (PCS-MTL), Senneville, QC, 

Canada. 

#607 4:04 VARIATION IN ARTERIAL BLOOD 

PRESSURE MEASURED WITH 

IMPLANTABLE TELEMETRY 

TRANSMITTERS IN CYNOMOLGUS 

MONKEYS: IS IT A CAUSE FOR CONCERN? 

A. Jenkins, F. Kirchner and R. Sarazan. Covance 

Laboratories, Madison, WI. 


2:15 PM to 3:15 PM 

Room 155 C 

Exhibitor Hosted Session: The Scientific Quest for a New 

Millennium of Drug Discovery and Development 

Presented by: Covance Inc. 

Ten years after starting the Drug Development “New Millennium,” 

researchers are feeling the impact of new guidelines, an increased emphasis 

on safety, challenges in the development of biologics, globalization, strategically 

integrated approaches, and CROs as scientific partners. We invite you 

to participate in this interactive scientific review of the challenges that have 

been overcome, those that still exist, and what might lie ahead. 

Abstract # 


2:15 PM to 3:15 PM 

Room 155 B 

Exhibitor Hosted Session: Therapeutic Monoclonal 

Antibodies—Predicting Antibody-Mediated Cytokine Release 

Presented by: Huntingdon Life Sciences 

Acute cytokine release after clinical dosing has been seen with a small 

number of therapeutic monoclonal antibodies. The ability to understand this 

potential in human and toxicity species is essential prior to clinical studies. 

Understand the mechanisms of cytokine release and the design of in vitro 

and in vivo studies. 


2:15 PM to 3:15 PM 

Room 155 F 

Exhibitor Hosted Session: The Usefulness of the 

Minipig in Regulatory Toxicology 

Presented by: LAB Research Inc. 

The seminar will highlight the minipig as the non-rodent species in regulatory 

studies and how in some cases it is preferable over dogs and primates. 

In particular, their use in general toxicology testing employing the continuous 

intravenous infusion and dermal route will be discussed. 


4:30 PM to 6:00 PM 

Room 255 A 

Specialty Section Presidents and Officers Meeting 

If you will be a President or a Vice President of a Specialty Section in 

2010–2011, please make plans to attend the Specialty Section Presidents 

meeting scheduled for 4:30 PM–6:00 PM. The agenda for the meeting will 

include an overview of the SOT Long-Range Plan. If you have long-range 

planning ideas that you would like to add to the agenda, please send a 

message to Kim von Brook at kimberly@toxicology.org. 

MOnday 







155


MOnday 




4:35 PM to 5:55 PM 

Ballroom A 

SOT/EUROTOX Debate 

Motion: Threshold of Toxicological Concern (TTC): 

Is It Based on Science or Politics? 

Endorsed by: 

Society of Toxicology (SOT) 

European Societies of Toxicology (EUROTOX) 

Debaters: 

SOT Debater: Mitchell Cheeseman, U.S. FDA, Center for Food 

Safety and Applied Nutrition, College Park, MD 

EUROTOX Debater: Sue Barlow, Independent Consultant in Toxicology, 

Brighton, Great Britain 

Chairperson(s): Jon C. Cook, Pfizer Global Research and 

Development, Groton, CT, and Nancy Claude, Institut de Recherches 

Internationales Servier, Courbevoie, France. 

Each year the SOT Annual Meeting includes a debate that continues a 

tradition that originated in the early 1990s in which leading toxicologists 

advocate opposing sides of an issue of great toxicological importance. 

This year, our debaters will address the proposition: Threshold of 

Toxicological Concern (TTC): Is It Based on Science or Politics? 

The concept that “safe levels of exposure” for humans can be identified 

for individual chemicals is central to the risk assessment of compounds 

with known toxicological profiles. The Threshold of Toxicological 

Concern (TTC) is a concept that refers to the establishment of a level of 

exposure for chemicals for which there are insufficient or no chemicalspecific 

toxicity data, below which there would be no appreciable risk to 

human health. The concept proposes that a low level of exposure with a 

negligible risk can be identified for many chemicals, including those of 

unknown toxicity, based on knowledge of their chemical structures. The 

debate will present some of the challenges both scientists and regulators 

are facing to integrate the TTC principle and its potential applications in 

the Risk Assessment paradigm. 

Regardless of framework differences and personal convictions, each 

scientific delegate will present relevant evidence and compelling scientific 

arguments to persuade and appeal to the response of the audience 

in order to obtain the approval or refusal of the motion. In addition to 

being a featured session at the Annual Meeting, this debate will again 

take place in Barcelona during the 2010 XII International Congress of 

Toxicology, July 19–23, 2010. 


4:35 PM to 5:55 PM 

Ballroom B 

Roundtable Session: Inhaled Particles: From the Nose to the 

Brain? 

Chairperson(s): Flemming R. Cassee, National Institute for Public 

Health and the Environment (RIVM), Bilthoven, Netherlands, and Alison 

C. Elder, University of Rochester, Department of Environmental Medicine, 


Sponsor: 


Endorsed by: 




Particle toxicology has come a long way from revealing the prominent role 

for coal and silica-induced diseases in the early 20 th century, to investigating 

the infamous asbestos fibers, to the more recent discussion on man made 

mineral fibers, ambient particulate matter, and engineered nanoparticles. 

The focus has gradually expanded from the traditional target organ, the 

respiratory system, to extra-pulmonary organs such as the heart, vascular 

system, and more recently the brain. While particle translocation into the 

brain occurs under certain conditions, the specific mechanisms linking 

particle exposures to physiological responses in the central nervous system 

remain to be investigated. The same is true for the functional effects noted in 

volunteers exposed to (combustion derived) ultrafine or nanoparticles. This 

session will present the latest findings regarding nose-particle-brain interactions 

both from the viewpoint of ambient (ultrafine) particles and engineered 

nanoparticles. 

#608 4:35 INHALED PARTICLES: FROM THE NOSE 

TO THE BRAIN: AN OVERVIEW. F. R. 

Cassee. Center for Environmental Health Research 

(MGO), National Institute for Public Health and the 


4:40 TRANSLOCATION OF NANO-SIZED 

PARTICLES TO THE CENTRAL 

NERVOUS SYSTEM: PHYSIOCHEMICAL 

CONSIDERATIONS. Alison Elder 

4:53 NANOPARTICLE TRANSPORT FROM THE 

LUNGS TO THE BRAIN: ROLE OF THE 

CIRCULATORY PATHWAY. Wolfgang G. 

Kreyling 

5:06 CONCENTRATED PARTICULATE 

MATTER, OXIDATIVE STRESS, AND 

NEURODEGENERATION: IN VIVO AND 

IN VITRO MODELS. Bellina Veronesi 

5:19 EFFECTS OF DIESEL ENGINE EXHAUST 

AND CARBON NANOPARTICLE 

INHALATION IN RAT AND MOUSE BRAIN. 

Roel P.F. Schins 

5:31 BRAIN REGIONS SHOW VARIATION 

IN RESPONSE AFTER DIESEL ENGINE 

EXHAUST AND TRAFFIC-DERIVED 

PARTICULATE MATTER. Arezoo Campbell 

5:43 EXPOSURE TO DILUTED DIESEL ENGINE 

EXHAUST CAUSES CHANGES IN BRAIN 

ACTIVITY BUT NOT IN COGNITIVE 

PERFORMANCE IN HUMAN VOLUNTEERS 

OR RATS. Paul J.A. Borm 

156 






Platform Sessions



Abstract # 


4:35 PM to 5:55 PM 

Ballroom D 

Roundtable Session: Safety of Vitamins and Minerals: 


Chairperson(s): Madhu G. Soni, Vero Beach Hematology & Oncology, 

Vero Beach, FL, and Stanley T. Omaye, University of Nevada Reno, 

Department of Nutrition, Reno, NV. 

Sponsor: 


Endorsed by: 




Available information suggests that currently over 47% of males and 59% 

of females use dietary supplements for health benefits, and the number 

of users is rapidly increasing. However, numerous studies published over 

more than a decade have linked some supplements (including vitamins E, 

C, D, A, and B, as well as selenium) to no health benefits or even to adverse 

health effects. The recent studies with negative results to draw media attention 

include: a 2008 study on the ability of vitamin E and selenium to lower 

prostate cancer risk that was halted amidst fear of potential harm; vitamin C 

may do more harm than good as it may protect cancer cells; intake of vitamins 

E and C by 15,000 male physicians for 10 years had no health benefits. 

In contrast, there are compelling cause and effect data linking use of folic 

acid containing multivitamins with consistent and significant reductions in 

adverse pregnancy outcomes; benefits of calcium and vitamin D supplements 

in improving bone strength and reducing fractures. These conflicting 

findings have left consumers confused about the benefits and wary of the 

possible adverse effects of vitamin and mineral supplementation. The objectives 

of this session are to characterize the current state of the science as 

it relates to the impact of vitamin and mineral supplementation on human 

health; review the statutory and regulatory perspective on vitamin use from 

a safety perspective; assess the credibility of meta-analysis in the safety 

assessment of vitamins; and elicit the mechanisms of these interactions— 

prooxidant vs. antioxidant effects or beneficial vs. adverse effects. 

#609 4:35 SAFETY OF VITAMINS AND MINERALS: 

CONTROVERSIES AND PERSPECTIVES. M. 

G. Soni 1 , T. S. Thurmond 5 , E. R. Miller 2 , A. Bendich 3 

and S. Omaye 4 . 1 Soni & Associates Inc., Vero Beach, 

FL, 2 Center for Food safety and Applied Nutrition, 

Food and Drug Administartion, College Park, MD, 

3 

Welch Center for Prevention, Epidemiology and 

Clinical Research, The Johns Hopkins Medical 

Institutions, Baltimore, MD, 4 GSK Consumer 

Healthcare, Parsippany, NJ and 5 Department of 

Nutrition, University of Nevada Reno, Reno, NV. 

4:40 ARE VITAMINS AND MINERALS USED 

FOR PREVENTION OR TREATMENT? 

STATUTORY AND REGULATORY 

PERSPECTIVE. Thane S. Thurmond 

4:55 META-ANALYSIS: HIGH-DOSAGE VITAMIN 

E SUPPLEMENTATION MAY INCREASE 

ALL-CAUSE MORTALITY. Edgar R. Miller 

5:10 BETA-CAROTENE SUPPLEMENTATION: 

EXAMPLE OF WHEN LIFESTYLE HABITS 

CAN INCREASE RISK FACTORS. Tracey 

Spriggs 

5:25 SUPPLEMENTS: PRO-OXIDANT VERSUS 

ANTIOXIDANT EFFECTS OR BENEFICIAL 

VERSUS ADVERSE EFFECTS. Stanley T. 

Omaye 


Abstract # 


4:35 PM to 5:55 PM 

Ballroom F 

Roundtable Session: The Evolution of the Extended One- 

Generation Study Design for Agricultural and Industrial 


Chairperson(s): Sue Marty, The Dow Chemical Company, Toxicology & 

Environmental Research & Consulting, Midland, MI, and James C. Lamb, 

Exponent, Inc., Toxicology and Mechanistic Biology Center, Alexandria, 

VA. 

Sponsor: 


Endorsed by: 


In 2006, the International Life Sciences Institute (ILSI) Health and Environmental 

Sciences Institute (HESI) recommended a new approach to the 

safety assessment of agricultural chemicals (36:37, 2006). This approach 

modified the testing required for agricultural chemicals and emphasized the 

use of pharmacokinetics in dose level selection. Among the most significant 

changes is the inclusion of an extended one-generation study design 

in which chemicals can be evaluated for effects on the developing nervous, 

reproductive, and immune systems. Since its inception in 2006, several 

laboratories have worked with the extended one-generation study design. 

Based on the experiences of these laboratories, modifications to the study 

design have been introduced. Furthermore, the extended one-generation 

study is being developed as an OECD test guideline with some additional 

design modifications. Therefore, the implementation has reached a critical 

nexus, where for the first time data are available to assess the practicality of 

the design and remaining challenges. This roundtable session will present 

experiences with the extended one-generation study and opinions on its use 

from both laboratory scientists and regulators. The goal of this session will 

be to discuss the strengths and weaknesses of the extended one-generation 

study approach proposed for the hazard assessment of both agricultural and 

industrial chemicals. 

#610 4:35 THE EVOLUTION OF THE EXTENDED 

ONE-GENERATION STUDY DESIGN FOR 

AGRICULTURAL AND INDUSTRIAL 

CHEMICAL HAZARD IDENTIFICATION. 

S. Marty. Toxicology & Environmental Research & 

Consulting, Dow Chemical Company, Midland, MI. 

4:35 THE EXTENDED ONE-GENERATION 

STUDY DESIGN: A NEW APPROACH TO 

LIFE STAGES TOXICITY TESTING. Ralph 

Cooper 

4:50 EUROPEAN CHEMICAL PRODUCERS 

ASSOCIATION (ECPA) DEMONSTRATION 

STUDIES: POSITIVE CONTROL STUDIES 

FOR DEVELOPMENTAL NEUROTOXICITY, 

DEVELOPMENTAL IMMUNOTOXICITY, 

AND REPRODUCTIVE TOXICITY USING 

THE EXTENDED ONE-GENERATION 

STUDY DESIGN. Larry Sheets 

5:05 USING THE EXTENDED ONE- 

GENERATION STUDY TO FULFILL DATA 

REQUIREMENTS: A CASE STUDY WITH 2, 

4-D. Sue Marty and Barbara Neal 

5:20 DEVELOPMENT OF AN OECD TEST 

GUIDELINE ON THE EXTENDED ONE- 

GENERATION STUDY. Liz Mendez 


MOnday 







157


MOnday 




5:00 PM to 7:00 PM 


Regional Chapter Joint Receptions: Gulf Coast and South 

Central Mixer (Lumpy’s Downtown), Mountain West and 

Southern California (Squatters Pub Brewery) 


5:00 PM to 8:00 PM 


Regional Chapter Reception: Pacific Northwest 

Monday Evening, March 8 

6:00 PM to 7:30 PM 

Hilton Canyons B 

MOnDAY EvEning 

Regional Chapter Reception: Southeastern 


6:00 PM to 7:30 PM 


Special Interest Group Meetings/Receptions: 

Association of Scientists of Indian Origin (Room 355 D), 

Korean Toxicologists Association in America (Room 260) 


6:00 PM to 8:00 PM 


Special Interest Group Meetings/Receptions: 

American Association of Chinese in Toxicology 

(Hilton Grand Ballroom A), Toxicologists of African Origin 

(Salt Lake Plaza Hotel Salt Room) 


6:00 PM to 7:30 PM 


Specialty Section Meetings/Receptions: Carcinogenesis 

(Room 355 B), Dermal Toxicology (Room 355 A), 

Food Safety (Room 255 D), Medical Device (Room 258), 

Metals (Room 255 C), Molecular Biology (Room 255 B), 

Nanotoxicology (Room 255 E), Ocular Toxicology 

(Room 259), Risk Assessment (Room 355 E) 

Tuesday Morning, March 9 

7:00 AM to 8:30 AM 

Room 255 A 


7:30 AM to 8:50 AM 

Ballroom D 


TUESDAY MORning 

Regional Chapter Presidents and Officers Meeting 

If you will be a President or a Vice President of a Regional Chapter in 

2010–2011, please make plans to attend the Regional Chapter Presidents 

meeting scheduled for 7:00 AM–8:30 AM. The agenda for the meeting 

will include an overview of the SOT Long-Range Plan. If you have longrange 

planning ideas that you would like to add to the agenda, please send 

a message to Kristen Meletti at kristen@toxicology.org. 


7:00 AM to 8:30 AM 


Specialty Section Officers Meetings: Carcinogenesis 

Officers (Room 258), Comparative and Veterinary 

Officers (Room 255 D), Immunotoxicology (Elevations 

Restaurant, Marriott Downtown), Mechanisms 

Officers (Room 255 E), Mixtures Officers (Room 255 F), 

Nanotoxicology Officers (Room 355 A), Reproductive and 

Developmental Toxicology Officers (Room 255 C) 


7:00 AM to 8:00 AM 

Room 255 B 

Specialty Section Officers Meeting: Inhalation and 

Respiratory Officers 

Roundtable Session: Can Animal Neurotoxicity Predict 

Human Dysfunction? 

Chairperson(s): Philip J. Bushnell, U.S. EPA, National Health and 

Environmental Effects Research Laboratory, Research Triangle Park, NC, 

and William K. Boyes, U.S. EPA, National Health and Environmental 

Effects Research Laboratory, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 


An important purpose of animal toxicity studies is to predict human disease, 

with the goal of minimizing the impact of chemical exposures on public 

health. Animal experiments can assert causal relationships between exposure 

and effect, characterize profiles of effects and, in conjunction with 

pharmacokinetic and empirical models, quantify dose-response relationships 

and their impact on public health. This discussion will evaluate the ability 

of animal models to predict effects on public health, including advantages 

and disadvantages of several approaches, by addressing the following. What 

aspects of an animal model enable one to predict impacts on human health? 

What information is needed to make such predictions quantitative? Can 

animal models account for differences in sensitivity to chemical toxicants? 

What is the role of behavioral and other whole-animal tests in toxicology 

158 






Platform Sessions



Abstract # 

in the 21 st century? How can animal models facilitate the development of 

biomarkers of neurotoxicity? These questions will be explored using four 

cases in which animal models have revealed significant characteristics of 

exposure to neurotoxic chemicals. 

#611 7:30 CAN ANIMAL NEUROTOXICITY PREDICT 

HUMAN DYSFUNCTION? W. K. Boyes 1 , 

P. J. Bushnell 1 , R. Nass 2 , S. L. Schantz 3 and M. 

Lattal 4 . 1 National Health and Environmental Effects 

Research Laboratory, U.S. EPA, Research Triangle 

Park, NC, 2 Center for Environmental Health, Stark 

Neuroscience Research Institute, Indiana University 

School of Medicine, Indianapolis, IN, 3 Department 

of Veterinary Biosciences, University of Illinois 

Urbana-Champaign, Urbana, IL and 4 Department of 

Behavioral Neuroscience, Oregon Health & Science 

University, Portland, OR. 

7:30 INTRODUCTION: RAISING THE ISSUES. 

William K. Boyes 

7:35 WORMS, METALS, AND PARKINSON’S 

DISEASE. Richard Nass 

7:50 PCBS, ATTENTION, AND IMPULSIVITY: 

STUDIES IN ANIMALS AND HUMANS AND 

PARALLELS WITH ATTENTION DEFICIT 

HYPERACTIVITY DISORDER (ADHD). 

Susan L. Schantz 

8:05 TRANSLATIONAL STUDIES OF 

ORGANOPHOSPHORUS PESTICIDE- 

INDUCED NEUROBEHAVIORAL DEFICITS. 

K. Matthew Lattal 

8:20 MODELING ACUTE NEUROBEHAVIORAL 

EFFECTS OF INHALED VOLATILE 

ORGANIC SOLVENTS. Philip J. Bushnell 



7:30 AM to 8:50 AM 

Ballroom B 

Roundtable Session: Weighing Complex Data in Risk 

Decisions: Concepts of Evidence-Based Toxicology 

Chairperson(s): James S. Bus, The Dow Chemical Company, Toxicology 

Research Laboratory, Midland, MI, and Barbara D. Beck, Gradient 

Corporation, Cambridge, MA. 

Sponsor: 

Academy of Toxicological Sciences 

Endorsed by: 




One of the most significant challenges facing toxicology today is how the 

regulatory community can incorporate complex mode-of-action information 

into science-based decision making. Toxicology has made significant 

progress in developing and promoting use of mode-of-action frameworks as 

tools to transparently organize complex toxicology datasets for regulatory 

evaluations. However, implementation of framework approaches continues 

to be hindered by a lack of understanding and agreement as to how to efficiently 

and effectively weigh the data used in ultimate decision-making, 

i.e., when is it known how much is enough. The medical community has 

initiated the practice of Evidence-Based Medicine (EBM), a data evaluation 

approach that has been successfully used to improve translation of complex 

clinical information into effective medical practice. The principles and 

approaches of EBM offer significant opportunity for parallel application to 

complex problems in toxicology, and in recent years active discussion has 

Abstract # 

emerged within the field of toxicology on the potential value of incorporating 

EBM into what has been termed Evidence-Based Toxicology (EBT). 

The exploration and discussion of EBT is of great importance to toxicology 

in that the ability to sustain core support for mode-of-action research is in 

part dependent on its efficient and reasoned incorporation into regulatory 

decision-making. Therefore the goal of this roundtable will be to introduce 

the topic of EBT and to discuss its potential as a tool for moving complex 

toxicology mode-of-action datasets into regulatory decision-making. 

#612 7:30 WEIGHING COMPLEX DATA IN RISK 

DECISIONS: CONCEPTS OF EVIDENCE- 

BASED TOXICOLOGY. J. Bus 1 and B. Beck 2 . 

1 

The Dow Chemical Company, Midland, MI and 

2 

Gradient Corporation, Cambridge, MA. 

7:35 EVIDENCE-BASED TOXICOLOGY: 

LEARNINGS FROM EVIDENCE-BASED 

MEDICINE. Phil Guzelian 

7:45 EVIDENCE-BASED TOXICOLOGY: 

IMPROVING THE RELIABILITY OF 

DATA AND TOOL APPRAISAL IN 

TOXICOLOGICAL PRACTICE. Thomas 

Hartung 

7:55 HYPOTHESIS-BASED APPROACHES TO 

WEIGHING INFORMATION OF COMPLEX 

DATASETS. Lorenz Rhomberg 

8:05 INCORPORATION OF COMPLEX 

MODE-OF-ACTION INFORMATION 

INTO MODE-OF-ACTION FRAMEWORK 

ANALYSES. Vicki Dellarco 



7:30 AM to 8:50 AM 

Ballroom G 


Informational Session: Human Hepatocytes Derived from 

Embryonic Stem Cells: A New Tool for In Vitro Toxicity 

Testing 

Chairperson(s): Claudia McGinnis, Apredica, Watertown, MA, and Glenn 

Prestwich, The University of Utah, Center for Therapeutic Biomaterials, 

Salt Lake City, UT. 

Sponsor: 


In vitro methods for liver toxicity testing have seen poor acceptance as an 

alternative to animal testing because of low specificity and sensitivity to in 

vivo outcomes. Hepatocytes are highly differentiated cells with complex 

functions that are particularly difficult to be maintained over an acceptable 

timeframe. Recently, some advances have been made to improve hepatocyte 

longevity and functionality using 3D and co-culture technologies. However, 

these models rely on the continuous availability of human primary liver cells 

obtained from a limited number of human donors. As a result, good quality 

cells are in short supply for research purposes. Generating functional hepatocytes 

from pluripotent stem cells would provide a continuous cell pool 

capable of expansion. The use of human embryonic stem cells (hESC) and 

differentiation into mature cell lineages is a new and rapidly evolving area 

of research with a great promise in generating alternative in vitro models to 

study human toxicities. However, while considerable advances have been 

made in recent years to develop hepatocyte-like cells from embryonic and 

other stem cells, the application of hESC-derived hepatocytes in toxicology 

still faces several challenges. This session will describe methods, current 

and, future applications of hESC-derived hepatocytes for the assessment 

of mechanisms leading to hepatotoxicity. An overview will be given on 

technology developments necessary to generate an hESC-hepatocyte model 

tueSday 







159


tueSday 



which mimic adult liver function in vitro, has adequate enzymatic/transporter 

expression and longevity in long-term culture, and is translatable into 

higher throughput screening applications for predictive toxicity and ADME 

testing. Novel support systems will be described which have improved functionality 

and longevity of hESC-derived hepatocytes. 

#613 7:30 HUMAN HEPATOCYTES DERIVED FROM 

EMBRYONIC STEM CELLS: A NEW TOOL 

FOR IN VITRO TOXICITY TESTING. C. 

McGinnis 1 , G. D. Prestwich 2 and D. C. Hay 3 . 

1 

Apredica, Watertown, MA, 2 Department of 

Medicinal Chemistry, The University of Utah, Salt 

Lake City, UT and 3 MRC Centre for Regenerative 

Medicine, Edinburgh, United Kingdom. 

7:35 A POLYMER MATRIX PROMOTES AND 

STABILIZES HESC-DERIVED HEPATOCYTE 

FUNCTION. David C. Hay 

7:55 APPLICATIONS OF HESC-DERIVED 

HEPATOCYTES IN TOXICITY AND ADME 

TESTING. Claudia McGinnis 

8:15 ENGINEERED EXTRACELLULAR 

MATRICES FOR REGENERATIVE 

MEDICINE AND DRUG EVALUATION. Glenn 

D. Prestwich 



7:30 AM to 8:50 AM 

Ballroom F 

Informational Session: Recent Advances in Pulmonary 

Surfactant Toxicological Assessment and Therapeutics 

Chairperson(s): Richard A. Parent, Consultox Ltd., Damariscotta, ME, 

and Michelle De Crosta, Discovery Laboratories, Inc., Warrington, PA. 

Sponsor: 


Endorsed by: 



Pulmonary surfactant is critical for proper respiratory function. The primary 

role of pulmonary surfactant is to reduce surface tension in the lung and 

prevent collapse of alveoli and distal airways, thereby preserving functional 

residual capacity and promoting gas exchange. Surfactants are a complex 

mixture of phospholipids and proteins. Phospholipids lower surface tension, 

while proteins play a critical role in a variety of functions related to respiratory 

health and development, including the further lowering of surface 

tension by maintaining the phospholipid monolayer. The introduction of 

surfactant replacement therapy (SRT) in the United States (U.S.) in 1990 

for the treatment of respiratory distress syndrome (RDS) has led to reduced 

morbidity and mortality in preterm infants. There is evidence that surfactant 

dysfunction exists in other lung diseases, and clinical trials have been 

conducted investigating the use of SRT beyond the treatment of RDS. The 

initial exogenous pulmonary surfactant introduced in the U.S. was a blend of 

synthetic phospholipids. However, the exogenous surfactants currently available 

for therapeutic use all contain proteins extracted from animal sources, 

raising the possibility for the inclusion of prions and non-target substances 

into the surfactant. In addition, analyses of these animal-derived surfactants 

have revealed considerable variability in terms of purity as well as the 

concentration of the target surfactant proteins. These concern in turn raise 

questions regarding the potential toxicity of exogenous surfactants. 

#614 7:30 RECENT ADVANCES IN PULMONARY 

SURFACTANT TOXICOLOGICAL 

ASSESSMENT AND THERAPEUTICS. M. De 

Crosta. Discovery Laboratories, Inc., Warrington, PA. 

Sponsor: R. Parent. 

7:35 INHERENT TOXICOLOGICAL ISSUES 

RELATED TO ANIMAL-DERIVED 

PULMONARY LUNG SURFACTANTS FOR 

TREATMENT OF RDS. Michael F. Beers 

7:55 CASE STUDIES OF IN-VIVO MODELS FOR 

ASSESSING SRT. Russell G. Clayton 

8:15 UTILIZATION OF HIGH-PERFORMANCE 

LIQUID CHROMATOGRAPHY WITH 

CHARGED AEROSOL DETECTION (HPLC- 

CAD) TECHNOLOGY FOR ASSESSING 

IMPURITY PROFILES IN SYNTHETIC 

AND ANIMAL-DERIVED PULMONARY 

SURFACTANTS. John G. Nikelly 



8:00 AM to 8:50 PM 

Room 251 A 




Lecturer: Kenneth E. McMartin, LSU Health Sciences 

Center, Shreveport, LA. 

Drug development usually brings to mind the toxicity 

testing needed to bring a drug to the market. Important toxicological 

research also involves the development of antidotes to treat chemical 

toxicities. Antidotal development starts best with mechanism-based 

research to uncover key therapeutic targets. Despite the difficulties in 

conducting clinical studies on antidotes, the major goal of our research 

is to bring useful antidotes to the market. Studies in animal models by 

us and colleagues demonstrated convincingly that methanol and ethylene 

glycol are toxic because of their metabolism to active metabolites. With 

the knowledge that 4-methylpyrazole (fomepizole) potently inhibits 

alcohol dehydrogenase, we showed in animals that fomepizole reverses 

the toxicity from these alcohols. Grants from the FDA’s Office of Orphan 

Products allowed Phase 1 studies to show that fomepizole was relatively 

safe and had desirable kinetic properties in humans. Moving antidotal 

development from an academic laboratory to a drug company for the critical 

Phase 2/3 studies is a formidable obstacle. Nevertheless, fomepizole 

was finally approved for marketing and now is the world-wide standard 

of care for treating methanol and ethylene glycol poisoning. Currently, 

we are examining compounds that inhibit binding of oxalate crystals to 

the kidney tubular epithelium, as a means of preventing renal toxicity 

from hyperoxaluria and the recurrent formation of kidney stones. 


8:30 AM to 9:30 AM 

Room 155 B 

Exhibitor Hosted Session: Obese Animal Models of Metabolic 

Disease 


Animal models for the assessment of metabolic changes associated with 

the onset and development of obesity and diabetes are important tools for 

studying the safety and efficacy of novel therapeutics. This session will 

focus on how two widely used models (ZDF rat and large animals fed on a 

high-fat diet) can aide in the development of new drugs to treat insulin resistance, 

insulin resistance-associated chronic diseases and obesity. 

160 






Platform Sessions



Abstract # 


9:00 AM to 4:30 PM 

Room 254 A 



Laboratory, Richland, WA. 

Sponsor: 


All meeting attendees interested in National Institute of Health (NIH) 

funding are encouraged to take advantage of this opportunity to meet 

with staff from NIH Center for Scientific Review and NIEHS who will be 

available in the NIH Resource Room for individual conversations. Learn 

about the match of research interests to grant programs, check the ins and 

outs of the new application guidelines, and discuss in depth the specifics 

of proposals. Drop in, attend the NIH Brown Bag Lunch on Tuesday 

to make an appointment, or check the posted schedule to meet with the 

relevant NIH staff member. New investigators are especially encouraged 

to meet with program staff. Handouts will be available. 


9:00 AM to 11:45 AM 

Ballroom J 


Symposium Session: Anti-Drug Antibody-Mediated Toxicity 

in Nonclinical Toxicity Studies: Impact and Relevance to 

Human Safety 

Chairperson(s): Barbara Mounho, Amgen, Inc, Thousand Oaks, CA, and 

Marque Todd, Pfizer, Inc., San Diego, CA. 

Sponsor: 


Endorsed by: 



Immunogenicity is a unique property of biotherapeutics thus it is accepted 

that the administration of a biotherapeutic to humans or animals has the 

potential to elicit an antibody response against the drug if the biotherapeutic 

is perceived as foreign. Most biologics are human-specific proteins or monoclonal 

antibodies and it is not unexpected that the administration these drugs 

may result in the production of anti-drug antibodies (ADA). ADA responses 

are a common challenge during the conduct of nonclinical toxicity studies 

for biologics, and these responses can potentially affect the outcome and 

interpretation of a toxicity study. The impact of ADA on toxicology studies 

can vary having no affect, an alteration of the pharmacokinetic profile 

resulting in decreased/increased systemic exposure, an abrogation of the 

pharmacological activity, or neutralization of the biological activity of an 

endogenous protein that mediates a critical biological function. Another 

potential consequence of the production of ADA is ADA-drug immune 

complex formation with deposition in various organs and tissues. These 

immune complexes can result in significant inflammation and tissue damage 

with resultant organ dysfunction. A common example of immune complexmediated 

toxicity is immune complex-mediated glomerulonephritis. 

Immune complex formation has also been associated with “anaphylactoidlike” 

hypersensitivity reactions and serum sickness. In addition, although 

rare, ADA have been associated with classical IgE-mediated acute hypersensitivity 

reactions and autoimmunity. These various ADA-associated 

toxicities can confound the conduct and interpretation of toxicity studies. 

This session will highlight case studies to explore potential ADA-mediated 

toxicities including hypersensitivity reactions and immune complex formation/deposition 

and impact on clinical development/safety will be discussed. 

Abstract # 

#615 9:00 ANTI-DRUG ANTIBODY-MEDIATED 

TOXICITY IN NONCLINICAL TOXICITY 

STUDIES: IMPACT AND RELEVANCE TO 

HUMAN SAFETY. B. Mounho 2 and M. D. Todd 1 . 

1 

Drug Safety R&D, Pfizer, Inc., San Diego, CA and 

2 

Toxicology, Amgen, Inc., Thousand Oaks, CA. 

#616 9:05 INTRODUCTION: GENERAL REVIEW OF 

THE TYPES OF ANTI-DRUG ANTIBODY- 

MEDIATED RESPONSES THAT CAN OCCUR 

IN TOXICOLOGY STUDIES. B. Mounho. 

Toxicology, Amgen, Thousand Oaks, CA. 

#617 9:37 MECHANISMS OF ANTI-DRUG MEDIATED 

TOXICITIES OBSERVED IN NONCLINICAL 

TOXICOLOGY STUDIES AND IMPACT ON 

CLINICAL TRIAL DESIGN AND HUMAN 

SAFETY. A. Weir. Navigator Services Charles 

River Laboratories, Reno, NV. 

#618 10:09 ATYPICAL HYPERSENSITIVITY 

REACTIONS ELICITED BY A MAB 

TARGETING A HUMAN FC RECEPTOR. M. 

Flaherty, T. MacLachlan, M. Troutt, C. Rogers, R. 

Garman and L. Andrews. Genzyme, Framingham, 

MA. 

#619 10:41 CASE STUDY ON THE IMPACT OF 

IMMUNOGENICITY ON ADVERSE 

EFFECTS IN TOXICOLOGY STUDIES AND 

CONSEQUENCES FOR THE CLINICAL 

DEVELOPMENT PROGRAM. J. Bussiere and 

C. Johnson. CBSS, Amgen Inc., Thousand Oaks, CA. 

#620 11:13 CHARACTERIZATION OF POTENTIAL 

IMMUNE COMPLEXES OBSERVED 

IN CYNOMOLGUS MONKEYS AND 

RELATIONSHIP TO OBSERVED 

TOXICITIES OF MONOCLONAL ANTIBODY 

DRUG CANDIDATES. M. D. Todd. Drug Safety 

R&D, Pfizer, Inc., San Diego, CA. 


9:00 AM to 11:45 AM 

Ballroom F 

Symposium Session: Bile Salt Transport and Liver Injury 

Chairperson(s): Hisham K. Hamadeh, Amgen, Inc., Comparative Biology 

and Safety Sciences, Thousand Oaks, CA, and John W. Davis II, Pfizer 

Global Research & Development, Chesterfield, MO. 

Sponsor: 


Endorsed by: 



Bile formation is one of the key functions of mammalian liver. It involves 

vectorial transport of bile acids and other cholephilic compounds across 

hepatocytes from the sinusoidal blood into bile. Thereby, bile acids are 

concentrated more than 500-fold in bile as compared to sinusoidal blood. 

This concentrative, energy driven process is dependent on the bile salt export 

pump BSEP. Pathophysiological alterations in BSEP function by inherited 

mutations, inhibition of function by drugs, or disease-related down regulation 

may lead to a wide spectrum of mild to severe forms of liver disease. 

Furthermore, many genetic variants of BSEP are known, some of which 

potentially render individuals susceptible to certain acquired forms of liver 

disease. Drug-induced disruption in BSEP-mediated bile acid excretion 

has been implicated in the development of clinical liver injury for several 

marketed or withdrawn compounds. Unfortunately, nonclinical species are 

not reliable predictors of drug-induced liver injury routinely seen in clinical 

tueSday 







161


tueSday 



trials and attributed to BSEP inhibition. The challenge for the pharmaceutical 

industry is to understand the relationship between perturbation of bile 

acid flow and development of liver injury in humans. Investigations on the 

potential involvement of disruption of BSEP function in the manifestation 

of clinical liver injury are very timely in drug development. This session will 

focus on both nonclinical models and clinical manifestations of perturbation 

of hepatobiliary transporters in drug-induced liver injury. 

#621 9:00 BILE SALT TRANSPORT AND LIVER 

INJURY. H. Hamadeh 1 and J. W. Davis 2 . 

1 

Comparative Biology and Safety Sciences, Amgen 

Inc., Thousand Oaks, CA and 2 Worldwide Safety 

Sciences, Pfizer Inc., Chesterfield, MO. 

#622 9:05 BILE SALT PUMP (BSEP) REGULATION 

IN ACQUIRED CHOLESTATIC LIVER 

DISEASES. M. H. Trauner. Internal Medicine, 

Medical University of Graz, Graz, Styria, Austria. 

Sponsor: H. Hamadeh. 

#623 9:37 BSEP INHIBITION AS A CONTRIBUTOR 

TO DRUG-INDUCED LIVER INJURY IN 

HUMANS. H. Hamadeh. Investigative Toxicology, 

Amgen Inc., Thousand Oaks, CA. 

#624 10:09 IMPAIRED HEPATIC BILE ACID 

TRANSPORT AND DRUG-INDUCED 

HEPATOTOXICITY: MECHANISMS AND 

MODEL SYSTEMS. K. L. Brouwer. School of 

Pharmacy, University of North Carolina at Chapel 

Hill, Chapel Hill, NC. Sponsor: H. Hamadeh. 

#625 10:41 INHIBITION OF HEPATOBILIARY 

TRANSPORTERS BY A NOVEL KINASE 

INHIBITOR CONTRIBUTES TO LIVER 

TOXICITY IN NONCLINICAL SPECIES. 

J. S. Daniels 1 , Y. Lai 1 , J. Stevens 1 , R. Mourey 2 , 

D. Anderson 2 and J. Davis 3 . 1 Pharmacokinetics, 

Dynamics and Metabolism, Pfizer, Inc., Chesterfield, 

MO, 2 Discovery Chemistry and Biology, Pfizer, Inc., 

Chesterfield, MO and 3 Drug Safety Research and 

Development, Pfizer, Inc., Chesterfield, MO. 

#626 11:13 UNDERSTANDING THE CROSS- 

TALK BETWEEN BILE SALT EXPORT 

PUMP (BSEP) AND OTHER EFFLUX 

TRANSPORTERS IN THE MANIFESTATION 

OF DRUG-INDUCED LIVER INJURY. J. E. 

Manautou. Pharmaceutical Sciences, University of 



9:00 AM to 11:45 AM 

Ballroom A 


Symposium Session: MAP Kinase Signaling: A Common 

Target Eliciting Unique Tissue Responses 

Chairperson(s): Haitian Lu, Michigan State University, East Lansing, MI, 

and Sarah Campion, Brown University, Providence, RI. 

Sponsor: 

Student Advisory Council and Postdoctoral Assembly 

Endorsed by: 



The mitogen-activated protein kinase (MAPK) signal transduction pathways 

are triggered by a variety of extracellular stimuli. Upon activation, MAPKs 

phosphorylate downstream targets, transducing these extracellular stimuli 

into cellular responses. Since their identification, MAPK signal transduction 

162 

pathways have been found to regulate diverse and critical cellular processes 

such as gene expression, cell proliferation, differentiation, motility, survival 

and apoptosis, by altering the phosphorylation status of key regulatory 

proteins. Numerous studies have revealed that activation of MAPK signaling 

cascades also occurs in response to a variety of chemical and physical 

stresses. The activation status of critical MAPKs, including extracellular 

signal-related kinase (ERK), p38 and c-Jun N-terminal kinase (JNK), may 

be modulated by exposure to xenobiotics. Ongoing research continues 

to elucidate the role of MAPK signaling alterations during chemicalinduced 

toxicity. Despite the ubiquitous nature of MAPK signal transduction 

pathways, the modulation and function of each individual MAPK has 

been suggested to be highly cell type and context dependent. Therefore, 

in-Department studies are needed to understand the mechanisms underlying 

tissue-specific toxicity involving alterations of MAPK signaling pathways. 

This session will highlight the most recent research progress made to characterize 

the alterations of MAPK signaling pathways in response to toxicant 

exposures, and how these alterations contribute to toxicity and/or pathogenesis 

in different tissues and cell types. The qualitative comparison among 

data presented in this session will either suggest a paradigm of MAPK 

response to various toxicants, or illustrate the cell type/tissue specific difference 

in the role of MAPK signaling alterations during toxic responses. 

#627 9:00 MAP KINASE SIGNALING: A COMMON 

TARGET IN DIFFERENT TISSUES. S. 

N. Campion 1 and H. Lu 2 . 1 Brown University, 

Providence, RI and 2 Michigan State University, East 

Lansing, MI. 

#628 9:05 GENE EXPRESSION STUDIES 

DEMONSTRATE THAT THE K-RAS/ERK 

MAP KINASE SIGNAL TRANSDUCTION 

PATHWAY CONTRIBUTES TO THE 

PATHOGENESIS OF CUMENE-INDUCED 

LUNG TUMORS. S. A. Lahousse 1 , H. Hong 1 , 

J. Collins 2 , T. Ton 1 , T. Devereux 1 and R. C. Sills 1 . 

1 

Cellular and Molecular Pathology Branch, National 

Institute of Environmental Health Sciences, Research 

Triangle Park, NC and 2 Laboratory of Molecular 

Toxicology, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC . 

#629 9:37 ROLE OF MAP KINASES AND 

PHOSPHATIDYLINOSITOL-3 KINASE/ 

AKT IN REGULATING KERATINOCYTE 

ANTIOXIDANT EXPRESSION IN RESPONSE 

TO 4-HYDROXYNONENAL, A LIPID 

PEROXIDATION END PRODUCT. R. Zheng 1 , 

A. T. Black 1 , M. P. Shakarjian 2 , D. E. Heck 2 , D. 

L. Laskin 1 and J. D. Laskin 3 . 1 Department of 

Pharmacology and Toxicology, Rutgers University, 

Piscataway, NJ, 2 Environmental Health, New York 

Medical College, Valhalla, NY and 3 Department 

of Medicine and Environmental and Occupational 

Medicine, UMDNJ-Robert Wood Johnson Medical 

School, Piscataway, NJ. 

#630 10:09 ACTIVATION OF C-JUN N-TERMINAL 

PROTEIN KINASE IS A COMMON 

MECHANISM UNDERLYING 

PARAQUAT- AND ROTENONE-INDUCED 

DOPAMINERGIC CELL APOPTOSIS. H. 

M. Klintworth 1 , K. Newhouse 1 , T. Li 1 , W. Choi 1 , 

R. Faigle 1 and Z. Xia 1,2 . 1 Environmental and 

Occupational Health Sciences, University of 

Washington, Seattle, WA and 2 Graduate Program in 

Neurobiology & Behavior, University of Washington, 

Seattle, WA. 

#631 10:41 TOXICANT MEDIATED ANTI- 

INFLAMMATORY EFFECTS AND THE 

ROLE OF MAP KINASE. W. Tan 1 , Q. Dai 2 , 

R. Fan 2 , M. Glover 2 , B. Cheng 2 and S. Pruett 1,2 . 

1 

Mississippi State University, Mississippi State, MS 

and 2 LSU Health Science Center, Shreveport, LA. 






Platform Sessions



Abstract # 

#632 11:13 MULTIPARAMETRIC SINGLE 

CELL ANALYSIS OF TOLL-LIKE 

RECEPTOR ACTIVATED KINASE 

PHOSPHORYLATION ALTERATION BY 2, 

3, 7, 8-TETRACHLORODIBENZO-P-DIOXIN. 

C. North, R. B. Crawford, H. Lu and N. E. Kaminski. 

Pharmacology & Toxicology, Michigan State 



9:00 AM to 11:45 AM 

Ballroom D 


Symposium Session: Molecular Determinants of 

Mitochondrial Disease 

Chairperson(s): Kendall B. Wallace, University of Minnesota Medical 

School, Duluth, MN, and Rick G. Schnellmann, Medical University of 

South Carolina, Charleston, SC. 

Sponsor: 


Endorsed by: 


Metabolic disorders have gained increasing recognition as important 

outcomes to many toxicities, the etiologies of which include environmental 

and occupational exposures, as well as adverse drug reactions. Because of 

its fundamental role in cell bioenergetics and intermediary metabolism, the 

mitochondrion is implicated in the pathogenesis of many of these disease 

states. While the majority of studies have been directed at understanding 

the acute response to mitochondrial toxicity, only recently have investigators 

come to realize the significance of subtle molecular changes that 

occur in response to mitochondrial injuries that define the metabolically 

compensated state of the cell. Such changes are essential to the cell being 

able to withstand low doses and chronic exposures to agents that interfere 

with mitochondrial function. Collectively, it is these events that define the 

biological response to sub-lethal exposures and that offer unique opportunities 

for identifying exposures that may otherwise go unrecognized as a 

potential metabolic liability for the individual. To adequately address these 

issues, a general overview of mitochondrial metabolism followed by a series 

of focused discussions of the molecular changes that define the biological 

response will be highlighted. The session concludes by leveraging this 

understanding of the molecular response to the identification of potential 

biomarkers for reporting subtle, nonclinical cases of mitochondrial toxicity. 

#633 9:00 MOLECULAR DETERMINANTS OF 

MITOCHONDRIAL DISEASE. K. B. Wallace 1 

and R. G. Schnellmann 2 . 1 Biochemistry & Molecular 

Biology, University of Minnesota, Duluth, MN and 

2 

Pharmaceutical Sciences, Medical University of 

South Carolina, Charelston, SC. 

#634 9:10 MITOCHONDRIAL TOXICITY AND THE 

COMPENSATED METABOLIC STATE. K. 

B. Wallace. Biochemistry & Molecular Biology, 

University of Minnesota, Duluth, MN. 

#635 9:45 TRANSCRIPTIONAL PROFILING OF 

MITOCHONDRIAL TOXICITY. V. G. Desai 

and J. C. Fuscoe. Division of Systems Toxicology, 

NCTR, U.S. FDA, Jefferson, AR. 

#636 10:25 METABONOMIC AND FLUXOMIC 

FINGERPRINTING OF METABOLIC AND 

MITOCHONDRIAL STRESS. P. Dzeja. Mayo 

Clinic, Rochester, MN. Sponsor: K. Wallace. 

Abstract # 

#637 11:05 MITOCHONDRIAL BIOGENESIS – RESCUE 

FROM METABOLIC DISORDERS. R. G. 

Schnellmann. Pharmaceutical Sciences, Medical 

University of South Carolina, Charleston, SC. 


9:00 AM to 11:45 AM 

Ballroom I 

Symposium Session: POPs: What’s New and Why Should We 

Care? 

Chairperson(s): Arnold Schecter, University of Texas at Dallas, Dallas, 

TX, and Linda Birnbaum, National Institute of Environmental Health 


Sponsor: 


The persistent organic pollutants, or POPs, are of increasing concern among 

the general public, health care providers, and scientists. These synthetic 

pollutants are characterized as being very persistent in biota and the environment, 

toxic, undergo trans-boundary migration, and are bioaccumulative. 

Legacy or classical POPs include PCBs, organochlorine pesticides, and 

chlorinated dioxins/furans. Presently, considerable interest is focused 

on newly emerging POPs such as brominated flame retardants (BFRs), 

including polybrominated diphenyl ethers or PBDEs, and polyfluoroalkyl 

chemicals (PFCs) which include PFOS and PFOA. Tremendous improvements 

in analytical chemistry have improved the rates of detection of these 

compounds in the environment and in humans. Increasing levels of many 

of the emerging POPs measured in human and environmental samples has 

become cause for concern. Questions regarding these compounds include 

exposure assessment, toxicity, possible substitutes, interactions, metabolism, 

and regulations. Therefore, this session will provide a current overview from 

leaders in these important areas and will be followed by detailed recent findings 

from the scientists actively researching these compounds. 

#638 9:00 POPS: WHAT’S NEW AND WHY SHOULD 

WE CARE? A. Schecter 1 and L. Birnbaum 2 . 

1 

University of Texas School of Public Health 

at Dallas, Dallas, TX and 2 National Institute of 

Environmental Health Sciences, Research Triangle 

Park, NC. 

#639 9:05 LEGACY AND EMERGING POPS. L. 

Birnbaum. National Institute of Environmental 


#640 9:32 ARE CONCENTRATIONS OF 

POLYFLUOROALKYL CHEMICALS IN 

THE GENERAL U.S. POPULATION ARE 

DECLINING?: DATA FROM THE NATIONAL 

HEALTH AND NUTRITION EXAMINATION 

SURVEYS (NHANES). A. Calafat, L. Wong, K. 

Kato, Z. Kuklenyik and L. L. Needham. Centers for 

Disease Control and Prevention, Atlanta, GA. 

#641 9:59 POPS IN THE U.S. POPULATION AND 

IN U.S. FOOD. A. Schecter 1 , J. Colacino 2 , T. 

Harris 1 , M. Opel 3 , O. Paepke 3 , K. Kannan 4 and L. 

Birnbaum 5 . 1 University of Texas School of Public 

Health, Dallas, TX, 2 University of Michigan, 

Ann Arbor, MI, 3 Eurofins Laboratory, Hamburg, 

Germany, 4 University at Albany, SUNY, Albany, 

NY and 5 National Institutes of Environmental Health 


tueSday 







163


tueSday 



#642 10:26 LEVELS AND TRENDS OF HISTORIC POPS 

(PCDD/FS AND PCBS ) AND NEWER POPS 

(PBDES) IN U.S. MEAT AND POULTRY AND 

IIMPLICATIONS FOR HUMAN EXPOSURE. 

J. Huwe 1 , D. Pagan-Rodriguez 1 , N. Abdelmajid 1 , 

N. Clinch 1 , D. Gordon 2 , J. Holterman 1 , E. Zaki 1 , 

M. Lorentzsen 3 and K. Dearfield 1 . 1 Agricultural 

Research Service, U.S. Department of Agriculture, 

Fargo, ND, 2 Food Safety and Inspection Service, 

U.S. Department of Agriculture, Washington, DC 

and 3 Food Safety and Inspection Service, U.S. 

Department of Agriculture, St. Louis, MO. 

#643 10:53 EMERGING POPS IN EDIBLE TISSUES: 

ADME STUDY OF BDE-47 IN CHICKENS. H. 

Hakk 1 , J. Huwe 1 , K. Murphy 2 and D. Rutherford 2 . 

1 

Agricultural Research Service, United States 

Department of Agriculture, Fargo, ND and 

2 

Department of Chemistry, Concordia College, 

Moorhead, MN. Sponsor: A. Schecter. 

#644 11:19 PBDE EXPOSURE FROM PRODUCTS TO 

PERSON. T. Webster 1 , H. Stapleton 2 and M. 

McClean 1 . 1 Environmental Health, Boston University 

School of Public Health, Boston, MA and 2 Duke 



9:00 AM to 11:45 AM 

Room 151 


Workshop Session: Opportunities to Modify Current 

Regulatory Testing Guidelines and Advance the Assessment of 

Carcinogenicity Risk in the 21 st Century 

Chairperson(s): Frank D. Sistare, Merck and Co., Inc., West Point, PA, 

and David Jacobson-Kram, U.S. FDA, Silver Spring, MD. 

Sponsor: 


Endorsed by: 




The two-year rodent bioassay is currently the most expensive and 

time-consuming animal test required for pharmaceutical and chemical carcinogenicity 

assessment. A vision for the 21 st century is proposed for a staged 

approach to altering the current pharmaceutical carcinogenicity testing paradigm 

that reduces the timeline, animal and human resources, and improves 

human risk assessment. Analyses of decades of shared data from pharmaceutical 

carcinogenicity testing are helping to define an approach to preserve 

protections and benefits afforded to patients, while providing support for 

a near-term significant modification to testing guidelines. These data are 

also helping to define a research strategy that will deliver further improved 

testing. In the past decade, genetically modified animal models have been 

introduced and incorporated as an addition to the pharmaceutical test battery 

option. A new paradigm supported by decades of test data proposes to maximize 

the value of such mouse models to minimize the need for two-year 

rat carcinogenicity studies. Furthermore, advances are being made through 

collaborative research initiatives that point to anticipated growth in qualified 

biomarkers for monitoring in both animal models, and in vitro test systems 

that may allow quicker resource sparing approaches to improved cancer risk 

identification. These approaches promise not only to allow earlier identification 

of rodent tumorigenic chemicals, but also to provide deeper insights 

into mode-of-action and better understanding of human relevance. Therefore 

it is a goal of this session to provide new understanding of key lessons 

learned from decades of pharmaceutical testing experience, of emerging 

carcinogenomic based biomarkers, of development of in vitro screening and 

mechanistic models, of integrated mode-of-action systems biology based 

approaches to identify and assess genotoxic and nongenotoxic mechanisms, 

and offer regulatory perspectives on the impact of these developments on the 

near-term and long-term future of carcinogenicity testing. 

#645 9:00 OPPORTUNITIES TO ADVANCE 

THE ASSESSMENT OF CHEMICAL 

CARCINOGENICITY RISK AND MODIFY 

CURRENT REGULATORY TESTING 

GUIDELINES. F. D. Sistare 1 and D. Jacobson- 

Kram 2 . 1 Safety Assessment, Merck & Co Inc., West 

Point, PA and 2 CDER, U.S. FDA, Silver Spring, MD. 

#646 9:05 LESSONS LEARNED FROM AN 

ANALYSIS OF PHARMACEUTICAL 

EXPERIENCE WITH DECADES OF RAT 

CARCINOGENICITY TESTING. F. D. Sistare. 

Safety Assessment, Merck & Co Inc., West Point, 

PA. 

#647 9:37 A PROPOSED VISION ON THE FUTURE OF 

CARCINOGENICITY TESTING. D. Jacobson- 

Kram. CDER/U.S. FDA, Silver Spring, MD. 

#648 10:09 INTEGRATING PREDICTIVE AND 

MECHANISTIC CARCINOGENICITY 

BIOMARKER INTO DRUG DISCOVERY 

AND DEVELOPMENT. M. Fielden. Amgen, 

South San Francisco, CA. 

#649 10:41 IMPROVING CANCER RISK ASSESSMENT 

OF DRUG CANDIDATES BY INTEGRATING 

SYSTEMS BIOLOGY TO DEFINE MODE- 

OF-ACTION OF CARCINOGENS. J. Aubrecht. 

Drug Safety Research and Development, Pfizer Inc., 

Groton, CT. 

#650 11:13 USING IN VITRO HAZARD 

IDENTIFICATION APPROACHES FOR 

IMPROVING HUMAN CANCER RISK 

ASSESSMENT AND PRECLINICAL 

TESTING. J. H. van Delft 1,2 , C. Magkoufopoulou 1,2 , 

K. Mathijs 1,2 , D. G. Jennen 1,2 , D. Lizarraga 1,2 , S. 

H. Claessen 1 , K. J. Brauers 1 and J. C. Kleinjans 1,2 . 

1 

Health Risk Analysis and Toxicology, Maastricht 

University, Maastricht, Netherlands and 2 Netherlands 

Toxicogenomics Center, Maastricht University, 

Maastricht, Netherlands. Sponsor: F. Sistare. 


9:00 AM to 11:45 AM 

Ballroom B 

Workshop Session: Research Advances and Enduring Needs 

in Children’s Environmental Health Protection 

Chairperson(s): Sally P. Darney, U.S. EPA, Research Triangle Park, NC, 

and Allen Dearry, NIEHS, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




Children may be more vulnerable and susceptible to health impacts of environmental 

contaminants based upon age-specific behaviors that increase 

exposure; developmental processes that are differentially susceptible to 

disruption; and genetic variables that alter biological responses to toxicants. 

Federal laws require consideration of children’s unique vulnerability in rule 

making activities. Recent research about how children are exposed and react 

164 






Platform Sessions



Abstract # 

to environmental contaminants helps decision makers set environmental 

standards based on scientific information rather than default assumptions. In 

1998, the U.S. EPA and NIEHS partnered to fund the Centers for Children’s 

Environmental Health and Disease Prevention Research Program. These 

centers are examining interactions between key environmental exposures 

and a range of child prevalent diseases such as asthma and autism. Emphasizing 

multidisciplinary basic, applied, and community-based participatory 

approaches, their common goal is to reduce children’s health risks from 

environmental contaminants, prevent childhood diseases, and share findings 

with the affected communities and the broader public. In 2009, NIH 

launched the National Children’s Study (NCS) in partnership with CDC, 

U.S. EPA, and NIEHS. NCS will recruit and follow 100,000 children from 

before birth to adulthood, gathering both exposure and health outcome information 

and evaluating how early life exposures may affect their subsequent 

health. Therefore it is important that we seize the opportunity through these 

initiatives to synthesize recent research advances in child-specific exposure 

science and health effects, including lessons learned from the Children’s 

Centers, illustrate how these advances are being integrated into new studies 

such as the NCS, consider how this new knowledge can be used in risk 

assessment, and address ongoing challenges. Specifically, these challenges 

include interpreting biomonitoring data, finding and eliminating exposure 

sources, predicting health effects, communicating the findings to regulators 

and the public in meaningful ways, and informing policy decisions. 

#651 9:00 RESEARCH ADVANCES AND ENDURING 

NEEDS IN CHILDREN’S ENVIRONMENTAL 

HEALTH PROTECTION. S. P. Darney. ORD, 


#652 9:05 FEDERAL EFFORTS TO ADDRESS 

CHILDREN’S ENVIRONMENTAL HEALTH. 

A. Dearry. NIEHS, NIH, Research Triangle Park, 

NC. Sponsor: S. Darney. 

#653 9:20 CHILDREN’S EXPOSURES TO CHEMICALS. 

L. S. Sheldon. NERL, U.S. EPA ORD, Durham, NC. 

Sponsor: S. Darney. 

#654 9:57 GENE-ENVIRONMENT INTERACTIONS 

AND CHILDREN’S SUSCEPTIBILITY. E. M. 

Faustman. Center for Child Environmental Health 

Risks Research, University of Washington, Seattle, 

WA. 

#655 10:34 UNIQUE OPPORTUNITIES IN THE 

NATIONAL CHILDREN’S STUDY. J. Park, L. 

E. Palmer, J. Gilliland, S. Firth, P. Silberman and J. 

Johnson. Pediatrics, University of Utah, Salt Lake 

City, UT. Sponsor: S. Perreault Darney. 

#656 11:10 HOW CAN SCIENCE INFORM RISK-BASED 

DECISIONS AND PROTECT CHILDREN’S 

HEALTH? S. Barone. NCEA, U.S. EPA, 


Abstract # 


9:00 AM to 11:45 AM 

Ballroom G 

Education-Career Development Session: Where Do I Go 

Now? Rational Career Development Planning for Early- 

Career Scientists 

Chairperson(s): Betina J. Lew, University of Rochester Medical Center, 

Rochester, NY, and Amy Wang, U.S. EPA, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 

Career Resource and Development Committee 


Toxicology training during graduate school and postdoctoral fellowships 

provides early-career scientists with a wide array of transferable skills that 

can be used in many job sectors, but navigating the all of the possible career 

options can be a daunting task. Additionally, finding and preparing for a 

career path that is right for yourself is not always easy, particularly when 

it differs from that of your mentor or is non-traditional. The majority of 

students and postdocs are trained in academic institutions with resources 

that prepare them for a career in academia. However, a recent National Postdoctoral 

Association survey indicated that even though 45% of the postdocs 

plan on being a tenure-track faculty member, less than 20% will obtain this 

position. Therefore, it is important for early-career scientists to gather ample 

information and diverse experiences to better prepare them for multiple 

career paths. The first step in this process is to identify transferable skills 

and translate them into realistic paths towards a rewarding job. With broad 

coverage of non-traditional career paths in toxicology, this session will 

provide early-career scientists with insight on how to map a career path that 

fits their passion and skills. Using an interactive format, speakers will identify 

tools to utilize in pursuit to navigating different paths. Discussions will 

include identifying marketable skills, rational career planning, networking, 

and improving marketability. Grant preparation will also be discussed during 

a presentation on writing a successful career transition grant application. 

Specifically, the K99/R00 grant program, which has no citizenship restrictions, 

provides support to an individual postdoctoral fellow transitioning to 

an independent faculty position. 

#657 9:00 WHERE DO I GO NOW? RATIONAL 

CAREER DEVELOPMENT PLANNING FOR 

EARLY-CAREER SCIENTISTS, B. J. Lew 1 and 

A. Wang 2 . 1 Environmental Medicine, University of 

Rochester, Rochester, NY and 2 National Center for 

Environmental Assessment, U.S. EPA, Research 


#658 9:15 How to Identify Your Skills and Passions, K. 

Keefe. Pharmacology and Toxicology, University of 

Utah, Salt Lake City, UT. Sponsor: B. Lew. 

#659 9:38 Career Planning and Development for Early- 

Career Scientists, D. C. Wolf. ORD/NHEERL, 

U. S. EPA, Research Triangle Park, NC. 

#660 10:01 Improving Networking and Communication 

Skills, L. Conlan. Office of Intramural Training & 

Education, NIH, Bethesda, MD. Sponsor: B. Law. 

#661 10:24 Making Yourself More Marketable in Private 

Industry, J. A. Popp. Stratoxon, Lancaster, PA. 

#662 10:46 The NIH Pathways to Independence Award: 

A Transition to an Academic Career, C. Shreffler. 

Division of Extramural Research and Training, 

NIEHS, Research Triangle Park, NC. Sponsor: S. 

Nadadur. 

11:09 Panel Discussion/Q&A 

tueSday 







165


tueSday 




9:00 AM to 11:45 AM 

Room 250 

Platform Session: Epidemiological Insights: Effects of 

Environmental and Occupational Exposures 

Chairperson(s): Ellen Silbergeld, Johns Hopkins School of Public Health, 

MD, and Anne Chappelle, Sunoco, Inc., Lester, PA. 

#663 9:00 A POLYMORPHISM IN THE AH-RECEPTOR 

GENE IS RELATED TO HYPERTENSION 

AND ENDOTHELIUM-DEPENDENT 

VASODILATION. L. Lind 1 and M. P. Lind 2,3 . 

1 

Acute and Internal Medicine, Department of 

Medical Sciences, Uppsala University Hospital, 

Uppsala University, Uppsala, Sweden, 2 Occupational 

and Environmental Medicine, Department of Medical 

Sciences, Uppsala University, Uppsala, Sweden and 

3 

Institute of Environmental Medicine, Karolinska 

institutet, Stockholm, Sweden. 

#664 9:21 BIOMARKERS AND ONSET OF NON- 

SPECIFIC BUILDING RELATED 

SYMPTOMS IN THE DWELLING. A 

COHORT STUDY FROM 1992 TO 2002. 

B. G. Sahlberg 1 , D. Norbäck 1 , G. Weslander 1 and 

C. Janson 2 . 1 Department of Medical Sciences, 

Occupational and Environmental Medicine, Uppsala, 

Sweden and 2 Department of Medical Sciences, 

Respiratory Medicine & Allergology, Uppsala, 

Sweden. 

#665 9:41 EPIDEMIOLOGIC EVIDENCE 

FOR FORMALDEHYDE-INDUCED 

LYMPHOHEMATOPOIETIC 

MALIGNANCIES. B. Sonawane, T. Bateson, 

J. Whalan and D. DeVoney. National Center for 

Environmental Assessment, U.S. EPA, Washington, 

DC. 

#666 10:01 ASSOCIATION OF LOW-LEVEL BLOOD 

LEAD AND BLOOD PRESSURE IN THE 

NHANES 1999–2006. F. Scinicariello, H. Abadin 

and E. Murray. Division Tox and Env.Med., ATSDR/ 

CDC, Atlanta, GA. Sponsor: B. Fowler. 

#667 10:22 PREVALENCE OF NEUROPATHIC 

CAMPYLOBACTER JEJUNI (CJ) ON 

COMMERCIAL BROILER CHICKEN 

PRODUCTS. C. G. Hardy 1 , E. K. Silbergeld 1 , J. 

Cannon 2 , L. Lackey 1 and L. B. Price 2 . 1 Johns Hopkins 

SPH, Baltimore, MD and 2 TGEN, Flagstaff, AZ. 

#668 10:42 INTERACTION BETWEEN PRE- 

PREGNANCY BODY MASS INDEX AND 

MATERNAL TOBACCO SMOKING ON 

BIRTH WEIGHT OF NEW YORK CITY 

INFANTS. M. La Merrill, P. J. Landrigan, C. R. 

Stein, S. M. Engel and D. A. Savitz. Preventive 

Medicine, Mount Sinai School of Medicine, New 

York. 

#669 11:03 MIXED AMPHETAMINE SALTS TOXICOSIS 

IN CATS–A RETROSPECTIVE REVIEW 

OF 152 CASES REPORTED TO THE ASPCA 

ANIMAL POISON CONTROL CENTER 

BETWEEN JANUARY 2002 AND JUNE 2009. 

A. Salem Sreenivasan 1 , S. A. Khan 2 , S. Gwaltney- 

Brant 2 , M. R. Slater 1 and V. R. Beasley 1 . 1 Veterinary 

Biosciences, University of Illinois at Urbana- 

Champaign, Urbana, IL and 2 ASPCA APCC, Urbana, 

IL. 

#670 11:24 META-ANALYSIS OF AIRWAY HYPER- 

RESPONSIVENESS IN ASTHMATICS AFTER 

NITROGEN DIOXIDE EXPOSURE. J. K. 

Chandalia, J. E. Goodman, S. Thakali and M. Seeley. 

Gradient, Cambridge, MA. 


9:00 AM to 11:45 AM 

Room 150 


Platform Session: Gene Environmental Interactions in 

Cacinogenesis 

Chairperson(s): John House, North Carolina State University, Raleigh, 

NC, and Tohru Inoue, National Institute of Health Sciences, Tokyo, Japan. 

#671 9:00 PHARMACOLOGICAL INHIBITION 

OF TGFb1 SIGNALING ENHANCES 

MALIGNANT PROGRESSION OF 

CHEMICALLY-INDUCED SKIN CANCERS 

THROUGH CHANGES IN INFLAMMATORY 

RESPONSE. L. Mordasky Markell 1 , R. Pérez- 

Lorenzo 1 , K. E. Masiuk 1 , H. Kwon 2 and A. 

B. Glick 1 . 1 Center for Molecular Toxicology 

and Carcinogenesis, The Pennsylvania State 

University, University Park, PA and 2 Department 

of Microbiology, College of Medicine. Hallym 

University, Chuncheon, Republic of Korea. 

#672 9:19 GENE EXPRESSION PROFILE OF THE 

BONE MARROW AFTER BENZENE 

EXPOSURE IN C57BL/6 AND C3H/ 

HE MICE: ELUCIDATION OF STRAIN 

DIFFERENCE BY MICROARRAY STUDY 

WITH RECIPROCAL GENE EXPRESSION 

PROFILE, THE COMMON GENE 

EXPRESSION, AND THE STOCHASTIC 

GENE EXPRESSION. T. Inoue 1 , B. Yoon 2,3 , K. 

Igarashi 2 , Y. Kodama 2 , K. Sekita 2 , T. Kaneko 2 , J. 

Kanno 2 and Y. Hirabayashi 2 . 1 Center for Biol Safety 

& Res, Nat’l Inst of Health Sciences, Tokyo, Japan, 

2 

Div of Cellular & Molecular Toxicology Center for 

Biol Safety & Res, Nat’l Inst of Health Sciences, 

Tokyo, Japan and 3 Lab of Histology & Molecular 

Pathogenesis, School of Vet Med, Kangwon Nat’l 

University Chuncheon, Republic of Korea. 

#673 9:37 IMMUNOSUPPRESSIVE 

CYCLOSPORIN A ACTIVATES AKT IN 

KERATINOCYTES THROUGH PTEN 

SUPPRESSION: IMPLICATIONS IN SKIN 

CARCINOGENESIS. Y. He 1 , W. Han 1 , M. Ming 1 

and T. He 2 . 1 Medicine/Dermatology, University of 

Chicago, Chicago, IL and 2 Surgery, University of 

Chicago, Chicago, IL. 

#674 9:55 IN VITRO REGULATION OF MMP-2 AND 

MMP-9 EXPRESSION BY CYTOKINES, 

MITOGENS, INDUCERS AND INHIBITORS 

IN ADULT SARCOMA CELL LINES. M. 

Roomi, J. C. Monterrey, M. Rath and A. Niedzwiecki. 

Dr. Rath Research Institute, Santa Clara, CA. 

166 






Platform Sessions



Abstract # 

#675 10:13 C/EBP-ALPHA AND C/EBP-BETA 

ARE DETERMINANTS OF SKIN 

CARCINOGENESIS AND ARE ESSENTIAL 

REGULATORS OF KERATINOCYTE AND 

SEBOCYTE DIFFERENTIATION. J. S. House 1 , 

S. Zhu 1 , R. Ranjan 1 , K. Linder 2 and R. C. Smart 1 . 

1 

Department of Environmental and Molecular 

Toxicology, North Carolina State University, 

Raleigh, NC and 2 Department of Population Health 

and Pathobiology, College of Veterinary Medicine, 

NCSU, Raleigh, NC. 

#676 10:31 TUMOR-ELICITED ALVEOLAR 

MACROPHAGES PRODUCE IGF-1 TO 

AUGMENT NEOPLASTIC EPITHELIAL 

PROLIFERATION IN AN ERK1/2 

DEPENDENT MANNER. J. M. Fritz, L. D. 

Dwyer-Nield and A. M. Malkinson. Department of 


Denver, Aurora, CO. 

#677 10:49 CR(VI) EXPOSURE INDUCES TELOMERE 

LOSS AND DEFECTS. F. Liu, A. Barchowsky 

and P. L. Opresko. Environmental and Occupational 

Health, University of Pittsburgh, Pittsburgh, PA. 

#678 11:07 PERSISTENT NUCLEAR-CYTOPLASMIC 

ERK OSCILLATIONS ARE DEREGULATED 

BY TOXIC INSULT. T. J. Weber 1 , H. Shankaran 2 , 

W. B. Chrisler 1 and R. D. Quesenberry 1 . 1 Cell 

Biology & Biochemistry, Pacific Northwest National 

Laboratory, Richland, WA and 2 Computational 

Biology and Bioinformatics Group, Pacific 

Northwest National Laboratory, Richland, WA. 

#679 11:26 THE ROLE OF HYPOXIA IN 

2-BUTOXYETHANOL-INDUCED 

HEMANGIOSARCOMA. M. Lawton 1 , D. 

Laifenfeld 2 , A. Gilchrist 2 , D. Drubin 2 , M. Jorge 2 , 

S. Eddy 2 , B. Frushour 2 , B. Ladd 2 , K. Ellison 2 , L. 

Obert 1 , M. Gosink 1 , C. Somps 1 , P. Koza-Taylor 1 , K. 

Criswell 1 and J. Cook 1 . 1 Drug Safety Research and 

Development, Pfizer, Groton, CT and 2 Genstruct Inc., 



9:00 AM to 11:45 AM 

Room 251 A 

Platform Session: Reproductive and Developmental Effects 

Using Fish Models 

Chairperson(s): Robert L. Tanguay, Oregon State University, Corvallis, 

OR, and Michael J. Carvan, III, University of Wisconsin Milwaukee, 

Milwaukee, WI. 

#680 9:00 THE FUNGAL PRODUCT AFLATOXIN B1 

AFFECTS VISUAL DEVELOPMENT IN 

LARVAL ZEBRAFISH. E. J. McGlumphy 1 , V. P. 

Connaughton 2 and M. A. Connaughton 1 . 1 Biology, 

Washington College, Chestertown, MD and 2 Biology, 

American University, Washington, DC. Sponsor: M. 

Reynolds. 

#681 9:21 FETAX CORRELATION WITH IN 

VIVO EMBRYOTOXICITY STUDIES 

AND COMPARISON TO DANIO RERIO 

TERATOGENICITY ASSAY (DART). I. 

Leconte 1 , I. Mouche 1 , L. Malésic 1 , O. Gillardeaux 1 , 

A. Delise 2 and M. Feuston 2 . 1 Drug Safety Evaluation, 

sanofi-aventis, Porcheville, France and 2 sanofiaventis, 

Bridgewater, NJ. 

Abstract # 

#682 9:41 TCDD DIFFERENTIALLY DECREASES 

EGFP EXPRESSION IN TWO DIFFERENT 

ZEBRAFISH SOX9B REPORTER LINES. K. 

M. Xiong 1 , A. Gooding 2 , R. E. Peterson 2 and W. 

Heideman 1,2 . 1 Biomolecular Chemistry, University of 

Wisconsin, Madison, WI and 2 Pharmacy, University 

of Wisconsin, Madison, WI. 

#683 10:02 BENZO(A)PYRENE EFFECTS ON GLYCINE 

N-METHYLTRANSFERASE EXPRESSION 

AND ACTIVITY IN FUNDULUS 

HETEROCLITUS AND DANIO RERIO. X. Fang, 

W. Dong, C. Thornton and K. L. Willett. Department 

of Pharmacology and Toxicology, the University of 

Mississippi, University, MS. 

#684 10:22 UNRAVELING THE ROLE OF THE AHR 

IN DIFFERENTIAL DEVELOPMENTAL 

TOXICITY OF POLYCYCLIC AROMATIC 

HYDROCARBONS IN ZEBRAFISH. B. 

C. Goodale, J. K. La Du and R. L. Tanguay. 

Environmental and Molecular Toxicology, Oregon 


#685 10:43 COMBUSTION-DERIVED POLYNUCLEAR 

AROMATIC HYDROCARBON (PAHS) 

INTERFERE WITH ZEBRAFISH EMBRYO 

DEVELOPMENT AND ARE RETAINED 

AFTER EXPOSURES END. A. Bui, K. Kleinow 

and A. Penn. LSU School of Veterinary Medicine, 


#686 11:03 PLEIOTROPIC NATURE OF ETHANOL 

ACTION IN MEDAKA EMBRYOGENESIS. 

A. K. Dasmahapatra 1,2,3 , Y. Hu 1,3 and I. A. Khan 1 . 

1 

National Center for Natural Product Research, 

University of Mississippi, University, MS, 

2 

Pharmacology, University of Mississippi, University, 

MS and 3 Environmental Toxicology Research 

Program, University of Mississippi, University, MS. 

#687 11:24 TERATOGENIC EFFECTS OF 

BLUE COHOSH (CAULOPHYLLUM 

THALICTROIDES) IN JAPANESE MEDAKA 

(ORYZIAS LATIPES) ARE MEDIATED 

THROUGH GATA2/EDN1 SIGNALING 

PATHWAY. M. Wu 1,2 , Y. Hu 1,3 , Z. Ali 1 , I. A. Khan 1 

and A. K. Dasmahapatra 1,2,3 . 1 National Center for 

Natural Product Research, University of Mississippi, 

University, MS, 2 Department of Pharmacology, 

University of Mississippi, University, MS and 

3 

Environmental Toxicology Research Program, 

University of Mississippi, University, MS. 

tueSday 







167


tueSday 




9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Mutagenicity 

Chairperson(s): Nan Mei, NCTR, U.S. FDA, Jefferson, AR. 




GAMMA-TOCOPHEROL QUINONE IS NOT 

MUTAGENIC IN A VARIETY OF IN VITRO 

AND IN VIVO GENOTOXICITY ASSAYS. L. 

F. Stankowski 1 , H. Murli 1 , A. Hawi 2 , S. Paisley 2 and 

R. E. Stoll 3 . 1 Covance Laboratories, Inc., Vienna, VA, 

2 

Penwest Pharmaceuticals, Co., Patterson, NY and 

3 

Stoll and Associates, LLC, Storrs-Mansfield, CT. 


PIG-A GENE MUTATION IN MAMMALIAN 

RED BLOOD CELLS. V. N. Dobrovolsky, J. A. 

Bhalli, S. A. Ferguson, D. R. Doerge, S. M. Morris 

and R. H. Heflich. NCTR, Jefferson, AR. Sponsor: 

B. Parsons. 


PIG-A MUTATION ASSAY: INTER- 

LABORATORY STUDY CONFIRMS 

TRANSFERABILITY AND 

REPRODUCIBILITY. S. Dertinger 1 , S. 

Phonethepswath 1 , R. D. Fiedler 2 , W. C. Gunther 2 , C. 

J. Thiffeault 2 , T. J. Shutsky 2 , A. D. Henwood 3 , L. L. 

Custer 3 , K. S. Sweder 3 , J. Shi 4 , L. Krsmanovic 4 , D. 

Franklin 1 , P. Weller 1 , S. M. Bryce 1 , J. C. Bemis 1 and 

D. K. Torous 1 . 1 Litron Laboratories, Rochester, NY, 

2 

Pfizer Global R&D, Groton, CT, 3 Bristol-Myers 

Squibb, Syracuse, NY and 4 BioReliance, Rockville, 

MD. 


INTEGRATION OF PIG-A GENE MUTATION 

AND MICRONUCLEATED RETICULOCYTE 

MEASUREMENTS INTO A 28-DAY REPEAT 

DOSING SCHEDULE. D. K. Torous 1 , S. 

Phonethepswath 1 , D. Franklin 1 , P. Weller 1 , S. M. 

Bryce 1 , J. C. Bemis 1 , J. T. MacGregor 2 and S. 

Dertinger 1 . 1 Litron Laboratories, Rochester, NY and 

2 

Toxicology Consulting Services, Arnold, MD. 


USE OF CUSTOM COMPARATIVE 

GENOMIC HYBRIDIZATION (CGH) 

MICROARRAYS TO EVALUATE 

THYMIDINE KINASE (TK) MUTANTS OF 

L5178Y MOUSE LYMPHOMA CELLS. T. 

Han 1 , Y. Chen 2 , M. M. Moore 2 and J. C. Fuscoe 1 . 

1 

Division of Systems Toxicology, National Center 

for Toxicological Research, U.S. FDA, Jefferson, 

AR and 2 Division of Genetic and Reproductive 

Toxicology, National Center for Toxicological 

Research, U.S. FDA, Jefferson, AR. 


CYTOTOXICITY AND MUTAGENICITY 

OF RETINOL WITH ULTRAVIOLET A 

IRRADIATION IN MOUSE LYMPHOMA 

CELLS. N. Mei 1 , J. Hu 1 , Q. Xia 2 , P. P. Fu 2 , M. 

M. Moore 1 and T. Chen 1 . 1 Division of Genetic 

and Reproductive Toxicology, NCTR/U.S. FDA, 

Jefferson, AR and 2 Division of Biochemical 

Toxicology, NCTR/U.S. FDA, Jefferson, AR. 


GENOTOXIC EFFECTS OF CIGARETTE 

SMOKE CONDENSATES IN MOUSE 

LYMPHOMA CELLS. X. Guo 1 , N. Mei 1 , T. L. 

Verkler 1 , P. A. Richter 2 , G. M. Polzin 3 and M. M. 

Moore 1 . 1 Division of Genetic and Reproductive 


Research (NCTR), U.S. FDA, Jefferson, AR, 

2 

National Center for Chronic Disease Prevention 

and Health Promotion, Atlanta, GA and 3 National 

Center for Environmental Health, Centers for Disease 

Control and Prevention, Atlanta, GA. 


EVALUATION OF PUBLICLY AVAILABLE 

MOUSE LYMPHOMA ASSAY DATA USING 

CURRENTLY ACCEPTED STANDARDS TO 

ESTABLISH A CURATED DATABASE. B. 

Gollapudi 1 , M. R. Schisler 1 and M. M. Moore 2 . 1 The 

Dow Chemical Company, Midland, MI and 2 National 

Center for Toxicological Research, Jefferson, AR. 


GENOTOXICITY OF 2, 6- AND 3, 

5-DIMETHYLANILINE, AND THEIR 

METABOLITES IN CHINESE HAMSTER 

OVARY CELLS. M. Kim, C. L. Belanger, L. J. 

Trudel and G. N. Wogan. Massachusetts Institute of 

Technology, Cambridge, MA. 


AMES ASSAY PREDICTION OF 

GENOTOXICITY: COMPARING THE OF 

SALMONELLA TA 102 TO E. COLI STRAIN 

WP2 UVRA PKM101. S. H. Robison, D. P. Gibson 

and M. J. Aardema. Product Safety & Regulatory 

Affairs, Procter & Gamble Company, Cincinnati, 

OH. 


PREDICTING THE OUTCOME OF 

OPTIMIZED SALMONELLA ASSAYS. M. J. 

Nicolich 1 , R. H. McKee 2 , C. A. Schreiner 3 and T. M. 

Gray 4 . 1 Cogimet, Lambertville, NJ, 2 Toxicology and 

Environmental Sciences, ExxonMobil Biomedical 

Sciences, Inc., Annandale, NJ, 3 C&C Consulting 

in Toxicology, Meadowbrook, PA and 4 American 

Petroleum Institute, Washington, DC. 


PROMUTAGEN ACTIVATION AND P450 

ACTIVITIES OF LIVER, KIDNEY, AND 

LUNG S9 FROM MALE SPRAGUE-DAWLEY 

RATS TREATED WITH P450 INDUCERS. J. 

Song 2 , V. Nugyen 1 , S. Sharma 2 , P. Kirby 2 and A. 

P. Li 1 . 1 In Vitro ADMET Laboratories, Advanced 

Pharmaceutical Sciences, Columbia, MD and 

2 

SITEK Research Laboratories Inc., Rockville, MD. 


GENOTOXICITY STUDIES OF TACRINE. 

M. A. Mulla, V. Goyal, A. Govindarajan, S. Ingle, 

S. Jana and R. Nirogi. Toxicology, Suven Life 

Sciences Limited, Hyderabad, Andhra Pradesh, India. 

Sponsor: V. Reddy. 

168 






Platform Sessions



Abstract # 


CONTRIBUTION OF SINGLE SMOKE 

CONSTITUENTS TO THE MUTAGENIC 

ACTIVITY OF THE GAS/VAPOR PHASE OF 

CIGARETTE MAINSTREAM SMOKE. S. 

Weber 1 , T. J. Meisgen 1 , J. Diekmann 1 , A. Wittig 1 and 

K. Rustemeier 2 . 1 Philip Morris Research Laboratories 

GmbH, Koeln, Germany and 2 Rustemeier Consulting, 

Meckenheim, Germany. Sponsor: E. Roemer. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: DNA Damage and Repair 

Chairperson(s): Menghang Xia, NIH, Bethesda, MD. 




INDUCTION OF THE BASE EXCISION 

REPAIR GLYCOSYLASE NIEL1/2 IN 

ANILINE-INDUCED SPLENIC TOXICITY. 

H. Ma 1 , J. Wang 1 , T. K. Hazra 2 , S. Z. Abdel- 

Rahman 3 , P. J. Boor 1 and M. Khan 1 . 1 Pathology, 

University of Texas Medical Branch, Galveston, TX, 

2 

Biochemistry and Molecular Biology, University 

of Texas Medical Branch, Galveston, TX and 

3 

Obstetrics and Gynecology, University of Texas 

Medical Branch, Galveston, TX. 


XPC IS ESSENTIAL FOR NUCLEOTIDE 

EXCISION REPAIR OF ZIDOVUDINE- 

INDUCED DNA DAMAGE IN HUMAN 

HEPATOMA CELLS. Q. Wu, F. A. Beland and J. 

Fang. National Center for Toxicological Research/ 

U.S. FDA, Jefferson, AR. 


IDENTIFICATION OF A MOUSE NOVEL 

GENE THAT WAS INDUCED UPON 

GENOTOXIC STRESS AND POTENTIALLY 

INVOLVED IN DNA DAMAGE RESPONSE 

OR REPAIR. Y. Wu 1 , Y. Luan 1 , X. Qi 1 , T. Suzuki 2 

and J. Ren 1 . 1 Center for Drug Safety Evaluation and 

Research, Shanghai Institute of Materia Medica, 

Chinese Academy of Sciences, Shanghai, China and 

2 

Division of Cellular and Gene Therapy Products, 

National Institute of Health Sciences, Tokyo, Japan. 


EFFECT OF DEFICIENT BASE 

EXCISION REPAIR (BER) STATUS ON 

METHYLMERCURY (MeHg)-INITIATED 

TOXICITY IN VITRO. S. L. Ondovcik 1 , G. P. 

McCallum 1 and P. G. Wells 1,2 . 1 Faculty of Pharmacy, 

University of Toronto, Toronto, ON, Canada and 

2 


University of Toronto, Toronto, ON, Canada. 


CHARACTERIZATION OF POLY(ADP- 

RIBOSE)POLYMERASE-1 KINETICS AND 

INHIBITION BY ARSENITE: AN IN VIVO 

STUDY. B. S. King, K. L. Cooper and L. G. 

Hudson. Pharmaceutical Sciences, University of New 

Mexico, Albuquerque, NM. 

Abstract # 


IDENTIFYING GENOTOXIC COMPOUNDS 

USING A BATTERY OF ISOGENIC DNA 

REPAIR DEFICIENT DT40 CELL LINES IN 

A QUANTITATIVE HIGH-THROUGHPUT 

SCREENING (QHTS) PLATFORM. K. 

Nakamura 1,4 , S. Sakamuru 2 , R. Huang 2 , K. Witt 3 , C. 

P. Austin 2 , Y. Taniguchi 1 , K. Kono 4 , R. R. Tice 3 , S. 

Takeda 1 and M. Xia 2 . 1 Radiation Genetics, Graduate 

School of Medicine, Kyoto University, Kyoto, Japan, 

2 

NIH Chemical Genomics Center, Bethesda, MD, 

3 

National Toxicology Program, National Institute of 


Park, NC and 4 Hygiene and Public Health, Graduate 

School of Medicine, Osaka Medical College, Osaka, 

Japan. 


METHANOL EXPOSURE DOES NOT LEAD 

TO ACCUMULATION OF OXIDATIVE 

DNA DAMAGE IN MICE, RABBITS, OR 

PRIMATES. G. P. McCallum 1 , M. Sui 1 , S. L. 

Ondovcik 1 and P. G. Wells 1,2 . 1 Faculty of Pharmacy, 


2 

Pharmacology and Toxicology, University of 



POTENT INHIBITION OF PEROXYNITRITE- 

INDUCED DNA STRAND BREAKAGE 

AND HYDROXYL RADICAL FORMATION 

BY THE COMMONLY USED DRUG 

VEHICLE DMSO AT EXTREMELY LOW 

CONCENTRATIONS. Z. Jia, H. Zhu, Y. Li and H. 

P. Misra. Edward Via Virginia College of Osteopathic 

Medicine, Virginia Tech Corporate Research Center, 

Blacksburg, VA. 


IDENTIFICATION OF A NOVEL ROLE 

FOR THE RNA SURVEILLANCE PROTEIN, 

UPF1, IN OXIDATIVE STRESS INDUCED 

P53 ACTIVATION. J. S. Gewandter 1 and M. A. 

O’Reilly 2 . 1 Biochemistry and Biophysics, University 

of Rochester, Rochester, NY and 2 Pediatrics, 

University of Rochester, Rochester, NY. Sponsor: B. 

Lew. 


EXPLORING MECHANISMS OF 

INFLAMMATION-ASSOCIATED SYSTEMIC 

GENOTOXICITY. A. M. Westbrook 1 , B. Wei 2 , J. 

Braun 2 and R. H. Schiestl 2,1 . 1 Molecular Toxicology 

Interdepartmental Program, UCLA, Los Angeles, 

CA and 2 Department of Pathology and Laboratory 

Medicine, UCLA, Los Angeles, CA. 


DOUBLE STRAND BREAK REPAIR IN 

HUMAN MITOCHONDRIAL EXTRACTS. 

S. Hunter 1 , J. Meyer 1 and B. Van Houten 2 . 1 Duke 

University, Durham, NC and 2 University of 

Pittsburgh, Pittsburgh, PA. 

tueSday 







169


tueSday 




DIFFERENCE OF ACRYLAMIDE 

INDUCING GENOTOXICITY AND ADDUCT 

FORMATION BETWEEN CHILD AND 

ADULT RATS. M. Honma 1 , N. Koyama 1,2 , M. 

Yasui 1 , S. Takami 1 , M. Takahashi 1 , K. Inoue 1 , M. 

Yoshida 1 , K. Masumura 1 , T. Nohmi 1 , S. Masuda 2 , N. 

Kinae 2 , T. Suzuki 3 , T. Matsuda 3 , M. Shibutani 4 and T. 

Imai 5 . 1 National Institute of Health Sciences, Tokyo, 

Japan, 2 University of Shizuoka, Shizuoka, Japan, 

3 

Kyoto University, Kyoto, Japan, 4 Tokyo University 

of Agriculture and Technology, Tokyo, Japan and 

5 

National Cancer Center, Tokyo, Japan. 


PREGNANE X RECEPTOR (PXR) 

PROTECTS LIVER CELLS AGAINST DNA 

DAMAGES: EVIDENCE AND MECHANISMS. 

M. Huang 1 , H. Cui 1 , Y. Xie 2 , S. Ke 2 , P. Thomas 3 , 

J. Luo 4 , Z. Zhou 1 and Y. Tian 2 . 1 Fudan University, 

Shanghai, China, 2 TAMU, College Station, TX, 

3 

Rutgers University, Piscataway, NJ and 4 University 

of Massachusetts Medical School, Worcester, MA. 


ASSESSING THE DNA DAMAGING 

POTENTIAL OF CHEMICALS VIA 

ACTIVATION OF THE p53 PATHWAY USING 

QUANTITATIVE HIGH-THROUGHPUT 

SCREENING (qHTS). K. L. Witt 1 , R. Huang 2 , 

K. Shockley 1 , C. P. Austin 2 , M. Zheng 3 , Y. Sun 3 , 

R. R. Tice 1 and M. Xia 2 . 1 National Toxicology 

Program, National Institute of Environmental 

Health Sciences, Research Triangle Park, NC, 2 NIH 

Chemical Genomics Center, National Institutes of 

Health, Bethesda, MD and 3 Department of Radiation 

Oncology, University of Michigan Comprehensive 

Cancer Center, Ann Arbor, MI. 


THE ROLE OF MYELOPEROXIDASE (MPO) 

IN DNA DAMAGE INDUCTION BY PCB3 

METABOLITES. W. Xie, L. W. Robertson and G. 

Ludewig. University of Iowa, Iowa City, IA. 


INORGANIC CALCIUM (CA2+) INDUCES 

DNA DAMAGE IN VIVO. M. Fjordholt 1 , C. 

Beevers 2 , J. Schützsack 1 , D. Kirkland 2 , D. Tweats 3 

and I. Stuart 1 . 1 Preclinical Development, LEO 

Pharmacology A/S, Ballerup, Denmark, 2 Genetic 

Toxicology, Covance, Harrogate, United Kingdom 

and 3 The School of Medicine, University of Swansea, 

Swansea, United Kingdom. 


GENOTOXICITY OF ORGANIC EXTRACTS 

FROM THE AIR PARTICLES MEASURED IN 

AN ACELLULAR SYSTEM WITH A NATIVE 

DNA. J. Topinka 1,2 , J. Hovorka 2 , A. Milcova 1 , 

J. Schmuczerova 1 , J. Krouzek 2 and R. J. Sram 1 . 

1 

Genetic Ecotoxicology, Institute of Experimental 

Medicine ASCR, v.v.i., Prague, Czech Republic and 

2 

Institute for Environmental Studies, Prague, Czech 

Republic. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Pharmaceutical Toxicology I 

Chairperson(s): Alan Bass, Schering-Plough Research Institute, 

Kenilworth, NJ. 




DETERMINATION OF CYCLOSPORINE 

A IN RABBIT OCULAR TISSUES USING 

LC-MS/MS. Y. Li, K. Miller, H. Ding, J. 

Gutierrez, G. Zhou, E. Goodin and T. Lu. Medpace 

Bioanalytical Laboratories, Cincinnati, OH. 


URINARY METABONOMIC ASSESSMENT 

OF DRUG-INDUCED PHOSPHOLIPIDOSIS 

(PLD) IN THE RAT. D. G. Robertson 1 , P. 

Shipkova 1 , N. Aranibar 1 , S. Hnatyshyn 1 , J. Williams 2 , 

L. Gong 2 , S. Stryker 1 , M. Otieno 2 , T. Reilly 3 and L. 

Lehman-McKeeman 2 . 1 Applied and Investigative 

Metabonomics, Bristol-Myers Squibb, Princeton, 

NJ, 2 Discovery Toxicology, Bristol-Myers Squibb, 

Princeton, NJ and 3 Drug Safety Evaluation, Bristol- 

Myers Squibb, Syracuse, NY. 


PRECLINICAL TOXICOLOGY 

ASSESSMENT OF SHETA2, A NOVEL 

CHEMOPREVENTIVE AGENT, IN RATS 

AND DOGS. K. K. Kabirov 1 , I. M. Kapetanovic 2 , 

M. Lindeblad 1 , A. Zakharov 1 , D. M. Benbrook 3 and A. 

V. Lyubimov 1 . 1 Pharmacology, Toxicology Research 

Laboratory, University of Illinois at Chicago, 

Chicago, IL, 2 National Cancer Institute, Bethesda, 

MD and 3 University of Oklahoma HSC, Oklahoma 

City, OK. 


GENOME-WIDE SCREENING FOR 

DETERMINANTS OF ADRIAMYCIN 

SENSITIVITY IN SACCHAROMYCES 

CEREVISIAE. K. Hirose, T. Takahashi and A. 

Naganuma. Graduate School of Pharmaceutical 

Sciences, Tohoku University, Sendai, Japan. 


ROLE OF PROTEIN PHOSPHATASE TYPE 

1 (PP1) IN THE PROTECTIVE MECHANISM 

AGAINST TOXICITY OF ADRIAMYCIN. T. 

Takahashi, K. Hirose and A. Naganuma. Graduates 

School of Pharmaceutical Sciences, Tohoku 

University, Sendai, Japan. 


EFFICACY AND SAFETY STUDIES 

ON NOVEL, NQO1-DIRECTED 

LAVENDAMYCIN ANTICANCER AGENTS. 

H. D. Beall 1 , M. Hassani 1 , W. Cai 2 and M. 

Behforouz 2 . 1 Center for Environmental Health 

Sciences, University of Montana, Missoula, MT and 

2 

Department of Chemistry, Ball State University, 

Muncie, IN. 

170 






Platform Sessions



Abstract # 


SILYMARIN SUPPLEMENTATION 

INCREASES GLUCONEOGENESIS PPAR- 

GAMMA AND PEPCK AND REDUCES 

LACTATE PRODUCTION IN LOW- 

INTENSITY EXERCISE RATS. E. Choi and 

S. Kim. School of Medicine Kyungpook National 

University, Daegu, Republic of Korea. 


CHRYSIN INHIBITS IGE-MEDIATED 

ALLERGIC REACTIONS AND 

INFLAMMATORY CYTOKINE 

PRODUCTIONS IN HUMAN MAST CELLS. 

Y. Bae and S. Kim. Kyungpook National University, 

Daegu, Republic of Korea. 


IN VITRO EVALUATION OF LEPTOMYCIN B 

CYTOTOXIC EFFECTS ON LUNG CANCER 

CELLS. C. Shao 1 , L. Chen 1 , E. Cobos 2 and W. 

Gao 1,2 . 1 The Institute of Environmental and Human 

Health (TIEHH), Lubbock, TX and 2 Texas Tech 

University Health Sciences Center, Lubbock, TX. 


ARTEMISININ ANTI-MALARIALS 

ARE MORE POTENT THAN QUININE 

DERIVATIVES IN INHIBITING 

TESTOSTERONE PRODUCTION IN MOUSE 

LEYDIG CELLS. R. A. Clewell and M. E. 

Andersen. Computational Biology, The Hamner 


Park, NC. 


EFFECT OF THE 

CYCLOOCTADEPSIPEPTIDE, 

EMODEPSIDE, ON VOLTAGE-ACTIVATED 

CURRENTS IN ASCARIS SUUM. S. Buxton, A. 

P. Robertson and R. J. Martin. Biomedical Science, 

Iowa State University, Ames, IA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Inflammation and the Pathogenesis of Toxicity 

Chairperson(s): James Luyendyk, University of Kansas Medical Center, 

Kansas City, KS. 




A SINGLE INSTILLATION OF PM 

2.5 INDUCES CHRONIC LUNG 

INFLAMMATION WITH INCREASED 

GENE EXPRESSION OF MATRIX 

METALLOPROTEINASE IN MICE. K. Park 1 

and E. Park 2 . 1 College of Pharmacy, Dongduk 

Women’s University, Seoul, Republic of Korea 

and 2 Inhalation Department, Korea Institute of 

Toxicology, Jeongeup, Republic of Korea. Sponsor: 

B. Lee. 

Abstract # 


NEUTRALIZATION OF LUNG TOXICITY 

AND INFLAMMATION INDUCED BY 

SUPERANTIGENS USING RESVERATROL. 

S. A. Rieder, P. Nagarkatti and M. Nagarkatti. 

Pathology Microbiology and Immunology, University 

of South Carolina, Columbia, SC. 


INHIBITION OF CIGARETTE SMOKE- 

INDUCED CHEMOKINE PRODUCTION BY 

THE NRF2 ACTIVATOR - SULFORAPHANE. 

D. J. Blake 1 and S. Biswal 2 . 1 Department of Biology, 

Fort Lewis College, Durango, CO and 2 Bloomberg 

School of Public Health, Johns Hopkins University, 

Baltimore, MD. Sponsor: G. Acquaah-Mensah. 


REFERENCE SMOKELESS TOBACCO 

EXTRACT INDUCED INFLAMMATORY 

GENE EXPRESSION IN VITRO. J. S. Edmiston, 

Y. Guo and M. W. Fariss. Altria Client Services, 

Richmond, VA. 


EFFECT OF INHALATION OF GAS METAL 

ARC STAINLESS STEEL WELDING FUME 

ON MOUSE LUNG INFLAMMATION AND 

TUMORIGENESIS. P. C. Zeidler-Erdely, L. A. 

Battelli, S. Young, A. Erdely, S. Stone, B. T. Chen, D. 

G. Frazer, M. L. Kashon and J. M. Antonini. HELD, 

NIOSH, Morgantown, WV. 


IL-17 MEDIATED INFLAMMATORY 

RESPONSE INDUCES POLYMERIC IG 

RECEPTOR AND ELEVATED IGA LEVELS 

IN SILICA EXPOSED RAG1-/- MICE. C. 

A. Beamer 1 , M. L. Trapkus 1 , G. G. Goodman 1 , F. 

Jessop 1 , C. T. Migliaccio 1 , D. Yuan 2 , K. Roberts 1 

and A. Holian 1 . 1 Biomedical & Pharmaceutical 

Sceinces, University of Montana, Missoula, MT 

and 2 Pathology, University of Texas Southwestern 

Medical Center, Dallas, TX. 


DIFFERENTIAL EFFECTS OF 

1-NITROPYRENE AND 1-AMINOPYRENE 

ON CXCL8 (IL-8) AND CCL5 (RANTES) IN 

BEAS-2B CELLS: ROLE OF AHR, ARNT, 

NF-kB AND AP-1. J. Øvrevik 1 , M. Låg 1 , V. 

Lecureur 2 , D. Gilot 2 , S. Mollerup 3 , D. Lagadic- 

Gossmann 2 , O. Fardel 2 , M. Refsnes 1 , P. E. Schwarze 1 

and J. A. Holme 1 . 1 Norwegian Institute of Public 

Health, Oslo, Norway, 2 EA 4427 SeRAIC/Université 

de Rennes, Rennes Cédex, France and 3 National 

Institute of Occupational Health, Oslo, Norway. 

Sponsor: M. Løvik. 


DEVELOPMENT OF A MODIFIED GLUCAN- 

SPECIFIC LIMULUS AMEBOCYTE LYSATE 

METHOD WHICH CORRELATES MURINE 

PULMONARY INFLAMMATION INDUCED 

BY FLOOR DUST COLLECTED FROM A 

WATER-DAMAGED BUILDING. S. Young, J. 

M. Cox-Ganser, E. S. Shogren, M. G. Wolfarth, S. Li, 

J. M. Antonini, V. Castranova and J. Park. NIOSH, 


tueSday 







171


tueSday 




ROLE OF SURFACTANT PROTEIN D IN 

OZONE-INDUCED LUNG INJURY AND 

INFLAMMATION. A. M. Groves 1 , A. Gow 1 , J. 

D. Laskin 2 and D. L. Laskin 1 . 1 Rutgers University, 

Piscataway, NJ and 2 UMDNJ-RWJ Med School, 



IDENTIFICATION OF CYTOKINES AND 

GROWTH FACTORS ASSOCIATED WITH 

EXPOSURE OF MESOTHELIAL CELLS 

TO ASBESTOS AND PROGRESSION OF 

MESOTHELIOMA GROWTH IN MICE. J. 

M. Hillegass 1 , A. Shukla 1 , M. MacPherson 1 , S. 

Beuschel 1 , S. Lathrop 1 , C. Steele 2 and B. Mossman 1 . 

1 

Pathology, University of Vermont, Burlington, 

VT and 2 Medicine and Microbiology, University 

of Alabama at Birmingham School of Medicine, 

Birmingham, AL. 


INHIBITION OF CF AIRWAY HMGB1 

REDUCES P. AERUGINOSA INFECTION AND 

NEUTROPHILIC INFLAMMATORY LUNG 

INJURY. L. Mantell 1,2 , T. Zaher 1 , D. Weiss 3 , E. 

Miller 2 and K. J. Tracey 2 . 1 Pharmaceutical Sciences, 

St. John’s University, Queens, NY, 2 Center for 

Lung and Heart Research, The Feinstein Institute 

for Medical Research, NS-LIJ Health System, 

Manhasset, NY and 3 Medicine, University of 

Vermont College of Medicine, Burlington, VT. 


RODENT INHALATION STUDIES AND 

CIGARETTE SMOKE: INFLAMMATION- 

MEDIATED PROMOTION OF TUMOR 

CELLS. G. M. Curtin and J. E. Swauger. 

Regulatory Oversight, RAI Services Company, 

Winston Salem, NC. 


EFFECTS OF STRAIN AND GENDER 

ON 4-AMINOBIPHENYL-INDUCED 

HEPATOTOXICITY IN THE MOUSE. A. 

Emami and D. M. Grant. Pharmacology and 

Toxicology, University of Toronto, Toronto, ON, 

Canada. 


POLYCHLORINATED BIPHENOLS (PCB) 

INDUCE TUMOR NECROSIS FACTOR 

a (TNFa) PRODUCTION IN RAW 264.7 

CELLS. N. Kershner 1 , A. Stocker 1 , K. C. 

Falkner 1 , C. McClain 1,2 and M. Cave 1 . 1 Medicine/ 

Gastroenterology, University of Louisville, 

Louisville, KY and 2 Louisville VA Medical Center, 



CLASSICAL AND ALTERNATIVE 

ACTIVATION OF RAT LIVER KUPFFER 

CELLS AND ENDOTHELIAL CELLS: 

IMPACT OF ACETAMINOPHEN (APAP). Y. 

Liu 1 , C. Gardner 1 , J. Laskin 2 and D. L. Laskin 1 . 

1 

Pharmacology & Toxicology, Rutgers University, 

Piscataway, NJ and 2 UMDNJ-RWJ Medical School, 



MAPK1 IS REQUIRED FOR MACROPHAGE 

ACTIVATION BY FACTORS RELEASED 

FROM ACETAMINOPHEN-INJURED 

HEPATOCYTES. POTENTIAL ROLE OF 

HMGB1. A. Dragomir 1 , J. D. Laskin 2 and D. 

L. Laskin 1 . 1 Department of Pharmacology & 

Toxicology, Rutgers University, Piscataway, NJ and 

2 

UMDNJ-RW Johnson Medical School, Piscataway, 

NJ. 


MACROPHAGE INHIBITORY CYTOKINE-1 

(MIC-1) AND SUBSEQUENT PRODUCTS 

MEDIATE EPITHELIAL TUMOR CELL 

DEATH RESPONSES BY THERAPEUTIC 

RIBOTOXIC INSULT. H. Choi and Y. Moon. 

Department of Microbiology and Immunology, Pusan 

National University School of Medicine and Medical 

Research Institute, Yangsan, Republic of Korea. 


NUCLEAR FACTOR ERYTHROID 2 (NF- 

E2): IDENTIFICATION OF A NOVEL 

IMMUNOMODULATOR THAT REGULATES 

PULMONARY INFLAMMATION. S. Jin 1 , P. 

Johnson 1 , T. Manning 1 , L. Cai 3 , A. B. Lentsch 4 and 

M. J. Rane 1,2 . 1 Medicine, University of Louisville, 

Louisville, KY, 2 Biochemistry and Molecular 

Biology, University of Louisville, Louisville, KY, 

3 

Pediatrics, University of Louisville, Louisville, 

KY and 4 The Laboratory of Trauma, Sepsis & 

Inflammation Research, Department of Surgery, 

University of Cincinnati, Cincinnati, OH. 


ANTI-INFLAMMATORY AND ANTI- 

CANCER EFFECTS OF POLYPHENOLICS 

FROM YAUPON HOLLY (ILEX VOMITORIA) 

IN COLON CELLS. G. D. Noratto, Y. Kim, 

S. Talcott and S. Mertens-Talcott. Texas A&M 

University, College Station, TX. 


ARSENIC EXPOSURE INCREASES 

IL-8 FORMATION AND LEUKOCYTE 

TRANSMIGRATION IN ENDOTHELIAL 

CELLS. S. D. Sithu 1,2 , T. Patel 1 , E. N. 

Vladykovskaya 2 , S. E. D’Souza 1 and S. Srivastava 2 . 

1 

Physiology & Biophysics, University of Louisville, 

Louisville, KY and 2 Diabetes and Obesity Center, 



CHARACTERIZATION OF AN 

INFLAMMATORY STRESS MODEL 

OF AMIODARONE IDIOSYNCRATIC 

HEPATOTOXICITY IN RATS. J. Lu 1 , R. A. 

Roth 2 and P. E. Ganey 2 . 1 Department of Biochemistry 

and Molecular Biology, Michigan State University, 

East Lansing, MI and 2 Department of Pharmacology 

and Toxicology, Michigan State University, East 

Lansing, MI. 

172 






Platform Sessions



Abstract # 


INTEGRATION OF MICROARRAY 

AND PROTEOMIC DATA REVEALS 

SUSCEPTIBILITY FACTORS FOR 

EXACERBATED IMMUNE RESPONSE IN 

DIET-INDUCED OBESE MICE EXPOSED TO 

CIGARETTE SMOKE. K. M. Waters 1 , B. Webb- 

Robertson 1 , N. J. Karin 1 , X. Zhang 1 , J. M. Jacobs 1 , D. 

J. Bigelow 1 , M. Lee 2 , J. G. Pounds 1 and R. A. Corley 1 . 

1 

Pacific Northwest National Labortory, Richland, WA 

and 2 Battelle Toxicology Northwest, Richland, WA. 


IDENTIFICATION OF MODIFIED LUNG 

PROTEINS AS BIOMARKERS OF SYSTEMIC 

CHRONIC INFLAMMATORY AND 

OXIDATIVE STRESS IN MICE. X. Zhang 1 , J. 

M. Jacobs 1 , K. M. Waters 1 , B. Webb-Robertson 1 , D. 

J. Bigelow 1 , M. Lee 2 , J. G. Pounds 1 and R. A. Corley 1 . 

1 

Pacific Northwest National Labortory, Richland, WA 

and 2 Battelle Toxicology Northwest, Richland, WA. 


CYTOTOXIC RESPONSES TO REFERENCE 

MOIST SMOKELESS TOBACCO EXTRACTS 

IN A THREE DIMENSIONAL ORAL CELL 

CULTURE SYSTEM (EPIORAL TM ). T. B. 

Langston 1 , J. S. Edmiston 1 , M. Scian 2 , C. Lombard 2 , 

O. Greengauz-Roberts 3 , V. Baliga 1 , M. T. Fisher 1 , M. 

W. Fariss 1 and J. W. Flora 1 . 1 Altria Client Services, 

Richmond, VA, 2 RemX Specialty Staffing c/o Altria 

Client Services, Richmond, VA and 3 Lancaster 

Laboratories c/o Altria Client Services, Richmond, 

VA. 


ROLE OF CRYPT PANETH CELLS IN 

INTESTINAL INFLAMMATORY RESPONSE 

TO TOTAL-BODY GAMMA-IRRADIATION. 

N. V. Gorbunov and J. G. Kiang. Armed Forces 

Radiobiology Research Institute, Bethesda, MD. 


AN AUTOMATED, QUANTITATIVE HIGH- 

CONTENT CELL-BASED IMAGING ASSAY 

FOR CHEMOTAXIS. R. N. Ghosh 1 , S. J. 

Hong 1 , T. Worzella 2 , E. Vu 2 , I. Meyvantsson 2 and S. 

Hayes 2 . 1 Thermo Fisher Scientific, Rockford, IL and 

2 

BellBrook Labs, Madison, WI. Sponsor: J. Haskins. 


AHR ACTIVATION SUPPRESSES COLITIS 

BY INHIBITING INFLAMMATORY TH1 

CELLS THROUGH INDUCTION OF 

FOXP3+REGULATORY T CELLS AND 

TH17 CELLS. P. Nagarkatti, U. Singh, N. Singh 

and M. Nagarkatti. Pathology, Microbiology, and 

Immunology, University of South Carolina School of 

Medicine, Columbia, SC. 


EFFECT OF MICROCYSTIS AERUGINOSA 

LIPOPOLYSACCHARIDE ON NEONATAL 

RAT BRAIN MICROGLIA: CYTOKINE 

EXPRESSION PROFILING BY ANTIBODY 

ARRAY TECHNOLOGY. N. Patel 1 , J. 

A. Clifford 1 , M. L. Hall 1 , K. B. Glaser 3,1 , P. 

B. Jacobson 3 , J. P. Berry 2 and A. M. Mayer 1 . 

1 

Pharmacology, Midwestern University, Downers 

Grove, IL, 2 Chemistry and Biochemistry, Florida 

International University, Miami, FL and 3 Abbott 

Laboratories, Chicago, IL. 

Abstract # 


SDF-1bP2G, A NOVEL CXCR4 ANTAGONIST 

DERIVED FROM HUMAN SDF-1b: 

PATHOPHYSIOLOGICAL EVALUATION 

AND POTENTIAL CLINICAL APPLICATION. 

L. Cai and Y. Tan. Department of Pediatrics, 



ENDOTOXINS IN AFRICAN DUST (PM10): 

POSSIBLE IMPLICATION IN PUERTO 

RICAN ASTHMA EXACERBATION. M. G. 

Ortiz-Martínez 1 , E. Rivera-Ramírez 3 , L. B. Méndez- 

Torres 2 and B. D. Jiménez-Vélez 1 . 1 Biochemistry, 

University of Puerto Rico Medical Sciences Campus, 

San Juan, 2 Microbiology and Molecular Genetics, 

University of California, Irvine, Irvine, CA and 

3 

Biology, University of Puerto Rico, Río Piedras 

Campus, San Juan. 


EFFECTS OF PM2.5 FROM PUERTO 

RICO ON THE MRNA HALF-LIVES OF 

PRO-INFLAMMATORY CYTOKINES. E. 

Rivera-Ramírez 2 , L. B. Méndez-Torres 3,2 and B. D. 

Jiménez-Vélez 1 . 1 Biochemistry, University of PR 

Medical Sciences Campus, San Juan, 2 Biology, 

University of Puerto Rico Rio Piedras Campus, San 

Juan and 3 Microbiology and Molecular Genetics, 

University of California, Irvine, Irvine, CA. 


DEVELOPMENT OF NOVEL LC-MS/ 

MS METHOD TO QUANTIFY 

F2-ISOPROSTANES IN BIOLOGICAL 

SAMPLES. F. Rohrbach 2 , M. Schwald 1 , V. Riebel 1 , 

F. Pognan 1 , A. Wolf 1 and M. Dong 1 . 1 Preclinical 

Safety, Novartis Institute for BioMedical Research, 

Muttenz, Switzerland and 2 Food Chemistry 

and Toxicology, University of Kaiserslautern, 

Kaiserslautern, Germany. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Oxidative Injury and Redox Biology 

Chairperson(s): Donna Zhang, University of Arizona, Tucson, AZ. 




NADPH OXIDASES ARE CRITICAL 

TARGETS FOR PREVENTION OF 

ETHANOL-INDUCED BONE LOSS. J. Chen, 

O. P. Lazarenko, K. Shankar, M. L. Blackburn, T. 

M. Badger and M. J. Ronis. Arkansas Children’s 

Nutrition Center, University of Arkansas for Medical 

Sciences, Little Rock, AR. 


CELL CYCLE EFFECTS OF THIOREDOXIN 

REDUCTASE AND SELENO-COMPOUNDS 

IN HUMAN CANCER CELL LINES. R. 

Poerschke, M. Franklin and P. Moos. University of 

Utah, Salt Lake City, UT. 

tueSday 







173


tueSday 




EFFECT OF PARAQUAT ON RESPIRATION- 

AND THIOREDOXIN-DEPENDENT 

HYDROGEN PEROXIDE REMOVAL IN 

BRAIN MITOCHONDRIA. D. Drechsel and M. 

Patel. School of Pharmacy, University of Colorado 

Denver, Aurora, CO. 


ROLE OF CYTOCHROME P450 REDUCTASE 

IN MEDIATING REDOX CYCLING OF 9, 

10-PHENANTHRENEQUINONE. R. G. Udasin 1 , 

K. C. Fussell 1 , Y. Wang 2 , D. E. Heck 3 , V. Mishin 2 , 

P. J. Smith 4 , D. L. Laskin 5,1 and J. D. Laskin 2,1 . 

1 

Joint Graduate Program in Toxicology, Rutgers 

Unversity/UMDNJ, Piscataway, NJ, 2 Environmental 

and Occupational Medicine, UMDNJ-RWJMS, 

Piscataway, NJ, 3 Environmental Health Science, 

New York Medical College, Valhalla, NY, 

4 

BioCurrents Research Center, Marine Biological 

Laboratory, Woods Hole, MA and 5 Pharmacology & 

Toxicology, Rutgers University, Piscataway, NJ. 


REGULATION OF INFLAMMATORY 

RESPONSES: POSSIBLE REDOX 

SYNAPSE BETWEEN NEUTROPHILS AND 

MACROPHAGES. W. Feng 1 , J. Shi 3 , N. V. 

Konduru 1 , H. Bayir 2 , B. Fadeel 3 and V. E. Kagan 1 . 

1 

Department of Environmental and Occupational 

Health, Univeristy of Pittsburgh, Pittsburgh, PA, 

2 

Critical Care Medicine, Univerity of Pittsburgh, 

Pittsburgh, PA and 3 Division of Molecular 

Toxicology, Institute of Environmental Medicine, 

Karolinska Institutet, Stockholm, Sweden. 


HIGH SATURATED-FAT DIET 

AND DEFICIENT NICOTINAMIDE 

NUCLEOTIDE TRANSHYDROGENASE 

ARE CONTRIBUTING FACTORS TO 

MITOCHONDRIAL DYSFUNCTION IN 

C. ELEGANS. S. Bryner 1 , C. Thomas 1 and L. 

Carnell 2 . 1 Chemistry, Central Washington University, 

Ellensburg, WA and 2 Biology, Central Washington 

University, Ellensburg, WA. 


TREATMENT WITH AN ETC COMPLEX 

III INHIBITOR STIMULATES APICAL 

CHOLINE TRANSPORT IN PRIMARY 

CULTURES OF CHOROID PLEXUS. A. 

R. Villalobos and R. K. Young. Nutrition & Food 

Science, Texas A&M University, College Station, 

TX. 


PARAQUAT-INDUCED CHANGES IN EARLY 

PHASE PROTEIN EXPRESSION IN RAT 

LIVER MITOCHONDRIA AND TISSUE 

HOMOGENATE. P. Venkatakrishnan, E. S. 

Nakayasu, I. C. Almeida and R. T. Miller. Biological 

Sciences, University of Texas at El Paso, El Paso, 

TX. 


LYSOSOMAL IRON RELEASE 

ENHANCES CELL KILLING AFTER 

PHOTODYNAMIC THERAPY MEDIATED 

BY A MITOCHONDRIA-TARGETED 

PHOTOSENSITIZER IN CANCER CELLS. 

S. Saggu, G. Quiogue, H. Hung, J. J. Lemasters and 

A. Nieminen. Medical University of South Carolina, 

Charleston, SC. 


CURCUMIN PROTECTS AGAINST 

ACRYLONITRILE-INDUCED TOXICITY IN 

RAT ASTROCYTES VIA NF-E2 RELATED 

FACTOR 2 ACTIVATION. X. Zhao 1 , R. Lu 1 

and M. Aschner 2 . 1 Preventive Medicine, Jiangsu 

University, Zhenjiang, Jiangsu, China and 2 Pediatrics/ 

Toxicology, Vanderbilt University, Nashville, TN. 


NRF-2 NULL MICE ARE MORE 

SUSCEPTIBLE TO 1-BROMOPROPOANE- 

INDUCED HEPATOTOXICITY. F. Liu 1 , 

S. Ichihara 2,1 , S. Sheik Mohideen 1 , K. Itoh 3 , M. 

Yamamoto 4 , W. M. Valentine 5 and G. Ichihara 1 . 

1 

Department of Occupational & Environmental 

Health, Nagoya University Graduate School of 

Medicine, Nagoya, Japan, 2 Mie University Graduate 

School of Regional Innovation Studies, Tsu, Mie, 

Japan, 3 Hirosaki University Graduate School 

of Medicine, Hirosaki, Aomori, Japan, 4 Tohoku 

University Graduate School of Medicine, Sendai, 

Japan and 5 Vanderbilt University Medical Center, 



NRF2 PROTECTS AGAINST DIQUAT- 

INDUCED TOXICITY. K. C. Wu, Y. Zhang and C. 

D. Klaassen. University of Kansas Medical Center, 



ACTIVATION OF YAP1 BY HYDROGEN 

PEROXIDE OR CYSTEINE THIOL- 

REACTIVE MICHAEL ACCEPTORS 

LEADS TO SPECIFIC ADAPTIVE 

GENE RESPONSES IN THE YEAST 

SACCHAROMYCES CEREVISIAE. X. 

Ouyang, N. Q. Tran, C. Sutter and T. R. Sutter. W. 

Harry Feinstone Center for Genomic Research, 

University of Memphis, Memphis, TN. 


CALIFORNIA WILDFIRES OF 2008: LUNG 

ANTIOXIDANT RESPONSE TO COARSE 

AND FINE PARTICULATE MATTER. T. C. 

Wegesser 1 , L. M. Franzi 1 , M. M. Frank 2 , E. Arantza 3 

and L. A. Jerold 1 . 1 Pulmonary and Critical Care 

Medicine, University of California Davis, Davis, 

CA, 2 Animal Science, University of California, 

Davis Davis, CA and 3 COEH-SCPC Department, 

University of California Los Angeles, Los Angeles, 

CA. 


UP-REGULATION OF HEME OXYGENASE-1 

IN RAT SPLEEN FOLLOWING ANILINE 

EXPOSURE. J. Wang 1 , H. Ma 1 , P. J. Boor 1 , V. 

M. Sadagopa Ramanujam 2 , G. A. Ansari 1 and M. 

Khan 1 . 1 Pathology, University of Texas Medical 

Branch, Galveston, TX and 2 Preventive Medicine 

and Community Health, University of Texas Medical 

Branch, Galveston, TX. 

174 






Platform Sessions



Abstract # 


RADICAL MECHANISMS IN NITROSAMINE 

AND NITROSAMIDE-INDUCED GENE 

EXPRESSION MODULATIONS IN CACO-2 

CELLS. D. Hebels, J. J. Briedé, R. Khampang, J. 

C. Kleinjans and T. M. de Kok. Health Risk Analysis 

and Toxicology, Maastricht University, Maastricht, 

Netherlands. Sponsor: H. van Loveren. 


POST-TRANSLATIONAL MODIFICATION 

AND REGULATION OF GLUTAMATE 

CYSTEINE LIGASE BY THE a, 

b-UNSATURATED ALDEHYDE 4-HYDROXY- 

2-NONENAL (4-HNE). D. Backos 1 , K. S. Fritz 1 , 

J. R. Roede 2 , D. R. Petersen 1 and C. C. Franklin 1 . 

1 

Toxicology, University of Colorado Denver, Aurora, 

CO and 2 Pulmonology, Emory University School of 

Medicine, Atlanta, GA. 


HYDROQUINONE-THIOL CONJUGATES 

AND BENZENE-MEDIATED 

HEMATOTOXICITY. C. L. Kuhlman 1 , D. R. 

Petersen 2 , S. B. Bratton 3 , M. Butterworth 4 , T. J. 

Monks 1 and S. S. Lau 1 . 1 Pharm Toxicology University 

of Arizona, Tucson, AZ, 2 Pharmacentical Sciences, 

University of Colorado, Denver, Co., 3 Pharm 

Toxicology University of Texas, Austin, TX and 

4 

MRC Tox Unit, University of Leicester, Leicester, 



METABOLIC ACTIVATION OF SULFUR 

MUSTARD TO FREE RADICALS INVOLVES 

REACTION WITH O2. A. A. Brimfield 1 , S. 

D. Soni 1 , K. A. Trimmer 1 , M. A. Zottola 2 , R. E. 

Sweeney 1 and J. S. Graham 3 . 1 Pharmacology, 

USAMRICD, Aberdeen Proving Ground, MD, 

2 

Analytical Toxicology, USAMRICD, Aberdeen 

Proving Ground, MD and 3 PSO Office, USAMRICD, 



DISCOVERY OF PROTEIN-PROTEIN 

INTERACTIONS WITHIN THE 

SULFUR TRAFFICKING SYSTEMS OF 

ESCHERICHIA COLI. H. M. Bolstad and M. 

J. Wood. Environmental Toxicology, University of 

California Davis, Davis, CA. Sponsor: A. Buckpitt. 


AGING AND LIFE-STAGE SUSCEPTIBILITY: 

TOLUENE EFFECTS ON BRAIN OXIDATIVE 

STRESS PARAMETERS IN BROWN 

NORWAY RATS. P. S. Kodavanti, J. E. Royland, J. 

H. Richards, J. Besas and R. C. MacPhail. NHEERL, 



CHRONIC HIPPOCAMPAL 

MITOCHONDRIAL OXIDATIVE AND 

NITROSATIVE STRESS FOLLOWING 

KAINATE ADMINISTRATION. K. Ryan, 

L. Liang and M. Patel. Pharmaceutical Sciences, 

University of Colorado Denver, Aurora, CO. 

Abstract # 


HAART DRUGS INDUCE OXIDATIVE 

STRESS IN BLOOD BRAIN BARRIER- ROLE 

IN HIV ASSOCIATED DEMENTIA. K. C. 

Manda 1 , A. Banerjee 1 , N. Ercal 1 and W. Banks 2 . 

1 

Chemistry, Missouri University of Science and 

Technology, Rolla, MO and 2 Internal Medicine, St. 

Louis University Medical Center, St. Louis, MO. 


ZINC DEFICIENCY CONTRIBUTES 

TO ALCOHOL-INDUCED INTESTINAL 

BARRIER DISRUPTION: ROLE OF HNF- 

4a W. Zhong 1 , Y. Zhao 1 , C. McClain 1,2 , Y. Kang 2 

and Z. Zhou 1 . 1 Medicine, University of Louisville, 

Louisville, KY and 2 Pharmacology & Toxicology, 



INVOLVEMENT OF LIVER FATTY 

ACID BINDING PROTEIN IN LIPID 

ACCUMMULATION CHARACTERISTIC 

TO ALCOHOLIC LIVER DISEASE. R. L. 

Smathers 1 , K. S. Fritz 1 , C. T. Shearn 1 , B. J. Stewart 2 

and D. R. Petersen 1 . 1 School of Pharmacy, University 

of Colorado Denver, Aurora, CO and 2 Center for 

Accelerator Mass Spectrometry, Lawrence Livermore 

National Laboratory, Livermore, CA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology—Carbon Nanostructures 

Chairperson(s): Ofek Bar-Ilan, University of Wisconsin Madison, 

Madison, WI. 




PULMONARY TOXICITY ASSESSMENT 

OF MULTI-WALL CARBON NANOTUBES 

AFTER SINGLE INTRATRACHEAL 

INSTILLATION IN RATS. M. Naya, M. Ema, 

N. Kobayashi and J. Nakanishi. National Institute of 

Advanced Industrial Science and Technology (AIST), 

Tsukuba, Ibaraki, Japan. 


DIFFERENTIAL EFFECTS OF SINGLE- 

WALLED CARBON NANOTUBES ON 

HUMAN CARCINOMA CELL LINES. K. 

Hitoshi 1 , M. Katoh 1 , A. Hiramitsu 1 , Y. Ando 2 and 

M. Nadai 1 . 1 Pharmacy, Meijo University, Nagoya, 

Japan and 2 Materials Science and Engineering, Meijo 

University, Nagoya, Japan. Sponsor: G. Ichihara. 


EVALUATION OF THE INTERACTIONS 

BETWEEN MULTI-WALLED CARBON 

NANOTUBES AND AN IN VITRO MODEL OF 

THE HUMAN INTESTINE. J. P. Bressler 2,1 , K. 

Clark 1 , M. Husain 1 , C. O’Driscoll 2,1 , H. Fairbrother 1 

and P. Lees 1 . 1 Johns Hopkins University, Baltimore, 

MD and 2 Neurology, Kennedy Krieger Institute, 

Baltimore, MD. 

tueSday 







175


tueSday 




ADVERSE EFFECTS OF FULLERENOL: 

MITOCHONDRIAL DYSFUNCTION AND 

CYTOSKELETAL DYSRUPTION IN A 

RENAL CELL MODEL. D. N. Johnson 1 , K. 

Peifley 2 , B. S. Neun 1 , S. Lockett 2 , S. E. McNeil 1 

and S. T. Stern 1 . 1 Nanotechnology Characterization 

Lab, SAIC-Frederick, Inc., Frederick, MD and 

2 

Optical Microscopy and Analysis Laboratory, SAIC- 

Frederick, Inc., Frederick, MD. 


SAFETY EVALUATION OF FULLERENE 

NANOWHISKER AS A NEW 

NANOPRODUCT—IN VITRO EXPERIMENT. 

S. Koyama, G. Hasegawa and Y. Ishihara. Public 

Health, Kurume University, Kurume, Japan. Sponsor: 

G. Oberdorster. 


PULMONARY RESPONSE, OXIDATIVE 

STRESS AND GENOTOXICITY INDUCED 

BY CARBON NANOFIBERS. E. Kisin 1 , A. R. 

Murray 1 , D. Schwegler-Berry 1 , J. Scabilloni 1 , R. R. 

Mercer 1 , M. Chirila 2 , S. H. Young 1 , S. S. Leonard 1 , P. 

Keohavong 3 , B. Fadeel 4 , V. E. Kagan 3 , V. Castranova 1 

and A. A. Shvedova 1 . 1 PPRB, NIOSH, Morgantown, 

WV, 2 EAB, NIOSH, Morgantown, WV, 3 Department 

of Environmental and Occupational Health, 

University of Pittsburgh, Pittsburgh, PA and 4 Institute 

of Environmental Medicine, Karolinska Institutet, 

Stockholm, Sweden. 


CHARACTERIZATION OF MULTI-WALLED 

CARBON NANOTUBES (MWNTS). K. E. 

Levine 1 , R. A. Fernando 1 , K. E. Amato 1 , J. M. 

Perlmutter 1 , A. C. McWilliams 1 , L. Han 1 , D. S. 

Ensor 1 , K. Guzan 1 , D. B. Browning 1 , N. N. Walker 2 

and B. J. Collins 2 . 1 RTI International, Durham, NC 

and 2 NIEHS, NTP, Durham, NC. 


MULTI-WALLED CARBON NANOTUBE 

EXPOSURE INDUCES MAST CELL 

ACTIVATION AND ALTERS AORTIC 

VASCULAR REACTIVITY. J. M. Brown 1 , D. M. 

Walters 2 , P. Katwa 1 , B. L. Cathey 2 , B. S. Harrison 3 

and C. J. Wingard 2 . 1 Pharmacology & Toxicology, 

East Carolina University, Greenville, NC, 

2 

Physiology, East Carolina University, Greenville, 

NC and 3 Institute for Regenerative Medicine, Wake 

Forest University, Winston-Salem, NC. 


NEUROTOXICITY AND CELLULAR 

DISTRIBUTION OF SINGLE-WALLED 

CARBON NANOTUBES. Y. Zhang 1 , Y. Xu 2 , S. M. 

Lantz 1 , G. D. Newport 1 , B. Robinson 1 , M. G. Paule 1 , 

W. Slikker 1 , A. S. Biris 2 and S. F. Ali 1 . 1 Division of 

Neurotoxicology, National Center for Toxicological 

Research, Food and Drug Administration, Jefferson, 

AR and 2 Nanotechnology Center, University of 

Arkansas at Little Rock, Little Rock, AR. 


DISPERSION STATUS OF SINGLE 

WALLED CARBON NANOTUBES IS A KEY 

DETERMINANT OF THEIR BIOLOGICAL 

ACTIVITIES. L. Wang 1,2 , A. Mishra 1,2 , V. 

Castranova 1,2 , D. Schwegler-Berry 1 , B. Chen 1 , R. 

R. Mercer 1,2 and Y. Rojanasakul 2 . 1 HELD/PPRB, 

National Institute for Occupational Safety and 

Health, Morgantown, WV and 2 School of Pharmacy, 

West Virginia University, Morgantown, WV. 


GRAPHENE INDUCED CYTOTOXICITY 

AND OXIDATIVE STRESS: AN IN VITRO 

STUDY. S. F. Ali 1 , Y. Zhang 1 , E. Dervishi 2 , Y. 

Xu 2 , S. M. Lantz 1 , B. Robinson 1 , C. Wang 1 , P. C. 

Howard 3 , M. G. Paule 1 , W. Slikker 1 and A. S. Biris 2 . 

1 

Division of Neurotoxicology, National Center for 

Toxicological Research/U.S. FDA, Jefferson, AR, 

2 

Nanotechnology Center, University of Arkansas 

at Little Rock, Little Rock, AR and 3 Division of 

Biochemical Toxicology, National Center for 

Toxicological Research/FDA, Jefferson, AR. 


INDUCTION OF MITOTIC SPINDLE 

ABERRATIONS BY OCCUPATIONALLY- 

RELEVANT DOSES OF SINGLE-WALLED 

CARBON NANOTUBES. L. Sargent 1 , A. F. 

Hubbs 1 , A. A. Shvedova 1 , M. L. Kashon 1 , J. L. 

Salisbury 2 , D. T. Lowry 1 , A. Murray 1 , E. Kisin 1 , S. 

A. Benkovic 1 , K. T. McKinstry 1 and S. H. Reynolds 1 . 

1 


Health, Morgantown, WV and 2 Mayo Clinic, 

Rochester, MN. 


PULMONARY TOXICITY ASSESSMENT 

OF MULTI-WALL CARBON NANOTUBES 

IN VITRO. A. Mishra 1,2 , V. Castranova 1,2 , Y. 

Rojanasakul 2 , J. Hall 2 and L. Wang 1,2 . 1 HELD/PPRB, 

National Institute Occupational Safety and Health, 

Morgantown, WV and 2 School of Pharmacy, West 

Virginia University, Morgantown, WV. 


CHARACTERIZATION OF THE SURFACE 

ADSORPTION PROPERTIES OF MULTI- 

WALLED CARBON NANOTUBES 

IN BIOLOGICAL CONDITIONS VIA 

QUANTITATIVE STRUCTURE-ACTIVITY 

RELATIONSHIP (QSAR). Y. Chen, X. 

Xia, N. A. Monteiro-Riviere and J. E. Riviere. 



Raleigh, NC. 


NOVEL MOLECULAR PATHWAYS 

INDUCED IN FUNCTIONALIZED 

FULLERENE EXPOSED HUMAN 

EPIDERMAL KERATINOCYTES AND 

HUMAN BRONCHIAL EPITHELIAL CELLS. 

J. Gao and R. Iyer. LANL, Los Alamos, NM. 

176 






Platform Sessions



Abstract # 


ENVIRONMENTAL FATE AND EFFECTS 

OF METALLOFULLERENE SYNTHESIS- 

GENERATED SOOT IN A TERRESTRIAL 

SYSTEM. D. R. Johnson 1 , A. J. Bednar 1 , R. E. 

Boyd 3 , C. A. Weiss 2 , C. J. Banks 1 , P. Tumenillo 1 , 

L. Brady 4 , J. G. Coleman 1 and J. A. Steevens 1 . 

1 

Environmental Laboratory, U.S. Army Engineer 

Research & Development Center, Vicksburg, MS, 

2 

Geotechnical and Structures Laboratory, U.S. 

Army Engineer Research & Development Center, 

Vicksburg, MS, 3 SpecPro, Inc., Vicksburg, MS and 

4 

Alcorn State University, Lorman, MS. 


EFFECT OF CARBON NANOTUBES ON 

ANTIOXIDANT BALANCE IN THE LUNGS. 

A. Banerjee 1 , T. Stoeger 2 and N. Ercal 1 . 1 Chemistry, 

Missouri University of Science and Technology, 

Rolla, MO and 2 Institute of Inhalation Biology, 

Helmholtz Zentrum Munchen, German Research 

Centre for Environmental Health, Neuherberg, 

Germany. 


COMPARATIVE CLASTOGENIC STUDY 

OF FUNCTIONALIZED AND NON- 

FUNCTIONALIZED MULTI-WALLED 

CARBON NANOTUBE IN BONE MARROW 

CELLS OF SWISS-WEBSTER MICE. A. 

Patlolla 1 , S. M. Hussain 2 and P. Tchounwou 1 . 

1 

Jackson State University, Jackson, MS and 2 Air 

Force Research Laboratory-AFB-Wright-Patterson, 

Dayton, OH. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Kidney I 

Chairperson(s): Alan Parrish, Texas A&M University, College Station, 

TX, and Monica Valentovic, Marshall University School of Medicine, 

Huntington, WV. 




NEPHSTICK: A RAPID MUTIPLEX TEST 

FOR THE SENSITIVE AND SPECIFIC 

DETECTION OF URINARY KIDNEY INJURY 

MOLECULE-1 AND CYSTATIN-C. M. 

Ferguson 1 , M. B. Clement 2 , J. Koyner 3 , G. Ford 4 , 

W. E. Glaab 5 , S. P. Troth 5 , F. D. Sistare 5 , W. C. 

Prozialeck 6 and V. S. Vaidya 2 . 1 Medicine, Children’s 

Hospital Boston, Harvard Medical School, Boston, 

MA, 2 Medicine, Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA, 3 Nephrology, 

University of Chicago, Chicago, IL, 4 BioAssay 

Works, Ijamsville, MD, 5 Safety Assessment, 

Merck Research Laboratories, West Point, PA and 

6 

Pharmacology, Midwestern University, Downers 

Grove, IL. 

Abstract # 


COMPARISON OF BASELINE VALUES 

OF RAT URINARY NEPHROTOXICITY 

BIOMARKERS USING BASI CULEX ® 

SYSTEM VS. METABOLIC CAGES. Y. Chen, 

D. Brott, P. Bentley, H. Kamendi, D. J. Lengel, 

L. Kinter and R. A. Bialecki. Safety Assessment, 

AstraZeneca Pharmaceuticals, Wilmington, DE. 


RENAL TOXIC EFFECTS OF 

NEPHROTOXICANTS. B. Choi 1 , T. Lee 2 and 

J. Park 1 . 1 Department of Preventive Medicine, 

Chung-Ang University, College of Medicine, Seoul, 

156-756, Republic of Korea and 2 Department of 

Pathology, Chung-Ang University, College of 

Medicine, Seoul, 156-756, Republic of Korea. 


NMR METABOLIC ANALYSIS OF 

PROXIMAL EPITHELIA TUBULUS CELLS 

DURING DIFFERENTIATION. C. J. Burek 1 , 

K. Herrgen 1 , M. Gruene 2 , P. Jennings 3 and W. 

Dekant 1 . 1 Department of Toxicology, University of 

Wüerzburg, Wüerzburg, Germany, 2 Department 

of Organic Chemistry, University of Wüerzburg, 

Wüerzburg, Germany and 3 Department of Physiology 

and Medical Physics, Innsbruck Medical University, 

Innsbruck, Austria. 


IN SEARCH OF RENAL PROGENITORS: 

IDENTIFICATION OF INDEPENDENT AND 

OVERLAPPING GENES DURING KIDNEY 

DEVELOPMENT AND REGENERATION 

IN RATS. V. Ramirez 1 , C. Basudev 1 , J. Barrera 2 , 

R. Gali 1 , N. A. Bobadilla 2 and V. S. Vaidya 1 . 

1 

Medicine, Renal Division, Brigham and Women’s 

Hospital, Harvard Medical School, Boston, MA and 

2 

Molecular Physiology Unit, National University of 

Mexico, Mexico, DF, Mexico. 


BROMATE INDUCES RENAL CELL CYCLE 

ARREST VIA DNA DAMAGE-DEPENDENT 

AND -INDEPENDENT PATHWAYS. X. Zhang 1 , 

B. Sun 1 , R. J. Bull 2 , J. A. Cotruvo 3 , J. Fisher 4 and B. 

S. Cummings 1 . 1 Department of Pharmaceutical and 

Biomedical Sciences, University of Georgia, Athens, 

GA, 2 MoBull Consulting, Richland, WA, 3 Joseph 

Cotruvo & Associates, LLC, Washington, DC and 

4 

Department of Environmental Health Sciences, 



IN VIVO DISPOSITION AND 

NEPHROTOXICITY OF BROMATE IN F344 

RATS. N. Kolisetty 1 , S. Muralidhara 1 , R. J. Bull 2 , O. 

Quiñones 3 , Z. X. Guo 4 , S. A. Snyder 3 , J. A. Cottruvo 5 , 

J. W. Fisher 6 , C. N. Ong 7 and B. S. Cummings 1 . 

1 


of Georgia, Athens, GA, 2 Mo Bull Consulting, 

Richland, WA, 3 Water Quality Res. and Dev., 

Southern Nevada Water Authority, Henderson, NV, 

4 

Center for Adv. Water Tech., Public Utilities Board, 

Singapore, Singapore, 5 Joseph Cotruvo & Assoc., 

LLC, Washington, DC, 6 Environment Health Sci., 

University of GA, Athens, GA and 7 Epid. and Public 

Health, National University of Singapore, Singapore, 

Singapore. 

tueSday 







177


tueSday 




ANTIOXIDANT DEFENSE IN RENAL 

PROXIMAL TUBULAR CELLS FROM 

NORMAL AND DIABETIC RATS. L. H. 

Lash, D. A. Putt, S. R. Terlecky and Q. Zhong. 

Pharmacology, Wayne State University School of 

Medicine, Detroit, MI. 


FLOW CYTOMETRIC 


MITOCHONDRIAL SUBPOPULATIONS IN 

THE KIDNEY. J. E. Saunders, C. Beeson and R. 

G. Schnellmann. Pharmaceutical and Biomedical 




ACUTE DOXORUBICIN (DXR)-INDUCED 

NEPHROTOXICITY INVOLVES MASSIVE 

OXIDATIVE STRESS AND AN ORGANIZED 

PERTURBATION OF MITOCHONDRIA- 

CENTRIC PRO- AND ANTI-APOPTOTIC 

GENES. T. Lahoti and S. D. Ray. Mol. Toxicology 

Labs, Division of Pharm Sci, AMS College of 

Pharmacology & Health Sciences, Brooklyn, NY. 


RENAL COLLECTING DUCT AND 

HEPATOBILIARY TOXICITY INDUCED BY 

AN ANTIRETROVIRAL DRUG CANDIDATE. 

J. C. Sasaki 1,2 , S. De Jonghe 3 , S. Lachau-Durand 1 , 

J. Aerssens 1 , J. Fransen 3 , K. Goossens 1,5 , D. 

Jochmans 1 , B. Kesteleyn 1 , P. Lory 1 , E. Moesen 3 , 

M. Ott 1,6 , F. Schoetens 4 and M. Sonee 2 . 1 Tibotec 

BVBA, Mechelen, Belgium, 2 Johnson & Johnson 

Pharmaceutical Research and Development, 

Raritan, NJ, 3 Johnson & Johnson Pharmaceutical 

Research and Development, a Division of Janssen 

Pharmaceutica NV, Beerse, Belgium, 4 Johnson & 

Johnson Pharmaceutical Research and Development, 

La Jolla, CA, 5 Current Affiliation: Sint-Vincentius 

Hospital, Antwerp, Belgium and 6 Current Affiliation: 

Bayer CropScience AG, RD IT, Monheim am Rhein, 

Germany. 


INTENSIFIED SYSTEMIC TOXICITY BY 

MELAMINE IN COMBINATION WITH 

CYANURIC ACID IN RATS. Y. Park, S. Jeong, 

J. Seo, Y. Jean, J. Kang, H. Shin, E. Kim, J. Cho and 

S. Son. Toxicology Division, National Veterinary 

Research & Quarantine Service, Anyang, KyungGi, 

Republic of Korea. 


RESVERATROL REDUCTION OF 

CISPLATIN MEDIATED RENAL OXIDATIVE 

STRESS AND TOXICITY. M. Valentovic, J. G. 

Ball and J. Brown. Pharmacology, Physiology, and 

Toxicology, Marshall University School of Medicine, 



3, 4-DICHLORONITROBENZENE AND 

1, 2, 3-TRICHLORO-5-NITROBENZENE 

NEPHROTOXICITY IN ISOLATED RENAL 

CORTICAL CELLS FROM MALE FISCHER 

344 RATS. B. Greene, C. Schuetz, D. Anestis 

and G. O. Rankin. Department of Pharmacology, 

Physiology, and Toxicology, Marshall University, 



CLEARANCE OF PERFLUOROOCTANOATE 

IN ISOLATED PERFUSED KIDNEYS FROM 

MALE AND FEMALE RATS—EFFECTS OF 

PROTEIN BINDING AND RENAL ORGANIC 

ANION TRANSPORT INHIBITORS. D. 

Nabb, M. Golt, R. Mingoia and X. Han. DuPont 

Haskell Global Centers for Health & Environmental 

Sciences, Newark, DE. 


KIDNEY INJURY MOLECULE-2 

GENE DEFICIENT MICE ARE MORE 

SUSCEPTIBLE TO CISPLATIN INDUCED 

KIDNEY TOXICITY. A. Krishnamoorthy, E. 

O’Leary, J. V. Bonventre and V. S. Vaidya. Medicine, 

Renal Division, Brigham and Women’s Hospital, 

Harvard Medical School, Boston, MA. 


COMPARATIVE NEPHROTOXICITY OF 

LOW-OSMOLAR AND ISO-OSMOLAR 

IODINATED CONTRAST AGENTS. L. A. 

Gardiner 1 , R. C. Burghardt 2 and A. R. Parrish 1 . 

1 

Systems Biology and Translational Medicine, Texas 

A&M Health Science Center, College Station, TX 

and 2 Veterinary Integrated Biosciences, Texas A&M 

Health Science Center, College Station, TX. 


EVALUATION OF CADMIUM 

EXPOSURE AND KIDNEY FUNCTION 

IN OCCUPATIONALLY NON-EXPOSED 

POPULATION. J. Park, M. Huang, B. Choi, D. 

Kim, N. Kim and H. Bae. Preventive Medicine, 

Chung-Ang University, Seoul, Republic of Korea. 


THE COMPARISON OF GLOBAL GENE 

EXPRESSION IN ACUTE AND CHRONIC 

CADMIUM EXPOSURE IN CULTURES OF 

HUMAN PROXIMAL TUBULE CELLS. S. H. 

Garrett, S. Somji, M. Sens and D. A. Sens. Pathology, 

University of North Dakota, Grand Forks, ND. 


REGULATION OF BISPHENOL A-INDUCED 

APOPTOSIS IN HUMAN EMBRYONIC 

KIDNEY CELLS. H. Kim 1 , S. Yang 2 , M. P. 

Shakajian 1 , A. M. Vetrano 2 , M. T. Lalloo 1 , J. D. 

Laskin 2 and D. E. Heck 1 . 1 Environmental Health 

Science, New York Medical College, Valhalla, NY 

and 2 Environmental and Occupational Medicine, 

UMDNJ-RW Johnson Medical School, Piscataway, 

NJ. 


THE EFFECTS OF FLUORIDE ON 

RENAL FUNCTION OF ICR-DERIVED 

GLOMERULONEPHRITIS (ICGN) BY 

SUBACUTE ADMINISTRATION OF 

FLUORIDE IN DRINKING WATER. H. 

Mayuko 1 , A. Hideo 2 , K. Takaya 1 , S. Chiemi 2 , I. 

Yoko 2 , T. Masashi 2 , I. Kazuyoshi 3 , K. Yukio 4 , S. 

Yoshiko 4 and A. Yoshiharu 2 . 1 Kitasato University 

Graduate School of Medical Sciences, Sagamihara, 

Kanagawa, Japan, 2 Preventive Medicine and Public 

Health, Kitasato University School of Medicine, 

Sagamihara, Kanagawa, Japan, 3 School of Medicine 

Iwate Medical University, Morioka, Iwate, Japan 

and 4 National Institute of Science, Setagaya, Tokyo, 

Japan. 

178 






Platform Sessions



Abstract # 


INDUCTION OF APOPTOSIS IN PRIMARY 

MESANGIAL CELL BY DEOXYNIVALENOL. 

J. Seo 1,2 , J. Kim 1 and J. J. Pestka 1 . 1 Food Science 

and Human Nutrition, Michigan State University, 

East Lansing, MI and 2 Korea Food and Drug 

Administration, Seoul, Republic of Korea. 


HIERARCHY AMONG EXECUTIONERS: 

CYTOTOXIC ENDONUCLEASES 

REGULATE ONE ANOTHER IN VITRO AND 

IN MOUSE MODELS OF TOXIC KIDNEY 

INJURY. A. G. Basnakian 1,2 , E. O. Apostolov 1 , X. 

Wang 1 and S. V. Shah 1,2 . 1 University of Arkansas 

for Medical Sciences, Little Rock, AR and 2 Central 

Arkansas Veterans Healthcare System, Little Rock, 

AR. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Developmental Toxicology 

Chairperson(s): Christopher J. Bowman, Pfizer Global Research and 

Development, Groton, CT, and Asok Dasmahapatra, University of 





THE IN VITRO SCREENING OF 

TERATOGENICITY USING GENE 

EXPRESSION PROFILING IN CULTURED 

EMBRYOS IN RATS. R. Fukushima, K. 

Nishimura, C. Kondo, A. Hishikawa, T. Uehara, 

M. Kaneto and M. Torii. Drug Safety Evaluation, 

Shionogi & Co., Ltd., Toyonaka, Osaka, Japan. 

Sponsor: K. Nakamura. 


DEVELOPMENTAL TOXICITY OF 

PERFLUOROALKYL ACID MIXTURES IN 

CD-1 MICE. K. R. Tatum-Gibbs 1 , C. Lau 2 , K. P. 

Das 2 and B. Abbott 2 . 1 Curriculum in Toxicology, 

University of North Carolina, Chapel Hill, NC and 

2 

Developmental Biology Branch, U.S. EPA, Research 



MAMMARY GLAND DEVELOPMENT AND 

RESPONSE TO PRENATAL ATRAZINE 

EXPOSURE IN THE SPRAGUE-DAWLEY 

AND LONG-EVANS RAT. C. J. Wolf, J. P. Stanko 

and S. E. Fenton. Toxicity Assessment Division, U.S. 

EPA, ORD, NHEERL, Research Triangle Park, NC. 


DEVELOPMENTAL TOXICITY 

EVALUATION IN THE CYNOMOLGUS 

MONKEY: VARIABILITY OF PREGNANCY 

LOSS AND STATISTICAL GROUP SIZE 

CONSIDERATIONS. G. F. Weinbauer 1 , P. Jarvis 2 , 

S. Srivastav 1 , E. Vogelwedde 1 , J. Stewart 2 and T. 

Mitchard 2 . 1 Covance Laboratories GmbH, Muenster, 

Germany and 2 AstraZeneca Pharmaceuticals, 

Macclesfield, United Kingdom. 

Abstract # 


NEUROPATHY TARGET ESTERASE (NTE) 

MIGHT BE PLAYING A RELEVANT ROLE 

DURING CELL DIFFERENTIATION. M. A. 

Sogorb, D. Pamies, C. Estevan, A. C. Romero and 

E. Vilanova. Unidad de Toxicología y Seguridad 

Química, Instituto de Bioingeniería, Universdad 

Miguel Hernández de Elche, Elche, Alicante, Spain. 


SPECIES DIFFERENCES IN CATALASE AND 

ALCOHOL DEHYDROGENASE ACTIVITY 

IN MICE AND RABBITS. J. Sweeting 1 and P. G. 

Wells 1,2 . 1 Pharmaceutical Sciences, The University of 

Toronto, Toronto, ON, Canada and 2 Pharmacology 

and Toxicology, The University of Toronto, Toronto, 

ON, Canada. 


INHALED CADMIUM OXIDE 

NANOPARTICLES (NP) CAN POSE A RISK 

TO THE DEVELOPING FETUS. J. T. Zelikoff, 

S. P. Doherty, C. Hoffman and J. Xiong. New York 

University School of Medicine, Tuxedo, NY. 


COMPARISON OF RAT AND RABBIT 

CONCEPTUS RESPONSES TO INHIBITORS 

OF HISTIOTROPHIC NUTRITION. E. 

Carney 1 , B. Tornesi 1 , V. Marshall 1 , R. Rasoulpour 1 

and N. Moore 2 . 1 The Dow Chemical Company, 

Midland, MI and 2 Dow Europe GmBH, Horgen, 

Switzerland. 


ALTERED GENE EXPRESSION IN 

THE BRAIN FOLLOWING REPEATED 

CHLORPYRIFOS EXPOSURE IN LATE 

PREWEANLING RATS. C. A. Nail and R. L. 

Carr. Center for Environmental Health Sciences, 

College of Veterinary Medicine, Mississippi State 

University, MS State, MS. 


ARSENIC DELAYS THE DIFFERENTIATION 

OF MOUSE MUSCLE CELLS THROUGH 

THE REPRESSION OF MYOGENIN AND 

ALTERATION OF DNA METHYLATION. G. 

Hong and L. J. Bain. Biological Sciences, Clemson 

University, Pendleton, SC. 


DEVELOPMENTAL EXPOSURE OF 

CD-1 MICE TO PFOA IDENTIFIES THE 

MAMMARY GLAND AS A LOW DOSE 

TARGET TISSUE. M. B. Macon 1 , J. P. Stanko 2,3 

and S. E. Fenton 2,3 . 1 Curriculum in Toxicology, 

University of North Carolina Chapel Hill, Chapel 

Hill, NC, 2 Toxicology Assessment Division, U.S. 

EPA, Research Triangle Park, NC and 3 Cellular and 

Molecular Pathology Branch, NIESH/NTP, Research 



ANALYTICAL METHOD VALIDATION FOR 

DIISOBUTYL PHTHALATE IN RODENT 

FEED IN SUPPORT OF DEVELOPMENTAL 

AND REPRODUCTIVE TOXICOLOGY 

STUDIES. J. C. Blake 1 , R. A. Fernando 1 , G. 

McNeill 1 , J. A. Gilliam 1 , D. B. Browning 1 and B. 

J. Collins 2 . 1 RTI International, Durham, NC and 

2 

NIEHS, NTP, Durham, NC. Sponsor: T. Fennell. 

tueSday 







179


tueSday 




DEVELOPMENTAL IMMUNOTOXICITY 

OF METHYLMERCURY: THE RELATIVE 

SENSITIVITY OF DEVELOPMENTAL AND 

IMMUNE PARAMETERS. E. C. Tonk 1,2,3 , 

D. M. de Groot 3 , A. H. Penniks 3 , I. D. Waalkens- 

Berendsen 3 , A. P. Wolterbeek 3 , A. H. Piersma 2,4 and 

H. van Loveren 1,2 . 1 Maastricht University, Maastricht, 

Netherlands, 2 National Institute for Public Health 

and the Environment, Bilthoven, Netherlands, 3 TNO, 

Quality of Life, Zeist, Netherlands and 4 Institute 

for Risk Assessment Sciences, Utrecht University, 

Utrecht, Netherlands. 


EFFECTS OF FIGITUMUMAB, AN ANTI- 

IGF1R MONOCLONAL ANTIBODY, ON 

EMBRYO-FETAL DEVELOPMENT IN 

CYNOMOLGUS MONKEYS. C. J. Bowman 1 , 

C. Gary 1 , S. Oneda 2 and M. Todd 3 . 1 Pfizer, Groton, 

CT, 2 SNBL USA, Ltd., Everett, WA and 3 Pfizer, La 

Jolla, CA. 


FETAL EXPOSURE TO BREVETOXIN 

IN CD-1 MICE: DOSE TO TISSUE 

AND EFFECTS ON LYMPHOCYTE 

POPULATIONS. G. J. Chavez 1 , J. Hutt 1 , B. 

Tibbetts 1 , K. Gott 1 , D. Baden 2 and J. Benson 1 . 

1 

Lovelace Respiratory Research Institute, 

Albuquerque, NM and 2 Center for Marine Science, 

University of North Carolina, Wilmington, NC. 


REGULATION OF VENTRAL EPITHELIAL 

BUD PATTERNS IN MOUSE UROGENITAL 

SINUS (UGS) BY ANDROGEN SIGNALING 

AND 2, 3, 7, 8-TETRACHLORODIBENZO-p- 

DIOXIN (TCDD). R. W. Moore 1,2 , S. H. Allgeier 2 , 

T. M. Lin 1 , C. M. Vezina 3,2 , L. L. Abler 1 and R. E. 

Peterson 1,2 . 1 Sch. Pharmacy, University Wisconsin, 

Madison, WI, 2 Mol. Environment Toxicol. Ctr., 

University Wisconsin, Madison, WI and 3 Compar. 

Biosci., University Wisconsin, Madison, WI. 


THE EFFECTS OF L-CARNITINE ON 

KETAMINE-INDUCED NEUROTOXICITY IN 

RAT FOREBRAIN CULTURES. C. Wang 1 , N. 

Sadovova 2 , X. Zou 1 , X. Zhang 1 , F. Liu 1 , T. Patterson 1 , 

J. Hanig 3 , M. Paule 1 and W. Slikker 1 . 1 Division of 

Neurotoxicology, NCTR/U.S. FDA, Jefferson, AR, 

2 

Toxicological Pathology Associates, Jefferson, AR 

and 3 CDER, U.S. FDA, Silver Spring, MD. 


GENETIC AND EPIGENETIC EFFECTS OF 

IN UTERO EXPOSURE TO BISPHENOL A. J. 

LaRocca, S. Duncan Smith and M. Hixon. Brown 



EFFECTS OF METHYLMERCURY 

PUBESCENT EXPOSURE ON THE BRAIN 

AND REPRODUCTIVE SYSTEM. J. C. Heath 1 , 

C. A. Jackson 1 , N. M. Yamani 1 , J. Aaron 2 , S. Cruz 2 , 

M. Owen 2 and N. Stobaeus 2 . 1 Biomedical Sciences, 

Tuskegee University, Tuskegee, AL and 2 CVMNAH, 

Tuskegee University, Tuskegee, AL. 


INVESTIGATING THE ROLE OF 

DNA DOUBLE-STRAND BREAKS 

AND DNA RECOMBINATION IN 

BENZENE-METABOLITE INDUCED 

HEMATOTOXICITY. K. MacDonald 1 and L. M. 

Winn 1,2 . 1 Pharmacology and Toxicology, Queen’s 

University, Kingston, ON, Canada and 2 School 

of Environmental Studies, Queen’s University, 

Kingston, ON, Canada. 


OBSERVATIONS OF THE EFFECTS OF 

NANOPARTICLES ON REPRODUCTION 

AND DEVELOPMENT IN DROSOPHILA 

MELANOGASTER AND CD-1 MICE. N. 

A. Philbrook 1 , V. K. Walker 3,1 and W. M. Louise 2,1 . 

1 

School of Environmental Studies, Queen’s 

University, Kingston, ON, Canada, 2 Pharmacology 

and Toxicology, Queen’s University, Kingston, ON, 

Canada and 3 Biology, Queen’s University, Kingston, 

ON, Canada. 


DEVELOPMENTAL REGULATION 

OF RETINOIC ACID SIGNALING: 

TERATOGENIC ROLE OF MICRORNAS. J. 

A. Franzosa, T. L. Tal and R. L. Tanguay. Department 

of Environmental and Molecular Toxicology, Oregon 



EVALUATION OF THE EFFECTS 

OF SURGERY AND CONTINUOUS 

INTRAVENOUS INFUSION ON 

EMBRYOFETAL DEVELOPMENT IN 

PREGNANT SPRAGUE-DAWLEY RATS. S. K. 

Sahambi 1 , A. LeBlanc 2 , C. Gordon 1 , E. Lebel 1 and G. 

Washer 1 . 1 Study Management, LAB Research Inc., 

Laval, QC, Canada and 2 Toxicology, LAB Research 

Inc., Laval, QC, Canada. 


EMBRYOFETAL TOXICITY OF BORIC 

ACID: VALIDATION OF PROCEDURES AND 

EVALUATION METHODS, INCLUDING 

CONTINUOUS INTRAVENOUS INFUSION 

IN NEW ZEALAND WHITE RABBITS. C. 

Gordon 1 , S. K. Sahambi 1 , A. LeBlanc 2 , E. Lebel 1 and 

G. Washer 1 . 1 Study Management, LAB Research Inc., 

Laval, QC, Canada and 2 Toxicology, LAB Research 

Inc., Laval, QC, Canada. 


LIPID MEDIATORS LINK CELL CYCLE 

PROGRESSION WITH PLACENTAL 

AND NEURAL TUBE DEFECTS AFTER 

MATERNAL FUMONISIN EXPOSURE. J. 

Gelineau-van Waes 1 , J. Maddox 1 , K. Voss 2 and R. 

Riley 2 . 1 Pharmacology, Creighton University School 

of Medicine, Omaha, NE and 2 USDA Toxicology & 

Mycotoxin Research Unit, Athens, GA. 


IS REDUCED FOOD CONSUMPTION A 

PREDICTOR OF ABORTIONS IN RABBITS? 

C. K. Lanphear 1 , B. Tornesi 2 and A. S. Faqi 1 . 

1 

Developmental and Reproductive Toxicology, MPI 

Research, Mattawan, MI and 2 Toxicology, Abbott 

Laboratories, Abbott Park, IL. 

180 






Platform Sessions



Abstract # 


ARRAY ANALYSIS OF LASTING BRAIN 

EFFECTS FROM PERINATAL PESTICIDE 

EXPOSURE. J. Zhang 1 , T. L. Lassiter 1 , A. A. 

Leontovich 2 , P. J. Park 3 , M. McKinney 1 and S. 

Brimijoin 1 . 1 Pharmacology, Mayo Clinic, Rochester, 

MN, 2 Microarray Core Facility, Mayo Clinic, 

Rochester, MN and 3 Harvard Medical School, 

Boston, MA. 


EXTENDED ONE-GENERATION 

REPRODUCTION STUDY WITH 

METHIMAZOLE AS A REFERENCE 

CHEMICAL. A. Milius 2 , D. Dandekar 2 and L. 

Sheets 1 . 1 Toxicology, Bayer CropScience, Research 

Triangle Park, NC and 2 Toxicology, Xenometrics 

LLC, Stilwell, KS. 


FEASIBILITY OF THE F1-EXTENDED-ONE 

GENERATION REPRODUCTION TOXICITY 

STUDY. L. Sheets 1 , I. Fegert 2 , S. Schneider 2 , 

B. van Ravenzwaay 2 , B. Stahl 3 , R. Lewis 4 , P. 

Botham 4 , T. Hanley 5 , R. Billington 6 and E. Carney 7 . 

1 

Toxicology, Bayer CropScience, Research Triangle 

Park, NC, 2 Toxicology, BASF, Ludwigshafen, 

Germany, 3 Toxicology, Bayer CropScience, Sophia- 

Antipolis, France, 4 Toxicology, Syngenta, Raleigh, 

NC, 5 Toxicology, Syngenta, Greensboro, NC, 

6 

Toxicology, Dow AgroSciences, Abingdon, United 

Kingdom and 7 Toxicology, Dow Chemical, Midland, 

MI. 


CATALASE IN THE MECHANISM OF 

METHANOL DEVELOPMENTAL TOXICITY. 

M. Siu 1 and P. G. Wells 1,2 . 1 Faculty of Pharmacy, 


2 




IN UTERO BISPHENOL A EXPOSURE MAY 

CAUSE STRUCTURAL AND FUNCTIONAL 

CHANGES IN THE DEVELOPING MURINE 

NERVOUS SYSTEM. A. M. Shapiro 1 , J. C. 

Poon 2 , L. Miller 2 , A. Kanawaty 1 , J. T. Henderson 1 , 

A. Ramkissoon 1 and P. G. Wells 1,2 . 1 Pharmaceutical 

Science, University of Toronto, Toronto, ON, Canada 

and 2 Pharmacology & Toxicology, University of 



SUBTHRESHOLD DOSES OF CADMIUM 

AND ARSENITE, BUT NOT OTHER 

METALS, COMBINE TO PRODUCE NEURAL 

TUBE DEFECTS IN C57BL/6J MICE. A. F. 

Machado 1 , F. K. Huynh 1 , N. Dekeyan 1 , A. F. Elsaid 2 , 

H. Shimizu 2 and M. D. Collins 2 . 1 Environmental and 

Occupational Health, California State University, 

Northridge, Northridge, CA and 2 Molecular 

Toxicology Interdepartmental Program, University of 

California, Los Angeles School of Public Health, Los 

Angeles, CA. Sponsor: D. Hovland. 

Abstract # 


ACTIVATION OF ARYL HYDROCARBON 

RECEPTOR SIGNALING IS ASSOCIATED 

WITH DOWN REGULATION OF 

SLUG DURING MOUSE PROSTATE 

DEVELOPMENT AND TRANSGENIC 

ADENOCARCINOMA OF THE MOUSE 

PROSTATE (TRAMP) TUMOR METASTASIS. 

H. Hardin 1 , C. M. Vezina 3,2 , T. Lin 1 , R. W. Moore 1,2 

and R. E. Peterson 1,2 . 1 Sch. Pharmacy, University 

of Wisconsin-Madison, Madison, WI, 2 Mol. 

Environment Toxicol. Ctr., University of Wisconsin- 

Madison, Madison, WI and 3 Compar. Biosci., 

University of Wisconsin-Madison, Madison, WI. 


ULTRASONIC VOCALISATIONS (USVS) 

IN RAT PUPS. AN ANIMAL FRIENDLY 

MARKER FOR NEUROTOXICITY DURING 

DEVELOPMENT. D. De Groot 1 , J. Swierstra 1 , 

L. Damsteegt 1 , L. Blauw 1 , L. v.d. Horst 1 , M. Otto 1 , 

H. v.d. Wiel 2 and R. Bulthuis 3 . 1 TNO Quality of 

Life, Zeist, Netherlands, 2 TNO Defense, Security 

& Safety, Rijswijk, Netherlands and 3 Metris BV, 

Hoofdorp, Netherlands. Sponsor: R. Woutersen. 


REDUCED ETHANOL EMBRYOPATHIES IN 

EMBRYO CULTURE IN TRANSGENIC MICE 

EXPRESSING HUMAN CATALASE. L. Miller 1 

and P. G. Wells 1,2 . 1 Pharmacology & Toxicology, 


2 

Pharmaceutical Sciences, University of Toronto, 

Toronto, ON, Canada. 


SEXING OF EARLY POSTIMPLANTATION 

RAT EMBRYOS BY AMPLIFICATION OF 

SRY GENE IN STORED 2-DE SAMPLES FOR 

DEVELOPMENTAL TOXICITY STUDIES. 

A. Miyajima-Tabata 1 , M. Sunouchi 1 , K. Mitsunaga 2 , 

Y. Yamakoshi 3 , K. Nakazawa 1 and M. Usami 1 . 

1 

Division of Pharmacology, National Institute of 

Health Sciences, Tokyo, Japan, 2 Graduate School of 

Pharmaceutical Sciences, Toho University, Chiba, 

Japan and 3 Department of Radiology, Department of 

Chemistry, University of Pennsylvania, Philadelphia, 

PA. Sponsor: A. Hirose. 


NEURODEGENERATION INDUCED 

BY GASEOUS ANESTHETICS IN THE 

PERINATAL RHESUS MONKEY. X. Zou 1 , 

T. A. Patterson 1 , B. L. Divine 2 , N. Sadovova 2 , X. 

Zhang 1 , J. P. Hanig 3 , M. G. Paule 1 , W. Slikker 1 and 

C. Wang 1 . 1 Division of Neurotoxicology, National 

Center for Toxicological Research, Jefferson, AR, 

2 

Toxicologic Pathology Associates, National Center 

for Toxicological Research, Jefferson, AR and 

3 

Division of Applied Pharmacology Research, Center 

for Drug Evaluation and Research, U.S. FDA, Silver 

Spring, MD. 


EXTRACELLULAR MATRIX CHANGES IN 

THE DISSECTING AORTIC ANEURYSM 

(DAA) CAUSED BY N-(2-AMINOETHYL) 

ETHANOLAMINE (AEEA) IN RAT. Y. Xu 1 , 

S. Treumann 2 , R. Rossbacher 2 , S. Schneider 2 and P. 

J. Boor 1 . 1 Pathology, University of Texas Medical 

Branch at Galveston, Galveston, TX and 2 BASF, 

Ludwigshafen, Germany. 

tueSday 







181


tueSday 




MELATONIN AMELIORATES 

CYCLOPHOSPHAMIDE-INDUCED TRANS- 

PLACENTAL GENOTOXICITY, GERM CELL 

TOXICITY AND AND UROTOXICITY IN 

RAT: ROLE OF NUCLEAR ERYTHROID 

2-RELATED FACTOR 2 AND NUCLEAR 

FACTOR-KAPPAB. D. N. Tripathi and G. Jena. 

Pharmacology and Toxicology, National Institute of 

Pharmaceutical Education and Research (NIPER), 

SAS Nagar, Chandigarh, Punjab, India. Sponsor: K. 

Rao. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Biological Modeling: Multiple Scales of 

Parameters, Structures, and Applications 

Chairperson(s): Jimena Davis, U.S. EPA, Research Triangle Park, NC, 

and Jerry Campbell, Hamner Institutes for Heatlh Sciences, Durham, NC. 




AN UPDATED, THREE-DIMENSIONAL 

DOSIMETRY MODEL FOR UPTAKE OF 

INHALED SOLUBLE VAPORS IN THE 

HUMAN UPPER RESPIRATORY TRACT. 

J. Kimbell 1 , B. Asgharian 2 and J. D. Schroeter 3 . 

1 

Otolaryngology/Head & Neck Surgery, University of 

North Carolina, Chapel Hill, NC, 2 Applied Research 

Associates, Raleigh, NC and 3 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC. 


A DOSIMETRY MODEL FOR UPTAKE 

OF INHALED SOLUBLE VAPORS IN THE 

HUMAN LOWER RESPIRATORY TRACT. 

B. Asgharian 1 , O. T. Price 1 , J. D. Schroeter 2 and J. 

S. Kimbell 3 . 1 Health Effects & Medical Response, 

Applied Research Associates, Raleigh, NC, 

2 

Computational Biology, The Hamner Institutes for 

Health Sciences, Durham, NC and 3 Department of 

Otolaryngology/Head and Neck Surgery, University 

of North Carolina School of Medicine, Chapel Hill, 

NC. 


COMPARATIVE COMPUTATIONAL FLUID 

DYNAMICS SIMULATIONS OF AIRFLOWS 

IN THE FULL RESPIRATORY SYSTEM 

OF RATS, MONKEYS, AND HUMANS. R. 

A. Corley 1 , S. Kabilan 1 , J. Carson 1 , R. Jacob 1 , A. 

Kuprat 1 , K. Minard 1 , R. Glenny 2 , E. Postlethwait 3 and 

D. Einstein 1 . 1 Pacific Northwest National Laboratory, 

Richland, WA, 2 University of Washington, Seattle, 

WA and 3 University of Alabama at Birmingham, 

Birmingham, WA. 


VALIDATION OF COMPUTATIONAL 

PREDICTIONS OF AIRFLOWS AND 3D 

VELOCITY FIELDS IN THE RODENT LUNG 

WITH 3HE MRI AND FLUORESCENT 

MICROSPHERE DEPOSITION. D. R. Einstein 1 , 

K. R. Minard 1 , R. E. Jacob 1 , T. C. Cox 2 , H. T. 

Robertson 2 , W. Lamb 2 , A. P. Kuprat 1 , S. Kabilan 1 , 

J. P. Carson 1 and R. A. Corley 1 . 1 Pacific Northwest 

National Laboratory, Richland, WA and 2 University 



MULTI-SCALE MODELING OF THE 

RODENT RESPIRATORY SYSTEM. S. 

Kabilan 1 , A. Kuprat 1 , R. A. Corley 1 , M. P. Hlastala 2 

and D. R. Einstein 1 . 1 Pacific Northwest National 

Laboratory, Richland, WA and 2 University of 

Washington, Seattle, WA. 


A GENERAL APPROACH FOR SPECIFYING 

INFORMATIVE PRIOR DISTRIBUTIONS 

FOR PBPK MODEL PARAMETERS. J. Davis 1 , 

R. Tornero-Velez 2 and R. Setzer 1 . 1 National Center 

for Computational Toxicology, U.S. EPA, Research 

Triangle Park, NC and 2 National Exposure Research 



MONTE CARLO ANALYSIS OF 

VARIABILITY IN TCE METABOLISM 

ACROSS A PANEL OF INBRED MOUSE 

STRAINS WITH A PBPK MODEL. J. 

Campbell 1 , H. Clewell 1 , S. Kim 2 , L. Collins 2 , 

O. Kosyk 2 and I. Rusyn 2 . 1 Center for Human 

Health Assess., The Hamner Institutes, Research 

Triangle Park, NC and 2 Environment Science and 

Engineering, University of North Carolina, Chapel 

Hill, NC. 


PROGRESS IN DEVELOPMENT 

OF A PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC MODEL FOR 

AVIATION FUELS. S. A. Martin, R. T. Tremblay 

and J. W. Fisher. Environmental Health Science, 



TISSUE PARTITION COEFFICIENTS FOR 

NONANE AND ITS ISOMERS. G. Joshi, J. 

W. Fisher and R. Tremblay. Environmental Health 

Science, University of Georgia, Athens, GA. 


A PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC MODEL OF 

ENDOTOXIN FROM SALMONELLA 

TYPHIMURIUM IN THE RAT BRAIN AND 

PERIPHERAL ORGANS. J. C. Hutter 1 and C. S. 

Kim 2 . 1 Center for Devices and Radiological Health, 

Office of Device Evaluation, U.S. FDA, Silver 

Spring, MD and 2 Center for Food Safety and Applied 

Nutrition, Office of Applied Research and Safety 

Assessment, Division of Toxicology, U.S. FDA, 

Laurel, MD. Sponsor: S. Sahu. 

182 






Platform Sessions



Abstract # 


COMPARISON OF TRADITIONAL 

EXPOSURE ASSESSMENT AND 

PHYSIOLOGICALLY BASED 

PHARMACOKINETIC MODELING. D. B. 

Moffett 1,3 , C. Welsh 1,3 , D. Fowler 1 , R. Rogers 1 , M. 

Ray 2 , S. Ritger 2 , D. Keys 2 and J. Fisher 2 . 1 ATSDR, 

CDC/ATSDR, Atlanta, GA, 2 Environmental Health 

Science, University of Georgia, Athens, GA and 

3 

U.S. Public Health Service, DHHS, Atlanta, GA. 


DEVELOPMENT OF A PHYSIOLOGICALLY 

BASED PHARMACOKINETIC (PBPK) TOOL 

KIT TO ADDRESS PUBLIC EXPOSURES 

TO ENVIRONMENTAL POLLUTANTS. 

M. Mumtaz 1 , P. Ruiz 1 , M. Ray 2 , J. Fisher 2 and S. 

Hays 3 . 1 Computational Toxicology and Methods 

Development Lab, Division of Toxicology and 

Environmental Medicine, ATSDR, Atlanta, GA, 

2 

College of Public Health, University of Georgia, 

Athens, GA and 3 Summit Toxicology, Lyons, CO. 


A UNIFIED ALGORITHM FOR PREDICTING 

PARTITION COEFFICIENTS (PCS) FOR 

PBPK MODELING OF DRUGS AND 

ENVIRONMENTAL CHEMICALS. T. Peyret, 

P. Poulin and K. Krishnan. Département de santé 

environnementale et santé au travail, Université de 



RELATIONSHIP BETWEEN INPUT 

PARAMETERS OF PHYSIOLOGICALLY- 

BASED (PB) PHARMACOKINETIC (PK) 

MODELS AND MACRO-CONSTANTS OF 

COMPARTMENTAL PK MODELS: A CASE 

STUDY WITH STYRENE. M. Beliveau 1 , M. 

E. Andersen 2 and K. Krishnan 3 . 1 RAS, Pharsight 

Corporation, Montréal, QC, Canada, 2 The Hamner 


Park, NC and 3 Santé Environmentale et Santé au 

Travail, Université de Montréal, Montréal, QC, 

Canada. 


THE CHEMICAL LANDSCAPE OF 

EXISTING PBPK MODELS AND ITS 

OVERLAP WITH AVAILABLE OPEN- 

ACCESS CHEMICAL DATABASES. Y. Tan 1 , 

S. D. Peterson 2 , D. T. Chang 1 , M. Goldsmith 1 , R. 

Tornero-Velez 1 , X. Zhang 3 , J. B. Knaak 4 and C. 

Dary 2 . 1 National Exposure Research Laboratory, 

U.S. EPA, Research Triangle Park, NC, 2 National 

Exposure Research Laboratory, U.S. EPA, Las Vegas, 

NV, 3 General Dynamics Information Technology, 

Henderson, NV and 4 Department of Pharmacology 

and Toxicology, The State University of New York at 

Buffalo, Buffalo, NY. 


WHOLE-BODY VISUALIZATION OF 

PHYSIOLOGICALLY-RELEVANT DATA: 

OF MICE AND MEN. M. Goldsmith 1 , T. R. 

Transue 2 , D. T. Chang 1 , Y. Tan 1 , R. Tornero-Velez 1 , 

S. Peterson 3 , J. Johnson 3 and C. C. Dary 3 . 1 National 

Exposure Research Laboratory, U.S. EPA, Research 

Triangle Park, NC, 2 Lockheed-Martin Information 

Technology, Research Triangle Park, NC and 

3 

National Exposure Research Laboratory, U.S. EPA, 

Las Vegas, NV. 

Abstract # 


ASSESSING THE TRACER KINETICS OF 

MANGANESE IN MONKEYS AND HUMANS 

WITH PBPK MODELING. J. D. Schroeter 1 , A. 

Nong 1 , M. Yoon 1 , M. D. Taylor 2 , H. J. Clewell 1 and 

M. E. Andersen 1 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 Afton 

Chemical Corporation, Richmond, VA. 


TARGET-TISSUE DOSIMETRY MODELING 

TO SUPPORT THE RISK ASSESSMENT OF 

MANGANESE. M. D. Taylor 1 , M. Yoon 2 , J. D. 

Schroeter 2 , D. C. Dorman 3 , M. E. Andersen 2 and H. 

J. Clewell 2 . 1 Afton Chemical Corp, Richmond, VA, 

2 

The Hamner Institutes, Research Triangle Park, NC 

and 3 North Carolina State University, Raleigh, NC. 


APPLICATION OF A PHYSIOLOGICALLY- 

BASED PHARMACOKINETIC MODEL OF 

TRICHLOROETHYLENE IN RATS FOR 

ESTIMATION OF INTERNAL DOSE. C. R. 

Eklund, M. V. Evans and J. Simmons. Integrated 

Systems Toxicology Division, U.S. EPA, Research 



MODELING THE IMPACT OF WORKLOAD 

ON THE BIOLOGICAL EXPOSURE 

INDICATORS OF STYRENE: COMPARISON 

BETWEEN SINGLE EXPOSURE AND 

BINARY EXPOSURE WITH ACETONE. A. 

Bérubé 1 , G. Truchon 2 , G. Charest-Tardif 1 and R. 

Tardif 1 . 1 Santé environnementale et santé au travail, 

Université de Montréal, Montréal, QC, Canada 

and 2 Institut de recherche Robert-Sauvé en santé et 

sécurité du travail, Montréal, QC, Canada. 


MODELING THE TOXICOKINETICS OF 

24-HOUR TOLUENE EXPOSURE IN RATS: 

IMPACT OF ACTIVITY PATTERNS AND 

ENZYME INDUCTION. E. Kenyon, W. Oshiro, 

C. Eklund, C. Gordon, T. Krantz and P. Bushnell. 

ORD/NHEERL/ISTD/PB, U.S. EPA, Research 



APPLICATION OF TISSUE-TIME COURSE 

DATA TO ELUCIDATE MECHANISTIC 

DETAILS OF CARBON TETRACHLORIDE 

(CCL4) TRANSPORT USING AN 

UPDATED PHYSIOLOGICALLY BASED 

PHARMACOKINETIC (PBPK) MODEL 

IN RATS. M. V. Evans 1 , C. R. Eklund 1 , U. Y. 

Sanzgiri 2 , J. V. Bruckner 2 and J. E. Simmons 1 . 

1 

Pharmacokinetics, U.S. EPA, Research Triangle 

Park, NC and 2 Department of Pharmaceutical and 


GA. 


ALTERNATIVE APPROACH TO 

MAXIMUM FLUX FOR TTC APPLIED TO 

SAFETY EVALUATION OF COSMETIC 

INGREDIENTS. A. Garrigues-Mazert, S. Grégoire 

and J. Meunier. Safety Research Department, 

L’Oréal, Aulnay sous Bois, France. Sponsor: G. 

Nohynek. 

tueSday 







183


tueSday 




SKIN ABSORPTION STRATEGY: FROM 

IN SILICO TO EX VIVO. A. Garrigues, S. 

Grégoire, W. Wargniez, C. Patouillet, I. Durand, J. 

Becquet and J. Meunier. Safety Research, L’Oréal, 

Aulnay sous Bois, France. Sponsor: G. Nohynek. 


COMPARISON OF ESTIMATED PCB-153 

CONCENTRATIONS IN HUMAN MILK 

USING VARIOUS PHARMACOKINETIC 

MODELS. D. G. Farrer 1 , M. Poulsen 2 , D. Davoli 3 , 

M. Bailey 3 , D. Moffett 4 , D. Fowler 4 , C. Welsh 4 , R. 

Yang 5 , P. Ayotte 6 , M. Verner 7 , G. Muckle 6 and S. 

Haddad 7 . 1 Oregon DHS, Portland, OR, 2 Oregon 

DEQ, Portland, OR, 3 U.S. EPA, Seattle, WA, 

4 

ATSDR, Atlanta, GA, 5 Ray Yang Consulting LLC, 

Ft. Collins, Co., 6 Centre Hospitalier Universitaire de 

Québec, Montréal, QC, Canada and 7 Department of 

Biological Sciences, Université du Québec, Montréal, 

QC, Canada. 


UNVEILING ASSOCIATIONS BETWEEN 

LACTATIONAL EXPOSURE TO 

POLYCHLORINATED BIPHENYLS (PCBS ) 

AND INFANT NEURODEVELOPMENT: USE 

OF PBPK MODELING VS TRADITIONAL 

EXPOSURE METRICS. M. Verner 1 , P. 

Plusquellec 2 , G. Muckle 2 , P. Ayotte 2 , . Dewailly 2 , 

S. W. Jacobson 3 , J. L. Jacobson 3 , M. Charbonneau 4 

and S. Haddad 1 . 1 Université du Québec à Montréal, 

Montréal, QC, Canada, 2 Université Laval, Québec, 

QC, Canada, 3 Wayne State University School of 

Medicin, Detroit, MI and 4 INRS-Institut Armand- 

Frappier, Laval, QC, Canada. 


A BBDR-HPT AXIS MODEL FOR THE 

LACTATING RAT AND NURSING PUP: 

EVALUATION OF IODIDE DEFICIENCY. 

S. Li 1 , M. Gilbert 2 , T. Zoeller 3 , K. Crofton 4 , E. 

McLanahan 5 , D. Mattie 6 , B. Blount 7 , L. Valentin- 

Blasini 7 , K. Kurunthachalam 8 , T. Kunisue 8 and J. 

W. Fisher 1 . 1 College of Public Health, University of 

Georgia, Athens GA, GA, 2 Toxicology Assessment 

Division, U.S. EPA, Research Triangle Park, NC, 

3 

Biology Department, University of Massachusetts, 

Amherst, MA, 4 Integrated Systems Toxicology 

Division, U.S. EPA, Research Triangle Park, NC, 

5 

National Center for Environmental Assessment, 

U.S. EPA, Research Triangle Park, NC, 6 RHPB, 

USAF/AFRL 711 HPW, Wright-Patterson AFB, OH, 

7 

CCEHIP/NCEH, CDC, Atlanta, GA and 8 Wadsworth 

Center, NYS Department of Health, Albany, NY. 


USING IN VITRO PHARMACOKINETIC 

AND PHARMACODYNAMIC DATA TO 

REFINE THE PHARMACOKINETIC 

MODEL FOR CARBARYL IN THE RAT. M. 

Yoon 1 , G. Kedderis 2 , Y. Tan 1 and H. Clewell 1 . 1 The 

Hamner Institutes, Research Triangle Park, NC and 

2 

Consultant, Chapel Hill, NC. 


LINKING REAL-WORLD 

PHYSIOLOGY AND EXPOSURES TO 

PHARMACODYNAMIC ENDPOINTS: A 

CASE STUDY USING CHLORPYRIFOS. P. 

M. Hinderliter 1 , P. S. Price 2 , K. D. Schnelle 3 , M. 

J. Bartels 2 , C. Timchalk 1 and T. S. Poet 1 . 1 Battelle, 

Pacific Northwest Division, Richland, WA, 2 The 

Dow Chemical Company, Midland, MI and 3 Dow 

AgroSciences, LLC, Indianapolis, IN. 


DEVELOPMENT AND DEMONSTRATION 

OF A COMPUTATIONAL FRAMEWORK 

FOR FORWARD AND REVERSE 

DOSIMETRY OF ORGANOPHOSPHORUS 

INSECTICIDE MIXTURES. J. H. Ivy 1,2 , J. 

M. Wright 1 , A. N. Mayeno 1,3 , M. A. Lyons 1,2 and 

B. Reisfeld 1,2,3 . 1 Quantitative & Computational 

Toxicology Research Group, Colorado State 

University, Fort Collins, CO, 2 Department of 

Chemical and Biological Engineering, Colorado 

State University, Fort Collins, CO and 3 Department 

of Environmental and Radiological Health Sciences, 

Colorado State University, Fort Collins, CO. 


A SYSTEMS MODEL OF BILE SALT 

METABOLISM AND ITS APPLICATIONS TO 

CHOLESTASIS. M. K. Narasimha, R. Nalini and 

K. Subramanian. Strand Life Sciences, Bangalore, 

India. 


A PHYSIOLOGICALLY BASED 

PHARMACOKINETIC MODLE FOR 

PRALIDOXIME IN THE GUINEA PIG AND 

HUMAN. K. O. Yu, C. D. Ruark, E. C. Hack, T. R. 

Sterner, T. R. Covington and J. M. Gearhart. Applied 

Biotechnology, U.S. Air Force, Wright-Patterson 

AFB, OH. 


ADAPTIVE RESPONSES TO PROCHLORAZ 

EXPOSURE IN THE HYPOTHALAMIC- 

PITUITARY-GONADAL AXIS OF FATHEAD 

MINNOWS. M. Breen 2,1 , D. L. Villeneuve 3 , G. T. 

Ankley 3 , K. H. Watanabe 4 , M. S. Breen 5 , A. L. Lloyd 2 

and R. Conolly 1 . 1 NHEERL, U.S. EPA, Research 

Triangle Park, NC, 2 Biomathematics Program, 

Department of Statistics, North Carolina State 

University, Raleigh, NC, 3 Mid-Continent Ecology 

Division, U.S. EPA, Duluth, MN, 4 Division of 

Environmental and Biomolecular Systems, Oregon 

Health & Science University, Beaverton, OR and 

5 

National Exposure Research Laboratory, U.S. EPA, 



DEVELOPMENT OF A PHYSIOLOGICALLY 

BASED PHARMACOKINETIC MODEL 

FOR TRIADIMEFON AND TRIADIMENOL 

IN RATS AND HUMANS. S. R. Crowell 1 , W. 

M. Henderson 2 , J. F. Kenneke 2 and J. W. Fisher 1 . 

1 


Georgia, Athens, GA and 2 National Exposure 

Research Laboratory, U.S. EPA, Athens, GA. 

184 






Platform Sessions



Abstract # 


A DERMAL ABSORPTION MODEL 

BASED ON SUCCESSIVE PARTITIONING 

THROUGH A NON-HOMOGENOUS 

STRATUM CORNEUM LIPID MATRIX. D. 

Van Der Merwe 1 , P. Schumm 2 and C. M. Scoglio 2 . 

1 

Diagnostic Medicine/Pathobiology, Kansas State 

University, Manhattan, KS and 2 Department of 

Electrical and Computer Engineering, Kansas State 

University, Manhattan, KS. 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Animal Models—Emerging Methods 

Chairperson(s): Kimberly Jarema, U.S. EPA, Research Triangle Park, 

NC. 




THE UTILITY OF THE MINI-PIG IN P38 

MAP KINASE INHIBITOR TESTING. J. 

Schützsack 1 , A. Gibbs 2 , J. Parish 2 and K. Gill 2 . 1 LEO 

Pharmacology A/S, DK-2750 Ballerup, Denmark 

and 2 Covance Laboratories Ltd., Harrogate, United 

Kingdom. Sponsor: D. Everett. 


ZINC FINGER NUCLEASE-MEDIATED 

CREATION OF RODENT KNOCKOUT 

MODELS ON TOXICOLOGY. I. D. Carbery 1 , 

X. Cui 1 , A. Harrington 2 , L. Liaw 2 and E. Weinstein 1 . 

1 

Sigma Advanced Genetic Engineering Labs, Sigma- 

Aldrich, St. Louis, MO and 2 Transgenic Core, Maine 

Medical Center, Scarborough, ME. Sponsor: I. 

Grossi. 


GSH-DEPLETED ERYTHROCYTE RAT 

MODEL OF DRUG-INDUCED HEMOLYTIC 

ANEMIA. J. M. McMillan, R. Mosley and D. 

C. McMillan. Pharmacology and Experimental 

Neurosciences, University of Nebraska Medical 

Center, Omaha, NE. 


EVALUATION OF SCORE METHODS FOR 

THE PREDICTION OF DRUG-INDUCED 

LIVER INJURY IN HUMANS BY USING 

CHIMERIC PXB-MICE ® WITH HIGHLY 

HUMANIZED LIVER. S. Nagatsuka 1 , D. Hynes 1 , 

S. Ninomiya 1 , M. Kakuni 2 , C. Tateno-Mukaidani 2 , 

T. Shimada 2 and Y. Yamazoe 3 . 1 ADME & Toxicology 

Research Institute, Sekisui Medical Co., Ltd., 

Tokai-mura, Ibaraki, Japan, 2 PhoenixBio Co., Ltd., 

Higashi-Hiroshima, Hiroshima, Japan and 3 Graduate 

School of Pharmaceutical Sciences, Tohoku 

University, Sendai, Miyagi, Japan. 

Abstract # 


DIFFERENTIAL EXPRESSION OF 

PROTEINS IN THE LIVERS OF HEPATIC 

ALCOHOL DEHYDROGENASE-DEFICIENT 

DEER MICE AFTER SUBCHRONIC 

EXPOSURE TO ETHANOL. K. K. Bhopale 1 , 

K. V. Soman 2 , G. Ansari 1 and B. S. Kaphalia 1 . 

1 

Pathology, University of Texas Medical Branch, 

Galveston, TX and 2 Biochemistry & Molecular 

Biology, University of Texas Medical Branch, 



DETERMINATION OF 

TETRABROMOBISPHENOL A IN 

RAT SERUM AND URINE BY LIQUID 

CHROMATOGRAPHY-TANDEM MASS 

SPECTROMETRY. J. W. Yoo 1 , H. W. Ha 1 , 

G. S. Ko 1 , M. J. Kang 1 , W. Kang 2 and T. Jeong 1 . 

1 

Pharmacy, Yeungnam University, Gyeongsan, 

Gyeongbuk, Republic of Korea and 2 Pharmacy, 

Catholic University of Daegu, Gyeongsan, Republic 

of Korea. 


ENHANCED EXPRESSION AND ACTIVITIES 

OF MMP-9 AND NADPH OXIDASE IN 

CENTRAL NERVOUS SYSTEM AND 

SPLEEN TISSUES OF EAE MICE MODEL. 

L. Kandagaddala 1,2 , M. Kang 1,2 , B. Chung 1,2 and O. 

Kwon 1,2 . 1 Korea Institute of Science and Technology, 

Seoul, Republic of Korea and 2 University of Science 

and Technology, Daejon, Republic of Korea. 


ESTABLISHMENT OF 2-STAGE SKIN 

CARCINOGENESIS MODEL IN CB6F1 TG 

RASH2 MICE. H. Tsutsumi 1 , M. Kawabe 2 , M. 

Suguro 2 , M. Ogawa 2 , K. Urano 1 and F. Furukawa 2 . 

1 

Central Institute for Experimental Animals, 

Kawasaki, Japan and 2 DIMS Institute of Medical 

Science, Inc., Ichinomiya, Japan. 


CARCINOGENIC SUSCEPTIBILITY 

MONITORING OF CB6F1 TG RASH2 MICE 

IN THE EARLY STAGE OF A SHORT-TERM 

CARCINOGENICITY TEST. K. Urano, K. 

Machida, M. Yoshimura, M. Tomizawa, H. Tsutsumi 

and T. Nomura. Central Institute for Experimental 

Animals, Kawasaki, Japan. 


COMMERCIAL FISH DIETS INDUCE 

VITELLOGENIN PRODUCTION IN MALE 

TILAPIA (OREOCHROMIS MOSSAMBICUS), 

A CONSIDERATION FOR ENDOCRINE 

DISRUPTOR STUDIES. L. Davis 1,2 , T. Hirano 2 

and E. Grau 2 . 1 Endocrine Toxicity Branch, U.S. EPA, 

Research Triangle Park, NC and 2 Hawaii Institute of 

Marine Biology, University of Hawaii, Kaneohe, HI. 

Sponsor: J. Goldman. 


DEVELOPMENTAL TOXICITY STUDY OF 

CBLB502 IN WISTAR RATS. P. Chow 1 , F. Fort 1 

and A. S. Faqi 2 . 1 Toxicology, Cleveland BioLabs, 

Buffalo, NY and 2 Toxicology, MPI Research, 

Mattawan, MI. 

tueSday 







185


tueSday 




ANIMAL MODEL OF AUTISM USING 

GSTM1 KNOCKOUT MICE AND EARLY 

POSTNATAL VPA TREATMENT. C. L. 

Yochum 1 and G. C. Wagner 2 . 1 EOHSI, UMDNJ, 

Piscataway, NJ and 2 Psychology, Rutgers University, 

New Brunswick, NJ. Sponsor: J. Richardson. 


SCHEDULED SAMPLING OF 

CARDIOVASCULAR PARAMETERS; HOW 

OFTEN SHOULD ONE COLLECT DATA? 

S. Guild 2,1 , S. Malpas 1,2 , C. Barrett 2 , B. VanVliet 3 

and F. McBryde 2 . 1 Telemetry Research, Auckland, 

New Zealand, 2 Physiology, University of Auckland, 

Auckland, New Zealand and 3 Memorial University of 

Newfoundland, St. Johns, NF, Canada. 


AN OBSERVATIONAL ASSESSMENT OF 

AGING IN BROWN NORWAY RATS. R. C. 

MacPhail 1 , P. M. Phillips 1 , D. M. Kurtz 2 and K. A. 

Jarema 1 . 1 NHEERL, U.S. EPA, Research Triangle 

Park, NC and 2 Experimental Pathology Laboratories, 

Inc., Research Triangle Park, NC. 


THE EFFECT OF ENRICHMENT ON 

THE INCIDENCE OF DIARRHEA IN 

CYNOMOLGUS MACAQUES. G. J. Fleurie 1 

and C. Heining 2 . 1 Covance Research Products, Alice, 

TX and 2 Covance Research Products, Denver, PA. 

Sponsor: G. Weinbauer. 


USE OF MIXED-EFFECT MODELS TO 

EVALUATE MONKEY BODY WEIGHT 

VARIABILITY AND TRENDS IN BODY 

WEIGHT CHANGE DURING PRECLINICAL 

TOXICOLOGY STUDIES. D. Zhao 1 , R. 

L. Yeager 1 , Y. Lan 2 , C. Lin 2 and M. DuVall 1 . 

1 

Toxicology, GPRD, Abbott Laboratories, Abbott 

Park, IL and 2 Statistics, GPRD, Abbott Laboratories, 

Abbott Park, IL. 


LUTEINIZING HORMONE (LH), 

FOLLICULAR-STIMULATING 

HORMONE (FSH), ESTRADIOL (E2), 

AND PROGESTERONE (P) LEVELS IN 

CYNOMOLGUS MONKEYS AT MENSTRUAL 

ONSET AND MID-CYCLE. C. N. Diabo, M. 

A. Kob and A. S. Faqi. Toxicology, MPI Research, 

Mattawan, MI. 


POSITIVE REINFORCEMENT TRAINING 

IN GÖTTINGEN MINIPIGS. P. Glerup 1 , D. B. 

Sorensen 2 , S. Molgaard 1 and L. Andersen 1 . 1 LAB 

Research, Lille Skensved, Denmark and 2 Faculty 

of Life Sciences, University of Copenhagen, 

Copenhagen, Denmark. Sponsor: A. Makin. 


USE OF SPECTRAL-DOMAIN OPTICAL 

COHERENCE TOMOGRAHY (SD-OCT) 

FOR LONGITUDINAL EVALUATION 

OF SUBRETINAL INJECTIONS IN 

NON-HUMAN PRIMATES IN OCULAR 

TOXICOLOGY STUDIES. M. Vézina, S. 

Wise and M. Bussières. Toxicology, Charles River 

Laboratories, Preclinical Services (PCS-MTL), 

Senneville, QC, Canada. 


A STUDY OF PHOTOTOXICITY 

FOLLOWING INTRAVENOUS 

ADMINISTRATION TO BALB/C MICE. Y. 

Yamashita, S. Utsunomiya, Y. Takahashi, T. Ichii, Y. 

Otsubo, T. Nakamura, H. Izumi, T. Sukamoto and 

R. Nagata. Drug Safety Research Laboratories, Shin 

Nippon Biomedical Laboratories, Ltd., Kagoshima, 

Japan. 


DEVELOPMENT OF A WEANLING PIG 

MODEL OF CUTANEOUS INJURY INDUCED 

BY CHLORINE VAPOR. R. C. Kiser 1 , M. R. 

Perry 1 , F. M. Reid 1 , J. L. Plahovinsak 1 , T. H. Snider 1 , 

M. C. Babin 1 , J. A. Blank 1 and J. S. Graham 2 . 

1 

Battelle Biomedical Research Center, Columbus, 

OH and 2 U.S. Army Medical Research Institute of 

Chemical Defense, Aberdeen Proving Ground, MD. 


EFFICACY AND TREATMENT 

OPTIMIZATION OF ANTI-INFLAMMATORY 

DRUGS APPLIED TO CUTANEOUS SULFUR 

MUSTARD INJURIES IN A WEANLING PIG 

MODEL. J. L. Plahovinsak 1 , F. M. Reid 1 , R. C. 

Kiser 1 , M. C. Babin 1 , J. A. Blank 1 , N. M. Gargas 1 and 

J. S. Graham 2 . 1 Battelle Biomedical Research Center, 

Columbus, OH and 2 U.S. Army Medical Research 


Ground, MD. 


TRI-SPECIES COMPARISON OF 

RESPIRATORY MECHANICS: BEAGLE 

DOGS, GÖTTINGENS MINIPIGS, AND 

CYNOMOLGUS MONKEYS. R. Mikaelian 1 , L. 

Gold 3 , A. Robichaud 3 , E. Troncy 2 and S. Authier 1,2 . 

1 

LAB Research Inc., Laval, QC, Canada, 2 Faculty 

of Veterinary Medicine, University of Montréal, 

Montréal, QC, Canada and 3 SCIREQ Scientific 

Respiratory Equipment Inc., Montréal, QC, Canada. 

Sponsor: G. Washer. 


CORRELATION OF FUNCTIONAL AND 

MORPHOLOGIC CHANGES IN A MOUSE 

MODEL OF EMPHYSEMA. K. Lee, K. M. 

Gideon, S. J. Harbo, J. T. Pierce, J. C. Blessing, L. A. 

Wisse and B. D. MacIsaac. Toxicology NW, Battelle, 

Richland, WA. 


A 13-WEEK INHALATION TOXICITY 

STUDY IN JUVENILE RATS. P. McDonald 1 , X. 

Li 1 and M. Eddie 2 . 1 Inhalation Toxicology, Charles 

River, Edinburgh, Edinburgh, United Kingdom and 

2 

Department Nonclinical Drug Safety, Boehringer 

Ingelheim Pharmacology GmbH & Co. KG, 

Biberach, Germany. Sponsor: J. Finch. 


A 13-WEEK INHALATION TOXICITY 

STUDY IN JUVENILE DOGS. X. Li 1 , P. 

McDonald 1 , M. Eddie 2 and A. Mauz 2 . 1 Inhalation 

Toxicology, Charles River, Edinburgh, United 

Kingdom and 2 Department Nonclinical Drug Safety, 

Boehringer Ingelheim Pharmacology GmbH & Co. 

KG, Biberach, Germany. Sponsor: J. Finch. 

186 






Platform Sessions



Abstract # 


FOURTEEN DAY INHALATION STUDY OF 

LIPOPOLYSACCHARIDE AND CIGARETTE 

SMOKE IN DOGS. R. Q. Meng 1 , L. M. Staska 1 , 

H. S. Deford 1 , S. J. Harbo 1 , N. J. Machesky 2 , M. K. 

Lee 1 , R. E. Johnson 1 , K. M. Gideon 1 , J. D. Penner 1 

and J. C. Blessing 1 . 1 Battelle Toxicology Northwest, 

Richland, WA and 2 Battelle Biomedical Research 

Center, West Jefferson, OH. 


OVARIECTOMY-RELATED CHANGES IN 

SPRAGUE-DAWLEY RATS OVER A THREE- 

MONTH PERIOD. K. H. Horn 1 , F. Simutis 2 , 

S. Clark 2 , C. Euler 2 , T. Van Vleet 1 , G. Pilcher 1 , 

R. T. Bunch 1 , W. M. Peden 2 and T. Sanderson 1,2 . 

1 

Toxicology, Bristol-Myers Squibb Company, Mt. 

Vernon, IN and 2 Pathology, Bristol-Myers Squibb 

Company, Mt. Vernon, IN. 


CHLORINE VAPOR CUTANEOUS 

EXPOSURE SYSTEM FOR WEANLING 

PIGS. M. R. Perry 1 , T. H. Snider 1 , W. R. Richter 1 , 

R. C. Kiser 1 , F. M. Reid 1 and J. S. Graham 2 . 1 Battelle 

Biomedical Research Center, Columbus, OH and 

2 

U.S. Army Research Institute of Chemical Defense, 



ELECTRORETINOGRAPHY: COMPARISON 

OF A STANDARD PROTOCOL IN NEW 

ZEALAND WHITE RABBITS, BEAGLE 

DOGS, AND GÖTTINGEN MINIPIGS. C. 

Ponzi 1 , S. Authier 1,2 , F. Chaurand 1 and E. Troncy 2 . 

1 

LAB Research Inc., Laval, QC, Canada and 2 Faculté 

de Médecine Vétérinaire, Université de Montréal, 

St-Hyacinthe, QC, Canada. Sponsor: G. Washer. 


SPARC-NULL MICE DEMONSTRATE 

REDUCED LUNG COLLAGEN AFTER 

ASBESTOS EXPOSURE. E. Putnam, A. M. 

Smartt and M. Trapkus. Biomed & Pharm Sci/CEHS, 

The University of Montana, Missoula, MT. Sponsor: 

M. Pershouse. 


HEALTH EFFECTS FOLLOWING 

EXPERIMENTAL EXPOSURE TO IRAQ 

PARTICULATE MATTER AND CIGARETTE 

SMOKE. V. P. Mokashi 1 , D. J. Wagner 1 , A. O. 

Olabisi 1 , B. Wong 2 , O. Moss 3 , E. Fornero 4 , J. A. 

Centeno 4 , D. A. Jackson 5 , J. A. Lewis 5 and G. 

D. Chapman 6 . 1 Environmental Health Effects 

Laboratory, Naval Health Research Center, Wright- 

Patterson AFB, OH, 2 The Hamner Institutes, 

Research Triangle Park, NC, 3 POK Research, 

Apex, NC, 4 Department of Environmental and 

Infectious Disease Sciences, Armed Forces Institute 

of Pathology, Washington, DC, 5 United States 


Fort Detrick, MD and 6 MIDRP, U.S. Army Medical 

Research & Material Command, Fort Detrick, MD. 


MEASUREMENT OF 

LYMPHOCRYPTOVIRUS (LCV)-SPECIFIC 

IMMUNE RESPONSES IN CYNOMOLGUS 

MONKEYS. L. M. O’Donnell, P. A. Schneider, 

S. H. Cole, C. Kamperschroer and T. T. Kawabata. 

Immunotoxicology, Pfizer, Inc., Groton, CT. 

Abstract # 


8-OXOGUANINE DNA GLYCOSYLASE 

1(OGG1) IS REQUIRED IN THE 

DEVELOPING BRAIN. A. Gu and X. Wang. 

Institute of Toxicology, Nanjing Medical University, 

Nanjing, China. 


EVALUATION OF GENETIC DIVERSITY 

IN NON-HUMAN PRIMATES USED IN 

RESEARCH. D. P. Waller 1 , P. Baneux 1,3 , J. 

Dubach 2 , K. Draper 4,1 and T. J. Welsh 1,3 . 1 PreLabs 

LLC, Oak Park, IL, 2 Loyola University Medical 

Center, Maywood, IL, 3 Northwestern University, 

Chicago, IL and 4 Draper Consulting, Reno, NV. 


ICCVAM RECOMMENDATIONS FOR THE 

ROUTINE USE OF TOPICAL ANESTHETICS, 

SYSTEMIC ANALGESICS, AND HUMANE 

ENDPOINTS TO REFINE OCULAR 

TOXICITY TESTING. J. Merrill 1 , M. Wind 2 , D. 

Lowther 3 , W. Chambers 1 , T. McMahon 3 , J. Chen 3 , 

M. Hashim 3 , M. Lewis 3 and W. Stokes 4 . 1 U.S. FDA, 

Silver Spring, MD, 2 CPSC, Bethesda, MD, 3 U.S. 

EPA, Washington, DC and 4 NICEATM, NIEHS, 

Research Triangle Park, NC . 


APPLICATION OF MAGNETIC RESONANCE 

IMAGING (MRI) FOR NON-INVASIVE 

LOCAL ASSESSMENT OF ACUTE AND 

CHRONIC LUNG RESPONSE. R. E. Jacob, B. 

Amidan, J. Soelberg, K. R. Minard and C. Timchalk. 

Biological Monitoring & Modeling, Battelle, Pacific 

Northwest Division, Richland, WA. 


A WIRELESS MULTISENSOR TELEMETRY 

CAPSULE FOR MONITORING 

GASTROINTESTINAL FUNCTION IN THE 

DOG. S. Milano 1 , J. Briffaux 1 , B. Rohde 1 , S. 

Baudet 1 , E. Chalencon 1 , P. Lege 1 , C. Dupuis 2 and 

J. Semler 2 . 1 MDS Pharmacology Services, Saint- 

Germain sur l’Arbresle, France and 2 SmartPill 

Corporation, Buffalo, NY. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Education 

Chairperson(s): Steven Gilbert, INND, Seattle, WA. 




CREATING A VIRTUAL GLOBAL 

TOXICOLOGY VILLAGE—THE WORLD 

LIBRARY OF TOXICOLOGY (WLT). P. 

Wexler 2 , S. Gilbert 1 , E. M. Faustman 3 and N. Thorp 1 . 

1 

INND, Seattle, WA, 2 National Library of Medicine, 

Bethesda, MD and 3 University of Washington, 

Seattle, WA. 


THE ETHICAL TOXICOLOGIST— 

CONSIDERATIONS OF ETHICAL, LEGAL, 

SOCIAL, AND PROFESSIONAL ISSUES IN 

TOXICOLOGY. S. Gilbert. INND, Seattle, WA. 

tueSday 







187


tueSday 




USING RESEARCH TO DEVELOP A WEB- 

BASED PORTAL FOR TOXICOLOGICAL 

INFORMATION. M. Hartin and C. Scheel. 

Centers for Disease Control and Prevention, Atlanta, 

GA. Sponsor: B. Fowler. 


TOXICOLOGY AND UNDERGRADUATE 

EDUCATION: AN APPROACH THROUGH 

RESEARCH AND SERVICE-LEARNING. T. 

Dodd-Butera, S. Zarubick, C. Trepp and J. Wardell. 

College of Natural Sciences, California State 

University, San Bernardino, San Bernardino, CA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Arsenic I 

Chairperson(s): Lawrence Updyke, Pfizer Global Research and 

Development, Groton, CT. 




ALTERED COBALAMIN AND FOLATE 

CONTRIBUTE TO ABERRANT METHYL 

METABOLISM DURING CHRONIC 

ARSENIC EXPOSURE. J. Coppin and M. P. 

Waalkes. ICS, NCI at NIEHS, Research Triangle 

Park, NC. 


POLYNUCLEOTIDE PHOSPHORYLASE 

(PNPase) AND ATP SYNTHASE PROMOTE 

REDUCTION OF ARSENATE (AsV) BY 

GLUTATHIONE (GSH) VIA FORMING AMP- 

AsV AND ADP-AsV, RESPECTIVELY. Z. 

Gregus 1 , B. Nemeti 1 and P. Tortora 2 . 1 University Pecs, 

Pecs, Hungary and 2 University Milano-Bicocca, 

Milan, Italy. 


AS3MT INTRONIC VARIANTS ENCLOSED 

IN A LARGE LINKAGE DISEQUILIBIRUM 

CLUSTER ARE ASSOCIATED WITH 

ARSENIC METHYLATION EFFICIENCY. 

P. Gomez-Rubio 1 , M. M. Meza-Montenegro 2 , E. 

Cantu-Soto 2 and W. T. Klimecki 1 . 1 Pharmacology and 

Toxicology, University of Arizona, Tucson, AZ and 

2 

Environmental Sciences, Instituto Tecnologico de 

Sonora, Obregon, Sonora, Mexico. 


METHYLATION AND RETENTION OF 

ARSENIC IN CELLS EXPRESSING HUMAN 

AS3MT. T. Watanabe 1 , Y. Kobayashi 1,2 and S. 

Hirano 1,2 . 1 Graduate School of Pharmaceutical 

Sciences, Chiba University, Chiba, Japan and 

2 

National Institute for Environmental Studies, 

Tsukuba, Japan. 


INTESTINAL ABSORPTION OF ARSENATE 

IN RAT. V. Sorribas and R. Villa-Bellosta. 

Laboratory of Molecular Toxicology, University of 

Zaragoza, Zaragoza, Spain. Sponsor: A. Anadón. 


ARSENITE DOWN-REGULATES 

THE CARCINOGEN ACTIVATING 

ENZYME CYTOCHROME P450 1A1 

AT THE TRANSCRIPTIONAL AND 

POST-TRANSLATIONAL LEVELS. A. Anwar- 

Mohamed and A. O. El-Kadi. Faculty of Pharmacy 

and Pharmaceutical Sciences, University of Alberta, 

Edmonton, AB, Canada. 


N-6 ADENINE-SPECIFIC DNA 

METHYLTRANSFERASE 1 MAY PLAY A 

ROLE IN ARSENIC METABOLISM AND 

TOXICITY. X. Ren 1 , M. Aleshin 1 , R. Dills 2 , W. J. 

Jo 3 , M. T. Smith 1 , D. A. Kalman 2 , C. D. Vulpe 3 and L. 

Zhang 1 . 1 Division of Environmental Health Sciences, 

University of California Berkeley, Berkeley, CA, 

2 

Department of Environmental and Occupational 

Health Sciences, University of Washington, Seattle, 

WA and 3 Department of Nutritional Sciences and 

Toxicology, University of California Berkeley, 

Berkeley, CA. 


INVESTIGATING BETA-DEFENSIN-1 

DOWN-REGULATION IN ARSENIC 

TOXICITY. N. L. Dangleben, C. F. Skibola and 

M. T. Smith. School of Public Health, University of 

California Berkeley, Berkeley, CA. 


EXPOSURE OF A HUMAN BLADDER 

CELL LINE TO SHORT-TERM, LOW- 

LEVEL MONOMETHYLARSONOUS 

ACID PRODUCES CRITICAL AND 

IRREVERSIBLE EVENTS RESULTING IN 

MALIGNANT TRANSFORMATION. S. M. 

Wnek, T. J. Jensen, P. L. Severson, B. W. Futscher 

and A. Gandolfi. Pharmacology and Toxicology, 



SHORT-TERM, LOW-LEVEL EXPOSURE 

OF A HUMAN BLADDER CELL LINE 

TO MONOMETHYLARSONOUS ACID 

DAMAGES DNA AND ALTERS REPAIR 

ACTIVITY. A. Gandolfi, S. M. Wnek, T. J. Jensen 

and B. W. Futscher. Pharmacology and Toxicology, 



CYTOTOXICITY OF ARSENICALS IN 

PRIMARY HUMAN EPITHELIAL CELL 

CULTURES. M. K. Medeiros, J. M. Camarillo, S. 

M. Wnek, C. Escudero, X. Zheng and A. Gandolfi. 




LOW-DOSE ARSENIC DECREASES THE 

MIGRATION OF DENDRITIC CELLS. C. D. 

Kozul 1 , R. J. Horvath 1 , J. M. Bomberger 2 and J. W. 

Hamilton 3 . 1 Pharmacology/Toxicology, Dartmouth 

Medical School, Hanover, NH, 2 Physiology, 

Dartmouth Medical School, Hanover, NH and 3 Bay 

Paul Center for Comparative Molecular Biology & 

Evolution, Marine Biological Laboratory, Woods 

Hole, MA. 

188 






Platform Sessions



Abstract # 


LOW DOSE ARSENIC HAS PRO- 

ATHEROGENIC EFFECTS ON 

MACROPHAGES IN VITRO AND IN A 

MURINE MODEL. M. Lemaire, C. A. Lemarié, E. 

L. Schiffrin, S. Lehoux and K. K. Mann. Lady Davis 

Institute for Medical Research, McGill University, 



ROLE OF IL-8 IN 

MONOMETHYLARSENOUS ACID-INDUCED 

HUMAN BLADDER CELL MALIGNANT 

TRANSFORMATION. C. Escudero-Lourdes 2,1 , 

T. Wu 1 and J. A. Gandolfi 1 . 1 Pharmacology and 

Toxicology, University of Arizona, Tucson, AZ 

and 2 Facultad de Ciencias Quimicas, Universidad 

Atuonoma de San Luis Potosi, San Luis Potosi, 

Mexico. 


CHRONIC EXPOSURE TO 

ENVIRONMENTAL LEVELS OF ARSENIC 

INCREASE NFkB ACTIVATION AND ALTER 

ENDOTHELIAL FUNCTION. J. E. Thorpe 1 , B. 

Disch 1 , Z. Roberts 1 , Y. Shumate 1 , A. Weingartner 1 , 

T. Hampton 3 , C. Kozul 3 , J. W. Hamilton 2 and M. A. 

Ihnat 1 . 1 Cell Biology, University of Oklahoma Health 

Sciences Center, Oklahoma City, OK, 2 Josephine 

Bay Paul Center, Marine Biological Research 

Laboratories, Wood Hole, MA and 3 Pharmacology 

and Toxicology, Dartmouth Medical School, 

Hanover, NH. 


ROLE OF ENDOPLASMIC RETICULUM 

STRESS IN INFLAMMATORY RESPONSES 

TO ARSENIC IN ENDOTHELIAL CELLS 

AND MACROPHAGES. E. Vladykovskaya 1 , 

P. Haberzettl 1 , J. States 2 , J. A. Suttles 3 and S. 

Srivastava 1 . 1 Diabetes and Obesity Center, University 

of Louisville, Louisville, KY, 2 Department of 


Louisville, Louisville, KY and 3 Department of 

Microbiology and Immunology, University of 



THE ROLE OF CYTOKINE SIGNALING IN 

ARSENIC INDUCED INSULIN RESISTANCE. 

I. Druwe, J. J. Sollome and R. R. Vaillancourt. 

Department of Pharmacology & Toxicology, The 



DISTINCTIVE ROLES OF NUCLEAR 

FACTOR-E2-RELATED FACTORS IN 

ARSENIC-INDUCED ANTIOXIDANT 

RESPONSE AND CYTOTOXICITY IN 

HUMAN KERATINOCYTES. R. Zhao, C. 

Woods, J. Fu, P. Xue, Y. Hou, M. Andersen and J. Pi. 

The Hamner Institutes for Health Sciences, Research 



EXPOSURE TO ARSENIC COMBINED 

WITH HIGH FAT DIET PROMOTES THE 

IMPAIRMENT OF GLUCOSE TOLERANCE 

IN C57BL/6 MICE. M. Styblo, D. S. Paul and F. 

S. Walton. Nutrition, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 

Abstract # 


EFFECT OF ARSENIC ON MOUSE 

EMBRYONIC STEM CELL GENE 

EXPRESSION FOR DIFFERENTIATION. A. 

R. Calabro and F. A. Barile. Toxicology, St. Johns 

University, Jamaica, NY, NY. 


CARCINOGENICITY OF WHOLE LIFE 

EXPOSURE TO INORGANIC ARSENIC IN 

MICE. M. P. Waalkes 1 , E. J. Tokar 1 , D. A. Delker 2 

and B. A. Diwan 3 . 1 ICS, NCI at NIEHS, Research 

Triangle Park, NC, 2 University of Utah, Salt Lake 

City, UT and 3 BRP, SAIC-Frederick, Frederick, MD. 


EVALUATION OF OXIDATIVE STRESS 

BY INORGANIC ARSENIC AND ORAL 

CONTRACEPTIVE PILL AMONG THE 

FEMALES IN ARSENIC-CONTAMINATED 

AREA OF BANGLADESH. N. Sultana 1 , C. 

Watanabe 1 , H. Furusawa 1 , M. Umezaki 1 and T. 

Inaoka 2 . 1 Department of Human Ecology, The 

University of Tokyo, Tokyo, Japan and 2 Department 

of Environmental Sciences, Saga University, Saga, 

Japan. 


ARSENIC TRANSFORMATION/ 

ADAPTATION PREDISPOSES HUMAN 

SKIN KERATINOCYTES TO OXIDATIVE 

DNA DAMAGE YET ENHANCES THEIR 

SURVIVAL. Y. Sun 1 , C. Kojima 1 , C. Chignell 2 , 

R. Mason 2 and M. P. Waalkes 1 . 1 NCI at NIEHS, 

Research Triangle Park, NC and 2 LP, NIEHS, 



NEW ORLEANS SOIL ARSENIC SURVEYS: 

CHILDREN’S PLAY AREAS POSSESS 

LOCALIZED HAZARDS. H. Mielke 1,2 , C. 

Gonzales 3 , E. Cahn 4 , J. Brumfield 3 , E. Powell 5 

and P. W. Mielke 6 . 1 Chemistry, Tulane University, 

New Orleans, LA, 2 Center for Bioenvironmental 

Research, Tulane University, New Orleans, LA, 

3 

Chemistry, Xavier University, New Orleans, LA, 

4 

Pitzer College, Claremont, CA, 5 Lead Lab, Inc., 

New Orleans, LA and 6 Colorado State University, 

Fort Collins, CO. 


A NOVEL NITRIC OXIDE DONOR, V-PROLI/ 

NO, PROTECTS AGAINST ARSENIC- 

INDUCED TOXICITY IN LIVER CELLS. 

W. Qu 1 , L. Cheng 1 , A. L. Dill 1 , J. E. Saavedra 2 , 

L. K. Keefer 2 and M. P. Waalkes 1 . 1 Inorganic 

Carcinogenesis Section, NCI at NIEHS, Research 

Triangle Park, NC and 2 Chemistry Section, LCC, 

NCI- Frederick, Frederick, MD. 


FERRIHYDRITE AS AN ENTEROSORBENT 

FOR ARSENIC. J. F. Taylor, A. Robinson, A. 

Marroquin-Cardona, N. Johnson, N. Mitchell, 

B. Brattin, R. Taylor and T. Phillips. Veterinary 

Integrative Biosciences, Texas A&M, College 

Station, TX. 

tueSday 







189


tueSday 




EPIGENETIC ALTERATIONS IN FETAL 

MOUSE LIVERS AFTER IN UTERO 

EXPOSURE TO ARSENIC. Z. Drobna 1 , M. 

Niculescu 1,3 , R. Fry 2 , I. Pogribny 4 , M. Waalkes 5 , 

S. Zeisel 1,3 and M. Styblo 1 . 1 Nutrition, University 

of North Carolina at Chapel Hill, Chapel Hill, 

NC, 2 Environmental Engineering and Sciences, 

University of North Carolina at Chapel Hill, Chapel 

Hill, NC, 3 Nutrition Research Institute, Kannapolis, 

NC, 4 National Center for Toxicological Research, 

Jefferson, AR and 5 NCI at NIEHS, Research Triangle 

Park, NC . 


INFLUENCE OF PHOSPHATE ON THE 

BIOAVAILABILITY OF ARSENIC FROM 

SOIL IN CYNOMOLGUS MONKEYS. S. M. 

Roberts 1 , J. W. Munson 1 and Y. W. Lowney 2 . 1 Center 

for Environmental & Human Toxicology, University 

of Florida, Gainesville, FL and 2 Exponent, Boulder, 

CO. 


METHYL-SELENIC ACID MODIFIES GENE 

EXPRESSION AND RESPONSE TO ARSENIC 

EXPOSURE IN HUMAN BLADDER CANCER 

CELLS. A. S. Andrew 1 , R. A. Mason 1 , Z. Wei 2 , 

D. A. Jewell 1 and C. Gabel-Jenson 3 . 1 Dartmouth 

Medical School, Lebanon, NH, 2 Department 

of Biostatistics and Epidemiology, University 

of Pennsylvania, Philadelphia, PA and 3 Danish 

University of Pharmaceutical Sciences, Copenhagen, 

Denmark. 


HEAVY METAL (HM) CONCENTRATIONS 

OF DIFFERENT COMMERCIALLY 

AVAILABLE GRAIN-BASED DIETS (CHOWS) 

ARE VARIABLE AND INCREASE RENAL, 

SPLENIC, AND HEPATIC ARSENIC (AS) 

AND COBALT (CO) LEVELS RELATIVE TO 

PURIFIED DIETS IN WEANLING, FEMALE 

SPRAGUE-DAWLEY RATS. M. R. Ricci 1 , M. A. 

Pellizzon 1 , J. F. Couse 2 and E. A. Ulman 1 . 1 Research 

Diets, Inc., New Brunswick, NJ and 2 Taconic, Inc., 

Albany, NY. Sponsor: P. Marone. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Metal Neurotoxicity: General 

Chairperson(s): Chris Toscano, U.S. FDA, Silver Spring, MD. 




INITIAL RESPONSE AND 

CELLULAR PROTECTION AGAINST 

METHYLMERCURY THROUGH NRF2/ 

KEAP1 SYSTEM. T. Toyama 1 , A. Yasutake 2 and 

Y. Kumagai 1 . 1 Comprehensive Human Sciences, 

University of Tsukuba, Tsukuba, Ibaraki, Japan 

and 2 Biochemistry Section, National Institute for 

Minamata Disease, Minamata, Kumamoto, Japan. 

Sponsor: A. Naganuma. 


THE POSSIBLE PROTECTIVE ROLE 

OF CALBINDIN-D28K, A CALCIUM 

BINDING PROTEIN, IN RESISTANCE TO 

METHYLMERCURY TOXICITY IN RAT 

PC12 CELLS. S. Fox 1,2 , R. K. Hajela 1 and W. D. 

Atchison 1,2 . 1 Pharmacology and Toxicology, Michigan 

State University, East Lansing, MI and 2 Center for 

Integrative Toxicology, Michigan State University, 



CHRONIC METHYLMERCURY EXPOSURE 

POTENTIATES [ZN 2+ ] I 

IN MOTOR NEURONS 

OF HSOD1 MICE. A. Chitrakar 3,1 , F. O. 

Johnson 2,1 and W. D. Atchison 1,2 . 1 Pharmacology and 


MI, 2 Center for Integrative Toxicology, Michigan 

State University, East Lansing, MI and 3 Saint Peter’s 

College, Jersey City, NJ. 


TOXIC EFFECTS OF MANGANESE ON 

MITOCHONDRIAL CATALASE AND 

CYTOCHROME C OXIDASE IN GILL OF 

CRASSOSTREA VIRGINICA. K. Brown, K. 

Kelly, R. Saint-Dic, E. J. Catapane and M. A. 

Carroll. Biology, Medgar Evers College, Brooklyn, 

NY. 


CORRELATION OF MEMBRANE 

POTENTIAL AND CILIARY ACTIVITY 

OF LATERAL CILIATED CELLS OF GILL 

OF CRASSOSTRA VIRGINICA, AND THE 

NEUROTOXIC EFFECTS OF MANGANESE. 

M. Nelson, T. Adams, M. A. Carroll and E. J. 

Catapane. Biology, Medgar Evers College, Brooklyn, 

NY. 


EFFECTS OF MANGANESE ON 

MITOCHONDRIAL RESPIRATION 

AND MITOCHONDRIAL MEMBRANE 

POTENTIAL IN GILL OF CRASSOSTREA 

VIRGINICA. S. Crawford, C. Saddler, E. J. 

Catapane and M. A. Carroll. Biology, Medgar Evers 

College, Brooklyn, NY. 


EFFECT OF MANGANESE ON DOPAMINE 

D2 RECEPTORS IN GILL OF CRASSOSTREA 

VIRGINICA AND THE PROTECTION BY 

P-AMINOSALICYLIC ACID. S. Anador, C. 

Brown, R. Licorish, N. Cilli, R. Fleming, M. Nelson, 

M. A. Carroll and E. J. Catapane. Biology, Medgar 

Evers College, Brooklyn, NY. 


IS CHELATION THE MECHANISM 

OF ACTION OF P-AMINOSALICYLIC 

ACID (PAS) IN THE TREATMENT OF 

MANGANISM. A. Augustin, A. Nuhar, J. Rios, 

K. Ruddock and D. Skeete. Biology, Medgar Evers 

College, Brooklyn, NY. Sponsor: E. Catapane. 


REGULATION OF COPPER (CU) 

HOMEOSTASIS AT THE BRAIN BARRIERS: 

EFFECTS OF FE-OVERLOAD AND 

FE-DEFICIENCY. A. D. Monnot, S. Ho and W. 

Zheng. Purdue University, West Lafayette, IN. 

190 






Platform Sessions



Abstract # 


INCREASED P-GLYCOPROTEIN 

EXPRESSION AT THE BLOOD- 

CEREBROSPINAL FLUID BARRIER 

FOLLOWING ACUTE LEAD EXPOSURE. X. 

Fu, Y. Zhang, W. Jiang, M. Behl, A. Monnot and W. 

Zheng. School of Health Sciences, Purdue University, 

West Lafayette, IN. 


GENDER INFLUENCE ON ABILITY 

OF ORAL MANGANESE TO DAMAGE 

BRAIN. H. L. Komiskey 1 , M. Choi 2 and C. Mehta 2 . 

1 

Philadelphia College of Osteopathic Medicine 

Georgia Campus, Suwanee, GA and 2 College of 

Pharmacy and Health, Texas Southern University, 

Houston, TX. 


PROTEIN KINASE CDELTA (PKCd) 

REGULATES PROINFLAMMATORY 

EVENTS IN MANGANESE-INDUCED 

NEUROTOXICITY. C. Hogan, R. Gordon, A. 

Kanthasamy, V. Anantharam and A. G. Kanthasamy. 

Department of Biomedical Sciences, Iowa Center for 

Advanced Neurotoxicology, Iowa State University, 

Ames, IA. 


MECHANISM OF INHIBITION OF 

SEPIAPTERIN REDUCTASE BY MERCURY. 

S. Yang 1 , V. Mishin 2 , D. E. Heck 3 , D. L. Laskin 2 and J. 

D. Laskin 1 . 1 UMDNJ-Robert Wood Johnson Medical 

School, Piscataway, NJ, 2 Rutgers University, 

Piscataway, NJ and 3 New York Medical College, 

Valhalla, NY. 


NEUROTOXIC ACTIONS OF 6-OHDA, 

5, 7-DHT AND MANGANESE ON 

SEROTONERGIC AND DOPAMINERGIC 

INNERVATION OF LATERAL CILIATED 

CELLS OF GILL OF CRASSOSTREA 

VIRGINICA. S. Murray, A. Hernandez, M. A. 

Carroll and E. J. Catapane. Biology, Medgar Evers 

College, Brooklyn, NY. 


PRETREATMENT WITH ASCORBIC ACID 

AMELIORATES COGNITIVE CHANGES 

IN RATS REPEATEDLY EXPOSED TO 

LEAD. O. O. Oladipo 1,2 , J. O. Ayo 2 , S. A. Ojo 3 , 

S. F. Ambali 2 and D. O. Akanbi 2 . 1 Biochemistry & 

Applied Molecular Biology, National Veterinary 

Research Institute, Vom, Jos, Nigeria, 2 Department 

of Veterinary Physiology and Pharmacology, Ahmadu 

Bello University, Zaria, Nigeria and 3 Department 

of Veterinary Anatomy, Ahmadu Bello University, 

Zaria, Nigeria. Sponsor: J. Manautou. 


MANGANESE NEUROTOXICITY IS 

ASSOCIATED WITH PROTEASOME 

DYSFUNCTION IN a-SYNUCLEIN OVER 

EXPRESSED DOPAMINERGIC NEURONS. 

K. Prabhakaran 1 , G. D. Chapman 2 and P. G. 

Gunasekar 1 . 1 Naval Health Research Center 

Detachment / Environmental Health Effects 

Laboratory, Dayton, OH and 2 U.S. Army Medical 

Research & Material Command, MIDRP, Fort 

Detrick, MD. 

Abstract # 


THE EFFECT OF TUNGSTEN ALLOY 

SURROGATES ON PC12 CELL 

CYTOTOXICITY AND NEURITOGENESIS. 

V. H. Adams 1 , D. I. Bannon 1 , G. D. Chapman 2 , 

M. G. Stockelman 3 and V. P. Mokashi 3 . 1 U.S. 


Medicine, Aberdeen Proving Ground, MD, 2 U.S. 

Army Medical Research and Material Command, 

Fort Detrick, MD and 3 Naval Health Research 

Center Detachment, Environmental Health Effects 

Laboratory, Wright-Patterson AFB - Dayton, OH. 


DIFFERENTIAL EFFECTS OF MANGANESE 

ON LPS INDUCTION OF HO-1 IN 

MICROGLIA AND NEURONAL CELL 

LINES. C. A. Dodd, I. I. Georgieva and N. M. 

Filipov. Physiology and Pharmacology, University of 

Georgia, Athens, GA. 



THROUGHPUT ASSAY TO ASSESS 

MANGANESE TRANSPORT KINETICS IN A 

STRIATAL CELL MODEL OF HUNTINGTON 

DISEASE. G. F. Kwakye, D. Li, B. B. Williams and 

A. B. Bowman. Department of Neurology, Vanderbilt 

Kennedy Center, Vanderbilt Brain Institute, and 

Center for Molecular Toxicology, Vanderbilt 

University Medical Center, Nashville, TN. 


SKN-1/NRF2 INHIBITS CELLULAR STRESS 

IN A NOVEL C. ELEGANS MODEL OF 

METHYLMERCURY TOXICITY. N. VanDuyn 1 , 

R. Settivari 1 and R. Nass 1,2,3 . 1 Department of 

Pharmacology & Toxicology, Indiana University 

School of Medicine, Indianapolis, IN, 2 STARK 

Neuroscience Research Institute, Indiana University 

School of Medicine, Indianapolis, IN and 3 Center for 

Environmental Health, Indiana University School of 

Medicine, Indianapolis, IN. 



STUDY (DNT) OF DIETARY BISPHENOL 

A (BPA) IN SPRAGUE-DAWLEY RATS. 

D. G. Stump 1 , M. J. Beck 1 , A. Radovsky 1 , R. H. 

Garman 2 , L. P. Sheets 3 , M. S. Marty 4 , S. S. Dimond 5 , 

J. P. Van Miller 6 , R. N. Shiotsuka 7 , D. Beyer 8 , J. 

M. Waechter 4 and S. G. Hentges 9 . 1 WIL Research 

Laboratories, LLC, Ashland, OH, 2 Consultants 

in Veterinary Pathology, Inc., Murrysville, PA, 

3 

Bayer CropScience, Research Triangle Park, 

NC, 4 The Dow Chemical Co., Midland, MI, 

5 

SABIC Innovative Plastics, Pittsfield, MA, 6 TRS, 

Charlottesville, VA, 7 Bayer Material Science, 

Pittsburgh, PA, 8 Bayer Healthcare AG, Wuppertal, 

Germany and 9 Polycarbonate BPA Global Group, 

Arlington, VA. 


COPPER SELECTIVELY DAMAGES 

NEURONS AND INDUCES PARALYSIS AT 

CONCENTRATIONS FAR BELOW LETHAL 

CONCENTRATIONS IN THE NEMATODE 

CAENORHABDITIS ELEGANS. K. A. Hedges 

and B. A. O’Gara. Biological Sciences, Humboldt 

State University, Arcata, CA. Sponsor: M. Ronis. 

tueSday 







191


tueSday 




IN VIVO CORRELATES OF THE 

MANGANESE ACCUMULATION DEFICIT IN 

A HUNTINGTON DISEASE MOUSE MODEL. 

M. Wegrzynowicz and A. B. Bowman. Department 

of Neurology, Center for Molecular Toxicology, 

Vanderbilt Kennedy Center. Vanderbilt University 

Medical Center, Nashville, TN. 


SUPPRESSION OF MANGANESE-INDUCED 

OXIDATIVE DAMAGE AND NEURONAL 

INJURY. D. Milatovic 1 , Y. Yu 1 , S. Zaja-Milatovic 1 , 

R. C. Gupta 2 and M. Aschner 1 . 1 Pediatrics, Vanderbilt 

University, Nashville, TN and 2 Breathitt Veterinary 

Center, Murray State University, Hopkinsville, KY. 


FERROPORTIN IS A MANGANESE- 

RESPONSIVE PROTEIN THAT DECREASES 

MANGANESE CYTOTOXICITY AND 

ACCUMULATION. Z. Yin 1 , H. Jiang 1 , E. Y. Lee 2 , 

M. Ni 1 , D. Milatovic 1 , A. Bowman 1 and M. Aschner 1 . 

1 

Vanderbilt Medical Center, Nashville, TN and 

2 

Meharry Medical College, Nashville, TN. 


GABA INCREASES IN BASAL GANGLIA 

IN MANGANESE EXPOSED SMELTERS. U. 

Dydak 1,2 , Y. Jiang 3 , Z. Long 1 , L. Long 3 , J. Chen 4 , 

J. Harezlak 2 , H. Zhu 5 , A. Michael 6 , J. Murdoch 7 

and Z. Wei 1 . 1 School of Health Sciences, Purdue 

University, West Lafayette, IN, 2 Indiana University 

School of Medicine, Indianapolis, IN, 3 Guangxi 

Medical University, Nanning, China, 4 Guizhou 

Institute of Occupational Safety and Health, Zunyi, 

China, 5 Johns Hopkins University, Baltimore, MD, 

6 

Vanderbilt University, Nashville, TN and 7 Toshiba 

Medical Research Institute, Cleveland, OH. 


ENDOPLASMIC RETICULUM STRESS 

INDUCED BY SINGLE METHYLMERCURY 

EXPOSURE IN RAT BRAINS: TIME COURSE 

AND REGION SPECIFICITY. R. Lu 1 , Y. Zhang 1 

and M. Aschner 2 . 1 Preventive Medicine, Jiangsu 

University, Zhenjiang, Jiangsu, China and 2 Pediatrics/ 

Toxicology, Vanderbilt University, Nashville, TN. 


ESTROGEN AND TAMOXIFEN ATTENUATE 

MANGANESE-INDUCED GLUTAMATE 

TRANSPORTER GLT-1 IMPAIRMENT IN 

RAT PRIMARY ASTROCYTES. E. Y. Lee 1,2 , 

M. Sidoryk 2 , Z. Yin 2 , H. Jiang 2 and M. Aschner 2 . 

1 

Neurology, Meharry Medical College, Nashville, TN 

and 2 Pediatrics, Vanderbilt University, Nashville, TN. 


9:45 AM to 10:45 AM 

Room 155 C 

Exhibitor Hosted Session: Preclinical Anticancer Drug 

Development: Shifting Challenges 

Presented by: Accelera Srl 

Development of oncology treatments involves a unique set of challenges. 

Learn from the people behind the preclinical development of marketed 

treatments (Adriamycin, Ellence, Sutent) how to advance your anticancer 

program smoothly, from screening/lead selection to the development of 

tailor-made IND packages, and how ICHS9 may impact the future landscape. 


9:45 AM to 10:45 AM 

Room 155 F 

Exhibitor Hosted Session: Functional Biomarkers of 

Renal Injury—Optimizing Interpretive Value in Renal 

Pharmacology Studies 


Recognition of adverse renal pharmacodynamic effects requires sophisticated 

experimental designs and appropriate quantitative evaluations. 

Biochemistry and histopathology evaluations routinely used have limitations 

in adequately characterizing drug effects. This session proposes appropriate 

designs for renal safety pharmacology studies incorporating the use of functional 

biomarkers for identification and characterization of drug effects. 


9:45 AM to 10:45 AM 

Room 155 B 

Exhibitor Hosted Session: Introduction to the Development 

and Validation Study of the New Technology “Cell able” for 

New Drug Discovery 

Presented by: Transparent Inc. 

Introduction to the development of and validation study of the new technology 

“Cell able” for new drug discovery. It is possible to culture human 

hepatocytes and maintain their functions for a long period using “Cell able.” 

It could be used for prediction of the toxicity of a large number of drug 

candidates at one time. 


11:00 AM to 12:00 NOON 

Room 155 F 

Exhibitor Hosted Session: A System’s Toxicology Approach 

for Drug Discovery and Development 

Presented by: Ingenuity Systems 

Learn how IPA-Tox can help you with your research and provide the 

following: An understanding of drug toxicity and mechanism of action; 

Identify specific molecular toxicity components; Industry relevant case 

study will demonstrate the functionality of the toxicity module. 


11:00 AM to 12:00 NOON 

Room 155 B 

Exhibitor Hosted Session: Predictive Multiparametric In Vitro 

Assay Combinations for Cytotoxicity, Viability, Apoptosis and 

ADME Applications with Hepatocytes and Human Stem-Cell 

Derived Cardiomyocytes 

Presented by: Promega Corporation 

Combining bioluminescent and fluorescent cell-based assays allows multiparametric 

measurements from single samples, simplifying mechanistic 

studies. Multiplex approaches, using human-cell model systems, streamlines 

data collection, improves data quality, strengthens interpretation, and 

removes ambiguity. This seminar reviews multiplex applications of viability, 

cytotoxicity, apoptosis, cytochrome P450 induction/inhibition, and genetic 

reporter assays. 

192 






Platform Sessions



Abstract # 


11:00 AM to 12:00 NOON 

Room 155 C 

Exhibitor Hosted Session: SkinEthic Laboratories— 

Providing You Available, Predictive, User-Friendly, and 

Sustainable In Vitro Solutions 

Presented by: SkinEthic Laboratories 

SkinEthic models are predictive in vitro tools for efficacy and safety 

screening tests. The usefulness of Episkin and RHE will be discussed 

within the frame of the GHS classification as well the on-going validation 

of the HCE—human corneal model. The reproducibility of our production 

processes for these validated or under-validation models will be presented. 

This updated information will create a forum of information for all scientists 

and toxicologists on reliable and relevant tools for decision making during 

preclinical safety phases. 

Tuesday Afternoon, March 9 

12:00 NOON to 1:15 PM 

Room 255 B 


TUESDAY AfTERnOOn 

NIH Brown Bag Lunch 



Sponsor: 


Join staff from the NIH Center for Scientific Review (CSR) and the 

NIEHS program officers for lunch and informal discussions about review 

and grant opportunities at NIEHS. There will be a brief grantsmanship 

presentation, time for questions, and discussion. You can make arrangements 

to meet these representatives later in the NIH Resource Room. Bag 

lunches will be available for the first 75 participants. 


12:00 NOON to 1:15 PM 

Room 255 E 



Chairperson(s): Betina Lew, University of Rochester, Rochester, NY. 

Sponsor: 


Amidst scrambling to attend all of the events at the meeting, this will 

be time for postdocs to kick back and relax! All postdoctoral fellows 

are invited to a casual luncheon organized by the Postdoctoral 

Assembly (PDA). We will announce the recipients of the Best Postdoctoral 

Publication Awards and acknowledge the postdocs who received 

awards this year from Regional Chapters, Special Interest Groups, and 

Specialty Sections. The PDA Board members will present an overview 

of accomplishments and future directions for the PDA and will 

introduce the new board members for 2010–2011. There will be 

a drawing for door prizes. Postdocs can reserve a ticket when registering 

for the Annual Meeting. Lunch is served at the beginning of 

the event and service concludes before the talk/main program begins. 

Meal service may not be available to ticket holders who arrive after 

12:30 PM. 

Abstract # 


12:00 NOON to 1:30 PM 


Special Interest Group Luncheon: ASIO Lunch and Learn 



12:00 NOON to 1:30 PM 

Room 255 C 

Specialty Section Meeting/Luncheon: In Vitro and 

Alternative Methods 


12:00 NOON to 1:20 PM 

Room 150 


Roundtable Session: The Ying and Yang of 

Immunomodulatory Biopharmaceuticals: What Have We 

Learned since MABEL and How Close Are We to the Clinical 

Dose? 

Chairperson(s): Joy A. Cavagnaro, Access BIO LC, Boyce, VA, and Tony 

R. Arulanandam, Toxikon Corporation, Bedford, MA. 

Sponsor: 


Endorsed by: 



Given the fine balance between achieving the desired pharmacology versus 

unintended pharmacology, immunomodulatory biopharmaceuticals present 

significant challenges for identification of risks from preclinical models 

to estimation of First in Human (FIH) doses. As an extension to last year’s 

biotherapeutics roundtable discussion on the concepts of when a Minimal 

Anticipated Biological Effect Level (MABEL), a Pharmacologically Active 

Dose (PAD), or No Observable Adverse Effect Level (NOAEL) approach 

should be considered for setting FIH doses, this session will discuss application 

and clinical validation of the various approaches. Selection of the 

most appropriate approach is dependent on a clear understanding of the 

target biology and pharmacology of the biopharmaceutical in question 

in pharmacologically relevant animal species and/or animal models of 

disease and appropriate human in vitro systems that can better predict the 

outcome in humans. In cases where immune activation is desired, exaggerated 

immune responses could lead to adverse immune related events (e.g. 

cytokine release, systemic inflammatory response, and organ failure) that 

in some cases may have serious consequences. Similarly in cases where 

immune modulation is desired to combat autoimmune inflammatory disease 

the exaggerated pharmacology can result in immunosuppression resulting in 

serious infections that in some cases have also been fatal. Immune antagonist 

targets may also be considered high risk in causing unintended immune 

activation and may warrant MABEL or alternate preclinical strategies for 

estimating FIH dosing. A retrospective analysis of estimated FIH doses for 

both immune agonist and antagonist classes of immunomodulator biopharmaceuticals 

in clinical development will be presented and compared to the 

eventual dose used in the clinical trial to demonstrate safety and efficacy. 

Case examples of when MABEL vs. NOAEL vs. PAD approach was relevant 

to FIH dosing will be discussed. 

tueSday 







193


tueSday 



#1003 12:00 THE YING AND YANG OF 

IMMUNOMODULATORY 

BIOPHARMACEUTICALS: WHAT HAVE 

WE LEARNED SINCE MABEL AND HOW 

CLOSE ARE WE TO THE CLINICAL DOSE? 

T. Arulanandam 1 and J. Cavagnaro 2 . 1 Toxicology, 

Regeneron Pharmaceuticals, Tarrytown, NY and 

2 

Preclinical Development, Access BIO LC, Boyce, 

VA. 

12:00 INTRODUCTION. Joy Cavagnaro and Tony 

Arulanandam 

12:05 ANTAGONIZING THE SUPPRESSOR, 

THE ANTI-CTLA4 MAB EXPERIENCE IN 

CANCER. Jesus Gómez -Navarro 

12:13 IL-21 CASE STUDY FOR CANCER: 

RETROSPECTIVE ANALYSIS OF THE 

MABEL APPROACH. Dennis Miller 

12:21 ANTI-IL12 MAB A POTENT INHIBITOR 

OF IL-12 AND IL-23 RESPONSES FOR 

AUTOIMMUNE DISEASE INDICATIONS. 

William Bracken 

12:29 FIH DOSE ESTIMATION STRATEGIES 

FOR HIGH RISK IMMUNE ANTAGONIST 

TARGETS: ANTI-OX40L MAB AND ANTI- 

BETA7 INTEGRIN MAB EXPERIENCES 

IN CLINICAL DOSE EVALUATION. Tom 

Gelzleichter 

12:37 MABEL VS NOAEL: WHAT THE FOOD 

AND DRUG ADMINISTRATION HAS 

LEARNED ABOUT FROM THEIR REVIEW 

OF IMMUNOMODULATORY BIOLOGIC 

DRUGS. Carmen Booker 



12:00 NOON to 1:20 PM 

Ballroom D 

Roundtable Session: Women’s Health: Toxicology and Safety 

of Complementary and Alternative Medicine 

Chairperson(s): Brinda Mahadevan, Schering-Plough Research Institute, 

Summit, NJ, and Diana J. Auyeung-Kim, Charles River Laboratories, 

Reno, NV. 

Sponsor: 


Endorsed by: 




The World Health Organization estimates that 65–80% of the world’s 

population use traditional medicine as their primary form of health care. As 

the incidence in disease states affecting women increases, a corresponding 

increase in the use of complementary and alternative medicines (CAM) 

has been observed. In the Asian cultures, CAM has had a long history of 

development and application in the treatment of many diseases affecting 

multiple organ systems. Approximately 38% of adults in the U.S. currently 

use some form of CAM therapy (20% of women in the U.S. use some form 

of CAM therapy for control of menopausal symptoms or other related health 

concerns alone), some of which are used in conjunction with conventional 

medicine. In 21 st century medicine, the value of CAM has been considered 

and questioned due in part to the use of advanced technologies in bringing 

novel insights into the unique features of CAM. However, there are safety 

concerns in the use of CAM that may interfere with conventional medicine 

or pose unique safety risks for susceptibility to other disease states. 

Presenters in this session will discuss the use of CAM to improve women’s 

health. Specific topics that will be addressed are the impact of CAM on 

breast and endometrial cancers and menopause in addition to the advantages 

and disadvantages of CAM in each health related paradigm. The overall goal 

of this session is to highlight the current status of toxicology issues in the 

use of CAM in women’s health. In addressing these issues, we are hopeful 

that attendees will develop a better appreciation of the use of CAM and the 

challenges that arise with their use with respect to safety. 

#1004 12:00 WOMEN’S HEALTH: TOXICOLOGY AND 

SAFETY OF COMPLEMENTARY AND 

ALTERNATIVE MEDICINE. B. Mahadevan 1 , 

D. Auyeung-Kim 2 , J. Liu 3 , M. Cline 4 and B. 

Helferich 5 . 1 Mechanistic and Predictive Toxicology, 

Schering-Plough Research Institute, Summit, NJ, 

2 

Developmental and Reproductive Toxicology, 

Charles River, Reno, NV, 3 National Cancer 

Institute, National Institute of Environmental Health 

Sciences, Research Triangle Park, NC, 4 Pathology/ 

Comparative Medicine, Wake Forest University 

School of Medicine, Winston-Salem, NC and 5 Food 

Science and Human Nutrition, University of Illinois 

at Urbana-Champaign, Urbana, IL. 

12:05 INTRODUCTION. Diana J. Auyeung-Kim 

12:10 CURRENT STATUS AND TOXICOLOGY 

ISSUES IN CAM USED FOR WOMEN’S 

HEALTH. Jie Liu 

12:25 BREAST AND ENDOMETRIAL SAFETY OF 

CAM INTERVENTIONS. J. Mark Cline 

12:40 DIETARY PHYTOESTROGENS AND 

BREAST CANCER: A COMPLEX SAFETY 

ISSUE INVOLVING DOSE AND TIMING OF 

EXPOSURE. Bill Helferich 



12:00 NOON to 1:20 PM 

Ballroom F 

Education-Career Development Session: Science 

Communication in 2010: A New Decade in Toxicology and 

Need for Better Communication 

Chairperson(s): Banalata Sen, NIEHS, Durham, NC, and Sneha Bhatia, 

Research Institute of Fragrance Materials, Inc., Woodcliff, NJ. 

Endorsed by: 




Scientists do science, writers write. Wrong! Scientists do science and write 

about it as well. It is imperative that scientists publish their work. Furthermore, 

publishing is just one aspect of science. Scientists also have to be able 

to communicate complex scientific concepts to the non-scientific audience. 

This large group of constituents include the general public, media, policymakers, 

communities, and individuals. This is an obligation scientists have 

towards the community-at-large and one that can be accomplished with relative 

ease once the basic nuances of effective communication are understood. 

Effective communication is therefore, not just an icing on the cake; rather it 

is fundamental to interpretation and dissemination of science. Yet science 

communication is not an integral part of science education. Most scientists 

do not have any formal training in science writing. They learn to write by 

following the style and approach of their mentors or other authors. Some 

form of training in science writing becomes even more crucial for authors 

for whom English is a second language. Laying this basic foundation is 

important since the public learns about science from many different sources, 

194 






Platform Sessions



Abstract # 

including newspapers, magazines, books, radio, television, the Internet, 

electronic news services, and films. Because information is readily available 

at our finger tips it can easily be distorted with the unfortunate circumstance 

that bad science sometimes triumphs over good science. Therefore it is 

important for U.S. to effectively communicate science messages to distinguish 

the myths from the facts. This session will aim to highlight strategies, 

techniques, and resources that make the field of good science communication 

invaluable. 

#1005 12:00 Science Communication in 2010—A New 

Decade in Toxicology and Need for Better 

Communication, B. Sen 1 and S. Bhatia 2 . 

1 

Environmental Health Perspective, National Institute 

of Environmental Health Sciences, Research Triangle 

Park, NC and 2 Research Institute for Fragrance 

Materials, Woodcliff, NJ. 

12:04 Science Writing, Jane Schroeder 

12:23 Blogs, Podcasts, and More, Sneha Bhatia 

12:42 Communicating Hazard, Linda Birnbaum 

1:01 Communication As a Career, Banalata Sen 


12:15 PM to 1:15 PM 

Room 155 C 

Exhibitor Hosted Session: Higher Throughput In Vitro 

Screening Assays for Drug-Drug Interactions and Organ- 

Specific Toxicity Using Human Hepatocytes and IdMOC 

Presented by: ADMET Group 

Screening of new chemical entities for adverse drug properties would aid 

the selection of drug candidates without such liabilities. Higher throughput 

human hepatocyte P450 inhibition, P450 induction, and cytotoxicity assays 

and the Integrated Discrete Multiple Organ Co-culture (IdMOC) assay for 

the evaluation of multiple organ toxicity, will be described. 


12:15 PM to 1:15 PM 

Room 155 F 

Exhibitor Hosted Session: Systems Toxicology Data Analysis 

with GeneGo 

Presented by: GeneGo, Inc. 

GeneGo provides a rich database and powerful suite of tools for analyzing 

high content molecular toxicology data. Current capabilities of the system 

and upcoming enhancements for safety assessment will be presented. A 

guest speaker from industry will present a case study investigating sex and 

strain differences in toxic response. 


12:15 PM to 1:15 PM 

Room 155 B 

Exhibitor Hosted Session: How to Screen for Arrhythmias 

in Safety Pharmacology When More Than 86,400 Beats Are 

Recorded in One Dog over 24 Hours 

Presented by: LAB Research Inc. 

Telemetry is essential for continuous monitoring of ECG in safety pharmacology. 

On the flip side, the amount of data generated presents a challenge 

during analysis and interpretation, particularly for identification of cardiac 

arrhythmias. ECG analysis strategies and arrhythmia detection beyond QT 

interval measurements will be presented and discussed. 

Abstract # 


12:30 PM to 1:20 PM 

Room 251 A 


Lecture: Toxic Injury: Initiation, Expansion, 

and Repair 

Lecturer: Harihara M. Mehendale,University of 

Louisiana at Monroe, Monroe, LA 

To date, toxicology research has dealt with understanding 

how chemicals initiate tissue injury. Very little effort has focused on the 

mechanisms of progression, or regression of initiated injury. When it 

progresses, how it expands even after the chemical that initiated injury 

is all gone from the body is not unknown. In the mid 90’s, my associates 

and I began to investigate the ultimate outcomes of initiated injury. 

Necrotic cell lyses lead to spillage of cellular enzymes including the 

highly hydrolytic proteases and phospholipases (death proteins), known 

to be activated by extracellular high Ca 2+ compromising the plasma 

membranes leading to death of surrounding cells. Normally, the injured 

tissue stimulates the wherewithal to replace the dead cells with new cells, 

which over-express endogenous inhibitors of these death proteins (EIDPs, 

e.g., calpastatin, annexins) rendering them resistant to destruction by 

this self-perpetuating expansion of injury. This process leads to restoration 

of tissue structure, function, and animal recovery. At high doses, 

blocked cell division means absent EIDPs and unabated progression of 

injury. Injury progression overwhelms the tissue’s resistive mechanisms, 

yielding to continued tissue destruction, injury expansion, and loss of 

tissue function, making survival unsustainable. These discoveries have 

helped us to identify and characterize the mechanisms governing the 

ultimate outcomes of the initiated injury in blood, liver, lung and kidney. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment I: New Data and Derivations 

across Chemicals from A to V 

Chairperson(s): Ari Lewis, Gradient Corporation, Cambridge, MA, and 

Palur G. Gunasekar, NHRC Detachment Environmental Health Effects 

Laboratory, Wright-Patterson Air Force Base, Dayton, OH. 




DEVELOPMENT OF RFDS FOR 

ACETANILIDE DEGRADATES. M. Dourson 1 , 

B. Gadagbui 1 , A. Parker 1 , J. Christopher 2 , A. 

Maier 1 and A. Willis 1 . 1 Toxicology Excellence For 

Risk Assessment, Cincinnati, OH and 2 California 

Environmental Protection Agency, Sacramento, CA. 


RISK ASSESSMENT OF EXTRACTABLES 

FROM PLATINUM-CURED SILICONE 

TUBING MATERIALS USED IN THE 

MANUFACTURING OF BIOLOGICS. K. L. 

Li 1 , J. Wisler 1 , Y. Nashed-Samuel 2 and A. Mire- 

Sluis 3 . 1 Comparative Biology and Safety Sciences, 

Amgen Inc., Thousand Oaks, CA, 2 Product Contact 

Assessment, Amgen Inc., Thousand Oaks, CA and 

3 

Corporate Product Quality, Amgen Inc., Thousand 

Oaks, CA. 

tueSday 







195


tueSday 




SELECTION OF PERFORMANCE 

REFERENCE COMPOUNDS VIA SOLVATION 

ENERGY DESCRIPTORS FOR SORBENT 

BASED PASSIVE SAMPLING DEVICES 

FOR POLAR ORGANIC POLLUTANTS 

IN WATER. X. Q. Kong 1 , D. Shea 1 and X. Xia 2 . 

1 

Department of Biology, North Carolina State 

University, Raleigh, NC and 2 Chemical Toxicology 

Research & Pharmacokinetics, North Carolina State 



CHEMICAL RISK ASSESSMENT OF 

PICRAMIC ACID—A SURROGATE 

APPROACH. N. C. Wang and S. C. Wesselkamper. 

U.S. EPA, ORD, National Center for Environmental 

Assessment, Cincinnati, OH. 


HUMAN EXPOSURE ESTIMATES AND 

ORAL EQUIVALENTS OF IN VITRO 

BIOACTIVITY FOR PRIORITIZING, 

MONITORING AND TESTING OF 

ENVIRONMENTAL CHEMICALS. D. 

Rotroff 1,2 , R. Thomas 3 , F. Boellmann 3 , H. Clewell 3 , 

K. Houck 1 , R. Judson 1 , R. Kavlock 1 , M. Martin 1 , 

D. Reif 1 , J. Wambaugh 1 , B. Wetmore 3 and D. Dix 1 . 

1 

Office of Research and Development, U.S. EPA, 

Research Triangle Park, NC, 2 Department of 

Environmental Science and Engineering, University 

of North Carolina, Chapel Hill, NC and 3 The Hamner 


Park, NC . 


GENOTOXICITY TESTS CONDUCTED ON 

A GROUP OF STRUCTURALLY RELATED 

ALDEHYDES. S. Bhatia, V. T. Politano and A. Api. 

RIFM, Woodcliff Lake, NJ. 


CALCULATIONS FOR HYPER-ACUTE, 

HIGH-CONCENTRATION INHALATION 

EXPOSURES. S. N. Chesler 1,2 , J. Moser 1,2 and 

H. Salem 3 . 1 Chemical Security Analysis Center, 

Department of Homeland Security, Aberdeen 

Proving Ground, MD, 2 Battelle Memorial Institute, 

Columbus, OH and 3 Edgewood Chemical Biological 

Center, Aberdeen Proving Ground, MD. 


PROPOSED ACUTE, 8-HOUR AND CHRONIC 

INHALATION REFERENCE EXPOSURE 

LEVELS FOR CAPROLACTAM. D. Dodge, 

B. Winder, R. Blaisdell and A. Salmon. Office of 

Environmental Health Hazard Assessment, California 

EPA, Sacramento, CA. 


PROVISIONAL ADVISORY LEVELS (PALS) 

FOR TEAR GAS (CS). C. Troxel 1 , P. McGinnis 2 , 

L. Koller 3 and F. Adeshina 4 . 1 CMTox., Inc., Lander, 

WY, 2 Syracuse Research Corporation, Syracuse, NY, 

3 

Environmental Health & Toxicology, Corvallis, OR 

and 4 U.S. EPA, Washington, DC. 


ACUTE STUDIES OF INHALED CHLORINE 

IN F344 RATS SUGGEST ALTERNATIVE 

TO HABER’S RULE FOR RISK 

EXTRAPOLATIONS. T. S. Peay 1 , J. McKee 1 , 

G. A. Willson 2 , M. H. George 1 , R. H. Jaskot 1 , D. 

G. Ross 1 , T. M. Moore 1 and A. M. Jarabek 1 . 1 U.S. 

EPA, Research Triangle Park, NC and 2 EPL, Inc., 



SUBACUTE MECHANISTIC STUDIES OF 

INHALED CHLORINE IN F344 RATS. M. H. 

George 1 , J. McKee 1 , G. A. Willson 2 , T. S. Peay 1 , R. 

H. Jaskot 1 , D. G. Ross 1 , M. R. Knight 1 and A. M. 

Jarabek 1 . 1 U.S. EPA, Research Triangle Park, NC 

and 2 EPL Inc., Research Triangle Park, NC . 


STOP-EXPOSURE STUDIES OF INHALED 

CHLORINE PROVIDE IMPORTANT 

INSIGHTS ON PATHOGENESIS. A. M. 

Jarabek 1 , J. McKee 1 , G. A. Willson 2 , M. H. George 1 , 

R. H. Jaskot 1 , D. G. Ross 1 , T. M. Moore 1 and T. S. 

Peay 1 . 1 U.S. EPA, Research Triangle Park, NC and 

2 

EPL, Inc., Research Triangle Park, NC . 


POTENTIAL HEALTH RISKS ASSOCIATED 

WITH SOUR GAS EXPLORATION AND 

DEVELOPMENT IN WESTERN CANADA: 

A CASE STUDY. D. Davies and K. Phillipps. 

Intrinsik Environmental Sciences Inc., Calgary, AB, 

Canada. Sponsor: E. Sigal. 


HUMAN METABOLISM IN VITRO OF DI 

(2-ETHYLHEXYL) PHTHALATE AND ITS 

ANTI-ANDROGENIC EFFECTS ON LEYDIG 

CELLS. K. Choi, R. Clewell, J. Campbell and H. 

Clewell. The Hamner Institutes for Health Sciences, 



IS THERE A ROLE FOR SENSITIZATION 

IN SETTING REFERENCE EXPOSURE 

LEVELS? B. Winder 1 , A. Salmon 2 and M. Marty 2 . 

1 

OEHHA, CalEPA, Sacramento, CA and 2 OEHHA, 

CalEPA, Oakland, CA. 


EXPOSURE AND HEALTH RISK 

ASSESSMENT FOR CHILDREN AND 

ADULTS POTENTIALLY EXPOSED TO 

BROMINATED FLAME RETARDANTS ON 

TELEVISIONS AND IN HOUSE DUST. E. 

Shay 1 , A. Burns 1 and L. Sweet 2 . 1 ChemRisk, LLC, 

Pittsburgh, PA and 2 University of Michigan SPH, 

Ann Arbor, MI. 


A VAPOR CALIBRATION SYSTEM 

FOR EXAMINING THE EFFECTS OF 

TEMPERATURE AND HUMIDITY ON 

DIACETYL MEASUREMENTS. M. C. Jackson, 

W. T. Goldsmith, W. G. McKinney, A. Afshari and D. 

G. Frazer. HELD, CDC/NIOSH, Morgantown, WV. 

Sponsor: A. Hubbs. 

196 






Platform Sessions



Abstract # 


METHYL FORMATE AS A SUBSTITUTE 

BLOWING AGENT FOR PLASTICS. J. F. 

Collins, A. G. Salmon and M. A. Marty. OEHHA, 

CalEPA, Oakland, CA. 


PROVISIONAL ADVISORY LEVEL (PAL) 

DEVELOPMENT FOR MALATHION. C. 

S. Wood 1 , D. Gardner 2 , E. McConnell 3 and F. 

Adeshina 4 . 1 Oak Ridge National Lab, Oak Ridge, 

TN, 2 Inhalation Toxicology Associates, Savannah, 

GA, 3 ToxPath, Inc., Raleigh, NC and 4 U.S. EPA, 



EFFECTS OF DECOSAHEXAENOIC 

ACID ON DEVELOPMENTAL 

METHYLMERCURY TOXICITY IN MICE: 

NEUROBEHAVIOURAL IMPACTS. S. 

Jayashankar 1 , C. Glover 2 , K. Folven 1 , T. Bratellid 1 , 

C. Hogstrand 3 and A. Lundebye 1 . 1 National Institute 

of Nutrition and Seafood Research, Bergen, 

Norway, 2 University of Canterbury, Christchurch, 

New Zealand and 3 King’s College, London, United 

Kingdom. Sponsor: T. Syversen. 


IN UTERO AND LACTATIONAL EXPOSURE 

TO 2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN (TCDD) INDUCES DISRUPTION OF 

THE PROSTATE GLANDS AND FIBROSIS 

IN RHESUS MONKEYS. H. Kato, R. Ise, T. 

Hara, H. Wakamatsu, K. Matsushita, A. Matsushita, 

Y. Ooshima, R. Nagata and A. Arima. Drug Safety 

Research Laboratories, Shin Nippon Biomedical 

Laboratories Ltd., (SNBL), Kagoshima, Japan. 


EVALUATION OF ORGAN WEIGHT DATA 

FOR RODENT TOXICITY STUDIES. S. Jana, 

M. A. Mulla, S. K. Pandey, A. Govindarajan, V. 

Goyal, S. Ingle and R. Nirogi. Toxicology, Suven 

Life Sciences Limited, Hyderabad, Andhra Pradesh, 

India. Sponsor: V. Reddy. 


PROVISIONAL ADVISORY LEVEL (PAL) 

DEVELOPMENT FOR FENAMIPHOS. P. B. 

Selby 1 , C. Weese 2 , P. McGinnis 3 and F. Adeshina 4 . 

1 

Oak Ridge National Laboratory, Oak Ridge, 

TN, 2 U.S. Army Center for Health Promotion and 

Preventive Medicine, Aberdeen Proving Ground, 

MD, 3 Syracuse Research Corporation, North 

Syracuse, NY and 4 U.S. EPA, Washington, DC. 


ATSDR’S ACUTE- AND INTERMEDIATE- 

DURATION ORAL MINIMAL RISK LEVELS 

(MRLS) FOR ACRYLAMIDE. O. Faroon 1 , 

P. Ruiz 1 , D. Wholers 2 and M. Mumtaz 1 . 1 ATSDR, 

Atlanta, GA and 2 SRC Inc., North Syracuse, NY. 


ASSESSING HUMAN HEALTH RISK 

FROM EXPOSURE TO N, N-DIPHENYL-1, 

4-BENZENEDIAMINE. H. Choudhury 1 , J. Reid 2 

and N. Wang 3 . 1 ORD/NCEA, U.S. EPA, Cincinnati, 

OH, 2 ORD/NCEA, U.S. EPA, Cincinnati, OH and 

3 

ORD/NCEA, U.S. EPA, Cincinnati, OH. 

Abstract # 


CYTOTOXICITY OF MIDDLE EASTERN 

DUST IN RAT LUNG EPITHELIAL CELLS. 

M. M. Struve 1 , M. Henderson 1 , V. Mokashi 2 , M. 

Stockelman 2 , D. Wagner 2 , G. D. Chapman 3 , D. 

Jackson 4 and D. C. Dorman 1 . 1 College of Veterinary 

Medicine, North Carolina State University, Raleigh, 

NC, 2 Naval Health Research Center Detachment / 

Environmental Health Effects Laboratory, Dayton, 

OH, 3 U.S. Army Medical Research & Material 

Command, MIDRP, Fort Detrick, MD and 4 U.S. 


Fort Detrick, MD. 


TOXICITY AND HEALTH HAZARD 

ASSESSMENT FOR SYNTHETIC 

PARAFFINIC KEROSENE. D. R. Mattie 1 , J. 

P. Hinz 2 , D. J. Wagner 3 , G. Reddy 4 , D. R. Steup 5 , B. 

A. Wong 6 and E. Zeiger 7 . 1 AFRL/711 HPW/RHPB, 

Wright-Patterson AFB, OH, 2 USAFSAM/OEHTH, 

BCB, TX, 3 NHRC/EHEL, Wright-Patterson AFB, 

OH, 4 USACHPPM, Aberdeen Proving Ground, MD, 

5 

Shell International, Shell Health, Houston, TX, 6 The 


Triangle Park, NC and 7 Errol Zeiger Consulting, 



CARCINOGENIC POTENCY OF 2, 3’, 4, 4’, 

5-PENTACHLOROBIPHENYL (PCB118) IN 

FEMALE HARLAN SPRAGUE-DAWLEY 

RATS. N. J. Walker 1 , M. Easterling 2 , A. Nyska 1 , G. 

E. Kissling 1 , C. S. Smith 1 , D. E. Malarkey 1 and M. 

J. Hooth 1 . 1 National Toxicology Program, NIEHS, 

Research Triangle Park, NC and 2 SRA International 



PROVISIONAL ADVISORY LEVELS (PALS) 

DEVELOPMENT FOR OXAMYL. J. L. 

Rayner 1 , P. McGinnis 2 , G. Henningsen 3 and F. 

Adeshina 4 . 1 Oak Ridge National Laboratory, Oak 

Ridge, TN, 2 Syracuse Research Corp., North 

Syracuse, NY, 3 Front Range Environmental 

Toxicological Services, LLC, Monument, CO and 

4 

U.S. EPA, Washington, DC. 


MORTALITY AND IN-LIFE PATTERNS 

IN SPRAGUE-DAWLEY (IGS) RAT 

TUMORIGENICITY STUDIES, COMPLETED 

OVER THE PERIOD OF 1998 TO 2009. W. 

N. Hooks. Safety Assessment, Huntingdon Life 

Sciences, Huntingdon, Cambridgeshire, United 

Kingdom. Sponsor: C. Hardy. 


AUTOMATED BEHAVIORAL 

OBSERVATIONS OF SOCIALLY HOUSED 

CYNOMOLGUS MONKEYS TREATED 

WITH AMPHETAMINE AND DIAZEPAM. 

S. H. Korte, C. M. Luetjens, C. Rose and G. F. 

Weinbauer. Research & Safety Assessment, Covance 

Laboratories GmbH, Muenster, Germany. 


COMPARATIVE SAFETY OF RECENTLY 

REGISTERED NEW ACTIVE INGREDIENTS 

IN CALIFORNIA. C. N. Aldous and P. Leung. 

Department of Pesticide Regulation, California 

Environmental Protection Agency, Sacramento, CA. 

tueSday 







197


tueSday 




PAHS AND DIOXINS NOT PRESENT IN FLY 

ASH AT LEVELS OF CONCERN. L. J. Bradley, 

E. Perry, K. Vosnakis and C. Archer. AECOM, 

Westford, MA. 


BLUE SOIL AT FORMER MGP SITES - IS IT 

A HEALTH HAZARD? M. Seeley, B. D. Beck and 

P. J. Drivas. Gradient Corporation, Cambridge, MA. 


RISK ASSESSMENT OF VALERIAN ROOT 

EXTRACT AS A FOOD INGREDIENT. R. A. 

Matulka. Burdock Group, Orlando, FL. 


DERIVATION OF CHEMICAL-SPECIFIC 

AND GENERIC BLOOD-BASED 

BIOMARKER SCREENING CRITERIA 

FOR VOLATILE ORGANIC COMPOUNDS 

(VOCS)—APPLICATION OF STEADY-STATE 

PBPK MODEL SOLUTIONS. L. L. Aylward 1 , 

C. Kirman 2 , B. Blount 3 and S. Hays 4 . 1 Summit 

Toxicology, LLP, Falls Church, VA, 2 Summit 

Toxicology, LLP, Orange, OH, 3 Centers for Disease 

Control and Prevention, Atlanta, GA and 4 Summit 

Toxicology, LLP, Lyons, CO. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Pharmaceutical Toxicology II 

Chairperson(s): Vikrant Vijay, North Carolina State University, Raleigh, 

NC. 




A 26-WEEK REPEAT-DOSE TOXICITY 

STUDY IN CYNOMOL-GUS MONKEYS 

WITH XOMA 052, A NOVEL MONOCLONAL 

ANTIBODY TARGETING IL-1 BETA. K. E. 

Meyer 1 , K. Der 1 , J. Ma 1 , L. Cao 1 , Y. Espinoza 1 , C. 

Gasper 1 and C. Bechtel 2 . 1 Preclinical Research, 

XOMA (U.S. ) LLC, Berkeley, CA and 2 Charles 

River Laboratories, Reno, NV. 


NONCLINICAL TOXICOLOGY 

EVALUATION OF A MONOCLONAL 

ANTIBODY AGAINST THE VEGF 

CO-RECEPTOR NEUROPILIN-1. C. de Zafra 1 , 

K. Allamneni 1 , D. Kennedy 1 , G. Cain 1 , H. Xiang 1 , D. 

Auyeung-Kim 2 , S. Gariepy 3 , R. Watts 1 and R. Prell 1 . 

1 

Genentech, South San Francisco, CA, 2 Charles 

River Laboratories, Sparks, NV and 3 Charles River 

Laboratories, Montréal, QC, Canada. 


SUBCHRONIC TOXICITY EVALUATION OF 

A NOVEL VITAMIN D ANALOG IN BEAGLE 

DOGS. W. D. Johnson 1 , D. L. McCormick 1 , M. 

Muzzio 1 , A. L. Usburne 2 and I. M. Kapetanovic 3 . 

1 

IIT Research Institute, Chicago, IL, 2 Pathology 

Associates, Chicago, IL and 3 National Cancer 

Institute, Bethesda, MD. 


IMPORTANCE OF IMMUNOGENICITY 

DETERMINATIONS IN PRECLINICAL TK 

STUDIES. A. Jackson, I. Seibold, K. Leuenberger, 

J. Orth, D. Schröder and P. Sagelsdorff. Harlan 

Laboratories Ltd., Itingen, Switzerland. 


OPTIMIZATION OF AN INTEGRATIVE IN 

VIVO PK-PD PHARMACOLOGY MODEL. 

D. J. Lengel, H. W. Kamendi, Y. Chen, C. Fonck, 

D. Brott, D. Litwin and R. A. Bialecki. Safety 

Assessment, AstraZeneca Pharmaceuticals, 



CHARACTERIZATION OF ACUTE 

EFFECTS OF A SCP-123 IN THE RAT 

CCI NEUROPATHIC PAIN MODEL: 

PHARMACOLOGIC, TOXICOLOGIC, AND 

PHARMACOKINETIC ASSESSMENT. D. J. 

Millington, J. Kaufman, J. Obirek, C. Villanueva, M. 

E. Downey, C. Smith and K. W. Narducy. St Charles 

Pharmaceuticals, Inc., Alachua, FL. 


DEVELOPMENT OF A MODIFIED 

LYMPHOCYTE TRANSFORMATION TEST 

(LTT) FOR THE DIAGNOSIS OF ALLERGIES 

TO DRUGS. Q. Zong. DSRD, Pfizer, San Diego, 

CA. 


SAFETY EVALUATION OF MM-111, 

A NOVEL BISPECIFIC MOLECULE 

TARGETING ERBB2 AND ERBB3. K. J. 

Olivier 1 , K. Stec 2 , L. Grotti 2 , M. Elliott 2 , M. Jokinen 2 

and W. Slichenmyer 1 . 1 Toxicology, Merrimack 

Pharmaceuticals, Cambridge, MA and 2 Charles River 

Laboratories, Shrewsbury, MA. 


BENCHMARKING THE BILE SALT EXPORT 

PUMP (BSEP), VESICLE TRANSPORT 

ASSAY. R. E. Morgan 1 , C. J. van Staden 2 , P. Lee 2 , 

B. Ramachandran 2 , C. W. Qualls 1 , R. Lightfoot- 

Dunn 1 and H. K. Hamadeh 1 . 1 CBSS, Investigative 

Toxicology, Amgen, Newbury Park, CA and 

2 

Chemistry, Lead Discovery, Amgen, Newbury Park, 

CA. 


A COMPREHENSIVE SUMMARY OF THE 

EFFECTS OF OSELTAMIVIR IN JUVENILE 

RATS. C. Freichel 1 , H. Gerhard 1 , A. Breidenbach 1 , 

T. Pfister 1 , S. Platz 1 and E. Prinssen 2 . 1 Nonclinical 

Safety, F. Hoffmann - La Roche Ltd., Basel, 

Switzerland and 2 Discovery Neuroscience, F. 

Hoffmann - La Roche Ltd., Basel, Switzerland. 


GENE EXPRESSION PATTERN FROM 

RATS TREATED WITH ATYPICAL 

ANTIPSYCHOTIC DRUGS AS A 

MECHANISM-BASED SIGNATURE FOR 

PREDICTING DRUG-INDUCED INSULIN 

RESISTANCE. M. Diamond, B. D. Jeffy, J. Saye 

and Y. Dragan. Safety Assessment U.S., AstraZeneca, 


198 






Platform Sessions



Abstract # 


COMPARATIVE STUDY ASSESSING 

DIFFERENT PROCEDURES FOR 

INTRAMUSCULAR INJECTION IN THE 

RABBIT. L. Segal 1 , M. Prinsen 2 , F. Kuper 2 , M. 

Bisteau 1 , D. Morelle 1 and S. Veenstra 1 . 1 R&D / 

RA, GSK Biologicals, Rixensart / Wavre, Belgium 

and 2 Toxicology, TNO Quality of Life, Zeist, 

Netherlands. 


QUALIFICATION OF CARDIOPULMONARY 

SAFETY PHARMACOLOGY MONITORING 

METHOD USING TELEMETRY IN 

CYNOMOLGUS MONKEYS EVALUATED 

WITH PHARMACOLOGICAL 

MODULATORS. S. Authier 1,2 , P. Haefner 3 , S. 

Fournier 1 , E. Troncy 2 and B. Moon 3 . 1 LAB Research 

Inc., Laval, QC, Canada, 2 Faculty of Veterinary 

Medicine, University of Montréal, Montréal, QC, 

Canada and 3 Data Science International, St. Paul, 

MN. Sponsor: G. Washer. 


FUNCTIONAL AND ANATOMIC 

CONSEQUENCES OF SUBRETINAL DOSING 

IN THE CYNOMOLGUS MACAQUE. B. 

J. Christian 1 , C. B. Kim 2 , J. N. Ver Hoeve 2 , C. A. 

Rasmussen 2 , K. M. Munsey 2 , P. E. Miller 2 , H. D. 

Wabers 2 , M. W. Neider 2 , R. R. Dubielzig 2 , C. J. 

Murphy 2 , R. J. McCulloh 2 and T. M. Nork 2 . 1 Covance 

Inc., Madison, WI and 2 University of Wisconsin, 

Madison, WI. 


PRECLINICAL SAFETY EVALUATION 

OF CMX157: A LIPID-CONJUGATED 

NUCLEOTIDE ANALOG FOR TREATMENT 

OF HIV. L. C. Trost, B. M. Lampert, R. Lanier and 

G. R. Painter. Toxicology, Chimerix, Inc., Durham, 

NC. 


TOXICITY STUDIES OF 

COCHLOSPERMUM TINCTORIUM 

AQUEOUS ROOT EXTRACT IN WISTAR 

RATS. C. J. Dawurung 1,2 , P. A. Onyeyili 2 , S. 

Sanni 2 , J. S. Dawurung 3 , M. S. Auwal 2,4 and S. 

B. Aji 2,5 . 1 Biochemistry and Applied Molecular 

Biology, Toxicology Unit, National Veterinary 

Research Institute (NVRI) Vom Nigeria, Jos, 

Plateau State, Plateau State, Nigeria, 2 Department 

of Veterinary Pharmacology and Physiology, 

University of Maiduguri, Maiduguri, Borno 

State, Nigeria, 3 Department of Microbiology, 

University of Maiduguri, Maiduguri, Borno State, 

Nigeria, 4 Department of Animal Health, College 

of Agriculture Maiduguri, Maiduguri, Borno 

State, Nigeria and 5 Department of Animal Health, 

Adamawa State College of Agriculture, Mubi, 

Adamawa State, Nigeria. Sponsor: B. Gadagbui. 


VALPROATE INHIBITS CEREBRAL 

GLUTAMINE UPTAKE AND OXIDATION: A 

CARBON 13 CELLULAR METABOLOMIC 

APPROACH APPLICABLE TO DRUG 

DEVELOPMENT. M. El Hage, B. Ferrier, G. 

Martin and G. Baverel. Metabolys Inc., Lyon, France. 

Abstract # 


EFFECTS OF CAL-101, A SELECTIVE 

INHIBITOR OF THE CLASS 1 PI3K 

P110DELTA, ON LYMPHOCYTES IN 

SPLEEN AND LYMPH NODES. H. K. Webb 1 , R. 

G. Ulrich 1 , K. D. Puri 1 , H. Chen 1 , J. E. Sutherland 2 

and W. C. Hall 3 . 1 Calistoga Pharmaceuticals, 

Seattle, WA, 2 Preclinical Services, Charles River 

Laboratories, Shrewsbury, MA and 3 Hall Consulting, 

Mt. Airy, MD. 


6-MONTH TOXICITY STUDY OF 

IDURSULFASE VIA MONTHLY 

INTRATHECAL LUMBAR INJECTIONS 

AND WEEKLY IV INJECTIONS IN 

CYNOMOLGUS MONKEYS. T. L. Wright 1 , J. 

B. Lieb 1 , R. W. Pfeifer 1 , R. B. Boyd 2 , M. T. Butt 3 , J. 

A. Ruiz 1 , J. A. Durant 1 , K. J. Zaleski 1 , N. Savioli 1 , 

L. M. Sturk 1 , J. Pan 1 , J. Lamsa 1 and P. Calias 1 . 1 Shire 

HGT, Inc., Cambridge, MA, 2 Northern Biomedical 

Research, Inc., Muskegon, MI and 3 Tox Path 

Specialists, LLC, Federick, MD. 


HEPATOBILIARY TOXICITY OF A SMALL 

MOLECULE KINASE INHIBITOR IN THE 

DOG: INVESTIGATIVE ASSESSMENT. D. 

Diaz 1 , H. Wang 1 , G. Cain 1 , E. Choo 1 , R. Pai 1 , J. 

Tarrant 1 , W. Smith 2 , D. Hartley 3 , B. Liederer 1 , J. 

Rudolph 1 and D. Dambach 1 . 1 Genentech, South San 

Fancisco, CA, 2 Qualyst, Durham, NC and 3 Array 

Biopharma, Boulder, CO. 


MOLECULAR MECHANISM OF 

OLANZAPINE-INDUCED OBESITY AND 

WEIGHT GAIN. M. Guha, A. Easter, P. Campbell, 

M. Diamond, J. Morelli, H. Lin and Y. Dragan. Astra 

Zeneca, Wilmington, DE. 


2-YEAR INHALATION CARCINOGENICITY 

STUDY OF NEBULIZED DENUFOSOL 

TETRASODIUM IN SPRAGUE-DAWLEY 

RATS. R. S. Verhoeven, C. Crean and M. Cowlen. 

Inspire Pharmaceuticals, Inc., Durham, NC. 


DERISKING NEMO HEPATOTOXICITY 

USING SIRNA IN RODENT AND HUMAN 

HEPATOMA CELL LINES. A. M. Fajardo 1 , 

O. Ukairo 2 , T. G. Brayman 2 , A. Burdick 2 , T. 

Reichenbacher 2 , M. D. Mitchell 2 , D. C. Thompson 2 

and J. W. Davis 2 . 1 Toxicology, University of New 

Mexico, Albuquerque, NM and 2 Drug Safety 

Research & Development, Pfizer, Chesterfield, MO. 


SAFETY EVALUATION OF SIBUTRAMINE 

IN WISTAR RATS. A. Govindarajan, M. A. Mulla, 

V. Goyal, S. Jana and R. Nirogi. Toxicology, Suven 

Life Sciences Limited, Hyderabad, Andhra Pradesh, 

India. Sponsor: V. Reddy. 

tueSday 







199


tueSday 




APPLICATION OF AN INTELLIGENT 

TESTING STRATEGY SUPPLEMENTED 

WITH IN VITRO CYTOTOXICITY 

SCREENS TO ESTIMATE STARTING 

DOSE FOR ACUTE TOXICITY STUDIES, 

FACILITATE LEAD SELECTION, HELP 

RISK ASSESSMENT, AND SUPPORT 

CRITICAL GLP/GMP MANUFACTURING 

ISSUES. N. Zidek 1 , J. Bluemel 1 , J. Nussbaum 2 , P. 

Bartholomae 2 and R. Class 2 . 1 Nonclinical Safety, 

Merz Pharmaceuticals GmbH, Frankfurt, Germany 

and 2 Toxicology & Preclinical Development, 

Pharmacelsus GmbH, Saarbruecken, Germany. 


INTEGRATED CARDIOVASCULAR AND 

NEUROBEHAVIORAL FUNCTIONS 

ASSESSMENT IN THE CONSCIOUS 

TELEMETERED MONKEY. K. Meecham 1 , G. 

McPhie 1 , E. Moscardo 2 , N. Fasdelli 2 , R. Dorigatti 2 

and C. Hardy 1 . 1 Pharmacology, Huntingdon Life 

Sciences, Huntingdon, United Kingdom and 2 Safety 

Assessment Department, GlaxoSmithKline R&D 

Centre, Verona, Italy. 


INVESTIGATION OF LIVER X RECEPTOR 

PATHWAYS AS AN OFF-TARGET 

MECHANISM FOR INCREASED LIPID 

ACCUMULATION AND ADRENAL 

VACUOLATION IN THE RAT. A. D. Burdick, 

B. D. Hollingshead, T. M. Reichenbacher, C. N. 

Steininger, J. C. Davila, B. L. Homer and J. W. Davis. 

Drug Safety Research and Development, Pfizer 

Global Research and Development, Chesterfield, 

MO. 


MITOCHONDRIAL AND NEUROPATHIC 

TOXICITY OF THE ANTIBIOTIC 

LINEZOLID. G. Garrabou 1 , À. Soriano 2 , T. Pinós 3 , 

D. Pacheu-Grau 4 , J. Casanova-Mollà 5 , C. Morén 1 , 

E. García-Arumí 3 , E. Ruiz-Pesini 4 , M. Morales 5 , 

M. Nicolàs 1 , J. Martinez 2 , J. Grau 1 , Ò. Miró 1 , J. 

Montoya 4 , A. Andreu 3 , J. Mensa 2 and F. Cardellach 1 . 

1 

Mitochondrial Research Lab, IDIBAPS, University 

of Barcelona, Hospital Clínic of Barcelona (HCB), 

CIBERER, Barcelona, Spain, 2 Infectious Diseases 

Department, HCB, Barcelona, Spain, 3 Mitochondrial 

and Neuromuscular Pathology Department, CIBBIM, 

Lab-Institute of Research Hospital Universitari 

Vall d’Hebrón, CIBERER, Barcelona, Spain, 

4 

Biochemical, Molecular and Cellular Biology 

Department, University of Zaragoza, CIBERER, 

Zaragoza, Spain and 5 Neurology Department, HCB, 

Barcelona, Spain. Sponsor: J. Domingo. 


IDIOSYNCRASY IN TOXICOLOGY 

STUDIES. J. R. Senior 1 and W. B. Mattes 2 . 1 OSE, 

CDER, FDA, Silver Spring, MD and 2 PharmPoint 

Consulting, Poolesville, MD. 


ALANINE AMINOTRANSFERASE (ALT) 

ELEVATIONS DURING ACETAMINOPHEN 

THERAPY IN OSTEOARTHRITIS (OA) 

PATIENTS ARE TRANSIENT AND NOT 

CLINICALLY MEANINGFUL. E. Kuffner, K. 

Cooper, J. Baggish, J. Lynch, B. Zimmerman and 

A. Temple. McNeil Consumer Healthcare, Fort 

Washington, PA. 


REFINED TECHNIQUES FOR COLLECTION 

OF SERIAL BLOOD SAMPLES FROM 

RODENTS AND NON-RODENTS FOR 

GENERATION OF TOXICOKINETIC 

DATA. J. Burnett, L. Tasker, K. Hanson-Williams, 

T. Jameson, C. Price, R. Stoner, P. Turpin and E. 

Wall. Covance Laboratories Ltd., Harrogate, United 

Kingdom. Sponsor: D. Everett. 


VALIDATION OF 

IMMUNOHISTOCHEMICAL STAINING 

IN TISSUE CROSS REACTIVITY AND 

INVESTIGATIVE TOXICOLOGY STUDIES: 

LESSONS LEARNED FROM IMAGE 

ANALYSIS QUANTIFICATIONS. M. Valin 1 , T. 

Lemarchand 1 , B. Palate 1 , R. Forster 1 and K. Lillard- 

Wetherell 2 . 1 CIT, Evreux, France, 2 University of 

Paris 12, Créteil, France and 3 Aperio, San Diego, CA. 


EXOCRINE PANCREATIC TOXICITY 

INDUCED BY AN ARGININE-BASED INOS 

INHIBITOR. J. Sagartz 1 , R. Bell 2 , D. Thake 1 , P. 

Manning 3 , D. C. Thompson 2 , J. C. Davila 2 , M. D. 

Mitchell 2 , K. Walters 4 , L. Kraus 2 , K. Hotz 5 and D. L. 

Morris 2 . 1 Seventh Wave, Chesterfield, MO, 2 Drug 

Safety R&D, Pfizer, Chesterfield, MO, 3 Washington 

University School of Medicine, St. Louis, MO, 

4 

Drug Safety R&D, Pfizer, Groton, CT and 5 PDM, 

Pfizer, Chesterfield, MO. 


TOXICITY OF ARGININE-BASED INOS 

INHIBITORS IS DUE TO ACCUMULATION 

OF HIGH LEVELS OF COMPOUND IN 

EXOCRINE PANCREATIC TISSUE. R. Bell 1 , 

J. Sagartz 2 , P. Manning 3 , D. Thake 2 , J. C. Davila 1 , M. 

D. Mitchell 1 , W. M. Moore 1 , G. Jerome 1 , T. Misko 1 , 

J. Zobel 1 , J. Connor 4 , K. Walters 1 , D. L. Morris 1 

and D. C. Thompson 1 . 1 Drug Safety R&D, Pfizer, 

Chesterfield, MO, 2 Seventh Wave, Chesterfield, MO, 

3 

Washington University School of Medicine, St. 

Louis, MO and 4 MedImmune, St. Louis, MO. 


MECHANISM OF EXOCRINE PANCREATIC 

TOXICITY INDUCED BY AN ARGININE- 

BASED INOS INHIBITOR. D. C. Thompson 1 , M. 

A. Panyik 1 , J. Sagartz 2 , P. Manning 3 , R. Bell 1 and D. 

L. Morris 1 . 1 Drug Safety Research & Development, 

Pfizer, Chesterfield, MO, 2 Seventh Wave, 

Chesterfield, MO and 3 Washington University School 

of Medicine, St. Louis, MO. 


A CELLULAR SYSTEMS BIOLOGY 

METHOD OF EVALUATING IN VITRO 

CARDIOTOXICITY. N. M. Radio, P. Hodor, 

L. Vernetti, A. Gough and P. Johnston. Cellular 

Toxicology, Cellumen, Pittsburgh, PA. 


A CELLULAR SYSTEMS BIOLOGY 

APPROACH TO DISCRIMINATE HEPATIC 

TOXICITY WITHIN STRUCTURAL 

CLASSES. L. Vernetti, N. M. Radio, P. Hodor, 

A. Gough and P. Johnston. Cellular Toxicology, 

Cellumen, Pittsburgh, PA. 

200 






Platform Sessions



Abstract # 


OPTIMISING CELL MODELS FOR 

DETECTING DRUG-INDUCED 

MITOCHONDRIAL DYSFUNCTION. K. 

Howe, L. Bazley, S. Song and J. Dykens. Drug Safety 

R&D, Pfizer, Sandwich, United Kingdom. 


IMPACT AND FREQUENCY OF DIFFERENT 

TOXICITIES THROUGHOUT THE 

PHARMACEUTICAL LIFE CYCLE. W. S. 

Redfern 1 , L. Ewart 1 , T. G. Hammond 1 , R. Bialecki 2 , 

L. Kinter 2 , S. Lindgren 3 , C. E. Pollard 1 , R. Roberts 1 , 

M. G. Rolf 1 and J. P. Valentin 1 . 1 Global Safety 

Assessment, AstraZeneca, Macclesfield, Cheshire, 

United Kingdom, 2 Global Safety Assessment, 

AstraZeneca, Wilmington, DE and 3 Global Safety 

Assessment, AstraZeneca, Sodertalje, Sweden. 


THE USE OF IMPLANTATION OF 

TRANSPONDERS IN TG.RASH2 MODELS 

FOR CARCINOGENICITY ASSESSMENT 

THE USE OF SUBCUTANEOUS 

IMPLANTATION OF TRANSPONDERS 

IN TG.RASH2 MODELS FOR 

CARCINOGENICITY ASSESSMENT. M. 

Paranjpe, M. Wenk and E. A. Zahalka. Toxicology, 

BioReliance Corporation, Rockville, MD. 


METHODS FOR SUCCESSFUL 

CONDUCT OF CHRONIC TOXICOLOGY 

INTRAVENOUS TAIL VEIN INJECTION 

STUDIES IN RATS. R. Gendron, C. Parente, 

S. Y. Smith and C. Copeman. Toxicology, Charles 

River Laboratories, Preclinical Services (PCS-MTL), 

Senneville, QC, Canada. Sponsor: M. Vézina. 


ATRIOVENTRICULAR (AV) VALVULAR 

INJURY CAUSED BY A VASCULAR 

ENDOTHELIAL GROWTH FACTOR 

RECEPTOR (VEGFR) INHIBITOR IN RATS 

APPEARS TO BE RODENT SPECIFIC. S. 

Ottinger 1 , T. Salcedo 1 , W. Freebern 1 , R. Westhouse 2 , 

S. Martin 1 , J. Li 2 , D. Li 2 , A. Fletcher 1 , H. Fang 1 , W. 

Foster 2 , R. Zidell 1 , S. Chen 2 , P. Levesque 2 , B. Car 2 , 

G. Schulze 1 and T. Reilly 1 . 1 Drug Safety Evaluation, 

Bristol-Myers Squibb, Syracuse, NY and 2 Discovery 

Toxicology, Bristol-Myers Squibb, Lawrenceville, 

NJ. 


COMBINATIONAL TREATMENT OF 

GAP JUNCTIONAL ACTIVATOR AND 

TAMOXIFEN IN BREAST CANCER CELLS. 

T. A. Nguyen, G. Gakhar and D. H. Hua. Diagnostic 

Medicine, Kansas State University, Manhattan, KS. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Biotransformation II 

Chairperson(s): Chad Moore, University of Utah, Salt Lake City, UT. 




ALTERATION OF CYTOCHROME P450 

GENE EXPRESSION IN THE KIDNEY AND 

LIVER OF MALE SPRAGUE-DAWLEY RATS 

BY ACUTE DOXORUBICIN TOXICITY. B. 

Zordoky and A. El-Kadi. Pharmaceutical Sciences, 

University of Alberta, Edmonton, AB, Canada. 


REACTIVE METABOLITES OF 

BISPHENOL A FORMED BY RAT LIVER 

MICROSOMES AND TRAPPED BY DANSYL 

GLUTATHIONE. T. Buranachokpaisan, B. 

Winnik, B. Buckley and P. E. Thomas. Rutgers, 

The State University of NJ, and Environmental & 

Occupational Health Sciences Institute, Piscataway, 

NJ. 


A KEY ROLE FOR CYP3A4 IN MDMA 

(ECSTASY)-INDUCED HEPATOTOXICITY 

AND IMPLICATIONS FOR ACUTE MDMA 

TOXICITY TREATMENT. I. Antolino Lobo 1 , 

S. Nijmeijer 1 , I. Meijerman 2 , J. Meulenbelt 3 , M. van 

den Berg 1 and M. van Duursen 1 . 1 Institute for Risk 


Netherlands, 2 Department of Pharmaceutical 


and 3 National Institute for Public Health and the 



THE MITOCHONDRIAL TRANSPORTER 

ABCB6 REGULATES CYTOCHROME P450 

ENZYME EXPRESSION. H. Chavan, M. 

Oruganti and P. Krishnamurthy. Pharmacology, 

Toxicology, & Therapeutics, Kansas University 

Medical Center, Kansas City, KS. Sponsor: U. Apte. 


ST. JOHN’S WORT REDUCES 

TRIBROMOETHANOL-INDUCED SLEEP 

TIMES IN HUMAN-SXR TRANSGENIC 

MICE. M. G. Bonney, E. L. Lively, C. S. Gardiner 

and G. K. DeKrey. Biological Sciences, University of 

Northern Colorado, Greeley, CO. 


EXPRESSION OF CYP3A GENES IN 

THE MICE FED CHRONICALLY WITH 

ETHANOL. Y. Je, H. Yin and B. Lee. College 

of Pharmacy, Seoul National University, Seoul, 



CHIPING THE CISTROME OF PXR IN 

MOUSE LIVER. Y. J. Cui, S. S. Gunewardena 

and C. D. Klaassen. University of Kansas Medical 

Center, Kansas City, KS. 

tueSday 







201


tueSday 




QUANTIFICATION OF P450 CYP3A 

ACTIVITIES IN TWELVE ORGANS OF A 

CYNOMOLGUS MONKEY. Y. LaForge 1,2 , 

J. Seagrave 3,2 and A. P. Li 1,2 . 1 In Vitro ADMET 

Laboratories, Advanced Pharmaceutical Sciences 

Inc., Columbia, MD, 2 ALIVE LLC, Albuquerque, 

NM and 3 Lovelace Respiratory Research Institute, 

Albuquerque, NM. 


LUCIFERIN ISOPROPYL ACETAL: A NEW, 

HIGHLY SELECTIVE AND SENSITIVE 

BIOLUMINOGENIC CYP3A4 SUBSTRATE 

FOR INDUCTION AND INHIBITION 

ASSAYS. M. Curtin 1 , J. J. Cali 1 , M. Sobal 1 , D. 

Ma 1 , P. Meisenheimer 1 and T. Moeller 2 . 1 Research 

and Development, Promega Corp., Madison, WI and 

2 

Research, Celsis/In Vitro Technologies, Baltimore, 

MD. Sponsor: A. Li. 


EFFECTS OF P450 INHIBITOR, 

1-AMINOBENZOTRIAZOLE (ABT), 

ON THE CYTOTOXICITY OF MODEL 

HEPATOTOXICANTS IN HUMAN 

HEPATOCYTES. U. Doshi, V. Nguyen and A. P. 

Li. Advanced Pharmaceutical Sciences Inc and In 

Vitro ADMET Laboratories LLC, Columbia, MD. 


PREDICTIONS OF P450 BIOACTIVATION 

OF TAMOXIFEN ARE IMPROVED BY NEW 

COMPUTATIONAL SUBSTRATE-ENZYME 

MODELS. K. Shahrokh 1 , T. E. Cheatham 2 and G. 

S. Yost 1 . 1 Pharmacology & Toxicology, University of 

Utah, Salt Lake City, UT and 2 Medicinal Chemistry 

and of Pharmaceutics and Pharmaceutical Chemistry, 



CYP3A4 ACTIVE-SITE RESIDUES 

THAT MODULATE THE SELECTIVE 

DEHYDROGENATION OF RALOXIFENE TO 

ITS PROTEIN BINDING INTERMEDIATE. C. 

Moore, K. Shahrokh and G. S. Yost. Pharmacology 

and Toxicology University of Utah, Salt Lake City, 

UT. 


FLUTICASONE PROPIONATE, AN 

INHALED GLUCOCORTICOID, IS A 

POTENT INACTIVATOR OF CYP3A5, 

THE PREDOMINANT PULMONARY P450 

ENZYME. G. S. Yost, T. Murai, K. Shahrokh, 

C. Moore and C. R. Orton. Pharmacology and 

Toxicology, University of Utah, Salt Lake City, UT. 


A NOVEL FEEDBACK DEFENSIVE 

MECHANISM AGAINST ACETAMINOPHEN- 

INDUCED TOXICITY IN THE LATERAL 

NASAL GLAND: INVOLVEMENTS 

OF CYP2A5-MEDIATED ANDROGEN 

METABOLISM AND MODULATION OF THE 

PRODUCTION OF SALIVARY ANDROGEN- 

BINDING PROTEINS. X. Ding 1,2 and X. Zhou 1,2 . 

1 

Wadsworth Center, New York State Department of 

Health, Albany, NY and 2 School of Public Health, 

State University of New York at Albany, Albany, NY. 


ROLES OF CYTOCHROME P450 

REDUCTASE IN MODULATING AMYLOID 

BETA PLAQUE FORMATION IN A MOUSE 

MODEL OF ALZHEIMER’S DISEASE. J. Gu, 

C. Fang, Y. Yao, H. Luo, V. Bolivar, W. Yang and X. 

Ding. Wadsworth Center, Albany, NY. 


CACO-2 CELL PERMEATION OF 

FIVE BENZEARSONATES INCREASES 

THE LIKELIHOOD OF HEPATIC 

BIOTRANSFORMATIONS. D. K. Robinson 1 , 

K. Jackson 1 , L. Hammonds-Odie 3 , K. Ward 2 and G. 

S. Bayse 1 . 1 Chemistry, Spelman College, Atlanta, 

GA, 2 Pharmacology/Toxicology, Morehouse 

School of Medicine, Atlanta, GA and 3 School of 

Science and Technology, Georgia Gwinnett College, 

Lawrenceville, GA. 


DOWN-REGULATION OF GSTA1 BY 

EGF IS REQUIRED FOR CACO-2 CELL 

PROLIFERATION. G. Kirby, H. Quach and M. 

Antenos. Biomedical Sciences, University of Guelph, 

Guelph, ON, Canada. Sponsor: T. Massey. 


TISSUE DISTRIBUTION, ONTOGENY, AND 

CHEMICAL INDUCTION OF MICROSOMAL 

EPOXIDE HYDROLASE IN MICE. F. Selwyn 

Samraj, Y. Cui and C. D. Klaassen. Pharmacology 

and Toxicology, University of Kansas Medical 

Center, Kansas City, KS. 


TRANSCRIPTIONAL AND TISSUE SPECIFIC 

REGULATION OF HUMAN MICROSOMAL 

EPOXIDE HYDROLASE (EPHX1) 

EXPRESSION IS MODULATED BY DIETARY 

ISOTHIOCYANATE DERIVATIVES. S. Su 1,2 , X. 

Yang 1,2 and C. J. Omiecinski 2,3 . 1 Huck Institute of Life 

Sciences, Pennsylvania State University, University 

Park, PA, 2 Center for Molecular Toxicology and 

Carcinogenesis, Pennsylvania State University, 

University Park, PA and 3 Department of Veterinary 

and Biomedical Sciences, Pennsylvania State 

University, University Park, PA. 


OXIDATION OF 4-CHLOROBIPHENYL 

METABOLITES TO THEIR FREE RADICAL 

SPECIES BY PROSTAGLANDIN H 

SYNTHASE-2. O. Wangpradit 1 , E. Moman 2 , K. 

B. Nolan 3 , G. R. Buettner 4 , L. W. Robertson 1 and 

G. Luthe 1,5 . 1 Interdisciplinary Graduate Program 

in Human Toxicology, The University of Iowa, 

Iowa city, IA, 2 Department of Pharmaceutical 

and Medicinal Chemistry, Saarland University, 

Saarbruckken, Germany, 3 Department of 

Pharmaceutical and Medicinal Chemistry, Royal 

College of Surgeons Ireland, Dublin, Ireland, 4 Free 

Radical and Radiation Biology Program, The 

University of Iowa, Iowa city, IA and 5 Institute for 

Life Science and Technology, Saxion University, 

Enschede, Netherlands. 

202 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Genotoxicity 

Chairperson(s): Sandra Wise, University of Southern Maine, Portland, 

ME. 




MICRONUCLEUS FREQUENCIES AND DNA 

DAMAGE IN MALE MICE ADMINISTERED 

HYDROXYUREA. C. A. Hobbs 1 , L. Recio 1 , K. 

Shepard 1 , C. Baldetti 1 , A. Green 1 , J. Winters 1 , M. 

Streicker 2 and K. L. Witt 3 . 1 Genetic and Molecular 

Toxicology, ILS, Inc., Research Triangle Park, 

NC, 2 Investigative Toxicology, ILS, Inc., Research 

Triangle Park, NC and 3 National Toxicology Program 

(NTP), NIEHS, Research Triangle Park, NC. 


EVALUATION OF PHOTOGENOTOXICITY 

IN THE IN VITRO MICRONUCLEUS 

ASSAY IN HUMAN PERIPHERAL BLOOD 

LYMPHOCYTES. C. S. Farabaugh, M. M. Chan, 

A. N. Valliere, L. F. Stankowski and B. R. Fisher. 

Covance Laboratories, Inc., Vienna, VA. 


STYRENE-INDUCED TOXIC EFFECTS IN 

ALDH2 KNOCKOUT MICE. R. Wang 1 , K. 

Ohtani 1 , L. J. McGarrity 2 , Z. Weng 1 and N. Mei 2 . 

1 

Japan National Institute of Occupational Safety and 

Health, Kawasaki, Japan and 2 National Center for 

Toxicological Research/U.S. FDA, Jefferson, AR. 


EVALUATION OF L-MENTHONE IN AN 

IN VIVO MOUSE MICRONUCLEUS TEST. 

J. Scognamiglio, V. T. Politano and A. Api. Research 

Institute for Fragrance Materials, Woodcliff Lake, 

NJ. 


EVALUATION OF ISOAMYL ALCOHOL IN 

AN IN VIVO MOUSE MICRONUCLEUS TEST. 

D. McGinty, V. T. Politano and A. Api. Research 

Institute for Fragrance Materials, Inc., Woodcliff 

Lake, NJ. 


AN IN VIVO MOUSE MICRONUCLEUS TEST 

WITH GAMMA-NONALACTONE. C. Letizia, 

A. Api and V. Politano. RIFM, Woodcliff Lake, NJ. 


DOSE-RESPONSE CHARACTERIZATION 

OF VINYL ACETATE AND ACETALDEHYDE- 

INDUCED MICRONUCLEI IN HUMAN 

TK6 CELLS. R. Budinsky 1 , B. Gollapudi 1 , 

R. J. Albertini 2 , R. Valentine 3 , M. Stavanja 4 , J. 

Teeguarden 5 , R. J. Fensterheim 6 and L. Recio 7 . 

1 

The Dow Chemical Company, Midland, MI, 2 The 

University of Vermont, Burlington, VT, 3 DuPont 

Haskell Global Centers for Health and Environmental 

Sciences, Newark, DE, 4 Celanese International 

Corporation, Dallas, TX, 5 Battelle, Pacific Northwest 

Division, Richland, WA, 6 RegNet Environmental 

Services, Washington, DC and 7 ILS, Inc., Research 


Abstract # 


AUTOMATED MICRONUCLEUS/DNA 

CONTENT ASSAY BY QUANTITATIVE 

IMAGING CYTOMETRY. E. Holden, M. 

Henriksen, E. Luther and S. Baldwin. CompuCyte 

Corporation, Westwood, MA. Sponsor: P. 

Narayanan. 


MECHANISTIC ASSESSMENT OF A P38 

KINASE INHIBITOR DEVELOPMENT 

CANDIDATE POSITIVE IN RAT 

MICRONUCLEUS STUDY. S. G. Sawant and 

K. Tarlo. Comparative Biology and Safety Sciences, 



AUTOMATED IN VITRO MICRONUCLEUS 

SCORING REPRESENTS AN EFFICIENT 

TOOL FOR EVALUATING CHEMICALS’ 

GENOTOXIC THRESHOLDS. J. C. Bemis, 

S. M. Bryce, S. Avlasevich, R. J. Napodano and S. 

Dertinger. Litron Laboratories, Rochester, NY. 


TRANSFERABILITY AND 

REPRODUCIBILITY OF THE IN VITRO 

MICRONUCLEUS ASSAY IN CO-CULTURE. 

G. Ouédraogo 1 , F. Nesslany 2 , S. Simar 2 , S. Talahari 2 , 

D. Lagache 2 , E. Vercauteren 2 , M. Polyn 2 , D. 

Marzin 2 , M. Feltès 1 , L. Bourouf 1 , N. Flamand 1 and 

J. Meunier 1 . 1 International Safety Research, L’Oréal, 

Aulnay sous bois, France and 2 Laboratoire de 

toxicologie, Institut Pasteur de Lille, Lille, France. 



DEFINING EXPERIMENTAL PARAMETERS 

FOR A 4-DAY COMBINED MICRONUCLEUS 

AND COMET GENOTOXICITY ASSAY 

(MN/COMET) IN RODENTS: OPTIMAL 

SAMPLING TIME AND USE OF FRESHLY 

PREPARED VS FROZEN TISSUES. L. Recio 1 , 

C. Hobbs 1 and K. L. Witt 2 . 1 ILS, Inc., Research 

Triangle Park, NC and 2 National Toxicology 

Program/NIEHS, Research Traingle Park, NC. 


THE PRESENCE OF DIETHYL 

FUMARATE IMPACTS CLASTOGENICITY 

TEST RESULTS FOR DIETHYL 

2-ETHOXYSUCCINATE IN CHINESE 

HAMSTER OVARY CELLS. L. M. Milchak 1 , R. 

Gudi 2 , R. B. Prince 1 , S. Gerber 1 , P. H. Lieder 1 and 

D. Luebker 1 . 1 3M, St. Paul, MN and 2 BioReliance, 

Rockville, MD. 


EVALUATION OF ZIDOVUDINE (AZT)- 

INDUCED GENOTOXICITY CHANGES 

IN HUMAN CELLS EXPOSED TO THE 

CYTOPROTECTIVE AGENT WR1065, USING 

THE CYTOME ASSAY. H. M. Braun, D. Momot, 

M. C. Poirier and O. A. Olivero. Carcinogen-DNA 

Interactions, National Cancer Institute, Bethesda, 

MD. 

tueSday 







203


tueSday 




TOPOISOMERASE IIa INHIBITION BY 

FLUOROQUINOLONES IN V79 CELLS 

LEADS TO GENOTOXICITY. G. M. Williams 1 , 

K. Brunnemann 1 , A. M. Jeffrey 1 , J. Duan 1 , D. 

Molina 1 , M. J. Iatropoulos 1 and G. Schmuck 2 . 

1 

Pathology, New York Medical College, Valhalla, NY 

and 2 Bayer Schering Pharmacology AG, Wuppertal, 

Germany. 


INVESTIGATION OF THE GENOTOXIC 

EFFECTS OF THREE BLACK TONER 

POWDERS IN CULTURED HUMAN 

EPITHELIAL A549 LUNG CELLS. R. 

Gminski 1 , R. Gieré 3 , M. Könczöl 1 , K. Decker 1 , C. 

Heinz 1 , A. Seidel 2 , E. Goldenberg 3 , B. Grobéty 4 

and V. Mersch-Sundermann 1 . 1 Department of 

Environmental Health Sciences, University Medical 

Center Freiburg, Freiburg, Germany, 2 Biochemical 

Institute for Environmental Carcinogens, 

Grosshansdorf, Germany, 3 Institute of Geosciences, 

University of Freiburg, Freiburg, Germany and 

4 

Department of Geosciences, Université de Fribourg, 

Fribourg, Switzerland. 


ASSESSMENT OF THE IN VIVO 

CYTOGENETIC POTENTIAL OF 

PETROLEUM-DERIVED SUBSTANCES. R. 

H. McKee 1 , C. A. Schreiner 2 , M. J. Nicolich 3 and T. 

M. Gray 4 . 1 Toxicology and Environmental Sciences, 

ExxonMobil Biomedical Sciences, Inc., Annandale, 

NJ, 2 C&C Consulting in Toxicology, Meadowbrook, 

PA, 3 Cogimet, Lambertville, NJ and 4 American 

Petroleum Institute, Washington, DC. 


DNA DAMAGING AND CLASTOGENIC 

EFFECTS OF PHYTOCHEMICALS 

PARTIALLY ISOLATED FROM CRUDE 

EXTRACT OF GLINUS LOTOIDES. J. D. 

Kimmo 1,2 , E. Engidawork 2 , T. Leta 3 , U. Goranson 3 

and B. Hellman 1 . 1 Pharmaceutical Biosciences, 

Division of Toxicology, Uppsala University, Uppsala, 

Uppland, Sweden, 2 Pharmacology, School of 

Pharmacy, Addis Ababa University, Addis Ababa, 

A. A., Ethiopia and 3 Medicinal Chemistry, Division 

of Pharmacognosy, Uppsala University, Uppsala, 

Uppland, Sweden. Sponsor: M. Stigson. 


DISCRIMINATION OF CLASTOGENIC 

AND ANEUGENIC COMPOUNDS 

IN HUMAN LYMPHOCYTES BY 

IMMUNOFLOURESCENT TECHNIQUES IN 

THE CB MICRONUCLEUS TEST. A. H. Poth 

and S. Bohnenberger. Harlan Cytotest Cell Research, 

Rossdorf, Germany. Sponsor: R. Fautz. 


GADD45 INDUCTION IN THE 

GREENSCREEN HC INDICATOR ASSAY 

DOES NOT OCCUR INDEPENDENTLY OF 

CYTOTOXICITY. A. J. Olaharski 1 , S. Albertini 2 , 

L. Mueller 2 , A. Zeller 2 , M. Struwe 2 , E. Gocke 2 and K. 

Kolaja 1 . 1 Nonclinical Safety, Hoffmann-La Roche, 

Nutley, NJ and 2 Nonclinical Safety, Hoffman-La 

Roche, Basel, Switzerland. 


SIMULATED SPACEFLIGHT INCREASES 

CHROMATE-INDUCED GENOTOXICITY. 

J. P. Wise 1,2 , S. Wise 1,2,3 , J. Wise 1,2 , J. McKay 1,2 , 

M. Browne 4 , K. Joyce 1,2 , M. Braun 1,2 , C. Wise 1,2 , 

R. Duffy 1,2 , E. Estelle 4 , J. Brown 4 , C. Gianios 1,2 , 

M. Mason 4 , T. Shehata 5 , D. Hammond 6 and J. P. 

Wise 1,2,3 . 1 Wise Laboratoey of Environmental and 

Genetic Toxicology, University of Southern Maine, 

Portland, ME, 2 Maine Center of Toxicology and 

Environmental Health, University of Southern Maine, 

Portland, ME, 3 Department of Applied Medical 

Sciences, University of Southern Maine, Portland, 

ME, 4 Department of Biological and Chemical 

Engineering, University of Maine, Orono, ME, 

5 

Maine Space Grant Consortium, Portland, ME and 

6 

NASA Johnson Space Center, Houston, TX. 


CHEMICAL EXPOSURE AND THE 

GENERATION OF COPY NUMBER 

VARIANTS (CNVS). J. L. Freeman and S. 

Peterson. Health Sciences, Purdue University, West 

Lafayette, IN. 


BOWHEAD (BALAENA MYSTICETUS) 

LUNG CELLS ARE RESISTANT TO 

CHROMIUM-INDUCED DAMAGE. S. Wise 1,2,3 , 

H. Xie 1,2,3 , A. L. Holmes 1,2 , C. F. Wise 1,2 , A. Doering 1 , 

D. McGovern 1 , A. Sample 1 , M. Stephenson 1 , T. Li 

Chen 1,2 , J. Martino 1,2 , M. Bickford 1 , T. J. Goodwin 4 , 

T. O’Hara 5 and J. P. Wise 1,2,3 . 1 Wise Laboratory of 

Environmental and Genetic Toxicology, University 

of Southern Maine, Portland, ME, 2 Maine Center for 

Toxicology and Environmental Health, Universtiy 

of Southern Maine, Portland, ME, 3 Department of 

Applied Medical Sciences, University of Southern 

Maine, Portland, ME, 4 NASA Johnson Space Center, 

Houston, TX and 5 University of Alaska, Fairbanks, 

AK. 


KINETIC AND MECHANISTIC 

ASSESSMENT OF MICRONUCLEATED 

PERIPHERAL BLOOD RETICULOCYTES 

(MNRETS) IN RODENTS USING FLOW 

CYTOMETRY. D. J. Roberts 1 , D. K. Torous 2 , 

A. Valliere 1 , M. Chan 1 , P. Yurt 1 , Y. Xu 1 and L. F. 

Stankowski 1 . 1 Genetic & Molecular Toxicology, 

Covance Laboratories, Inc., Vienna, VA and 2 Litron 

Laboratories, Rochester, NY. Sponsor: B. Fisher. 


ADEQUATE CONDITIONS FOR 

PERFORMANCE OF THE COMET 

ASSAY USING 3-DIMENSIONAL HUMAN 

EPIDERMAL MODEL. H. Kojima 1 , M. Hojyo 1 

and S. Arai 2 . 1 Division of Pharmacology, National 

Institute of Health Sciences, Tokyo, Japan and 

2 

Hatano Research Institue, Food and Drug Safety 

Center, Hadano, Japan. 

204 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Safety Concerns of Food and Natural 

Products 

Chairperson(s): Ramesh Gupta, Murray State University, Hopkinsville, 

KY. 




TOXICITY STUDY OF AN ETHANOLIC 

EXTRACT OF ACORUS CALAMUS IN 

WISTAR RATS. P. D. Shah 1 , M. Ghag 2 , P. 

Deshmukh 2 and Y. Kulkarni 3 . 1 Pharmacology, 

Maliba Pharmacy College, Surat, Gujarat, India, 

2 

Toxicology, Jai Research Foundation, Vapi, 

Gujarat, India and 3 Pharmacology, SPTM, SVKM’s 

University, Mumbai, Maharashtra, India. 


GUM GUGGUL EXTRACT: ANALYTICAL 

METHOD DEVELOPMENT AND 

VALIDATION. B. Jayaram 2 , C. S. Smith 2 , O. L. 

Beverly 1 , K. E. Schnare 1 , A. K. Clay 1 , P. J. Schebler 1 , 

J. W. Algaier 1 and R. K. Harris 1 . 1 Energy and Life 

Sciences Division, Midwest Research Institute, 

Kansas City, MO and 2 National Toxicology Program, 



PARTIAL CONTRIBUTION OF 

GINKGOLIDE A TO RAT AND HUMAN 

PREGNANE X RECEPTOR ACTIVATION 

BY GINKGO BILOBA EXTRACT. A. Lau and 

T. K. Chang. Faculty of Pharmaceutical Sciences, 

The University of British Columbia, Vancouver, BC, 

Canada. 


THE RELATIVE ROLES OF SELECTED 

STRESSORS IN THE PATHOGENESIS OF 

SUMMER SLUMP IN A RAT MODEL. T. J. 

Evans, P. A. Eichen, E. M. Walters, V. K. Ganjam, 

G. E. Rottinghaus and D. E. Spiers. University of 

Missouri, Columbia, MO. 


SAFETY ASSESSMENT OF AN ACAI- 

ENRICHED MIXED FRUIT AND BERRY 

BLEND (MONAVIE). A. Schauss. Natural and 

Medicinal Products Research, AIBMR Life Sciences, 

Puyallup, WA. 

Abstract # 


ELECTROCHEMICAL PROFILING 

USING COPPER NANOPARTICLE- 

PLATED ELECTRODE FOR QUICK 

IDENTIFICATION OF OSTRICH MEAT AND 

EVALUATION OF MEAT GRADES. C. Chou 1 , 

C. Hung 1 , H. Ho 2 , C. Chang 3 , M. Lee 2 , S. Guo 1 and 

C. Chuang 4 . 1 Department of Veterinary Medicine, 

National Chung-Hsing University, Taichung, Taiwan, 

2 

Department of Chemistry, National Chung Hsing 

University, Taichung, Taiwan, 3 Graduate Institute 

of Microbiology and Public Health, National Chung 

Hsing University, Taichung, Taiwan and 4 Department 

of Biomedical Engineering and Environmental 

Sciences, National Tsing Hua University, Hsinchu, 

Taiwan. 


ANALYSIS OF DNA BINDING OF [3, 

4-14C]-FURAN IN RAT LIVER BY 

ACCELERATOR MASS SPECTROMETRY. 

C. Hamberger 1 , S. Moro 1 , M. Malfatti 2 , K. 

Turteltaub 2 , W. Dekant 1 and A. Mally 1 . 1 Department 

of Toxicology, University of Wüerzburg, Wüerzburg, 

Germany and 2 Lawrence Livermore National 

Laboratory, Livermore, CA. 


IDENTIFICATION OF TARGET PROTEINS 

OF FURAN IN RAT LIVER. S. Moro 1 , C. 

Hamberger 1 , W. Dekant 1 , K. Chipman 2 and A. Mally 1 . 

1 

Department of Toxicology, University of Wüerzburg, 

Wüerzburg, Germany and 2 School of Biosciences, 

The University of Birmingham, Birmingham, United 

Kingdom. 


DIETARY SUPPLEMENT-DRUG 

INTERACTION: DEVELOPMENT OF 

P450 INHIBITION PROFILE METHOD. 

K. Hayamizu, I. Yamasaki, M. Yamada and K. 

Yamaguchi. Research Institute, FANCL Corp., 

Yokohama, Kanagawa, Japan. 


ASSESSMENT OF THE NEPHROTOXICITY 

OF A SEVEN-DAY COMBINED-EXPOSURE 

TO MELAMINE AND CYANURIC ACID IN 

F344 RATS. G. Gamboa da Costa 1 , C. C. Jacob 1 , 

L. VonTungeln 1 , G. Olson 4 , A. Warbritton 4 , D. G. 

Hattan 3 , R. Reimschuessel 2 and F. A. Beland 1 . 1 U.S. 

FDA National Center for Toxicological Research, 

Jefferson, AR, 2 U.S. FDA Center for Veterinary 

Medicine, Laurel, MD, 3 U.S. FDA Center for Food 

Safety and Applied Nutrition, College Park, MD and 

4 

Toxicologic Pathology Associates, Jefferson, AR. 


INFLUENCE OF DIETARY STEROL 

EXPOSURE ON HEPATIC OXYSTEROL 

PROFILES AND GENETIC STABILITY. A. E. 

Albrecht 1 , S. Keller 2 , G. Jahreis 2 and L. Lehmann 1 . 

1 

University of Wüerzburg, Wüerzburg, Germany and 

2 

University of Jena, Jena, Germany. 

tueSday 







205


tueSday 




THERAPEUTIC AND SAFETY 

EVALUATIONS OF UC-II OR 

GLUCOSAMINE PLUS CHONDROITIN OR 

UC-II, GLUCOSAMINE AND CHONDROITIN 

COMBINATION IN OSTEOARTHRITIC 

HORSES. R. C. Gupta 1 , E. Tapp 1 , E. Tapp 1 , J. 

Goad 1 , T. D. Canerdy 1 , R. Doss 1 , M. Bagchi 2 and 

D. Bagchi 2 . 1 Toxicology, Murray State University, 

Hopkinsville, KY and 2 InterHealth Research Center, 

Benicia, CA. 


DEOXYNIVALENOL INGESTION 

PREVENTS AND AMELIORATES DIET- 

INDUCED OBESITY IN THE MOUSE. B. 

Flannery 1,2 , C. Amuzie 4 , A. Ulrich 1 and J. Pestka 1,3 . 

1 

Food Science and Human Nutrition, Michigan State 



MI, 3 Department of Microbiology and Molecular 

Genetics, Michigan State University, East Lansing, 

MI and 4 Comparative Medicine and Integrative 

Biology, Michigan State University, East Lansing, 

MI. 


RELATIVE PHOTOMUTAGENIC POTENCY 

OF FUROCOUMARINS AND LIMETTIN. 

N. Raquet, C. Lohr and D. Schrenk. University of 

Kaiserslautern, Kaiserslautern, Germany. 


BROAD SPECTRUM SAFETY OF A NOVEL 

CHROMIUM(III) COMPLEX: CHROMIUM 

DINICOCYSTEINATE (CDNC). D. Bagchi 1,2 , 

S. Nair 3 , P. A. Marone 4 , F. C. Lau 2 and M. Bagchi 2 . 

1 

University of Houston College of Pharmacy, 

Houston, TX, 2 Research and Development, 

InterHealth Research Center, Benicia, CA, 

3 

University of Wyoming, Laramie, WY and 

4 

Eurofins/Product Safety Laboratories, Dayton, NJ. 


SAFETY ASSESSMENT OF A 28-DAY 

REPEATED-DOSE EXPOSURE TO AN EPA- 

RICH OIL PRODUCED FROM YEAST. S. A. 

MacKenzie, L. A. Belcher, G. P. Sykes, S. R. Frame 

and P. Gillies. DuPont Haskell Global Centers for 

Health & Environmental Sciences, Newark, DE. 


SAFETY ASSESSMENT OF A 90-DAY 

SUBCHRONIC EXPOSURE TO AN EPA- 

RICH OIL PRODUCED FROM YEAST. L. A. 

Belcher, S. A. MacKenzie, G. P. Sykes, S. R. Frame, 

P. Mukerji and P. Gillies. DuPont Haskell Global 

Centers for Health & Environmental Sciences, 

Newark, DE. 


EVALUATION OF THE POTENTIAL 

DEVELOPMENTAL TOXICITY AND 

GENOTOXICITY OF YEAST OIL 

CONTAINING EICOSAPENTAENOIC ACID. 

S. M. Munley, L. Belcher, E. M. Donner and P. 

Gillies. DuPont Haskell Global Centers for Health 

and Environmental Sciences, Newark, DE. 


DIETARY INTAKE IS ASSOCIATED 

WITH PHTHALATE BODY BURDEN IN 

A NATIONALLY REPRESENTATIVE 

SAMPLE. J. Colacino 1 , T. Harris 2 and A. Schecter 3 . 

1 

Environmental Health Sciences, University of 

Michigan School of Public Health, Ann Arbor, 

MI, 2 Dallas Regional Campus, University of Texas 

School of Public Health, Dallas, TX and 3 Division 

of Environmental and Occupational Health Sciences, 

University of Texas School of Public Health, Dallas, 

TX. 


EXPOSURE OF FINNISH INFANTS TO 

FOOD BORNE FURAN. K. Peltonen 1 , M. 

Jestoi 1 , T. Järvinen 1 , E. Järvenpää 2 , H. Tapanainen 3 

and S. Virtanen 3 . 1 Chemistry and Toxicology, 

Finnish Food Safety Authority, Helsinki, Finland, 

2 

Biochemistry, University of Turku, Turku, Finland 

and 3 Epidemiology and Health Promotion, National 

Public Health, Helsinki, Finland. 


INHIBITION OF HEME PEROXIDASES 

BY MELAMINE. P. Vanachayangkul and W. 

H. Tolleson. Division of Biochemical Toxicology, 




INACTIVATION OF RICIN CYTOTOXIC 

ACTIVITY BY PERACETIC ACID AND 

SODIUM HYPOCHLORITE. A. Triplett 1 , K. 

T. Nguyen 1 , L. S. Jackson 2 and W. H. Tolleson 1 . 

1 

Division of Biochemical Toxicology, National 

Center for Toxicological Research, Jefferson, AR and 

2 

National Center for Food Safety and Technology, 

Summit-Argo, IL. 


INFLUENCE OF PH ON THE KINETICS OF 

CHEMICAL INACTIVATION FOR ABRIN 

AND RICIN. W. H. Tolleson 1 , A. Triplett 1 , 

K. T. Nguyen 1 and L. S. Jackson 2 . 1 Division of 


Toxicological Research, Jefferson, AR and 2 National 

Center for Food Safety and Technology, Summit- 

Argo, IL. 


GENETICALLY-MODIFIED SOYBEANS— 

CRITICAL EVALUATION OF 

STUDIES ADDRESSING POTENTIAL 

ULTRASTRUCTURAL CHANGES 

ASSOCIATED WITH INGESTION. A. Lavin 

Williams and J. M. DeSesso. Exponent, Alexandria, 

VA. 


TOXICOLOGY STUDIES WITH 

N-ACETYLGLYCINE. M. S. Harper 1 , J. F. 

Barnett 3 , Z. Shen 2 , L. Krsmanovic 4 , E. W. Dakoulas 4 

and B. Delaney 1 . 1 Regulatory Science Product Safety, 

Pioneer, A DuPont Company, Ankeny, IA, 2 DuPont 

Haskell Global Centers for Health and Environmental 

Sciences, E.I. du Pont de Nemours and Company, 

Newark, DE, 3 Charles River Laboratories Preclinical 

Services, Horsham, PA and 4 BioReliance, Rockville, 

MD. 

206 






Platform Sessions



Abstract # 


HEALTH HAZARD ASSESSMENT FOR 

GLUTEN IN CELIAC DISEASE. S. A. Assimon 

and P. M. Bolger. CFSAN, U.S. FDA, College Park, 

MD. 


DIETARY FACTORS THAT INFLUENCE 

KIDNEY CALCINOSIS (KC) IN WEANLING, 

FEMALE SPRAGUE-DAWLEY RATS. M. A. 

Pellizzon, M. R. Ricci and E. A. Ulman. Research 

Diets, Inc., New Brunswick, NJ. Sponsor: P. Marone. 


PHARMACOKINETICS OF MELAMINE 

IN A RUMINANT MODEL. B. M. Barlow, R. 

E. Baynes and J. E. Riviere. Center for Chemical 

Toxicology Research and Pharmacokinetics, North 



EXTRUSION COOKING USING A TWIN- 

SCREW APPARATUS REDUCES TOXICITY 

OF FUMONISIN-CONTAMINATED CORN 

GRITS. K. A. Voss 1 , L. S. Jackson 2 , J. E. Jablonski 2 , 

M. A. Hanna 3 , L. B. Bullerman 3 and D. Ryu 4 . 

1 

Toxicology & Mycotoxin Research Unit, USDA, 

ARS, Athens, GA, 2 National Center for Food Safety 

& Technology, U.S. FDA, Summit-Argo, IL, 3 Food 

Science & Technology, University of Nebraska, 

Lincoln, NE and 4 Nutrition & Food Sciences, Texas 

Woman’s University, Denton, TX. 


IN VITRO EVALUATION OF NOVASIL CLAY 

FOR REDUCTION OF AFLATOXIN B 1 

IN 

COMMON GHANAIAN FOODS. N. J. Mitchell, 

A. Robinson, N. M. Johnson, A. Marroquin-Cardona, 

J. Taylor and T. D. Phillips. College of Veterinary 

Medicine, Texas A&M University, College Station, 

TX. 


EVALUATION OF AFLATOXIN B 1 

ADSORPTION CAPACITY OF EDIBLE 

CLAYS FROM THE MARKETPLACE IN 

GHANA. A. Marroquin-Cardona 1 , Y. Deng 2 , 

C. Bangira 2 , N. M. Johnson 1 , N. Mitchell 1 , J. F. 

Taylor 1 , A. Robinson 1 and T. D. Phillips 1 . 1 Veterinary 

Integrative Biosciences, Texas A&M University, 

College Station, TX and 2 Soil & Crop Sciences, 



ANTILISTERIAL EFFICACY AND 

LACK OF GENOTOXIC POTENTIAL OF 

LISTERIA MONOCYTOGENES SPECIFIC 

BACTERIOPHAGES. W. J. Mackay 2 , C. H. 

Sommers 1 , K. T. Rajkoswki 1 and D. M. Barton 2 . 

1 

Agricultural Research Service, U.S. Department of 

Agriculture, Wyndmoor, PA and 2 Biology, Edinboro 

University, Edinboro, PA. 


DEVELOPMENT OF A NON-ANTIBODY 

METHOD FOR RAPID DETECTION OF 

SERUM AFLATOXIN B1-LYSINE ADDUCT. 

G. Qian 1 , L. Tang 1 , L. Wenwei 2 and J. Wang 1 . 

1 


Georgia, Athens, GA and 2 Wuxi CDC, Wuxi, 

Jiangsu, China. 

Abstract # 


USE OF HUMAN GENETIC AND REGIONAL 

DIET VARIATION TO IDENTIFY GENES, 

CELLULAR AND DISEASE PROCESSES 

MODULATED BY DIET OF POPULATIONS: 

POSSIBLE EXPLANATIONS FOR 

DIFFERENCES IN CURRENT OBSERVED 

DISEASE SUSCEPTIBILITIES. R. Thomas 1 , J. 

Gohlke 1 , C. Portier 1 and S. Mehrotra 2 . 1 Laboratory 

of Molecular Toxicology, National Institute 

of Environmental Health Sciences, Research 

Triangle Park, NC and 2 Industrial Engineering and 

Management Sciences, Northwestern University, 

Evanston, IL. 


INVOLVEMENT OF JNK AND CASPASE 

ACTIVATION IN HOIAMIDE A-INDUCED 

NEUROTOXICITY IN NEOCORTICAL 

NEURONS. Z. Cao 1 , W. H. Gerwick 2 and T. F. 

Murray 1 . 1 Department of Pharmacology, School of 

Medicine, Creighton University, Omaha, NE and 

2 

Center for Marine Biotechnology and Biomedicine, 

Scripps Institution of Oceanography, University of 

California, San Diego, La Jolla, CA. 


EXPOSURE TO ACROLEIN CAUSES 

PLATELET ACTIVATION. S. E. D’Souza 1 , S. D. 

Sithu 1,2 , D. Conklin 2 , M. A. Siddiqui 2 , P. Haberzettl 2 , 

T. E. O’Toole 2 , A. Bhatnagar 2 and S. Srivastava 2 . 

1 

Physiology and Biophysics, University of Louisville, 

Louisville, KY and 2 Diabetes and Obesity Center, 



IMPACTS OF INSECT DAMAGE ON 

FUNGAL INFECTION, FUMONISIN 

LEVELS, AND GRAIN QUALITY FOR 

ETHANOL PRODUCTION IN BT AND NON- 

BT MAIZE HYBRIDS. E. Bilsten 1 , G. Munkvold 1 

and A. L. Pometto 2 . 1 Plant Pathology, Iowa State 

University, Ames, IA and 2 Food Science and Human 

Nutrition, Clemson University, Clemson, SC. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Safety Assessment: Commercial and 

Consumer Products 

Chairperson(s): Ron Brown, U.S. FDA, Silver Spring, MD, and Tessa 

Serex, DuPont Haskell Global Centers for Health and Environmental 

Sciences, Newark, DE. 




NONCLINICAL SAFETY EVALUATION OF 

BORIC ACID AND A BORATE-BUFFERED 

CONTACT LENS CARE MULTIPURPOSE 

SOLUTION. D. M. Lehmann 1 , M. E. Cavet 1 , D. J. 

O’Mara 1 , K. L. Harrington 2 and M. E. Richardson 1 . 

1 

Nonclinical Safety, Bausch & Lomb, Rochester, NY 

and 2 Pharmacology, Bausch & Lomb, Rochester, NY. 

tueSday 







207


tueSday 




COMBINED REPEATED DOSE TOXICITY 

STUDY WITH THE REPRODUCTION/ 

DEVELOPMENTAL TOXICITY SCREENING 

TEST AND MAMMALIAN ERYTHROCYTE 

MICRONUCLEUS TEST VIA INHALATION 

WITH TYPE LLL BUILT-UP ROOFING 

(BURA) ASPHALT FUME CONDENSATE. 

R. Fuhst, J. Buschmann, H. Ernst, T. Hansen, G. 

Pohlmann, A. Preiss and C. Ziemann. Fraunhofer 

ITEM, Hannover, Germany. Sponsor: H. Muhle. 


GENOTOXICITY STUDIES ON REFERENCE 

SMOKELESS TOBACCO PRODUCTS USING 

GREENSCREEN HC GADD45A-GFP ASSAY. 

J. H. Lauterbach 1 , L. Birrell 2,1 , P. A. Cahill 2 , C. 

Jagger 2 and N. Billinton 2 . 1 Lauterbach & Associates, 

LLC, Macon, GA and 2 Gentronix Ltd., Manchester, 



HISTOPATHOLOGY AND NEUROTOXICITY 

SCREENING IN F344 RATS IN A 

90-DAY INHALATION EXPOSURE TO 

AEROSOLIZED SYNTHETIC JET FUEL. B. 

A. Wong 1 , C. U. Parkinson 1 , M. F. Struve 2 , G. A. 

Willson 3 , D. J. Wagner 4 , D. R. Mattie 5 and D. E. 

Dodd 1 . 1 The Hamner Institutes for Health Sciences, 

Research Triangle Park, NC, 2 North Carolina State 

University, Raleigh, NC, 3 Experimental Pathology 

Laboratories, Research Triangle Park, North 

Carolina, 4 Naval Health Research Center, EHEL, 

Wright-Patterson AFB, OH and 5 AFRL/711 HPW/ 

RHPB, Wright-Patterson AFB, OH. 


STUDIES ON THE GENOTOXICITY OF 

2, 5-DIMETHYLFURAN, A POTENTIAL 

BIOFUEL. M. Fromowitz, J. Shuga, A. Yip 

Wlassowsky, L. Zhang and M. T. Smith. School of 

Public Health, University of California Berkeley, 

Berkeley, CA. 


REPEAT DOSE ORAL AND REPRODUCTIVE 

TOXICITY OF THE CHLORINATED FLAME 

RETARDANT DECHLORANE PLUS (DP). 

W. J. Brock 1 , R. Schroeder 2 , C. MacKnight 2 , J. 

VanSteenhouse 2 and J. Nyberg 3 . 1 Brock Scientific 

Consulting, Montgomery Village, MD, 2 MPI 

Research, Mattawan, MI and 3 Occidental Chemical 

Corporation, Wichita, KS. 


EMODIN INHIBITED ATP BINDING TO 

TOPOISOMERASE II TO INDUCE DNA 

DOUBLE-STRAND BREAKS. Y. Li, Y. Luan 

and J. Ren. Shanghai Institute of Materia Medica, 

Chinese Academy of Science, Shanghai, China. 


70% HYDROFLUORIC ACID (HF) 

CUTANEOUS DECONTAMINATION: 

COMPARISON OF DIFFERENT WASHING 

PROTOCOLS WITH A NEW TYPE OF EX 

VIVO DATA. F. Burgher 1 , L. Mathieu 1 , A. H. Hall 3 , 

E. Lati 2 and H. I. Maibach 4 . 1 PREVOR, Valmondois, 

France, 2 BIO EC Laboratory, Longjumeau, 

France, 3 School of Public Health, Denver, CO 

and 4 Dermatology, University of California San 

Francisco, San Francisco, CA. 


USE OF HUMAN REPEAT INSULT PATCH 

TESTING TO SUPPORT MARKET CLAIMS 

OF HYPO-ALLERGENICITY N. Pechacek, T. 

Brunshidle, D. Stein and R. Skoglund. 3M, St. Paul, 

MN. 


IMMUNOTOXICITY EFFECT OF 

MERCURIC SULFIDE IN MALE RAT. M. 

Kim, E. Choi, S. Lee, S. Park, T. Singh, Y. Bae and 

S. Kim. Pharmacology, Department of Pharmacology 

School of Medicine Kyungpook National University, 

Daegu, Republic of Korea. 


SAFETY OF GINGER OIL AND GINGER 

OLEORESIN AS FOOD INGREDIENTS. L. C. 

Dolan and G. Burdock. Burdock Group, Orlando, FL. 


A WEIGHT-OF-EVIDENCE BASED 

APPROACH FOR THE SAFETY 

ASSESSMENT OF NATURAL PLANT- 

DERIVED INGREDIENTS OF PERSONAL 

CARE PRODUCTS: A CASE STUDY WITH 

JUNIPER (JUNIPERUS COMMUNIS ) BERRY 

OIL. T. A. Re 1 , R. Persaud 1 , E. Antignac 2 , I. Bark 1 , 

J. Clouzeau 2 , V. Srinivasan 1 and G. Nohynek 2 . 1 Safety 

Evaluation, L’Oréal USA, Clark, NJ and 2 Worldwide 

Safety Evaluation, L’Oréal R&D, Asnieres, France. 


Vip3Aa20, A VARIANT OF BACILLUS 

THURINGIENSIS VEGETATIVE 

INSECTICIDAL PROTEIN Vip3A, IS NOT 

CYTOTOXIC TO MAMMALIAN CELLS. L. 

S. Meyer 1 , K. A. Leiner 1 , S. A. Huber 1 , M. Ono 1 , S. 

Nagaoka 2 and T. Manabe 2 . 1 Syngenta Biotechnology, 

Inc., Research Triangle Park, NC and 2 Syngenta 

Japan K.K., Tokyo, Japan. 


SAFETY ASSESSMENT OF THE 

INSECTICIDAL PROTEIN eCry3.1Ab, 

PRESENT IN GENETICALLY ENGINEERED 

SYN-Ø5307 MAIZE PLANTS. A. K. Sauve, 

W. Jones, A. Nelson, B. Harper and L. Seastrum. 

Syngenta Biotechnology, Inc., Research Triangle 

Park, NC. Sponsor: K. Leiner. 


TRIDECAFLUOROHEXYLETHYL 

METHACRYLATE (6-2 FMA) TOXICITY 

ASSESSMENT. S. S. Anand 1 , T. L. Serex 1 , C. 

Carpenter 1 , M. Donner 1 , R. Hoke 1 , R. Buck 2 and S. 

E. Loveless 1 . 1 DuPont Haskell Global Centers for 

Health and Environmental Sciences, Newark, DE and 

2 

DuPont Chemical Solutions Enterprise, Wilmington, 

DE. 


PREPARATION AND STABILITY TESTING 

OF BUTYLPARABEN FORMULATIONS 

IN RODENT FEED. V. Godfrey 2 , T. Cristy 1 , S. 

Graves 1 and C. Smith 2 . 1 Battelle, Columbus, OH and 

2 


208 






Platform Sessions

49 th Annual Society Meeting of Toxicology and ToxExpo 2010 


Abstract # 


N-VINYLPYRROLIDONE DIMER (VPD), 

A NOVEL VEHICLE FOR PRECLINICAL 

TOXICITY STUDIES: FOUR-WEEK ORAL 

TOXICITY IN SPRAGUE-DAWLEY RATS 

INCLUDING A 4-WEEK RECOVERY 

PERIOD. D. Bury, S. Halm and S. Weber. 

Toxicology, Abbott GmbH & Co. KG, Ludwigshafen, 

Germany. Sponsor: G. Nohynek. 


CEREBROSPINAL DELIVERY VIA 

INTRATHECAL INJECTION/INFUSION 

IN THE ALBINO RAT, BEAGLE DOG, AND 

CYNOMOLGUS MONKEY. J. Perron, M. Mus, 

Y. Trudel, S. Caron and C. Copeman. Toxicology, 

Charles River Laboratories, Preclinical Services 

(PCS-MTL), Senneville, QC, Canada. Sponsor: M. 

Vézina. 


INTRA-CISTERNA MAGNA DELIVERY IN 

RATS. S. Gariepy, J. Perron, Y. Trudel, S. Caron and 

C. Copeman. Toxicology, Charles River Laboratories, 


Canada. Sponsor: M. Vézina. 


STRUCTURAL CATEGORIZATION OF 

COMPOUNDS RELEASED FROM MEDICAL 

DEVICE MATERIALS USING TOXTREE 

QSAR SOFTWARE. R. Brown 1 , B. Safron 2 , M. 

Stojanovic 2 , P. Kulkarni 1 and H. Dinesdurage 1 . 

1 

CDRH, U.S. FDA, Silver Spring, MD and 

2 

Marquette University, Milwaukee, WI. 


TOXICITY ASSESSMENT OF A 

FLUOROALKYL METHACRYLATE 

COPOLYMER AQUEOUS DISPERSION. T. 

L. Serex 1 , S. S. Anand 1 , B. P. Singh 1 , S. R. Frame 1 , 

J. M. Lewis 1 , R. C. Buck 2 and S. E. Loveless 1 . 

1 

DuPont Haskell Global Centers for Health and 

Environmental Sciences, DuPont, Newark, DE and 

2 

DuPont Chemical Solutions Enterprise, DuPont, 



ORAL GAVAGE SUBCHRONIC 

NEUROTOXICITY AND INHALATION 

SUBCHRONIC IMMUNOTOXICITY 

STUDIES OF ETHYLBENZENE IN THE 

RAT. A. A. Li 1 , J. P. Maurissen 2 , J. F. Barnett 3 , J. 

A. Foss 3 , L. Freshwater 4 , R. Garman 5 , V. Peachee 6 , 

S. Hong 1 , D. Stump 7 and J. S. Bus 8 . 1 Exponent, Inc., 

San Francisco, CA, 2 JPM NeuroTox, Midland, 

MI, 3 Charles River Laboratories, Horsham, PA, 

4 

BioSTAT Consultants, Portage, MI, 5 Consultants 

in Veterinary Pathology, Inc., Monroeville, PA, 

6 

ImmunoTox Incorporated, Richmond, VA, 7 WIL 

Research Laboratories, Ashland, OH and 8 Dow 

Chemical Company, Midland, MI. 


GREAT INTEREST OF CHEMICAL 

REACTIVITY PROPERTY FOR EYE 

IRRITANCY ASSESSMENT USING IN VITRO 

RECONSTRUCTED HUMAN CORNEAL 

EPITHELIAL MODEL (SKINETHIC HCE). 

N. Alépée, J. Eilstein, D. Lelièvre, G. Lereaux, C. 

Rousseau, E. Arbey, J. Ovigne, J. Cotovio, D. Duché 

and J. Meunier. L’Oréal, Aulnay sous Bois, France. 


Abstract # 


COLIPA PROGRAM FOR ASSESSING 

EYE IRRITATION: INTRA AND INTER 

LABORATORY EVALUATIONS OF 

SKINETHIC HUMAN CORNEAL 

EPITHELIUM (HCE) AND DIRECT PEPTIDE 

REACTIVITY (DPRA) ASSAYS. M. Marrec- 

Fairley 1 , F. Van Goethem 2 , S. Bessou Touya 3 , B. 

De Wever 4 , B. Le Varlet 5 , U. Pfannenbecker 6 , P. 

McNamee 7 and N. Alépée 8 . 1 Colipa, Bruxelles, 

Belgium, 2 Johnson & Johnson, Beerse, Belgium, 

3 

Laboratoire Pierre Fabre, Castres, France, 4 Henkel, 

Dusseldorf, Germany, 5 Link Ingénierie, Paris, 

France, 6 Beiersdorf A.G., Hamburg, Germany, 

7 

Procter & Gamble, Egham, United Kingdom and 

8 

L’Oréal, Aulnay sous Bois, France. Sponsor: G. 

Nohynek. 


HYDROFLUORIC ACID (HF) BURNS: A NEW 

EFFICACIOUS MODEL WITH EX VIVO BIO- 

EC HUMAN SKIN EXPLANTS. L. Mathieu 1 , F. 

Burgher 1 , C. Fosse 1 , E. Lati 2 , A. H. Hall 3 and H. I. 

Maibach 4 . 1 PREVOR, Valmondois, France, 2 BIO EC 

Laboratory, Lonjumeau, France, 3 Colorado School 

of Pubic Health, Denver, CO and 4 Dermatology, 

University of California San Francisco, Denver, CA. 


ERYTHROCYTOTOXICITY OF 

METHACRYLONITRILE IN MALE 

SPRAGUE-DAWLEY RATS. M. Y. Farooqui 

and J. Garcia. Biology, University of Texas Pan 

American, Edinburg, TX. 


1:00 PM to 4:30 PM 

Exhibit Hall 


Poster Session: Ah Receptor Biology and Toxicology 

Chairperson(s): Jason Matthews, University of Toronto, Toronto, ON, 

Canada. 




esiRNA AND siRNA HIGH-THROUGHPUT 

SCREENING AS A MECHANISM FOR 

EXPLORING DIOXIN INDUCED CYP1A1 

GENE REGULATION. P. S. Solaimani, B. Peter, 

I. Bebenek, F. Wang and O. Hankinson. Molecular 

Toxicology IDP, University of California Los 

Angeles, Los Angeles, CA. 


IDENTIFICATION OF DIRECT AHR- 

REGULATED GENES INVOLVED IN B CELL 

DIFFERENTIATION. K. De Abrew 1 , N. E. 

Kaminski 2 and R. S. Thomas 1 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC and 

2 

Center for Integrated Toxicology, Michigan State 


tueSday 







209


tueSday 




HYPOXIA INDUCIBLE FACTORS 

POTENTIATE ARYL HYDROCARBON 

RECEPTOR SIGNALING IN 

MESENCHYMAL STEM CELLS. M. 

H. Kung 1,2 , R. J. O’Keefe 2 and M. J. Zuscik 2 . 

1 

Environmental Medicine, University of Rochester, 

Rochester, NY and 2 Orthopedics, University of 

Rochester, Rochester, NY. 


SELECTIVE SUPPRESSION OF 

COMPLEMENT EXPRESSION BY AHR. I. A. 

Murray, J. Shpilsky, G. Narayanan and G. Perdew. 

Vet. & Biomed. Sciences, Pennsylvania State 



GENOMIC ANALYSIS OF DIOXIN- 

DEPENDENT RECRUITMENT OF AHR TO 

PROMOTER REGIONS IN MOUSE LIVER. 

R. Lo 1 , A. Forgacs 2 , T. Celius 1 , L. MacPherson 1 , 

P. Harper 1 , T. Zacharewski 2 and J. Matthews 1 . 

1 

Pharmacology & Toxicology, University of 

Toronto, Toronto, ON, Canada and 2 Biochemistry & 


Lansing, MI. 


THE AHR REGULATES CELL CYCLE 

PROGRESSION IN HUMAN BREAST 

CANCER CELLS VIA A FUNCTIONAL 

INTERACTION WITH CDK4. M. A. 

Barhoover 1 , J. M. Hall 1,2 , W. F. Greenlee 1 and R. 

S. Thomas 1 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 Campbell 

University, Buies Creek, NC. 


ANALYSIS OF AHR PROTEIN TURNOVER 

IN AN ESTABLISHED YEAST EXPRESSION 

MODEL. S. E. Wilson, K. H. Schmidt and R. S. 

Pollenz. Cell Biology, Microbiology, and Molecular 

Biology, University of South Florida, Tampa, FL. 


DEVELOPING A MONOCLONAL 

ANTIBODY BASED CAPTURE ASSAY 

TO QUANTIFY CYTOSOLIC AHR. A. S. 

Devasthanam 1 , N. J. Alles 1 , C. M. Vezina 2 , J. R. 

Olson 1 and K. Rittenhouse-Olson 1 . 1 University at 

Buffalo, Buffalo, NY and 2 University of Wisconsin, 

Madison, WI. 


AHR-MEDIATED GENE EXPRESSION IN 

THE DEVELOPING MOUSE HEART. X. 

Chang, R. Thomas, J. Foley, F. M. Parham and C. J. 

Portier. NIEHS, Reseach Triangle Park, NC. 


ARYL HYDROCARBON RECEPTOR-DNA 

BINDING AND FUNCTION INVOLVING 

A NOVEL REGULATORY ELEMENT 

INDEPENDENT OF THE ARNT PROTEIN. 

G. Huang and C. Elferink. Pharmacology and 

Toxicology, University of Texas Medical Branch, 



TCDD INDUCED PERICARDIAL EDEMA 

AND RELATIVE COX-2 EXPRESSION IN 

MEDAKA EMBRYOS. W. Dong 1,2 , F. Matsumura 3 

and S. W. Kullman 1 . 1 Environmental and Molecular 


NC, 2 College of Marine Science, HuaiHai Institute 

of Technology, LianyunGang, Jiangsu, China and 

3 

Environmental Toxicology, University of California 



A RAPID, CELL-BASED BIOLUMINESCENT 

ARYL HYDROCARBON RECEPTOR 

ACTIVATION ASSAY THAT USES CYP1A1 

ENZYME ACTIVITY AS A SELECTIVE 

MARKER ACTIVITY. J. Cali, D. Ma and P. 

Meisenheimer. Research and Development, Promega 

Corporation, Madison, WI. Sponsor: A. Li. 


SYNERGY BETWEEN ARYL 

HYDROCARBON RECEPTOR AND 

CONSTITUTIVE ANDROSTANE RECEPTOR 

ACTIVATION PROMOTES MURINE LIVER 

HYPERPLASIA. S. Wilson 1 , K. Mitchell 2 and C. 

Elferink 1 . 1 Pharmacology and Toxicology, University 

of Texas Medical Branch, Galveston, TX and 

2 

Biological Sciences, Boise State University, New 

London, CT. 


TELOMERASE INHIBITION BY ARYL 

HYDROCARBON RECEPTOR (AHR) 

AGONISTS IN HUMAN MAMMARY 

EPITHELIAL CANCER CELLS. S. Pittet and 

M. Charbonneau. INRS-Institut-Armand-Frappier, 

Université du Québec, Laval, QC, Canada. 


INHIBITION OF ARYL HYDROCARBON 

RECEPTOR-DEPENDENT TRANSCRIPTION 

BY RESVERATROL OR KAEMPFEROL IS 

INDEPENDENT OF ESTROGEN RECEPTOR 

ALPHA IN T-47D HUMAN BREAST CANCER 

CELLS. L. M. MacPherson and J. Matthews. 




LIGAND SPECIFIC DIFFERENCES 

IN AHR DEPENDENT CHANGES IN 

HISTONE MODIFICATION. J. L. Ovesen 1 , M. 

Schnekenburger 2 and A. Puga 2 . 1 Cell and Cancer 

Biology, University of Cincinnati, Cincinnati, OH 

and 2 Enviromental Health, University of Cincinnati, 

Cincinnati, OH. 



(AHR) REGULATES DRUG TRANSPORTERS 

AT THE BLOOD-BRAIN BARRIER (BBB). X. 

Wang, S. Destiny and D. S. Miller. Laboratory of 

Pharmacology, National Institute of Environmental 


210 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Apoptosis/Cell Death 

Chairperson(s): Sudha Kondraganti, Baylor College of Medicine, 

Houston, TX. 




GONIOTHALAMIN-INDUCED OXIDATIVE 

STRESS, GENOTOXICITY AND 

APOPTOSIS VIA CASPASE-2 AND BCL-2 

INDEPENDENT PATHWAYS IN JURKAT 

T-LYMPHOBLASTIC LEUKEMIA CELLS. 

S. H. Inayat-Hussain 1,2 , K. M. Chan 1 , N. F. Rajab 1 , 

S. C. Chow 5 , A. Kizilors 3 , F. Farzaneh 3 and G. 

T. Williams 4 . 1 Environmental Health Program, 

Universiti Kebangsaan Malaysia, Kuala Lumpur, 

WP, Malaysia, 2 UKM Medical Molecular Biology 

Institute, Universiti Kebangsaan Malaysia, Kuala 

Lumpur, Malaysia, 3 Hematological Medicine, King’s 

College, London, United Kingdom, 4 Institute for 

Science and Technology in Medicine and School 

of Life Sciences, Keele University, London, United 

Kingdom and 5 Monash University, Kuala Lumpur, 

Malaysia. 


ETHYL-3, 4-DIHYDROXYBENZOATE 

PREVENTS CHELATABLE IRON 

MOVEMENT FROM LYSOSOMES TO 

MITOCHONDRIA AND PROTECTS 

AGAINST CELL KILLING AFTER 

CHEMICAL HYPOXIA TO CULTURED 

RAT HEPATOCYTES. K. Lee 1 , G. L. Lovelace 1 , 

V. K. Ramshesh 1 , X. Zhang 1 , H. Jaeschke 2 and J. 

J. Lemasters 1 . 1 Center for Cell Death, Injury & 

Regeneration, Department of Pharmaceutical & 

Biomedical Sciences, Medical University of South 

Carolina, Charleston, SC and 2 University of Kansas 

Medical Center, Kansas. 


MINOCYCLINE AND DOXYCYCLINE, 

BUT NOT OTHER TETRACYCLINE- 

DERIVED COMPOUNDS PROTECT LIVER 

CELLS FROM CHEMICAL HYPOXIA 

AND ISCHEMIA/REPERFUSION INJURY. 

J. Schwartz, E. Holmuhamedov, X. Zhang, G. 

L. Lovelace, C. D. Smith and J. J. Lemasters. 

Pharmaceutical Sciences, Medical University of 



DISULFIRAM SENSITIZES HEPATOCYTES 

TO ISCHEMIA REPERFUSION INJURY 

BY A MECHANISM INDEPENDENT 

OF ALDEHYDE DEHYDROGENASE 

INHIBITION. X. Zhang, G. L. Lovelace, V. K. 

Ramshesh, E. N. Maldonado and J. J. Lemasters. 

Center for Cell Death, Injury & Regeneration, 

Department of Pharmaceutical & Biomedical 



Abstract # 


ROLE OF ERK IN OXIDATIVE STRESS- 

INDUCED APOPTOSIS IN THE OP6 

OLFACTORY SENSORY NEURON CELL 

LINE. J. Kim 1 , J. Seo 1,2 , C. Hegg 1 and J. J. Pestka 1 . 

1 

Food Science and Human Nutrition, Michigan State 

University, East Lansing, MI and 2 Korea Food and 

Drug Administration, Seoul, Republic of Korea. 


TRANSLATION-DEPENDENT AND 

-INDEPENDENT MECHANISMS FOR 

SATRATOXIN G-INDUCED APOPTOSIS. 

N. Shimada 1,2 , J. Kim 1 , J. Shinozuka 3 , C. C. Hegg 1 

and J. J. Pestka 1 . 1 Michigan State University, East 

Lansing, MI, 2 National Institute of Animal Health, 

Ibaraki, Japan and 3 Mitsubishi Tanabe Pharmacology 

Corporation, Saitama, Japan. 


ENHANCEMENT OF 

ERYTHROPHAGOCYTOSIS AND 

ERYTHROCYTE CLEARANCE BY A 

BETA-LAPACHONE DERIVATIVE: A 

NEW ROLE OF PHOSPHATIDYLSERINE 

EXTERNALIZATION IN THE DRUG- 

INDUCED ANEMIA. J. Noh, J. Park, K. Kim, 

K. Lim and J. Chung. College of Pharmacy, Seoul 

National University, Seoul, Republic of Korea. 


INTRACELLULAR BAX TRAFFICKING: 

A DETERMINANT OF CELL DEATH? S. 

Krishnan 1 , W. Miller 1 , M. Gill 2 and J. Perez-Polo 1 . 

1 

University of Texas Medical Branch, Galveston, TX 

and 2 Northwestern University, Chicago, IL. Sponsor: 

J. Ward. 


QUERCETIN INDUCES TUMOR- 

SELECTIVE APOPTOSIS THROUGH 

DOWN-REGULATION OF MCL-1 AND 

ACTIVATION OF BAX. S. Cheng 1 , G. Chen 2 , 

J. Luo 2 and X. Shi 1 . 1 University of Kentucky, 

Lexington, KY and 2 University of Kentucky, 

Lexington, KY. 


ROLE OF EXTRACELLULAR FREE IRON 

AND MAPK SIGNALING IN SMOKELESS 

TOBACCO-INDUCED NECROTIC CELL 

DEATH IN HUMAN ORAL KERATINOCYTE 

CULTURES. M. W. Fariss 1 , C. Mitchell 2 , A. R. 

Joyce 2 and D. Farthing 1 . 1 Health and Analytical 

Sciences, Altria Client Services, Richmond, VA and 

2 

RemX Specialty Staffing c/o Altria Client Services, 

Richmond, VA. 


HUMAN PRIMARY ALVEOLAR CELL 

INJURY INDUCED BY CIGARETTE SMOKE. 

B. Kosmider, H. Chu and R. J. Mason. Medicine, 

National Jewish Health, Denver, CO. Sponsor: B. 

Day. 


INHIBITION OF APOPTOTIC DNA- 

FRAGMENTATION BY 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN. M. 

Chopra 1 , G. Meiss 2 and D. Schrenk 1 . 1 University 

of Kaiserslautern, Kaiserslautern, Germany and 

2 

Biochemistry, Justus-Liebig-University, Giessen, 

Hessen, Germany. 

tueSday 







211


tueSday 




LOCALIZATION OF ENDONUCLEASE 

G AND FRAGMENTED DNA DURING 

ACETAMINOPHEN LIVER INJURY IN 

MICE. N. Braman 1 , E. O. Apostolov 1 , L. Cortez 1 , 

J. Hinson 1 and A. G. Basnakian 1,2 . 1 University of 

Arkansas for Medical Sciences, Little Rock, AR and 

2 

Central Arkansas Veterans Healthcare System, Little 

Rock, AR. 


ENDONUCLEASE G MEDIATES 

ENDOTHELIAL TOXICITY INDUCED BY 

CISPLATIN. Y. Apostolov 1 , D. Ray 1 , A. Savenka 1 

and A. Basnakian 1,2 . 1 Pharmacology/Toxicology, 

University of Arkansas for Medical Sciences, Little 

Rock, AR and 2 Central Arkansas Veterans Healthcare 

System, Little Rock, AR. 


1, 1-BIS(3’-INDOLYL)-1-(P-SUBSTITUTED 

PHENYL) METHANES ACTIVATE 

MITOCHONDRIAL PERMEABILITY 

TRANSITION PORE-MEDIATED 

APOPTOSIS IN BOTH COLON AND 

PANCREATIC CANCER CELLS. P. Lei, S. 

Zhang, K. Kim, X. Liu and S. Safe. Institute of 

Biosciences and Technology, Texas A&M Health 

Science Center, Houston, TX. 


P62 SEQUESTERS KEAP1 INTO 

AUTOPHAGOSOMES, PREVENTING THE 

KEAP1-DEPENDENT UBIQUITINATION 

AND DEGRADATION OF NRF2. A. Lau, X. 

Wang, F. Zhao, N. F. Villeneuve, T. Jiang, T. Wu, Z. 

Sun and D. D. Zhang. Pharmacology and Toxicology, 



AUTOPHAGY: A KEY MECHANISM IN 

ARSENITE-INDUCED CYTOTOXICITY 

IN HUMAN LYMPHOBLASTOID CELL 

LINES. A. M. Bolt, R. M. Byrd and W. T. Klimecki. 




RAPTOR, A COMPONENT OF MTORC1, 

PLAYS A KEY ROLE IN AUTOPHAGY IN 

ADAPTION OF RADIORESISTANCE IN A549 

LUNG CANCER CELLS. J. Shin and M. Cho. 

Laboratory of Toxicology, College of Veterinary 

Medicine, Seoul National University, Seoul, Republic 



MECHANISMS OF AMIODARONE AND 

DESETHYLAMIODARONE CYTOTOXICITY 

IN HUMAN LUNG CELLS. J. E. Black, J. 

F. Brien, W. J. Racz and T. E. Massey. Queen’s 

University, Kingston, ON, Canada. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Neurotoxicity of Pesticides 

Chairperson(s): Timothy J. Shafer, U.S. EPA, Research Triangle Park, 

NC, and Stephanie Padilla, U.S. EPA, Durham, NC. 




EVALUATION OF MOTOR ACTIVITY 

AND BRAIN MORPHOMETRICS IN DNT 

STUDIES WITH OPS. A. Terrell 1 and A. B. 

Lowit 2 . 1 Environmental Health Sciences, University 

of Minnesota, Minneapolis, MN and 2 Office of 

Pesticide Programs, U.S. EPA, Washington, DC. 


PARAQUAT INDUCES BOTH NIGRAL AND 

STRIATAL DOPAMINERGIC DAMAGE 

IN OCT3-/- MICE. M. Cui 1,2 , P. Rappold 1,2 and 

K. Tieu 1,2,3 . 1 Neurology, University of Rochester, 

Rochester, NY, 2 Center for Translational 

Neuromedicine, University of Rochester, Rochester, 

NY and 3 Environmental Medicine, University of 



PYRETHROID INHIBITION OF A HUMAN 

T-TYPE VOLTAGE-SENSITIVE CALCIUM 

CHANNEL IS STRUCTURAL SPECIFIC 

AND CONCENTRATION -DEPENDENT. E. 

M. Mutanguha, Z. H. Valentine and S. B. Symington. 

Biology and Biomedical Science, Salve Regina 

University, Newport, RI. 


EARLY DIFFERENTIAL NECROSIS AND 

APOPTOSIS INITIATE AND CONTRIBUTE 

TO THE DEVELOPMENT OF OPIDN: A 

STUDY OF MOLECULAR, CELLULAR, AND 

ANATOMICAL STUDIES. T. V. Damodaran 2,1 , 

M. K. Attia 2 and M. B. Abou-Donia 2 . 1 Biology, 

North Carolina State University, Durham, NC and 

2 

Pharmacology and Cancer Biology, Duke University 

Medical Center, Durham, NC. 



DELTAMETHRIN RESULTS IN GENDER 

SPECIFIC CHANGES IN HEPATIC 

UDP-GLUCORONOSYLTRANSFERASE 

EXPRESSION. A. L. Green, A. A. Baker and J. R. 

Richardson. Toxicology, UMDNJ-Rutgers University, 



UTILITY OF C6-GLIOMA CELLS FOR 

EXPLORATORY RISK ASSESSMENT 

OF COMPLEX MIXTURES OF 

ORGANOPHOSPHATE AND PYRETHROID 

INSECTICIDES. D. M. Romero, A. Alaimo, R. 

Gorojod, M. L. Kotler and M. J. Wolansky. Biological 

Chemistry (Toxicology), ARG NRC/University of 

Buenos Aires, Buenos Aires, Argentina. 

212 






Platform Sessions



Abstract # 


CELLULAR CONSEQUENCES OF 

DIELDRIN ANALOG EXPOSURE IN 

DOPAMINERGIC CELLS. E. M. Allen, Y. 

Jinsmaa and J. A. Doorn. Medicinal and Natural 

Products Chemistry, University of Iowa, Iowa City, 

IA. 


BIOMARKERS OF CHLORPYRIFOS 

EXPOSURE AND EFFECT IN EGYPTIAN 

COTTON FIELD WORKERS. F. M. Farahat 1 , 

J. R. Olson 2 , B. P. Mcgarrigle 2 , M. R. Bonner 2 , C. A. 

Ellison 2 , R. A. Fenske 3 , K. Galvin 3 , D. S. Rohlman 4 , P. 

J. Lein 4,5 and K. Anger 4 . 1 Menoufia University, Shibin 

el-Kom, Egypt, 2 University at Buffalo, Buffalo, NY, 

3 

University of Washington, Seattle, WA, 4 Oregon 

Health & Science University, Portland, OR and 

5 

University of California Davis School of Veterinary 

Medicine, Davis, CA. 


SUBCHRONIC CHLORPYRIFOS EXPOSURE 

ALTERS APPETITIVE BEHAVIOR AND 

CONTEXTUAL FEAR CONDITIONING 

IN RATS. M. Lattal 1 , D. Yang 2 , D. Bruun 2 , W. 

Anger 3 and P. J. Lein 2,3 . 1 Behavioral Neuroscience, 

Oregon Health & Science University, Portland, OR, 

2 

Molecular Biosciences, University of California 

Davis, Davis, CA and 3 Center for Research on 

Occupational and Environmental Toxicology, Oregon 

Health & Science University, Portland, OR. 


EXPOSURE OF RAT HIPPOCAMPAL 

ASTROCYTES TO ZIRAM INCREASES 

OXIDATIVE STRESS. A. Matei and L. D. 

Trombetta. College of Pharmacy & Allied Health 

Professions, St Johns University, Jamaica, NY. 


BIOMARKERS OF ORGANOPHOSPHORUS 

PESTICIDE-INDUCED NEUROTOXICITY. P. 

J. Lein 1 , F. Farahat 2 , J. R. Olson 3 , D. Rohlman 4 , M. 

Bonner 3 , M. Lattal 4 , R. A. Fenske 5 , K. Galvin 5 , M. 

Lasarev 4 and W. Anger 4 . 1 University of California 

Davis, Davis, CA, 2 Menoufia University, Shebin 

El-kom, Egypt, 3 SUNY, Buffalo, NY, 4 Oregon 

Health & Science University, Portland, OR and 

5 

University of Washington, Seattle, WA. 


SELECTIVE ACTIVE-SITE-DIRECTED 

IRREVERSIBLE INHIBITORS OF INSECT 

ACETYLCHOLINESTERASES. G. A. 

Polsinelli 1 , Y. Gao 1 , L. Peng 1 , S. K. Singh 1 , R. K. 

Mishra 1 , R. Suranyi 2 , D. Ragsdale 3 , A. M. Fallon 3 , 

K. Zhu 4 , Y. Pang 1 and S. Brimijoin 1 . 1 Molecular 

Pharmacology and Experimental Therapeutics, Mayo 

Clinic, Rochester, MN, 2 McLaughlin Gormley 

King Company, Minneapolis, MN, 3 Department of 

Entomology, University of Minnesota, Saint Paul, 

MN and 4 Department of Entomology, Kansas State 

University, Manhattan, KS. 


ACHE DEPRESSION IS RELATED TO OP 

METABOLITES IN URINE OF ORCHARD 

WORKERS PERFORMING THINNING. Z. 

Guerrette 1 , W. C. Griffith 1 , G. D. Coronado 2 , E. M. 

Vigoren 1 , B. Thompson 1,2 and E. M. Faustman 1 . 

1 

University of Washington, Seattle, WA and 2 Fred 

Hutchinson Cancer Research Center, Seattle, WA. 

Abstract # 


INHIBITION OF 

ACETYLCHOLINESTERASE (ACHE) AND 

BUTYRYLCHOLINESTERASE (BCHE) 

IN HUMAN BLOOD FOLLOWING IN 

VITRO AND IN VIVO EXPOSURE TO 

CHLORPYRIFOS. A. L. Crane 1 , R. W. Browne 1 , 

J. B. Knaak 1 , M. R. Bonner 1 , R. A. Fenske 2 , F. M. 

Farahat 3 , K. Anger 4 , P. J. Lein 4,5 and J. R. Olson 1 . 

1 

University at Buffalo, Buffalo, NY, 2 University of 

Washington, Seattle, WA, 3 Menoufia University, 

Shibin el-Kom, Egypt, 4 Oregon Health & Science 

University, Portland, OR and 5 University of 

California Davis School of Veterinary Medicine, 

Davis, CA. 


THE EFFECTS OF THE FUNGICIDE 

MANEB (MANGANOUS ETHYLENEBIS 

[DITHIOCARBAMATE]) ON RAT 

HIPPOCAMPAL ASTROCYTES. M. Akhtar 

and L. D. Trombetta. College of Pharmacy & Allied 

Health Professions, Saint Johns University, Jamaica, 

NY. 


PYRETHROID INSECTICIDE 

ACCUMULATION IN PRIMARY CULTURES 

OF CORTICAL NEURONS IN VITRO. T. J. 

Shafer 1 , A. N. Jay 2 and M. F. Hughes 1 . 1 Integrated 

Systems Toxicology Division NHEERL, U.S. 

EPA, Research Triangle Park, NC and 2 Biology 

Department North Carolina State University, Raleigh, 

NC. 


COMPARISON OF EEG CHANGES 

PRODUCED BY CARBARYL (CARBAMATE), 

PERMETHRIN (TYPE I PYRETHROID), AND 

DELTAMETHRIN (TYPE II PYRETHROID. 

D. F. Lyke and D. W. Herr. Toxicity Assessment 

Division, U.S. EPA, Research Triangle Park, NC . 


AGING-RELATED CARBARYL EFFECTS IN 

BROWN NORWAY RATS. K. A. Jarema, P. M. 

Phillips and R. C. MacPhail. NHEERL, U.S. EPA, 



REPEATED EXPOSURE TO LOW DOSES 

OF CHLORPYRIFOS: HIPPOCAMPAL 

DAMAGE, DEFICITS IN SPATIAL 

LEARNING, AND INHIBITION OF THE 

ERK-CREB SIGNAL SYSTEM. S. Peng 1,2 and 

C. Yan 1,2 . 1 Beijing Institute of Pharmacology and 

Toxicology, Beijing, China and 2 Beijing Institute of 

Disease Control and Prevention, Beijing, China. 


KINETIC OF THE ESTEREOSPECIFIC 

INTERACTION OF A MODEL CHIRAL 

PHOSPHORAMIDATE WITH ESTERASES 

IN PERIPHERAL NERVE SOLUBLE 

FRACTION. E. Vilanova Gisbert, J. Barril and J. 

Estevez. Unidad de Toxicologia, Universidad Miguel 

Hernandez. Institute Bioingenieria, Elche, Spain. 

tueSday 







213


tueSday 




ROLE OF CALCIUM INFLUX AND CALPAIN 

ACTIVATION IN PYRETHROID PESTICIDE- 

INDUCED DOWN-REGULATION OF 

SODIUM CHANNEL EXPRESSION. J. P. 

Magby 1,2 and J. R. Richardson 1,2 . 1 Joint Graduate 

Program in Toxicology, Rutgers University/UMDNJ, 

Piscataway, NJ and 2 Graduate School of Biomedical 

Sciences, UMDNJ, Piscataway, NJ. 


DEVELOPMENTAL EXPOSURE 

TO DELTAMETHRIN RESULTS IN 

GENDER SPECIFIC CHANGES IN 

CARBOXYLESTERASE EXPRESSION 

AND INCREASED METABOLISM OF 

METHYLPHENIDATE. A. A. Baker, M. M. 

Taylor and J. R. Richardson. Toxicology, UMDNJ- 



FULLERENE ANTIOXIDANTS DECREASE 

ORGANOPHOSPHATE-INDUCED 

ACETYLCHOLINESTERASE INHIBITION 

IN VITRO. M. Ehrich 1 , K. Fuhrman 1 , X. Wu 1 , J. 

Hinckley 1 , S. Werre 1 , Y. Li 2 , Z. Jia 2 , R. Van Tassell 3 

and C. Kepley 4 . 1 Virginia-Maryland Regional College 

of Veterinary Medicine, Virginia Tech, Blacksburg, 

VA, 2 Via College of Osteopathic Medicine, 

Blacksburg, VA, 3 Luna Innovations, Blacksburg, VA 

and 4 Luna nanoWorks, Danville, VA. 


VESTIBULAR TOXICITY OF CIS- 

CROTONONITRILE IN 129S1 

FEMALE MICE PRE-TREATED WITH 

DIALLYLSULFIDE. J. Llorens, C. Soler-Martín 

and S. Saldaña-Ruíz. D. Ciencies Fisiologiques II, 

Universitat de Barcelona, Hospitalet de Llobregat, 

Catalunya, Spain. 


NEUROTOXICANTS MALATHION AND 

LEAD ACETATE INCREASE GENE 

EXPRESSION OF SCAFFOLD PROTEINS 

ZO1 AND ZO2, AND CALCIUM CHANNEL 

PROTEIN TRPC1 IN ENDOTHELIAL CELLS. 

P. Balbuena, W. Li and M. Ehrich. Virginia-Maryland 

Regional College of Veterinary Medicine, Virginia 

Tech, Blacksburg, VA. 


ALTERATIONS IN MITOCHONDRIAL 

DYNAMICS AND AXONAL TRANSPORT 

AFTER EXPOSURE TO CHLORPYRIFOS 

AND CHLORPYRIFOS-OXON IN RAT 

CORTICAL NEURONS. M. Middlemore-Risher 1 

and A. V. Terry 1,2 . 1 College of Pharmacy, University 

of Georgia, Augusta, GA and 2 Pharmacology and 

Toxicology, Medical College of Georgia, Augusta, 

GA. Sponsor: D. Sickles. 


EFFECT OF LOW-LEVEL EXPOSURE TO 

DIISOPROPYLFLUOROPHOSPHATE (DFP) 

ON REGIONAL BRAIN METABOLISM IN 

F344 RATS. D. A. Mahle 1,2 , J. M. Gearhart 1 and N. 

V. Reo 2 . 1 AFRL, RHPB, Wright-Patterson AFB, OH 

and 2 Wright State University, Fairborn, OH. 


ORGANOPHOSPHORUS-INDUCED 

DELAYED NEUROPATHY: AN EFFECTIVE 

THERAPEUTIC STRATEGY. G. H. DeOliveira 

and G. L. Emerick. Natural Actives Principles and 

Toxicology, UNESP São Paulo State University, 

Araraquara, São Paulo, Brazil. Sponsor: G. 

DeOliveira. 


ACUTE TOLUENE EXPOSURE ALTERS 

EXPRESSION OF GENES ASSOCIATED 

WITH SYNAPTIC STRUCTURE AND 

FUNCTION. S. D. Hester, A. M. Johnstone, W. 

K. Boyes, P. J. Bushnell and T. J. Shafer. ISTD, 

NHEERL, U.S. EPA, Research Triangle Park, NC . 


TETRAMETHRIN AND DDT INHIBIT 

SPONTANEOUS FIRING IN CORTICAL 

NEURONAL NETWORKS. A. M. Johnstone 1 , A. 

Jay 2 and T. J. Shafer 1 . 1 ISTD, NHEERL, U.S. EPA, 

Research Triangle Park, NC and 2 Biology, North 



MANEB ENHANCES MPP + -INDUCED 

CYTOTOXICITY THROUGH ACTIVATION 

OF NF-KAPPA B IN PC12 CELLS. S. Cheng, J. 

Quinones and A. Maynard. Science, John Jay College 

of Criminal Justice, New York. 


ANALYSIS OF C57BL/6 MICE AT 8 AND 16 

MONTHS AFTER REPEATED DOSING OF 

PARAQUAT AND MANEB. L. J. McIntosh 1 , S. 

A. Benkovic 2 , D. B. Miller 2 , J. P. O’Callaghan 2 , R. 

Patten 3 , M. J. Collier 3 , C. Willoughby 3 , D. Myers 3 , 

R. C. Switzer 4 and A. A. Li 1 . 1 Exponent, Inc., 

Menlo Park, CA, 2 Neurotoxicology Laboratories, 

Centers for Disease Control, Morgantown, WV, 

3 

Reproductive and Behavioural Studies Groups, 

Huntingdon Life Sciences, Suffolk, United Kingdom 

and 4 NeuroScience Associates, Knoxville, TN. 


LOCOMOTIVE ACTIVITY AS AN 

INDICATOR OF ACUTE CHLORPYRIFOS 

TOXICITY IN C. ELEGANS. M. J. Pomeroy- 

Black. Biology, LaGrange College, LaGrange, GA. 


STRAIN AND DOSE-RELATED EFFECTS 

OF SUBCHRONIC CHLORPYRIFOS 

(CPF) EXPOSURE ON BIOMARKERS OF 

EXPOSURE AND OXIDATIVE STRESS IN 

RATS. J. R. Olson 1 , M. Lasarev 2 , D. Bruun 3 , 

D. Milatovic 4 , M. Aschner 4 and P. J. Lein 3,2 . 

1 

Pharmacology & Toxicology, University at Buffalo, 

Buffalo, NY, 2 CROET, Oregon Health & Science 

University, Portland, OR, 3 Molecular Biosciences, 

University of California Davis, Davis, CA and 

4 

Pediatric Toxicology, Vanderbilt University, 


214 






Platform Sessions



Abstract # 


IN-COMMUNITY STUDY OF LONG 

TERM LOW-LEVEL EXPOSURE TO 

ORGANOPHOSPHATE PESTICIDES 

(OP)—ARE THERE NEUROBEHAVIORAL 

EFFECTS AFTER THREE DECADES? Y. 

Finkelstein 1 , M. Aschner 2 , A. Ophir 3 , U. Wormser 3 

and E. D. Richter 4 . 1 Neurology and Toxicology, 

Shaare Zedek Med Ctr, Jerusalem, Israel, 

2 

Department of Pediatrics, Vanderbilt University 

Medical Center, Nashville, TN, 3 Institute of 

Drug Research, School of Pharmacy, Faculty of 

Medicine, Hebrew University, Jerusalem, Israel and 

4 

Department of Occupational and Environmental 

Medicine, Faculty of Medicine, Hebrew University, 

Jerusalem, Israel. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Neurodegenerative Disease 

Chairperson(s): Richard Nass, Indiana University School of Medicine, 

Indianapolis, IN, and Rao Uppu, Southern University and A&M College, 





JP-8 JET FUEL EXPOSURE CAN SENSITIZE 

THE EAR TO SUBSEQUENT NOISE 

INDUCED HEARING LOSS. L. Fechter, C. 

Gearhart and S. Fulton. Research (151), Loma Linda 

Veterans Administration Medical Center, Loma 

Linda, CA. 


VACUOLAR CHANGES IN SENSORY 

NEURONS IN ORGANOPHOSPHATE- 

INDUCED DELAYED NEUROTOXICITY 

(OPIDN). INCIDENCE AND STRUCTURE. T. 

S. Rogers-Cotrone, M. P. Burgess, S. K. Hancock, J. 

Hinckley, K. Lowe, M. F. Ehrich and B. S. Jortner. 

Laboratory for Neurotoxicity Studies, Virginia Tech, 

Blacksburg, VA. 


2, 5-HEXANEDIONE (HD) IMPAIRS THE 

CYTOSKELETAL PROTEIN INTERACTIONS 

OF MICROTUBULE ASSOCIATED 

PROTEINS (MAPS). L. Zhang 1 , R. M. LoPachin 1 

and A. P. DeCaprio 2 . 1 Anesthesiology, Albert 

Einstein College of Medicine, Bronx, NY and 

2 

Chemistry and Biochemistry, Florida International 

University, Miami, FL. 


POSITIVE MODULATION OF THE NOVEL 

ANTI-APOPTOTIC KINASE PKD1 CAN 

PROTECT DOPAMINERGIC NEURONS 

AGAINST OXIDATIVE DAMAGE IN 

PARKINSON’S DISEASE MODELS. A. 

Asaithambi, A. Kanthasamy, V. Anantharam and 

A. Kanthasamy. Biomedical Sciences, Iowa State 

University, Ames, IA. 

Abstract # 


UNCOUPLING PROTEIN 2-INITIATED 

AUTOPHAGY PROMOTES CYANIDE- 

INDUCED NEUROTOXICITY: 

INVOLVEMENT OF BNIP3 UPREGULATION. 

L. Li, X. Zhang, L. Zhang, H. Liu, S. Mukhopadhyay, 

J. L. Borowitz and G. E. Isom. Medicinal Chemistry 

& Molecular Pharmacology, Purdue University, West 



THE HUMAN DOPAMINERGIC NEURONAL 

CELL LINE LUHMES AS IN VITRO MODEL 

FOR PARKINSONS DISEASE. S. Schildknecht, 

D. Poeltl and M. Leist. University of Konstanz, 

Konstanz, Germany. Sponsor: A. Buerkle. 


PROTEIN MODIFICATION 

AND ADVERSE FUNCTIONAL 

CONSEQUENCES MEDIATED BY 3, 

4-DIHYDROXYPHENYLACETALDEHYDE. 

L. M. Mexas, V. Florang, J. Yunden and J. A. 

Doorn. Medicinal and Natural Products Chemistry, 

University of Iowa, Iowa City, IA. 


CHRONIC EXPOSURE TO CORT PRIMES 

THE CNS PROINFLAMMATORY RESPONSE 

IN MPTP AND METH MODELS OF 

NEUROTOXICITY. J. P. O’Callaghan and D. B. 

Miller. HELD, CDC-NIOSH, Morgantown, WV. 


TANESPIMYCIN PROTECTS CULTURED 

RAT DORSAL ROOT GANGLIA FROM 

BORTEZOMIB TOXICITY. O. Flint 1 , J. Kwagh 1 , 

F. Wang 1 , C. Storck 1 , F. Moulin 1 , J. Oberdoerster 2 , D. 

Berman 1 and B. Car 1 . 1 Discovery Toxicology, Bristol- 

Myers Squibb, Princeton, NJ and 2 Drug Safety, 

Bristol-Myers Squibb, Syracuse, NY. 


INTERACTION OF AN 

ENDOGENOUS NEUROTOXIN, 3, 

4-DIHYDROXYPHENYLACETALDEHYDE, 

AND GLIAL CELLS: METABOLISM, 

ACTIVATION, AND TOXICITY. L. L. Eckert, 

J. Yunden, V. R. Florang and J. A. Doorn. MNPC, 

College of Pharmacy, The University of Iowa, Iowa 

City, IA. 


OXIDATION OF 3, 

4-DIHYDROXYPHENYLACETALDEHYDE 

AND REACTIVITY WITH PROTEIN 

NUCLEOPHILES. D. G. Anderson, V. Florang 

and J. A. Doorn. Medicinal and Natural Products 

Chemistry, University of Iowa, Iowa City, IA. 


RESVERATROL PROTECTS AGAINST 

MPP+ AND METHAMPHETAMINE 

NEUROTOXICITY BY MODULATING THE 

PKC-DELTA APOPTOTIC SIGNALING 

PATHWAY AND MICROGLIAL ACTIVATION. 

K. Kanthasamy, R. Gordon, C. E. Hogan, V. 

Anantharam, A. G. Kanthasamy and A. Kanthasamy. 

Department of Biomedical Sciences, Iowa State 

University, Ames, IA. 

tueSday 







215


tueSday 




EFFECTS OF MEMANTINE ON NEURONAL 

OXIDATIVE DAMAGE. S. Zaja-Milatovic, M. 

Aschner and D. Milatovic. Pediatrics, Vanderbilt 

University, Nashville, TN. 


PINK1 AND MITOCHONDRIAL 

DYNAMICS: A NEW PERSPECTIVE OF 

MITOCHONDRIAL DYSFUNCTION IN 

PARKINSON’S DISEASE? K. Tieu 1,2,3 , M. Cui 1,2 , 

X. Tang 1,2 , W. V. Christian 3 and Y. Yoon 4 . 1 Neurology, 

University of Rochester, Rochester, NY, 2 Center 

for Translational Neuromedicine, University of 

Rochester, Rochester, NY, 3 Environmental Medicine, 

University of Rochester, Rochester, NY and 

4 

Anesthesiology, University of Rochester, Rochester, 

NY. 


FUNCTIONAL ROLE OF THE 

NEUROTOXICITY BIOMARKER PROTEIN 

TSPO/PBR IN PRIMARY MICROGLIA. J. 

Choi 1 , M. Ifuku 2 , M. Noda 2 and T. R. Guilarte 1 . 

1 

Environmental Health Sciences, Johns Hopkins 

School of Public Health, Baltimore, MD and 2 Lab 

of Pathophysiology, Kyushu University, Fukuoka, 

Japan. 


OVARIECTOMY POTENTIATES 

REDUCTIONS IN STRIATAL NERVE 

TERMINAL DOPAMINE LEVELS AFTER 

CHRONIC PCB EXPOSURE. A. Dreiem 1,2 , V. M. 

Miller 1,2 , S. Sanchez-Morrissey 1 , K. L. Andrews 1 , N. 

Neu 1 , K. O. Brosch 1 and R. F. Seegal 1,2 . 1 Wadsworth 

Center, Albany, NY and 2 School of Public Health, 

University at Albany, Albany, NY. 


TANESPIMYCIN BLOCKS BORTEZOMIB- 

INDUCED PERIPHERAL NEUROPATHY IN 

RATS. J. Oberdoerster 1 , B. D. Car 2 , O. P. Flint 2 , T. 

P. Reilly 1 , J. Arezzo 4 , M. Litwak 4 , A. M. Fletcher 1 , G. 

E. Schulze 1 , R. Westhouse 2 and D. M. Berman 3 . 1 Drug 

Safety Evaluation, Bristol-Myers Squibb Company, 

East Syracuse, NY, 2 Discovery Toxicology, Bristol- 

Myers Squibb Company, Princeton, NJ, 3 Global 

Clinical Research, Bristol-Myers Squibb Company, 

Princeton, NJ and 4 Neuroscience and Neurology, 

Albert Einstein College of Medicine, Bronx, NY. 


THE PROGRESSION OF EXPERIMENTAL 

AUTOIMMUNE ENCEPHALITIS 

IS DEPENDENT ON NOD2 AND 

RICK ACTIVATION IN MICROGLIA 

REPRESENTING A NOVEL THERAPEUTIC 

TARGET FOR MULTIPLE SCLEROSIS. 

P. J. Shaw, J. R. Lukens, S. Burns, H. Chi, M. 

A. McGargill and T. Kanneganti. Department of 

Immunology, St. Jude Children’s Research Hospital, 

Memphis, TN. 


BETA-SECRETASE GENE EXPRESSION 

AND ACTIVITY IN MURINE GT1-7 

HYPOTHALAMIC NEURONS EXPOSED TO 

CHOLESTEROL SECOALDEHYDE. S. Babu 1 , 

A. C. Raghavamenon 1 , R. J. Martin 2 , B. Prakhya 3 and 

R. M. Uppu 1 . 1 Environmental Toxicology, Southern 

University and A&M College, Baton Rouge, LA, 

2 

Neurobehavior Laboratory, Pennington Biomedical 

Research Center, Baton Rouge, LA and 3 Genetic 

Toxicology, International Institute of Biotechnology 

and Toxicology, Padappai, India. 


STRUCTURALLY DIVERSE CATIONIC 

NEUROTOXICANTS ATTENUATE ATP- 

DEPENDENT CALCIUM SIGNALING IN 

ASTROCYTES. B. Trout, K. M. Streifel and R. 

B. Tjalkens. Environmental Radiological and Health 

Science, Colorado State University, Fort Collins, CO. 


BLOCKADE OF NUCLEAR FACTOR 

KAPPA B PREVENTS MPTP-INDUCED 

EXPRESSION OF INDUCIBLE NITRIC 

OXIDE SYNTHASE IN PRIMARY 

ASTROCYTES. K. A. Popichak 1 , D. L. Carbone 1 , 

J. A. Miller 1 , S. Safe 2 and R. B. Tjalkens 1 . 1 ERHS, 

Colorado State University, Fort Collins, CO and 2 Vet 

Physiol and Pharmacology Texas A&M University, 

College Station, TX. 


OXIDATIVE STRESS MAY LEAD 

TO NEURODEGENERATION IN 

CAENORHABDITIS ELEGANS FOLLOWING 

CHRONIC EXPOSURE TO MANCOZEB. R. 

Negga, O. Mirallas and V. A. Fitsanakis. Biology, 

King College, Bristol, TN. 


NEURONAL DEGENERATION FOLLOWING 

TOUCHDOWN EXPOSURE IN C. ELEGANS 

MAY BE DUE TO OXIDATIVE STRESS. J. 

Stuart, R. E. Barnett and V. A. Fitsanakis. Biology, 

King College, Bristol, TN. 


PYRETHROID PESTICIDE-INDUCED 

APOPTOSIS: ROLE OF THE ER STRESS 

PATHWAY. M. M. Hossain and J. R. Richardson. 

Environmental and Occupational Medicine, Robert 

Wood Johnson Medical School, University of 

Medicine and Dentistry of New Jersey, Piscataway, 

NJ. 


ACRYLAMIDE ADDUCTION AND 

S-NITROSYLATION OF NEURONAL 

PROTEINS. D. S. Barber 1 , C. J. Martyniuk 1 , 

A. Feswick 1 , S. Stevens 3 and R. M. LoPachin 2 . 

1 

Center for Environmental and Human 

Toxicology, University of Florida, Gainesville, FL, 

2 

Anesthesiology, Montefiore Medical Center, Bronx, 

NY and 3 Cell Biology, Microbiology, and Molecular 

Biology, University of South Florida, Tampa, FL. 

216 






Platform Sessions



Abstract # 


ROLE OF THE DIVALENT METAL 

TRANSPORTER, GLUTATHIONE-S- 

TRANSFERASE PI, AND ER STRESS 

RESPONSE PROTEINS IN C. ELEGANS 

MODELS OF PARKINSON’S DISEASE 

AND MANGANISM. R. Settivari, J. LeVora and 

R. Nass. Pharmacology and Toxicology, Indiana 

University School of Medicine, Indianapolis, IN. 


EXPOSURE TO GLYPHOSATE- 

CONTAINING HERBICIDES OR COMBINED 

TREATMENT WITH MANZATE LEADS TO 

SELECTIVE NEURODEGENERATION IN 

CAENORHABDITIS ELEGANS. S. Richardson, 

A. L. Smith, M. B. Johnson, A. S. Fields, A. L. 

Valente and V. A. Fitsanakis. Biology, King College, 

Bristol, TN. 


STRIATUM AND SUBSTANTIA NIGRA 

COMPACTA ULTRASTRUCTURAL 

ALTERATIONS AFTER MNCL2-MNOAC3 

MIXTURE INHALATION. J. Ordoñez-Librado, 

A. Gutierrez-Valdez, V. Anaya-Martinez, E. Montiel- 

Flores, P. Aley, J. Espinosa, L. Colin-Barenque and 

M. Avila-Costa. Department de Biologia Celular y 

Tisular, Universidad Nacional Autonoma de Mexico, 

Tlalnepantla, Mexico. 


REDOX METABOLOMIC ANALYSIS OF 

PLASMA GLUTATHIONE REDOX STATUS 

OF HUMAN PARKINSON’S DISEASE. J. 

Roede 1 , Y. Liang 2 , J. M. Johnson 1 , R. Patel 3 , A. 

A. Quyyumi 3 , G. W. Miller 4,5 and D. P. Jones 1,2 . 

1 

Medicine, Emory University, Atlanta, GA, 

2 

Clinical Biomarkers Laboratory, Emory University, 

Atlanta, GA, 3 Cardiovascular Research Center, 

Emory University, Atlanta, GA, 4 Center for 

Neurodegenerative Disease, Emory University, 

Atlanta, GA and 5 Environmental and Occupational 

Health, Emory University, Atlanta, GA. 


SYNERGISTIC TOXICITY OF ARSENIC AND 

DOPAMINE IN SH-SY5Y NEUROBLASTOMA 

CELLS, AND THE PROTECTIVE EFFECT 

OF NICOTINE. M. R. Waters, D. H. Petroni and 

W. J. George. Pharmacology, Tulane, New Orleans, 

LA. 


METHYLMERCURY, NEUROBLASTOMA 

CELLS, AND MARKERS OF ALZHEIMER’S 

DISEASE. D. Petroni, J. Tsai and W. J. George. 

Tulane University, New Orleans, LA. 


GENE DELETION OF INDUCIBLE NITRIC 

OXIDE SYNTHASE SUPPRESSES GLIAL 

INFLAMMATION AND PROTECTS AGAINST 

MANGANESE NEUROTOXICITY. K. 

Streifel 1,2 , J. A. Moreno 2 , B. R. Trout 1 and R. B. 

Tjalkens 1,2 . 1 Environmental Radiological Health 

Science, Colorado State University, Fort Collins, 

CO and 2 Molecular, Cellular, and Integrative 

Neuroscience, Colorado State University, Fort 

Collins, CO. 

Abstract # 


INVESTIGATION OF THE NEUROTOXIC 

MECHANISMS INVOLVED IN BETA- 

AMYLOID DEPOSITION IN PSAPP MICE. 

M. Dhanasekaran, M. Ahuja and V. Suppiramaniam. 

Pharmacal Sciences, Harrison School of Pharmacy, 

Auburn, AL. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Biomarkers 

Chairperson(s): Craig E. Thomas, Eli Lilly, Indianapolis, IN. 




NEONATAL EXPOSURE OF MALE RATS TO 

BISPHENOL A IMPAIRS EXPRESSION OF 

SERTOLI CELL JUNCTIONAL PROTEINS 

IN THE TESTIS. S. S. Salian, T. Doshi and G. 

Vanage. National Center for Preclinical Reproductive 

and Genetic Toxicology, National Institute for 

Research in Reproductive Health (ICMR), Mumbai, 

Maharashtra, India. 


DETECTING BIOMARKERS OF CHRONIC 

ARSENIC EXPOSURE BY USING SELDI- 

TOF-MS PROTEIN CHIP TECHNOLOGY. L. 

Zhao 1 , D. Sun 1 , Y. Gao 1 , Y. Wei 2 , Y. Li 1 , W. Wei 1 , H. 

Feng 1 and Y. Ding 1 . 1 The Center for Endemic Disease 

Control, China CDC, Harbin Medicial University, 

Harbin, China and 2 Department of Community 

Medicine, Mercer University School of Medicine, 

Macon, GA. 


EFFECTS OF ORAL ADMINISTRATION OF 

PIOGLITAZONE, SODIUM SACCHARIN 

OR SODIUM O-PHENYLPHENATE ON THE 

EXPRESSION OF ONCOMODULIN IN THE 

BLADDER EPITHELIUM OF MALE F344 

RATS. M. Yokohira 1 , M. Wei 2 , H. Wanibuchi 2 , S. 

Suzuki 3 , K. L. Pennington 1 , S. Kakiuchi-Kiyota 1 , 

L. L. Arnold 1 and S. M. Cohen 1 . 1 Pathology & 

Microbiology, University of Nebraska Medical 

Center, Omaha, NE, 2 Department of Pathology, 

Osaka City University Medical School, Osaka, Japan 

and 3 Department of Experimental Pathology and 

Tumor Biology, Nagoya City University Graduate 

School of Medical Sciences, Nagoya, Aichi, Japan. 


SIMULTANEOUS ANALYSIS OF ELEVEN 

VOC METABOLITES IN HUMAN URINE. U. 

Alwis 1 , B. C. Blount 1 , A. N. Sheppard 1 , S. P. Proctor 2 

and D. L. Ashley 1 . 1 Centers for Disease Control and 

Prevention, Atlanta, GA and 2 U.S. Army Research 

Institute of Environmental Medicine, Natick, MA. 

Sponsor: B. Fowler. 

tueSday 







217


tueSday 




TOXICOGENOMIC IDENTIFICATION OF 

BIOMARKERS OF ACUTE RESPIRATORY 

EXPOSURE TO SENSITIZING AGENTS. C. 

Pucheu-Haston 1 , L. B. Copeland 2 , E. Boykin 2 and 

M. D. Ward 2 . 1 Curriculum in Toxicology, University 

of North Carolina, Chapel Hill, NC and 2 NHEERL, 



DEPLETION OF KUPFFER CELLS AS A 

MECHANISM FOR INCREASED SERUM 

ENZYMES. P. Koza-Taylor, R. Giovanelli, C. 

Tabor, L. Obert, S. Sadis, H. Runnels, R. Bell and M. 

Lawton. Pfizer, Groton, CT. 


ANALYSIS OF LYMPHOCYTE SUBSETS 

IN PERIPHERAL BLOOD AMONG 

EXPOSED WORKERS AND PATIENTS 

WITH HYPERSENSITIVITY DERMATITIS 

INDUCED BY TRICHLOROETHYLENE. Y. 

Dai 1 , Y. Teng 1 , J. Yi 2 , W. Zhou 2 , H. Dong 1 , X. Huang 2 

and Y. Zheng 1 . 1 National Institute for Occupational 

Health and Poison Control, Chinese Center for 

Disease Control and Prevention, Beijing, China 

and 2 Hospital for Occupational Disease Control of 

Shenzhen, Shenzhen, Guangdong, China. Sponsor: 

H. Wang. 


GROUP SPECIFIC COMPONENT: URINARY 

BIOMARKER OF SUBCLINICAL RENAL 

INJURY IN NEPHROTOXIN MODELS. C. 

Mauzy, J. Frey, V. Chan, R. Pitsch and P. Shiyanov. 

Applied Biotechnology Branch-Human Effectiveness 

Directorate, Air Force Research Laboratory, Wright- 

Patterson AFB, OH. Sponsor: J. Schlager. 


DEVELOPMENT OF AN IN VITRO ASSAY 

FOR RESPIRATORY SENSITIZATION 

CONSIDERING THE VISION ON TOXICITY 

TESTING IN THE 21 ST CENTURY. S. 

Verstraelen 1 , J. Hooyberghs 1 , I. Nelissen 1 , H. 

Witters 1 , G. Schoeters 1,2 , P. Van Cauwenberge 3 and R. 

Van Den Heuvel 1 . 1 Environmental Risk and Health, 

Flemish Institute for Technological Research - 

Centre for Advanced R&D on Alternative Methods 

(VITO - CARDAM), Mol, Belgium, 2 University 

of Antwerp, Antwerp, Belgium and 3 Department of 

Otorhinolaryngology, University of Ghent, Ghent, 



SELECTIVE MEASUREMENT OF ALT 

ISOFORMS IN RAT SERUM BY LC/MS. C. 

Drupa and J. Colangelo. DSRD, Pfizer, Groton, CT. 


SERUM CARDIAC TROPONIN I 

CONCENTRATIONS ARE TRANSIENTLY 

INCREASED IN RATS DOSED WITH 

ROSIGLITAZONE, A PEROXISOME 


g AGONIST. G. M. Hirkaler 1 , R. Fernandes 1 , D. 

Coluccio 1 , C. Kanwal 2 , E. Rasmussen 3 , T. Visalli 1 , 

M. O. Bachynsky 4 , H. Hilton 2 , R. Nicklaus 1 , J. 

Hoflack 5 , A. Buness 5 , F. Herting 6 , L. Suter-Dick 5 

and I. Mikaelian 1 . 1 Toxicology, Hoffmann-La 

Roche, Nutley, NJ, 2 RNA, Hoffmann-La Roche, 

Nutley, NJ, 3 InS, Hoffmann-La Roche, Nutley, NJ, 

4 

Phar, Hoffmann-La Roche, Nutley, NJ, 5 PRNB, 

Hoffmann-La Roche, Basel, Switzerland and 6 TR-D, 

Hoffmann-La Roche, Penzberg, Germany. 


DISTRIBUTION ANALYSIS OF THE ALT 

ISOZYMES IN CANINE TISSUES. Y. Sudo 1 , Y. 

Takai 1 , M. Aoki 1 , K. Hirai 1 , Y. Matsumoto 1 , N. Inui 1 , 

Y. Miyamoto 1 , H. Hamajou 1 , E. Maeda 1 , T. Ito 2 , S. 

Ohkubo 2 , R. Fukuda 1 and K. Takami 1 . 1 Development 

Research Center, Takeda Pharmaceutical Company 

Limited, Osaka, Japan and 2 Discovery Research 

Center, Takeda Pharmaceutical Company Limited, 

Osaka, Japan. 


CYTOKINES OF INFLAMMATION AND 

OXIDATIVE STRESS IN THE URINE OF 

COCAINE USERS. M. M. Bourgeois and I. S. 

Richards. EOH, University of South Florida COPH, 

Tampa, FL. 


HIGH CONTENT SCREENING FOR 

BIOMARKERS OF CIGARETTE SMOKE- 

INDUCED OXIDATIVE STRESS AND 

DAMAGE IN VITRO: EFFECTS OF 

MENTHOL. R. Leverette. Life Sciences, Lorillard, 

Greensboro, NC. 


PROTEOMIC SCREENING OF CIGARETTE 

SMOKE-EXPOSED RAT LUNGS IN A 

SHORT-TERM STUDY. C. A. Carter and M. 

Misra. Life Sciences, Lorillard Tobacco Company, 

Greensboro, NC. 


EVALUATION OF URINARY BIOMARKERS 

IN EARLY STAGE OF KIDNEY INJURY 

INDUCED BY AMINOGLYCOSIDES. Y. Yagi, 

Y. Shibazaki, K. Ago, F. Itoh, Y. Shoji, K. Hiratsuka, 

H. Suzuki and T. Kurosawa. Toxicology Laboratory, 

Meiji Seika, Yokohama, Japan. Sponsor: T. Kadota. 


EVALUATION OF GENDER AS A VARIABLE 

IN RENAL BIOMARKER RESPONSE IN 

RATS GIVEN A NEPHROTOXIC DOSE OF 

GENTAMICIN. M. Guffroy 1 , J. Beaufils 1 , T. 

Gury 1 , R. Masson 1 , J. Gautier 1 , E. Pham 1 , E. Harpur 2 

and S. Pettit 3 . 1 sanofi-aventis, Paris, France, 2 sanofiaventis, 

Alnwick, United Kingdom and 3 HESI 

Biomarkers Committee, Washington, DC. 

218 






Platform Sessions



Abstract # 


EVALUATION OF 3- AND 

1-METHYLHISTIDINE AS PRECLINICAL 

URINE BIOMARKERS OF DRUG-INDUCED 

SKELETAL MUSCLE TOXICITY IN RATS. J. 

D. Vassallo 1 , N. Aranibar 1 , J. A. Rathmacher 2 , E. B. 

Janovitz 1 , S. Stryker 1 , J. DiPiero 1 , D. M. Wescott 1 , D. 

Robertson 1 , L. J. Lowe-Krentz 3 and L. D. Lehman- 

McKeeman 1 . 1 Discovery Toxicology, Bristol-Myers 

Squibb, Princeton, NJ, 2 Metabolic Technologies, 

Inc., Ames, IA and 3 Department of Biological 

Sciences, Lehigh University, Bethlehem, PA. 


IN VITRO HIGH CONTENT SCREENING 

OF CIGARETTE SMOKE MEDIATED 

BIOMARKERS OF EFFECT: TOBACCO 

TYPES. M. Misra, C. A. Carter, R. D. Leverette 

and B. T. Smith. Life Sciences, Lorillard Tobacco 

Company, Greensboro, NC. 


SERUM CYTOKERATIN 18 AND 

ADIPOCYTOKINES IN ALCOHOLIC 

HEPATITIS VERSUS NON-ALCOHOLIC 

STEATOHEPATITIS. M. Zewdu 1 , L. Henry 1 , K. 

C. Falkner 1 , C. McClain 1,2 and M. Cave 1,2 . 1 Medicine/ 





CORRELATION OF URINARY 

BIS(MONOACYL)GLYCEROL PHOSPHATE 

LEVELS WITH DRUG-INDUCED 

PHOSPHOLIPIDOSIS IN THE RAT. K. 

Thompson, K. Haskins, B. Rosenzweig, S. Stewart, 

D. Peters, P. S. Pine and J. Hanig. DAPR, CDER, 

U.S. FDA, Silver Spring, MD. 


MITOCHONDRIAL PATHOLOGIES 

INDUCED BY COMMON CHEMICALS AND 

TOXINS AS VALUABLE RESEARCH TOOLS. 

W. A. Irwin and E. Scollon. OPPTS, HED, U.S. EPA, 

Arlington, VA. 


SERUM CYTOKERATIN-18 LEVELS ARE 

NORMAL IN HIGHLY-EXPOSED STYRENE 

WORKERS SUGGESTING THAT THEY DO 

NOT SUFFER FROM LIVER NECROSIS 

OR APOPTOSIS. A. Stocker 1 , N. Kershner 1 , K. 

Falkner 1 , C. McClain 1,2 and M. Cave 1,2 . 1 Medicine/ 





BIOMARKERS FOR HEPATIC 

HEMANGIOSARCOMA. L. Henry 1 , M. Zewdu 1 , 

K. Falkner 1 , C. McClain 1,2 and M. Cave 1,2 . 1 Medicine/ 




Abstract # 


ANALYSIS OF KIDNEY DAMAGE 

BIOMARKERS IN PLASMA AND URINE 

SAMPLES FROM PATIENTS WITH 

DOCUMENTED RENAL INJURY. J. J. 

Hedberg 1 , I. Schuppe-Koistinen 1 , D. Eisinger 2 and J. 

Mapes 2 . 1 Molecular Toxicology, Safety Assessment, 

AstraZeneca, Sodertalje, Sweden and 2 RBM Inc., 

Lake Placid, NY. Sponsor: J. Stevens. 


NOVEL BIOMARKERS OF CISPLATIN- 

INDUCED KIDNEY DAMAGE. D. Eisinger 2 , 

J. Mapes 2 , S. Chibout 1 , G. Maurer 1 and F. Dieterle 1 . 

1 

Translational Sciences, Novartis, Basel, Switzerland 

and 2 RBM Inc., Lake Placid, NY. Sponsor: J. Stevens. 


ELECTROENCEPHALOGRAPHIC 

SIGNATURES PREDICT SEIZUREGENIC 

POTENTIAL OF NMDA RECEPTOR 

ANTAGONISTS KETAMINE AND 

MEMANTINE. R. P. Rothstein, M. C. Quirk, J. 

C. Roberts, M. J. Bock, C. Fonck and R. Bialecki. 

AstraZeneca Pharmaceuticals, Wilmington, DE. 


RAT SKELETAL MUSCLE TOXICITY 

MEDIATED BY A PPAR-DELTA AGONIST: 

EVALUATION OF BIOMARKERS. C. 

Thompson 1 , L. Peng 1 , J. Dwyer 1 , T. Ackerson 1 , 

O. Mendes 1 , K. Chandross 1 , K. Morgan 1 , M. 

Gerl 2 , K. Kotlenga 2 , A. Roberts 1 and Z. Jayyosi 1 . 

1 

sanofi-aventis U.S. Inc., Bridgewater, NJ and 

2 

sanofi-aventis, Frankfurt, Germany. 


QUANTIFICATION OF 

TETRAHYDROPHTHALIMIDE AND 

PHTHALIMIDE BIOMARKERS OF 

EXPOSURE TO CAPTAN AND FOLPET 

BY LIQUID CHROMATOGRAPHY - 

ATMOSPHERIC PRESSURE CHEMICAL 

IONIZATION-TANDEM MASS 

SPECTROMETRY (LC-APCI-MS). A. 

Berthet 1,2 , P. Schüpfer 1 , F. Storti 1 , C. Huyn 1 and 

M. Bouchard 2 . 1 Institute for Work and Health, 

Lausanne, Switzerland and 2 Département de Santé 

Environnementale et Santé au Travail, Université de 



SUSCEPTIBILITY FACTORS FOR 

PULMONARY INFECTION DURING DIET- 

INDUCED OBESITY FROM GENOMICS 

ANALYSIS OF MICE EXPOSED TO 

LIPOPOLYSACCHARIDE. S. Tilton 1 , K. M. 

Waters 1 , N. J. Karin 1 , R. C. Zangar 1 , M. Lee 2 , J. 

G. Pounds 1 and R. A. Corley 1 . 1 Pacific Northwest 

National Labortory, Richland, WA and 2 Battelle 

Toxicology Northwest, Richland, WA. 


HEMOGLOBIN ADDUCTS AND PLASMA 

METABOLITES AS BIOMARKERS OF 

EXPOSURE TO 1, 6–HEXAMETHYLENE 

DIISOCYANATE. S. L. Flack 1 , L. G. Gaines 1 , K. 

W. Fent 1 , J. M. Thomasen 1 , S. G. Whittaker 2 , L. M. 

Ball 1 and L. A. Nylander French 1 . 1 Department of 

Environmental Sciences and Engineering, University 

of North Carolina at Chapel Hill, Chapel Hill, NC 

and 2 Local Hazardous Waste Management Program, 

Public Health – Seattle & King County, Seattle, WA. 

tueSday 







219


tueSday 




EXPOSURE TO NAPHTHALENE 

INDUCES NAPHTHYL-KERATIN ADDUCT 

FORMATION IN HUMAN EPIDERMIS IN 

VITRO AND IN VIVO. L. A. Nylander French 1 , 

J. C. Kang-Sickel 1 , V. P. Stober 1 and J. E. French 2 . 

1 

Department of Environmental Sciences and 


Hill, Chapel Hill, NC and 2 Host Susceptibility 

Branch, National Toxicology Program, National 




BIOLOGICAL QUALIFICATION OF NEW 

KIDNEY TOXICITY BIOMARKERS IN RAT 

USING TWO NEPHROTOXIC COMPOUNDS 

WITH DISTINCT TOXICITY PROFILES. D. 

G. Peters 1 , R. L. Hall 1 , W. A. Meier 1 , K. Runnels 1 , 

K. Rodocker 1 , H. Smith 2 , J. Akunda 2 , C. Thomas 2 , S. 

Iturria 2 , D. Hamlin 2 , K. Diegel 2 and D. E. Watson 2 . 

1 

Covance Laboratories, Madison, WI and 2 Eli Lilly 

and Company, Indianapolis, IN. 


METABOLOMIC ANALYSIS OF URINE 

FROM RESVERATROL-TREATED MALE, 

FEMALE, AND PREGNANT WISTAR HAN 

RATS. S. C. Sumner 1 , R. Snyder 1 , T. Fennell 1 , R. 

Fernando 1 and B. J. Collins 2 . 1 RTI International, 

Research Triangle Park, NC and 2 NIEHS, National 

Toxicology Program, Research Triangle Park, NC. 


1:30 PM to 4:15 PM 

Ballroom A 


Symposium Session: Genetics: The Link between Exposures, 

Gene x Environment Interaction, and Toxicity 

Chairperson(s): John E. French, NIEHS, Research Triangle Park, NC, 

and David W. Threadgill, North Carolina State University, Raleigh, NC. 

Sponsor: 


Endorsed by: 




Exposure to drugs and/or environmental toxicants that exceed an individual’s 

capacity or ability to metabolize and eliminate active metabolites may 

have a significant impact on toxicity and the dysregulation of homeostasis 

and the development of exposure-related human disease. Significant differences 

exist between individuals at the population level based upon their 

inherited genetic (single nucleotide polymorphisms and copy number variants) 

and/or epigenetic differences in environmentally responsive genic and 

non-genic sequences and pathways. To better understand these differences, 

will be begin with an overview of the current research, new strategies, and 

models for pharmacology and toxicology using genetically defined and/or 

genetically altered inbred mouse models. These genetically diverse cell or 

tissue based models will be used to highlight acute or chronic human disease 

in large genetically-diverse human populations. Together, the speakers will 

provide both insight and new hypotheses for the role of individual (heritable 

SNPs, CNV, methylated sequences, RNAi, etc.) and environmental factors 

that affect the development of major polygenic human diseases including 

asthma, drug induced liver injury, respiratory, cancer, and cardiovascular 

diseases. 

#1332 1:30 GENETICS—THE LINK BETWEEN 

EXPOSURES, GENE X ENVIRONMENT 

INTERACTION, AND TOXICITY. J. E. French 1 

and D. W. Threadgill 2 . 1 Host Susceptibility Branch, 

NIEHS, Research Triangle Park, NC and 2 Genetics, 

North Carolina State University, Raleigh, NC. 

#1333 1:35 THE NTP HOST SUSCEPTIBILITY 

INITIATIVE: A NEW STRATEGY 

AND PARADIGM FOR HAZARD 

IDENTIFICATION AND RISK 

CHARACTERIZATION. J. E. French. Host 

Susceptibility Branch, NTP, NIEHS, Research 


#1334 2:15 AFFECT OF GENETIC VARIATION ON 

DRUG METABOLISM AND TOXICITIES 

IN INBRED MOUSE STRAINS. M. Pletcher. 

Investigative Toxicology, Pfizer Global Research & 

Development, Groton, CT. 

#1335 2:55 GENETIC VARIATION IN 

MICE: MODELING DISEASE, 

PHARMACOGENETICS, AND BASIC 

BIOLOGY. T. Wiltshire. Pharmacotherapy and 

Experimental Therapeutics, University of North 

Carolina at Chapel Hill, Chapel Hill, NC. Sponsor: J. 

French. 

#1336 3:35 MOUSE MODEL OF THE HUMAN 

OPULATION (MMHP) FOR SYSTEMS 

BIOLOGY AND TOXICOLOGY. D. W. 

Threadgill. Genetics, North Carolina State 



1:30 PM to 4:15 PM 

Ballroom F 


Symposium Session: It’s Not Your Father’s Aryl Hydrocarbon 

Receptor: New Biological Roles for a Misunderstood Receptor 

Chairperson(s): Russell S. Thomas, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, and J. Craig Rowlands, The Dow 


Sponsor: 


Endorsed by: 


The aryl hydrocarbon receptor (AhR) has been traditionally associated with 

regulating responses to a variety of environmental chemicals. However, the 

AhR has been highly conserved throughout evolution and there is a growing 

body of evidence that the receptor modulates critical aspects of cellular 

function that are independent of its response to xenobiotics. The modulation 

of cell responses are highly context specific resulting in growth promotion 

in certain cell types and growth arrest and differentiation in other cells. 

Endogenous chemicals have been identified in animals with AhR agonist 

activity indicating they are endogenous ligands for this receptor. These 

results suggest that the AhR should be viewed in the same light as other 

cellular receptors (e.g., ER, AR, and PPAR) with a physiological role that 

can be disrupted by xenobiotic chemicals rather than a receptor that evolved 

primarily as a xenobiotic sensor. Thefore, we will address new research on 

the biological roles for the AhR in cell growth, death, and differentiation 

and the potential human health risks and therapeutic benefits associated with 

exposure to exogenous AhR ligands. Molecular aspects of AhR signaling 

are conserved across other nuclear receptor pathways and therefore the 

issues discussed may have relevance to the modes-of-action for xenobiotics 

220 






Platform Sessions



Abstract # 

mediated by other nuclear receptors. This session will be of interest to 

investigators and regulators wanting to understand the latest research on the 

underlying biological roles for this remarkable pleiotropic receptor. 

#1337 1:30 IT’S NOT YOUR FATHER’S ARYL 

HYDROCARBON RECEPTOR: 

NEW BIOLOGICAL ROLES FOR A 

MISUNDERSTOOD RECEPTOR. R. S. Thomas 1 

and C. Rowlands 2 . 1 The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC and 2 The Dow 


#1338 1:35 THE ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN MAMMARY 

DIFFERENTIATION AND DISEASE. J. M. 

Hall 1,2 , M. A. Barhoover 1 , D. P. McDonnell 3 , W. F. 

Greenlee 1 and R. S. Thomas 1 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC, 

2 

Department of Pharmaceutical Sciences, Campbell 

University, Buies Creek, NC and 3 Department of 

Pharmacology and Cancer Biology, Duke University, 

Durham, NC. 

#1339 2:07 DIRECT REGULATION OF ARYL 

HYDROCARBON RECEPTOR FUNCTION 

BY SELECTIVE ESTROGEN RECEPTOR 

MODULATORS (SERMS). D. P. McDonnell. 

Department of Pharmacology and Cancer Biology, 

Duke University, Durham, NC. Sponsor: R. Thomas. 

#1340 2:39 FUNCTIONAL CROSS-TALK BETWEEN 

AHR AND WNT SIGNALING: 

OPPORTUNITIES TO MODULATE 

EPITHELIAL AND MESENCHYMAL 

INTERACTIONS. R. L. Tanguay. Department of 



#1341 3:11 THE ARYL HYDROCARBON 

RECEPTOR HAS A NOVEL ROLE IN 

THE MAINTENANCE AND FUNCTION 

OF HEMATOPOIETIC STEM CELLS 

AND POSSIBLY OTHER STEM CELL 

POPULATIONS. T. A. Gasiewicz. Department of 



#1342 3:43 DEVELOPMENT OF SELECTIVE 

AHR MODULATORS (SAHRMS) FOR 

TREATMENT OF DISEASE. S. H. Safe. 

Department of Veterinary Physiology and 


Station, TX. 

Abstract # 


1:30 PM to 4:15 PM 

Ballroom J 

Symposium Session: Mechanisms of Chemical-Induced Liver 

Cancer: Putting the Pieces Together 


and Jay Goodman, Michigan State University, East Lansing, MI. 

Sponsor: 


Endorsed by: 



A large number of chemicals, including non-genotoxic compounds, increase 

the incidence of liver tumors in mice and rats. Key events in liver tumor 

formation include perturbation of gene expression homeostasis, increases 

in oxidative stress, and activation of cell growth pathways. The mechanisms 

that underlie these events may include activation of pathways under control 

of nuclear receptors. Although hepatocellular carcinoma (HCC) in humans 

is the fifth most common neoplasm worldwide and the third most common 

cause of cancer-related death, the human relevance of the rodent liver tumor 

response remains controversial. Differences in nuclear receptor levels and 

down-stream responses between rodents and humans might contribute to a 

species difference in sensitivity. A number of new techniques that interrogate 

changes in the epigenome have been applied to rodent liver carcinogenesis 

and are illuminating the molecular events in the ‘black box” between nuclear 

receptor activation and liver tumor induction. These techniques can assess 

changes in the methylation status of the DNA, gene expression, alternative 

splicing, and miRNA levels. Information from these data streams can be 

integrated into mathematical models of the structure and function of the liver 

to identify genetic networks required for liver tumor induction and allow 

prediction of the ability of chemicals to induce liver cancer through different 

modes of action. Our panel of experts will discuss how the assessment of 

genetic and genomic changes have increased our understanding of the key 

events and human relevance of rodent liver tumors. We will conclude with a 

discussion of computational strategies to integrate different types of data in 

biologically-relevant models of hepatic functions that can be used to predict 

liver cancer after chemical exposure. This session will be of interest to those 

in systems biology, liver toxicity, nuclear receptors, and the impact of modulation 

of stress pathways on chemical toxicity. 

#1343 1:30 MECHANISMS OF CHEMICAL-INDUCED 

LIVER CANCER: PUTTING THE PIECES 

TOGETHER. C. Corton 1 and J. Goodman 2 . 

1 

NHEERL, U.S. EPA, Research Triangle Park, NC 

and 2 Michigan State University, East Lansing, MI. 

#1344 1:35 IDENTIFICATION OF GENETIC 

DETERMINANTS OF SUSCEPTIBILITY TO 

LIVER TUMOR INDUCTION. N. Drinkwater. 

University of Wisconson, Madison, WI. Sponsor: C. 

Corton. 

#1345 2:07 IDENTIFICATION OF GENES INVOLVED 

IN PHENOBARBITAL-INDUCED 

CARCINOGENESIS: EMPHASIS ON 

ALTERED DNA METHYLATION, 

EXPRESSION, AND PATHWAYS. J. I. 

Goodman. Pharmacology & Toxicology, Michigan 

State University East Lansing, MI. 

#1346 2:39 THE OTHER WORLD OF THE 

TRANSCRIPTOME: ROLE OF NUCLEAR 

RECEPTORS IN CHEMICAL–INDUCED 

EFFECTS ON ALTERNATIVE SPLICING 

IN THE LIVER. C. Corton. U.S. EPA, Research 


tueSday 







221


tueSday 



#1347 3:11 IMPACT OF ALTERED MICRORNA 

EXPRESSION IN LIVER CARCINOGENESIS. 

I. Pogribny and F. A. Beland. Division of 



#1348 3:43 PREDICTIVE MODELS OF LIVER CANCER. 

I. Shah, J. Jack, J. Wambaugh and C. Corton. U.S. 



1:30 PM to 4:15 PM 

Room 151 

Symposium Session: New Strategies for the Use of Genetic 

Toxicology Data in Human Risk Assessment 

Chairperson(s): B. Bhaskar Gollapudi, Dow Chemical Company, 

Midland, MI, and James Kim, ILSI Health and Environmental Sciences 

Institute, Washington, DC. 

Sponsor: 


Endorsed by: 



The field of genetic toxicology is in need of new approaches in experimental 

design and data interpretation to improve the scientific basis of its utility 

for the purpose of accurate human risk assessment. Furthermore, there is 

an urgent need for a framework for the integration of the in vitro testing 

results into a risk-based assessment of the effects of chemical exposures to 

human health. A tripartite initiative under the auspices of the ILSI Health 

and Environmental Institute involving scientists from regulatory, academic, 

and industrial sectors was initiated to address and make recommendations 

on these issues. The scientists involved in this initiative were charged with 

systematically examining the state of the science in genotoxicity assessment, 

assessing the utility of new and emerging genetic toxicology tools, and 

addressing a shift away from qualitative genotox assessment to a quantitative 

approach. The recommendations emerging from this initiative as well 

as those advanced by others are expected to advance the field of genetic 

toxicology into the 21 st century. 

#1349 1:30 INTRODUCTION TO THE HESI IVGT 

PROJECT COMMITTEE. J. H. Kim 1 and B. 

Gollapudi 2 . 1 ILSI Health and Environmental Sciences 

Institute, Washington, DC and 2 Dow Chemical 

Company, Midland, MI. 

#1350 1:37 CURRENT STRATEGIES IN ASSESSING 

GENOTOXIC RISK. K. Dearfield. U.S. 

Department of Agriculture, FSIS, Washington, DC. 

#1351 2:04 NEED FOR A NEW APPROACH TO 

GENETIC TOXICITY ASSESSMENT: 

LESSONS LEARNED AND NEW 

OPPORTUNITIES. J. T. MacGregor. Toxicology 

Consulting Services, Arnold, MD. 

#1352 2:31 APPROACHES TO FOLLOW-UP ON 

POSITIVE RESULTS IN GENETIC 

TOXICOLOGY TESTS IN THE CONTEXT 

OF HUMAN RISK ASSESSMENT. V. Thybaud. 

sanofi-aventis, Vitry Sur Seine, France. Sponsor: B. 

Gollapudi. 

#1353 2:58 NEW TECHNOLOGIES TO PREDICT 

GENOTOXIC RISK IN HUMANS. D. Jacobson- 

Kram. U.S. FDA, Silver Spring, MD. 

#1354 3:25 BEYOND POSITIVE OR NEGATIVE: 

A QUANTITATIVE APPROACH FOR 

INTERPRETING GENOTOXICITY DATA. B. 

Gollapudi. Dow Chemical Company, Midland, MI. 

#1355 3:50 OPTIMAL DESIGN FOR IN VIVO MUTATION 

STUDIES TO INFORM CANCER MODE- 

OF-ACTION ASSESSMENT. M. M. Moore 1 , R. 

Heflich 1 , M. Manjanatha 1 and L. Haber 2 . 1 U.S. FDA, 

Jefferson, AR and 2 Toxicology Excellence for Risk 

Assessment (TERA), Cincinnati, OH. 


1:30 PM to 4:15 PM 

Ballroom D 


Symposium Session: Recent Knowledge on Critical 

Regulators of Lipid Homeostasis in Metabolic Disease 

Chairperson(s): Shashi Ramaiah, Pfizer Global Research and 

Development, St. Louis, MO, and Mayuranjan Mitra, Washington 

University Medical School, Monroe, LA. 

Sponsor: 


Endorsed by: 



Modifications in human lifestyle and nutritional status over the recent 

decades have lead to an increase in the incidence of obesity and insulin 

resistance, leading to metabolic syndrome. Metabolic syndrome is a culmination 

of risk factors for diseases such as diabetes, hepatic steatosis, 

cardiovascular disorders, stroke, and drug-induced toxicities. Insulin resistance, 

a hallmark of metabolic syndrome, is thought to play an important 

role in the development of hyperglycemia, hyperlipidemia, and lipotoxicity. 

Metabolic abnormalities such as insulin resistance, lipotoxicity, and hypertriglyceridemia 

are not only associated with lifestyle changes but also by 

consumption of xenobiotics such as ethanol. The accumulation of highly 

toxic lipid metabolites has been shown to contribute towards ER stress and 

organ toxicities. In the past, various strategies for increasing tissue glucose 

uptake and metabolism and fatty acid oxidation have been devised for 

normalizing the elevated blood glucose and lipid levels thereby improving 

insulin sensitivity and the metabolic syndrome. There is a greater need for 

precise understanding of the molecular basis of metabolic syndrome so that 

effective therapies can be developed. Cell surface receptors were shown to 

transport glucose and fatty acids into the tissue thereby lower blood glucose 

and fatty acid levels. The nuclear hormone receptor PPARa and its binding 

partner PPARg coactivator-1 (PGC-1) were shown to induce the cellular 

fatty acid oxidation machinery thereby prevent accumulation of excess fat in 

the body. Recently, significant progress has been made in identifying novel 

molecules and their unique mechanisms that play a critical role in regulating 

and maintaining lipid homeostasis. Novel molecules such as lipin 1, PPARg 

binding protein (PBP), SIRT 1, and PAS kinase have been recently added to 

the list of critical regulators of lipid homeostasis. This session will introduce 

the latest advancements in the field of metabolic research and discuss the 

functions of these novel mediators of lipid homeostasis. 

#1356 1:30 RECENT KNOWLEDGE ON CRITICAL 

REGULATORS OF LIPID HOMEOSTASIS 

IN METABOLIC DISEASE. S. K. Ramaiah. 

Drug Safety Research and Development, Pfizer, 

Chesterfield, MO. 

#1357 1:30 PAS KINASE AND THE CONTROL OF 

LIPID METABOLISM. J. Rutter. Department 

of Biochemistry, University of Utah School of 

Medicine, Salt Lake City, UT. Sponsor: M. Mitra. 

222 






Platform Sessions



Abstract # 

#1358 1:30 THE ROLE OF SIRT1 IN ALCOHOLIC 

FATTY LIVER. M. You. Department of Molecular 

Pharmacology & Physiology, University of South 

Florida, Tampa, FL. Sponsor: M. Mitra. 

#1359 1:30 ROLE OF PPAR BINDING PROTEIN (PBP) 

IN CARDIAC MITOCHONDRIAL BIOLOGY. 

P. M. Barger. Department of Internal Medicine, 

Washington University School of Medicine, St. 

Louis, MO. Sponsor: M. Mitra. 

#1360 1:30 ROLE OF LIPIN 1 PROTEIN IN LIPID 

HOMEOSTASIS. M. S. Mitra and B. N. Finck. 

Department of Internal Medicine, Washington 

University School of Medicine, St. Louis, MO. 

#1361 1:30 PAS KINASE AND THE CONTROL OF LIPID 

METABOLISM. J. Rutter. Biochemistry, U of 

Utah, Salt Lake City, UT. Sponsor: S. Ramaiah. 


1:30 PM to 4:15 PM 

Room 250 


Symposium Session: Zinc, Copper, and Their Metabolic 

Effect: Myths and Musts 

Chairperson(s): Lu Cai, University of Louisville, Louisville, KY, and Karl 

T. Weber, University of Tennessee Health Science Center, Memphis, TN. 

Sponsor: 


Endorsed by: 




Metabolic syndromes are featured by a group of metabolic risk factors in 

one person, including abdominal obesity, atherogenic dyslipidemia, elevated 

blood pressure, insulin resistance, and proinflammatory state. While the 

exact mechanism remains elusive, an altered homeostasis of essential metals 

such as zinc (Zn) and copper (Cu) is known to contribute to the etiology 

of metabolic syndromes. Zn and Cu are the metals indispensable for the 

structure and activity of many enzymes and proteins; their deficiency and 

overload have been associated to numerous patho-physiological changes, 

including insulin resistance syndrome. Zn deficiency is closely related to 

the metabolic syndrome, cardiovascular diseases, and insulin resistance, 

while increased systemic Cu levels may be related to the risk of cardiovascular 

disease, brain diseases, and other metabolic syndromes. The current 

understanding of the roles of Zn and Cu homeostasis in the insulin signaling, 

cardiovascular inflammation, diabetes, and diabetic complications will be 

explored. A brief overview highlighting the association of Zn and Cu with 

inflammation, diabetes, and diabetic complications will begin this session. 

Important components of this exploration will cover how Zn sensitizes 

insulin function and protects endothelial cells from oxidative stress. The 

effect of Zn dyshomeostasis on cardiac mitochondrial dysfunction, oxidative 

stress, and pathogenic remodeling will then be examined. The dysregulation 

of Cu homeostasis in brain and cerebrospinal fluid as the consequence of 

iron (Fe) metabolic disorders will also be discussed. Given that metallothionein 

(MT) plays a critical role in Zn homeostasis, therefore, how Zn via 

MT’s gene upregulation was used to prevent diabetes and diabetic complications 

will be addressed in the final presentation. 

#1362 1:30 OVERVIEW ON ZINC, COPPER, AND THEIR 

METABOLIC EFFECT: MYTHS AND MUSTS. 

L. Cai. Pediatrics, University of Louisville, 


Abstract # 

#1363 1:35 ROLE OF ZINC IN ENDOTHELIAL 

CELL FUNCTION: IMPLICATIONS IN 

ATHEROSCLEROSIS. B. Hennig. University of 

Kentucky, Lexington, KY. 

#1364 2:07 COUPLED CALCIUM AND ZINC 

DYSHOMEOSTASIS IN CARDIAC 

MYOCYTES AND MITOCHONDRIA 

DURING CHRONIC ALDOSTERONISM. K. 

T. Weber. Division of Cardiovascular Diseases, 

University of Tennessee Health Science Center, 

Memphis, TN. Sponsor: L. Cai. 

#1365 2:39 REGULATION OF COPPER HOMEOSTASIS 

IN BRAIN AND CEREBROSPINAL FLUID: 

EFFECT OF IRON DEFICIENCY AND 

OVERLOAD. W. Zheng 1 , A. Monnot 1 , B. Choi 2 and 

Y. Zhang 1,3 . 1 Purdue University, West Lafayette, IN, 

2 

Preventive Medicine, Chung-Ang University, Seoul, 

Republic of Korea and 3 Occupational Medicine, 

North-China Coal Medical College, Tangshan, 

Heibei, China. 

#1366 3:11 MODULATION OF THE METABOLIC 

EFFECTS OF GSK-3 ISOFORMS BY ZN AND/ 

OR CU- IMPLICATIONS FOR DIABETES. T. 

Force. Center for Translational Medicine, Thomas 

Jefferson University, Philadelphia, PA. Sponsor: L. 

Cai. 

#1367 3:43 POTENTIAL EFFECTS OF ZINC ON 

DIABETIC COMPLICATIONS: ROLE OF 

METALLOTHIONEIN. L. Cai 1,2 . 1 Pediatrics, 

University of Louisville, Louisville, KY and 

2 

Radiation Oncology, University of Louisville, 



1:30 PM to 4:15 PM 

Ballroom B 

Workshop Session: Immunotoxicity and Other Safety 

Considerations in the Development of Therapeutic Vaccines 

Chairperson(s): Michaela Sharpe, Pfizer Limited, Sandwich, United 

Kingdom, and Ken Draper, Draper Consulting, LLC, Reno, NV. 

Sponsor: 


Endorsed by: 




Prophylactic vaccination has proven highly effective against many highly 

virulent infectious diseases and has reduced the medical burden from these 

infections throughout the world. Despite these successes, many infectious 

agents, such as human immunodeficiency virus (HIV), herpes simplex virus 

(HSV), and Epstein Barr Virus (EBV) establish chronic latent infections 

and create considerable morbidity upon reactivation following immunosuppression. 

Traditional vaccines that generate antibody-mediated immunity 

have limited effects on chronic quiescent infections and do little to inhibit 

the spread of these viruses. While monoclonal antibody therapy can provide 

limited passive vaccination for these maladies, the cost is great and patient 

compliance is low. A therapeutic vaccination that induces both humoral 

(antibody-mediated) and cellular (T cell-mediated) immunity holds promise 

in combating these latent infections, as well reducing the medical impact 

for other chronic human maladies, including cancer, addiction, and genetic/ 

metabolic disease. In addition to cost and compliance issues, successful 

therapeutic vaccination will need to overcome immune tolerance while 

controlling dysregulation and/or deleterious effects of immune activation 

(i.e., unwanted T cell activation and undesirable off-target effects will need 

tueSday 







223


tueSday 



to be minimized). An overview of clinical indications under consideration 

for therapeutic vaccination (HIV, caffeine and nicotine addiction, cancer, 

etc.), approaches to development of therapeutic vaccines (adjuvant use, 

dendritic cell activation, viral vectors, etc.), and safety concerns of therapeutic 

immune activation (induction of autoimmunity, unregulated T cell 

activation, etc.) will be presented. 

#1368 1:30 OVERVIEW OF THERAPEUTIC VACCINES. 

K. Draper. Draper Consulting, LLC, Reno, NV. 

#1369 1:35 SAFETY CONSIDERATIONS IN THE 

DEVELOPMENT OF THERAPEUTIC 

VACCINES—INTRODUCTION. M. E. Sharpe. 

Drug Safety Research and Development, Pfizer 

Global Research & Development, Sandwich, United 

Kingdom. 

#1370 2:07 MECHANISMS FOR MAINTAINING 

AND BREAKING IMMUNOLOGICAL 

TOLERANCE: APPLICATIONS AND 

POTENTIAL CONSEQUENCES IN THE 

DEVELOPMENT OF THERAPEUTIC 

VACCINES. B. Champion. Vaccines Research Unit, 

Pfizer Global Research & Development, Sandwich, 

United Kingdom. Sponsor: K. Draper. 

#1371 2:39 SAFETY ASSESSMENT OF THERAPEUTIC 

VACCINES AND ADJUVANTS FOR 

NON-INFECTIOUS DISEASES: CBER 

PERSPECTIVE. T. Chen. Division of Clinical 

Evaluation and Pharmacology/Toxicology (DCEPT), 

Office of Cellular, Tissue and Gene Therapies 

(OCTGT), Center for Biologic Evaluation and 

Research (CBER), U.S. FDA, Silver Spring, MD. 

Sponsor: K. Draper. 

#1372 3:11 SAFETY ASSESSMENT OF THERAPEUTIC 

VACCINES AND ADJUVANTS—AN 

INDUSTRY PERSPECTIVE. L. Segal. 

Toxicology, GlaxoSmithKline Biologicals, Wavre, 

Belgium. 

#1373 3:43 CASE STUDY—ISSUES IN NONCLINICAL 

SAFETY TESTING AND IMMUNE-RELATED 

CLINICAL TOXICITY IMPACTING THE 

DEVELOPMENT OF A VACCINE FOR 

ALZHEIMER’S DISEASE. G. Warner. Wyeth 

Research, Andover, MA. 


1:30 PM to 4:15 PM 

Room 150 

Workshop Session: Widely Varying Strategies Implemented 

in Discovery to Reduce the Failure Rate of Clinical Lead 

Candidates in Development 

Chairperson(s): Alan S. Bass, Merck Research Laboratories, Kenilworth, 

NJ, and Mark E. Cartwright, Merck Research Laboratories, Kenilworth, 

NJ. 

Sponsor: 


Endorsed by: 

Safety Pharmacology Society 

The current discovery screening paradigm for the selection of novel molecular 

candidates to progress into development is fraught with a high level of 

failure in the early-to-late stages of development. The relationship of the 

number of candidates entering Phase I to achieve one successful registration 

varies from one pharmaceutical company to another. However, published 

data suggests that for every 12 new molecular entities entering Phase I, 

only one successfully achieves marketing authorization. The significant 

cost of such an endeavor in terms of operating expenses, lost time, and 

missed opportunities to advance the best candidates for the treatment of 

devastating diseases is too great to justify continuing with the status quo. 

As a result, there has been significant effort devoted across the pharmaceutical 

industry to early identification of potential liabilities of promising lead 

candidates that may lead to failure of those candidates in development. A 

goal of this session will be to advance the topic of discovery risk mitigation 

introduced in recent years in an attempt to reduce the number of failures 

being witnessed in early-to-late development. Topics include, identifying 

the potential on-target-related toxicities during lead finding, deselecting 

those candidates likely to fail in development due to on-target or off-target 

related toxicities, staged approaches to evaluating the pharmacodynamic 

safety (safety pharmacology) of potential lead candidates, integrating safety 

endpoints into proof of concept studies, and application of structure activity 

toxicology (SAT) identifying and mitigating the risk of metabolite-related 

toxicity. Presenters will share their experiences in each of these emerging 

areas of safety science and engage the audience in a debate of best practices. 

Important deliverables will include advancing knowledge in the conceptual 

and practical approaches to mitigating the risk of failure of promising new 

drugs progressing towards marketing authorization. 

#1374 1:30 WIDELY VARYING STRATEGIES 

IMPLEMENTED IN DISCOVERY TO 

REDUCE THE FAILURE RATE OF 

CLINICAL LEAD CANDIDATES IN 

DEVELOPMENT. A. S. Bass and M. E. 

Cartwright. Drug Safety, Merck Research 

Laboratories, Kenilworth, NJ. 

#1375 1:35 MITIGATION STRATEGIES DURING 

EARLY RESEARCH: EVALUATION OF 

NOVEL THERAPEUTIC TARGETS FOR 

POTENTIAL ON-TARGET TOXICITY. J. W. 

Davis. Drug Safety R&D, PGRD, Chesterfield, MO. 

#1376 2:07 MITIGATION STRATEGIES DURING 

DISCOVERY LEAD OPTIMIZATION: 

MANAGEMENT OF A PRECLINICAL OFF- 

TARGET ADRENAL FINDING. B. L. Homer, 

M. T. Baratta, J. C. Davila, A. D. Burdick and J. W. 

Davis. Global Research and Development, Pfizer, 

Chesterfield, MO. 

#1377 2:39 MITIGATION STRATEGIES CARRIED 

OUT IN DISCOVERY TO ASSESS THE 

PHARMACODYNAMIC SAFETY OF 

PROMISING NEW MOLECULES. A. S. 

Bass. Drug Safety, Merck Research Laboratories, 

Kenilworth, NJ. 

#1378 3:11 MANAGING RESOURCE LIMITATIONS IN 

DISCOVERY TOXICOLOGY: INTEGRATION 

OF RISK MITIGATION APPROACHES 

INTO EFFICACY STUDIES AND OTHER 

STRATEGIES FOR NOVEL THERAPEUTIC 

TARGETS. B. D. Car. Discovery Toxicology, 

Bristol-Myers Squibb Inc., Princeton, NJ. 

#1379 3:43 STRUCTURE ACTIVITY TOXICOLOGY 

(SAT) AS A MEANS OF DE-RISKING 

COMPOUND FAILURE. M. E. Cartwright. Drug 

Safety, Merck Research Laboratories, Kenilworth, 

NJ. 

224 






Platform Sessions



Abstract # 


1:30 PM to 4:15 PM 

Ballroom G 


Platform Session: Emphasis on the Embryo: HTS, PBPK, and 

Virtual Tissue Technologies 

Chairperson(s): Yumei Tan, U.S. EPA, Research Triangle Park, NC. 

#1380 1:30 HIGH-THROUGHPUT COMPUTATIONAL 

SCREENING FOR PLAUSIBLE GENE- 

ENVIRONMENT INTERACTIONS IN 

AUTISM. T. Tie 1 , E. Demchuk 1 and M. Schwartz 2 . 

1 

Division Tox and Env.Med., ATSDR/CDC, Atlanta, 

GA and 2 NCEH, Atlanta, GA. Sponsor: B. Fowler. 

#1381 1:51 MODELING THE ESTERASE DOMAIN OF 

NEUROPATHY TARGET ESTERASE (NTE). 

S. J. Wijeyesakere and R. J. Richardson. Toxicology 

Program, University of Michigan, Ann Arbor, MI. 

#1382 2:12 PREDICTIVE SIGNATURES OF 

DEVELOPMENTAL TOXICITY MODELED 

WITH HTS DATA FROM TOXCAST 

BIOACTIVITY PROFILES. T. B. Knudsen 1 , R. 

Judson 1 , M. Rountree 1 , N. Kleinstreuer 1 , N. Sipes 1 , 

R. DeWoskin 2 , K. Chandler 3 , A. Singh 4 , R. Spencer 4 , 

R. Setzer 1 , R. Kavlock 1 and D. Dix 1 . 1 NCCT, U.S. 

EPA, Research Triangle Park, NC, 2 NCEA, U.S. 

EPA, Research Triangle Park, NC, 3 NHEERL, U.S. 

EPA, Research Triangle Park, NC and 4 Contractor, 

Lockheed Martin, Research Triangle Park, NC. 

#1383 2:33 A BBDR-HPT AXIS MODEL FOR THE 

PREGNANT RAT AND FETUS: EVALUATION 

OF IODIDE DEFICIENCY. J. W. Fisher 1 , M. 

Gilbert 2 , T. Zoeller 3 , K. Crofton 4 , E. McLanahan 5 , 

D. Mattie 6 and S. Li 1 . 1 College of Public Health, 

University of Georgia, Athens, GA, 2 Toxicology 

Assessment Division, U.S. EPA, Research Triangle 

Park, NC, 3 Biology Department, University of 

Massachusetts, Amherst, MA, 4 Integrated Systems 

Toxicology Division, U.S. EPA, Research Triangle 

Park, NC, 5 National Center for Environmental 

Assessment, U.S. EPA, Research Triangle Park, 

NC and 6 RHPB, USAF/AFRL 711 HPW, Wright- 

Patterson AFB, OH. 

#1384 2:54 DEVELOPMENT OF A RAT GESTATION 

PBPK MODEL FOR PFOA/PFOS. A. E. 

Loccisano 1 , Y. Tan 2 , M. E. Andersen 1 and H. J. 

Clewell 1 . 1 The Hamner Institutes, Research Triangle 

Park, NC and 2 U.S. EPA, Research Triangle Park, 

NC . 

#1385 3:15 COMPARISON OF SULFURYL FLUORIDE 

PHARMACOKINETICS ACROSS GENDER 

AND GESTATION IN RATS USING PBPK 

MODELING. T. Poet 1 , P. M. Hinderliter 1 , D. 

Eisenbrandt 2 , M. S. Marty 3 and M. J. Bartels 3 . 

1 

Biological Monitoring & Modeling, Battelle, 

Pacific Northwest Division, Richland, WA, 2 Dow 

AgroSciences, LLC., Indianapolis, IN and 3 The Dow 


Abstract # 

#1386 3:35 PLASMA-BINDING PARAMETERS IN THE 

EMBRYONIC COMPARTMENT: AN IN 

SILICO SCREENING TOOL FOR ALPHA- 

FETOPROTEIN. D. T. Chang 1 , M. Goldsmith 1 , 

T. R. Transue 2 , R. Tornero-Velez 1 , S. Peterson 3 , Y. 

Tan 1 and C. Dary 3 . 1 National Exposure Research 

Laboratory, U.S. EPA, Research Triangle Park, NC, 

2 

Lockheed-Martin Information Technology, Research 

Triangle Park, NC and 3 National Exposure Research 

Laboratory, U.S. EPA, Las Vegas, NV. 

#1387 3:55 MODELING THE DISRUPTION OF 

VASCULAR DEVELOPMENT IN A 

VIRTUAL EMBRYO USING TOXCAST HTS 

BIOACTIVITY PROFILES. N. Kleinstreuer 1 , 

D. Dix 1 , R. Judson 1 , R. Kavlock 1 , M. Rountree 1 , N. 

Sipes 1 , R. DeWoskin 2 , A. Singh 3 , R. Spencer 3 and 

T. Knudsen 1 . 1 NCCT, U.S. EPA, Research Triangle 

Park, NC, 2 NCEA, U.S. EPA, Research Triangle 

Park, NC and 3 Contractor, Lockheed Martin, 



1:30 PM to 4:15 PM 

Ballroom I 

Platform Session: Model Systems in Neurodevelopmental 

Toxicity 

Chairperson(s): Edward D. Levin, Duke University Medical Center, 

Durham, NC, and Ruth A. Roberts, Astra Zeneca UK, Macclesfield, 


#1388 1:30 PET, MRI, AND GENE EXPRESSION 

COMPARED TO CONVENTIONAL 

INDICATORS OF DEVELOPMENTAL 

NEUROTOXICITY TESTING. D. De Groot 1 , R. 

Stierum 1 , M. Radonjic 1 , F. Kuper 1 , A. Wolterbeek 1 , 

V. de Groot 1 , R. Nederlof 1 , M. Boogaard 1 , M. Berk 2,1 , 

A. Veltien 2 , A. Heerschap 2 and E. de Vries 3 . 1 TNO 

Quality of Life, Zeist, Netherlands, 2 University 

Medical Center Groningen, Groningen, Netherlands 

and 3 University Medical Center St Radboud, 

Nijmegen, Netherlands. Sponsor: R. Woutersen. 

#1389 1:54 QUANTITATIVE ASSESSMENT OF NEURITE 

OUTGROWTH IN HUMAN EMBRYONIC 

STEM CELL-DERIVED NEURONS USING 

AUTOMATED HIGH-CONTENT IMAGE 

ANALYSIS. J. A. Harrill 1 , T. M. Freudenrich 1 , 

D. W. Machacek 2 , S. L. Stice 2,3 and W. R. Mundy 1 . 

1 

Systems Biology Branch, Integrated Systems 

Toxicology Division, NHEERL, ORD, U.S. EPA, 

Research Triangle Park, NC, 2 ArunA Biomedical, 

Athens, GA and 3 Regenerative Bioscience Center, 


#1390 2:17 ACUTE INTOXICATION WITH MPTP 

ALTERS LOCOMOTOR ACTIVITY IN 

LARVAL ZEBRAFISH. T. D. Irons 1,2 , R. 

C. MacPhail 3 , D. L. Hunter 2 and S. Padilla 2 . 

1 

Curriculum in Toxicology, University of North 

Carolina Chapel Hill, Chapel Hill, NC, 2 ISTD, U.S. 

EPA, Research Triangle Park, NC and 3 TAD, U.S. 


#1391 2:41 CHLORPYRIFOS DISRUPTS NEUROLIGIN- 

MEDIATED SYNAPSE FORMATION. D. Yang 

and P. J. Lein. Molecular Biosciences, University of 

California Davis, Davis, CA. 

tueSday 







225


tueSday 



#1392 3:05 DEVELOPMENTAL NEUROBEHAVIORAL 

TOXICITY OF BISPHENOL A: DEFINING 

THE ROLE OF ESTROGEN RELATED 

RECEPTOR GAMMA. K. S. Saili 1,2 , M. T. 

Simonich 1,2 and R. L. Tanguay 1,2 . 1 Department of 

Environmental & Molecular Toxicology, Oregon 

State University, Corvallis, OR and 2 Environmental 

Health Sciences Center, Oregon State University, 

Corvallis, OR. 

#1393 3:28 ARSENIC INHIBITS NEURITE 

OUTGROWTH BY INHIBITING LKB1- 

AMPK SIGNALING PATHWAY. X. Wang 1 , D. 

Meng 2 , Q. Chang 3 , J. Pan 1 , Z. Zhang 1 , G. Chen 3 , Z. 

Ke 2 , J. Luo 3 and X. Shi 1 . 1 Toxicology, University of 

Kentucky, Lexington, KY, 2 Institute for Nutritional 

Sciences, Shanghai Institutes for Biological Sciences, 

Chinese Academy of Sciences, Shanghai, China and 

3 

Department of Internal Medicine, University of 

Kentucky, Lexington, KY. Sponsor: S. Cheng. 

#1394 3:52 TARGETING OF DEVELOPING 

DOPAMINERGIC NEURONS BY 

METHYLMERCURY IN THE PICOMOLAR 

RANGE. M. Leist, B. Zimmer, B. Baudis, F. Matt 

and S. Kadereit. Doerenkamp-Zbinden Chair for 

Alternative In Vitro Methods, University Konstanz, 

Konstanz, Germany. Sponsor: A. Buerkle. 


1:30 PM to 4:15 PM 

Room 251 A 

Platform Session: Nanotoxicology—Pulmonary Effects 

Chairperson(s): Lisa Truong, Oregon State University, Corvallis OR, and 

Claude Emond, Université de Montréal, Montréal, QC, Canada. 

#1395 1:30 INHALATION TOXICITY STUDIES WITH 

12 NANOMATERIALS USING DIFFERENT 

DOSIMETRIES—NONE FITTED ALL. R. 

Landsiedel 1 , Y. Staal 3 , L. Ma-Hock 2 , K. Wiench 1 , S. 

Treumann 1 , V. Strauss 1 and B. van Ravenzwaay 1 . 

1 

Experimental Toxicology and Ecology, BASF SE, 

Ludwigshafen am Rhein, Germany, 2 Product Safety, 

BASF SE, Ludwigshafen am Rhein, Germany and 

3 

TNO Quality of Life, Zeist, Netherlands. 

#1396 1:48 OCCUPATIONAL RISK ASSESSMENT OF 

MULTIWALL CARBON NANOTUBES. A. 

Lecloux 1 , F. Luizi 1 , M. Del Tedesco 3 , D. Brouwer 2 , 

R. Muir 2 , D. Green 4 , L. Ma-Hock 4 , K. E. Wiench 4 

and R. Landsiedel 4 . 1 Nanocyl S.A., Sambreville, 

Belgium, 2 Naneum Ltd., Canterbury, Kent, United 

Kingdom, 3 TNO, Zeist, Netherlands and 4 BASF SE, 


#1397 2:07 MESOTHELIOMA INDUCTION 

BY MICROMETER-SIZED MULTI- 

WALL CARBON NANOTUBE 

INTRAPERITONEALLY INJECTED TO 

P53 HETEROZYGOUS MICE. J. Kanno 1 , A. 

Takagi 1 , T. Nishimura 2 and A. HIrose 3 . 1 Division 

of Cellular and Molecular Toxicology, National 

Institute of Health Sciences, Tokyo, Japan, 2 Division 

of Environmental Chemistry, National Institute of 

Health Sciences, Tokyo, Japan and 3 Division of Risk 

Assessment, National Institute of Health Sciences, 

Tokyo, Japan. 

#1398 2:25 PULMONARY TOXICITY OF CERIUM 

DIOXIDE PARTICLES IS MODULATED 

BY SIZE AND COATING: INHALATION 

STUDIES WITH NANO-, AGGREGATED 

NANO-, AND MICRON-SCALE PARTICLES 

AND PARTICLES WITH DIFFERENT 

SURFACE CHEMISTRY. Y. Staal 1 , L. 

Ma-Hock 2 , H. Muijser 1 , S. Treumann 2 , V. Strauss 2 

and R. Landsiedel 2 . 1 Quality of Life, TNO, 

Zeist, Netherlands and 2 Product Safety, BASF, 


#1399 2:43 INTRATRACHEAL EXPOSURE TO MULTI- 

WALLED CARBON NANOTUBES CAUSED 

GRANULOMATOUS INFLAMMATION 

ON MURINE LUNG. J. Kim 1,2 , H. Lim 1,2 , A. 

Minai-Tehrani 1 , J. Kwon 1 , J. Shin 1 and M. Cho 1,2 . 

1 

Laboratory of Toxicology, College of Veterinary 

Medicine, Seoul National University, Seoul, 

Republic of Korea and 2 Department of Nano Fusion 

Technology, Graduate School of Convergence 

Science and Technology, Seoul National University, 

Seoul, Republic of Korea. 

#1400 3:01 ASSESSMENT OF PULMONARY TOXICITY 

FOLLOWING INTRATRACHEAL 

EXPOSURE TO SILICON NANOWIRES. J. 

R. Roberts 1 , R. S. Chapman 1 , G. M. Cohen 2 , S. 

Bangsaruntip 2 , D. Schwegler-Berry 1 , J. M. Antonini 1 

and S. S. Leonard 1 . 1 HELD/PPRB, NIOSH, 

Morgantown, WV and 2 T. J. Watson Research Center, 

IBM, Yorktown Heights, NY. 

#1401 3:20 IN VIVO AND IN VITRO ASSESSMENTS 

OF MICRONUCLEUS INDUCTION BY 

AMORPHOUS SILICA PARTICLES. K. 

Glover 1 , C. M. Sayes 2 , A. Myhre 1 , K. L. Reed 1 , 

K. A. Swain 3 , E. M. Donner 1 and D. B. Warheit 1 . 

1 

DuPont Haskell Laboratory, Newark, DE, 2 Texas 

A&M University, College Station, TX and 3 DuPont 

Company, Wilmington, DE. 

#1402 3:38 TISSUE DISTRIBUTION OF FULLERENE 

AFTER INJECTION INTO TAIL VEIN IN 

RAT. T. Nishimura 1 , R. Kubota 1 , M. Tahara 1 , K. 

Shimizu 1 , T. Obama 1 , N. Sugimoto 1 , J. Kanno 2 and 

A. Hirose 3 . 1 Environmental Chemistry, National 

Institute of Health Sciences, Tokyo, Japan, 2 Cellular 

& Molecular Toxicology, Biological Safety Research 

Center, National Institute of Health Sciences, 

Tokyo, Japan and 3 Risk Assessment, Biological 

Safety Research Center, National Institute of Health 

Sciences, Tokyo, Japan. 

#1403 3:57 SHORT-TERM INHALATION TOXICITY 

STUDY WITH CD-BASED QUANTUM DOTS. 

S. Brill 1 , R. Landsiedel 1 , L. Ma-Hock 1 , P. M. Farias 2 , 

B. S. Santos 2 , A. Fontes 2 , S. Treumann 1 , V. Strauss 1 

and B. van Ravenzwaay 1 . 1 Experimental Toxicology 

and Ecology, BASF SE, Ludwigshafen, Germany and 

2 

Departamento de Biofísica e Radiobiologia, UFPE, 

Recife, PE, Brazil. Sponsor: A. Van Cott. 

226 






Platform Sessions



Abstract # 


1:30 PM to 4:15 PM 

Room 251 D 


Platform Session: Toxicity Detection—Alternatives to Animal 

Models 

Chairperson(s): Cathy Yang, CertiChem Inc., Austin, TX, and Christopher 

Kirton, Huntingdon Life Sciences, Alcanbury, United Kingdom. 

#1404 1:30 AN IN VITRO ASSAY FOR THE 

PREDICITION OF CYTOKINE RELEASE 

SYNDROME. C. M. Kirton 1 , A. Roghanian 1 and 

E. Moore 2 . 1 Experimental Biology, Huntingdon 

Life Sciences, Alconbury, United Kingdom and 

2 

Toxicology Operations, Huntingdon Life Sciences, 

Alconbury, United Kingdom. 

#1405 1:48 USE OF THP-1 CELLS TO IDENTIFY 

PROHAPTENS. I. Chipinda, T. B. Ruwona, S. P. 

Templeton and P. D. Siegel. HELD, CDC/NIOSH, 


#1406 2:06 CYTOKINE LEVELS IN TISSUE AND 

MEDIUM OF PRECISION-CUT LUNG 

SLICES DURING PRODUCTION AND 

INCUBATION. H. P. Behrsing 1 , M. J. Furniss 1 , J. 

E. Tomaszewski 2 and R. E. Parchment 1 . 1 Predictive 

Toxicology Section, Laboratory of Human 

Toxicology and Pharmacology, SAIC-Frederick/NCI- 

Frederick, Frederick, MD and 2 Division of Cancer 

Treatment & Diagnosis, National Cancer Institute, 

Bethesda, MD. 

#1407 2:24 APPLICATION OF AN IN SILICO LIVER 

MODEL TO DETERMINE NUCLEAR 

RECEPTOR MEDIATED PATHWAYS IN 

LIVER CANCER. I. Shah 1 , D. C. Wolf 2 , K. 

Houck 1 , R. Judson 1 , J. Jack 1 , J. Wambaugh 1 , M. 

T. Martin 1 and C. Corton 2 . 1 National Center for 

Computational Toxicology, U.S. EPA, Durham, NC 

and 2 National Health and Environmental Effects Lab, 

U.S. EPA, Research Triangle Park, NC . 

#1408 2:43 A ROBOTIC MCF-7 CELL PROLIFERATION 

ASSAY TO DETECT ER AGONISTS AND 

ANTAGONISTS. C. Z. Yang, N. Bodon and G. 

Bittner. CertiChem, Inc., Ausin, TX. Sponsor: R. 

Tice. 

#1409 3:01 PREDICTIVITY OF LIVER AND KIDNEY 

TOXICITY USING HIGH CONTENT 

IMAGING. A. M. Peters, D. M. Miller, B. A. 

Samson, C. Vasudevan and S. L. Sanford. Cellular 

Imaging and Analysis, Thermo Fisher Scientific, 

Pittsburgh, PA. Sponsor: J. Haskins. 

#1410 3:20 CELLULAR SYSTEMS BIOLOGY (CSB) 

ASSAY PANELS PROVIDE AN IMPROVED 

METHOD FOR PREDICTING HUMAN 

LIVER INJURY. B. Gough 2 , P. Hodor 2 , K. 

Johnston 2 and Y. Will 1 . 1 Compound Safety Prediction, 

Pfizer Global Research & Development, Groton, CT 

and 2 Cellumen, Pittsburgh, PA. 

Abstract # 

#1411 3:38 CYTOTOXICITY OF 130 TOXCAST 

CHEMICALS IN HUMAN HEPATOCYTES, 

RENAL PROXIMAL TUBULE CELLS, AND 

SMALL AIRWAY EPITHELIAL CELLS 

CO-CULTURED IN THE INTEGRATED 

DISCRETE MULTIPLE ORGAN 

CO-CULTURE (IDMOC) EXPERIMENTAL 

SYSTEM. A. P. Li and Y. LaForge. In Vitro ADMET 

Laboratories, Advanced Pharmaceutical Sciences, 

Columbia, MD. 

#1412 3:57 NEW SCREENING ASSAYS TO EVALUATE 

THE DEVELOPMENTAL NEUROTOXIC 

POTENTIAL OF CHEMICALS AND DRUGS 

USING THE ZEBRAFISH EMBRYO AND 

LARVA. I. Selderslaghs, J. Hooyberghs and H. 

Witters. Toxicology, VITO NV - Flemish Institute for 

Technological Research, Mol, Belgium. Sponsor: B. 

De Wever. 


1:30 PM to 2:30 PM 

Room 155 F 

Exhibitor Hosted Session: Noninvasive Blood Pressure and 

Respiration Measurements on Large Animals 

Presented by: emka TECHNOLOGIES 

This presentation will explain how recent improvements in hardware and in 

a software algorithm enabled higher efficiency and reliability in the noninvasive 

study of blood pressure and respiration, as well as the computation 

of new parameters. Studies done to compare these measurements with those 

obtained using traditional methods will be presented. Fixed and recurring 

costs of doing such measurements will also be discussed. 


1:30 PM to 2:30 PM 

Room 155 C 

Exhibitor Hosted Session: Tips and Tricks to Maximize Your 

Literature Search Results 

Presented by: Quertle, LLC 

The workshop will cover the following: 1. Understanding the difference 

between relationships versus simple occurrence of keywords, 2. Using 

Power Terms such as $AdverseEffects to enhance results, 3. Constructing 

efficient queries, including use of capitalization, 4. Searching full-text documents 

and MEDLINE simultaneously, and 5. Effective filtering to refine 

results. 


1:30 PM to 2:30 PM 

Room 155 B 

Exhibitor Hosted Session: Making New Connections: 

Networking Strategically 

Presented by: Science/AAAS 

Find ways to make networking work for you. By being strategic about how 

you meet people, you can increase your number of contacts with ease. We’ll 

discuss myths and realities surrounding networking and different strategies 

for networking in various arenas. Learn about informational interviews, 

business cards, elevator pitches, and more. 

tueSday 







227


tueSday 




2:45 PM to 3:45 PM 

Room 155 B 

Exhibitor Hosted Session: Quantitative Tissue Analysis: 

How to Get the Most from Your Pathologist 

Presented by: Aperio 

Toxicologists will learn what to expect in new imaging techniques from 

their pathologists. Computer-assisted measurements across an entire tissue 

section lead to a truly quantitative pathology evaluation. The expert use of 

whole slide imaging by the pathologist allows many improvements in workflow 

and communication of study results. 


2:45 PM to 3:45 PM 

Room 155 C 

Exhibitor Hosted Session: Lead Optimization—What Does 

the Future Look Like? 

Presented by: Covance Inc. 

Now, more than ever, it is crucial to make the right decisions early in the 

development process. Lead Optimization advancements in the last 10 years 

have led to the ability to make faster, more concrete decisions, increasing the 

probability of bringing a successful drug candidate forward. In this session, 

explore what advancements have been made, why they are important, and 

what we expect to happen in the next 10 years. 

Tuesday Afternoon, March 

2:45 PM to 3:45 PM 

Room 155 F 

Exhibitor Hosted Session: The Minipig—A Non-Rodent 

Species in Regulatory Toxicity Testing 

Presented by: Ellegaard Göttingen Minipigs A/S 

This session highlights the relevance of the minipig as a non-rodent model 

in regulatory toxicity testing, and, in this context, discusses species selection 

in non-clinical safety studies. The session also provides an overview of 

marketed drug products (case studies) where minipigs have been used as the 

non-rodent species. 


3:30 PM to 4:30 PM 

Room 355 A 

Undergraduate Faculty Meeting 

Chairperson(s): Aaron Barchawsky, University of Pittsburgh, 


Sponsor: 


The Education Committee and the Undergraduate Education Subcommittee 

are hosting the Undergraduate Toxicology Faculty Meeting for all 

faculty involved in the teaching of toxicology to undergraduates, or for 

those interested in including toxicology at the undergraduate level. Hear 

an update on initiatives for undergraduate faculty, provide your input, and 

network. 


4:30 PM to 6:00 PM 

Ballroom A 

SOT Annual Business Meeting 

Chairperson(s): Cheryl Lyn Walker, Ph.D., University of Texas 

MD Anderson Cancer Center 

(SOT Members Only; Full, Associate, Postdoctoral, Student 

Members Invited) 

Members are invited and encouraged to attend the 49 th Annual SOT 

Business Meeting. If you have long-range planning ideas that you would 

like added to the agenda, please send them to Shawn Lamb at SOT 

Headquarters. The agenda includes a discussion of the strategic planning 

activities, financial summary, a review of the 2009–2010 activities, and 

plans for the future. 

Tuesday Evening, March 9 

6:00 PM to 9:00 PM 


TUESDAY EvEning 

Regional Chapter Reception: Northern California 


6:00 PM to 7:30 PM 


Specialty Section Meetings/Receptions: Biological Modeling 

(Room 260 B), Comparative and Veterinary (Room 258), 

Drug Discovery Toxicology (Room 355 D), Inhalation and 

Respiratory (Room 255 B), Mechanisms (Room 255 E), 

Mixtures (Room 259), Regulatory and Safety Evaluation 

Reception (Room 355 B) 


6:00 PM to 8:00 PM 

Room 355 E 

Specialty Section Meeting/Reception: Immunotoxicology 


6:30 PM to 8:30 PM 


Special Interest Group Meeting/Reception: Hispanic 

Organization for Toxicologists 

228 






Platform Sessions



Abstract # 

Wednesday Morning, March 10 

7:30 AM to 8:50 AM 

Ballroom F 

WEDnESDAY MORning 

Informational Session: Impact of Tungsten and Tungsten 

Alloys on Health Risk 

Chairperson(s): Palur G. Gunasekar, NHRC Detachment Environmental 

Health Effects Laboratory, Wright-Patterson Air Force Base, Dayton, OH, 

and Michelle J. Hooth, NIEHS National Toxicology Program, Research 


Sponsor: 


Endorsed by: 




Debate of the potential human health effects of tungsten (W) is fostered by 

widespread exposure to naturally occurring W in air, soil, water, and the 

diet and anthropogenic sources including the use of tungsten alloy (WA) 

in military munitions. There is particular concern about the exposure of 

military personnel to retained W-based munitions fragments. The cellular 

and molecular mechanisms of systemic W toxicity and the role of W speciation 

in W-induced toxicity remain poorly defined. Intensive research on the 

characterization of potential adverse health effects associated with tungsten 

exposure is underway and employs multiple routes of exposure including 

oral, inhalation and implantation. Other recent studies have characterized 

W transport mechanisms, pharmacokinetic parameters, and biochemical and 

pathological indices in vitro and in vivo. These efforts have identified new 

biomarkers of exposure and effect as well as new opportunities for therapeutic 

intervention or management of potential health hazards. This session 

will review current research programs as well as describe the recent studies 

examining the toxicity and carcinogenicity of embedded tungsten and heavy 

metal tungsten alloy pellets and refined corrosion assessments to define the 

degradation rate of the pellets. Our panel of experts will discuss the absorption/transport, 

distribution and elimination of tungsten and effects on the 

nervous system and immune system with particular emphasis on the mechanisms 

through which W may produce toxic effects. 

#1413 7:30 IMPACT OF TUNGSTEN AND TUNGSTEN 

ALLOYS ON HEALTH RISK. P. G. Gunasekar 1 

and M. J. Hooth 2 . 1 NHRC Det Environmental 

Health Effects Laboratory, Wright-Patterson Air 

Force Base, Dayton, OH and 2 Toxicology Branch, 

National Toxicology Program, National Institute 

of Environmental Health Science, NIH, Research 


7:35 TUNGSTEN AND TUNGSTEN HEAVY 

ALLOYS: HEALTH EFFECTS AND 

METALLOGRAPHIC ANALYSIS OF 

TUNGSTEN AND TUNGSTEN HEAVY 

ALLOYS FOLLOWING IMPLANTATION IN 

RAT MUSCLE. Brian Schuster 

7:50 CHEMICAL AND MICROSCOPY 

ASSESSMENT OF TUNGSTEN IN TISSUES. 

Jose Centeno 

8:05 THE PHARMACOKINETICS OF INHALED 

TUNGSTEN. David Dorman 

8:20 RAT SERUM ANTIBODIES INDICATE 

OXIDATIVE STRESS AND RENAL 

TOXICITY, BUT NOT NEUROTOXICITY 

FOLLOWING SUBCHRONIC EXPOSURE TO 

SODIUM TUNGSTATE. Wilfred C. McCain 

Abstract # 

8:35 IMMUNOTOXICITY OF TUNGSTATE 

FOLLOWING ORAL EXPOSURE. Michael 

Stockelman 


7:30 AM to 8:50 AM 

Ballroom D 

Informational Session: The 2009 Tennessee Fly Ash Spill— 

An Environmental Emergency Case Study 

Chairperson(s): Michael E. Ottlinger, U.S. EPA, Cincinnatti, OH, and 

Angela J. Harris, Center for Toxicology & Environmental Health LLC, 

North Little Rock, AR. 

Sponsor: 


On December 22, 2008, at approximately 1:00 AM, a retaining wall supporting 

a surface impoundment of fly ash sludge at the Kingston Fossil Plant 

in Harriman, Tennessee, breached releasing an estimated 5.4 million cubic 

yards of material into the Emory and Clinch Rivers and surrounding areas. 

The release extended over approximately 300 acres of land outside of the 

containment site. A wave of ash and water destroyed homes, disrupted 

electrical and natural gas lines, covered roads and rail tracks, and necessitated 

the evacuation of nearby residents. Responders at the scene pursued 

a variety of activities intended to assess the extent of both the release and 

the potential hazard posed by the event and to contain the spread of any 

hazardous materials released into the environment. The roles, responsibilities, 

and interactions of various local, state, and federal partners present at 

the scene had a substantial impact on response activities. This included 

oversight of the development and initiation of a large program of environmental 

sampling of the air, soil, and water followed by analysis of the 

resulting data. The Tennessee fly ash spill is representative of other environmental 

emergencies, and is therefore an excellent case study in which 

to provide a framework for discussions concerning the role of toxicology 

in protecting environmental and human health in affected communities, and 

in determining the appropriate roles and actions of the various regulators at 

the scene. Information about the formation and toxicological hazards associated 

with fly ash will be presented, along with a discussion of the U.S. EPA 

incident command structure, regulatory issues, sampling strategies and limitations, 

as well as integration of all of this information into effective public 

health practice following such emergencies. 

#1414 7:30 THE 2009 TENNESSEE FLY ASH SPILL: AN 

ENVIRONMENTAL EMERGENCY CASE 

STUDY. M. E. Ottlinger. Office of Emergency 

Management, U.S. EPA, Erlanger, KY. 

7:30 A REPRISE OF FLY ASH CHEMISTRY AND 

TOXICITY. Michael E. Ottlinger 

7:40 FLY ASH RADIOISOTOPES AND 

ASSOCIATED HAZARDS. Jeffrey Nemhauser 

7:50 U.S. EPA EMERGENCY RESPONSE 

TO THE TVA FLY ASH RELEASE: A 

FEDERAL ON-SCENE-COORDINATOR’S 

PERSPECTIVE. David Dorian 

8:00 U.S. EPA EMERGENCY RESPONSE 

TO THE TVA FLY ASH RELEASE: A 

FEDERAL ON-SCENE-COORDINATOR’S 

PERSPECTIVE. Tim Frederick 

8:10 REVIEW OF THE STATUTORY BASIS FOR 

FEDERAL AUTHORITIES AND DISCUSSION 

OF THE STATUS OF FLY ASH UNDER 

EXISTING ENVIRONMENTAL LAW. John 

Benitez 

WedneSday 







229


WedneSday 



8:25 REVIEW OF THE STATUTORY BASIS FOR 

FEDERAL AUTHORITIES AND DISCUSSION 

OF THE STATUS OF FLY ASH UNDER 

EXISTING ENVIRONMENTAL LAW. Saralyn 

Williams 



7:30 AM to 8:50 AM 

Ballroom B 

Education-Career Development Session: Career Alternatives 

in Toxicology: Lessons Learned 

Chairperson(s): Judy L. Raucy, Puracyp Inc., Carlsbad, CA, and Hisham 

K. Hamadeh, Amgen, Inc., Comparative Biology and Safety Sciences, 

Thousand Oaks, CA. 

Sponsor: 


For individuals who desire to take a career break or those set to retire, many 

options are available. There are many avenues to explore including those 

that involve technical opportunities for toxicologists and environmental 

scientists. Of the many opportunities to explore, the Peace Corps and U.N. 

volunteer programs offer a myriad of opportunities for environmental 

scientists wishing to practice their trade abroad. In addition to these two 

examples, other alternatives will be discussed including those available in 

academia, which provides its own set of unique experiences. For example, 

just how does one go about leaving a career in cancer research and epigenetic 

toxicology to become an administrator at the Radiation Effects Research 

Foundation in Hiroshima, Japan? There are many positive sides to such a 

decision, including work on a historic project in a foreign country and interactions 

with scientists who may benefit from your insight; however, there 

can be disadvantages as well. Experienced panel members will highlight 

the “price-paid” for such decisions. What about options other than academic 

research, such as toxicologists with innovative ideas who wish to capitalize 

on their talents and drive by starting a biotechnology company? Our panel of 

experts will provide insight and tips on the challenges involved in bringing 

an idea for a commercial product to the market place. This specific discussion 

will note the distinct advantages and disadvantages of embarking on a 

career change from academia to establishing a biotechnology company. This 

last discussion will highlight the specific and unique challenges of starting 

a company, including acquisition of intellectual property rights, obtaining 

funding, and marketing of products. This session should be of interest to 

anyone looking to explore career alternatives off the beaten path. 

#1415 7:30 Career Alternatives in Toxicology: Lessons 

Learned, J. Raucy 1 , T. D. Landry 2 , J. E. Trosko 3 

and H. K. Hamadeh 4 . 1 Puracyp, Inc., Carlsbad, 

CA, 2 Tecnico Unidad de Gestion Ambiental, 

Tlaxcala, Mexico, 3 Department Pediatrics/Human 

Development, Michigan State University, East 

Lansing, MI and 4 Comparative Biology and Safety 

Sciences, Amgen, Thousand Oaks, CA. 

7:34 International Technical Volunteering for 

Toxicology, Timothy D. Landry 

7:53 How Sutnik, Radiation Fallout, Chemical 

Toxicants, Bioethics for Hippies, Stem Cells, 

Sushi, Kimchie, and Gelato Led to a ‘Biological 

Rosetta Stone’ for Human Diseases, James E. 

Trosko 

8:12 From Academia to Biotechnology: Beginning 

Your Own Company, Judy Raucy 

8:31 Panel Discussion/Q&A 


8:00 AM to 9:00 AM 

Ballroom A 

Keynote Medical Research Council 

(MRC) Lecture: The Interplay between 

Phosphorylation and Ubiquitination in 

Regulating the Innate Immune System 

Lecturer: Sir Philip Cohen, Medical Research Council 

Protein Phosphorylation Unit, University of Dundee, 

The Sir James Black Centre, Dundee, United Kingdom 

Infection by bacteria and viruses triggers cells of the innate immune 

system to produce pro-inflammatory cytokines and interferons that 

mount the responses to fight the invading pathogens. However these 

defence mechanisms are a double-edged sword because the uncontrolled 

production of these substances causes chronic inflammatory and 

autoimmune diseases. This talk will focus on the signaling pathways 

downstream of Toll-Interleukin Receptors. The engagement of these 

receptors by their agonists triggers the formation of Lys63-linked polyubiquitin 

chains and polyubiquitylated proteins, which then recruit and 

activate the key protein kinases that drive the production of pro-inflammatory 

cytokines and type 1 interferons. The mechanisms that initiate 

the formation of Lys63-linked polyubiquitin chains and the proteins 

that interact with them (NEMO, OPTN, ABIN1 and ABIN2) will be 

discussed. Finally, the characterization of mice that express an ABIN1 

mutant unable to bind to Lys63-linked polyubiquitin chains will be 

described and a model that accounts for the striking phenotype displayed 

by these knock-in mice will be presented. (Dr. Cohen is an SOT 2010 

Honorary Member, see p.81) 


8:30 AM to 9:30 AM 

Room 155 B 

Exhibitor Hosted Session: Innovative Safety Studies and 

Successful Strategies for an Efficient IND-Enabling Program 


Early stage developers need a clear view of the path forward to human trials. 

Most failures to win FIH trial approval stem from underestimating timelines 

and the complexity of toxicology programs. Effective planning of toxicology 

programs and cost-effective innovative approaches to preclinical study 

design for IND-enabling programs are critical to generating data that will 

add value to a novel drug or biologic and increase regulatory success. 

230 






Platform Sessions



Abstract # 


9:00 AM to 4:30 PM 

Room 254 A 




Sponsor: 


All meeting attendees interested in National Institute of Health (NIH) 

funding are encouraged to take advantage of this opportunity to meet 

with staff from NIH Center for Scientific Review and NIEHS who will be 

available in the NIH Resource Room for individual conversations. Learn 

about the match of research interests to grant programs, check the ins and 

outs of the new application guidelines, and discuss in depth the specifics 

of proposals. Drop in, attend the NIH Brown Bag Lunch on Tuesday 

to make an appointment, or check the posted schedule to meet with the 

relevant NIH staff member. New investigators are especially encouraged 

to meet with program staff. Handouts will be available. 


9:00 AM to 11:45 AM 

Room 150 

Symposium Session: Gender Divergent Xenobiotic Responses 

Chairperson(s): Kathleen Gabrielson, Johns Hopkins Medical 

Institutions, Baltimore, MD, and DeLisa Fairweather, The Johns Hopkins 

University Bloomberg School of Public Health, Baltimore, MD. 

Sponsor: 


Endorsed by: 




Differences in exposure, anatomy, physiology, biochemistry, and behavior 

between males and females dramatically affect the biological response; 

yet gender differences have not received adequate attention in toxicology. 

This session will highlight cutting-edge discoveries within gender divergent 

biology that have a major impact on the toxicological response. Both 

mechanisms and relevant examples of gender-dependent toxicities will be 

provided. To fully understand these issues, an overview will be provided 

that will allow participants to review recent findings on the divergence of 

gene expression between males and females in response to toxic insults 

influenced by gender specific drug elimination and cellular efflux. Elegant 

studies that demonstrate sex and growth hormonal dependence reveal the 

importance of these factors in toxic and therapeutic responses. Further 

exploration will allow U.S. to focus on the mechanisms behind gender 

differences in cation transporter expression in the GI tract and kidney. 

Interplay between gender and the underlying nutritional status of zinc, iron, 

and calcium, as well as the influence of transporter expression and toxicity. 

Essential element deficiencies result in gender specific up-regulation of 

transporters, thereby facilitating the transport of toxic metals such as lead 

and cadmium. Adequate focus will be provided on the immune system and 

how steroid hormones influence immunomodulatory proteins of the tolllike 

receptor family. These findings have relevance not only to the toxic 

response, but also to the pathogenesis and severity of infectious disease 

influenced by concurrent toxin exposure. Finally, gender divergence in gene 

expression in the heart during cancer therapy will be addressed and how 

it affects signal transduction pathways controlling mitochondrial function 

and protein translation differently in males and females which will explain 

why females are better protected from the cardiotoxic effects of the chemotherapy. 

Abstract # 

#1416 9:00 GENDER DIVERGENT XENOBIOTIC 

RESPONSES. K. Gabrielson 3 , D. Fairweather 3 , C. 

Klaassen 1 and M. Gochfeld 2 . 1 University of Kansas 

Medical Center, Kansas City, KS, 2 Robert Wood 

Johnson Medical School, Piscataway, NJ and 3 The 

Johns Hopkins University, Baltimore, MD. 

#1417 9:05 MECHANISM OF GENDER-DIVERGENT 

EXPRESSION OF PHASE II ENZYMES 

AND MULTIDRUG RESISTANCE (MDR) 

TRANSPORTERS-IMPLICATIONS TO 

TOXICOLOGY. C. D. Klaassen. Pharmacology, 

Toxicology and Therapeutics, University of Kansas 


#1418 9:45 SEX AND TRANSPORTERS IN THE 

GI TRACT AND KIDNEY. M. Gochfeld. 

Environmental and Occupational Health, Robert 

Wood Johnson Medical School, Piscataway, NJ. 

Sponsor: K. Gabrielson. 

#1419 10:25 SEX DIFFERENCES, CIGARETTE SMOKE, 

AND INFLAMMATORY HEART DISEASE: 

ROLE OF ALTERNATIVELY ACTIVATED 

MACROPHAGES. D. Fairweather 1,2 and M. J. 

Coronado 1 . 1 Environmental Health Sciences, Johns 

Hopkins University, Baltimore, MD and 2 Pathology, 

Johns Hopkins University, Baltimore, MD. 

#1420 11:05 MECHANISMS OF GENDER DIFFERENCES 

IN CHEMOTHERAPY INDUCED CARDIAC 

TOXICITY. K. Gabrielson. Molecular and 

Comparative Pathobiology, The Johns Hopkins 

University School of Medicine, Baltimore, MD. 


9:00 AM to 11:45 AM 

Ballroom J 


Symposium Session: Mitochondrial Toxicity in Disease and 

Death 

Chairperson(s): Boris Zhivotovsky, Karolinska Institutet, Stockholm, 

Sweden, and Dean P. Jones, Emory University, Atlanta, GA. 

Sponsor: 


Endorsed by: 



Mitochondria play a central role in cell life and death and are known to be 

important in a wide range of diseases. Many attempts were undertaken to 

develop drugs that target mitochondria and suggested to be used to treat 

mitochondrial dysfunctions associated with various disease. However, it is 

known that such drugs induce mitochondrial toxicity. At the same time mitochondria 

are central to many chronic toxicities the details of the mechanisms 

remain unknown and effective preventive strategies have not been established. 

Therefore our approach to explore these issues will be to delineate 

therapy-related toxicities, which are essential to understanding the mechanisms 

behind the role of mitochondria in disease and death. To achieve 

this goal, an interaction between both fundamental and applied research 

is important. Our panel of experts represent different areas of toxicology, 

from academia to and industry, which will provide attendees a varying 

perspectives on this important issue which will lend itself to broad and deep 

discussions relative to where the field of toxicology is headed. 

WedneSday 







231


WedneSday 



#1421 9:00 MITOCHONDRIAL TOXICITY IN DISEASE 

AND DEATH. B. Zhivotovsky. Institute of 

Environmental Medicine, Division of Toxicology, 


#1422 9:05 MITOCHONDRIA AS TARGET FOR 

CHEMOTHERAPY. B. Zhivotovsky, V. 

Gogvadze, E. Norberg and S. Orrenius. Institute of 

Environmental Medicine, Division of Toxicology, 


#1423 9:37 MITOCHONDRIAL REDOX PROTEOME: 

SUSCEPTIBLE SITE OF CHRONIC 

TOXICITY. D. P. Jones, Y. Go and J. Pohl. 

Division of Pulmonary Medicine, Emory University, 

Atlanta, GA. 

#1424 10:09 IRON, LYSOSOMAL FRAGILITY, AND 

MITOCHONDRIAL DYSFUNCTION. J. 

J. Lemasters. Center for Cell Death, Injury, and 

Regeneration, Departments of Pharmaceutical & 

Biomedical Sciences and Biochemistry & Molecular 

Biology, Medical University of South Carolina, 


#1425 10:41 MITOCHONDRIAL OXIDATIVE STRESS: 

IMPLICATIONS FOR CELL DEATH. S. 

Orrenius, E. Norberg, V. Gogvadze and B. 

Zhivotovsky. Institute of Environmental Medicine, 

Division of Toxicology, Karolinska Institutet, 

Stockholm, Sweden. 

#1426 11:13 METHODS TO DETECT MITOCHONDRIAL 

TOXICITY CAUSED BY ANTI-RETROVIRAL 

AND ANTIBACTERIAL THERAPY. S. 

Nadanaciva. Pfizer R&D, Groton, CT. Sponsor: B. 

Zhivotovsky. 


9:00 AM to 11:45 AM 

Room 250 

Symposium Session: The Fetal Basis of Adult Disease 

Chairperson(s): Don A. Delker, University of Utah School of Medicine, 

Salt Lake City, UT, and Erik J. Tokar, NIEHS, Research Triangle Park, 

NC. 

Sponsor: 


Endorsed by: 




Recent studies provide convincing evidence for the fetal basis of adult 

disease. Gestation is a period of high sensitivity to toxicants, with a variety 

of maternal exposures leading to consequent diseases such as cancer, 

atherosclerosis, hypertension, obesity, and diabetes in the offspring often 

much later in adulthood. There is strong suspicion that embryonic/fetal stem 

cells (SCs) are key targets in the transplacental chemical attack that is the 

etiological basis of these diseases, in part because of their relative abundance 

and their role in organogenesis and differentiation. The long latency 

period between in utero exposure and development of adulthood diseases is 

consistent with lesions in conditionally immortal SC populations with their 

limitless capacity for self-renewal. Beginning with the theory of the fetal 

basis of adult disease (the Barker Hypothesis) and how it relates to alterations 

in SCs and SC numbers, the symposium will then describe the impact 

of transplacental arsenic exposure on skin SC dynamics, illustrating how 

early life arsenic exposure plays a role in skin cancer much later in life. The 

transplacental arsenic-induced changes in liver programming associated with 

accelerated atherosclerosis in adulthood, and the effects of maternal lead 

(Pb) exposure on the hypothalamic-pituitary-adrenal axis and development 

of Pb-associated adult diseases will then be covered. Next, in vitro SC model 

systems demonstrating arsenic transforms SCs into a pluripotent cancer 

SC (CSC) phenotype and how this phenomenon may be specific to arsenic 

as opposed to other carcinogenic metals (e.g. cadmium) are described. 

Concluding this session, our panel of experts will discuss genomic profiling 

of SC signaling pathways in adult animals following environmental chemical 

exposure and how the activation of these pathways in vivo may predict 

tumor outcome. This session will be of interest to those researching developmental 

exposure to metals and other toxicants, metal toxicology, molecular 

mechanisms involved the regulation of SCs, and the initiation of CSCs, as 

well as those interested in the fetal basis of adult disease. 

#1427 9:00 THE FETAL BASIS OF ADULT DISEASE. D. 

A. Delker 2 and E. J. Tokar 1 . 1 NCI at NIEHS, Research 

Triangle Park, NC and 2 University of Utah School of 

Medicine, Salt Lake City, UT. 

#1428 9:05 MODULATION OF HUMAN STEM 

CELLS DURING IN UTERO EXPOSURES 

TO TOXICANTS: A MECHANISTIC 

EXPLANATION TO THE BARKER 

HYPOTHESIS. J. E. Trosko. Department 

Pediatrics/Human Development, Michigan State 


#1429 9:32 FETAL ARSENIC EXPOSURE ENHANCES 

SKIN CANCER IN ADULTHOOD WITH 

CONTEMPORANEOUS DISTORTION OF 

TUMOR STEM CELL DYNAMICS. M. P. 

Waalkes. NCI at NIEHS, Research Triangle Park, 

NC. 

#1430 9:59 TRANSPLACENTAL ARSENIC EXPOSURE 

INDUCED CHANGES IN LIVER 

PROGRAMMING ASSOCIATED WITH 

ACCELERATED ATHEROSCLEROSIS. J. C. 

States 1 , A. Singh 2 , T. Knudsen 2 , E. Rouchka 3 , M. S. 

Ko 5 , Y. Piao 5 , N. O. Ngalame 1 , J. Arteel 1 , G. Arteel 1 

and S. Srivastava 4 . 1 Pharmacology & Toxicology, 

University of Louisville, Louisville, KY, 2 Molecular, 

Cellular & Craniofacial Biology, University of 

Louisville, Louisville, KY, 3 Computer Engineering 

& Computer Science, University of Louisville, 

Louisville, KY, 4 Medicine, University of Louisville, 

Louisville, KY and 5 Laboratory of Genetics, National 

Institute on Aging, Baltimore, MD. 

#1431 10:26 PERMANENT EFFECTS OF MATERNAL 

LEAD (PB) EXPOSURE ON THE HPA AXIS: 

A BIOLOGICAL UNIFYING MECHANISM 

FOR PB-ASSOCIATED ADULT DISEASES. 

D. A. Cory-Slechta. Department of Environmental 

Medicine, University of Rochester School of 

Medicine, Rochester, NY. 

#1432 10:53 ARSENIC-INDUCED STEM CELL 

INITIATION PRODUCES A CANCER STEM 

CELL PHENOTYPE DURING MALIGNANT 

TRANSFORMATION. E. J. Tokar. NCI at 


#1433 11:20 EPIGENETIC SIGNALING AS A TARGET 

FOR CHEMICAL TOXICITY AND 

CARCINOGENESIS. D. A. Delker 1 and W. O. 

Ward 2 . 1 University of Utah School of Medicine, Salt 

Lake City, UT and 2 U.S. EPA, Research Triangle 

Park, NC. 

232 






Platform Sessions



Abstract # 


9:00 AM to 11:45 AM 

Room 151 

Workshop Session: Current Thinking and Experiences 

Related to Developmental and Reproductive Safety 


Chairperson(s): Christopher J. Bowman, Pfizer Global Research and 

Development, Groton, CT, and Tacey E. White, GlaxoSmithKline, King of 

Prussia, PA. 

Sponsor: 


Endorsed by: 


As scientific thinking and regulatory expectations around highly targetspecific 

biotherapeutics have evolved, it has become increasingly difficult 

to design meaningful nonclinical strategies that reduce uncertainty around 

the risk of effects on human reproduction and development. Importantly, 

these nonclinical studies are likely the most reliable method available to 

prevent drug-induced birth defects and infertility since clinical evaluation 

of these endpoints is unethical or rare. These studies should generally be 

in compliance with ICH S5, which is designed primarily to detect toxicity 

to reproduction and development (hazard identification). From ICH S5 

relatively standard nonclinical strategies for small molecules have evolved, 

but for practical, technical, and sometimes ethical reasons may have limited 

value for large molecules or vaccines (issues ranging from placental transfer 

to limited off-target toxicity). Although most biological effects of biotherapeutics 

have an origin in modification of a target or target signaling, it is 

not uncommon to have unexpected effects on reproduction and/or development 

since regulation/function of the target during these lifestages is often 

not well understood, particularly for novel drug targets. As described in 

ICH S6, for biotherapeutics careful scrutiny of the nonclinical strategy and 

conduct of specific studies is necessary to appropriately account for many 

issues, particularly species specificity, immunogenicity, biological activity 

and/or elimination half-life. In order to adhere to ever-changing regulatory 

expectations, minimize the use of animals; and improve the performance of 

safety assessment/toxicology around potential treatment-related effects on 

reproduction and development; innovative strategies using a combination of 

animal models (e.g., transgenic) and study designs (e.g., use of homologues 

or combined pre/postnatal development in non-human primate) are currently 

being developed and applied by many companies. 

#1434 9:00 CURRENT THINKING AND EXPERIENCES 

ON DEVELOPMENTAL AND 

REPRODUCTIVE SAFETY ASSESSMENT OF 

BIOTHERAPEUTICS. C. J. Bowman 1 and T. E. 

White 2 . 1 Pfizer, Groton, CT and 2 GlaxoSmithKline, 

King of Prussia, PA. 

#1435 9:05 CURRENT REGULATORY EXPERIENCE 

AND PROPOSED MODIFICATIONS TO ICH 

S6. J. van der Laan. Center for Biological Medicines 

and Medical Technology, National Institute for 

Public Health and the Environment, Bilthoven, 

Netherlands. Sponsor: C. Bowman. 

#1436 9:37 PRECLINICAL STRATEGY 

CONSIDERATIONS FOR ASSESSING THE 


TOXICITY POTENTIAL OF 

BIOPHARMACEUTICALS. J. Cavagnaro. 

Access BIO, Boyce, VA. 

#1437 10:09 CHALLENGES AND SOLUTIONS FOR 

EVALUATING THE DEVELOPMENTAL 

TOXICITY POTENTIAL OF 

BIOTHERAPEUTICS. L. Andrews. Genzyme 

Corporation, Framingham, MA. 

Abstract # 

#1438 10:41 CASE STUDIES: DEVELOPMENTAL AND 

REPRODUCTIVE TOXICITY (DART) 

STRATEGIES EMPLOYED TO SUPPORT 

THE REGISTRATION OF GOLIMUMAB 

AND USTEKINUMAB. C. Sachs, G. Treacy and 

P. Martin. Centocor R&D, Inc., Radnor, PA. 

#1439 11:13 STATE OF THE SCIENCE ON 


SAFETY ASSESSMENT ON VACCINES AND 

ADJUVANTS. S. J. Gould. Sanofi Pasteur, Lyon 

Marcy L’Etoile, France. 


9:00 AM to 11:45 AM 

Ballroom G 


Workshop Session: Novel Research Approaches and Animal 

Models in Translational Toxicology 

Chairperson(s): Shashi Ramaiah, Pfizer Global Research and 

Development, St. Louis, MO, and Benjamin D. Humphreys, Harvard 

University, Boston, MA. 

Sponsor: 


Endorsed by: 



Translational toxicology is defined by the ability to translate preclinical 

animal safety findings to human is integral to successful drug development. 

Preclinical safety studies are mostly carried out in both rodent and a nonrodent 

species, with the primary goal to demonstrate or identify target organ 

effects translatable to human health. In addition these studies also enable 

selection of the dose for first-in-human studies, demonstrate a margin of 

safety between the efficacious and toxic doses, and establish mechanisms 

for monitoring safety during clinical trials such as biomarkers. In order to 

demonstrate translatability, it is critical to develop the most relevant animal 

model and to select the appropriate endpoints that can accurately predict 

human toxicity. If a safety issue is identified, it is of utmost importance 

to have the most sensitive and specific translatable biomarker of organ 

toxicity in addition to the ideal assay platform to monitor such biomarkers 

clinically. Without these, the incidence of drug failure due to toxicity during 

clinical development and the occurrence of morbidity and mortality in 

human patients will continue to increase. The goal of this session will be 

to provide novel research approaches and examples to address certain gaps 

in drug development to ensure clinical translatability. The application of 

novel research approaches, animal models, and biomarker platforms will be 

discussed from clinical and nonclinical scientists actively engaged in these 

areas. 

#1440 9:00 NOVEL RESEARCH APPROACHES, ANIMAL 

MODELS, AND CLINICAL EXAMPLES IN 

TRANSLATIONAL TOXICOLOGY. S. K. 

Ramaiah. Drug Safety Research and Development, 

Pfizer Global Research and Development, Saint 

Louis, MO. 

#1441 9:05 WHY DO ANIMAL MODELS FAIL 

TO PREDICT IDIOSYNCRATIC 

HEPATOTOXICITY IN HUMANS. A. Regev. 

Global Patient Safety, Eli Lilly, Indianapolis, IN. 

#1442 9:45 NOVEL TRANSLATIONAL RESEARCH 

APPROACHES TO UNDERSTAND AND 

PREDICT DRUG INDUCED LIVER INJURY. 

P. B. Watkins. Center for Drug Safety Sciences, 

University of North Carolina, Chapel Hill, NC. 

WedneSday 







233


WedneSday 



#1443 10:25 KIDNEY AND VASCULAR TOXICITIES OF 

VEGF SIGNALING PATHWAY INHIBITORS: 

MECHANISM-DEPENDENT BIOMARKERS 

FOR TREATMENT EFFICACY? B. D. 

Humphreys. Translational Research in Kidney 

Repair, Harvard University, Boston, MA. Sponsor: S. 

Ramaiah. 

#1444 11:05 LEAD OPTIMIZATION STRATEGIES AND 

NOVEL BIOMARKER TECHNOLOGIES 

TO ENSURE DRUG SAFETY. J. S. Ozer. 

Pharmacokinetics, Dynamics and Metabolism, Pfizer, 

Chesterfield, MO. Sponsor: S. Ramaiah. 


9:00 AM to 11:45 AM 

Ballroom F 


Workshop Session: Toxicity Testing in the 21 st Century for 

Ecotoxicology 

Chairperson(s): Stephen Edwards, U.S. EPA, Research Triangle Park, 

NC, and Gerald Ankley, U.S. EPA, Duluth, MN. 

Sponsor: 


Endorsed by: 



The National Research Council (NRC) report, Toxicity Testing in the 

Twenty-first Century: A Vision and a Strategy has relevance for ecological 

as well as human health risk assessment. In April 2009, the Society of 

Environmental Toxicology and Chemistry (SETAC) held a workshop that 

considered key elements of the scientific foundation that would be needed to 

implement the vision of toxicity pathway-based testing in support of ecological 

risk assessment The term adverse outcome pathway (AOP) was used 

to describe the linkage of molecular events modeled in a toxicity pathway 

assay to downstream biologic effects considered adverse from an ecotoxicological 

perspective (i.e., effects on survival, reproduction). Five challenges 

related to the elucidation and description of AOPs were considered. First, 

consistent with the NRC strategy concerning toxicity pathway elucidation 

and linkage to adversity, the challenge of describing AOPs from the extant 

literature and quantitatively modeling key components was addressed. 

Second, approaches for reverse engineering AOPs from combinations of 

transcriptomic, proteomic, metabolomic, and/or phenotypic data were examined. 

Because adversity in an ecological risk context is typically considered 

at the population level, approaches for translating toxicity pathway outputs 

into appropriate parameters for population modeling was a third challenge 

discussed. The fourth related to the challenge of discriminating adaptive 

(i.e., homeostatic, allostatic) responses from adverse ones and incorporating 

that knowledge into AOP models. Finally, because species extrapolation is a 

central challenge in ecological risk assessment, the workshop examined how 

to determine conservation of AOPs among species and use this information 

in predicting species sensitivity to support ecological risk assessments. This 

session will summarize the results of the SETAC effort and invite discussion 

with SOT members regarding development of an integrated toxicity testing 

paradigm that supports both human health and ecological risk assessment. 

#1445 9:00 TOXICITY TESTING IN THE 21 ST CENTURY 

FOR ECOTOXICOLOGY. S. Edwards 1 and G. 

T. Ankley 2 . 1 ORD/NHEERL, U.S. EPA, Research 

Triangle Park, NC and 2 ORD/NHEERL, U.S. EPA, 

Duluth, MN. 

#1446 9:05 ADVERSE OUTCOME PATHWAY (AOP) 

MODELING OF KNOWN PATHWAYS. M. 

E. Andersen 1 , K. Watanabe 2 and I. R. Schultz 3 . 1 The 

Hamner Institutes, Research Triangle Park, NC, 

2 

Oregon Health and Science University School 

of Medicine, Portland, OR and 3 Battelle Pacific 

Northwest, Sequim, WA. 

#1447 9:30 REVERSE ENGINEERING ADVERSE 

OUTCOME PATHWAYS FROM ‘OMICS 

DATA. E. J. Perkins 1 , K. Chipman 2 , F. Falciani 2 , S. 

Edwards 3 , T. Habib 4 , R. Taylor 5 , G. Van Aggelen 6 , 

C. Vulpe 7 and N. V. Garcia-Reyero 8 . 1 Environmental 

Laboratory, U.S. Army ERDC, Vicksburg, MS, 

2 

College of Life and Environmental Sciences, 

University of Birmingham, Birmingham, United 

Kingdom, 3 NHRL, U.S. EPA, Research Triangle 

Park, NC, 4 Biological Sciences, University of 

Southern Mississippi, Hattiesburg, MS, 5 Systems 

Biology, Pacific Northwest National Laboratories, 

Richland, WA, 6 Pacific Environmental Science 

Center, Environment Canada, Vancouver, BC, 

Canada, 7 Nutritional Science and Toxicology, 

University of California at Berkeley, Berkeley, CA 

and 8 Chemistry, Jackson State University, Jackson, 

MS. 

#1448 9:55 ADVERSE OUTCOME PATHWAYS AND 

ECOLOGICAL RISK ASSESSMENT: 

BRIDGING TO POPULATION LEVEL 

EFFECTS. G. Ankley 1 , V. Kramer 2 , M. Etterson 1 , 

M. Hecker 3 , C. Murphy 4 , G. Roesijadi 5 , D. Spade 6 , J. 

Spromberg 7 and M. Wang 8 . 1 U.S. EPA, Duluth, MN, 

2 

Dow AgroSciences LLC, Indianapolis, IN, 3 Entrix 

Inc., Saskatoon, SK, Canada, 4 Michigan State 

University, East Lansing, MI, 5 Battelle, Sequim, WA, 

6 

University of Florida, Gainesville, FL, 7 NOAA, 

Seattle, WA and 8 RIFCON GmbH, Heidelberg, 

Germany. Sponsor: S. Edwards. 

#1449 10:20 TESTING AND RISK ASSESSMENT OF 

CHEMICALS THAT IMPACT HIGHLY 

ADAPTIVE BIOLOGICAL SYSTEMS: THE 

CASE OF ENDOCRINE SYSTEMS. J. W. 

Nichols 1 , M. Breen 2 , R. Denver 3 , J. DiStefano III 4 , 

J. Edwards 5 , R. Hoke 6 , D. Volz 7 and X. Zhang 8 . 

1 

U.S. EPA, Duluth, MN, 2 U.S. EPA, Research 

Triangle Park, NC, 3 University of Michigan, Ann 

Arbor, MI, 4 UCLA, Los Angeles, CA, 5 University 

of New Mexico, Albuquerque, NM, 6 Dupont 

Haskell Laboratory, Newark, NJ, 7 University of 

South Carolina, Columbia, SC and 8 University of 

Saskatchewan, Saskatoon, SK, Canada. 

#1450 10:45 SPECIES EXTRAPOLATION FOR THE 21 ST 

CENTURY. J. Goldstone 1 , M. C. Celander 2 , N. D. 

Denslow 3 , T. Iguchi 4 , P. Kille 5 , R. D. Meyerhoff 6 , 

B. A. Smith 7 , T. H. Hutchinson 8 and J. R. Wheeler 9 . 

1 

Woods Hole Oceanographic Institution, Woods 

Hole, MA, 2 Göteborg University, Göteborg, Sweden, 

3 

University of Florida, Gainesville, FL, 4 Okazaki 

Institute for Integrative Bioscience, Okazaki, Japan, 

5 

Cardiff University, Cardiff, United Kingdom, 6 Lilly 

Research Laboratories, Indianapolis, IN, 7 Stantec 

Consulting Ltd., Guelph, ON, Canada, 8 Centre for 

Environment, Fisheries & Aquaculture Science, 

Weymouth, United Kingdom and 9 Syngenta 

Environmental Safety, Bracknell, United Kingdom. 

#1451 11:10 PREDICTIVE ECOTOXICOLOGY IN THE 

21 ST CENTURY. D. L. Villeneuve 1 and N. Garcia- 

Reyero 2 . 1 U.S. EPA Mid-Continent Ecology Division, 

Duluth, MN and 2 Department of Chemistry, Jackson 

State University, Jackson, MS. Sponsor: S. Edwards. 

234 






Platform Sessions



Abstract # 


9:00 AM to 11:45 AM 

Ballroom D 

Workshop Session: Understanding Nonlinearities at the Low- 

End of the Dose-Response Curve: Insights from Molecular 

Network Analysis 

Chairperson(s): Sally P. Darney, U.S. EPA, Research Triangle Park, NC, 

and Robert E. Chapin, Pfizer Global Research & Development, Groton, 

CT. 

Sponsor: 


Endorsed by: 


As we move more and more into predictive toxicology, there will be a 

pressing need to more fully understand the world of in vivo effects and 

how (or if, or when) those translate into measurable impacts on health. This 

includes responses seen at very low doses or internal concentrations. We 

will explore the world of low dose effects reported for endocrine disrupting 

chemicals thought to exert health effects primarily by interfering with 

steroid hormone receptor function. Participants will learn the latest details 

of steroid hormone action including binding of endogenous hormone and/ 

or hormone mimics to steroid receptors and the possibility of non-receptormediated 

actions. This will set the stage for examining mechanisms by 

which low levels of exogenous ligand may alter endogenous responses or 

developmental processes. With this foundation, diverse effects reported for 

the weakly estrogenic compound Bisphenol A will be reviewed, particularly 

surprises seen at very low doses where the dose-response deviates from 

the expected linear relationship. Recent explorations of gene regulatory 

networks suggest explanations for these unexpected nonlinearities, especially 

at very low levels of signal. Discussants will add perspectives on the 

mechanistic and risk assessment implications provided by the new science 

of steroid signaling and gene regulatory networks. By providing this information, 

we hope that the audience will come away from this session with 

a better understanding of the biological plausibility of low dose effects of 

endocrine disrupting chemicals as well as implications for risk assessment 

and predictive toxicology. Additionally participants will gain insights on 

how to focus on nonlinear biological networks, as opposed to our accustomed 

linear pathways, and how to leverage all available biological data to 

translate very low dose effects into outcomes more conventionally measured 

in toxicity studies. 

#1452 9:00 UNDERSTANDING NONLINEARITIES AT 

THE LOW END OF THE DOSE-RESPONSE 

CURVE: INSIGHTS FROM MOLECULAR 

NETWORK ANALYSIS. S. P. Darney. ORD, U.S. 


#1453 9:05 ESTROGEN RECEPTORS AS SENSORS 

AND MEDIATORS OF DIVERSE LIGAND 

RESPONSES. G. L. Greene. The Ben May 

Department for Cancer Research, University of 

Chicago, Chicago, IL. Sponsor: S. Darney. 

#1454 9:45 LOW DOSE EFFECTS OF BISPHENOL A IN 

ANIMAL STUDIES. K. Thayer and J. Bucher. 

NIEHS, Research Triangle Park, NC . 

#1455 10:25 DOSE-RESPONSE RELATIONSHIPS IN 

GENE REGULATORY NETWORKS AND 

LACK OF LINEARITY AT LOW DOSE. 

Q. Zhang. The Hamner Institutes, Durham, NC. 

Sponsor: M. Andersen. 

11:05 ROBERT E. CHAPIN, VICKIE DELLARCO, 

AND KEVIN GAIDO. Panel Discussion/Q&A 

Abstract # 


9:00 AM to 11:45 AM 

Ballroom I 

Platform Session: Advances in Mycotoxin Toxicity 

Chairperson(s): Alicia Marroquin-Cardona, Texas A&M University, 

College Station, TX, and Edmond Creppy, University of Bordeaux, 

Bordeaux, France. 

#1456 9:00 THE KINETICS OF URINARY FUMONISIN 

EXCRETION IN HUMANS CONSUMING 

MAIZE-BASED FOODS. R. T. Riley 1,2 . 

1 

Toxicology and Mycotoxin Research Unit, USDA- 

ARS, Athens, GA and 2 Interdisciplinary Toxicology 

Program, University of Georgia, Athens, GA. 

#1457 9:19 INITIATION OF GLOBAL NETWORK FOR 

AFLATOXIN EXPOSURE STUDIES. L. 

Tang 1 , G. Qian 1 , L. Xu 1 , N. Johnson 2 , P. Jolly 3 , J. 

H. Williams 1 , T. D. Phillips 2 and J. S. Wang 1 . 1 The 

University of Georgia, Athens, GA, 2 Texas A&M 

University, College Station, TX and 3 University of 

Alabama at Birmingham, Birmingham, AL. 

#1458 9:37 ASSOCIATION BETWEEN TORTILLA, 

PEANUT, AND RICE CONSUMPTION AND 

URINARY AFLATOXIN M 1 

LEVELS IN A 

U.S. POPULATION WITH AN ELEVATED 

INCIDENCE OF LIVER CANCER. N. M. 

Johnson 1 , D. Tietze 1 , A. Marroquin-Cardona 1 , A. 

Robinson 1 , N. Mitchell 1 , J. Taylor 1 , G. Qian 2 , L. 

Xu 2 , M. Rodriguez 3 , L. Kaufman 3 , K. Cunningham 3 , 

F. Guerra 3 , K. C. Donnelly 1 , J. S. Wang 2 and T. D. 

Phillips 1 . 1 College of Veterinary Medicine, Texas 

A&M University, College Station, TX, 2 College of 

Public Health, University of Georgia, Athens, GA 

and 3 San Antonio Metropolitan Health District, San 

Antonio, TX. 

#1459 9:55 CLINICAL INTERVENTION WITH 

NOVASIL CLAY REDUCES FUMONISIN 

B1 EXPOSURE IN A WEST AFRICAN 

POPULATION. A. Robinson 1 , N. M. Johnson 1 , 

A. Strey 2 , J. F. Taylor 1 , A. Marroquin-Cardona 1 , 

E. Afriyie-Gyawu 3 , R. Nachman 2 , N. A. Ankrah 4 

and T. D. Phillips 1 . 1 College Vet Med, Texas A&M 

University, College Station, TX, 2 USDA/ARS, 

College Station, TX, 3 Georgia Southern University, 

Statesboro, GA and 4 NMIMR, University of Ghana, 

Accra, Ghana. 

#1460 10:14 SUPPRESSIVE EFFECT OF PECTIN 

GELATION ON ABSORPTION OF 

DEOXYNIVALENOL IN MICE. Y. Sugita- 

Konishi 1 , D. Koyama 2 , T. Kadota 3 , S. Itoh 2 , K. 

Sugiyama 1 , C. Tamura 1 , M. Nishijima 4 and Y. 

Kamata 1 . 1 Division of Microbiology, National 

Institute of Health Sciences, Tokyo, Japan, 

2 

School of Veterinary Medicine, Azabu University, 

Kanagawa, Japan, 3 Kirin Holdings Company 

Limited, Gunma, Japan and 4 Department of Food and 

Health Sciences, Jissen Women’s University, Tokyo, 

Japan. 

#1461 10:32 FORMATION OF MIXED ADDUCTS WITH 

GLUTATHION AND ADENINE: A POSSIBLE 

CONTRIBUTION TO THE MUTAGENICITY 

OF THE MYCOTOXIN PATULIN. H. L. 

Esch 1 , E. Pfeiffer 2 , M. Metzler 2 and L. Lehmann 1 . 

1 

University of Wüerzburg, Wüerzburg, Germany and 

2 

University of Karlsruhe, Karlsruhe, Germany. 

WedneSday 







235


WedneSday 



#1462 10:50 INDIVIDUAL AND COMBINED EFFECTS 

OF THE MAIN FUSARIUM TOXINS IN THE 

MOUSE AFTER A 7 DAYS TREATMENT. E. 

E. Creppy, S. Moukha, J. H. Kouadio and T. Mobio. 

Toxicology, University Bordeaux 2, Bordeaux, 

France. 

#1463 11:08 DEOXYNIVALENOL-INDUCED 

MODULATION OF MICRORNA 

EXPRESSION IN RAW 264.7 

MACROPHAGES—A POTENTIAL NOVEL 

MECHANISM FOR TRANSLATIONAL 

INHIBITION. K. He 1,2 , L. Vines 2,3 and J. Pestka 1,2,3 . 

1 

Microbiology & Molecular Genetics, Michigan State 



MI and 3 Food Science & Human Nutrition, Michigan 


#1464 11:26 POTENTIAL CYTOTOXIC EFFECTS OF 

FUSARIUM MYCOTOXINS IN OVARIAN 

AND KIDNEY CELL LINES. G. Font 1 , P. 

Macakova 1 , P. Franzova 1 , M. J. Ruiz 1 and A. 

Anadon 2 . 1 Laboratorio de Toxicología, Facultat de 

Farmacia, Universitat de Valencia, Valencia, Spain 

and 2 Department of Toxicology and Pharmacology, 

Faculty of Veterinary Medicine, Universidad 

Complutense, Madrid, Spain. 


9:00 AM to 11:45 AM 

Room 251 D 


Platform Session: Impact of Receptors and Gene Regulation 

in Toxicological Response 

Chairperson(s): Richard Pollenz, University of South Florida, Tampa, FL, 

and Andrew Wallace, North Carolina State University, Raleigh, NC. 

#1465 9:00 PDK-1 AND THE AKT-1/2 COMPLEX 

REGULATE C. ELEGANS 

METALLOTHIONEIN TRANSCRIPTION IN 

RESPONSE TO CADMIUM. J. Hall and J. H. 

Freedman. NIEHS, Research Triangle Park, NC. 

#1466 9:21 ACTIVATION OF FXR IN TRANSGENIC 

MICE INDUCED HEPATOTOXICITY AND 

INFLAMMATION. Q. Cheng and W. Xie. 

Center for Pharmacogenetics and Department of 

Pharmaceutical Sciences, University of Pittsburgh, 


#1467 9:41 SEXUAL DIMORPHISM IN CIRCADIAN 

CLOCK DISRUPTION OF XENOBIOTIC 

RESPONSE. L. A. Hooven, L. M. Beaver, K. A. 

Sherman and J. M. Giebultowicz. Oregon State 

University, Corvallis, OR. 

#1468 10:02 THE CRYPTIC STORY OF 

GLUCOCORTICOIDS. S. Sengupta 1 , W. H. 

Bisson 1 , L. K. Mathew 2 , R. Abagyan 3 and R. L. 

Tanguay 1 . 1 EMT, Oregon State University, Corvallis, 

OR, 2 University of Pennsylvania Cancer Center, 

Philadelphia, PA and 3 The Scripps Research Institute, 

La Jolla, CA. 

#1469 10:22 TRANSCRIPTIONAL REGULATION OF 

HUMAN MRP4 GENE EXPRESSION UNDER 

PROOXIDATIVE STRESS CONDITIONS. X. 

Gu and J. E. Manautou. University of Connecticut, 

Storrs, CT. 

#1470 10:43 IMPACT OF DEHP METABOLITES 

ON HUMAN ANDROGEN RECEPTOR 

ACTIVITY. A. D. Wallace 1 , I. Rice 1 , P. Thompson 1 , 

F. Nuti 2 and A. Papini 2 . 1 Toxicology, North Carolina 

State University, Raleigh, NC and 2 Organic 

Chemistry, University of Florence, Firenze, Italy. 

#1471 11:03 ASSESSMENT OF AH RECEPTOR 

ACTIVITY IN THE ABSENCE OF AN 

EXOGENOUS LIGAND. T. A. Harper and C. 

Elferink. Pharmacology and Toxicology, University 

of Texas Medical Branch, Galveston, TX. 

#1472 11:24 FEEDBACK LOOP BETWEEN RETINOIC 

ACID RECEPTORS AND NOVEL 

COREGULATOR TNIP1. I. Gurevich, C. C. 

Zhang, C. P. Struzynski and B. J. Aneskievich. 

University of Connecticut, Storrs, CT. 


9:00 AM to 11:45 AM 

Ballroom B 

Platform Session: Inhalation Toxicology of Ultrafine or 

Nanoparticles 

Chairperson(s): David Warheit, DuPont Haskell Laboratory, Newark, DE, 

and Daniel Kirkpatrick, Wil Research Laboratories, LLC, Ashland, OH. 

#1473 9:00 PROGRESSIVE EXPOSURE TO AMBIENT 

FINE PARTICLES IS ASSOCIATED 

WITH CHANGES IN PULMONARY AND 

SYSTEMIC INFLAMMATION IN MICE. L. 

E. Plummer and K. E. Pinkerton. Center for Health 

and the Environment, University of California Davis, 

Davis, CA. 

#1474 9:21 PARTIAL CHARACTERIZATION OF 

AMBIENT PM2.5 EXTRACT FROM 

SAHARAN DUST EVENTS. R. Rodríguez 1 , 

L. B. Méndez-Torres 2 and B. D. Jiménez-Vélez 1 . 

1 

Biochemistry, University of Puerto Rico-Medical 

Sciences Campus, San Juan and 2 University of Puerto 

Rico-Medical Sciences Campus, San Juan. 

#1475 9:42 PULMONARY BIOASSAY STUDY WITH 

POTASSIUM TITANATE NONFIBROUS 

PARTICULATES (TERRACESS JS) IN RATS. 

D. B. Warheit 1 , K. L. Reed 1 and S. Sakai 2 . 1 DuPont 

Haskell Laboratory, Newark, DE and 2 Otsuka 

Chemical Company, Osaka, Japan. 

#1476 10:03 PLEURAL TRANSLOCATION, FATE, 

AND PATHOLOGICAL RESPONSE 

OF CHRYSOTILE IN COMBINATION 

WITH FINE PARTICLES COMPARED 

TO AMOSITE ASBESTOS FOLLOWING 

SHORT TERM INHALATION EXPOSURE. 

D. M. Bernstein 1 , R. A. Rogers 2 and S. E. Holm 3 . 

1 

Consultant in Toxicology, Geneva, GE, Switzerland, 

2 

Rogers Imaging Corporation, Needham, MA and 

3 

Georgia-Pacific, LLC, Atlanta, GA. 

#1477 10:24 SOLUBLE COMPONENTS OF ULTRAFINE 

PARTICULATE MATTER STIMULATE 

ENDOTHELIAL H 2O 2 PRODUCTION. S. J. 

Snow 1 and M. Carraway 2 . 1 Curriculum of Toxicology, 


Hill, NC and 2 U.S. EPA, Human Studies Facility, 

National Health and Environmental Effects Research 

Laboratory, Chapel Hill, NC. Sponsor: M. Madden. 

236 






Platform Sessions



Abstract # 

#1478 10:44 THE EFFECTS OF CONCENTRATED 

AMBIENT PARTICLES (CAPS) AND NICKEL 

NANOPARTICLES ON ENDOTHELIAL 

PROGENITOR CELL NUMBER AND 

FUNCTION. E. N. Liberda, A. Madrid, Q. Qu and 

L. Chen. Department of Environmental Medicine, 

New York University, New York City, NY. 

#1479 11:04 INHALED TOLERANCE AND 

COMPARATIVE PK PROFILE OF INHALED 

NANOGENT IN NON-HUMAN PRIMATES. 

M. D. Reed 1 , M. Doyle-Eisle 1 , P. Kuehl 1 , E. 

Hammond 2 , B. Eppler 2 and J. Talton 2 . 1 Lovelace 

Respiratory Research Institute, Albuquerque, NM 

and 2 NanoTherapeutics, Alachua, FL. 

#1480 11:24 INHALED MAXIMUM TOLERATED DOSE 

OF NANOGENT IN RODENTS. P. Kuehl 1 , M. 

D. Reed 1 , M. Doyle-Eisle 1 , E. Hammond 2 , B. Eppler 2 

and J. Talton 2 . 1 Lovelace Respiratory Research 

Institute, Albuquerque, NM and 2 Nanotherapeutics, 

Alachua, FL. 


9:00 AM to 11:45 AM 

Room 251 A 

Platform Session: Reproductive and Developmental Toxicity 

of Phthlates 

Chairperson(s): Claude Emond, Université de Montréal, Montréal, QC, 

Canada, and Kim Boekelheide, Brown University, Providence, RI. 

#1481 9:00 DI(N)BUTYL PHTHALATE REDUCES 

TESTICULAR WEIGHT, TESTOSTERONE 

AND ASSOCIATED GENE EXPRESSION 

IN FETAL HARLAN SPRAGUE-DAWLEY 

RATS. K. L. Howdeshell, J. Furr, C. R. Lambright, 

V. S. Wilson and L. Gray. Reproductive Toxicology 

Branch, U.S. EPA, Research Triangle Park, NC . 

#1482 9:19 MEHP-INDUCED DISRUPTION OF 

JUNCTIONAL COMPLEXES IN THE 

SEMINIFEROUS EPITHELIUM OF THE 

RODENT TESTIS IS MEDIATED BY MMP-2. 

P. Yao, Y. Lin and J. H. Richburg. the University of 

Texas at Austin, Austin, TX. 

#1483 9:38 EFFECTS OF DI-(2-ETHYLHEXYL) 

PHTHALATE AND MONO-(2- 

ETHYLHEXYL)PHTHALATE ON OVARIAN 

GRANULOSA CELLS IN MICE. M. Ma 1,2 , 

Y. Zhang 1,2 , X. Pei 1,2 and Z. Duan 1,2 . 1 Department 

of Toxicology, Shenyang Medical College, 

Shenyang, Liaoning, China and 2 Key Laboratory 

of Environment and Population Health of Liaoning 

Education Ministry, Shenyang Medical College, 

Shenyang, Liaoning, China. 

#1484 9:57 COMPARISON OF THE EFFECTS 

OF INTRAVENOUS AND ORAL DI(2- 

ETHYLHEXYL)PHTHALATE (DEHP) 

ON TESTICULAR WEIGHT AND GENE 

EXPRESSION IN NEONATAL RATS. L. 

Camacho, S. J. Moon and K. Delclos. Division 

Biochemical Toxicology, NCTR, U.S. FDA, 


#1485 10:15 EFFECTS OF IN UTERO EXPOSURE TO 

MONO-2-ETHYLHEXYLPHTHALATE 

(MEHP) ON THE ADULT FEMALE. B. J. 

Moyer and M. Hixon. Brown University, Providence, 

RI. 

Abstract # 

#1486 10:33 THREE DIMENSIONAL CO-CULTURE 

OF TESTICULAR CELLS AS AN IN VITRO 

MODEL FOR TESTIS: TOXICOGENOMIC 

RESPONSES OF PHTHALATE ESTERS, 

BISPHENOL A, AND GLYCOL ETHERS. 

S. H. Wegner, X. Yu, S. Hong, H. Kim and E. M. 

Faustman. DEOHS, University of Washington, 

Seattle, WA. 

#1487 10:51 PHTHALATES DECREASE 

SPERMATOGONIAL STEM CELLS 

PROLIFERATION BY ALTERING GDNF 

SIGNALING. B. E. Lucas. Veterinary Biosciences, 

University of Illinois, Urbana, IL. Sponsor: R. Hess. 

#1488 11:09 THE EFFECTS OF DIBUTYLPHTHALATE 

(DBP) ON TRANSCRIPTION FACTOR-DNA 

BINDING TO FETAL RAT TESTES GENES 

RELEVANT TO PHTHALATE-INDUCED 

TESTICULAR MALDEVELOPMENT 

(PITMD). S. M. Plummer 1 , D. Dan 1 , J. C. Quinney 1 , 

N. Hallmark 2 , R. D. Phillips 2 and C. R. Elcombe 1 . 

1 

CXR Biosciences, Dundee, United Kingdom and 

2 

ExxonMobil Petroleum & Chemical, Hermeslaan, 

Belgium. 

#1489 11:27 DI-(2-ETHYLHEXYL) PHTHALATE 

INHIBITS EXPRESSION OF ANTIOXIDANT 

ENZYMES IN MOUSE ANTRAL FOLLICLES. 

R. K. Gupta, J. Singh and J. A. Flaws. Veterinary 



9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Inhalation Toxicology 

Chairperson(s): David Bernstein, Toxicology Consultant, Geneva, 

Switzerland. 




BRONCHIOLITIS OBLITERANS-LIKE 

LESIONS IN RATS TREATED WITH 

DIACETYL, ACETOIN, OR ACETYL 

PROPIONYL BY INTRATRACHEAL 

INSTILLATION. G. P. Flake 1 , P. J. Kirby 1 , H. 

C. Price 2 , P. S. Gage 2 , F. L. Kelly 3 , S. M. Palmer 3 , 

J. F. Foley 1 and D. L. Morgan 1 . 1 NIEHS, Research 

Triangle Park, NC, 2 Alion Science Technologies, 

Inc., Research Triangle Park, NC and 3 Duke 

University Medical Center, Durham, NC. 


A PBPK MODEL FOR INSPIRED VAPOR 

UPTAKE IN THE HUMAN AND ITS 

APPLICATION TO DIACETYL DOSIMETRY. 

J. B. Morris. Toxicology Program, University of 



INHALATION TOXICITY OF ACETYL 

PROPIONYL IN RATS AND MICE. D. L. 

Morgan 1 , P. J. Kirby 1 , H. C. Price 2 , R. W. Bousquet 2 , 

G. J. Taylor 2 , N. Gage 2 and G. P. Flake 1 . 1 NIEHS, 

Research Triangle Park, NC and 2 Alion, Research 


WedneSday 







237


WedneSday 




DIESEL EXHAUST PARTICULATE ALTERS 

ENDOTHELIAL CELL NOS, ENDOTHELIN 

AND MCP1 GENE EXPRESSION IN TWO 

IN VITRO MODELS OF EXPOSURE. C. S. 

Weldy 1 , D. P. Cox 1 , T. V. Larson 2 , J. A. Stewart 1 , H. 

Wilkerson 1 and T. J. Kavanagh 1 . 1 Environmental 

and Occupational Health, University of Washington, 

Seattle, WA and 2 Civil and Environmental 

Engineering, University of Washington, Seattle, WA. 


CYP-DEPENDENT SENSORY IRRITATION 

OF NAPHTHALENE AND STYRENE. D. 

N. Willis and J. B. Morris. Toxicology Program, 



AUTOMATED AEROSOLIZATION, 

DISPERSION, AND CONCENTRATION 

CONTROL OF SILICA POWDER FOR USE 

IN INHALATION EXPOSURE STUDIES. 

W. McKinney, A. Afshari, B. Chen and D. Frazer. 

NIOSH / CDC, Morgantown, WV. Sponsor: V. 

Castranova. 


COMPARISON OF COMPOSITION OF PM2.5 

FROM PAVED ROADS AND IN AMBIENT 

AIR. J. L. Mauderly and J. D. McDonald. Lovelace 

Respiratory Research Institute, Albuquerque, NM. 


PRELIMINARY RESULTS INVESTIGATING 

DIESEL EXHAUST PARTICULATE 

MEDIATED LUNG INFLAMMATION IN 

WILD TYPE AND GCLM-HETEROZYGOUS 

MICE. C. S. Weldy 1 , C. C. White 1 , T. V. Larson 2 , 

J. A. Stewart 1 and T. J. Kavanagh 1 . 1 Environmental 

and Occupational Health, University of Washington, 

Seattle, WA and 2 Civil and Environmental 

Engineering, University of Washington, Seattle, WA. 


DIFFERENTIAL ELECTROCARDIOGRAM 

EFFECTS IN NORMAL AND 

HYPERTENSIVE RATS AFTER 

INHALATION EXPOSURE TO TRANSITION 

METAL RICH PARTICULATE MATTER. 

C. M. Lamb 1 , N. Haykal-Coates 2 , A. P. Carll 1 , M. 

S. Hazari 2 , D. W. Winsett 2 , D. L. Costa 3 and A. K. 

Farraj 2 . 1 University of North Carolina Chapel Hill, 

Chapel Hill, NC, 2 Environmental Public Health 

Division, U.S. EPA, Research Triangle Park, NC and 

3 




A TWO-WEEK (9-EXPOSURE) INHALATION 

STUDY IN F344 RATS: PULMONARY 

TOXICITY OF FOUR UCON FLUIDS. J. 

Pitt 1 , D. Kirkpatrick 2 and J. Hotchkiss 1 . 1 The Dow 

Chemical Co., Midland, MI and 2 WIL Research 

Laboratories LLC, Ashland, OH. 


OXIDIZED LIPIDS AND LIPID MEDIATORS 

ARE INVOLVED IN CARDIOVASCULAR 

INJURY INDUCED BY DIESEL EXHAUST 

PARTICLES (DEP) AND OZONE. U. 

P. Kodavanti 1 , R. Thomas 1 , A. Lund 2 , M. C. 

Schladweiler 1 , M. J. Campen 3 , J. H. Shannahan 4 , 

A. D. Ledbetter 1 , J. E. Richards 1 , A. Nyska 5 , R. H. 

Jaskot 1 , E. O. Butler 6 and N. L. Parinandi 6 . 1 EPHD/ 

NHEERL, U.S. EPA, Research Triangle Park, 

NC, 2 LRRI, Albuquerque, NM, 3 Department 

Pharmacology, University New Mexico, 

Albuquerque, NM, 4 Curriculum in Toxicology, 

University North Carolina, Chapel Hill, NC, 5 Tel 

Aviv University, Timrat, Israel and 6 Ohio State 

University College of Medicine, Columbus, OH. 


PARTICULATE INHALATION IN RATS 

CAUSES CONCENTRATION-DEPENDENT 

ELECTROCARDIOGRAPHIC, AUTONOMIC, 

AND CARDIAC MICRORNA EXPRESSION 

CHANGES. A. K. Farraj 1 , M. S. Hazari 1 , N. 

Haykal-Coates 1 , C. M. Lamb 2 , D. W. Winsett 1 , Y. Ge 1 , 

A. D. Ledbetter 1 , A. P. Carll 2 , M. Bruno 1 and D. L. 

Costa 1 . 1 U.S. EPA, Research Triangle Park, NC and 

2 

University of North Carolina, Chapel Hill, NC. 


MAST CELLS CONTRIBUTE TO 

ALTERATIONS IN VASCULAR REACTIVITY 

AND EXACERBATION OF ISCHEMIA/ 

REPERFUSION INJURY FOLLOWING 

ULTRAFINE PM EXPOSURE. C. J. Wingard 1 , 

R. M. Lust 1 , D. M. Walters 1 , R. B. Devlin 4 , W. 

E. Cascio 2 and J. M. Brown 3 . 1 Physiology, East 

Carolina University, Greenville, NC, 2 Cardiovascular 

Sciences, East Carolina University, Greenville, 

NC, 3 Pharmacology & Toxicology, East Carolina 

University, Greenville, NC and 4 National Health and 

Environmental Effects Research Laboratory, U.S. 

EPA, Research Triangle Park, NC . 


EXAMINATION OF SUSCEPTIBILITY 

TO LIBBY AMPHIBOLE ASBESTOS- 

INDUCED INJURY IN RAT MODELS OF 

CARDIOVASCULAR DISEASE. J. Shannahan 1 , 

M. Schladweiler 2 , D. Carlin 1 , J. Richards 3 , S. Gavett 2 

and U. Kodavanti 2 . 1 Curriculum in Toxicology, 

University of North Carolina, Chapel Hill, NC, 

2 

CIB, EPHD, NHEERL, U.S. EPA, Durham, NC and 

3 

ACC, RCU, NHEERL, U.S. EPA, Durham, NC. 


DOBUTAMINE CARDIAC STRESS TEST 

REVEALS INCREASED ARRHYTHMIA 

RISK IN CONSCIOUS RATS AFTER A 

SINGLE EXPOSURE TO ACROLEIN. M. S. 

Hazari, N. Haykal-Coates, D. W. Winsett, D. L. 

Costa and A. K. Farraj. Environmental Public Health 

Division, U.S. EPA, Research Triangle Park, NC. 

238 






Platform Sessions



Abstract # 


PM 2.5–INDUCED CHANGES IN HEART 

RATE VARIABILITY IN SPONTANEOUSLY 

HYPERTENSIVE RATS ARE ASSOCIATED 

WITH SPECIFIC SOURCES IN DETROIT, MI 

AND STEUBENVILLE, OH. J. G. Wagner 1 , A. S. 

Kamal 2 , M. Morishita 2 , B. Mukherjee 2 , G. J. Keeler 2 , 

J. R. Harkema 1 and A. C. Rohr 3 . 1 Michigan State 

University, East Lansing, MI, 2 University Michigan, 

Ann Arbor, MI and 3 Electical Power Research 

Institute, Palo Alto, CA. 


AIRWAY EPITHELIAL TOXICITY OF THE 

FLAVORING AGENT, 2, 3-PENTANEDIONE. 

A. F. Hubbs, A. E. Moseley, W. T. Goldsmith, M. C. 

Jackson, M. L. Kashon, L. A. Battelli, D. Schwegler- 

Berry, M. P. Goravanahally, D. Frazer, J. S. Fedan, 

K. Kreiss and V. Castranova. NIOSH, Morgantown, 

WV. 


AIR POLLUTION ON OBESITY AND 

INSULIN RESISTANCE: ROLE OF P47 PHOX 

S. Y. Jiang 1 , X. Xu 1 , Z. Yavar 1 , M. Verdin 1 , Z. 

Ying 1 , G. Mihai 1 , A. Wang 1 , M. Zhong 2 , L. Chen 2 , 

S. Rajagopalan 1 and Q. Sun 1 . 1 The Ohio State 

University, Columbus, OH and 2 Department of 

Environmental Medicine, New York University, 

Tuxedo, NY. 


COMPARATIVE IN VITRO TOXICITY OF 

AMBIENT PARTICULATE MATTER (PM) 

FROM DIFFERENT U.S. AND CHINESE 

CITIES. C. A. Hickey 1 , Z. Bai 2 , J. Wang 2 , X. Guo 2 , 

T. Zhu 3 , F. Tian 3 , C. Chen 3 , Y. Shang 3 , J. Zhang 4 , L. 

Chen 1 and T. Gordon 1 . 1 New York University School 

of Medicine, Tuxedo, NY, 2 Nankai University, 

Tianjin, China, 3 Peking University, Beijing, China 

and 4 UMDNJ, Piscataway, NJ. 


VASCULAR LIPID PEROXIDATION AND 

DYSFUNCTION INDUCED BY COMPLEX 

COMBUSTION EMISSIONS: AN UPDATE OF 

THE NPACT STUDY. M. Campen 1,2 , A. Lund 2 , J. 

Buntz 1 , J. Lucero 2 , N. Mathews 2 , J. L. Mauderly 2 and 

J. D. McDonald 2 . 1 College of Pharmacy, University 

of New Mexico, Albuquerque, NM and 2 Lovelace 



COMPARISON OF HEALTH EFFECTS AND 

COMPOSITION OF TOLUENE DERIVED 

SECONDARY ORGANIC AEROSOLS 

FORMED WITH AND WITHOUT SULFUR 

DIOXIDE. J. McDonald 1 , M. Doyle-Eisele 1 , E. 

Knipping 2 , A. Rohr 2 , A. Lund 1 and M. Campen 1 . 

1 

Lovelace, Albuqueruque, NM and 2 Electric Power 

Research Institute, Palo Alto, CA. 


STATIN-TREATMENT EFFECTIVELY 

REDUCES INHALED VEHICULAR 

EMISSIONS-MEDIATED EXPRESSION 

OF VASCULAR MARKERS ASSOCIATED 

WITH THE PROGRESSION OF 

ATHEROSCLEROSIS. A. K. Lund, J. Lucero, N. 

Mathews, J. McDonald and M. Campen. Lovelace 


Abstract # 


EXACERBATED INFLAMMATORY 

LUNG INJURY IN NEPRILYSIN NULL 

MICE FOLLOWING DIESEL PARTICLES 

EXPOSURE. S. Wong 1 , C. D. Fastje 1 , B. Lu 2 , J. L. 

Burgess 1 , R. Lantz 1 , C. J. Gerard 2 and M. L. Witten 1 . 

1 

The Southwest Environmental Health Sciences 

Center (SWEHSC) & Center for Toxicology, The 

University of Arizona, Tucson, AZ and 2 Harvard 

Medical School, Boston, MA. 


EFFECT OF DIESEL PARTICLES ON HEART 

RATE IN 15-MONTH OLD HYPERTENSIVE 

RATS COMPARED WITH NORMAL RATS. 

Y. Ishihara 1 , S. Koyama 1 , M. Kyoso 2 and K. Yana 3 . 

1 

Public Health, Kurume University, Kurume, Japan, 

2 

Tokyo City University, Tokyo, Japan and 3 Hosei 

University, Tokyo, Japan. Sponsor: G. Oberdorster. 


COMPARAITIVE REPEAT-EXPOSURE 

INHALATION TOXICITY OF DEXTRAN 

POLYMERS. D. Vodak 2 , M. Channel 1 , D. 

McClintock 2 and M. D. Reed 1 . 1 Lovelace Respiratory 

Research Institute, Albuquerque, NM and 2 Bend 

Research, Bend, OR. 


EXPOSURE OF HUMAN LUNG CELLS 

WITH CIGARETTE SMOKE USING A 

NOVEL CELL CULTURE SYSTEM. F. Glahn 1 , 

A. Rogers 2 , S. Kerwien 1 , S. Thomas 1 , M. Ahmad 1 and 

H. W. Foth 1 . 1 Institute of Environmental Toxicology, 

University, Halle (Saale), Germany and 2 TSE 

Systems GmbH, Bad Homburg, Germany. 


INFLAMMATORY RESPONSE TO 

INHALED LPS IN NON-HUMAN 

PRIMATES:TREATMENT WITH STEROIDS 

OR CARBON MONOXIDE. P. Kuehl 1 , J. 

McDonald 1 , L. Mitchell 1 , C. Royer 1 and A. Choi 2 . 

1 

Lovelace, Albuqueruque, NM and 2 Harvard Brigham 

and Womens Hospital, Boston, MA. 


EFFECT OF ETHANOL VAPORS ON 

PULMONARY INFLAMMATION IN A 

RAT MODEL OF ALLERGIC ASTHMA. A. 

Scarino 1 , R. Tardif 2 , P. Renzi 2 and M. Charbonneau 1 . 

1 

INRS-Institut Armand-Frappier, Université du 

Québec, Laval, QC, Canada and 2 Université de 



DIFFERENTIAL EFFECT OF LOW AND 

HIGH ORGANIC CARBON CONTENT 

PARTICULATE MATTER IN POSTNATAL 

AND ADULT RAT AIRWAYS. L. S. Van Winkle 1 , 

J. K. Chan 1 , D. S. Anderson 1 and M. V. Fanucchi 2 . 

1 

CHE; Vet Med: Anatomy, Physiology & Cell 

Biology, University of California Davis, Davis, CA 

and 2 Environmental Health Science, School of Public 

Health, University of Alabama, Birmingham, AL. 

WedneSday 







239


WedneSday 




THE IMPACT OF NEUTROPHIL 

RECRUITMENT ON THE MOUSE LUNG 

AFTER DAIRY BARN PARTICULATE 

MATTER INSTILLATION. K. Williams, 

T. Wegesser, L. Franzi and J. Last. Center for 

Comparative Respiratory Biology and Medicine, 

University of California Davis, Davis, CA. 


EFFECT OF INHALATION EXPOSURE TO 

MOTORCYCLE EXHAUST ON RAT HEART. 

T. Ueng 1 , C. Chen 1 , W. Chan 1 and J. Liao 2 . 1 Institute 

of Toxicology, National Taiwan University College of 

Medicine, Taipei, Taiwan and 2 Institute of Veterinary 

Pathobiology, National Chung Hsing University 

College of Veterinary Medicine, Taichung, Taiwan. 


RETENTION OF PAH-RICH SOOT 

PARTICLES ACCOMPANIES ALTERED 

LUNG GENE EXPRESSION PROFILES 

FOLLOWING BRIEF EXPOSURE 

TO COMBUSTION-DERIVED 

NANOPARTICLES. Z. Perveen, D. Paulsen and 

A. Penn. LSU School of Vet.Med., Baton Rouge, LA. 


ELECTROCARDIOGRAPHIC AND 

AUTONOMIC EFFECTS OF ACUTE 

PARTICULATE MATTER (PM) EXPOSURE 

IN A RAT MODEL OF CARDIOMYOPATHY. 

A. P. Carll 1 , N. Haykal-Coates 2 , D. W. Winsett 2 , 

M. S. Hazari 2 , A. D. Ledbetter 2 , J. Callaway 3 , 

J. H. Richards 2 , D. L. Costa 4 and A. K. Farraj 2 . 

1 

Environment Sci. & Engrg., University of 

North Carolina Chapel Hill, Chapel Hill, NC, 

2 

Environmental Public Health Division, U.S. EPA, 

Research Triangle Park, NC, 3 University of North 

Carolina, Chapel Hill, NC and 4 ORD, U.S. EPA, 



JET FUEL KEROSENE ATMOSPHERE 

GENERATION AND VALIDATION FOR 

MICE AND RAT IMMUNOTOXICITY 

STUDIES. M. P. DeLorme 1 , K. L. White 2 , V. L. 

Peachee 2 and K. C. Wise 3 . 1 Haskell Laboratory, 

Newark, DE, 2 ImmunoTox, Inc., Richmond, VA and 

3 

American Petroleum Institute, Washington, DC. 


LUNG GLUTATHIONE ADAPTIVE 

RESPONSES TO CIGARETTE SMOKE 

DECLINE WITH AGE. N. S. Gould 1,2 , E. Min 2 , 

H. Chu 2 , R. Martin 2 and B. J. Day 1,2 . 1 Pharmaceutical 

Sciences, University of Colorado Denver, Denver, 

CO and 2 Medicine, National Jewish Health, Denver, 

CO. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Immunotoxicology: Mechanisms 

Chairperson(s): Berran Yucesoy, CDC/NIOSH, Morgantown, WV. 




DIFFERENTIAL EFFECTS OF DELTA 9 - 

TETRAHYDROCANNABINOL (D 9 -THC) ON 

CD40 LIGAND (CD40L) EXPRESSION IN 

ACTIVATED HUMAN PERIPHERAL BLOOD 

CD4 + T CELLS. T. Ngaotepprutaram 1,2 , B. F. 

Kaplan 1,2 , R. B. Crawford 1 and N. E. Kaminski 1,2 . 

1 

Pharmacology and Toxicology, Michigan State 

University, East Lansing, MI and 2 Center for 




D 9 -TETRAHYDROCANNABINOL IMPAIRS 

CYTOTOXIC T LYMPHOCYTE EFFECTOR 

FUNCTION DUE IN PART TO ABERRANT 

EARLY T CELL SIGNALING INDEPENDENT 

OF CANNABINOID RECEPTORS 1 AND 

2. P. Karmaus 1,3 , W. Chen 2,3 , B. Kaplan 4,2 and N. 

Kaminski 4,2 . 1 Cell and Molecular Biology, Michigan 

State University, East Lansing, MI, 2 Microbiology 

and Molecular Genetics, Michigan State University, 

East Lansing, MI, 3 Center for Integrative Toxicology, 

Michigan State University, East Lansing, MI and 

4 




ENDOGENOUS CANNABINOIDS 

REGULATE IMMUNE FUNCTIONS 

THROUGH INDUCTION OF MYELOID- 

DERIVED SUPPRESSOR CELLS. A. R. 

Jackson, V. Hegde, M. Nagarkatti and P. Nagarkatti. 

Pathology, Microbiology, Immunology, University of 

South Carolina, Columbia, SC. 


D 9 -TETRAHYDROCANNABINOL 

MODULATES ANTI-HIV GP120-SPECIFIC 

CYTOTOXIC T LYMPHOCYTE (CTL) 

FUNCTION. W. Chen 1,5 , P. Karmaus 2,5 , S. Pike 5 , 

S. Dantas 3 , S. Fox 4 , B. Kaplan 4,5 and N. Kaminski 4,5 . 

1 

Microbiology and Molecular Genetics, Michigan 

State University, East Lansing, MI, 2 Cell and 


Lansing, MI, 3 College of Veterinary Medicine, 


4 


University, East Lansing, MI and 5 Center for 




TARGETING CANNABINOID RECEPTORS 

AS A NOVEL TREATMENT MODALITY 

AGAINST LIVER INJURY AND CHRONIC 

INFLAMMATION INDUCED BY CHEMICAL 

TOXICANTS. S. Kanada, M. Nagarkatti and P. 

Nagarkatti. Department of Pathology, Microbiology, 

and Immunology, University of South Carolina 

School of Medicine, Columbia, SC. 

240 






Platform Sessions



Abstract # 


2, 3, 7, 8-TETRACHLORODIBENZO- 

P-DIOXIN (TCDD) SUPPRESSES 

LPS-ACTIVATED BINARY SWITCHING OF 

B CELLS TO PLASMA CELLS. D. E. Kline 1 , 

Q. Zhang 2 , S. Bhattacharya 2 , M. E. Andersen 2 , R. 

B. Conolly 3 , R. B. Crawford 4 and N. E. Kaminski 1,4 . 

1 

Center for Integrative Toxicology, Michigan State 

University, East Lansing, MI, 2 Hamner Institutes 

for Health Sciences, Research Triangle Park, NC, 

3 

National Center for Computational Toxicology, U.S. 

EPA, Research Triangle Park, NC and 4 Pharmacology 

& Toxicology, Michigan State University, East 

Lansing, MI. 


INSIGHT INTO AHR-MEDIATED 

INCREASES IN NEUTROPHILIA DURING 

INFECTION: INOS AS A POTENTIALLY 

NEW AHR TARGET GENE. J. Head 1,3 and B. 

Lawrence 1,2,3 . 1 Environmental Medicine, University 

of Rochester, Rochester, NY, 2 Microbiology & 

Immunology, University of Rochester, Rochester, 

NY and 3 Toxicology Training Program, University of 




MODULATES DENDRITIC CELL 

FUNCTION DURING RESPIRATORY VIRAL 

INFECTION. G. Jin, J. L. Head, A. J. Moore and 

B. Lawrence. Environmental Medicine, University of 



CHARACTERIZATION OF 2, 3, 7, 

8-TETRACHLORODIBENZO-P-DIOXIN 

EFFECT ON THE CD40L-INDUCED IGM 

ANTIBODY RESPONSES IN PRIMARY 

MOUSE AND HUMAN B LYMPHOCYTES. 

H. Lu 1,2 , R. B. Crawford 2 , B. F. Kaplan 1,2 and N. 

E. Kaminski 1,2 . 1 Center for Integrative Toxicology, 


2 




EXPOSURE TO TCDD INCREASES 

EXPRESSION OF MONOCYTE 

CHEMOATTRACTANT PROTEIN (MCP)-1 

AND CYCLOOXYGENASE (COX)-2 DURING 

LIVER REGENERATION. A. McCartney, C. 

L. Lamb, C. Horras, E. Ponce and K. A. Mitchell. 

Biological Sciences, Boise State University, Boise, 

ID. 


GENERATION OF TCDD-INDUCED 

REGULATORY PHENOTYPES IN BONE 

MARROW-DERIVED DENDRITIC CELLS. T. 

Simones, J. Bankoti and D. M. Shepherd. University 

of Montana, Missoula, MT. 


ROLE OF SPECIFIC PROTEIN BINDING 

MOTIFS IN TCDD-INDUCED ACTIVATION 

OF THE HUMAN POLYMORPHIC HS1, 2 

ENHANCER. S. Ochs, T. Fernando and C. E. 

Sulentic. Pharmacology & Toxicology, Wright State 


Abstract # 


EXPOSURE TO TCDD DECREASES 

SPLEEN CELLULARITY DURING LIVER 

REGENERATION. C. J. Horras, C. L. Lamb, S. L. 

D’Ingillo, J. C. Hanley and K. A. Mitchell. Biological 

Sciences, Boise State University, Boise, ID. 


ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN TCDD-INDUCED 

ALTERATION OF IMMUNOGLOBULIN 

EXPRESSION. M. J. Wourms and C. E. Sulentic. 

Pharmacology & Toxicology, Wright State 



NF-kB/REL PROTEINS ROLE IN 

MODULATING THE 3’IgHRR BY LPS, 

CpG, AND TCDD. R. L. Salisbury and C. E. 

Sulentic. Pharmacology & Toxicology, Wright State 



A DRE IN THE MULTIPLE CLONING 

REGION OF THE pGL3 LUCIFERASE 

REPORTER INFLUENCES 

TRANSCRIPTIONAL ACTIVITY. C. E. 

Sulentic, T. Fernando, M. J. Wourms, S. Ochs and M. 

Sharma. Pharmacology & Toxicology, Wright State 



PHTHALATE (2-ETHYLHEXYL) ESTER 

AFFECTS IL-4 EXPRESSION THROUGH 

CA/NFAT SIGNALING IN SPLEEN 

LYMPHOCYTES. X. Pei, Y. Zhang, L. Guo, 

M. Ma and Z. Duan. Department of Toxicology, 

Shenyang Medical College, Shenyang, Liaoning 

Province, China. 


EFFECTS OF TETRABROMOBISPHENOL 

A (TBBPA) ON THE HOST IMMUNE 

RESPONSE TO RESPIRATORY SYNCYTIAL 

VIRUS (RSV) INFECTION IN MICE. W. 

Watanabe 1 , T. Shimizu 2 , R. Sawamura 2 , A. Hino 2 

and M. Kurokawa 2 . 1 Department of Microbiology, 

Kyushu University of Health and Welfare, School of 

Pharmaceutical Sciences, Nobeoka, Miyazaki, Japan 

and 2 Department of Biochemistry, Kyushu University 

of Health and Welfare, School of Pharmaceutical 

Sciences, Nobeoka, Miyazaki, Japan. Sponsor: A. 

Hirose. 


MOLECULAR MECHANISM OF THE 

INHIBITION OF INNATE IMMUNE 

RESPONSE TO LPS BY SODIUM 

METHYLDITHIOCARBAMATE. X. Deng, T. 

Sebastian, W. Tan and S. B. Pruett. Basic Sciences, 

Mississippi State University, Mississippi State, MS. 


MODULATION OF NF-kB PATHWAY BY 

GOLD NANOPARTICLES IN B CELLS. M. 

Sharma 1,2 . 1 Wright-Patterson AFB, Dayton, OH 

and 2 Biomedical Sciences, Wright State University, 

Dayton, OH. Sponsor: S. Hussain. 

WedneSday 







241


WedneSday 




ENDOSULFAN-a ENHANCES LPS- 

STIMULATED CYTOKINE PRODUCTION 

IN RAW 264.7 CELLS. S. L. Benitez-Kruidenier, 

F. M. Fuchs and G. K. DeKrey. Biological Sciences, 

University Northern Colorado, Greeley, CO. 


SUPPRESSIVE EFFECT OF ASBESTOS- 

EXPOSURE ON THE DIFFERENTIATION 

INTO HUMAN CYTOTOXIC T 

LYMPHOCYTES. N. Kumagai, Y. Nishimura, 

M. Maeda, H. Hayashi and T. Otsuki. Hygiene, 

Kawasaki Medical School, Kurashiki, Japan. 


ASBESTOS-EXPOSURE CAUSES 

SUPPRESSED EXPRESSION OF NKP46 

WITH LOW CYTOTOXICITY IN NK 

CELLS, RELATED WITH MALIGNANT 

MESOTHELIOMA. Y. Nishimura 1 , N. Kumagai 1 , 

M. Maeda 1 , H. Hayashi 1 , T. Kishimoto 2 and T. 

Otsuki 1 . 1 Hygiene, Kawasaki Medical School, 

Kurashiki, Japan and 2 Okayama Rosai Hospital, 

Okayama, Japan. 


FUNCTIONAL ANALYSIS OF HUMAN 

CD4 + T CELLS WITH DECREASED CXCR3 

EXPRESSION BY LONG-TERM, LOW- 

LEVEL EXPOSURE TO ASBESTOS. M. 

Maeda 1 , Y. Nishimura 1 , N. Kumagai 1 , H. Hayashi 1 , 

Y. Miura 2 , T. Kishimoto 3 and T. Otsuki 1 . 1 Hygiene, 

Kawasaki Medical School, Kurashiki, Okayama, 

Japan, 2 Molecular Genetics, Medical Institute of 

Bioregulation, Kyushu University, Fukuoka, Japan 

and 3 Okayama Rosai Hospital, Okayama, Japan. 


TRIBUTYLTIN: B CELL TOXICANT AND 

BONE MARROW MICROENVIRONMENT 

MODULATOR. A. R. Haas 1 , S. C. Yanik 2 , D. 

H. Sherr 2 , L. C. Gerstenfeld 1 and J. Schlezinger 2 . 

1 

Boston University School of Medicine, Boston, MA 

and 2 Boston University School of Public Health, 

Boston, MA. 


MICROBIAL COMPOUNDS ALTER 

ACETAMINOPHEN-INDUCED IMMUNE 

RESPONSES IN THE LIVER. I. S. Ludwig, D. 

Fiechter, L. M. Kwast and R. H. Pieters. Institute 

for Risk Assessment Sciences, Utrecht University, 

Utrecht, Netherlands. 


ORGANOTIN-MEDIATED PPARg 

ACTIVATION AND ADIPOCYTE 

DIFFERENTIATION IN BONE MARROW 

STROMAL CELLS. S. C. Yanik, D. H. Sherr and 

J. Schlezinger. Boston University School of Public 

Health, Boston, MA. 


GENE EXPRESSION PROFILING OF 

HUMAN T CELLS UPON EXPOSURE TO 

THE MYCOTOXIN DON. M. M. Katika 1,2 , P. 

ad 1 , H. Peter 1 and V. Henk 2 . 1 TE, RIKILT-Institute of 

Food Safety, Wageningen, Netherlands and 2 GRAT, 

Maastricht University, Maastricht, Netherlands. 

Sponsor: S. Rangarajan. 


THE ROLE OF OSTEOPONTIN IN 

ASBESTOS-MEDIATED INFLAMMATION. 

T. Sabo-Attwood 1 , M. Ramos-Nino 2 , M. Ariza 1 , J. 

Clark 1 , S. McGee 1 and B. T. Mossman 2 . 1 University 

of South Carolina, Columbia, SC and 2 University of 

Vermont, Burlington, VT. Sponsor: D. Volz. 


EFFECTS OF 

PERFLUOROOCTANESULFONIC ACID 

(PFOS) ON NF-KB, AP-1 AND PPAR-ALPHA. 

M. M. Peden-Adams 1 , M. Mollenhauer 2 , M. Morse 3 , 

L. Wills 4 and D. E. Keil 3 . 1 Harry Reid Center for 

Environmental Studies, University of Nevada, Las 

Vegas, Las Vegas, NV, 2 NOAA/NOS, Charleston, 

SC, 3 Clinical Laboratory Sciences, University of 

Nevada, Las Vegas, Las Vegas, NV and 4 Department 

of Pharmaceutical Sciences, Medical University of 



IN VITRO EVALUATION OF THE 

IMMUNOTOXIC POTENTIAL OF 

PERFLUORINATED COMPOUNDS 

(PFCS). E. Corsini 1 , A. Avogadro 1 , L. Lucchi 1 , 

M. Marinovich 1 , C. L. Galli 1 and D. R. Germolec 2 . 

1 

Department of Pharmacological Sciences, University 

of Milan, Milan, Italy and 2 National Toxicology 

Program, National Institute of Environmental Health 

Sciences, Research Triangle Park, NC . 


TH2 SKEWING BY NRF2 ACTIVATION 

IN CD4+ T CELLS AS EVIDENCED BY 

INCREASED PRODUCTION OF IL-4, IL-5, 

AND IL-13 AND DECREASED PRODUCTION 

OF IFNg C. E. Rockwell 1 , P. E. Fields 2 and C. 

D. Klaassen 1 . 1 Department of Pharmacology, 

Toxicology, & Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Department 

of Pathology & Laboratory Medicine, University of 

Kansas Medical Center, Kansas City, KS. 


5-NITROAPOCYNIN REVERSES LPS-, BUT 

NOT PMA-INDUCED IL-6 RELEASE BY 

MOUSE J774 MACROPHAGES: A POSSIBLE 

ROLE OF PROTEIN KINASE-C. A. C. 

Raghavamenon 1 , S. Babu 1 , V. Achuthan 1 , X. Gao 1 , 

O. D’Auvergne 2 , R. Atmakuru 3 and R. M. Uppu 1 . 

1 

Environmental Toxicology, Southern University 

and A&M College, Baton Rouge, LA, 2 Biological 

Sciences, Southern University and A&M College, 

Baton Rouge, LA and 3 Analytical Chemistry, 

International Institute of Biotechnology and 

Toxicology, Padappai, Tamil Nadu, India. 


TUNGSTEN INDUCES DNA DAMAGE AND 

ALTERS GROWTH OF DEVELOPING B 

LYMPHOCYTES. C. Guilbert and K. K. Mann. 

Lady Davis Institute for Medical Research, McGill 

University, Montréal, QC, Canada. 

242 






Platform Sessions



Abstract # 


TRANSCRIPTIONAL REGULATION 

OF HISTOCOMPATIBILITY COMPLEX 

CLASS II (MHC-II) GENES BY AGONIST 

AND ANTAGONIST OF PREGNANE X 

RECEPTOR. E. Fuentes-Mattei 1,2 , R. I. Rodriguez- 

Cotto 1,2 and B. D. Jimenez-Velez 1,2 . 1 Biochemistry, 

UPR Medical Sciences Campus, San Juan and 

2 

Center for Environmental and Toxicological 

Research, UPR Medical Sciences Campus, San Juan. 


ASSOCIATION OF COPPER TO 

IMMUNOLOGICAL MARKERS RESULTING 

FROM EXPOSURE TO POLAR ORGANIC 

EXTRACTS FROM AIRBORNE FINE 

PARTICULATE MATTER (PM2.5) FROM 

PUERTO RICO IN BEAS-2B CELLS. E. 

Fuentes-Mattei 1,4 , D. Sanchez-Rivera 2,4 , N. E. 

Crespo-Hernandez 3,4 , F. R. Roman-Velazquez 2,4 and 

B. D. Jimenez-Velez 1,4 . 1 Biochemistry, UPR Medical 

Sciences Campus, San Juan, 2 Chemistry, UPR 

Mayaguez Campus, Mayaguez, 3 Chemistry, UPR 

Rio Piedras Campus, Rio Piedras and 4 Center for 

Environmental and Toxicological Research, UPR 

Medical Sciences Campus, San Juan. 


ANTI-ALLERGIC INFLAMMATORY 

EFFECTS PUTRANJIVAIN A: SIGNALING 

PATHWAY AND ROLE OF NFAT AND NF-kB. 

S. Park and S. Kim. Pharmacology, Kyungpook 

University, Daegu, Republic of Korea. 

#1562 Poster Board ....................................................238 

TOXICITY OF 1-BROMOHEXANE AND ITS 

CONJUGATION WITH GLUTATHIONE IN 

MICE. G. S. Ko, H. W. Ha, J. W. Yoo, S. K. Lee, 

M. J. Kang and T. Jeong. Pharmacy, Yeungnam 

University, Gyeongsan, Gyeongbuk, Republic of 

Korea. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Studies in Pharmacokinetics and Disposition 

Chairperson(s): Mary Beth Genter, University of Cincinnati, Cincinnati, 

OH. 




DONEPEZIL TRANSDERMAL DELIVERY: 

USE OF ABSORPTION-DISTRIBUTION- 

EXCRETION (ADE) DATA TO 

SUCCESSFULLY BRIDGE EXISTING RAT 

ORAL CARCINOGENICITY DATA. S. Meier- 

Davis 1 , M. Rodrigue 3 , U. Ramesh 1 , M. Yamaji 1 , Y. 

Katori-Stowell 1 , J. Wen 1 , A. Korey 1 and H. Maibach 2 . 

1 

Teikoku Pharmacology USA, Inc., San Jose, 

CA, 2 Dermatology, University of California, San 

Francisco, San Francisco, CA and 3 DMPK, Charles 

River Laboratories, Senneville, QC, Canada. 

Abstract # 


DEVELOPMENT OF A PHYSIOLOGICAL 

PARAMETERS DATABASE FOR 

PHYSIOLOGICALLY-BASED 

PHARMACOKINETIC (PBPK) MODELING. 

D. Johns 1 , R. Dewoskin 1 , C. Thompson 2 , K. 

Krishnan 3 , H. A. Barton 4 and B. Sonawane 5 . 1 ORD, 

NCEA, U.S. EPA, Research Triangle Park, NC, 

2 

ToxStrategies, Katy, TX, 3 University of Montréal, 

Montréal, QC, Canada, 4 Pfizer, Groton, CT and 

5 

ORD, NCEA, U.S. EPA, Washington, DC. 


INFLUENCE OF EXPOSURE ROUTE 

AND DOSAGE REGIMEN ON 1, 

1-DICHLOROETHYLENE (DCE) 

TOXICOKINETICS (TK) AND TOXICITY. 

J. V. Bruckner 1 , C. A. White 2 , S. Muralidhara 3 , C. 

Hines 4 and C. E. Dallas 5 . 1 Pharmaceutical and 


GA, 2 Pharmaceutical and Biomedical Sciences, 

University of Georgia, Athens, GA, 3 Pharmaceutical 

and Biomedical Sciences, University of Georgia, 

Athens, GA, 4 Pharmaceutical and Biomedical 

Sciences, University of Georgia, Athens, GA and 

5 




ARSENIC METHYLATION PHENOTYPE 

AFFECTS ACCUMULATION AND 

RETENTION OF ARSENIC IN MICE. M. F. 

Hughes, B. C. Edwards, K. M. Herbin-Davis and 

D. J. Thomas. NHEERL/ORD, U.S. EPA, Research 



DETERMINATION OF TISSUE BLOOD 

PARTITION COEFFICIENTS FOR NON- 

VOLATILE HERBICIDES AND FUNGICIDES 

USING NEGLIGIBLE DEPLETION SOLID 

PHASE MICROEXTRACTION (ND-SPME). 

R. T. Tremblay 1 , D. Kim 2 and J. W. Fisher 1 . 

1 


Georgia, Athens, GA and 2 Syngenta Crop Protection 

Inc., Greensboro, NC. 


THE TOXICOKINETICS (TK) OF 

DELTAMETHRIN (DLM) DURING 

MATURATION OF THE RAT. R. Tornero- 

Velez 1 , J. W. Fisher 2 , K. B. Kim 3 , S. S. Anand 3 , C. 

A. White 3 and J. V. Bruckner 3 . 1 National Exposure 

Research Laboratory, U.S. EPA, Research Traingle 

Park, NC, 2 Environmental Health Science and 

Interdisciplinary Toxicology Program (ITP), 

University of Georgia, Athens, GA and 3 PBS, 



PLASMA, FAT, AND MILK 

CONCENTRATION DATA FOR 

INDOXACARB ESTABLISH 

BIOEQUIVALENCE OF EXPOSURE IN 

LACTATING RATS AND OFFSPRING. M. 

W. Himmelstein 1 , L. A. Malley 1 , J. J. Stry 2 and J. F. 

Barnett 3 . 1 DuPont Haskell Global Centers, Newark, 

DE, 2 DuPont Crop Protection, Newark, DE and 

3 

Charles River Laboratories Preclinical Services, 

Horsham, PA. 

WedneSday 







243


WedneSday 




TOXICOKINETIC DIFFERENCES 

BETWEEN TWO MAJOR HBCD 

STEREOISOMERS: EFFECT OF DOSE, 

TIME, REPEATED EXPOSURE, AND ROUTE. 

D. T. Szabo 1 , J. J. Diliberto 2 , H. Hakk 3 , J. K. Huwe 3 

and L. S. Birnbaum 4 . 1 UNC, CH, NC, 2 U.S. EPA, 

Research Triangle Park, NC, 3 USDA, Fargo, ND and 

4 

NCI/NIEHS, Research Triangle Park, NC . 


TETRABROMOBISPHENOL A IS 

NOT NEPHROTOXIC DUE TO ITS 

TOXICOKINETIC CHARACTERISTICS. T. 

Jeong 1 , M. J. Kang 1 , J. W. Yoo 1 , H. W. Ha 1 , G. S. 

Ko 1 , W. Kang 2 and S. K. Lee 1 . 1 Pharmacy, Yeungnam 

University, Gyeongsan, Gyeongbuk, Republic of 

Korea and 2 Pharmacy, Catholic University of Daegu, 

Gyeongsan, Republic of Korea. 


EFFECTS OF RUTAECARPINE ON THE 

PHARMACOKINETICS OF CAFFEINE IN 

RATS. M. J. Kang 1 , Y. M. Seo 1 , G. S. Ko 1 , H. W. 

Ha 1 , J. W. Yoo 1 , W. Kang 2 , Y. Jahng 1 and T. Jeong 1 . 

1 

Pharmacy, Yeungnam University, Gyeongsan, 

Gyeongbuk, Republic of Korea and 2 Pharmacy, 

Catholic University of Daegu, Gyeongsan, Republic 



DISPOSITION AND METABOLISM OF 

2-HYDROXY-4-METHOXYBENZOPHENONE 

IN MALE SPRAGUE-DAWLEY RATS. M. 

Doyle-Eisele 1 , Z. Gao 1 , D. Kramer 1 , L. Thomas 1 , D. 

Kracko 1 , K. J. Dix 1 , S. S. Auerbach 2 , J. M. Sanders 2 

and J. M. McDonald 1 . 1 LRRI, Albuquerque, NM and 

2 



DISPOSITION OF THE BROMINATED 

FLAME RETARDANT HBCD ALPHA AND 

GAMMA IN DEVELOPING MICE OVER 

TIME. J. J. Diliberto 1 , D. T. Szabo 2 , J. Huwe 3 and L. 

S. Birnbaum 4 . 1 NHEERL ORD, U.S. EPA, Research 

Triangle Park, NC, 2 Curriculum of Toxicology, 

University of North Carolina, Chapel Hill, NC, 

3 

BRL-ARS, USDA, Fargo, ND and 4 NCI/NIEHS, 



BUPRENORPHINE MODULATES 

METHAMPHETAMINE-INDUCED 

EXTRACELLULAR DOPAMINE RELEASE 

IN THE RAT CAUDATE-PUTAMEN. B. Gough, 

S. Ali and Z. Binienda. Neurotoxicology, U.S. FDA/ 

NCTR, Jefferson, AR. 


TOXICOKINETICS OF RESVERATROL 

IN MALE, FEMALE, PREGNANT, AND 

LACTATING WISTAR HAN RATS. T. Fennell 1 , 

N. L. Gaudette 1 , B. L. Fletcher 1 , S. D. Cooper 1 , 

M. Silinski 1 , J. Blake 1 , F. Thomas 1 , R. Fernando 1 

and B. J. Collins 2 . 1 RTI International, Research 

Triangle Park, NC and 2 NIEHS, National Toxicology 

Program, Research Triangle Park, NC. 


PRECLINICAL SAFETY ASSESSMENT OF 

A NEW ANTITHROMBOTIC DRUG, THE 

NANOBODY ® ALX-0081. S. Jacobs 1 , H. Ulrichts 1 , 

S. Priem 1 , S. Rossenu 1 , P. Stanssens 1 , J. Leuschner 2 , 

J. Baumeister 1 and J. Holz 1 . 1 Ablynx, Zwijnaarde, 

Belgium and 2 LPT, Hamburg, Germany. Sponsor: V. 

Chen. 


TOXICOKINETICS OF 

PERFLUOROOCTANOIC ACID (PFOA) 

AND PERFLUOROOCTANE SULFONATE 

(PFOS) USING MALE SPRAGUE-DAWLEY 

RATS AND AUTOMATED DOSING/SAMPLE 

COLLECTION INSTRUMENTS (EMPIS/ 

CULEX). S. Gibbs 1 , V. Godfrey 2 , S. Hong 1 , J. 

D. Johnson 1 , B. L. Burback 1 , S. W. Graves 1 and C. 

Smith 2 . 1 Battelle Memorial, Columbus, OH and 

2 

NIEHS, NIH, Research Triangle Park, NC. 


CHARACTERIZATION OF THE 

EFFECT OF MULTIROUTE EXPOSURE 

ON THE INTERNAL DOSE OF 2, 2, 

4-TRIMETHYLPENTANE (TMP) IN THE 

RAT. M. Gagné, G. Charest-Tardif, R. Tardif and K. 

Krishnan. DSEST, Université de Montréal, Montréal, 

QC, Canada. 


COMPARISON OF THE TOXICOKINETIC 

(TK) PARAMETERS OF A RECOMBINANT 

PROTEIN (ENB-0040) ESTIMATED 

BY NON-COMPARTMENTAL AND 

COMPARTMENTAL POPULATION 

ANALYSIS FOLLOWING MULTIPLE DOSES 

IN RATS. C. Jomphe 1 , I. Lemire 2 , P. Leonard 2 , 

M. Reimer 1 , J. Marier 1 and M. Beliveau 1 . 1 RAS, 

Pharsight Corporation, Montréal, QC, Canada and 

2 

Enobia Pharmacology, Montréal, QC, Canada. 


A STUDY OF VALPROIC ACID-INDUCED 

ENDOGENOUS AND EXOGENOUS 

METABOLITE ALTERATIONS USING LC/ 

MS-BASED METABOLOMICS. R. D. Beger 1 , 

J. Sun 1 , L. K. Schnackenberg 1 and D. K. Hansen 2 . 

1 

Division of Systems Toxicology, U.S. FDA-NCTR, 

Jefferson, AR and 2 Division of Personalized Nutrition 

and Medicine, U.S. FDA-NCTR, Jefferson, AR. 


PHARMACOKINETICS AND DISTRIBUTION 

OF SB 9002-1 PRO-DRUG FOR HEPATITIS 

TREATMENT. K. O’Loughlin 1 , C. E. Green 1 , L. 

Tang 1 , R. P. Iyer 2 , A. Furimsky 1 , S. Rhee 1 , A. Ta 1 , L. 

Rausch 1 , J. Coughlin 2 , S. Padmanabhan 2 , J. Marquis 3 

and J. C. Mirsalis 1 . 1 SRI International, Menlo Park, 

CA, 2 Spring Bank Pharmaceuticals, Inc., Milford, 

MA and 3 Genzyme Corporation, Marlborough, MA. 


ALLOMETRIC SCALING TO PREDICT 

CLEARANCE (CL) OF A RECOMBINANT 

PROTEIN (ENB-0040) IN INFANTS AND 

ADULTS. S. Mouksassi 1 , I. Lemire 2 , P. Leonard 2 , 

J. Marier 1 and M. Beliveau 1 . 1 RAS, Pharsight 

Corporation, Montréal, QC, Canada and 2 Enobia 

Pharmacology, Montréal, QC, Canada. 

244 






Platform Sessions



Abstract # 



TRANSPORT AND INHIBITORY EFFECTS 

OF N-BUTYLPYRIDINIUM CHLORIDE AND 

ITS STRUCTURALLY RELATED IONIC 

LIQUIDS TO ROCT1/2. Y. Cheng 1 , S. Wright 2 , 

R. Kuester 1 , M. Hooth 3 and I. Sipes 1 . 1 Pharmacology, 

University of Arizona, Tucson, AZ, 2 Physiology, 

University of Arizona, Tucson, AZ and 3 NIEHS, 



COMPARATIVE PHARMACOKINETICS 

OF PERFLUOROHEXANESULFONATE 

(PFHXS) IN RATS AND MONKEYS. S. Chang 1 , 

D. J. Ehresman 1 , P. E. Noker 2 , G. W. Olsen 1 , G. S. 

Gorman 2 , J. A. Hart 1 , T. N. John 3 , M. Sundström 4 , 

. Bergman 4 and J. L. Butenhoff 1 . 1 3M Company, 

St. Paul, MN, 2 Sourthern Research Institute, 

Birmingham, AL, 3 Pace Analytical Services, 

Minneapolis, MN and 4 Stockholm University, 

Stockholm, Netherlands. 


THE EFFECT OF COLESEVELAM 

HYDROCHLORIDE ON THE ELIMINATION 

OF POTASSIUM PERFLUOROOCTANOATE 

(PFOA) FROM SERUM IN MALE AND 

FEMALE CYNOMOLGUS MONKEYS. D. J. 

Ehresman 1 , P. E. Noker 2 , G. W. Olsen 1 , L. R. Zobel 1 , 

S. Chang 1 and J. L. Butenhoff 1 . 1 3M Company, 

St. Paul, MN and 2 Southern Research Institute, 

Birmingham, AL. 


ANALYTICAL METHOD VALIDATION OF 

N-BUTYL GLYCIDYL ETHER IN CORN 

OIL. J. W. Algaier 1 , D. M. Logan 1 , V. F. Ault 1 , 

O. L. Beverly 1 , A. Kazerooni 1 , B. M. O’Brien 1 , P. 

J. Schebler 1 , R. K. Harris 1 , B. Jayaram 2 and C. S. 

Smith 2 . 1 Energy and Life Sciences Division, Midwest 

Research Institute, Kansas City, MO and 2 National 


Park, NC. 


ANALYTICAL METHOD VALIDATION 

FOR THE QUANTITATION OF SIX 

NITROSAMINES IN NTP-2000 RODENT 

FEED. P. J. Schebler 1 , A. D. Ammenhauser 1 , J. 

L. Cookinham 1 , J. W. Algaier 1 , R. K. Harris 1 , B. 

Jayaram 2 and C. S. Smith 2 . 1 Energy and Life Sciences 

Division, Midwest Research Institute, Kansas City, 

MO and 2 National Toxicology Program, NIEHS, 



ANALYTICAL METHOD VALIDATION OF 

TRIS(2-CHLOROISOPROPYL)PHOSPHATE 

IN AQUEOUS 0.5% METHYLCELLULOSE 

FORMULATION. R. K. Harris 1 , V. F. Ault 1 , A. D. 

Ammenhauser 1 , J. L. Cookinham 1 , B. M. O’Brien 1 , 

P. J. Schebler 1 , J. W. Algaier 1 , B. Jayaram 2 and C. S. 

Smith 2 . 1 Energy and Life Sciences, Midwest Research 

Institute, Kansas City, MO and 2 National Toxicology 

Program, NIEHS, Research Triangle Park, NC. 

Abstract # 


EXPOSURE TO N-ETHYL PERFLUORO- 

OCTANESULFONAMIDOETHANOL 

RESULTS IN THE FORMATION OF 

PERFLUOROOCTANESULFONATE AND 

ALTERS SUPEROXIDE DISMUTASE 

ACTIVITY IN FEMALE RATS. H. Lehmler 1 , Q. 

Wu 2 , I. Kania-Korwel 1 , J. C. Tharappel 3 , S. Telu 1 , M. 

C. Coleman 4 , K. Kannan 2 , S. V. Mariappan 5 , D. R. 

Spitz 4 , J. Weydert 6 and H. P. Glauert 3 . 1 Department of 


of Iowa, Iowa City, IA, 2 Wadsworth Center, New 

York State Department of Health, Albany, NY, 

3 

Graduate Center for Nutritional Sciences, University 

of Kentucky, Lexington, KY, 4 Free Radical and 

Radiation Biology Program, University of Iowa, 

Iowa City, IA, 5 Department of Chemistry, University 

of Iowa, Iowa City, IA and 6 Department of Pathology, 

University of Iowa, Iowa City, IA. 


PHARMACOKINETICS OF SULFURYL 

FLUORIDE IN CRL:CD(SD) RAT DAMS, 

FETUSES, AND PUPS FOLLOWING 

INHALATION OR GAVAGE EXPOSURE 

DURING GESTATION AND LACTATION. M. 

S. Marty 1 , S. M. Krieger 1 , D. A. Markham 1 , D. L. 

Rick 1 , M. J. Bartels 1 and D. Eisenbrandt 2 . 1 The Dow 

Chemical Co., Midland, MI and 2 Dow AgroSciences, 

Indianapolis, IN. 


PHARMACOKINETICS OF SULFURYL 

FLUORIDE IN WEANLING CRL:CD(SD) 

RATS FOLLOWING INHALATION 

EXPOSURE ON POSTNATAL DAY (PND) 

22. M. J. Bartels 1 , M. S. Marty 1 , S. M. Krieger 1 , 

D. A. Markham 1 , D. L. Rick 1 and D. Eisenbrandt 2 . 

1 

The Dow Chemical Co., Midland, MI and 2 Dow 

AgroSciences, Indianapolis, IN. 


THE EFFECT OF INCREASING 

DMSO CONCENTRATIONS ON THE 

PHARMACOKINETICS OF ORALLY DOSED 

RESERPINE IN MALE SPRAGUE-DAWLEY 

RATS. M. Koch, R. Melton, D. Xiao and A. Vick. 

Seventh Wave Laboratories, Chesterfield, MO. 

Sponsor: J. Sagartz. 


PHARMACOKINETICS AND 

BIOAVAILABILITY TESTING OF 

CIPROFLOXACIN IN CANNULATED RATS. 

M. Lindeblad 1 , A. Zakharov 1 , I. Mankovskaya 1 , K. 

Bauer 2 and A. Lyubimov 1 . 1 Toxicology Research 

Laboratory, University of Illinois at Chicago, 

Chicago, IL and 2 Univeristy of Maryland, Baltimore, 

MD. 


DETERMINATION OF HEPATOCELLULAR 

VOLUME IN RAT AND HUMAN SANDWICH- 

CULTURED HEPATOCYTES. J. Lee and K. R. 

Brouwer. Research and Development, Qualyst, Inc., 

Durham, NC. Sponsor: D. Kemp. 

WedneSday 







245


WedneSday 




TRANSPORTER EXPRESSION IN RAT 

NASAL OLFACTORY AND RESPIRATORY 

EPITHELIA. M. Genter 1 , L. M. Augustine 2 and 

N. J. Cherrington 2 . 1 Department of Environmental 

Health, University of Cincinnati, Cincinnati, OH and 

2 

Department of Pharmacology & Toxicology, College 

of Pharmacy, University of Arizona, Tucson, AZ. 


ASSESSING SUSCEPTIBILITY TO 

DICLOFENAC TOXICITY IN MRP3- 

NULL MICE. R. Scialis 1,2 , L. M. Aleksunes 3,4 , 

I. Csanaky 3 , M. J. Goedken 5 , C. D. Klaassen 3 and 

J. E. Manautou 2 . 1 Pharmacokinetics, Dynamics & 

Metabolism, Pfizer Inc., Groton, CT, 2 University 

of Connecticut, Storrs, CT, 3 University of Kansas, 

Kansas City, KS, 4 Rutgers University, Piscataway, 

NJ and 5 Schering-Plough Research Institute, 

Lafayette, NJ. 


THE INTERACTION OF PLACENTAL 

EFFLUX TRANSPORTERS WITH 

XENOBIOTICS. L. Taylor 2 , P. Mistry 1 , J. Wright 1 

and J. Penny 2 . 1 Syngenta, Bracknell, United Kingdom 

and 2 School of Pharmacy and Pharmaceutical 

Sciences, The University of Manchester, Manchester, 

United Kingdom. Sponsor: P. Botham. 


THE IMPACT OF REPEATED NICOTINE 

AND ALCOHOL CO-EXPOSURE 

ON THE IN VIVO CHLORPYRIFOS 

PHARMACOKINETICS AND 

PHARMACODYNAMICS. S. Lee, T. S. Poet, 

J. N. Smith, A. L. Busby-Hjerpe and C. Timchalk. 

Biological Monitoring and Modeling, Pacific 

Northwest National Lab, Richland, WA. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Neurodevelopmental Toxicity of Metals 

Chairperson(s): Rafael A. Ponce, Amgen, Inc., Seattle, WA. 




THE DEVELOPMENTAL EFFECTS OF 

LEAD, MANGANESE, AND CHRONIC 

STRESS ON RAT BEHAVIOR. D. L. Graham, 

R. M. Amos-Kroohs, A. A. Braun, C. E. Grace, T. 

L. Schaefer, M. R. Skelton, C. V. Vorhees and M. T. 

Williams. Neurology, Cincinnati Children’s Research 

Foundation, Cincinnati, OH. 


FETAL OXIDATIVE DNA DAMAGE 

AND REPAIR IN METHYLMERCURY 

NEURODEVELOPMENTAL DEFICITS. 

K. Lam 1 , G. P. McCallum 2 and P. G. Wells 2,1 . 

1 


Toronto, Toronto, ON, Canada and 2 Pharmaceutical 

Sciences, University of Toronto, Toronto, ON, 

Canada. 


EPIGENETIC REPROGRAMMING AND 

GENE EXPRESSION ALTERATIONS IN 

RESPONSE TO DEVELOPMENTAL-LEAD 

EXPOSURE IN MICE. R. S. Dosunmu, H. 

Alashwal and N. H. Zawia. Biomedical and 

Pharmaceutical Sciences, University of Rhode Island, 

Kingston, RI. 


INCREASED EXPRESSION OF RETINAL 

GABA TRANSPORTERS AND GABA 

TRANSAMINASE (GABA-T) LIMIT 

THE ROD-MEDIATED (SCOTOPIC) 

ELECTRORETINOGRAM (ERG) B-WAVE 

AMPLITUDE INCREASES IN MICE WITH 

GESTATIONAL LEAD-EXPOSURE (GLE). R. 

Hamilton 1 , J. E. Johnson 2 , W. Xiao 1 , M. Wang 1 , L. 

J. Frishman 1 and D. A. Fox 1 . 1 University of Houston, 

Houston, TX and 2 University of Houston-Downtown, 

Houston, TX. 


DETRIMENTAL EFFECTS OF LEAD ON 

HIPPOCAMPAL MECP2 REGULATION AND 

DNA METHYLATION. D. W. Anderson and J. 

S. Schneider. Pathol., Anat. & Cell Biol., Thomas 

Jefferson University, Philadelphia, PA. 


BEHAVIOR CHANGES AND TRIBUTYLTIN 

(TBT) CONCENTRATION IN CEREBRUMS 

OF PREGNANT RATS EXPOSED TO TBT. T. 

Kaido 1,2 , H. Asakawa 2 , Y. Takeuchi 3 , R. Yoshioka 3 , R. 

Ikeuchi 1,2 , M. Hosokawa 1,2 , C. Sugaya 2 , Y. Inoue 2 , Y. 

Kudo 2 , M. Tsunoda 2 , H. Akita 4 , M. Saji 4 , T. Tashiro 3 , 

S. Ohhira 5 and Y. Aizawa 2 . 1 Kitasato University 

Graduate School of Medical Science, Sagamihara, 

Kanagawa, Japan, 2 Preventive Medicine and Public 

Health, Kitasato University School of Medicine, 

Sagamihara, Kanagawa, Japan, 3 Chemistry and 

Biological Science, Aoyama Gakuin University 

School of Science and Engineering, Sagamihara, 

Kanagawa, Japan, 4 Physiology, Kitasato University 

School of Allied Health Science, Sagamihara, 

Kanagawa, Japan and 5 International Environmental 

Hygiene Center, Dokkyo University School of 

Medicine, Mibu, Tochigi, Japan. 


PERINATAL ARSENIC EXPOSURE INHIBITS 

BINDING ABILITY OF GLUCOCORTICOID 

RECEPTORS TO NUCLEAR RESPONSE 

ELEMENTS ALTERING GENE EXPRESSION 

AND AFFECTING LEARNING BEHAVIOR 

IN C57BL/6J ADOLESCENT MICE. E. J. 

Martinez-Finley 1,2 and A. M. Allan 2 . 1 Toxicology, 

University of New Mexico College of Pharmacy, 

Albuquerque, NM and 2 Neurosciences, University of 

New Mexico School of Medicine, Albuquerque, NM. 


METHYLMERCURY-INDUCED 

CYTOTOXICITY IN GFP-EXPRESSING 

NEURONAL CULTURES OF 

CAENORHABDITIS ELEGANS. K. R. Sherer 1,3 , 

R. K. Hajela 3,1 and W. D. Atchison 1,2,3 . 1 Pharmacology 


Lansing, MI, 2 Neuroscience Program, Michigan 

State University, East Lansing, MI and 3 Center for 



246 






Platform Sessions



Abstract # 


EVALUATION OF TBT NEUROTOXICITY 

IN DEVELOPING MALE F1 RATS BY OPEN 

FIELD TESTS. M. Tsunoda 1 , T. Kaido 1,2 , R. 

Ikeuchi 1,2 , M. Hosokawa 1,2 , C. Sugaya 1 , Y. Inoue 1 , 

Y. Kudo 1 , H. Akita 3 , M. Saji 3 , Y. Takeuchi 4 , R. 

Yoshioka 4 , T. Tashiro 4 and Y. Aizawa 1 . 1 Preventive 

Medicine and Public Health, Kitasato University 

School of Medicine, Sagamihara, Kanagawa, 

Japan, 2 Kitasato University Graduate School of 

Medical Sciences, Sagamihara, Kanagawa, Japan, 

3 

Physiology, Kitasato University School of Allied 

Health Science, Sagamihara, Kanagawa, Japan and 

4 

Chemistry and Biological Scinece, Aoyama Gakuin 

University School of Science and Engineering, 

Sagamihara, Kanagawa, Japan. 


EFFECTS OF DEVELOPMENTAL LEAD 

EXPOSURE AND PRENATAL STRESS ON 

GRANULE CELL NEUROGENESIS IN THE 

HIPPOCAMPUS DENTATE GYRUS. T. Verina 1 , 

D. A. Cory-Slechta 2 , S. Kiihl 3 and T. R. Guilarte 1 . 

1 

Env Hlth Sci, Johns Hopkins Sch Pub Hlth, 

Baltimore, MD, 2 Env Med, University Rochester 

Sch Med. & Dentistry, Rochester, NY and 3 Statistics, 

Johns Hopkins Sch Pub Hlth, Baltimore, MD. 


ALTERED BDNF PROTEIN EXPRESSION 

AND RELEASE BY CHRONIC PB2+ 

EXPOSURE DURING SYNAPTOGENESIS IN 

PRIMARY HIPPOCAMPAL NEURONS. K. 

Stansfield and T. Guilarte. Environmental Health 

Sciences, Johns Hopkins University, Baltimore, MD. 


AN IN VITRO METABOLOMICS APPROACH 

FOR NEUROTOXICITY ASSESSMENT. E. van 

Vliet, H. Hogberg and T. Hartung. Environmental 

Health Sciences, Johns Hopkins University, 

Bloomberg School of Public Health, Baltimore, MD. 



OF SILVER NANOPARTICLES MODELED 

IN PC12 CELLS. C. M. Powers, I. T. Ryde, N. 

Wrench, F. J. Seidler and T. A. Slotkin. Pharmacology 

& Cancer Biology, Duke University Medical Center, 

Durham, NC. 


METHYLMERCURY EXPOSURE 

DOWNREGULATES THE EXPRESSION 

OF RACL AND LEADS TO NEURITIC 

DEGENERATION AND ULTIMATELY 

APOPTOSIS IN CEREBROCORTICAL 

NEURONS. M. Fujimura 1 , F. Usuki 2 , W. Rostene 3 , 

D. Godefroy 3 and A. Takashima 4 . 1 Basic Medical 

Sciences, National Institute for Minamata Disease, 

Minamata, Kumamoto, Japan, 2 Clinical Medicine, 

National Institute for Minamata Disease, Minamata, 

Kumamoto, Japan, 3 UMRS 732, INSERM, Paris, 

France and 4 Brain Science Institute, RIKEN, Wako, 

Saitama, Japan. Sponsor: A. Naganuma. 

Abstract # 


POTENTIATED IMPAIRMENT OF 

LEARNING IN FEMALE OFFSPRING 

EXPOSED TO CONTINUOUS LEAD (PB) 

AND PRENATAL STRESS. D. A. Cory- 

Slechta, D. D. Weston and S. Stern. Department of 

Environmental Medicine, University of Rochester 

Medical School, Rochester, NY. 


MITOCHONDRIAL DYSFUNCTION IN AN 

APP/PS1 MOUSE MODEL OF ALZHEIMER’S 

DISEASE. R. A. Schuh 1,2 , A. Schlappal 3 and P. S. 

Fishman 1,2 . 1 Research and Development Service, 

VA Maryland Health Care System, Baltimore, 

MD, 2 Neurology, University of Maryland School 

of Medicine, Baltimore, MD and 3 Neuroscience 

and Cognitive Science Graduate Program, Animal 

Sciences, University of Maryland, College Park, MD. 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Hepatotoxicity: Role of Bile Acid Metabolism 

and Homeostasis 

Chairperson(s): Supriya Kulkarni, University of Rhode Island, Kingston, 

RI. 




EFFECT OF AGING ON EXPRESSION OF 

HEPATIC TRANSPORTERS AND BILE ACID 

SYNTHESIZING ENZYMES IN MOUSE 

LIVER. Z. D. Fu, I. L. Csanaky and C. D. Klaassen. 

Pharmacology, Toxicology, and Therapeutics, 

University of Kansas Medical Center, Kansas City, 

KS. 


HEPATOCYTE-SPECIFIC DELETION OF 

NADPH-CYTOCHROME P450 REDUCTASE 

(H-CPR-NULL) IN MICE DISTURBS BILE- 

ACID HOMEOSTASIS BY MINIMIZING 

THE CLASSICAL PATHWAY OF BILE-ACID 

BIOSYNTHESIS. X. Cheng, Y. Zhang and C. 

D. Klaassen. Pharmacology, Toxicology, and 

Therapeutics, KUMC, Kansas City, KS. 


LIVER BILE ACID METABOLISM IN MALE 

AND FEMALE C57BL/6 MICE FED BILE 

ACID-SUPPLEMENTED DIETS. Y. Zhang 

and C. D. Klaassen. Pharmacology, Toxicology and 



WedneSday 







247


WedneSday 




BILE ACIDS INCREASE 

PROINFLAMMATORY GENE EXPRESSION 

IN HEPATOCYTES BY EARLY GROWTH 

RESPONSE FACTOR-1-DEPENDENT AND 

INDEPENDENT MECHANISMS. K. Allen 1 , N. 

Kim 1,2 and B. L. Copple 1 . 1 Pharmacology, Toxicology, 

and Experimental Therapeutics, University of Kansas 

Medical Center, Kansas City, KS and 2 Pharmacy, 

Pusan National University, Busan, Republic of 

Korea. 


THROMBIN SIGNALING ENHANCES TGF- 

BETA INDUCTION OF INTEGRIN BETA6 

IN BILE DUCT EPITHELIAL CELLS. B. 

P. Sullivan and J. P. Luyendyk. Pharmacology, 

Toxicology and Therapeutics, University of Kansas 



ONTOGENY OF HEPATIC EFFLUX 

TRANSPORTERS IN OBESE MICE. A. C. 

Donepudi, Q. Cheng and A. Slitt. Department of 

Biomedical and Pharmaceutical Sciences, University 

of Rhode Island, Kingston, RI. 


LONG-TERM EFFECT OF A HIGH 

CHOLESTEROL DIET ON HEPATIC DRUG 

TRANSPORTER EXPRESSION IN AKR AND 

C57BL/6 MICE. M. A. Paranjpe and A. Slitt. 

Biomedical and Pharmaceutical Sciences, University 

of Rhode Island, Kingston, RI. 


CHANGES IN EXPRESSION OF LIVER 

MRP2 EXPRESSION IN MOUSE MODELS 

OF FASTING AND CALORIC RESTRICTION. 

S. Kulkarni and A. Slitt. Biomedical and 


Kingston, RI. 


TRANSPORTER EXPRESSION IN DB/ 

DB AND DIET-INDUCED OBESE (DIO) 

MICE. V. R. More and A. L. Slitt. Biomedical and 


Kingston, RI. 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Causes and Progression of Hepatic Metabolic 

Dysfunction 

Chairperson(s): Rhiannon Hardwick, University of Arizona, Tucson, AZ. 




ANALYSIS OF GLOBAL GENE EXPRESSION 

ALTERATIONS IN THE PROGRESSIVE 

STAGES OF NON-ALCOHOLIC FATTY 

LIVER DISEASE. A. D. Lake, M. D. Merrell, R. 

N. Hardwick, L. M. Augustine, W. Klimecki, P. Novak, 

D. Billheimer and N. J. Cherrington. Pharmacology 

& Toxicology, University of Arizona, Tucson, AZ. 


ALTERED EXPRESSION AND REGULATION 

OF EFFLUX DRUG TRANSPORTERS IN 

THE PROGRESSION OF HUMAN NON- 

ALCOHOLIC FATTY LIVER DISEASE. R. 

N. Hardwick, C. D. Fisher, M. J. Canet and N. 

J. Cherrington. Pharmacology and Toxicology, 



THE EFFECT OF DIETARY FAT CONTENT 

ON TCDD-ELICITED HEPATOTOXICITY IN 

C57BL/6 MICE. B. D. Mets 1,2 , A. K. Kopec 1,2 , J. R. 

Harkema 2,3 and T. Zacharewski 1,2 . 1 Biochemistry and 




3 

Pathobiology & Diagnostic Investigations, Michigan 



HEPATIC STEATOSIS AND 

HYPERTRIGLYCERIDEMIA IN TCDD 

TREATED WILD TYPE AND SCD1(-/-) 

C57BL/6 MICE. M. M. Angrish 1,3 , B. D. Mets 2,3 

and T. R. Zacharewski 1,2,3 . 1 Genetics, Michigan State 

University, East Lansing, MI, 2 Biochemistry and 


Lansing, MI and 3 Center for Integrative Toxicology, 



SYNERGISM BETWEEN ‘OMICS: WHAT 

TRANSCRIPTOMICS AND METABOLOMICS 

REVEAL ABOUT TCDD EFFECTS IN RAT 

AND MOUSE LIVER. M. Kent 1 , M. K. Makley 1 , 

N. DelRaso 2 , G. L. Jahns 3 , B. Metz 4 , L. D. Burgoon 4,5 

and T. Zacharewski 4 . 1 Biochem/ Mol Biol, Wright 

State University, Dayton, OH, 2 AFRL/HEPB, 

Wright-Patterson AFB, Dayton, OH, 3 BAE Systems, 

San Diego, CA, 4 Biochem & Mol Biol, National 

Food Safety & Toxicol Ctr, Ctr Integrative Toxicol, 


5 

Quant Biol Initiative, Michigan State University, 


248 






Platform Sessions



Abstract # 


COMPARATIVE TOXICOGENOMIC 

EXAMINATION OF PPARa-REGULATED 

HEPATIC RESPONSES IN VIVO AND IN 

VITRO. S. Kim 1,2 , N. Kiyosawa 4 , L. D. Burgoon 1,2 , 

C. C. Chang 3 and T. Zacharewski 1,2 . 1 Biochemistry 

and Molecular Biology, Michigan State University, 

East Lansing, MI, 2 Center for Integrative Toxicology, 


3 

Pediatrics & Human Development, Michigan State 

University, East Lansing, MI and 4 Medicinal Safety 

Research Labs, Daiichi-Sankyo Co., Ltd., Fukuroi, 

Shizuoka, Japan. 


SELECTIVE UPR SIGNALING IN A 

RODENT MODEL OF CHRONIC ETHANOL 

INGESTION. J. Galligan, B. J. Stewart and D. R. 

Petersen. Toxicology, University of Colorado Denver, 

Aurora, CO. 


CHRONIC ALCOHOL AND CIGARETTE 

SMOKE INCREASE HEPATOTOXICITY 

IN HYPERLIPIDEMIC APOE KNOCKOUT 

MICE. S. M. Bailey 1 , S. K. Mantena 1 , T. 

Millender-Swain 1 , A. L. King 1 , K. E. Pinkerton 3 

and S. W. Ballinger 2 . 1 Environmental Health 

Sciences, University of Alabama at Birmingham, 

Birmingham, AL, 2 Pathology, University of Alabama 

at Birmingham, Birmingham, AL and 3 Center for 

Health and the Environment, University of California 



CHRONIC ALCOHOL INCREASES 

SENSITIVITY TO MITOCHONDRIAL 

CALCIUM OVERLOAD LEADING TO 

ENHANCED SUSCEPTIBILITY TO 

PERMEABILITY TRANSITION AND LIVER 

APOPTOSIS. A. L. King and S. M. Bailey. 


Alabama at Birmingham, Birmingham, AL. 


ROLE OF TGFb-MEDIATED HEPATOCYTE 

EPITHELIAL TO MESENCHYMAL 

TRANSITION (EMT) IN ALCOHOL- 

INDUCED LIVER FIBROSIS. B. A. Hocevar, 

Z. Wang, J. E. Klaunig and L. M. Kamendulis. 


Indiana University School of Medicine, Indianapolis, 

IN. 


PTEN INHIBITION BY 4-HNE IN HEPG2 

CELLS LEADS TO INCREASED AKT 

ACTIVATION AND CELL SURVIVAL. C. T. 

Shearn and D. R. Petersen. School of Pharmacy, 

University of Colorado Denver, Aurora, CO. 


HYPOXIA-INDUCIBLE FACTOR-1ALPHA 

REGULATES EXPRESSION OF GENES 

IN HYPOXIC HEPATIC STELLATE 

CELLS IMPORTANT FOR COLLAGEN 

DEPOSITION AND ANGIOGENESIS. B. L. 

Copple 1 , L. D. Burgoon 2 and S. Bai 1 . 1 Department 

of Pharmacology, Toxicology, & Therapeutics, 


KS and 2 Department of Biochemistry & Molecular 


MI. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Toxicogenomics—Continuing Advances in 

Molecular Toxicology 

Chairperson(s): Craig Thomas, Eli Lilly & Company, Indianapolis, IN, 

and Zhen Li, University North Carolina Chapel Hill, Chapel Hill, NC. 




METABONOMIC ASSESSMENT OF THE 

OVERNIGHT FAST: A TRANSLATIONAL 

EVALUATION IN RATS AND HUMANS. 

S. Stryker 1 , D. G. Robertson 1 , S. Hnatyshyn 1 , P. 

Shipkova 1 , C. Mcnaney 1 , N. Aranibar 1 , M. Reily 1 , 

W. Shyu 2 , S. Griffen 2 and O. Fiehn 3 . 1 Applied and 

Investigative Metabonomics, Bristol-Myers Squibb, 

Princeton, NJ, 2 Discovery Medicine & Clinical 

Pharmacology, Bristol-Myers Squibb, Princeton, 

NJ and 3 Molecular and Cellular Biology & Genome 

Center, University of California Davis, Davis, CA. 


METABONOMIC ASSESSMENT OF 

RAT LIVER SLICES INCUBATED WITH 

DICLOFENAC AND LPS. V. T. Ly 2 , B. Brock 2 , D. 

Robertson 3 , S. Stryker 3 and M. D. Reily 1 . 1 Analytical 

and Investigative Metabonomics, Bristol-Myers 

Squibb, Pharmaceutical Candidate Optimization, 

Princeton, NJ, 2 Biotransformation, Bristol-Myers 

Squibb, Pharmaceutical Candidate Optimization, 

Princeton, NJ and 3 Discovery Toxicology, 

Bristol-Myers Squibb, Pharmaceutical Candidate 

Optimization, Princeton, NJ. 


EFFECTS OF DIET INDUCED 

OBESITY ON TOXICOLOGICAL AND 

TRANSCRIPTIONAL ENDPOINTS. S. 

Ruepp 1 , E. Janovitz 2 , W. Foster 1 , S. Stryker 1 and D. 

Robertson 1 . 1 Discovery Toxicology, Bristol-Myers 

Squibb, Princeton, NJ and 2 Discovery Toxicology, 

Bristol-Myers Squibb, Hopewell, NJ. 


DEVELOPMENT OF AN IN VITRO GENE 

EXPRESSION SIGNATURE PANEL FOR 

PREDICTING SKELETAL MUSCLE INJURY 

IN RAT. G. H. Searfoss 1 , A. H. Roter 2 , J. P. Stutz 1 , 

R. Tammen 1 , R. A. Jolly 1 and C. E. Thomas 1 . 1 Eli 

Lilly & Co., Indianapolis, IN and 2 Entelos, Inc., 

Foster City, CA. 


TOXICOGENOMIC COMPARISON OF RAT 

STRAINS AND GENDER IN AN ACUTE 

MODEL OF CISPLATIN INDUCED RENAL 

INJURY. J. Milano, B. Jeffy and Y. Dragan. Safety 

Assessment, AstraZeneca, Wilmington, DE. 


IMPACT OF RAT STRAIN AND GENDER 

ON TOXICOLOGICAL RESPONSE TO 

DOXORUBICIN. B. D. Jeffy, J. Milano, D. Brott 

and Y. Dragan. Safety Assessment U.S., AstraZeneca, 


WedneSday 







249


WedneSday 




MECHANISTIC INVESTIGATION OF DRUG- 

INDUCED CATARACTS USING GENOMICS 

ANALYSIS OF LENS EXPLANTS. L. McLean 1 , 

S. Sampath 1 , P. Patel 1 , N. Shangari 1 and P. Moulin 2 . 

1 

Novartis Institutes for BioMedical Research, 

East Hanover, NJ and 2 NIBR, Basel, Switzerland. 

Sponsor: A. Wolf. 


AGE- AND SEX-RELATED DIFFERENCES 

IN HEPATIC GENE EXPRESSION DURING 

THE RAT LIFE CYCLE. J. C. Kwekel, V. 

G. Desai, W. S. Branham, C. L. Moland, T. Han 

and J. C. Fuscoe. Systems Toxicology/Center for 

Functional Genomics, U.S. FDA/National Center for 



PATHWAY-BASED DOSE-RESPONSE 

ANALYSIS OF TOXICOGENOMICS DATA. 

Z. Li 1,2 , I. Rusyn 2,3 and F. Wright 1,2 . 1 Department of 

Biostatistics, University of North Carolina at Chapel 

Hill, Chapel Hill, NC, 2 Carolina Environmental 

Bioinformatics Center, Chapel Hill, NC and 

3 



Hill, Chapel Hill, NC. 


THE INDIVIDUAL AND 

COMBINED METABOLITE 

PROFILES (METABOLOMICS) 

OF DIBUTYLPHTHALATE AND 

DIETHYLHEXYLPHTHALATE 

FOLLOWING A 28-DAY DIETARY 

EXPOSURE IN RATS. B. van Ravenzwaay, M. 

Herold, H. Kamp, E. Fabian, E. Leibold, R. Looser, 

G. Krennrich, A. Prokoudine, V. Strauss, T. Walk and 

J. Wiemer. Experimental Toxicology and Ecology, 

BASF SE, Ludwigshafen, Germany. Sponsor: C. 

Hastings. 


TOXICOGENOMIC EVALUATION 

OF SR13668, A NOVEL INDOLE 

BEING DEVELOPED FOR CANCER 

CHEMOPREVENTION. D. L. McCormick 1 , 

K. E. Torres 2 , W. S. Reed 1 , M. Muzzio 1 and I. M. 

Kapetanovic 3 . 1 IIT Research Institute, Chicago, IL, 

2 

GenUS Biosystems, Northbrook, IL and 3 National 

Cancer Institute, Bethesda, MD. 


TRANSLATIONAL TOXICOLOGY: 

NEXTGEN TOOLS TO APPLY ADVERSE 

HUMAN RESPONSE INFORMATION 

INTO RELEVANT ANIMAL MODELS. 

I. DETECTION OF GENOME-WIDE 

ALTERNATIVE SPLICING. S. Srinivasan 1,2 , D. 

E. Johnson 1,3 and S. Sudarsanam 1,3 . 1 JEM Bioscience, 

Emeryville, CA, 2 Jivan Biologics, Larkspur, CA and 

3 

Emiliem, Emeryville, CA. 


GLOBAL CHIP-CHIP ANALYSIS OF 

AHR ENRICHMENT IN C57BL/6 MOUSE 

LIVERS. E. Dere 1 , A. Forgacs 1,2 , L. Burgoon 1,2 , J. 

Matthews 3 and T. Zacharewski 1,2 . 1 Biochemistry & 




3 

Pharmacology & Toxicology, University of Toronto, 



TRANSCRIPTOMIC ANALYSIS IN 

UMBILICAL CORD BLOOD OF CHILDREN 

EXPOSED TO GENOTOXIC COMPOUNDS 

THROUGH THE MATERNAL DIET. D. 

M. Hoff - van Leeuwen 1 , H. Gmuender 2 , K. 

Hochstenbach 1 , M. Løvik 3 , B. Granum 3 , U. C. 

Nygaard 3 , S. B. Stølevik 3 , E. Namork 3 , M. Haugen 4 , 

J. Alexander 4 , H. M. Meltzer 4 , M. Kirsch-Volders 5 , 

I. Decordier 5 , K. Vande Loock 5 , M. Botsivali 6 , 

S. Hepworth 7 , H. Besselink 8 , H. van Loveren 1 

and J. H. van Delft 1 . 1 Department of Health Risk 

Analysis and Toxicology, Maastricht University, 

Maastricht, Netherlands, 2 Genedata, Basel, 

Switzerland, 3 Department of Environmental 

Immunology, Norwegian Institute of Public Health, 

Oslo, Norway, 4 Department of Food Safety and 

Nutrition, Norwegian Institute of Public Health, 

Oslo, Norway, 5 Laboratory of Cell Genetics, Free 

University Brussels, Brussels, Belgium, 6 National 

Hellenic Research Foundation, Athens, Greece, 

7 

Pediatric Epidemiology Group, University of Leeds, 

Leeds, United Kingdom and 8 BioDetection Systems, 

Amsterdam, Netherlands. 


ENVIRONMENTAL TOXICANT ANALYSIS 

BY MIRNA EXPRESSION PROFILING. 

S. Hwang 1,2,3 , S. Kim 1,2 , H. Park 2,3 , Y. An 1 and 

M. Oh 2 . 1 Molecular and Life Science, Hanyang 

University, Ansan, Gyeonggi-do, Republic of Korea, 

2 

GenoCheck Co. Ltd., Ansan, Republic of Korea and 

3 

Bio-Nanotechnology, Hanyang University, Ansan, 



N-NITROSO COMPOUNDS AND COLON 

CARCINOGENESIS: AN IN VITRO 

TOXICOGENOMICS APPROACH. T. M. de 

Kok, D. G. Hebels, D. G. Jennen and J. C. Kleinjans. 

Health Risk Analysis and Toxicology, Maastricht 

University, Maastricht, Netherlands. Sponsor: H. van 

Loveren. 


TOWARDS QUANTITATIVE RISK 

ASSESSMENT IN SYSTEMS TOXICOLOGY: 

ACETAMINOPHEN-INDUCED 

HEPATOTOXICITY AS A CASE. A. S. 

Kienhuis 1,2 and L. T. van der Ven 1 . 1 Laboratory for 

Health Protection Research, National Insititute 

for Public Health and the Environment (RIVM), 

Bilthoven, Netherlands and 2 RIKILT - Institute of 

Food Safety, Wageningen, Netherlands. Sponsor: H. 

van Loveren. 

250 






Platform Sessions



Abstract # 


BLOOD BASED TRANSCRIPTOMIC AND 

METABOLOMIC SIGNATURES FOR 

HUMAN EXPOSURE TO LOW DOSES OF 

ACETAMINOPHEN. R. D. Fannin 1 , M. Russo 2 , 

T. M. O’Connell 3,4 , K. Gerrish 1 , J. H. Winnike 4 , J. 

Macdonald 4 , J. Newton 5 , S. Malik 5 , S. O. Sieber 1 , 

J. Parker 7 , R. Shah 6 , P. W. Watkins 3,4 , T. Zhou 3,4 

and R. S. Paules 1 . 1 NIH/NIEHS, Research Triangle 

Park, NC, 2 Carolinas Medical Center, Charlotte, 

NC, 3 The Hamner Institute, Research Triangle Park, 

NC, 4 The University of North Carolina, Chapel Hill, 

NC, 5 Chenomx, Edmonton, AB, Canada, 6 SRA 

International, Durham, NC and 7 Expression Analysis, 

Durham, NC. 


USE OF LASER CAPTURE 

MICRODISSECTION AND AFFYMETRIX 

GENECHIP PROFILING TO DEVELOP A 

COMPREHENSIVE GENE EXPRESSION 

DATABASE FROM MULTIPLE RAT TISSUES. 

L. Nelms 1 , M. Barcus 2 , L. Obert 1 , K. Petal 1 , A. Ryan 1 

and M. Lawton 1 . 1 Pfizer, Groton, CT and 2 Gene 

Logic, Gaithersburg, MD. 


LAMP-2 IMMUNOHISTOCHEMISTRY 

(IHC) ENHANCES TISSUE DETECTION OF 

DRUG-INDUCED PHOSPHOLIPIDOSIS IN 

RATS. J. H. Yearley 1 , E. Janovitz 2 , L. Lehman- 

McKeeman 3 , R. Gullo 1 , S. Raiti 1 and M. Otieno 3 . 

1 

Drug Safety Evaluation, Bristol-Myers Squibb Co., 

New Brunswick, NJ, 2 Discovery Toxicology, Bristol- 

Myers Squibb Co., Hopewell, NJ and 3 Discovery 

Toxicology, Bristol-Myers Squibb Co., Princeton, 

NJ. 


CORRELATION OF PHYSIOCHEMICAL 

PROPERTIES WITH IN VITRO RESPONSE: 

INVOLVEMENT OF LYSOSOME IN DRUG 

INDUCED CYTOTOXICITY. S. Lu 1 , K. 

Dillman 2 , Y. Will 2 , M. Pletcher 2 and B. Jessen 1 . 1 Pfizer 

Inc., San Diego, CA and 2 Pfizer Inc., Groton, CT. 


COMPARISON OF IN VITRO 

PHOSPHOLIPIDOSIS (PLD) ASSAYS IN 

PRIMARY MACROPHAGES AND CELL 

LINES USING DIFFERENT PLATFORMS 

AND DETECTION DYES. L. Lecureux 1 , G. 

Gong 1 , C. Cheng 3 , J. Herbst 3 , T. Reilly 2 , L. Lehman- 

McKeeman 1 and M. Otieno 1 . 1 Discovery Toxicology, 

Bristol-Myers Squibb, Princeton, NJ, 2 Drug Safety 

Evaluation, Bristol-Myers Squibb, Syracuse, NY and 

3 

Lead Profiling, Bristol-Myers Squibb, Wallingford, 

CT. 


DIFFERENTIAL GENE EXPRESSION 

PROFILES OF G-PROTEIN COUPLED 

RECEPTOR (GPCR) SIGNALING PATHWAYS 

IN THE DUODENAL AND BLADDER 

TISSUES OF THE RATS TREATED WITH 

ATROPINE IN VIVO. S. Qin, D. Zhou, J. Ye, Y. 

Liu and J. Barsoum. Synta Pharmaceuticals Corp., 

Lexington, MA. 

Abstract # 


DISTINGUISHING GENOTOXIC FROM 

NON-GENOTOXIC COMPOUNDS USING 

AN 11 GENE RT-QPCR GENE EXPRESSION 

PROFILE ANALYSIS. Y. Zhang, G. Liu, S. 

Sellappan and X. Zeng. SABioSciences Corp, 

Frederick, MD. Sponsor: L. Guo. 


IN VITRO 3D LIVER CO-CULTURES FOR 

TOXICOGENOMIC ASSESSMENT OF 

CHEMICALLY-INDUCED LIVER CANCER. 

C. I. Pearson 1 , D. R. Applegate 1 , L. New 1 , R. S. 

Thomas 2 , R. Brennan 4 , A. H. Roter 3 , S. V. Su 1 and 

B. A. Naughton 1 . 1 Research, RegeneMed Inc., San 

Diego, CA, 2 Center for Human Health Assessment, 

The Hamner Institutes for Health Sciences, Research 

Triangle Park, NC, 3 Research, Entelos, Inc., Foster 

City, CA and 4 Research, GeneGo, Inc., Encinitas, 

CA. 


DEEP SEQUENCING THE CYNOMOLGUS 

MONKEY TRANSCRIPTOME—IMPACT 

FOR DRUG SAFETY SCIENCES. O. Grenet 1 , 

A. Mueller 1 , P. Couttet 1 , M. Marcellin 1 , F. Pognan 1 , 

D. Gaidatzis 2 , M. Stadler 2 , D. J. Heard 1 and J. 

Moggs 1 . 1 Translational Sciences, Novartis, Basel, 

Switzerland and 2 Computational Biology Group, 

Friedrich Miescher Institute, Basel, Switzerland. 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Signal Transduction 

Chairperson(s): Wu Dong, North Carolina State University, Raleigh, NC, 

and Thomas Sutter, University of Memphis, Memphis, TN. 




INHIBITION OF CALCIUM-INDEPENDENT 

PHOSPHOLIPASE A 2 

ACTIVATES MAP 

KINASE SIGNALING PATHWAYS DURING 

CYTOSTASIS IN PROSTATE CANCER 

CELLS. B. Cummings, B. Sun and X. Zhang. 




DEATH RECEPTOR-REGULATED 

TESTICULAR GERM CELL APOPTOSIS 

IN FASL GENE-DEFICIENT MICE AFTER 

MONO-(2-ETHYLHEXYL) PHTHALATE 

EXPOSURE IS MEDIATED BY CFLAR 

(C-FLIP). Y. Lin, P. Yao and J. H. Richburg. College 

of Pharmacy, University of Texas at Austin, Austin, 

TX. 

WedneSday 







251


WedneSday 




ROLE OF HMGB1 IN SILICA-INDUCED 

INFLAMMATION AND FIBROGENESIS IN 

MOUSE LUNGS. L. B. Joseph 1 , J. A. Cervelli 1 , D. 

A. Elzind 1 , N. M. Bremer 1 , Y. Kim 1 , V. Castranova 2 , 

J. D. Laskin 1 and D. L. Laskin 1 . 1 Rutgers University/ 

UMDNJ-Robert Wood Johnson Medical Center, 

Piscataway, NJ and 2 NIOSH, Morgantown, WV. 


USING MULTIPARAMETRIC HIGH 

CONTENT IMAGING TO ASSESS 

MECHANISMS OF CELLULAR STRESS 

AND TOXICITY. D. M. Miller 1 , B. A. Samson 1 , 

S. J. Hong 2 and A. M. Peters 1 . 1 Cellular Imaging and 

Analysis, Thermo Fisher Scientific, Pittsburgh, PA 

and 2 High Content Reagent Development, Thermo 

Fisher Scientific, Rockford, IL. Sponsor: J. Haskins. 


MALDI-MS-BASED DRUG AND PROTEIN 

IMAGING TO SIMULTANEOUSLY 

DETERMINE DRUG DISPOSITION AND 

PROTEIN MODIFICATION IN CELLS. N. 

Mastrandrea, J. D. Cohen, M. J. Kimzey, T. J. Monks 

and S. S. Lau. Pharm/Toxicology University of 



ANNEXINS: AN EARLY RESPONSE TO 

ENVIRONMENTAL TOXICANTS AND 

A POTENTIAL NEW BIOMARKER OF 

TUMORIGENESIS. B. L. Upham 1 , P. Babica 1 , 

J. Park 1 , I. Sovadinova 1 , D. A. Whitten 2 , C. G. 

Wilson 2 , J. E. Trosko 1 and L. Blaha 3 . 1 Pediatrics/ 

Human Development, Michigan State University, 

East Lansing, MI, 2 RTSF Proteomic Core, Michigan 

State University, East Lansing, MI and 3 Masaryk 

University, Brno, Czech Republic. 


CYTOTOXICITY OF CYCLODEXTRINS: 

IMPLICATIONS IN CELLULAR 

CHOLESTEROL LIPID RAFT STUDIES. 

S. R. Kotha 1 , A. H. Hinzey 1 , M. A. Kline 1 , E. S. 

O’Connor Butler 1 , R. M. Uppu 2 and N. L. Parinandi 1 . 

1 

Pulmonary, Allergy, Critical Care, and Sleep 

Medicine, The Ohio State University College of 

Medicine, Columbus, OH and 2 Department of 

Environmental Toxicology, Southern University and 

A&M College, Baton Rouge, LA. 


CHARACTERIZATION OF A 

CONSTITUTIVELY NUCLEAR, 

DOMINANT-NEGATIVE ZEBRAFISH 

MTF-1 TRANSCRIPTION FACTOR. M. 

Jenny. Biological Sciences, University of Alabama, 

Tuscaloosa, AL. 


PROTEIN TYROSINE PHOSPHATASES, 

TC-PTP, SHP1, AND SHP2, COOPERATE IN 

RAPID DEPHOSPHORYLATION OF STAT3 

IN SKIN FOLLOWING UVB IRRADIATION. 

D. J. Kim and J. DiGiovanni. Department of 

Carcinogenesis, The University of Texas M.D. 

Anderson Cancer Center, Smithville, TX. 


IFN-g INDUCTION OF DUOX2 VIA A NOVEL, 

NON-CANONICAL PATHWAY. T. Hill 1 and R. 

W. Harper 2 . 1 Pharmacology & Toxicology Graduate 

Group, University of California Davis, Davis, 

CA and 2 Division of Pulmonary & Critical Care 

Medicine, University of California Davis, Davis, CA. 


DICHLOROACETIC ACID PREVENTS 

SIMVASTATIN-INDUCED MUSCLE 

DAMAGE IN THE RAT SUGGESTING THAT 

IMPAIRED MITOCHONDRIAL GLUCOSE 

OXIDATION IS RESPONSIBLE FOR STATIN 

INDUCED MYOPATHY. J. E. Sidaway 1 , J. 

E. Mallinson 2 , P. D. Glaves 1 , E. A. Martin 1 , W. J. 

Davies 1 , F. Westwood 1 , D. Constantin-Teodosiu 2 and 

P. L. Greenhaff 2 . 1 Safety Assessment, AstraZeneca, 

Macclefield, Cheshire, United Kingdom and 2 Centre 

for Integrated Systems Biology and Medicine, School 

of Biomedical Sciences, Queen’s Medical Centre, 

University of Nottingham, Nottingham, United 

Kingdom. Sponsor: R. Roberts. 


TONALIDE- AND GALAXOLIDE-INDUCED 

CELL DEGENERATION IS ASSOCIATED 

WITH POLYISOPRENYLATED 

METHYLATED PROTEIN METHYL 

ESTERASE (PMPMEASE) INHIBITION. L. 

T. Ayuk-Takem 2,1 , F. Amissah 2 and L. Nazarius 2 . 

1 

Chemistry, Florida A&M University, Tallahassee, FL 

and 2 College of Pharmacy, Florida A&M University, 

Tallahassee, FL. Sponsor: A. Ndifor. 


HEAT SHOCK PROTEIN 70-KDA (HSP70) 

AS A CRITICAL REGULATOR OF 

PROTEOTOXIC STRESS IN PANCREATIC 

CANCER MODELS. M. C. White, W. Qi and D. J. 

McConkey. MD Anderson, Houston, TX. 


PKCDELTA PROTEOLYTIC ACTIVATION 

AS A POTENTIAL EARLY MARKER FOR 

DRUG-INDUCED MITOCHONDRIAL 

TOXICITY. V. Anantharam 1 , N. Li 2 , P. 

Anantharam 1 , P. Narayanan 2 and A. Kanthasamy 1,3 . 

1 

PK Biosciences Corporation, Ames, IA, 

2 

Investigative Toxicology, Amgen Inc., Seattle, WA 

and 3 Iowa State University, Ames, IA. 


MECHANISMS OF IMPAIRED INSULIN 

SIGNALING IN CALCINEURIN A-ALPHA 

KNOCKOUT MICE. R. N. Reddy 1 , T. K. Roberts 1 , 

S. R. Price 1 and J. L. Gooch 1,2 . 1 Nephrology/Renal 

Medicine, Emory University, Atlanta, GA and 

2 

Altanta VA Medical Center, Atlanta, GA. 

252 






Platform Sessions



Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Stem Cell Toxicology 

Chairperson(s): Sudheer Reddy Beedanagari, University of California 

Los Angeles, Los Angeles, CA. 




BENZENE-INDUCED BONE-MARROW 

TOXICITY: A HEMATOPOIETIC STEM- 

CELL-SPECIFIC, ARYL HYDROCARBON 

RECEPTOR-MEDIATED ADVERSE EFFECT. 

Y. Hirabayashi 1 , B. Yoon 1,2 , G. Li 1 , Y. Fujii- 

Kuriyama 3 , T. Kaneko 1 , J. Kanno 1 and T. Inoue 4 . 

1 

Division of Cellular & Molecular Toxicology Center 

for Biol Safety & Res, Nat’l Inst of Health Sciences, 

Tokyo, Japan, 2 Lab of Histology & Molecular 

Pahtogenesis, School of Vet Med, Kangwon Nat’l 

University Chuncheon, Republic of Korea, 3 TARA, 

University of Tsukuba, Tsukuba, Japan and 4 Center 

for Biol Safety & Res, Nat’l Inst of Health Sciences, 

Tokyo, Japan. 


INORGANIC ARSENIC EXPOSURE 

INDUCES A CANCER PHENOTYPE IN 

KIDNEY STEM/PROGENITOR CELLS IN 

VITRO. E. J. Tokar 1 , A. O. Perantoni 2 and M. P. 

Waalkes 1 . 1 ICS, NCI at NIEHS, Research Triangle 

Park, NC and 2 DNS, CDBL, NCI- Frederick, 

Frederick, MD. 


EVALUATION OF CYTOTOXIC, 

GENOTOXIC, AND EMBRYOTOXIC 

EFFECTS OF DANOFLOXACIN USING 

MOUSE EMBRYONIC STEM CELLS AND 

DIFFERENTIATED CELLS. S. Jeong, E. Kim, 

E. Park, J. Cho, H. Shin, J. Kang, Y. Park, J. Seo and 

S. Son. Toxicology and Chemistry Division, National 

Veterinary Research & Quarantine Service, Anyang, 

KyungGi, Republic of Korea. 



REGULATES INTERACTIONS BETWEEN 

HEMATOPOIETIC STEM CELLS AND 

THEIR MICROENVIRONMENT. F. L. Casado- 

Pena, K. P. Singh and T. A. Gasiewicz. Environmental 

Medicine, University of Rochester, Rochester, NY. 



NULL MOUSE STRAIN (AHR-KO) HAS 

ABNORMAL HEMATOPOIETIC STEM 

CELL FUNCTIONS: FURTHER EVIDENCE 

OF AHR ROLE IN HEMATOPOIESIS. K. 

P. Singh, F. L. Casado and T. A. Gasiewicz. 


School of Medicine and Dentistry, Rochester, NY. 

Abstract # 


EVALUATION OF A MOUSE EMBRYONIC 

STEM CELL ADHERENT CELL 

DIFFERENTIATION AND CYTOTOXICITY 

(ACDC) ASSAY. M. Barrier, S. Jeffay, H. Nichols 

and S. Hunter. ISTD, U.S. EPA, Research Triangle 

Park, NC . Sponsor: T. Knudsen. 


EFFECTS OF HALOACETIC ACIDS 

AND THEIR MAJOR METABOLITES IN 

A MOUSE EMBRYONIC STEM CELL 

ADHERENT CELL DIFFERENTIATION AND 

CYTOTOXICITY (ACDC) ASSAY. S. Jeffay, H. 

Nichols, M. Barrier and S. Hunter. ISTD, U.S. EPA, 

Research Triangle Park, NC . Sponsor: T. Knudsen. 


EFFECTS OF HALOACETIC ACID 

MIXTURES IN A MOUSE EMBRYONIC 

STEM CELL ADHERENT CELL 

DIFFERENTIATION AND CYTOTOXICITY 

(ACDC) ASSAY. H. Nichols 1 , S. Jeffay 1 , M. 

Barrier 1 , M. G. Narotsky 1,2 , J. E. Simmons 1 and S. 

Hunter 1 . 1 ISTD, U.S. EPA, Research Triangle Park, 

NC and 2 TAD, U.S. EPA, Research Triangle Park, 

NC . Sponsor: T. Knudsen. 


EFFECTS OF ACUTE EXPOSURE OF LI, 

MN, NI, AND PB ON CELL PROLIFERATION 

AND DNA REPAIR GENE EXPRESSION IN 

DIFFERENTIATNG MOUSE EMBRYONIC 

STEM CELLS. D. I. Gazarian and F. A. Barile. 

Toxicology, St. John’s University, New York. 


INHALED ACROLEIN DECREASED 

CIRCULATING ENDOTHELIAL 

PROGENITOR CELLS AND THEIR 

RECRUITMENT IN MICE. D. J. Conklin 1 , S. 

Baba 1 , M. Bertke 2 , P. Haberzettl 1 , J. Hellmann 1,3 , 

L. Wheat 1,3 , T. E. O’Toole 1 and A. Bhatnagar 1,3 . 

1 

Diabetes and Obesity Center, University of 

Louisville, Louisville, KY, 2 School of Medicine, 


3 

Physiology and Biophysics, University of Louisville, 



THE ROLE OF THE ARYL HYDROCARBON 

RECEPTOR IN PREGNANCY 

IMMUNOLOGY. J. Epple-Farmer, S. Ke, Y. Xie, 

H. Cui, N. Ouyang and Y. Tian. Veternary Physiology 

and Pharmacology, Texas A&M University, College 

Station, TX. 


TRANSCRIPTOMICS-BASED 

IDENTIFICATION OF DEVELOPMENTAL 

TOXICANTS BY THEIR MODULATION 

OF EARLY EMBRYONIC STEM CELL 

DIFFERENTIATION. D. A. van Dartel 1,2 , J. L. 

Pennings 1 , T. E. Pronk 1 , M. H. van Herwijnen 2 , F. 

J. van Schooten 2 and A. H. Piersma 1,3 . 1 Laboratory 

for Health Protection Research, National Institute 


Bilthoven, Netherlands, 2 Department of Health Risk 

Analysis and Toxicology, Maastricht University, 

Maastricht, Netherlands and 3 Institute for Risk 


Netherlands. Sponsor: H. van Loveren. 

WedneSday 







253


WedneSday 




ASSESSMENT OF THE MOUSE 

EMBRYONIC STEM CELL TEST AND 

PROPOSAL OF PREDICTION PROCEDURE. 

K. Iwashita, N. Horie, K. Inawaka, H. Higuchi 

and S. Kawamura. Environmental Health Science 

Laboratory, Toxicology Group, Developmental & 

Reproductive Toxicology Team, Sumitomo Chemical 

Co., Ltd., Osaka, Japan. Sponsor: H. Kaneko. 


ETHANOL CAUSES DISREGULATION 

OF MOUSE EMBRYONIC STEM CELL 

DEVELOPMENT. S. L. Worley, C. S. Gardiner 

and G. K. DeKrey. Biological Sciences, University of 

Northern Colorado, Greeley, CO. 


9:00 AM to 12:30 PM 

Exhibit Hall 

Poster Session: Nanotoxicology—Gold or Silver Nanoparticles 

Chairperson(s): Hilary Afeseh Ngwa, Iowa State University, Ames, IA. 




UPTAKE OF GOLD NANOPARTICLES 

IN MURINE MACROPHAGE CELLS 

OCCURS WITHOUT CYTOTOXICITY OR 

PRODUCTION OF PRO-INFLAMMATORY 

MEDIATORS. Q. Zhang 1 , A. Schrand 2 , V. M. 

Hitchins 1 , S. Hussain 2 and P. L. Goering 1 . 1 Center 

for Devices and Radiological Health, U.S. Food 

and Drug Administration, Silver Spring, MD and 

2 

Applied Biotechnology Branch, 711th Human 

Performance Wing, Wright-Patterson AFB, Dayton, 

OH. 


EFFECTS OF NANOMATERIAL 

DOSIMETRY ON TOXICOLOGICAL 

STUDIES. R. C. Murdock, L. K. Braydich-Stolle 

and S. M. Hussain. USAF 711 HPW/RHPB, Dayton, 

OH. 


GOLD NANOPARTICLES HAVE SIZE, 

CONCENTRATION, AND LENGTH-OF- 

EXPOSURE DEPENDENT EFFECTS ON 

VIABILITY AND CELLULAR SIGNAL 

TRANSDUCTION IN PC12 CELLS. D. Ellis, 

L. K. Braydich-Stolle and S. M. Hussain. AFRL/711 

HPW/RHPB, Wright-Patterson AFB, OH. 


DIFFERENTIAL CELLULAR RESPONSE 

TO GOLD NANOPARTICLES BASED ON 

SURFACE CHARGE. N. M. Schaeublin 1 , L. K. 

Braydich-Stolle 1 , J. M. Miller 2 , J. J. Schlager 1 and S. 

M. Hussain 1 . 1 711 HPW; RHPB, Air Force Research 

Labs, Wright Patterson, OH and 2 Department of 

Chemistry, University of Oregon, Eugene, OR. 


GOLD NANOPARTICLES FACILITATE 

ACTIVATION OF EPIDERMAL GROWTH 

FACTOR RECEPTOR. S. M. Hussain 1 , N. 

M. Schaeublin 1 , L. K. Braydich-Stolle 1 , R. I. 

MacCuspie 2 , K. W. Park 2 , R. A. Vaia 2 and J. J. 

Schlager 1 . 1 711 HPW; RHPB, Air Force Research 

Labs, Wright Patterson, OH and 2 RXBN, AFRL, 

Wright Patterson, OH. 


GENE EXPRESSION ANALYSIS OF 

OXIDATIVE STRESS INDUCED BY 

NANOSILVER IN MOUSE LYMPHOMA 

CELLS. Y. Chen, N. Mei, M. Moore and T. Chen. 

DGRT, U.S. FDA/NCTR, Jefferson, AR. 



INTERACTION BETWEEN DNA AND 

ENGINEERED SILICA NANOMATERIALS. 

K. Clark 1 , Q. Zheng 2 , H. Katz 2 and E. K. Silbergeld 1 . 

1 


Bloomberg School of Public Health, Johns Hopkins 

University, Baltimore, MD and 2 Department of 

Material Sciences and Engineering, Johns Hopkins 

University, Baltimore, MD. 


SILVER NANOPARTICLES INDUCED 

TOXICITY IN CAENOHABDITIS ELEGANS 

THROUGH P38 MAPK MEDIATED 

OXIDATIVE STRESS: FUNCTIONAL 

GENOMICS APPROACH. J. Roh and J. Choi. 

Faculty of Environmental Engineering, College of 

Urban Science, University of Seoul, Seoul, Republic 

of Korea. Sponsor: D. Ryu. 


INVESTIGATION ON DNA DAMAGE, 

CELL CYCLE ARREST AND P38 MAPK 

ACTIVATION AS MECHANISMS OF SILVER 

NANOPARTICLES TOXICITY IN HUMAN 

LYMPHOMA CELL, JURKAT. H. Eom, J. Choi 

and S. Park. Faculty of Environmental Engineering, 

College of Urban Science, University of Seoul, 

Seoul, Republic of Korea. Sponsor: D. Ryu. 


MODULATION OF AN ASTHMATIC 

RESPONSE BY NANOPARTICLES IN A 

MOUSE MODEL OF CHEMICAL-INDUCED 

ASTHMA. S. Hussain 1,2 , J. A. Vanoirbeek 2 , K. 

Luyts 2 , V. De Vooght 2 , E. Verbeken 3 , S. Boland 1 , 

F. Marano 1 , B. Nemery 2 and P. H. Hoet 2 . 1 Unit of 

Functional and Adaptive Biology (BFA) CNRS 

EAC 7059, University Paris Diderot, Paris, France, 

2 

Research Unit for Lung Toxicology, K.U.Leuven, 

Leuven, Belgium and 3 Morphology and Molecular 

Pathology Section, K.U. Leuven, Leuven, Belgium. 

254 






Platform Sessions



Abstract # 


SILVER NANOPARTICLE TOXICITY IN 

SKIN CELLS AND EFFICACY IN BACTERIA. 

M. E. Samberg 1,2 , P. E. Orndorff 3 and N. A. Monteiro- 

Riviere 1,2 . 1 Department of Clinical Sciences, 



Raleigh, NC, 2 Joint Department of Biomedical 

Engineering at North Carolina State University 

and the University of North Carolina Chapel Hill, 

North Carolina State University, Raleigh, NC and 

3 

Department of Population Health and Pathobiology, 

North Carolina State University, Research Triangle 

Park, NC. 


GENOTOXICITY OF NANOSILVER IN 

MOUSE LYMPHOMA CELLS. T. Chen 1 , W. 

Ding 1 , Y. Chen 1 , X. Guo 1 , Y. Zhang 2 , A. Biris 3 , P. 

Rice 4 , S. Ali 2 , A. Aidoo 1 , M. Moore 1 and N. Mei 1 . 

1 

Devision of Genetic and Reproductive Toxicology, 


Jefferson, AR, 2 Division of Neurotoxicology, 


Jefferson, AR, 3 Nanotechnology Center, University 

of Arkansas at Little Rock, Little Rock, AR and 

4 

Office of Food Additive Safety, for Food Safety and 

Applied Nutrition, College Park, MD. 


REACTIVE OXYGEN SPECIES AND 

GENE EXPRESSION ALTERATIONS IN 

THE HUMAN EPITHELIAL CELL LINE 

A549 AFTER EXPOSURE TO SILVER 

NANOPARTICLES IN VITRO. R. Foldbjerg, 

D. A. Dang and H. Autrup. Environmental and 

Occupational Medicine, iNANO Center, University 

of Aarhus, Aarhus, Denmark. 


ANALYSIS OF PERTURBATIONS IN 

HEPG2 CELL CYCLE AFTER GOLD 

NANOPARTICLE EXPOSURES: CELLULAR 

RESPONSE IS DEPENDENT ON PARTICLE 

SIZE AND SURFACE CHARGE. N. Banerjee, 

M. Berg, R. Taylor and C. M. Sayes. Texas A&M 

University, Bryan, TX. 


THE SURFACE FUNCTIONALITY OF GOLD 

NANOPARTICLES IMPACTS EMBRYONIC 

GENE EXPRESSION RESPONSES. L. 

Truong 1,2 , J. Miller 2,3 , J. Hutchison 2,3 and R. 

Tanguay 1,2 . 1 Environmental & Molecular Toxicology 

Oregon State University, Corvallis, OR, 2 Oregon 

Nanoscience and Microtechnologies Institute and 

the Safer Nanomaterials and Nanomanufacturing 

Initiative, Eugene, OR and 3 Chemistry, University of 

Oregon, Eugene, OR. 


DIFFERENTIAL SEDIMENTATION FOR 

THE CHARACTERIZATION OF SURFACE 

MODIFIED GOLD NANOPARTICLES IN 

WHOLE BLOOD. P. Carpinone 1 , J. Munson 2 , D. 

Barber 2 , K. Siebein 1 , K. Powers 1 and S. Roberts 2 . 

1 

Particle Engineering Research Center, University 

of Florida, Gainesville, FL and 2 Center for 

Environmental & Human Toxicology, University of 

Florida, Gainesville, FL. 

Abstract # 


9:00 AM to 12:30 PM 

Exhibit Hall 


Poster Session: Gene Regulation 

Chairperson(s): Rais Ansari, Nova Southeastern University, Fort 

Lauderdale, FL. 




TRANSCRIPTIONAL PROFILING OF LIVER 

RNA FROM MALE RATS TREATED WITH 

A BRISTOL-MYERS SQUIBB COMPOUND 

MODULATING GABA ACTIVITY. T. R. Van 

Vleet 1 , C. Colleton 1 , A. J. Reisinger 1 , S. P. Clark 1 , W. 

Foster 2 , D. Bounous 3 , T. P. Sanderson 1 , R. T. Bunch 1 , 

B. E. Schilling 1 and M. A. Dominick 1 . 1 Drug Safety 

Evaluation, Bristol-Myers Squibb, Mt. Vernon, 

IN, 2 Discovery Toxicology, Bristol-Myers Squibb, 

Lawrenceville, NJ and 3 Drug Safety Evaluation, 

Bristol-Myers Squibb, Lawrenceville, NJ. 


MODULATION OF GENE EXPRESSION BY 

GOLD NANOPARTICLES OF DIFFERENT 

SIZE AND SHAPE. C. M. Garrett 1,2 , A. M. 

Schrand 1 , J. N. McDougal 2 and S. M. Hussain 1 . 

1 

Applied Biotechnology Branch, 711th Human 

Performance Wing/RHPB, Wright-Patterson AFB, 

Wright-Patterson AFB, OH and 2 Boonshoft School of 

Medicine, Wright State University, Dayton, OH. 


THE ANTIDIABETIC DRUG METFORMIN 

INHIBITS PMA-INDUCED MATRIX 

METALLOPROTEINASE-9 ACTIVATION 

THROUGH A CALCIUM AND PKCa/ERK/ 

AP-1-DEPENDENT PATHWAY. Y. Jeong 1,2 , 

Y. Hwang 1,3 , J. Choi 1,2 and H. Jeong 1 . 1 Pharmacy, 

Chungnam National University, Daejeon, Republic 

of Korea, 2 Pharmacy, Chosun University, Gwangju, 

Republic of Korea and 3 Pharmacy, Chonnam 

National University, Gwangju, Republic of Korea. 


METALLOTHIONEIN ENHANCES 

VASCULAR ENDOTHELIAL GROWTH 

FACTOR EXPRESSION THROUGH THE 

ACTIVATION OF HIF-1a H. Kim 1,2 , J. Kim 1,2 

and H. Jeong 1 . 1 Pharmacy, Chungnam National 

University, Daejeon, Republic of Korea and 

2 

Pharmacy, Chosun University, Gwangju, Republic 



A SCREEN FOR NOVEL REGULATORY 

AGENTS OF CYP2S1. I. G. Bebenek 1 , J. Suarez 2 , 

P. Bui 1 and O. Hankinson 1 . 1 Pathology, Molecular 

Toxicology Interdepartmental Program, UCLA, Los 

Angeles, CA and 2 University of Puerto Rico, Cayey. 

WedneSday 







255


WedneSday 




GENE EXPRESSION PROFILES PREDICT 

GENDER SUSCEPTIBILITY TO BROMATE- 

INDUCED RENAL CARCINOGENESIS IN 

RATS. C. Nelson 1 , X. Zhang 2 , N. Kolisetty 2 , B. 

S. Cummings 2 , D. Bull 3 , J. Cotruvo 4 , J. Fisher 5 , B. 

Milash 6 and D. Delker 1,6 . 1 School of Med., University 

of Utah, Salt Lake City, UT, 2 Pharmacology and 

Biomed. Sci., University of Georgia, Athens, GA, 

3 

MoBull Consulting, Richland, WA, 4 Joseph Cotruvo 

& Assoc., Washington, DC, 5 Envion. Health Sci., 

University of Georgia, Athens, GA and 6 Huntsman 

Cancer Inst., University of Utah, Salt Lake City, UT. 


CHARACTERIZATION OF HEPATIC GENE 

REGULATION FOLLOWING SHORT-TERM 

PERTURBATIONS IN THYROID HORMONE 

LEVELS IN JUVENILE MICE. M. Paquette 1 , 

H. Dong 2 , M. Malowany 3 , M. Wade 2 and C. Yauk 1 . 

1 

Mechanistic Studies Division, Health Canada, 

Healthy Environments and Consumer Safety, Ottawa, 

ON, Canada, 2 Hazard Identification Division, Health 

Canada, Healthy Environments and Consumer 

Safety, Ottawa, ON, Canada and 3 Population Studies 

Division, Health Canada, Healthy Environments and 

Consumer Safety, Ottawa, ON, Canada. Sponsor: G. 

Bondy. 


REDUCTION IN MIR-101A EXPRESSION 

LEVEL AND ASSOCIATED CHANGES 

IN TCDD-EXPOSED MOUSE LIVER. W. 

Yoshioka, W. Higashiyama and C. Tohyama. The 

University of Tokyo, Tokyo, Japan. 


INDUCTION OF GSTT AND GSTA BY 

ORGANOPHOSPHORUS PESTICIDES IN 

HEPG2 CELLS. I. M. Medina 1 , W. A. Maldonado 1 , 

C. Martínez 1 , M. Rubio 1 , A. Rojas 1 , J. Velazquez 1 , I. 

Girón 1 , G. Azuela 2 and L. Robledo 1 . 1 Secretaria de 

Investigacion y Posgrado, Universidad Autonoma 

de Nayarit, Tepic, Nayarit, Mexico and 2 Biología 

Celular, Centro de Investigación y de Estudios 

Avanzados del IPN, México DF., Mexico. Sponsor: 

B. Quintanilla. 


QUANTITATIVE NUCLEASE 

PROTECTION ASSAYS (QNPA) AS 

WINDOWS INTO CHEMICAL-INDUCED 

ADAPTIVE RESPONSE IN CULTURES 

OF PRIMARY HUMAN HEPATOCYTES 

(CONCENTRATION- & TIME-RESPONSE). 

S. S. Ferguson, J. P. Jackson, K. Freeman and A. 

Beam. Hepatic Biology, Invitrogen Corporation (a 

part of Life Technologies), Durham, NC. Sponsor: 

I. Ruysn. 


DIURNAL VARIATION OF CYTOCHROME 

P450 2S1 EXPRESSION IN PULMONARY 

EPITHELIAL CELLS. T. W. Madanayake and 

A. M. Rowland. Chemistry and Biochemistry, New 

Mexico State University, Las Cruces, NM. 


STIMULATION OF INFLAMMATION 

AND MITOCHONDRIAL DYSFUNCTION 

PATHWAYS BY ARSENIC EXPOSURE IN 

LIVERS OF APOE-KNOCKOUT MICE. M. 

Zajack 1 , Y. Piao 3 , M. S. Ko 3 , E. Rouchka 2 and J. 

States 1 . 1 Pharmacology and Toxicology, University of 

Louisville, Louisville, KY, 2 Computer Engineering 

and Computer Science, University of Louisville, 

Louisville, KY and 3 Laboratory of Genetics, National 

Institute on Aging, Baltimore, MD. 


ORGAN-SPECIFIC ROLES OF CYP1A1 

IN DETOXICATION OF ORAL BENZO[A] 

PYRENE. Z. Shi, B. Wang, E. B. Hay, S. Uno, N. 

Dragin and D. W. Nebert. Department Environmental 

Health, University of Cincinnati, Cincinnati, OH. 


9:45 AM to 10:45 AM 

Room 155 B 

Exhibitor Hosted Session: Inhalation Study Test Article 

Consumption—Ensuring Preclinical Inhalation Toxicology 

Programs Don’t Break the Bank 


Aerosol generation and exposure techniques employed historically for Inhalation 

pre-clinical programs did not consider test article costs. Increasing 

sensitivity within the pharmaceutical industry to spiralling pre-clinical 

program costs together with extreme manufacturing costs for many large 

molecule therapeutics has required refinement of existing systems and engineered 

solutions to minimise consumption. 

WEDnESDAY AfTERnOOn 

Wednesday Afternoon, March 10 

12:00 NOON to 1:30 PM 

Room 255 E 

Specialty Section Meeting/Luncheon: Toxicologic and 

Exploratory Pathology 


12:00 NOON to 1:20 PM 

Ballroom B 

Informational Session: Life-Stage Adjustment Five Years 

Later—Experiences from the Cancer Risk Assessment Field 

Chairperson(s): Michael L. Dourson, Toxicology Excellence for Risk 

Assessment, Cincinnati, OH, and Clifton J. Mclellan, NSF International, 

Toxicology Services, Ann Arbor, MI. 

Sponsor: 


Endorsed by: 



In 2005, the U.S. EPA released the Guidelines for Cancer Risk Assessment 

(Cancer Guidelines) and the Supplemental Guidance Assessing 

Susceptibility from Early-Life Exposure to Carcinogens (Supplemental 

Guidance). The Cancer Guidelines describe the Agency’s current methods 

for conducting cancer risk assessments, and introduce the framework for 

256 






Platform Sessions



Abstract # 

determining the mode-of-action (MOA) by which the chemical induces 

cancer. The Supplemental Guidance also considers MOAs and recommends 

the development of separate cancer potencies, based on early-and later-life 

exposures, for compounds with mutagenic MOAs. With the issuance of 

the Supplemental Guidance, the potential for children’s risk to carcinogenic 

chemicals was explicitly addressed for the first time. During the past 

several years, risk assessors in the public health field, state governments, 

and industry, have implemented the MOA framework and addressed the 

concept of life-stage susceptibility through a variety of approaches. The 

purpose of this session will be to share experiences and recent developments 

in the application of potency adjustments for carcinogens acting through 

a mutagenic or unknown MOA. Setting the stage will be a review from 

the U.S. EPA of the basis for early-life default factors and the conditions 

for their use in quantitative assessment. An example life-stage adjustment 

will be presented to illustrate an application of the guidance in establishing 

allowable concentrations in drinking water. In the consumer product area, 

the impact of the guidance on different population groups will be examined. 

Approaches taken by the Minnesota Department of Health in addressing 

groundwater contaminants and by the California EPA in addressing lifestage 

susceptibility will be presented. 

#1721 12:00 LIFE-STAGE ADJUSTMENT FIVE YEARS 

LATER; EXPERIENCES FROM THE 

CANCER RISK ASSESSMENT FIELD. J. C. 

English 1 , R. Schoeny 2 , S. Felter 3 , H. Goeden 4 , P. 

Moyer 4 , L. Zeise 5 and M. Sandy 5 . 1 NSF International, 

Ann Arbor, MI, 2 U.S. . EPA, Washington, DC, 

3 

Procter & Gamble Company, Cincinnati, OH, 

4 

Minnesota Department of Health, St. Paul, MN and 

5 

California EPA, Oakland, CA. 

12:05 U.S. EPA’S AGE-DEPENDENT ADJUSTMENT 

FACTORS (ADAFS): WHAT’S MODE-OF- 

ACTION (MOA) GOT TO DO WITH IT? Rita 

Schoeny 

12:20 KEEPING IT TRANSPARENT: THE USE 

OF AGE-DEPENDENT ADJUSTMENT 

FACTORS IN ESTABLISHING ALLOWABLE 

CONCENTRATIONS IN DRINKING WATER. 

J. Caroline English 

12:30 APPLICATION OF U.S. EPA 

SUPPLEMENTAL GUIDANCE FOR 

EARLY LIFE EXPOSURE TO CONSUMER 

PRODUCTS. Susan Felter 

12:45 USE OF EARLY LIFE-STAGE CANCER 

POTENCY ADJUSTMENTS IN MINNESOTA 

GROUNDWATER RULES. Helen Goeden 

1:00 POTENCY DISTRIBUTIONS FOR AGE- 

SENSITIVE FACTORS INFORM LIFE-STAGE 

ADJUSTMENTS. Lauren Zeise 


Abstract # 


12:00 NOON to 1:20 PM 

Ballroom D 


Informational Session: Measuring Immune Responses 

in Monkeys for Drug Development: Opportunities 

and Challenges for Predicting Human Efficacy and 

Immunotoxicity 

Chairperson(s): Cris Kamperschroer, Pfizer, Inc., Immunotoxicology, 

Groton, CT, and Herve N. Lebrec, Amgen, Inc., Department of Toxicology, 

Seattle, WA. 

Sponsor: 


As drug targets become increasingly diverse, we must adapt the approaches 

we use to evaluate drug efficacy and safety testing. Immunomodulatory 

drugs can be challenging to develop because some immunomodulatory 

targets are only expressed during an immune response, or they are expressed 

but display no measurable function in the absence of an immune response. 

In these cases, we must track immune responses in order to evaluate drug 

effects. In addition, immunomodulatory drugs may cause immunosuppression 

that can lead to opportunistic infections, creating a need to monitor 

immune responses against those infections. In recent years, there have been 

significant advances in methods for tracking immune responses. In drug 

development, monkeys (eg. macaques) are often used for studies when 

other species do not express the target or have insufficient homology to 

the intended human target or relevant biological system. These situations 

are becoming more common, increasing the need to induce and measure 

immune responses in monkeys. For human translation, it is desirable to 

develop and employ methods of immune monitoring that can be used in the 

clinic. Antigen-specific responses are preferred because they are more physiologically 

relevant than those driven by polyclonal stimulators or mitogens. 

However, there are significant challenges to measuring antigen-specific 

immune responses in monkeys, such as a lack of appropriate antigen, lack 

of specific reagents, and the inherently variable nature of immune responses 

in outbred populations. This session will focus on various methods currently 

being used to track immune responses in monkeys and how those measurements 

are being used to assess either efficacy or immunotoxic potential of 

test compounds. The session will include discussion of experiences from 

scientists in an academic setting, where the most current technologies are 

being developed, as well as experiences and challenges encountered by 

those in industry attempting to track immune responses in monkeys to 

support drug development. 

#1722 12:00 MEASURING IMMUNE RESPONSES IN 

MONKEYS FOR DRUG DEVELOPMENT— 

OPPORTUNITIES AND CHALLENGES FOR 

PREDICTING HUMAN EFFICACY AND 

IMMUNOTOXICITY. C. Kamperschroer. Pfizer, 

Groton, CT. 

12:05 IMMUNOTOXICOLOGY ASSESSMENT OF 

TUBERCULOSIS RISK. JoAnne Flynn 

12:20 MONITORING T CELL RESPONSES 

AGAINST CHRONIC VIRAL INFECTIONS IN 

MONKEYS. Amitinder Kaur 

12:35 T-DEPENDENT ANTIBODY RESPONSES 

AND IMMUNOPHENOTYPING IN 

MONKEYS—IMPACT ON STUDY DESIGN 

AND INTERPRETATION. Herve Lebrec 

12:50 EXPLOITING LATENT VIRUSES 

TO MEASURE EFFECTS OF 

IMMUNOMODULATORY DRUGS ON 

IMMUNE RESPONSES IN MONKEYS. Cris 

Kamperschroer 

WedneSday 







257


WedneSday 





12:00 NOON to 1:20 PM 

Ballroom F 


Informational Session: The Tox21 st Community and the 

Future of Toxicology Testing 

Chairperson(s): Raymond R. Tice, NIEHS, National Toxicology Program, 

Research Triangle Park, NC, and Robert J. Kavlock, U.S. EPA, National 

Center for Computational Toxicology, Research Triangle Park, NC. 

Sponsor: 


Endorsed by: 




In early 2008, the National Institute of Environmental Health Sciences/ 

National Toxicology Program, the NIH Chemical Genomics Center, and 

the U.S. EPA’s National Center for Computational Toxicology entered into 

a Memorandum of Understanding to collaborate on the research, development, 

validation, and translation of new and innovative test methods that 

characterize key steps in toxicity pathways. A central component is the 

exploration of high-throughput screening assays and tests using phylogenetically 

lower animal species (e.g., fish, worms), as well as high-throughput 

whole genome analytical methods, to evaluate mechanisms of toxicity. The 

goals of the Tox21 Community are to investigate the use of these new tools 

to prioritize substances for further in-Department toxicological evaluation, 

identify mechanisms of action for further investigation, and develop predictive 

models for in vivo biological response. Success is expected to result 

in test methods for toxicity testing that are more mechanistically based 

and economically efficient; as a consequence, a reduction or replacement 

of animals in regulatory testing is anticipated to occur in parallel with an 

increased ability to evaluate the large numbers of chemicals that currently 

lack adequate toxicological evaluation. The initial focus of this collaboration 

has been on identifying toxicity-related pathways (and assays for those pathways), 

establishing a Tox21 library of ~10000 compounds, and developing 

the databases and bioinformatic tools needed to mine the resulting data. 

This session will inform the scientific community of progress in meeting 

the Tox21 goals, successful efforts to expand the collaboration nationally 

and internationally, novel assay platforms that have been integrated into the 

screening strategy, and how Tox21 data might be used for hazard identification 

and risk assessment. 

#1723 12:00 THE TOX21 ST COMMUNITY AND THE 

FUTURE OF TOXICOLOGY TESTING. 

R. Tice 1 , R. Kavlock 2 , C. Smith 1 , M. Xia 3 , R. Judson 2 

and L. Birnbaum 1 . 1 U.S. National Institute of 

Environmental Health Sciences/National Toxicology 

Program, Research Triangle Park, NC, 2 U.S. EPA, 

Research Triangle Park, NC and 3 NIH Chemical 

Genomics Center, Bethesda, MD. 

12:05 THE TOX21 COMPOUND LIBRARY— 

SETTING THE STAGE FOR 

HIGH-THROUGHPUT TESTING. Cynthia 

Smith 

12:20 PREDICTING TOXICOLOGICAL EFFECTS: 

IDENTIFYING CRITICAL CELLULAR 

PATHWAYS AND ASSAYS FOR THOSE 

PATHWAYS. Menghang Xia 

12:35 TOX21: DATABASES, DATA MINING, AND 

PREDICTIVE PATTERNS. Richard Judson 

12:50 THE TOX21 INITIATIVE AND THE FUTURE 

OF TOXICOLOGY. Linda Birnbaum 



12:15 PM to 1:15 PM 

Room 155 C 

Exhibitor Hosted Session: New Applications of the Latest 

Telemetry Technology in Toxicology and Safety Pharmacology 

Presented by: Data Sciences International 

Advances in wireless technology have enabled noninvasive and implantable 

telemetric monitoring to provide additional new cardiovascular and respiratory 

parameters. Leading researchers will present their latest validation data 

from current work with new innovative applications in toxicology and safety 

pharmacology. Data from canine and NHP model studies will be presented. 


12:15 PM to 1:15 PM 

Room 155 B 

Exhibitor Hosted Session: Mechanisms of Toxicity and 

Prediction of Whole-Organ Toxicity: In Vitro Assays and 

Their Validation—What Can We Predict Early on to Avoid 

Costly Mistakes Later? 

Presented by: Gentronix Limited and Apredica LLC 

The session will review predictive toxicology strategies for genotoxicity 

and other early attrition rate toxicities. New approaches for HT profiling 

and HCA will be presented. Delegates will also have opportunity for input 

through an interactive open forum session to discuss current issues and 

future directions in this important field. 


12:30 PM to 1:20 PM 

Room 251 A 


Opening Doors in Research, Teaching, and 

Service 

Lecturer: Marion F. Ehrich, Virginia-Maryland 

Regional College of Veterinary Medicine, Blacksburg, 

VA. 

As an academic scientist hired for a new veterinary college, energetic 

contributions to discovery, teaching and service were needed and 

expected. A primary requirement was the teaching of pharmacology, and 

it was important to use this course to transition the students from basic 

to applied science so they could function as clinicians. The graduate 

program began a few years later, and graduate students, too, needed to be 

mentored so they would transition from learners to critical thinkers. Both 

then and now, examples set for both groups of students helped them see 

that discovery is a journey, not only an endpoint, and that collaborations 

are beneficial. Enthusiasm for discovery can engage others, too. Research 

discoveries have been primarily associated with the Laboratory of 

Neurotoxicity Studies investigations with organophosphorus compounds, 

using biochemical, behavioral and pathological approaches. Among 

the findings include species differences in organophosphorus-induced 

delayed neuropathy, in vitro identification of compounds causing acute 

and delayed neurotoxicity in vivo, and evaluation of potential means 

for amelioration of these toxicities. Presenting this information to the 

Society of Toxicology at its annual meetings and contributing to SOT’s 

programs have been important associated activities. 

258 






Platform Sessions



Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Cardiovascular Toxicology 

Chairperson(s): Charles Zhang, Purdue Pharma LP, Canbury, NJ. 




VALVULAR HEART LESIONS IN HAN 

WISTAR RATS DOSED WITH ALK5 

INHIBITORS. M. J. Anderton 1 , A. Heier 2 , A. Bell 1 , 

C. Sadler 1 , M. Pass 3 , S. Powell 3 and R. Roberts 1 . 

1 

General Toxicology Sciences, Safety Assessment 

UK, AstraZeneca, Cheshire, United Kingdom, 

2 

Pathology, Safety Assessment UK, AstraZeneca, 

Cheshire, United Kingdom and 3 Cancer Bioscience, 

AstraZeneca, Cheshire, United Kingdom. 


MECHANISTIC INVESTIGATION OF 

A RECEPTOR TYROSINE KINASE 

INHIBITOR–INDUCED MYOCARDIAL 

DYSFUNCTION IN RATS. W. Hu, B. Hirakawa, 

B. Jessen and S. Aguirre. Drug Safety, Pfizer Global 

Research and Development, San Diego, CA. 


EFFECTS OF TRICHLOROETHYLENE ON 

HEART DEVELOPMENT. O. Makwana 1 , N. 

King 1 , L. Ahles 1 , H. L. Granzier 2 , O. Selmin 3 and R. 

B. Runyan 1 . 1 Cell Biology & Anatomy, University of 

Arizona, Tucson, AZ, 2 Department of Physiology, 

University of Arizona, Tucson, AZ and 3 Department 

of Veterinary Sciences & Microbiology, University of 

Arizona, Tucson, AZ. Sponsor: R. Lantz. 


NON-INVASIVE BLOOD PRESSURE 

MONITORING IN AMBULATORY BEAGLE 

DOGS. J. Le Bigot 1 , A. Bétat 1 , G. Froget 1 , J. 

Napoléoni 2 , R. Forster 1 and A. Simonnard 1 . 1 CIT, 

Evreux, France and 2 EMKA Technologies, Paris, 

France. 


NANOPARTICLE INHALATION 

MODULATES ARTERIOLAR SYMPATHETIC 

CONSTRICTION: ROLE OF NITRIC OXIDE, 

PROSTANOIDS, AND a-ADRENERGIC 

RECEPTORS. T. L. Knuckles 1 , D. G. Frazer 2 , 

J. L. Cumpston 2 , B. T. Chen 2 , V. Castranova 2 and 

T. R. Nurkiewicz 1 . 1 Center for Cardiovascular and 

Respiratory Sciences, West Virginia University, 

Morgantown, WV and 2 National Institute for 

Occupational Safety and Health, Morgantown, WV. 


QT CORRECTION IN BEAGLE DOGS AND 

GÖTTINGEN MINIPIGS. A. Jackson, O. Pohl 

and A. Lefranc. Harlan Laboratories Ltd., Itingen, 

Switzerland. 


DIESEL EXHAUST PARTICLE 

EXPOSURE AUGMENTS ARTERIOLAR 

MECHANOTRANSDUCTION. K. Porter and 

T. R. Nurkiewicz. CCRS, West Virginia University, 








259 

Abstract # 


CARDIAC, RENAL, AND HEPATIC 

MITOCHONDRIAL TOXICITY OF 

DOXORUBICIN IN A CHRONIC AND ACUTE 

IN VIVO MODEL. G. C. Pereira 1 , S. P. Pereira 1 , 

J. A. Lumini 2 , C. V. Pereira 1 , J. Magalhães 2 , A. 

Ascenção 2 , A. J. Moreno 3 , M. S. Santos 1 and P. 

J. Oliveira 1 . 1 Center for Neuroscience and Cell 

Biology, University of Coimbra, Coimbra, Portugal, 

2 

Faculty of Sport Sciences, University of Porto, 

Porto, Portugal and 3 Institute for Marine Research, 

University of Coimbra, Coimbra, Portugal. Sponsor: 

K. Wallace. 


INCREASED CARDIAC RISK IN 

CONCOMITANT METHADONE 

AND DIAZEPAM TREATMENT: 

PHARMACODYNAMIC INTERACTIONS IN 

CARDIAC ION CHANNELS. A. M. Brown, Y. 

Kuryshev and G. E. Kirsch. ChanTest Corporation, 

Cleveland, OH. 


RECOVERY OF CYTOCHROME C 

OXIDASE ACTIVITY IS REQUIRED FOR 

COPPER SUPPLEMENTATION-INDUCED 

REGRESSION OF HYPERTROPHIC 

CARDIOMYOPATHY IN MICE. L. Zhan 1 , 

Y. Yao 1 , W. Xue 2 , W. Feng 2 , K. S. Bourcy 1 , Z. 

Zhou 2 , J. W. Eaton 2 and Y. Kang 1 . 1 Department 

of Pharmacology & Toxicology, University of 

Louisville, Louisville, KY and 2 Department of 

Medicine, University of Louisville School of 

Medicine, Louisville, KY. 


ASSOCIATION OF VASCULAR 

ENDOTHELIAL GROWTH FACTOR 

RECEPTOR-1 WITH CGMP-DEPENDENT 

PROTEIN KINASE-1 IS INVOLVED 

IN COPPER-INDUCED REGRESSION 

OF HUMAN CARDIAC MYOCYTE 

HYPERTROPHY IN CULTURES. K. S. 

Bourcy 1 , W. Feng 2 and Y. Kang 1 . 1 Pharm/Toxicology 


2 

Medicine, University of Louisville, Louisville, KY. 


TEGASEROD: AN ASSESSMENT OF SAFETY 

AND EFFICACY IN ISOLATED HUMAN 

TISSUE. S. Lynagh, E. Moss, C. Stevenson and D. 

C. Bunton. Biopta Ltd., Glasgow, United Kingdom. 

Sponsor: S. Kirk. 


CARDIOVASCULAR EFFECTS OF 

ACUTE ISOTONIC VOLUME OVERLOAD 

IN TELEMETERED CYNOMOLGUS 

MONKEYS: MAJOR ROLE FOR ANP. E. 

Bou-Abboud 1 , N. Crosby 1 , F. Sannajust 1 , B. Lee 1 , R. 

Harris 1 , Y. Mori 1 , J. Tilton 1 , J. Ogle 1 , P. Franklin 1 , R. 

Eyre 1 , J. Klaassen 1 , S. Meyer 1 and R. Nagata 2 . 1 SNBL 

USA Ltd., Everett, WA and 2 Shin Nippon Biomedical 

Laboratories, Ltd., Tokyo, Japan. 


DOWN-REGULATION OF MYOCARDIAL 

LIPIN 1 GENE EXPRESSION BY 

LIPOPOLYSACCHARIDE (LPS) IS NOT 

RESCUED BY PGC-1a OVEREXPRESSION. 

M. S. Mitra, J. D. Schilling, Z. Chen and B. N. 

Finck. Department of Internal Medicine, Washington 

University School of Medicine, St. Louis, MO. 

WedneSday


WedneSday 




ASSESSMENT OF DRUG-INDUCED 

QT PROLONGATION IN HUMAN 

INDUCED PLURIPOTENT STEM CELL- 

DERIVED CARDIOMYOCYTES USING 

MICROELECTRODE ARRAY RECORDING 

TECHNIQUES. B. Anson 2 , L. Guo 1 , S. Fiene 2 , 

D. Majewski 2 , J. Ma 2 , N. Tandon 1 , J. Modi 1 , D. 

Misner 3 and K. L. Kolaja 1 . 1 Nonclinical Safety, 

Hoffmann-LaRoche, Nutley, NJ, 2 Cellular Dynamics 

International, Madison, WI and 3 Nonclinical Safety, 

Roche SSF, Palo Alto, CA. 


CHARACTERIZATION OF CARDIAC 

CHANNEL FUNCTION IN HUMAN 

INDUCED PLURIPOTENT STEM CELL- 

DERIVED CARDIOMYOCYTES USING 

AUTOMATED AND MANUAL PATCH 

CLAMP TECHNIQUES. L. Guo 1 , J. Modi 1 , 

D. Misner 3 , N. Tandon 1 , J. Ma 2 , S. Fiene 2 , B. 

Anson 2 and K. L. Kolaja 1 . 1 Nonclinical Safety, 

Hoffmann-LaRoche, Nutley, NJ, 2 Cellular Dynamics 

International, Madison, WI and 3 Nonclinical Safety, 

Roche SSF, Palo Alto, CA. 


PROFILING COMPOUNDS WITH 

CARDIOTOXIC POTENTIAL USING 

HIGH CONTENT IMAGING IN RAT 

H9C2 CELLS AND HUMAN INDUCED 

PLURIPOTENT STEM CELL-DERIVED 

CARDIOMYOCYTES. A. Hoffman 3 , S. 

Hamilton 3 , K. Zipf 3 , S. Kameoka 1 , N. Tandon 1 , B. 

Swanson 2 , W. Wang 2 , B. Anson 2 and K. L. Kolaja 1 . 

1 

Nonclinical Safety, Hoffmann-LaRoche, Nutley, 

NJ, 2 Cellular Dynamics International, Madison, WI 

and 3 Discovery Technology, Hoffmann-LaRoche, 

Nutley, NJ. 


THE TECHNICAL MERITS REQUIRED 

TO DEVELOP HIGH CONTENT IMAGING 

APPLICATIONS FOR CARDIOMYOCYTES 

DERIVED FROM HUMAN INDUCED 

PLURIPOTENT STEM CELLS. S. Hamilton 3 , 

A. Hoffman 3 , W. Wang 2 , J. Ma 2 , N. Tandon 1 , S. 

Kameoka 1 , B. Swanson 3 , B. Anson 2 , K. Zipf 3 and K. 

L. Kolaja 1 . 1 Nonclinical Safety, Hoffmann-LaRoche, 

Nutley, NJ, 2 Cellular Dynamics International, 

Madison, WI and 3 Discovery Technology, Hoffmann- 

LaRoche, Nutley, NJ. 


REPRODUCIBILITY OF AORTIC PLAQUE 

DEVELOPMENT IN APOE-/- MICE 

FOLLOWING CIGARETTE SMOKE 

INHALATION EXPOSURE. J. E. Swauger and 

G. M. Curtin. Regulatory Oversight, RAI Services 

Company, Winston Salem, NC. 


COMPROMISE IN MITOCHONDRIAL 

OXIDATIVE CAPACITY INDUCED 

BY CHRONIC EXPOSURE OF 

CARDIOMYOCYTES TO NUCLEOSIDE 

REVERSE TRANSCRIPTASE INHIBITORS 

(NRTIS). Y. Liu, T. Baris and M. C. Poirier. 

National Cancer Institute, Bethesda, MD. 


EFFECTS OF MODULATING IN VIVO 

NITRIC OXIDE PRODUCTION ON 

THE INCIDENCE AND SEVERITY OF 

PHOSHODIESTERASE 4 (PDE4) INHIBITOR 

CI-1044 INDUCED VASCULAR INJURY. C. 

M. Sheth 1 , B. E. Enerson 2 , D. Peters 1 , S. Stewart 1 , 

M. Lawton 2 and J. L. Weaver 1 . 1 DAPR, CDER FDA, 

Silver Spring, MD and 2 Safety Sciences, Pfizer 

Groton Laboratories, Groton, CT. 


INVOLVEMENT OF SHEAR STRESS IN 

FENOLDOPAM AND DOPAMINE INDUCED 

MESENTERIC MEDIAL ARTERIAL 

NECROSIS. D. Dalmas, M. Scicchitano, K. 

Roland, D. Mullins, T. Chordia, K. Frazier and H. 

Thomas. Safety Assessment, GlaxoSmithKline, King 

of Prussia, PA. 


IDENTIFICATION AND ANALYSIS 

OF CIRCULATING ENDOTHELIAL 

MICROPARTICLES AS A POTENTIAL 

BIOMARKER OF DRUG-INDUCED 

VASCULAR INJURY. B. Enerson, C. Conley, 

C. Huang, M. Kate and S. Sokolowski. Drug Safety 

Research and Development, Pfizer Global Research 

and Development, Groton, CT. Sponsor: M. Lawton. 


A NOVEL MECHANISM FOR ALCOHOLIC 

CARDIOMYOPATHY: SUPEROXIDE 

GENERATION IS A PIVOTAL MEDIATOR 

FOR SUPPRESSION OF GAPDH THAT 

TRIGGERS CARDIAC IMBALANCE OF 

ENERGY UTILIZATION, OXIDATIVE 

STRESS, AND REMODELING. Y. Tan 1 , Z. Zhou 2 

and L. Cai 1 . 1 Pediatrics, University of Louisville, 

Louisville, KY and 2 Medicine, University of 



POLYCHLORINATED BIPHENYL INDUCED 

VCAM-1 EXPRESSION IS ABOLISHED IN 

AORTIC ENDOTHELIAL CELLS ISOLATED 

FROM CAVEOLIN-1 DEFICIENT MICE. S. 

Han 1 , M. Toborek 2 and B. Hennig 1 . 1 Animal and 

Food Sciences, University of Kentucky, Lexington, 

KY and 2 Department of Neurosurgery, University of 

Kentucky, Lexington, KY. 


SINGLE NUCLEOTIDE POLYMORPHISMS 

(SNPS) IN MULTIDRUG RESISTANT 

PROTEIN 1 (MRP1; ABCC1) IMPACT 

TRANSPORT OF PRODUCTS OF 

OXIDATIVE STRESS. M. Vore and P. 

Jungsuwadee. Graduate Center for Toxicology, 

University of Kentucky, Lexington, KY. 


THE EFFECTS OF PRENATAL BAP- 

EXPOSURE ON THE DEVELOPING 

CARDIOVASCULAR SYSTEM OF LEH 

RAT OFFSPRING. G. E. Jules and D. B. Hood. 

Neuroscience and Pharmacology, Meharry Medical 

College, Nashville, TN. 

260 






Platform Sessions



Abstract # 


CIGARETTE SMOKE INCREASES DILATED 

CARDIOMYOPATHY IN A COXSACKIE 

VIRUS B3 MODEL OF MYOCARDITIS 

BY INDUCING PERICARDIAL FIBROSIS. 

M. Coronado 1 , S. Frisancho-Kiss 1 , D. Bedja 2 , J. 

Frisancho 1 , K. Gabrielson 2,1 , S. Biswal 1 and D. 

Fairweather 1 . 1 Johns Hopkins University, Bloomberg 

School of Public Health, Baltimore, MD and 2 Johns 

Hopkins University, School of Medicine, Baltimore, 

MD. 


COMPARISON OF SUBCUTANEOUS 

AND EPICARDIAL LEAD PLACEMENT 

ELECTROCARDIOGRAPHY SIGNAL 

QUALITY IN CYNOMOLGUS MONKEYS. P. 

J. Kruzich, H. Jones, J. J. Kremer, M. Taschwer, T. 

W. Beck and R. D. Sarazan. Covance Laboratories 

Inc., Madison, WI. 


STEM CELL-DERIVED HUMAN 

CARDIOMYOCYTE ACTION POTENTIAL 

ASSAY FOR CARDIAC RISK EVALUATION. 

G. E. Kirsch, S. Peng, A. Bruening-Wright, A. E. 

Lacerda and A. M. Brown. ChanTest Corporation, 



EVALUATION OF CARDIAC LIABILITY BY 

TWO IN VITRO FUNCTIONAL ASSAYS. S. 

Wang, T. Lin, K. Bernards, Y. Ovechkina, C. O’Day 

and D. Small. MDS Pharmacology Services, Bothell, 

WA. Sponsor: J. Briffaux. 


VALIDATION OF AN INSTANT HEK 293 

CELL LINE FOR REGULATORY CARDIAC 

SAFETY TESTING. C. Stevenson, S. Lynagh, K. 

Macdonald and D. Bunton. Biopta Ltd., Glasgow, 

United Kingdom. Sponsor: S. Kirk. 


ROLE OF MIRNA SPECIES AND 

ALTERED MRNA TRANSLATION IN 

DOXORUBICIN AND QUINONE MEDIATED 

CARDIOTOXICITY IN VIVO AND IN VITRO. 

T. W. Gant 1 , J. D. Parry 2 , K. M. Phillips 1 , J. Riley 1 , 

J. Luo 1 , S. Zhang 3,1 , E. L. Tayor 1 and J. J. Lyon 2 . 

1 

Systems Toxicology, Medical Research Council 

Toxicology Unit, Leicester, United Kingdom, 2 Safety 

assessment, GSK Ltd., Ware, United Kingdom and 

3 

Queens University, Belfast, United Kingdom. 


MULTI-COMPARTMENTAL PK-PD 

MODELING OF BACLOFEN. H. W. Kamendi 1 , 

K. H. Bui 2 , D. J. Lengel 1 and R. A. Bialecki 1 . 

1 

Safety Assessment, AstraZeneca Pharmaceuticals, 

Wilmington, DE and 2 Drug Disposition, Metabolism 

and Pharmacokinetics, Astrazeneca Pharmaceuticals, 


Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Beneficial Effects of Natural Products 

Chairperson(s): Janice Huwe, U.S. Department of Agriculture, 

Fargo, ND. 




GINKGO BILOBA EXTRACT INDUCES 

GENE EXPRESSION CHANGES IN 

XENOBIOTICS METABOLISM AND THE 

MYC-CENTERED NETWORK. L. Guo 1 , 

N. Mei 1 , W. Liao 2 , P. Chan 3 and P. Fu 1 . 1 NCTR, 

Jefferson, AR, 2 PhalanxBio, Palo Alto, CA and 

3 

National Institute of Environmental Health Sciences, 



PROTECTIVE EFFECTS OF THE 

ANTHOCYANIN FROM PURPLE- 

FLESHED SWEET POTATO ON 

DIMETHYLNITROSAMINE-INDUCED 

FIBROSIS OF THE LIVER IN RATS. C. Ho 1,2 , 

J. Yang 1,2 , Y. Hwang 1,3 , C. Choi 4 , Y. Chung 4 and H. 

Jeong 1 . 1 Pharmacy, Chungnam National University, 

Daejeon, Republic of Korea, 2 Pharmacy, Chosun 

University, Gwangju, Republic of Korea, 3 Pharmacy, 

Chonnam National University, Gwangju, Republic of 

Korea and 4 Division of Food Science, International 

University of Korea, Jinju, Republic of Korea. 


CURCUMIN PREVENTS DAPSONE- 

INDUCED METHEMOGLOBINEMIA. M. 

M. Bergamaschi and R. C. Queiroz. University of 

São Paulo, Ribeirão Preto, SP, Brazil. Sponsor: D. 

Oliveira. 


CYP450 DIETARY INHIBITORS 

BERGAMOTTIN INHIBITION OF TUMOR 

INVASION VIA SUPPRESSING PKCd/P38 

MAPK AND JNK/NF-kB-DEPENDENT 

MMP-9 ACTIVATION IN FIBROSARCOMA 

CELLS. Y. Hwang 1,2 , H. Yun 1,3 , J. Choi 1,3 and H. 


Daejeon, Republic of Korea, 2 Pharmacy, Chonnam 

National University, Gwangju, Republic of Korea 

and 3 Pharmacy, Chosun University, Gwangju, 



CAFFEIC ACID PHENETHYL 

ESTER DOWN-REGULATES 7, 

12-DIMETHYLBENZANTHRACENE 

INDUCED CYP 1A1 EXPRESSION IN 

HEPA-1C1C7 CELLS. P. Hee 1,2 , E. Han 1,2 and H. 


Daejeon, Republic of Korea and 2 Pharmacy, Chosun 

University, Gwangju, Republic of Korea. 

WedneSday 







261


WedneSday 




THE 3-CAFFEOYL, 4-DIHYDROCAFFEOYL 

QUINIC ACID FROM SALICORNIA 

HERBACEA PROTECTS AGAINST TERT- 

BUTYL HYDROPEROXIDE-INDUCED 

HEPATOTOXICITY THROUGH ACTIVATION 

OF THE NRF2-ARE PATHWAY. H. Yong-Pil 1,2 , 

H. Yun 1,3 and H. Jeong 1 . 1 Pharmacy, Chungnam 

National University, Daejeon, Republic of Korea, 

2 

Pharmacy, Chonnam National University, Gwangju, 

Republic of Korea and 3 Pharmacy, Chosun 



INHIBITORY EFFECT OF SAPONINS 

FROM THE ROOT OF PLATYCODON 

GRANDIFLORUM ON ACROLEIN-INDUCED 

MUCIN EXPRESSION. J. Yang 1,2 , J. Choi 1,2 


University, Daejeon, Republic of Korea and 

2 




PROTECTIVE EFFECTS OF SAPONINS 

FROM THE ROOT OF PLATYCODON 

GRANDIFLORUM AGAINST LIVER INJURY 

IN CHRONIC ETHANOL FEEDING VIA 

THE ACTIVATION OF AMP-DEPENDENT 

PROTEIN KINASE. T. Khanal 1,2 , J. Choi 1,2 , Y. 

Hwang 1,3 , Y. Chung 4 and H. Jeong 1 . 1 Pharmacy, 

Chungnam National University, Daejeon, Republic 

of Korea, 2 Pharmacy, Chosun University, Gwangju, 

Republic of Korea, 3 Pharmacy, Chonnam National 

University, Gwangju, Republic of Korea and 

4 

Division of Food Science, International University 

of Korea, Jinju, Republic of Korea. 


KAHWEOL INHIBITS ANGIOGENESIS 

THROUGH SUPPRESSION OF STAT3 

ACTIVATION IN HUMAN ENDOTHELIAL 

CELLS. J. Kim 1,2 , H. Kim 1,2 and H. Jeong 1 . 

1 

Pharmacy, Chungnam National University, 




SUPPRESSION OF PMA-INDUCED TUMOR 

CELL INVASION BY PIPERINE VIA THE 

INHIBITION OF PKCa/ERK/ NF-kB AND 

AP-1-DEPENDENT MMP-9 EXPRESSION. 

H. Yun 1,2 , J. Choi 1,2 , Y. Hwang 1 and H. Jeong 1 . 

1 





PUERARIN OF MULTIDRUG RESISTANCE 

PROPERTY OF CARCINOMA CELLS BY 

DOWN-REGULATING TRANSCRIPTION 

OF MDR-1. T. Hien 1,2 , H. Kim 1,2 and H. Jeong 1 . 

1 





INHIBITORY EFFECT OF PMA-INDUCED 

TUMOR CELL METASTASIS BY AQUEOUS 

EXTRACT ISOLATED FROM PRUNELLA 

VULGARIS VIA THE INHIBITION OF 

NF-kB-DEPENDENT MMP-9 EXPRESSION. 

J. Choi 1,2 , Y. Hwang 1 , C. Choi 3 , Y. Chung 3 , J. Seo 3 


University, Daejeon, Republic of Korea, 2 Pharmacy, 

Chosun University, Gwangju, Republic of Korea and 

3 

Division of Food Science, International University 

of Korea, Jinju, Republic of Korea. 


S-ALLYL CYSTEINE PREVENTS FREE 

FATTY ACID-INDUCED LIPOTOXICITY 

IN HEPG2 CELLS: INVOLVEMENT OF 

MAINTENANCE OF AMP-ACTIVATED 

PROTEIN KINASE ACTIVATION. Y. Hwang 1,2 , 

H. Kim 1,3 , E. Han 1,3 , J. Choi 1,3 , H. Yun 1,3 and H. 


Daejeon, Republic of Korea, 2 Pharmacy, Chonnam 

National University, Gwangju, Republic of Korea 

and 3 Pharmacy, Chosun University, Gwangju, 



PSIDIUM GUAJAVA EXTRACT SUPPRESSES 

IGE-MEDIATED ALLERGIC RESPONSE BY 

INHIBITING MULTIPLE STEPS OF FCeRI 

SIGNALING IN MAST CELLS. H. Hee 1,2 , 

J. Park 1,2 and H. Jeong 1 . 1 Pharmacy, Chungnam 

National University, Daejeon, Republic of Korea and 

2 




INHIBITORY MECHANISM OF PLEUROTUS 

ERYNGIL EXTRACT ON IGE-MEDIATED 

ALLERGIC RESPONSE IN MAST CELLS. 

E. Han 1,2 , J. Park 1,2 and H. Jeong 1 . 1 Pharmacy, 

Chungnam National University, Daejeon, Republic of 

Korea and 2 Pharmacy, Chosun University, Gwangju, 



INHIBITORY MECHANISM OF CYP1A1 

EXPRESSION BY CAPSAICIN MEDIATED 

ARYL HYDROCARBON RECEPTOR AND 

CCAAT/ENHANCER-BINDING PROTEIN IN 

MURINE HEPATOMA HEPA-1C1C7 CELLS. 

J. Im 1,2 , E. Han 1,2 and H. Jeong 1 . 1 Pharmacy, 





INHIBITORY EFFECT OF 3-CAFFEOYL- 

4-DICAFFEOYLQUINIC ACID FROM 

SALICORNIA HERBACEA AGAINST 

PMA-INDUCED CYCLOOXYGENASE-2 

EXPRESSION IN MACROPHAGES. H. Jeong 1 , 

E. Han 1,2 and H. Kim 1,2 . 1 Pharmacy, Chungnam 


2 



262 






Platform Sessions



Abstract # 


INHIBITION OF LIPID SYNTHESIS 

THROUGH ACTIVATION OF AMP- 

ACTIVATED PROTEIN KINASE BY 

SAPONINS DERIVED FROM ROOTS OF 

PLATYCODON GRANDIFLORUM. H. 

Park 1,2 , E. Han 1,2 , H. Kim 1,2 , Y. Hwang 1 and H. 





MOLECULAR MECHANISMS OF THE 

SAPONINS DERIVED FROM ROOTS 

OF PLATYCODON GRANDIFLORUM- 

MEDIATED ENDOTHELIAL NITRIC-OXIDE 

SYNTHASE ACTIVATION. K. Gyun 1,2 , T. Hien 2 , 

E. Han 1,2 and H. Jeong 1 . 1 Pharmacy, Chungnam 


2 




DIHYDRO-N-CAFFEOYLTYRAMINE 

DOWN-REGULATES CYCLOOXYGENASE-2 

EXPRESSION BY INHIBITING THE 

ACTIVITIES OF C/EBP AND AP-1 

TRANSCRIPTION FACTORS. S. Lee 1 , H. 

Hee 1,2 , H. Kim 1,2 , E. Woo 2 and H. Jeong 1 . 1 Pharmacy, 





CARDIOPROTECTIVE POTENTIAL OF 

DIETARY PHYTOCHEMICALS. L. Wang, 

W. Jiang, B. Moorthy and S. R. Kondraganti. 

Department of Pediatrics, Baylor College of 

Medicine, Houston, TX. 


DIFFERENTIAL INDUCTION OF 

APOPTOSIS IN MALIGNANT MCF-7 AND 

NORMAL MCF-10A HUMAN MAMMARY 

EPITHELIAL CELLS BY LAMELLARINS. 

M. van Duursen 1 , S. Nijmeijer 1 , V. Cangieter 1 , S. 

Ruchirawat 2 , P. Ploypradith 2 and M. van den Berg 1 . 

1 


University, Utrecht, Netherlands and 2 Chulabhorn 

Research Institute, Bangkok, Thailand. 


ANTIANDROGENIC AND 

ANTIPROLIFERATIVE EFFECTS OF 3, 

3’-DIINDOLYLMETHANE (DIM) AND 

RING-SUBSTITUTED ANALOGS (RING- 

DIMS) IN LNCAP HUMAN PROSTATE 

CANCER CELLS. K. Abdelbaqi 1 , S. Stephen 2 

and J. Sanderson 1 . 1 Institut Armand-Frappier, INRS, 

Laval, QC, Canada and 2 Veterinary Physiology and 


Station, TX. 


ACTIVATION OF THE TUMOR 

SUPPRESSOR P53 IS NOT ESSENTIAL 

FOR GROWTH INHIBITION OF HUMAN 

HEPATOCELLULAR CARCINOMA 

CELLS BY ISOTHIOCYANATES. V. Mersch- 

Sundermann, E. Lamy, H. Weimann and M. Wagner. 


University Medical Center Freiburg, Freiburg, 

Germany. 

Abstract # 


MODULATION OF HUMAN LYMPHOMA 

VIABILITY AND PROLIFERATION BY RICE 

BRAN FROM GENETICALLY DIVERSE 

VARIETIES. E. P. Ryan 1 , A. Heuberger 2 , M. 

Lewis 3 and J. Leach 4 . 1 Clinical Sciences, Colorado 

State University, Fort Collins, Co., 2 Soil and 

Crop Sciences, Colorado State University, Fort 

Collins, Co., 3 Metabolomics Core-Biochemistry, 

Colorado State University, Fort Collins, CO and 

4 

Bioagricultural Sciences, Colorado State University, 

Fort Collins, CO. 


SUPPRESSION OF LIPOPOLYSACCHARIDE- 

INDUCED INFLAMMATION BY 

ELLAGITANNIN. S. Lee 1 and S. Kim 2 . 

1 

Pharmacology, Kyungpook National University, 

Daegu, Republic of Korea and 2 Toxicology Branch, 

National Toxicology Program/NIEHS, Durham, NC. 


CONSUMPTION OF DOCOSAHEXAENOIC 

ACID ATTENUATES LUPUS NEPHRITIS- 

RELATED GENE EXPRESSION AND 

DISEASE PROGRESSION IN NZBWF1 MICE. 

L. L. Vines 1,2 , I. M. Langohr 3 and J. J. Pestka 1,2,4 . 

1 

Food Science & Human Nutrition, Michigan State 



MI, 3 Pathobiology & Diagnostic Investigation, 


4 

Microbiology & Molecular Genetics, Michigan 



MODULATION OF BODY FAT MASS AND 

LEAN WEIGHT IN DEOXYNIVALENOL- 

INDUCED BODY WEIGHT REDUCTION IN 

THE OBESE MOUSE. K. Hattori 1,2 , B. Flannery 1 , 

C. Amuzie 1 and J. J. Pestka 1 . 1 Food Science and 

Human Nutrition, Michigan State University, 

East Lansing, MI and 2 Nutritional Science, Tokyo 

University of Agriculture, Setagaya-ku, Tokyo, 

Japan. 


NORMAL RANGE AND FORMS OF 

DIETARY SELENIUM PREVENTS 

METHYLMERCURY TOXICITY IN LONG 

EVANS RATS. N. V. Ralston. Energy & 

Environmental Research Center, University of North 

Dakota, Grand Forks, ND. Sponsor: M. Aschner. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Regulations and Policy in Toxicology 

Chairperson(s): Arunkumar Asaithambi, Iowa State University, Ames, IA. 




PRECLINCAL SAFETY EVALUATION OF 

U.S. FDA-APPROVED ONCOLOGY DRUGS: 

RECENT TRENDS IN CONCURRENCE 

WITH DRAFT ICH S9 GUIDELINE. M. Z. 

Dieter, S. L. Ralston, L. A. Gallenberg and J. E. 

Burkhardt. Abbott Laboratories, Abbott Park, IL. 

WedneSday 







263


WedneSday 




IMPACT OF DATA AVAILABILITY ON THE 

CALCULATION OF REACH DNELS FOR 

WORKER AND CONSUMER POPULATIONS. 

R. Roy, N. Pechacek, L. Milchak and R. Skoglund. 

3M Company, St. Paul, MN. 


ICCVAM RECOMMENDATIONS FOR 

USE OF THE LLNA FOR EVALUATING 

THE ALLERGIC CONTACT DERMATITIS 

POTENTIAL OF PESTICIDE 

FORMULATIONS. J. Matheson 1 , A. Jacobs 2 , 

M. Wind 1 , J. Chen 3 , M. Hashim 3 , M. Lewis 3 , 

E. Margosches 3 , D. McCall 3 , T. McMahon 3 , J. 

Redden 3 , R. Ward 3 and W. Stokes 4 . 1 CPSC, Bethesda, 

MD, 2 U.S. FDA, Silver Spring, MD, 3 U.S. EPA, 

Washington, DC and 4 NICEATM, NIEHS, Research 



CURRENT DRUG SCHEDULING REVIEWS 

REPORTED BY THE DRUG ENFORCEMENT 

ADMINISTRATION. J. Vodela, S. Ghozland, C. 

Prioleau, S. Tella, S. Carr and C. Sannerud. Drug 

Enforcement Administration, U.S. Department of 

Justice, Arlington, VA. 


USE OF LINEAR EXTRAPOLATION OF 

CANCER POTENCY FOR REGULATING 

CHEMICALS: COLLISION OF SCIENCE 

AND POLICY. M. E. Stelljes 1 and A. Bailey 2 . 1 SLR 

International Corporation, Martinez, CA and 2 SLR 

International Corporation, Bothell, WA. 


TOXICOLOGICAL PRINCIPLES FOR AN 

IMPROVED HAZARD NOTATION SYSTEM 

TO PROTECT WORKERS FROM DERMAL 

EXPOSURES. A. Maier 1 , B. Gadagbui 1 and 

G. Dotson 2 . 1 Toxicology Excellence for Risk 

Assessment (TERA), Cincinnati, OH and 2 CDC/ 

NIOSH, Cincinnati, OH. 


APPLYING THE MODERN PRINCIPLES 

OF RISK ASSESSMENT TO PROTECT 

WORKERS: UPDATE OF THE DERIVATION 

METHODS FOR IMMEDIATELY 

DANGEROUS TO LIFE AND HEALTH 

(IDLH) VALUES. G. Dotson 1 , A. Parker 2 , A. 

Maier 2 and L. Haber 2 . 1 CDC/NIOSH, Cincinnati, 

OH and 2 Toxicology Excellence for Risk Assessment 

(TERA), Cincinnati, OH. 


ISSUES RELATED TO THE APPLICATION 

OF THE GHS STOT CRITERIA TO INHALED 

POORLY SOLUBLE PARTICULATES (PSP) 

OF LOW TOXICITY. T. Petry 1 , V. Verougstraete 2 , 

B. Davies 3 , S. A. Hubbard 4 , H. Waeterschoot 5 , 

N. R. Ranggasami 1 and A. R. Oller 6 . 1 ToxMinds 

BVBA, Brussels, Belgium, 2 EuroMetaux, Brussels, 

Belgium, 3 International Council on Mining and 

Metals (ICMM), London, United Kingdom, 4 Rio 

Tinto, London, United Kingdom, 5 Nickel Institute, 

Brussels, Belgium and 6 NIPERA, Durham, NC. 


MEETING GHS AND REACH SAFETY DATA 

SHEET TOXICOLOGY REQUIREMENTS. A. 

M. Johnson, C. F. Jacobson, A. M. Stieffenhofer and 

R. Skoglund. 3M Company, St. Paul, MN. 


BIOMONITORING AS PRAGMATIC TOOL 

FOR HEALTH RISK ASSESSMENT UNDER 

THE NEW EU CHEMICALS REGULATION 

(REACH). P. J. Boogaard 1 , S. M. Hays 2 and L. L. 

Aylward 3 . 1 Shell Health, Shell International, The 

Hague, 2 Summit Toxicology, Allenspark, CO and 

3 

Summit Toxicology, Falls Church, VA. 


EPA’S HIGH PRODUCTION VOLUME 

CHEMICAL CHALLENGE: EXPERT 

REVIEW. J. Patterson 1 , C. Franz 2 , H. B. Matthews 3 , 

C. B. Sandusky 4 and M. L. Dourson 1 . 1 Toxicology 

Excellence for Risk Assessment, Cincinnati, 

OH, 2 American Chemistry Council, Arlington, 

VA, 3 Matthews Toxicology Consulting Company, 

Hertford, NC and 4 Physician’s Committee for 

Responsible Medicine, Washington, DC. 


GLOBAL PRODUCT STRATEGY 

TO IMPROVE CHEMICAL RISK 

CHARACTERIZATION AND RISK 

MANAGEMENT PROCEDURES. M. 

Bausen 1 , B. Gollapudi 2 and G. G. Bond 2 . 1 BASF, 

Ludwigshafen, Germany and 2 TERC, The Dow 



GUIDANCE ON THE APPLICATION OF 

GHS (GLOBALLY HARMONIZED SYSTEM 

OF CLASSIFICATION AND LABELLING) 

CRITERIA TO PETROLEUM SUBSTANCES. 

C. Smulders 4,1 , R. Clark 4,2 and J. Freeman 4,3 . 1 Shell 

Canada Ltd., Calgary, AB, Canada, 2 ConocoPhillips, 

Bartlesville, OK, 3 ExxonMobil Biomedical Sciences, 

Inc., Annandale, NJ and 4 International Petroleum 

Industry Environmental Conservation Association 

(IPIECA), London, United Kingdom. 


EVALUATING HUMAN DATA FOR REACH: 

PROPOSED RELIABILITY SCORING 

SYSTEM FOR NICKEL COMPOUNDS. 

D. Staskal 1 , A. Oller 2 , T. Lyons-Darden 2 and 

R. Henderson 2 . 1 ToxStrategies, Austin, TX and 

2 

NiPERA, Durham, NC. 


RESIDENTIAL USE OF WOOD-BURNING 

APPLIANCES IN CANADA: EXPOSURES, 

HEALTH RISKS, AND INTERVENTION 

STRATEGIES. K. von Stackelberg 2 and P. R. 

Williams 1 . 1 E Risk Sciences, LLP, Boulder, CO and 

2 

E Risk Sciences, LLP, Boston, MA. 


IDENTIFICATION OF FACTORS 

CONTRIBUTING TO THE DETECTION 

OF TEST ARTICLE IN CONTROL 

BIOANALYTICAL SAMPLES. H. Skaggs, S. 

Williams, S. Wolford, J. Walisser and L. Kreckler. 

Covance Laboratories, Inc., Madison, WI. 

264 






Platform Sessions



Abstract # 


CONSIDERATIONS ON ADDRESSING THE 

SAFETY OF NON-ABSORBABLE POLYMER 

EXCIPIENTS. L. Sarkissian 1 , J. W. Card 1,2 , H. 

Fikree 1 , J. Wan 1 , N. Bullock 2 , B. Lynch 1,2 and L. A. 

Haighton 1,2 . 1 Ashuren Health Sciences, Mississauga, 

ON, Canada and 2 Cantox Health Sciences 

International, Mississauga, ON, Canada. 


PREDICTIVE PERFORMANCE OF 

SOME STRUCTURE ACTIVITY TOOLS 

FOR IDENTIFICATION OF DERMAL 

SENSITIZERS IN PHARMACEUTICAL 

OPERATIONS. A. Quayson 1 , C. Seaman 2 , M. 

Olson 3 and F. Guerriero 4 . 1 University of Birmingham, 

Birmingham, United Kingdom, 2 HS&P, 

GlaxoSmithKline, Ware, United Kingdom, 3 HS&P, 

GSK, Research Triangle Park, NC and 4 HS&P, GSK, 



REDUCTION IN ANIMAL NUMBERS BY 

17% IN NON-RODENT REPEAT DOSE 

TOXICOLOGY STUDIES WITHOUT 

COMPROMISING SCIENTIFIC QUALITY. K. 

Konigsson 1 , S. Robinson 2 and H. Harleman 2 . 1 Safety 

Assessment, AstraZeneca, Sodertalje, Sweden and 

2 

Safety Assessment, AstraZeneca, Cheshire, United 

Kingdom. 


IMPACT OF REDUCING THE SAMPLE SIZE 

ON THE PERFORMANCE OF THE LLNA. 

E. Salicru 1 , J. Haseman 2 , M. Paris 1 , J. Strickland 1 , 

D. Allen 1 and W. Stokes 3 . 1 NICEATM-ILS, Inc., 

NIEHS, Research Triangle Park, NC, 2 J.K. Haseman 

Consulting, Raleigh, NC and 3 NICEATM, NIEHS, 



USING THE MURINE LOCAL LYMPH NODE 

ASSAY TO CATEGORIZE STRONG SKIN 

SENSITIZERS. J. Strickland 1 , J. Matheson 2 , M. 

Wind 2 , A. Jacobs 3 , F. Stack 1 , D. Allen 1 and W. Stokes 4 . 

1 

ILS, Inc./NICEATM, NIEHS, Research Triangle 

Park, NC, 2 CPSC, Bethesda, MD, 3 U.S. FDA, Silver 

Spring, MD and 4 NICEATM, NIEHS, Research 



IMPLEMENTATION OF THE NICEATM- 

ICCVAM FIVE-YEAR PLAN: ADVANCING 

THE DEVELOPMENT, VALIDATION, 

ACCEPTANCE, AND APPROPRIATE USE 

OF ALTERNATIVE TEST METHODS. S. 

Fitzpatrick 1 , M. Wind 2 , A. Jacobs 1 , D. Hattan 1 , J. 

Kulpa-Eddy 3 , V. Malshet 1 , M. Mumtaz 4 , M. Snyder 5 , 

D. McCarley 6 , S. Morefield 7 , C. Sprankle 7 , D. 

Allen 7 and W. Stokes 6 . 1 U.S. FDA, Silver Spring, 

MD, 2 CPSC, Bethesda, MD, 3 USDA, Washington, 

DC, 4 ATSDR, Atlanta, GA, 5 NIH, Bethesda, MD, 

6 

NICEATM, NIEHS, Research Triangle Park, NC 

and 7 ILS, Inc./NICEATM, NIEHS, Research Triangle 

Park, NC. 


IS THE RECENT JECFA ADI FOR 

PHYTOSTEROLS, PHYTOSTANOLS, 

AND THEIR ESTERS UNNECESSARILY 

RESTRICTIVE? R. R. Simon, R. Kaur and A. 

W. Wong. Cantox Health Sciences International, 

Mississauga, ON, Canada. 







265 

Abstract # 


RETROSPECTIVE REVIEW OF 

CARDIOVASCULAR FINDINGS FROM 

REPEAT-DOSE TOXICITY STUDIES IN 

BEAGLE DOGS. K. Sachdeva 1 , S. Mittelstadt 2 

and M. DuVall 1 . 1 Toxicology, GPRD, Abbott 

Laboratories, Abbott Park, IL and 2 Integrative 

Pharmacology, GPRD, Abbott Laboratories, Abbott 

Park, IL. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Metals I 

Chairperson(s): Michael Waalkes, NIEHS-NCI, Research Triangle Park, 

NC. 




EFFECTS OF VARIOUS METALS 

ON SECRETION OF MATRIX 

METALLOPROTEINASE2 FROM MOUSE 

FIBROBLAST CELLS. M. Takiguchi, M. 

Moriishi, S. Ishimoto, T. Ueno, K. Okuda, T. 

Fukuuchi and Y. Shin’ichi. Hiroshima International 

University, Kure, Hiroshima, Japan. 


TRANSCRIPTIONAL ACTIVATION OF 

MTF-1: THE ROLE OF PKC AND CK2 

CONSENSUS SITES ON METAL-INDUCIBLE 

ACTIVITY. M. Song and J. H. Freedman. LMT, 



REGULATION OF CELL 

DIFFERENTIATION BY 

METALLOTHIONEIN-3 (MT-3) IN HUMAN 

PROXIMAL TUBULE CELLS. C. Bathula, S. 

Somji, M. Sens, J. R. Dunlevy, D. A. Sens and S. 

H. Garrett. Pathology, University of North Dakota, 

Grand Forks, ND. 


THE CARBOXYL-TERMINAL CYSTEINE 

RESIDUES OF MTF1 ARE CRITICAL FOR 

ARSENIC SENSING AND INDUCTION OF 

MT1. X. He 1 and Q. Ma 1,2 . 1 Receptor Biology Lab/ 

TMBB/HELD, NIOSH, Morgantown, WV and 

2 

Biochemistry, West Virgina University School of 

Medicine, Morgantown, WV. 


TWO PKC CONSENSUS SITES IN MTF-1 

REGULATE ITS TRANSCRIPTIONAL 

ACTIVITY. E. K. Braithwaite, A. Treece, M. 

Song and J. H. Freedman. Laboratory of Molecular 

Toxicology, National Institute of Environmental 



CD-INDUCED EGFR TRANSACTIVATION 

LEADS TO STAT3 ACTIVATION BY A 

MECHANISM INVOLVING PKC, SRC, 

AND NADPH OXIDASE. M. Gutiérrez-Ruiz, K. 

Martínez, B. Uribe, V. Souza, L. Bucio, E. Hernández 

and L. Gómez. Ciencias de la Salud. DCBS, 

Universidad Autónoma Metropolitana Iztapalapa, 

México, D.F., Mexico. 

WedneSday


WedneSday 




LOW-LEVEL CADMIUM EXPOSURES DO 

NOT ALTER INTRACELLULAR CALCIUM 

LEVELS. B. Tvermoes 1 , G. S. Bird 2 and J. H. 

Freedman 1 . 1 Laboratory of Molecular Toxicology, 

NIEHS, Research Triangle Park, NC and 2 Laboratory 

of Signal Transduction, NIEHS, Research Triangle 

Park, NC. 


ROLE OF THE CYTOSKELETON IN 

CADMIUM-INDUCED DEATH OF MOUSE 

MESANGIAL CELLS. D. M. Templeton and 

Y. Liu. Laboratory Medicine and Pathobiology, 


Sponsor: J. Duffus. 


CYTOTOXIC AND GENOTOXIC EFFECTS 

OF COEXPOSURE TO NICKEL AND 

CADMIUM. K. Chowdhury and M. Reynolds. 

Department of Biology, Washington College, 

Chestertown, MD. 


CADMIUM EXPOSURE LEADS TO 

ERK ACTIVATION IN THE HUMAN 

OSTEOBLAST-LIKE CELL LINE, SAOS-2. 

W. A. Harvey 1,2 , K. S. Arbon 1 and S. J. Heggland 1 . 

1 

Biology, The College of Idaho, Caldwell, ID and 

2 

Biology, Boise State University, Boise, ID. 


BLOOD AND URINARY CADMIUM 

CONCENTRATION OF RESIDENTS 

AROUND ABANDONED METAL MINES IN 

KOREA. Y. S. Hong 1 , B. G. Kim 1 , D. S. Kim 2 and 

B. C. Yu 3 . 1 Preventive Medicine, Dong-A University, 

Busan, Republic of Korea, 2 National Institute of 

Environmental Research, Seoul, Republic of Korea 

and 3 Preventive Medicine, Kosin University, Busan, 

Republic of Korea. Sponsor: B. Choi. 


OVEREXPRESSION OF CDC34 OR UBC4, 

UBIQUITIN-CONJUGATING ENZYMES, 

CONFER RESISTANCE TO CADMIUM 

THROUGH DIFFERENT MECHANISMS IN 

YEAST CELLS. G. Hwang and A. Naganuma. 

Graduate School of Pharmaceutical Sciences, Tohoku 

University, Sendai 980-8578, Japan. 


LONG-TERM CADMIUM EXPOSURE 

RESULTS IN ENHANCED NITRIC OXIDE 

PRODUCTION FROM LPS-STIMULATED 

RAT SPLENOCYTES. J. Goral 2 , W. Prozialeck 1 

and J. Edwards 1 . 1 Department of Pharmacology, 

Midwestern University, Downers Grove, IL and 

2 

Department of Anatomy, Midwestern University, 

Downers Grove, IL. 


SUBCHRONIC CADMIUM EXPOSURE 

RESULTS IN DECREASED INSULIN 

SECRETION AND HYPERGLYCEMIA 

PRIOR TO ONSET OF RENAL 

DYSFUNCTION IN RATS. J. Edwards, P. Lamar 

and W. Prozialeck. Department of Pharmacology, 

Midwestern University, Downers Grove, IL. 


GENETIC EVIDENCE OF RESISTANCE 

TO CADMIUM-INDUCED TESTICULAR 

TOXICITY IN INBRED WISTAR-IMAMICHI 

RATS. H. Shimada, I. Hata, T. Hashiguchi and Y. 

Imamura. Kumamoto University, Kumamoto, Japan. 


KERATIN 7 EXPRESSION IN INDEPENDENT 

ISOLATES OF CADMIUM TRANSFORMED 

HUMAN UROTHELIAL CELLS (UROTSA). 

S. Somji 1 , X. Zhou 1 , M. Sens 1 , J. R. Dunlevy 2 , S. H. 

Garrett 1 and D. A. Sens 1 . 1 Pathology, University of 

North Dakota, Grand Forks, ND and 2 Anatomy and 

Cell Biology, University of North Dakota, Grand 

Forks, ND. 


CIGARETTE SMOKE CADMIUM 

INCREASES RELEASE OF CALCIUM-41 

FROM BONE IN HUMANS. M. H. 

Bhattacharyya 1 and A. Ebert-McNeill 2 . 1 Medical 

College of Georgia, Augusta, GA and 2 Argonne 

National Laboratory, Lemont, IL. 


OVER-EXPRESSION OF HSULF-1 IN 

HUMAN LUNG EPITHELIAL CELLS 

ENHANCES THE TOXIC EFFECTS OF LEAD 

AND CADMIUM. H. Zhang, D. R. Newman, J. 

C. Bonner and P. L. Sannes. North Carolina State 



SEVERAL METAL COMPOUNDS AFFECT 

HUMAN PERIOD GENE EXPRESSION 

LEVELS. N. Miura. National Institute of 

Occupational Safety and Health (JNIOSH), 

Kawasaki, Japan. Sponsor: M. Satoh. 


VARIANT GLUTATHIONE S-TRANSFERASE 

PI 1 PROTEIN EXHIBITS DIFFERENTIAL 

ENZYMATIC ACTIVITY AND MERCURY 

INHIBITION. J. Goodrich and N. Basu. 


Michigan, Ann Arbor, MI. 


A GENE-ENVIRONMENT STUDY OF 

MERCURY IN THE MICHIGAN DENTAL 

ASSOCIATION COHORT. N. Basu 1 , J. 

Goodrich 1 , Y. Wang 1 , B. W. Gillespie 2 , R. A. 

Werner 1,3 and A. Franzblau 1 . 1 Environmental Health 

Sciences, University of Michigan, Ann Arbor, MI, 

2 

Biostatistics, University of Michigan, Ann Arbor, 

MI and 3 Physical Medicine and Rehabilitation, 

University of Michigan, Ann Arbor, MI. 


TOXICOGENOMIC RESPONSES TO 

INORGANIC AND METHYL MERCURY 

AND IDENTIFICATION OF MERCURIAL 

RESISTANCE GENES IN CAENORHABDITIS 

ELEGANS. M. K. McElwee 1,2 , J. W. Chou 1 and J. H. 

Freedman 1 . 1 NIEHS, Research Triangle Park, NC and 

2 

Duke University, Durham, NC. 

266 






Platform Sessions



Abstract # 


ESTIMATION OF MERCURY IN HAIR AS 

AN INDICATIVE TOOL TO ITS LEVELS 

IN BOVINE TISSUES. A. A. Sharkawy 1 , T. A. 

Ibrahim 1 , A. S. Seddek 2 , A. Shehata 1 and Y. A. Doha 1 . 

1 

Forensic Medicine and Toxicology, Faculty of 

Veterinary Medicine, Assiut University, Assiut, Egypt 

and 2 Forensic Medicine and Toxicology, Faculty of 

Veterinary Medicine, South Valley University, South 

Valley, Egypt. Sponsor: K. Abdel-Razak. 


METHYLMERCURY INDUCES ALVEOLAR 

TYPE II EPITHELIAL CELL DAMAGE 

THROUGH AN OXIDATIVE STRESS- 

RELATED MITOCHONDRIAL CELL 

DEATH PATHWAY. D. Hung 1 , T. Lu 2 , Y. 

Chen 3,4 , M. Lee 7 , C. Yen 8 , T. Ho 5,9 and C. Huang 5,6 . 

1 

Graduate Institute of Drug Safety, China Medical 

University, Taichung City, Taiwan, 2 School of 

Nutrition & Institute of Nutrition, Department of 

Physiology, China Medical University, Taichung, 

Taiwan, 3 Department of Physiology, China Medical 

University, Taichung, Taiwan, 4 Graduate Institute of 

Basic Medical Science, College of Medicine, China 

Medical University, Taichung, Taiwan, 5 School of 

Chinese Medicine, Taichung, Taiwan, 6 Graduate 

Institute of Chinese Medical Science, College 

of Chinese Medicine, China Medical University, 

Taichung, Taiwan, 7 Department of Surgery, Chia- 

Yi Hospital, Department of Health, Executive 

Yuan, Taiwan, Taichung, Taiwan, 8 Department of 

Occupational Safety and Health, College of Health 

Care and Management, Chung Shan Medical 

University, Taichung, Taiwan and 9 Chinese Medicine 

Department, China Medical University Beigang 

Hospital, Taichung, Taiwan. Sponsor: S. Lin-Shiau. 


IN UTERO EXPOSURE TO MERCURY(HG) 

& ITS ADVERSE EFFECTS ON BIRTH 

OUTCOMES. I. Al-Saleh 1 , N. Shinwari 1 and A. 

Rabbah 2 . 1 KFSH&RC, Riyadh, Saudi Arabia and 

2 

KKH, Kharj, Saudi Arabia. 


EFFECTS OF SOIL MERCURY 

CONCENTRATIONS ON MERCURY 

BIOACCUMULATION IN EARTHWORMS. 

A. C. Nichols and D. A. Steffy. Physical and Earth 

Sciences, Jacksonville State University, Jacksonville, 

AL. 


INVOLVEMENT OF RIP1, A COMPONENT 

OF ELECTRON TRANSPORT SYSTEM 

COMPLEX III, IN METHYLMERCURY 

TOXICITY IN BUDDING YEAST. J. Lee, 

G. Hwang and A. Naganuma. Graduate School of 

Pharmaceutical Sciences, Tohoku University, Sendai, 

Japan. 


LOW LEVEL OF MERCURY 

INDUCES PROCOAGULANT 

ACTIVITY IN ERYTHROCYTES 

THROUGH THROMBOGENIC 

MICROVESICLE GENERATION AND 

PHOSPHATIDYLSERINE EXPOSURE. K. 

Lim, S. Kim, J. Noh, K. Kim, W. Jang, O. Bae, S. 

Chung and J. Chung. College of Pharmacy, Seoul 

National University, Seoul, Republic of Korea. 

Abstract # 


METHYLMERCURY INDUCES ACUTE 

OXIDATIVE STRESS, ALTERATING 

NRF2 PROTEIN LEVEL IN PRIMARY 

MICROGLIA. M. Ni 1 , Z. Yin 2 , H. Jiang 2 , X. 

Li 3 , D. Milatovic 2 , J. Cai 4 and M. Aschner 2,1,3 . 

1 

Pharmacology, Vanderbilt University, Nashville, TN, 

2 

Pediatrics, Vanderbilt University, Nashville, TN, 

3 

Neuroscience, Vanderbilt University, Nashville, TN 

and 4 Vanderbilt Eye Institute, Vanderbilt University, 



LEAD AFFECTED UPTAKE OF 

GLUTAMATE IN GLIAL PLASMALEMMAL 

VESICLES AND PRE-SYNAPTIC NERVE 

TERMINALS. N. Naraindas and F. A. Schanne. 

Pharmaceutical Sciences, St. John’s University, 

Queens, NY. Sponsor: D. Gazarian. 


ACTIVATION OF PROTEIN KINASE C IN 

LEAD-INDUCED ACCUMULATION OF 

b-AMYLOID IN THE CHOROID PLEXUS: 

RELATIONSHIP TO SUBCELLULAR 

RELOCATION OF LOW DENSITY 

LIPOPROTEIN RECEPTOR PROTEIN-1 

(LRP1). M. Behl 1 , Y. Zhang 1 , Y. Shi 2 , J. Cheng 2 

and W. Zheng 1 . 1 School of Health Sciences, Purdue 

University, West Lafayette, IN and 2 School of 

Biomedical Engineering, Purdue University, West 



LONG TERM TREATMENT OF LEAD 

POISONING AFTER RETAINED BULLET 

WITH DIMERCAPTOSUCCINIC ACID. 

G. G. Garcia-Vargas 1 , J. Bernal 2 and M. Rubio- 

Andrade 1 . 1 Investigación, Universidad Juarez Estado 

de Durango, Gómez Palacio, Durango, Mexico 

and 2 Hematology, Medicos Especialistas, Torreon, 

Coahuila, Mexico. 


CHARACTERIZATION OF GENE 

EXPRESSION ALTERATIONS INDUCED 

BY DEVELOPMENTAL EXPOSURE OF 

ZEBRAFISH TO LEAD (PB). S. Peterson and 

J. L. Freeman. Health Sciences, Purdue University, 

West Lafayette, IN. 


CORRELATION BETWEEN LEAD LEVELS 

IN HAIR AND SOME BOVINE TISSUES. 

A. Shehata 1 , K. Abdo 2 , A. S. Seddek 3 , A. A. 

Sharkawy 1 and Y. A. Doha 1 . 1 Forensic Medicine and 

Toxicology, Faculty of Veterinary Medicine, Assiut 

University, Assiut, Egypt, 2 Forensic Medicine and 

Toxicology, Faculty of Veterinary Medicine, Beni- 

Sueif University, Beni-Sueif, Egypt and 3 Forensic 

Medicine and Toxicology, Faculty of Veterinary 

Medicine, South Valley University, South Valley, 

Egypt. Sponsor: A. Kadry. 


SYSTEMATIC SCREENING OF YEAST 

SUSCEPTIBILITY GENES TO CADMIUM, 

LEAD AND ZINC TOXICITY. W. J. Jo 1 , P. 

Wong 1 , A. Loguinov 1 , L. Zhang 2 , M. Smith 2 and C. 

Vulpe 1 . 1 Department of Nutritional Sciences and 

Toxicology, University of California Berkeley, 

Berkeley, CA and 2 School of Public Health, 

University of California Berkeley, Berkeley, CA. 

WedneSday 







267


WedneSday 




1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Exposure Assessment and Emerging 

Biomonitoring Applications 

Chairperson(s): Katherine Squibb, University of Maryland School 

of Medicine, Columbia, MD, and Janis Hulla, U.S. Army Corps of 

Engineers, Sacramento, CA. 




INVESTIGATION OF TECHNIQUES TO 

MAXIMIZE THE POTENTIAL OF DRIED 

BLOOD SPOT ANALYSIS (DBS) TO 

REDUCE SAMPLE VOLUMES IN MOUSE 

TOXICOKINETIC STUDIES. T. C. Dainty, I. 

Davies, F. Kosar, M. P. Blackwell, R. E. Hill and L. 

M. Burns. Sequani Ltd., Ledbury, United Kingdom. 


USUAL DIETARY ACRYLAMIDE 

EXPOSURE AND HEMOGLOBIN ADDUCTS 

OF ACRYLAMIDE AND GLYCIDAMIDE— 

NHANES 2003-04. N. L. Tran, L. Barraj, M. 

Murphy and B. Xiaoyu. Center for Chemical 

Regulation and Food Safety, Exponent, Washington, 

DC. 


SECOND ORDER RATE CONSTANTS 

FOR THE IN VITRO REACTION OF 

THE TOXIC INDUSTRIAL CHEMICAL 

ACRYLONITRILE WITH THE MOST 

REACTIVE SITES IN HUMAN BLOOD. F. W. 

Benz, J. Cai, D. E. Nerland, H. E. Hurst and W. M. 

Pierce. Pharmacology & Toxicology, University of 

Louisville Medical School, Louisville, KY. 


DEVELOPMENT OF A METHOD FOR THE 

DETERMINATION OF BISPHENOL A AT 

TRACE LEVELS IN HUMAN BLOOD AND 

URINE AND ELUCIDATION OF FACTORS 

INFLUENCING METHOD ACCURACY 

AND SENSITIVITY. J. M. Waechter 1 , D. A. 

Markham 1 , P. Connolly 2 , J. C. Chuang 3 , N. Rao 4 and 

M. Wimber 5 . 1 Toxicology & Environmental Research 

and Consulting, The Dow Chemical Company, 

Midland, MI, 2 MPI Research, State College, 

PA, 3 Battelle Memorial Institute, Columbus, OH, 

4 

General Electric Company on behalf of SABIC 

Innovative Plastics, Bangalore, India and 5 Bayer 

Material Science, AG, Leverkusen, Germany. 


ASSESSMENT OF ENVIRONMENTAL DATA 

COLLECTED IN A COMMUNITY WITH 

NUMEROUS PETROLEUM REFINING 

AND PETROCHEMICAL FACILITIES. A. 

Tachovsky, D. Staskal, J. Urban, M. A. Harris and L. 

Haws. ToxStrategies, Austin, TX. 


JOB-BASED ANALYSIS OF BENZENE AIR 

CONCENTRATIONS ASSOCIATED WITH 

REFINERY OPERATIONS. A. M. Burns 1 , J. M. 

Panko 1 , M. L. Kreider 1 , K. M. Unice 1 , S. H. Gaffney 2 , 

D. J. Paustenbach 2 , L. E. Booher 3 and R. H. Gelatt 4 . 

1 

ChemRisk, LLC, Pittsburgh, PA, 2 ChemRisk, LLC, 

SanFrancisco, CA, 3 Exxon Mobil Corporation, 

Houston, TX and 4 ExxonMobil Biomedical Sciences 

Inc., Clinton, NJ. 


USING THE BIOMONITORING 

EQUIVALENT FOR BENZENE TO HELP 

INTERPRET BIOMONITORING DATA. 

S. Hays 1 , D. Pyatt 1,2 and L. Aylward 1 . 1 Summit 

Toxicology, Superior, CO and 2 School of Public 

Health, University of Colorado, Denver, CO. 


CLINICAL METHOD TO ASSESS SITE 

OF USE EXPOSURE TO SMOKELESS 

TOBACCO CONSTITUENTS. J. Flora 1 , J. S. 

Edmiston 1 , D. Farthing 1 , J. Liu 1 , A. R. Joyce 2 , G. 

Patskan 1 and M. Fariss 1 . 1 Altria Client Services, 

Richmond, VA and 2 RemX Specialty Staffing c/o 

Altria Client Services, Richmond, VA. 


BAYESIAN FEATURE SELECTION 

IDENTIFIES HUMAN PLASMA PROTEOMIC 

BIOSIGNATURES OF SYSTEMIC CHRONIC 

INFLAMMATORY AND OXIDATIVE 

STRESS. B. Webb-Robertson 1 , K. Waters 1 , J. 

Jacobs 1 , X. Zhang 1 , S. Varnum 1 , D. Bigelow 1 , J. R. 

Hoidal 2 , M. Scholand 2 and J. G. Pounds 1 . 1 Pacific 

Northwest National Laboratory, Richland, WA and 

2 

University of Utah Medical School, Salt Lake City, 

UT. 


ACTIVATED CHARCOAL FILTERS 

PROVIDE LITTLE PROTECTION FROM ETS 

GENERATED CO AND TSP EXPOSURE AND 

LUNG INFLAMMATION. T. Muthumalage 2 , K. 

W. Hunter 3 , D. Redelman 4 , K. L. Pritsos 1 and C. A. 

Pritsos 1,2 . 1 Nutrition, University of Nevada, Reno, 

NV, 2 Environmental Science Program, University of 

Nevada, Reno, NV, 3 Microbiology and Immunology, 

University of Nevada, Reno, NV and 4 Physiology and 

Cell Biology, University of Nevada, Reno, NV. 


AIR POLLUTION EXPOSURE MODEL FOR 

INDIVIDUALS (EMI) IN HEALTH STUDIES: 

EVALUATION OF INDOOR AIR QUALITY 

MODEL FOR PARTICULATE MATTER. M. 

Breen 1 , M. Breen 2,3 , T. Long 4 , R. Williams 1 and B. 

Schultz 1 . 1 National Exposure Research Laboratory, 

U.S. EPA, Research Triangle Park, NC, 2 National 

Center for Computational Toxicology, U.S. EPA, 

Research Triangle Park, NC, 3 Biomathematics 

Program, Department of Statistics, North Carolina 

State University, Raleigh, NC and 4 National Center 

for Environmental Assessment, U.S. EPA, Research 


268 






Platform Sessions



Abstract # 


ALTERATION OF PERIPHERAL BLOOD 

MONOCYTE GENE EXPRESSION IN 

HUMANS FOLLOWING DIESEL EXHAUST 

INHALATION. A. P. Pettit 1,2,3 , A. Brooks 3 , R. 

Laumbach 2,3 , N. Fiedler 2,3 , J. Zhang 2 and H. Kipen 2,3 . 

1 

Rutgers University, Piscataway, NJ, 2 UMDNJ- 

RWJMS, Piscataway, NJ and 3 EOHSI, Piscataway, 

NJ. 


TOXICITY EFFECT OF DIESEL EXHAUST 

PARTICLES ON BIOMECHANICS AND 

CELL SURFACE BIOPOLYMERS OF 

HUMAN LUNG CARCINOMA EPITHELIAL 

CELLS A549: PRELIMINARY STUDY BY 

ATOMIC FORCE MICROSCOPY/RAMAN 

MICROSPECTROSCOPY. A. Zhou 1 , G. D. 

McEwen 1 , Y. Wu 1 , T. Yu 2 , T. A. Gilbertson 2 and 

R. A. Coulombe 3 . 1 Biological Engineering, Utah 

State University, Logan, UT, 2 Biology, Utah State 

University, Utah and 3 Animal, Dairy, and Veterinary 

Sciences, Utah State University, Utah. 


TOXICITY OF LUNAR DUST IN LUNGS 

ASSESSED BY EXAMINING BIOMARKERS 

IN EXPOSED MICE. C. Lam 1,2 , J. T. James 1 , P. 

C. Zeidler-Erdely 3 , V. Castranova 3 , S. H. Young 3 , 

C. Quan 1,4 , N. Khan-Mayberry 1 and L. A. Taylor 5 . 

1 

NASA Johnson Space Center Toxicology Lab., 

Houston, TX, 2 Wyle, Houston, TX, 3 HELD, 


Health, Morgantown, WV, 4 USRA, Houston, TX 

and 5 Planetary Geosciences Institute, University of 

Tennessee, Knoxville, TN. 


DNA DAMAGE DETECTED BY 

MICRONUCLEI AND COMET ASSAYS 

IN LYMPHOCYTES ISOLATED FROM 

WORKERS EXPOSED TO COKE OVEN 

EMISSIONS. J. Sun 1 , P. Nan 1 , L. Guo 1 and H. 

Liang 2 . 1 General Hospital, Taiyuan Iron and Steel 

Company, Taiyuan, Shanxi, China and 2 Center for 

Disease Control and Prevention, Taiyuan Iron and 

Steel Company, Taiyuan, Shanxi, China. Sponsor: 

L. Chen. 


ARE SINGLE NUCLEOTIDE 

POLYMORPHISMS (SNPS) ASSOCIATED 

WITH SYSTEMIC DOSE CRITICAL IN 

EXPOSURE ASSESSMENT? R. Jiang 1 , V. P. 

Stober 1 , J. E. French 2 and L. A. Nylander French 1 . 

1 



Hill, Chapel Hill, NC and 2 Host Susceptibility 

Branch, National Toxicology Program, National 




PROGRESS TOWARD ESTABLISHING 

QUANTITATION OF ONCOGENIC POINT 

MUTATIONS AS AN ENDPOINT FOR 

ASSESSING CARCINOGENIC POTENTIAL. 

F. Meng, Y. Wang, M. Myers, P. McKinzie and B. 

Parsons. Division of Genetic and Reproductive 


Research/U.S. FDA, Jefferson, AR. 

Abstract # 


INTEGRATING HUMAN SOMATIC 

MUTATION BIOMARKERS INTO CANCER 

RISK ASSESSMENT. M. B. Myers, F. Meng, Y. 

Wang, P. B. McKinzie and B. L. Parsons. Division 

of Genetic and Reproductive Toxicology, National 

Center for Toxicological Research, U.S. FDA, 



BIOMARKER ANALYSIS OF 1, 

6-HEXAMETHYLENE DIISOCYANATE 

EXPOSURE. L. G. Gaines 1 , K. W. Fent 1 , S. 

L. Flack 1 , J. M. Thomasen 1 , L. M. Ball 1 , S. G. 

Whittaker 2 and L. A. Nylander French 1 . 1 Department 

of Environmental Sciences and Engineering, 


Hill, NC and 2 Local Hazardous Waste Management 

Program, Public Health - Seattle & King County, 

Seattle, WA. 


PHARMACOKINETICS OF 3, 5, 

6-TRICHLORO-2-PYRIDINOL (TCPY), A 

CHLORPYRIFOS METABOLITE, IN RAT 

SALIVA. J. N. Smith, J. Wang, Y. Lin and C. 

Timchalk. Biological Monitoring & Modeling, 

Battelle Memorial Institute, Pacific Northwest 

Division, Richland, WA. 


ELABORATION OF MICROPLATE 

SPECTROSCOPIC METHODS FOR 

BIOMONITORING OF WARFARE 

ORGANOPHOSPHATES SOMAN AND 

RUSSIAN VX. N. Goncharov, D. Prokofieva, N. 

Voitenko, L. Gustyleva, E. Savelieva, A. Radilov, 

V. Babakov, E. Ermolaeva, N. Khlebnikova, Y. 

Pechenevsky and V. Rembovsky. RIHOPHE, Saint 

Petersburg, Russian Federation. Sponsor: R. Gupta. 


PESTICIDE DISTRIBUTION AFTER 

RELEASE OF CYPERMETHRIN AND 

CHLORPYRIFOS INDOOR FOGGERS. R. 

I. Krieger 2 and J. J. Keenan 1,2 . 1 ChemRisk, San 

Francisco, CA and 2 Personal Chemical Exposure 

Program, University of California, Riverside, CA. 


MEASUREMENT OF AIR CONCENTRATION 

AND DEPOSITION ON COTTON 

DOSIMETERS OF METOFLUTHRIN 

GENERATED BY A PERSONAL OUTDOOR 

INSECT REPELLENT DEVICE IN AN 

OUTDOOR ENVIRONMENT. S. Selim 1 and J. 

J. Olson 2 . 1 Golden Pacific Laboratories LLC, Fresno, 

CA and 2 Product Safety, SC Johnson & Son, Racine, 

WI. 


LONG-TERM USUAL FISH INTAKE, 

NHANES 1999–2006. B. Leila 1 , N. L. Tran 1,2 and 

X. Bi 1 . 1 Center for Chemical Regulation and Food 

Safety, Exponent, Washington, DC and 2 Health 

Policy & Management, Johns Hopkins University, 

Bloomberg School of Public Health, Baltimore, MD. 

WedneSday 







269


WedneSday 




IDENTIFICATION AND QUANTIFICATION 

OF THE PROHAPTEN, DEHYDROABIETIC 

ACID IN NON-LATEX SURGICAL AND 

EXAM GLOVES. P. D. Siegel 1 , B. F. Law 1 , J. F. 

Fowler 2 , L. M. Fowler 2 and D. Beezhold 1 . 1 HELD, 

CDC/NIOSH, Morgantown, WV and 2 University of 



EVALUATION OF THE IMPACT OF 

SOIL EXPOSURES TO DIOXIN-LIKE 

COMPOUNDS ON BODY BURDEN IN A 

POPULATION IN MIDLAND MICHIGAN. 

L. Haws 1 , A. Tachovsky 1 , D. Staskal 1 , T. Simon 2 , K. 

Burkhalter 1 and M. A. Harris 1 . 1 ToxStrategies, Austin, 

TX and 2 Ted Simon LLC, Winston, GA. 


ASSESSMENT OF THE IMPACT OF 

VARIOUS SOIL CLEANUP LEVELS ON 

SERUM CONCENTRATIONS OF DIOXIN- 

LIKE COMPOUNDS IN HUMANS. M. A. 

Harris 1 , A. Tachovsky 1 , D. Staskal 1 , T. Simon 2 , K. 

Burkhalter 1 , J. Urban 1 and L. Haws 1 . 1 ToxStrategies, 

Inc., Austin, TX and 2 Ted Simon LLC, Winston, GA. 


RE-INTERPRETING HISTORICAL 

EXPOSURE DATA ASSOCIATED WITH 

THE USE OF CHRYSOTILE-CONTAINING 

JOINT COMPOUND. G. Brorby 1 , P. Sheehan 1 , 

W. Berman 2 and S. Holm 3 . 1 Exponent, Oakland, CA, 

2 

Aeolus, Inc., Albany, CA and 3 Georgia-Pacific, LLC, 

Atlanta, GA. 


COMPARISON OF PAIRED EXPOSURE 

MEASUREMENTS OF LIBBY AMPHIBOLE 

ASBESTOS IN AIR MEASURED BY DIRECT 

AND INDIRECT PREPARATION ANALYSES. 

M. Goldade and W. O’Brien. U.S. EPA, Region 8, 

Denver, CO. Sponsor: M. Hornung. 


PREVALENCE RATES OF PLEURAL 

ABNORMALITIES AMONG POPULATIONS 

WITH ENVIRONMENTAL ASBESTOS AND 

NON-ASBESTOS EXPOSURES. J. Gujral 1 , S. 

Su 2 and V. Craven 3 . 1 Toxicology and Mechanistic 

Biology, Health Sciences, Exponent, Irvine, CA, 

2 

Health Sciences, Exponent, New York and 3 Health 

Sciences, Exponent, Oakland, CA. 


AN EVALUATION OF HEALTH RISKS 

ASSOCIATED WITH EXPOSURE TO 

ERIONITE FIBERS IN NORTH DAKOTA. 

S. Griffin 1 , J. Lockey 2 , P. Ryan 3 and C. Partridge 1 . 

1 

U.S. EPA Region 8, Denver, Co., 2 Department of 

Environmental Health, University of Cincinnati, 

Cincinnati, OH and 3 College of Medicine, University 

of Cincinnati, Cincinnati, OH. 


CHARACTERIZATION OF MODEL 

UNCERTAINTY IN ASBESTOS CANCER 

RISK CALCULATIONS. S. Foster 1 , W. Brattin 2 

and A. Bacom 2 . 1 U.S. EPA, Washington, DC and 

2 

SRC, Inc., Denver, CO. 


URINARY BIOMARKER PANEL 

SELECTION INDICATIVE OF EARLY 

SUBCLINICAL RENAL INJURY TO TOXIN 

EXPOSURES. J. Frey 1 , V. Chan 1 , D. Kaziska 2 

and C. Mauzy 1 . 1 Applied Biotechnology Branch- 

Human Effectiveness Directorate, Air Force Research 

Laboratory, Wright-Patterson AFB, OH and 2 ENC, 

Air Force Institute of Technology, Wright-Patterson 

AFB, OH. Sponsor: J. Schlager. 


TRANSPLACENTAL DISTRIBUTION OF 

METALS AND THEIR INTERACTIONS 

ASSESSED BY BIOMONITORING IN 

MOTHER/CHILD PAIRS. H. Käfferlein 1 , 

R. Kopp 1,2 , E. Gutwinski 1 , M. Kumbartski 2 and 

T. Brüning 1 . 1 BGFA - Ruhr University, Bochum, 

Germany and 2 University of Duisburg-Essen, Essen, 

Germany. 


SURVEILLANCE FOR SYSTEMIC EFFECTS 

OF METALS AND OTHER MATERIALS 

RELEASED FROM RETAINED EMBEDDED 

FRAGMENTS IN U.S. SOLDIERS. K. S. 

Squibb 1 , J. Gaitens 1 , C. Dorsey 1 , J. Centeno 2 and 

M. McDiarmid 1 . 1 University of Maryland School 

of Medicine, Baltimore, MD and 2 Division of 

Biophysical Toxicology, Armed Forces Institute of 

Pathology, Washington, DC. 


DOD IMPACT ASSESSMENT AND 

MANAGEMENT OF NAPHTHALENE- 

RELATED RISKS. J. Hulla 1 , J. E. Snawder 2 , 

S. P. Proctor 3 and G. D. Chapman 4 . 1 SPK-ED-EC, 

U.S. Army Corps of Engineers, Sacramento, CA, 

CA, 2 Biomonitoring Team, National Institute for 

Occupational Safety and Health, Cincinnati, OH, 

3 

Military Performance Division, U.S. Army Research 

Institute of Environmental Medicine, Natick, ME and 

4 

Military Infectious Disease Research Program, U.S. 

Army Medical Research and Materiel Command, 



EFFECTS OF STYRENE CO-EXPOSURE ON 

FORMATION OF 1, 3-BUTADIENE DERIVED 

N7-GUANINE ADDUCTS. M. T. Thompson 1 , S. 

Goel 1 , L. M. Hallberg 2 , J. B. Ward 2 , J. A. Swenberg 3 

and G. Boysen 1 . 1 Environmental and Occupational 

Health, University of Arkansas for Medical 

Sciences, Little Rock, AR, 2 Preventive Medicine 

and Community Health, University of Texas Medical 

Branch, Galveston, TX and 3 Environmental Sciences 

& Engineering, University of North Carolina at 

Chapel Hill, Chapel Hill, NC. 


POLYCHLORINATED BIPHENYL, LEAD, 

AND MERCURY EXPOSURES ARE 

ASSOCIATED WITH ALT ELEVATION 

IN AMERICAN ADULTS: NHANES 2003- 

2004. M. Cave 1,2 , S. Appana 1 , M. Patel 1 , K. 

Falkner 1 , C. McClain 1,2 and G. Brock 1 . 1 Medicine/ 




270 






Platform Sessions



Abstract # 


FEASIBILITY AND METHODOLOGY OF 

THE DEVELOPMENT OF A PORTABLE IN 

VIVO X-RAY FLUORESCENCE (XRF) BONE 

LEAD (PB) MEASUREMENT SYSTEM. H. 

L. Nie 1 , L. Grodzins 2 , R. O. Cleveland 3 and M. G. 

Weisskopf 4 . 1 School of Health Sciences, Purdue 

University, West Lafayette, IN, 2 Thermo Fisher 

Scientific Inc., Billerica, MA, 3 Department of 

Mechanical Engineering, Boston University, Boston, 

MA and 4 Harvard School of Public Health, Boston, 

MA. Sponsor: W. Zheng. 


NOVEL SERUM BIOMARKERS FOR RISK 

OF BREAST CANCER: RESULTS FROM 

A USA CASE-CONTROL STUDY. L. Yang 1 , 

E. Cavalieri 2 , E. Rogan 1,2 , J. Ingle 3 and S. Pruthi 3 . 

1 

Department of Environmental, Agricultural, and 

Occupational Health, University of Nebraska 

Medical Center, Omaha, NE, 2 Eppley Institute for 

Research in Cancer and Allied Diseases, University 

of Nebraska Medical Center, Omaha, NE and 

3 

Department of Medical Oncology, Mayo Clinic, 

Rochester, MN. 


META-ANALYSIS OF NITROGEN 

DIOXIDE EFFECTS ON AIRWAY HYPER- 

RESPONSIVENESS IN ASTHMATICS: 

EFFECTS OF THE TYPES OF AIRWAY 

CHALLENGE, EXPOSURE METHODS, AND 

ACTIVITIES DURING EXPOSURE. S. Thakali, 

J. K. Chandalia, M. Seeley and J. E. Goodman. 

Gradient, Cambridge, MA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Pesticides: General 

Chairperson(s): Tammy Stoker, U.S. EPA, Research Triangle Park, NC. 




COMPARATIVE PHARMACOKINETICS 

OF CHLORPYRIFOS VERSUS ITS MAJOR 

METABOLITES FOLLOWING ORAL 

ADMINISTRATION IN THE RAT. C. Timchalk 1 , 

J. A. Campbell 1 , A. L. Busby 1 , J. N. Smith 1 , S. Lee 1 , T. 

S. Poet 1 and D. B. Barr 2 . 1 Biological Monitoring and 

Modeling, Pacific Northwest National Laboratory, 

Richland, WA and 2 Centers for Disease Control 

and Prevention, National Center for Environmental 

Health, Atlanta, GA. 


UP-REGULATION OF AROMATASE BY 

O, P’-DDT IS MEDIATED THROUGH 

CYCLOOXYGENASE-2 EXPRESSION IN 

HUMAN BREAST CANCER CELLS. E. 

Ha 1,2 , J. Park 1,2 , J. Im 1,2 and H. Jeong 1 . 1 Pharmacy, 




Abstract # 


UP-REGULATION OF 

CYCLOOXYGENASE-2 EXPRESSION BY 

ENDOSULFAN IN MACROPHAGES. J. Park 1,2 , 

E. Han 1,2 and H. Jeong 1 . 1 Pharmacy, Chungnam 


2 




INVESTIGATION OF 

ETHYLENEBISDITHIOCARBAMATE 

PESTICIDE TOXICITY IN HT-29 AND CACO- 

2 HUMAN COLON CELLS. L. Hoffman and 

D. Hardej. Pharmaceutical Sciences, St. John’s 

University, Jamaica, NY. 


MULTI-RESIDUE DETERMINATION OF 

PESTICIDES IN THE MILK OF CATTLE 

AND GOAT IN FAISALABAD-PAKISTAN. F. 

Muhammad 1 , Z. U. Rahman 1 , I. Javed 1 , M. Akhtar 2 , 

T. Khaliq 1 and M. I. Anwar 3 . 1 Physiology and 

Pharmacology, University of Agriculture Faisalabad, 

Faisalabad, Pakistan, 2 Department of Parasitology, 

University of Agriculture Faisalabad, Faisalabad, 

Pakistan and 3 Department of Livestock and Dairy 

Development, Government of Punjab, Lahore, 

Pakistan. Sponsor: J. Riviere. 


EFFECT OF LAMBDA-CYHALOTHRIN ON 

SOME DRUG-METABOLIZING ENZYMES. 

A. Anadon, M. A. Martínez, M. Martínez, E. Ramos, 

I. Ares, M. R. Martínez-Larrañaga and V. Castellano. 

Department of Toxicology and Pharmacology, 

Faculty of Veterinary Medicine, Universidad 

Complutense, Madrid, Spain. 


ORGANOPHOSPHATE IMMUNOTOXICITY 

LINKED TO OXIDATIVE STRESS. M. 

D. Saulsbury, S. O. Heyliger and D. J. Johnson. 

Pharmaceutical Sciences, Hampton University, 

Hampton, VA. 


EXPOSURE ESTIMATES AND PBPK 

MODELING OF CHLORPYRIFOS IN RATS 

AND HUMANS. C. A. Ellison 1 , P. J. Lein 2,3 , J. B. 

Knaak 1 , R. A. Fenske 4 , F. M. Farahat 5 , M. R. Bonner 1 , 

K. Anger 2 and J. R. Olson 1 . 1 University at Buffalo, 

Buffalo, NY, 2 Oregon Health & Science University, 

Portland, OR, 3 University of California Davis School 

of Veterinary Medicine, Davis, CA, 4 University of 

Washington, Seattle, WA and 5 Menoufia University, 

Shibin el-Kom, Egypt. 


EVALUATION OF URINARY PESTICIDE 

BIOMARKERS AMONG RESIDENTS OF 

THE UNITED STATES. A. LeBeau, G. Johnson, 

J. McCluskey and R. D. Harbison. Environmental and 

Occupational Health, University of South Florida- 

COPH, Tampa, FL. 


THE ALTERED EXPRESSION OF PROTEINS 

IN MICE LIVER AND CHICKEN EMBRYOS 

CAUSED BY AN ORGANOPHOSPHORUS 

INSECTICIDE DIAZINON. J. Seifert. PEPS, 

University of Hawaii, Honolulu, HI. 

WedneSday 







271


WedneSday 




HYDROLYSIS OF PARAOXON, 

DIAZOXON, CHLORPYRIFOS-OXON, 

AND DIHYDROCOUMARIN BY HUMAN 

SERUM PARAOXONASE 1 (PON1) AND 

RELATIONSHIP TO ATHEROSCLEROSIS 

AND DIABETES. H. Coombes, A. Crow, H. 

Chambers, R. Wills, E. Meek and J. Chambers. 

Center for Environmental Health Sciences, College 

of Veterinary Medicine, Mississippi State University, 

Mississippi State, MS. 


MECHANISM OF PARAQUAT-INDUCED 

PULMONY TOXICITY IN TIME COURSE 

AND INTERVENTION OF PYRROLIDINE 

DITHIOCARBAMATE. Z. Zhou. School of 

Public Health, Fudan University, Shanghai, China. 


LINKING DDT EXPOSURE TO DIABETES. 

B. Arroyo-Salgado 1,2,3 , A. Guerrero-Castilla 1,2,3 , E. 

Benedetti-Padron 3 and J. Olivero-Verbel 1,2 . 1 Faculty 

of Pharmaceutical Sciences. Environmental and 

Computational Chemistry Group, University of 

Cartagena, Cartagena, Colombia, 2 Ph.D. Program 

on Biomedical Sciences, University of Cartagena, 

Cartagena, Colombia and 3 Faculty of Medicine, 

University of Cartagena, Cartagena, Colombia. 


CONSTRUCTION OF A PBPK/PD MODEL 

WITH THE EXPOSURE-RELATED DOSE 

ESTIMATING MODEL (ERDEM) FOR 

THE PESTICIDE METHAMIDOPHOS IN 

THE RAT AND HUMAN. X. Zhang 1 , C. Tan 2 , 

R. Tornero-Velez 2 , R. Goldsmith 2 , D. Chang 2 , J. B. 

Knaak 3 and C. C. Dary 4 . 1 GDIT, Henderson, NV, 

2 

National Exposure Research Laboratory, U.S. 

EPA, Research Triangle Park, NC, 3 Department of 

Pharmacology and Toxicology, the State University 

of New York at Buffalo, Buffalo, NY and 4 National 

Exposure Research Laboratory, U.S. EPA, Las Vegas, 

NV. 


DEVELOPING METHODS USING TOXCAST 

DATA FOR THE CLASSIFICATION AND 

PRIORITIZATION OF ANTIMICROBIALS 

AND INERTS. M. T. Martin 1 , T. McMahon 2 , 

T. Leighton 2 , P. Shah 2 , D. M. Reif 1 , K. Houck 1 , R. 

Judson 1 , R. Kavlock 1 and D. J. Dix 1 . 1 ORD/NCCT, 

U.S. EPA, Research Triangle Park, NC and 2 OPP, 



ORGANOPHOSPHATE PESTICIDE 

POISONING, EXPOSURE SURVEILLANCE 

SYSTEMS, AND REGULATORY ACTIONS. 

A. M. Fan 1 and T. Satoh 2 . 1 Office of Environ Health 

Hazard Assessment, California Environ Protection 

Agency, Oakland, CA and 2 Chiba University, HAB 

Research Institute, Chiba, Japan. 


EFFECT OF OXYFLUORFEN ON MEDAKA 

(ORYZIAS LATIPES) DEVELOPMENT. D. 

K. Powe 1 , I. A. Khan 2 , A. K. Dasmahapatra 2,3,1 and 

P. B. Tchounwou 1 . 1 Department of Environmental 

Toxicology, Jackson State University, Jackson, MS, 

2 

National Center for Natural Product Research, 

University of Mississippi, University, MS and 

3 

Department of Pharmacology, University of 



TOXICOLOGICAL ASSESSMENT OF 

INITIUM ® S. Stinchcombe 1 , I. Fegert 1 , W. 

Kaufmann 2 , R. Landsiedel 2 , W. Mellert 2 and B. 

van Ravenzwaay 2 . 1 Product Stewardship, BASF 

SE, Ludwigshafen, Germany and 2 Experimental 

Toxicology and Ecology, BASF SE, Ludwigshafen, 

Germany. 


EFFECTS OF PESTICIDES ON AROMATASE 

EXPRESSION IN BIOLUMINESCENT 

MICE AND GSK-3BETA/BETA-CATENIN 

SIGNALLING IN LNCAP HUMAN 

PROSTATE CANCER CELLS. P. Rivest and J. 

Sanderson. Institut Armand-Frappier, INRS, Laval, 

QC, Canada. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Risk Assessment II: Methodological 

Challenges and Metals 

Chairperson(s): Lynne Haber, Toxicology Excellence for Risk Assessment 

(TERA), Cincinnati, OH, and Deborah Proctor, ToxStrategies, Inc., 

Rancho Santa Margarita, CA. 




A METHOD FOR CALCULATING 

CUMULATIVE IMPACTS. G. V. Alexeeff, J. 

Faust, L. Meehan and L. Zeise. OEHHA, Cal/EPA, 

Oakland, CA. 


THE NRC REPORT ON PHTHALATES AND 

CUMULATIVE RISK ASSESSMENT: FOCUS 

ON CUMULATIVE RISK AND COMMON 

ADVERSE OUTCOMES. D. A. Cory-Slechta. 

Department of Environmental Medicine, University 

of Rochester Medical Center, Rochester, NY. 

Sponsor: D. Cory-Slechta. 


PROPOSED MODE-OF-ACTION 

FOR PHTHALATE-INDUCED 

MALE REPRODUCTIVE EFFECTS: 

CONTRIBUTIONS OF DIET-INDUCED 

OBESITY AND PHTHALATE EXPOSURE. 

X. Arzuaga 1 , J. Hess-Wilson 2 and J. Strong 1 . 

1 

National Center for Environmental Assessment, 

U.S. EPA, Washington, DC and 2 National Center for 

Environmental Assessment, U.S. EPA, Cincinnati, 

OH. 

272 






Platform Sessions



Abstract # 


CRITICAL EVALUATION OF THE DATA 

UNDERLYING THE USA TODAY RANKINGS 

OF AIR QUALITY AT SCHOOLS. D. 

Proctor 1 , L. Haws 2 , A. Tachovsky 2 and M. Harris 2 . 

1 

ToxStrategies, Inc., Rancho Santa Margarita, CA 

and 2 ToxStrategies, Inc., Austin, TX. 


AGE GROUPINGS FOR APPLICATION OF 

AGE-SENSITIVITY FACTORS IN ASSESSING 

RISK FROM CARCINOGEN EXPOSURE 

EARLY IN LIFE. M. A. Marty, A. G. Salmon, J. 

Budroe, M. Miller and M. Sandy. OEHHA, Cal/EPA, 

Oakland, CA. 


CONSIDERATION OF CHILDREN’S 

RISK: METHODS AND ADEQUACY OF 

UNCERTAINTY FACTORS. L. T. Haber 1 , 

L. M. Sweeney 1 , B. Gadagbui 1 , J. Strawson 1 , I. 

Abraham 1 , A. M. Maier 1 , M. L. Dourson 1 and R. 

Grant 2 . 1 Toxicology Excellence for Risk Assessment 

(TERA), Cincinnati, OH and 2 Texas Commission on 

Environmental Quality, Austin, TX. 


USE OF LIFE-STAGE ADJUSTMENT 

IN ORAL RISK ASSESSMENT FOR 

O-TOLUIDINE. C. English, V. S. Bhat, G. L. Ball 

and C. J. McLellan. NSF International, Ann Arbor, 

MI. 


DATA-DERIVED EXTRAPOLATION 

FACTORS FOR INTER- AND INTRASPECIES 

EXTRAPOLATION. J. C. Lipscomb 1 , A. B. 

Lowit 2 , M. Broder 3 , B. Foos 4 , A. Galizia 5 , E. 

Kenyon 6 , V. C. Moser 6 and R. Schoeny 7 . 1 Office of 

Research and Development, U.S. EPA, Cincinnati, 

OH, 2 Office of Pesticide Programs, U.S. EPA, 

Washington, DC, 3 Office of the Science Advisor, 

U.S. EPA, Washington, DC, 4 Office of Childrens’ 

Health Protection, U.S. EPA, Washington, DC, 

5 


Edison, NJ, 6 Office of Research and Development, 

U.S. EPA, Research Triangle Park, NC and 7 Office of 

Water, U.S. EPA, Washington, DC. 


EVALUATION OF THE MAGNITUDE OF 

TOXICOKINETIC INTER-INDIVIDUAL 

VARIABILITY FACTOR (IVF-TK): IMPACT 

OF SUBPOPULATIONS AND CHEMICAL 

CHARACTERISTICS. M. Valcke and K. 

Krishnan. Santé Environnementale et Santé au 

Travail, Université de Montréal, Montréal, QC, 

Canada. 


RISK ASSESSMENT STRATEGIES FOR 

PROTECTING CHILDREN’S HEALTH. A. G. 

Salmon, M. A. Marty, B. Winder, K. Riveles and J. P. 

Brown. OEHHA, CalEPA, Oakland, CA. 


A COMPARISON OF THREE DIFFERENT 

METHODS FOR ESTIMATING CHILDRENS’ 

SOIL AND DUST INGESTION. T. Simon. Ted 

Simon LLC, Winston, GA. 

Abstract # 


DEVELOPMENT OF PREDICTIVE 

TOXICITY MEASURES FOR ASSESSING 

RISKS FROM CATASTROPHIC CHEMICAL 

RELEASES. I. J. Boyer 1 , R. S. Kutzman 1 , A. 

L. Williams 2 , J. M. DeSesso 2 , J. L. Buthod 1 , J. A. 

Cox 3 , M. T. Whitmire 1 and L. E. Roszell 3 . 1 Noblis, 

Falls Church, VA, 2 Noblis, Currently Exponent, 

Alexandria, VA and 3 Department of Homeland 

Security, Edgewood, MD. 


A METHOD FOR SELECTING TOXICITY 

REFERENCE VALUES FROM MULTIPLE 

SOURCES FOR HUMAN HEALTH RISK 

ASSESSMENTS. K. Bresee and K. Phillipps. 

Intrinsik Environmental Science, Calgary, AB, 

Canada. Sponsor: E. Sigal. 


DEVELOPMENT AND APPLICATION OF 

A RISK ASSESSMENT PARADIGM TO 

ACETALDEHYDE: A TOBACCO SMOKE 

CONSTITUENT. F. H. Cunningham, C. Meredith 

and E. D. Massey. Group Research & Development, 

British American Tobacco, Southampton, United 

Kingdom. 


ANALYSIS AND COMPARISON OF 

BLADDER TUMOR INDUCTION BY 

BIPHENYL, SACCHARIN AND MELAMINE. 

Z. Li 1 , S. Rieth 1 , P. McClure 2 and D. Wohlers 2 . 1 U.S. 

EPA, Washington, D.C. and 2 SRC, Inc., Syracuse, 

NY. 


A CRITICAL REVIEW OF THE 

EFFECTIVENESS OF PHARMACEUTICAL 

CARCINOGENESIS TESTING. C. L. Alden 1 , A. 

Lynn 1 , A. Bissonnette 1 , V. J. Kadambi 1 , A. Bourdeau 1 , 

F. Sistare 2 and D. Morton 3 . 1 Drug Safety Evaluation, 

Millennium: The Takeda Oncology Company, 

Cambridge, MA, 2 Pfizer, Groton, CT and 3 Merck, 



ESTIMATING THE FREQUENCY OF 

HORMESIS IN THE AMES ASSAY. E. J. 

Calabrese 1 and M. A. Nascarella 2 . 1 Environmental 

Health Sciences Division, University of 

Massachusetts, Amherst, MA and 2 Gradient, 



TOXICOGENOMICS IN RISK ASSESSMENT: 

APPLICATIONS AND CHALLENGES. C. 

Keshava. U.S. EPA, Research Triangle Park, NC. 


EVALUATING THE ROLE OF a 2u 

-GLOBULIN 

ACCUMULATION IN THE RENAL 

CARCINOGENICITY AND TOXICITY OF 

HEXACHLOROETHANE (HCE). A. Rooney 1 , 

J. Cowden 1 , J. Stanek 1 and S. Jones 2 . 1 National 

Center for Environmental Assessment, U.S. EPA, 

Durham, NC and 2 National Center for Environmental 

Assessment, U.S. EPA, Washington, DC. Sponsor: 

A. Persad. 

WedneSday 







273


WedneSday 




CHALLENGES IN THE IRIS HEALTH 

ASSESSMENT OF HALOGENATED 

PLATINUM SALTS AND PLATINUM 

COMPOUNDS. A. S. Persad, A. K. Hotchkiss, 

J. Cowden, J. S. Lee, C. Keshava, A. Marcus and 

A. A. Rooney. National Center for Environmental 

Assessment, Office of Research and Development, 



SKIN SENSITIZATION: THE COLIPA 

STRATEGY FOR DEVELOPING AND 

EVALUATING NON-ANIMAL TEST 

METHODS FOR RISK ASSESSMENT. P. 

Aeby 1 , T. Ashikaga 2 , S. Bessou-Touya 3 , F. 

Gerberick 5 , P. Kern 5 , M. Marrec-Fairley 1 , G. 

Maxwell 11 , J. Ovigne 6 , H. Sakaguchi 7 , A. Schepky 4 , 

K. Schroeder 8 , M. Tailhardat 9 , S. Teissier 6 and P. 

Winkler 10 . 1 Colipa, Brussels, Belgium, 2 Shiseido 

Research Centre, Yokohama-Shi, Japan, 3 Pierre 

Fabre, Castres, France, 4 Beiersdorf, Hamburg, 

Germany, 5 Procter & Gamble, Cincinnati, 

OH, 6 L’Oréal, Aulnay sous Bois, France, 7 Kao 

Corporation, Tochigi, Japan, 8 Henkel AG & Co., 

Duesseldorf, Germany, 9 LVMH Recherche, Saint 

Jean de Braye, France, 10 Johnson & Johnson, 

Neuss, Germany and 11 Unilever, Sharnbrook, United 

Kingdom. 


MAJOR CHALLENGES TO BIOLOGICALLY- 

BASED DOSE-RESPONSE MODELING FOR 

ESTIMATING LOW-DOSE HUMAN RISK 

USING MOLECULAR TOXICOLOGY DATA. 

R. P. Subramaniam 1 , K. S. Crump 2 , C. Chen 1 , W. A. 

Chiu 1 , T. A. Louis 3 and C. J. Portier 4 . 1 ORD, U.S. 

EPA, Washington, DC, 2 Louisiana Tech University, 

Ruston, LA, 3 Johns Hopkins University, Baltimore, 

MD and 4 NIEHS, Research Triangle Park, NC . 

Sponsor: S. Vulimiri. 


POLYMORPHISM IN NAD(P)H:QUINONE 

OXIDOREDUCTASE (NQO1): POPULATION 

DISTRIBUTION AND POTENTIAL USE IN 

RISK ASSESSMENT. G. Ginsberg 1 , J. Schimek 2 , 

K. Z. Guyton 3 , D. O. Johns 3 and B. Sonawane 3 . 

1 

Connecticut Department of Public Health, Hartford, 

CT, 2 Research Triangle Institute, Washington, DC 

and 3 U.S. EPA, Washington, DC. 


A REVIEW OF DEVELOPMENTAL 

NEUROTOXICITY STUDIES FOR 

PYRETHROID PESTICIDES AND 

THEIR USE IN HUMAN HEALTH RISK 

ASSESSMENTS. A. B. Lowit, E. J. Scollon, K. B. 

Middleton, M. D. King, T. Levine and J. Fowle. Office 

of Pesticide Programs, U.S. EPA, Arlington, VA. 


DEVELOPMENT OF A RELATIVE 

SOURCE CONTRIBUTION FACTOR FOR 

DRINKING WATER CRITERIA: THE CASE 

OF HEXAHYDRO-1, 3, 5-TRINITRO-1, 3, 

5-TRIAZINE (RDX). B. Gadagbui 1 , J. Patterson 1 , 

S. S. Kueberuwa 3 , A. Rak 2 , R. S. Kutzman 2 , G. 

Reddy 4 and M. S. Johnson 4 . 1 Toxicology Excellence 

For Risk Assessment, Cincinnati, OH, 2 Noblis 

Inc., Alexandria, VA, 3 U.S. EPA, Washington, DC 

and 4 U.S. Army Center for Health Promotion and 

Preventive Medicine, Aberdeen Proving Ground, 

MD. 


ISSUES IN USING HUMAN VARIABILITY 

DISTRIBUTIONS TO ESTIMATE LOW- 

DOSE RISK. W. A. Chiu 1 , K. S. Crump 2 and R. 

Subramaniam 1 . 1 U.S. EPA, Washington, DC and 

2 

Louisiana Tech University, Ruston, LA. Sponsor: K. 

Guyton. 


PROPOSED MODES OF ACTION FOR 

NEUROTOXICITY INDUCED BY VARIOUS 

CHLORINATED SOLVENTS. A. Bale, S. 

Barone, C. S. Scott and G. S. Cooper. NCEA/ORD, 



MODELS USED TO SUPPORT EXPOSURE 

AND RISK ANALYSES BY THE U.S. 

ENVIRONMENTAL PROTECTION AGENCY. 

P. R. Williams 1 , B. J. Hubbell 2 , E. Weber 3 , C. 

Fehrenbacher 4 , D. Hrdy 5 and V. Zartarian 6 . 1 E Risk 

Sciences, LLP, Boulder, Co., 2 Office of Air Quality 

Planning and Standards, U.S. EPA, Research Triangle 

Park, NC, 3 National Exposure Research Laboratory, 

U.S. EPA, Athens, GA, 4 Office of Pollution 

Prevention and Toxics, U.S. EPA, Washington, 

DC, 5 Office of Pesticide Programs, U.S. EPA, 

Washington, DC and 6 National Exposure Research 



RISK ASSESSMENT OF METALS IN 

CONSUMER PRODUCTS INTENDED FOR 

CHILDREN. M. Wade, E. Sciullo, K. Day, R. 

Sarala, D. Chand, M. DeGuzman, J. Garcha, 

F. Hussain, M. Snider and T. Behrsing. Toxic 

Substances Control, Cal EPA, Sacramento, CA. 


POPULATION RISK FROM ARSENIC 

EXPOSURE IN COMMUNITIES LIVING 

NEAR COAL COMBUSTION WASTE 

FACILITIES. A. Lewis 1 , R. R. Mattuck 1 , K. E. 

Ladwig 3 and B. R. Hensel 2 . 1 Gradient, Cambridge, 

MA, 2 Electric Power Research Institute, Palo Alto, 

CA and 3 Natural Resource Technology, Pewaukee, 

WI. 

274 






Platform Sessions



Abstract # 


IDENTIFYING PREDICTORS FOR 

BIOAVAILABILITY OF ARSENIC IN SOIL 

AT MINING SITES. V. L. Mitchell 1 , C. N. Alpers 2 , 

N. T. Basta 3 , D. L. Berry 1 , J. P. Christopher 1 , D. D. 

Eberl 4 , C. S. Kim 6 , R. L. Fears 1 , A. E. Foster 5 , P. 

A. Myers 1 and B. Parsons 1 . 1 Department of Toxic 

Substances Control, Cal EPA, Sacramento, CA, 

2 

U.S. Geological Survey, Sacramento, CA, 3 Ohio 

State University, Columbus, OH, 4 U.S. Geological 

Survey, Boulder, Co., 5 U.S. Geological Survey, 

Menlo Park, CA and 6 Chapman University, Orange, 

CA. 


THE UTILITY OF STUDIES SINCE THE NRC 

2001 REPORT ON ARSENIC TO ESTIMATE 

LUNG AND BLADDER CANCER RISK AT 

LOW CONCENTRATIONS OF ARSENIC IN 

DRINKING WATER. S. Ramasamy 1 , J. S. Lee 2 , C. 

Chen 3 , P. White 3 , R. Sams 2 , C. Haver 4 and H. Gibb 4 . 

1 

Office of Water, U.S. EPA, Washington, DC, 2 Office 

of Research and Development, U.S. EPA, Durham, 

NC, 3 Office of Research and Development, U.S. 

EPA, Washington, DC and 4 Tetratech, Arlington, VA. 


GENOMIC CHANGES IN HUMAN PRIMARY 

UROEPITHELIAL CELLS FOLLOWING 

EXPOSURES TO ARSENITE AND ITS 

METABOLITES. J. W. Yager 1 , H. J. Clewell 2 , R. 

S. Thomas 2 , J. M. McKim 3 , P. C. Wilga 3 , R. Gentry 4 

and S. M. Cohen 5 . 1 University of New Mexico, 

Albuquerque, NM, 2 The Hamner Institutes for 

Health Sciences, Research Triangle Park, NC, 

3 

CeeTox, Kalamazoo, MI, 4 Environ International, 

Monroe, LA and 5 University of Nebraska Medical 

Center, Omaha, NE. 


MODE-OF-ACTION FOR THE CANCER 

RISK ASSESSMENT OF INGESTED 

HEXAVALENT CHROMIUM: IDENTIFYING 

AND RESOLVING DATA GAPS. C. 

Thompson 1 , D. Proctor 2 , L. Haws 2 and M. A. Harris 1 . 

1 

ToxStrategies, Inc., Katy, TX and 2 ToxStrategies, 

Austin, TX. 


WATER QUALITY IN WYOMING 

LIVESTOCK AND WILDLIFE. B. L. Wise. 

University of Wyoming, Laramie, WY. Sponsor: M. 

Raisbeck. 


ASSESSMENT OF THE ORAL CANCER 

POTENCY OF HEXAVALENT CHROMIUM 

(CR+6). A. H. Stern and G. B. Post. Office of 

Science, New Jersey Department Environmental 

Protection, Trenton, NJ. 


MODE-OF-ACTION PROPOSAL FOR 

ORAL HEXAVALENT CHROMIUM 

CARCINOGENESIS. M. Nascarella, A. S. Lewis 

and B. D. Beck. Gradient, Cambridge, MA. 

Abstract # 


DEVELOPMENT OF PUBLIC HEALTH 

GOALS (PHGS) FOR HEXAVALENT 

CHROMIUM AND TRIHALOMETHANES IN 

DRINKING WATER. R. A. Howd, R. Sedman, Y. 

Wang and A. M. Fan. Office of Environmental Health 

Hazard Assessment, Cal/EPA, Oakland, CA. 


HEALTH RISK OF INTERNAL NICKEL 

EXPOSURE FROM MEDICAL DEVICES. J. 

Tsuji 1 , K. Hentz 2 and S. Rosenbloom 3 . 1 Exponent, 

Bellevue, WA, 2 Exponent, Alexandria, VA and 

3 

Exponent, Philadelphia, PA. 


ATSDR’S CHRONIC INHALATION 

MINIMAL RISK LEVEL (MRL) FOR 

VANADIUM. L. Ingerman 1 , J. Taylor 2 and L. 

Cseh 2 . 1 Environmental Science, SRC (formerly 

Syracuse Research Corporation), North Syracuse, 

NY and 2 Agency for Toxic Substances and Disease 

Registry, Atlanta, GA. Sponsor: G. Diamond. 


EVALUATION OF RECENT 

INFORMATION ON CARCINOGENICITY 

OF PERCHLOROETHYLENE (PCE)IN 

HUMANS. L. A. Beyer, L. R. Rhomberg and B. D. 

Beck. Gradient, Cambridge, MA. 


PEAK AND DECLINE OF CANCER RATES 

AT OLD AGE. C. Harding, F. Pompei, E. E. 

Lee, D. Burmistrov, M. N. Bassily and R. Wilson. 

Jefferson Laboratories, Department of Physics, 

Harvard University, Cambridge, MA. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Models and Mechanisms of Hepatotoxicity 

Chairperson(s): Robert Dunn, Amgen,Thousand Oaks, CA, and James 

Luyendyk, University of Kansas Medical Center, Kansas City, KS. 




STUDY ON THE INHIBITION OF 

PROTOPORPHYRINOGEN OXIDASE 

(PPO) FROM RATS, MICE, RABBITS AND 

HUMANS. A. Doi 1 , T. Bernshausen 2 , E. Fabian 2 , 

R. Niggeweg 2 , C. Werner 2 , R. Landsiedel 2 and B. 

van Ravenzwaay 2 . 1 Toxicology, BASF, Research 

Triangle Park, NC and 2 Experimental Toxicology and 

Ecology, BASF SE, Ludwigshafen, Germany. 


AH RECEPTOR ACTIVATION SUPPRESSES 

STAT1 ACTIVATION DURING LIVER 

REGENERATION. C. L. Lamb, C. L. 

McClanahan, W. A. Harvey and K. A. Mitchell. 

Biological Sciences, Boise State University, Boise, 

ID. 

WedneSday 







275


WedneSday 




LIVER SPECIFIC ABALATION OF 

INTERGRIN LINKED KINASE LEADS TO 

SUSTAINED PROLIFERATIVE RESPONSE 

TO A MITOGENIC STIMULI. S. Donthamsetty 

and G. Michalopolous. University of Pittsburgh, 



NON-NUCLEOSIDE HIV-1 REVERSE 

TRANSCRIPTASE INHIBITOR NEVIRAPINE 

INHIBITS GROWTH OF HUMAN 

HEPATOCYTES BY INDUCTION OF CELL 

CYCLE ARREST. J. Fang and F. A. Beland. 

NCTR/U.S. FDA, Jefferson, AR. 


TCDD ENHANCES INFLAMMATORY LIVER 

INJURY IN RESPONSE TO CONCANAVALIN 

A ADMINISTRATION. A. M. Fullerton 1,2 , R. 

A. Roth 1,2 and P. E. Ganey 1,2 . 1 Pharmacology and 


MI and 2 Center for Integrative Toxicology, Michigan 



PARP INHIBITOR ATTENUATES COCAINE- 

INDUCED HEPATOTOXICITY. J. McCluskey, 

S. C. Harbison, D. Sava and R. D. Harbison. 

Environmental and Occupational Health, University 

of South Florida-COPH, Tampa, FL. 


INVOLVEMENT AND ROLE OF 

OXIDIZED-LDL (OXLDL) AND 

ITS RECEPTOR CXCL16 IN THE 

PATHOGENESIS OF INFLAMMATION- 

INDUCED MONOCROTALINE (MCT) 

HEPATOTOXICITY IN MICE. M. A. Hammad, 

M. S. Abdel-Bakky, L. A. Walker and M. K. Ashfaq. 

University of Mississippi, University, MS. 


D-AMPHETAMINE-INDUCED 

CYTOTOXICITY AND OXIDATIVE STRESS 

IN ISOLATED RAT HEPATOCYTES. O. S. 

El-Tawil 1 , A. H. Abou-Hadeed 2 and A. A. Shalaby 3 . 

1 

Department of Toxicology and Forensic Medicine, 

Faculty of Veterinary Medicine, Cairo University, 

Cairo, Egypt, 2 Department of Forensic Medicine and 

Toxicology, Faculty of Veterinary Medicine, Zagazig 

University, Zagazig, Egypt and 3 Department of 

Biochemistry, Faculty of Veterinary Medicine, Suez 

Canal University, Ismalia, Egypt. Sponsor: A. Kadry. 


OXIDATIVE STRESS IS A POTENTIAL 

PLAYER IN THE PATHOGENESIS OF 

LIVER INJURY INDUCED BY SULINDAC 

AND LIPOPOLYSACCHARIDE. W. Zou 1,2 , R. 

A. Roth 2,3 , H. S. Younis 4 , L. D. Burgoon 2,3 and P. E. 

Ganey 2,3 . 1 Michigan State University, East Lansing, 

MI, 2 Department of Pharmacology and Toxicology, 


3 


University, East Lansing, MI and 4 Pfizer Global 

Research and Development, Drug Safety R&D, San 

Diego, CA. 


TRANSITION METAL-CATALYZED 

OXIDATIVE STRESS IN ISOLATED RAT 

HEPATOCYTES: TREATMENT WITH B1/ 

B6 VITAMINS AND METAL CHELATING 

DRUGS. R. Mehta and P. J. O’Brien. 

Pharmaceutical Sciences, University of Toronto, 



ALPHA-NAPHTHYLISOTHIOCYANATE- 

INDUCED BILE DUCT EPITHELIAL CELL 

INJURY IN VITRO IS ASSOCIATED WITH 

PROCOAGULANT MICROPARTICLE 

RELEASE. K. Flanagan and J. P. Luyendyk. 

Pharmacology, Toxicology, and Therapeutics, The 


KS. 


FRUCTOSE ACTIVATES THE POLYOL 

PATHWAY IN THE DEVELOPMENT OF 

METABOLIC SYNDROME. M. A. Lanaspa, L. 

G. Sanchez-Lozada, C. Roncal, A. Andres-Hernando 

and R. J. Johnson. Renal Medicine, University of 

Colorado AMC, Denver, CO. Sponsor: G. Cantor. 


IN VITRO USNIC ACID CONCENTRATION/ 

TIME DEPENDENCY TOXICITY 

EVALUATION. B. J. Sonko 1 , L. Guo 1 , T. C. 

Schmitt 1 , L. Boros 2 and R. Beger 1 . 1 NCTR, Jefferson, 

AR and 2 SIDMAP LLC, Los Angeles, CA. 


MODULATION OF THE HEPATIC 

ANTIOXIDANT ENZYME ACTIVITIES 

OF MICE BY DICHLOROACETATE AND 

TRICHLOROACETATE. E. Hassoun and J. 

Cearfoss. Pharmacology, The University of Toledo, 

Toledo, OH. 


PREGNANE X RECEPTOR PLAYS A 

CENTRAL ROLE IN HEPATIC TOXICITY 

INDUCED BY A SMALL MOLECULE 

INHIBITOR OF BETA SECRETASE. R. T. 

Dunn 1 , S. Vonderfecht 1 , N. Everds 1 , D. Hickman 2 , 

M. Hayashi 2 , R. Pham 2 , Y. Kiang 3 , D. Lei 3 , L. 

Carlock 1 , S. Moss 1 , C. Afshari 1 , H. Hamadeh 1 , M. 

Higgins 1 , Y. Chen 1 , R. Hu 1 , R. Morgan 1 , A. Mongan 1 , 

Y. He 1 , R. Cattley 1 , J. Bussiere 1 and T. Williamson 1 . 

1 

Comparative Biology and Safety Sciences, Amgen 

Inc., Thousand Oaks, CA, 2 PKDM, Amgen Inc., 

Thousand Oaks, CA and 3 Small Molecule P.P.D., 




HEPATOTOXICITY INDUCED BY 1-FURAN- 

2-YL-3-PYRIDIN-2-YL-PROPENONE, A 

NEW ANTI-INFLAMMATORY AGENT. H. W. 

Ha 1 , T. W. Jeon 2 , G. S. Ko 1 , J. W. Yoo 1 , S. K. Lee 1 , 

M. J. Kang 1 , E. S. Lee 1 and T. Jeong 1 . 1 Pharmacy, 

Yeungnam University, Gyeongsan, Gyeongbuk, 

Republic of Korea and 2 BioToxtech Incorporation, 

Ochang, Republic of Korea. 

276 






Platform Sessions



Abstract # 


ALGINATE SPONGES AS 

PHYSIOLOGICALLY RELEVANT CULTURE 

ENVIRONMENTS FOR PRIMARY RAT 

HEPATOCYTES. A. Sams, Z. Li, M. Gonzalez, 

J. Jackson, J. Hill and M. Powers. PSCS R&D, 

Invitrogen Corporation, Frederick, MD. 


CHARACTERIZATION OF AN 

IMMORTALIZED MURINE KUPFFER 

CELL LINE FOR USE IN TOXICOLOGICAL 

STUDIES. Z. Wang, J. E. Klaunig, B. Hocevar 

and L. M. Kamendulis. Pharmacology & Toxicolgy, 

Center for Environmental Health, Indiana University 

School of Medicine, Indianapolis, IN. 


IN VITRO 3-D LIVER CO-CULTURES 

FOR ADMET ASSESSMENT OF NEW 

COMPOUNDS. D. R. Applegate, L. New and B. 

A. Naughton. RegeneMed Inc., San Diego, CA. 

Sponsor: R. Thomas. 


PHENOBARBITAL INDUCES 

TRANSCRIPTIONAL AND FUNCTIONAL 

CHANGES WITH TIME IN 3-D LIVER 

CO-CULTURES CONSISTENT WITH 

HEPATOCARCINOGENESIS. R. Brennan 3 , L. 

New 1 , R. S. Thomas 2 , C. I. Pearson 1 , A. H. Roter 4 , 

B. A. Naughton 1 and D. R. Applegate 1 . 1 Research, 

RegeneMed Inc., San Diego, CA, 2 Genomic Biology 

and Bioinformatics, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, 3 Research, 

GeneGo, Inc., Encinitas, CA and 4 Research, Entelos, 

Inc., Foster City, CA. 


A HUMAN HEPG2 LUCIFERASE ASSAY 

FOR METABOLICALLY ACTIVATED 

HEPATOTOXINS AND GENOTOXINS. X. 

Liu, K. A. Jeffrey, Y. Hu, J. M. Schmidt, J. Jiang and 

A. G. Wilson. Drug Metabolism, Pharmacokinetics, 

and Toxicology, Lexicon Pharmaceuticals, The 

Woodlands, TX. 


TOXICOGENOMIC STUDY OF 

MICROCYSTIN-LR IN WISTAR HAN 

RATS. L. Fomby 1 , C. Sabourin 1 , N. Machesky 1 , J. 

Price 1 , M. Kasoji 1 , M. Wendling 1 , D. Bornman 1 , M. 

Hejtmancik 1 , S. Auerbach 2 , M. Hooth 2 , M. Vallant 2 

and N. J. Walker 2 . 1 Battelle, Columbus, OH and 

2 

NTP, NIEHS, Research Triangle Park, NC. 

Abstract # 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Fetal Basis of Adult Disease 

Chairperson(s): Didima DeGroot, TNO Quality of Life, Zeist, The 

Netherlands. 




INHALATION OF AMBIENT TRAFFIC 

RELATED PARTICULATE MATTER 

DURING POSTNATAL LUNG 

DEVELOPMENT INDUCES EARLY 

AND PERSISTENT PULMONARY AND 

NEUROINFLAMMATION. C. J. Johnston, L. 

Opanashuk, R. Gelein, J. N. Finkelstein, D. A. Cory- 

Slechta and G. Oberdörster. University of Rochester, 



CHRONIC LOW-LEVEL ARSENITE 

EXPOSURE AND ITS EFFECTS ON 

CARDIOVASCULAR DEVELOPMENT AND 

DISEASE. P. Sanchez Soria 1 , D. Broka 1 and T. 

D. Camenisch 1,2,3 . 1 Pharmacology and Toxicology, 

University of Arizona, Tucson, AZ, 2 BIO5 Institute, 

University of Arizona, Tucson, AZ and 3 Steele 

Children’s Research Center, University of Arizona, 

Tucson, AZ. Sponsor: J. Gandolfi. 


GESTATIONAL LEAD EXPOSURE 

(GLE) PRODUCES LATE-ONSET MALE- 

SELECTIVE OBESITY, HYPERGLYCEMIA, 

AND PARA-INFLAMMATION: RISK 

FACTORS FOR METABOLIC SYNDROME 

AND NEURODEGENERATION. D. A. Fox 1 , 

L. Leasure 1 , S. Chaney 1 , R. Hamilton 1 , R. Hao 1 , W. 

Xiao 1 , S. Mukherjee 1 and J. E. Johnson 2 . 1 University 

of Houston, Houston, TX and 2 University of 

Houston-Downtown, Houston, TX. 


INTERSPECIES APPROACH TO 

THE ASSESSMENT OF HUMAN 

SUSCEPTIBILITY TO PHTHALATE- 

INDUCED ENDOCRINE DISRUPTION. 

N. Heger 1 , S. Hall 1 , M. Sandrof 1 , J. Hensley 2 , 

K. Johnson 3 , E. Houseman 1 , K. Gaido 2 and K. 

Boekelheide 1 . 1 Pathology and Laboratory Medicine, 

Brown University, Providence, RI, 2 The Hamner 


Park, NC and 3 3 Alfred I. duPont Hospital for 

Children, Wilmington, DE. 


FETAL STRESS BY CIGARETTE SMOKE 

EXPOSURE IN UTERO PREDISPOSES 

ADULT MALE MICE TO HEPATIC 

FIBROSIS. S. P. Doherty Lyons 1 , J. Allina 1,2 , J. T. 

Zelikoff 1 , J. Grabowski 1 , M. I. Fiel 2 and J. A. Odin 1,2 . 

1 

Environmental Medicine, New York University 

School of Medicine, Tuxedo, NY and 2 Mount Sinai 

School of Medicine, New York. 

WedneSday 







277


WedneSday 




DEVELOPMENTAL ARSENIC EXPOSURE 

CAUSES OBESITY, HYPERGLYCEMIA, 

AND LIVER DISEASE IN MALE MICE IN 

ADULTHOOD. A. L. Carlton, M. W. Carmody and 

R. J. Sommer. Biology Department, Bates College, 

Lewiston, ME. 


PRENATAL EXPOSURE TO CIGARETTE 

SMOKE ALTERS REGULATORY T-CELLS 

ASSOCIATED WTH ANTI-TUMOR IMMUNE 

RESPONSES IN A MOUSE MODEL. K. 

Yoshida 2 , S. Ng 3 , A. Silverstone 4 and J. T. Zelikoff 1 . 

1 

New York University School of Medicine, Tuxedo, 

NY, 2 Duke University Medical Center, Durham, 

NC, 3 Lovelace Respiratory Research Institute, 

Albuquerque, NM and 4 SUNY Upstate Medical 

University, Syracuse, NY. 


BODY WEIGHT AND AUDITORY STARTLE 

RESPONSE IN RATS PERMANENTLY 

CHANGED AFTER REPROGRAMMING OF 

DIET AND EARLY EXPOSURE TO MEHG. 

D. De Groot, J. van Esterik, C. De Esch, I. Waalkens, 

H. Hendriks and A. Wolterbeek. Toxicology & 

Applied Pharmacology, TNO Quality of Life, Zeist, 

Netherlands. Sponsor: R. Woutersen. 


1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Immunotoxicology: Methods and Models 

Chairperson(s): Enrique Fuentes-Mattei, University of Puerto Rico, San 

Juan, PR. 




PRACTICAL ADVANCES IN THE CONDUCT 

OF IMMUNOTOXICITY TESTING. D. 

R. Boverhof, L. Sosinski and M. R. Woolhiser. 

Toxicology and Environmental Research & 


MI. 


ANALYTICAL VALIDATION AND REAGENT 

COMPARISON FOR PERIPHERAL BLOOD 

IMMUNOPHENOTYPING IN BEAGLE 

DOGS. J. E. Arrington 1 and P. Marshall 2 . 

1 

Toxicology Study Direction, Covance, Madison, WI 

and 2 Clinical Pathology, Covance, Madison, WI. 


THE MINI-PIG IN IMMUNOTOXICITY 

TESTING. A. H. Penninks, G. van Mierlo, M. de 

Zeeuw-Brouwer, M. Schijf and M. Otto. Toxicology 

and Applied Pharmacology, TNO Quality of Life, 

Zeist, Netherlands. Sponsor: R. Woutersen. 


MEASURING T CELL RESPONSES 

IN MONKEYS FOR PRECLINICAL 

DEVELOPMENT. S. H. Cole, L. M. O’Donnell, 

A. W. Hudson, K. M. Herbert, C. Kamperschroer and 

T. T. Kawabata. Pfizer, Groton, CT. 


EVALUATING THE IMMUNOTOXICITY 

POTENTIAL OF DRUGS BY FLOW 

CYTOMETRY. J. R. Piccotti, J. L. Wardrope, L. 

Lin and N. D. Collins. Department of Drug Safety, 

Schering-Plough Research Institute, Summit, NJ. 


VALIDATION OF FLOW CYTOMETRY 

IMMUNOPHENOTYPING FOR 

PRECLINICAL APPLICATIONS IN NON- 

HUMAN PRIMATES. C. C. Cornwall 1 , A. R. 

Macintyre 1 , N. Pratt 1 , F. Day 1 , T. Salewsky 1 , J. 

Klaassen 1 , S. Meyer 1 and R. Nagata 2 . 1 SNBL USA, 

Ltd., Everett, WA and 2 Shin Nippon Biomedical 

Laboratories, Ltd., Kagoshima, Japan. Sponsor: R. 

Eyre. 


CD159a: A NEW MARKER FOR 

IDENTIFYING NK CELLS IN 

CYNOMOLGUS MONKEY WHOLE BLOOD 

BY IMMUNOPHENOTYPING. A. R. 

Macintyre 1 , T. Salewsky 1 , C. C. Cornwall 1 , N. Pratt 1 , 

F. Day 1 , J. Klaassen 1 , S. Meyer 1 and R. Nagata 2 . 

1 

SNBL USA, Ltd., Everett, WA and 2 Shin Nippon 

Biomedical Laboratories, Ltd., Kagoshima, Japan. 

Sponsor: R. Eyre. 


CYNOMOLGUS MONKEY 

INTRACELLULAR CYTOKINE STAINING 

AND DETECTION USING FLOW 

CYTOMETRY. F. Day 1 , C. C. Cornwall 1 , T. 

Salewsky 1 , A. R. Macintyre 1 , N. Pratt 1 , J. Klaassen 1 , 

S. Meyer 1 and R. Nagata 2 . 1 SNBL USA, Ltd., Everett, 

WA and 2 Shin Nippon Biomedical Laboratories, Ltd., 

Kagoshima, Japan. Sponsor: R. Eyre. 


ANALYTICAL COMPARISON 

OF BONE MARROW SAMPLE 

COLLECTION TECHNIQUES AND 

IMMUNOPHENOTYPING FOR 

CYNOMOLGUS MONKEYS. P. Joshi 2 , J. 

E. Arrington 1 and R. Haas 3 . 1 Toxicology Study 

Direction, Covance, Madison, WI, 2 Clinical 

Pathology, Covance, Madison, WI and 3 Toxicology 

Services, Covance, Madison, WI. 


EFFECTS OF RBC LYSE PROCEDURE ON 

ACCURATE MEASUREMENT OF CD16+ 

NK CELLS IN CYNOMOLGUS MONKEYS. 

M. Murillo, K. Prevete, N. Collins, E. Evans and 

J. R. Piccotti. Schering-Plough Research Institute, 

Summit, NJ. 


OPTIMIZATION OF KLH IMMUNIZATION 

AND VALIDATION OF TDAR IN 

CYNOMOLGUS MONKEYS USING FK506. 

L. Dong 1 , K. Hershman 1 , D. Gunson 1 , J. Omerza 1 , 

L. Talbot 1 , E. Skuba 1 , P. Ulrich 2 and K. Henson 1 . 

1 

Preclinical Safety, Novartis Institutes for Biomedical 

Research, East Hanover, NJ and 2 Preclinical Safety, 

Novartis Institutes for Biomedical Research, Basel, 

Switzerland. 

278 






Platform Sessions



Abstract # 


A 6-WEEK STUDY TO DETERMINE 

THE ANTIBODY RESPONSE OF FK506- 

IMMUNOSUPPRESSED CYNOMOLGUS 

MONKEYS FOLLOWING THE 

SUBCUTANEOUS ADMINISTRATION OF 

KEYHOLE LIMPET HEMOCYANIN AND 

TETANUS TOXOID IN THE PRESENCE OR 

ABSENCE OF INCOMPLETE FREUND’S 

ADJUVANT. J. N. Tichenor 1 , C. Dumont 2 , K. 

S. Colletti 1 , L. LeSauteur 2 and C. M. Satterwhite 1 . 

1 

Lab Sciences, Charles River Laboratories, Reno, 

NV and 2 Immunology, Charles River Laboratories, 



PARTIAL VALIDATION OF 

A SEMI-QUANTITATIVE 

ELECTROCHEMILUMINESCENCE 

(ECL) METHOD FOR THE DETECTION 

OF ANTI-MAB ANTIBODIES IN FETAL 

CYNOMOLGUS MONKEY SERUM. C. 

Gélinas 1 , N. Corsillo 1 , J. Haney 1 , L. LeSauteur 1 , K. 

Stubenrauch 2 and A. Ahene 3 . 1 Immunology, Charles 

River Laboratories, Preclinical Services (PCS- 

MTL), Senneville, QC, Canada, 2 Roche Penzberg, 

Penzberg, Germany and 3 Roche Palo Alto LLC, Palo 

Alto, CA. 


COMPARISON OF DELAYED- 

TYPE HYPERSENSITIVITY MOUSE 

MODELS UTILIZING KEYHOLE 

LIMPET HEMOCYANIN (KLH), SHEEP 

ERYTHROCYTES (SRBC), OR CANDIDA 

ALBICANS (C. ALBICANS) AS SENSITIZING 

ANTIGENS. M. J. Smith, A. S. Rapisardi and K. 

L. White. Pharmacology and Toxicology, Virginia 

Commonwealth University, Richmond, VA. 


ASSESSMENT OF ACUTE INFLAMMATORY 

RESPONSES IN CYNOMOLGUS MACAQUE. 

M. Perpetua, K. Maddali, B. Litzenberger, M. Wing, 

D. Zammit and G. Bannish. Experimental Biology, 

Huntingdon Life Sciences, East Millstone, NJ. 


EVALUATION OF AN IMMUNOTOXICITY 

SCREENING METHOD IN THE RAT USING 

TETANUS TOXOID. S. Cahill, A. Head, C. Smith, 

E. Kelshaw and D. Everett. Covance Laboratories 

Ltd., Harrogate, North Yorkshire, United Kingdom. 


VALIDATION OF A SENSITIVE, 

QUANTITATIVE, AND ISOTYPE-SPECIFIC 

ELISA FOR DETERMINING T-CELL 

DEPENDENT ANTIBODY RESPONSE TO 

KEYHOLE LIMPET HEMOCYANIN IN RAT 

SERUM. T. Testorf, D. DeVona, K. Price, H. 

Haggerty and W. Freebern. Bristol-Myers Squibb, 

East Syracuse, NY. 


DEVELOPMENT AND VALIDATION 

OF AN INNOVATIVE MULTIPLEX 

ASSAY FOR DETERMINING SERUM 

IMMUNOGLOBULIN (IG) LEVELS IN RATS. 

D. A. DeVona, M. Abbott, C. Gleason, T. Reilly, H. 

Haggerty and W. J. Freebern. Bristol-Myers Squibb, 

East Syracuse, NY. 

Abstract # 


TRANSCRIPTOMIC PROFILE INDICATIVE 

OF IMMUNOTOXIC EXPOSURE: IN 

VITRO STUDIES IN PERIPHERAL BLOOD 

MONONUCLEAR CELLS. K. Hochstenbach 1 , 

D. M. van Leeuwen 1 , H. Gmuender 2 , S. B. Stølevik 3 , 

U. C. Nygaard 3 , B. Granum 3 , E. Namork 3 , J. H. van 

Delft 1 and H. van Loveren 1 . 1 Health Risk Analysis 

and Toxicology, Maastricht University, Maastricht, 

Netherlands, 2 Genedata AG, Basel, Switzerland 

and 3 Department of Environmental Immunology, 

Norwegian Institute of Public Health, Oslo, Norway. 


A MODEL TO MIMIC THE EFFECT OF 

TCDD-CONTAMINATED SOIL INGESTION 

ON IMMUNE FUNCTION. B. L. Kaplan 1,2 , R. B. 

Crawford 1,2 , A. Arencibia 3 , S. Kim 3 , T. J. Pinnavaia 1,3 

and N. E. Kaminski 1,2 . 1 Center for Integrative 


MI, 2 Pharmacology and Toxicology, Michigan 

State University, East Lansing, MI and 3 Chemistry, 



1:00 PM to 4:30 PM 

Exhibit Hall 

Poster Session: Carcinogenesis: Breast and Reproductive 

Chairperson(s): James Sherman, Monsanto Company, St. Louis, MO, and 

David Castro, Burham Institute for Medical Research, LaJolla, CA. 




DIFFERENCES IN THE CIRCADIAN 

EXPRESSION OF DNA DAMAGE 

RESPONSIVE GENES CONTRIBUTE TO 

THE DIFFERENTIAL SUSCEPTIBILITY 

OF RAT STRAINS TO MAMMARY 

CARCINOGENESIS. M. Fang 1 , X. Zhang 2 

and H. Zarbl 1,2 . 1 Environmental Occupational 

Medicine, Robert Wood Johnson Medical School, 

University of Medicine and Dentistry of New Jersey, 

Piscataway, NJ and 2 Division of Human Biology, 

Fred Hutchinson Cancer Research Center, University 



CHEMICAL EXPOSURE AND BREAST 

CANCER: IDENTIFYING COMPOUNDS OF 

CONCERN. E. Chan 1 , S. Dairkee 2 , S. Janssen 3 , 

J. Latimer 4 , R. A. Rudel 5 , M. Schwarzman 1 , A. 

Wlassowsky 1 , L. Zeise 6 and D. E. Johnson 1 . 

1 

University California Berkeley, Berkeley, CA, 

2 

California Pacific Med Ctr, San Francisco, CA, 

3 

Nat Res Defense Council, San Francisco, CA, 

4 

University of Pittsburgh Cancer Institute, Pittsburg, 

PA, 5 Silent Spring Institute, Newton, MA and 

6 

OEHHA, Cal/EPA, Oakland, CA. 


ENVIRONMENTAL ESTROGENS AND 

BREAST CANCER. S. R. Kondraganti and B. 

Moorthy. Department of Pediatrics, Baylor College 

of Medicine, Houston, TX. 

WedneSday 







279


WedneSday 




THE FRY GENE IS INVOLVED IN 

MAMMARY TUMOR PROGRESSION. J. 

Graham 1 , H. Zarbl 1 and X. Ren 2 . 1 Toxicology, JGPT, 

UMDNJ-RWJMS, Piscataway, NJ and 2 University of 

Caifornia Berkeley, Berkeley, CA. 


CHEMICAL GENETIC APPROACHES TO 

ELUCIDATE KEY SIGNALING PATHWAYS 

FOR THE DIFFERENTIATION OF A 

MOUSE MAMMARY CANCER STEM 

CELL. D. Castro, J. Maurer and R. Oshima. 

Tumor Development, Burnham Institute for Medical 

Research, La Jolla, CA. 


MODULATION OF UP-A, MMPS AND THEIR 

INHIBITORS BY A NOVEL NUTRIENT 

MIXTURE IN HUMAN BREAST, CERVIX, 

AND OVARIAN CANCER CELL LINES. N. W. 

Roomi, M. Roomi, M. Rath and A. Niedzwiecki. Dr. 

Rath Research Institute, Santa Clara, CA. 


THE MAMMARY SECRETORY 

EPITHELIAL CELL SPECIFIC ROLE OF 

PEROXISOME PROLIFERATOR-ACTIVATED 

RECEPTOR (PPAR)g IN DMBA-MEDIATED 

BREAST TUMOURIGENESIS. A. J. Apostoli 1 , 

N. T. Peterson 1 , S. K. SenGupta 1 and C. J. Nicol 1,2 . 

1 

Pathology & Molecular Medicine, Queen’s 

University, Kingston, ON, Canada and 2 Division 

of Cancer Biology & Genetics, CRI, Queen’s 

University, Kingston, ON, Canada. 


EVALUATION OF INTRAUTERINE 

ADMINISTRATION OF QUINACRINE IN A 

LIFETIME CANCER BIOASSAY IN RATS. 

D. Creasy 1 , A. Cancel 2 , J. Dillberger 3 , C. Kelly 1 , H. 

Bolte 1 and D. Sokol 2 . 1 Huntingdon Life Sciences, 

East Millstone, NJ, 2 Family Health International, 

Research Triangle Park, NC and 3 J. Dillberger LLC, 

Nashville, IN. 


DOSE-RELATED EFFECTS OF QUERCETIN 

IN THE HUMAN BREAST CARCINOMA 

MCF-7 CELL LINE. B. Obinaju and F. L. Martin. 

Lancaster Environment Centre, Lancaster University, 

Lancaster, United Kingdom. 


SECOND GENERATION CURCUMIN 

ANLOGS AS NOVEL DRUGS FOR THE 

TREATMENT OF ER-NEGATIVE BREAST 

CANCER. S. Taurin 1 , L. Larsen 2 , B. Yadav 1 , T. J. 

Somers-Edgar 1 and R. J. Rosengren 1 . 1 Pharmacology 

& Toxicology, Univeristy of Otago, Dunedin, New 

Zealand and 2 Plant and Food Research Limited, 

Dunedin, New Zealand. 


BETULINIC ACID INHIBITS BT474 AND 

SKBR3 BREAST CANCER CELL GROWTH 

BY TARGETING SP PROTEINS AND 

ERBB2. X. Liu 1 and S. H. Safe 2,3 . 1 Department 

of Biochemistry and Biophysics, Texas A&M 

University, College Station, TX, 2 Department of 



of Biosciences and Technology, Texas A&M 

University Health Science Center, Houston, TX. 


MURINE HIPEC MODEL FOR STUDY OF 

IN VIVO EFFECTS OF CHEMOTHERAPY 

AGAINST METASTATIC HUMAN OVARIAN 

CANCER. C. S. Muenyi, V. A. States, J. H. Masters, 

T. Fan, C. Helm and J. States. Pharmacology & 

Toxicology, University of Louisville, Louisville, KY. 


1:15 PM to 2:15 PM 

Room 251 D 

Featured Session: A Conversation with the EPA’s Office of 

Research and Development Director: Paul Anastas 

The Meet the Director program is a special 60-minute session that 

provides an opportunity for the leaders of major federal agencies to 

engage in a panel discussion of emerging trends in toxicology research 

and its funding. This session will be a particularly valuable opportunity 

for SOT members to gain some insight on many of the U.S. EPA’s 

priorities, research opportunities, including the STAR Grant program, 

and other potential collaborative opportunities that attendees would find 

interesting. 


1:30 PM to 4:15 PM 

Ballroom A 

Symposium Session: Aging As a Determinant of Xenobiotic 

Toxicity 


and Harihara Mehendale, University of Louisiana Monroe, Monroe, LA. 

Sponsor: 


Endorsed by: 



One of the greatest achievements of the last eight decades is better health 

care which has led to a burgeoning aging population. By 2030, the number 

of individuals older than 65 will more than double to 72 million and one of 

every five Americans will be older than 65. The rapid growth in the number 

of older Americans has many implications for public health including the 

need to better understand the risks posed to older adults by environmental 

exposures to chemicals. The capacity to appropriately respond to toxicant 

exposure declines with normal aging and may be exacerbated in individuals 

with pre-existing conditions. This decline can result in compromised pharmacokinetic 

and pharmacodynamic responses to environmental exposures 

encountered in daily activities. Thus our objectives will be to highlight 

recent studies of altered sensitivities to xenobiotic exposure by aging in 

a number of tissues and to bring forward substantial new information on 

what is known about their mechanisms. We will include an overview of 

molecular pathways that are altered in aging including those involved in 

280 






Platform Sessions



Abstract # 

xenobiotic metabolism that will include important examples of how aging 

alters chemical sensitivity in the liver, lung, and brain. This session will be 

of interest to those studying the impact of modulation of stress pathways 

on chemical toxicity and risk assessors interested in incorporating data on 

sensitive subpopulations. 

#2010 1:30 AGING AS A DETERMINANT OF 

XENOBIOTIC TOXICITY. C. Corton 1 and 

H. Mehendale 2 . 1 NHEERL, U.S. EPA, Research 

Triangle Park, NC and 2 University of Louisiana, 

Monroe, LA. 

#2011 1:35 EVIDENCE FOR GENETIC PATHWAYS 

IN HUMANS SIMILAR TO THOSE 

THAT REGULATE AGING IN MODEL 

ORGANISMS. R. Bell. Prolexys Pharmaceuticals, 

Salt Lake City, UT. Sponsor: C. Corton. 

#2012 2:07 DIVERGENT GENDER-DEPENDENT 

GENETIC NETWORKS IN THE AGING 

MAMMALIAN LIVER: ALTERATION OF 

XENOBIOTIC METABOLISM GENES. C. 

Corton. NHEERL, U.S. EPA, Research Triangle 

Park, NC. 

#2013 2:39 AGING RATS ARE PROTECTED 

FROM CHLORDECONE AMPLIFIED 

PROGRESSION OF CARBON 

TETRACHLORIDE HEPATOTOXICITY. H. 

M. Mehendale. Toxicology, University of Louisiana 

at Monroe, Monroe, LA. 

#2014 3:11 COMPARATIVE EFFECTS OF THE 

ORGANOPHOSPHORUS INSECTICIDES 

CHLORPYRIFOS AND PARATHION IN 

ADULT AND AGING RATS. C. N. Pope 1 , J. 

Liu 1 and N. Mirajkar 1,2 . 1 Physiological Sciences, 

Oklahoma State University, Stillwater, OK and 

2 

Pharmaceutical Sciences, Texas Tech University, 

Amarillo, TX. 

#2015 3:43 PULMONARY EFFECTS OF INHALED 

AIR POLLUTANTS IN ELDERLY MICE: 

ROLE OF OXIDATIVE STRESS AND 

INFLAMMATORY CYTOKINES. D. Laskin. 



1:30 PM to 4:15 PM 

Ballroom B 


Symposium Session: TRPing the Sensor: The Role of TRP 

Channel Signaling in Cardiopulmonary Toxicity 

Chairperson(s): Sven-Eric Jordt, Yale University, New Haven, CT, and 

Daniel J. Conklin, University of Louisville, Louisville, KY. 

Sponsor: 


Endorsed by: 



Transient receptor potential (TRP) ion channels comprise a large family 

of cationic (calcium) conducting channels (TRP A, C, M, V) responsive 

to environmental and endogenous stimuli. TRP channels are activated by 

noxious airborne compounds such as tear gas and reactive aldehydes, as 

well as endogenously generated unsaturated aldehydes associated with 

Abstract # 

tissue injury and inflammation, including a, b-unsaturated aldehydes like 

acrolein and 4-hydroxynonenal. The TRP receptor channels transduce 

a variety of chemical signals via neural afferents (C-fibers) into sensory 

signals, including pain (nociceptive) responses. Increasingly, these channels 

are being found in other cell types, including airway epithelial and 

cardiovascular endothelium. The TRPA1 and TRPV1 (vanilloid- or capsaicin-sensitive) 

channels are implicated in pulmonary inflammation and 

asthma associated with exposure to noxious stimuli including chlorine, tear 

gases, isocyanates, tobacco smoke, and aldehydes. TRP channel activation 

triggers the release of neuropeptides such as substance P and CGRP, which 

stimulate local inflammatory responses, vasodilation, and edema. Recent 

work extends these findings to include complex cardiovascular responses, 

such as circulatory collapse and hypotension. These responses are triggered 

by specific TRP agonists, as well as by unsaturated aldehydes, which 

implicate a role of TRP channels located in cardiovascular cells or sensory 

afferents in these tissues in these effects. This session will explore several 

pathophysiological models that implicate various TRP channels in deleterious 

effects of noxious stimuli in cardiopulmonary toxicity and probe the 

mechanisms that connect channel activation/inhibition in these responses 

to exogenous and endogenous stimuli. The relevance of TRP signaling to 

human health and the potential for therapeutic targeting will be addressed. 

#2016 1:30 TRPING THE SENSOR: THE ROLE 

OF TRP CHANNEL SIGNALING IN 

CARDIOPULMONARY TOXICITY. S. Jordt 2 , 

D. J. Conklin 1 , J. Morris 3 , A. Caceres 2 , L. Lee 4 and 

R. Willette 5 . 1 Medicine, Univesrity of Louisville, 

Louisville, KY, 2 Pharmacology, Yale University, 

New Haven, CT, 3 Pharmacy, University of 

Connecticut, Storrs, CT, 4 Physiology, University of 

Kentucky, Lexington, KY and 5 Heart Failure DPU, 

GlaxoSmithKline Pharmaceuticals, King of Prussia, 

PA. 

#2017 1:35 TRPA1 MEDIATES THE NOXIOUS EFFECTS 

OF TEAR GASES AND INDUSTRIAL 

ISOCYANATES. S. Jordt. Pharmacy, Yale 

University, New Haven, CT. 

#2018 2:02 TOBACCO SMOKE, TRPA1, AND 

ENDOTHELIUM DYSFUNCTION: ROLE OF 

ACROLEIN. D. J. Conklin. Medicine, University 

of Louisville, Louisville, KY. 

#2019 2:29 TRP RECEPTORS AND SENSORY 

IRRITATION. J. B. Morris. School of Pharmacy, 


#2020 2:56 ROLE OF TRPA1 IN AIRWAY 

INFLAMMATION AND HYPERREACTIVITY. 

A. Caceres. Pharmacology, Yale University, New 

Haven, CT. Sponsor: D. Conklin. 

#2021 3:23 ROLE OF TRPV1 IN AIRWAY 

HYPERSENSITIVITY INDUCED BY 

MUCOSAL INFLAMMATION. L. Lee. 

Physiology, University of Kentucky, Lexington, KY. 

Sponsor: D. Conklin. 

#2022 3:50 THE ENDOTHELIAL TRPV4 CHANNEL: 

PHARMACOLOGY, TOXICOLOGY, AND 

THERAPEUTIC TARGET. R. N. Willette. Heart 

Failure DPU, GlaxoSmithKline Pharmaceuticals, 

King of Prussia, PA. Sponsor: D. Conklin. 

WedneSday 







281


WedneSday 




1:30 PM to 4:15 PM 

Ballroom D 

Symposium Session: Zebrafish Models for Developmental 


Chairperson(s): Edward D. Levin, Duke University Medical Center, 

Durham, NC, and Stephanie Padilla, U.S. EPA, Durham, NC. 

Sponsor: 


Endorsed by: 



With the emerging techniques for toxicology in the 21 st century, zebrafish 

can provide a key mechanistic model for developmental neurobehavioral 

toxicology because they have already become the predominant aquatic 

model for the study of molecular aspects of development in general and 

neurodevelopment in particular. Developmental neurobehavioral toxicology 

can benefit enormously from using the zebrafish model for higher 

throughput screening as well as to identify critical molecular and cellular 

interaction mechanisms of functional behavioral impairment. To use 

zebrafish for neurobehavioral toxicity research, we must develop sensitive, 

efficient, valid, and reliable behavioral test methods. Recently, a 

variety of researchers have been doing just that. In this symposium several 

investigators representing the field will describe how they have developed 

neurobehavioral tests for zebrafish and used them for the assessment of the 

adverse effects of environmental toxicants, including pesticides and metals. 

The advantages of computerized video tracking systems for behavioral 

analysis in zebrafish will be assessed. The complementary relationships 

of developmental neurobehavioral toxicology studies using zebrafish and 

classic rodent models will be discussed. Each paradigm has its own set 

of advantages and limitations. In concert, complementary fish and rodent 

models as well other developmental model systems can answer a broad 

array of pressing questions in neurobehavioral toxicology. The use of these 

neurobehavioral behavioral paradigms for both screening of functional 

effects and mechanistic studies of the neurotoxic events underlying the 

behavioral impairments will be presented. Future directions for zebrafish 

models for developmental neurobehavioral toxicology will be discussed. 

#2023 1:30 ZEBRAFISH MODELS FOR 

DEVELOPMENTAL NEUROBEHAVIORAL 

TOXICOLOGY. E. D. Levin 1 and S. Padilla 2 . 

1 

Department of Psychiatry, Duke University Medical 

Center, Durham, NC and 2 Integrated Systems 

Toxicology Division, U.S. EPA, Research Triangle 

Park, NC. 

#2024 1:35 THE BENEFITS OF ZEBRAFISH AS 

A COMPLEMENTARY MODEL FOR 

STUDYING THE MOLECULAR BASES OF 

DEVELOPMENTAL NEUROTOXICOLOGY. 

E. Linney, J. Yen, S. Donerly, L. Upchurch and E. 

D. Levin. Duke University Medical Center, Durham, 

NC. 

#2025 2:07 BEHAVIORAL SCREENS FOR DETECTING 

DEVELOPMENTAL NEUROTOXICITY IN 

LARVAL ZEBRAFISH. S. Padilla. Integrated 

Systems Toxicology Division, U.S. EPA, Research 


#2026 2:39 A ZEBRAFISH MODEL FOR WHAT AILS, 

AND POSSIBLY CURES, US: A BEHAVIORAL 

PERSPECTIVE OF DEVELOPMENTAL 

LEAD AND MERCURY TOXICITY. D. Weber 1 , 

L. Smith 1 , M. Wolter 1 , X. Xu 2 and M. Carvan 1 . 

1 

University of Wisconsin-Milwaukee, Milwaukee, WI 

and 2 Grand Valley State University, Allendale, MI. 

#2027 3:11 THE ZEBRAFISH AS A MODEL FOR 


PYRETHROID PESTICIDES. L. A. White 1 , 

A. DeMicco 1 , K. R. Cooper 1 and J. R. Richardson 2 . 

1 

Biochemistry and Microbiology, Rutgers University, 

New Brunswick, NJ and 2 EOSHI, UMDNJ, 


#2028 3:43 PERSISTING EFFECTS OF EARLY 

DEVELOPMENTAL OP PESTICIDE 

EXPOSURE ON COGNITIVE AND 

SENSORIMOTOR FUNCTION. E. D. Levin. 

Department of Psychiatry, Duke University Medical 

Center, Durham, NC. 


1:30 PM to 4:15 PM 

Room 150 


Workshop Session: High-Throughput Electrophysiology— 

21 st Century Toxicity Testing Approaches with Functional 

Outcomes 

Chairperson(s): Timothy J. Shafer, U.S. EPA, Research Triangle Park, 

NC, and Glenn E. Kirsch, ChanTest Corporation, Cleveland, OH. 

Sponsor: 


Endorsed by: 




The NAS report on Toxicity Testing in the 21 st Century envisions a 

future approach to toxicity testing that relies on in vitro, high-throughput 

approaches to identify and characterize toxicity hazards of environmental 

chemicals. These approaches are expected to replace or reduce the number 

of animals needed for toxicity testing. However, description of adverse 

effects for the purpose of hazard identification has relied predominantly on 

changes in structure and/or function in animals. In addition, many endpoints 

measured in high-throughput or high-content assays are biochemical and 

difficult to link directly to functional changes. For excitable tissues such 

as in the nervous and cardiac system, in vivo electrophysiological assessments 

have been widely and successfully utilized to describe adverse 

effects, whereas in vitro electrophysiological approaches have provided 

important information on mechanisms-of-actions of pesticides, metals, and 

other compounds. In recent years, new high-throughput/high-content electrophysiological 

assays have been developed and widely utilized for drug 

target screening and/or safety pharmacology—for example, screening of 

compound effects on HERG channels to identify those that produce torsades 

de pointes, a lethal cardiac side-effect of some drugs. Many of these electrophysiological 

approaches can be readily adapted to toxicity testing and will 

provide high-content information in addition to their throughput capabilities. 

Thus, these approaches can provide not only information on functional 

changes in electrically excitable tissues, but also information regarding 

potential toxicity pathways by which compounds may disrupt function. This 

session will describe a number of these HTS approaches for electrophysiology, 

and discuss their use for safety and toxicity testing. More importantly, 

it will focus on how these approaches can be further adapted for use in 21 st 

century toxicity testing for toxicity pathway and hazard identification. 

#2029 1:30 HIGH-THROUGHPUT 

ELECTROPHYSIOLOGY—21 ST CENTURY 

TOXICITY TESTING APPROACHES WITH 

FUNCTIONAL OUTCOMES. T. J. Shafer 1 

and G. Kirsch 2 . 1 Neurotoxicology Division U.S. 

EPA, Research Triangle Park, NC and 2 ChanTest, 


282 






Platform Sessions



Abstract # 

#2030 1:35 USE OF CELL- AND TISSUE-BASED 

METHODS FOR RAPID IDENTIFICATION 

OF CARDIOVASCULAR TOXICITY 

PATHWAYS IN DISCOVERY TOXICOLOGY. 

P. C. Levesque. Discovery Toxicology, Bristol-Myers 

Squibb, Pennington, NJ. Sponsor: T. Shafer. 

#2031 2:05 AUTOMATED PATCH CLAMP ASSESSMENT 

OF PYRETHROID INSECTICIDE 

INTERACTIONS WITH CLONED HUMAN 

NA+ CHANNELS. G. Kirsch and Y. Kuryshev. 

ChanTest Corporation, Cleveland, OH. 

#2032 2:35 THE PROMISE OF MICROELECTRODE 

ARRAY APPROACHES FOR TOXICITY 

TESTING: EXAMPLES WITH 

NEUROACTIVE CHEMICALS. A. Johnstone 

and T. J. Shafer. Integrated Systems Toxicology 

Division U.S. EPA, Research Triangle Park, NC. 

#2033 3:05 FDA USE OF DATA FROM IN VITRO 

ELECTROPHYSIOLOGY IN A 

REGULATORY ENVIRONMENT: 

APPLYING LESSONS LEARNED IN SAFETY 

PHARMACOLOGY TO TOXICITY TESTING. 

J. Koerner. U.S. Food and Drug Administration, 

Silver Spring, MD. Sponsor: T. Schafer. 



1:30 PM to 4:15 PM 

Ballroom I 

Workshop Session: Minerals and Metals: Pros and Cons of 

Deliberate Exposure 

Chairperson(s): Ruth A. Roberts, Astra Zeneca UK, Macclesfield, United 

Kingdom, and Jonathan Powell, MRC Centre for Human Nutrition UK, 

Cambridge, United Kingdom. 

Sponsor: 


Endorsed by: 




Metals and minerals are known to induce adverse effects ranging from 

oxidative stress to carcinogenesis. However, some are administered or are 

under consideration for therapeutic intent either as direct administration or 

as a consequence of metal-to-metal joint replacement. For example, oral 

iron can reduce the incidence of anemia—number 11 on the World Health 

Organization’s top 20 list of global disease burden. On the other hand, 

there is a risk of increasing infection and morbidity/mortality in developing 

countries or risk of chronic subclinical inflammation and colon cancer in the 

developed world. We will explore the potential of metals and minerals in 

therapy and in parallel will consider the potential adverse effects that need 

to be considered. The presentations are designed to provide attendees with 

important and biologically relevant issues related to in vivo exposures to 

metals and minerals, a comprehensive and stimulating state-of-the-art update 

on innovative testing methods, and a vision of expected scientific advances 

in the understanding of how minerals and metals can affect developmental, 

degenerative, and carcinogenic processes. The focus of this session encompasses 

concepts and themes from cell physiology through to molecular 

biology with an overall goal of ensuring a better understanding of the assessment 

of hazard and risk associated with exposures to minerals and metals. 

As such, it is intended for basic and applied scientists in academia, government, 

and industry. 

Abstract # 

#2034 1:30 MINERALS AND METALS: PROS AND CONS 

OF DELIBERATE EXPOSURE. R. Roberts 1 

and J. Powell 2 . 1 Safety Assessment, AstraZeneca, 

Macclesfield, United Kingdom and 2 MRC Centre for 

Human Nutrition, Cambridge, United Kingdom. 

#2035 1:35 THERAPEUTIC USES OF METALS 

AND MINERALS: THE RISK-BENEFIT 

INTERFACE. J. Powell. Department of 

Micronutrient Status Research, MRC Institute for 

Human Nutrition Research, Cambridge, United 

Kingdom. 

#2036 2:10 PROTECTION AGAINST CHROMIUM 

(VI)-INDUCED OXIDATIVE STRESS AND 

APOPTOSIS BY NRF2. Q. Ma. Toxicology and 

Molecular Biology Branch, NIOSH, Morgantown, 

WV. 

#2037 2:45 FUNCTIONAL PROFILING TO IDENTIFY 

METAL TOXICITY PATHWAYS IN YEAST. 

C. Vulpe 1 , W. Jo 1 , X. Ren 2 , M. North 1 , L. Zhang 2 and 

M. Smith 2 . 1 Nutritional Science and Toxicology, 

University of California Berkeley, Berkeley, CA and 

2 

Division of Environmental Health Sciences, School 

of Public Health, University of California Berkeley, 

Berkeley, CA. 

#2038 3:20 METALS AND OXIDATIVE IMPAIRMENT 

IN NEURODEGENERATIVE DISORDERS. 

M. Aschner 1 , D. Milatovic 1 , N. Zhang 2 , J. Williams 4 , 

K. M. Erikson 3 , M. J. Avison 4 and V. A. Fitsanakis 5 . 

1 

Pediatrics, Vanderbilt University, Nashville, TN, 

2 

Electrical and Computer Engineering, Clarkson 

University, Potsdam, NY, 3 Nutrition, University 

of North Carolina, Greensboro, NC, 4 Radiology 

and Radiological Sciences, Vanderbilt University, 

Nashville, TN and 5 Biology, King College, Bristol, 

TN. 



1:30 PM to 4:15 PM 

Ballroom J 


Workshop Session: ‘Omics Profiling of Cell and Tissue 

Interactions of Nanomaterials: Insight into Mechanisms of 

Action 

Chairperson(s): Mary Jane Cunningham, Nanomics Biosciences, Inc., 

Cary, NC, and Frank Witzmann, Indiana University School of Medicine, 


Sponsor: 


Endorsed by: 


Nanomaterials (NMs) are nano-scale materials which are engineered or 

naturally-occurring. NMs are being developed for a variety of products 

ranging from medical therapies to consumer goods and often exhibit novel 

properties not seen with other large scale materials of similar chemical 

composition. However, the adverse effects, if any, of NMs have not been 

adequately tested. Future testing assays for the 21 st century include highthroughput 

screening technologies to identify cellular interactions with 

NMs for efficacy and safety. This session will present ongoing genomics, 

proteomics, and metabolomics studies of interactions between natural and 

engineered NMs and biological systems. Findings of novel interactions of 

NMs and biological systems will be highlighted and the feasibility of these 

WedneSday 







283


WedneSday 



approaches for future comprehensive studies of NM efficacy and safety 

will be discussed. Examples of in vitro cellular interactions with a variety 

of NMs will be provided which include mRNA, miRNA, and proteomic 

expression profiles of human and mammalian cells exposed to nanotubes, 

nanocrystals (quantum dots), dendrimers and nano-scale particles of 

both terrestrial and extra-terrestrial origin. Selective activation of specific 

genes, proteins, and cellular signaling pathways will be related to possible 

mechanisms of action. We will highlight how the addition of metabolomics 

to other ‘omics based studies can further define the effects of NMs on 

biological systems after environmental exposures. The final presentation will 

expand upon the systems biology approach and show how multiple ‘omics 

technologies can provide mechanistic meaning when individual data sets are 

analyzed ranging from a global to subcellular view. This session should be 

of interest to all investigators interested in state-of-the-art ‘omics technologies 

for screening the effects of foreign materials, including NMs, in humans 

and other organisms. 

#2039 1:30 ‘OMICS PROFILING OF CELL AND TISSUE 

INTERACTIONS OF NANOMATERIALS: 

INSIGHT INTO MECHANISMS OF 

ACTION—OVERVIEW. M. Cunningham 1 and 

F. Witzmann 2 . 1 Nanomics Biosciences, Inc., Cary, 

NC and 2 Indiana University School of Medicine, 


#2040 1:35 MESSENGER RNA AND MICRORNA 

EXPRESSION PROFILING OF 

NANOMATERIAL INTERACTIONS WITH 

PRIMARY HUMAN SKIN AND LUNG 

CELLS. M. Cunningham. Nanomics Biosciences, 

Inc., Cary, NC. 

#2041 2:05 CARBON NANOPARTICLE EXPOSURE 

ALTERS BARRIER EPITHELIAL 

CELL FUNCTION: PROTEOMIC AND 

ELECTROPHYSIOLOGICAL ANALYSES. 

F. A. Witzmann. Department of Cellular & Integrative 

Physiology, Indiana University School of Medicine, 


#2042 2:35 GENOMIC SIGNATURES FOR SIZE- 

DEPENDENT BIOLOGICAL EFFECTS 

OF GOLD NANOPARTICLES. F. F. Chen. 

Life Sciences, Lawrence Berkeley National Lab, 

Berkeley, CA. Sponsor: M. Cunningham. 

#2043 3:05 IN VITRO AND IN VIVO METABOLOMIC 

AND PROTEOMIC BIOMARKER STUDIES 

OF III-V SEMICONDUCTORS ON RENAL 

PROXIMAL TUBULE CELLS. B. A. Fowler 1 , 

E. A. Conner 2 and H. Yamauchi 3 . 1 Division Tox and 

Env.Med., ATSDR/CDC, Atlanta, GA, 2 Laboratory 

of Experimental Carcinogenesis, NCI, Bethesda, MD 

and 3 Pharmaceutical Sciences, Kitasato University, 

Tokyo, Japan. 

#2044 3:35 DYNAMIC NETWORK ANALYSIS OF 

NANOSILICA-INDUCED TOXICITY 

PATHWAYS USING MICROARRAY AND 

PROTEOMIC DATA. K. Waters. Computational 

Biology & Bioinformatics, Pacific Northwest 

National Laboratory, Richland, WA. Sponsor: M. 

Cunningham. 



1:30 PM to 4:15 PM 

Ballroom G 

Workshop Session: The Process of Defining Risk for 

Environmental Chemicals Having Significant Skin Exposure 

and Absorption Potential 

Chairperson(s): William G. Reifenrath, Stratacor, Inc., Richmond, CA, 

and John H. Ross, Gem Quality Risk Inc, Carmichael, CA. 

Sponsor: 


Endorsed by: 



Skin exposure and subsequent absorption of environmental contaminants 

are often critical issues for regulatory decisions concerning the treatment of 

contaminants or remediation at hazardous waste sites. Likewise, these issues 

are important in the registration or re-registration of pesticides. To address 

these points, laboratory studies are generally conducted with excised skin 

or animal models to determine the extent (percent absorption) or rate of 

penetration (permeability constant) of a chemical in question. In addition, 

exposure determinations, often based on field studies, determine the form 

and amount of chemical that can potentially reach the skin. Biomonitoring 

studies can integrate the processes of skin exposure and systemic absorption. 

The forgoing studies generate numbers, which require a translation 

into the potential for bioeffect, and the significance of that effect, which 

leads to a risk assessment. Regulators, such as the U.S. EPA, then make 

decisions based on the assembled data. The process works best when there 

is communication between all parties, starting with the design of experimental 

protocols. In recent years, there has been an increasing reliance on in 

vitro permeation data. While test guidelines are available for percutaneous 

absorption, actual studies have unique aspects that need to be addressed or 

negotiated. Decisions on seemingly small details at any level can ultimately 

have major impacts. Therefore, it is our intent to give a vertical perspective 

on the process by which safety assessments are made, starting at the laboratory 

and ending with a regulatory decision, and highlighting those aspects 

that can shape the outcome. 

#2045 1:30 THE PROCESS OF DEFINING RISK FOR 

ENVIRONMENTAL CHEMICALS HAVING 

SIGNIFICANT SKIN EXPOSURE AND 

ABSORPTION POTENTIAL. W. G. Reifenrath 1 

and J. H. Ross 2 . 1 Stratacor, Inc., Richmond, CA and 

2 

Risk Sciences, LLC, Sacramento, CA. 

#2046 1:35 DERMAL ABSORPTION IN THE EXPOSURE 

ASSESSMENT PROCESS. J. H. Ross. Risk 

Sciences LLC, Sacramento, CA. 

#2047 2:02 TRANSLATING IN VITRO SKIN 

ABSORPTION DATA INTO ESTIMATES OF 

HUMAN SKIN ABSORPTION. W. G. Reifenrath. 

Stratacor, Inc., Richmond, CA. 

#2048 2:29 IN VITRO DERMAL ABSORPTION OF 

SOIL CONTAMINANTS: IMPORTANCE 

OF MODELING FIELD EXPOSURE 

CONDITIONS. R. P. Moody. Environmental 

Health Centre, Health Canada, Ottawa, ON, Canada. 

Sponsor: H. Maibach. 

284 






Platform Sessions



Abstract # 

#2049 2:56 SURFACE DEPOSITION OF PESTICIDES 

AND DERMAL ABSORPTION OF RESIDUES 

IN AGRICULTURAL AND URBAN 

ENVIRONMENTS, DETERMINANTS 

OF PESTICIDE ABSORPTION IN 

AGRICULTURAL AND RESIDENTIAL 

SETTINGS. R. I. Krieger, Z. Chen, G. Sankaran 

and W. Song. Department of Entomology, University 

of California Riverside, Riverside, CA. 

#2050 3:23 REGULATORY PERSPECTIVES ON THE 

USE OF DERMAL ABSORPTION DATA FOR 

RISK ASSESSMENT. P. V. Shah, J. P. Ryman- 

Rasmussen, J. Rowland and J. Evans. Office of 

Pesticide Programs, U.S. EPA, Washington, DC. 

#2051 3:50 EU/OECD GUIDELINES, A PERSPECTIVE 

FROM BAYER CROPSCIENCE. P. Fisher. 

Human Safety, Bayer CropScience, Sophia Antipolis, 

France. Sponsor: J. Ross. 


1:30 PM to 4:15 PM 

Room 151 


Workshop Session: Translation of Nonclinical Models to 

Clinical Risk Management Strategies of Severe Infectious 

Diseases with Immunomodulatory Drugs 

Chairperson(s): Wendy J. Komocsar, Eli Lilly and Company, Indianapolis, 

IN, and Thomas T. Kawabata, Pfizer, Inc., Groton, CT. 

Sponsor: 


The recent development of immunomodulatory drugs to treat autoimmune 

and inflammatory diseases has resulted in significant patient benefit. 

However, modulation of immune responses may also result in decreased 

host resistance mechanisms and increased risk for infectious diseases and 

cancer. Some infrequent, but severe infectious diseases such as Progressive 

Multi-Focal Leukoencephalopathy (PML) and tuberculosis, have had significant 

impact on public health and the development of immunomodulatory 

therapies. The mechanism for the development of these diseases with drugs 

of different mechanisms of action and the susceptibility factors of certain 

patients is not clear. Currently, knowledge of the mechanism-of-action of the 

drug being developed, findings from standard toxicology studies and studies 

of immune function assessment may help determine potential risk for PML 

or tuberculosis, but do not provide decision making information on relative 

risk in the early stages of drug development. Given the low incidence 

of these severe infectious diseases and strict inclusion criteria of clinical 

trials, it is difficult to determine if severe infections will be a risk until larger 

populations are treated. Moreover, clinical monitoring to assess changes in 

immune function that may lead to decreased host resistance or biomarkers 

of recrudescence of microbes have not been adequately developed and validated. 

Application of approaches used in infection monitoring/prevention in 

the setting of clinical transplantation may provide some additional insight 

for the development of less suppressive immunomodulators. To address 

these significant gaps, research across many disciplines is needed to better 

predict and risk manage severe infectious diseases. The goal of this session 

is to increase awareness of this issue and stimulate discussion on approaches 

to develop translatable nonclinical and clinical assays/biomarkers for better 

risk assessment and management of infection liability in the clinic. 

Abstract # 

#2052 1:30 TRANSLATION OF NONCLINICAL 

MODELS TO CLINICAL RISK 

MANAGEMENT STRATEGIES OF 

SEVERE INFECTIOUS DISEASES WITH 

IMMUNOMODULATORY DRUGS. W. J. 

Komocsar 1 and T. Kawabata 2 . 1 Autoimmune Disease 

Platform, Eli Lilly & Company, Indianapolis, IN and 

2 

Pfizer Global Research and Development, Groton, 

CT. 

#2053 1:35 CLINICAL CONSEQUENCES OF ADVERSE 

UNINTENDED IMMUNOMODULATION. 

I. Gourley. Early Development and Clinical 

Pharmacology, Wyeth Research, Collegeville, PA. 

Sponsor: W. Komocsar. 

#2054 2:07 RISK MANAGEMENT OF INFECTIONS 

WITH TRANSPLANTATION. C. 

Kotton. Clinical Director, Transplant and 

Immunocompromised Host Infectious Diseases, 

Infectious Diseases Division, Massachusetts General 

Hospital, Boston, MA. Sponsor: W. Komocsar. 

#2055 2:39 PROGRESSIVE MULTIFOCAL 

LEUKOENCEPHALOPATHY AND 

IMMUNOMODULATORY DRUGS. T. 

Kawabata. Pfizer, Groton, CT. 

#2056 3:11 MYCOBACTERIUM TUBERCULOSIS 

OVERVIEW AND THE REACTIVATION OF 

LATENT TUBERCULOSIS. W. J. Komocsar. 

Autoimmune Disease Platform, Eli Lilly & 

Company, Indianapolis, IN. 

#2057 3:43 THE USE OF NONCLINICAL 

ASSESSMENT STRATEGIES IN THE 

PREDICTION OF CLINICAL RISKS OF 

IMMUNOMODULATORY MOLECULES: 

CASE STUDY FOR ABATACEPT, 

A SELECTIVE CO-STIMULATION 

MODULATOR. H. G. Haggerty. Drug Safety 

Evaluation, Bristol-Myers Squibb, Syracuse, NY. 


1:30 PM to 4:15 PM 

Ballroom F 

Platform Session: Insights into Polyaromatic Hydrocarbon- 

Induced Toxicities 

Chairperson(s): Mary Walker, University of New Mexico, Albuquerque, 

NM, and Lynn Allen-Hoffmann, University of Wisconsin-Madison, 

Madison, WI. 

#2058 1:30 CYTOCHROME P4501A1 (CYP1A1) IS 

REQUIRED TO MEDIATE VASCULAR 

DYSFUNCTION, REACTIVE OXYGEN 

SPECIES, AND HYPERTENSION INDUCED 

BY 2, 3, 7, 8-TETRACHLORODIBENZO-P- 

DIOXIN (TCDD). P. G. Kopf, L. N. Agbor, J. 

Scott and M. K. Walker. Pharmaceutical Sciences, 

University of New Mexico, Albuquerque, NM. 

#2059 1:54 TCDD TREATMENT INDUCES HBD-3 

EXPRESSION IN HUMAN KERATINOCYTES 

IN VITRO AND IN ORGAN CULTURE OF 

HUMAN SKIN BIOPSIES. L. Allen-Hoffmann 1,2 , 

N. De Abrew 2 and J. Loertscher 2 . 1 Pathology and 

Laboratory Medicine, University of Wisconsin 

Madison, Madison, WI and 2 Molecular and 

Environmental Toxicology Center, University of 

Wisconsin Madison, Madison, WI. 

WedneSday 







285


WedneSday 



#2060 2:18 TCDD INDUCES DERMAL ACCUMULATION 

OF KERATINOCYTE-DERIVED MATRIX 

METALLOPROTEINASE-10 IN A THREE 

DIMENSIONAL MODEL OF HUMAN SKIN. 

C. Thomas-Virnig 1 , N. De Abrew 2 , C. Rasmussen 1 , 

E. Bolterstein 2 , S. Schlosser 1 and L. Allen- 

Hoffmann 1,2 . 1 Pathology and Laboratory Medicine, 

University of Wisconsin Madison, Madison, WI and 

2 

Molecular and Environmental Toxicology Center, 

University of Wisconsin Madison, Madison, WI. 

#2061 2:41 HEPATIC EFFECTS OF VERY LOW TEQ 

CONTAMINATED NDL-PCBS 180 AND 52 

IN ADULT SPRAGUE-DAWLEY RATS. R. 

Roos 1 , P. Andersson 2 , H. Schmitz 1 , H. M. Miettinen 3 , 

P. Heikkinen 3 , L. van der Ven 4 , M. Viluksela 3 

and D. Schrenk 1 . 1 University of Kaiserslautern, 

Kaiserslautern, Germany, 2 University of Umea, 

Umea, Sweden, 3 National Public Health Institute, 

Kuopio, Finland and 4 National Institute for Public 

Health and the Environment (RIVM), Bilthoven, 

Netherlands. 

#2062 3:04 BIOAVAILABILITY NORMALIZED 

CLEARANCE OF POLYCHLORINATED 

BIPHENYL ENANTIOMERS IS 

ENANTIOSELECTIVE IN FEMALE C57BL/6 

MICE. I. Kania-Korwel 1 , M. El-Komy 2 , P. 

Veng-Pedersen 2 and H. Lehmler 1 . 1 Department 

of Occupational and Environmental Health, 

University of Iowa, Iowa City, IA and 2 Division of 

Pharmaceutics, College of Pharmacy, University of 

Iowa, Iowa City, IA. 

#2063 3:28 LEVELS OF DIOXINS AND 

POLYBROMINATED DIPHENYL ETHERS IN 

HUMAN MILK IN NORTHERN CHINA AND 

THE RELATED DIETARY RISK FACTORS. 

F. Kayama 1 , S. Sun 1,2 , J. Zhao 3 , J. Leng 4 , H. Fukatsu 5 , 

D. Liu 2 and X. Liu 2 . 1 Center for Community 

Medicine, Jichi Medical University, Shimotsuke, 

Tochigi, Japan, 2 College of Public Health, Hebei 

Medical University, Shijazhuang, Hebei, China, 

3 

The Second Hospital, Hebei Medical University, 

Shijazhuang, Hebei, China, 4 School of Public 

Health, Peking University, Beijing, China and 5 S.R.L. 

Inc., Hachioji, Tokyo, Japan. Sponsor: M. Denison. 

#2064 3:51 SUPPRESSION OF TELOMERASE 

ACTIVITY AND EROSION OF TELOMERES 

BY PCB CONGENERS AND MIXTURES: 

A POSSIBLE NEW MECHANISM OF PCB 

CARCINOGENESIS? S. Pk, J. Jacobus, H. 

Lehmler, L. Robertson and G. Ludewig. Human 

Toxicology Program, The University of Iowa, Iowa 

City, IA. 


1:30 PM to 4:15 PM 

Room 251 A 

Platform Session: Nanotoxicology—Metals and Metal Oxide 

Particles 

Chairperson(s): Jim Riviere, North Carolina State University, Raleigh, 

NC. 

#2065 1:30 PHOTO-ACTIVATED TITANIUM DIOXIDE 

NANOPARTICLES INDUCE TOXICITY 

THROUGH AN OXIDATIVE STRESS 

MECHANISM IN ZEBRAFISH EMBRYOS. 

O. Bar-Ilan, J. Pedersen, R. E. Peterson and W. 

Heideman. Division of Pharmaceutical Sciences and 

NSEC, University of Wisconsin, Madison, WI. 

#2066 1:48 DERMAL ABSORPTION OF ZNO 

PARTICLES FROM SUNSCREENS. B. 

Gulson 1,2 , M. McCall 3 , L. Gomez 1 , M. Korsch 2 , P. 

Casey 4 and L. Kinsley 5 . 1 Macquarie Uni, Sydney, 

NSW, Australia, 2 CSIRO, Sydney, NSW, Australia, 

3 

CSIRO, Sydney, NSW, Australia, 4 CSIRO, 

Melbourne, VIC, Australia and 5 ANU, Canberra, 

ACT, Australia. 

#2067 2:07 ASSESSMENT OF UVB-DAMAGED SKIN IN 

VIVO WITH SUNSCREEN FORMULATIONS 

CONTAINING TITANIUM AND ZINC 

NANOPARTICLES. A. O. Inman 1 , R. Landsiedel 2 , 

K. Wiench 2 , J. E. Riviere 1 , S. Schulte 2 and N. A. 

Monteiro-Riviere 1 . 1 Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina 

State University, Raleigh, NC and 2 BASF SE, 


#2068 2:25 IN VITRO PENETRATION STUDIES OF 

FOUR SUNSCREEN FORMULATIONS 

CONTAINING TITANIUM AND ZINC 

NANOPARTICLES IN UVB DAMAGED 

SKIN. N. A. Monteiro-Riviere 1 , K. Wiench 2 , R. 

Landsiedel 2 , S. Schulte 2 , S. Champ 2 , A. O. Inman 1 

and J. E. Riviere 1 . 1 Center for Chemical Toxicology 

Research and Pharmacokinetics, North Carolina 

State University, Raleigh, NC and 2 BASF SE, 


#2069 2:44 CERIA ENGINEERED NANOMATERIAL 

DISTRIBUTION IN AND CLEARANCE 

FROM BLOOD: SIZE MATTERS. R. A. 

Yokel 1,2 , M. Dan 1,2 , R. L. Florence 1 , J. M. Unrine 3 , 

M. T. Tseng 8 , U. M. Graham 4 , R. Sultana 5 , S. S. 

Hardas 5 , D. Butterfield 5,6 , P. Wu 7 and E. A. Grulke 7 . 

1 

Pharmaceutical Sciences, University of Kentucky, 

Lexington, KY, 2 Toxicology, University of Kentucky, 

Lexington, KY, 3 Plant and Soil Science, University 

of Kentucky, Lexington, KY, 4 Center for Applied 

Energy Research, U Kentucky, Lexington, KY, 

5 

Chemistry, University of Kentucky, Lexington, 

KY, 6 Center of Membrane Sciences, University of 

Kentucky, Lexington, KY, 7 Chemical & Materials 

Engineering, University of Kentucky, Lexington, 

KY and 8 Anatomical Sciences & Neurobiology, 


#2070 3:02 NEURAL STEM CELL DIFFERENTIATION 

AFTER EXPOSURE TO QUANTUM DOTS. 

T. L. Oreskovic, N. S. Goldstein and K. M. Jeerage. 

Materials Reliability Division, National Institute of 

Standards and Technology (NIST), Boulder, CO. 

Sponsor: V. Castranova. 

286 






Platform Sessions



Abstract # 

#2071 3:20 REGULATION OF PLASMINOGEN 

ACTIVATOR INHIBITOR-1 EXPRESSION 

IN ENDOTHELIAL CELLS EXPOSED TO 

METAL NANOPARTICLES. R. Wan, M. Yu, 

Y. Mo, D. J. Tollerud and Q. Zhang. Environmental 

and Occupational Health Sciences, University of 


#2072 3:38 EXPRESSION OF THE LYMPHOCYTE 

CHEMOKINE, CXCL10, BY MULTIWALLED 

CARBON NANOTUBES AND NICKEL 

NANOPARTICLES IS REGULATED BY 

CYCLOOXYGENASE-2 (COX-2). B. C. 

Sayers, E. E. Glista, A. J. Taylor and J. C. Bonner. 


NC. 

#2073 3:57 INTERLEUKIN-13 POTENTIATES 

INDUCTION OF VASCULAR ENDOTHELIAL 

CELL GROWTH FACTOR (VEGF) BY 

NICKEL NANOPARTICLES. E. E. Glista, B. C. 

Sayers, A. J. Taylor and J. C. Bonner. Toxicology, 

North Carolina State University, Raleigh, NC. 


1:30 PM to 4:15 PM 

Room 250 


Platform Session: Predicting Hepatotoxicity: Computational 

Approaches to a Critical Target 

Chairperson(s): Kalyanasundaram Subramanian, Strand Life Sciences, 

Bangalore, India, and Luis Valerio, U.S. FDA, Silver Spring, MD. 

#2074 1:30 COMPUTATIONAL ASSESSMENT OF THE 

SAFETY OF BOTANICAL EXTRACTS 

WIDELY USED BY WOMEN IN THE 

UNITED STATES FOR TREATMENT OF 

MENOPAUSAL SYMPTOMS. Y. Wang 1,2 , J. 

Dou 3 , B. L. Minnier 1,2 and L. G. Valerio 1 . 1 Office of 

Pharmaceutical Science, CDER, U.S. FDA, Silver 

Spring, MD, 2 GlobalNet Services Inc., Rockville, 

MD and 3 Office of New Drugs, Botanical Review 

Team, CDER, U.S. FDA, Silver Spring, MD. 

#2075 1:50 EVALUATION OF A BIOCHIP 

TECHNOLOGY FOR THE PREDICTION 

OF METABOLISM-MEDIATED TOXICITY. 

M. Thomas, R. R. Note, J. Eilstein, H. Nocairi, 

D. Duché, G. Ouédraogo and J. Meunier. Safety 

Research, L’Oréal, Aulnay Sous Bois, France. 


#2076 2:11 DATA- AND SIMULATION-DRIVEN 

SYSTEMS FOR PREDICTIVE TOXICOLOGY. 

A. H. Roter 1 , S. Siler 1 , A. Harrill 2 and A. Kadambi 1 . 

1 

Informatics, Entelos, Inc., Foster City, CA and 2 The 


Triangle Park, NC. Sponsor: R. Brennan. 

Abstract # 

#2077 2:32 A NOVEL NON-PARAMETRIC STATISTICAL 

ALGORITHM IN GENE EXPRESSION 

ANALYSIS HELPS DIFFERENTIATE 

PREGNANE X RECEPTOR-DEPENDENT 

AND INDEPENDENT MECHANISMS OF 

TOXICITY. M. Mongan, Y. D. He, M. Higgins- 

Garn, C. Yuan, N. Li, P. Narayanan, R. T. Dunn, 

C. A. Afshari, T. L. Williamson, S. Vonderfecht, N. 

Everds, L. Carlock, C. DiPalma, S. Moss, R. Hu, C. 

Qualls, J. Bussiere and H. K. Hamadeh. Amgen, Inc., 

South San Francisco, CA. 

#2078 2:53 DISCRIMINATION BETWEEN GENE 

EXPRESSION CHANGES IN BLOOD THAT 

ARISE FROM LIVER NECROSIS AND 

FLUCTUATION OF HEMATOCYTES USING 

CANONICAL CORRELATION ANALYSIS. 

Y. Minowa 1 , N. Nakatsu 1 , A. Ono 2 , M. Kanki 3 , Y. 

Okuno 4 , H. Yamada 1 , Y. Ohno 2 and T. Urushidani 1,5 . 

1 

National Institute of Biomedical Innovation, Ibaraki- 

City, Japan, 2 National Institute of Health Sciences, 

Setagaya-ku, Japan, 3 Astellas Pharmacology Inc., 

Osaka, Japan, 4 Kyoto University, Kyoto, Japan 

and 5 Doshisha Women’s College of Liberal Arts, 

Kyotanabe, Japan. 

#2079 3:13 A VIRTUAL RAT LIVER TO PREDICT 

SUSCEPTIBILITY TO DILI IN METABOLIC 

SYNDROME. S. Das, R. Kumar, S. Raghavan and 

K. Subramanian. Strand Life Sciences, Bangalore, 

India. 

#2080 3:34 SIMULATING MICRODOSIMETRY OF 

ENVIRONMENTAL CHEMICALS IN EPA’S 

VIRTUAL LIVER. J. F. Wambaugh and I. Shah. 

National Center for Computational Toxicology, U.S. 


#2081 3:54 MODELING NUCLEAR RECEPTOR- 

MEDIATED ACTIVITY AND 

HEPATOTOXICITY WITH BOOLEAN 

NETWORKS. J. Jack and I. Shah. NCCT, U.S. 



1:30 PM to 2:30 PM 

Room 155 B 

Exhibitor Hosted Session: Determining Mechanisms of Action 

in Toxicology Using Metabolomics 

Presented by: Metabolon, Inc. 

Metabolomics is defined as “the non-biased quantification and identification 

of all metabolites present in a biological system,” but in practice the 

term metabolomics is used in a rather broad sense and covers many different 

analytical methodologies. To address the challenges associated with metabolomics, 

a comprehensive, integrated analytical and data handling platform 

was developed that provides a chemo-centric global metabolomics analyses 

of biological systems. 

WedneSday 







287


WedneSday 




2:30 PM to 3:30 PM 

Room 251 D 

Featured Session: A Conversation with the NIEHS 

Director: Linda Birnbaum 

Chairperson: Michael Holsapple, ILSI Health and Environmental 

Sciences Institute, Washington, DC 

Lecturer: Linda Birnbaum, National Institute of Environmental Health 

Sciences 

The Meet the Director program is a special 60 minute session that 

provides an opportunity for the leaders of major federal agencies to 

engage in a panel discussion of emerging trends in toxicology research 

and its funding. 

This session will be a particularly valuable opportunity to update SOT 

members on the future directions of the National Institute of Environmental 

Health Sciences (NIEHS) and the National Toxicology Program 

(NTP). Dr. Birnbaum will talk about her plans for leading NIEHS and 

NTP in its fifth decade of promoting the environmental public health of 

the United States and the world through research directed at preventing 

and treating disease. 


3:45 PM to 4:45 PM 

Room 251 D 


U.S. FDA National Center for Toxicological Research: 

William Slikker, Jr. 

The National Center for Toxicological Research (NCTR) is an internationally 

recognized FDA research center that provides leadership and 

innovative scientific solutions to improve public health. As its mission, 

NCTR conducts peer-reviewed scientific research in support of the FDA 

and provides data and expertise that enables FDA's science based regulatory 

decisions. The role of the NCTR to foster national and international 

collaborations and conduct training with scientists from government, 

academia, and industry to improve the science of regulatory decision 

making will be discussed. 


4:30 PM to 6:00 PM 


Special Interest Group Meeting/Reception: Women in 

Toxicology 


4:30 PM to 5:50 PM 

Room 150 

Roundtable Session: Overview of Current Regulatory 

Expectations for Oligonucleotide-Based Therapeutics: 

Case Studies for Different Classes of ODNs 

Chairperson(s): Scott P. Henry, Isis Pharmaceuticals, Toxicology and PK/ 

ADME, Carlsbad, CA, and Doug J. Kornbrust, Preclinsight, Toxicology 

Consultant, Reno, NV. 

Sponsor: 


Endorsed by: 


The field of oligonucleotide (ON) therapeutics is expanding rapidly, with 

applications to a broad array of molecular targets and disease indications. 

In general, various classes of ONs are categorized by their 

mechanism of action. Historically, the most familiar subclass is comprised 

of single-stranded DNA antisense ON, where hybridization to specific 

mRNA sequences inhibits expression of targeted proteins. Antisense 

ONs have been intensively investigated for nearly two decades, with one 

approved product and numerous other undergoing clinical development, 

several of which have recently been reported to exhibit compelling clinical 

pharmacology. Another type of application is the aptamer subclass. These 

molecules are identified through an elaborate screening process that selects 

for high affinity binding of a target protein. Thus far, one ON aptamer has 

been approved, and several other are undergoing clinical evaluation. As 

more is learned about RNA biology, the field has expanded to include therapeutic 

ONs that work through novel molecular mechanisms. An example 

is the emerging subclass of small interfering RNAs (siRNAs), which are 

double-stranded RNA molecules that act through RNA interference (RNAi). 

These siRNA also inhibit expression of proteins via targeted hybridization to 

specific mRNA sequences. The pharmacologic potency of these molecules 

has been impressive in nonclinical investigations, and several have entered 

the clinic. On the horizon are several new applications of ONs involving 

modulation of gene expression, and the one that has garnering most attention 

is the microRNA subclass. The expansion of the potential therapeutic 

utility of ONs is driven by a boom in the appreciation of the native role that 

RNA plays in regulation of the production of proteins through endogenous 

antisense, RNAi or micro-RNA interactions. This session will provide an 

overview of the regulatory perspective on development of ON-based therapeutics 

and will provide several examples of development programs that 

represent the various subclasses of ONs. 

#2082 4:30 OVERVIEW OF CURRENT 

DEVELOPMENT AND REGULATORY 

EXPERIENCE OLIGONUCLEOTIDE- 

BASED THERAPEUTICS: CASE 

STUDIES FOR DIFFERENT CLASSES 

OF OLIGONUCLEOTIDESS. S. P. Henry. 

Toxicology and PK/ADME, Isis Pharmaceuticals, 

Carlsbad, CA. 

4:40 SCREENING AND SELECTION OF 

ANTISENSE OLIGONUCLEOTIDES FOR 

DEVELOPMENT. Scott Henry 

4:50 CHALLENGES OF SIRNA DELIVERY FOR 

THERAPEUTIC APPLICATION. Thomas 

Singer 

5:00 UNIQUE THERAPEUTIC OPPORTUNITIES 

AND CHALLENGES FOR MICRO RNA. Lisa 

Hildebrandt-Eriksen 

5:10 GENERAL CONSIDERATIONS AND 

TOXICOLOGY PROGRAM DESIGN FOR 

THERAPEUTIC APTAMERS. Page Bouchard 


288 






Platform Sessions



Abstract # 


4:30 PM to 5:50 PM 

Ballroom D 

Informational Session: Seeking Funding for Undergraduate 

Research 

Chairperson(s): Joan B. Tarloff, University of the Sciences in 

Philadelphia, Philadelphia, PA, and Vanessa A. Fitsanakis, King College, 

Bristol, TN. 

Sponsor: 


Endorsed by: 



Most undergraduate professors are adept at finding teaching and learning 

resources for their classrooms and students. It is often more difficult, 

however, for them to readily know where to go for research funding. Additionally, 

many undergraduate faculty may find the information posted on 

National Institutes of Health (NIH) or National Science Foundation (NSF) 

Web sites intimidating and difficult to navigate if the faculty are not used 

to the language of granting bodies or institutions. Available grants could be 

in the form of classroom and teaching enhancement, professional development, 

or research opportunities for faculty and students. Both the NIH and 

the NSF have grants specifically tailored to the needs of undergraduate 

students and faculty. This session will provide undergraduate faculty with 

the opportunity to hear presentations from representatives from both federal 

programs, and to ask questions of each. The goal is to link toxicology 

faculty and undergraduate teaching institutions with appropriate contacts 

at the NIH and NSF, as well as encourage them to apply for funding. Such 

opportunities will directly benefit the faculty and students, thus strengthening 

the future applicants for toxicology programs around the nation. 

#2083 4:30 SEEKING FUNDING FOR 

UNDERGRADUATE RESEARCH. J. B. 

Tarloff 1 and V. A. Fitsanakis 2 . 1 Pharmaceutical 

Sciences, University of the Sciences in Philadelphia, 

Philadelphia, PA and 2 Biology, King College, Bristol, 

TN. 

4:35 ACADEMIC RESEARCH ENHANCEMENT 

AWARDS (AREA) THROUGH NIH. Michael 

Humble 

4:52 RESEARCH EXPERIENCES FOR 

UNDERGRADUATES (REU) AWARDS 

THROUGH NSF. Sally O’Connor 

5:09 EXPERIENCES WITH THE AREA 

PROGRAM. Eli Hestermann 



5:00 PM to 6:30 PM 

TBD 

Regional Chapter Happy Hour: Michigan 

Wednesday Evening, March 10 

6:00 PM to 7:30 PM 


WESDnESDAY EvEning 

Specialty Section Meetings/Receptions: Biotechnology 

(Room 355 A), Ethical, Legal, and Social Issues 

(Room 258), Neurotoxicology (Room 255 E), 

Reproductive and Developmental Toxicology (Room 255 B) 

Abstract # 

Thursday Morning, March 11 

7:30 AM to 8:50 AM 

Ballroom I 


8:30 AM to 12:00 NOON 


ThURSDAY MORning 

Issues Sessions: National Academy of Sciences Vision for 


Chairperson(s): Jon C. Cook, Pfizer Inc., Groton, CT. 

This Issues Session will continue the dialog begun at the highly 

successful 2008 NRC session in which the Annual Meeting participants 

were provided an overview of the three National Academy 

reports addressing key issues impacting the Society and the profession 

of toxicology. These reports included Toxicity Testing in the 21 st 

Century: A Vision and Strategy, Application of Toxicogenomics Technologies 

to Predictive Toxicology and Risk Assessment, and Models 

in Environmental Regulatory Decision Making. For the past two years, 

Toxicological Sciences has published a Forum Series on the Vision for 

Toxicology Testing in the 21 st Century. This is the third year we have 

had an Issues Session at the Annual Meeting dedicated to this discussion. 

In this installment, the Dr. Boekelheide will provide his perspective 

on distinguishing adaptive from adverse responses in in vitro systems, 

Dr. Hubal will introduce the concept of the exposome, and Dr. Wogan 

will describe the scientific challenges to the exposome approach. 

Dr. Chris Wild has argued that we need to complement the efforts around 

the genome with an exposome, which he defined as representing all environmental 

exposures from conception onwards including exposures from 

diet, lifestyle, and endogenous sources as a critical interest to disease 

eitiology as well as influencing toxicological outcome. 

• Distinguishing Adaptive from Adverse Responses in the 

New Testing Paradigm, Kim Boekelheide, Brown University, 


• Does Exposure Imitate Art: Exposure Science for 21 st Century 

Toxicity Testing, Elaine Cohen Hubal, U.S. EPA, Research Triangle 

Park, NC. 

• Scientific Challenges to the Exposome Approach, Gerald N. Wogan, 

Massachusetts Institute of Technology (MIT), Cambridge, MA. 

Poster Session: Endocrine Toxicology 

Chairperson(s): Melanie J. Powers Fraites, U.S. EPA, Research Triangle 

Park, NC, and Robert Landsiedel, BASF SE, Ludwigshafen, Germany. 

Displayed: 8:30 AM–12:00 NOON 



INHIBITION OF 11b-HSD1 DECREASES 

CIRCULATING ANDROGEN LEVELS AND 

INDUCES ATROPHY AND DECREASED 

ORGAN WEIGHT IN MALE ACCESSORY 

SEX GLANDS. J. A. Wisler, D. Branstetter, C. 

DiPalma, A. Mongan, H. Hamadeh, B. Boren, C. 

Fotsch, M. Wang and I. Pyrah. Amgen, Thousand 

Oaks, CA. 

thurSday 







289


thurSday 




EFFECTS OF HEPATCITIC ENZYME 

INDUCERS ON THYROXINE(T 4 

) 

CATABOLISM IN PRIMARY RAT 

HEPATOCYTES. V. M. Richardson 1,2 and M. 

J. DeVito 3 . 1 ORD/NHEERL, U.S. EPA, Research 

Triangle Park, NC, 2 Curriculum in Toxicology, 


Hill, NC and 3 NTP, NIEHS, Research Triangle Park, 

NC. 


EFFECTS OF IN UTERO AND LACTATIONAL 

EXPOSURE TO BISPHENOL A ON HIGHER 

BRAIN FUNCTION OF MALE C57BL/6J 

MICE: BEHAVIORAL AND PATHOLOGICAL 

ANALYSES. R. Hojo 1 , H. Kubota 2 , K. Kobayashi 2 

and M. Miyagawa 2 . 1 International Center for 

Research Promotion and Informatics, National 

Institute of Occupational Safety and Health, Japan, 

Kawasaki, Kanagawa Prefecture, Japan and 2 Division 

of Health Effects Research Group, National Institute 

of Occupational Safety and Health, Japan, Kawasaki, 

Kanagawa Prefecture, Japan. Sponsor: M. Ema. 


ATRAZINE DOES NOT INDUCE 

GASTROINTESTINAL DISTRESS (PICA) 

IN RATS AT DOSES THAT INCREASE 

HPA-AXIS ACTIVATION AND CAUSE 

CONDITIONED TASTE AVERSION. M. G. 

Hotchkiss, R. L. Cooper and S. C. Laws. Toxicity 

Assessment Division, NHEERL, ORD, U.S. EPA, 



EVALUATING THE INVOLVEMENT OF 

GLUCOCORTICOID FEEDBACK ON 

THE REPRODUCTIVE EFFECTS OF 

ENVIRONMENTAL CHEMICALS. M. J. 

Fraites 1 , S. Hester 2 , A. Buckalew 1 and R. L. Cooper 1 . 

1 

ORD, NHEERL, Toxicology Assessment Division, 

U.S. EPA, Research Triangle Park, NC and 2 ORD, 

NHEERL, Research Cores Unit, U.S. EPA, Research 



DIETHYLHEXYL PHTHALATE 

(DEHP) EFFECTS ON TESTOSTERONE 

PRODUCTION IN BLTK1 MOUSE LEYDIG 

CELLS. Q. Ding 1,2 , N. A. Rahman 3 , I. T. 

Huhtaniemi 3 and T. Zacharewski 1,2 . 1 Center for 


East Lansing, MI, 2 Biochemistry & Molecular 


MI and 3 Department of Physiology, University of 

Turku, Turku, Finland. 


MECHANISM OF THYROID 

TUMORIGENESIS IN RATS. A NON- 

RADIOACTIVE METHOD TO STUDY 

THE INDUCTION OF T4-SPECIFIC UDP- 

GLUCURONOSYL TRANSFERASE. E. 

Fabian 1 , N. Keller 1 , D. Dlugosch 1 , C. Werner 2 , B. 

van Ravenzwaay 1 and R. Landsiedel 1 . 1 Experimental 

Toxicology and Ecology, BASF SE, Ludwigshafen, 

Germany and 2 Product Safety, BASF SE, 



ESTROGEN RECEPTOR 

TRANSACTIVATION ASSAYS: COMPARING 

HELA-CELL- AND YEAST-BASED 

METHODS. S. N. Boehn, H. Huener, J. Knickel, 

C. Woitkowiak, B. van Ravenzwaay and R. 

Landsiedel. Experimental Toxicology and Ecology, 

BASF SE, Ludwigshafen, Germany. 


INDUCTION OF TESTOSTERONE 

PRODUCTION IN BLTK1 MURINE LEYDIG 

CELLS BY TRIAZINES AND THEIR 

PRIMARY METABOLITES. D. M. Wright 1 , 

A. Forgacs 1,2 , Q. Ding 1,2 , I. T. Huhtaniemi 3 , N. A. 

Rahman 3 and T. Zacharewski 1,2 . 1 Biochemistry & 




3 

Physiology, University of Turku, Turku, Finland. 


CADMIUM-INDUCED PANCREATIC ISLET 

b-CELLS DYSFUNCTION AND CELL 

DEATH: THROUGH ROS MEDIATED 

MAPK-MITOCHONDRIAL DEPENDENT 

APOPTOSIS PATHWAY. C. Huang 1 , Y. Chen 2 , C. 

Yang 3,5 , C. Yen 6 , D. Hung 4 and S. Liu 3,5 . 1 Graduate 

Institute of Chinese Medical Science, School of 

Chinese Medicine, China Medical University, 

Taichung, Taiwan, 2 Department of Physiology, China 

Medical University, Taichung, Taiwan, 3 Institute 

of Toxicology, National Taiwan University, Taipei, 

Taiwan, 4 Graduate Institute of Drug Safety, China 

Medical University, Taichung, Taiwan, 5 Department 

of Surgery, National Taiwan University Hospital, 

Taipei, Taiwan and 6 Department of Occupational 

Safety and Health, Chung Shan Medical University, 

Taichung, Taiwan. Sponsor: S. Lin-Shiau. 


GENE EXPRESSION IN THYROID AFTER 

PERCHLORATE TREATMENT COMPARED 

TO IODINE DEFICIENCY. J. N. McDougal 1 , K. 

L. Jones 2 , B. Fatuyi 2 and J. W. Fisher 2 . 1 Department 

of Pharmacology and Toxicology, Wright State 

University, Dayton, OH and 2 Department of 

Environmental Health Science, College of Public 

Health, University of Georgia, Athens, GA. 


MERCURY CHLORIDE-INDUCES 

PANCREATIC b-CELL DEATH: INVOLVE 

OF APOPTOSIS AND NECROSIS. Y. Chen 1 , 

C. Huang 2 , C. Yen 3 , D. Hung 4 , C. Yang 6,5 and S. 

Liu 5,6 . 1 Department of Physiology, China Medical 

University, Taichung, Taiwan, 2 School of Chinese 

Medicine, China Medical University, Taichung, 

Taiwan, 3 Department of Occupational Safety and 

Health, Chung San Medical University, Taichung, 

Taiwan, 4 Graduate Institute of Drug Safety, China 

Medical University, Taichung, Taiwan, 5 Institute 

of Toxicology, National Taiwan University, Taipei, 

Taiwan and 6 Department of Surgery, National Taiwan 

University Hospital, Taipei, Taiwan. Sponsor: S. Lin- 

Shiau. 

290 






Platform Sessions



Abstract # 


GUIDANCE ON IDENTIFYING ENDOCRINE 

DISRUPTING EFFECTS. I. Fegert 1 , R. Bars 2 , R. 

Lewis 3 , N. Hallmark 4 , F. Broeckaert 5 , S. O’Hagan 6 , 

J. Wheeler 3 , G. Panter 7 , A. Weyers 8 , T. Kedwards 9 

and M. Galay-Burgos 10 . 1 BASF SE, Ludwigshafen, 

Germany, 2 Bayer Crop Science, Sophia Antipolis, 

France, 3 Syngenta, Jealotts Hill, United Kingdom, 

4 

Exxon Mobil, Machelen, Belgium, 5 Total 

Petrochemicals, Seneffe, Belgium, 6 Unilever, 

Sharnbrook, United Kingdom, 7 AstraZeneca, 

Brixham, United Kingdom, 8 Currenta, Leverkusen, 

Germany, 9 SC Johnson, Camberley, United Kingdom 

and 10 ECETOC, Brussels, Belgium. 


MIXTURE EFFECTS OF THREE 

FLAVONOID PHYTOCHEMICALS 

ON ADRENAL AND SEX HORMONE 

SECRETION IN THE HUMAN 

ANDRENOCORTICAL CELL LINE H295R. 

A. Oskarsson 1 , . Ohlsson 1 , N. Cedergreen 2 and E. 

Ullerås 1 . 1 Biomedical Sciences and Veterinary Public 

Health, Swedish University of Agricultural Sciences, 

Uppsala, Sweden and 2 Agricultural Sciences, 

University of Copenhagen, Copenhagen, Denmark. 


THE EFFECTS OF SIMAZINE, A 

CHLOROTRIAZINE HERBICIDE, ON 

FEMALE PUBERTAL DEVELOPMENT. L. 

M. Zorrilla 1,2 , E. K. Gibson 2 and T. E. Stoker 2 . 

1 

Molecular Biomedical Science, College of 

Veterinary Medicine, North Carolina State 

University, Raleigh, NC and 2 Endocrine Toxicology 

Branch, Toxicity Assessment Division, NHEERL, 




DIETARY IODIDE DEFICIENCY AND 

DISRUPTION OF THE HYPOTHALAMIC- 

PITUITARY-THYROID (HPT) AXIS BY 

PERCHLORATE IN ADULT RATS. B. Fatuyi 1 , 

K. Jones 1 , E. McLanahan 2 , J. McDougal 3 , B. 

Blount 4 , L. Valentin-Blasini 4 , K. Kurunthachalam 5 , T. 

Kunisue 5 , W. Henderson 6 and J. W. Fisher 1 . 1 College 

of Public Health, University of Georgia, Athens, GA, 

2 

National Center for Environmental Assessment, U.S. 

EPA, Research Triangle Park, NC, 3 Pharmacology 

and Toxicology, Wright State University, Dayton, 

OH, 4 CCEHIP/NCEH, CDC, Atlanta, GA, 

5 

Wadsworth Center, NYS Department of Health, 

Albany, NY and 6 National Exposure Research 

Laboratory, U.S. EPA, Athens, GA. 


BONE AS A TARGET TISSUE IN THE 

TOXICOLOGICAL ASSESSMENT OF 

ANTI-DIABETES DRUG CLASS OF SGLT1 

INHIBITORS. T. Kissner 2 , N. Doyle 1 , R. 

Samadfam 1 , E. Krupp 2 , M. Heinrichs 2 , S. Haile 1 and 

S. Y. Smith 1 . 1 Toxicology, Charles River Laboratories, 


Canada and 2 Sanofi-Aventis Deutschland GmbH, 

Frankfurt, Germany. Sponsor: M. Vézina. 

Abstract # 


GENISTEIN MODULATION OF BLOOD 

GLUCOSE LEVELS IN DIABETIC MALE 

MOUSE MODELS. T. L. Guo 1 , J. F. Zheng 1 , D. 

R. Germolec 2 and K. L. White, Jr. 1 . 1 Pharmacology 

and Toxicology, Virginia Commonwealth University, 

Richmond, VA and 2 NIEHS, Research Triangle Park, 

NC. 


INTERACTION OF POTENTIAL 

ENDOCRINE-DISRUPTING CHEMICALS 

WITH CYP3A4, CYP1A2, P-GLYCOPROTEIN 

AND RAT CYP3A1 PROMOTER REGIONS. 

J. G. Lamb 1 , J. Raucy 2 , M. R. Franklin 1 and M. 

Peterson 3 . 1 Pharmacology and Toxicology, University 

of Utah, Salt Lake City, UT, 2 Puracyp Inc., Carlsbad, 

CA and 3 3Obstetrics and Gynecology, University of 



PERINATAL EXPOSURE TO PCB52 

AND PCB180 INCREASES AROMATASE 

ACTIVITY IN RAT LIVER, OVARY AND 

ADRENAL GLAND. E. Antunes Fernandes, J. van 

den Brink, F. Daamen, C. Bouki, M. van den Berg 

and M. van Duursen. Institute for Risk Assessment 

Sciences, Utrecht University, Utrecht, Netherlands. 


TRICLOSAN DISRUPTS THYROXINE: 

CONTRIBUTION OF HEPATIC TRANSPORT 

TO THE MODE OF ACTION. K. B. Paul 1,3 , J. M. 

Hedge 3 , M. J. DeVito 4,1 , K. R. Brouwer 2,1 and K. M. 

Crofton 3,1 . 1 Curriculum in Toxicology, University of 

North Carolina, Chapel Hill, NC, 2 Eshelman School 

of Pharmacy, University of North Carolina, Chapel 

Hill, NC, 3 Integrated Systems Toxicology Division, 

NHEERL, ORD, U.S. EPA, Research Triangle Park, 

NC and 4 Toxicology Branch, NTP, NIEHS, Research 



RECRUITMENT OF COREGULATORY 

PROTEINS TO THE ESTROGEN RECEPTOR 

COMPLEX BY XENOESTROGEN LIGANDS. 

J. C. Clark 1 , S. McGee 1 , P. Ferguson 2 and T. 

Sabo-Attwood 1 . 1 Environmental Health Sciences, 

University of South Carolina, Columbia, SC and 

2 

Engineering, Duke University, Durham, NC. 

Sponsor: D. Volz. 


GENDER DIFFERENCES IN ESTROGEN 

RECEPTOR EXPRESSION AND 

ACTIVATION IN THE LUNG BY 

XENOESTROGENS. S. McGee 1 , J. C. Clark 1 , 

W. Karmaus 2 , H. Zhang 2 and T. Sabo-Attwood 1 . 

1 

Environmental Health Sciences, University of South 

Carolina, Columbia, SC and 2 Epidemiology and Bio- 

Statistics, University of South Carolina, Columbia, 

SC. Sponsor: D. Volz. 


ORGANIZATIONAL VERSUS 

ACTIVATIONAL EFFECTS OF THE 

ANTIANDROGEN FLUTAMIDE ON MALE 

MEDAKA. C. V. Rider, A. T. Watson and D. E. 

Hinton. Nicholas School of the Environment, Duke 


thurSday 







291


thurSday 




VALIDATION OF 15-DAY ADULT MALE 

ASSAY. C. Sloan 1 , R. W. Tyl 1 , B. T. Hamby 1 , C. B. 

Myers 1 and R. A. Becker 2 . 1 Discovery and Analytical 

Sciences, RTI International, Research Triangle Park, 

NC and 2 American Chemistry Council, Arlington, 

VA. 


VALIDATION OF AN AUTOMATED 

AUDITORY STARTLE RESPONSE (ASR) 

SYSTEM BY CHEMICAL AND NON- 

CHEMICAL MEANS. E. R. Frizell, R. M. Parker, 

G. Theerman, C. Savidge and S. Wilcox. Huntingdon 

Life Sciences, East Millstone, NJ. 


FEMALE PUBERTAL ASSAY: VALIDATION 

USING KNOWN ENDOCRINE DISRUPTORS. 

E. R. Frizell 1 , R. M. Parker 1 , E. M. Horsley 2 and K. 

Hazelden 3 . 1 DART, Huntingdon Life Sciences, East 

Millstone, NJ, 2 Pfizer, Sandwich, United Kingdom 

and 3 MedImmune, Cambridge, United Kingdom. 


MALE PUBERTAL ASSAY: VALIDATION 

USING KNOWN ENDOCRINE DISRUPTORS. 

R. M. Parker 1 , E. R. Frizell 1 , E. Horsley 2 and K. 

Hazelden 3 . 1 DART, Huntingdon Life Sciences, East 

Millstone, NJ, 2 Pfizer, Sandwich, United Kingdom 

and 3 MedImmune, Cambridge, United Kingdom. 


INTERACTION OF PERFLUOROALKYL 

ACIDS WITH HUMAN ESTROGEN 

RECEPTOR ALPHA. A. D. Benninghoff, D. 

Koch, W. Bisson, S. K. Kolluri and D. E. Williams. 




THE ATRAZINE METABOLITE DACT 

CAUSES SUPPRESSION OF LH RELEASE IN 

LbT2 PITUITARY CELLS. A. C. Schell, R. B. 

Tjalkens, M. E. Legare and W. Hanneman. Colorado 

State University, Fort Collins, CO. 


8:30 AM to 12:00 NOON 


Poster Session: Juvenile Toxicity 

Chairperson(s): Ali Faqi, MPI Research, Mattawan, MI. 


Author Attended: 10:15 AM–12:00 NOON 


A 28-DAY TOXICITY STUDY IN JUVENILE 

BEAGLE DOGS WITH A ONE MONTH 

RECOVERY FOLLOWING ORAL 

ADMINISTRATION OF FAROPENEM 

MEDOXOMIL. A. S. Faqi 1 , C. Lanphear 1 , S. 

Gill 2 and D. B. Colagiovanni 2 . 1 Developmental & 

Reproductive Toxicology, MPI Research, Mattawan, 

MI and 2 Toxicology, Replidyne, Inc., Louisville, CO. 


TRANSCRIPTIONAL PROFILING 

OF MOUSE AND HUMAN LIVERS AT 

DIFFERENT LIFE STAGES. J. Lee, W. Ward, H. 

Ren, B. Vallanat, B. Abbott and C. Corton. NHEERL, 



COMPARATIVE ANALYSIS OF CARDIAC 

RHYTHM AND QUANTITATIVE ELEMENTS 

OF THE ELECTROCARDIOGRAM (ECG) 

IN JUVENILE AND ADULT BEAGLE DOGS. 

B. A. Thorsrud 1 , A. S. Faqi 1 , D. L. Holdsworth 2 

and T. J. Baird 2 . 1 Developmental and Reproductive 

Toxicology, MPI Research, Mattawan, MI and 

2 

Safety Pharmacology, MPI Research, Mattawan, MI. 


MITOCHONDRIAL TOXICITY OF 

TOBBACCO IN SMOKING PREGNANT 

MOTHERS AND THEIR NEWBORN. F. 

Cardellach 1 , A. Hernandez 2 , G. Garrabou 1 , C. 

Morén 1 , M. Nicolàs 1 , O. Coll 2 and Ò. Miró 1 . 

1 

Mitochondrial Research Laboratory, IDIBAPS, 

University of Barcelona, Hospital Clínic of 

Barcelona, CIBERER, Barcelona, Spain and 

2 

Materno-Fetal Medicine Service, Hospital Clínic of 

Barcelona, Barcelona, Spain. Sponsor: J. Domingo. 


ACCURATE AND EFFICIENT ANALYSIS 

OF METALS IN CONSUMER PRODUCTS 

USING XRF TECHNOLOGY. S. Goldberg 2 , A. 

Goldberg 2 and S. Gilbert 1 . 1 INND, Seattle, WA and 

2 

Environmental Services & Solutions Corporation— 

Essco Safety Check, Redmond, WA. 


SAFETY PHARMACOLOGY TECHNIQUES 

FOR ASSESSMENT OF RESPIRATORY 

MINUTE VOLUME IN JUVENILE RATS. K. 

Norton, K. Robinson and M. Vézina. Toxicology, 

Charles River, Preclinical Services (PCS-MTL), 



ATTENUATION OF HYPEROXIA-INDUCED 

RETINOPATHY IN THE NEWBORN RAT 

MODEL BY b-NAPHTHOFLAVONE. X. I. 

Couroucli, Y. W. Liang, W. Jiang and B. Moorthy. 

Pediatrics, Baykir College of Medicine, Houston, 

TX. 


MITOCHONDRIAL DNA DEPLETION IN 

HIV-INFECTED CHILDREN. C. Morén 1,3 , 

A. Noguera 2 , G. Garrabou 1,3 , N. Rovira 2 , M. 

Nicolàs 1,3 , F. Cardellach 1,3 , Ò. Miró 1,3 and C. 

Fortuny 2 . 1 Mitochondrial Research Laboratory- 

IDIBAPS-University of Barcelona-Hospital Clinic of 

Barcelona-CIBERER, Barcelona, Spain, 2 Pediatric 

Department, Hospital St. Joan de Déu, Barcelona, 

Spain and 3 CIBER de Enfermedades Raras, Valencia, 

Spain. Sponsor: J. Domingo. 

292 






Platform Sessions



Abstract # 


8:30 AM to 12:00 NOON 



Poster Session: Drug-Induced Liver Injury 

Chairperson(s): Aaron Fullerton, Michigan State University, Lansing, MI. 




BSEP INHIBITION AND RISK OF DRUG 

INDUCED LIVER INJURY IN MAN. S. Stahl, 

S. Dawson, J. Barber, N. Paul and J. G. Kenna. 

Molecular Toxicology, AstraZeneca, Macclesfield, 

Cheshire, United Kingdom. Sponsor: R. Roberts. 


TROVAFLOXACIN AND TUMOR NECROSIS 

FACTOR-a INTERACT TO CAUSE CELL 

DEATH IN HEPG2 CELLS. K. M. Beggs 1,2 , P. 

E. Ganey 1,2 and R. A. Roth 1,2 . 1 Pharmacology and 


MI and 2 Center for Integrative Toxicology, Michigan 



TOLERANCE IN AN ANIMAL MODEL OF 

AMODIAQUINE-INDUCED LIVER INJURY. 

P. Cai, T. Nakagawa and J. Uetrecht. Faculty of 


Canada. 


TROVAFLOXACIN POTENTIATES LPS- 

INDUCED TNFa EXPRESSION IN A 

MACROPHAGE CELL LINE. K. L. Poulsen, R. 

Singhal, P. E. Ganey and R. A. Roth. Pharmacology 


Lansing, MI. 


ASSESS THE SEVERITY OF DILI USING 

HIGH CONTENT SCREENING ASSAY 

BASED ON RAT PRIMARY HEPATOCYTES. 

M. Chen, Q. Shi, L. Guo, L. Shi and W. Tong. U.S. 

FDA NCTR, Jefferson, AR. 


POTENTIAL HEPATOTOXICITY OF 

5-(3, 5-DICHLOROPHENYLMETHYL)-2, 

4-THIAZOLIDINEDIONE (5-DCPMT) IN 

RATS. D. M. Frederick, E. Y. Jacinto, R. Tchao 

and P. J. Harvison. Department of Pharmaceutical 

Sciences, University of the Sciences in Philadelphia, 


Abstract # 


CORRELATION OF TOXICITY INDUCED 

ENDOGENOUS METABOLITES 

DISREGULATION WITH XENOBIOTIC 

METABOLISM BY AN INTEGRATED 

METABONOMIC APPROACH: EFFECTS 

OF LIVER-SPECIFIC KNOCKOUT OF THE 

NADPH-CYTOCHROME P450 REDUCTASE 

GENE ON TRIPTOLIDE INDUCED 

TOXICITY. X. Xue 1 , X. Liu 1 , L. Gong 1 , Y. Xiao 1 , 

Y. Luan 1 , Y. Wu 1 , G. Xing 1 , X. Qi 1 , Y. Li 1 , H. Lu 1 , 

J. Gu 2 , D. Lin 1 and J. Ren 1 . 1 Shanghai Institute of 

Materia Medica, Shanghai, China and 2 New York 

State Department of Health, Albany, NY. 


INCREASED MITOCHONDRIAL 

PEROXYNITRITE STRESS AND 

HEPATIC MITOCHONDRIAL INJURY IN 

HETEROZYGOUS Sod2+/- MICE EXPOSED 

TO TROVAFLOXACIN. C. J. Hsiao 1 , H. Younis 2 

and U. A. Boelsterli 1 . 1 Pharmaceutical Sciences, 

University of Connecticut, Storrs, CT and 2 Pfizer 

Global Research and Development, San Diego, CA. 


ACETAMINOPHEN INDUCES 

HEPATOTOXICITY IN Ppif-/- MICE 

DEFICIENT IN CYCLOPHILIN D, A MAJOR 

REGULATOR OF THE MITOCHONDRIAL 

PERMEABILITY TRANSITION (MPT). A. 

LoGuidice and U. A. Boelsterli. Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT. 


ENHANCED OXIDATIVE STRESS 

RESPONSE IN FEMALE VANIN- 

1 NULL MICE EXPOSED TO A 

MINIMALLY HEPATOTOXIC DOSE OF 

ACETAMINOPHEN. D. W. Ferreira 1 , F. Galland 2 , 

P. Naquet 2 and J. E. Manautou 1 . 1 Pharmaceutical 

Sciences, University of Connecticut, Storrs, CT and 

2 

Centre d’Immunologie de Marseille-Luminy CNRS- 

INSERM-Université de la Méditerranée, Marseille, 

France. 


BCRP -/- MICE SHOW INCREASED 

TOXICITY AND REDUCED RECOVERY 

FROM LIVER AND KIDNEY INJURY 

FOLLOWING TOXIC ACETAMINOPHEN 

TREATMENT. M. O’Connor 1 , S. N. Campion 1 , 

M. Goedken 2 and J. E. Manautou 1 . 1 Department of 

Pharmaceutical Sciences, University of Connecticut, 

Northford, CT and 2 Pathology Department, Schering- 

Plough Research Institute, Lafayette, NJ. 


LOW OXYGEN TENSION ATTENUATES 

ACETAMINOPHEN-INDUCED 

HEPATOCYTE CELL DEATH IN CULTURE. 

A. Ramachandran 1 , H. Yan 1 , J. J. Lemasters 2 

and H. Jaeschke 1 . 1 Pharmacology, Toxicology & 


Kansas City, KS and 2 Medical University of South 

Carolina, Charleston, SC. 

thurSday 







293





EFFECT OF INTERLEUKIN-1BETA 

ON NEUTROPHIL ACTIVATION AND 

ACETAMINOPHEN HEPATOTOXICITY. C. 

Williams, M. Bajt and H. Jaeschke. Pharmacology, 

Toxicology & Therapeutics, University of Kansas 



HEPARG CELLS: A NEW HUMAN MODEL 

FOR THE STUDY OF ACETAMINOPHEN 

HEPATOTOXICITY. M. R. McGill, H. Yan 

and H. Jaeschke. Pharmacology, Toxicology & 




THE ROLE OF TOLL-LIKE RECEPTOR 4 IN 

ACETAMINOPHEN HEPATOTOXICITY. R. 

Singhal 1 , J. F. Maddox 1 , L. D. Lehman-McKeeman 2 , 

T. P. Reilly 3 , M. A. Tirmenstein 3 , V. M. Bhaskaran 2 , 

P. E. Ganey 1 and R. A. Roth 1 . 1 Pharmacology and 


MI, 2 Discovery Toxicology, Bristol-Myers Squibb, 

Princeton, NJ and 3 Drug Safety Evaluation, Bristol- 

Myers Squibb, Syracuse, NY. 


HIF-1a DELETION PROTECTS MICE FROM 

ACETAMINOPHEN HEPATOTOXICITY 

AND REDUCES ACTIVATION OF THE 

HEMOSTATIC SYSTEM. E. M. Sparkenbaugh, 

Y. Saini, J. J. LaPres, J. F. Maddox, P. E. Ganey 

and R. A. Roth. Center for Integrative Toxicology, 



ACETAMINOHPEN ALTERATIONS 

OF SUBCELLUAR S-ADENOSYL-L- 

METHIONINE LEVELS AND HEPATIC 

METABOLISM. J. Brown, J. G. Ball and 

M. Valentovic. Pharmacology, Physiology, and 

Toxicology, Marshall University School of Medicine, 



ROLE OF INTERLEUKIN-6 IN OZONE 

EXACERBATION OF ACETAMINOPHEN- 

INDUCED LIVER INJURY. D. Ibrahim Aibo 1,3 , 

J. Maddox 2,3 , N. Birmingham 3 , P. Ganey 2,3 , R. Roth 2,3 , 

J. Wagner 1,3 and J. Harkema 1,3 . 1 Pathobiology and 

Diagnostic Investigation, Michigan State University, 

East Lansing, MI, 2 Pharmacology and Toxicology, 


3 




8:30 AM to 12:00 NOON 



Poster Session: Receptors 


and Linda Mota, Clemson University, Pendleton, SC. 




ROLE OF GABA RECEPTORS IN THE 

ANTINOCICEPTION OF GABAPENTIN 

AND TRAMADOL. X. Dai 1 , C. D. Brunson 1 , I. 

I. Eriator 1 and T. Ma 2 . 1 Anesthesiology, UMMC, 

Jackson, MS and 2 Pharmacology&Toxicolgy, 

UMMC, Jackson, MS. 


HUMAN PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR MRNA AND 

PROTEIN EXPRESSION DURING 

DEVELOPMENT. A. M. Watkins, C. R. Wood, 

K. P. Das and B. D. Abbott. Toxicity Assessment 

Division, U.S. EPA, Research Triangle Park, NC. 


PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-b/d (PPAR 

b/d) INHIBITS VIRAL HRAS1 

(V-HRAS1)-INDUCED NEOPLASTIC 

TRANSFORMATION OF MOUSE PRIMARY 

KERATINOCYTES. B. Zhu 1 , M. Bility 1 , N. 

Blazanin 1 , A. B. Glick 1 , F. J. Gonzalez 2 and J. M. 

Peters 1 . 1 Ctr. for Molec. Toxic. & Carcin, Penn State 

University, University Park, PA and 2 Laboratory of 

Metabolism, National Cancer Institute, Bethesda, 

MD. 


PPARb/d -DEPENDENT AND INDEPENDENT 

FUNCTIONS OF THE PPARb/d ANTAGONIST 

GSK3787. P. S. Palkar 1 , M. G. Borland 1 , C. Lee 1 , 

C. H. Ferry 1 , A. K. Sharma 2 , S. Amin 2 , A. N. Billin 3 , 

T. M. Wilson 3 , F. J. Gonzalez 4 and J. M. Peters 1 . 

1 

Department of Vet. and Biomed Sci, Penn State 

University, State College, PA, 2 Department of 

Pharmacology, Penn State Cancer Institute, Hershey, 

PA, 3 Nuclear Receptor Discovery Research, 

GlaxoSmithKline, Research Triangle Park, NC and 

4 

Laboratory of Metabolism, NCI, Bethesda, MD. 

thurSday 


FUNCTIONAL EXAMINATION OF THE 

ROLE OF PEROXISOME PROLIFERATOR- 

ACTIVATED RECEPTOR-b/d (PPARb/d) IN 

HUMAN COLON CANCER. J. E. Foreman 1 , 

J. L. Williams 2 , B. Rigas 2 , F. J. Gonzalez 3 and J. 

M. Peters 1 . 1 The Center for Mol. Toxicology & 

Carcinogenesis, Penn. State University, University 

Park, PA, 2 Division of Cancer Prevention, Stony 

Brook University, Stony Brook, NY and 3 Laboratory 

of Metabolism, NCI, Bethesda, MD. 

294 






Platform Sessions



Abstract # 


DIELDRIN INDUCES THE RAT 

PARAOXONASE (PON1) PROMOTER VIA 

PXR, RXR. M. Dail, R. R. Pickin, J. A. Crow and 

J. E. Chambers. Center for Environmental Health, 

Mississippi State, Mississippi State, MS. 


NATURALLY OCCURRING HUMAN 

CONSTITUTIVE ANDROSTANE RECEPTOR 

SPLICE VARIANTS UNDERGO LIGAND 

SELECTIVE PROTEIN INTERACTIONS. E. 

M. Laurenzana, J. G. DeKeyser and C. J. Omiecinski. 

Canter for Molecular Toxicology and Carcinogenesis, 

Department of Veterinary and Biomedical Sciences, 

The Pennsylvania State University, University Park, 

PA. 


A SINGLE AMINO ACID CONTROLS 

THE FUNCTIONAL SWITCH OF HUMAN 

CAR1 TO THE XENOBIOTIC ACTIVATED 

SPLICING VARIANT CAR3. T. Chen 1,2 , L. 

M. Tompkins 2 , G. Kim 2 , C. J. Omiecinski 1 and H. 

Wang 2 . 1 Center for Molecular Toxicology and 

Carcinogenesis, Pennsylvania State University, 

University Park, PA and 2 Pharmaceutical Sciences, 

University of Maryland School of Pharmacy, 

Batimore, MD. 

#2148 Poster Board ....................................................329 

PXR STATUS IS ASSOCIATED WITH CYP 

INDUCTION, HISTOPATHOLOGICAL 

EFFECTS, AND REDUCED CLEARANCE OF 

NONYLPHENOL. L. C. Mota and W. Baldwin. 

Environmental Toxicology, Clemson University, 

Clemson, SC. 


CRITICAL ROLE OF NRF2 CYSTEINE 

RESIDUES IN OXIDANT/ELETROPHILE- 

SENSING AND SIGNAL TRANSDUCTION. 

Q. Ma 1,2 and X. He 1 . 1 Receptor Biology Lab/TMBB/ 

HELD, National Institute for Occupational Safety 

and Health, Morgantown, WV and 2 Department of 

Biochemistry, West Virginia University School of 

Medicine, Morgantown, WV. 


SEARCHING FOR THE SPECIFIC 

INTRACELLULAR TARGET OF BORIC 

ACID THAT LEADS TO THE INHIBITION 

OF CALCIUM RELEASE IN PROSTATE 

CANCER CELL LINES. S. E. Kobylewski 1 , 

K. A. Henderson 1 and C. D. Eckhert 2 . 1 Molecular 

Toxicology, University of California Los Angeles, 

Los Angeles, CA and 2 Environmental Health 

Sciences, University of California Los Angeles, Los 

Angeles, CA. 


TRPV1 MEDIATES LUNG TOXICITIES OF 

SPECIFIC PARTICULATE MATERIALS. C. 

A. Reilly, M. Johansen, K. Thomas, J. Veranth and G. 

Yost. Pharmacology and Toxicology, University of 


Abstract # 


ELUCIDATING THE CONSTITUITIVE AND 

INDUCIBLE ACTIVITY OF THE HUMAN 

TNIP1 PROMOTER. P. C. Encarnacao, C. Zhang 

and B. Aneskievich. Pharmacology/Toxicology, 

University of Connecticut, Storrs, CT. Sponsor: J. 

Manautou. 


CONTRIBUTIONS OF TRPV1, THE 

ENDOPLASMIC RETICULUM STRESS 

RESPONSE, AND ENDOVANILLOIDS TO 

INFLAMMATORY LUNG INJURY AND 

LUNG CELL DEATH IN VITRO. K. C. Thomas, 

G. S. Yost and C. A. Reilly. Pharmacology and 

Toxicology, University of Utah, Salt Lake City, UT. 


CAR AND PXR-DEPENDENT 

TRANSCRIPTIONAL CHANGES IN THE 

MOUSE LIVER AFTER EXPOSURE TO 

THE FUNGICIDE AND MOUSE LIVER 

CARCINOGEN, PROPICONAZOLE. C. 

Corton 1 , S. Hester 1 , L. Aleksunes 2 , H. Ren 1 , C. Jones 1 , 

T. Moore 1 , C. Klaassen 2 and S. Nesnow 1 . 1 U.S. EPA, 

Research Triangle Park, NC and 2 University of 



CHARACTERIZATION OF PEROXISOME 


ALPHA (PPARALPHA)—INDEPENDENT 

EFFECTS OF PPARALPHA ACTIVATORS IN 

THE RODENT LIVER: DI-(2-ETHYLHEXYL) 

PHTHALATE ALSO ACTIVATES THE 

CONSTITUTIVE ACTIVATED RECEPTOR. 

H. Ren 1 , L. Aleksunes 2 , C. Wood 1 , B. Vallanat 1 , M. 

George 1 , C. Klaassen 2 and C. Corton 1 . 1 U.S. EPA, 

Research Triangle Park, NC and 2 University of 



LIVER MRNA AND MIRNA PROFILING 

OF PHENOBARBITAL (PB)-TREATED 

PXR/CAR DOUBLE KNOCK-OUT AND 

HUMANIZED MICE PROVIDES INSIGHT 

INTO MECHANISM(S) OF PB-MEDIATED 

MOUSE HEPATOCARCINOGENESIS. C. R. 

Elcombe 1 , D. Dhritiman 1 , C. Wolf 1 , N. Scheer 2 and 

S. M. Plummer 1 . 1 CXR Biosciences Ltd., Dundee, 

United Kingdom and 2 TaconicArtemis GmbH, 

Cologne, Germany. 


LOSS OF PREGNANE X RECEPTOR 

CONTRIBUTES TO COLON CANCER CELL 

INVASION VIA REGULATING b-CATENIN 

CYTOPLASMIC ACCUMULATION. N. 

Ouyang, H. Yao, N. Eagleton-Harvey, S. Ke, Y. Xie, 

B. Zhou and Y. Tian. Texas A&M University, College 

Station, TX. 

thurSday 







295


thurSday 




8:30 AM to 12:00 NOON 


Poster Session: Metals II 

Chairperson(s): Louis Trombetta, St. John’s University, Jamaica, NY. 




HEALTH MANIFESTATIONS ASSOCIATED 

WITH OCCUPATIONAL EXPOSURE TO 

NICKEL. F. M. Metwally 1 , A. M. El Safty 2 , H. 

M. Rashad 1 and F. S. Bayoumi 3 . 1 Enviromental 

& Occupational Medicine Department, National 

Research Center, Giza, Egypt, 2 Industrial Medicine 

Department, Cairo University, Cairo, Egypt and 

3 

Immuno-genetics Department, National Research 

Center, Giza, Egypt. 


SACCHAROMYCES CEREVISIAE GENOME- 

WIDE DELETION MUTANT SCREEN FOR 

ALTERED SENSITIVITY AND RESISTANCE 

TO NICKEL SULFATE. A. G. Arita 1 , X. Zhou 1 , 

T. Ellen 1 , X. Liu 1 , J. Bai 1 , J. Rooney 2 , C. Klein 1 , 

W. Dai 1 , T. Begley 2 and M. Costa 1 . 1 Environmental 

Medicine, New York University, Tuxedo, NY and 

2 

Department of Biomedical Sciences, Gen*NY*Sis 

Center for Excellence in Cancer Genomics, SUNY- 

Albany, Albany, NY. 


TOXICOLOGICAL EFFECTS OF 

COEXPOSURE TO NICKEL AND COBALT 

IN HUMAN LUNG EPITHELIAL CELLS. C. 

Lynch and M. Reynolds. Department of Biology, 

Washington College, Chestertown, MD. 


ELEVATED LEVELS OF COPPER AND 

NICKEL IN ELDERLY SUBJECTS WITH 

LEFT VENTRICULAR HYPERTROPHY. 

M. P. Lind 1 and L. Lind 2 . 1 Department of Medical 

Sciences/Occupational and Environmental 

Medicine, University of Uppsala, Uppsala, Sweden 

and 2 Department of Medical Sciences/Medicine, 

University of Uppsala, Uppsala, Sweden. 


AGE-DEPENDENT TRANSPORT 

OF COPPER (CU) AT THE BLOOD- 

CEREBROSPINAL FLUID BARRIER. Y. 

Zhang 1,2 , Q. Fan 3 , M. Behl 1 , W. Jiang 1 , S. Fu 1 , L. 

Hong 1 , A. D. Monnot 1 and W. Zheng 1 . 1 Purdue 

University, West Lafayette, IN, 2 North China Coal 

Medical University, Tangshan, Hebei, China and 

3 

Zunyi Medical College, Zunyi, Guizhou, China. 


TRANSFORMATION-DISSOLUTION 

STUDIES OF TUNGSTEN SUBSTANCES. R. 

Lemus 1 , K. Heim 1 , J. Skeaff 2 , M. Jackson 1 and M. 

Pardus 1 . 1 ARCADIS U.S. Inc., Pittsburgh, PA and 

2 

CANMET-MMSL, Ottawa, ON, Canada. 


BIOACCESSIBILITY STUDY OF 

HARDMETALS. K. E. Heim 1 , M. Jackson 1 , R. 

Lemus 1 , D. Capellini 2 and M. Pardus 1 . 1 ARCADIS, 

Durham, NC and 2 Kirby Memorial Health Center, 

Wilkes-Barre, PA. 


BIOAVAILABILITY STUDY OF FIVE 

TUNGSTEN SUBSTANCES USING 

SIMULATED GASTRIC, ALVEOLAR, 

INTERSTITIAL, LYSOSOMAL, AND SWEAT 

FLUIDS. M. Jackson 1 , K. Heim 1 , R. Lemus 1 , M. 

Muzzio 2 and M. Pardus 1 . 1 ARCADIS U.S. Inc., 

Pittsburgh, PA and 2 Life Sciences Group, IIT 

Research Institute, Chicago, IL. 


REGULATION OF CYTOCHROME P450 

1A1 (CYP1A1) BY VANADIUM IN HUMAN 

HEPATOMA HEPG2 CELLS. G. Abdelhamid, 

A. Anwar-Mohamed and A. O. El-Kadi. Faculty of 

Pharmacy and Pharmaceutical Sciences, University 

of Alberta, Edmonton, AB, Canada. 


ACTIVATION OF JAK STAT IN 

MEGAKARYOCYTES BY INHALED 

VANADIUM. A. Gonzalez-Villalva, V. Rodriguez- 

Lara and T. I. Fortoul. Biologia Celular y Tisular, 

Facultad de Medicina, UNAM, Mexico City, Mexico. 


ACTIN CHANGES IN TESTICULAR 

CELLS AFTER VANADIUM PENTOXIDE 

INHALATION. V. Rosdriguez-Lara, A. Morales- 

Rivero and T. I. Fortoul. Biologia Celular y Tisular, 

UNAM, Mexico City, Mexico. 


STUDY ON MECHANISM FOR DEPLETED 

URANIUM-INDUCED TRANSFORMATION 

IN HUMAN LUNG EPITHELIAL CELLS. H. 

Xie, C. LaCerte and J. P. Wise. Applied Medical 

Science, University of Southern Maine, Portland, 

ME. 


DEPLETED URANIUM INDUCED DNA 

SINGLE STRAND BREAKS IN CHINESE 

HAMSTER OVARY CELLS. M. Yellowhair 1 

and R. Lantz 2 . 1 Pharmacology & Toxicology, The 

University of Arizona, Tucson, AZ and 2 Cell Biology 

and Anatomy, The University of Arizona, Tucson, 

AZ. 


EVALUATION OF ZINC BIOAVAILABILITY 

TO THE STRATUM CORNEUM FROM A 

BISGLYCINATE CHELATE IN VITRO. J. W. 

Hartle 1 and L. B. Joseph 2 . 1 R&D, Albion, Clearfield, 

UT and 2 Pharmacology and Toxicology, Rutgers 


296 






Platform Sessions



Abstract # 


ULTRASTRUCTURAL AND 

TOXICOPROTEOMIC STUDIES OF 

STRUCTURE AND FUNCTION OF THE 

BLOOD-CSF BARRIER IN MANGANESE- 

EXPOSED RAT MODEL. G. J. Li 1,2 , H. M. Jing 1 , 

K. H. Wei 3 , F. Yang 3 , W. H. Gao 1 , C. Y. Zhao 1 , L. 

Ma 1 , J. Z. Liu 1 , T. Zhang 3 and W. Zheng 4 . 1 Beijing 

Research Center for Preventive Medicine, Beijing, 

China, 2 Capital Medical University, Beijing, China, 

3 

Beijing Proteome Research Center, Beijing, China 

and 4 Purdue University, West Lafayette, IN. 


TELLURIUM TETRACHLORIDE INDUCES 

APOPTOSIS IN RAT HIPPOCAMPAL 

ASTROCYTES. D. Hardej and S. Roy. 

Pharmaceutical Sciences, St. John’s University, 

Jamaica, NY. 


HYPOXIA INDUCIBLE FACTOR 1a 

MODULATES COBALT-INDUCED ACUTE 

LUNG INFLAMMATION. Y. Saini 1,2,3 , D. Aibo 2,4 , 

K. Greenwood 3 , L. Bramble 4 , J. R. Harkema 2,4 

and J. J. LaPres 1,2,3 . 1 Genetics, Michigan State 



MI, 3 Department of Biochemistry and Molecular 


MI and 4 Pathobiology and Diagnostic Investigation, 



METALS RELATED TO PARTICULATE 

MATTER INDUCED DIFFERENTIAL 

CYTOKINE RESPONSES IN HUMAN 

EPITHELIAL LUNG CELLS. M. Låg, 

J. Øvrevik, E. M. Lilleaas, M. Refsnes, A. 

Thormodsaeter, A. I. Totlandsdal, J. A. Holme and P. 

E. Schwarze. Norwegian Institute of Public Health, 

Oslo, Norway. Sponsor: M. Løvik. 


HEPATIC AND PULMONARY 

DIFFERENTIAL TOXICITY AND 

PATHOGENICITY OF HEVAVALENT 

CHROMIUM, NICKEL, AND CADMIUM. M. 

C. Valerie 1 , C. C. Rebecca 1 , J. Hall 1 , T. Meighan 1 , D. 

Pack 1 , J. A. Lewis 2 , D. Jackson 2 , V. Vallyathan 1 and S. 

S. Leonard 1 . 1 NIOSH, Morgantown, WV and 2 U.S. 




ACUTE SYSTEMIC INFLAMMATION 

TO WELDING FUME: COMPARISON OF 

VARIOUS TYPES. A. Erdely, P. C. Zeidler-Erdely, 

A. Liston, R. Salmen-Muniz, T. Hulderman, J. M. 

Antonini and P. P. Simeonova. National Institute for 

Occupational Safety and Health, Morgantown, WV. 

Abstract # 


8:30 AM to 12:00 NOON 


Poster Session: Immune System Safety Evaluation/ 

Developmental Immunotoxicology 

Chairperson(s): Sharon Meyer, University of Louisiana Monroe, Monroe, 

LA. 




BREVETOXIN INHALATION ALTERS THE 

PULMONARY RESPONSE TO INFLUENZA 

A IN THE F344 RAT. M. Wolf 1 , T. March 1 , B. 

Tibbetts 1 , A. Kajon 1 , A. Bourdelais 2 , D. Baden 2 and 

J. Benson 1 . 1 Lovelace Respiratory Research Institute, 

Albuquerque, NM and 2 Center for Marine Science, 

University of North Carolina, Wilmington, NC. 


CARBON NANOFIBERS AND NANOTUBES 

DIFFER IN THEIR ALLERGY-PROMOTING 

CAPACITY IN MICE. U. C. Nygaard 1 , M. 

Samuelsen 1 , C. D. Marioara 2 and M. Lovik 1,3 . 

1 

Environmental Immunology, Norwegian Institute 

of Public Health, Oslo, Norway, 2 SINTEF Materials 

and Chemistry, Trondheim, Norway and 3 Department 

of Cancer Research and Molecular Medicine, 

Norwegian University of Science and Technology, 

Trondheim, Norway. 


EVALUATION OF INNATE AND HUMORAL 

IMMUNITY FOLLOWING IN VIVO 

EXPOSURE TO MICRO AND NANOFIBROUS 

ELECTROSPUN POLYCAPROLACTONE 

FOR TISSUE ENGINEERING 

APPLICATIONS. C. E. McLoughlin 1 , G. L. 

Bowlin 1 and K. L. White 2 . 1 Biomedical Engineering, 

Virginia Commonwealth University, Richmond, 

VA and 2 Pharmacology and Toxicology, Virginia 

Commonwealth University, Richmond, VA. 


EFFECTS OF SAUROPUS ANDROGYNUS 

ON MOUSE LYMPHOCYTES AND 

MACROPHAGES. Q. Huang, X. Xi Kun and H. 

Jun Ming. Center for Disease Control and Prevention 

of Guangdong Province, P.R.China, Institution of 

Toxicology, Guangzhou, Guangdong, China. 


PARTICLES FROM DUTCH TRAIN 

UNDERGROUND INDUCE PULMONARY 

INFLAMMATION IN VITRO AND IN VIVO. 

M. Steenhof 1 , R. Pieters 1 and I. Gosens 2 . 1 Toxicology, 


University, Utrecht, Netherlands and 2 Centre for 

Environmental Health Research, National Institute 


Bilthoven, Netherlands. 

thurSday 







297


thurSday 




KLH ANTIBODY RESPONSE, LYMPH 

NODE CELL SUBSET ANALYSIS, AND 

LYMPHOID TISSUE HISTOLOGY IN RATS 

TREATED WITH CYCLOSPORINE OR 

HEXACHLOROBENZENE. J. Descotes 2 , 

J. Legrand 1 , R. Fleurance 1 , F. Gervais 1 and P. 

Rousseau 1 . 1 CIT, Evreux, France and 2 Poison Center, 

Lyon, France. 


EFFECTS OF SUBCHRONIC EXPOSURE 

OF MUNITION RDX ENVIRONMENTAL 

DEGRADATION PRODUCT MNX. S. 

Ramasahayam and S. A. Meyer. Toxicology, 

University of Louisiana Monroe, Monroe, LA. 


COMPARISON OF LOCAL 

REACTOGENICITY IN NZW RABBITS 

FOLLOWING MULTIPLE INOCULATIONS 

WITH AN ALPHAVIRUS REPLICON 

PARTICLE VACCINE FOR INFLUENZA 

FORMULATED IN HUMAN SERUM 

ALBUMIN OR RABBIT SERUM ALBUMIN. 

Y. Wang 1 , S. Negri 2 , E. Krause 1 and R. Olmsted 2 . 

1 

Bridge Laboratories, Gaithersburg, MD and 

2 

AlphaVax, Inc., Research Triangle Park, NC. 


INVESTIGATION OF BLOOD-BRAIN 

BARRIER (BBB) PERMEABILITY AND 

IMMUNE-CELL POPULATION OF BRAIN 

TISSUE IN BELATACEPT-TREATED 

MONKEYS. W. J. Freebern 1 , V. Demby 1 , V. Jack 1 , 

M. Slade 1 , S. Wells 1 , T. J. Bigwarfe 1 , W. Victor 1 , H. 

Dong 1 , J. T. White 1 , R. Diters 1 , P. Zavorskas 2 and H. 

G. Haggerty 1 . 1 Research and Development, Bristol- 

Myers Squibb Co., East Syracuse, NY and 2 Charles 

River Laboratory, Shrewsbury, MA. 


NOSE-ONLY EXPOSURE TO JET 

FUEL KEROSENE DOES NOT ALTER 

IMMUNOCOMPETENCE IN FEMALE 

B6C3F1 MICE OR SPRAGUE-DAWLEY 

RATS. K. L. White 1 , V. L. Peachee 1 , M. P. DeLorme 2 

and K. C. Wise 3 . 1 ImmunoTox, Inc., Richmnd, VA, 

2 

Haskell Laboratory, Newark, DE and 3 American 

Petroleum Institute, Newark, DC. 


EFFECTS OF A COMPLEX MIXTURE OF 

PCBS ON IMMUNE FUNCTION IN B6C3F1 

MICE. P. A. Fair 1 , M. Mollenhauer 1 , N. Henry 1 , 

G. Bossart 2 , L. Wills 3 , D. E. Keil 4 and M. M. Peden- 

Adams 5 . 1 NOAA/NOS, Charleston, SC, 2 Harbor 

Branch Oceanographic Institute, Ft. Pierce, FL, 

3 

Department of Pharmaceutical Sciences, Medical 

University of South Carolina, Charleston, SC, 

4 

Clinical Laboratory Sciences, University of Nevada 

Las Vegas, Las Vegas, NV and 5 Harry Reid Center 

for Environmental Studies, University of Nevada Las 

Vegas, Las Vegas, NV. 


MALATHION, LINDANE, AND PIPERONYL 

BUTOXIDE, SINGLY OR COMBINED AS 

MIXTURES, INDUCE IMMUNOTOXICITY 

VIA INCREASED CELL DEATH IN MURINE 

SPLENOCYTES, IN VITRO. C. L. Battaglia 2 , 

R. M. Gogal 1 , K. Zimmerman 3 and H. P. Misra 4 . 

1 

Department of Anatomy and Radiology, University 

of Georgia, Athens, GA, 2 Environmental and 

Radiological Health Sciences, Colorado State 

University, Fort Collins, CO., 3 Biomedical Sciences 

and Pathobiology, Virginia Tech, Blacksburg, VA and 

4 

Biomedical Sciences, Edward Via Virginia College 

of Osteopathic Medicine, Blacksburg, VA. 


IDENTIFICATION OF STAGE SPECIFIC 

GENE MODULATION DURING EARLY 

THYMOCYTE DEVELOPMENT BY 

WHOLE GENOME PROFILING ANALYSIS 

FOLLOWING ARYL HYDROCARBON 

RECEPTOR ACTIVATION. M. Laiosa 1 , J. H. 

Mills 2 , Z. Lai 2 , K. Singh 1 , F. A. Middleton 3 , T. A. 

Gasiewicz 1 and A. E. Silverstone 2 . 1 Environmental 

Medicine, University of Rochester, Rochester, NY, 

2 

Microbiology and Immunology, Upstate Medical 

University, Syracuse, NY and 3 Neuroscience and 

Physiology, Upstate Medical University, Syracuse, 

NY. 


AN IMMUNOLOGICAL RESPONSE 

ASSESSMENT TO KLH IMMUNIZATION 

IN INFANT CYNOMOLGUS MONKEYS. N. 

Lalayeva 1 , W. Komocsar 4 , N. Makori 1 , S. Oneda 1 , 

A. Macintyre 3 , R. Eyre 1 , J. Klaassen 2 , S. Meyer 2 , 

K. Fukuzaki 5 and R. Nagata 5 . 1 Safety Assessment, 

SNBL USA, Ltd., Everett, WA, 2 Corporate, SNBL 

USA, Ltd., Everett, WA, 3 Analytical Biology, 

SNBL USA, Ltd., Everett, WA, 4 Musculoskeletal 

and Immunomodulation Transition Team, Eli Lilly 

& Company, Indianapolis, IN and 5 Corporate, Shin 

Nippon Biomedical Laboratories, Ltd., Kagoshima, 

Japan. 


EARLY LIFE EXPOSURE TO CIGARETTE 

SMOKE INCREASES LATER LIFE TUMOR 

SUSCEPTIBILITY POSSIBLY VIA EFFECTS 

ON T-REGULATORY CELLS. S. P. Ng 1 , A. E. 

Silverstone 2 , Z. Lai 2 , S. P. Doherty-Lyons 3 and J. T. 

Zelikoff 3 . 1 Preclinical Drug Development, Lovelace 

Respiratory Research Institute, Albuquerque, NM, 

2 

SUNY Upstate Medical University, Syracuse, NY 

and 3 New York University School of Medicine, 

Tuxedo, NY. 


ARE DEVELOPMENTALLY-EXPOSED 

C57BL/6 MICE INSENSITIVE TO 

SUPPRESSION OF TDAR BY PFOA? J. DeWitt 

and Q. Hu. Pharmacology and Toxicology, East 

Carolina University, Greenville, NC. 


FETAL BASIS OF ADULT DISEASE: 

PRENATAL EXPOSURE TO 

DIETHYLSTILBESTROL (DES) HAS 

PROFOUND EFFECT ON THE IMMUNE 

SYSTEM IN POSTNATAL LIFE. M. Nagarkatti, 

N. Singh and P. Nagarkatti. Pathology, Microbiology, 

and Immunology, University of South Carolina 

School of Medicine, Columbia, SC. 

298 






Platform Sessions



Abstract # 


IMMUNOPHENOTYPING OF CORD AND 

MATERNAL BLOOD: THE INFLUENCE 

OF EXPOSURE TO DIETARY TOXICANTS 

DURING PREGNANCY. S. Stølevik 1 , U. 

Nygaard 1 , B. Granum 1 , M. Haugen 1 , H. Meltzer 1 , 

J. Alexander 1 , H. van Loveren 2 and M. Løvik 1,3 . 

1 

Norwegian Institute of Public Health, Oslo, Norway, 

2 

Maastricht University, Maastricht, Netherlands and 

3 

Norwegian University of Science and Technology, 

Trondheim, Norway. 


AGE AND SEX INFLUENCE PRIMARY AND 

SECONDARY PREVENTION STRATEGIES 

FOR CONTROLLING ASTHMA AS 

MODELED IN THE MOUSE. J. F. Regal 1 , 

R. R. Regal 2 and M. Mohrman 1 . 1 Biochemistry & 

Molecular Biology, University of Minnesota Medical 

School Duluth, Duluth, MN and 2 Mathematics & 

Statistics, University of Minnesota, Duluth, MN. 


9:00 AM to 11:45 AM 

Ballroom I 

Workshop Session: Blood-Based Genomic Profiles As 

Biomarkers of Exposure and Effect 

Chairperson(s): Russell S. Thomas, The Hamner Institutes for Health 

Sciences, Research Triangle Park, NC, and Richard S. Paules, NIEHS, 


Sponsor: 


Endorsed by: 



Over the past decade, advances in genomic technology have transitioned 

its application from a specialized research tool to a robust, off-the-shelf 

commodity for both research and clinical use. Current technology has 

become more reliable and reproducible with broad-coverage of genomic 

analytes thereby providing an ideal platform for biomarker discovery, validation, 

and application. However, identifying genomic-based biomarkers 

of chemical exposure and, in particular, biomarkers of effect from most 

target tissues (e.g., liver, kidney) would require biopsy samples from human 

subjects that would be difficult, if not impossible to obtain. As a result, 

recent research has focused on deriving blood-based genomic biomarkers 

that can predict exposure and organ-specific toxicity. This session will 

provide an overview of the new research on the identification and validation 

of genomic biomarkers from peripheral blood mononuclear cells, 

exosomal microparticles, and circulating miRNA and mRNA with application 

to predicting chemical exposure and effects. This session should be of 

wide-ranging interest to those involved in drug development, biomonitoring 

interpretation, and risk assessment. 

#2198 9:00 BLOOD-BASED GENOMIC PROFILES 

AS BIOMARKERS OF EXPOSURE AND 

EFFECT. R. S. Thomas 1 and R. S. Paules 2 . 1 The 


Triangle Park, NC and 2 National Institute of 


Park, NC. 

Abstract # 

#2199 9:05 ISOLATION AND CHARACTERIZATION 

OF BLOOD-BORNE FREE AND 

MICROPARTICLE-ASSOCIATED MRNAS 

TO PREDICT DRUG-INDUCED LIVER 

INJURY. B. A. Wetmore 1 , D. J. Brees 2 , P. B. 

Watkins 1 and R. S. Thomas 1 . 1 The Hamner Institutes 

for Health Sciences, Research Triangle Park, NC and 

2 

Pfizer, Inc., Sandwich, Kent, United Kingdom. 

#2200 9:45 BLOOD TRANSCRIPTOMIC FINDINGS 

IN ACUTE LIVER INJURY. R. S. Paules. 

Laboratory of Molecular Toxicology, National 



#2201 10:25 APPLICATION OF CIRCULATING MIRNAS 

TO PREDICT DRUG INDUCED LIVER 

INJURY. D. J. Galas. Institute for Systems Biology, 

Seattle, WA. Sponsor: R. Thomas. 

#2202 11:05 BLOOD-BASED GENOMIC PROFILES OF 

HUMANS EXPOSED TO CARCINOGENS. M. 

T. Smith, C. McHale and L. Zhang. School of Public 

Health, University of California, Berkeley, CA. 


9:00 AM to 11:45 AM 

Ballroom F 


Workshop Session: Humanized Models in Toxicology and 

Their Application to Hazard Characterization and Risk 

Assessment 

Chairperson(s): Darrell R. Boverhof, Dow Chemical Company, Midland, 

MI, and Cliff Elcombe, CXR Biosciences, Dundee, United Kingdom. 

Sponsor: 


Endorsed by: 


The toxicity testing paradigm is at a turning point. Many are calling for 

the implementation of new approaches, models, and technologies in order 

to enhance and refine the hazard and risk assessment process. Important 

components to the emerging views are implementation of mode/mechanismof-action 

data, a greater focus on human models/relevance, and a reduction 

in the use of animals. One important emerging tool that has the potential to 

advance the field is the use of humanized mouse models. Humanized models 

clearly offer the potential for increased use of mechanism/mode-of-action 

while inherently providing data on the potential human risk. Furthermore, 

if implemented strategically into the hazard and risk assessment paradigms, 

such models could obviate the need for large-scale animal testing thereby 

reducing animal use. However, the application of these data to human risk 

assessment requires appropriate and consistent interpretation of the data 

and acceptance of a given mode-of-action and its relevance to humans. 

Such acceptance requires discussion and consensus among all relevant 

stakeholders. The goal of this session is to provide examples of humanized 

models that are being used in toxicology and to initiate discussions on the 

use of these data in the evaluation of hazard relevance and risk assessment 

in humans. 

#2203 9:00 HUMANIZED MODELS IN TOXICOLOGY 

AND THEIR APPLICATION TO HAZARD 

CHARACTERIZATION AND RISK 

ASSESSMENT. D. R. Boverhof. The Dow 


thurSday 







299


thurSday 



#2204 9:05 TRANSGENIC HUMAN AHR MOUSE AND 

HUMAN RISK ASSESSMENT. G. H. Perdew 

and C. A. Flaveny. Center for Molecular Toxicology 

and Carcinogenesis and the Department of Veterinary 

and Biomedical Sciences, The Pennsylvania State 


#2205 9:35 NUCLEAR RECEPTOR (CAR/PXR) 

HUMANIZED MOUSE MODELS TO 

INVESTIGATE NONGENOTOXIC 

HEPATOCARCINOGENESIS. C. R. Elcombe. 

CXR Biosciences Ltd., Dundee, United Kingdom. 

#2206 10:05 HUMANIZED DRUG METABOLIZING 

ENZYME MOUSE MODELS-POTENTIAL 

APPLICATION IN SAFETY ASSESSMENT 

OF DRUG METABOLITES. A. Galijatovic- 

Idrizbegovic 1 , M. W. Powley 2 , C. B. Frederick 1 , F. D. 

Sistare 1 and J. J. DeGeorge 1 . 1 Safety Assessment, 

Merck, West Point, PA and 2 Center for Drug 

Evaluation and Research, U.S. FDA, Silver Spring, 

MD. 

#2207 10:35 PPARa-HUMANIZED MICE AND HUMAN 

RISK ASSESSMENT. F. Gonzalez, A. Qu and Y. 

M. Shah. National Cancer Institute, Bethesda, MD. 

Sponsor: D. Boverhof. 

#2208 11:05 HUMANIZED MODELS IN THE 

ASSESSMENT OF NOVEL PRODUCTS USED 

UNDER INVESTIGATIONAL NEW DRUGS. 

M. Green and J. Wally. Center for Biologics 

Evaluation and Research, U.S. FDA, Rockville, MD. 

Sponsor: D. Boverhof. 



9:00 AM to 11:45 AM 

Ballroom B 


Workshop Session: Systems Biology Approaches to 

Understanding Cell Signaling in Dermal and Ocular 

Toxicology 

Chairperson(s): Carol L. Sabourin, Battelle, Columbus, OH, and Jeffrey 

Yourick, Joint Science & Technology, Fort Belvoir, VA. 

Sponsor: 


Endorsed by: 

Ocular Toxicology Specialty Section 

Transcriptomics, proteomics, and metabolomics provide high-throughput 

global analysis of the genome and associated interactive players. These 

approaches are colloquially described as ‘omics technologies and have been 

used to enhance the understanding of function, toxicological mechanisms, 

and risk assessment by identifying novel biomarkers of exposure including 

alterations in biological processes, cell signaling pathways, and specific 

genes. These ‘omics studies typically generate large data sets in which 

bioinformatic interpretation requires unique and evolving computer-based 

analytical approaches, including large databases and an assortment of 

analytical tools. As the largest organ of the body, the skin performs multifunctional 

roles as a physical barrier, physiological mediator, communicator 

between the external environment and internal biological processes, and 

a vehicle for drug delivery. The skin consists of the epidermis and dermis 

composed of a multitude of cell types separated by a basement membrane. 

The eye consists of many diverse components such as the cornea, iris, pupil, 

lens, retina, macula, optic nerve, choroid, and vitreous. The corneal epithelium 

functions as a barrier to the environment and is susceptible to toxicant 

injury. The cornea must remain intact and transparent to refract light properly 

and disruption or disorganization of this structure can interfere with this 

process. The dynamic cell types of the skin and eye control multicellular 

processes through extensive networks of cell-to-cell communication that 

ultimately influence gene transcription and protein expression. Elucidating 

the complex molecular events underlying dermal and ocular responses to 

toxicants and drugs will assist in identifying biomarkers, developing safety 

assessment strategies, and accelerating the development of effective medical 

countermeasures. The practical applications of ‘omics to understanding the 

toxic responses will be discussed. 

#2209 9:00 SYSTEMS BIOLOGY APPROACHES TO 

UNDERSTANDING CELL SIGNALING IN 

DERMAL AND OCULAR TOXICOLOGY. C. 

L. Sabourin 1 and J. J. Yourick 2 . 1 Biomedical Research 

Center, Battelle, Columbus, OH and 2 Joint Science 

&Technology Office, Defense Threat Reduction 

Agency, Fort Belvoir, VA. 

#2210 9:05 TRANSCRIPTOMICS IN CHEMICAL- 

EXPOSED SKIN: CURRENT STATUS AND 

FUTURE DIRECTIONS. J. Rogers. Battelle 

Memorial Institute, Columbus, OH. 

#2211 9:37 CUTTING THE MUSTARD: APPLICATION 

OF SYSTEMS BIOLOGY APPROACHES TO 

IDENTIFY THERAPEUTIC STRATEGIES 

FOR TREATING DERMAL SULFUR 

MUSTARD INJURIES. J. F. Dillman, A. L. 

Ruff and P. A. Everley. Cell and Molecular Biology 

Branch, USAMRICD, Aberdeen Proving Ground, 

MD. 

#2212 10:09 USING GENE EXPRESSION PROFILING OF 

NANO-SCALE MATERIALS IN PRIMARY 

HUMAN EPIDERMAL KERATINOCYTES TO 

UNDERSTAND CELLULAR INTERACTIONS. 

M. Cunningham. Nanomics Biosciences, Inc., Cary, 

NC. 

#2213 10:41 OCULAR TOXICITY PROTEOMICS: 

APPROACHES FOR DIFFERENTIAL 

CORNEAL PROTEIN IDENTIFICATION. J. 

J. Schlager 1 , M. C. Babin 2 , P. A. Shiyanov 3 and M. L. 

Meade 3 . 1 Applied Biotechnology Branch, 711 Human 

Performance Wing, Air Force Research Laboratory, 

Wright-Patterson AFB, Dayton, OH, 2 Biomedical 

Research Center, Battelle, Columbus, OH and 3 Henry 

M. Jackson Foundation, Wright-Patterson AFB, 

Dayton, OH. 

#2214 11:13 METABOLOMICS: A NOVEL TOOL FOR 

UNDERSTANDING THE EARLY-STAGE 

MECHANISTIC UNDERPINNINGS OF 

SAFETY. M. Milburn. Metabolon, Inc., Research 

Triangle Park, NC. Sponsor: C. Sabourin. 

300 






Platform Sessions



Abstract # 


9:00 AM to 11:45 AM 

Ballroom D 

Workshop Session: Toxicological Challenges in Green Product 

Development 

Chairperson(s): Erica L. Dahl, Institute for In Vitro Sciences, 

Gaithersburg, MD, and David G. Allen, Integrated Laboratory Systems, 


Abstract # 

Sponsor: 


Endorsed by: 


In recent years there has been a tremendous increase in the demand for 

products that are green. However, this claim can be difficult to define, and in 

some cases (e.g. restrictions on reproductive toxins or carcinogens) conflicts 

with the equally desirable claim that a product was not tested on animals. 

A number of independent organizations have emerged with the stated goal 

of validating these claims to help consumers navigate a bewildering array 

of products in their efforts to shop conscientiously. A closer examination 

of the safety testing required by these certifying organizations reveals some 

apparent conflicts. For example, organizations offering green certification 

forbid carcinogens or reproductive toxins in cleaning products, while 

organizations offering not tested on animal certifications forbid the in vivo 

testing that would be required to detect these endpoints. The purpose of 

this session is to bring together toxicologists who are working to reduce 

the environmental impacts of household and institutional cleaning products 

with those who are working to reduce animal testing. Our panel of experts 

includes toxicologists from industry, non-governmental organizations, and 

the government. It is our intent to identify strategies to reconcile apparent 

conflicts between green and not tested on animal claims while maintaining 

the high standards of safety testing required to protect human health and the 

environment. The overall goal is to begin building a consensus regarding 

a definition of green that is scientifically sound and minimizes reliance on 

animal testing. 

#2215 9:00 TOXICOLOGICAL CHALLENGES IN 

GREEN PRODUCT DEVELOPMENT. E. L. 

Dahl. IIVS, Gaithersburg, MD. 

#2216 9:05 THE ROLE OF TOXICOLOGY IN SETTING 

GREEN PRODUCT STANDARDS. S. S. 

Willems 1 and D. A. Daggett 2 . 1 Global Product Safety, 

JohnsonDiversey, Inc., Sturtevant, WI and 2 Corporate 

Sustainability, JohnsonDiversey, Inc., Sturtevant, WI. 

#2217 9:37 DEVELOPING AND USING NON-ANIMAL 

TESTS FOR THE CONSUMER PRODUCTS 

INDUSTRY. H. Raabe. IIVS, Gaithersburg, MD. 

#2218 10:09 EVALUATING AND CERTIFYING GREEN 

CLAIMS. C. McLellan. Toxicology Services, NSF 

International, Ann Arbor, MI. 

#2219 10:41 THE U.S. EPA DESIGN FOR THE 

ENVIRONMENT PROGRAM. E. Lavoie 1 , 

D. Difiore 1 , M. Cushmac 1 , K. Grant 2 , M. Vrabel 1 , 

E. Sommer 1 , K. Hart 1 and C. Davies 1 . 1 U.S. EPA, 

Washington, DC and 2 AAAS Science Policy Fellow, 


#2220 11:13 INCORPORATING NOT TESTED ON 

ANIMALS INTO SAFETY ASSESSMENT 

OF NATURAL CLEANING PRODUCTS. N. 

Galvan, K. Reddy, S. Mobley and S. Cate. The Clorox 

Company, Pleasanton, CA. 

thurSday 







301


Notes 

302 




All sessions will be held at the Salt Palace Convention Center. 

General Scientific Sessions 

(Listed by type, then date and time) 




an exhibiting company. The Exhibitor Hosted Session Index is located on 

pages 45–46. 


Monday 


Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 


Mechanistic Role of Reactive 

Intermediate Protein Covalent 

Binding in Target Organ 

Toxicity: Past, Present, and 

Future #14–18 and 18A 

Neurological Responses after 

Exposure to Inhaled Metal 

Particles #19–24 

Ovarian Toxicity: Current 

Concepts in Toxicology, 

Pathology, and Mechanisms 

#25–29 

Silica and Asbestos 

Immunotoxicity: Mechanisms 

to Fibrosis, Autoimmunity, and 

Modified Tumor Resistance 

#30–35 


Room 150 103 




Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 






Does Background Disease Lead 

to Low Dose Linearity? #36–40 

Heart Smart: Innovative 

Approaches for Improving 

Cardiovascular Safety through 

Collaboration #41–46 

Toxicology in the 21 st Century: 

Stem Cells in Drug Discovery 

and Development #47–52 






Room 151 105 


Room 250 106 



Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 

Monday 

9:15 AM 


Biomarkers of Target-Organ 


Chemical and Biological 

Weapons—Sulfur Mustard 

#61–69 

Immunopharmacogenomics 

and Immune Regulation 

#70–78 

Mitochondrial-Mediated 

Mechanisms of Toxicity of 





Room 

251 A 

109 




Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 

Monday 

9:30 AM 


Models I #85–118 


Carcinogenesis I #119–144 


* Epigenetics #145–154 


Neurodevelopmental Toxicity: 

General #155–184 


* Screening and Predicting 

Toxicity: Computational 

Approaches to Identify Targets 

#185–215 


Mechanistic Aspects of 

Persistent Organic Chemical 



* Investigations of Chemical 

Mixtures #242–254 


601–607 

Nanotoxicology I #255–292 


* Hypersensitivity, Autoimmunity, 

and Idiosyncratic Drug 

Reactions #293–317 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

110 

112 

114 

115 

117 

120 

122 

123 

126 

SESSion indEx 




SESSion indEx 



Monday 

12:10 PM 

Monday 

12:10 PM 

Combination Toxicology 

Studies for Pharmaceutical 

Agents: Design Considerations 

and Impact on Clinical 

Development #318 

Melamine Contamination 

of Infant Formulas: Lessons 

Learned #319 

HISTORICAL HIGHLIGHTS SESSION 




Monday 

12:10 PM 


Translating Toxicology to Public 

Health Protection: Lessons 

Learned from Superfund #320 





Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

Monday 

1:00 PM 

* Chemical and Biological 

Weapons #321–354 


Genetic Diversity and Response 

to Xenobiotics #355–366 


* Nanotoxicology II #367–375 


Reproductive Toxicology 

#376–422 


* Environmental Impact of 



Biotransformation I #442–459 



Models II #460–492 


Advances in Dermal Toxicology 

#493–505 


* Carcinogenesis II #506–535 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

131 

134 

135 

136 

139 

141 

142 

145 

146 



Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

WORKSHOP SESSION 

Alterations in Regulatory 

T Cells: Novel Pathways to 


Faster Science for Better 

Decisions: Characterizing 

Environmental Contaminant 

Risk from High–Throughput 

Data #541–546 

Genotoxic Impurities in 

Drugs and Drug Products: 

What Is the Right Way to 

Deal with Impurities in R&D 

versus Regulatory Guidance? 

#547–552 

Metabolic Syndrome and 

Increased Sensitivity to Drug– 

Induced Liver Injury (DILI): 

Nonclinical Models and Clinical 

Implications #553–558 

Phthalate Reproductive and 

Developmental Toxicity: 

Implications for Cumulative Risk 


Room 151 148 


Room 250 149 




Monday 

1:40 PM 

Determination of the 

Contribution of Individual 

Stressors in Cumulative Risk 

Assessments #565–570 

REGIONAL INTEREST SESSION 

Room 150 151 


Monday 

1:40 PM 


Signaling Mechanisms for 

Metabolic Dysfunction 

Following Low-Level Arsenic 


#571–576 



Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Monday 

1:40 PM 

Advances in Biomarkers of 

Renal Injury #577–582 

Animal Models in the 21 st 

Century #583–591 

Lipid Metabolism and 

Apoptosis #592–599 

Methods and Animal Models 

in Cardiovascular Safety 

Pharmacology #600–607 




Room 

251 A 

154 

94 






Monday 

4:35 PM 

Monday 

4:35 PM 

Monday 

4:35 PM 

Inhaled Particles: From the 

Nose to the Brain? #608 


Safety of Vitamins and Minerals: 


#609 

The Evolution of the Extended 

One-Generation Study Design 

for Agricultural and Industrial 


#610 

Tuesday 





Tuesday 

7:30 AM 

Tuesday 

7:30 AM 

Can Animal Neurotoxicity 

Predict Human Dysfunction? 

#611 

Weighing Complex Data in 

Risk Decisions: Concepts of 

Evidence-Based Toxicology 

#612 





Tuesday 

7:30 AM 

Tuesday 

7:30 AM 

Human Hepatocytes Derived 

from Embryonic Stem Cells: 

A New Tool for In Vitro Toxicity 

Testing #613 

Recent Advances in Pulmonary 

Surfactant Toxicological 

Assessment and Therapeutics 

#614 





Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 


Anti-Drug Antibody-Mediated 

Toxicity In Nonclinical Toxicity 

Studies: Impact and Relevance 

to Human Safety #615–620 

Bile Salt Transport and Liver 

Injury #621–626 

MAP Kinase Signaling: A 

Common Target Eliciting 

Unique Tissue Responses 

#627–632 

Molecular Determinants 

of Mitochondrial Disease 

#633–637 

POPs: What’s New and Why 

Should We Care? #638–644 







Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Opportunities to Modify 

Current Regulatory Testing 

Guidelines and Advance the 

Assessment of Carcinogenicity 

Risk in the 21 st Century 

#645–650 

Research Advances and 

Enduring Needs in Children’s 

Environmental Health 

Protection #651–656 

Room 151 164 




Tuesday 

9:00 AM 

Where Do I Go Now? Rational 

Career Development Planning 

for Early-Career Scientists 

#657–662 




Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Epidemiological Insights: 

Effects of Environmental 

and Occupational Exposures 

#663–670 

Gene Environmental 

Interactions in Cacinogenesis 

#671–679 


Developmental Effects Using 

Fish Models #680–687 

Room 250 166 

Room 150 166 

Room 

251 A 

167 

SESSion indEx 




SESSion indEx 





Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

Tuesday 

9:00 AM 

* Mutagenicity #688–701 


DNA Damage and Repair 

#702–718 


* Pharmaceutical Toxicology I 

#719–729 


Inflammation and the 

Pathogenesis of Toxicity 

#730–761 


* Oxidative Injury and Redox 

Biology #762–787 


Nanotoxicology—Carbon 

Nanostructures #788–805 


* Kidney I #806–828 


Developmental Toxicology 

#829–867 


501–515 

* Biological Modeling: Multiple 

Scales of Parameters, 

Structures, and Applications 

#868–902 


601–605 

Animal Models—Emerging 

Methods #903–940 


* Education #941–944 


Arsenic I #945–974 


* Metal Neurotoxicity: General 

#975–1002 



Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

168 

169 

170 

171 

173 

175 

177 

179 

182 

185 

187 

188 

190 


Tuesday 

12:00 

NOON 

Tuesday 

12:00 

NOON 

The Ying and Yang of 

Immunomodulatory 

Biopharmaceuticals: What 

Have We Learned since MABEL 

and How Close Are We to the 

Clinical Dose ? #1003 

Women’s Health: Toxicology 

and Safety of Complementary 

and Alternative Medicine #1004 

Room 150 193 


96 



Tuesday 

12:00 

NOON 


Science Communication 

in 2010: A New Decade in 

Toxicology and Need for Better 

Communication #1005 





Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

Tuesday 

1:00 PM 

* Risk Assessment I: New 

Data and Derivations across 

Chemicals from A to V 

#1006–1041 


Pharmaceutical Toxicology II 

#1043–1085 


* Biotransformation II 

#1086–1105 


Genotoxicity #1106–1130 


* Safety Concerns of Food and 

Natural Products #1131–1167 


Safety Assessment: Commercial 

and Consumer Products 

#1168–1193 


501–517 

* Ah Receptor Biology and 



Apoptosis/Cell Death 

#1211–1229 


607–607 

* Neurotoxicity of Pesticides 

#1230–1264 


Neurodegenerative Disease 

#1265–1297 


701–729 

* Biomarkers #1298–1331 


828–828 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

195 

198 

201 

203 

205 

207 

209 

211 

212 

215 

217 






Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Genetics: The Link between 

Exposures, Gene x Environment 

Interaction, and Toxicity 

#1332–1336 

It’s Not Your Father’s Aryl 

Hydrocarbon Receptor: 

New Biological Roles for a 

Misunderstood Receptor 

#1337–1342 

Mechanisms of Chemical- 

Induced Liver Cancer: Putting 

the Pieces Together 

#1343–1348 

New Strategies for the Use 

of Genetic Toxicology Data 

in Human Risk Assessment 

#1349–1355 

Recent Knowledge on 

Critical Regulators of Lipid 

Homeostasis in Metabolic 

Disease #1356–1361 

Zinc, Copper, and Their 

Metabolic Effect: Myths and 

Musts #1362–1367 




Room 151 222 


Room 250 223 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 


Immunotoxicity and Other 

Safety Considerations in the 

Development of Therapeutic 

Vaccines #1368–1373 

Widely Varying Strategies 

Implemented in Discovery 

to Reduce the Failure Rate of 

Clinical Lead Candidates in 

Development #1374–1379 


Room 150 224 


Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Tuesday 

1:30 PM 

Emphasis on the Embryo: 

HTS, PBPK, and Virtual Tissue 

Technologies #1380–1387 

Model Systems in 

Neurodevelopmental Toxicity 

#1388–1394 

Nanotoxicology—Pulmonary 

Effects #1395–1403 

Toxicity Detection— 

Alternatives to Animal Models 

#1404–1412 



Room 

251 A 

Room 

251 D 

226 

227 

Wednesday 



Wednesday 

7:30 AM 

Wednesday 

7:30 AM 

Impact of Tungsten and 

Tungsten Alloys on Health Risk 

#1413 

The 2009 Tennessee Fly Ash 

Spill—An Environmental 

Emergency Case Study #1414 





Wednesday 

7:30 AM 


Career Alternatives in 

Toxicology: Lessons Learned 

#1415 



Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 


Gender Divergent Xenobiotic 

Responses #1416–1420 

Mitochondrial Toxicity in 

Disease and Death #1421–1426 

The Fetal Basis of Adult Disease 

#1427–1433 

Room 150 231 


Room 250 232 


Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Current Thinking and 

Experiences Related 

to Developmental and 

Reproductive Safety 


#1434–1439 

Novel Research Approaches 

and Animal Models in 


#1440–1444 

Toxicity Testing in the 21 st 

Century for Ecotoxicology 

#1445–1451 

Understanding Nonlinearities 

at the Low-End of the 

Dose-Response Curve: Insights 

from Molecular Network 

Analysis #1452–1455 

Room 151 233 




SESSion indEx 






Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Advances in Mycotoxin Toxicity 

#1456–1464 

Impact of Receptors and Gene 

Regulation in Toxicological 

Response #1465–1472 

Inhalation Toxicology of 

Ultrafine or Nanoparticles 

#1473–1480 


Developmental Toxicity of 

Phthlates #1481–1489 


Room 

251 D 

236 


Room 

251 A 

237 



Wednesday 

12:00 

NOON 

Wednesday 

12:00 

NOON 

Wednesday 

12:00 

NOON 

Life-Stage Adjustment Five 

Years Later—Experiences from 

the Cancer Risk Assessment 

Field #1721 

Measuring Immune Responses 

in Monkeys for Drug 

Development: Opportunities 

and Challenges for Predicting 

Human Efficacy and 

Immunotoxicity #1722 

The Tox21 st Community and 

the Future of Toxicology Testing 

#1723 




SESSion indEx 





Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

Wednesday 

9:00 AM 

* Inhalation Toxicology 

#1490–1524 


Immunotoxicology: 

Mechanisms #1525–1562 


* Studies in Pharmacokinetics 

and Disposition #1563–1599 


301–331 

Neurodevelopmental Toxicity of 

Metals #1600–1615 


* Hepatotoxicity: Role of Bile Acid 

Metabolism and Homeostasis 

#1616–1624 


Causes and Progression of 

Hepatic Metabolic Dysfunction 

#1625–1636 


* Toxicogenomics—Continuing 

Advances in Molecular 



501–502 

Signal Transduction 

#1663–1677 


* Stem Cell Toxicology 

#1678–1691 


Nanotoxicology—Gold or Silver 

Nanoparticles #1692–1707 


601–610 

* Gene Regulation #1708–1720 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

237 

240 

243 

246 

247 

248 

249 

251 

253 

254 

255 





Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

Wednesday 

1:00 PM 

* Cardiovascular Toxicology 

#1724–1757 


Beneficial Effects of Natural 

Products #1758–1786 


* Regulations and Policy in 



301–306 

Metals I #1811–1845 


* Exposure Assessment and 

Emerging Biomonitoring 

Applications #1846–1886 


Pesticides: General #1887–1905 


501–513 

* Risk Assessment II: 

Methodological Challenges and 

Metals #1906–1947 


601–609 

Models and Mechanisms of 

Hepatotoxicity #1948–1969 


* Fetal Basis of Adult Disease 

#1970–1977 


Immunotoxicology: Methods 

and Models #1978–1997 


* Carcinogenesis: Breast and 

Reproductive #1998–2009 


Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

Exhibit 

Hall 

259 

261 

263 

265 

268 

271 

272 

275 

277 

278 

279 

98 






Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 


Aging As a Determinant of 

Xenobiotic Toxicity #2010–2015 

TRPing the Sensor: The Role 

of TRP Channel Signaling in 

Cardiopulmonary Toxicity 

#2016–2022 

Zebrafish Models 

for Developmental 


#2023–2028 





Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

High-Throughput 

Electrophysiology—21 st 

Century Toxicity Testing 

Approaches with Functional 

Outcomes #2029–2033 

Minerals and Metals: Pros and 

Cons of Deliberate Exposure 

#2034–2038 

‘Omics Profiling of Cell 

and Tissue Interactions of 

Nanomaterials: Insight into 

Mechanisms of Action 

#2039–2044 

The Process of Defining Risk 

for Environmental Chemicals 

Having Significant Skin 

Exposure and Absorption 

Potential #2045–2051 

Translation of Nonclinical 

Models to Clinical Risk 

Management Strategies of 

Severe Infectious Diseases with 

Immunomodulatory Drugs 

#2052–2057 

Room 150 282 




Room 151 285 

ROUNDTABLE SESSION 


Wednesday 

4:30 PM 

Overview of Current 

Regulatory Expectations 

for Oligonucleotide-Based 

Therapeutics: Case Studies for 

Different Classes of ODNs #2082 

INFORMATIONAL SESSION 

Room 150 288 


Wednesday 

4:30 PM 


Seeking Funding for 

Undergraduate Research #2083 

Thursday 



10:15 AM–12:00 NOON. Poster Board Surface Maps are on pages 33–37. 


Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

Thursday 

8:30 AM 

* Endocrine Toxicology 

#2084–2113 


Juvenile Toxicity #2114–2121 


* Drug-Induced Liver Injury 

#2122–2139 


Receptors #2140–2157 


* Metals II #2158–2178 

Poster Boards 421–440 and 501 

Immune System Safety 

Evaluation/Developmental 



Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

Exhibit 

Hall E 

289 

292 

293 

294 

296 

297 



Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Wednesday 

1:30 PM 

Insights into Polyaromatic 

Hydrocarbon-Induced Toxicities 

#2058–2064 

Nanotoxicology—Metals and 

Metal Oxide Particles 

#2065–2073 

Predicting Hepatotoxicity: 

Computational Approaches to a 

Critical Target #2074–2081 


Room 

251 A 


286 

Room 250 287 



Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Thursday 

9:00 AM 

Blood-Based Genomic Profiles 

As Biomarkers of Exposure and 

Effect #2198–2202 

Humanized Models in 

Toxicology and Their 

Application to Hazard 

Characterization and Risk 


Systems Biology Approaches to 

Understanding Cell Signaling in 

Dermal and Ocular Toxicology 

#2209–2214 

Toxicological Challenges in 

Green Product Development 

#2215–2220 





SESSion indEx

50 th Anniversary 


& ToxExpo 

2011 


March 6–10, 2011 

Walter E. Washington Convention Center 

Photos courtesy of Destination DC. The Kennedy Center photographed by Carol Pratt. 

Deadline for proposals for SoT 2011 

Annual Meeting Sessions: April 30, 2010 

WHy SUBMiT A pRopoSAL? 

1. To present new developments in toxicology. 

2. To provide attendees an opportunity to learn about 

state-of-the-art technology and how it applies to 

toxicological research. 

3. To provide attendees an opportunity to learn about the 

emerging fields and how they apply to toxicology. 

SeSSion TypeS 

Continuing Education—Emphasis on quality 

presentations of generally accepted, established knowledge 

in toxicology 

Note: CE Courses will be held on Sunday. 

Symposia—Cutting-edge science; new areas, concepts, 

or data 

Workshops—State-of-the-art knowledge in toxicology 

Roundtables—Controversial subjects 

Historical Highlights—Review of a historical 

body of science that has impacted toxicology 

Informational Sessions—Scientific planning or 

membership development 

Education-Career Development Sessions—Sessions that 

provide the tools and resources to toxicologists that will 

enhance their professional and scientific development 

2011 Thematic Approach 

The Scientific Program Committee will continue the 

thematic approach for the 2011 Annual Meeting. All 

proposal submissions will be reviewed for their relevance 

under the following themes for the 2011 meeting. 

• Global Air Quality and Human Health 

• Novel Approaches to Preclinical Safety Assessment: 

Bridging the Gap between Discovery and the Clinic 

through Translational Toxicology 

• Environment and Disease 

• Toxicity Testing: State of Science and Strategies to 

Improve Public Health 

• Integration of Toxicological and Epidemiological 

Evidence to Understand Human Risk 

• Emerging Global Public Health Issues 

Please note that while we are actively soliciting proposals 

for the themes listed above, all proposal submissions will 

be reviewed under the current criteria for their timeliness 

and relevance to the field of toxicology. 

Please refer to the Scientific Program Overview on the 

fold-out cover for a list of 2010 sessions highlighted under 

the thematic approach. 

Submit your proposal on-line at www.toxicology.org 



Author Index 

Author Index (Continued) 

A 

Aardema, M J....................................... 697 

Aaron, J ................................................ 847 

Abadin, H ............................................. 666 

Abagyan, R ........................................ 1468 

Abbott, B .................................... 830, 2115 

Abbott, B D ................................ 219, 2141 

Abbott, M ........................................... 1995 

Abdel-Bakky, M S.............................. 1954 

Abdel-Rahman, S Z ..................... 361, 702 

Abdelbaqi, K .................................... 1780* 

Abdelhamid, G ................................. 2167* 

Abdelmajid, N ...................................... 642 

Abdo, K .............................................. 1844 

Abdo, K A ............................................ 381 

Abler, L L ............................................. 844 

Abo, T .................................................. 301 

Abou-Donia, M B .............................. 1233 

Abou-Hadeed, A A ............................. 381* 

Abou-Hadeed, A H ............................. 1955 

Abraham, I ......................................... 1911 

Achuthan, V ............................... 592, 1557 

Ackerson, T ........................................ 1325 

Acquaah-Mensah, G .......................... 193* 

Acuff, K ............................................... 471 

Ad, P .................................................. 1552 

Ada, A O .............................................. 356 

Adamcakova-Dodd, A .......................... 370 

Adams, S .............................................. 117 

Adams, T .............................................. 979 

Adams, V H ........................................ 991* 

Adamson, G ......................................... 108 

Adamson, J ............................................. 92 

Adam čáková-Dodd, A ......................... 237 

Adeshina, F .......... 1014, 1024, 1028, 1034 

Adewale, H B ....................................... 406 

Aeby, P ............................................. 1926* 

Aerssens, J ............................................ 816 

Afeseh Ngwa, H ................................. 272* 

Afriyie-Gyawu, E ............................... 1459 

Afshari, A ................................. 1022, 1495 

Afshari, C ........................................... 1962 

Afshari, C A ....................................... 2077 

Agarwal, R ............................. 69, 352, 353 

Agbor, L N ......................................... 2058 

Ageev, V .............................................. 210 

Ago, K ................................................ 1313 

Aguirre, S ........................................... 1725 

Ahene, A ............................................ 1990 

Ahles, L .............................................. 1726 

Ahmad, M .......................................... 1515 

Ahuja, M ............................................ 1297 

Aibo, D ............................................... 2175 

Aidoo, A ............................................. 1703 

Aizawa, Y ................................ 1605, 1608 

Ajani, E K ............................................ 423 

Aji, S B............................................... 1058 

Ajibola, R ............................................. 490 

Akanbi, D O ......................................... 989 

Åkesson, A ........................................... 408 

Akhtar, M ............................... 1244*, 1891 

Akhurst, L C ....................................... 475* 

Akita, H .................................... 1605, 1608 

Akunda, J ........................................... 1330 

Al-Saleh, I ........................................ 1835* 

Alaimo, A ........................................... 1235 

Alakoskela, J ........................................ 208 

Alashwal, H ........................................ 1602 

Albertini, R J ...................................... 1112 

Albertini, S ......................................... 1125 

Albini, E ................................................. 23 

Albores, A ............................................ 355 

Albrecht, A E ................................... 1141* 

Alden, C L ........................................ 1921* 

Aldous, C N ..................................... 1037* 

Aleksunes, L ............................ 2154, 2155 

Aleksunes, L M .................................. 1597 

Aleo, M .................................................. 86 

Aleo, M D ............................................ 85* 

Aleshin, M ............................................ 951 

Alexander, A ........................................ 506 

Alexander, D ...................................... 136* 

Alexander, J ............................. 1650, 2196 

Alexeeff, G V ........................... 566, 1906* 

Aley, P ................................................ 1292 

Algaier, J W ....... 1132, 1587*, 1588, 1589 

Ali, I ................................................... 408* 

Ali, S ........................................ 1575, 1703 

Ali, S F ............................... 281, 796, 798* 

Ali, Z .................................................... 687 

Allais, L ................................................ 409 

Allamargot, C ....................................... 134 

Allamneni, K ...................................... 1044 

Allan, A M ......................................... 1606 

Allard, P ............................................. 460* 

Allen, D .......... 101, 300, 1806, 1807, 1808 

Allen, E M ........................................ 1236* 

Allen, K ............................................ 1619* 

Allen-Hoffmann, L ..................... 112, 500, 

2059*, 2060 

Alles, N J ............................................ 1201 

Allgeier, S H ........................................ 844 

Allina, J .............................................. 1974 

Almeida, I C ......................................... 769 

Almond, R .......................................... 296* 

Alonso, A ............................................. 491 

Alper, S ................................................ 356 

Alpers, C N ........................................ 1936 

Altenhofen, E ..................... 157, 173*, 175 

Alvarez, P J .......................................... 255 

Alwis, U ........................................... 1301* 

Alépée, N ............... 498, 504, 1190*, 1191 

Amaral, F ................................... 488*, 504 

Amato, K E .......................................... 794 

Ambali, S F .......................................... 989 

Amberg, A .................................... 57*, 189 

Ames, M M .......................................... 357 

Amidan, B ............................................ 939 

Amin, S .............................................. 2143 

Amissah, F ......................................... 1674 

Ammenhauser, A D ................. 1588, 1589 

Amos-Kroohs, R M ............................ 1600 

Amuzie, C ................................ 1143, 1785 

An, Y .................................................. 1651 

Anadon, A .............................. 1464, 1892* 

Anador, S ........................................... 981* 

Anand, S S ................... 1182*, 1188, 1568 

Anantharam, P .................................... 1676 

Anantharam, V ........ 272, 986, 1268, 1276, 

1676* 

Anaya-Martinez, V ............................ 1292 

Andersen, L .......................................... 920 

Andersen, M ......................................... 962 

Andersen, M E .... 573, 728, 881, 884, 885, 

1384, 1446*, 1530 

Anderson, D ................................. 350, 625 

Anderson, D G ................................. 1275* 

Anderson, D S .................................... 1518 

Anderson, D W ........................ 147, 1604* 

Anderson, S E ............................ 304, 305* 

Andersson, B ........................................ 291 

Andersson, H ...................................... 456* 

Andersson, M ....................................... 167 

Andersson, P .............................. 162, 2061 

Anderton, M J .................................. 1724* 

Ando, Y ................................................ 789 

Andres-Hernando, A .......................... 1959 

Andreu, A ........................................... 1070 

Andrew, A S ....................................... 973* 

Andrews, K L ..................................... 1280 

Andrews, L ........................... 2, 618, 1437* 

Andrus, A K ....................................... 421* 

Aneskievich, B ................................... 2152 

Aneskievich, B J ................................ 1472 

Anestis, D ............................................. 819 

Anger, K ......................... 1237, 1243, 1894 

Anger, W .................................. 1238, 1240 

Angrish, M M ................................... 1628* 

Ankley, G ......................................... 1448* 

Ankley, G T ............................... 900, 1445 

The numerals following the author’s names refer to the abstract numbers. 


Ankrah, N A ....................................... 1459 

Annalisa, Z ............................................. 23 

Ansari, G ...................................... 309, 907 

Ansari, G A .......................................... 777 

Anson, B ............ 1738*, 1739, 1740, 1741 

Antenos, M ......................................... 1102 

Antignac, E ........................................ 1179 

Antolino Lobo, I............................... 1088* 

Antonini, J M ... 19*, 734, 737, 1400, 2178 

Antunes Fernandes, E ...................... 2103* 

Anwar, M I ......................................... 1891 

Anwar-Mohamed, A ................ 950*, 2167 

Aoki, M .............................................. 1309 

Apana, S M .......................................... 163 

Api, A ... 308, 401, 1011, 1109, 1110, 1111 

Apostoli, A J .................................... 2004* 

Apostolov, E O ........................... 828, 1223 

Apostolov, Y .................................... 1224* 

Appana, S ........................................... 1883 

Applegate, D R ............. 1661, 1966*, 1967 

Arai, S ................................................ 1130 

Aranibar, N ...................... 720, 1315, 1637 

Arantza, E ............................................ 776 

Arbey, E ............................................. 1190 

Arbon, K S ......................................... 1820 

Arch, D D ............................................. 454 

Archer, C ............................................ 1038 

Arencibia, A ....................................... 1997 

Ares, I ................................................. 1892 

Arezzo, J ............................................ 1281 

Arezzo, J C ........................................... 586 

Arima, A .................................... 403, 1026 

Arita, A G ......................................... 2159* 

Ariza, M ..................................... 371, 1553 

Arlt, V M .............................................. 522 

Armento, A ........................................ 478* 

Arnaud, M ............................................ 334 

Arnold, L L ................................ 516, 1300 

Aronstam, R S .............................. 288, 373 

Arp, E ................................................... 508 

Arrant, A E ........................................... 184 

Arrington, J E ......................... 1979*, 1986 

Arroyo-Salgado, B ........................... 1899* 

Arteel, G ............................................. 1430 

Arteel, J .............................................. 1430 

Arulanandam, T ............................... 1003* 

Arvidson, K B .................................... 213* 

Arzuaga, X ....................................... 1908* 

Asaithambi, A .................................. 1268* 

Asakawa, H ........................................ 1605 

Ascenção, A ....................................... 1731 

Aschner, M .................. 462, 494, 771, 998, 

999, 1001, 1002, 1263, 1264, 1277, 1839, 

2038* 

Asgharian, B .............................. 868, 869* 

Ashfaq, M K ....................................... 1954 

Ashikaga, T ................................ 301, 1926 

Ashley, D L ........................................ 1301 

Assimon, S A ................................... 1156* 

Atchison, W D ................... 976, 977, 1607 

Atmakuru, R ....................................... 1557 

Attia, M K .......................................... 1233 

Au, C .................................................... 462 

Aubrecht, J ................................... 58, 649* 

Auerbach, S ........................................ 1969 

Auerbach, S S ..................................... 1573 

Augustin, A ........................................ 982* 

Augustine, L M ........................ 1596, 1625 

Ault, V F .................................. 1587, 1589 

Aunskjar, U .......................................... 418 

Aust, L .................................................. 471 

Austin, C .............................................. 196 

Austin, C P ................................... 707, 715 

Authier, S ......................... 925, 932, 1055* 

Autrup, H ........................................... 1704 

Auttachoat, W .................................... 297* 

Auwal, M S ........................................ 1058 

Auyeung-Kim, D ...................... 1004, 1044 

Avalos, J ............................... 106, 471, 485 

Averill-Garafolo, D .............................. 117 

Avila, D .............................................. 462* 

Avila-Costa, M ................................... 1292 

Avison, M J ........................................ 2038 

Avlasevich, S ............................. 472, 1115 

Avogadro, A ....................................... 1555 

Ayehunie, S ................................ 303*, 412 

Aylward, L ......................................... 1852 

Aylward, L L .................. 544, 1041*, 1796 

Ayo, J O ............................................... 989 

Ayoola, S O ........................................ 423* 

Ayotte, P ...................................... 892, 893 

Ayuk-Takem, L T ............................ 1674* 

Azuela, G ........................................... 1716 

Azzopardi, D .......................................... 92 

B 

Baba, S ............................................... 1687 

Babakov, V ......................................... 1866 

Babcock, G ........................................... 328 

Babica, P ............................................ 1668 

Babin, M .............................................. 347 

Babin, M C ......................... 923, 924, 2213 

Babu, S ................................... 1283*, 1557 

Baccam, M ........................................... 484 

Bachynsky, M O ................................. 1308 

Backos, D ........................................... 779* 

Bacom, A............................................ 1877 

Baden, D .................................... 843, 2179 

Badger, T M ......................................... 762 

Badtke, L ............................................ 360* 

Bae, H .................................................. 823 

Bae, O ................................................ 1838 

Bae, Y ....................................... 726*, 1177 

Baer, C E ................................................ 90 

Bagchi, D ............................... 1142, 1145* 

Bagchi, M ................................. 1142, 1145 

Baggish, J ........................................... 1072 

Bai, J .................................................. 2159 

Bai, S .................................................. 1636 

Bai, Z .................................................. 1508 

Bailey, A ............................................. 1791 

Bailey, K............................................... 507 

Bailey, M .............................................. 892 

Bailey, S M ............................. 1632*, 1633 

Bailey, W J ......................................... 581* 

Bain, L J ............................................... 838 

Baird, T D ............................................ 523 

Baird, T J ............................................ 2116 

Bajt, M ............................................... 2134 

Baker, A A .............................. 1234, 1251* 

Baker, T K .............................................. 79 

Balbuena, P ...................................... 1254* 

Baldetti, C .......................................... 1106 

Baldwin, S .......................................... 1113 

Baldwin, W ........................................ 2148 

Bale, A.............................................. 1932* 

Baliga, V .............................................. 753 

Ball, G L ............................................. 1912 

Ball, J G ..................................... 818, 2138 

Ball, L M .................................. 1328, 1864 

Ballinger, S W .................................... 1632 

Banerjee, A ................................. 785, 804* 

Banerjee, N ...................................... 1705* 

Baneux, P ............................................. 937 

Bangira, C .......................................... 1161 

Bangsaruntip, S .................................. 1400 

Bankoti, J ........................................... 1535 

Banks, C J ............................................ 803 

Banks, W .............................................. 785 

Bannish, G .......................................... 1992 

Bannon, D I .................................. 216, 991 

Bar-Ilan, O ....................................... 2065* 

Baratta, M T ....................................... 1379 

Barber, D ............................................ 1707 

Barber, D S ....................................... 1289* 

Barber, J ....................................... 78, 2122 

Barchowsky, A ................. 571*, 576*, 677 

Barcus, M ........................................... 1655 

Barger, M ............................................. 257 

Barger, P M ...................................... 1359* 

304 




Barhoover, M A ...................... 1199*, 1338 

Barhoumi, R ......................................... 531 

Barile, F A .................................. 964, 1686 

Baris, T ............................................... 1743 

Bark, I ................................................ 1179 

Barker, M L .......................................... 454 

Barlow, B M ..................................... 1158* 

Barnard, C ............................................ 602 

Barnard, S M ...................................... 126* 

Barnes, N .............................................. 109 

Barnett, J F ..................... 1155, 1189, 1569 

Barnett, R E ........................................ 1287 

Barnholtz-Sloan, J S ............................. 357 

Barone, S ........................ 546*, 656*, 1932 

Barr, D B ............................................ 1887 

Barraj, L ............................................. 1847 

Barrera, J .............................................. 810 

Barrett, C .............................................. 915 

Barrier, M ..................... 1683*, 1684, 1685 

Barril, J ............................................... 1249 

Barrow, P C ........................................ 409* 

Barrón-Vivanco, B S .......................... 355* 

Bars, R ................................................ 2096 

Barsoum, J .......................................... 1659 

Bartels, M J .......... 896, 1385, 1591, 1592* 

Barter, R A ........................................... 508 

Bartholomae, P ................................... 1067 

Barton, D M ....................................... 1162 

Barton, H A ........................................ 1564 

Barve, A S ............................................ 152 

Barve, S ................................................ 152 

Basavarajappa, M ............................... 399* 

Basavarajappa, M S .............................. 398 

Baskin, S .............................................. 338 

Basnakian, A ...................................... 1224 

Basnakian, A G ........................ 828*, 1223 

Bass, A S .............................. 1374*, 1376* 

Bassily, M N ....................................... 1947 

Basta, N T .......................................... 1936 

Basu, N ................................... 1830, 1831* 

Basudev, C ........................................... 810 

Bateson, T ............................................ 665 

Bathula, C ........................................ 1813* 

Battaglia, C L ................................... 2190* 

Battelli, L A ................................ 734, 1506 

Baud, F ............................................... 334* 

Baudet, S ............................ 603*, 604, 940 

Baudis, B ............................................ 1394 

Bauer, K ............................................. 1594 

Baumeister, J ...................................... 1577 

Bausen, M ........................................ 1798* 

Baverel, G .................................. 577, 1059 

Bayir, H ................................................ 766 

Baynes, R E .............................. 503*, 1158 

Bayoumi, F S ..................................... 2158 

Bayse, G S .......................................... 1101 

Bazar, M A ........................................... 493 

Bazley, L ............................................ 1080 

Beall, H D .................................. 357, 724* 

Beam, A...................................... 98*, 1717 

Beamer, C ............................................... 32 

Beamer, C A ....................................... 735* 

Beasley, V R ......................................... 669 

Beatty, P ....................................... 124, 357 

Beaufils, J ........................................... 1314 

Beaver, L M........................................ 1467 

Bebenek, I .......................................... 1194 

Bebenek, I G .................................... 1712* 

Bechtel, C ........................................... 1043 

Beck, B ................................................. 612 

Beck, B D ............... 514, 1039, 1942, 1946 

Beck, M J ............................................. 995 

Beck, T W .......................................... 1752 

Becker, B .............................................. 497 

Becker, R A ........................................ 2108 

Becquet, J ............................................. 891 

Bedja, D ............................................. 1751 

Bednar, A J ........................................... 803 

Beedanagari, S R ................................ 154* 

Beeson, C ............................................. 814 

Beevers, C ............................................ 717 

Beezhold, D ........................................ 1870 

Beezhold, K ........................................ 119* 

Beger, R.............................................. 1960 

Beger, R D ........................................ 1581* 

Beggs, K M ...................................... 2123* 

Begley, T ............................................ 2159 

Behforouz, M ....................................... 724 

Behl, M .......................... 984, 1841*, 2163 

Behrsing, H P ........................... 481, 1406* 

Behrsing, T ......................................... 1934 

Belaidi, J .............................................. 496 

Beland, F A ..... 131, 148, 703, 1140, 1347, 

1951 

Belanger, C L ....................................... 696 

Belcher, L ........................................... 1148 

Belcher, L A ........................... 1146, 1147* 

Beliveau, M .................... 881*, 1580, 1583 

Bell, A ................................................ 1724 

Bell, R .... 1075, 1076*, 1077, 1303, 2011* 

Beloni, J ............................................... 347 

Bemis, J C ........................ 690, 691, 1115* 

Benbrook, D M .................................... 721 

Bendich, A............................................ 609 

Benedetti-Padron, E ........................... 1899 

Benedetto, A ......................................... 462 

Benitez-Kruidenier, S L ................... 1545* 

Benkovic, S A .................. 587*, 799, 1261 

Benninghoff, A D ............. 128, 428, 2112* 

Benson, J .................... 68, 351*, 843, 2179 

Bentley, P ..................................... 584, 807 

Benz, F W ........................................ 1848* 

Berdasco, N A ...................................... 139 

Berg, J M ............................................ 282* 

Berg, M .............................................. 1705 

Berg, N ................................................. 484 

Bergamaschi, M M ........................... 1760* 

Berglund, M ......................................... 408 

Bergman, ........................... 217, 223, 1585 

Berk, M .............................................. 1388 

Berman, D .......................................... 1273 

Berman, D M ..................................... 1281 

Berman, W ......................................... 1873 

Bermudez, D S ................................... 249* 

Bermudez, E ......................................... 143 

Bernal, J ............................................. 1842 

Bernal-Hernández, Y Y ...................... 434* 

Bernards, K ........................................ 1754 

Berninger, J P ..................................... 437* 

Bernshausen, T ................................... 1948 

Bernstein, D M ................................. 1476* 

Berridge, B ............................................. 45 

Berridge, M S ....................................... 163 

Berry, D L .......................................... 1936 

Berry, J P .............................................. 757 

Berthet, A ......................................... 1326* 

Bertino, B ............................. 307, 491, 504 

Bertke, M ........................................... 1687 

Bérubé, A ........................................... 887* 

Besas, J ................................................. 783 

Besselink, H ....................................... 1650 

Bessou Touya, S ................................. 1191 

Bessou-Touya, S................................. 1926 

Bétat, A ...................................... 600, 1727 

Beuschel, S ........................................... 739 

Beverly, O L ............................. 1132, 1587 

Bevilacqua, V ..................................... 341* 

Beyer, D ............................................... 995 

Beyer, L A ........................................ 1946* 

Bhalli, J A............................................. 689 

Bhaskaran, V ........................................ 117 

Bhaskaran, V M ................................. 2136 

Bhat, V S ............................................ 1912 

Bhatia, S ................................. 1005, 1011* 

Bhatnagar, A ............................. 1166, 1687 

Bhattacharya, S .................................. 1530 

Bhattacharyya, M H ......................... 1827* 

Bhopale, K K ..................................... 907* 

Bi, X ................................................... 1869 

Bi, Y ................................................... 527* 



Bialecki, R .................... 42, 43, 1081, 1324 

Bialecki, R A .................... 807, 1047, 1757 

Bickford, M ........................................ 1128 

Bigelow, D ......................................... 1854 

Bigelow, D J ......................... 59*, 751, 752 

Bigwarfe, D .......................................... 117 

Bigwarfe, T ...................................... 1042* 

Bilgen, S ............................................... 356 

Bility, M ............................................. 2142 

Billheimer, D ...................................... 1625 

Billin, A N .......................................... 2143 

Billington, R ................................. 521, 857 

Billinton, N ........................................ 1170 

Bilsten, E .......................................... 1167* 

Binienda, Z ......................................... 1575 

Bird, G S ............................................ 1817 

Biris, A ............................................... 1703 

Biris, A S ...................................... 796, 798 

Birmingham, N .................................. 2139 

Birnbaum, L ............. 638, 639*, 641, 1723 

Birnbaum, L S .......................... 1570, 1574 

Birrell, L ............................................. 1170 

Bisson, W ........................................... 2112 

Bisson, W H ....................................... 1468 

Bissonnette, A .................................... 1921 

Bisteau, M .......................................... 1054 

Biswal, S ............................ 193, 732, 1751 

Bitter, H ................................................ 187 

Bittner, G ............................................ 1408 

Bjork, J A ........................................... 229* 

Black, A T .............................. 61, 62*, 629 

Black, J E ......................................... 1229* 

Black, W ............................................. 214* 

Blackburn, M L .................................... 762 

Blackman, C F ..................................... 262 

Blackwell, M P ................................... 1846 

Blaha, L .............................................. 1668 

Blair, I A ............................................... 453 

Blair, L ................................................... 63 

Blaisdell, R ......................................... 1013 

Blake, D J ........................................... 732* 

Blake, J ............................................... 1576 

Blake, J C ........................................... 840* 

Blakeman, D P ..................................... 113 

Blank, J A ..................................... 923, 924 

Blauw, L ............................................... 862 

Blazanin, N ........................................ 2142 

Blessing, J C................................. 926, 929 

Bleumink, R ......................... 293, 294, 295 

Bloemen, K .......................................... 55* 

Blomme, E A ........................................ 582 

Blossom, S ........................................... 310 

Blount, B .......................... 894, 1041, 2099 

Blount, B C ........................................ 1301 

Bluemel, J .......................................... 1067 

Bobadilla, N A ..................................... 810 

Bock, M J ........................................... 1324 

Bodon, N ............................................ 1408 

Boehn, S N ....................................... 2091* 

Boekelheide, K ................... 393, 394, 1973 

Boellmann, F ...................................... 1010 

Boelsterli, U A ......................... 2129, 2130 

Boere, J ................................................ 279 

Bohnenberger, S ................................. 1124 

Bol, M .................................................. 538 

Bol-Schoenmakers, M ................ 293*, 294 

Boland, S ............................................ 1701 

Bolger, P M ........................................ 1156 

Bolivar, V ........................................... 1100 

Bolmarcich, J ............................. 470, 477* 

Bolstad, H M ...................................... 782* 

Bolt, A M ......................................... 1227* 

Bolte, H .............................................. 2005 

Bolterstein, E ...................................... 2060 

Bomberger, J M .................................... 956 

Bond, G G .......................................... 1798 

Bonner, J C ............. 286, 1828, 2072, 2073 

Bonner, M .......................................... 1240 

Bonner, M R ................... 1237, 1243, 1894 

Bonney, M G .................................... 1090* 

Bontempi, E ........................................... 23 

Bonventre, J V ...................................... 821 

Boogaard, M ...................................... 1388 

Boogaard, P J ................................... 1796* 

Booher, L E ........................................ 1851 

Boon, L ................................................ 293 

Boor, P J ....................... 309, 702, 777, 866 

Booth, D ............................................... 470 

Boren, B ............................................. 2084 

Borghoff, S J ...................................... 591* 

Borland, M G ..................................... 2143 

Bornman, D ........................................ 1969 

Boros, L .............................................. 1960 

Borowitz, J L ...................................... 1269 

Borsay Horowitz, D ............................. 431 

Bory, C ................................................. 604 

Bose, D D ........................................... 177* 

Bossart, G ........................................... 2189 

Botham, P ............................................. 857 

Botsivali, M ........................................ 1650 

Botta, D ................................................ 276 

Bou Aram, B A ..................................... 457 

Bou-Abboud, E ................................ 1736* 

Bouchard, A ......................................... 606 

Bouchard, M ...................................... 1326 

Boucheix, O ......................................... 603 

Bouki, C ............................................. 2103 

Bounous, D ........................................ 1708 

Bourcy, K S ............................ 1733, 1734* 

Bourdeau, A ....................................... 1921 

Bourdelais, A...................................... 2179 

Bourgeois, M M ....................... 578, 1310* 

Bourouf, L .................................. 199, 1116 

Bousquet, R W ................................... 1492 

Boverhof, D R ...................... 1978*, 2203* 

Bowlin, G L........................................ 2181 

Bowman, A........................................... 999 

Bowman, A B ............................... 993, 997 

Bowman, C J .......................... 842*, 1434* 

Bowman, L ................................... 271, 528 

Box, K .................................................. 208 

Boyd, R B ........................................... 1061 

Boyd, R E ............................................. 803 

Boyd, W A .......................................... 461* 

Boyer, I J .......................................... 1917* 

Boyes, W .............................................. 158 

Boyes, W K .................... 263*, 611*, 1258 

Boykin, E ........................................... 1302 

Boysen, G ........................................... 1882 

Bradford, B U ..................................... 364* 

Bradley, L J ...................................... 1038* 

Brady, K ............................................... 435 

Brady, L ................................................ 803 

Brain, J ................................................. 278 

Braithwaite, E K ............................... 1815* 

Braman, N ........................................ 1223* 

Bramble, L ......................................... 2175 

Brandenburg, A .................................. 197* 

Brander, S M ...................................... 433* 

Branham, W S .................................... 1644 

Branstetter, D ..................................... 2084 

Bratellid, T ......................................... 1025 

Brattin, B .............................................. 970 

Brattin, W ........................................... 1877 

Bratton, S B .......................................... 780 

Brauers, K J .......................................... 650 

Braun, A A ......................................... 1600 

Braun, H M ...................................... 1119* 

Braun, J ................................................ 711 

Braun, M ............................................ 1126 

Braydich-Stolle, L .............................. 372* 

Braydich-Stolle, L K ..... 1693, 1694, 1695, 

1696 

Brayman, T G ..................................... 1065 

Breen, M .......... 900*, 1449, 1856*, 1856* 

Breen, M S ........................................... 900 

Brees, D J ........................................... 2199 

Breidenbach, A ................................... 1052 

Bremer, N M ...................................... 1665 

Bremer, S.............................................. 101 

Author Index 



Author Index 


Brennan, R ............................. 1661, 1967* 

Bresee, K .......................................... 1918* 

Bressler, J P ........................................ 790* 

Bridges, C .......................................... 378* 

Briede, J J ........................................... 517* 

Briedé, J J ............................................. 778 

Brien, J F ............................................ 1229 

Briffaux, J ................... 409, 603, 604*, 940 

Brill, S .............................................. 1403* 

Brimfield, A A .................................... 781* 

Brimijoin, S ................................ 855, 1241 

Brittebo, E .................................... 167, 456 

Brock, B ............................................. 1638 

Brock, G ............................................. 1883 

Brock, W J ................................ 25*, 1173* 

Brocker, C .......................................... 595* 

Brockman, R ........................................ 482 

Broder, M ........................................... 1913 

Brodsky, B ............................................ 494 

Broeckaert, F ...................................... 2096 

Broka, D ............................................. 1971 

Brooks, A ........................................... 1857 

Brooks, B ............................................. 437 

Brooks, B W ......................................... 465 

Brooks, J D ........................................... 495 

Brooks, K ............................................. 397 

Brorby, G .......................................... 1873* 

Brosch, K O ....................................... 1280 

Brott, D .................... 584, 807, 1047, 1642 

Brouwer, D ......................................... 1396 

Brouwer, K L ..................................... 624* 

Brouwer, K R ........................... 1595, 2104 

Brown, A M............................ 1732*, 1753 

Brown, C ...................................... 410, 981 

Brown, H .............................................. 601 

Brown, J ......................... 818, 1126, 2138* 

Brown, J M ............................... 795*, 1502 

Brown, J P .......................................... 1915 

Brown, K ............................................ 978* 

Brown, M ............................................. 400 

Brown, R ............................ 70, 213, 1187* 

Browne, M ......................................... 1126 

Browne, R W ...................................... 1243 

Browning, D B ............................. 794, 840 

Bruckner, J V .................. 889, 1565*, 1568 

Bruening-Wright, A ........................... 1753 

Brumfield, J .......................................... 968 

Brunnemann, K .................................. 1120 

Bruno, M ............................................ 1501 

Brunshidle, T ...................................... 1176 

Brunson, C D ..................................... 2140 

Brusch-Richardson, L ........................ 371* 

Bruun, D ................................... 1238, 1263 

Bryce, S .............................................. 472* 

Bryce, S M ......................... 690, 691, 1115 

Bryner, S ............................................ 767* 

Brüning, T .......................................... 1879 

Bucher, J ............................................. 1454 

Bucio, L .............................................. 1816 

Buck, R .............................................. 1182 

Buck, R C ................................... 450, 1188 

Buck, W R ............................................ 582 

Buckalew, A ....................................... 2088 

Buckley, B .......................................... 1087 

Budai, M .............................................. 349 

Budinsky, R .............................. 430, 1112* 

Budroe, J ............................................ 1910 

Buettner, G R ..................................... 1105 

Bui, A ................................................. 685* 

Bui, K H ............................................. 1757 

Bui, P.................................................. 1712 

Bui, P H .............................................. 451* 

Bull, D ................................................ 1713 

Bull, R J ....................................... 811, 812 

Bullard, K L ........................................... 88 

Bullerman, L B ................................... 1159 

Bullock, N .......................................... 1803 

Bulthuis, R ........................................... 862 

Bunch, R T ................................. 930, 1708 

Bunderson, B ........................................ 446 

Buness, A ........................................... 1308 

Bunton, D ........................................... 1755 

Bunton, D C ....................................... 1735 

Buntz, J .............................................. 1509 

Buono-Dalton, C .................................. 469 

Buranachokpaisan, T ........................ 1087* 

Burback, B L ...................................... 1578 

Burch, P .................................................. 86 

Burdick, A .......................................... 1065 

Burdick, A D .......................... 1069*, 1379 

Burdick, J ............................................. 471 

Burdock, G ......................................... 1178 

Burek, C J ........................................... 809* 

Burgess, J L ........................................ 1512 

Burgess, M P ...................................... 1266 

Burghardt, R ......................................... 531 

Burghardt, R C ..................................... 822 

Burgher, F .............................. 1175*, 1192 

Burgoon, L ......................................... 1649 

Burgoon, L D ...................... 84, 244, 1629, 

1630, 1636, 1956 

Burkhalter, K ............................ 1871, 1872 

Burkhardt, J E .................................... 1787 

Burmistrov, D ..................................... 1947 

Burnett, D M ........................................ 508 

Burnett, J .......................................... 1073* 

Burns, A ............................................. 1021 

Burns, A M ....................................... 1851* 

Burns, L M ......................................... 1846 

Burns, S .............................................. 1282 

Burns, T .............................................. 300* 

Burrows, A M ..................................... 489* 

Bursian, S ............................................. 430 

Bury, D ............................................. 1184* 

Bus, J .................................................. 612* 

Bus, J S..................... 419*, 420, 421, 1189 

Busby, A L ......................................... 1887 

Busby-Hjerpe, A L ............................. 1599 

Buschmann, J ..................................... 1169 

Bushnell, P ........................................... 888 

Bushnell, P J....................... 159, 611, 1258 

Bussiere, J ...................... 619*, 1962, 2077 

Bussières, M ......................................... 921 

Butenhoff, J L .......... 226, 407, 1585, 1586 

Buthod, J L ......................................... 1917 

Butler, D ............................................... 601 

Butler, E O ......................................... 1500 

Butt, M T ............................................ 1061 

Butterfield, D ............................. 277, 2069 

Butterfield, D A .................................... 269 

Butterworth, M ..................................... 780 

Buxton, S............................................ 729* 

Buzanska, L .......................................... 170 

Byrd, R M .......................................... 1227 

C 

Cable, C ................................................ 357 

Caceres, A .............................. 2016, 2020* 

Cahill, P A .......................................... 1170 

Cahill, S............................................ 1993* 

Cahn, E ................................................. 968 

Cai, J ........................................ 1839, 1848 

Cai, L ........ 747, 758*, 1362*, 1367*, 1747 

Cai, P ................................................ 2124* 

Cai, W .................................................. 724 

Cain, G ..................................... 1044, 1062 

Calabrese, E J ................................... 1922* 

Calabro, A R....................................... 964* 

Calafat, A ................................. 560*, 640* 

Calderon-Garciduenas, L ..................... 24* 

Cali, J ............................................... 1205* 

Cali, J J ............................................... 1094 

Calias, P ............................................. 1061 

Callaway, J ......................................... 1522 

Camacho, L ...................................... 1484* 

Camargo, J V ........................................ 507 

Camarillo, J M ..................................... 955 

Camenisch, T D.................................. 1971 

Cameron, D .......................................... 601 

Campbell, J .............................. 874*, 1019 



Campbell, J A ..................................... 1887 

Campbell, P ................................ 584, 1063 

Campen, M ................... 1509*, 1510, 1511 

Campen, M J ...................................... 1500 

Campion, S N ......... 393*, 394, 627*, 2132 

Camps, M ............................................. 136 

Cancel, A ............................................ 2005 

Canerdy, T D ...................................... 1142 

Canet, M J .......................................... 1626 

Cangieter, V ....................................... 1779 

Cannon, C .......................................... 412* 

Cannon, J .............................................. 667 

Cantore, M ........................................... 595 

Cantu-Soto, E ....................................... 947 

Cao, C J ................................................ 322 

Cao, L ................................................. 1043 

Cao, Z ............................................... 1165* 

Capellini, D ........................................ 2165 

Car, B ....................................... 1084, 1273 

Car, B D ................................. 1281, 1377* 

Carathers, M ......................................... 479 

Carbery, I d ......................................... 904* 

Carbone, D L ...................................... 1285 

Card, J W ............................................ 1803 

Cardellach, F ................ 1070, 2117*, 2121 

Cardoso, A F ........................................ 507 

Cardozo-Pelaez, F ................................ 358 

Carfagna, M A .................................... 586* 

Carlin, D ............................................. 1503 

Carll, A P ...................... 1498, 1501, 1522* 

Carlock, L ................................ 1962, 2077 

Carlsson, G ........................................... 466 

Carlton, A L ..................................... 1975* 

Carmody, M W ................................... 1975 

Carnell, L ............................................. 767 

Carney, E ............................ 397, 836*, 857 

Caron, S .................................... 1185, 1186 

Carpenter, C ............................... 99*, 1182 

Carpenter, T .......................................... 198 

Carpinone, P ..................................... 1707* 

Carr, G J ................................................. 97 

Carr, R L..................................... 168*, 837 

Carr, S ................................................ 1790 

Carrasquer, C........................................ 188 

Carraway, M ....................................... 1477 

Carroll, M A ......... 978, 979, 980, 981, 988 

Carson, J ............................................... 870 

Carson, J P ........................................... 871 

Carter, C A ............................. 1312*, 1316 

Carter, J N ............................................ 475 

Cartwright, M E ..................... 1374, 1378* 

Carvan, M........................................... 2026 

Casado, F L ........................................ 1682 

Casado-Pena, F L ............................. 1681* 

Casanova-Mollà, J .............................. 1070 

Cascio, W E ........................................ 1502 

Casey, P .............................................. 2066 

Casillas, R P ............................... 61, 62, 65 

Cassee, F .............................................. 279 

Cassee, F R ......................................... 608* 

Cassens, K J ......................................... 275 

Cassidy, P ............................................. 265 

Castellano, V ...................................... 1892 

Castle, A ............................................... 372 

Castorena-Torres, F .............................. 355 

Castranova, V .............. 119, 225, 270, 271, 

278, 528, 737, 793, 797, 800, 1506, 1665, 

1728, 1859 

Castro, D .......................................... 2002* 

Castro, L ............................................... 413 

Catalán, J .............................................. 266 

Catapane, E J ........ 978, 979, 980, 981, 988 

Cate, S ................................................ 2220 

Cater, K ...................................... 471, 473* 

Catheline, D ......................................... 596 

Cathey, B L .......................................... 795 

Catlin, N ............................................. 394* 

Cattley, R ............................................ 1962 

Cavagnaro, J ........................... 1003, 1436* 

Cavalieri, E ......................................... 1885 

Cave, M ...... 743, 1317, 1320, 1321, 1883* 

Cavet, M E ......................................... 1168 

Cearfoss, J .......................................... 1961 

Cedergreen, N .................................... 2097 

Ceger, P .............................................. 101* 

Celander, M C .................................... 1450 

Celius, T ............................................. 1198 

Centeno, J ........................................... 1880 

Centeno, J A ......................................... 934 

Cervelli, J A........................................ 1665 

Cerven, D ..................................... 106, 473 

Cerven, D R................................ 479, 485* 

Cesta, M ............................................... 100 

Cezar, G G ............................................ 207 

Chadalapaka, G .......................... 531, 532* 

Chai, Y ................................................. 240 

Chaisson, C F ....................................... 567 

Chalencon, E ........................ 603, 604, 940 

Chambers, H .............................. 324, 1897 

Chambers, J ................................ 324, 1897 

Chambers, J E ............................ 242, 2145 

Chambers, W ........................................ 938 

Champ, S .................................... 258, 2068 

Champion, B .................................... 1370* 

Chan, E ............................................. 1999* 

Chan, J .................................................. 205 

Chan, J K ............................................ 1518 

Chan, J Y .............................................. 382 

Chan, K M .......................................... 1211 

Chan, M .............................................. 1129 

Chan, M M ......................................... 1107 

Chan, P ............................................... 1758 

Chan, V .................................... 1305, 1878 

Chan, W ............................................. 1520 

Chand, D ............................................ 1934 

Chanda, S M ....................................... 318* 

Chandalia, J K .......................... 670*, 1886 

Chandler, K ........................................ 1382 

Chandross, K ...................................... 1325 

Chaney, J .............................................. 110 

Chaney, S ........................................... 1972 

Chang, C ............................................ 1136 

Chang, C C ......................................... 1630 

Chang, D ............................................ 1900 

Chang, D T ....................... 882, 883, 1386* 

Chang, E ............................................... 525 

Chang, Q ............................................ 1393 

Chang, S ................................. 1585*, 1586 

Chang, S C ........................................... 226 

Chang, T K ......................................... 1133 

Chang, X .......................................... 1202* 

Chang, Y ............................................... 343 

Channel, M ......................................... 1514 

Chanock, S ........................................... 127 

Chao, J .................................................. 441 

Chapin, R E ............................................ 7* 

Chapman, G ......................................... 328 

Chapman, G D ............................ 934, 990, 

991, 1031, 1881 

Chapman, R S .................................... 1400 

Charbonneau, M ............... 893, 1207, 1517 

Charest-Tardif, G ....................... 887, 1579 

Chaurand, F .......................................... 932 

Chavakis, T .......................................... 595 

Chavan, H ......................................... 1089* 

Chavez, G J ........................................ 843* 

Cheatham, T E.................................... 1096 

Cheikh Rouhou, M ............................. 243* 

Chen, B ...................................... 797, 1495 

Chen, B T ................................... 734, 1728 

Chen, C ........ 210, 1508, 1520, 1927, 1937 

Chen, F ................................................. 119 

Chen, F F .......................................... 2042* 

Chen, G .................................... 1219, 1393 

Chen, H ............................ 153, 458*, 1060 

Chen, J ............ 147, 762*, 938, 1000, 1789 

Chen, L .......................... 19, 22, 129*, 233, 

234, 441, 727, 1478, 1507, 1508 

Chen, M .................................... 390, 2126* 

Chen, S ............................................... 1084 

306 




Chen, T ........ 56, 693, 1371*, 1697, 1703*, 

2147* 

Chen, W ................................. 1526, 1528* 

Chen, Y .................. 692, 801*, 807*, 1047, 

1697*, 1703, 1834, 1962, 2093, 2095* 

Chen, Z ..................................... 1737, 2049 

Cheng, B .............................................. 631 

Cheng, C ............................................ 1658 

Cheng, J .............................................. 1841 

Cheng, L ............................................... 969 

Cheng, Q ................................ 1466*, 1621 

Cheng, S ............................... 1219*, 1260* 

Cheng, X .......................................... 1617* 

Cheng, Y ........................................... 1584* 

Cherr, G N ............................................ 433 

Cherrington, N J ... 557*, 1596, 1625, 1626 

Chesler, S N ..................................... 1012* 

Chi, H ................................................. 1282 

Chibout, S .......................................... 1323 

Chiemi, S.............................................. 826 

Chignell, C ........................................... 967 

Chihara, K ............................................ 377 

Child, M ............................................... 303 

Childress, J ........................................... 338 

Chipinda, I ................................ 490, 1405* 

Chipman, K .............................. 1138, 1447 

Chirila, M ............................................. 793 

Chitrakar, A ........................................ 977* 

Chittim, B ............................................. 244 

Chiu, A O ........................................... 138* 

Chiu, N H ............................................. 138 

Chiu, W A .............................. 1927, 1931* 

Cho, J ......................................... 817, 1680 

Cho, M ..................................... 1228, 1399 

Choi, A ............................................... 1516 

Choi, B ............................. 808*, 823, 1365 

Choi, C ..................................... 1759, 1769 

Choi, E ..................................... 725*, 1177 

Choi, H ............................................... 746* 

Choi, J ............... 1279*, 1699, 1700, 1710, 

1761, 1764, 1765, 1767, 1769*, 1770 

Choi, K ............................................. 1019* 

Choi, M ................................................ 985 

Choi, S S .............................................. 204 

Choi, W ................................................ 630 

Choi, Y ............................... 233*, 234, 448 

Choo, E .............................................. 1062 

Chopra, M ........................................ 1222* 

Chordia, T .......................................... 1745 

Chou, C ............................................ 1136* 

Chou, J W ........................................... 1832 

Choudhury, H ................................... 1030* 

Chow, P .............................................. 913* 

Chow, S C .......................................... 1211 

Chowdhury, K .................................. 1819* 

Chrisler, W B................................ 275, 678 

Christian, B J .................................... 1056* 

Christian, W V.................................... 1278 

Christopher, J ..................................... 1006 

Christopher, J P .................................. 1936 

Christopher, S ....................................... 512 

Chu, H ...................................... 1221, 1524 

Chuang, C .......................................... 1136 

Chuang, J C ........................................ 1849 

Chung, B .............................................. 909 

Chung, J ................................... 1217, 1838 

Chung, S ............................................. 1838 

Chung, Y ................ 298, 1759, 1765, 1769 

Churchwel, M I .................................... 131 

Cilli, N.................................................. 981 

Ciurlionis, R ......................................... 582 

Claessen, S H ....................................... 650 

Clark, C R .......................................... 508* 

Clark, E B ........................................... 655* 

Clark, G ................................................ 101 

Clark, J ............................................... 1553 

Clark, J C ............................... 2105*, 2106 

Clark, K .................................... 790, 1698* 

Clark, O .................................................. 66 

Clark, R .............................................. 1799 

Clark, S ................................................ 930 

Clark, S P ........................................... 1708 

Clarkson, E D ..................................... 342* 

Class, R .............................................. 1067 

Clay, A K ............................................ 1132 

Clement, M B ....................................... 806 

Cleveland, R O ................................... 1884 

Clewell, H ........ 492, 874, 895, 1010, 1019 

Clewell, H J .............. 884, 885, 1384, 1938 

Clewell, R........................................... 1019 

Clewell, R A ....................................... 728* 

Clifford, J A.......................................... 757 

Clinch, N .............................................. 642 

Cline, M ............................................. 1004 

Clouzeau, J ......................................... 1179 

Coban, A .............................................. 242 

Cobos, E ....................................... 129, 727 

Coecke, S ..................................... 114, 170 

Cohen, G M ........................................ 1400 

Cohen, J D ................................ 518*, 1667 

Cohen, M ................................................ 64 

Cohen, S M ...................... 516, 1300, 1938 

Coil, R .................................................. 135 

Coker, L................................................ 312 

Colacino, J ................................ 641, 1149* 

Colagiovanni, D B .............................. 2114 

Colaiacovo, M ...................................... 460 

Colangelo, J ........................................ 1307 

Cole, S H .................................. 935, 1981* 

Coleman, J ............................................ 200 

Coleman, J G ........................................ 803 

Coleman, M C .................................... 1590 

Colin-Barenque, L .............................. 1292 

Coll, O ................................................ 2117 

Colleton, C ......................................... 1708 

Collette, T W ........................................ 580 

Colletti, K S ....................................... 1989 

Collier, M J ........................................ 1261 

Collins, B J ............... 794, 840, 1331, 1576 

Collins, J .............................................. 628 

Collins, J F ....................................... 1023* 

Collins, J L ........................................... 344 

Collins, L...................................... 238, 874 

Collins, L B .......................................... 143 

Collins, M C ........................................... 8* 

Collins, M D......................................... 860 

Collins, N ........................................... 1987 

Collins, N D ....................................... 1982 

Collins, P .............................................. 67* 

Collins, S .............................................. 573 

Coluccio, D ........................................ 1308 

Comer, A .............................................. 112 

Compagnoni, A .................................... 114 

Conjard-Duplany, A ........................... 577* 

Conklin, D .......................................... 1166 

Conklin, D J ............... 1687*, 2016, 2018* 

Conlan, L ............................................ 660* 

Conley, C ............................................ 1746 

Connaughton, M A ....................... 429, 680 

Connaughton, V P ................................ 680 

Conner, E A ........................................ 2043 

Connolly, P ......................................... 1849 

Connor, J ............................................ 1076 

Conolly, R ............................................ 900 

Conolly, R B ................................. 36, 1530 

Constantin-Teodosiu, D ..................... 1673 

Constantine, L ...................................... 232 

Conti, M ............................................... 350 

Cook, J ................................................. 679 

Cookinham, J L ........................ 1588, 1589 

Coombes, H ...................................... 1897* 

Cooper, G S ........................................ 1932 

Cooper, K ........................................... 1072 

Cooper, K L .......................................... 706 

Cooper, K R ....................................... 2027 

Cooper, R L .............................. 2087, 2088 

Cooper, S D ........................................ 1576 

Copeland, L B ............................ 298, 1302 

Copeland, T L ...................................... 227 

Copeman, C .................... 1083, 1185, 1186 

Coppin, J ............................................ 945* 

Copple, B L ............................ 1619, 1636* 



Corcoran, G B ...................... 14, 553, 554* 

Corley, R .............................................. 280 

Corley, R A ................ 751, 752, 870*, 871, 

872, 1327 

Cornwall, C C .............. 1983*, 1984, 1985 

Coronado, G D ................................... 1242 

Coronado, M .................................... 1751* 

Coronado, M J .................................... 1419 

Corsillo, N .......................................... 1990 

Corsini, E ............................... 536*, 1555* 

Cortes, M M ......................................... 382 

Cortez, L ............................................ 1223 

Corthals, S M ....................................... 523 

Corton, C ............. 5*, 1343*, 1346*, 1348, 

1407, 2010*, 2012*, 2115, 2154*, 2155 

Corum, D .............................................. 463 

Cory-Slechta, D A ....... 563*, 1431*, 1609, 

1614*, 1907*, 1970 

Costa, D .................................................... 3 

Costa, D L ............ 1498, 1501, 1504, 1522 

Costa, L G ............................................ 222 

Costa, M ..................................... 153, 2159 

Costin, G .............................. 104, 109, 491 

Cotovio, J ......... 488, 498, 504, 505*, 1190 

Cotruvo, J ........................................... 1713 

Cotruvo, J A ......................................... 811 

Cottruvo, J A ........................................ 812 

Coughlin, J ......................................... 1582 

Coulombe, R ........................................ 287 

Coulombe, R A........................... 446, 1858 

Couroucli, X I .......................... 457, 2120* 

Couse, J F ............................................. 974 

Couttet, P............................................ 1662 

Covington, T R ..................................... 899 

Cowden, J ....................... 165*, 1924, 1925 

Cowlen, M .......................................... 1064 

Cox, D P ..................................... 455, 1493 

Cox, G .................................................. 258 

Cox, J A .............................................. 1917 

Cox, T C ............................................... 871 

Cox-Ganser, J M .................................. 737 

Crane, A L ........................................ 1243* 

Craven, V ........................................... 1875 

Crawford, R B ................. 632, 1525, 1530, 

1533, 1997 

Crawford, S ........................................ 980* 

Crean, C ............................................. 1064 

Creasy, D .......................................... 2005* 

Creppy, E E ...................................... 1462* 

Crespo-Hernandez, N E ..................... 1560 

Cristy, T .............................................. 1183 

Criswell, K ........................................... 679 

Crivello, J F .......................................... 425 

Croasdell, A.......................................... 446 

Crocker, T L ................................... 82, 184 

Crofton, K ........................ 170*, 894, 1383 

Crofton, K M ...................................... 2104 

Crosby, N ........................................... 1736 

Crouse, L .............................................. 493 

Crow, A .............................................. 1897 

Crow, J A ............................................ 2145 

Crowell, S R ....................................... 901* 

Crump, K S ...................... 37*, 1927, 1931 

Cruz, E ................................................. 469 

Cruz, S .................................................. 847 

Csanaky, I ........................................... 1597 

Csanaky, I L ............................. 589*, 1616 

Cseh, L ............................................... 1945 

Cui, H ......................................... 714, 1688 

Cui, M .................................... 1231*, 1278 

Cui, X ................................................... 904 

Cui, Y ................................................. 1103 

Cui, Y J ............................................. 1092* 

Culbreth, M E ..................................... 156* 

Cummings, B ........................... 593, 1663* 

Cummings, B S ................... 519, 594, 811, 

812, 1713 

Cumpston, J L .................................... 1728 

Cunningham, A R............................... 188* 

Cunningham, F H ............................. 1919* 

Cunningham, K .................................. 1458 

Cunningham, M ... 6, 2039*, 2040*, 2212* 

Cunningham, M L ........................ 362, 363 

Cunningham, S L ................................. 188 

Curran, C .............................................. 157 

Curran, C P ................................... 173, 175 

Curren, R ...................... 114, 472, 473, 489 

Currie, R ....................................... 533, 534 

Curtin, G M .............................. 741*, 1742 

Curtin, M .......................................... 1094* 

Cushmac, M ....................................... 2219 

Custer, L L ........................................... 690 

Cyr, D ................................................... 411 

Czich, A.............................................. 189* 

D 

D’Angiulli, A ......................................... 24 

D’Auvergne, O ................................... 1557 

D’Ingillo, S L ..................................... 1537 

D’Souza, S E ............................ 749, 1166* 

Daamen, F .......................................... 2103 

Dachir, S ............................................... 64* 

Daggett, D A ...................................... 2216 

Dahl, E L .................................. 472, 2215* 

Dai, Q ................................................... 631 

Dai, W ................................................ 2159 

Dai, X ............................................... 2140* 

Dai, Y ............................................... 1304* 

Dail, M ............................................. 2145* 

Dainty, T C ....................................... 1846* 

Dairkee, S ........................................... 1999 

Dakoulas, E W ................................... 1155 

Dallas, C E ......................................... 1565 

Dalmas, D ........................................ 1745* 

Dambach, D ....................................... 1062 

Damodaran, T V ............................... 1233* 

Damsteegt, L ........................................ 862 

Dan, D ................................................ 1488 

Dan, M ............................. 269, 277*, 2069 

Dandekar, D ......................................... 856 

Dang, D A .......................................... 1704 

Dangleben, N L .................................. 952* 

Daniels, J S ......................................... 625* 

Danielsson, C ....................................... 162 

Dantas, S ............................................ 1528 

Darney, S P ............................. 651*, 1452* 

Daronnat, E .......................................... 486 

Dary, C ....................................... 882, 1386 

Dary, C C ................................... 883, 1900 

Das, K P ................... 218*, 219, 830, 2141 

Das, S ............................................... 2079* 

Dasmahapatra, A K .......... 686*, 687, 1903 

Daston, G ............................................. 39* 

Daston, G P ............................................ 97 

Davies, B ............................................ 1794 

Davies, C ............................................ 2219 

Davies, D .......................................... 1018* 

Davies, I ............................................. 1846 

Davies, W J ........................................ 1673 

Davila, J C ..................... 556*, 1069, 1075, 

1076, 1379 

Davis, J ....................................... 625, 873* 

Davis, J T ............................................. 207 

Davis, J W ....................... 553*, 621, 1065, 

1069, 1375*, 1379 

Davis, L .............................................. 912* 

Davis, M ............................................... 242 

Davis, T A ............................................ 330 

Davoli, D .............................................. 892 

Dawson, D A .............. 248*, 251, 252, 253 

Dawson, S .......................................... 2122 

Dawurung, C J.................................. 1058* 

Dawurung, J S .................................... 1058 

Day, B J .............................................. 1524 

Day, F ........................... 1983, 1984, 1985* 

Day, K ................................................ 1934 

Day, R M .............................................. 330 

De Abrew, K ..................................... 1195* 

De Abrew, N ............................. 2059, 2060 

de Brugerolle de Fraissinette, A .......... 307, 

491, 498*, 504 

De Crosta, M ...................................... 614* 

Author Index 



Author Index 


De Esch, C ......................................... 1977 

De Groot, D ................ 862*, 1388*, 1977* 

de Groot, D M ...................................... 841 

de Groot, V ......................................... 1388 

de Jong, W ............................................ 279 

De Jonghe, S ........................................ 816 

de Kok, T M ..................... 517, 778, 1652* 

de la Fonteyne, L .................................. 279 

De La Rosa, V .................................... 224* 

de Lange, J ........................................... 101 

De Vooght, V .............................. 299, 1701 

de Vries, E .......................................... 1388 

De Wever, B ....................................... 1191 

de Zafra, C ....................................... 1044* 

de Zeeuw-Brouwer, M ....................... 1980 

Deal, F .................................................. 101 

Dearfield, K .............................. 642, 1350* 

Dearman, R J .......... 74, 75*, 296, 308, 476 

Dearry, A ............................................ 652* 

Debure, L ............................................. 596 

DeCaprio, A ......................................... 227 

DeCaprio, A P .................................... 1267 

Decker, K ........................................... 1121 

Decordier, I ........................................ 1650 

Deering-Rice, C ................................. 287* 

Deford, H S .......................................... 929 

DeGeorge, G L ............................. 479, 485 

DeGeorge, J J ..................................... 2206 

Degn, L................................................. 158 

Degn, L L ............................................. 263 

DeGuzman, M .................................... 1934 

Dehaudt, C ............................................. 80 

Dekant, W ........................ 809, 1137, 1138 

Dekeyan, N........................................... 860 

DeKeyser, J G .................................... 2146 

DeKrey, G K .................. 1090, 1545, 1691 

Del Bufalo, A ....................................... 307 

Del Tedesco, M .................................. 1396 

Delaney, B .......................................... 1155 

Delclos, K .......................................... 1484 

Delise, A ............................................... 681 

Delker, D ............................................ 1713 

Delker, D A .................. 965, 1427*, 1433* 

DeLong, A ............................................ 410 

DeLorme, M P ....................... 1523*, 2188 

DelRaso, N ......................................... 1629 

Demby, V ........................................... 2187 

Demchuk, E ........................................ 1380 

Demetrulias, J .................................... 471* 

DeMicco, A ........................................ 2027 

Dendelé, B ............................................ 596 

Deng, X ............................................ 1543* 

Deng, Y ...................................... 348, 1161 

Denlinger, R ........................................... 54 

Denny, K H ........................................ 376* 

Denslow, N D ..................................... 1450 

Denver, R ........................................... 1449 

DeOliveira, G H ............................... 1257* 

Der, K ................................................. 1043 

Dere, E ............................................. 1649* 

Dertinger, S .............. 472, 690*, 691, 1115 

Dervishi, E ........................................... 798 

Desager, K .............................................. 55 

Desai, U S ............................................ 483 

Desai, V G ................................ 635*, 1644 

DeSantis, A S ..................................... 347* 

Descotes, J ........................................ 2184* 

DeSesso, J M ............................ 1154, 1917 

Deshmukh, P ...................................... 1131 

DeSilva, A T ......................................... 525 

Destiny, S ........................................... 1210 

Devasthanam, A S ............................ 1201* 

Devereux, T .......................................... 628 

DeVito, M J .............................. 2085, 2104 

Devlin, R B ........................................ 1502 

DeVona, D .......................................... 1994 

DeVona, D A .................................... 1995* 

DeVoney, D ................................ 520*, 665 

Dewailly, ............................................. 893 

DeWitt, J .......................................... 2194* 

DeWoskin, R ............................ 1382, 1387 

Dewoskin, R ....................................... 1564 

Dhanasekaran, M ............................. 1297* 

Dhritiman, D ...................................... 2156 

Diabo, C N ......................................... 919* 

Diagaradjane, P .................................... 289 

Diamond, M ................... 584, 1053*, 1063 

Diao, H ........................................... 78, 416 

Diaz, D ............................................. 1062* 

Diegel, K ............................................ 1330 

Diekmann, J ......................................... 701 

Diembeck, W ......................................... 91 

Dieter, M Z ....................................... 1787* 

Dieterle, F .......................................... 1323 

Dietrich, D R ........................................ 230 

Difiore, D ........................................... 2219 

DiGiovanni, J ..................................... 1671 

Diliberto, J J ........................... 1570, 1574* 

Dill, A L ............................................... 969 

Dillberger, J ........................................ 2005 

Dillman, J F .............................. 345, 2211* 

Dillman, K .................................... 95, 1657 

Dills, R ................................................. 951 

Dimanche-Boitrel, M ........................... 596 

Dimond, S S ......................................... 995 

Dinesdurage, H .................................. 1187 

Ding, H ................................................. 719 

Ding, M ........................................ 271, 528 

Ding, Q ................................... 2089*, 2092 

Ding, W .............................................. 1703 

Ding, X ................................... 1099*, 1100 

Ding, Y ............................................... 1299 

Dingemans, M M ....................... 217*, 223 

Dingus, C ............................................. 247 

Dionnet, F ............................................ 480 

DiPalma, C ............................... 2077, 2084 

DiPiero, J ............................................ 1315 

Disch, B ................................................ 959 

DiStefano III, J ................................... 1449 

Diters, R ............................................. 2187 

Divine, B L ........................................... 865 

Diwan, B A ........................................... 965 

Dix, D ......... 96, 98, 212, 1010, 1382, 1387 

Dix, D J ................... 198, 463, 541*, 542*, 

580, 1901 

Dix, K J .............................................. 1573 

Dixon, D ............................................... 413 

Dlugosch, D ....................................... 2090 

Dobrovolsky, V N............................... 689* 

Dodd, C A .......................................... 992* 

Dodd, D E .......................................... 1171 

Dodd-Butera, T .................................. 944* 

Dodge, D .......................................... 1013* 

Dodge, D G ........................................ 514* 

Doerge, D R ................................. 166, 689 

Doering, A .......................................... 1128 

Doha, Y A ................................. 1833, 1844 

Doherty, S P ......................................... 835 

Doherty-Lyons, S P ................ 1974*, 2193 

Doi, A ............................................... 1948* 

Dolan, L C ........................................ 1178* 

Dominick, M A .................................. 1708 

Donaghey, T ......................................... 278 

Donahue, D A ............................. 106*, 485 

Donaubauer, H ..................................... 189 

Donepudi, A C ................................. 1621* 

Donerly, S .......................................... 2024 

Dong, H .......................... 1304, 1714, 2187 

Dong, L ............................................ 1988* 

Dong, M ............................................... 761 

Dong, W ................................... 683, 1204* 

Donley, E R .......................................... 207 

Donna, F ................................................. 23 

Donnelly, K C .................................... 1458 

Donner, E M ............................. 1148, 1401 

Donner, M .......................................... 1182 

Donthamsetty, S ............................... 1950* 

Doorn, J A ............ 1236, 1271, 1274, 1275 

Dordick, J S .......................................... 468 

Dorigatti, R ........................................ 1068 



Dorman, D C ...................... 20*, 885, 1031 

Dorsey, C ............................................ 1880 

Doshi, T .............................................. 1298 

Doshi, U ........................................... 1095* 

Doshna, C ............................................. 86* 

Doshna, C M .......................................... 85 

Doss, R ............................................... 1142 

Dosunmu, R S .................................. 1602* 

Dotson, G ............................... 1792, 1793* 

Dou, J ................................................. 2074 

Dourson, M ...................................... 1006* 

Dourson, M L ........................... 1797, 1911 

Downey, M E ..................................... 1048 

Doyle, N ............................................. 2100 

Doyle, T L .......................................... 427* 

Doyle-Eisele, M ..................... 1510, 1573* 

Doyle-Eisle, M ......................... 1479, 1480 

Dragan, Y ............. 1053, 1063, 1641, 1642 

Dragin, N ............................................ 1720 

Dragomir, A ....................................... 745* 

Draper, C ........................................ 42, 602 

Draper, K .................................. 937, 1368* 

Drechsel, D ........................................ 764* 

Dreher, K ............................................ 261* 

Dreiem, A ......................................... 1280* 

Drinkwater, N ................................... 1344* 

Drivas, P J .......................................... 1039 

Drobna, Z ........................................... 971* 

Drubin, D ............................................. 679 

Drupa, C ........................................... 1307* 

Druwe, I ............................................. 961* 

Druwe, I L ............................................ 574 

Duan, J ....................................... 141, 1120 

Duan, Z .................................... 1483, 1541 

Dubach, J .............................................. 937 

Dubielzig, R R ................................... 1056 

Ducatman, A ........................................ 225 

Duche, D ............................................ 501* 

Duché, D .......................... 486, 1190, 2075 

Duffy, R ............................ 292*, 375, 1126 

Dugan, C M ........................................ 590* 

Duggan, A J ........................................ 190* 

Duistermaat, E ...................................... 367 

Dumont, C .......................................... 1989 

Duncan Smith, S .......................... 410, 846 

Dunlap, D ............................................. 261 

Dunlevy, J R ............................. 1813, 1826 

Dunn, R T ............................... 1962*, 2077 

Dunster, J S .......................................... 418 

Dupuis, C ..................................... 603, 940 

Durand, I .............................................. 891 

Durant, J A ......................................... 1061 

During, D C .......................................... 126 

Durrieu, F ............................................... 57 

DuVall, M ................................... 918, 1810 

Dwyer, J ............................................. 1325 

Dwyer-Nield, L D ................................ 676 

Dydak, U .......................................... 1000* 

Dykens, J ............................................ 1080 

Dzeja, P .............................................. 636* 

E 

Eaddy, A C ......................................... 594* 

Eagleton-Harvey, N ............................ 2157 

Easter, A ............................................. 1063 

Easterling, M ...................................... 1033 

Eaton, D L .................................... 374, 455 

Eaton, J W .......................................... 1733 

Eberl, D D .......................................... 1936 

Ebert-McNeill, A ................................ 1827 

Ebihara, S ............................................. 403 

Eblin, K E ........................................... 474* 

Eckardt, K .................................. 404, 405* 

Eckert, L L ....................................... 1274* 

Eckhert, C D ....................................... 2150 

Eddie, M ....................................... 927, 928 

Eddy, S ................................................. 679 

Edmiston, J S ................... 733*, 753, 1853 

Edward, P ............................................. 348 

Edwards, B C ..................................... 1566 

Edwards, J .................... 1449, 1823, 1824* 

Edwards, S ............................. 1445*, 1447 

Ehinger, M............................................ 400 

Ehresman, D J ................ 226, 1585, 1586* 

Ehrich, M ............................... 1252*, 1254 

Ehrich, M F ........................................ 1266 

Eichen, P A......................................... 1134 

Eickholt, E ............................................ 357 

Eilstein, J ................ 486*, 501, 1190, 2075 

Einstein, D ............................................ 870 

Einstein, D R .............................. 871*, 872 

Eisenbrandt, D ................ 1385, 1591, 1592 

Eisenmann, C ....................................... 471 

Eisinger, D.............................. 1322, 1323* 

Eisner, C ............................................... 333 

Eklund, C ............................................. 888 

Eklund, C R ................................ 886*, 889 

Ekman, D R .......................................... 580 

El Hage, M ....................................... 1059* 

El Safty, A M ...................................... 2158 

El-Kadi, A .......................................... 1086 

El-Kadi, A O .............................. 950, 2167 

El-Komy, M........................................ 2062 

El-Sayed, S R ....................................... 381 

El-Tawil, O S .................................... 1955* 

El-Zein, R A ......................................... 361 

Elcombe, C R ............. 1488, 2156*, 2205* 

Elferink, C ...................... 1203, 1206, 1471 

Eling, T E ............................................. 400 

Elizondo-Azuela, G .............................. 355 

Ellen, T ............................................... 2159 

Ellinger, H .............................................. 57 

Elliott, K ............................................... 602 

Elliott, M ............................................ 1050 

Ellis, D ............................................. 1694* 

Ellis, G ................................................. 108 

Ellis-Hutchings, R .............................. 397* 

Ellison, C A ............................ 1237, 1894* 

Ellison, K ............................................. 679 

Elsaid, A F ............................................ 860 

Elzind, D A......................................... 1665 

Ema, M ....................................... 391*, 788 

Emami, A ........................................... 742* 

Emeigh Hart, S G ................................... 12 

Emerick, G L ...................................... 1257 

Emery, S ............................................. 116* 

Emily, B ............................................... 213 

Emter, R ............................................... 108 

Enayetallah, A .................................... 206* 

Encarnacao, P C ............................... 2152* 

Endo, T ............................................... 174* 

Enerson, B ........................................ 1746* 

Enerson, B E ...................................... 1744 

Engel, S M ........................................... 668 

Engidawork, E .................................... 1123 

Engin, A ............................................... 529 

Engin, B A .......................................... 529* 

English, C ......................................... 1912* 

English, J C ...................................... 1721* 

Ensor, D S ............................................ 794 

Eom, H ............................................. 1700* 

Epperly, M ............................................ 597 

Epple-Farmer, J ................................ 1688* 

Eppler, B .................................. 1479, 1480 

Ercal, N ........................................ 785, 804 

Erdely, A .................................. 734, 2178* 

Eriator, I I ........................................... 2140 

Erikson, K M ...................................... 2038 

Eriksson, P ......................................... 176* 

Ermolaeva, E ...................................... 1866 

Ernst, H .............................................. 1169 

Escalon, L ............................................ 348 

Esch, H L ......................................... 1461* 

Escudero, C .......................................... 955 

Escudero-Lourdes, C .......................... 958* 

Espandiari, P ........................................ 579 

Espinosa, J .......................................... 1292 

Espinoza, Y ........................................ 1043 

Estelle, E ............................................ 1126 

Estevan, C ............................................ 833 

308 




Estevez, J ............................................ 1249 

Estey, T ................................................. 595 

Estrem, S T ............................................. 79 

Etterson, M ......................................... 1448 

Etzel, C ................................................. 361 

Euler, C ................................................ 930 

Eum, S .................................................. 233 

Evans, E ................................... 109*, 1987 

Evans, J .............................................. 2050 

Evans, M V ................................. 886, 889* 

Evans, T J ......................................... 1134* 

Everds, N .................................. 1962, 2077 

Everett, D ................................... 302, 1993 

Everley, P A ........................................ 2211 

Evers, A ................................................ 189 

Ewart, L ................................ 42*, 43, 1081 

Exil, V .................................................. 462 

Eyre, R ............................. 379, 1736, 2192 

F 

Fabian, E ...................... 1646, 1948, 2090* 

Fadeel, B ............ 270, 271, 291*, 766, 793 

Fagerland, J A ...................................... 582 

Faigle, R ............................................... 630 

Fair, P A ........................................... 2189* 

Fairbrother, H ....................................... 790 

Fairweather, D .............. 1416, 1419*, 1751 

Faiz, H .................................................. 577 

Fajardo, A M .................................... 1065* 

Falciani, F........................................... 1447 

Falck, G C ............................................ 266 

Falkner, K ....................... 1320, 1321, 1883 

Falkner, K C ............................... 743, 1317 

Fallon, A M ........................................ 1241 

Falzareno, T ......................................... 477 

Fan, A M ................................ 1902*, 1943 

Fan, C ................................................... 165 

Fan, Q ................................................. 2163 

Fan, R ................................................... 631 

Fan, T ................................................. 2009 

Fan, X ................................................... 311 

Fang, C ............................................... 1100 

Fang, H ............................................... 1084 

Fang, J ...................................... 703, 1951* 

Fang, M ............................................ 1998* 

Fang, N ................................................. 272 

Fang, X ............................................... 683* 

Fannin, R D ...................................... 1654* 

Fanucchi, M V .................................... 1518 

Faqi, A .................................................... 25 

Faqi, A S ...................... 27*, 376, 854, 913, 

919, 2114*, 2116 

Farabaugh, C S ................................. 1107* 

Farahat, F ........................................... 1240 

Farahat, F M ................. 1237*, 1243, 1894 

Fardel, O............................................... 736 

Farias, P M ......................................... 1403 

Fariss, M............................................. 1853 

Fariss, M W ...................... 733, 753, 1220* 

Faroon, O ................................. 209, 1029* 

Farooqui, M Y .................................. 1193* 

Farraj, A K.......... 1498, 1501*, 1504, 1522 

Farrer, D G ......................................... 892* 

Farthing, D ............................... 1220, 1853 

Farzaneh, F ......................................... 1211 

Fasdelli, N .......................................... 1068 

Fastje, C D.......................................... 1512 

Fasulo, L................................................. 86 

Fatuyi, B ................................. 2094, 2099* 

Faust, J ....................................... 566, 1906 

Faustman, E M ....... 654*, 941, 1242, 1486 

Fay, K A ............................................. 264* 

Fazzi, F ................................................. 599 

Fears, R L ........................................... 1936 

Fechter, L ......................................... 1265* 

Fedan, J S ........................................... 1506 

Fegert, I .......................... 857, 1904, 2096* 

Fehrenbacher, C ................................. 1933 

Felies, A ............................................... 405 

Feliu, N ................................................ 291 

Felter, S .............................................. 1721 

Feltès, M ............................................ 1116 

Feng, H ............................................... 1299 

Feng, W .......... 256, 599, 766*, 1733, 1734 

Fennell, T ............................... 1331, 1576* 

Fenske, R A .......... 1237, 1240, 1243, 1894 

Fensterheim, R J ................................. 1112 

Fent, K W ................................. 1328, 1864 

Fenton, S E ................................... 831, 839 

Ferguson, D C ...................................... 482 

Ferguson, M ....................................... 806* 

Ferguson, P......................................... 2105 

Ferguson, S A ....................................... 689 

Ferguson, S S ................................... 1717* 

Fernandes, R ...................................... 1308 

Fernando, R .............................. 1331, 1576 

Fernando, R A .............................. 794, 840 

Fernando, T .............................. 1536, 1540 

Fernando, T M........................................ 71 

Ferrara, T M ......................................... 342 

Ferreira, D W ................................... 2131* 

Ferri, R ................................................... 23 

Ferrick, D ............................................... 81 

Ferrier, B .................................... 577, 1059 

Ferro, A .................................................. 34 

Ferry, C H ........................................... 2143 

Feswick, A.......................................... 1289 

Feuston, M ........................................... 681 

Fick, D B ...................................... 335, 346 

Fidler, T P ............................................. 132 

Fiechter, D .................. 293, 295, 317, 1550 

Fiedler, N............................................ 1857 

Fiedler, R D .......................................... 690 

Fiehn, O .............................................. 1637 

Fiel, M I ............................................. 1974 

Fielden, M .......................................... 648* 

Fields, A S .......................................... 1291 

Fields, P E .......................................... 1556 

Fiene, S .................................... 1738, 1739 

Fikes, J ................................................. 584 

Fikree, H ............................................ 1803 

Filipov, N M ......................................... 992 

Finck, B N ................................ 1360, 1737 

Finkelstein, J N .......................... 274, 1970 

Finkelstein, Y ................................... 1264* 

Firth, S.................................................. 655 

Fisher, B R ......................................... 1107 

Fisher, C D ......................................... 1626 

Fisher, J ...................... 811, 878, 879, 1713 

Fisher, J W................... 812, 875, 876, 894, 

901, 1383*, 1567, 1568, 2094, 2099 

Fisher, M T ........................................... 753 

Fisher, P ........................................... 2051* 

Fishman, P S ...................................... 1615 

Fitsanakis, V A .............. 1286, 1287, 1291, 

2038, 2083 

Fitzpatrick, S .................................... 1808* 

Fjordholt, M ....................................... 717* 

Flack, S L ............................... 1328*, 1864 

Flaherty, M ......................................... 618* 

Flake, G P ............................... 1490*, 1492 

Flamand, N ......................................... 1116 

Flanagan, B F ....................................... 296 

Flanagan, K ...................................... 1958* 

Flannery, B ............................. 1143*, 1785 

Flaveny, C A ....................................... 2204 

Flaws, J................................................. 399 

Flaws, J A ........... 383, 388, 395, 398, 1489 

Fleming, E ............................................ 327 

Fleming, R............................................ 981 

Fletcher, A .......................................... 1084 

Fletcher, A M ..................................... 1281 

Fletcher, B L....................................... 1576 

Fleurance, R ....................................... 2184 

Fleurie, G J ......................................... 917* 

Flint, O ............................................. 1273* 

Flint, O P ............................................ 1281 

Flor, S ................................................. 236* 

Flora, J .............................................. 1853* 

Flora, J W ............................................. 753 



Florang, V ................................ 1271, 1275 

Florang, V R ....................................... 1274 

Florence, R L ............................. 277, 2069 

Floyd, R .............................. 157, 173, 175* 

Fluharty, K ........................................... 305 

Foertsch, L ......................................... 110* 

Foldbjerg, R ..................................... 1704* 

Foley, J ............................................... 1202 

Foley, J F ............................................ 1490 

Folven, K ............................................ 1025 

Fomby, L .......................................... 1969* 

Fomin, B............................................... 210 

Fomin, O .............................................. 210 

Fonck, C ................................... 1047, 1324 

Font, G ............................................. 1464* 

Fontes, A ............................................ 1403 

Foos, B ............................................... 1913 

Force, T ............................................ 1366* 

Ford, G ................................................. 806 

Foreman, J E .................................... 2144* 

Forgacs, A .............. 84*, 1198, 1649, 2092 

Fornero, E............................................. 934 

Forsberg, E C ....................................... 136 

Forster, R .......................... 600, 1074, 1727 

Fort, D J.............................................. 426* 

Fort, F ................................................... 913 

Fortin, D ................................................. 80 

Fortoul, T I ............................... 2168, 2169 

Fortuny, C ........................................... 2121 

Foss, J A ............................................. 1189 

Fosse, C .............................................. 1192 

Foster, A E .......................................... 1936 

Foster, P................................................ 562 

Foster, S............................................ 1877* 

Foster, W ........................ 1084, 1639, 1708 

Foth, H W ........................................... 1515 

Fotsch, C ............................................ 2084 

Fournier, S .......................................... 1055 

Fowers, C ............................................. 312 

Fowle, J .............................................. 1929 

Fowler, B A .............................. 209, 2043* 

Fowler, D ...................................... 878, 892 

Fowler, J F .......................................... 1870 

Fowler, L M........................................ 1870 

Fox, D A ................................. 1603, 1972* 

Fox, S ....................................... 976*, 1528 

Foxenberg, R ........................................ 471 

Fraites, M J ....................................... 2088* 

Frame, S R ..................... 1146, 1147, 1188 

Frank, M M .......................................... 776 

Franklin, C A ...................................... 567* 

Franklin, C C ........................................ 779 

Franklin, D ................................... 690, 691 

Franklin, M .......................................... 763 

Franklin, M R ........................... 454*, 2102 

Franklin, P .......................................... 1736 

Franko, J ............................................... 305 

Franko, J L ......................................... 304* 

Fransen, J ............................................. 816 

Franz, C .............................................. 1797 

Franzblau, A ....................................... 1831 

Franzi, L ............................................. 1519 

Franzi, L M .......................................... 776 

Franzosa, J A .............................. 172, 850* 

Franzova, P ......................................... 1464 

Frasier, A .............................................. 506 

Frawley, R P ......................................... 70* 

Frazer, D ................................... 1495, 1506 

Frazer, D G ....................... 734, 1022, 1728 

Frazier, K............................................ 1745 

Frederick, C B .................................... 2206 

Frederick, D M ................................. 2127* 

Fredriksson, A ...................................... 176 

Freebern, W .............................. 1084, 1994 

Freebern, W J ......................... 1995, 2187* 

Freedman, J H ....... 461, 1465, 1812, 1815, 

1817, 1832 

Freeman, J .......................................... 1799 

Freeman, J J ......................................... 508 

Freeman, J L ........................... 1127*, 1843 

Freeman, K ......................................... 1717 

Freichel, C ........................................ 1052* 

French, A .............................................. 601 

French, J E .................... 591, 1329, 1332*, 

1333*, 1861 

Freshwater, L...................................... 1189 

Freudenrich, T M ....................... 156, 1389 

Frey, J ..................................... 1305, 1878* 

Frisancho, J ........................................ 1751 

Frisancho-Kiss, S ............................... 1751 

Frishman, L J ..................................... 1603 

Fritz, J M ............................................ 676* 

Fritz, K S ...................................... 779, 787 

Fritz, S .................................................... 86 

Frizell, E R ................. 2109*, 2110*, 2111 

Froetschl, R ........................................ 549* 

Froget, G .................................... 600, 1727 

Fromowitz, M................................... 1172* 

Frushour, B ........................................... 679 

Fry, R .................................................... 971 

Fu, J .............................................. 573, 962 

Fu, P ................................................... 1758 

Fu, P P .................................................. 693 

Fu, S ................................................... 2163 

Fu, X .................................................. 984* 

Fu, Z D ............................................. 1616* 

Fuchs, F M ......................................... 1545 

Fuchs, H W .......................................... 497 

Fuentes-Mattei, E ................. 1559*, 1560* 

Fuhrman, K ........................................ 1252 

Fuhst, R ............................................ 1169* 

Fujii-Kuriyama, Y .............................. 1678 

Fujimura, M ..................................... 1613* 

Fukami, T ............................................... 77 

Fukatsu, H .......................................... 2063 

Fukuda, C ............................................. 377 

Fukuda, R ........................................... 1309 

Fukushima, R ..................................... 829* 

Fukuuchi, T ........................................ 1811 

Fukuzaki, K ........................................ 2192 

Fulcher, S M ......................................... 418 

Fullerton, A M .................................. 1952* 

Fulton, S ............................................. 1265 

Funabashi, H ........................................ 377 

Furimsky, A ........................................ 1582 

Furniss, M J .............................. 481*, 1406 

Furr, J ......................................... 562, 1481 

Furukawa, F ......................................... 910 

Furukawa, S ......................................... 509 

Furusawa, H ......................................... 966 

Fuscoe, J C ......................... 635, 692, 1644 

Fussell, K C ................................ 510*, 765 

Futscher, B W ............................... 953, 954 

G 

Gabel-Jenson, C ................................... 973 

Gabos, S ............................................... 389 

Gabrielson, K ............. 1416*, 1420*, 1751 

Gabrielsson, S ...................................... 291 

Gadagbui, B ....... 1006, 1792, 1911, 1930* 

Gadet, R ............................................... 577 

Gaffney, S H ............................... 124, 1851 

Gage, N .............................................. 1492 

Gage, P S ............................................ 1490 

Gagne, G D .......................................... 582 

Gagné, M .......................................... 1579* 

Gaidatzis, D ........................................ 1662 

Gaido, K ............................................. 1973 

Gaido, K W .......................................... 393 

Gaines, L G ............................ 1328, 1864* 

Gaitens, J ............................................ 1880 

Gakhar, G ........................................... 1085 

Galas, D J ......................................... 2201* 

Galay-Burgos, M ................................ 2096 

Galbraith, D .......................................... 124 

Gali, R .................................................. 810 

Galijatovic-Idrizbegovic, A .............. 2206* 

Galizia, A ........................................... 1913 

Galland, F ........................................... 2131 

Gallegos, A ........................................... 125 

Author Index 



Author Index 


Gallegos, A C ....................................... 363 

Gallenberg, L A .................................. 1787 

Galli, C L ........................................... 1555 

Galligan, J ........................................ 1631* 

Gallo, M A ........................................... 510 

Galvan, N ......................................... 2220* 

Galvin, K .................................. 1237, 1240 

Gamboa da Costa, G ........................ 1140* 

Gandolfi, A ......................... 953, 954*, 955 

Gandolfi, J A ........................................ 958 

Ganey, P ............................................. 2139 

Ganey, P E ............... 590, 750, 1952, 1956, 

2123, 2125, 2136, 2137 

Ganjam, V K ...................................... 1134 

Gannon, S ........................................... 450* 

Gant, T W ......................................... 1756* 

Gao, J ......................................... 283, 802* 

Gao, L ........................................ 238*, 443 

Gao, W ......................................... 129, 727 

Gao, W H ........................................... 2173 

GAO, X .............................................. 413* 

Gao, X ................................ 264, 374, 1557 

Gao, Y ...................................... 1241, 1299 

Gao, Z ................................................ 1573 

Garabrant, D H ..................................... 122 

Garcha, J ............................................ 1934 

Garcia, J ............................................. 1193 

Garcia-Reyero, N ............................... 1451 

Garcia-Reyero, N V............................ 1447 

Garcia-Vargas, G G .......................... 1842* 

García-Arumí, E ................................. 1070 

Gardiner, C S ............................ 1090, 1691 

Gardiner, L A ..................................... 822* 

Gardinier, K............................................ 79 

Gardner, C ............................................ 744 

Gardner, C R .......................................... 61 

Gardner, D .......................................... 1024 

Garg, N ................................................. 525 

Gargas, N M ......................................... 924 

Gariepy, S ............................... 1044, 1186* 

Garman, R .................................. 618, 1189 

Garman, R H ........................................ 995 

Garrabou, G .................. 1070*, 2117, 2121 

Garrett, C M ..................................... 1709* 

Garrett, S H .................... 824*, 1813, 1826 

Garrett, T L ................................ 335*, 346 

Garrigues, A ....................................... 891* 

Garrigues-Mazert, A .......................... 890* 

Garry, M R ......................................... 438* 

Gary, C ................................................. 842 

Gasiewicz, T A ... 1341*, 1681, 1682, 2191 

Gasper, C ............................................ 1043 

Gasteiger, J ........................................... 211 

Gatti, D M ............................................ 148 

Gaudette, N L ..................................... 1576 

Gautier, J ............................................ 1314 

Gavett, S ............................................. 1503 

Gaytan, B ........................................... 115* 

Gazarian, D I .................................... 1686* 

Gaça, M D ............................................ 92* 

Ge, Y .................................................. 1501 

Gearhart, C ......................................... 1265 

Gearhart, J ............................ 324, 327, 329 

Gearhart, J M ..................... 325, 899, 1256 

Gelatt, R H ......................................... 1851 

Gelein, R ............................................ 1970 

Gelhaus, S ............................................ 453 

Gélinas, C ......................................... 1990* 

Gelineau-van Waes, J ......................... 853* 

Genco, N .................................... 251, 252* 

Gendron, R ....................................... 1083* 

Genter, M ......................................... 1596* 

Gentry, R .................................... 492, 1938 

George, M .......................................... 2155 

George, M H ................ 1015, 1016*, 1017 

George, W J .............................. 1294, 1295 

Georgieva, I I........................................ 992 

Gerard, C J ......................................... 1512 

Gerber, S ............................................ 1118 

Gerberick, F ....................... 110, 306, 1926 

Gerberick, G ......................................... 308 

Gerecke, D R ............ 61, 62, 67, 343*, 347 

Gerhard, H .......................................... 1052 

Gerl, M ............................................... 1325 

Gerlach, S ............................................... 91 

Germolec, D ......................................... 536 

Germolec, D R ........... 70, 297, 1555, 2101 

Gerrish, K ........................................... 1654 

Gerstenfeld, L C ................................. 1549 

Gervais, F ........................................... 2184 

Gerwick, W H .................................... 1165 

Geter, D .............................................. 139* 

Geter, D R ............................................ 521 

Gewandter, J S.................................... 710* 

Ghag, M ............................................. 1131 

Ghantous, H N ..................................... 318 

Ghare, S ................................................ 152 

Ghosh, R N ......................................... 755* 

Ghozland, S ........................................ 1790 

Gianios, C .......................................... 1126 

Gibb, H ............................................... 1937 

Gibbs, A ............................................... 903 

Gibbs, S ............................................ 1578* 

Gibson, D P .......................................... 697 

Gibson, E K ........................................ 2098 

Gibson, R ............................................. 114 

Gideon, K M ................................ 926, 929 

Giebultowicz, J M .............................. 1467 

Gieré, R .............................................. 1121 

Gilbert, K ........................................... 310* 

Gilbert, M ................................... 894, 1383 

Gilbert, M E ............................... 158*, 160 

Gilbert, S .......................... 941, 942*, 2118 

Gilberti, E ............................................. 471 

Gilbertson, T A ................................... 1858 

Gilchrist, A ........................................... 679 

Gill, G .................................................. 492 

Gill, K .................................................. 903 

Gill, M ................................................ 1218 

Gill, S ................................................. 2114 

Gillardeaux, O ...................................... 681 

Gillespie, B W .................................... 1831 

Gillespie, M E ........................................ 1* 

Gillespie, P ........................................... 22* 

Gilliam, J A .......................................... 840 

Gillies, P ......................... 1146, 1147, 1148 

Gilliland, J ............................................ 655 

Gilot, D ................................................ 736 

Gingell, R ............................................. 139 

Ginsberg, G ................................ 38, 1928* 

Giordano, G ........................................ 222* 

Giovanelli, R ...................................... 1303 

Girón, I ............................................... 1716 

Girón-Pérez, I ....................................... 434 

Giuliano, K ............................................. 79 

Glaab, W E ........................................... 806 

Glahn, F ............................................ 1515* 

Glaser, K B ........................................... 757 

Glauert, H P ............................... 134, 1590 

Glaves, P D ........................................ 1673 

Gleason, C .......................................... 1995 

Glenny, R ............................................. 870 

Glerup, P ............................................ 920* 

Glick, A B .................................. 671, 2142 

Glista, E E ...................... 286, 2072, 2073* 

Glover, C ............................................ 1025 

Glover, K .......................................... 1401* 

Glover, M ............................................. 631 

Gminski, R ....................................... 1121* 

Gmuender, H .................... 197, 1650, 1996 

Go, Y .................................................. 1423 

Goad, J ............................................... 1142 

Gobejishvili, L ..................................... 152 

Gochfeld, M ........................... 1416, 1418* 

Gocke, E ................................... 551*, 1125 

Godefroy, D ........................................ 1613 

Godfrey, V .............................. 1183*, 1578 

Goeden, H .......................................... 1721 

Goedken, M ........................................ 2132 

Goedken, M J ..................................... 1597 



Goel, S ...................................... 547*, 1882 

Goering, P L ....................................... 1692 

Gogal, R M ......................... 78, 439*, 2190 

Gogvadze, V ............................. 1422, 1425 

Goh, J ................................................... 135 

Gohlke, J ............................................ 1164 

Gold, L ................................................. 925 

Goldade, M ...................................... 1874* 

Goldberg, A ................................ 170, 2118 

Goldberg, S ...................................... 2118* 

Goldenberg, E .................................... 1121 

Goldsmith, M ........... 203, 882, 883*, 1386 

Goldsmith, R ...................................... 1900 

Goldsmith, W T ........................ 1022, 1506 

Goldstein, D ......................................... 187 

Goldstein, K M ..................................... 79* 

Goldstein, N S .................................... 2070 

Goldstone, J ...................................... 1450* 

Gollapudi, B ...... 695*, 1112, 1349, 1354*, 

1798 

Golt, M ................................................. 820 

Gomez, C ............................................. 459 

Gomez, C F ........................................ 232* 

Gómez, L ............................................ 1816 

Gomez, L ............................................ 2066 

Gomez Vidales, V................................. 254 

Gomez-Rubio, P ................................. 947* 

Goncharov, N ................................... 1866* 

Gong, G .............................................. 1658 

Gong, L ...................................... 720, 2128 

Gonzales, C .......................................... 968 

Gonzalez, F ...................................... 2207* 

Gonzalez, F J .................. 2142, 2143, 2144 

Gonzalez, L .......................................... 268 

Gonzalez, M ....................................... 1964 

Gonzalez-Gonzalez, L ............................ 24 

Gonzalez-Villalva, A ........................ 2168* 

Gonzaludo, N ....................................... 187 

González-Arias, C A ............................ 434 

Gooch, J L .......................................... 1677 

Goodale, B C ...................................... 684* 

Gooderham, N ...................................... 533 

Goodin, E ............................................. 719 

Gooding, A ........................................... 682 

Goodman, G G ..................................... 735 

Goodman, J ........................................ 1343 

Goodman, J E ..................... 514, 670, 1886 

Goodman, J I ............................ 145, 1345* 

Goodrich, J ............................. 1830*, 1831 

Goodwin, T J ...................................... 1128 

Goossens, K ......................................... 816 

Goral, J ............................................. 1823* 

Goranson, U ....................................... 1123 

Goravanahally, M P ............................ 1506 

Gorbunov, N V ................................... 754* 

Gordon, C ........................... 851, 852*, 888 

Gordon, C J .......................................... 159 

Gordon, D ............................................ 642 

Gordon, M ............................................ 343 

Gordon, M K ........................................ 347 

Gordon, R ................................... 986, 1276 

Gordon, T ........................................... 1508 

Gorman, G S ...................................... 1585 

Gorojod, R .......................................... 1235 

Gorski, J R ........................................... 111 

Gosens, I .................................. 279*, 2183 

Gosink, M ............................................ 679 

Goth, S R ................................................ 72 

Gott, K .................................................. 843 

Gottschalk, R W ................................... 517 

Gough, A .................................. 1078, 1079 

Gough, B ........................ 83, 1410*, 1575* 

Gould, G G ......................................... 465* 

Gould, N S ....................................... 1524* 

Gould, S J ......................................... 1439* 

Gourley, I ......................................... 2053* 

Govarts, E ............................................... 55 

Govindarajan, A ............. 700, 1027, 1066* 

Gow, A ......................................... 336, 738 

Goyal, V ........................... 700, 1027, 1066 

Grabowski, J....................................... 1974 

Grace, C E .......................................... 1600 

Graham, D L .................................... 1600* 

Graham, J ................................. 502, 2001* 

Graham, J S .................. 781, 923, 924, 931 

Graham, U M ............................. 277, 2069 

Grandidier, M ............................... 488, 505 

Grant, D M ........................................... 742 

Grant, K .............................................. 2219 

Grant, R .............................................. 1911 

Granum, B ...................... 1650, 1996, 2196 

Granzier, H L ..................................... 1726 

Grassian, V H ....................................... 370 

Gratz, K ................................................ 112 

Gratz, K R .......................................... 500* 

Grau, E ................................................. 912 

Grau, J ................................................ 1070 

Graves, S ............................................ 1183 

Graves, S W ....................................... 1578 

Gray, J P ..................................... 61, 62, 67 

Gray, L ....................................... 249, 1481 

Gray, L E .................................... 380, 562* 

Gray, T M ................................... 698, 1122 

Green, A ............................................. 1106 

Green, A L ........................................ 1234* 

Green, C E .......................................... 1582 

Green, D ............................................. 1396 

Green, J D .............................................. 2* 

Green, M .......................................... 2208* 

Green, S ................................................ 139 

Greenberger, J ...................................... 597 

Greene, B ........................................... 819* 

Greene, G L ...................................... 1453* 

Greene, N ............................................. 206 

Greengauz-Roberts, O .......................... 753 

Greenhaff, P L .................................... 1673 

Greenlee, W F .......................... 1199, 1338 

Greenwood, K .................................... 2175 

Gregus, Z ............................................ 946* 

Grenet, O .......................................... 1662* 

Griffen, S ............................................ 1637 

Griffin, J ............................................... 534 

Griffin, S .......................................... 1876* 

Griffith, W C ...................................... 1242 

Griggs, J ............................................... 265 

Grimes, J H .......................................... 364 

Grobéty, B .......................................... 1121 

Grodzins, L ........................................ 1884 

Gross, C ........................................ 66, 354* 

Grotendorst, G .......................... 63, 68, 351 

Grotti, L .............................................. 1050 

Groves, A M ....................................... 738* 

Growcock, A C ..................................... 288 

Gruene, M ............................................ 809 

Grulke, E A ........................ 269, 277, 2069 

Grégoire, S ................................... 890, 891 

Gu, A .......................................... 390, 936* 

Gu, J ....................................... 1100*, 2128 

Gu, X ................................................ 1469* 

Gu, Y .................................................... 272 

Gualtieri, M .......................................... 267 

Guan, X ................................................ 348 

Guarisco, J ............................................ 321 

Gudi, R ............................................... 1118 

Guerra, F ............................................ 1458 

Guerrero-Castilla, A ........................... 1899 

Guerrette, Z ...................................... 1242* 

Guerriero, F ................................ 102, 1804 

Guest, R ................................................ 102 

Guffroy, M........................................ 1314* 

Guha, M ........................................... 1063* 

Guilarte, T .......................................... 1610 

Guilarte, T R ............................ 1279, 1609 

Guilbert, C ........................................ 1558* 

Guild, S .............................................. 915* 

Guiney, P D .......................................... 426 

Guinn, D ............................................. 253* 

Gujral, J ............................................ 1875* 

Gulhan, M ............................................ 356 

Gulledge, W ......................................... 139 

310 




Gullo, R .............................................. 1656 

Gulson, B ......................................... 2066* 

Gunasekar, P G......................... 990, 1413* 

Gunewardena, S S .............................. 1092 

Gunson, D .......................................... 1988 

Gunther, W C ....................................... 690 

Guo, L ..................... 169, 179, 1541, 1738, 

1739*, 1758*, 1860, 1960, 2126 

Guo, S ................................................ 1136 

Guo, T L ................................... 297, 2101* 

Guo, X .................... 441, 694*, 1508, 1703 

Guo, Y .................................................. 733 

Guo, Z X .............................................. 812 

Guo-Ross, S ......................................... 242 

Gupta, R C ............................... 998, 1142* 

Gupta, R K ....................................... 1489* 

Gurevich, I ....................................... 1472* 

Gurnani, M ........................................... 469 

Gury, T ............................................... 1314 

Gustyleva, L ....................................... 1866 

Gutierrez, J ........................................... 719 

Gutierrez-Valdez, A ............................ 1292 

Gutiérrez-Ruiz, M ............................ 1816* 

Gutjahr-Gobell, R................................. 431 

Gutman, H .............................................. 64 

Gutwinski, E ...................................... 1879 

Guyot, J ................................................ 409 

Guyton, K Z ....................................... 1928 

Guzan, K .............................................. 794 

Gwaltney-Brant, S ................................ 669 

Gyun, K ............................................ 1776* 

H 

Ha, E ................................................ 1888* 

Ha, H W ..... 908, 1562, 1571, 1572, 1963* 

Haas, A R ......................................... 1549* 

Haas, R ............................................... 1986 

Haber, C ............................................. 208* 

Haber, L.................................... 1355, 1793 

Haber, L T ........................................ 1911* 

Haberzettl, P ..................... 960, 1166, 1687 

Habib, T ............................................. 1447 

Hack, C .................................... 327*, 329* 

Hack, C E ............................................. 325 

Hack, E C ............................................. 899 

Haddad, S ............................. 243, 892, 893 

Haefner, P ........................................... 1055 

Hagan-Hughes, M ................................ 447 

Hagenbuch, B ....................................... 226 

Haggerty, H .............................. 1994, 1995 

Haggerty, H G ........................ 2057*, 2187 

Hahn, R A............................................. 347 

Haighton, L A..................................... 1803 

Haile, S ............................................... 2100 

Haines, D ............................................ 339* 

Haines, S R ........................................... 506 

Hajela, R K ................................. 976, 1607 

Hakk, H .................................... 643*, 1570 

Hala, D ....................................... 194*, 447 

Hall, A H .................................. 1175, 1192 

Hall, J ............................. 800, 1465*, 2177 

Hall, J M ................................. 1199, 1338* 

Hall, M L .............................................. 757 

Hall, R L ............................................. 1330 

Hall, S ................................................ 1973 

Hall, S J ................................................ 394 

Hall, W C ........................................... 1060 

Hallberg, L M ..................................... 1882 

Halldin, K ............................................. 408 

Hallmark, N .............................. 1488, 2096 

Halm, S .............................................. 1184 

Halstead, B W ........................................ 79 

Hamadeh, H ......... 621*, 623*, 1962, 2084 

Hamadeh, H K ............... 1051, 1415, 2077 

Hamajou, H ........................................ 1309 

Hamberger, C ......................... 1137*, 1138 

Hamby, B T ........................................ 2108 

Hamilton, J W .............................. 956, 959 

Hamilton, R ............................ 1603*, 1972 

Hamilton, R F......................................... 32 

Hamilton, S ............................ 1740, 1741* 

Hamlin, D ........................................... 1330 

Hammad, M A .................................. 1954* 

Hammond, D ...................... 292, 375, 1126 

Hammond, E ............................ 1479, 1480 

Hammond, T .................................... 42, 43 

Hammond, T G .................................. 1081 

Hammonds-Odie, L ............................ 1101 

Hampton, T .......................................... 959 

Han, E ............... 1762, 1770, 1772*, 1773, 

1774, 1775, 1776, 1889 

Han, L .................................................. 794 

Han, S ............................................... 1748* 

Han, T....................................... 692*, 1644 

Han, W ................................................. 673 

Han, X .................................................. 820 

Hancock, S ........................................... 182 

Hancock, S K ..................................... 1266 

Haney, J .............................................. 1990 

Hanig, J ...................... 169, 179, 845, 1318 

Hanig, J P ............................................. 865 

Hankinson, O ........... 154, 451, 1194, 1712 

Hanley, J C ......................................... 1537 

Hanley, T .............................................. 857 

Hanna, M A ........................................ 1159 

Hanneman, W ..................................... 2113 

Hansen, D K ....................................... 1581 

Hansen, H ............................................. 209 

Hansen, T ........................................... 1169 

Hanson-Williams, K ........................... 1073 

Hanumegowda, U ................................. 117 

Hanzlik, R P ......................................... 18* 

Hao, R ................................................ 1972 

Hara, T ............................................... 1026 

Harada, T .............................................. 509 

Harbison, R D .......................... 1895, 1953 

Harbison, S C ..................................... 1953 

Harbo, S J ..................................... 926, 929 

Harbom, K M ....................................... 429 

Harby, H ............................................... 357 

Hardas, S S ......................... 269, 277, 2069 

Hardej, D ................................ 1890, 2174* 

Hardin, H ............................................ 861* 

Hardin, H A .......................................... 386 

Harding, C ........................................ 1947* 

Hardman, R ............................................ 89 

Hardwick, R N ....................... 1625, 1626* 

Hardy, C ............................................. 1068 

Hardy, C G ......................................... 667* 

Hardy, C J ............................................. 601 

Harezlak, J .......................................... 1000 

Harkema, J ......................................... 2139 

Harkema, J R .......... 244, 1505, 1627, 2175 

Harleman, H ....................................... 1805 

Harlow, P .............................................. 579 

Harmon, A ............................................ 324 

Haroutunian, G ..................................... 603 

Harper, B ............................................ 1181 

Harper, M S ...................................... 1155* 

Harper, P ............................................ 1198 

Harper, R W ....................................... 1672 

Harper, T A ....................................... 1471* 

Harpur, E ............................................ 1314 

Harri, A ................................................ 260 

Harrill, A ............................................ 2076 

Harrill, A H ........................................ 365* 

Harrill, J A ................................ 156, 1389* 

Harrington, A ....................................... 904 

Harrington, K L .................................. 1168 

Harris, D L ......................................... 137* 

Harris, M ............................................ 1909 

Harris, M A ........ 1850, 1871, 1872*, 1939 

Harris, R ............................................. 1736 

Harris, R K ......... 1132, 1587, 1588, 1589* 

Harris, T ..................................... 641, 1149 

Harrison, A R ....................................... 525 

Harrison, B S ........................................ 795 

Hart, J A ............................................. 1585 

Hart, K ................................................ 2219 

Hartin, M ............................................ 943* 



Hartle, J W ....................................... 2172* 

Hartley, D ........................................... 1062 

Hartung, T .................................. 114, 1611 

Harvey, W A ........................... 1820*, 1949 

Harvison, P J ...................................... 2127 

Hasegawa, G ........................................ 792 

Haseman, J ......................................... 1806 

Hashiguchi, T ..................................... 1825 

Hashim, M .................................. 938, 1789 

Haskins, K .......................................... 1318 

Hassani, M ........................................... 724 

Hassing, I ............................. 293, 294, 295 

Hasson, V ............................................. 480 

Hassoun, E ....................................... 1961* 

Hata, I ................................................. 1825 

Hathaway, L B ...................................... 454 

Hattan, D ............................................ 1808 

Hattan, D G ........................................ 1140 

Hattori, K ......................................... 1785* 

Haugen, M ................................ 1650, 2196 

Hauser, R ............................................ 561* 

Haver, C ............................................. 1937 

Hawi, A ................................................ 688 

Haws, L .... 1850, 1871*, 1872, 1909, 1939 

Hay, D C ............................................... 613 

Hay, E B ............................................. 1720 

Hayamizu, K .................................... 1139* 

Hayashi, H ................ 35, 1546, 1547, 1548 

Hayashi, M ......................................... 1962 

Hayden, P J ................... 62, 303, 470, 477, 

478, 483, 487, 499 

Hayes, M .............................................. 74* 

Hayes, S ............................................... 755 

Haykal-Coates, N .................... 1498, 1501, 

1504, 1522 

Hays, B ............................... 157*, 173, 175 

Hays, S ........................... 879, 1041, 1852* 

Hays, S M ................................. 544*, 1796 

Hazari, M S ........ 1498, 1501, 1504*, 1522 

Hazelden, K .............................. 2110, 2111 

Hazra, T K ............................................ 702 

He, K ................................................ 1463* 

He, T..................................................... 673 

He, X ...................................... 1814*, 2149 

He, Y ........................................ 673*, 1962 

He, Y D .............................................. 2077 

Head, A .............................................. 1993 

Head, J .............................................. 1531* 

Head, J L ............................................ 1532 

Heard, D J .......................................... 1662 

Heart, E .................................................. 67 

Heath, J C ........................................... 847* 

Hebels, D ............................................ 778* 

Hebels, D G ........................................ 1652 

Heck, D E ... 61, 62, 65, 629, 765, 825, 987 

Hecker, M ........................................... 1448 

Hedberg, J J ...................................... 1322* 

Hedge, J M ......................................... 2104 

Hedges, K A ....................................... 996* 

Hee, H .................................... 1771*, 1777 

Hee, P ............................................... 1762* 

Heerschap, A ...................................... 1388 

Heflich, R ........................................... 1355 

Heflich, R H ......................................... 689 

Hegde, V ............................................ 1527 

Heger, N ........................................... 1973* 

Hegg, C .............................................. 1215 

Hegg, C C ........................................... 1216 

Heggland, S J ..................................... 1820 

Heideman, W ............. 235, 440, 682, 2065 

Heier, A .............................................. 1724 

Heikkinen, P ............................... 162, 2061 

Heim, K .................................... 2164, 2166 

Heim, K E ........................................ 2165* 

Heining, C ............................................ 917 

Heinrichs, M ...................................... 2100 

Heinz, C ............................................. 1121 

Heisler, E .............................................. 497 

Heitfeld, F ............................................ 489 

Hejtmancik, M ................................... 1969 

Helferich, B ........................................ 1004 

Hellman, B ......................................... 1123 

Hellmann, J ........................................ 1687 

Helm, C .............................................. 2009 

Helm, M ............................................... 277 

Helmestam, M ...................................... 456 

Helton, D R .................................. 335, 346 

Hemmer, M J ...................................... 428* 

Henderson, J T ..................................... 859 

Henderson, K A .................................. 2150 

Henderson, M ..................................... 1031 

Henderson, R ...................................... 1800 

Henderson, W ..................................... 2099 

Henderson, W M ........................ 580*, 901 

Hendriks, H ........................................ 1977 

Henk, V .............................................. 1552 

Hennig, B ............... 233, 234, 1363*, 1748 

Hennings, L .......................................... 310 

Henningsen, G .................................... 1034 

Henriksen, M ...................................... 1113 

Henry, L ................................. 1317, 1321* 

Henry, N ............................................. 2189 

Henry, S P ........................................ 2082* 

Hensel, B R ........................................ 1935 

Hensley, J ................................... 393, 1973 

Henson, K .......................................... 1988 

Hentges, S G ........................................ 995 

Hentz, K ............................................. 1944 

Henwood, A D ..................................... 690 

Hepworth, S ....................................... 1650 

Herbert, K M ...................................... 1981 

Herbin-Davis, K M ............................ 1566 

Herbst, J ............................................. 1658 

Hernandez, A .............................. 988, 2117 

Hernández, E ...................................... 1816 

Hernández-Ochoa, I ... 383, 395, 398*, 399 

Herold, M ........................................... 1646 

Herr, D W ........................................... 1246 

Herrera, L ............................................... 63 

Herrgen, K ............................................ 809 

Herrin, S ............................................... 379 

Hershman, K ...................................... 1988 

Herting, F ........................................... 1308 

Hess-Wilson, J.................................... 1908 

Hester, S ........................... 507, 2088, 2154 

Hester, S D ....................................... 1258* 

Heuberger, A ...................................... 1782 

Heusinkveld, H J .......................... 217, 223 

Heyliger, S O ...................................... 1893 

Hickey, C A ...................................... 1508* 

Hickman, D ........................................ 1962 

Hideo, A ............................................... 826 

Hien, T ................................... 1768*, 1776 

Higashiyama, W ................................. 1715 

Higgins, M ......................................... 1962 

Higgins-Garn, M ................................ 2077 

Higuchi, H .......................................... 1690 

Hilberer, A ............................................ 114 

Hill, A ..................................................... 85 

Hill, J .................................................. 1964 

Hill, R ................................................... 138 

Hill, R E ............................................. 1846 

Hill, T ............................................... 1672* 

Hillegass, J M ..................................... 739* 

Hilton, H ............................................ 1308 

Himmelstein, M W ........................... 1569* 

Hinckley, J ................................ 1252, 1266 

Hinderliter, P ........................................ 280 

Hinderliter, P M ....................... 896*, 1385 

Hines, C .............................................. 1565 

Hino, A ............................................... 1542 

Hinson, J ............................................ 1223 

Hinton, D ................................................ 89 

Hinton, D E ........................................ 2107 

Hinz, J P ............................................. 1032 

Hinzey, A H ........................................ 1669 

Hirabayashi, Y .......................... 672, 1678* 

Hirai, K .............................................. 1309 

Hirakawa, B ....................................... 1725 

Hiramitsu, A ......................................... 789 

Author Index 



Author Index 


Hirano, S .............................................. 948 

Hirano, T .............................................. 912 

Hiratsuka, K ....................................... 1313 

Hirkaler, G M ................................... 1308* 

HIrose, A ............................................ 1397 

Hirose, A ............................................ 1402 

Hirose, K .................................... 722*, 723 

Hishikawa, A ........................................ 829 

Hitchins, V M ..................................... 1692 

Hitoshi, K ........................................... 789* 

Hixon, M .................................... 846, 1485 

Hixon, M L ......................................... 410* 

Hlastala, M P ........................................ 872 

Hnacer, F .............................................. 356 

Hnatyshyn, S .............................. 720, 1637 

Ho, C ................................................ 1759* 

Ho, H .................................................. 1136 

Ho, S .................................... 147, 151, 983 

Ho, T .................................................. 1834 

Hoang, Y D .......................................... 382 

Hobbs, C ............................................ 1117 

Hobbs, C A ....................................... 1106* 

Hocevar, B .......................................... 1965 

Hocevar, B A ............................ 526, 1634* 

Hochstenbach, K .................... 1650, 1996* 

Hodor, P ......................... 1078, 1079, 1410 

Hoet, P H ............................ 268, 299, 1701 

Hofbeck, C ......................................... 404* 

Hoff - van Leeuwen, D M ................ 1650* 

Hoffman, A............................. 1740*, 1741 

Hoffman, C........................................... 835 

Hoffman, L ....................................... 1890* 

Hoffmann, J J ..................................... 497* 

Hoflack, J ........................................... 1308 

Hofsteen, P ........................................... 440 

Hogan, C ............................................ 986* 

Hogan, C E ......................................... 1276 

Hogberg, H ......................................... 1611 

Hogg, M G ........................................... 468 

Hogstrand, C ...................................... 1025 

Hoidal, J R ................................... 59, 1854 

Hoivik, D .............................................. 12* 

Hojo, R ............................................. 2086* 

Hojyo, M ............................................ 1130 

Hoke, R .................................... 1182, 1449 

Holden, E ......................................... 1113* 

Holdsworth, D L ................................ 2116 

Holian, A ...................... 30*, 32*, 583, 735 

Holladay, J ............................................ 439 

Holladay, S D ............................... 78*, 439 

Hollingshead, B D .............................. 1069 

Hollingsworth, J ................................... 283 

Holm, S .............................................. 1873 

Holm, S E ........................................... 1476 

Holme, J A ....................... 596*, 736, 2176 

Holmes, A L ....................................... 1128 

Holmes, W ........................................... 350 

Holmuhamedov, E .............................. 1213 

Holt, P A............................................... 188 

Holterman, J ......................................... 642 

Holz, J ................................................ 1577 

Homer, B L............................. 1069, 1379* 

Hong, G .............................................. 838* 

Hong, H ................................................ 628 

Hong, L .............................................. 2163 

Hong, S .......................... 1189, 1486, 1578 

Hong, S J .................................... 755, 1666 

Hong, Y S ......................................... 1821* 

Honma, M .......................................... 713* 

Hood, D B .................. 137, 171, 180, 1750 

Hooks, W N ...................................... 1035* 

Hooth, M .................................. 1584, 1969 

Hooth, M J ............... 297, 396, 1033, 1413 

Hooven, L A ..................................... 1467* 

Hooyberghs, J ................... 107, 1306, 1412 

Hordych, D ........................................... 469 

Horie, N .............................................. 1690 

Horn, K H ........................................... 930* 

Hornbuckle, K C .................................. 237 

Horras, C ............................................ 1534 

Horras, C J ....................................... 1537* 

Horsley, E ........................................... 2111 

Horsley, E M ...................................... 2110 

Horsmon, M S .................................... 273* 

Horvath, R J ......................................... 956 

Horwitz, V .............................................. 64 

Hosokawa, M ........................... 1605, 1608 

Hossain, M M ................................... 1288* 

Hotchkiss, A ......................................... 562 

Hotchkiss, A K ................................... 1925 

Hotchkiss, J ........................................ 1499 

Hotchkiss, M G ................................ 2087* 

Hotz, K ............................................... 1075 

Hou, Y .................................................. 962 

Houck, K .......... 96, 212, 1010, 1407, 1901 

Houck, K A .................................. 198, 463 

Houle, C ................................................. 58 

House, J S ........................................... 675* 

Houseman, E .............................. 393, 1973 

Houze, P ............................................... 334 

Hovorka, J ............................................ 718 

Howard, P C ......................................... 798 

Howarth, D ............................................. 89 

Howd, R A........................................ 1943* 

Howdeshell, K ...................................... 562 

Howdeshell, K L .............................. 1481* 

Howe, K ........................................... 1080* 

Howell, G ........................................... 220* 

Howlett, K ............................................ 357 

Hoyer, P.......................................... 25, 28* 

Hoyer, P B .................................... 387, 402 

Hrdy, D ............................................... 1933 

Hsiao, C J ......................................... 2129* 

Hsu, E ................................................... 451 

Hu, D .................................................... 237 

Hu, J ..................................................... 693 

Hu, Q .................................................. 2194 

Hu, R ........................................ 1962, 2077 

Hu, T .................................................. 484* 

Hu, W ............................................... 1725* 

Hu, X .......................... 142, 237*, 264, 374 

Hu, Y .................................. 686, 687, 1968 

Hua, D H ............................................ 1085 

Huang, C .... 373, 1746, 1834, 2093*, 2095 

Huang, D Y ........................................ 389* 

Huang, G .......................................... 1203* 

Huang, M ................................... 714*, 823 

Huang, Q .......................................... 2182* 

Huang, R .............................. 196, 707, 715 

Huang, S C ........................................... 222 

Huang, W ............................................... 54 

Huang, X ............................................ 1304 

Huang, Y .................................... 288, 373* 

Hubbard, A ........................................... 127 

Hubbard, J O ........................................ 475 

Hubbard, S A ...................................... 1794 

Hubbell, B J ....................................... 1933 

Hubbs, A F ............................... 799, 1506* 

Huber, S A .......................................... 1180 

Huc, L .................................................. 596 

Huderson, A C .................................... 535* 

Hudson, A W ...................................... 1981 

Hudson, L G ......................................... 706 

Huener, H ........................................... 2091 

Huggett, D ............................................ 459 

Huggett, D B ........................ 194, 232, 447 

Hughes, M F ........................... 1245, 1566* 

Huhtaniemi, I T ........................ 2089, 2092 

Hulderman, T ..................................... 2178 

Hulla, J ............................................. 1881* 

Humphreys, B D .............................. 1443* 

Hung, C .............................................. 1136 

Hung, D ........................ 1834*, 2093, 2095 

Hung, H ................................................ 770 

Hung, P ................................................ 118 

Hunter, D .............................................. 165 

Hunter, D L ................................ 463, 1390 

Hunter, K W ....................................... 1855 

Hunter, S .............. 712*, 1683, 1684, 1685 

Hurst, H E .......................................... 1848 



Husain, M ............................................. 790 

Hussain, F .......................................... 1934 

Hussain, S ...................... 372, 1692, 1701* 

Hussain, S M ........... 281, 805, 1693, 1694, 

1695, 1696*, 1709 

Hussainzada, N .................................... 90* 

Hutchinson, T H ................................. 1450 

Hutchison, J ........................................ 1706 

Hutt, J ................................................... 843 

Hutter, J C .......................................... 877* 

Huwe, J ............................ 642*, 643, 1574 

Huwe, J K ........................................... 1570 

Huyn, C .............................................. 1326 

Huynh, F K ........................................... 860 

Hwang, G ............................... 1822*, 1837 

Hwang, S .......................................... 1651* 

Hwang, Y........... 1710, 1759, 1761*, 1765, 

1767, 1769, 1770*, 1775 

Hynes, D .............................................. 906 

Håkansson, H ....................................... 408 

I 

Iatropoulos, M ...................................... 509 

Iatropoulos, M J ......................... 141, 1120 

Ibrahim, T A ....................................... 1833 

Ibrahim Aibo, D ............................... 2139* 

Ichihara, G .................................... 415, 772 

Ichihara, S .................................... 415, 772 

Ichii, T .................................................. 922 

Ifuku, M ............................................. 1279 

Igarashi, K ............................................ 672 

Igarashi, Y .......................................... 191* 

Iguchi, T ............................................. 1450 

Ihlaseh, S M ....................................... 507* 

Ihnat, M A ............................................ 959 

Ikeuchi, R ................................. 1605, 1608 

Il’Giovine, Z............................... 251*, 252 

Im, J ........................................ 1773*, 1888 

Imai, T .................................................. 713 

Imamura, Y ......................................... 1825 

Imsilp, K .............................................. 444 

Inada, H .............................................. 377* 

Inakura, H ............................................ 290 

Inaoka, T .............................................. 966 

Inawaka, K ......................................... 1690 

Inayat-Hussain, S H ......................... 1211* 

Ingerman, L ...................................... 1945* 

Ingle, J ................................................ 1885 

Ingle, S ....................................... 700, 1027 

Inglis, H ........................................ 109, 491 

Inman, A O ............................. 2067*, 2068 

Inoue, A .............................................. 403* 

Inoue, K ................................................ 713 

Inoue, T .................................... 672*, 1678 

Inoue, Y .................................... 1605, 1608 

Inturi, S ........................................ 69, 352* 

Inui, N ................................................ 1309 

Irons, T D ......................................... 1390* 

Irwin, W A ........................................ 1319* 

Isariyodom, S ....................................... 444 

Iscan, M .............................................. 356* 

Ise, R .................................................. 1026 

Ishihara, Y ................................ 792, 1513* 

Ishimoto, S ......................................... 1811 

Isom, G E ........................................... 1269 

Itagaki, H .............................................. 301 

Ito, K .................................................... 441 

Ito, T ................................................... 1309 

Itoh, F ................................................. 1313 

Itoh, K .................................................. 772 

Itoh, S ................................................. 1460 

Iturria, S ............................................. 1330 

Iversen, T ............................................. 267 

Ivy, J H ............................................... 897* 

Iwashita, K ....................................... 1690* 

Iyer, R ......................................... 283*, 802 

Iyer, R P ............................................. 1582 

Izumi, H ............................................... 922 

J 

J. Rane, M ............................................ 747 

Jabbour, R ............................................ 341 

Jablonski, J E ..................................... 1159 

Jacinto, E Y ........................................ 2127 

Jack, J ........................... 1348, 1407, 2081* 

Jack, V ................................................ 2187 

Jackson, A ............................ 1046*, 1729* 

Jackson, A R..................................... 1527* 

Jackson, C A......................................... 847 

Jackson, D ................................ 1031, 2177 

Jackson, D A .................................. 90, 934 

Jackson, G R .............................. 470*, 477 

Jackson, J ........................................... 1964 

Jackson, J P ........................................ 1717 

Jackson, K .......................................... 1101 

Jackson, L ............................................ 305 

Jackson, L G ......................................... 304 

Jackson, L S ................... 1152, 1153, 1159 

Jackson, M ................... 2164, 2165, 2166* 

Jackson, M C .......................... 1022*, 1506 

Jackson, R ............................................ 337 

Jacob, C C .......................................... 1140 

Jacob, R ................................................ 870 

Jacob, R E .................................. 871, 939* 

Jacobs, A ................ 100, 1789, 1807, 1808 

Jacobs, J ............................................. 1854 

Jacobs, J M ............................. 59, 751, 752 

Jacobs, L M .......................................... 362 

Jacobs, S ........................................... 1577* 

Jacobson, C F ..................................... 1795 

Jacobson, J L ........................................ 893 

Jacobson, P B ....................................... 757 

Jacobson, S W ...................................... 893 

Jacobson-Kram, D ........... 548*, 645, 647*, 

1353* 

Jacobus, J ........................................... 2064 

Jaeschke, H .......... 1212, 2133, 2134, 2135 

Jagger, C ............................................. 1170 

Jahng, Y .............................................. 1572 

Jahns, G L .......................................... 1629 

Jahreis, G ............................................ 1141 

Jain, A K....................................... 69, 353* 

James, J T ........................................... 1859 

James, R C ......................................... 122* 

Jameson, T ......................................... 1073 

Jamrogowicz, J L ............................... 429* 

Jan, Y .................................................... 65* 

Jana, S ............................ 700, 1027*, 1066 

Jang, W ............................................... 1838 

Janovitz, E ................................ 1639, 1656 

Janovitz, E B ...................................... 1315 

Jansky, K .............................................. 339 

Janson, C .............................................. 664 

Janssen, S ........................................... 1999 

Jarabek, A M ................ 1015, 1016, 1017* 

Jarema, K A .............................. 916, 1247* 

Jarrett, T ............................................... 439 

Järvenpää, E ....................................... 1150 

Järventaus, H ........................................ 266 

Järvinen, T .......................................... 1150 

Jarvis, P .................................... 42, 43, 832 

Jaskot, R H ........... 1015, 1016, 1017, 1500 

Javed, I ............................................... 1891 

Jay, A .................................................. 1259 

Jay, A N .............................................. 1245 

Jayaram, B .......... 1132*, 1587, 1588, 1589 

Jayashankar, S .................................. 1025* 

Jayjock, M A ........................................ 567 

Jayyosi, Z ........................................... 1325 

Je, Y .................................................. 1091* 

Jean, Y .................................................. 817 

Jeerage, K M ...................................... 2070 

Jeevaragen, A ............................... 292, 375 

Jeffay, S ........................ 1683, 1684*, 1685 

Jeffrey, A M .............................. 141*, 1120 

Jeffrey, K A ........................................ 1968 

Jeffy, B ............................................... 1641 

Jeffy, B D ............................... 1053, 1642* 

Jena, G .................................................. 867 

312 




Jenkins, A ........................................... 607* 

Jenkins, A C ......................................... 605 

Jennen, D G ................................ 650, 1652 

Jennings, P ........................................... 809 

Jenny, M ........................................... 1670* 

Jensen, K .............................................. 165 

Jensen, T F ........................................... 418 

Jensen, T J .................................... 953, 954 

Jeon, T W ........................................... 1963 

Jeong, H .............. 1710, 1711, 1759, 1761, 

1762, 1763, 1764, 1765, 1766, 1767, 1768, 

1769, 1770, 1771, 1772, 1773, 1774*, 

1775, 1776, 1777, 1888, 1889 

Jeong, S .................................... 817, 1680* 

Jeong, T ...... 908, 1562, 1571*, 1572, 1963 

Jeong, Y ............................................ 1710* 

Jerold, L A ............................................ 776 

Jerome, G ........................................... 1076 

Jessen, B ................................... 1657, 1725 

Jessop, F ....................................... 583, 735 

Jestoi, M ............................................. 1150 

Jesudhasan, P R .................................... 435 

Jewell, D A ........................................... 973 

Ji, Z ............................................ 123*, 127 

Jia, Z ......................................... 709*, 1252 

Jiang, B ................................................ 271 

Jiang, H ............................ 999, 1002, 1839 

Jiang, J ................................................ 1968 

Jiang, R ............................................ 1861* 

Jiang, S Y ......................................... 1507* 

Jiang, T ............................................... 1226 

Jiang, W ......... 457, 984, 1778, 2120, 2163 

Jiang, Y ............................................... 1000 

Jimenez-Velez, B D .................. 1559, 1560 

Jiménez-Vélez, B D ........... 759, 760, 1474 

Jin, G ................................................ 1532* 

Jin, S ................................................... 747* 

Jing, H M ........................................... 2173 

Jinsmaa, Y .......................................... 1236 

Jo, W .................................................. 2037 

Jo, W J ...................................... 951, 1845* 

Jochmans, D ......................................... 816 

Johansen, M ....................................... 2151 

Johansson, N ........................................ 176 

John, K ............................................... 131* 

John, T N ............................................ 1585 

John-Baptiste, A ................................... 54* 

Johns, D ............................................ 1564* 

Johns, D O .......................................... 1928 

Johnson, A M ................................... 1795* 

Johnson, C ............................................ 619 

Johnson, D E .................... 205, 1648, 1999 

Johnson, D J ....................................... 1893 

Johnson, D N ...................................... 791* 

Johnson, D R ...................................... 803* 

Johnson, F O ........................................ 977 

Johnson, G .......................................... 1895 

Johnson, J ..................................... 655, 883 

Johnson, J D ....................................... 1578 

Johnson, J E ............................. 1603, 1972 

Johnson, J M ...................................... 1293 

Johnson, K .......................................... 1973 

Johnson, M ........................................... 246 

Johnson, M B ..................................... 1291 

Johnson, M S ...................................... 1930 

Johnson, N .................................. 970, 1457 

Johnson, N M ..... 1160, 1161, 1458*, 1459 

Johnson, P ............................................ 747 

Johnson, R E ........................................ 929 

Johnson, R J ....................................... 1959 

Johnson, V ............................................ 305 

Johnson, V J ............................................. 9 

Johnson, W D ................................... 1045* 

Johnston, C J .................................... 1970* 

Johnston, K .......................... 79, 83*, 1410 

Johnston, P ............................... 1078, 1079 

Johnstone, A ..................................... 2032* 

Johnstone, A F ...................................... 216 

Johnstone, A M ...................... 1258, 1259* 

Jokinen, M .......................................... 1050 

Jolly, P ................................................ 1457 

Jolly, R A ...................................... 79, 1640 

Jomphe, C ........................................ 1580* 

Jones, C .............................. 496, 507, 2154 

Jones, D P ............................... 1293, 1423* 

Jones, F A ............................................. 474 

Jones, H .............................................. 1752 

Jones, K .............................................. 2099 

Jones, K L .......................................... 2094 

Jones, M ................................................. 85 

Jones, S .............................................. 1924 

Jones, S R ........................................... 411* 

Jones, W ............................................. 1181 

Jordt, S ................................. 2016*, 2017* 

Jorge, M ............................................... 679 

Jortner, B S ......................................... 1266 

Joseph, L B ............... 61, 350, 1665*, 2172 

Joseph, P .............................................. 305 

Joshee, L .............................................. 378 

Joshi, G .............................................. 876* 

Joshi, P ............................................. 1986* 

Joshi-Barve, S ...................................... 152 

Joyce, A R ................................ 1220, 1853 

Joyce, K .............................................. 1126 

Judson, R ............................... 96*, 98, 215, 

1010, 1382, 1387, 1407, 1723, 1901 

Judson, R S........................................... 198 

Jules, G E ......................................... 1750* 

Jun Ming, H ....................................... 2182 

Jungsuwadee, P .................................. 1749 

Jutooru, I D ................................ 531*, 532 

K 

Kabalka, G ........................................... 163 

Kabilan, S ........................... 870, 871, 872* 

Kabirov, K K ...................................... 721* 

Kachanova, T ....................................... 210 

Kadambi, A ........................................ 2076 

Kadambi, V J ...................................... 1921 

Kadar, T .................................................. 64 

Kadereit, S .......................................... 1394 

Kadota, T ............................................ 1460 

Kagan, V ............................ 597, 598*, 599 

Kagan, V E ........................... 270, 766, 793 

Kaido, T ................................. 1605*, 1608 

Kajon, A ............................................. 2179 

Kakeyama, M ....................................... 174 

Kakiuchi-Kiyota, S .................. 516*, 1300 

Kakuni, M ............................................ 906 

Kallman, M .......................................... 586 

Kalman, D A ........................................ 951 

Kamal, A S ......................................... 1505 

Kamata, Y ........................................... 1460 

Kamau-cheggeh, C ............... 157, 173, 175 

Kamendi, H .......................................... 807 

Kamendi, H W ....................... 1047, 1757* 

Kamendulis, L M ..... 524, 526, 1634, 1965 

Kameoka, S .............................. 1740, 1741 

Kaminski, N ............................. 1526, 1528 

Kaminski, N E ..... 73, 140, 145, 632, 1195, 

1525, 1530, 1533, 1997 

Kamp, H ............................................. 1646 

Kamperschroer, C .......... 935, 1722*, 1981 

Kan, H .................................................. 119 

Kan, L .................................................. 181 

Kan, M J ............................................... 521 

Kan, R .................................................. 333 

Kan, R K .............................................. 344 

Kanada, S ......................................... 1529* 

Kanawaty, A ......................................... 859 

Kandagaddala, L ................................ 909* 

Kandarova, H ....................... 478, 487, 499 

Kaneko, T ................................... 672, 1678 

Kaneto, M ............................................ 829 

Kang, G .................................................. 22 

Kang, J ....................................... 817, 1680 

Kang, M ............................................... 909 

Kang, M J ... 908, 1562, 1571, 1572*, 1963 

Kang, W ........................... 908, 1571, 1572 

Kang, Y ............................ 786, 1733, 1734 



Kang-Sickel, J C ................................ 1329 

Kania-Korwel, I ..................... 1590, 2062* 

Kanki, M ............................................ 2078 

Kannan, K .................................. 641, 1590 

Kanneganti, T ..................................... 1282 

Kanno, J ............... 672, 1397*, 1402, 1678 

Kanthasamy, A ........ 272, 986, 1268, 1268, 

1276, 1676 

Kanthasamy, A G ............... 272, 986, 1276 

Kanthasamy, K ................................. 1276* 

Kanwal, C .......................................... 1308 

Kapetanovic, I M.............. 721, 1045, 1647 

Kaphalia, B S ............................... 309, 907 

Kaplan, B ................................. 1526, 1528 

Kaplan, B F .............................. 1525, 1533 

Kaplan, B L ...................................... 1997* 

Kaplan, E S .......................................... 177 

Kappeler, C J ...................................... 387* 

Kapralova, V ................................ 597, 598 

Karahalil, B .......................................... 529 

Karakaya, A .......................................... 529 

Karin, N J ................................... 751, 1327 

Karlsson, O ........................................ 167* 

Karman, B N ...................................... 388* 

Karmaus, P ............................. 1526*, 1528 

Karmaus, W ....................................... 2106 

Karschuk, N ........................................... 91 

Kashon, M ............................................ 305 

Kashon, M L ...................... 734, 799, 1506 

Kasoji, M ............................................ 1969 

Kate, M .............................................. 1746 

Katika, M M ..................................... 1552* 

Kato, A ................................................. 415 

Kato, H ............................................. 1026* 

Kato, K ................................................. 640 

Katoh, M .............................................. 789 

Katori-Stowell, Y ............................... 1563 

Katwa, P ............................................... 795 

Katz, H ............................................... 1698 

Kaufman, J ......................................... 1048 

Kaufman, L ................................ 106, 1458 

Kaufmann, W ..................................... 1904 

Kaur, R ............................................... 1809 

Kavanagh, K L ..................................... 595 

Kavanagh, T J ... 264, 276, 374, 1493, 1497 

Kavlock, R ........ 13*, 96, 212, 1010, 1382, 

1387, 1723, 1901 

Kavlock, R J ......................................... 198 

Kawabata, T ........................... 2052, 2055* 

Kawabata, T T ............................ 935, 1981 

Kawabe, M ........................................... 910 

Kawamura, S ...................................... 1690 

Kay, D .................................................. 430 

Kayama, F ........................................ 2063* 

Kaynar, A ............................................. 598 

Kazerooni, A ...................................... 1587 

Kaziska, D .......................................... 1878 

Kazmi, P ............................................... 491 

Kazuyoshi, I ......................................... 826 

Ke, S ................................. 714, 1688, 2157 

Ke, Z................................................... 1393 

Keating, A F ....................................... 402* 

Kedderis, G .......................................... 895 

Kedwards, T ....................................... 2096 

Keefe, K ............................................. 658* 

Keefer, L K ........................................... 969 

Keeler, G J .......................................... 1505 

Keenan, J J ............................... 124*, 1867 

Kegelman, L ......................................... 584 

Keil, D E .................................. 1554, 2189 

Kelkar, N .............................................. 200 

Keller, D J .......................................... 111* 

Keller, N ............................................. 2090 

Keller, S .............................................. 1141 

Kelly, C .............................................. 2005 

Kelly, F L ........................................... 1490 

Kelly, K ................................................ 978 

Kelshaw, E.......................................... 1993 

Kenfield, J ............................................ 379 

Kenna, J G .......................................... 2122 

Kennedy, D ......................................... 1044 

Kennedy, G L ....................................... 407 

Kenneke, J F ......................................... 901 

Kent, M ............................................ 1629* 

Kent, M L ............................................. 414 

Kenyon, E ................................. 888*, 1913 

Kenyon, E M ........................................ 159 

Keohavong, P ....................................... 793 

Kepley, C ............................................ 1252 

Keravec, V ............................................ 480 

Kerger, B D ................................ 122, 227* 

Kerkvliet, N ........................................ 539* 

Kern, P ............................................... 1926 

Kerr, R .................................................. 439 

Kershner, N .............................. 743*, 1320 

Kerwien, S .......................................... 1515 

Keshava, C ............................. 1923*, 1925 

Kesteleyn, B ......................................... 816 

Keys, D ................................................. 878 

Khaliq, T ............................................ 1891 

Khampang, R ....................................... 778 

Khan, I A ............................ 686, 687, 1903 

Khan, M ....................... 309, 311, 702, 777 

Khan, S ................................................. 309 

Khan, S A ............................................. 669 

Khan-Mayberry, N ............................. 1859 

Khanal, T .......................................... 1765* 

Khlebnikova, N .................................. 1866 

Kiang, J G ............................................ 754 

Kiang, Y ............................................. 1962 

Kienhuis, A S ................................... 1653* 

Kiihl, S ............................................... 1609 

Kille, P ............................................... 1450 

Killeen, S Z .......................................... 326 

Kim, B G ............................................ 1821 

Kim, C B ............................................ 1056 

Kim, C S..................................... 877, 1936 

Kim, D ........................................ 823, 1567 

Kim, D J ........................................... 1671* 

Kim, D S ............................................ 1821 

Kim, E ........................................ 817, 1680 

Kim, G ................................................ 2147 

Kim, H ............... 825*, 1486, 1711*, 1766, 

1768, 1770, 1774, 1775, 1777 

Kim, H W ............................................. 205 

Kim, J .................. 370*, 446*, 827, 1215*, 

1216, 1399*, 1711, 1766* 

Kim, J H ........................................... 1349* 

Kim, K ............................ 1217, 1225, 1838 

Kim, K B ............................................ 1568 

Kim, M ......................... 235*, 696*, 1177* 

Kim, N ........................................ 823, 1619 

Kim, S ......................... 364, 725, 726, 874, 

1177, 1561, 1630*, 1651, 1783, 1838, 

1997 

Kim, Y ........................................ 748, 1665 

Kimbell, J ........................................... 868* 

Kimbell, J S .......................................... 869 

Kimber, I .................. 74, 75, 296, 308, 476 

Kimmo, J D ...................................... 1123* 

Kimura, J .............................................. 377 

Kimzey, M J ....................................... 1667 

Kinae, N ............................................... 713 

Kindt, E .................................................. 54 

King, A L ............................... 1632, 1633* 

King, B S ............................................ 706* 

King, M D .......................................... 1929 

King, N ............................................... 1726 

Kinniburgh, D W .................................. 389 

Kinnunen, P .......................................... 208 

Kinsley, L ........................................... 2066 

Kinsner-Ovaskainen, A ........................ 114 

Kinter, L ..................................... 807, 1081 

Kipen, H ............................................. 1857 

Kirby, G ............................................ 1102* 

Kirby, P ................................................ 699 

Kirby, P J .................................. 1490, 1492 

Kirchner, F ........................................... 607 

Kirk, S .................................................. 302 

Kirkland, D .......................................... 717 

Author Index 



Author Index 


Kirkpatrick, D .................................... 1499 

Kirman, C ........................................... 1041 

Kirsch, G ................................ 2029, 2031* 

Kirsch, G E ............................. 1732, 1753* 

Kirsch-Volders, M ...................... 268, 1650 

Kirton, C M ...................................... 1404* 

Kiser, R ................................................ 502 

Kiser, R C ........................... 923*, 924, 931 

Kishimoto, T ............................ 1547, 1548 

Kisin, E ...................... 270, 599, 793*, 799 

Kisin, E R ............................................. 271 

Kissling, G ........................................... 196 

Kissling, G E ...................................... 1033 

Kissner, T ......................................... 2100* 

Kitchin, K T ......................................... 262 

Kiyosawa, N ....................................... 1630 

Kizilors, A .......................................... 1211 

Klaassen, C .................... 1416, 2154, 2155 

Klaassen, C D .......... 589, 773, 1092, 1103, 

1417*, 1556, 1597, 1616, 1617, 1618 

Klaassen, J ... 379, 1736, 1983, 1984, 1985, 

2192 

Klangkaew, N ....................................... 444 

Klaunig, J E ....... 228, 523, 524, 526, 1634, 

1965 

Klausner, M ................. 303, 412, 470, 477, 

478, 483, 487, 499* 

Klei, L R ............................................... 576 

Klein, C .............................................. 2159 

Klein, J ................................................. 605 

Kleinjans, J C ............. 517, 650, 778, 1652 

Kleinow, K ........................................... 685 

Kleinstreuer, N ....................... 1382, 1387* 

Kligerman, A D .................................... 262 

Klimecki, W ....................................... 1625 

Klimecki, W T ............................ 947, 1227 

Kline, D E ........................................ 1530* 

Kline, M A ......................................... 1669 

Klintworth, H M ................................. 630* 

Kluz, T ................................................. 153 

Knaak, J B .............. 882, 1243, 1894, 1900 

Knaut, H ............................................... 170 

Knickel, J ........................................... 2091 

Knight, M R ....................................... 1016 

Knipping, E ........................................ 1510 

Knuckles, T L ................................... 1728* 

Knudsen, G A ............................. 362, 363* 

Knudsen, T ................. 96, 212, 1387, 1430 

Knudsen, T B ................... 198, 463, 1382* 

Ko, G S ....... 908, 1562*, 1571, 1572, 1963 

Ko, M S .................................... 1430, 1719 

Kob, M A .............................................. 919 

Kobayashi, E .......................................... 77 

Kobayashi, K ...................................... 2086 

Kobayashi, M ......................................... 77 

Kobayashi, N ........................................ 788 

Kobayashi, Y ........................................ 948 

Kobylewski, S E ............................... 2150* 

Koch, D .............................................. 2112 

Koch, M ........................................... 1593* 

Kodama, Y ............................................ 672 

Kodavanti, P S .................................... 783* 

Kodavanti, U ...................................... 1503 

Kodavanti, U P ................................. 1500* 

Koenig, J .............................................. 321 

Koerner, J ................................. 44*, 2033* 

Kojima, C ............................................. 967 

Kojima, H ................................. 101, 1130* 

Kolaja, K .................................... 187, 1125 

Kolaja, K L .... 47*, 49*, 1738, 1739, 1740, 

1741 

Kolisetty, N .............................. 812*, 1713 

Koller, L ............................................. 1014 

Kolluri, S K ........................................ 2112 

Komiskey, H L ................................... 985* 

Komocsar, W ...................................... 2192 

Komocsar, W J ..................... 2052*, 2056* 

Kondo, C .............................................. 829 

Kondraganti, S.................................... 309* 

Kondraganti, S R .................... 1778, 2000* 

Konduru, N V ....................................... 766 

Kong, A ................................................ 104 

Kong, M M ........................................... 527 

Kong, W ............................................. 125* 

Kong, X Q ........................................ 1008* 

Konig, R ............................................... 309 

Konigsson, K .................................... 1805* 

Kono, K ................................................ 707 

Kopec, A K ............................... 244*, 1627 

Kopf, P G ......................................... 2058* 

Kopp, R .............................................. 1879 

Koppen, G .............................................. 55 

Kopylev, L .......................................... 210* 

Korey, A ............................................. 1563 

Korsch, M ........................................... 2066 

Korte, S H ........................................ 1036* 

Korwel, I .............................................. 237 

Kosak, J ................................................ 400 

Kosar, F .............................................. 1846 

Kosmider, B ..................................... 1221* 

Kostrubsky, S ....................................... 88* 

Kosyk, O .............................. 201, 364, 874 

Kotha, S R ........................................ 1669* 

Kotlenga, K ........................................ 1325 

Kotler, M L ......................................... 1235 

Kotton, C .......................................... 2054* 

Kouadio, J H ...................................... 1462 

Koufaris, C ......................................... 533* 

Kowalkowski, K L ............................... 582 

Koyama, D ......................................... 1460 

Koyama, N ........................................... 713 

Koyama, S ................................ 792*, 1513 

Koyner, J .............................................. 806 

Koza-Taylor, P.......................... 679, 1303* 

Kozul, C ............................................... 959 

Kozul, C D ......................................... 956* 

Kracko, D ........................................... 1573 

Kraemer, S............................ 157, 173, 175 

Kraft, J .................................................. 323 

Kramer, D ........................................... 1573 

Kramer, V ........................................... 1448 

Krantz, Q T .......................................... 159 

Krantz, T .............................................. 888 

Kraus, L .............................................. 1075 

Krause, E ............................................ 2186 

Kreckler, L ......................................... 1802 

Kreider, M L....................................... 1851 

Kreiss, K ............................................ 1506 

Kremer, J J ......................................... 1752 

Krennrich, G ...................................... 1646 

Kriech, A J ........................................... 508 

Krieger, R I ........................... 1867*, 2049* 

Krieger, S M ............................. 1591, 1592 

Krishna, G .......................................... 550* 

Krishnamoorthy, A ............................. 821* 

Krishnamurthy, P ............................... 1089 

Krishnan, K ............. 250*, 568*, 880, 881, 

1564, 1579, 1914 

Krishnan, S ............................... 289, 1218* 

Kristovich, R ........................................ 273 

Krouzek, J ............................................ 718 

Krsmanovic, L ............................ 690, 1155 

Krucoff, M W ....................................... 46* 

Krug, H F ............................................. 291 

Kruhlak, N L ........................................ 204 

Krupp, E ............................................. 2100 

Kruzich, P J ...................................... 1752* 

Kubilus, J ..................................... 487, 499 

Kubota, H ........................................... 2086 

Kubota, R ........................................... 1402 

Kudo, Y .................................... 1605, 1608 

Kueberuwa, S S .................................. 1930 

Kuehl, P ...................... 1479, 1480*, 1516* 

Kuester, R ......................... 125, 362*, 1584 

Kuester, R K ......................................... 363 

Kuffel, M J ........................................... 357 

Kuffner, E ......................................... 1072* 

Kuhlman, C L ..................................... 780* 

Kuklenyik, Z ........................................ 640 

Kulkarni, P ......................................... 1187 



Kulkarni, S ....................................... 1623* 

Kulkarni, Y ......................................... 1131 

Kullman, S ............................................. 89 

Kullman, S W ..................................... 1204 

Kulpa-Eddy, J ..................................... 1808 

Kumagai, N ............ 35, 1546*, 1547, 1548 

Kumagai, S ................................... 444, 445 

Kumagai, Y .......................................... 975 

Kumar, R ............................................ 2079 

Kumbartski, M ................................... 1879 

Kunak, S C ........................................... 356 

Kung, M H ....................................... 1196* 

Kunisue, T .................................. 894, 2099 

Kunzmann, A ....................................... 291 

Kuper, F............................ 367, 1054, 1388 

Kuprat, A ...................................... 870, 872 

Kuprat, A P ........................................... 871 

Kurita, H............................................. 146* 

Kurokawa, M...................................... 1542 

Kurosawa, T ....................................... 1313 

Kurt, B .................................................. 356 

Kurtz, D M ........................................... 916 

Kurunthachalam, K .................... 894, 2099 

Kuryshev, Y .............................. 1732, 2031 

Kushida, M ................................. 523*, 524 

Kushman, M E ................................... 452* 

Kushner, J P ......................................... 454 

Kutzman, R S ........................... 1917, 1930 

Kuwagata, M .............................. 161*, 178 

Kuzmitcheva, G .......................... 338, 349* 

Kwagh, J ............................................ 1273 

Kwakye, G F ...................................... 993* 

Kwast, L ............................................. 317* 

Kwast, L M ........................................ 1550 

Kwekel, J C ...................................... 1644* 

Kwok, D ............................................... 458 

Kwon, H ............................................... 671 

Kwon, J .............................................. 1399 

Kwon, O ............................................... 909 

Kwon, S ................................................ 468 

Kyle, A D ............................................. 566 

Kyoso, M ............................................ 1513 

Käfferlein, H .................................... 1879* 

Könczöl, M ........................................ 1121 

L 

La Du, J K ............................................ 684 

La Merrill, M ........................... 320*, 668* 

LaBranche, T P .................................. 555* 

Lacerda, A E ....................................... 1753 

LaCerte, C .......................... 292, 375, 2170 

Lachau-Durand, S ................................ 816 

Lacher, S ............................................ 358* 

Lackey, L .............................................. 667 

Ladd, B ................................................. 679 

Ladiges, W ........................................... 135 

Ladwig, K E ....................................... 1935 

LaForge, Y .............................. 1093*, 1411 

Låg, M .............................. 267, 736, 2176* 

Lagache, D ......................................... 1116 

Lagadic-Gossmann, D .................. 596, 736 

Lahoti, T ............................................. 815* 

Lahousse, S A..................................... 628* 

Lai, I ..................................................... 239 

Lai, I K ................................................. 240 

Lai, Y .................................................... 625 

Lai, Z ........................................ 2191, 2193 

Laifenfeld, D ........................................ 679 

Lainee, P ............................................ 602* 

Laiosa, M ......................................... 2191* 

Lake, A D ......................................... 1625* 

Lalayeva, N .............................. 379, 2192* 

Lalko, J ............................................... 308* 

Lalloo, M T .......................................... 825 

Lam, C .............................................. 1859* 

Lam, K ............................................. 1601* 

Lamar, P ............................................. 1824 

Lamb, C L .................... 1534, 1537, 1949* 

Lamb, C M ............................. 1498*, 1501 

Lamb, J C ........................................... 228* 

Lamb, J G ................................. 121, 2102* 

Lamb, W ............................................... 871 

Lambert, J C ....................................... 569* 

Lambrechts, N .................................... 107* 

Lambright, C ........................................ 562 

Lambright, C R .................................. 1481 

Lampert, B M ..................................... 1057 

Lamsa, J ............................................. 1061 

Lamy, E .............................................. 1781 

Lan, Q .......................................... 123, 127 

Lan, Y ................................................... 918 

Lanaspa, M A ................................... 1959* 

Landauer, M R ................................... 330* 

Landolph, J R ..................................... 525* 

Landrigan, P J ...................................... 668 

Landry, T D ........................................ 1415 

Landsiedel, R ...... 258, 1395*, 1396, 1398, 

1403, 1904, 1948, 2067, 2068, 2090, 2091 

Langohr, I M ...................................... 1784 

Langston, J L ........................................ 340 

Langston, T B ..................................... 753* 

Lanier, R ............................................. 1057 

Lankveld, D .......................................... 279 

Lanphear, B P ....................................... 147 

Lanphear, C ........................................ 2114 

Lanphear, C K .................................... 854* 

Lantz, R .................................... 1512, 2171 

Lantz, S M ............................ 281, 796, 798 

LaPres, J J .......................... 84, 2137, 2175 

LaRocca, J .......................................... 846* 

LaRosa, K ............................................ 412 

Larsen, L ............................................ 2007 

Larson, T V .............................. 1493, 1497 

Lasarev, M ................................ 1240, 1263 

Lash, L H ........................................... 813* 

Laskin, D .................................. 336, 2015* 

Laskin, D L ................. 61, 62, 65, 67, 350, 

629, 738, 744, 745, 765, 987, 1665 

Laskin, J ....................................... 336, 744 

Laskin, J D ........................ 61*, 62, 65, 67, 

350, 510, 629, 738, 745, 765, 825, 987, 

1665 

Lasley, S M ........................................ 160* 

Lassen, N .............................................. 595 

Lassiter, T L ......................................... 855 

Last, J ................................................. 1519 

Lathrop, S ............................................. 739 

Lati, E ....................................... 1175, 1192 

Latimer, J............................................ 1999 

Lattal, M ......................... 611, 1238*, 1240 

Latz, E .................................................. 33* 

Lau, A ................................... 1133*, 1226* 

Lau, C ................................... 218, 219, 830 

Lau, F C ............................................. 1145 

Lau, S S .............................. 518, 780, 1667 

Laumbach, R ...................................... 1857 

Laura, B .................................................. 23 

Laurent, S ............................................. 291 

Laurenzana, E M .............................. 2146* 

Lauterbach, J H ................................ 1170* 

Lavin Williams, A ............................ 1154* 

Lavoie, E .......................................... 2219* 

Law, B F ............................................. 1870 

Lawrence, B ............................. 1531, 1532 

Laws, S C ........................................... 2087 

Lawson, G ............................................ 382 

Lawton, M .... 365, 679*, 1303, 1655, 1744 

Laynes, L ............................................ 592* 

Lazarenko, O P ..................................... 762 

Le Bigot, J ........................................ 1727* 

Le Varlet, B ........................................ 1191 

Leach, J .............................................. 1782 

Leachman, S ......................................... 265 

Leasure, L .......................................... 1972 

LeBaron, M J ....................................... 521 

LeBeau, A ........................................ 1895* 

Lebel, E ........................................ 851, 852 

LeBlanc, A ................................... 851, 852 

Leclaire, J ............................. 486, 501, 505 

Lecloux, A ........................................ 1396* 

314 




Leconte, I ........................................... 681* 

Lecureur, V ........................................... 736 

Lecureux, L ...................................... 1658* 

Ledbetter, A D ................ 1500, 1501, 1522 

Lee, B ....................................... 1091, 1736 

Lee, C ....................................... 255*, 2143 

Lee, E E .............................................. 1947 

Lee, E S .............................................. 1963 

Lee, E Y .................................... 999, 1002* 

Lee, H ................................................... 120 

Lee, J ........................ 1595*, 1837*, 2115* 

Lee, J S ..................................... 1925, 1937 

Lee, K ..................................... 926*, 1212* 

Lee, L ..................................... 2016, 2021* 

Lee, M ... 120, 468*, 751, 752, 1136, 1327, 

1834 

Lee, M K .............................................. 929 

Lee, P ....................................... 118*, 1051 

Lee, P W ............................................... 138 

Lee, S ... 1177, 1599*, 1777*, 1783*, 1887 

Lee, S K ......................... 1562, 1571, 1963 

Lee, T ................................................... 808 

Lees, P .................................................. 790 

Lefranc, A .......................................... 1729 

Legare, M E........................................ 2113 

Lege, P ................................. 603, 604, 940 

Legrand, J ........................................... 2184 

Legrand, P ............................................ 596 

Lehman, M ............................................. 63 

Lehman-McKeeman, L .... 720, 1656, 1658 

Lehman-McKeeman, L D ........ 1315, 2136 

Lehmann, D M ................................. 1168* 

Lehmann, L .............................. 1141, 1461 

Lehmler, H ... 236, 237, 1590*, 2062, 2064 

Lehoux, S ............................................. 957 

Lei, D ................................................. 1962 

Lei, P ........................................ 531, 1225* 

Leibold, E ........................................... 1646 

Leighton, T ......................................... 1901 

Leila, B ............................................. 1869* 

Lein, P .................................................. 170 

Lein, P J .... 177, 1237, 1238, 1240*, 1243, 

1263, 1391, 1894 

Leiner, K A ......................................... 1180 

Leishman, D ..................................... 42, 43 

Leist, M .................................. 1270, 1394* 

Lelièvre, D ......................... 488, 505, 1190 

Lemaire, M ................................. 575, 957* 

Lemarchand, T ................................... 1074 

Lemarié, C A ........................................ 957 

Lemasters, J J ........ 770, 1212, 1213, 1214, 

1424*, 2133 

Lemire, I ................................... 1580, 1583 

Lemus, R ...................... 2164*, 2165, 2166 

Leng, J ................................................ 2063 

Lengel, D J ..................... 807, 1047*, 1757 

Lennox, L ............................................. 379 

Lentsch, A B......................................... 747 

Leon, A ............................................... 588* 

Leonard, P ................................ 1580, 1583 

Leonard, S ............................................ 225 

Leonard, S S ..... 270, 271, 793, 1400, 2177 

Leontovich, A A ................................... 855 

Lepoittevin, J ........................................ 110 

Léreaux, G ............................................ 486 

Lereaux, G .................................. 501, 1190 

Leroy, M ............................................... 409 

LeSauteur, L ............................. 1989, 1990 

LeSauteur, L A ....................................... 4* 

Leseman, D .......................................... 279 

Leta, T ................................................ 1123 

Letizia, C .......................................... 1111* 

Leuenberger, K ................................... 1046 

Leung, E ............................................... 458 

Leung, M C .................................. 82, 184* 

Leung, P ............................................. 1037 

Leuschner, J........................................ 1577 

Leverette, R ...................................... 1311* 

Leverette, R D .................................... 1316 

Levesque, P ........................................ 1084 

Levesque, P C................................... 2030* 

Levin, E D .................. 2023*, 2024, 2028* 

Levine, K E ........................................ 794* 

Levine, T ............................................ 1929 

LeVora, J ............................................ 1290 

Lew, B J .............................................. 657* 

Lewandowski, T A ............................... 245 

Lewis, A ........................................... 1935* 

Lewis, A S .......................................... 1942 

Lewis, E ............................................... 417 

Lewis, J A ............................. 90, 934, 2177 

Lewis, J M .......................................... 1188 

Lewis, M .......................... 938, 1782, 1789 

Lewis, R ..................................... 857, 2096 

Li, A ..................................................... 458 

Li, A A .................................... 1189*, 1261 

Li, A P .......... 322, 699, 1093, 1095, 1411* 

Li, C ..................................................... 467 

Li, D ................................... 255, 993, 1084 

Li, G ................................... 123, 127, 1678 

Li, G J ............................................... 2173* 

Li, J ............................................ 313, 1084 

Li, K L .............................................. 1007* 

Li, L .................................................. 1269* 

Li, M .................................................... 166 

Li, N ......................................... 1676, 2077 

Li, Q ..................................................... 179 

Li, S .................................. 737, 894*, 1383 

Li, T ...................................................... 630 

Li, W .................................................. 1254 

Li, X ............... 441, 530*, 927, 928*, 1839 

Li, Y .. 315, 709, 719*, 1174*, 1252, 1299, 

2128 

Li, Y H .................................................. 527 

Li, Z ............ 56*, 200, 1645*, 1920*, 1964 

Li Chen, T .......................................... 1128 

Liang, H ............................................. 1860 

Liang, L ................................................ 784 

Liang, Y .............................................. 1293 

Liang, Y W ......................................... 2120 

Liao, J ................................................. 1520 

Liao, W ............................................... 1758 

Liaw, L ................................................. 904 

Liberati, T............................................. 93* 

Liberda, E N ..................................... 1478* 

Licorish, R ............................................ 981 

Lieb, J B ............................................. 1061 

Liebel, F ............................................... 112 

Lieder, P H ......................................... 1118 

Liederer, B.......................................... 1062 

Lightfoot-Dunn, R .............................. 1051 

Lilienthal, H H ................................... 162* 

Lillard-Wetherell, K ........................... 1074 

Lilleaas, E M ...................................... 2176 

Lim, H ................................................ 1399 

Lim, K .................................... 1217, 1838* 

Lin, C ................................................... 918 

Lin, D ................................................. 2128 

Lin, H ......................................... 53*, 1063 

Lin, J K ................................................. 525 

Lin, L .................................................. 1982 

Lin, T .................................. 374, 861, 1754 

Lin, T M ............................................... 844 

Lin, Y ........................... 1482, 1664*, 1865 

Lind, L ...................................... 663*, 2162 

Lind, M P ................................. 663, 2162* 

Lindauer, K .......................................... 189 

Lindberg, H K ...................................... 266 

Lindeblad, M ............................ 721, 1594* 

Linder, K .............................................. 675 

Lindgren, S ............................. 42, 43, 1081 

Lindstrom, A ........................................ 218 

Linney, E .......................................... 2024* 

Lipscomb, J C .................................. 1913* 

Lison, D ................................................ 268 

Lisowski, A R ....................................... 582 

Liston, A ............................................. 2178 

Little, S ....................................... 203, 215* 

Litwak, M ........................................... 1281 

Litwin, D ............................................ 1047 



Litzenberger, B ................................... 1992 

Liu, D ................................................. 2063 

Liu, F ...................... 169*, 677*, 772*, 845 

Liu, G ................................................. 1660 

Liu, H ......................................... 441, 1269 

Liu, J .............................. 1004, 1853, 2014 

Liu, J Z ............................................... 2173 

Liu, S ........................................ 2093, 2095 

Liu, X .... 1225, 1968*, 2008*, 2063, 2128, 

2159 

Liu, Y ................. 744*, 1659, 1743*, 1818 

Lively, E L .......................................... 1090 

Lizarraga, D ......................................... 650 

Llorens, J .......................................... 1253* 

Lloyd, A L ............................................ 900 

Lo, R ................................................ 1198* 

Loccisano, A E ................................. 1384* 

Lockett, S ............................................. 791 

Lockey, J ............................................ 1876 

Loertscher, J ....................................... 2059 

Logan, D M ........................................ 1587 

LoGuidice, A .................................... 2130* 

Loguinov, A ........................................ 1845 

Lohr, C ............................................... 1144 

Lokeshwar, B L .................................... 130 

Lombard, C .......................................... 753 

Long, L ............................................... 1000 

Long, T ............................................... 1856 

Long, T E ............................................. 519 

Long, Z ............................................... 1000 

Looser, R ............................................ 1646 

LoPachin, R M ......................... 1267, 1289 

Lopez, S ............................................... 351 

Lorentzsen, M ...................................... 642 

Loretz, L ............................................... 471 

Lory, P .................................................. 816 

Losa, S ................................................ 406* 

Louis, T A .......................................... 1927 

Louise, W M ........................................ 849 

Lovelace, G L ................. 1212, 1213, 1214 

Loveless, S E .............. 99, 450, 1182, 1188 

Løvik, M .................................. 1650, 2196 

Lovik, M............................................. 2180 

Lowe, K .............................................. 1266 

Lowe-Krentz, L J ............................... 1315 

Lowit, A B .................... 1230, 1913, 1929* 

Lowney, Y W ........................................ 972 

Lowry, D T ........................................... 799 

Lowther, D ........................................... 938 

Lu, B .................................................. 1512 

Lu, C .................................................... 390 

Lu, H ...................... 627, 632, 1533*, 2128 

Lu, J .................................................... 750* 

Lu, K .................................................. 143* 

Lu, R ........................................ 771, 1001* 

Lu, S ................................................. 1657* 

Lu, T ........................................... 719, 1834 

Lu, X ............................................ 269, 519 

Lu, Y ..................................................... 271 

Luan, Y ............................. 704, 1174, 2128 

Lucas, B E ........................................ 1487* 

Lucchi, L ............................................ 1555 

Lucchini, R ........................................... 23* 

Lucero, J ................................... 1509, 1511 

Lucock, A ............................................. 302 

Lucot, J B ................................... 335, 346* 

Luderer, U ............................................ 382 

Ludewig, G.................. 236, 239, 240, 241, 

360, 716, 2064 

Ludwig, I .............................. 294, 317, 538 

Ludwig, I S ....................................... 1550* 

Luebker, D.......................................... 1118 

Luetjens, C M ........................... 392*, 1036 

Luizi, F ............................................... 1396 

Lukens, J R ......................................... 1282 

Lumini, J A......................................... 1731 

Lumley, L ............................................. 323 

Lumley, L A ......................................... 345 

Lund, A .......................... 1500, 1509, 1510 

Lund, A K......................................... 1511* 

Lundebye, A ....................................... 1025 

Luo, B .................................................. 441 

Luo, F ................................................... 176 

Luo, H ................................................ 1100 

Luo, J ...................... 714, 1219, 1393, 1756 

Luo, Z ................................................... 213 

Lust, R M ........................................... 1502 

Luthe, G ............................................. 1105 

Luther, E ............................................. 1113 

Luyendyk, J P ........................... 1620, 1958 

Luyts, K .................................... 299*, 1701 

Ly, V T.............................................. 1638* 

Lyke, D F ......................................... 1246* 

Lyman, M ............................................. 333 

Lynagh, S ............................... 1735*, 1755 

Lynch, B ............................................. 1803 

Lynch, C ........................................... 2160* 

Lynch, J .............................................. 1072 

Lynn, A ............................................... 1921 

Lynn, S G ............................................... 84 

Lyon, J J ............................................. 1756 

Lyons, M A........................................... 897 

Lyons-Darden, T ................................ 1800 

Lyubimov, A ....................................... 1594 

Lyubimov, A V ..................................... 721 

M 

Ma, D ....................................... 1094, 1205 

Ma, H ....................... 311, 464*, 702*, 777 

Ma, J ..................... 1043, 1738, 1739, 1741 

Ma, J K ................................................. 257 

Ma, J Y ............................................... 257* 

Ma, L .................................................. 2173 

Ma, M ..................................... 1483*, 1541 

Ma, Q ......................... 1814, 2036*, 2149* 

Ma, T .................................................. 2140 

Ma-Hock, L .......... 1395, 1396, 1398, 1403 

Maas, L M ............................................ 517 

Macakova, P ....................................... 1464 

MacCuspie, R I .................................. 1696 

Macdonald, J ...................................... 1654 

MacDonald, K .................................... 848* 

Macdonald, K ..................................... 1755 

MacGregor, J T ........................ 691, 1351* 

Machacek, D W .................................. 1389 

Machado, A F ..................................... 860* 

Machesky, N....................................... 1969 

Machesky, N J ...................................... 929 

Machida, K ........................................... 911 

Machii, K ............................................. 445 

MacIntyre, A ........................................ 379 

Macintyre, A ...................................... 2192 

Macintyre, A R ............. 1983, 1984*, 1985 

MacIsaac, B D ...................................... 926 

Mackay, W J ..................................... 1162* 

MacKenzie, S A ..................... 1146*, 1147 

MacKnight, C ..................................... 1173 

MacLachlan, T ..................................... 618 

Macon, M B ....................................... 839* 

MacPhail, R C ........ 783, 916*, 1247, 1390 

MacPherson, L ................................... 1198 

MacPherson, L M ............................. 1208* 

MacPherson, M .................................... 739 

Madanayake, T W ............................ 1718* 

Maddali, K ......................................... 1992 

Maddox, J ................................... 853, 2139 

Maddox, J F ............................. 2136, 2137 

Madren-Whalley, J S ............................ 341 

Madrid, A ........................................... 1478 

Maeda, E ............................................ 1309 

Maeda, M ............... 35, 1546, 1547, 1548* 

Magalhães, J ....................................... 1731 

Magby, J P ........................................ 1250* 

Magkoufopoulou, C ............................. 650 

Maguire, M .................................. 171, 180 

Mahadevan, B .................................. 1004* 

Mahendra, S ......................................... 255 

Mahle, D A ....................................... 1256* 

Maholtra, D .......................................... 193 

Mai, D .................................................. 525 

Author Index 



Author Index 


Maibach, H ......................................... 1563 

Maibach, H I ............................ 1175, 1192 

Maier, A ....................... 1006, 1792*, 1793 

Maier, A M ......................................... 1911 

Majewski, D ....................................... 1738 

Majithia, R ........................................... 285 

Mäkelä, S I ........................................... 408 

Makley, M ............................................ 327 

Makley, M K ...................................... 1629 

Makori, N ................................... 379, 2192 

Makris, S ............................................ 559* 

Makwana, O ..................................... 1726* 

Malarkey, D E .................................... 1033 

Malaviya, R ........................................ 350* 

Maldonado, E N ................................. 1214 

Maldonado, W A ................................ 1716 

Maldonado-Vázquez, W ...................... 434 

Malfatti, M ......................................... 1137 

Malik, S .............................................. 1654 

Malkinson, A M ................................... 676 

Mallampati, R ...................................... 483 

Malley, L A ........................................ 1569 

Mallinson, J E .................................... 1673 

Mally, A .................................... 1137, 1138 

Malowany, M ..................................... 1714 

Malpas, S .............................................. 915 

Malshet, V .......................................... 1808 

Malésic, L ............................................ 681 

Man, S .................................................. 293 

Manabe, T .......................................... 1180 

Manage, A ............................................ 338 

Manautou, J E ....... 14*, 626*, 1469, 1597, 

2131, 2132 

Manda, K C ........................................ 785* 

Manjanatha, M ................................... 1355 

Mankovskaya, I .................................. 1594 

Mann, A................................................ 189 

Mann, K K ............... 575*, 576, 957, 1558 

Manning, P ..................... 1075, 1076, 1077 

Manning, T ........................................... 747 

Mantell, L ........................................... 740* 

Mantena, S K ..................................... 1632 

Manyin, T ........................................... 424* 

Manzan, M A ......................................... 73 

Manzano Leon, N ................................. 254 

Mao, G ................................................. 205 

Mapes, J ................................... 1322, 1323 

Maquire, J M ........................................ 188 

Marano, F ........................................... 1701 

Marcellin, M ...................................... 1662 

March, T ......................... 63, 68, 351, 2179 

Marcinkiewicz, J L ............................... 384 

Marcondes Rezende, M ............... 293, 294 

Marcondez Rezende, M ....................... 538 

Marcus, A ........................................... 1925 

Margillo, K M ...................................... 184 

Margosches, E .................................... 1789 

Mariappan, S V .................................. 1590 

Marier, J ................................... 1580, 1583 

Marinovich, M ................................... 1555 

Marioara, C D .................................... 2180 

Markham, D A ............... 1591, 1592, 1849 

Markillie, L M ...................................... 275 

Marone, P A ....................................... 1145 

Marquis, J ........................................... 1582 

Marr, M C............................................. 396 

Marrec-Fairley, M .................. 1191*, 1926 

Marroquin-Cardona, A .............. 970, 1160, 

1161*, 1458, 1459 

Marrot, L .............................................. 496 

Marshall, P ......................................... 1979 

Marshall, V ........................................... 836 

Martens, J ............................................. 268 

Martin, A .............................................. 288 

Martin, E A......................................... 1673 

Martin, F L ......................................... 2006 

Martin, G .................................... 577, 1059 

Martin, M ............................... 96, 98, 1010 

Martin, M T .................... 463, 1407, 1901* 

Martin, P ............................................ 1438 

Martin, R .................................... 287, 1524 

Martin, R J ................................. 729, 1283 

Martin, S .................................... 349, 1084 

Martin, S A ......................................... 875* 

Martinez, J .......................................... 1070 

Martinez-Finley, E J ......................... 1606* 

Martino, J ........................................... 1128 

Martinozzi Teissier, S ......................... 307* 

Marty, M ............................................ 1020 

Marty, M A ................... 1023, 1910*, 1915 

Marty, M S .................. 419, 420, 421, 995, 

1385, 1591*, 1592 

Marty, S ...................................... 181, 610* 

Martyniuk, C J ................................... 1289 

Martínez, C ........................................ 1716 

Martínez, K ........................................ 1816 

Martínez, M ........................................ 1892 

Martínez, M A .................................... 1892 

Martínez-Larrañaga, M R .................. 1892 

Marzin, D ........................................... 1116 

Masashi, T ............................................ 826 

Masiuk, K E ......................................... 671 

Mason, M ........................... 292, 375, 1126 

Mason, R .............................................. 967 

Mason, R A .......................................... 973 

Mason, R J ......................................... 1221 

Massey, E ............................................. 442 

Massey, E D ....................................... 1919 

Massey, T E ........................................ 1229 

Masson, R .......................................... 1314 

Masters, J H ....................................... 2009 

Mastrandrea, N ................................. 1667* 

Masuda, S ............................................. 713 

Masumura, K ........................................ 713 

Matei, A............................................ 1239* 

Matheson, J ............................ 1789*, 1807 

Mathew, L K ...................................... 1468 

Mathew, P ............................................. 366 

Mathews, N .............................. 1509, 1511 

Mathieu, L .............................. 1175, 1192* 

Mathijs, K ............................................ 650 

Matsuda, T ........................................... 713 

Matsumoto, Y ..................................... 1309 

Matsumura, F ............................... 72, 1204 

Matsushita, A ..................................... 1026 

Matsushita, K ..................................... 1026 

Matsuyama, T....................................... 379 

Matt, F ................................................ 1394 

Mattes, W B ....................................... 1071 

Matthew, M T ....................................... 198 

Matthews, H B ................................... 1797 

Matthews, J .................... 1198, 1208, 1649 

Mattie, D .................................... 894, 1383 

Mattie, D R ............................. 1032*, 1171 

Mattison, D R ....................................... 166 

Mattsson, A ........................................ 466* 

Mattuck, R R ...................................... 1935 

Matulka, R A .................................... 1040* 

Mauderly, J L ......................... 1496*, 1509 

Maurer, E.............................................. 372 

Maurer, G ........................................... 1323 

Maurer, J ............................................ 2002 

Maurissen, J P .................................... 1189 

Mauz, A ................................................ 928 

Mauzy, C ................................ 1305*, 1878 

Mawn, M P ........................................... 450 

Maxey, S ............................................. 205* 

Maxwell, G ................................ 476, 1926 

Mayeno, A N ................................ 202, 897 

Mayer, A M .......................................... 757 

Mayer, J .............................................. 195* 

Maynard, A ........................................ 1260 

Mayuko, H ......................................... 826* 

Mazza, A .............................................. 333 

McAlonan, R M ................................... 155 

McAughey, J .......................................... 92 

McBryde, F .......................................... 915 

McCall, D ................................... 100, 1789 

McCall, M .......................................... 2066 

McCallister, M ........................... 171*, 180 



McCallum, G P ................ 705, 708*, 1601 

McCarley, D ....................................... 1808 

McCarthy, A ......................................... 213 

McCarthy, T ......................................... 471 

McCartney, A ................................... 1534* 

McClain, C .............. 743, 786, 1317, 1320, 

1321, 1883 

McClain, C J ........................................ 152 

McClanahan, C L ............................... 1949 

McClean, M ......................................... 644 

McClintock, D .................................... 1514 

McClure, E A ..................................... 145* 

McClure, P ......................................... 1920 

McCluskey, J .......................... 1895, 1953* 

McConkey, D J ................................... 1675 

McConnell, E ..................................... 1024 

McCormick, D L .................... 1045, 1647* 

McCulloh, R J .................................... 1056 

McDiarmid, M ................................... 1880 

McDonald, J ................. 1510*, 1511, 1516 

McDonald, J D ......................... 1496, 1509 

McDonald, J M .................................. 1573 

McDonald, P .............................. 927*, 928 

McDonald, S ...................................... 552* 

McDonnell, D P ..................... 1338, 1339* 

McDonough, J ...................................... 321 

McDonough, J H ........................ 333*, 340 

McDougal, J ....................................... 2099 

McDougal, J N ....................... 1709, 2094* 

McElwee, M K ................................. 1832* 

McEwen, G D .................................... 1858 

McGargill, M A .................................. 1282 

Mcgarrigle, B P .................................. 1237 

McGarrity, L J .................................... 1108 

McGee, S ...................... 1553, 2105, 2106* 

McGill, M R ..................................... 2135* 

McGinnis, C ............................. 425*, 613* 

McGinnis, P ................... 1014, 1028, 1034 

McGinty, D ...................................... 1110* 

McGlumphy, E J ................................ 680* 

McGovern, D ..................................... 1128 

McGrath, P ......................................... 467* 

McGuinn, D W ....................................... 11 

McHale, C .................................. 127, 2202 

McIntosh, L J ........................... 190, 1261* 

McKay, J ............................................ 1126 

McKee, J ........................ 1015, 1016, 1017 

McKee, R H ............................. 698, 1122* 

McKeever, M........................................ 184 

McKernan, R .................................. 47, 50* 

McKim, J M ............................... 199, 1938 

McKim, Jr., J M ........... 105, 111, 113, 492 

McKinney, M ....................................... 855 

McKinney, W ................................... 1495* 

McKinney, W G ................................. 1022 

McKinstry, K T .................................... 799 

McKinzie, P ....................................... 1862 

McKinzie, P B .................................... 1863 

McLanahan, E .................. 894, 1383, 2099 

McLean, L ................................ 469, 1643* 

McLellan, C ..................................... 2218* 

McLellan, C J ..................................... 1912 

McLoughlin, C E ............................. 2181* 

McMahon, C ...................................... 605* 

McMahon, T..................... 938, 1789, 1901 

McMillan, D C ..................................... 905 

McMillan, J M ................................... 905* 

McMullen, G ........................................ 131 

McNamee, P ....................................... 1191 

Mcnaney, C ........................................ 1637 

McNeil, S E .......................................... 791 

McNeill, G ........................................... 840 

McNeish, J D ......................................... 50 

McPhie, G .......................................... 1068 

McShane, M ......................................... 285 

McWilliams, A C ................................. 794 

Meade, B .............................................. 304 

Meade, M L ........................................ 2213 

Medeiros, M K ................................... 955* 

Medina, I M ..................................... 1716* 

Medina-Cortina, H ................................. 24 

Medina-Díaz, I M ................................. 355 

Medina-Díaz, M ................................... 434 

Meecham, K ............................. 601, 1068* 

Meehan, L .......................................... 1906 

Meek, E ...................................... 324, 1897 

Meek, E C .......................................... 242* 

Megill, J ............................................... 117 

Mehendale, H ..................................... 2010 

Mehendale, H M .............................. 2013* 

Mehrotra, S ........................................ 1164 

Mehta, C ............................................... 985 

Mehta, R ........................................... 1957* 

Mehta, V ............................................. 440* 

Mei, N ................... 693*, 694, 1108, 1697, 

1703, 1758 

Meier, W A ......................................... 1330 

Meier-Davis, S ................................. 1563* 

Meighan, T ......................... 119, 257, 2177 

Meijerman, I ....................................... 1088 

Meisenheimer, P ....................... 1094, 1205 

Meisgen, T J ......................................... 701 

Meiss, G ............................................. 1222 

Meissner, K .......................................... 285 

Meistrich, M L ..................................... 289 

Melara, R .............................................. 417 

Melchior, W B ............................ 331*, 332 

Meldrum, B .......................................... 439 

Mellard, D ............................................ 246 

Mellert, W .......................................... 1904 

Melliti, K .............................................. 601 

Melton, R ........................................... 1593 

Meltzer, H .......................................... 2196 

Meltzer, H M ...................................... 1650 

Mendes, O .......................................... 1325 

Méndez-Torres, L B ........... 759, 760, 1474 

Menelaou, E ......................................... 172 

Meng, D ............................................. 1393 

Meng, F .................................. 1862*, 1863 

Meng, R Q .......................................... 929* 

Mensa, J ............................................. 1070 

Mercado Feliciano, M ........................ 396* 

Mercer, R R .......................... 257, 793, 797 

Merchant, J ........................................... 360 

Meredith, C ........................ 92, 442*, 1919 

Merrell, M D ...................................... 1625 

Merrill, J ..................................... 100, 938* 

Mersch-Sundermann, V ......... 1121, 1781* 

Mertens-Talcott, S ................................ 748 

Mets, B D ....................... 244, 1627*, 1628 

Metushi, I ............................................. 448 

Metwally, F M .................................. 2158* 

Metz, B ............................................... 1629 

Metzler, M .......................................... 1461 

Meulenbelt, J ...................................... 1088 

Meunier, J .................... 116, 199, 307, 486, 

496, 498, 501, 504, 890, 891, 1116, 1190, 

2075 

Mexal, S ............................................... 346 

Mexas, L M ...................................... 1271* 

Meyer, J ................................................ 712 

Meyer, J N ...................................... 82, 184 

Meyer, K E ....................................... 1043* 

Meyer, L S ........................................ 1180* 

Meyer, S ...... 379, 1736, 1983, 1984, 1985, 

2192 

Meyer, S A ................................. 348, 2185 

Meyerhoff, J L ...................................... 345 

Meyerhoff, R D .................................. 1450 

Meyvantsson, I ..................................... 755 

Meza-Montenegro, M M ...................... 947 

Michael, A .......................................... 1000 

Michael, D L ........................................ 565 

Michalopolous, G ............................... 1950 

Micheletti, S ........................................... 23 

Mickens, J A ......................................... 406 

Middlemore-Risher, M ..................... 1255* 

Middleton, F A ................................... 2191 

Middleton, K B .................................. 1929 

Mielke, H ........................................... 968* 

316 




Mielke, P W ......................................... 968 

Miettinen, H M ................................... 2061 

Migliaccio, C .......................................... 32 

Migliaccio, C T .......................... 583*, 735 

Mihai, G ............................................. 1507 

Mikaelian, I ........................................ 1308 

Mikaelian, R ....................................... 925* 

Milano, J .......................... 53, 1641*, 1642 

Milano, S ............................ 603, 604, 940* 

Milash, B ............................................ 1713 

Milatovic, D .................... 998*, 999, 1263, 

1277, 1839, 2038 

Milburn, M ....................................... 2214* 

Milchak, L .......................................... 1788 

Milchak, L M ................................... 1118* 

Milcova, A ............................................ 718 

Milius, A ............................................ 856* 

Millender-Swain, T ............................ 1632 

Miller, A ....................................... 66*, 354 

Miller, D ............................................... 323 

Miller, D B ....................... 587, 1261, 1272 

Miller, D M ............................ 1409, 1666* 

Miller, D S .......................................... 1210 

Miller, E ............................................... 740 

Miller, E R ............................................ 609 

Miller, G W ........................................ 1293 

Miller, J .............................................. 1706 

Miller, J A .......................................... 1285 

Miller, J M .......................................... 1695 

Miller, K ....................................... 512, 719 

Miller, L ..................................... 859, 863* 

Miller, M ............................................ 1910 

Miller, P E .......................................... 1056 

Miller, R T .................................... 183, 769 

Miller, V M ........................................ 1280 

Miller, W ............................................ 1218 

Millington, D J ................................. 1048* 

Mills, J H ............................................ 2191 

Mills, L J ............................................ 431* 

Milner, V .............................................. 601 

Min, E ................................................ 1524 

Minai-Tehrani, A ................................ 1399 

Minard, K ............................................. 870 

Minard, K R ................................. 871, 939 

Minet, E ................................................ 442 

Ming, M ............................................... 673 

Mingoia, R ........................................... 820 

Minnier, B L ............................... 204, 2074 

Minowa, Y ................................ 191, 2078* 

Minsavage, G D ................................... 508 

Mirajkar, N ......................................... 2014 

Mirallas, O ......................................... 1286 

Mire-Sluis, A ...................................... 1007 

Mirsalis, J C ....................................... 1582 

Mirsky, M ....................................... 25, 26* 

Miró, Ò ........................... 1070, 2117, 2121 

Mishin, V...................................... 765, 987 

Mishra, A.................................... 797, 800* 

Mishra, R K ........................................ 1241 

Misko, T ............................................. 1076 

Misner, D.................................. 1738, 1739 

Misra, H P .................................. 709, 2190 

Misra, M ................................. 1312, 1316* 

Mistry, P ............................................. 1598 

Mitchard, T........................................... 832 

Mitchell, A ........................................... 605 

Mitchell, C ......................................... 1220 

Mitchell, K ......................................... 1206 

Mitchell, K A ................. 1534, 1537, 1949 

Mitchell, L .......................................... 1516 

Mitchell, M D ................. 1065, 1075, 1076 

Mitchell, N ....................... 970, 1161, 1458 

Mitchell, N J ..................................... 1160* 

Mitchell, V L .................................... 1936* 

Mitcheltree, L W .................................. 344 

Mitra, M S ............................ 1360*, 1737* 

Mitsunaga, K ........................................ 864 

Mittelstadt, S ...................................... 1810 

Miura, N ........................................... 1829* 

Miura, Y ....................................... 35, 1548 

Miyagawa, M ..................................... 2086 

Miyajima-Tabata, A ........................... 864* 

Miyamoto, Y ...................................... 1309 

Mo, Y ....................................... 368*, 2071 

Mobio, T............................................. 1462 

Mobley, S ........................................... 2220 

Mock, J N ........................................... 519* 

Modi, J ..................................... 1738, 1739 

Moeller, T ........................................... 1094 

Moen, M A ........................................... 232 

Moesen, E ............................................ 816 

Moffett, D............................................. 892 

Moffett, D B ....................................... 878* 

Moffit, J S................................................. 7 

Moggs, J ............................................. 1662 

Moghe, A............................................ 152* 

Mohrman, M ...................................... 2197 

Mokashi, V ................................. 328, 1031 

Mokashi, V P .............................. 934*, 991 

Moland, C L ....................................... 1644 

Moldeus, P ........................................... 15* 

Mole, J .................................................. 208 

Molgaard, S .......................................... 920 

Molina, D ........................................... 1120 

Molina, L T .......................................... 254 

Molina, R ............................................. 278 

Molinier, B ........................................... 189 

Mollenhauer, M ........................ 1554, 2189 

Mollerup, S .......................................... 736 

Molm, R ............................................... 357 

Moman, E ........................................... 1105 

Momot, D ........................................... 1119 

Mongan, A ................................ 1962, 2084 

Mongan, M ....................................... 2077* 

Monks, T J.......................... 518, 780, 1667 

Monnot, A .................................. 984, 1365 

Monnot, A D ............................ 983*, 2163 

Monteil, C .............................................. 80 

Monteiro Riviere, N ............................. 258 

Monteiro-Riviere, N A ........ 259, 284, 801, 

1702, 2067, 2068* 

Monterrey, J C ...................................... 674 

Montiel-Flores, E ............................... 1292 

Montoya, J .......................................... 1070 

Montoya, L A ..................................... 132* 

Montoya-Durango, D E ..................... 150* 

Moody, R P ...................................... 2048* 

Moon, B ............................................. 1055 

Moon, S J ........................................... 1484 

Moon, Y ......................................... 60, 746 

Moore, A B........................................... 413 

Moore, A J .......................................... 1532 

Moore, C ................................ 1097*, 1098 

Moore, E ............................................ 1404 

Moore, J ............................................... 430 

Moore, M ................................. 1697, 1703 

Moore, M M ..... 692, 693, 694, 695, 1355* 

Moore, N ...................................... 397, 836 

Moore, R W ................................ 844*, 861 

Moore, S A ........................................... 601 

Moore, T............................................. 2154 

Moore, T M .............................. 1015, 1017 

Moore, W M ....................................... 1076 

Moorthy, B ........... 457*, 1778, 2000, 2120 

Moos, P ................................................ 763 

Moos, P J ............................................ 265* 

Morakinyo, M K .................................. 490 

Morales, M ......................................... 1070 

Morales-Rivero, A .............................. 2169 

Moran, T............................................... 273 

Mordasky Markell, L ......................... 671* 

More, V R......................................... 1624* 

Morefield, S ....................................... 1808 

Morelle, D .......................................... 1054 

Morelli, J ............................................ 1063 

Moreno, A J ........................................ 1731 

Moreno, J A ........................................ 1296 

Morgan, D L ........................... 1490, 1492* 

Morgan, K .......................................... 1325 

Morgan, L............................................. 477 



Morgan, R .......................................... 1962 

Morgan, R E ..................................... 1051* 

Mori, Y ............................................... 1736 

Morici, L A........................................... 326 

Moriishi, M ........................................ 1811 

Morin, J .............................................. 480* 

Morishige, T ......................................... 290 

Morishita, M ...................................... 1505 

Moro, S .................................. 1137, 1138* 

Morris, D L .................... 1075, 1076, 1077 

Morris, J ............................................. 2016 

Morris, J B ................. 1491*, 1494, 2019* 

Morris, S M .................................. 166, 689 

Morse, M ............................................ 1554 

Mortensen, H ...................................... 212* 

Morton, D ........................................... 1921 

Morton, J .............................................. 135 

Morén, C ...................... 1070, 2117, 2121* 

Moscardo, E ....................................... 1068 

Moseley, A E ...................................... 1506 

Moser, G J .......................................... 400* 

Moser, J .............................................. 1012 

Moser, V C ......................................... 1913 

Mosher, M .................................... 597, 598 

Mosley, R ............................................. 905 

Moss, E .............................................. 1735 

Moss, O ................................................ 934 

Moss, S ..................................... 1962, 2077 

Mossman, B ......................................... 739 

Mossman, B T .................................... 1553 

Mota, L C ......................................... 2148* 

Mouche, I ............................................. 681 

Moukha, S .......................................... 1462 

Mouksassi, S .................................... 1583* 

Moulin, F............................................ 1273 

Moulin, P............................................ 1643 

Mounho, B ............................... 615*, 616* 

Mourey, R............................................. 625 

Mouser, E ............................................. 294 

Moyer, B J ........................................ 1485* 

Moyer, P ............................................. 1721 

Muckle, G .................................... 892, 893 

Mueller, A .......................................... 1662 

Mueller, L ................................... 551, 1125 

Muenyi, C S ..................................... 2009* 

Mugabe, B ............................................ 213 

Muhammad, F .................................. 1891* 

Muhammed, M ..................................... 291 

Muijser, H ................................ 367*, 1398 

Muir, R ............................................... 1396 

Mukai, Y ............................................... 290 

Mukerji, P .......................................... 1147 

Mukhamedova, M .................................. 53 

Mukherjee, B ...................................... 1505 

Mukherjee, S ...................................... 1972 

Mukhopadhyay, S............................... 1269 

Mulder, P ................................................ 80 

Mulderij, M .......................................... 367 

Muldoon, D B ...................................... 126 

Mulla, M A ..................... 700*, 1027, 1066 

Müller, R .............................................. 291 

Mullins, D .......................................... 1745 

Multu, E ............................................... 238 

Mumtaz, M ........... 246*, 879*, 1029, 1808 

Mumtaz, M M ...................................... 209 

Mumy, K L ........................................... 427 

Mun, G ................................................. 472 

Mundy, W ............................................. 170 

Mundy, W R ............... 156, 164, 263, 1389 

Munkvold, G ...................................... 1167 

Munley, S M ..................................... 1148* 

Munsey, K M...................................... 1056 

Munson, J ........................................... 1707 

Munson, J W ........................................ 972 

Murai, T ............................................. 1098 

Muralidhara, S ............................ 812, 1565 

Murdoch, J ......................................... 1000 

Murdock, R C ................................... 1693* 

Murillo, M ........................................ 1987* 

Murli, H ................................................ 688 

Murphy, C .......................................... 1448 

Murphy, C J ........................................ 1056 

Murphy, K ............................................ 643 

Murphy, M ......................................... 1847 

Murray, A ..................................... 599, 799 

Murray, A R ....................... 270*, 271, 793 

Murray, E ............................................. 666 

Murray, I A ....................................... 1197* 

Murray, S ............................................ 988* 

Murray, T F ........................................ 1165 

Mus, M ............................................... 1185 

Muse, W ............................................... 323 

Musgrove, D ........................................... 70 

Mutanguha, E M .............................. 1232* 

Muthumalage, T ............................... 1855* 

Muzquiz, L I ......................................... 357 

Muzzio, M ...................... 1045, 1647, 2166 

Muñiz Ortiz, J G .................................. 262 

Myers, C B ................................. 396, 2108 

Myers, D ............................................ 1261 

Myers, M ............................................ 1862 

Myers, M B ...................................... 1863* 

Myers, P A ......................................... 1936 

Myers, T M ........................................ 340* 

Myhre, A ............................................ 1401 

Mynhier, A ................................... 173, 175 

N 

Nabb, D .............................................. 820* 

Nabb, D L ............................................. 450 

Nachman, R ........................................ 1459 

Naciff, J M ........................................... 97* 

Nadadur, S S........................................... 6* 

Nadai, M .............................................. 789 

Nadanaciva, S ............... 81, 94*, 95, 1426* 

Naganuma, A ............ 722, 723, 1822, 1837 

Nagaoka, S ......................................... 1180 

Nagaosa, R ........................................... 391 

Nagarkatti, M ...... 76, 144, 731, 756, 1527, 

1529, 2195* 

Nagarkatti, P ............... 76, 144, 731, 756*, 

1527, 1529, 2195 

Nagata, R ................... 379, 403, 922, 1026, 

1736, 1983, 1984, 1985, 2192 

Nagata, T ...................................... 161, 178 

Nagatsuka, S ...................................... 906* 

Nagy, T ................................................... 78 

Nail, C A ............................................ 837* 

Nair, S ................................................ 1145 

Nakagawa, S ......................................... 290 

Nakagawa, T ............................ 448*, 2124 

Nakajima, M .......................................... 77 

Nakamura, B N .................................. 382* 

Nakamura, K ...................................... 707* 

Nakamura, M ....................................... 101 

Nakamura, T......................................... 922 

Nakanishi, J .......................................... 788 

Nakatsu, N .................................. 191, 2078 

Nakayama, H ........................................ 445 

Nakayasu, E S ...................................... 769 

Nakazawa, K ........................................ 864 

Nalini, R ............................................... 898 

Nallapaneni, A .................................... 326* 

Namork, E ................................ 1650, 1996 

Nan, P ................................................. 1860 

Napierska, D H ................................... 268* 

Napodano, R J .................................... 1115 

Napoléoni, J ....................................... 1727 

Naquet, P ............................................ 2131 

Naraindas, N .................................... 1840* 

Narasimha, M K ................................. 898* 

Narayanan, G ..................................... 1197 

Narayanan, P ............................ 1676, 2077 

Nardoni, C .............................................. 23 

Narducy, K W ..................................... 1048 

Narotsky, M G .................................... 1685 

Nascarella, M ................................... 1942* 

Nascarella, M A ................................. 1922 

Nash, J .................................................. 471 

Nash, J R ............................................ 104* 

Author Index 



Author Index 


Nashed-Samuel, Y .............................. 1007 

Nass, R ............................... 611, 994, 1290 

Nataraj, P .............................................. 500 

Natsch, A ............................................ 108* 

Naughton, B A ............... 1661, 1966, 1967 

Navas-Acien, A .................................. 572* 

Naven, R T ......................................... 186* 

Naya, M ...................................... 391, 788* 

Nazarius, L ......................................... 1674 

Ndifor, A .............................................. 417 

Neal, B H ................... 228, 419, 420*, 421 

Nealley, E ....................................... 66, 354 

Nebert, D W ....................................... 1720 

Nederlof, R ......................................... 1388 

Needham, L .......................................... 560 

Needham, L L ...................................... 640 

Neely, W W .......................................... 245 

Negga, R........................................... 1286* 

Negri, S .............................................. 2186 

Neider, M W ....................................... 1056 

Neilsen, B S ......................................... 418 

Nelissen, I .................................. 107, 1306 

Nelms, L ........................................... 1655* 

Nelson, A............................................ 1181 

Nelson, C .......................................... 1713* 

Nelson, M ................................... 979*, 981 

Nemery, B .......................... 268, 299, 1701 

Nemeti, B ............................................. 946 

Nerland, D E ...................................... 1848 

Nesnow, S ........................................... 2154 

Nesslany, F ......................................... 1116 

Neu, N ................................................ 1280 

Neun, B S ............................................. 791 

New, L ............................ 1661, 1966, 1967 

Newhard, W ......................................... 106 

Newhouse, K ........................................ 630 

Newman, D R ..................................... 1828 

Newport, G D ....................... 163, 281, 796 

Newton, J ........................................... 1654 

Newton, P E ......................................... 508 

Ng, S .................................................. 1976 

Ng, S P ............................................. 2193* 

Ng, W ................................................. 314* 

Ngalame, N O .................................... 1430 

Ngaotepprutaram, T ......................... 1525* 

Nguyen, A ............................................ 417 

Nguyen, K T ................... 332*, 1152, 1153 

Nguyen, T A ..................................... 1085* 

Nguyen, V .......................................... 1095 

Ni, M ........................................ 999, 1839* 

Niaz, M S ............................................. 535 

Nichols, A C ..................................... 1836* 

Nichols, H .................... 1683, 1684, 1685* 

Nichols, J W ..................................... 1449* 

Nicklaus, R ......................................... 1308 

Nicol, C J ........................................... 2004 

Nicolich, M J ............................ 698*, 1122 

Nicolàs, M ...................... 1070, 2117, 2121 

Niculescu, M ........................................ 971 

Nie, G ................................................... 256 

Nie, H L ........................................... 1884* 

Niedzwiecki, A ........................... 674, 2003 

Nieminen, A ......................................... 770 

Niggeweg, R ....................................... 1948 

Nijmeijer, S .............................. 1088, 1779 

Ninomiya, S ......................................... 906 

Nipwoda, M ......................................... 354 

Nirogi, R .......................... 700, 1027, 1066 

Nishida, Y ............................................. 403 

Nishijima, M ...................................... 1460 

Nishimura, K ........................................ 829 

Nishimura, T .......................... 1397, 1402* 

Nishimura, Y .......... 35, 1546, 1547*, 1548 

Nishiyama, N ....................................... 301 

Niu, J .................................................... 441 

Nocairi, H ................................... 199, 2075 

Noda, M ............................................. 1279 

Noguera, A ......................................... 2121 

Noh, J ..................................... 1217*, 1838 

Nohmi, T .............................................. 713 

Nohynek, G ........................................ 1179 

Noker, P E ................................ 1585, 1586 

Nolan, K B ......................................... 1105 

Nomura, T ............................................ 911 

Nong, A ................................................ 884 

Noratto, G D ....................................... 748* 

Norberg, E ................................ 1422, 1425 

Norbäck, D ........................................... 664 

Nork, T M .......................................... 1056 

Norppa, H ........................................... 266* 

North, C .............................................. 632* 

North, C M ........................................... 145 

North, M ............................. 115, 127, 2037 

Norton, K ................................. 606, 2119* 

Note, R R ................................. 199*, 2075 

Novak, P ............................................. 1625 

Novalen, M ......................................... 449* 

Nugyen, V ............................................ 699 

Nuhar, A ............................................... 982 

Nukada, Y ........................................... 301* 

Nurkiewicz, T R ............... 261, 1728, 1730 

Nussbaum, J ....................................... 1067 

Nuth, A ................................................. 482 

Nuti, F ................................................ 1470 

Nyberg, J ............................................ 1173 

Nygaard, U ......................................... 2196 

Nygaard, U C ............... 1650, 1996, 2180* 

Nylander French, L A ........... 1328, 1329*, 

1861, 1864 

Nyska, A ................................... 1033, 1500 

O 

O’Brien, B M ........................... 1587, 1589 

O’Brien, P J ........................................ 1957 

O’Brien, W ......................................... 1874 

O’Callaghan, J P ............ 587, 1261, 1272* 

O’Connell, T M .......................... 364, 1654 

O’Connor Butler, E S ......................... 1669 

O’Connor, M .................................... 2132* 

O’Day, C ............................................ 1754 

O’Donnell, J ......................................... 323 

O’Donnell, L M ....................... 935*, 1981 

O’Driscoll, C ........................................ 790 

O’Gara, B A ......................................... 996 

O’Hagan, S ......................................... 2096 

O’Hara, J .............................................. 288 

O’Hara, T ........................................... 1128 

O’Keefe, R J ....................................... 1196 

O’Leary, E ............................................ 821 

O’Loughlin, K .................................. 1582* 

O’Mara, D J ....................................... 1168 

O’Neal, C ............................................. 436 

O’Neill, A J ........................................ 493* 

O’Reilly, M A ....................................... 710 

O’Shaughnessy, P T ............................. 370 

O’Shea, S H ....................................... 201* 

O’Toole, T E............................. 1166, 1687 

Obach, R .............................................. 17* 

Obama, T ............................................ 1402 

Oberdoerster, J ....................... 1273, 1281* 

Oberdörster, G .................................... 1970 

Obert, L ............................ 679, 1303, 1655 

Obinaju, B ........................................ 2006* 

Obirek, J ............................................. 1048 

Ochs, S ............................. 71, 1536*, 1540 

Odin, J A ............................................ 1974 

Ogawa, M ............................................. 910 

Ogawa, T .................................... 161, 178* 

Ogle, J ................................................ 1736 

Oh, M ................................................. 1651 

Ohhira, S ............................................ 1605 

Ohkubo, S .......................................... 1309 

Ohlsson, ............................................ 2097 

Ohno, Y ...................................... 191, 2078 

Ohsako, S ............................................. 146 

Ohtani, K ............................................ 1108 

Ojo, S A ................................................ 989 

Okada, N .............................................. 290 

Okuda, K ............................................ 1811 

Okuno, Y .................................... 191, 2078 



Olabisi, A ............................................. 328 

Olabisi, A O ......................................... 934 

Oladipo, O O ...................................... 989* 

Olaharski, A J ......................... 187*, 1125* 

Oldenburg, S J ...................................... 281 

Oleksiak, M F ....................................... 231 

Olgun, N S ......................................... 422* 

Oliveira, M C ....................................... 507 

Oliveira, P J ........................................ 1731 

Olivera, D S ........................................ 344* 

Olivero, O A ....................................... 1119 

Olivero-Verbel, J ................................ 1899 

Olivier, K J ....................................... 1050* 

Oller, A ............................................... 1800 

Oller, A R ........................................... 1794 

Olmsted, R ......................................... 2186 

Olovsson, M ......................................... 456 

Olsen, G W ....................... 407, 1585, 1586 

Olson, G ............................................. 1140 

Olson, J ................................................ 238 

Olson, J J ............................................ 1868 

Olson, J R ...................... 1201, 1237, 1240, 

1243, 1263*, 1894 

Olson, M .................................... 102, 1804 

Omaye, S .............................................. 609 

Omaye, S T ........................................ 385* 

Omerza, J ........................................... 1988 

Omiecinski, C J .............. 1104, 2146, 2147 

Ondovcik, S L ............................ 705*, 708 

Oneda, S ........................... 379*, 842, 2192 

Ong, C N .............................................. 812 

Ono, A ................................ 101, 191, 2078 

Ono, M ............................................... 1180 

Onyeyili, P A ...................................... 1058 

Ooshima, Y ................................. 403, 1026 

Opanashuk, L ..................................... 1970 

Opel, M ................................................ 641 

Ophir, A .............................................. 1264 

Oppermann, U ...................................... 595 

Opresko, P L ........................................ 677 

Orak, D ................................................. 491 

Ordoñez-Librado, J .......................... 1292* 

Oreskovic, T L ................................. 2070* 

Orlova, V V .......................................... 595 

Orndorff, P E ...................................... 1702 

Orogo, A M ........................................ 204* 

Orr, G ................................................... 280 

Orr, G A .............................................. 275* 

Orrenius, S ............................. 1422, 1425* 

Ortega-Cervantes, L ............................. 434 

Orth, J ................................................. 1046 

Ortiz, L ................................. 31*, 382, 599 

Ortiz-Martínez, M G .......................... 759* 

Orton, C R .......................................... 1098 

Oruganti, M ........................................ 1089 

Osborn, L V .......................................... 508 

Oshima, R .......................................... 2002 

Oshiro, W ............................................. 888 

Oshiro, W M ...................................... 159* 

Oshunwusi, T ....................................... 126 

Oskarsson, A ............................ 466, 2097* 

Osornio Vargas, A R ............................. 254 

Osterburg, A ....................................... 328* 

Otieno, M ......................... 720, 1656, 1658 

Otsubo, Y ............................................. 922 

Otsuki, T................. 35*, 1546, 1547, 1548 

Ott, M ................................................... 816 

Ottinger, S ........................................ 1084* 

Ottlinger, M E .................................. 1414* 

Otto, M ....................................... 862, 1980 

Oukka, M ........................................... 537* 

Ouyang, N .............................. 1688, 2157* 

Ouyang, X .......................................... 774* 

Ouédraogo, G ......... 116, 199, 1116*, 2075 

Ovechkina, Y ...................................... 1754 

Overmann, G J ....................................... 97 

Overocker, J ........................................... 34 

Overturf, C ......................................... 459* 

Ovesen, J L ....................................... 1209* 

Ovigne, J .................................. 1190, 1926 

Øvrevik, J ................................. 736*, 2176 

Owen, M .............................................. 847 

Ozer, J S ........................................... 1444* 

P 

Pace, W .............................................. 447* 

Pacheu-Grau, D .................................. 1070 

Pack, D ............................................... 2177 

Padilla, S .... 165, 463*, 1390, 2023, 2025* 

Padmanabhan, S ................................. 1582 

Padnos, B ..................................... 165, 463 

Paepke, O ............................................. 641 

Pagan-Rodriguez, D ............................. 642 

Pai, R .................................................. 1062 

Painter, G R ........................................ 1057 

Painter, J ............................................... 591 

Paisley, S .............................................. 688 

Palate, B ............................................. 1074 

Palkar, P S ........................................ 2143* 

Palmeira, C ............................................. 10 

Palmer, L E........................................... 655 

Palmer, S M ........................................ 1490 

Pamela, R K ......................................... 201 

Pamies, D ............................................. 833 

Pan, J ........................................ 1061, 1393 

Pande, P ................................................ 200 

Pandey, S K ........................................ 1027 

Pang, Y ............................................... 1241 

Panko, J M.......................................... 1851 

Panter, G ............................................. 2096 

Panyik, M A ....................................... 1077 

Pape, W W.............................................. 91 

Papini, A ............................................. 1470 

Pappa, A ............................................... 595 

Paquette, M ...................................... 1714* 

Paranjpe, M ...................................... 1082* 

Paranjpe, M A .................................. 1622* 

Parchment, R E .......................... 481, 1406 

Pardus, M ....................... 2164, 2165, 2166 

Parent, R ................................................. 3* 

Parente, C ........................................... 1083 

Parham, F M ....................................... 1202 

Parinandi, N L .......................... 1500, 1669 

Paris, M .............................................. 1806 

Parish, J ................................................ 903 

Park, E ........................................ 730, 1680 

Park, H ................................... 1651, 1775* 

Park, J ...................... 737, 808, 823*, 1217, 

1668, 1771, 1772, 1888, 1889* 

Park, K ............................................... 730* 

Park, K W ........................................... 1696 

Park, P J................................................ 855 

Park, S .................. 60*, 1177, 1561*, 1700 

Park, Y ...................................... 817*, 1680 

Parker, A ................................... 1006, 1793 

Parker, C ............................................... 48* 

Parker, C K ............................................. 47 

Parker, C M .......................................... 508 

Parker, J .............................................. 1654 

Parker, R M .................. 2109, 2110, 2111* 

Parkinson, C U ................................... 1171 

Parrinello, G ........................................... 23 

Parrish, A R .......................................... 822 

Parry, J D ............................................ 1756 

Parsons, B................................. 1862, 1936 

Parsons, B L ....................................... 1863 

Partridge, C ........................................ 1876 

Pass, M ............................................... 1724 

Patel, H J .............................................. 422 

Patel, K ................................................. 336 

Patel, K J .............................................. 350 

Patel, M .............................. 764, 784, 1883 

Patel, N ............................................... 757* 

Patel, P ....................................... 469, 1643 

Patel, R ............................................... 1293 

Patel, S ................................................. 519 

Patel, T ......................................... 482, 749 

Pathi, S ............................................... 515* 

Patisaul, H B ........................................ 406 

Patlolla, A ........................................... 805* 

318 




Patlolla, R R ......................................... 483 

Patouillet, C .......................................... 891 

Patskan, G .......................................... 1853 

Patten, R ............................................. 1261 

Patterson, J ............................. 1797*, 1930 

Patterson, T .......................... 169, 179, 845 

Patterson, T A ............................. 166*, 865 

Patton, W F......................................... 200* 

Paul, D S .............................................. 963 

Paul, K B .......................................... 2104* 

Paul, N ................................................ 2122 

Paul, S .................................................. 120 

Paule, M ............................... 169, 179, 845 

Paule, M G ... 163, 166, 281, 796, 798, 865 

Paules, R S ................... 1654, 2198, 2200* 

Pauley, M L .......................................... 126 

Paulose, T ........................................... 395* 

Paulsen, D .......................................... 1521 

Paustenbach, D J ........................ 124, 1851 

Payne, R ............................................... 282 

Pazos, P ................................................ 101 

Peachee, V .......................................... 1189 

Peachee, V L ............................ 1523, 2188 

Peake, E ................................................ 601 

Peake, G ............................................... 601 

Pearson, C I ............................ 1661*, 1967 

Peat, T J ...................................... 523, 524* 

Peay, T S ...................... 1015*, 1016, 1017 

Pechacek, N ............................ 1176*, 1788 

Pechenevsky, Y ................................... 1866 

Peck, E C ............................................ 455* 

Peden, W M .......................................... 930 

Peden-Adams, M M ............... 1554*, 2189 

Pedersen, J .......................................... 2065 

Pei, X ...................................... 1483, 1541* 

Peifley, K .............................................. 791 

Pellizzon, M A ......................... 974, 1157* 

Peltonen, K ....................................... 1150* 

Pendlington, R...................................... 476 

Peng, L ..................................... 1241, 1325 

Peng, S ................................... 1248*, 1753 

Penn, A ....................................... 685, 1521 

Penner, J D ........................................... 929 

Penniks, A H ........................................ 841 

Penning, T M................................ 452, 453 

Pennings, J L ...................................... 1689 

Pennington, K L ......................... 516, 1300 

Penninks, A H .................................. 1980* 

Penny, J .............................................. 1598 

Penttinen Damdimopoulou, P E ........... 408 

Perantoni, A O .................................... 1679 

Perdew, G ........................................... 1197 

Perdew, G H ..................................... 2204* 

Pereira, C V ........................................ 1731 

Pereira, G C ...................................... 1731* 

Pereira, S P ......................................... 1731 

Peretz, J ...................................... 383*, 398 

Perez, P ................................................ 496 

Pérez-Lorenzo, R ................................. 671 

Perez-Polo, J ...................................... 1218 

Perkins, E J ....................................... 1447* 

Perkins, J ................................................ 92 

Perlmutter, J M ..................................... 794 

Permin, A ............................................. 418 

Perpetua, M ...................................... 1992* 

Perron, J ................................. 1185*, 1186 

Perry, E ............................................... 1038 

Perry, M ................................................ 502 

Perry, M R .................................. 923, 931* 

Persad, A S ....................................... 1925* 

Persaud, R .......................................... 1179 

Pershouse, M A .................................. 357* 

Perveen, Z ........................................ 1521* 

Pessah, I ................................................. 72 

Pessah, I N ........................................... 177 

Pestka, J .................................... 1143, 1463 

Pestka, J J ..... 827, 1215, 1216, 1784, 1785 

Petal, K ............................................... 1655 

Peter, B ............................................... 1194 

Peter, H ............................................... 1552 

Peters, A M............................. 1409*, 1666 

Peters, D ................................... 1318, 1744 

Peters, D G ....................................... 1330* 

Peters, J M ...................... 2142, 2143, 2144 

Petersen, D R ... 779, 780, 787, 1631, 1635 

Peterson, M ........................................ 2102 

Peterson, N T...................................... 2004 

Peterson, R E ............... 235, 386, 440, 682, 

844, 861, 2065 

Peterson, S ............ 883, 1127, 1386, 1843* 

Peterson, S D ........................................ 882 

Peterson, T ........................................... 414 

Petrikovics, I .............. 337, 338*, 339, 349 

Petroni, D ......................................... 1295* 

Petroni, D H ....................................... 1294 

Petry, T ............................................. 1794* 

Pettan-Brewer, C ................................ 135* 

Pettit, A P ......................................... 1857* 

Pettit, S ............................................... 1314 

Pettit, S D ................................. 41*, 44, 45 

Peyret, T ..................................... 250, 880* 

Pfannenbecker, U ............................... 1191 

Pfau, J ................................................... 312 

Pfau, J C ............................................... 34* 

Pfeifer, R W........................................ 1061 

Pfeiffer, E ........................................... 1461 

Pfister, T ............................................. 1052 

Phadnis, A S ......................................... 73* 

Pham, E .............................................. 1314 

Pham, R .............................................. 1962 

Philbrook, N A ................................... 849* 

Phillip, O S ......................................... 436* 

Phillipps, K .............................. 1018, 1918 

Phillips, J D .......................................... 454 

Phillips, K M ...................................... 1756 

Phillips, P M............................... 916, 1247 

Phillips, R D ....................................... 1488 

Phillips, T ............................................. 970 

Phillips, T D .................. 1160, 1161, 1457, 

1458, 1459 

Phonethepswath, S ....................... 690, 691 

Pi, J ............................................. 573*, 962 

Piao, Y ...................................... 1430, 1719 

Piccotti, J R ............................ 1982*, 1987 

Pickin, R R ......................................... 2145 

Piehl, M .............................. 474, 479*, 485 

Pierce, J T ............................................. 926 

Pierce, W M ....................................... 1848 

Piersma, A H .............................. 841, 1689 

Pieters, R ................... 293, 294*, 295, 317, 

538*, 2183 

Pieters, R H ........................................ 1550 

Pike, S ................................................ 1528 

Pilcher, G.............................................. 930 

Pillai, S D ............................................. 435 

Pine, P S ............................................. 1318 

Pinkerton, K E .......................... 1473, 1632 

Pinnavaia, T J ..................................... 1997 

Pinós, T .............................................. 1070 

Pirnstill, S C ......................................... 500 

Pitsch, R ............................................. 1305 

Pitt, B ................................... 597, 598, 599 

Pitt, J ................................................ 1499* 

Pittet, S ............................................. 1207* 

Pk, S ................................................. 2064* 

Plahovinsak, J L ......................... 923, 924* 

Planel, E ............................................. 496* 

Platz, S ............................................... 1052 

Pletcher, M ............................. 1334*, 1657 

Pletcher, M T ........................................ 365 

Plewa, M J ............................................ 247 

Ploypradith, P ..................................... 1779 

Plummer, L E ................................... 1473* 

Plummer, S M ........................ 1488*, 2156 

Plusquellec, P ....................................... 893 

Poapolathep, A ........................... 444*, 445 

Poapolathep, S ............................ 444, 445* 

Pöch, G ......................... 248, 251, 252, 253 

Poeltl, D ............................................. 1270 

Poerschke, R ...................................... 763* 



Poet, T .............................................. 1385* 

Poet, T S ........................... 896, 1599, 1887 

Pognan, F ........................... 469, 761, 1662 

Pogribny, I ................................ 971, 1347* 

Pogribny, I P ......................................... 148 

Pohl, J ................................................. 1423 

Pohl, O ............................................... 1729 

Pohlmann, G ...................................... 1169 

Poirier, M C ...................... 131, 1119, 1743 

Politano, V.......................................... 1111 

Politano, V T ........ 401*, 1011, 1109, 1110 

Pollard, C ......................................... 42, 43 

Pollard, C E ........................................ 1081 

Pollenz, R S ........................................ 1200 

Polsinelli, G A .................................. 1241* 

Polyn, M ............................................. 1116 

Polzin, G M .......................................... 694 

Pomeroy-Black, M J ........................ 1262* 

Pometto, A L ...................................... 1167 

Pompei, F ........................................... 1947 

Ponce, E ............................................. 1534 

Ponce, R ............................................. 540* 

Ponce, R A ............................................... 4 

Ponzi, C .............................................. 932* 

Poole, A ................................................ 397 

Poon, E ............................................... 155* 

Poon, J C .............................................. 859 

Pope, C N ......................................... 2014* 

Popichak, K A .................................. 1285* 

Popp, J A ............................................ 661* 

Porter, K ........................................... 1730* 

Porter, V ............................................... 583 

Portier, C ............................................ 1164 

Portier, C J ................................ 1202, 1927 

Portsmouth, C .................................... 476* 

Post, G B ............................................ 1941 

Postlethwait, E ..................................... 870 

Poth, A H .......................................... 1124* 

Potter, D ............................................... 244 

Poulin, P ............................................... 880 

Poulsen, K L ..................................... 2125* 

Poulsen, M ........................................... 892 

Pounds, J .............................................. 280 

Pounds, J G ........ 59, 751, 752, 1327, 1854 

Powe, D K ........................................ 1903* 

Powell, E .............................................. 968 

Powell, J ................................. 2034, 2035* 

Powell, S ............................................ 1724 

Powers, B E .......................................... 155 

Powers, C M ..................................... 1612* 

Powers, K ........................................... 1707 

Powers, M .......................................... 1964 

Powley, M W ...................................... 2206 

Prabhakaran, K ................................... 990* 

Prakhya, B .......................................... 1283 

Prasad, R Y ......................................... 262* 

Pratt, M M ............................................ 131 

Pratt, N ........................... 1983, 1984, 1985 

Preau, J ................................................. 560 

Pregenzer, J F ....................................... 380 

Pregenzer, J P ..................................... 113* 

Preiss, A ............................................. 1169 

Prell, R ............................................... 1044 

Prestwich, G D ..................................... 613 

Preterre, D ............................................ 480 

Prevete, K ........................................... 1987 

Price, A ................................................. 170 

Price, B ................................................. 110 

Price, C ............................................... 1073 

Price, C J .............................................. 396 

Price, H C ................................. 1490, 1492 

Price, J ...................................... 502*, 1969 

Price, K .............................................. 1994 

Price, L B ............................................. 667 

Price, O T ............................................. 869 

Price, P S .......................... 565*, 570*, 896 

Price, S R ........................................... 1677 

Priem, S .............................................. 1577 

Prieto, P .............................................. 114* 

Prince, R B ......................................... 1118 

Pringle, R ........................................... 324* 

Prinsen, M .......................................... 1054 

Prinssen, E .......................................... 1052 

Prioleau, C .......................................... 1790 

Priston, R.............................................. 109 

Pritsos, C A ........................................ 1855 

Pritsos, K L ........................................ 1855 

Proctor, D ............................... 1909*, 1939 

Proctor, S P .............................. 1301, 1881 

Prokofieva, D ..................................... 1866 

Prokoudine, A .................................... 1646 

Pronk, T E .......................................... 1689 

Proscura, E ........................................... 494 

Prozialeck, W ........................... 1823, 1824 

Prozialeck, W C ................................... 806 

Pruett, S ................................................ 631 

Pruett, S B .......................................... 1543 

Pruthi, S.............................................. 1885 

Pu, H .................................................... 233 

Pu, X .................................................. 526* 

Pucheu-Haston, C .................... 298, 1302* 

Puga, A ............................................... 1209 

Purbrick, S .......................................... 601* 

Puri, K D ............................................ 1060 

Putnam, E ........................................... 933* 

Putnam, E A ......................................... 357 

Putt, D A............................................... 813 

Pyatt, D .............................................. 1852 

Pylkkänen, L ........................................ 260 

Pyrah, I ............................................... 2084 

Q 

Qamar, S ............................................... 188 

Qi, W .................................................. 1675 

Qi, X ........................................... 704, 2128 

Qian, F .................................................. 169 

Qian, G ......................... 1163*, 1457, 1458 

Qian, Y ............................................... 225* 

Qin, S ............................................... 1659* 

Qu, A .................................................. 2207 

Qu, Q ........................................ 441*, 1478 

Qu, S .................................................... 441 

Qu, W ................................................. 969* 

Quach, H ............................................ 1102 

Qualls, C ............................................ 2077 

Qualls, C W ........................................ 1051 

Quan, C .............................................. 1859 

Quayson, A ....................................... 1804* 

Queiroz, R C ...................................... 1760 

Quertermous, J L .................................. 150 

Quesenberry, R D ................................. 678 

Quinn, T ............................................... 588 

Quinney, J C ....................................... 1488 

Quinones, J ......................................... 1260 

Quintana Belmares, R O .................... 254* 

Quiogue, G ........................................... 770 

Quirk, M C ......................................... 1324 

Quiñones, O ......................................... 812 

Quyyumi, A A .................................... 1293 

R 

Raabe, H ... 104, 109, 114, 489, 491, 2217* 

Raabe, H A ................................... 471, 473 

Rabbah, A ........................................... 1835 

Rabinowitz, J ...................................... 203* 

Rabolli, V ............................................. 268 

Racz, W J ........................................... 1229 

Radilov, A........................................... 1866 

Radio, N ................................................. 83 

Radio, N M ............................. 1078*, 1079 

Radonjic, M ........................................ 1388 

Radovsky, A ......................................... 995 

Raffaele, K ........................................... 182 

Raghavamenon, A C....... 592, 1283, 1557* 

Raghavan, S........................................ 2079 

Ragsdale, D ........................................ 1241 

Rahman, N A ............................ 2089, 2092 

Rahman, Z U ...................................... 1891 

Rahmani, K ........................................ 245* 

Raiti, S................................................ 1656 

Rajab, N F .......................................... 1211 

Author Index 



Author Index 


Rajagopalan, S ................................... 1507 

Rajkoswki, K T .................................. 1162 

Rak, A ................................................ 1930 

Ralston, N V ..................................... 1786* 

Ralston, S L ........................................ 1787 

Ramabhadran, R ................................... 165 

Ramachandran, A ............................. 2133* 

Ramachandran, B ............................... 1051 

Ramaiah, S K ....................... 1356*, 1440* 

Ramasahayam, S .............................. 2185* 

Ramasamy, S .................................... 1937* 

Rambo, C ........................................... 435* 

Ramesh, A .................... 137, 171, 180, 535 

Ramesh, U .......................................... 1563 

Ramirez, V ......................................... 810* 

Ramkissoon, A ..................................... 859 

Ramos, E ............................................ 1892 

Ramos, K S .......................................... 150 

Ramos-Nino, M .................................. 1553 

Ramshesh, V K......................... 1212, 1214 

Rana, P ................................................. 81* 

Randle, M ............................................... 93 

Ranggasami, N R ............................... 1794 

Ranjan, R .............................................. 675 

Rankin, G O ......................................... 819 

Rao, M .................................................. 257 

Rao, N ................................................ 1849 

Rapisardi, A S .................................... 1991 

Rapp, C R ..................................... 335, 346 

Rappaport, S M ............................ 123, 127 

Rappold, P .......................................... 1231 

Raquet, N ......................................... 1144* 

Raschke, M ............................................ 57 

Rashad, H M ...................................... 2158 

Rasmussen, C ........................... 112*, 2060 

Rasmussen, C A ......................... 500, 1056 

Rasmussen, D ..................................... 312* 

Rasmussen, E ..................................... 1308 

Rasoulpour, R ..................... 397, 430*, 836 

Rasoulpour, T ....................................... 410 

Rath, M ...................................... 674, 2003 

Rathmacher, J A ................................. 1315 

Rathman, J F ........................................ 211 

Raucy, J .................................. 1415*, 2102 

Rausch, L ........................................... 1582 

Ray, D ................................................ 1224 

Ray, M .......................................... 878, 879 

Ray, P D ............................................. 149* 

Ray, S D ............................................... 815 

Rayner, J L ....................................... 1034* 

Re, T ..................................................... 491 

Re, T A ............................................. 1179* 

Rebecca, C C ...................................... 2177 

Recio, L ........................ 1106, 1112, 1117* 

Redden, J .................................... 100, 1789 

Reddy, G ........................ 322*, 1032, 1930 

Reddy, K ............................................ 2220 

Reddy, R N ....................................... 1677* 

Redelman, D ...................................... 1855 

Redfern, W ....................................... 42, 43 

Redfern, W S .................................... 1081* 

Reed, K L ................................. 1401, 1475 

Reed, M D .................... 1479*, 1480, 1514 

Reed, W S .......................................... 1647 

Refsnes, M ....................... 267*, 736, 2176 

Regal, J F.......................................... 2197* 

Regal, R R .......................................... 2197 

Regev, A ........................................... 1441* 

Reichenbacher, T ................................ 1065 

Reichenbacher, T M ........................... 1069 

Reichling, T D ........................................ 97 

Reid, F .................................................. 502 

Reid, F M ............................. 923, 924, 931 

Reid, J ................................................ 1030 

Reif, D .......................... 98, 212, 215, 1010 

Reif, D M ......................... 198*, 463, 1901 

Reifenrath, W G ................... 2045*, 2047* 

Reilly, C A .............................. 2151*, 2153 

Reilly, L M ........................................... 341 

Reilly, T .................. 720, 1084, 1658, 1995 

Reilly, T P ................................ 1281, 2136 

Reily, M .............................................. 1637 

Reily, M D .......................................... 1638 

Reimer, D ............................................. 336 

Reimer, M .......................................... 1580 

Reimers, R ............................................ 435 

Reimschuessel, R ............................... 1140 

Reisfeld, B ............................ 202, 242, 897 

Reising, A ............................................. 469 

Reisinger, A J ..................................... 1708 

Rembovsky, V .................................... 1866 

Ren, H .......... 219, 507, 2115, 2154, 2155* 

Ren, J ................................ 704, 1174, 2128 

Ren, X .................... 127, 951*, 2001, 2037 

Renault, S ............................................. 577 

Renzi, P .............................................. 1517 

Reo, N V............................................. 1256 

Reuhl, K ............................................... 120 

Reuter, H ................................................ 91 

Reynolds, J ........................................... 379 

Reynolds, M ............................. 1819, 2160 

Reynolds, S H ...................................... 799 

Reznik, S E ........................................... 422 

Rhee, S ............................................... 1582 

Rhoades, R ......................................... 180* 

Rhomberg, L R ................... 36*, 40*, 1946 

Ricci, M R ................................ 974*, 1157 

Rice, G E .............................................. 247 

Rice, I ................................................. 1470 

Rice, J S ............................................... 341 

Rice, P ................................................ 1703 

Richard, A .................................... 185, 215 

Richard, A M ........................ 192, 198, 211 

Richard, V ............................................ 469 

Richards, I S ............................. 578*, 1310 

Richards, J .......................................... 1503 

Richards, J E ...................................... 1500 

Richards, J H .............................. 783, 1522 

Richardson, J R ............. 1234, 1250, 1251, 

1288, 2027 

Richardson, M E ................................ 1168 

Richardson, R J .................................. 1381 

Richardson, S ................................... 1291* 

Richardson, V M .............................. 2085* 

Richburg, J H ........................... 1482, 1664 

Richter, E D ........................................ 1264 

Richter, P A .......................................... 694 

Richter, W R ......................................... 931 

Rick, D L .................................. 1591, 1592 

Rider, C ................................................ 562 

Rider, C V ........................................ 2107* 

Riebel, V .............................................. 761 

Rieder, S A ......................................... 731* 

Riefke, B ................................................ 57 

Rieth, S ............................................... 1920 

Rigas, B .............................................. 2144 

Riley, J ................................................ 1756 

Riley, R................................................. 853 

Riley, R T ......................................... 1456* 

Ringeissen, S ........................................ 211 

Rios, J ................................................... 982 

Rioux, V ............................................... 596 

Rissel, M .............................................. 596 

Ritger, S ............................................... 878 

Rittenhouse-Olson, K ......................... 1201 

Ritter, D ................................................ 285 

Riveles, K ........................................... 1915 

Rivera, B ............................................ 183* 

Rivera-Ramírez, E ...................... 759, 760* 

Rivest, P ........................................... 1905* 

Riviere, J E ................ 284, 495*, 503, 801, 

1158, 2067, 2068 

Robert, D .............................................. 512 

Roberts, A .......................................... 1325 

Roberts, D J ...................................... 1129* 

Roberts, J .............................................. 263 

Roberts, J C ........................................ 1324 

Roberts, J R ...................................... 1400* 

Roberts, K ............................................ 735 

Roberts, L J .......................................... 137 

Roberts, R .................... 1081, 1724, 2034* 

Roberts, S ........................................... 1707 



Roberts, S M ...................................... 972* 

Roberts, T K ....................................... 1677 

Roberts, Z ............................................. 959 

Robertson, A P ..................................... 729 

Robertson, D .................. 1315, 1638, 1639 

Robertson, D G ........................ 720*, 1637 

Robertson, H T ..................................... 871 

Robertson, J D ...................................... 138 

Robertson, L ....................................... 2064 

Robertson, L W ................... 134, 236, 239, 

240, 716, 1105 

Robichaud, A........................................ 925 

Robinette, B ............................... 156, 164* 

Robinson, A..................... 970, 1160, 1161, 

1458, 1459* 

Robinson, B.................................. 796, 798 

Robinson, B L ...................................... 281 

Robinson, D K ................................. 1101* 

Robinson, J L ..................................... 202* 

Robinson, K ....................................... 2119 

Robinson, P .......................................... 327 

Robinson, P J ....................................... 325 

Robinson, S ........................................ 1805 

Robinson, S P ....................................... 342 

Robison, C L ........................................ 345 

Robison, S H ...................................... 697* 

Robledo, L .......................................... 1716 

Robledo-Marenco, L ............................ 434 

Robledo-Marenco, M ........................... 355 

Robles, C .............................................. 189 

Rockwell, C E .................................. 1556* 

Rockwood, G A .................................... 338 

Rodgers, K ............................................. 66 

Rodocker, K ....................................... 1330 

Rodrigue, M ....................................... 1563 

Rodriguez, M ..................................... 1458 

Rodriguez-Cotto, R I .......................... 1559 

Rodriguez-Lara, V.............................. 2168 

Rodríguez, R .................................... 1474* 

Roede, J ............................................ 1293* 

Roede, J R ............................................ 779 

Roesijadi, G ........................................ 1448 

Rogan, E ............................................. 1885 

Rogers, A............................................ 1515 

Rogers, C .............................................. 618 

Rogers, E N ........................................ 133* 

Rogers, J ................................... 502, 2210* 

Rogers, R .............................................. 878 

Rogers, R A ........................................ 1476 

Rogers, R L .......................................... 426 

Rogers-Cotrone, T S ........................ 1266* 

Roggen, E ............................................. 484 

Roghanian, A...................................... 1404 

Roguet, R ............................................. 505 

Roh, J ............................................... 1699* 

Rohde, B .............................................. 940 

Rohlman, D ................................ 539, 1240 

Rohlman, D S ..................................... 1237 

Rohr, A ............................................... 1510 

Rohr, A C ........................................... 1505 

Rohrbach, F ........................................ 761* 

Rojanasakul, Y ............................. 797, 800 

Rojas, A .............................................. 1716 

Rojas-García, A E ................................ 355 

Rojas-García, E .................................... 434 

Roland, K ........................................... 1745 

Rolf, M G ........................................... 1081 

Roman, E .............................................. 167 

Roman-Velazquez, F R ...................... 1560 

Romero, A C ........................................ 833 

Romero, D M ................................... 1235* 

Romoser, A ......................................... 285* 

Roncal, C ............................................ 1959 

Rondelli, C M..................................... 361* 

Ronis, M J ............................................ 762 

Roomi, M ................................. 674*, 2003 

Roomi, N W ..................................... 2003* 

Rooney, A ......................................... 1924* 

Rooney, A A ....................................... 1925 

Rooney, J ............................................ 2159 

Roos, R ............................................. 2061* 

Rosario, S ........................................... 369* 

Rosdriguez-Lara, V .......................... 2169* 

Rose, C ............................................... 1036 

Rosen, M .............................................. 507 

Rosen, M B ........................................ 219* 

Rosenbloom, S ................................... 1944 

Rosengarten, A ..................................... 494 

Rosengren, R J ......................... 506*, 2007 

Rosenzweig, B ........................... 579, 1318 

Ross, D G ....................... 1015, 1016, 1017 

Ross, J H ................................ 2045, 2046* 

Ross, M K ............................................ 168 

Rossbacher, R ....................................... 866 

Rossenu, S .......................................... 1577 

Rossi, E ................................................ 260 

Rostene, W ......................................... 1613 

Roszell, L E ........................................ 1917 

Roter, A H .......... 1640, 1661, 1967, 2076* 

Roth, R ............................................... 2139 

Roth, R A ................ 590, 750, 1952, 1956, 

2123, 2125, 2136, 2137 

Rothman, N .................................. 123, 127 

Rothstein, R P .................................. 1324* 

Rotroff, D ......................................... 1010* 

Rottinghaus, G E ................................ 1134 

Rouchka, E ............................... 1430, 1719 

Rountree, M ............................. 1382, 1387 

Rouse, M .............................................. 76* 

Rouse, R ............................................. 579* 

Rousseau, C ........................................ 1190 

Rousseau, P ........................................ 2184 

Rovira, N ............................................ 2121 

Rowe, C ................................................ 424 

Rowland, A M ............................ 132, 1718 

Rowland, J .......................................... 2050 

Rowlands, C ............................... 430, 1337 

Rowley, B ............................................. 310 

Roy, C J ................................................ 326 

Roy, R............................................... 1788* 

Roy, S ................................................. 2174 

Royer, C ............................................. 1516 

Royland, J E ......................................... 783 

Rozzell, D ............................................ 468 

Ru, H .................................................... 143 

Ruark, C D ................................... 325, 899 

Rubio, M ............................................ 1716 

Rubio-Andrade, M ............................. 1842 

Ruble, K ............................................... 471 

Rubtsov, D .......................................... 534* 

Ruchirawat, S ..................................... 1779 

Ruddock, K .......................................... 982 

Rudel, R A .......................................... 1999 

Rudolph, J .......................................... 1062 

Ruepp, S ........................................... 1639* 

Ruff, A L ............................................ 2211 

Ruiz, J A ............................................. 1061 

Ruiz, M J ............................................ 1464 

Ruiz, P .............................. 209*, 879, 1029 

Ruiz, R ................................................. 339 

Ruiz-Pesini, E .................................... 1070 

Rumbeiha, W K .................................. 319* 

Runnels, H .......................................... 1303 

Runnels, K .......................................... 1330 

Runyan, R B ....................................... 1726 

Russo, M ............................................ 1654 

Rustemeier, K ....................................... 701 

Rusyn, I ....................... 148, 185, 192, 201, 

364, 874, 1645 

Rutherford, D ....................................... 643 

Rutter, J ................................ 1357*, 1361* 

Ruwona, T B ............................ 490*, 1405 

Ryan, A .............................................. 1655 

Ryan, C .............................................. 306* 

Ryan, E P ......................................... 1782* 

Ryan, K .............................................. 784* 

Ryan, P ............................................... 1876 

Ryde, I T ............................................ 1612 

Ryman-Rasmussen, J P ...................... 2050 

Ryu, D ................................................ 1159 

320 




S 

Saavedra, J E........................................ 969 

Sabo-Attwood, T ... 371, 1553*, 2105, 2106 

Sabourin, C ........................................ 1969 

Sabourin, C L ................................... 2209* 

Sachdeva, K...................................... 1810* 

Sachdeva, M ....................................... 483* 

Sachs, C ............................................ 1438* 

Sadagopa Ramanujam, V M ................ 777 

Saddler, C ............................................. 980 

Sadis, S ............................................... 1303 

Sadler, C ............................................. 1724 

Sadovova, N ................. 163, 169, 845, 865 

Sadovova, N V.................................... 179* 

Sadrieh, N ............................................ 579 

Safe, S ...... 140, 435, 515, 530, 1225, 1285 

Safe, S H ................ 531, 532, 1342*, 2008 

Safgren, S L ......................................... 357 

Safron, B ............................................ 1187 

Sagartz, J ...................... 1075*, 1076, 1077 

Sagelsdorff, P ..................................... 1046 

Sager, T M .......................................... 278* 

Saggu, S ............................................. 770* 

Saghir, S ....................................... 419, 420 

Sahambi, S K ............................. 851*, 852 

Sahar, R .................................................. 64 

Sahlberg, B G ..................................... 664* 

Sahuc, F ................................................ 307 

Saili, K S .......................................... 1392* 

Saini, Y ................................... 2137, 2175* 

Saint-Dic, R .......................................... 978 

Saji, M ...................................... 1605, 1608 

Sakaguchi, H .............................. 301, 1926 

Sakai, S .............................................. 1475 

Sakamuru, S ......................................... 707 

Salazar, D ............................................. 534 

Salcedo, T........................................... 1084 

Saldaña-Ruíz, S .................................. 1253 

Saleh, N B ............................................ 371 

Salem, H ............................................. 1012 

Salem Sreenivasan, A ......................... 669* 

Salewsky, T .................... 1983, 1984, 1985 

Salian, S S ........................................ 1298* 

Salicru, E .................................. 300, 1806* 

Salinas, K A ......................................... 428 

Salisbury, J L ........................................ 799 

Salisbury, R L ................................... 1539* 

Salisbury, T B ..................................... 384* 

Sallette, J .............................................. 116 

Salmen-Muniz, R ............................... 2178 

Salmon, A ................................. 1013, 1020 

Salmon, A G ................. 1023, 1910, 1915* 

Salvail, D ............................................ 606* 

Samadfam, R ...................................... 2100 

Samandar, E ......................................... 560 

Samberg, M E .................................. 1702* 

Sambuissho, A ...................................... 29* 

Sampath, S ................................. 469, 1643 

Sample, A ........................................... 1128 

Sams, A ............................................ 1964* 

Sams, R .............................................. 1937 

Samson, B A............................. 1409, 1666 

Samuelsen, M ..................................... 2180 

Sanbuissho, A ......................................... 25 

Sanchez Soria, P ............................... 1971* 

Sanchez-Lozada, L G ......................... 1959 

Sanchez-Morrissey, S ......................... 1280 

Sanchez-Rivera, D.............................. 1560 

Sanders, J M ....................................... 1573 

Sanders, K ............................................ 263 

Sanderson, J ............................. 1780, 1905 

Sanderson, T......................................... 930 

Sanderson, T P ................................... 1708 

Sandrof, M ......................................... 1973 

Sandrof, M A ................................ 393, 394 

Sandusky, C B .................................... 1797 

Sandy, M ............................ 38, 1721, 1910 

Sanford, S L ....................................... 1409 

Sankaran, G ........................................ 2049 

Sannajust, F ........................................ 1736 

Sannerud, C ........................................ 1790 

Sannes, P L ......................................... 1828 

Sanni, S .............................................. 1058 

Santistevan, D C ............................. 68, 351 

Santos, B S ......................................... 1403 

Santos, M S ........................................ 1731 

Santos Ahmed, J ................................... 410 

Sanzgiri, U Y ........................................ 889 

Sarala, R ............................................. 1934 

Sarazan, D ............................................ 45* 

Sarazan, R .................................... 605, 607 

Sarazan, R D ...................................... 1752 

Sargent, L ........................................... 799* 

Sarkissian, L ..................................... 1803* 

Sarlo, K ........................................ 308, 484 

Sasaki, J C .......................................... 816* 

Satoh, T .............................................. 1902 

Satterwhite, C M ................................ 1989 

Saulsbury, M D ................................ 1893* 

Saunders, J E ...................................... 814* 

Sauve, A K ....................................... 1181* 

Sava, D ............................................... 1953 

Save, S .................................................. 295 

Savelieva, E ........................................ 1866 

Savenka, A ......................................... 1224 

Savidge, C .......................................... 2109 

Savioli, N ........................................... 1061 

Savitz, D A ........................................... 668 

Savolainen, K ............................. 260*, 266 

Sawamura, R ...................................... 1542 

Sawant, S G ...................................... 1114* 

Saye, J ...................................... 584*, 1053 

Sayers, B C ..................... 286, 2072*, 2073 

Sayes, C ................................................ 285 

Sayes, C M ....................... 282, 1401, 1705 

Scabilloni, J .......................................... 793 

Scandlyn, M J ....................................... 506 

Scarino, A ......................................... 1517* 

Scatchard, J ...................................... 42, 43 

Schaefer, T L ...................................... 1600 

Schaeublin, N M .................... 1695*, 1696 

Schaiff, W T ........................................... 54 

Schanne, F A ...................................... 1840 

Schantz, S L ................................. 155, 611 

Schauss, A ........................................ 1135* 

Schebler, P J ....... 1132, 1587, 1588*, 1589 

Schecter, A ..................... 638*, 641*, 1149 

Scheel, C .............................................. 943 

Scheer, N ............................................ 2156 

Schell, A C ....................................... 2113* 

Schepky, A ......................................... 1926 

Schepky, A G........................................ 91* 

Scheynius, A......................................... 291 

Schiavo, D ............................................ 469 

Schiestl, R H ........................................ 711 

Schiffrin, E L........................................ 957 

Schijf, M ............................................ 1980 

Schildknecht, S ................................ 1270* 

Schilling, B E ..................................... 1708 

Schilling, J D ...................................... 1737 

Schimek, J .......................................... 1928 

Schiner, J .............................................. 469 

Schisler, M R ........................................ 695 

Schladweiler, M ................................. 1503 

Schladweiler, M C .............................. 1500 

Schlager, J J .......... 281, 1695, 1696, 2213* 

Schlappal, A ....................................... 1615 

Schlezinger, J ........................... 1549, 1551 

Schlosser, S ........................................ 2060 

Schmid, J R .......................................... 219 

Schmidt, F ............................................ 189 

Schmidt, J M ...................................... 1968 

Schmidt, K H ..................................... 1200 

Schmitt, T C ....................................... 1960 

Schmitz, H .......................................... 2061 

Schmuck, G ................................ 141, 1120 

Schmucker, R ......................................... 91 

Schmuczerova, J ................................... 718 

Schnackenberg, L K ........................... 1581 

Schnare, K E ...................................... 1132 



Schneider, J S ........................... 147*, 1604 

Schneider, P A ...................................... 935 

Schneider, S.................................. 857, 866 

Schnekenburger, M ............................ 1209 

Schnelle, K D ....................................... 896 

Schnellmann, R G ...... 594, 633, 637*, 814 

Schoeny, R ............................... 1721, 1913 

Schoetens, F ......................................... 816 

Schoeters, G ......................... 55, 107, 1306 

Schofield, J ........................................... 602 

Scholand, M ................................. 59, 1854 

Schomaker, S J ..................................... 58* 

Schorl, C .............................................. 410 

Schrand, A .......................................... 1692 

Schrand, A M ..................................... 1709 

Schreiner, C A ............................ 698, 1122 

Schrenk, D ...................... 1144, 1222, 2061 

Schroeder, K ....................................... 1926 

Schroeder, R ....................................... 1173 

Schroeter, J D ............. 868, 869, 884*, 885 

Schröder, D ........................................ 1046 

Schueller, J ........................................... 511 

Schuetz, C ............................................ 819 

Schuh, R A ....................................... 1615* 

Schulte, S ......................... 258, 2067, 2068 

Schultz, B ........................................... 1856 

Schultz, G ............................................. 351 

Schultz, I ............................................ 432* 

Schultz, I R ......................................... 1446 

Schultz, T W................. 248, 251, 252, 253 

Schulz, S M .......................................... 342 

Schulz, V J ......................................... 295* 

Schulze, G .......................................... 1084 

Schulze, G E ....................................... 1281 

Schumm, P ........................................... 902 

Schuppe-Koistinen, I .......................... 1322 

Schussheim, Y ...................................... 494 

Schwald, M .......................................... 761 

Schwartz, J ....................................... 1213* 

Schwartz, M ....................................... 1380 

Schwarz, J ............................................ 201 

Schwarze, P .......................................... 267 

Schwarze, P E ............................ 736, 2176 

Schwarzman, M ................................. 1999 

Schwegler-Berry, D ..................... 270, 793, 

797, 1400, 1506 

Schüpfer, P ......................................... 1326 

Schützsack, J .............................. 717, 903* 

Scialis, R .......................................... 1597* 

Scian, M ............................................... 753 

Scicchitano, M ................................... 1745 

Scinicariello, F ................................... 666* 

Sciullo, E ............................................ 1934 

Sciuto, A M .......................................... 344 

Scoglio, C M ........................................ 902 

Scognamiglio, J ................................ 1109* 

Scollon, E ........................................... 1319 

Scollon, E J ........................................ 1929 

Scott, C S ........................................... 1932 

Scott, J ................................................ 2058 

Scott, K .................................................. 92 

Scott, W .................................................. 54 

Seagrave, J ......................... 63*, 351, 1093 

Seaman, C ................................ 102*, 1804 

Searfoss, G H ............................. 79, 1640* 

Seastrum, L ........................................ 1181 

Sebastian, T ........................................ 1543 

Seddek, A S .............................. 1833, 1844 

Sedman, R .......................................... 1943 

Sedykh, A ................................... 185*, 192 

Seegal, R F ......................................... 1280 

Seelbach, M J ....................................... 233 

Seeley, M ........................ 670, 1039*, 1886 

Segal, L ................................ 1054*, 1372* 

Seib, T .................................................... 34 

Seibold, I ............................................ 1046 

Seidel, A ............................................. 1121 

Seidler, F J .......................................... 1612 

Seifert, J ........................................... 1896* 

Seiler, A ................................................ 170 

Seki, T .................................................. 377 

Sekita, K ............................................... 672 

Selby, P B ......................................... 1028* 

Selcer, B A ........................................... 439 

Selderslaghs, I ............................ 87, 1412* 

Selim, S ............................................ 1868* 

Sellamuthu, R ....................................... 305 

Sellappan, S ........................................ 1660 

Selmin, O ........................................... 1726 

Selwyn Samraj, F ............................. 1103* 

Semler, J ............................................... 940 

Sen, B ............................................... 1005* 

Sen, N ........................................... 387, 402 

Seng, W ................................................ 467 

Sengupta, S ...................................... 1468* 

SenGupta, S K .................................... 2004 

Senior, J R ........................................ 1071* 

Sens, D A ......................... 824, 1813, 1826 

Sens, M ............................ 824, 1813, 1826 

Seo, J ............ 817, 827*, 1215, 1680, 1769 

Seo, Y M ............................................ 1572 

Serex, T L ....................... 450, 1182, 1188* 

Sergent, O............................................. 596 

Settivari, R................................ 994, 1290* 

Setzer, R ..................................... 873, 1382 

Setzer, R W ........................................ 545* 

Severson, P L ....................................... 953 

Sevilla Tapia, L .................................... 254 

Sgro, M P ............................................. 586 

Shafer, T J ..... 156, 164, 216, 1245*, 1258, 

1259, 2029*, 2032 

Shah, I ...... 198, 1348*, 1407*, 2080, 2081 

Shah, P ............................................... 1901 

Shah, P D ......................................... 1131* 

Shah, P V .......................................... 2050* 

Shah, R ............................................... 1654 

Shah, S V .............................................. 828 

Shah, Y M .......................................... 2207 

Shahrokh, K ................. 1096*, 1097, 1098 

Shakajian, M P ..................................... 825 

Shakarjian, M P .................................... 629 

Shalaby, A A ....................................... 1955 

Shang, Y ............................................. 1508 

Shangari, N .............................. 469*, 1643 

Shankar, K ............................................ 762 

Shankaran, H ........................................ 678 

Shannahan, J .................................... 1503* 

Shannahan, J H ................................... 1500 

Shao, C ....................................... 129, 727* 

Shao, S H ............................................. 289 

Shapira, E ............................................. 494 

Shapiro, A M ...................................... 859* 

Sharfstein, S T ...................................... 468 

Sharkawy, A A........................ 1833*, 1844 

Sharma, A ........................................... 315* 

Sharma, A K ....................................... 2143 

Sharma, M .............................. 1540, 1544* 

Sharma, S ............................................. 699 

Sharpe, M E ..................................... 1369* 

Shaw, P J .......................................... 1282* 

Shay, E ............................................. 1021* 

Shea, D ............................................... 1008 

Sheabar, F Z ......................................... 126 

Shearn, C T .............................. 787, 1635* 

Sheasgreen, J E .......................... 487*, 499 

Sheehan, P .......................................... 1873 

Sheets, L ..................................... 856, 857* 

Sheets, L P ........................................... 995 

Shehata, A .............................. 1833, 1844* 

Shehata, T........................... 292, 375, 1126 

Sheik Mohideen, S ............................... 772 

Sheldon, L S ....................................... 653* 

Shen, D ................................................. 200 

Shen, H ............................................... 239* 

Shen, J .................................................. 336 

Shen, M ........................................ 123, 127 

Shen, S ............................................... 443* 

Shen, Z ............................................... 1155 

Shepard, K .......................................... 1106 

Shepherd, D M ................................... 1535 

Author Index 



Author Index 


Sheppard, A N .................................... 1301 

Sherer, K R ....................................... 1607* 

Sherington, J .................................... 42, 43 

Sherman, J H ...................................... 509* 

Sherman, K A ..................................... 1467 

Sherr, D H ................................ 1549, 1551 

Sheth, C M ....................................... 1744* 

Shi, J ..................................... 291, 690, 766 

Shi, L .......................................... 169, 2126 

Shi, Q ......................................... 179, 2126 

Shi, X ....................................... 1219, 1393 

Shi, Y .................................................. 1841 

Shi, Z ................................................ 1720* 

Shibazaki, Y ....................................... 1313 

Shibutani, M ......................................... 713 

Shih, T ................................ 321*, 323, 333 

Shimada, H ....................................... 1825* 

Shimada, N ....................................... 1216* 

Shimada, T ........................................... 906 

Shimizu, H ........................................... 860 

Shimizu, K ......................................... 1402 

Shimizu, T .......................................... 1542 

Shin, H ....................................... 817, 1680 

Shin, J ..................................... 1228*, 1399 

Shin’ichi, Y ........................................ 1811 

Shinozuka, J ....................................... 1216 

Shinwari, N ........................................ 1835 

Shioda, S ...................................... 161, 178 

Shiotsuka, R N ..................................... 995 

Shipkova, P ................................ 720, 1637 

Shirshov, S ........................................... 210 

Shiyanov, P......................................... 1305 

Shiyanov, P A ..................................... 2213 

Shock, S S ............................................ 438 

Shockley, K ................................ 196*, 715 

Shogren, E S ......................................... 737 

Shoji, Y ............................................... 1313 

Shorey, L E ......................................... 128* 

Shpilsky, J .......................................... 1197 

Shreffler, C ......................................... 662* 

Shuga, J .............................................. 1172 

Shukla, A .............................................. 739 

Shumate, Y ........................................... 959 

Shutsky, T J .......................................... 690 

Shvedova, A ......................................... 599 

Shvedova, A A ............ 270, 271*, 793, 799 

Shyu, W .............................................. 1637 

Sidaway, J E ..................................... 1673* 

Siddiqui, M A ..................................... 1166 

Sidoryk, M ......................................... 1002 

Siebein, K ........................................... 1707 

Sieber, M ................................................ 57 

Sieber, S O ......................................... 1654 

Siegel, P D...................... 490, 1405, 1870* 

Silbergeld, E K ........................... 667, 1698 

Silberman, P ......................................... 655 

Siler, S ................................................ 2076 

Silinski, M .......................................... 1576 

Sills, R C .............................................. 628 

Silva, M ................................................ 560 

Silverstone, A ..................................... 1976 

Silverstone, A E........................ 2191, 2193 

Simar, S .............................................. 1116 

Simeonova, P P .................................. 2178 

Simmons, J ................................. 247*, 886 

Simmons, J E ............................. 889, 1685 

Simon, N .............................................. 112 

Simon, N J ............................................ 500 

Simon, R R ....................................... 1809* 

Simon, T ....................... 1871, 1872, 1916* 

Simones, T ....................................... 1535* 

Simonich, M T ................................... 1392 

Simonnard, A ........................... 600*, 1727 

Simoyi, R H ......................................... 490 

Sims, B ......................................... 335, 346 

Simutis, F ............................................. 930 

Singh, A.......................... 1382, 1387, 1430 

Singh, B P .......................................... 1188 

Singh, J ............................................... 1489 

Singh, K ............................................. 2191 

Singh, K P .............................. 1681, 1682* 

Singh, N ..................................... 756, 2195 

Singh, N P .......................................... 144* 

Singh, R K .................................. 130*, 516 

Singh, S K .......................................... 1241 

Singh, T .............................................. 1177 

Singh, U ............................................... 756 

Singhal, R ............................... 2125, 2136* 

Sipes, G ................................................ 362 

Sipes, I ........................ 125, 387, 402, 1584 

Sipes, I G .............................................. 363 

Sipes, N .................................... 1382, 1387 

Sistare, F ............................................ 1921 

Sistare, F D ............. 645*, 646*, 806, 2206 

Sithu, S D ................................. 749*, 1166 

Siu, M ................................................. 858* 

Sivasubramani, S K .............................. 326 

Skaggs, H ......................................... 1802* 

Skeaff, J .............................................. 2164 

Skeete, D .............................................. 982 

Skelton, M R ...................................... 1600 

Skibola, C F ................................. 127, 952 

Skoglund, R .................... 1176, 1788, 1795 

Skov, P ............................................... 302* 

Skovira, J .............................................. 321 

Skuba, E ............................................. 1988 

Skuland, T ............................................ 267 

Slade, M ............................................. 2187 

Slater, M R ........................................... 669 

Slichenmyer, W .................................. 1050 

Slikker, W.................... 163, 166, 169, 179, 

796, 798, 845, 865 

Slitt, A ............................ 1621, 1622, 1623 

Slitt, A L ............................................. 1624 

Sloan, C ............................................ 2108* 

Slotkin, T A ........................................ 1612 

Small, D ............................................. 1754 

Smart, R C ............................................ 675 

Smartt, A M .......................................... 933 

Smathers, R L ..................................... 787* 

Smelley, A ............................................ 321 

Smit, J .......................... 293, 294, 295, 538 

Smith, A ............................................. 207* 

Smith, A L .......................................... 1291 

Smith, A M ................................... 82*, 184 

Smith, B A .......................................... 1450 

Smith, B T .......................................... 1316 

Smith, C ..... 1048, 1183, 1578, 1723, 1993 

Smith, C D ......................................... 1213 

Smith, C S .. 1033, 1132, 1587, 1588, 1589 

Smith, H ............................................. 1330 

Smith, J N..................... 1599, 1865*, 1887 

Smith, L.............................................. 2026 

Smith, L W ........................................... 308 

Smith, M .................................. 1845, 2037 

Smith, M J ................................ 297, 1991* 

Smith, M T .................. 123, 127, 136, 951, 

952, 1172, 2202* 

Smith, M V ........................................... 461 

Smith, P J ..................................... 510, 765 

Smith, S Y ................................ 1083, 2100 

Smith, W .............................. 66, 354, 1062 

Smith, W E ......................................... 374* 

Smolarek, A K .................................... 120* 

Smulders, C ...................................... 1799* 

Snawder, J E ....................................... 1881 

Snell, M ................................................ 303 

Snider, M ............................................ 1934 

Snider, T H ................................... 923, 931 

Snow, S J .......................................... 1477* 

Snow, T A ............................................. 450 

Snyder, M ........................................... 1808 

Snyder, R ............................................ 1331 

Snyder, S A........................................... 812 

So, J ...................................................... 120 

Sobal, M ............................................. 1094 

Sobhakumari, A.................................. 134* 

Soda, R ................................................. 479 

Soelberg, J ............................................ 939 

Sogorb, M A ....................................... 833* 



Sokol, D ............................................. 2005 

Sokolowski, S ..................................... 1746 

Solaimani, P S .................................. 1194* 

Soler-Martín, C .................................. 1253 

Sollome, J J .......................................... 961 

Soman, K V .......................................... 907 

Somers-Edgar, T J ...................... 506, 2007 

Somji, S .......................... 824, 1813, 1826* 

Sommer, E .......................................... 2219 

Sommer, R J ....................................... 1975 

Sommers, C H .................................... 1162 

Somps, C .......................... 512*, 513*, 679 

Son, S ......................................... 817, 1680 

Sonawane, B........... 520, 665*, 1564, 1928 

Sonee, M .............................................. 816 

Song, J ................................................ 699* 

Song, M .................................. 1812*, 1815 

Song, S ............................................... 1080 

Song, W .............................................. 2049 

Soni, M ................................................. 319 

Soni, M G ........................................... 609* 

Soni, S D .............................................. 781 

Sonko, B J ........................................ 1960* 

Sono, S ................................................. 301 

Sorensen, D B ...................................... 920 

Soriano, M ............................................ 343 

Soriano, À .......................................... 1070 

Sorribas, V.......................................... 949* 

Sosinski, L.......................................... 1978 

Soussaline, F ........................................ 116 

Southall, M ........................................... 112 

Souza, V ............................................. 1816 

Sovadinova, I ...................................... 1668 

Spade, D ............................................. 1448 

Sparkenbaugh, E M .......................... 2137* 

Spencer, P ............................................. 397 

Spencer, R ................................ 1382, 1387 

Spieker, J ................................................ 91 

Spiers, D E ......................................... 1134 

Spinazze, P ............................................. 79 

Spirkl, H P ............................................ 189 

Spitz, D R ........................................... 1590 

Spradling, K D ................................... 345* 

Sprankle, C ......................................... 1808 

Spromberg, J ...................................... 1448 

Squibb, K S ...................................... 1880* 

Sram, R J .............................................. 718 

Sreevalsan, S .............................. 140*, 531 

Srinivasan, S ..................................... 1648* 

Srinivasan, V ............................ 491*, 1179 

Sriram, K .............................................. 21* 

Srisawat, P ............................................ 435 

Srivastav, S ........................................... 832 

Srivastava, S ............. 749, 960, 1166, 1430 

Staal, Y ........................... 367, 1395, 1398* 

Stack, F .............................................. 1807 

Stadler, M ........................................... 1662 

Stafford, K ............................................ 337 

Stagg, N J ........................................... 521* 

Stahl, B ................................................. 857 

Stahl, S ............................................. 2122* 

Stahlmann, R ................................ 404, 405 

Stammberger, I ..................................... 189 

Stanek, J ............................................. 1924 

Stanius, U ............................................. 408 

Stanko, J P .................................... 831, 839 

Stankowski, L F ............. 688*, 1107, 1129 

Stanley, K A ....................................... 414* 

Stansfield, K ..................................... 1610* 

Stanssens, P ........................................ 1577 

Stapleton, H .......................................... 644 

Staska, L M .......................................... 929 

Staskal, D ........... 1800*, 1850, 1871, 1872 

States, J .................... 133, 960, 1719, 2009 

States, J C ......................................... 1430* 

States, V A .......................................... 2009 

Stavanja, M ........................................ 1112 

Stebbins, K ........................................... 397 

Stec, K ................................................ 1050 

Steele, C ............................................... 739 

Steele, C L ............................................ 474 

Steenhof, M ...................................... 2183* 

Steevens, J A ........................................ 803 

Steffey, M E ......................................... 111 

Steffy, D A .......................................... 1836 

Stein, C R ............................................. 668 

Stein, D .............................................. 1176 

Steininger, C N ................................... 1069 

Stelljes, M E ..................................... 1791* 

Stephani, R ........................................... 422 

Stephen, S .......................................... 1780 

Stephenson, M .................................... 1128 

Stern, A H......................................... 1941* 

Stern, S ............................................... 1614 

Stern, S T.............................................. 791 

Sterner, T R ................................ 325*, 899 

Steup, D R .......................................... 1032 

Stevens, J .............................................. 625 

Stevens, S ........................................... 1289 

Stevenson, C ........................... 1735, 1755* 

Stewart, B J ................................ 787, 1631 

Stewart, C W ........................................ 508 

Stewart, J .............................................. 832 

Stewart, J A .............................. 1493, 1497 

Stewart, N ............................................. 599 

Stewart, S ......................... 579, 1318, 1744 

Stice, S L ............................................ 1389 

Stieffenhofer, A M ............................. 1795 

Stierum, R .......................................... 1388 

Stinchcombe, S ................................ 1904* 

Stobaeus, N .......................................... 847 

Stober, V P ............................... 1329, 1861 

Stockelman, M ........................... 328, 1031 

Stockelman, M G ................................. 991 

Stocker, A ................................. 743, 1320* 

Stoeger, T ............................................. 804 

Stojanovic, M ..................................... 1187 

Stoker, T E ......................................... 2098 

Stokes, W .................... 100, 101, 300, 938, 

1789, 1806, 1807, 1808 

Stoll, R E .............................................. 688 

Stolz, D B ............................................. 576 

Stone, I M ............................................. 358 

Stone, S ................................................ 734 

Stoner, R ............................................. 1073 

Storck, C ............................................ 1273 

Storti, F .............................................. 1326 

Straub, A C ........................................... 576 

Strauss, V ............. 1395, 1398, 1403, 1646 

Strawson, J ......................................... 1911 

Streicker, M ........................................ 1106 

Streicker, M A .............................. 400, 591 

Streifel, K ......................................... 1296* 

Streifel, K M ...................................... 1284 

Strey, A ............................................... 1459 

Stribinskis, V ........................................ 150 

Strickland, J .................... 300, 1806, 1807* 

Stromquist, A ....................................... 360 

Strong, J ............................................. 1908 

Strong, J B .......................................... 564* 

Struve, M F ........................................ 1171 

Struve, M M ..................................... 1031* 

Struwe, M ........................................... 1125 

Struzynski, C P................................... 1472 

Stry, J J ............................................... 1569 

Stryker, S .... 720, 1315, 1637*, 1638, 1639 

Strynar, M ............................................ 218 

Stuart, E C ............................................ 506 

Stuart, I ................................................. 717 

Stuart, J ............................................ 1287* 

Stubenrauch, K ................................... 1990 

Stump, D ............................................ 1189 

Stump, D G ........................................ 995* 

Sturk, L M .......................................... 1061 

Stutz, J P............................................. 1640 

Styblo, M.................................... 963*, 971 

Stølevik, S ........................................ 2196* 

Stølevik, S B ............................ 1650, 1996 

Su, S ....................................... 1104*, 1875 

Su, S V ............................................... 1661 

322 




Suarez, J ............................................. 1712 

Subramaniam, R ................................. 1931 

Subramaniam, R P ........................... 1927* 

Subramanian, K .......................... 898, 2079 

Sudarsanam, S .................................... 1648 

Sudo, Y ............................................. 1309* 

Sugaya, C ................................. 1605, 1608 

Sugimoto, M ........................................ 403 

Sugimoto, N ....................................... 1402 

Sugita-Konishi, Y ..................... 444, 1460* 

Sugita-konishi, Y .................................. 445 

Sugiyama, K ....................................... 1460 

Suguro, M ............................................ 910 

Suh, N .................................................. 120 

Suh, Y ................................................. 241* 

Suhonen, S ........................................... 266 

Sui, M ................................................... 708 

Sui, Y .................................................... 393 

Sukamoto, T ......................................... 922 

Sulentic, C E ................... 71*, 1536, 1538, 

1539, 1540* 

Sullivan, A W ....................................... 406 

Sullivan, B P..................................... 1620* 

Sultana, N ........................................... 966* 

Sultana, R ........................... 269, 277, 2069 

Sumner, S C ..................................... 1331* 

Sun, B ............................... 593*, 811, 1663 

Sun, D ................................................ 1299 

Sun, G .................................................. 142 

Sun, H .................................................. 153 

Sun, J ...................................... 1581, 1860* 

Sun, Q ................................................ 1507 

Sun, S ................................................. 2063 

Sun, Y ................................. 417, 715, 967* 

Sun, Z ................................................. 1226 

Sundström, M ..................................... 1585 

Sunil, V .............................................. 336* 

Sunil, V R ............................................. 350 

Sunouchi, M ......................................... 864 

Suppiramaniam, V.............................. 1297 

Suranyi, R........................................... 1241 

Suter-Dick, L ...................................... 1308 

Sutherland, J E ................................... 1060 

Sutter, C ............................................... 774 

Sutter, T R ............................................ 774 

Suttles, J A ........................................... 960 

Suzen, S H ............................................ 356 

Suzuki, H ............................................ 1313 

Suzuki, S .................................... 516, 1300 

Suzuki, T ...................................... 704, 713 

Suzuki, Y ............................................ 415* 

Svancara, D ...................................... 81, 94 

Svoboda, K ........................................... 172 

Swain, K A ......................................... 1401 

Swanson, B .............................. 1740, 1741 

Swanson, M S ...................................... 508 

Swauger, J E ............................. 741, 1742* 

Sweder, K S .......................................... 690 

Sweeney, L M .................................... 1911 

Sweeney, R E ....................................... 781 

Sweet, L ............................................. 1021 

Sweeting, J ......................................... 834* 

Swenberg, J .......................................... 238 

Swenberg, J A ............................ 143, 1882 

Swierstra, J ........................................... 862 

Switzer, R C ....................................... 1261 

Sykes, G P ................................ 1146, 1147 

Symington, S B .................................. 1232 

Szabo, D T.............................. 1570*, 1574 

Szeto, C ................................................ 147 

T 

Ta, A ................................................... 1582 

Tabor, C .............................................. 1303 

Tachovsky, A ...... 1850*, 1871, 1872, 1909 

Tagliani, F .............................................. 23 

Tahara, M ........................................... 1402 

Tailhardat, M ...................................... 1926 

Takagi, A ............................................ 1397 

Takahashi, M ........................................ 713 

Takahashi, T ............................... 722, 723* 

Takahashi, Y ......................................... 922 

Takai, Y .............................................. 1309 

Takami, K ........................................... 1309 

Takami, S ............................................. 713 

Takashima, A ...................................... 1613 

Takaya, K ............................................. 826 

Takeda, S .............................................. 707 

Takeuchi, Y............................... 1605, 1608 

Takiguchi, M .................................... 1811* 

Tal, T .................................................. 172* 

Tal, T L ................................................. 850 

Talahari, S .......................................... 1116 

Talbot, L ............................................. 1988 

Talcott, S .............................................. 748 

Talton, J ............................ 351, 1479, 1480 

Tammen, R ......................................... 1640 

Tamura, C ........................................... 1460 

Tan, C ................................................. 1900 

Tan, R ................................................... 275 

Tan, W ...................................... 631*, 1543 

Tan, Y .... 758, 882*, 883, 895, 1384, 1386, 

1747* 

Tandon, N ............. 1738, 1739, 1740, 1741 

Tang, H ......................................... 185, 192 

Tang, L ......... 142, 464, 1163, 1457*, 1582 

Tang, T ................................................. 288 

Tang, W .............................................. 151* 

Tang, X ............................................... 1278 

Tanguay, R ......................................... 1706 

Tanguay, R L ... 172, 414, 684, 850, 1340*, 

1392, 1468 

Taniguchi, Y ......................................... 707 

Tannenbaum, L..................................... 439 

Tapanainen, H .................................... 1150 

Tapp, E ..................................... 1142, 1142 

Tarantino, G ....................................... 558* 

Tarasevich, B J ..................................... 275 

Tardif, R ........................... 887, 1517, 1579 

Tarkhov, A ............................................ 211 

Tarlo, K .............................................. 1114 

Tarloff, J B ....................................... 2083* 

Tarrant, J............................................. 1062 

Tarzia, K ............................................... 321 

Taschwer, M ....................................... 1752 

Tashiro, C ............................................. 244 

Tashiro, T ................................. 1605, 1608 

Tasker, L ............................................. 1073 

Tatarinova, E ........................................ 116 

Tateishi, Y ............................................ 377 

Tateno-Mukaidani, C ........................... 906 

Tatum-Gibbs, K R .............................. 830* 

Taurin, S ........................................... 2007* 

Taylor, A J ...................... 286*, 2072, 2073 

Taylor, G J .......................................... 1492 

Taylor, J .......................... 1160, 1458, 1945 

Taylor, J F ....................... 970*, 1161, 1459 

Taylor, L ........................................... 1598* 

Taylor, L A ......................................... 1859 

Taylor, M ............................................ 181* 

Taylor, M D ................................ 884, 885* 

Taylor, M M ....................................... 1251 

Taylor, R ................... 282, 970, 1447, 1705 

Taylor, T ............................................... 273 

Tayor, E L ........................................... 1756 

Tchao, R ............................................. 2127 

Tchounwou, P ...................................... 805 

Tchounwou, P B ................................. 1903 

Teeguarden, J ..................................... 1112 

Teeguarden, J G .................................. 280* 

Teissier, S ........................................... 1926 

Tekpli, X............................................... 596 

Tella, S ............................................... 1790 

Telu, S ................................................ 1590 

Temple, A ........................................... 1072 

Templeton, D M ............................... 1818* 

Templeton, S P ................................... 1405 

Teneng, I............................................... 150 

Teng, X ................................................. 458 

Teng, Y ............................................... 1304 



Tennant, A H ........................................ 262 

Tepe, Y ................................................... 91 

Terfloth, L ............................................ 211 

Terlecky, S R ........................................ 813 

Terrell, A .......................................... 1230* 

Terry, A V ........................................... 1255 

Testorf, T .......................................... 1994* 

Teuschler, L K ...................................... 247 

Tewari-Singh, N ................... 69*, 352, 353 

Thach, C ............................................. 274* 

Thakali, S ................................. 670, 1886* 

Thake, D ........................... 509, 1075, 1076 

Thakur, S ................................................ 32 

Tham, K Y ............................................ 518 

Tharappel, J C .................................... 1590 

Thayer, K.......................................... 1454* 

Theerman, G ...................................... 2109 

Thiemann, A ......................................... 497 

Thiffeault, C J ...................................... 690 

Thomas, C .......................... 369, 767, 1330 

Thomas, C E ................................. 79, 1640 

Thomas, D J ....................................... 1566 

Thomas, F .......................................... 1576 

Thomas, H .......................................... 1745 

Thomas, J ............................................. 397 

Thomas, K .................................. 436, 2151 

Thomas, K C .................................... 2153* 

Thomas, L .......................................... 1573 

Thomas, M ............................... 199, 2075* 

Thomas, P ............................................ 714 

Thomas, P E ............................... 120, 1087 

Thomas, R ..... 366, 492, 541, 1010, 1164*, 

1202, 1500 

Thomas, R A .......................................... 73 

Thomas, R S ...... 543*, 1195, 1199, 1337*, 

1338, 1661, 1938, 1967, 2198*, 2199 

Thomas, S .......................................... 1515 

Thomas-Virnig, C ............................ 2060* 

Thomasen, J M ......................... 1328, 1864 

Thomassen, L ....................................... 268 

Thompson, B ...................................... 1242 

Thompson, C ...... 320, 1325*, 1564, 1939* 

Thompson, D C .. 1065, 1075, 1076, 1077* 

Thompson, K ............................ 579, 1318* 

Thompson, M T................................ 1882* 

Thompson, P ...................................... 1470 

Thomson, J ..................................... 47, 52* 

Thomson, S .......................................... 273 

Thormodsaeter, A ............................... 2176 

Thorne, P .............................................. 237 

Thorne, P S ........................................... 370 

Thornton, C .......................................... 683 

Thorp, N ............................................... 941 

Thorpe, J E ......................................... 959* 

Thorsrud, B A................................... 2116* 

Thrall, B ....................................... 275, 280 

Threadgill, D W ............. 585, 1332, 1336* 

Thuillez, C .............................................. 80 

Thurmond, T S ..................................... 609 

Thurnherr, T ......................................... 291 

Thybaud, V ....................................... 1352* 

Tian, F ................................................ 1508 

Tian, Y .............................. 714, 1688, 2157 

Tibbetts, B .......................... 68*, 843, 2179 

Tice, R .............................. 101, 196, 1723* 

Tice, R R ...................................... 707, 715 

Tichenor, J N .................................... 1989* 

Tie, T ................................................ 1380* 

Tiesman, J P ........................................... 97 

Tietze, D ............................................. 1458 

Tieu, K ................................... 1231, 1278* 

Tilton, J .............................................. 1736 

Tilton, S ............................................ 1327* 

Timchalk, C ....................... 896, 939, 1599, 

1865, 1887* 

Tirmenstein, M A ............................... 2136 

Tiu, G ................................................... 277 

Tjalkens, R B ....... 1284, 1285, 1296, 2113 

Toborek, M ......................... 233, 234, 1748 

Todd, K L ............................................. 406 

Todd, M ................................................ 842 

Todd, M D .................................. 615, 620* 

Todd, S T .............................................. 385 

Tohyama, C ........................ 146, 174, 1715 

Tokar, E J ........... 965, 1427, 1432*, 1679* 

Tollerud, D J ............................... 368, 2071 

Tolleson, W H ................... 331, 332, 1151, 

1152, 1153* 

Tomaszewski, J E ....................... 481, 1406 

Tomizawa, M........................................ 911 

Tompkins, L M ................................... 2147 

Tompson, D .......................................... 338 

Ton, T ................................................... 628 

Tong, W .............................................. 2126 

Tonk, E C ........................................... 841* 

Topinka, J ........................................... 718* 

Toprak, M S.......................................... 291 

Torii, M ................................................ 829 

Tornero-Velez, R ....... 873, 882, 883, 1386, 

1568*, 1900 

Tornesi, B ..................................... 836, 854 

Tornier, C ................................... 498, 504* 

Torous, D K ...................... 690, 691*, 1129 

Torres, K E ......................................... 1647 

Tortora, P .............................................. 946 

Totlandsdal, A I .................................. 2176 

Tourneix, F ........................................... 307 

Toyama, T .......................................... 975* 

Tracey, K J ........................................... 740 

Tracy, J H ............................................. 374 

Trammell, R ........................................... 93 

Tran, N L ................................ 1847*, 1869 

Tran, N Q ............................................. 774 

Transue, T ............................................ 203 

Transue, T R ............................... 883, 1386 

Trapkus, M ........................................... 933 

Trapkus, M L ........................................ 735 

Trauner, M H ...................................... 622* 

Treacy, G ............................................ 1438 

Treece, A ............................................ 1815 

Treichel, J L ......................................... 489 

Tremblay, R .......................................... 876 

Tremblay, R T .......................... 875, 1567* 

Trent, J O .............................................. 188 

Trepakova, E .......................................... 44 

Trepp, C ............................................... 944 

Treumann, S ........... 866, 1395, 1398, 1403 

Trickler, W J ....................................... 281* 

Trimmer, K A ....................................... 781 

Tripathi, D N ...................................... 867* 

Triplett, A ............................... 1152*, 1153 

Trombetta, L D ......................... 1239, 1244 

Troncy, E ............................ 925, 932, 1055 

Tropsha, A .................................... 185, 192 

Troschau, G .......................................... 189 

Trosko, J E ................... 1415, 1428*, 1668 

Trost, L C ......................................... 1057* 

Troth, S P ............................................. 806 

Trout, B ............................................ 1284* 

Trout, B R .......................................... 1296 

Troutt, M .............................................. 618 

Troxel, C .......................................... 1014* 

Truchon, G ........................................... 887 

Trudel, L J ............................................ 696 

Trudel, Y................................... 1185, 1186 

Truong, L ......................................... 1706* 

Tryndyak, V ....................................... 148* 

Tsai, J ................................................. 1295 

Tsai, Y .................................................. 255 

Tseng, M T ....................... 269*, 277, 2069 

Tsuji, J .............................................. 1944* 

Tsuji, Y ................................................. 149 

Tsunoda, M ............................ 1605, 1608* 

Tsunoda, S ............................................ 290 

Tsutsumi, H ................................ 910*, 911 

Tsutsumi, Y .......................................... 290 

Tuli, S ................................................... 351 

Tumenillo, P ......................................... 803 

Turalchuk, K ........................................ 210 

Turpin, P ............................................. 1073 

Author Index 



Author Index 


Turteltaub, K ...................................... 1137 

Tvermoes, B ..................................... 1817* 

Tverya, L ................................................ 64 

Twaddle, N C ....................................... 166 

Tweats, D ............................................. 717 

Tyl, R W ............................................. 2108 

Tyurin, V ...................................... 597, 598 

Tyurin, V A ......................................... 599* 

Tyurina, Y ........................... 597*, 598, 599 

U 

Udasin, R G ................................ 510, 765* 

Uehara, T .............................................. 829 

Ueng, T............................................. 1520* 

Ueno, T............................................... 1811 

Uetrecht, J ........................... 16*, 313, 314, 

315, 316, 448, 2124 

Uetrecht, J P ......................................... 449 

Ukairo, O ............................................ 1065 

Ullerås, E .................................... 466, 2097 

Ulman, E A................................. 974, 1157 

Ulrich, A ............................................. 1143 

Ulrich, P ............................................. 1988 

Ulrich, R ............................................... 458 

Ulrich, R G ......................................... 1060 

Ulrichts, H .......................................... 1577 

Umbright, C ......................................... 305 

Umezaki, M .......................................... 966 

Unice, K M ......................................... 1851 

Uno, S ................................................ 1720 

Unrine, J M ........................ 269, 277, 2069 

Upchurch, L ....................................... 2024 

Upham, B L ...................................... 1668* 

Uppu, R M ............. 592, 1283, 1557, 1669 

Upton, P ............................................... 238 

Urano, K ..................................... 910, 911* 

Urban, J .................................... 1850, 1872 

Uribe, B .............................................. 1816 

Urushidani, T ............................. 191, 2078 

Usami, M .............................................. 864 

Usburne, A L ...................................... 1045 

Uschi, G M ........................................... 269 

Usuki, F .............................................. 1613 

Utsunomiya, S ...................................... 922 

V 

v.d. Horst, L ......................................... 862 

v.d. Wiel, H .......................................... 862 

Vaia, R A ............................................ 1696 

Vaidya, V S........................... 806, 810, 821 

Vaillancourt, R R ........................ 574*, 961 

Valcke, M ......................................... 1914* 

Valente, A L ....................................... 1291 

Valentin, J ..................... 41, 42, 43, 44, 602 

Valentin, J P ....................................... 1081 

Valentin-Blasini, L ..................... 894, 2099 

Valentine, J ........................................... 357 

Valentine, R ........................................ 1112 

Valentine, W M .................................... 772 

Valentine, Z H .................................... 1232 

Valentovic, M ........................... 818*, 2138 

Valerie, M C ..................................... 2177* 

Valerio, L G ........................................ 2074 

Valin, M............................................ 1074* 

Vallanat, B ................................ 2115, 2155 

Vallant, M ........................................... 1969 

Vallant, M K ......................................... 396 

Valliere, A .......................................... 1129 

Valliere, A N ....................................... 1107 

Vallyathan, V ...................... 225, 271, 2177 

Van Aggelen, G .................................. 1447 

Van Cauwenberge, P .......................... 1306 

van Dartel, D A ................................ 1689* 

van Delft, J H ................. 650*, 1650, 1996 

van Delft, J M....................................... 517 

van den Berg, M ........ 217, 223, 295, 1088, 

1779, 2103 

van den Brink, J ................................. 2103 

Van Den Heuvel, R............... 55, 107, 1306 

van der Laan, J ................................. 1435* 

Van Der Merwe, D ............................. 902* 

van der Ven, L .................................... 2061 

van der Ven, L T ................................. 1653 

van Duursen, M .... 295, 1088, 1779*, 2103 

van Esterik, J ...................................... 1977 

Van Goethem, F ................................. 1191 

van Herwijnen, M H................... 517, 1689 

Van Houten, B ...................................... 712 

van Leeuwen, D M ............................. 1996 

van Loveren, H ....... 841, 1650, 1996, 2196 

van Mierlo, G ..................................... 1980 

Van Miller, J P ...................................... 995 

van Ravenzwaay, B ................... 857, 1395, 

1403, 1646*, 1904, 1948, 2090, 2091 

van Schooten, F J ............................... 1689 

Van Shura, K ........................................ 333 

van Staden, C J ................................... 1051 

Van Tassell, R ..................................... 1252 

Van Triel, J ........................................... 367 

Van Vleet, T.......................................... 930 

Van Vleet, T R .................................. 1708* 

van Vliet, E ....................................... 1611* 

Van Winkle, L S ............................... 1518* 

Vanachayangkul, P ........................... 1151* 

Vanage, G ........................................... 1298 

Vande Loock, K ................................. 1650 

Vanden Heuvel, J P .................................. 5 

Vander Zanden, M C ............................ 500 

VanDuyn, N ........................................ 994* 

Vanhala, E ............................................ 266 

Vanoirbeek, J A .......................... 299, 1701 

VanSteenhouse, J ................................ 1173 

VanVliet, B ........................................... 915 

Varnum, S ........................................... 1854 

Varnum, S M .......................................... 59 

Vasiliou, V .................................... 214, 595 

Vassallo, J D ..................................... 1315* 

Vasudevan, C ...................................... 1409 

Vazquez Lopez, I .................................. 254 

Veenstra, S .......................................... 1054 

Velazquez, J ........................................ 1716 

Veltien, A............................................ 1388 

Velázquez-Fernández, J B .................... 434 

Venables, B J ........................................ 447 

Veng-Pedersen, P ............................... 2062 

Venkatakrishnan, P ............................. 769* 

Ventura-Clapier, R.................................. 80 

Ver Hoeve, J N ................................... 1056 

Veranth, J ............................................ 2151 

Veranth, J M ......................................... 265 

Verbeken, E ........................................ 1701 

Vercauteren, E .................................... 1116 

Verdin, M ........................................... 1507 

Vergeade, A .......................................... 80* 

Verhoeven, R S ................................. 1064* 

Verina, T ........................................... 1609* 

Verkler, T L .......................................... 694 

Vermeulen, R ................................ 123, 127 

Verner, M.................................... 892, 893* 

Vernetti, L ........................ 83, 1078, 1079* 

Verougstraete, V ................................. 1794 

Verstraelen, S ................................... 1306* 

Vesper, S ............................................... 298 

Vetrano, A M .................................. 62, 825 

Vezina, C .............................................. 417 

Vezina, C M ............. 386*, 844, 861, 1201 

Vézina, M ......................... 606, 921*, 2119 

Viberg, H .............................................. 176 

Vick, A ............................................... 1593 

Victor, W ............................................ 2187 

Vieira, M ............................................ 482* 

Vigoren, E M ...................................... 1242 

Vijay, V ................................................ 503 

Vilanova, E ........................................... 833 

Vilanova Gisbert, E .......................... 1249* 

Villa-Bellosta, R ................................... 949 

Villalobos, A R ................................... 768* 

Villanueva, C ...................................... 1048 

Villeneuve, D L ........................ 900, 1451* 

Villeneuve, N F .................................. 1226 

Viluksela, M ............................... 162, 2061 



Vines, L .............................................. 1463 

Vines, L L ......................................... 1784* 

Vippola, M ........................................... 266 

Virtanen, S .......................................... 1150 

Visalli, T ............................................. 1308 

Vitovic, P .............................................. 208 

Vladykovskaya, E .............................. 960* 

Vladykovskaya, E N ............................ 749 

Vodak, D........................................... 1514* 

Vodela, J ........................................... 1790* 

Vogel, C F ............................................ 72* 

Vogelwedde, E ..................................... 832 

Vogt, C ................................................. 291 

Voitenko, N ........................................ 1866 

Volz, D ....................................... 89*, 1449 

von Stackelberg, K ........................... 1801* 

Vonderfecht, S .......................... 1962, 2077 

VonTungeln, L .................................... 1140 

Vorderstrasse, B A ................................ 522 

Vore, M............................................. 1749* 

Vorhees, C V ...................................... 1600 

Vosnakis, K ........................................ 1038 

Voss, K ................................................. 853 

Voss, K A.......................................... 1159* 

Vrabel, M ........................................... 2219 

Vu, E..................................................... 755 

Vulpe, C .............................. 115, 127, 224, 

1447, 1845, 2037* 

Vulpe, C D............................................ 951 

W 

Waalkens, I ......................................... 1977 

Waalkens-Berendsen, I D ..................... 841 

Waalkes, M ........................................... 971 

Waalkes, M P ............ 945, 965*, 967, 969, 

1429*, 1679 

Wabers, H D ....................................... 1056 

Wade, M ................................. 1714, 1934* 

Waechter, J M ........................... 995, 1849* 

Waeterschoot, H ................................. 1794 

Wagner, D .......................................... 1031 

Wagner, D J ...................... 934, 1032, 1171 

Wagner, E D ......................................... 247 

Wagner, G C ......................................... 914 

Wagner, J ............................................ 2139 

Wagner, J G ...................................... 1505* 

Wagner, K ............................................ 469 

Wagner, M .......................................... 1781 

Wakamatsu, H .................................... 1026 

Wakishita, M ........................................ 403 

Wales, M .............................................. 349 

Walisser, J .......................................... 1802 

Walk, T ............................................... 1646 

Walker, C L .......................................... 228 

Walker, L A ........................................ 1954 

Walker, M K ....................................... 2058 

Walker, N ............................................. 238 

Walker, N J ....................... 70, 1033*, 1969 

Walker, N N.......................................... 794 

Walker, V K .......................................... 849 

Wall, E ................................................ 1073 

Wallace, A D .................................... 1470* 

Wallace, K ............................................ 262 

Wallace, K B ............ 221, 229, 633*, 634* 

Wallace, W ................................... 292, 375 

Waller, D P ......................................... 937* 

Wallis, R ......................................... 42, 43* 

Wally, J ............................................... 2208 

Walters, D M .............................. 795, 1502 

Walters, E M ...................................... 1134 

Walters, K................................. 1075, 1076 

Walters, M .......................................... 221* 

Walton, F S ........................................... 963 

Wambaugh, J .......... 218, 1010, 1348, 1407 

Wambaugh, J F ................................. 2080* 

Wan, J ................................................. 1803 

Wan, R ...................................... 368, 2071* 

Wang, A ...................................... 657, 1507 

Wang, B ............................ 239, 240*, 1720 

Wang, C ...... 163, 169, 179, 798, 845*, 865 

Wang, F .................................... 1194, 1273 

Wang, G ................................... 289*, 311* 

Wang, H ................. 288*, 527, 1062, 2147 

Wang, J .... 129, 311, 343, 702, 777*, 1163, 

1508, 1865 

Wang, J S.................. 142, 464, 1457, 1458 

Wang, L .................. 457, 797*, 800, 1778* 

Wang, M ......................... 1448, 1603, 2084 

Wang, N ............................................. 1030 

Wang, N C ........................................ 1009* 

Wang, R .................................... 359, 1108* 

Wang, S ............................ 142, 390, 1754* 

Wang, T ...................................... 11*, 522* 

Wang, W ................................... 1740, 1741 

Wang, X ...................... 142, 390, 828, 936, 

1210*, 1226, 1393* 

Wang, Y ................. 765, 1831, 1862, 1863, 

1943, 2074*, 2186* 

Wang, Z ................................................ 142 

WANG, Z ......................................... 1965* 

Wang, Z ...................................... 526, 1634 

Wangpradit, O .................................. 1105* 

Wanibuchi, H...................................... 1300 

Waraich, N ............................................. 66 

Warbritton, A ...................................... 1140 

Ward, J B ............................................ 1882 

Ward, K .............................................. 1101 

Ward, M D................................ 298*, 1302 

Ward, R ...................................... 225, 1789 

Ward, W ............................................. 2115 

Ward, W O ......................................... 1433 

Wardell, J ............................................. 944 

Wardrope, J L ..................................... 1982 

Wargniez, W ......................................... 891 

Warheit, D B .................... 99, 1401, 1475* 

Warner, G ......................................... 1373* 

Washer, G ..................................... 851, 852 

Washington, M K ................................. 535 

Wasserloos, K............................... 597, 598 

Watanabe, C ......................................... 966 

Watanabe, K ....................................... 1446 

Watanabe, K H ..................................... 900 

Watanabe, T........................................ 948* 

Watanabe, W .................................... 1542* 

Waters, K ........................ 280, 1854, 2044* 

Waters, K M ............... 59, 751*, 752, 1327 

Waters, M R ..................................... 1294* 

Watkins, A M ................................... 2141* 

Watkins, P B ................... 365, 1442*, 2199 

Watkins, P W ...................................... 1654 

Watson, A T ........................................ 2107 

Watson, D E ....................................... 1330 

Watson, D G ................................. 335, 346 

Watts, R .............................................. 1044 

Weaver, J L ......................................... 1744 

Weaver, Y M ....................................... 226* 

Webb, H ............................................... 458 

Webb, H K........................................ 1060* 

Webb-Robertson, B .......... 751, 752, 1854* 

Webb-Robertson, B M ........................... 59 

Weber, D .......................................... 2026* 

Weber, E ............................................. 1933 

Weber, K T ....................................... 1364* 

Weber, S ................................... 701*, 1184 

Weber, T J .......................................... 678* 

Weber, W .................................. 63, 68, 351 

Webster, T .......................................... 644* 

Weed, M B ......................................... 585* 

Weeks, J A ............................................ 426 

Weems, J M ........................................ 121* 

Weese, C............................................. 1028 

Wegesser, T ........................................ 1519 

Wegesser, T C..................................... 776* 

Wegner, S H ..................................... 1486* 

Wegrzyn, J .............................................. 88 

Wegrzynowicz, M .............................. 997* 

Wei, B................................................... 711 

Wei, K H ............................................ 2173 

Wei, M ................................................ 1300 

Wei, W................................................ 1299 

324 




Wei, Y ................................................. 1299 

Wei, Z ......................................... 973, 1000 

Weichenthal, S ................................... 182* 

Weimann, H ....................................... 1781 

Weimans, S........................................... 497 

Weinbauer, G F ................ 392, 832*, 1036 

Weingartner, A ..................................... 959 

Weinstein, E ......................................... 904 

Weir, A ........................................... 8, 617* 

Weir, A M ............................................. 207 

Weisensee, D ...................................... 511* 

Weiss, C A ............................................ 803 

Weiss, D ............................................... 740 

Weisskopf, M G ................................. 1884 

Weldy, C S ............................ 1493*, 1497* 

Weller, P ....................................... 690, 691 

Wells, P G ... 705, 708, 834, 858, 859, 863, 

1601 

Wells, S .............................................. 2187 

Welsh, C ....................................... 878, 892 

Welsh, T J ............................................. 937 

Wen, J ................................................. 1563 

Wen, Z .................................................. 169 

Wen Gai, Z ........................................... 103 

Wenck, H ................................................ 91 

Wendling, M............................... 502, 1969 

Weng, C C ............................................ 289 

Weng, Z .................................... 359*, 1108 

Wenk, M ............................................. 1082 

Wenwei, L .......................................... 1163 

Werner, C ................................. 1948, 2090 

Werner, R A ........................................ 1831 

Werre, S .............................................. 1252 

Wescott, D M ..................................... 1315 

Weslander, G ........................................ 664 

Wesselkamper, S C ............................. 1009 

West, P R .............................................. 207 

Westbroek, M L.................................... 454 

Westbrook, A M ................................. 711* 

Westerink, R H ........................... 217, 223* 

Westhouse, R ............................ 1084, 1281 

Weston, D D ....................................... 1614 

Westwood, F ....................................... 1673 

Wetmore, B ........................................ 1010 

Wetmore, B A ................................... 2199* 

Wexler, P ............................................ 941* 

Weydert, J ........................................... 1590 

Weyers, A ........................................... 2096 

Whalan, J ...................................... 520, 665 

Whaley, K J .......................................... 326 

Whalley, C E ...................................... 323* 

Wheat, L ............................................. 1687 

Wheeler, J ........................................... 2096 

Wheeler, J R ....................................... 1450 

Whelan, M ............................................ 114 

White, C A ............................... 1565, 1568 

White, C C ......... 264, 276, 374, 455, 1497 

White, C W ............................ 69, 352, 353 

White, J T ........................................... 2187 

White, K L ...................... 297, 1523, 1991, 

2181, 2188* 

White, L A ........................................ 2027* 

White, M C ....................................... 1675* 

White, P .............................................. 1937 

White, T E .......................................... 1434 

White, Jr, K L ............................... 70, 2101 

Whitmire, M T ................................... 1917 

Whittaker, S G .......................... 1328, 1864 

Whitten, D A ...................................... 1668 

Whittingham, A .................................... 102 

Wholers, D ......................................... 1029 

Wick, P ................................................. 291 

Wickliffe, J K ....................................... 361 

Wiemer, J ........................................... 1646 

Wiench, K ...................... 1395, 2067, 2068 

Wiench, K E ............................. 258*, 1396 

Wijeyesakere, S J ............................. 1381* 

Wilbanks, M S .................................... 348* 

Wilcox, S ............................................ 2109 

Wild, S ............................................... 417* 

Wildman, R .......................................... 441 

Wilga, P C ................................ 492*, 1938 

Wilkerson, H ...................................... 1493 

Will, Y ..... 10*, 81, 83, 94, 95*, 186, 1410, 

1657 

Willems, S S ............................. 489, 2216* 

Willett, K L .......................................... 683 

Willette, R .......................................... 2016 

Willette, R N .................................... 2022* 

Williams, A L ..................................... 1917 

Williams, B B ....................................... 993 

Williams, C ...................................... 2134* 

Williams, D E ..................... 128, 428, 2112 

Williams, G M .......................... 141, 1120* 

Williams, G T ..................................... 1211 

Williams, J ................................. 720, 2038 

Williams, J H ...................................... 1457 

Williams, J L ...................................... 2144 

Williams, K ...................................... 1519* 

Williams, L ......................................... 231* 

Williams, L R ..................................... 216* 

Williams, M T .................................... 1600 

Williams, P L ....................................... 464 

Williams, P R ......................... 1801, 1933* 

Williams, R ........................................ 1856 

Williams, S ................................. 439, 1802 

Williamson, T ..................................... 1962 

Williamson, T L ................................. 2077 

Willis, A ............................................. 1006 

Willis, D N ....................................... 1494* 

Willoughby, C .................................... 1261 

Willoughby, Sr., J A ........................... 105* 

Wills, L ..................................... 1554, 2189 

Wills, R .............................................. 1897 

Willson, G A ........ 1015, 1016, 1017, 1171 

Wilson, A G ........................................ 1968 

Wilson, C G ........................................ 1668 

Wilson, D ............................................... 13 

Wilson, R ........................................... 1947 

Wilson, S .......................................... 1206* 

Wilson, S E ...................................... 1200* 

Wilson, T M ....................................... 2143 

Wilson, V ............................................. 562 

Wilson, V S ...................... 249, 380*, 1481 

Wilt, N .......................................... 104, 473 

Wiltshire, T .............................. 366, 1335* 

Wimber, M ......................................... 1849 

Wind, M ....... 100*, 938, 1789, 1807, 1808 

Winder, B ..................... 1013, 1020*, 1915 

Wing, M ............................................. 1992 

Wingard, C J............................. 795, 1502* 

Winkler, P........................................... 1926 

Winn, L M ............................................ 848 

Winnica, D ........................................... 599 

Winnik, B ........................................... 1087 

Winnike, J H....................................... 1654 

Winsett, D W ........ 1498, 1501, 1504, 1522 

Winters, J............................................ 1106 

Wipf, P ................................................. 598 

Wise, B L ......................................... 1940* 

Wise, C ............................................... 1126 

Wise, C F ............................................ 1128 

Wise, J .............................. 292, 375*, 1126 

Wise, J P .......................... 292, 375, 1126*, 

1128, 2170 

Wise, K C ................................. 1523, 2188 

Wise, S ........................... 921, 1126, 1128* 

Wisler, J .............................................. 1007 

Wisler, J A ........................................ 2084* 

Wisse, L A ............................................ 926 

Witriol, A M ......................................... 344 

Witt, K .................................................. 707 

Witt, K L ........................ 715*, 1106, 1117 

Witten, M L ........................................ 1512 

Wittern, K ............................................... 91 

Witters, E................................................ 55 

Witters, H ................. 87*, 107, 1306, 1412 

Wittig, A ............................................... 701 

Witzmann, F ....................................... 2039 

Witzmann, F A ................................. 2041* 



Wlassowsky, A ................................... 1999 

Wnek, S M ......................... 953*, 954, 955 

Wogan, G N .......................................... 696 

Wohlers, D ......................................... 1920 

Wohlleben, W ....................................... 258 

Woitkowiak, C .................................... 2091 

Wolansky, M J .................................... 1235 

Wolf, A ......................................... 469, 761 

Wolf, C ............................................... 2156 

Wolf, C J ............................................ 831* 

Wolf, D ................................................. 507 

Wolf, D C ................................. 659*, 1407 

Wolf, M ............................................ 2179* 

Wolfarth, M G ...................................... 737 

Wolff, H................................................ 260 

Wolford, S .......................................... 1802 

Wolter, M ........................................... 2026 

Wolterbeek, A........................... 1388, 1977 

Wolterbeek, A P ................................... 841 

Wong, A W ......................................... 1809 

Wong, B ............................................... 934 

Wong, B A .............................. 1032, 1171* 

Wong, L ................................................ 640 

Wong, P .............................................. 1845 

Wong, S ............................................ 1512* 

Woo, E ................................................ 1777 

Wood, A ............................................... 521 

Wood, C ............................................. 2155 

Wood, C R .......................................... 2141 

Wood, C S ........................................ 1024* 

Wood, E .............................................. 418* 

Wood, M J ............................................ 782 

Wood, S A .......................................... 230* 

Woodahl, E L ............................... 357, 358 

Woods, C .............................................. 962 

Woods, C G .......................................... 573 

Woolhiser, M R .................................. 1978 

Worley, S L....................................... 1691* 

Wormser, U .............................. 494*, 1264 

Worzella, T ........................................... 755 

Wourms, M J .......................... 1538*, 1540 

Wrench, N .......................................... 1612 

Wright, D M ..................................... 2092* 

Wright, F ............................................ 1645 

Wright, F A .......................................... 201 

Wright, J ............................. 533, 534, 1598 

Wright, J M .......................................... 897 

Wright, S ............................................ 1584 

Wright, T L ...................................... 1061* 

Wu, A ..................................................... 54 

Wu, D ..................................................... 72 

Wu, K C ............................................. 773* 

Wu, M ................................................ 687* 

Wu, P .................................. 269, 277, 2069 

Wu, Q ....................................... 703*, 1590 

Wu, T .......................................... 958, 1226 

Wu, X ................................................. 1252 

Wu, Y ................... 117*, 704*, 1858, 2128 

Wu, Z............................................ 393, 410 

X 

Xi Kun, X ........................................... 2182 

Xia, M ........................ 196, 707, 715, 1723 

Xia, Q ................................................... 693 

Xia, S .................................................... 513 

Xia, X ............................... 284*, 801, 1008 

Xia, Y ................................................. 390* 

Xia, Z ................................................... 630 

Xiang, H ............................................. 1044 

Xiang, Y ............................................... 200 

Xiangrong, L ........................................ 435 

Xiao, D ............................................... 1593 

Xiao, S .......................................... 78, 416* 

Xiao, W .................................... 1603, 1972 

Xiao, Y ............................................... 2128 

Xiaoyu, B ........................................... 1847 

Xie, H ..................... 292, 375, 1128, 2170* 

Xie, W .............................. 134, 716*, 1466 

Xie, Y ............................... 714, 1688, 2157 

Xing, G ............................................... 2128 

Xing Fen, Y ........................................ 103* 

Xiong, J ................................................ 835 

Xiong, K M ........................................ 682* 

Xu, L .............................. 142*, 1457, 1458 

Xu, X ........................................ 1507, 2026 

Xu, Y ................ 373, 796, 798, 866*, 1129 

Xue, P ................................................... 962 

Xue, W ............................................... 1733 

Xue, X .............................................. 2128* 

Y 

Yadav, B ............................................. 2007 

Yager, J W ................................ 492, 1938* 

Yagi, Y .............................................. 1313* 

Yamada, H .................................. 191, 2078 

Yamada, M ......................................... 1139 

Yamada, T ............................................ 377 

Yamada, Y ............................................ 415 

Yamaguchi, K ..................................... 1139 

Yamaguchi, T ....................................... 415 

Yamaji, M ........................................... 1563 

Yamakoshi, Y ....................................... 864 

Yamamoto, M ....................................... 772 

Yamani, N M ........................................ 847 

Yamasaki, I ......................................... 1139 

Yamashita, A ........................................ 377 

Yamashita, Y ...................................... 922* 

Yamauchi, H ....................................... 2043 

Yamazoe, Y .......................................... 906 

Yan, C ................................................. 1248 

Yan, H ...................................... 2133, 2135 

Yana, K ............................................... 1513 

Yang, A ................................................... 54 

Yang, C ........... 211*, 213, 215, 2093, 2095 

Yang, C S ............................................. 120 

Yang, C Z ......................................... 1408* 

Yang, D .................................. 1238, 1391* 

Yang, F ............................................... 2173 

Yang, J .................................... 1759, 1764* 

Yang, L ............................................. 1885* 

Yang, R ................................................. 892 

Yang, S ....................................... 825, 987* 

Yang, W .............................................. 1100 

Yang, X .............................................. 1104 

Yang, Y ............................................... 582* 

Yanik, S C .............................. 1549, 1551* 

Yano, B L ............................. 419, 420, 421 

Yao, H ................................................ 2157 

Yao, P ..................................... 1482*, 1664 

Yao, Y ....................................... 1100, 1733 

Yasui, M ............................................... 713 

Yasutake, A .......................................... 975 

Yauk, C ............................................... 1714 

Yavar, Z .............................................. 1507 

Ye, J .................................................... 1659 

Ye, X .............................................. 78, 416 

Yeager, R L .......................................... 918 

Yearley, J H ...................................... 1656* 

Yellowhair, M ................................... 2171* 

Yen, C ............................. 1834, 2093, 2095 

Yen, J .................................................. 2024 

Yi, J .................................................... 1304 

Yin, H ................................................. 1091 

Yin, S............................................ 123, 127 

Yin, Z ............................. 999*, 1002, 1839 

Ying, Y ................................................. 103 

Ying, Z ............................................... 1507 

Yip Wlassowsky, A ............................ 1172 

Yochum, C L ...................................... 914* 

Yokel, R A ........................ 269, 277, 2069* 

Yoko, I .................................................. 826 

Yokohira, M ............................. 516, 1300* 

Yokoi, T ................................................ 77* 

Yong-Pil, H ...................................... 1763* 

Yoo, J W ..... 908*, 1562, 1571, 1572, 1963 

Yoon, B ...................................... 672, 1678 

Yoon, M.............................. 884, 885, 895* 

Yoon, Y ............................................... 1278 

York, R G ........................................... 407* 

Yoshida, K ................................ 391, 1976* 

Author Index 



Author Index 


Yoshida, M ........................................... 713 

Yoshiharu, A ......................................... 826 

Yoshiko, S ............................................ 826 

Yoshimura, M ....................................... 911 

Yoshinaga, J ......................................... 146 

Yoshioka, R .............................. 1605, 1608 

Yoshioka, W ..................................... 1715* 

Yoshioka, Y ........................................ 290* 

Yost, G........................................ 287, 2151 

Yost, G S .... 121, 1096, 1097, 1098*, 2153 

You, H .................................................. 527 

You, M.............................................. 1358* 

Young, R K........................................... 768 

Young, S ..................................... 734, 737* 

Young, S H ......................... 270, 793, 1859 

Younis, H............................................ 2129 

Younis, H S ........................................ 1956 

Yourick, J J ......................................... 2209 

Yu, B C ............................................... 1821 

Yu, J C ................................................ 337* 

Yu, K O ...................................... 325, 899* 

Yu, L ..................................................... 413 

Yu, M.................................................. 2071 

Yu, T ................................................... 1858 

Yu, X .................................................. 1486 

Yu, Y ..................................................... 998 

Yuan, C ............................................... 2077 

Yuan, D ................................................ 735 

Yucesoy, B .............................................. 9* 

Yuen, B ................................................... 72 

Yukio, K ............................................... 826 

Yun, H ................ 1761, 1763, 1767*, 1770 

Yunden, J .................................. 1271, 1274 

Yurt, P ................................................ 1129 

Yvonne, D .............................................. 53 

Z 

Zablotny, C ........................................... 397 

Zablotny, C L ....................... 419, 420, 421 

Zacharewski, T ...... 244, 1198, 1627, 1629, 

1630, 1649, 2089, 2092 

Zacharewski, T R ......................... 84, 1628 

Zadworny, M ...................................... 276* 

Zahalka, E A ....................................... 1082 

Zaher, T ................................................ 740 

Zaja-Milatovic, S ..................... 998, 1277* 

Zajack, M ......................................... 1719* 

Zakharov, A ................................ 721, 1594 

Zaki, E .................................................. 642 

Zaleski, K J ........................................ 1061 

Zalups, R K .......................................... 378 

Zammit, D .......................................... 1992 

Zangar, R C .......................... 59, 275, 1327 

Zarbl, H .................................... 1998, 2001 

Zaroogian, G ........................................ 431 

Zartarian, V ........................................ 1933 

Zarubick, S ........................................... 944 

Zavadil, J .............................................. 153 

Zavorskas, P ....................................... 2187 

Zawia, N H ......................................... 1602 

Zebrowska, A ....................................... 456 

Zehr, D ................................................. 218 

Zehr, R D .............................................. 219 

Zeidler-Erdely, P C ........ 734*, 1859, 2178 

Zeiger, E ............................................. 1032 

Zeise, L ........ 38*, 566*, 1721, 1906, 1999 

Zeisel, S ................................................ 971 

Zeitlin, L .............................................. 326 

Zelikoff, J T .......... 835*, 1974, 1976, 2193 

Zeller, A ............................................. 1125 

Zeng, S ................................................. 443 

Zeng, X .............................................. 1660 

Zewdu, M ............................... 1317*, 1321 

Zhan, L ............................................. 1733* 

Zhang, B ..................................... 233, 234* 

Zhang, C ..................................... 458, 2152 

Zhang, C C ......................................... 1472 

Zhang, D D ......................................... 1226 

Zhang, F ............................................... 443 

Zhang, H ........................ 468, 1828*, 2106 

Zhang, J .................. 579, 855*, 1508, 1857 

Zhang, L .................. 123, 127*, 185, 192*, 

441, 453*, 579, 951, 1172, 1267*, 1269, 

1845, 2037, 2202 

Zhang, L W ........................................ 259* 

Zhang, N ............................................ 2038 

Zhang, Q ... 368, 573, 1455*, 1530, 1692*, 

2071 

Zhang, S ................................... 1225, 1756 

Zhang, T ............................................. 2173 

Zhang, X ................... 59, 163*, 169, 316*, 

366*, 593, 751, 752*, 811*, 845, 865, 882, 

1212, 1213, 1214*, 1269, 1449, 1663, 

1713, 1854, 1900*, 1998 

Zhang, Y .................... 773, 796*, 798, 984, 

1001, 1365, 1483, 1541, 1617, 1618*, 

1660*, 1703, 1841, 2163* 

Zhang, Z ............................................. 1393 

Zhao, B ................................................. 263 

Zhao, C Y ........................................... 2173 

Zhao, D .............................................. 918* 

Zhao, F ............................................... 1226 

Zhao, G ................................................ 477 

Zhao, J .............................. 271, 528*, 2063 

Zhao, L ............................................. 1299* 

Zhao, P ................................................. 359 

Zhao, R ............................................... 962* 

Zhao, X .............................................. 771* 

Zhao, Y ......................................... 256, 786 

Zheng, J ........................................ 443, 525 

Zheng, J F ........................................... 2101 

Zheng, M .............................................. 715 

Zheng, Q ............................................ 1698 

Zheng, R ............................................. 629* 

Zheng, W ..... 983, 984, 1365*, 1841, 2163, 

2173 

Zheng, X .............................................. 955 

Zheng, Y ..................................... 359, 1304 

Zhivotovsky, B ........... 1421*, 1422*, 1425 

Zhong, M.................................... 441, 1507 

Zhong, Q .............................................. 813 

Zhong, W ........................................... 786* 

Zhou, A ............................................ 1858* 

Zhou, B .............................................. 2157 

Zhou, D .............................................. 1659 

Zhou, G ................................................ 719 

Zhou, T ............................................... 1654 

Zhou, W ............................................. 1304 

Zhou, X ................ 153*, 1099, 1826, 2159 

Zhou, Z ......... 714, 786, 1733, 1747, 1898* 

Zhu, B .............................................. 2142* 

Zhu, H ........................ 185, 192, 709, 1000 

Zhu, K ................................................ 1241 

Zhu, M ................................................ 256* 

Zhu, P ................................................... 390 

Zhu, S ................................................... 675 

Zhu, T ................................................. 1508 

Zhu, X ................................................ 313* 

Zidek, N ........................................... 1067* 

Zidell, R ............................................. 1084 

Ziemann, C ......................................... 1169 

Zimmer, B .......................................... 1394 

Zimmer, M ........................................... 136 

Zimmerman, B ................................... 1072 

Zimmerman, K ................................... 2190 

Zimmerman, N J .................................... 23 

Zipf, K ...................................... 1740, 1741 

Zobel, J ............................................... 1076 

Zobel, L R .......................................... 1586 

Zodrow, K ............................................ 255 

Zoeller, T .................................... 894, 1383 

Zong, Q ............................................ 1049* 

Zoni, S .................................................... 23 

Zordoky, B ....................................... 1086* 

Zorrilla, L M .................................... 2098* 

Zottola, M ............................................ 338 

Zottola, M A ......................................... 781 

Zou, W ............................................. 1956* 

Zou, X ........................ 163, 169, 845, 865* 

Zucker, R .............................................. 263 



Zuscik, M J ......................................... 1196 

Zuvich, A.............................................. 584 

Zwiernik, M ......................................... 430 

326 



Abstract Key Word Index (Continued) 

The numerals following each key word refer to 

the relevant abstract number(s). 

1, 1-Dichloroethylene .................... 1565 

1, 6-Hexamethylene diamine ........ 1328, 

1864 

1-bromohexane............................... 1562 

1-Butyl-3-Methylimidazolium 

Chloride ............................................ 297 

1-Ethyl-3-Methylimidazolium 

Chloride ............................................ 297 

11b-HSD1 ...................................... 2084 

1Ç3-b-glucan ................................... 737 

2, 3, 7, 8-tetrachloro-dibenzo-p-dioxin 

(TCDD) ........ 84, 384, 1033, 1195, 1198 

2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 

(TCDD) .... 844, 1204, 1952, 2059, 2060 

2, 5-hexanedione ............................ 1267 

2-butoxyethanol ....................... 512, 679 

2-DE ................................................. 864 

2-step ................................................ 910 

21-hydroxylase ............................... 1379 

28 day study ................................... 1155 

3 dimensional in vitro model.......... 1486 

3, 3-diindolylmethane ...................... 128 

3, 4-Dihydroxyphenylacetaldehyde ....... 

1274, 1275 

3, 5, 6-trichloro-2-pyridinol ........... 1865 

3-caffeoyl-4-dicaffeoylquinic acid . 1774 

3-caffeoyl; 4-dihydrocaffeoyl quinic 

acid ................................................. 1763 

3-D skin model ................................... 62 

3A4 ................................................. 1094 

3D Model ......................................... 105 

3D reconstructed epidermis ............. 307 

3D tissue constructs ......................... 109 

4-aminobiphenyl cytotoxicity .......... 742 

4-Chlorobiphenyl metabolites ........ 1105 

4-HNE ...................................... 779, 787 

4-hydroxynonenal .................. 629, 1635 

4EBP1 ............................................ 1667 

8-hydroxy-2ʹ-deoxyguanosine ......... 966 

a 2u -globulin .................................... 1924 

Abandoned metal mine .................. 1821 

ABC transporter ...................... 411, 622, 

1621, 1626, 1749 

ABCB1 ............................................. 358 

Abcb6 ............................................. 1089 

abrin ............................................... 1153 

absorption ............................... 493, 1460 

Abuse Potential .............................. 1790 

acai ................................................. 1135 

ACB-PCR ......................................... 331 

acceptable daily intake (ADI) ........ 1809 

accumulation .................................. 1245 

acetaldehyde ......................... 1112, 1919 

Acetaminophen ... 744, 745, 1072, 1550, 

1653, 2130, 2131, 2132, 2133, 2134, 

2135, 2136, 2137, 2138, 2139 

acetanilides ..................................... 1006 

acetyl propionyl.............................. 1492 

acetylcholine esterase ....................... 899 

Acetylcholinesterase ..... 242, 434, 1237, 

1241, 1242, 1243, 1894 

acetylcholinesterase reactivator ....... 335 

aCGH ............................................... 692 

Acorus calamus .............................. 1131 

Acrolein ...................... 1166, 1764, 2018 

acrylamide .......... 713, 1029, 1289, 1847 

acrylic monomer ............................ 1182 

acrylonitrile .................... 526, 771, 1848 

Actin ............................................... 2169 

action potential ............................... 1753 

acute ................................................. 439 

acute inhalation .................... 1012, 1793 

Acute isotonic volume overload..... 1736 

Acute Kidney Injury......................... 806 

acute lung injury .............................. 597 

acute renal failure ............................. 319 

acute systemic toxicity ..................... 199 

acute toxicity ...... 185, 1131, 1917, 2075 

adaptation ....................................... 1449 

additivity to background .................... 36 

additivity-to-background .................... 40 

adduct ............................................. 1289 

Adenia cissampeloides ..................... 423 

ADHD .............................................. 166 

adipocyte .......................................... 220 

Adjuvant ......................................... 1372 

ADME .......................... 557, 1402, 1563 

ADME-related genes ..................... 1648 

adrenal .................................. 1069, 1379 

Adriamycin ...................... 634, 722, 723 

adult disease ................................... 1431 

Adverse drug reactions..................... 317 

adverse outcome pathway .... 1445, 1446 

aerosol exposure system................. 1515 

AFB1-Lysine .................................. 1457 

affymetrix gene array ..................... 1709 

Aflatoxin .............................. 1457, 1458 

aflatoxin B1 ... 444, 445, 446, 680, 1160, 

1161 

aflatoxin B1-lysine adduct ............. 1163 

aflatoxin B2 ...................................... 444 

Aflatoxins ......................................... 464 

age .................................................... 340 

age-dependent pharmacokinetics ....1592, 

1911 

age-specific .................................... 1947 

agglomeration .................................. 279 

aging ...................... 75, 916, 1247, 1524, 

1616, 1644, 2011, 2012, 2013, 2015 

Aging and evironmental health ...... 2010 

Ah Receptor 145, 539, 1200, 1206, 1534 

AHA ................................................. 692 

AHR ............................ 72, 89, 239, 240, 

386, 522, 596, 663, 861, 1197, 1205, 

1207, 1208, 1209, 1531, 1536, 1537, 

1538, 1539, 1949, 2058, 2167, 2191 

AhR ligands ....................................... 76 

AIDS .............................................. 1119 

air pollutants ......................... 1856, 2015 

air pollution ..... 24, 718, 736, 776, 1496, 

1505, 1510, 1520 

Air pollution metals ....................... 1560 

air quality ....................................... 1801 

air toxicants .................................... 1504 

Airborne PCBs ................................. 237 

Airway hyper-responsiveness ......... 670, 

1886 

airway toxicity ................................. 470 

AKR ............................................... 1622 

Akt .................................................. 1635 

alachlor ............................................. 509 

Albendazole ..................................... 404 

alcohol ........ 786, 787, 1599, 1632, 1633 

Alcoholic Cardiomyopathy ............ 1747 

Alcoholic liver disease .......... 907, 1358, 

1631 

Alcoholic steatosis ......................... 1765 

aldehyde ......................................... 1687 

aldehyde dehydrogenase .......... 214, 595 

aldehydes ...................... 701, 2016, 2018 

ALDH2 .................................. 359, 1108 

aldo keto reductase ........................... 452 

aldosterone ..................................... 1364 

alginate ........................................... 1964 

algorithm .......................................... 880 

ALK5 ............................................. 1724 

Alkylaniline ...................................... 696 

alkylation ............................................ 67 

allegic inflammation ........................ 726 

allergic contact dermatitis ....... 300, 303, 

1789, 1807, 1870 

allergic sensitization ......................... 305 

allergy................... 296, 298, 1302, 2180 

alpha class ........................................ 446 

ALS/PDC ......................................... 167 

ALT ...................... 58, 1072, 1307, 1309 

altered gravity ................................ 1126 

altered hepatic foci ........................... 134 

alternative ....................................... 1412 

alternative activation ........................ 744 

alternative medicine ....................... 1529 

Alternative Methods ........ 474, 479, 485, 

486, 501, 1408, 1808, 2218, 2220 

Alternative model ............................. 464 

alternative model organism .............. 461 

alternative splicing ............... 1346, 1648 

Alternative Test Methods ................. 170 

alternatively spliced variants ............ 214 

alternatives ..................................... 1415 

Alzheimer’s disease ............ 1100, 1295, 

1373, 1615 

Alzheimer’s disease ....................... 1283 

Ambient Particulate Matter ... 1473, 2183 

Ames Test ......................................... 698 

AMH ................................................ 387 

aminoglycoside .............................. 1313 

amiodarone ............................. 750, 1229 

Amphetamines ............................... 1955 

amphibole ....................................... 1476 

AMPK ............................................ 1765 

analysis ........................................... 1849 

analytics ........................................... 258 

anandamide .................................... 2153 

anastrozole ....................................... 431 

anatomy and physiology ...................... 8 

Androgen ........................................ 2084 

androgen receptor ........... 380, 425, 1470 

androgens ......................................... 844 

Aneugen ......................................... 1114 

Aneurysm ......................................... 866 

Angiogenesis .......................... 758, 1766 

Aniline ...................................... 702, 777 

animal ............................................... 237 

Animal - human extrapolation ......... 611 

animal alternative ............................. 110 

Animal health ................................... 588 

animal model ... 317, 449, 523, 591, 914, 

929, 1742, 2124 

animal models ............ 43, 349, 607, 904 

Animal models of human disease ... 611, 

2056 

Animal welfare ................................. 920 

animal-to-human extrapolation ...... 2145 

Animals .......................................... 1891 

ANIT ................................................ 117 

antagonism ....................................... 339 

anthocyanin .................................... 1759 

anti-allergic activity ............. 1771, 1772 

anti-allergic inflammation .............. 1561 

anti-cancer ........................................ 519 

anti-drug antibodies ... 615, 617, 619, 620 

anti-malarial ..................................... 728 

anti-tumor immunity ...................... 1548 

antiandrogenic ................................ 1780 

antiandrogens ................................... 562 

antibacterial ........................................ 95 

antibiotics ................................. 83, 1594 

antibody .......................... 417, 616, 1201 

anticancer agent ..................... 530, 1779 

Anticonvulsant ................................. 321 

antidote ............................................. 324 

Antimicrobial ................................. 1901 

antioxidant .................... 415, 1119, 1135 

antioxidant enzymes ....................... 1961 

antioxidant response element ........... 108 

antiretroviral ....................................... 95 

Antiretrovirals ................................ 1119 

antisense ......................................... 2082 

Antiviral drug ................................. 1582 

anxiety .............................................. 465 

Aorta ................................................ 866 

AP-1 ............................................... 1554 

ApcMin mice ................................... 137 

apoptosis ................. 163, 169, 179, 222, 

516, 596, 731, 815, 821, 825, 828, 1165, 

1211, 1216, 1221, 1222, 1223, 1233, 

1288, 1471, 1676, 1695, 1781, 2036, 

2144, 2174, 2195 

apoptosis and necrosis .................... 2095 

Apoptosis/cell survival ..................... 990 

applicability domain ....................... 1789 

aquatic pollutant ............................. 1008 

aquatic toxicology .......................... 2107 

Aristolochic acid .............................. 455 

Aromatase ............................ 1888, 1905 

aromatic amines ............................... 314 

arsenate ............................................ 949 

arsenic ............. 119, 149, 492, 571, 572, 

573, 574, 575, 576, 706, 749, 945, 946, 

947, 950, 951, 952, 955, 956, 957, 958, 

959, 960, 961, 962, 963, 964, 965, 966, 

967, 968, 969, 970, 971, 972, 973, 974, 

1227, 1294, 1393, 1429, 1430, 1432, 

1566, 1606, 1679, 1719, 1935, 1936, 

1937, 1938, 1971, 1975 

arsenic (+3 oxidation state) 

methyltransferase ............................. 948 

Arsenic exposure ............................ 1299 

Arsenic trioxide ................................ 531 

arsenite ........................................... 1971 

aryl hydrocarbon receptor ....... 295, 384, 

1196, 1201, 1203, 1205, 1337, 1338, 

1339, 1340, 1341, 1342, 1471, 1532, 

1681, 1682 

aryl hydrocarbon receptor (AHR) ... 388, 

398, 684, 1195, 1199, 1678, 2204 

Aryl hyrdocarbon receptor (AhR) .. 1198 

Arylhydrocarbon receptor ................ 399 

As3MT ................................... 947, 1566 

Asbestos ...... 30, 34, 35, 312, 739, 1546, 

1547, 1548, 1553, 1874, 1875, 1877 

asbestosis .................................. 122, 933 

Ascaris suum .................................... 729 

Ascorbic acid ........................... 515, 989 

Asphalt ................................... 508, 1169 

asthma ........ 260, 759, 1517, 2020, 2197 

astrocyte ............................... 1239, 1244 

astrocyte Mn ..................................... 985 

astrocytes .................... 1284, 1285, 2174 

ATCA ............................................... 337 

atherosclerosis ..... 575, 957, 1363, 1430, 

1748 

Athersclerosis ................................. 1778 

ATP synthase .................................... 946 

atrazine ................. 414, 831, 2087, 2092 

Atropine ......................................... 1659 

atropisomer .................................... 2062 

attrition ................................. 1081, 1377 

atypical antipsychotics ........... 584, 1063 

auditory .................................... 155, 162 

auditory startle ............................... 2109 

Autism .......................... 914, 1380, 1391 

autoimmune .............................. 34, 1282 

autoimmune disease ............... 310, 1751 

Autoimmunity .................. 309, 311, 537 

automation ........................................ 116 

autonomic ....................................... 1501 

autophagy ...................... 265, 791, 1226, 

227, 1228, 1269 

axonal transport .............................. 1255 

azoxymethane .................................. 506 

AZT .................................................. 785 

Ab aggregation ............................... 1283 

B cell .............................. 145, 632, 1997 

B cell development ......................... 1558 

B cells ................. 312, 1195, 1530, 1538 

B-cell .............................................. 1060 

B-Raf ................................................ 518 

BA homeostasis .............................. 1617 

babyfood ........................................ 1150 

BACE1 ........................................... 1283 

background additivity ........................ 39 

bacteria ............................................. 667 

bacterial infection ........................... 2056 

bacteriophages ................................ 1162 

Barker Hypothesis .......................... 1428 

Basophils .......................................... 302 

Bax ....................................... 1218, 1219 

Bayesian Analysis ............................ 873 

BBDR modeling............................. 1927 

Key Word Index 







BBDR-HPT axis model ......... 894, 1383 

BCOP ............................... 100, 473, 475 

BDE-47 ............................................ 643 

BDNF ..................................... 160, 1610 

Beagle ............................................ 2116 

Beagle dog ..................................... 1729 

beagle dogs ........................... 1810, 1979 

BEAS-2B ....................................... 1560 

behavior ................... 159, 174, 429, 465, 

1036, 1392, 2028 

behavioral development ................... 403 

Behavioral testing ............................ 166 

Belatacept ....................................... 2187 

Benchmark Dose Approach ............. 841 

Benfluralin ....................................... 521 

benzene ................... 123, 124, 127, 136, 

363, 514, 527, 672, 780, 848, 1678, 

1850, 1851, 1852 

benzenearsenicals ........................... 1101 

Benzo(a)pyrene ........ 137, 150, 535, 683 

benzo[a]pyrene ..... 451, 596, 1720, 2006 

Benzo[a]pyrene (BaP) .................... 1750 

Bergamottin .................................... 1761 

beta-amyloid, MAP kinase, 

Secretase ........................................ 1297 

beta-catenin .................................... 2157 

beta-naphthoflavone ....................... 2120 

beta-secretase ................................. 2077 

betulinic acid .................................. 2008 

Bhas42 cells ..................................... 511 

bile .................................................... 898 

bile acid synthesizing enzymes ...... 1616 

Bile acid transport ............................ 624 

Bile acids .......................... 57, 626, 1618 

bile duct epithelial cells ................. 1958 

Bile salt export pump ............... 621, 623 

bile salts ........................................... 622 

biliary epithelial cell ...................... 1620 

Binder ............................................... 970 

Bio-Plex ........................................... 739 

Bioaccessibility .............................. 2165 

bioaccumulation ............................. 1836 

bioactivation ................. 458, 1096, 1405 

bioaerosol ......................................... 230 

Bioanalytical .................................. 1444 

bioavailability ...... 803, 972, 1936, 2164, 

2166 

biochemical .................................... 2214 

Biochip Technology ....................... 2075 

biocides ............................................ 397 

Biocompatibility ............................ 1187 

Bioconcentration .............................. 232 

biodefense ...................................... 1479 

Biodegradation ................................. 427 

Biodistribution ................................. 843 

bioenergetics ...................................... 81 

biofuel .................................. 1167, 1172 

Bioinformatics................ 210, 751, 2042 

biological descriptor ......................... 185 

biological modeling ....... 881, 900, 2076 

biological pathway analysis ................. 1 

biological pathway networks ........... 410 

biologically-based models ............. 1451 

Biologicals ..................................... 1577 

biologicals, biologics ........................... 2 

Biologics .................... 1074, 1580, 1583 

biomakers ....................................... 2201 

Biomarker ........... 56, 57, 142, 579, 664, 

807, 952, 1308, 1313, 1314, 1315, 1330, 

1440, 1442, 1459, 1650, 1660, 1676, 

1746, 1862, 1878, 1885, 2042, 2199 

Biomarker and Biomonitoring ......... 320 

Biomarker discovery ........................ 534 

biomarker of exposure ......... 1861, 2202 

biomarker of neurotoxicity ............ 1279 

Biomarkers .......... 58, 59, 207, 578, 581, 

751, 752, 1238, 1240, 1299, 1301, 1302, 

1316, 1319, 1325, 1327, 1443, 1444, 

1854, 1863, 2049, 2078, 2198, 2202 

biomarkers and biomonitoring ....... 1881 

Biomaterials ................................... 2181 

biomethylation ................................. 951 

biomonitor ...................................... 1878 

biomonitoring ........ 544, 560, 640, 1041, 

1796, 1849, 1850, 1852, 1865, 1866, 

1871, 1879, 1880, 1887, 2045 

Biomonitoring Equivalents .............. 544 

Biopharmaceuticals .......................... 540 

biosolids ........................................... 435 

bioterrorism .................................... 1152 

biotherapeutics .. 2, 615, 617, 620, 1434, 

1435, 1436, 1437, 1438 

Biotransformation .... 137, 232, 442, 449 

Biotransformation/Cytochrome 

P450 ............................... 202, 452, 1093 

Biphenyl ......................................... 1920 

birds .................................................. 439 

birth defects ...................................... 853 

bispecific ........................................ 1050 

bisphenol .......................................... 406 

bisphenol A ............... 78, 151, 249, 383, 

460, 846, 859, 995, 1087, 1298, 1392, 

1452, 1454, 1849, 2086 

Bisphenol-A ............................. 416, 825 

bivalves ............................................ 988 

Bladder ................. 492, 955, 1300, 1826 

bladder cancer . 141, 531, 532, 953, 954, 

958, 973 

bladder chemical carcinogenesis ...... 507 

bladder tumor ................................. 1920 

blood .................................... 2069, 2078 

Blood biomarkers ....... 1328, 1654, 2200 

BLOOD BRAIN BARRIER ... 785, 1365 

Blood Cadmium ............................. 1821 

Blood Pressure ....................... 666, 1727 

blood-brain barrier ........ 234, 281, 1210, 

1254, 2163, 2187 

Blue cohosh ...................................... 687 

BMAA .............................................. 167 

BMP ................................................. 125 

body weight .............................. 668, 918 

bone ........................................ 762, 2100 

bone lead ........................................ 1884 

bone marrow .................................. 1986 

Bone marrow toxicity........... 1549, 1551 

Boric Acid .................... 852, 1168, 2150 

Botanical ........................................ 2074 

BOVINE ............................... 1833, 1844 

Bovine Corneal Opacity and 

Permeability Assay ........................... 106 

BP-DNA adducts .............................. 131 

BPDE ............................................... 133 

brain ........................................... 22, 608 

brain development .......... 158, 855, 1604 

brain metabolism ............................ 1256 

BrdU ................................................. 178 

Breast Cancer ...... 120, 522, 1085, 1207, 

1338, 1885, 1999, 2000, 2001, 2003, 

2004 

breast cancer cells .......................... 2008 

Breast milk ....................................... 892 

Brevetoxin .............................. 843, 2179 

Bromate .......................... 811, 812, 1713 

Brominated Flame Retardant ........ 1542, 

1570 

brominated flame retardants .......... 1574 

Bromine ............................................ 502 

bromopropane .................................. 772 

bronchiolitis obliterans ................... 1490 

bsep .................... 623, 1051, 1062, 2122 

Buprenorphine ................................ 1575 

Burn wound ...................................... 483 

butachlor........................................... 509 

Butadiene ....................................... 1882 

Butyrylcholinesterase ........... 1237, 1243 

C-DIM ............................................ 1225 

c-FLIP ............................................ 1664 

C. elegans .... 460, 462, 464, 1286, 1287, 

1465, 1832 

C/EPB .............................................. 675 

C60 ................................................... 369 

Ca/NFAT ........................................ 1541 

Cache Valley ..................................... 287 

Caco-2 .................................... 790, 1101 

Caco-2 cell proliferation ................ 1102 

cadmium ................ 408, 424, 824, 1432, 

1465, 1811, 1813, 1816, 1818, 1819, 

1820, 1822, 1823, 1824, 1825, 1826, 

1827, 1828, 1829, 2093 

Cadmium (Cd) ................................. 823 

Caenorhabditis elegans .......... 184, 1607 

Caenorhabditis elegans ............ 82, 1262 

Caenorhabditis elegans, silver 

nanoparticles, pmk-1 ...................... 1699 

Caffeic acid phenethyl ester ........... 1762 

caffeine ........................................... 1572 

Calcineurin ..................................... 1677 

Calcium ...... 177, 717, 1157, 1364, 1817 

Calcium channel ............................. 1232 

calcium ions ..................................... 525 

calcium signaling ........................... 1284 

Calcium-independent phospholipase 

A2 ..................................................... 594 

Calibration ...................................... 1022 

caloric restriction ................. 1134, 1623 

Calpain ........................................... 1250 

CAM .............................................. 1004 

cAMP ............................................... 518 

cancer ...................... 119, 763, 770, 945, 

965, 967, 1321, 1368, 1369, 1370, 1407, 

1675, 1826, 1942 

Cancer mode of action ......... 1355, 1939 

cancer risk ...................................... 1937 

Cancer Risk Assessment ..... 1721, 1862, 

1863, 1910, 1943, 1946 

canine ............................................. 1309 

Cannabinoids .......................... 140, 1525 

CAPs .............................................. 1505 

Capsaicin ........................................ 1773 

CAR ........................... 1206, 2147, 2155 

CAR/PXR ...................................... 2205 

Carbamate ............................ 1034, 1246 

carbaryl .................................. 895, 1247 

carbon monoxide ............................ 2117 

carbon nanoparticles ............ 2041, 2180 

carbon nanotube ............................... 788 

carbon nanotubes ..... 789, 796, 797, 800 

carbon tetrachloride toxicity .......... 2013 

Carboxyl esterase ........................... 1674 

carboxylesterase ............................. 1251 

Carcinogenesis .......... 56, 121, 523, 528, 

650, 1344, 1345, 1347, 1348, 1433, 

1668, 1713, 1791, 1921, 1947, 2034, 

2170 

Carcinogenesis Screening ................ 698 

carcinogenesis testing ...................... 647 

carcinogenic ................................... 1921 

carcinogenicity ........ 228, 508, 645, 646, 

648, 649, 1082, 2005 

carcinogenicity study ............... 910, 911 

carcinogenomics .............................. 645 

Cardiac arrhythmia ......................... 1504 

Cardiac Contractility ........................ 600 

Cardiac Ion Channels ..................... 1732 

Cardiac mitochondria ..................... 1359 

Cardiac Risk ................................... 1732 

Cardiac Safety ................................ 1735 

cardiac toxicity ..................... 1420, 1725 

Cardiac Toxicology ........................ 1078 

cardiolipin ........................................ 598 

cardiomyocyte ................................ 1743 

cardiomyocytes .................................. 49 

cardiomyopathy ................................ 207 

Cardiopulmonary ............................. 603 

cardiotoxicity .................. 79, 206, 1520, 

1754, 1755 

cardiovascular ................. 41, 42, 43, 44, 

45, 441, 601, 606, 1068, 1308, 1500, 

1503, 1505, 1736, 1751, 1752, 1971 

Cardiovascular disease .......... 572, 1513, 

1742, 1897, 2178 

Cardiovascular safety pharm 

study ............................................... 1752 

Cardiovascular Toxicity ....... 1376, 1744 

Cardiovascular Toxicology ............ 1726 

career ...................... 659, 660, 661, 1415 

career development .................. 658, 661 

Career industry ................................. 661 

career planning ................................. 657 

caribou .............................................. 438 

carosine .......................................... 1136 

Case Studies ....................................... 11 

Case Study ....................................... 550 

caspase ........................................... 1211 

caspase-3/7 activity ........................ 1779 

Caspase2 .......................................... 138 

caspases .......................................... 2123 

Catalase ............................................ 863 

Cataract .......................................... 1643 

cataractogenesis ............................... 469 

category .......................................... 1799 

Cats .................................................. 669 

caveolin .............................................. 61 

CBER Perspective .......................... 1371 

CCD-18Co ....................................... 748 

CCI Model ..................................... 1048 

CCl4 ................................................. 889 

CCO ............................................... 1733 

Cd-inducible MT transcription ...... 1812 

CD159a .......................................... 1984 

CD209 ............................................ 1074 

CD40 Ligand .................................. 1525 

CD40L ............................................ 1533 

CD86/CD54 ..................................... 301 

CDODA-Me ..................................... 532 

CEES ................................................ 353 

Celiac Disease ................................ 1156 

Cell based assays ............................ 2091 

Cell biology .......................................... 6 

cell biomechanics ........................... 1858 

Cell cycle.............................. 1199, 1951 

Cell cycle arrest ................................ 811 

cell cycle protein ............................ 1705 

cell death ..... 770, 827, 865, 1214, 1218, 

1276, 1422, 1425 

Cell Differentiation .......................... 809 

cell line ........................................... 1405 

cell microarray ................................. 468 

cell migration ................................... 755 

Cell Proliferation .............................. 132 

cell signaling ................... 267, 576, 627, 

1312, 1694 

cell therapy ......................................... 51 

Cell transformation .......... 116, 525, 678 

cell viability ..................................... 789 

cell-based assays ............................ 1666 

cell-mediated immunity ................. 1991 

Cells ............................................... 1755 

cellular function ................................... 4 

Cellular Toxicity............................... 374 

Cerebrocortical neuronal culture .... 1613 

ceria nanoparticle ........... 269, 277, 2069 

cerium oxide ................................... 1398 

CFD .................................. 870, 871, 872 

CFD-PBPK .................................... 1491 

characterization ........................ 284, 801 

chelate ............................................ 2172 

chelators ........................................... 378 

Chem-informatics ............................ 215 

chemical ......................................... 1792 

chemical allergy ........................... 74, 75 

chemical and biological weapons .. 1848 

chemical carcinogenesis ................. 2004 

chemical database ............................ 882 

chemical exposure ..... 1175, 1192, 1848, 

2210 

chemical exposures .......................... 655 

chemical genetics ........................... 2002 

chemical hazard assessment ............. 610 

328 






chemical mixture ...................... 252, 495 

chemical mixture toxicity ................ 253 

Chemical mixtures ........................... 310 

chemical prioritization . 198, 1010, 1723 

Chemical Reactivity ............... 248, 1190 

Chemical Safety ............................. 1798 

chemical selection ............................ 215 

chemical toxicity .............................. 201 

chemical warfare agent .... 335, 346, 1014 

Chemical warfare nerve agents ........ 325 

chemical workers ........................... 1321 

chemical wound ............................... 483 

chemical-gene interaction .............. 2145 

Chemical-induced asthma ...... 299, 1701 

chemicals ................................ 653, 1320 

Chemicals/drugs ................................. 27 

cheminformatics ............................... 882 

Chemistry ....................................... 1183 

chemoconvulsant .............................. 784 

CHEMOKINE ............................ 72, 274 

Chemoprevention ............. 144, 535, 721 

chemotaxis ....................................... 755 

chemotherapeutic ............................. 519 

chemotherapy ................................. 1420 

child health ..................................... 2118 

children .............. 23, 24, 652, 653, 2121 

children’s exposure assessment ........ 651 

Children’s Health ............ 651, 654, 656, 

1650, 1910 

children’s risk ................................. 1911 

children’s risk assessment ... 1910, 1915, 

1934 

ChIP-chip ....................................... 1649 

ChIP-Seq ........................................ 1092 

chloracne ........................................ 2059 

Chlorinated Flame Retardants ........ 1173 

Chlorine ...................... 1015, 1016, 1017 

Chlorine Vapor ......................... 923, 931 

chloroform ........................................ 878 

chloronitrobenzenes ......................... 819 

chlorotriazine herbicides ................ 2098 

chlorpyrifos ........... 168, 837, 855, 1237, 

1243, 1248, 1262, 1599, 1865, 1887, 

1893, 1894, 2028 

Cholestasis ................. 1619, 1620, 2122 

Cholesterol 274, 1141, 1146, 1147, 1622 

choline transport ............................... 768 

cholinersterase .................................. 323 

cholinesterase inhibition ................ 2014 

Chondroitin .................................... 1142 

Chorioallantoic Membrane Vascular 

Assay (CAMVA) .............................. 106 

choroid plexus ....... 768, 983, 984, 2163, 

2173 

chromium .................... 734, 1128, 1145, 

1941, 2036 

Chromium (VI) .................... 1939, 1942 

chromosomal aberrations ....... 805, 1118 

chromosome number ........................ 799 

Chronic bronchitis .......................... 2158 

chronic toxicity .............................. 1131 

chrysin .............................................. 726 

chrysotile .............................. 1476, 1873 

cigarette ............................................ 668 

Cigarette smoke....... 511, 701, 732, 741, 

934, 1221, 1312, 1419, 1524, 1632, 

1742, 1827, 1976, 2193 

Cigarette smoke condensate ............. 694 

Cigarette Smoke Exposure ............. 1855 

cinnabar .......................................... 1177 

Circadian Clock ............................. 1467 

circadian expression ....................... 1998 

Circadian Rhythm .......................... 1718 

Cisplatin ............... 818, 821, 1224, 1641 

cisterna magna ............................... 1186 

clastogenic ........................................ 805 

clinic ................................................. 558 

clinical .................................. 1081, 2053 

clinical transplant ........................... 2054 

clock gene ...................................... 1829 

Clodronate ...................................... 1303 

CNS .................................................. 585 

CNVs .............................................. 1127 

co-exposures..................................... 393 

Co-Solvents ...................................... 342 

coagulation ..................................... 1958 

Coal ash .......................................... 1038 

coal cumbustion products............... 1935 

cobalt .................................... 2160, 2175 

cocaine ........................... 80, 1310, 1953 

Cochlospermum tintorium ............. 1058 

Cock Overn Workers ...................... 1860 

cognitive decline .............................. 859 

Cohort study ..................................... 655 

cold sensitivity ................................. 462 

Colipa ............................................. 1191 

Collagen ........................................... 866 

colon ................................................. 748 

colon cancer ..................................... 135 

colon carcinogenesis ...... 506, 517, 1652 

colony scoring .................................. 116 

colorants ........................................... 488 

Combination toxicity ....................... 318 

combined toxicity ........................... 1462 

combustion particles .............. 685, 1521 

Comet ............................................. 1117 

Comet assay .................... 354, 526, 717, 

1106, 1130 

common adverse outcome ................ 563 

common adverse outcomes ............ 1907 

comparative toxicity ....................... 2014 

comparison ....................................... 932 

Complement System ...................... 1197 

compounds of concern ................... 1999 

computation toxicology ..................... 96 

computational ......................... 206, 1382 

computational fluid dynamics .......... 868 

Computational Modeling ............... 1096 

Computational Screening ................. 203 

computational toxicology ........ 192, 204, 

209, 211, 213, 541, 542, 1010, 2074, 

2080, 2081 

Computerized Risk Assessment ..... 1036 

computional toxicology ................... 198 

conazole ......................................... 2154 

conazoles .......................................... 901 

Concanavalin A .............................. 1952 

Constitutive Androstane 

Receptor ......................................... 2146 

consumer products ............... 2215, 2220 

contact allergen ................................ 476 

Contact Allergy ................................ 308 

Contact Hypersensitivity .................. 297 

contact lens ......................................... 88 

contact sensitization ........................... 91 

contact sensitizers ............................ 307 

Contact Transfer ............................. 2049 

Contaminated soils ......................... 1039 

contrast medium ............................... 822 

control bioanalytical sampling ....... 1802 

control contamination .................... 1802 

Controlled Substance Act ............... 1790 

convulsion ........................................ 586 

COPD ............................................... 193 

COPD animal model ........................ 926 

COPPER .............. 370, 983, 1365, 2163 

copper neurotoxicity ........................ 996 

Corepressor .................................... 1472 

cornea ............................................... 347 

Corneal damage ............................... 479 

corregulator .................................... 2152 

Corrositex ......................................... 489 

covalent binding ..... 14, 17, 18, 315, 458 

Cox-2 .................................... 1204, 1889 

Cox10 ............................................. 1733 

Creatine kinase ............................... 1303 

cross-species translation ......... 586, 1637 

crystalline silica ............................. 1665 

Cumulative ............................. 569, 1906 

Cumulative Exposure ............... 565, 567 

cumulative risk ................ 563, 565, 567, 

568, 570 

cumulative risk assessment ..... 559, 564, 

566, 1907 

curcumin ................ 133, 152, 771, 1760 

curumin analogs ............................. 2007 

Cutaneous ................................. 923, 931 

CXCL16 ......................................... 1954 

CXCR3 ........................................... 1548 

Cyanide ........ 337, 338, 339, 1039, 1269 

cyanobacteria ................................... 230 

Cyanuric acid ......................... 817, 1140 

cyclin D1 .......................................... 134 

cyclin-dependent kinase ................. 1206 

Cyclin-Dependent Kinase 4 ........... 1199 

Cyclodextrins ................................. 1669 

Cyclooxygenase-2 ................ 1774, 1777 

Cyclophilin D ................................. 2130 

Cyclophosphamide ........................... 867 

cyclosporin A ................................... 673 

Cyclosporine A................................. 719 

Cynomolgus ..................................... 832 

Cynomolgus monkey ...... 379, 605, 918, 

1093 

Cynomolgus monkeys ...................... 919 

cyp .................................................. 1094 

cyp 1a1 ........................................... 1205 

CYP enzymes ................................... 357 

CYP1 ................................................ 356 

CYP1A1 .... 154, 950, 1194, 1720, 1762, 

1773, 2058, 2167 

CYP1A2 ........................................... 455 

CYP1B1 ........................................... 154 

Cyp2a5 ........................................... 1099 

CYP2S1.......................... 132, 451, 1712 

CYP3A ........................................... 1091 

CYP3A11 ....................................... 1090 

CYP450 .......................................... 1089 

CYP4F3............................................ 527 

Cystatin C......................................... 806 

cystic fibrosis ......................... 740, 1064 

cytochrome c .................................... 978 

Cytochrome c oxidase inhibition ..... 339 

Cytochrome P450 .......... 454, 456, 1086, 

1088, 1094, 1098, 1712, 1778 

Cytochrome P450 2E1 ................... 1253 

cytochrome P450 reductase ........... 1100 

Cytochrome P4501B1 ...................... 457 

Cytochrome P450s ..... 1097, 2000, 2019 

cytokine .................. 290, 313, 735, 1992 

Cytokine release ............................. 1404 

Cytokine storm ............................... 1404 

Cytokines ................ 4, 63, 75, 267, 481, 

574, 674, 711, 760, 961, 1317, 1406, 

1555, 2176 

cytokines and inflammatory gene 

expression............................................. 9 

Cytoskeleton .................................. 1818 

Cytostatsis ........................................ 593 

Cytotoxic T Lymphocyte ............... 1528 

Cytotoxic T Lymphocyte (CTL) .... 1546 

cytotoxicity 88, 117, 126, 236, 292, 375, 

724, 789, 1031, 1121, 1229, 1464, 1657, 

1957 

cytotoxicity assays ......................... 1180 

cytotoxicity model.......................... 1607 

Cytotoxicity screening ................... 1411 

D2 receptors ..................................... 981 

dampness .......................................... 298 

danger signals ................................... 314 

danofloxacin ................................... 1680 

dapsone .......................................... 1760 

DART ................................................... 7 

data acquisition ................................ 915 

Data analysis .................................... 197 

Data Mining ................................... 1899 

database ............................................ 646 

DBS samples .................................. 1073 

DDT ..................................... 1888, 1899 

decontamination ............................. 1175 

Decosahexaenoic acid .................... 1025 

Deer mice ......................................... 907 

deer velvet ........................................ 506 

degradates....................................... 1006 

DEHP ............... 1470, 1483, 1484, 1489 

Dehydrogenation .................. 1097, 1098 

deiodinase ........................................ 482 

Delayed neurotoxicity .................... 1381 

delayed-type hypersensitivity ........ 1991 

delta-9-tetrahydrocannabinol ......... 1528 

deltamethrin ............... 1234, 1251, 1568 

DENDRITIC CELL ........... 72, 306, 476 

dendritic cells ................. 303, 956, 1532 

Dentritic Cells ................................ 1535 

Denufosol ....................................... 1064 

Deoxynivalenol ..................... 827, 1143, 

1460, 1463, 1785 

depleted uranium .................. 2170, 2171 

deposition ......................................... 329 

Dermal ................ 68, 99, 493, 508, 2066 

dermal absorption .. 495, 891, 902, 2046, 

2048 

Dermal Absorption Studies ............ 2051 

dermal exposure ......... 1329, 1870, 2045 

Dermal Sensitizers ........................... 490 

dermal toxicity ................................. 500 

desethylamiodarone ....................... 1229 

detoxication .......................... 1720, 1897 

detoxification ................................... 455 

detoxification enzyme .................... 1103 

developing mice ............................. 1574 

Developing no-human primate ......... 865 

development .............. 78, 169, 379, 386, 

659, 680, 831, 833, 845, 861, 995, 1518, 

1603, 1691, 2023 

development and regulatory 

requirements ................................. 2, 857 

developmental ... 835, 1148, 1392, 2025, 

2197 

Developmental & Reproductive 

toxicity ................................... 857, 1173 

developmental (neur)toxicity ......... 1977 

Developmental (Neuro)toxicity testing 

(DNT) ............................................... 862 

developmental and reproductive 

toxicology ....... 1434, 1435, 1436, 1437, 

1438, 1439 

developmental exposure ................. 1975 

Developmental Immunotoxicity ...... 841 

developmental immunotoxicology ....856, 

1976, 2192, 2193 

developmental neurotoxicity ... 156, 157, 

164, 165, 173, 175, 176, 178, 421, 837, 

1230, 1388, 1391, 1393, 1612, 1929 

Developmental Neurotoxicity 

Testing .............................................. 182 

developmental neurotoxicology ...... 172, 

1601, 2024 

developmental origins of adult 

disease ............................................ 1261 

Developmental Toxicity .......... 147, 195, 

409, 830, 832, 913, 1188, 1680, 1688, 

2192 

Developmental toxicology ...... 391, 728, 

838, 842, 843, 858, 1386, 1683, 1684, 

1685, 1726 

Dexamethasone .................................. 70 

dextran ............................................ 1514 

DFP ................................................ 1233 

Di (2-ethylhexyl) phthalate ............ 1019 

Di (n-butyl) phthalate ..................... 1973 

Di-isobutyl phthalate ........................ 840 

Di-n-butyl Phthalate ......................... 381 

Diabetes ................... 572, 573, 574, 813, 

963, 1362, 1367, 1624, 1824, 1899, 

2100, 2101 

Diacetyl ...................... 1022, 1490, 1491 

diarrhea ............................................ 917 

diazinon .......................................... 1896 

dibutylphthalate .............................. 1646 








dichlorodiphenyltrichloroethane ...... 220 

diclofenac ............................... 294, 1597 

Dieldrin .......................................... 1236 

Diesel ............................................. 1857 

Diesel exhaust .... 480, 1493, 1500, 1730 

diesel exhaust particle .................... 1858 

Diesel exhaust particles ....... 1497, 1512, 

1513 

Diet ........... 974, 1149, 1157, 1164, 1627 

diet induced obesity ....................... 1639 

diet restriction .................................. 340 

Dietary Phytochemicals ....... 1778, 1782 

Dietary Supplement ....................... 1139 

diethyl nitrosamine ........................... 134 

diethylhexylphthalate ..................... 1646 

Diethylstilbestrol ................................ 70 

Differentiation ........................ 833, 1689 

dihydro-N-caffeoyltyramine .......... 1777 

diindolylmethane............................ 1780 

DILI ................................ 555, 558, 2126 

Dimercaptosuccinic acid ................ 1842 

dimethylnitrosamine ...................... 1759 

Dinitrobenzene ................................. 183 

dinitrotoluene ................................... 348 

dioxin ...174, 430, 682, 1715, 1871, 1872 

Dioxins ......................... 642, 1038, 2063 

Diquat ............................................... 773 

Discovery ....................................... 1377 

Discovery Toxicology ......... 1374, 1375, 

1376, 1378, 2030 

disease .................................... 212, 1422 

Disease and Susceptibility ............. 1503 

disease biomarker ............................... 55 

disease models ............................... 1335 

Disinfection ByProducts .................. 247 

disposition ............................ 1573, 1574 

Disulfiram ...................................... 1214 

DIT ................................................. 2194 

dithiocarbamate .............................. 1239 

Diversity Panel ................................. 365 

DMSO .............................................. 709 

DNA ....................................... 712, 1698 

DNA adduct ..................................... 713 

DNA adducts .................. 143, 718, 1137 

DNA binding .................................. 1203 

DNA chip ....................................... 1651 

DNA damage ............. 66, 125, 136, 352, 

496, 704, 710, 715, 717, 811, 936, 1123, 

1126, 1128, 1860, 2171 

DNA damage responsive genes...... 1998 

DNA damages ................................ 1951 

DNA double-strand breaks ............. 1174 

DNA fragmentation .......................... 828 

DNA Methylation ............................ 154 

DNA Oxidation ................................ 708 

DNA repair .............. 135, 361, 702, 703, 

705, 707, 714, 1601 

DNA strand breaks ........................... 709 

DNEL ............................................. 1788 

DNT ............................................... 1412 

DNT test ........................................... 161 

dog.................................. 606, 928, 1073 

DOHaD .......................................... 1972 

DON ............................................... 1552 

Donepezil ....................................... 1563 

DOPAL ........................................... 1271 

dopamine ...... 162, 979, 981, 1294, 2027 

Dopamine metabolism ................... 1275 

dopaminergic neurons .................... 1270 

dose formulation .................. 1587, 1589 

dose reconstruction .......................... 897 

Dose-Response ............... 36, 1645, 1922 

Dose-Response modeling ............... 2044 

dose-additivity .................................... 37 

dose-response ........... 37, 40, 1351, 1877 

Dose-Response Curves .................. 1917 

dosimetry........................ 870, 883, 1693 

doxorubicin ........ 815, 1086, 1731, 1756 

Doxycycline ................................... 1213 

DRE................................................ 1540 

Dried blood spots ........................... 1846 

drinking water .................................. 397 

drug .................................... 81, 547, 616 

Drug accumulation ......................... 1076 

Drug Allergy .................................... 538 

Drug Cardiotoxicity ....................... 1642 

Drug Development ............... 1374, 1735 

Drug hepatotoxicity ....................... 2122 

drug induced liver injuries (DILI) ....1049 

drug metabolism ............................. 1334 

Drug Safety .................................... 1444 

Drug safety assessment ........ 1736, 2184 

Drug Scheduling ............................ 1790 

drug toxicity ..................................... 357 

drug transporters ............................ 1598 

drug-drug interaction ..................... 1088 

drug-induced hepatotoxicity ... 85, 2133, 

2134, 2135 

drug-induced liver injury......... 554, 906, 

1550, 1654, 2199 

Drug-induced Toxicity ................... 1666 

drug-induced vascular injury ......... 1745 

drugs ................................................. 243 

duox................................................ 1672 

dysfunction ..................................... 1424 

EAE .......................................... 76, 1282 

Early Growth Response Factor-1 ... 1619 

Early Predictive Biomarkers .............. 54 

ECG .................... 602, 1504, 1810, 2116 

Echocardiography ............................ 603 

ecolabel .......................................... 2216 

ecotoxicology ..... 900, 1445, 1446, 1451 

education .................................. 941, 944 

EEG .............................. 586, 1246, 1324 

EGF Signaling ................................ 1696 

EGFR ....................................... 585, 964 

ELAVL1 ............................................. 60 

Electrocardiogram ................ 1498, 1501 

Electrocardiography ..... 604, 1522, 1752 

electrochemical profiling ............... 1136 

electrochemiluminescence ............. 1990 

electron beam ................................... 435 

Electron microscopy ...................... 1154 

Electron spin resonance ................... 480 

electrophysiology .......... 164, 216, 1232, 

1259, 2029, 2030, 2032, 2033 

electroretinography .......................... 932 

ELISA ............................................ 1994 

ellagitannin ..................................... 1783 

Embedded metal fragments ............ 1880 

Embryo ................................. 1382, 1387 

Embryofetal development ........ 851, 852 

embryonic development ................... 994 

embryonic stem cell ....................... 1394 

Embryonic Stem Cell Test ............. 1690 

Embryonic stem cells ..................... 1689 

Embryopathies ................................. 863 

embryotoxin ....................................... 87 

EMEA .............................................. 549 

emergency response ....................... 1024 

Emodepside ...................................... 729 

emodin ............................................ 1174 

emphysema ...................................... 926 

endocannabinoid .............................. 168 

Endocannabinoids .......................... 1527 

Endocrine ......................... 113, 418, 420 

endocrine active agent .................... 2108 

Endocrine Disrupters ..................... 1452 

endocrine disrupting chemical ...... 2102, 

2108 

endocrine disrupting compound ....... 389 

endocrine disruption ...... 433, 912, 2096, 

2113 

Endocrine disruptor ... 1453, 1454, 2089, 

2091, 2098, 2107, 2108 

endocrine disruptors ............... 101, 2085 

Endocytosis ...................................... 282 

endogenous fructose ....................... 1959 

Endometrial cancer .......................... 456 

endonuclease .......................... 828, 1223 

endonuclease G .............................. 1224 

endoplasmic reticulum stress ......... 1001 

Endosulfan ........................... 1545, 1889 

Endothelial cell proliferation ........... 516 

endothelial cells .... 287, 513, 1363, 1477, 

1493 

endothelial dysfunction .......... 256, 1687 

Endothelial function ......................... 663 

endothelial progenitor cell ............. 1478 

Endothelial progenitor cells ............. 758 

Endothelin ........................................ 422 

endothelium .......................... 1224, 2022 

Endotoxin ......................................... 877 

Endotoxins ....................................... 759 

endrocrine disruptor ....................... 1449 

engineered nanoparticles .................. 371 

eNOS .............................................. 1776 

Enrichment ....................................... 917 

enterochromaffin-like cell ................ 509 

Enterosorbent ................................... 970 

environmental accident .................. 1414 

environmental chemicals ................ 2088 

environmental compounds ................... 7 

environmental contaminant ..... 171, 180, 

200 

Environmental Estrogen ................. 2000 

environmental exposure ......... 9, 55, 112 

Environmental Tobacco Smoke ..... 1855 

enzyme assay ................................... 332 

enzyme inactivation ....................... 1098 

enzyme induction ..................... 454, 888 

enzyme replacement therapy .......... 1061 

Epidemiology ................................... 664 

EpiDerm ..................................... 62, 489 

epidermis .......................................... 497 

Epididymis ....................................... 411 

epigenetic ................................. 146, 971 

epigenetic toxicity .......................... 1428 

Epigenetics .............. 145, 147, 148, 151, 

152, 838, 1345, 1602, 1604, 1686 

epileptogenesis ................................. 784 

EpiSkin ..................................... 504, 505 

Epithelial tumor cells ....................... 746 

EPR .................................................. 254 

ER Stress .............................. 1288, 1552 

ERalpha .......................................... 1208 

ErbB3 ............................................. 1050 

erionite fibers ................................. 1876 

ERK ...................................... 1248, 1820 

ERK Osciallations ............................ 678 

Erlotinib ......................................... 1667 

Erythrocyte ............................. 905, 1838 

Erythrocytes ................................... 1193 

erythrophagocytosis ....................... 1217 

ES-D3 ............................................. 1686 

esophageal cancer .................... 131, 142 

esterases ......................................... 1249 

Estrogen ............... 510, 966, 1002, 1280 

estrogen metabolism ...................... 1885 

estrogen receptor . 101, 120, 1408, 1453, 

2105, 2112 

Estrogen receptor alpha .......... 395, 2091 

estrogen receptors .......................... 2106 

estrogen-like-effects ......................... 408 

Estrogenicity ............................ 236, 389 

estrogens .................................... 97, 435 

Ethanol .................. 686, 762, 863, 1091, 

1517, 1634, 1691 

ethics ................................................ 942 

Ethyl Methanesulfonate ................... 551 

Ethylbenzene .................................. 1189 

ethylenebisdithiocarbamate ............ 1890 

ETS and Inflammation ................... 1855 

Eugenol ............................................ 442 

Evidence based medicine ................. 612 

Evidence based toxicology .............. 612 

Evolution ........................................ 1164 

excipient ......................................... 1803 

Excipients ....................................... 1593 

Excitotoxicity ................................... 587 

Exhaled breath ................................... 55 

Experimental autoimmune 

encephalomyelitis ............................ 909 

exposure .......... 653, 664, 733, 891, 923, 

931, 1150, 1332, 1457, 1750, 1853, 

1857, 1867, 1873, 1916, 1930, 2202 

Exposure Assessment .. 944, 1240, 1328, 

1850, 1851, 1864, 1868, 1871, 1872, 

1879, 1880, 1933 

exposure measurement ................... 1874 

exposure model .............................. 1856 

exposure models ............................. 1933 

exposure monitoring ............ 1868, 1881 

Exposure sources ............................. 639 

exposures ........................................ 1793 

expression....................................... 1651 

extended one generation study ........ 419, 

420, 421, 610 

External telemetry ............................ 604 

Extra-hepatic metabolism ................ 510 

Extracellular Matrix ......................... 476 

extracellular signal-regulated 

kinase 1/2 ....................................... 1215 

Extractables and Leachables .......... 1007 

Extrapolation .................................. 1913 

Extreme pH ...................................... 489 

extrusion cooking ........................... 1159 

eye ............................................ 102, 351 

eye irritation .................... 104, 473, 475, 

488, 1190, 1191 

Eye Irritation Test ..................... 103, 474 

F2-isoprostanes ................................ 761 

Faropenem Medoxomil .................. 2114 

Fas and FasL regulation ................. 2195 

FasL ................................................ 1664 

Fasting ............................................ 1637 

Fathead Minnow .............................. 205 

fatty acid hydroperoxides ................. 451 

Fatty acyl .......................................... 877 

Fatty liver disease ....... 1357, 1360, 1627 

FB1, DON, ZEA ............................ 1462 

FDA .................................................. 548 

FDA Critical Path Initiative ............... 46 

fear conditioning .............................. 160 

Feature Selection ............................ 1854 

federal funding ............................... 2083 

Feed formulation .............................. 840 

female pubertal assay ..................... 2110 

Female Puberty .............................. 2098 

female reproduction ............... 400, 2088 

Female reproductive tract ............... 2005 

fenamiphos ..................................... 1028 

Fenoldopam .................................... 1745 

Fentanyl Citrate ................................ 376 

Fenvalerate ....................................... 413 

ferroportin ........................................ 999 

Fertility ....................................... 27, 432 

Fertility study ..................................... 29 

fescue toxicosis .............................. 1134 

fetal ................................................ 2115 

Fetal alcohol spectrum disorder ....... 686 

fetal basis of adult disease ... 1427, 1974, 

1976 

fetal testis ....................................... 1488 

FETAX ............................................. 681 

fiber pleura toxicology ................... 1476 

fibrosis ................... 122, 797, 933, 1026, 

1634, 1636, 1759 

Fick’s Law ........................................ 902 

FIH ................................................. 1003 

fish .. 429, 431, 433, 437, 683, 912, 1786 

Fish intake ...................................... 1869 

FK506 ............................................ 1989 

flame retardant ......................... 115, 125 

Flame Retardants ................... 644, 1021 

flavonoids ....................................... 2097 

flavoring ......................................... 1506 

flow cytometry .............................. 1042, 

flow cytometry data........................ 1170 

fluconazole ......................................... 77 

330 






fluoride ................................... 826, 1385 

Fluorinated compounds .................... 450 

fluorinated hydrocarbons ................. 227 

Fluoroquinolone ............................. 1120 

fluoxetine ................................. 429, 432 

fluxomics.......................................... 636 

fly ash ............................................. 1414 

follicle-stimulating hormone ............ 398 

Food ..................................... 1040, 1178 

Food Additive ................................... 213 

food allergy .............. 293, 294, 295, 538 

food defense ......................... 1152, 1153 

food intake ..................................... 1785 

Food Safety .......................... 1144, 1160 

Food Survey ..................................... 642 

Formaldehyde... 143, 210, 520, 665, 868 

FPP-3.............................................. 1963 

Fragrance .......................................... 401 

Fragrance ingredient ...................... 1110 

Fragrance ingredients ..................... 1011 

Free Radicals .................. 778, 781, 1105 

FRY ................................................ 2001 

FSH, LH, Estradiol, Progesterone .... 919 

Fullerene ........................ 792, 802, 1402 

fullerene nanomaterials .......... 791, 1252 

Fumigant ........................................ 1385 

Fumonisin ............................ 1456, 1459 

fumonisins ...................................... 1159 

Functional Genomics ....................... 774 

Fungi ................................................ 737 

fungicide ........................................ 1904 

Furan .......................... 1137, 1138, 1150 

Furocoumarins ............................... 1144 

Fusarium toxins, ............................. 1462 

FXR ................................................ 1466 

G-protein coupled receptor 

(GPCR) .......................................... 1659 

G2 arrest ......................................... 2007 

gaba ........................................ 216, 1000 

Gaba-receptors ............................... 2140 

Gabapentin ........................... 1048, 2140 

Gadd45 ........................................... 1125 

gamma irradiation ............................ 754 

gamma-tocopherol quinone ............. 688 

gammadelta T cells .......................... 293 

gap junction .................................... 1085 

GAPDH .......................................... 1747 

gas and vapor uptake ........................ 869 

gas chromatography ....................... 1605 

Gasoline ........................................... 124 

gastric cancer ................................... 529 

gastro-intestinal barrier .................... 233 

Gastrointestinal function .................. 940 

GDNF Signalling ........................... 1487 

gender ..... 1416, 1417, 1418, 1420, 2106 

gender difference ............................ 1618 

Gender differences ........................... 742 

gene array ....................................... 1543 

Gene Environment Interaction ......... 654 

gene expession ............................... 2094 

gene expression ......... 39, 221, 394, 635, 

730, 816, 837, 1202, 1343, 1644, 1655, 

1659, 1686, 1703, 1704, 1706, 1708, 

1709, 1717, 1718, 1758, 2141, 2178, 

2212 

Gene expression analysis ............... 2077 

gene expression profile .................... 507 

gene expression profiles ................. 1640 

Gene regulation 1203, 1469, 1718, 2146 

gene regulatory network, nonlinear, 

feedback ......................................... 1455 

gene regulatory networks ............... 1452 

gene transfection .............................. 468 

gene-environment ................. 1830, 1831 

gene-environment interaction............... 9 

genetic diversity ....................... 362, 363 

Genetic markers ............................. 1306 

genetic polymorphism ...................... 898 

genetic polymorphisms .................. 1928 

genetic susceptibility ....... 157, 173, 175, 

1333, 1344 

genetic suseptability ......................... 591 

genetic toxicity ............................... 1148 

genetic toxicology ..... 1349, 1353, 1703, 

1968 

genetic variation ........... 366, 1334, 1335 

genetically modified ............. 1180, 1181 

Genetically-modified food ............. 1154 

genetics .... 937, 1164, 1332, 1336, 2024 

genistein ......................... 330, 445, 2101 

genomic database ............................. 214 

genomic responses ......................... 1486 

genomics .... 364, 502, 1643, 1843, 1938 

genomics technologies ......................... 6 

Genotoxic ................................. 547, 707 

Genotoxic Effects ............................. 793 

Genotoxic Impurities ............... 548, 549 

genotoxic impurity ........................... 688 

Genotoxicity ............ 126, 266, 292, 354, 

375, 550, 552, 695, 696, 697, 699, 700, 

703, 704, 711, 713, 716, 718, 1011, 

1109, 1111, 1113, 1114, 1115, 1116, 

1121, 1125, 1126, 1127, 1128, 1130, 

1162, 1170, 1172, 1351, 1354, 1660, 

2171 

Genotoxicity - Mechanism of 

action .............................................. 1124 

genotoxicity risk assessment .......... 1352 

genotoxicity testing ........................ 1350 

Genotoxicology ................................ 262 

germ cell ................................... 393, 394 

Gestation ................................ 854, 1384 

GHS ................................................ 1795 

GHS categories ................................ 199 

GHS classification.................. 498, 1799 

GHS hazard classification .............. 1794 

GHS-EU ........................................... 505 

GI Injury ............................................. 54 

Ginger ............................................ 1178 

Ginkgo biloba ....................... 1133, 1758 

ginkgolide A ................................... 1133 

Glia ................................................. 1296 

Glial plasmalemmal vesicle ........... 1840 

Glinus lotoides ............................... 1123 

global ................................................ 941 

Global Gene Expression 

Alterations ...................................... 1625 

Glucocorticoid ................................ 2084 

glucocorticoid receptor .................. 1606 

glucocorticoids ............................... 2088 

Glucocorticoids receptor ................ 1468 

gluconeogenesis ............................... 725 

Glucosamine .................................. 1142 

glucose uptake ........................ 584, 1053 

Glucuronidation ............................. 2090 

glutamate receptor subunit protein ... 171 

glutamate transporter ..................... 1002 

glutathione ............. 276, 779, 946, 1293, 

1497, 1524, 1562 

Glutathione S-transferase ...... 402, 1102, 

1830 

glutathione S-transferases .............. 1716 

glutatione S-transferases .................. 446 

Gluten ............................................. 1156 

Glycine N-methyltransferase ........... 683 

glycogen synthase kinase-3 ............ 1366 

glycosylation .................................... 296 

Glyphosate herbicides .................... 1291 

gold .................... 279, 1695, 1696, 1707 

gold nanoparticle ............................ 1694 

gold nanoparticles ..... 1544, 1692, 1701, 

1709 

goniothalamin ................................ 1211 

Göttingen mini-pig ................. 920, 1729 

grant ................................................. 662 

granulomatous inflammation ......... 1399 

granulosa cells ................................ 1483 

Graphene .......................................... 798 

green chemistry .............................. 2219 

green fluorescent protein (GFP) ....... 996 

green products ... 2215, 2216, 2218, 2220 

Greenscreen .................................... 1125 

Group specific component ............. 1305 

Growth Factors ................................. 513 

GRP78 ............................................ 1001 

GSEA ............................................... 191 

GSTM1 ............................................ 914 

guidance ......................................... 2096 

Guidelines ...................................... 1915 

Guillain Barre Syndrome ................. 667 

Gum Guggul Extract ...................... 1132 

h-CLAT ............................................ 301 

H-Cpr-null mouse .......................... 1617 

H295R ............................................ 2097 

HaCaT .............................................. 111 

HAIR .............................................. 1833 

hair cells ............................................. 86 

hairless guinea pig .............................. 64 

halogenated acetonitriles .................. 253 

halothane .................................... 77, 590 

Hardmetal ....................................... 2165 

Hazard assessment .... 1030, 1156, 1182, 

1723, 1978 

hazard communication ................... 1795 

hazard identification ....................... 1870 

HCS ................................................ 1079 

health hazard evaluation ................. 1904 

Health Hazards ..................... 1413, 2158 

health intervention.......................... 1801 

health risk assessment .......... 1013, 2048 

health risks ..................................... 1944 

Hearing loss ................................... 1265 

heart .................................. 80, 440, 1737 

heart development .......................... 1202 

heart failure model ......................... 1522 

HEART VALVE ................... 1084, 1724 

heart ventricle ................................... 235 

heat shock protein .......................... 1281 

heat shock proteins ......................... 1675 

heat stress ....................................... 1134 

Heavy Metals ................................... 974 

Hemangiosarcoma .................... 512, 679 

hematopoiesis ....................... 1681, 1682 

Hematopoietic Stem Cell ................. 136 

hematotoxicity ...... 672, 780, 1678, 2185 

heme oxygenase ............................... 775 

Heme oxygenase-1 ........................... 777 

hemodynamics ............... 605, 607, 1730 

Hemoglobin .................................... 1193 

Hemoglobin Adducts ..................... 1847 

Hemolytic anemia ............................ 905 

hemotoxicity .................................... 187 

HepaRG cells ................................. 2135 

hepatic effects ................................ 2061 

hepatic fibrosis ............................... 1974 

hepatic function .............................. 1072 

hepatic tissues ................................ 1961 

Hepatic Toxicology ........................ 1079 

hepatic transport ............................. 2104 

hepatic transporters ........................ 1616 

hepatitis ................................ 1458, 1529 

hepatobiliary .................. 625, 816, 1062 

Hepatocarcinogenesis .. 742, 1967, 2156 

hepatocellular ................................. 1705 

hepatocellular carcinoma ..... 1343, 1458 

Hepatocellular Volume ................... 1595 

hepatocyte ............................ 1957, 1964 

hepatocytes ..... 450, 556, 613, 624, 1080 

hepatosteatosis ................................. 787 

Hepatotoxicants .............................. 2200 

Hepatotoxicity ..... 58, 94, 374, 581, 623, 

624, 625, 1320, 1409, 1466, 1565, 1638, 

1653, 1953, 1954, 1963, 2125, 2137, 

2201 

hepatotoxicology .............................. 773 

Hepatotoxin .................................... 1968 

Hepatoxicity ......................... 1960, 1969 

herbicide ............................... 1903, 2113 

herbicide diuron ............................... 507 

hERG .......................... 1754, 1755, 2033 

HESI ............................................... 1349 

hexachloroethane ........................... 1924 

Hexavalent chromium .... 138, 677, 1943 

HgCl2 ............................................. 2095 

HIF-1 .............................................. 1711 

HIF-1 alpha ...................................... 368 

HIF-1alpha ..................................... 2175 

high concentration .......................... 1012 

high content analysis ...................... 1666 

high content biology ................ 83, 1410 

high content cell-based imaging .... 2002 

high content imaging .............. 755, 1409 

High Content Screening ...... 1078, 1311, 

1316 

High-content screen ......................... 156 

high-content screening assay ......... 2126 

high fat diet .................................... 2101 

high-fat diet ...................................... 963 

High Productive Volume (HPV) 

Challenge ....................................... 1797 

high saturated-fat diet ...................... 767 

high-throughput ............................ 6, 545 

high-throughput screening .... 543, 1194, 

1380, 1717 

high-throughput testing ............ 108, 546 

Hippocampus ....................... 1606, 1610 

histone H2AX ................................ 1120 

Histone H3 lysine 4 methylation ...... 153 

Histone Modification ............. 149, 1209 

Histones ............................................ 150 

histopathology ................................ 1058 

HIV ...................................... 1057, 2121 

HIV gp120 ..................................... 1528 

HIV/AIDS ...................................... 1057 

HMB .............................................. 1573 

HMGB1 ................ 740, 745, 1665, 2136 

HMPCC............................................ 401 

HO-1 .............................. 950, 992, 1763 

hoiamide A ..................................... 1165 

homeland security .......................... 1024 

Homologous Recombination ........... 848 

Homology modeling ...................... 1381 

Hopane-type saponin ..................... 1123 

hormesis ......................................... 1922 

host resistance ................................ 2057 

HPLC ............................................. 1163 

Hras ................................................ 2142 

HRIPT ............................................ 1176 

HSulf-1 ........................................... 1828 

HTS ............................................ 96, 542 

human ............................ 201, 577, 1536, 

1857, 1927, 1996 

human alpha-fetoprotein ................ 1386 

human beta-defensin ...................... 2059 

Human beta-defensin-1 .................... 952 

Human bronchial epithelial cells ... 1306 

human development ....................... 2141 

human embryonic stem cells ............ 613 

human epidermal model ................. 1130 

Human Exposures ............................ 644 

human health .................................. 1018 

Human Health Risk Assessment ... 1009, 

1013, 1917, 1928 

human hepatocytes ......................... 1095 

human lung cells .......... 452, 1515, 1858 

human metabolism ......................... 1019 

human milk .................................... 2063 

human placenta .............................. 1598 

human polymorphism ........................ 71 

human primary alveolar cells ......... 1221 

human serum albumin .................... 2186 

human skin model ............................ 500 

human stem cell ............................. 1389 

Human Tissue................................. 1735 

humane endpoints ............................ 938 

Humanized Liver .............................. 906 

humanized models ......................... 2208 

humanized mouse ....... 2203, 2204, 2205 








humans ........................................... 2066 

humoral immune response ............. 1525 

Huntington disease ................... 993, 997 

hydrofluoric acid .................. 1175, 1192 

hydrogen peroxide ......................... 1215 

Hydroquinone .......................... 514, 780 

hypercholesterolemia ....................... 227 

hyperglycemia ................................ 1775 

Hyperoxia ............................... 457, 2120 

hyperoxia lung injury ....................... 598 

hypersensitivity ........ 304, 305, 316, 618 

Hypersensitivity dermatitis ............ 1304 

Hypertension .......................... 663, 1498 

Hyperthyroidism ............................ 1714 

hypertrophy .................................... 1733 

Hypo-allergenic .............................. 1176 

hypothalamic-pituitary axis ............. 406 

hypothalamic-pituitary-adrenal 

axis ................................................. 2087 

hypothyroidism .............. 158, 160, 1714 

Hypoxia ...... 153, 513, 1212, 1636, 2175 

Hypoxia Inducible Factor..... 1196, 2137 

Hypoxia Inducible Factor (HIF) ...... 512 

Hypoxia-Ischemia .......................... 1218 

ICH Guidelines .................................. 11 

ICH S6 ........................................... 1435 

ICH S9 guidance ............................ 1787 

Idiosyncratic ......... 313, 365, 1441, 2125 

idiosyncratic drug reactions ...... 16, 314, 

315, 1071 

Idiosyncratic Hepatotoxicity .......... 1071 

Idiosyncratic liver toxicity ............. 2123 

IdMOC ................................... 322, 1411 

idursulfase-IT ................................. 1061 

IFN beta ......................................... 1046 

IFNgamma ..................................... 1556 

Ig heavy chain ...... 71, 1536, 1538, 1539 

IgE ............................................ 296, 302 

IGF-1 ................................................ 583 

III-V semiconductors ..................... 2043 

IL-1 receptor .................................... 417 

IL-8 .................................. 130, 749, 958 

image analysis ................................ 1113 

immune ............................................ 327 

immune cells .................................... 328 

immune complex ...................... 615, 620 

Immune dysfunction ...................... 2195 

immune function .................... 935, 2192 

immune response ........................... 1722 

immune-competent .......................... 291 

immune-mediated .............................. 16 

immunity suppression ...................... 631 

immunogenicity ........... 619, 1046, 1990 

immunohistochemistry ................... 1656 

immunomodulation ....... 371, 540, 2052, 

2053, 2056, 2057 

Immunomodulator ............................ 747 

immunomodulators .............................. 4 

immunophenotyping .. 1979, 1983, 1984 

Immunosuppression .. 1530, 1980, 1989, 

1997, 2054, 2184 

immunotoxicity ................. 78, 304, 305, 

309, 326, 1177, 1523, 1542, 1562, 1608, 

1978, 1982, 1993, 1996, 2124, 2184, 

2185, 2189, 2196 

Immunotoxicology .. 312, 315, 317, 536, 

1189, 1722, 1980, 1981, 1991, 2052, 

2053, 2054, 2055, 2180, 2181, 2188 

impedance ...................................... 1657 

Imposex ............................................ 436 

Impurities ................................. 547, 552 

impurity .......................................... 1118 

in silico ............... 195, 1348, 1386, 1450 

in utero ............................................. 971 

in utero exposure ............................ 1485 

in vitro ....................... 99, 102, 164, 249, 

442, 471, 473, 556, 613, 650, 819, 1116, 

1245, 1252, 1401, 1555, 1611, 1658, 

1702, 1960, 2102, 2190 

in vitro - in vivo ................................ 250 

in vitro airway model ............... 470, 477 

in vitro alternative ... 107, 112, 303, 306, 

1598 

in vitro Alternative Method .... 412, 1926 

in vitro alternatives ..................... 97, 500 

in vitro Animal Alternative Method 103, 

1966 

in vitro assay .................................... 181 

in vitro assays ................. 366, 380, 1982 

in vitro cytotoxicity ................ 114, 1692 

in vitro developmental neurotoxicity 

testing ............................................... 181 

in vitro dosimetry ............................... 92 

in vitro HTS........................................ 98 

in vitro human skin model.............. 2060 

in vitro Human Skin Models ............ 112 

in vitro micronucleus assay .... 472, 1172 

in vitro model ............... 753, 1389, 1540 

in vitro models................................ 1124 

in vitro screening ..... 109, 118, 181, 190, 

1051 

in vitro skin absorption........... 891, 2050 

in vitro Skin Diffusion.................... 2047 

in vitro skin model ................... 477, 478 

in vitro testing ...... 491, 792, 1118, 2217 

in vitro Tests ..................................... 405 

in vitro to in vivo extrapolation ........ 895 

in vitro toxicology ............................ 487 

in vitro /in vivo ................................. 280 

in vivo ................... 908, 922, 1731, 1963 

in vivo genotoxicity assay .............. 1110 

in vivo imaging with PET and 

MRI ................................................ 1388 

in vivo micronucleus assay .. 1106, 1109, 

1129 

in vivo mutation .............................. 1355 

in vivo Percutaneous Absorption ..... 342, 

2047 

in vivo toxicity ................................ 1495 

In-Utero ............................................ 846 

in-vitro in-vivo correlation ............. 2126 

In-vitro model for skin irritation ...... 499 

inbred mouse strains ........................ 366 

IND ................................................ 2208 

individual susceptibility ................. 1861 

Individual Variation ........................ 1071 

indole .............................................. 1647 

indoor ............................................. 1867 

inducible pluripotent cells .................. 47 

Industrial solvents ............................ 887 

Inert ................................................ 1901 

infant ................................................ 379 

infants ............................................... 319 

Infection ......................... 422, 740, 2057 

Inflammation ............. 93, 130, 275, 281, 

290, 350, 537, 578, 730, 732, 733, 735, 

738, 959, 986, 992, 1310, 1316, 1400, 

1493, 1512, 1516, 1553, 1619, 1626, 

1737, 1751, 1783, 1992, 2015 

Inflammatory cytokine ................... 1557 

Inflammatory cytokines ... 74, 736, 1545 

inflammatory heart disease ............ 1419 

Inflammatory liver injury ............... 2134 

influenza ................................. 956, 2179 

Influenza A virus ............................ 1531 

Informatics ............................. 211, 1079 

Informative Prior Distributions ........ 873 

informed substitution ..................... 2219 

infusion .......................................... 1185 

ingestion ......................................... 1941 

ingestive behavior .......................... 2087 

Inhalation .... 19, 22, 323, 367, 370, 608, 

835, 927, 928, 1020, 1032, 1398, 1401, 

1478, 1479, 1480, 1492, 1510, 1516, 

1518, 1521, 1523, 1794, 2179, 2188 

inhalation ........................................ 1514 

Inhalation exposure 237, 344, 929, 1495 

inhalation toxicity ...... 1171, 1395, 1403 

inhalation toxicology .... 934, 939, 1169, 

1499, 1503, 1506, 1509 

inhalational toxicology ................... 1511 

injection .......................................... 1186 

injury ............................ 579, 1597, 1828 

innate defense response .................... 754 

innate immune system .................... 1543 

Innate Immunity ............................... 676 

iNOS .................. 336, 1075, 1076, 1077 

insecticide ...................................... 1181 

Insecticides ..................................... 1241 

insulin ................................... 1677, 1824 

insulin like growth factor acid labile 

subunit ............................................ 1143 

Insulin Resistance ........ 961, 1053, 1507 

integrin linked kinase ..................... 1950 

Interaction .................. 1139, 1572, 1882 

interferon ........................................ 1672 

Interindividual variability factor .... 1914 

interleukin-17 ..................................... 77 

interleukin-4 ................................... 1541 

intestinal absorption ......................... 949 

intestinal barrier ............................... 786 

Intestinal inflammation .................... 711 

intestinal Paneth cells ....................... 754 

intracellular calcium ................ 217, 223, 

373, 976 

Intracellular Concentration ............ 1595 

Intracellular Staining ...................... 1985 

intramuscular injection ................... 1054 

Intraspecies Variability ..................... 874 

intrathecal ................... 1061, 1185, 1186 

intratracheal instillation ................. 1490 

Intravenous ............................. 922, 1484 

Intravenous infusion ......................... 851 

intravenous injection ...................... 1083 

Intrinsic Apoptosis ........................... 138 

invasion ................................ 1761, 2157 

investigational toxicology .............. 1375 

iodide .............................................. 2099 

iodine ................................................ 822 

Iodine deficiency ............................ 2094 

ion channel ..................................... 2030 

ion channels ................................... 2029 

Ionic liquids ................................... 1584 

iPLA 2 

.............................................. 1663 

iPS cells ........................................ 48, 52 

IRIS ................................................ 1925 

Iron ..................... 983, 1220, 1365, 1424 

iron oxide nanoparticle .................... 256 

Ischemia reperfusion ...................... 1214 

ischemia/reperfusion ........................ 810 

isocyanates ..................................... 2017 

isolated rat hepatocytes .................. 1955 

Isomer .............................................. 876 

Isoniazid ........................................... 448 

isotherms ........................................ 1161 

Isothiocyanates ............................... 1781 

isozyme .......................................... 1309 

jacket telemetry ................................ 605 

Japanese Medaka ........................... 1204 

JARID1A .......................................... 153 

jet fuel .......................... 875, 1523, 2188 

joint compound .............................. 1873 

Joint Toxicity of Mixtures ................ 248 

JP-8 .................................................. 876 

JP-8 jet fuel .................................... 1265 

juice ................................................ 1135 

Junction .......................................... 1482 

juvenile 606, 927, 928, 1052, 2116, 2119 

juvenile studies ............................... 1583 

Juvenile Toxicity ............................ 2114 

K-ras ................................................. 628 

K99/R00 ........................................... 662 

kahweol .......................................... 1766 

Keap1 ............................................... 975 

keratin adducts ............................... 1329 

Keratinocyte Differentiation ............ 675 

keratinocytes .................................... 259 

ketamine ........................... 163, 179, 845 

kidney ...................... 579, 807, 812, 814, 

820, 823, 824, 1313, 1314, 1330, 1443, 

1713, 1813 

kidney biomarkers .............................. 12 

Kidney Calcinosis .......................... 1157 

Kidney Cancer................................ 1679 

kidney injury molecule-1 ................. 806 

Kidney Injury Molecule-2 ................ 821 

Kidney toxicity ................................. 817 

kinase ..................................... 187, 1361 

kinases .................................... 632, 1818 

KLH ..................................... 1988, 1994 

Knockout ........................................ 1962 

Knockout Mice ......................... 524, 933 

knockout rats .................................... 904 

knowledge ........................................ 941 

Knowledgebase ................................ 213 

knowledgebases ................................... 1 

Kupffer Cell ........................... 524, 1965 

Kupffer cells ........................... 744, 1303 

L. monocytogenes .......................... 1162 

L1 retrotransposon ........................... 150 

laboratory animals ........................ 3, 588 

Lactating rat and pup ....................... 894 

lambda-cyhalothrin ........................ 1892 

lamellarin ....................................... 1779 

LAMP-2 ......................................... 1656 

Langerhans cells ............................... 307 

large animals .................................... 925 

laser capture microdissection ...582, 1655 

late phase ............................................ 63 

Lavendamycin antitumor agents ...... 724 

LC-APCI-MS ................................. 1326 

LC-MS/MS .............................. 719, 761 

LC/MS............................................ 1307 

LC/MS/MS ..................................... 1402 

lead .......................... 245, 439, 666, 984, 

989, 1254, 1602, 1603, 1610, 1614, 

1840, 1841, 1843, 1844, 1972 

lead (Pb) ............................... 1431, 1600 

lead exposure.................................... 147 

lead neurotoxicity ....... 1604, 1609, 2026 

Lead poisoning ............................... 1842 

learning .................................. 465, 1614 

learning and memory ............... 403, 989 

lectins ............................................... 259 

left ventricular hypertrophy ........... 2162 

legal .................................................. 942 

Leiomyoma ...................................... 413 

lens explant cultures ......................... 469 

leptin ................................................ 400 

leptomycin B .................................... 727 

leukemia ........... 123, 143, 514, 520, 665 

leukemia/lymphoma ......................... 128 

Leukemogenesis ............................... 848 

Leydig cell...................................... 2092 

Leydig cells .................................... 1019 

Libby Amphibole ........................... 1874 

Life-stage ....................................... 1721 

life-stage adjustment ...................... 1912 

life-stage susceptibility .................... 783 

lifestage ............................................ 656 

linezolid .......................................... 1070 

Linkage Disequilibrium ................... 947 

lipid ........................................ 571, 1356 

lipid metabolism......... 1357, 1360, 1361 

Lipid peroxidation .......................... 1509 

Lipid Rafts ..................................... 1669 

Lipids ............................................... 593 

Lipin ............................................... 1360 

lipin 1 ............................................. 1737 

lipopolysaccharide ....... 757, 1965, 2125 

lipotoxicity ..................................... 1770 

liver ..................... 84, 89, 219, 228, 309, 

557, 969, 1092, 1137, 1138, 1344, 1346, 

1347, 1348, 1440, 1441, 1442, 1534, 

1581, 1632, 1633, 1636, 1639, 1644, 

1715, 1950, 1962, 1965, 2115, 2124, 

2127, 2132, 2138, 2139 

liver cancer ..................................... 1343 

332 






liver carcinogenesis .................. 533, 534 

liver injury ................. 83, 148, 269, 621, 

626, 750, 1051, 1952, 1956 

Liver Regeneration ......................... 1537 

Liver Toxicity ... 1048, 1410, 2013, 2074 

liver X receptor .............................. 1069 

Livestock ........................................ 1940 

livestock health .............................. 1018 

LKB1-AMPK ................................. 1393 

LLNA ............................................... 111 

LNCaP............................................ 1905 

LOAEL ............................................. 839 

local lymph node assay .................. 1806 

local lymph node assay (LLNA) .... 1804 

Locomotion .................................... 1262 

long term corneal culture ................. 104 

long term toxicity ............................. 277 

loss of heterozygosity ...................... 694 

low dose ........................................... 678 

Low dose effects ............................ 1454 

low-dose ............................................. 39 

low-dose extrapolation ......... 1791, 1931 

low-dose linearity ............................... 38 

LPS ................................................... 750 

LRP1 .............................................. 1841 

luciferase reporter .......................... 1540 

Lunar dust ................................ 292, 375 

lung ......................... 286, 329, 350, 735, 

800, 1400, 1475, 2072, 2073, 2106, 

2151 

lung cancer ...................... 122, 356, 628, 

727, 734, 741 

Lung carcinogenesis ......................... 676 

Lung Development ......................... 1970 

lung dosimetry ................................. 869 

Lung Fibrosis ................................... 793 

lung function ............................ 336, 926 

Lung inflammation .......... 737, 776, 939, 

1473, 1497, 1665 

lung injury ...... 257, 344, 457, 804, 1031 

Lung Modeling ......................... 871, 872 

Lung slice ........................................... 93 

Lung surfactant ................................ 797 

lupus nephritis ................................ 1784 

lymphoblast ...................................... 201 

Lymphocryptovirus (LCV) .............. 935 

Lymphocyte .................................... 1060 

Lymphocyte subset ......................... 1304 

Lymphocyte Transformation Test 

(LTT) .............................................. 1049 

lymphocytes ........................... 536, 2182 

lymphoid toxicity ........................... 1227 

Lymphoma ..................... 520, 665, 1782 

lyse ................................................. 1987 

Lysosome ............................. 1212, 1657 

lysosomes ......................................... 770 

MABEL .......................................... 1003 

Macaca fascicularis ........................ 1036 

macaque ........................................... 917 

Machine Learning Algorithms ......... 193 

macrophage .............. 34, 583, 766, 1545 

Macrophages ... 32, 599, 676, 745, 1658, 

1692, 2182 

Magnetic Resonance Imaging .......... 939 

Magnetic Resonance 

Spectroscopy .................................. 1000 

Maize .............................................. 1456 

Malaria ........................................... 1241 

malathion........................................ 1254 

MALDI Imaging Mass 

Spectrometry .................................... 167 

MALDI-TOF .................................. 1667 

MALDI-TOF-MS............................. 428 

Male and female fertility .................. 376 

male infertility .................................. 390 

male pubertal assay ........................ 2111 

male reproduction ............................ 407 

Male Reproductive Toxicity ..... 289, 561 

Male reproductive toxicology .......... 393 

mammal-to-fish ................................ 437 

mammalian toxicology ............. 13, 1904 

Mammary Cancer ............................. 188 

mammary carcinogenesis ................. 831 

mammary gland ............................... 839 

mammary stem cells ...................... 2002 

maneb ................................... 1244, 1260 

Manganese .............. 272, 884, 885, 988, 

990, 997, 999, 1000, 1002, 1296, 1600, 

1890, 2038, 2173 

manganese and lead ........................... 23 

Manganese neurotoxicity ...981, 985, 998 

manganese synergism ...................... 986 

manganese toxicity ... 978, 979, 980, 982 

Manganese transport ........................ 993 

Manganeses .................................... 1909 

Manganism ....................................... 982 

Manufactured Gas Plants ............... 1039 

Manzate ................................ 1286, 1291 

MAP kinase .............................. 629, 631 

MAP kinases ............................ 627, 630 

MAPK .................................... 628, 1663 

mass spectrometry ............................ 341 

mast cell ....................... 795, 1502, 1561 

mast cells ................................ 726, 1772 

maternal diet manipulation and 

mercury exposure ........................... 1977 

maternal toxicity .............................. 397 

mathematical modeling .................... 897 

Mating .............................................. 392 

matrix metalloproteinase ................ 1511 

Matrix metalloproteinase-9 .............. 909 

matrix metalloproteinases .............. 2060 

Matrix Metalloproteinases-9 .......... 1761 

Maturation ...................................... 1568 

MCF-7 cells ................................... 2006 

Mcl-1 .............................................. 1219 

MCSF ............................................... 484 

MDA-kb2 ......................................... 113 

MDA-MB-231 ............................... 2007 

MDMA ........................................... 1088 

MDR1 ............................................ 1768 

MDSCs ........................................... 1527 

meat grade ...................................... 1136 

mechanism ..................................... 1932 

mechanism of action ...................... 2103 

mechanisms .................................... 2039 

medaka ........................... 686, 687, 1903 

media refinement.............................. 104 

medical device.................................... 88 

Medical devices.................... 1187, 1944 

Megakaryocyte ............................... 2168 

megalin ............................................... 86 

megaloblastic anemia ..................... 1058 

MEHP ........................ 1482, 1483, 1664 

Meiosis ............................................. 460 

Melamine ... 319, 817, 1140, 1151, 1158 

melanocytes ...................................... 497 

Melatonin ......................................... 867 

memantine ...................................... 1277 

Membrane Cholesterol ................... 1669 

menthol .................................. 447, 1311 

mercuric sulfide.............................. 1177 

mercury ............. 245, 1295, 1786, 1830, 

1831, 1832, 1833, 1835, 1836, 1838 

mercury toxicity ............................... 987 

Mesenchymal Stem Cell ................ 1196 

Mesothelioma ..... 739, 1397, 1546, 1547 

Meta-analysis ......................... 670, 1886 

Metabolic activation ....... 696, 699, 1968 

metabolic deactivation ..................... 466 

Metabolic deranegement ................ 1063 

Metabolic Disease ............................ 633 

Metabolic Diseases .......................... 209 

metabolic imprinting ...................... 1977 

metabolic interactions ...................... 243 

Metabolic Pathways ......................... 209 

metabolic poise .............................. 1080 

metabolic syndrome ........ 415, 553, 554, 

557, 584, 1053, 1356, 1362, 1959, 1975, 

2079 

Metabolism ............... 28, 211, 443, 444, 

445, 450, 477, 571, 634, 643, 889, 1095, 

1358, 1366, 1566, 1573 

Metabolism-mediated toxicity ........ 948, 

2075 

Metabolites ........................... 1301, 1378 

Metabolizing enzymes ............. 486, 501 

metabolomics .......... 207, 364, 534, 580, 

1059, 1293, 1331, 1611, 1629, 1646, 

2043, 2214 

Metabonomics ................... 57, 636, 720, 

809, 1637, 1638, 2128, 2209 

metal ...... 20, 130, 270, 438, 1811, 1814, 

1845, 2149 

metal oxides ..................................... 373 

metallic nickel .................................. 528 

metallothionein ... 146, 434, 1367, 1711, 

1813, 1814, 1815, 1816 

metallothioneins ............................. 1465 

Metals .................. 19, 90, 286, 794, 838, 

860, 879, 944, 998, 1290, 1367, 1427, 

1815, 1817, 1819, 1879, 1942, 2037, 

2072, 2073, 2118, 2160, 2162, 2165, 

2168, 2169, 2176 

Metals and Minerals ............. 2034, 2035 

Metformin ............................ 1584, 1710 

Methacrylonitrile ............................ 1193 

Methamidophos .............................. 1900 

Methamphetimine .......................... 1575 

Methanol .......................................... 708 

methanol metabolism ....................... 834 

methemoglobinemia ....................... 1760 

Method development ... 475, 1132, 1588, 

1589 

method validation ................. 1587, 1926 

methods .......................................... 1918 

methods and models ......................... 170 

Methoxychlor ........................... 395, 399 

methyl formate ............................... 1023 

Methyl mercury .............................. 1834 

Methylation .................... 453, 945, 1345 

methylmercury ........ 378, 705, 841, 847, 

976, 977, 994, 1001, 1025, 1394, 1601, 

1613, 1837, 1839 

Methylmercury neurotoxicity ......... 976, 

977, 1607, 2026 

methylphenidate ............................. 1251 

metofluthrin .................................... 1868 

Metylmercury ................................... 975 

MHC-II .......................................... 1559 

MIC-1 ............................................... 746 

micotoxins ...................................... 1464 

micro RNA ..................................... 1715 

microarray ................... 855, 1649, 1719, 

1832, 1845 

microarray analysis ................ 810, 1625 

microarrays .................................... 2212 

Microcystin .................................... 1969 

Microcystins ..................................... 230 

microcystis ....................................... 757 

Microdialysis .................................. 1575 

microelectrode array ...................... 2032 

Microencapsulation .......................... 285 

microfluidics .................................... 118 

microglia ....757, 1272, 1274, 1279, 1839 

micronuclei ........ 691, 1112, 1115, 1141 

micronucleus .............. 1108, 1113, 1117 

micronucleus assay ........................ 1111 

micronucleus test ........................... 1122 

Micronutrients ................................ 2035 

microorganisms ................................ 427 

microPET ......................................... 163 

Microphysiometer ............................ 100 

microRNA ........................... 53, 56, 119, 

172, 1347, 1463 

microRNAs ...................................... 850 

microsomal epoxide hydrolase ..... 1103, 

1104 

Microtox ................................... 251, 252 

Microtubule Associated Protein ..... 1267 

microvascular ....................... 1728, 1730 

Milk ................................................ 1891 

Minerals ........................................... 609 

Minimal Risk Level (MRL) ........... 1945 

mini-pig ........................ 903, 1073, 1980 

Minipigs ........................................... 601 

Mink ................................................. 430 

Minocycline ................................... 1213 

miRNA ..... 533, 1651, 1756, 2040, 2201 

Mitochondria ............... 82, 84, 369, 633, 

634, 635, 636, 712, 767, 769, 813, 814, 

1075, 1080, 1212, 1255, 1319, 1421, 

1422, 1423, 1424, 1425, 1426, 1615, 

1633, 1673, 1731, 2117, 2121 

Mitochondria Dysfunction ................. 79 

Mitochondria membrane potential ... 980 

mitochondria toxicity ....................... 980 

Mitochondrial ............... 81, 94, 95, 1743 

mitochondrial biogenesis ................. 637 

Mitochondrial DNA damage ............ 184 

mitochondrial dysfunction ...... 186, 637, 

978, 1278, 1719 

Mitochondrial dysfuntion ............... 1676 

mitochondrial heam transporter ..... 1089 

Mitochondrial Oxidative Stress ...... 764, 

2129, 2133 

Mitochondrial Permeability Transition .. 

2130 

mitochondrial protein synthesis ..... 1070 

mitochondrial toxicity ....... 10, 200, 637, 

1070 

Mitogen activated protein kinase ..... 592 

Mitogen-activated protein kinases ...2093 

mitogens ........................................... 674 

mitotic spindle .................................. 799 

Mixed Amphetamine Salts ............... 669 

mixture ......................... 324, 1570, 2189 

mixture toxicity ................................ 251 

Mixtures .................. 242, 245, 246, 247, 

250, 561, 562, 568, 569, 972, 1882 

MMP .............................................. 1811 

MMP-9 ....................... 1710, 1767, 1769 

MMPs ..................................... 368, 2003 

MN/Comet ..................................... 1117 

MnSOD ............................................ 240 

MNU ................................................ 911 

MOA ................................................ 521 

mode of action .... 139, 1129, 1721, 1908 

Mode-of-Action ......................... 5, 2104 

Model ............................................. 1877 

Modeling .......................................... 249 

mold ................................................. 298 

molds .............................................. 1302 

Molecular ......................................... 858 

Molecular Biology ........................... 633 

Molecular Docking .............. 1380, 1468 

molecular docking model ............... 2112 

molecular imprinted polymer stir bar 337 

Molecular Mechanisms .................. 1356 

molecular mimicry ........................... 667 

molecular modeling ............... 203, 1097 

molecular targets for toxicity ........... 203 

monkey ............ 1055, 1056, 1662, 1722, 

1987, 1988 

monkey fetal serum ........................ 1990 

monkey primary gall bladder epithelial 

cells .................................................. 117 

Monkey Study ................................ 2187 

Monkeys ......................................... 1586 

monoclonal antibody ....... 617, 618, 619, 

842, 1043, 1044, 1437, 1438 

monocyte adhesion ........................... 957 

Monomethylarsonous acid ....... 953, 954 

Moon Dust, Lunar Dust ................. 1859 

mortality ................................. 996, 1035 

motorcycle exhaust ........................ 1520 

mouse .................... 363, 826, 830, 1846, 

2086, 2190 

Mouse embryonic stem cells .......... 1691 

mouse Leydig cells......................... 2089 








Mouse Liver ..................................... 244 

mouse lymphoma ........................... 1697 

mouse lymphoma assay ........... 694, 695 

mouse model .................................... 741 

mouse models ....................... 1333, 1334 

mouse stem cell .............................. 1680 

Mouse strains ................... 299, 362, 589 

MPP+ ............................................. 1270 

MPTP ................................... 1225, 1390 

MRL ............................................... 1029 

mRNA ............................................ 2040 

mRNA expression ............................ 589 

mRNA stability ................................ 760 

Mrp2 ............................................... 1623 

Mrp3 ............................................... 1597 

MRP4 ............................................. 1469 

MTF-1 activation mechanism ........ 1812 

MTT Assay....................................... 183 

mucin .............................................. 1764 

Mucosal Immunoregulation ............. 538 

mucosal inflammation .................... 2021 

Multi-drug resistance transporter ... 1749 

Multi-walled carbon nanotube ........ 794, 

795, 1397, 1399 

Multidrug Resistance Proteins ......... 626 

multidrug resistance transporters ... 1417 

multielectrode array ....................... 1738 

multiparametric analysis .................. 199 

multiple sclerosis ........................... 1282 

Multiplex ........................................ 1995 

multipurpose solution..................... 1168 

multiroute exposure........................ 1579 

multiwalled carbon nanotube ........... 805 

munitions........................................ 2185 

murine HIPEC ................................ 2009 

murine local lymph node assay ....... 300, 

1807 

muscarinic receptor .......................... 288 

mustard ............................................. 347 

mutagen .......................................... 1922 

Mutagenesis ............................. 121, 689 

mutagenic activity ............................ 701 

Mutagenicity .................................. 1144 

mutation ................................... 690, 691 

mutation analysis ........................... 1862 

mutational analysis ......................... 1863 

mutiwall carbon nanotube .............. 1396 

Myc ................................................ 1758 

Mycophenolic Acid .......................... 405 

mycotoxin .................... 853, 1167, 1456 

Myeloperoxidase .............................. 716 

myopathy .............................. 1315, 1673 

Myotoxicity .................................... 1325 

n-3 polyunsaturated fatty acids ...... 1784 

N-Acetyl-L-Cysteine ........................ 183 

N-acetylglycine .............................. 1155 

n-alkane ............................................ 875 

n-butyl glycidyl ether ..................... 1587 

N-methyl-d-aspartate ....................... 179 

N-nitroso compounds ....................... 778 

N6AMT1 .......................................... 951 

NADPH oxidase ..... 233, 762, 909, 1557 

NADPH-cytochrome p450 

reductase ................................ 765, 2128 

NAFLD .................................... 555, 556 

NAG-1 .............................................. 400 

nano ........................................ 367, 1281 

Nano particle .................................... 792 

Nano-Cu ......................................... 2071 

Nano-materials ............................... 1395 

Nano-Nickel ..................................... 368 

nano-sized particles ............................ 22 

nanomaterial ............................. 263, 794 

Nanomaterials ......... 255, 265, 280, 284, 

290, 372, 801, 1693, 2039, 2040, 2181, 

2212 

nanoparticle .... 261, 273, 275, 282, 1478 

nanoparticles ........... 234, 257, 258, 259, 

262, 266, 270, 271, 272, 274, 276, 278, 

286, 288, 289, 291, 370, 372, 528, 608, 

793, 849, 1398, 1695, 1696, 1705, 1707, 

1728, 2035, 2072, 2073 

Nanoparticles or Ultrafine 

Particles .......................................... 2183 

nanosilica ......................................... 268 

nanosilver ....................................... 1697 

nanotechnology ................................ 790 

nanotherapeutics .................. 1479, 1480 

Nanotoxicity ..................................... 281 

Nanotoxicology ....... 255, 256, 264, 269, 

279, 285, 372, 791, 835, 1403, 1693, 

1694, 1698, 1703, 1706, 1707, 2042, 

2044 

nanotubes ............................... 790, 2041 

nanozinc ......................................... 2066 

naphthalene ...... 1329, 1494, 1861, 1881 

nasal mucosa .................................. 1099 

nasal passages .................................. 868 

nasal respiratory epithelium ........... 1596 

nasal trigeminal neuron .................. 2019 

NASH ............................................... 148 

National Children’s Study ............... 651, 

652, 655 

Natural Product ................................ 687 

Natural Products ......... 1132, 1179, 1783 

NBT Staining ..................................... 54 

necrosis ........................ 594, 1165, 1223 

Nei-like DNA glycosylase ............... 702 

NEMO ............................................ 1065 

Neonatal exposure .......................... 1298 

neonatal mice ................................... 388 

neonates ............................................ 385 

neopterin ........................................ 1046 

nephron .............................................. 12 

nephropathy ...................................... 813 

Nephrotoxicant ................................. 824 

Nephrotoxicity ........ 808, 815, 818, 819, 

822, 1140, 1314, 1330, 1409, 1924 

nephrotoxicity biomarkers .... 807, 1322, 

1323 

nephrotoxicology ............................. 577 

Neprilysin ....................................... 1512 

nerve agent ....................................... 333 

Nerve agents ............................. 321, 354 

networking ....................................... 660 

networks ......................................... 2011 

neural development .......................... 936 

neural differentiation ...................... 2070 

Neural Tube Defect .......................... 860 

neurite outgrowth ........................... 1389 

Neuritic degeneration ..................... 1613 

neurobehavior................................. 1264 

neurobehavioral changes .................... 23 

neurobehavioral toxicology..... 166, 893, 

1390, 2023, 2026 

neurobehaviour..................... 1025, 1068 

Neurodegeneration ........ 184, 587, 1277, 

1285, 1290, 1292 

neurodegenerative disease ...... 977, 1615 

neurodevelopment .................. 482, 1394 

neurodevelopmental toxicity ............ 859 

neuroendocrine ................................. 406 

neurofilament ................................. 1267 

Neurogenesis .................................. 1609 

neuroinflammation .......... 24, 345, 1272, 

1285, 1970 

neurological .................................... 1185 

neuropathology ................................ 161 

neuropathy ...................................... 1281 

Neuropathy Target Esterase ............. 833 

Neuropathy target esterase (NTE).. 1381 

neuroprogenitor cell ......................... 156 

Neuroprotection ................... 1273, 1276 

Neurotoxicity .............. 19, 21, 158, 217, 

223, 467, 796, 798, 845, 985, 987, 991, 

993, 995, 997, 999, 1235, 1238, 1244, 

1258, 1263, 1264, 1272, 1289, 1605, 

1608, 1611, 1932, 2025, 2038 

neurotoxicology .......... 174, 1059, 1189, 

1276, 1602, 2034 

neurotoxin ...................................... 1284 

neurotoxins ....................................... 988 

neutrophil ............................... 766, 1519 

Nevirapine ...................... 316, 449, 1951 

new method .................................... 1124 

new paradigms ................................. 647 

new technologies ............................ 1353 

New Zealand White Rabbits ............ 852 

Next generation sequencing ........... 1662 

NF kappa B ...................................... 959 

NF-kappa B .................................... 1260 

NF-kB ............................................ 1065 

NF-kB .................................. 1539, 1544 

NHANES ............. 640, 666, 1847, 1869 

nickel ................... 441, 525, 1800, 1819, 

1944, 2159, 2160, 2162 

nicotinamide nucleotide 

transhydrogenase ................................767 

nicotine ........................... 176, 447, 1599 

Nimodipine .................................... 1257 

Nitric Oxide ................. 969, 1744, 1823 

Nitrile ............................................. 1253 

Nitrogen dioxide .............................. 480 

nitrogen mustard ................................ 67 

nitrosamines ................................... 1588 

nitroso compounds ......................... 1652 

NK cell ..................................... 35, 1547 

NK cells ............................... 1984, 1987 

NLRP3 inflammasome ....................... 33 

NMDA ........................................... 1324 

NMR ...................................... 809, 1256 

NNK ........................................... 93, 129 

NO2 .................................................. 670 

NO 2 

................................................. 1886 

NOAEL .......................................... 1003 

noise ............................................... 1265 

Non Human Primate ........................ 921 

non human primates ......................... 842 

Non-alcoholic fatty liver disease ... 1625, 

1626 

non-animal testing ........ 114, 2215, 2217 

non-cellular ...................................... 261 

nonclinical ...................................... 1375 

non-dioxinlike ................................ 2061 

non-extractable radioactivity ............ 458 

Non-Human Primate ................ 600, 935 

non-human primates ............... 937, 1981 

Non-Invasive .................................. 1727 

non-invasive monitoring................... 915 

Non-invasiveness...................... 604, 940 

Non-pregnant and lactating rats ..... 1569 

Non-rodent toxicology studies ....... 1805 

non-steroidal anti-inflammatory ........ 94 

noncancer ........................................... 40 

nonclinical safety assessment ........ 1802 

nongenotoxic .................................. 2156 

non-human primate .......................... 832 

Nonylphenol ........................... 411, 2148 

Normal Neural Development ........... 862 

NOS2 .............................................. 1296 

NovaSil clay ......................... 1160, 1161 

novel gene ........................................ 704 

NQO1 ............................................... 724 

nrf-2 .................................................. 772 

Nrf2 .................................................. 775 

NSAIDs .................................. 294, 2144 

NSAIDs with Steroids ...................... 924 

NTP-200 feed ................................. 1588 

Nuclear factor E2-related factors ..... 962 

Nuclear Factor Erythroid 2 .............. 747 

nuclear hormone receptors ............. 1069 

nuclear receptor ............. 139, 622, 1210, 

1407, 1472, 2085, 2147, 2154, 2155 

Nuclear Receptors ..... 5, 229, 575, 1346, 

2145 

nucleoside reverse transcriptase 

inhibitor .......................................... 1743 

Nucleotide Reverse Transcriptase 

Inhibitor .......................................... 1057 

numerical chromosome aberrations . 123 

o-anisidine ........................................ 141 

o-toluidine ...................................... 1912 

obesity ............... 59, 554, 558, 585, 668, 

752, 1143, 1327, 1507, 1621, 1623, 

1624, 1785, 1972 

observation ....................................... 916 

occupational ................................... 1793 

occupational asthma ......................... 304 

Occupational Exposure ........ 1396, 1831 

occupational exposures ........ 1242, 1792 

occupational nickel exposure ......... 2158 

occupational safety ......................... 1169 

OCT .................................................. 921 

oct-4 ................................................. 964 

ocular .................... 99, 1056, 1168, 2213 

ocular safety testing ......................... 100 

Ocular tissue ............................. 487, 719 

ocular toxicity .............................. 8, 932 

Ocular toxicology ............................. 479 

OECD Guidance Notes .................. 2051 

OECD Toolbox................................. 205 

OGG1 ............................................... 936 

olfactory ............................................. 20 

olfactory epithelium ....................... 1596 

Olfactory sensory neurons ............. 1216 

oligonucleotide ............................... 2082 

omega 3 fatty acids .... 1146, 1147, 1148 

Omic biomarkers ................................ 53 

‘omics ............................................. 1654 

oncology ............................... 1050, 1787 

oncology drugs ............................... 1273 

Oncomodulin .................................. 1300 

Ontogeny ........................................ 1621 

OP antagonism ................................. 349 

OP6 olfactory sensory neuron 

cell line ........................................... 1215 

operant behavior ............................... 180 

OPH formulation .............................. 349 

OPIDN ................................. 1233, 1257 

optic tectum ...................................... 165 

Optimal Sampling Strategy ............ 1846 

oral polymer ................................... 1803 

Organ Weight ................................. 1027 

organ-specific toxicity ...................... 699 

organic cation transporters ............. 1584 

organophosphate ..... 168, 242, 324, 335, 

346, 1028, 1255, 1256, 1897 

organophosphate induced delayed 

neuropathy ...................................... 1266 

organophosphate pesticide ............ 1230, 

1248, 1264 

organophosphate pesticides............ 1242 

Organophosphate Toxicity ............... 345 

organophosphates ...... 1252, 1391, 1866, 

1893 

organophosphorus .......................... 1249 

organophosphorus insecticides ....... 897, 

1716, 1896 

Organophosphorus pesticides ....... 1238, 

1240, 1263 

organotypic cell culture ....... 1661, 1966, 

1967 

organotypic model............................ 412 

oseltamivir ...................................... 1052 

osmotic stress ................................... 595 

osteoblast ........................................ 1820 

osteopontin ........................... 1553, 1784 

osteoporosis .................................... 1827 

ovalbumin ....................................... 2020 

ovarian cancer ...................... 2003, 2009 

Ovarian follicle ........................ 377, 383 

Ovarian follicle growth .................... 398 

Ovarian function .............................. 919 

334 






Ovarian toxicity........ 25, 27, 28, 29, 377 

ovariectomy ...................................... 930 

Ovary ............. 25, 26, 29, 384, 387, 388, 

395, 402, 1485, 1489 

ovotoxicity ....................................... 402 

Oxamyl ........................................... 1034 

Oxidant Stress .................................. 594 

oxidative ......................................... 1697 

Oxidative Damage .................... 142, 708 

oxidative DNA damage .................... 238 

oxidative injury .... 277, 998, 1277, 2177 

oxidative lipidomics ......... 597, 598, 599 

oxidative phosphorylation ................ 186 

Oxidative potential ........................... 254 

Oxidative stress ..... 59, 65, 80, 149, 222, 

268, 311, 352, 369, 373, 382, 385, 517, 

526, 529, 578, 595, 710, 751, 752, 761, 

765, 768, 772, 774, 777, 779, 782, 783, 

785, 796, 798, 804, 818, 823, 990, 992, 

994, 1220, 1226, 1263, 1268, 1327, 

1469, 1474, 1590, 1635, 1749, 1893, 

1955, 1956, 1957, 2036, 2038, 2065, 

2093 

Oxidative stress signaling ................ 592 

Oxidative stress, DNA damage, 

Toxicity ............................................ 510 

Oxidative stress, functional 

genomics ........................................ 1699 

Oxidative stress; DNA adducts ...... 1704 

oxime ................................................ 899 

oximes .............................................. 325 

oxLDL .................................. 1511, 1954 

oxychlordane .................................... 220 

Oxyfluorfen .................................... 1903 

Oysters ............................................. 434 

ozone ............................ 738, 1500, 2139 

P-glycoprotein ................ 358, 984, 1210 

p27.................................................... 518 

p27kip1 ............................................ 413 

p38 Kinase inhibitor ....................... 1114 

p38 MAP kinase ................................. 61 

p38 MAP kinase inhibitor ................ 903 

p38 mitogen activated protein 

kinase ............................................. 1699 

P450 ....... 1087, 1095, 1096, 1099, 1139 

P450 CYP3A .................................. 1093 

P450s .............................................. 1892 

p53........................... 133, 496, 591, 710, 

715, 727, 1781 

PAH ................ 128, 355, 453, 736, 1521 

PAHs ...................................... 685, 1038 

PAI-1 .............................................. 2071 

PAL ................................................ 1028 

palaemonetes pugio .......................... 424 

Pancreas ..................... 1075, 1076, 1077 

PAR2 ................................................ 484 

parallel deletion analysis .......... 115, 224 

Parallelogram Method .................... 2161 

Parameter Uncertainty...................... 873 

paraoxon ................................... 176, 334 

Paraoxonase 1 .................................. 239 

Paraquat ....... 630, 764, 769, 1231, 1261, 

1898 

Parkinson Disease .......................... 1292 

Parkinson’s ....................................... 272 

Parkinson’s Disease....... 358, 986, 1231, 

1236, 1261, 1268, 1271, 1274, 1275, 

1278, 1280, 1286, 1287, 1290, 1291, 

1293, 1294 

Parkinsonism ...................................... 21 

Parkinsons Disease ......................... 1270 

PARP-1 ............................................. 706 

particle .............................................. 441 

particles ................................ 1401, 1475 

Particulate....................................... 2151 

Particulate Matter .......... 760, 934, 1496, 

1498, 1501, 1502, 1508, 1518, 1522, 

1856, 2176 

Particulate Matter (PM2.5) .... 730, 1560 

particulate matter air pollution ....... 1507 

particulates ......................................... 92 

Partition Coefficient ............... 876, 1567 

Partition coefficients ........................ 880 

Partitioning ....................................... 639 

Parvalbumin ..................................... 178 

PAS ................................................... 982 

PAS Kinase .................................... 1357 

Passive sampling device ................. 1008 

patch clamp .................................... 2031 

patch clamping ............................... 1739 

pathogenesis ..................................... 327 

Pathology ................................. 26, 1319 

pathway ............................................ 212 

pathway enrichment ....................... 1645 

pathways ........................................ 1447 

patulin ............................................ 1461 

PBDE ............................................. 2063 

PBDE metabolites .................... 217, 223 

PBDEs ...... 155, 222, 241, 642, 643, 644 

PBP ................................................ 1359 

PBPK............... 565, 874, 878, 881, 896, 

901, 1567, 1894 

PBPK model........... 568, 875, 888, 1384 

PBPK Modeling ...... 879, 880, 883, 885, 

886, 892, 893, 899, 1041, 1564 

PBPK parameters ............................. 882 

PBPK/PD Model ............................ 1900 

PBPK/PD Modeling ......................... 325 

PC12 cells ........................................ 991 

PCB .................... 892, 1280, 1748, 2189 

PCB126 .................................... 239, 240 

PCB153 ............................................ 234 

PCB3 metabolits .............................. 716 

PCBs ...... 155, 157, 173, 175, 233, 236, 

2064 

PCR Arrays .................................... 1660 

PDE inhibitor ................................. 1725 

PDTC ............................................. 1898 

Pectin gelation ................................ 1460 

peer review ..................................... 1797 

peptide reactivity ...................... 110, 308 

peptides ............................................ 494 

perchlorate ............................ 2094, 2099 

perchloroethylene ........................... 1946 

perfluorinated chemicals .......... 225, 580 

perfluorinated compounds ............. 1555 

perfluoroalkyl acid ......................... 2112 

Perfluoroalkyl acids ....... 428, 830, 1590 

Perfluoroalkyl compounds ............. 1188 

Perfluorohexanesulfonate............... 1585 

perfluorooctanesulfonate ................ 1590 

Perfluorooctanoate ................. 820, 1586 

perfluorooctanoic acid ..................... 218 

Performance reference compound ...1008 

perinatal exposure .......................... 1591 

period ............................................. 1829 

Peripheral Neuropathy ................... 1273 

peripubertal testis ............................. 410 

Permeability ..................................... 503 

permeation ...................................... 1101 

peroxidase ...................................... 1151 

peroxisome proliferator-activated 

receptor gamma .......... 1549, 1551, 2004 

Peroxisome proliferator-activated 

receptor- b/d ................................... 2142 

peroxisome proliferators ................ 2207 

Peroxynitrite ........................... 709, 2129 

Personal Care Products ............ 106, 485 

Pesticide ...1034, 1037, 1867, 1902, 2190 

Pesticide Exposure ......................... 2049 

Pesticide kinetics ............................ 1569 

Pesticide Mixtures .......................... 1235 

Pesticides ............. 182, 654, 1467, 1567, 

1890, 1891, 1895, 1905, 2027, 2050 

petroleum substance ............. 1122, 1799 

PFAAs ............................................ 1384 

PFCA................................................ 226 

PFHxS ............................................ 1585 

PFNA ............................................... 219 

PFOA ...................... 221, 229, 407, 839, 

1578, 1586, 2194 

PFOA/PFOS ..................................... 580 

PFOS ............................ 229, 1554, 1578 

PHAHs ............................................. 238 

pharmaceutical ....................... 646, 1708 

Pharmaceutical agents ...................... 318 

Pharmaceuticals ...... 232, 432, 437, 459, 

1184 

Pharmacodynamics .............. 1047, 1757 

pharmacogenetics ........................... 1335 

Pharmacogenomics ...... 365, 1661, 1966 

pharmacokinetic .................... 218, 1581, 

1591, 1592 

pharmacokinetic and pharmacodynamic 

modeling .............................. 1047, 1757 

pharmacokinetic model .................. 1580 

Pharmacokinetic models .................. 887 

pharmacokinetics .............. 20, 280, 543, 

544, 884, 1047, 1158, 1576, 1583, 1585, 

1593, 1594, 1757, 1887, 2069 

Pharyngeal Aspiration .................... 1859 

Phase II enzymes ............................ 1234 

phase-I enzymes ............................... 589 

Phencyclidine (PCP) ........................ 169 

Phencynonate ................................... 321 

phenobarbital ................ 533, 1950, 1967 

Phortress ................................. 481, 1406 

phosphatase ............................ 723, 1671 

phosphate transporter ....................... 949 

phosphatidylserine ......................... 1217 

Phosphodiesterase Inhibitors (PDE) 1744 

phospholipase ................................... 519 

phospholipidosis ..... 200, 204, 208, 720, 

1318, 1656, 1658 

phosphoramidates .......................... 1249 

phosphorylation ................................ 129 

photo-allergenicity ............................. 91 

Photogenotoxicity .......................... 1107 

photomutagenicity ............................ 693 

phototoxicity .............. 91, 189, 263, 922 

phthalate ...................... 190, 1481, 1487, 

1489, 2089, 2155 

Phthalate (2-ethylhexyl) ester ........ 1541 

phthalate ester ................................ 1486 

Phthalates ........ 559, 560, 561, 562, 563, 

564, 566, 1149, 1470, 1485, 1488, 1907, 

1908 

phthalimide .................................... 1326 

Physical exertion .............................. 887 

Physiological Parameters ............... 1564 

Physiologically Based Pharmacokinetic 

models .............................................. 889 

Physiologically-based Pharmacokinetic 

Model ............................................... 877 

phytoestrogens ................................. 390 

phytostanols ................................... 1809 

phytosterols .................................... 1809 

Phytotoxicity .................................... 255 

PI3K ............................................... 1060 

Picramic acid .................................. 1009 

Pig Model ......................................... 924 

Pig-A ........................................ 690, 691 

PINK1 ............................................ 1278 

piperine .......................................... 1767 

PKC and CK2 ................................ 1812 

PKD1 .............................................. 1268 

PKG ................................................ 1734 

PLA 2 

................................................. 593 

placenta ............................................ 378 

plant biotechnology ........................ 1181 

Plant Protection Products ............... 2051 

plasticizer ......................................... 418 

Platelets .......................................... 1166 

Platinum ......................................... 1925 

Platycodon grandiflorum .... 1764, 1765, 

1775, 1776 

Play areas ......................................... 968 

pleural plaque ................................. 1875 

Pleurotus eryngil ............................ 1772 

pluripotent cells .................................. 49 

PM10 .............................. 254, 759, 1519 

PM2.5 ..................................... 287, 1474 

poisoning ........................................ 1902 

Policy ............................................. 1798 

pollutants ........................................ 1883 

pollution burden ............................. 1906 

poly (ADP-ribose) polymerase 

(PARP) ........................................... 1953 

polyalkylene glycols ...................... 1499 

Polybrominated diphenylether ......... 426 

Polychlorinated Biphenyl ............... 2103 

polychlorinated biphenyls ....... 177, 893, 

2061, 2062 

polychlorinated biphenyls 

(PCBs ) ........................... 162, 454, 1033 

polycyclic aromatic hydrocarbon ... 1668 

polycyclic aromatic hydrocarbon 

(PAH) ............................................. 1122 

polycyclic aromatic 

hydrocarbons ............................ 171, 180 

Polycyclic Aromatic Hydrocarbons 

(PAH) ....................................... 684, 698 

Polyfluroalkyl chemicals.................. 640 

polyhalogenated aromatic 

hydrocarbons .................................. 1173 

Polymorphism .......................... 356, 360 

polymorphisms ................................. 361 

polyol pathway ............................... 1959 

PON1 ................................................ 360 

Poorly soluble particles .................. 1794 

POP mixtures ................................... 244 

POPs ......................................... 638, 639 

POPs in Food ................................... 641 

population exposures........................ 570 

Populations ..................................... 1448 

Porcine Ocular Reversibility Assay ...485 

portable x-ray fluorescence 

(XRF) ................................................1884 

Positive reinforcement ..................... 920 

postdoctoral ...................................... 662 

postmenopausal women ................... 930 

Potassium current ............................. 729 

PPAR ........................... 825, 1325, 1359, 

2141, 2143, 2207 

PPAR alpha .................................... 1630 

PPAR gamma agonist ....................... 516 

PPAR-alpha .................................... 1554 

PPAR-gamma, PEPCK .................... 725 

PPARalpha-null ................................ 219 

PPARs .............................................. 469 

PPARb/d ......................................... 2144 

PPARg ...................................... 60, 1300 

PPO ................................................ 1948 

PPO inhibitor ................................. 1948 

precision cut lung slices ......... 481, 1406 

preclinical ....................................... 1081 

Preclinical Safety ........................... 1810 

Preclinical Safety evaluation .............. 11 

Preclinical Toxicology ........... 918, 1577 

Prediction Model .............................. 202 

predictive ecotoxicology ................ 1450 

Predictive testing ................................ 13 

Predictive Toxicology .......... 1078, 1640 

Pregnancy success-rate .................... 392 

pregnane X receptor ... 1133, 2077, 2102 

Pregnant ......................................... 1385 

Pregnant rat and fetus ..................... 1383 

prenatal ........................................... 1750 

prenatal cigarette smoke................. 1974 

prenatal stress ................................. 1614 

Prenylation ..................................... 1674 

pressure sensors ............................. 2022 

Preterm Birth .................................... 422 

prevalence rate ............................... 1875 

Primaquine ....................................... 905 

Primary B Cell ............................... 1533 

Primary dendritic cells ..................... 107 

primary hepatocyte ......................... 1717 

primary hepatocytes ......................... 118 








Primary mesangial cell ..................... 827 

Primary mouse hepatocyte ............... 264 

Primate ........................................... 1068 

primates .......................................... 1516 

Prioritization .................................. 1901 

probabilistic risk assessment .......... 1931 

procoagulant activity ...................... 1838 

professional skills ............................. 658 

progression ..................................... 2001 

prohapten ........................................ 1405 

proinflammatory .............................. 743 

Promoter methylation ....................... 151 

Propoxur ........................................... 141 

Prostaglandin H synthase ............... 1105 

Prostate ........................... 386, 861, 1026 

prostate cancer ..................... 1780, 2150 

Protease allergen .............................. 484 

proteasome inhibition ..................... 1675 

Protein adducts ............................... 1138 

Protein array technology .................. 588 

Protein Binding .................................. 15 

Protein Degradation ....................... 1200 

protein expression .......................... 1896 

protein interactions ........................... 782 

protein kinase C ............................. 1841 

protein-protein interactions ...... 18, 2146 

Proteinkinase C activity ................. 1557 

proteome ........................................ 1423 

Proteomic ....................................... 1312 

proteomics ............... 341, 428, 753, 769, 

907, 2041, 2043, 2173, 2209, 2211, 

2213 

protoporphyrinogen oxidase .......... 1948 

Prunella vulgaris ............................ 1769 

Psidium guajava ............................. 1771 

PSTC ................................................ 581 

PTDM ............................................ 1677 

PTEN/AKT ...................................... 673 

Pubescent ......................................... 847 

public health ....... 878, 1014, 1414, 1808 

Puerarin .......................................... 1768 

pulmonary .................... 273, 1475, 1519 

pulmonary C-fibers ........................ 2021 

pulmonary fibrosis ........................... 257 

Pulmonary inflammation ...... 747, 1517, 

2183 

pulmonary surfactant ....................... 614 

pulmonary toxicity ................... 788, 929 

Puppies ........................................... 2114 

Purkinje .......................................... 1754 

putranjivain A ................................. 1561 

PXR ................... 714, 1090, 1091, 1092, 

1559, 1962, 2148, 2157 

Pyrethroid ......... 1246, 1250, 1259, 1288 

Pyrethroid pesticides ...................... 1232 

pyrethroids ....... 1245, 1892, 1929, 2031 

qHTS ................................ 185, 707, 715 

QSAR ............... 192, 195, 205, 503, 552 

QSAR model .................................. 1187 

QSAR modeling ....................... 204, 890 

QSPeR model ................................... 495 

qt ........................................................ 44 

QT prolongation ............................. 1738 

QTc ................................................ 1729 

Qualification Strategies .................... 550 

quantitative high-throughput 

screening .......................................... 196 

Quantitative structure-activity 

relationships QSAR ......................... 202 

Quantum Dot .................................... 285 

Quantum dots .......... 264, 276, 283, 289, 

374, 1403, 2070 

Quercetin .............................. 1219, 2006 

Quinacrine ...................................... 2005 

quinones ................................... 453, 688 

Rabbit ............................. 409, 854, 1054 

radiation ........................................... 330 

Radicals ............................................ 517 

Radioactive Measurement ................ 278 

radioprotection ................................. 330 

radioresistance ................................ 1228 

radiotelemetry ................................ 2014 

raptor .............................................. 1228 

rasH2 ........................................ 910, 911 

rat ............................ 159, 334, 401, 407, 

916, 927, 1052, 1066, 1247, 1266, 1994, 

2119, 2127 

rat strain difference ........................ 1642 

rats .......................................... 788, 1155 

RDX ....................................... 322, 1930 

REACH ................. 105, 470, 478, 1788, 

1795, 1796, 1800 

reactive electrophiles ............... 248, 251, 

252, 253 

reactive intermediate .......................... 14 

Reactive Intermediates ....................... 15 

reactive metabolite ................. 448, 1087 

reactive metabolites ............................ 18 

reactive oxygen species ... 225, 573, 592, 

705, 774, 781, 1217, 1477, 1508, 2177 

Reactivity ......................................... 490 

Reactome .............................................. 1 

real time PCR ................................... 331 

receptor tyrosine kinase ................... 582 

receptor tyrosine kinase inhibitor ... 1725 

Receptors ........................................ 1526 

Recombinant Protein ...................... 1580 

reconstructed human epidermis ....... 487 

Reconstructed human skin ............... 501 

Reconstructed skin ........................... 486 

reconstructed skin model ................. 472 

Reconstruction ................................. 194 

redox .................................... 1423, 1425 

redox biology ................................... 784 

redox cycling .................................. 1756 

Redox Cycling Agents ..................... 765 

redox synapse ................................... 766 

Reduce, Refine, Replace ................ 1805 

Reduced Food Consumption ............ 854 

reduced intrauterine growth ........... 2117 

Refrigerant ....................................... 391 

regeneration .............................. 235, 810 

regenerative medicine ...... 47, 48, 50, 52 

Regional blood flow ......................... 603 

regulation ......................................... 536 

Regulations............................... 548, 549 

regulatory ......................... 51, 645, 2033 

regulatory cleanup standard ........... 1872 

regulatory developmental 

neurotoxicity ............................ 170, 856 

regulatory policy ............................ 1791 

Regulatory T cells .... 537, 539, 540, 756 

regulatory/policy .............................. 102 

relative potency .............................. 1259 

relative source contribution 

(RSC) ............................................. 1930 

RELs .............................................. 1020 

renal .................................................. 816 

renal biomarker .................... 1305, 1322 

renal dysfunction ............................ 1322 

renal injury ..................................... 1878 

renal insufficiency ............................ 826 

renal pathology ................................... 12 

renal toxicity .................................. 1151 

repair ................................................ 712 

Reperfusion .................................... 1213 

repolarization ................................. 1753 

reproducibility .................................. 499 

reproduction ............................. 418, 847 

reproduction and development .... 7, 419, 

420, 421, 856 

Reproduction-Developmental .......... 430 

reproductive and developmental ..... 564, 

1591 

reproductive toxicity .... 559, 1030, 2107 

Reproductive toxicology ................. 391, 

417, 1481 

Reproductive/Developmental 

toxicity ........................................... 1973 

Research ............................................. 46 

Resistance ...................................... 1822 

resources ........................................ 1377 

respiration ................................ 334, 601 

Respiratory .......... 871, 872, 1015, 1016, 

1017, 1492, 2119 

respiratory mechanics ...................... 925 

respiratory modeling ........................ 870 

Respiratory Sensitization ....... 308, 1306 

Respiratory toxicity .......................... 105 

respiratory tract dosimetry ............. 1491 

Respiratory, lung .................................. 3 

Resveratrol ............ 144, 535, 731, 1208, 

1331, 1576 

Retained bullet ............................... 1842 

retina .............................................. 1603 

Retinoic Acid ......................... 132, 1468 

Retinol .............................................. 693 

retinopathy ..................................... 2120 

Retrospective study .......................... 392 

Reversibility ................................... 1805 

RfD ................................................. 1006 

Rhodanese ........................................ 338 

ribosome-inactivating protein .......... 332 

ribosylation ...................................... 129 

ribotoxic stress ........................... 60, 746 

ricin .............. 331, 332, 341, 1152, 1153 

Rip1 ................................................ 1837 

Risk .............................. 569, 1921, 1927 

risk assessment ............................ 36, 37, 

208, 246, 247, 250, 284, 542, 546, 612, 

649, 801, 812, 881, 884, 885, 886, 890, 

895, 900, 1013, 1014, 1015, 1016, 1017, 

1021, 1023, 1024, 1029, 1030, 1032, 

1235, 1349, 1351, 1354, 1355, 1396, 

1448, 1449, 1459, 1796, 1798, 1876, 

1900, 1908, 1912, 1914, 1916 , 1918, 

1919, 1923, 1929, 1933, 1934, 1935, 

1938, 1939, 1941, 1945, 2046, 2203, 

2204, 2205, 2208 

Risk Assessment Methods... 1913, 1915, 

1936 

Risk Assessments ........................... 1011 

Risk factors ...................................... 590 

RNA ............................................... 2199 

RNA interference ............................. 468 

road dust ......................................... 1496 

Rodent ............................................ 1027 

role, pathways, screening ..................... 5 

ROS ....... 1225, 1663, 1837, 2071, 2079, 

2095 

Rotenone .......................................... 630 

route of administration ................... 1565 

RT-CES ............................................ 389 

ruminants ........................................ 1158 

rutaecarpine .................................... 1572 

Ryanodine Receptor ....................... 2150 

Ryanodine Receptors ....................... 177 

S-adenosylmethionine .................... 2138 

S-allyl cysteine ............................... 1770 

saccharin and melamine ................. 1920 

Saccharomyces cerevisiae .............. 2159 

Safety ................. 609, 1040, 1145, 1178 

safety assessment ...... 1044, 1045, 1067, 

1171, 1803 

safety assessment pesticides ............ 857 

safety biomarkers ........................... 1323 

safety evaluation............................. 1043 

safety pharmacology ... 925, 1055, 1374, 

1376 

safety testing .................................. 1111 

Saharan Dust .................................. 1474 

Saint John’s wort ............................ 1090 

Salmonella Assay ............................. 697 

sample size ..................................... 1806 

Sand (PM10) .................................. 1031 

Sandwich-cultured hepatocytes...... 1062 

SAR ........................................ 188, 1804 

sarcomas ........................................... 674 

sarin .................................. 323, 345, 346 

Sarotherodon galilaeus ..................... 423 

Satratoxin G ................................... 1216 

Sauropus androgynus ..................... 2182 

SB 9002-1 ...................................... 1582 

scavenger receptor ............................ 275 

Scavenger receptors ........................... 32 

Scd1/mouse .................................... 1628 

SCGE ............................................. 1860 

Schools ........................................... 1909 

Science and Decisions ................ 38, 566 

Science Communication ................ 1005 

screening .......... 208, 380, 463, 467, 722 

Screening test ................................... 808 

Screening-level hazard 

characterization .................................. 85 

see-through medaka ........................... 89 

seizure ............................ 216, 333, 1324 

SELDI-TOF-MS ............................ 1299 

Selection ........................................... 231 

selective estrogen receptor 

modulators ...................................... 1339 

Selective Ligand ............................. 1197 

selenium ........................................... 775 

semen quality ................................... 390 

senescence ...................................... 1947 

sensitive populations ...................... 1906 

Sensitization ......... 111, 301, 1020, 1804 

sensory irritation ............................ 1494 

sensory neuron ............................... 1266 

sepiapterin reductase ........................ 987 

Seral learning test ........................... 2086 

serotonin ........................................... 979 

Sertoli Cell Junctional proteins ...... 1298 

Serum Biomarker ........................... 1307 

Serum immunoglobulin.................. 1995 

serum proteins ................................ 2178 

sex .......................................... 590, 2197 

sex differences ................................ 1419 

Sexing............................................... 864 

sexual development .......................... 414 

Sexual Dimorphism........................ 1467 

SGLT1/2 ......................................... 2100 

Shear Stress .................................... 1745 

SHetA2 ............................................. 721 

Sibutramine .................................... 1066 

sickle cell disease ........................... 1106 

signal transduction ...... 225, 1200, 1668, 

1670, 1672, 1817 

signaling pathways ......................... 1620 

silibinin .............................................. 69 

Silica .............. 30, 31, 32, 33, 583, 1495 

silica nanoparticles ......... 267, 599, 1698 

silicon dioxide .................................. 367 

Silicon Nanowires .......................... 1400 

silicones .......................................... 1007 

siloxanes ......................................... 1007 

silver nanoparticles .... 1612, 1702, 1704 

silver nanoparticles; Jurkat; 

p38 MAPK; DNA damage ............. 1700 

Silymarin .......................................... 725 

simulation ................................. 327, 329 

simulation modeling......................... 570 

single walled carbon Nanotubes ...... 799 

siRNA ................. 527, 1065, 1194, 2082 

Sirt1 ................................................ 1358 

skeletal malformation ....................... 396 

skeletal muscle ............................... 1640 

SKH-1 hairless mouse ................ 69, 353 

skin ............................ 74, 270, 271, 351, 

496, 502, 503, 675, 706, 967, 1792, 

2210 

skin absorption ......................... 471, 890 

skin burn ......................................... 1192 

skin cancer ....................................... 144 

Skin carcinogenesis .................. 671, 673 

Skin inflammation ............................ 671 

Skin irritation .................. 478, 494, 498, 

499, 504, 505 

skin lesion .......................................... 64 

skin model ........................................ 497 

skin penetration ........................ 258, 471 

336 






skin rash ........................................... 316 

Skin Residue .................................. 2047 

Skin sensitization .... 107, 110, 300, 306, 

1789, 1806, 1807, 1926 

skin sensitizers ................................. 108 

skin stem cells ................................ 1429 

skin tissue ......................................... 283 

SkinEthic .................................. 498, 504 

SkinEthic HCE ............................... 1191 

Skinethic HVE model ...................... 491 

SkinEthic-HCE ................................ 488 

slices ............................................... 1638 

Smokeless ........................................ 126 

Smokeless tobacco ........ 733, 753, 1170, 

1220, 1853 

Smokestack Effect Study ............... 1909 

SNP .................................................. 355 

SNPs ................................................. 231 

social ................................................ 942 

Sodium channel .............................. 1250 

sodium channels ............................. 2031 

Sodium methyldithiocarbamate ..... 1543 

sodium tungstate ...................... 328, 427 

Sodium valproate ............................. 377 

soil ............................................ 803, 968 

Soil Contaminants .......................... 2048 

soil ingestion .................................. 1916 

soluble vapor .................................... 869 

solvent .................................... 139, 1932 

soman ....................................... 333, 340 

soot ................................................... 803 

sour gas .......................................... 1018 

Sox9b ............................................... 682 

Sp dependent genes .......................... 515 

Sp proteins ..................................... 2008 

Sp transcription factors ............ 515, 530 

speciation ......................................... 948 

species differences ....................... 8, 834 

species extrapolation ...................... 1450 

Species specificity, Human liver stem 

cell .................................................. 1630 

Specificity protein .................... 531, 532 

Specificity transcription factors ....... 140 

Sperm parameters ............................. 376 

Spermatogenesis .............................. 382 

Spermatogonial Stem Cells ............ 1487 

sphingolipid...................................... 853 

splenocyte....................................... 1823 

Sprague-Dawley Rat ........................ 930 

Sprague-Dawley rats .............. 851, 1035 

SR13668 ......................................... 1647 

Sry gene ........................................... 864 

Stability Study ................................ 1183 

standard development..................... 2218 

standard operating procedures ....... 1083 

Staphylococcal enterotoxin B ....326, 731 

STAT1 ............................................ 1949 

Stat3 ........................... 1671, 1766, 1816 

statin ............................................... 1673 

Statistical Learning ........................ 1854 

Statistical Power ............................... 182 

steatosis .......................................... 1628 

Stem Cell ........................................ 1683 

stem cell derived 

cardiomyocytes .......... 1739, 1740, 1741 

stem cells ............. 47, 1427, 1428, 1432, 

1433, 1679, 1681, 1682, 1684, 1685, 

1687, 1986, 2070 

stem-cell derived cardiomyocytes ....1738 

Steroid hormone action .................. 1453 

Steroidogenesis ............ 194, 1379, 2103 

steroids ........................................... 2097 

sterol oxidation products ................ 1141 

stochastic gene expression ............... 672 

Stoichiometric .................................. 194 

Store Operated Calcium Entry ......... 288 

strain ............................................... 1641 

stratum corneum ............................... 902 

Stress ............................ 587, 1600, 1609 

stress response ................................ 1515 

Stromal cell derived factor 1 ............ 758 

Strombus gigas ................................. 436 

structure activity relationships ......... 186 

Structure Activity Toxicology ........ 1378 

Structure-Activity Relationship ....... 190 

Structure-Activity Relationships .... 1009 

Study design ............................. 318, 610 

styrene .................. 359, 443, 1108, 1494 

subchronic oral toxicity .................. 1188 

subfertility ........................................ 396 

Subretinal ............................... 921, 1056 

subsistence ....................................... 438 

substitutes ....................................... 1023 

sulfation .......................................... 1618 

Sulforaphane .................................. 1559 

Sulfur donors .................................... 338 

sulfur mustard ........... 61, 62, 63, 64, 65, 

66, 68, 69, 336, 343, 344, 350, 351, 352, 

353, 494, 781, 924, 2211, 2213 

sulindac .................................. 530, 1956 

Summary Basis of Approval .......... 1787 

sunscreen formulations ........ 2067, 2068 

Superantigenic shock ....................... 326 

Superfund ................................. 231, 320 

Superoxide ..................................... 1747 

Superoxide anion ........................... 1961 

superparamagnetic ........................... 291 

surface reactivity .............................. 261 

surfactant ........................................ 1499 

surfactant protein-D ......................... 738 

surveillance .................................... 1902 

susceptibility ................ 656, 1931, 1998 

sympathetic constriction ................ 1728 

synaptosomes ................................. 1840 

synergism ....................................... 1464 

synthetic jet fuel ................... 1032, 1171 

System toxicology ............................ 649 

systemic analgesic ............................ 938 

Systemic Inflammation .................. 1473 

systemic toxicity ...................... 114, 419 

systems biology ....... 10, 127, 679, 1336, 

2039, 2076, 2080, 2081 

Systems toxicology ........ 197, 898, 2079 

T cell .............................. 35, 1556, 1993 

T cell responses .............................. 1981 

T lymphocytes ................................ 2193 

T47D ................................................ 113 

Tacrine .............................................. 700 

tamoxifen ....................... 431, 456, 1085 

tau ................................................... 1295 

TCAB ............................................... 396 

TCDD .......... 71, 73, 235, 440, 522, 539, 

632, 756, 1026, 1202, 1222, 1530, 1533, 

1534, 1535, 1537, 1627, 1628, 1629, 

1649, 1949, 1997, 2058, 2191 

TCDD and PCB153 ......................... 244 

TCE ................................................ 1726 

TDAR ......................... 1988, 1989, 2194 

tear gas ........................................... 2017 

TEF ................................................ 1033 

Telemetry ..... 600, 602, 915, 1055, 1727 

Telemetry probe ............................... 940 

tellurium ......................................... 2174 

Telomerase ..................................... 1207 

Telomerase activity ........................ 2064 

Telomere........................................... 677 

Telomere length.............................. 2064 

teratogen ............................................. 87 

teratogenesis ..................................... 849 

Teratogenic ............................... 381, 466 

teratogenicity .................... 681, 829, 850 

Teratology ........................................ 860 

tert-butyl hydroperoxide ................ 1763 

Testes .............................................. 2169 

Testicular .......................................... 381 

testicular dysgenesis ....................... 1973 

testicular toxicity .............................. 415 

testing strategy ..................... 1067, 1190 

Testis .................... 53, 1482, 1484, 1825 

testosterone ............................ 728, 1481 

Tetanus Toxoid ............................... 1993 

tetrabromobisphenol A ........... 908, 1571 

Tg.rasH2 ......................................... 1082 

TGF beta ........................................ 1724 

TGFbeta ................................. 671, 1634 

Th17 ................................................. 313 

Th17 cells & autoimmunity ............. 756 

Therapeutic ............... 1368, 1369, 1370, 

1371, 1372, 1373 

Therapeutic antibody ..................... 1404 

therapy ............................................ 1426 

thiamazole ........................................ 403 

thiazolidinedione ............................ 2127 

Thinsulate ....................................... 1176 

Thiols ............................................... 490 

Thioredoxin ...................................... 764 

thioredoxin reductase ................. 65, 763 

THPI ............................................... 1326 

threshold ................................. 210, 1115 

Threshold of Toxicological Concern 

(TTC) ............................................... 551 

Thresholds ...................................... 1354 

thymocyte ....................................... 2191 

thyroid ................ 482, 1383, 2090, 2099 

Thyroid axis ............................. 426, 894 

Thyroid Hormone ................. 1714, 2085 

Tissue and milk concentrations ...... 1569 

Tissue Cross-Reactivity ................. 1074 

Tissue Distribution ................. 278, 1582 

tissue factor .................................... 1958 

Tissue factor pathway inhibitor-2 .... 152 

TISSUES ........................................ 1844 

titanium dioxide ....... 260, 262, 263, 266 

Titanium dioxide nanoparticles ..... 1701, 

2065 

titanium nanoparticles .......... 2067, 2068 

Tk mutant ......................................... 692 

TLR ................................................ 1550 

TLR4 .............................................. 2136 

TNF .................................................... 31 

TNIP1 ............................................. 2152 

TNT .................................................. 348 

tobacco ................................... 385, 1311 

tobacco smoke .......................... 92, 1919 

Tocopherols ...................................... 120 

Toll-like receptor 5 agonist .............. 913 

toluene .................... 159, 783, 888, 1258 

Toluene diisocyanate ........................ 299 

Tonalide .......................................... 1674 

Toner .............................................. 1121 

topical anesthetic .............................. 938 

topical application .......................... 2172 

topical route ................................... 1116 

topoisomerase II ................... 1120, 1174 

Torsade de pointes .......................... 1753 

total body irradiation ........................ 597 

TouchDown .................................... 1287 

ToxCast ............... 96, 98, 192, 198, 212, 

215, 463, 545, 1010, 1382, 1387, 1411 

toxic equivalency factor ................... 238 

Toxic mechanism ............................. 808 

Toxicant ............................................ 631 

toxicity ...................... 14, 218, 273, 322, 

328, 616, 1159, 1332, 1413, 1426, 1514, 

1571, 1825, 2159 

Toxicity Biomarkers in Mouse 

Lung ............................................... 1859 

toxicity mechanism ........................ 1898 

toxicity pathway .................... 115, 1445, 

1446, 1448 

toxicity reference value .................. 1918 

Toxicity study ................................. 1027 

Toxicity test ...................................... 423 

toxicity testing ...................... 2029, 2032 

Toxicity Testing in the 21 st Century ....13, 

1723 

toxicogenomics .............................. 2161 

Toxicogenomics, Hepatotoxicity, 

Liver ..................................... 1630, 1661 

Toxicokinetics ..... 68, 1568, 1570, 1571, 

1578, 1579, 1592, 1914, 2062 

toxicologic pathology ....................... 523 

toxicological information ................. 943 

toxicologists ................................... 1415 

Toxicology ...... 26, 602, 607, 943, 1333, 

1336, 1447, 1480, 2096 

toxicology and communication ........ 943 

Toxicology and Safety ................... 1004 

Toxicosis .......................................... 669 

tracheal instillation ......................... 1399 

Traffic Particulates ......................... 1970 

training ............................................. 659 

tramadol ......................................... 2140 

transcript profiling...... 1639, 2115, 2154 

transcription factor ............... 1814, 2149 

transcription factors ....................... 2152 

transcription networks ...................... 193 

transcription profiling ........................ 97 

Transcriptional Assay ..................... 1408 

transcriptional complexes .............. 2105 

transcriptional regulation ........ 73, 1472, 

1670, 1815 

transcriptome ........................ 1471, 1662 

transcriptomics ............ 206, 1629, 1650, 

1689, 1996, 2209, 2210 

Transcriptomics/gene expressing ... 1388 

Transdermal ................................... 1563 

transformation ................................ 2170 

Transformation in vitro .................... 511 

transgenic ............................... 618, 2206 

transgenic mice .......... 1100, 1466, 2207 

transient receptor potential ............. 2016 

Transition metals ............................ 2177 

Translation ....... 1440, 1441, 1442, 1443 

translational inhibition ................... 1463 

Translational Research ........... 879, 2052 

Translational toxicology ... 3, 320, 1506, 

2203 

transmigration .................................. 749 

transplacental ................................. 1429 

transplacental exposure ......... 836, 1430, 

1431 

transponders ................................... 1082 

transport ........................................... 226 

transporter .......... 625, 1231, 1617, 1624 

transporter genes ............................ 1418 

Transporters ................. 621, 1596, 1622 

Treatment ....................................... 1257 

Tregs ................................................... 76 

Triazines ......................................... 2092 

tribal population ............................... 357 

Tributyltin ........... 425, 436, 1549, 1551, 

1605, 1608 

Trichlorethylene ............................... 310 

Trichloroethene ................................ 311 

trichloroethylene ..... 224, 243, 364, 874, 

886, 1304 

Triclosan ................................. 241, 2104 

Trihalomethanes ............................. 1943 

Triple Pack or Parallelogram 

Approach ........................................ 2050 

tris chloropropyl phosphate ............ 1589 

Troglitazone ................................... 1595 

Trophoblast Stem Cell ................... 1688 

troponin .......................................... 1315 

Troponin I ...................................... 1308 

Trovafloxacin ................................. 2129 

TRPA1 ........................ 2017, 2018, 2020 

TRPV1 ............. 2019, 2021, 2151, 2153 

TRPV4 ........................................... 2022 

TSPO/PBR ..................................... 1279 

TTC ................................................ 1179 

Tumor Necrosis Factor alpha ......... 2123 

tumor promotion ............ 228, 524, 1222 

tumorigenesis ......................... 135, 2090 

Tumorigenicity ............................... 1035 

tumors .............................................. 521 

tungsten ............ 1413, 1558, 2164, 2166 

tungsten alloy ................................... 991 








Tungsten-Carbide Cobalt ................. 271 

Type I Hypersensitivity .................... 302 

Type II cartilage ............................. 1142 

Tyrosine Hydroxylase .................... 1271 

tyrosine kinase inhibitors ................... 79 

U.S. Food ......................................... 641 

Ubiquitin ........................................ 1822 

UCP-2 ............................................ 1269 

UDP-glucoronosyltransferase ........ 1234 

Ultrafine Particles .......................... 1477 

Ultrastructure ....................... 1154, 1292 

uncertainty .............................. 896, 1925 

uncertainty analysis .......................... 545 

uncertainty factor ................. 1911, 1913 

undergraduate research .................. 2083 

Unfolded Protein Response ............ 1631 

United States .................................. 1149 

uranium ............................................ 577 

Urea cycle ........................................ 221 

urinary biomarkers ....... 582, 1323, 1895 

Urinary Cadmium .......................... 1821 

Urine biomarkers ........................... 1864 

Uroepithelial .................................... 492 

urogenital sinus ................................ 844 

urothelium ........................................ 955 

UROtsa ..................................... 953, 954 

Usnic acid ....................................... 1960 

Usual intake ................................... 1869 

uterine receptivity ............................ 416 

Utrasonic Vocalizations .................... 862 

UV ...................................... 82, 241, 714 

UVA ................................................. 693 

UVB ............................................... 1671 

Vaccine ................................. 1370, 1373 

Vaccine immunogenicity .................. 409 

vaccine safety assessment .............. 1054 

Vaccines .................... 1368, 1369, 1371, 

1372, 1439 

vaginal irritation ............................... 109 

vaginal irritation testing ........... 412, 491 

Valerian Root ................................. 1040 

validation .............. 101, 908, 1808, 2217 

validation study .......... 2109, 2110, 2111 

valproate ................................. 161, 1059 

Valproic Acid ................................. 1581 

Vanadium ................... 1945, 2167, 2168 

vanilloid/capsaicin ............... 2016, 2153 

Vanin-1 ........................................... 2131 

vapor................................................. 493 

vapor exposure ............................... 1022 

Variability ......................... 98, 896, 2012 

vascular damage ............................. 1310 

Vascular injury ............................... 1746 

Vascular physiology ....................... 1509 

vascular remodeling ......................... 576 

Vasculitis .............................. 1746, 2186 

VCAM-1 ........................................ 1748 

VCD ................................................. 387 

VDBP ............................................. 1305 

vegetative insecticidal protein ........ 1180 

VEGF ............................................. 1734 

VEGFR ................................ 1084, 1734 

vehicle-effects ................................ 1184 

vesicant............................... 67, 343, 347 

Vestibular system ........................... 1253 

vinyl acetate ................................... 1112 

Vinylcyclohexene ............................... 28 

Vinylphenol ...................................... 443 

Viracept ............................................ 551 

Virtual ............................................ 1387 

Virtual Liver ............... 1407, 2080, 2081 

virus................................................ 1532 

Visual analytics ................................ 883 

vitamin D ....................................... 1045 

Vitamins ........................................... 609 

vitellogenin ...................................... 912 

VLCAD ............................................ 462 

VOC ............................................... 1258 

VOCs .................................... 1041, 1579 

Volatile Organic Compounds ......... 1301 

Von Willebrand Factor ................... 1577 

VRP ................................................ 2186 

VX .................................................... 342 

Waste sites ........................................ 246 

Water Quality ................................. 1940 

Weight of Evidence ........................ 1179 

welding fume ................................... 734 

Welding fumes ................................... 21 

Werner syndrome protein ................. 677 

Whole Embryo Culture .... 404, 829, 836 

Whole Life ....................................... 965 

Wildfire ............................................ 776 

Wistar rat .......................................... 913 

Wnt signalling ................................ 1433 

Women’s Health ............................. 1004 

woodsmoke .................................... 1801 

Wound Healing ................................ 343 

wound healing model ....................... 483 

X-radiation ....................................... 394 

xenobiotic exposure ....................... 2010 

xenobiotic metabolism ........ 1928, 2012, 

2128 

xenobiotics ............................... 10, 1416 

xenoestrogens ................................. 2105 

Xenopus ........................................... 426 

XOMA 052 .................................... 1043 

XPA(-/-)p53(+/-) mice ..................... 131 

XPC ........................................ 361, 2009 

XPC Lys939Gln and XRCC1 

Arg399Gln polymorphisms.............. 529 

XRF ................................................ 2118 

Y-H2AX ............................................. 66 

Yaupon ............................................. 748 

yeast ............................... 224, 722, 1845 

yolk sac ............................................ 836 

Zebrafish ................. 85, 86, 87, 90, 165, 

172, 414, 425, 440, 463, 466, 467, 680, 

681, 682, 684, 685, 850, 1127, 1390, 

1412, 1706, 1843, 2023, 2024, 2025, 

2027, 2028, 2065 

Zidovudine ....................................... 703 

zinc ... 146, 786, 1362, 1363, 1364, 1366 

zinc bisglycinate chelate ................ 2172 

zinc finger nuclease .......................... 904 

zinc nanoparticles ................. 2067, 2068 

zinc-sensing .................................... 1670 

Ziram .............................................. 1239 

ZnO .................................................. 265 

Zucker .............................................. 555 

Zymogen Granules ......................... 1077 

338 



Notes 



2009–2010 Council 

Cheryl Lyn Walker 

Michael P. Holsapple 

Jon C. Cook 

president 

2009–2010 

Vice president 

2009–2010 

Vice president-elect 

2009–2010 

LeAdershIp 

• Audit Committee, Council 

Contact 

• Board of Publications, Member 

• Endowment Fund Board, 

Ex-Officio Member 

• Finance Committee, Member 

• IUTOX Councilor, Member 

T: (512) 237-9525 F: (512) 237-2475 

cwalker@wotan.mdacc.tmc.edu 

• Board of Publications, ad hoc 

Member, Council Contact 

• Communications Subcommittee: 

Congressional Task Force, 

Member 

• Finance Committee, Member 

• Nominating Group for Honorary 

Members, Member 

• Scientific Program Committee, 

Chair, Member 

T: (202) 659-3306 F: (202) 659-3617 

mholsapple@hesiglobal.org 

• Awards Committee, Council 

Contact 

• Global Strategy Focus Group, 

Council Contact 

• Scientific Program Committee, 

Co-Chair, Member 

T: (860) 715-2693 F: (860) 715-9890 

jon.c.cook@pfizer.com 

Lawrence R. Curtis 

Martin A. Philbert 

Peter L. Goering 

treasurer 

2008–2011 

secretary 

2008–2010 

secretary-elect 

2009–2010 

• Council Subcommittee for 

Non-SOT Annual Meeting and 

Regional Chapter Funding, 

Member 



• Exhibitor Liaison Working Group, 


• Finance Committee, Chair, 


• 50 th Anniversary Task Force, 





Co-Chair, Council Contact 

• Newsletter Editor 

• Research Funding Committee, 


• Communications Committee, 





Member 

• Historian, Council Contact 

• Regional Chapters, Council 

Contact 

T: (541) 737-1764 F: (541) 737-3178 

larry.curtis@oregonstate.edu 

T: (734) 763-4523 F: (734) 763-8095 

philbert@umich.edu 

T: (301) 796-0253 F: (301) 796-9826 

peter.goering@fda.hhs.gov 

340 



2009–2010 Council (Continued) 

Kenneth S. Ramos 

Matthew S. Bogdanffy 

Susan J. Borghoff 

past president 

2009–2010 

Councilor 

2009–2011 

Councilor 

2009–2011 



• Nominating Committee, Council 

Contact 


Members, Member, Council 

Contact 

• IUTOX Councilor, Member, 


T: (502) 852-7207 F: (502) 852-3659 

kenneth.ramos@louisville.edu 

• Education Committee, Council 

Contact 

• Disease Prevention Task Force, 


• Specialty Sections, Council 

Contact 

T: (203) 798-5339 F: (203) 798-5797 

matthew.bogdanffy@boehringeringelheim.com 

• Committee on Diversity 

Initiatives, Council Contact 




Member 

• Membership Committee, Council 

Contact 

• Special Interest Groups, Council 

Contact 

T: (919) 281-1110 ext. 717 F: (919) 281-1118 

sborghoff@ils-inc.com 

LeAdershIp 

Patricia E. Ganey 

Ronald N. Hines 

Shawn Douglas Lamb 

Councilor 

2008–2010 

Councilor 

2008–2010 

executive director 

• Career Resource and 

Development Committee, 


• Postdoctoral Assembly, Council 

Contact 

• Professional Needs Assessment 

Task Force, Council Contact 

• Student Advisory Council and 

Graduate Committees, Council 

Contact 

• Contemporary Concepts 

in Toxicology Conferences 

Committee, Council Contact 

• Continuing Education 

Committee, Council Contact 




Co-Chair, Member 

• Scientific Liaison Task Force, 


• Audit Committee, Staff Liaison 



• Global Strategy Focus Group, 

Staff Liaison 

• Finance Committee, Staff Liaison 

• IUTOX Councilors, Staff Liaison 

• Nominating Committee, Staff 

Liaison 


Members, Staff Liaison 

T: (517) 432-1761 F: (517) 432-2310 

ganey@msu.edu 

T: (414) 955-4322 F: (414) 955-6651 

rhines@mcw.edu 

T: (703) 438-3115 F: (703) 438-3113 

shawnl@toxicology.org 



Officers and Councilors 


President (2009–2010) 

T: (512) 237-9525 

F: (512) 237-2475 

cwalker@wotan.mdacc.tmc.edu 

Michael P. Holsapple 

Vice President (2009–2010) 

T: (202) 659-3306 

F: (202) 659-3617 

mholsapple@hesiglobal.org 

Jon C. Cook 

Vice President-Elect (2009–2010) 

T: (860) 715-2693 

F: (860) 715-9890 

jon.c.cook@pfizer.com 

Martin A. Philbert 

Secretary (2008–2010) 

T: (734) 763-4523 

F: (734) 763-8095 

philbert@umich.edu 


Secretary-Elect (2009–2010) 

T: (301) 796-0253 

F: (301) 796-9826 

peter.goering@fda.hhs.gov 


Past President (2009–2010) 

T: (502) 852-7207 

F: (502) 852-3659 

kenneth.ramos@louisville.edu 


Councilor (2009–2011) 

T: (919)281-1110 ext. 717 

F: (919) 281-1118 

sborghoff@ils-inc.com 

Patricia E. Ganey 


T: (517) 432-1761 

F: (517) 432-2310 

ganey@msu.edu 

Ronald N. Hines 


T: (414) 955-4322 

F: (414) 955-6651 

rhines@mcw.edu 

LeAdershIp 


Treasurer (2008–2011) 

T: (541) 737-1764 

F: (541) 737-3178 

larry.curtis@oregonstate.edu 

Matthew S. Bogdanffy 


T: (203)798-5339 

F: (203) 798-5797 

matthew.bogdanffy@boehringeringelheim.com 

Past Presidents 

1961–1962 Harold C. Hodge* 

1962–1963 C. Boyd Shaffer* 

1963–1964 Paul S. Larson* 

1964–1965 Harry W. Hays* 

1965–1966 Frederick Coulston* 

1966–1967 Verald K. Rowe* 

1967–1968 John A. Zapp, Jr.* 

1968–1969 Carrol S. Weil* 

1969–1970 Ted A. Loomis 

1970–1971 Robert L. Roudabush* 

1971–1972 Wayland J. Hayes, Jr.* 

1972–1973 Victor A. Drill* 

1973–1974 Joseph F. Borzelleca 

1974–1975 Sheldon D. Murphy* 

1975–1976 Seymour L. Friess* 

1976–1977 Robert A. Scala 

1977–1978 Harold M. Peck* 

1978–1979 Leon Golberg* 

1979–1980 Tom S. Miya 

1980–1981 Perry J. Gehring* 

1981–1982 Robert B. Fowrney* 

1982–1983 Robert L. Dixon* 

1983–1984 Gabriel L. Plaa* 

1984–1985 Frederick W. Oehme 

1985–1986 Emil A. Pfitzer* 

1986–1987 John Doull 

1987–1988 Jerry B. Hook 

1988–1989 James E. Gibson 

1989–1990 Roger O. McClellan 

1990–1991 Curtis D. Klaassen 

1991–1992 Donald J. Reed 

1992–1993 John L. Emmerson 

1993–1994 I. Glenn Sipes 

1994–1995 Meryl H. Karol 

1995–1996 Jack H. Dean 

1996–1997 James S. Bus 

1997–1998 R. Michael McClain 

1998–1999 Steven D. Cohen 

1999–2000 Jay I. Goodman 

2000–2001 Daniel Acosta, Jr. 

2001–2002 David L. Eaton 

2002–2003 William F. Greenlee 

2003–2004 Marion F. Ehrich 

2004–2005 Linda S. Birnbaum 

2005–2006 Kendall B. Wallace 

2006–2007 James A. Popp 

2007–2008 George B. Corcoran 

2008–2009 Kenneth S. Ramos 

*Deceased 

342 



Elected Committees 

Appointed Committees 

Awards Committee 

James C. Lamb, IV, Chair (2009–2010), Member (2008–2010) 

Lori A. Dostal, Member (2009–2011) 

Jay I. Goodman, Member (2009–2011) 

Douglas A. Keller, Member (2009–2011) 

Lois D. Lehman-McKeeman, Member (2008–2010) 

Garold S. Yost, Member (2008–2010) 

Harold Zenick, Member (2009–2011) 

Jon C. Cook* 

Matthew Price** 


Aaron Barchowsky, Chair (2009–2010), Member (2007–2010) 

Lorrene A. Buckley, Member (2009–2012) 

Dori R. Germolec, Member (2008–2011) 

Robin C. Guy, Member (2009–2012) 

Stephen B. Pruett, Member (2008–2011) 

Sidhartha D. Ray, Member (2007–2010) 

Amy M. Skinner, Postdoctoral Representative (2009–2010) 

Erica Nicole Rogers, Student Representative (2009–2010) 

Matthew S. Bogdanffy* 

Betty Eidemiller** 

Membership Committee 

Thomas M. Monticello, Chair (2009–2010), Member (2008–2011) 

Robert E. Chapin, Member (2007–2010) 

Darol E. Dodd, Member (2008–2011) 

Terry Gordon, Member (2009–2012) 

MaryJane K. Selgrade, Member (2007–2010) 

Robert L. Tanguay, Member (2009–2012) 

Leah M. Zorrilla, Postdoctoral Representative (2009–2010) 

Ofek Bar-Ilan, Student Representative (2008–2010) 

Susan J. Borghoff* 

Matthew Price** 

Nominating Committee 

George B. Corcoran, Chair (2009–2010), Member (2009–2010) 

Tammy R. Dugas, Member (2009–2011) 

Suzanne Compton Fitzpatrick, Member (2008–2010) 

Julie E. Goodman, Member (2009–2011) 

Jack R. Harkema, Member (2008–2010) 

Laurie C. Haws, Member (2008–2010) 

Kendall B. Wallace, Member (2009–2011) 

Kenneth S. Ramos* 

Shawn Douglas Lamb ** 

* Council Contact 

** Staff Liaison 

TBD=To be determined 

50 th Year Anniversary SOT Task Force (FAST) 

Ernest Hodgson, Chair, Member (2006–2012) 

Meryl H. Karol, Co-Chair, Member (2006–2012) 

Linda S. Birnbaum, Member (2006–2012) 

James S. Bus, ad hoc (2008–2012) 

Gary P. Carlson, Member (2006–2012) 

Jack H. Dean, Member (2007–2012) 

Dennis J. Devlin, Member (2007–2012) 

John Doull, Member (2006–2012) 

David L. Eaton, Member (2006–2012) 

William C. Hays, Member (2006–2012) 

Lisa A. Opanashuk, Member (2007–2012) 

Dennis James Paustenbach, Member (2007–2012) 

Martin A. Philbert*, Member (2006–2012) 

Robert A. Scala, Member (2006–2012) 

Ronald B. Tjalkens, Member (2007–2012) 

Clarissa Russell Wilson** 

Audit Committee 

James S. Bus, Chair (2008–2010), Member (2007–2010) 

Jeffrey M. Charles, Member (2007–2012) 

George P. Daston, Member (2008–2011) 

Cheryl Lyn Walker* 

Shawn Douglas Lamb** 

Board of Publications 

Hartmut Jaeschke, Chair (2009–2010), Member (2007–2011) 

Michael P. Holsapple*, ad hoc (2009–2010) 

David Jacobson Kram, Member (2006–2010) 

Serrine S. Lau, Member (2009–2013) 

Lois D. Lehman-McKeeman, ToxSci Editor, Auditor (2003–2010) 

Ivan Rusyn, Member (2008–2012) 

Cheryl Lyn Walker, Member (2009–2010) 

Marcia Lawson** 


Judy L. Raucy, Chair (2009–2010), Member (2007–2010) 

Marila Cordeiro-Stone, Member (2009–2012) 

B. Bhaskar Gollapudi, Member (2007–2010) 

Hisham K. Hamadeh, Member (2008–2011) 

Christopher J. Portier, Member (2008–2011) 

Richard Davis Storer, Member (2009–2012) 

Richard R. Vaillancourt, Member (2007–2010) 

Vasilis Vasiliou, Member (2009–2012) 

Donna D. Zhang, Member (2008–2011) 

Rohit Singhal, Postdoctoral Representative (2009–2010) 

Haitian Lu, Student Representative (2009–2010) 

Patricia E. Ganey* 

Kristen Meletti and Matthew Price** 

Committee on Diversity Initiatives 

Adrian Nanez, Chair (2009–2010), Member (2008–2011) 

Yolanda Banks Anderson, Member (2009–2012) 

Nathan J. Cherrington, Member (2009–2012) 

Abraham Dalu, Member (2007–2010) 

Julio Cesar Davila, Member (2008–2011) 

Jose E. Manautou, ad hoc (2009–2010) 

Lin Mantell, Member (2007–2010) 

W. David McGuinn, Jr., Member (2008–2011) 

Jennifer L. Rayner, Member (2009–2012) 

Minerva Mercado Feliciano, Postdoctoral Representative (2009–2010) 

Patricia Gillespie, Student Representative (2008–2010) 

Enrique Fuentes-Mattei, Assistant Student Representative (2009–2010) 

Susan J. Borghoff* 


LeAdershIp 



Appointed Committees (Continued) 

LeAdershIp 

Communications Committee 

Daland R. Juberg, Chair (2009–2010), Member (2008–2011) 

Drew A. Badger, Member (2008–2011) 

Vicki L. Dellarco, Member (2008–2010) 

Nancy Doerrer, Member (2009–2010) 

Steven G. Gilbert, Member (2008–2010) 

Deb Hoivik, Member (2009–2012) 

Paul C. Howard, Member (2009–2012) 

Laine Peyton Myers, Member (2008–2011) 

Katie Sprugel, Member (2008–2011) 

Joan B. Tarloff, Member (2008–2010) 

Chunli Quan, Postdoctoral Representative (2009–2010) 

Heather M. Bolstad, Student Representative (2009–2010) 

Peter L. Goering* 

Martha Lindauer** 

Communications subcommittee: 

Animals in research Working Group 

Laine Peyton Myers, Chair (2009–2010), Member (2009–2010) 

Denise E. Fillman-Holliday, Member (2009–2010) 

Steven G. Gilbert, Member (2009–2010) 

Betina Lew, Member (2009–2010) 

Timothy P. Reilly, Member (2009–2010) 

Katie Sprugel, Member (2009–2010) 



Congressional task Force 

George Corcoran, Chair (2009–2010), Member (2009–2010) 

Bill Brock, Member (2009–2010) 

George Gray, Member (2009–2010) 

Daland Juberg, Member (2009–2010) 

Michael Holsapple, Member (2009–2010) 



editorial Board 

Joan B. Tarloff, Chair (2009–2010), Member (2009–2010) 


Jim Bus, Member (2009–2010) 

Paul Duffy, Member (2009–2010) 

Paul C. Howard, Member (2009–2010) 

Lois Lehman-McKeeman, Member (2009–2010) 

Jennifer Schellmann, Member (2009–2010) 

Judy Zelikoff, Member (2009–2010) 



emerging Issues task Force 

Vicki L. Dellarco, Chair (2009–2010), Member (2009–2010) 


Paul Duffy, Member (2009–2010) 

Steven Gilbert, Member (2009–2010) 



Worldwide Web task Force 

Deb Hoivik, Co-Chair (2009–2010), Member (2009–2010) 

Laine Peyton Myers, Co-Chair (2009–2010), Member (2009–2010) 

Marie Chantale Fortin, Member (2009–2010) 

Mark W. Powley, Member (2009–2010) 

Chunli Quan, Member (2009–2010) 

Eunice Musvasva Stagliola, Member (2009–2010) 

Martha Lindauer and Debbie O’Keefe** 

Contemporary Concepts in Toxicology (CCT) 

Conferences Committee 

Deborah A. Cory-Slechta, Chair (2009–2010), Member (2008–2012) 

Dale Hattis, Member (2008–2011) 

James P. Luyendyk, Member (2008–2011) 

Isaac N. Pessah, Member (2008–2010) 

Thomas J. Weber, Member (2008–2010) 

Timothy Richard Zacharewski, Member (2009–2012) 

Ronald N. Hines* 


Continuing Education Committee 

John C. Lipscomb, Chair (2009–2010), Member (2007–2010) 

Hadi Falahatpisheh, Member (2008–2011) 

Kathleen Gabrielson, Member (2009–2012) 

Michelle J. Hooth, Member (2009–2010) 

Debra L. Laskin, Member (2009–2012) 

Christopher A. Reilly, Member (2008–2011) 

Stephen H. Safe, Member (2009–2012) 

Courtney E. W. Sulentic, Member (2007–2010) 

Yanan Tian, Member (2008–2011) 

Anne Elizabeth Loccisano, Postdoctoral Representative (2009–2010) 

Sarah J. Gilpin, Student Representative (2009–2010) 


Dylan Amerine** 

Council Subcommittee for Non-SOT Annual Meeting and 

Regional Chapter Funding 

Ronald N. Hines, Co-Chair (2009–2010), Member (2009–2010) 

Martin A. Philbert*, Co-Chair (2009–2010), Member (2007–2010) 

Susan J. Borghoff, Member (2009–2010) 

Lawrence R. Curtis, Member (2009–2010) 

Peter L. Goering, Member (2009–2010) 


Data Task Force 

Ron N. Hines*, Member (2009–2010) 

Martin A. Philbert*, Member (2009–2010) 

Debbie O’Keefe and Betty Eidemiller** 

Disease Prevention Task Force 

Helmut Zarbl, Chair (2008–2010), Member (2008–2010) 

Thomas W. Kensler, Co-Chair (2009–2010), Member (2009–2012) 

Matthew J. Campen, Member (2008–2011) 

Erica L. Dahl, Member (2009–2012) 

James Patrick Mastin, Member (2008–2011) 

Jack P. Vanden Heuvel, Member (2008–2010) 

Matthew S. Bogdanffy* 


344 





(See elected listing page 343) 

education subcommittee: K–12 task Force 

Maureen Gwinn, Chair (2009–2011) 

Joanna Matheson, Member (2009–2011) 

Suzy Fitzpatrick, Member (2009–2011) 

Kathleen Gabrielson, Member (2009–2011) 

Dori Germolec, Education Committee Liaison (2009–2011) 


education subcommittee: toxLearn Work Group 

Phil Wexler, Chair (2004–2010), Member (2004–2010) 

Sue Ford, Member (2006–2010) 

John Duffus, Member (2004–2010) 

Tammy Dugas, Member (2006–2010) 

Jane Huggins, Member (2006–2010) 

Michael A. Kamrin, Member (2004–2010) 

Paul Wright, Member (2004–2010) 

Sid Ray, Education Committee Liaison (2007–2010) 


education subcommittee: undergraduate education 

Aaron Barchowsky, Chair (2009–2010), Member (2009–2010) 

Sue M. Ford, Member (2009–2010) 

Wesley G.N. Gray, Member (2009–2010) 

Sara Hegglund, Member (2009–2010) 

Stephen B. Pruett, Member (2009–2010) 

Mindy F. Reynolds, Member (2009–2010) 

Teresa G. Dodd–Butera, Member (2009–2010) 


Endowment Fund Board 

Jacqueline H. Smith, Chair (2009–2010), Member (2008–2011) 

George B. Corcoran, Member (2008–2010) 

Norbert E. Kaminski, Member (2007–2011) 

Kenneth S. Ramos*, Member (2009–2011) 

William Slikker, Jr., Member (2009–2013) 

Robert G. Tardiff, Member (2009–2010) 

James S. Woods, Member (2009–2012) 

Lawrence R. Curtis, Ex-Officio Member (2009–2011) 

Shawn Douglas Lamb, Ex-Officio Member (2006–2010) 

Cheryl Lyn Walker, Ex-Officio Member (2009–2010) 


Exhibitor Liaison Working Group 

Lawrence R. Curtis* (2009–2011) 

Cyndi Bono (2009–2012) 

Valerie Cole (2009–2011) 

Steve Hachtman (2009–2012) 

Shawn Herring (2009–2011) 

Clarissa Wilson and Liz Kasabian ** 

Finance Committee 

Lawrence R. Curtis*, Chair (2009–2010), Member (2008–2011) 

Gail Darlene Chapman, Member (2008–2011) 

John DiGiovanni, Member (2009–2012) 

Michael P. Holsapple, Member (2009–2011) 

Robert W. Kapp, Jr., Member (2007–2010) 

Cheryl Lyn Walker, Member (2008–2010) 


Global Strategy Task Force 

Ruth A Roberts, Chair (2009–2010) 

S. Satheesh Anand, Association of Scientists 

of Indian Origin (2009–2010) 

Laura Andrews, Women in Toxicology (2009–2010) 

Silvia B. M. Barros, Member (2009–2010) 

Kok Wah Hew, Member (2009–2010) 

Ji-Eun Lee, Korean Toxicologists Association in America (2009–2010) 

Anthony M. Ndifor, Toxicologists of African Origin (2009–2010) 

Betzabet Quintanilla-Vega, Hispanic Organization 

for Toxicologists (2009–2010) 

Denise Robinson Gravatt, Member (2009–2010) 

John C. Zhuang, American Association of Chinese 

in Toxicology (2009–2010) 

Jon C. Cook* 

Michael P. Holsapple* 


Historian 

Ernest Hodgson, Chair (2007–2011) 

Peter L. Goering* 


Nominating Group for Honorary Members 

George B. Corcoran, Chair (2009–2010) 

Michael P. Holsapple, Member (2009–2010) 

Kenneth S. Ramos*, Member (2009–2010) 


Postdoctoral Assembly (PDA) Executive Board 

Betina J. Lew, Chair (2009–2010), Member (2008–2010) 

Sarah Campion, Co-Chair (2009–2010), Member (2009–2010) 

Alison Hege Harrill, Secretary (2009–2011) 

Patrick Shaw, Treasurer (2009–2010) 

Lauren Aleksunes, Councilor (2008–2010) 



Professional Needs Assessment Task Force 

Daniel Acosta, Jr., Chair (2008–2010), Member (2008–2010) 

Barbara D. Davis, Member (2009–2011) 

Mary Beth Genter, Member (2009–2012) 

J. Kevin Kerzee, Member (2008–2010) 

James C. Lamb, IV, Member (2008–2011) 

James A. Popp, Member (2009–2012) 




Joel G. Pounds, Chair (2008–2010), Member (2008–2011) 

Stuart Z. Cagen, Member (2008–2010) 

Jonathan A. Doorn, Member (2009–2012) 

Nancy I. Kerkvliet, Member (2009–2012) 

Jeffrey Maurice Peters, Member (2008–2010) 

Alvaro Puga, Member (2008–2011) 

Martin A. Philbert* 


LeAdershIp 


* Council Contact 

** Staff Liaison 

TBD=To be determined



LeAdershIp 

Scientific Liaison Task Force 

Garold S. Yost, Chair (2008–2010), Member (2008–2010) 

David G. Kaufman, Co-Chair (2009-2010), Member (2009–2012) 

Patricia A. Buffler, Member (2009–2012) 

Jeffrey I. Everitt, ad hoc (2008–2011) 

Thomas B. Knudsen, Member (2008–2011) 

John B. Morris, Member (2008–2011) 

Thomas R. Sutter, Member (2008–2010) 



Scientific Program Committee 

Michael P. Holsapple*, Chair (2009–2010), Member (2008–2010) 

Jon C. Cook, Co-Chair (2009–2010), Member (2009–2011) 

Cynthia A. Afshari, Member (2008–2011) 

Michael Aschner, Member (2007–2010) 

William J. Brock, Member (2007–2010) 

Leigh Ann Burns Naas, Member (2009–2012) 

Myrtle A. Davis, Member (2008–2011) 

Paul M. D. Foster, Member (2009–2012) 

Annie M. Jarabek, Member (2009–2012) 

Charlene A. McQueen, Member (2007–2010) 

Terrence James Monks, Member (2008–2011) 

Richard S. Pollenz, Member (2008–2011) 

Hollie I. Swanson, Member (2007–2010) 

David B. Warheit, Member (2009–2012) 

Nichelle Sankey** 

Student Advisory Council (SAC) 

Erica Marie Sparkenbaugh, President (2009–2010), 

Member (2008–2010) 

Haitian Lu, President-Elect (2009–2010), Member (2009–2011) 

Sheppard A. Martin, Secretary/Treasurer (2009–2010), 

Member (2008–2010) 

Ofek Bar-IIan, Secretary/Treasurer-Elect (2009–2010), 

Member (2009–2011) 

Daniel J. Hochman, Member (2008–2010) 

Erica Nicole Rogers, Member (2009–2010) 



student Advisory Council (sAC): regional Chapter/special 

Interest Group Graduate Committee 

Erica Marie Sparkenbaugh, Chair (2009–2010) 

Ofek Bar-IIan, Chair-Elect, Midwest (2009–2010) 

Erica Nicole Rogers, Secretary, Ohio Valley (2009–2010) 

J. Michael Berg, Gulf Coast (2009–2010) 

Heather M. Bolstad, Northern California (2009–2010) 

Marie Bourgeois, Southeastern (2009–2010) 

Hunter Coombes, South Central (2009–2010) 

Enrique Fuentes-Mattei, Hispanic Organization 

for Toxicologists (2009–2010) 

Aaron Michael Fullerton, Michigan (2009–2010) 

Sarah J. Gilpin, Northland (2009–2010) 

Gabriel A. Knudsen, Mountain West (2009–2010) 

Courtney D. Kozul, Women in Toxicology (2009–2010) 

Prasad Krishnan, Association of Scientists 

of Indian Origin (2009–2010) 

Narae Lee, Korean Toxicologists Association in America (2009–2010) 

Katie Beth Paul, North Carolina (2009–2010) 

Jessica R. Placido, Mid-Atlantic (2009–2010) 

Hariharan Saminathan, Central States (2009–2010) 

Sumitra Sengupta, Pacific Northwest (2009–2010) 

Parrisa Sherry Solaimani, Southern California (2009–2010) 

Sandra S. Wise, Northeast (2009–2010) 

Li (Susan) Xu, American Association of Chinese 

in Toxicology (2009–2010) 

346 

TBA, Allegheny-Erie 

TBA, Lake Ontario 

TBA, National Capital Area 

TBA, Toxicologists of African Origin 



student Advisory Council (sAC): specialty section Graduate 

Committee 

Sheppard A. Martin, Chair (2009–2010) 

Haitian Lu, Chair-Elect, Immunotoxicology (2009–2010) 

Daniel J. Hochman, Secretary, Ethical, Legal, 

and Social Issues (2009–2010) 

Arunkumar Asaithambi, Drug Discovery Toxicology (2009–2010) 

Michael G. Borland, Carcinogenesis (2009–2010) 

Andrea S. DeSantis, In Vitro and AlternativeMethods (2009–2010) 

Derek A. Drechsel, Mechanisms (2009–2010) 

Patricia Gillespie, Nanotoxicology (2009–2010) 

Glenn Robert Gookin, Inhalation and Respiratory (2009–2010) 

Nicholas Heger, Reproductive and Developmental 

Toxicology (2009–2010) 

Adrienne Lester King, Occupational and Public Health (2009–2010) 

Jason Patrick Magby, Neurotoxicology (2009–2010) 

Lauren M. Markell, Dermal Toxicology (2009–2010) 

Andrew D. Monnot, Metals (2009–2010) 

Ronald B. Pringle, Mixtures (2009–2010) 

Susan E. Ritger, Biological Modeling (2009–2010) 

Thomas Simones, Regulatory and Safety Evaluation (2009–2010) 

David Taylor Szabo, Risk Assessment (2009–2010) 

Lu Wang, Toxicologic and Exploratory Pathology (2009–2010) 

Sarah Elizabeth Wilson, Molecular Biology (2009–2010) 

TBA, Comparative and Veterinary 

TBA, Food Safety 

TBA, Ocular Toxicology 



SOT Liaison Representatives 

American Association for the Advancement 

of science (AAAs) representative 

Charlene A. McQueen 

Association for Assessment and Accreditation of Laboratory 

Animal Care (AAALAC) Board of trustees representative 

Loren Koller 

International union of toxicology (Iutox) Councilors 

George B. Corcoran 

Jack H. Dean 

James A. Popp 

Kenneth S. Ramos* 



Virginia Inhalation toxicology Advisory Group representative 

John Morris 



Regional Chapter—Officers 

Allegheny-Erie (77*) 

Nicolas A. Stewart, President 

Kelly A. Brant, President-Elect 

Aaron Barchowsky, Vice President 

Robin E. Gandley, Secretary 

William James Mackay, Treasurer 

Jeffrey P. Smith, Past President 

James P. Fabisiak, Councilor 

Jeffrey R. Haskins, Councilor 

Jim Scabilloni, Councilor 

Mark Weisberg, Councilor 

Fujun Liu, Postdoctoral Representative 

TBA, Student Representative 

Central States (174*) 

Anumantha G. Kanthasamy, President 

Jonathan A. Doorn, Vice President 

Bryan L. Copple, Secretary/Treasurer 

Hartmut Jaeschke, Past President 

Lora L. Arnold, Councilor 

Claire Redman Croutch, Councilor 

James P. Luyendyk, Councilor 

Shashi K. Ramaiah, Councilor 

Cheryl E. Rockwell, Postdoctoral Representative 

Hariharan Saminathan, Student Representative 

Gulf Coast (116*) 

Shawn B. Bratton, President 

Bhagavatula Moorthy, Vice President 

Erica D. Bruce, Vice President-Elect 

Christie M. Sayes, Secretary 

Alice R. Villalobos, Treasurer 

Yahan Tian, Past President 

R. Timothy Miller, Councilor 

Gensheng Wang, Postdoctoral Representative 

J. Michael Berg, Student Representative 

Lake Ontario (19*) 

TBA 

Michigan (177*) 

Alan P. Brown, President 

J. Caroline English, President-Elect 

Roseann Vorce, Secretary/Treasurer 

Brad L. Upham, Past President 

Nancy Anne M. Berdasco, Councilor 

Darrell R. Boverhof, Councilor 

Alice Hudder, Councilor 

Bjorn A. Thorsrud, Councilor 

Rohit Singhal, Postdoctoral Representative 

Aaron Michael Fullerton, Student Representative 

Mid-Atlantic (502*) 

Anthony R. Schatz, President 

Kenneth R. Reuhl, Vice President 

Raymond G. York, Vice President-Elect 

Lauren M. Tarantino Hutchison, Secretary/Treasurer 

Judith T. Zelikoff, Past President 

Diann L. Blanset, Councilor 

John M. Mitchell, Councilor 

Karl A. Traul, Councilor 

Kirstie H. Stansfield, Postdoctoral Representative 

Jessica R. Placido, Senior Student Representative 

Josephine A. Bonventre, Junior Student Representative 

Midwest (248*) 

Walter C. Prozialeck, President 

Matthew D. Schroeder, President-Elect 

Louette J. Rausch, Secretary 

Molly S. Weiler, Treasurer 

Peter J. Thomford, Past President 

Jane A. Fagerland, Councilor 

Susan M. Henwood, Councilor 

Lise I. Loberg, Councilor 

Oliver Pelz, Councilor 

TBA, Postdoctoral Representative 

Ofek Bar-Ilan, Student Representative 

Mountain West (121*) 

Philip J. Moos, President 

Matthew D. Reed, Vice President 

Donna D. Zhang, Vice President-Elect 

Kevin D. Welch, Secretary/Treasurer 

Vasilis Vasiliou, Past President 

Vincent A. Murphy, Councilor 

Jean C. Pfau, Councilor 

Robert Kuester, Postdoctoral Representative 

Gabriel A. Knudsen, Student Representative 

National Capital Area (250*) 

Jennifer W. Sekowski, President 

Pamela L. Chamberlain, Vice President 

Erik R. Janus, Secretary 

Thomas J. Flynn, Treasurer 

Gary Burin, Past President 

Robert J. Mitkus, Councilor 

Syril D. Pettit, Councilor 

Katherine S. Squibb, Councilor 

Madhavi Billam, Postdoctoral Representative 


North Carolina (359*) 

David J. Thomas, President 

Melanie F. Struve, Vice President 

Darol E. Dodd, Vice President-Elect 

Michael F. Hughes, Secretary/Treasurer 

Brenda Faiola, Past President 

Jamie C. Dewitt, Councilor 

Melissa C. Rhodes, Councilor 

Brante P. Sampey, Postdoctoral Representative 

Katie Beth Paul, Student Representative 

Northeast (282*) 

Graeme B. J. Smith, President 

Laura Andrews, Vice President 

Paul Nugent, Secretary/Treasurer 

Jessica E. Sutherland, Past President 

Felicity April Grzemski, Councilor 

Daniel J. Lettiere, Councilor 

Xinsheng Gu, Postdoctoral Representative 

Sandra S. Wise, Senior Student Representative 

Nicholas Heger, Junior Student Representative 

* Membership totals as printed in the 

most recent Membership Directory 

LeAdershIp 



Regional Chapter—Officers (Continued) 

LeAdershIp 

Northern California (343*) 

Stephen M. DiZio, President 

Tao Wang, Vice President 

Karen L. Steinmetz, Vice President-Elect 

Kent E. Pinkerton, Secretary 

Jeffrey S. Tepper, Treasurer 

George R. Clemens, Past President 

Amy H. Kim, Councilor 

John A. Wisler, Councilor 

Zhiying Ji, Postdoctoral Representative 

Heather M. Bolstad, Student Representative 

Northland (88*) 

John W. Nichols, President 

Timothy M. O’Brien, President-Elect 

Catherine F. Jacobson, Secretary/Treasurer 

Laura E. Solem, Past President 

Michael W. Hornung, Councilor 

Anthony L. Kiorpes, Councilor 

John R. MacDonald, Councilor 


Sarah J. Gilpin, Student Representative 

Ohio Valley (216*) 

Amy L. Roe, President 

Courtney E. W. Sulentic, Vice President 

Mary Beth Genter, President-Elect 

Jason C. Lambert, Secretary 

Lynette K. Rogers, Treasurer 

David R. Mattie, Past President 

Janelle S. Crossgrove, Councilor 

Jeffrey D. Moehlenkamp, Councilor 

J. Christopher States, Councilor 

Raja S. Settivari, Postdoctoral Representative 

Erica Rogers, Student Representative 

Pacific Northwest (158*) 

Cecile M. Krejsa, President 

Rafael A. Ponce, Vice President 

Stacey Lynn Harper, Vice President-Elect 

Linda L. Carlock, Secretary/Treasurer 

Robert L. Tanguay, Past President 

Kristen A. Mitchell, Councilor 

Beth A. Vorderstrasse, Councilor 

Susan C. Tilton, Postdoctoral Representative 

Sumitra Sengupta, Student Representative 

South Central (95*) 

Russell L. Carr, President 

Heather E. Kleiner, Vice President 

Tucker A. Patterson, Vice President-Elect 

Kartik Shankar, Secretary 

Yunfeng Zhao, Treasurer 

Kristie Willett, Past President 

Asok K. Dasmahapatra, Councilor 

Barbara L. Parsons, Councilor 


Hunter Coombes, Student Representative 

Southeastern (91*) 

Brian S. Cummings, President 

Charlene McQueen, Vice President-Elect 

Carol Wood, Secretary/Treasurer 

Jeff Fisher, Councilors 

Rick Schnellmann, Councilors 

Gary Miller, Councilors 

James R. Roede, Postdoctoral Representative 

Marie M. Bourgeois, Student Representative 

Southern California (342*) 

Michelle J. Horner, President 

Robert T. Dunn, Vice President 

Anthony M. Ndifor, Vice President-Elect 

Thomas A. Zanardi, Secretary 

Tina Leakakos, Treasurer 

Husam S. Younis, Past President 

A. Jacob Jabbour, Councilor 

Andrew M. Seacat, Councilor 

Gregory J. Stevens, Councilor 

David J. Castro, Postdoctoral Representative 

Parrisa Sherry Solaimani, Student Representative 



348 



Speciality Section—Officers 

Biological Modeling (119*) 

Richard A. Corley, President 

Robert S. DeWoskin, Vice President 

James V. Bruckner, Vice President-Elect 

Hugh A. Barton, Secretary/Treasurer 

Craig M. Zwickl, Past President 

Michael J. Bartels, Councilor 

Bradford W. Gutting, Councilor 

Jeffry Schroeter, Councilor 


Susan E. Ritger, Student Representative 

Biotechnology (NEW) 

Leigh Ann Burns Naas, Interim Officer 

Janet B. Clarke, Interim Officer 

Hanan N. Ghantous, Interim Officer 

Timothy K. MacLachlan, Interim Officer 

Barbara J. Mounho, Interim Officer 

Theresa Reynolds, Interim Officer 

Andrea B. Weir, Interim Officer 

Carcinogenesis (235*) 

Charlene A. McQueen, President 

Vernon E. Walker, Vice President 

David E. Williams, Vice President-Elect 

Andrew D. Burdick, Secretary/Treasurer 

Barbara S. Shane, Past President 

Heather E. Kleiner, Councilor 

Barbara L. Parsons, Councilor 

Xuefeng Ren, Postdoctoral Representative 

Michael G. Borland, Student Representative 

Cardiovascular Toxicology (NEW) 

Timothy Nurkiewicz, President 

Matthew J. Campen, President-Elect 

Kevin L. Dreher, Interim Vice President 

Daniel J. Conklin, Councilor 

W. David McGuinn, Councilor 

Dennis J. Murphy, Councilor 

Srikanth S. Nadadur, Councilor 

Hong Wang, Councilor 

Comparative and Veterinary (92*) 

Mike J. Murphy, President 

Kathleen Gabrielson, Vice President 

Ann F. Hubbs, Vice President-Elect 

Ramesh Chandra Gupta, Secretary/Treasurer 

Jim E. Riviere, Past President 

Jacqueline K. Akunda, Councilor 

Uford A. Madden, Councilor 



Dermal Toxicology (134*) 

George DeGeorge, President 

William Gerald Reifenrath, President-Elect 

Jeffrey J. Yourick, Vice President 

Carol L. Sabourin, Secretary/Treasurer 

Carol S. Auletta, Past President 

Jens Thing Mortensen, Councilor 

Cynthia A. Ryan, Councilor 

Dae J. Kim, Postdoctoral Representative 

Lauren M. Markell, Student Representative 

Drug Discovery Toxicology (330*) 

John W. Davis, President 

Cynthia A. Afshari, Vice President 

Craig E. Thomas, Vice President-Elect 

Melissa C. Rhodes, Secretary/Treasurer 

Kyle L. Kolaja, Past President 

Daniel C. Kemp, Councilor 

Michael P. Lawton, Councilor 

Kimberly A. Henderson, Postdoctoral Representative 

Arunkumar Asaithambi, Student Representative 

Ethical, Legal, and Social Issues (77*) 

Melinda J. Pomeroy-Black, President 

Phil Wexler, Vice President 

John P. Norman, Vice President-Elect 

Cindy M. Hoorn, Secretary/Treasurer 

Mara Seeley, Past President 

William A. Frez, Councilor 

Don W. Korte, Councilor 


Daniel J. Hochman, Student Representative 

Food Safety (133*) 

Jia Sheng Wang, President 

Ray A. Matulka, Vice President 

Kenneth A. Voss, Vice President-Elect 

Wu Li, Secretary/Treasurer 

Craig Llewellyn, Past President 

James C. Griffiths, Councilor 

Kathryn R. Mahaffey, Councilor 

Stephen A. Ruckman, Councilor 

Daniel M. Wilson, Councilor 



Immunotoxicology (363*) 

Jean F. Regal, President 

Leigh Ann Burns Naas, Vice President 

Rodney R. Dietert, Vice President-Elect 

Jacintha M. Shenton, Secretary/Treasurer 

Jeanine L. Bussiere, Past President 

Wendy J. Komocsar, Councilor 

Marc J. Pallardy, Councilor 

Jennifer Franko, Postdoctoral Representative 

Haitian Lu, Student Representative 

In Vitro and Alternative Methods (216*) 

David G. Allen, President 

Sue M. Ford, Vice President 

Vincent A. Murphy, Vice President-Elect 

Sharon A. Meyer, Secretary/Treasurer 

Frank A. Barile, Past President 

Brian S. Cummings, Councilor 

Greg Falls, Councilor 

Joshua A. Harrill, Postdoctoral Representative 

Andrea S. DeSantis, Student Representative 

LeAdershIp 





Speciality Section—Officers (Continued) 

LeAdershIp 

Inhalation and Respiratory (263*) 

JeanClare Seagrave, President 

Vincent Castranova, Vice President 

James G. Wagner, Vice President-Elect 

Dale W. Porter, Secretary/Treasurer 

Lung-Chi Chen, Past President 

James M. Antonini, Councilor 

Amy K. Madl, Councilor 

Annette C. Rohr, Councilor 

Laura S. Van Winkle, Councilor 

Chunli Quan, Postdoctoral Representative 

Glenn Robert Gookin, Student Representative 

Mechanisms (312*) 

Dennis R. Petersen, President 

Jose E. Manautou, Vice President 

Joan B. Tarloff, Vice President-Elect 

Lois D. Lehman-McKeeman, Secretary/Treasurer 

Gary O. Rankin, Past President 

Peter J. Harvison, Councilor 

Alvaro Puga, Councilor 

Midhun C. Korrapati, Postdoctoral Representative 

Derek A. Drechsel, Student Representative 

Medical Device (NEW) 

Lori H. Moilanen, Interim President 

Ron Brown, Interim Officer 

Jon N. Cammack, Interim Officer 

Richard W. Hutchinson, Interim Officer 

Robert T. Przygoda, Interim Officer 

Edward E. Reverdy, Interim Officer 

Metals (149*) 

Wei Zheng, President 

Aaron Barchowsky, Vice President 

J. Christopher States, Vice President-Elect 

John P. Wise, Secretary/Treasurer 

Y. James Kang, Past President 

John J. LaPres, Councilor 

Koren K. Mann, Councilor 

Erik J. Tokar, Postdoctoral Representative 

Andrew D. Monnot, Student Representative 

Mixtures (68*) 

Jane Ellen Simmons, President 

Kannan Krishnan, Vice President 

Michael L. Dourson, Vice President-Elect 

David Mattie, Secretary/Treasurer 

Janice E. Chambers, Past President 

Bruce A. Fowler, Councilor 

Margaret H. Whittaker, Councilor 

Cynthia Vanessa Rider, Postdoctoral Representative 

Ronald B. Pringle, Student Representative 

Molecular Biology (169*) 

Michael J. Carvan, President 

Christopher A. Reilly, Vice President 

Russell S. Thomas, Vice President-Elect 

Kristine L. Willett, Secretary/Treasurer 

Thomas R. Sutter, Past President 

Nancy D. Denslow, Councilor 

Mark E. Hahn, Councilor 

Joanna Klapacz, Postdoctoral Representative 

Sarah Elizabeth Wilson, Senior Student Representative 

Karma C. Fussell, Junior Student Representative 

Nanotoxicology (244*) 

Annette B. Santamaria, President 

David B. Warheit, Vice President 

Justin G. Teeguarden, Vice President-Elect 

Stephen M. Roberts, Secretary/Treasurer 

Christie M. Sayes, Councilor 

Nigel J. Walker, Councilor 

Amy (Hui-Shan) Wang, Postdoctoral Representative 

Patricia Gillespie, Student Representative 

Neurotoxicology (334*) 

Susan L. Schantz, President 

Stephen M. Lasley, Vice President 

Gary W. Miller, Vice President-Elect 

Timothy Joseph Shafer, Secretary/Treasurer 

Marion F. Ehrich, Past President 

Vanessa A. Fitsanakis, Councilor 

Kathleen C. Raffaele, Councilor 

Donna Wai Ling Lee, Postdoctoral Representative 

Jason Patrick Magby, Student Representative 

Occupational and Public Health (184*) 

Eileen P. Hayes, President 

Allison L. Stock, Vice President 

Michael Christopher Madden, Vice President-Elect 

Amanda S. Persad, Secretary/Treasurer 

Angela J. Harris, Past President 

Anne H. Chappelle, Councilor 

Michael J. Olson, Councilor 

Michele La Merrill, Postdoctoral Representative 

Adrienne Lester King, Student Representative 

Ocular Toxicology (57*) 

Margaret C. Collins, Interim President 

Mark Vezina, Interim Vice President 

Anne G. Wiese, Interim Secretary/Treasurer 

David M. Lehmann, Interim Councilor 

Timothy K. MacLachlan, Interim Councilor 

Kenneth A. Schafer, Interim Councilor 





350 



Speciality Section—Officers (Continued) 

Regulatory and Safety Evaluation (694*) 

James C. Lamb, President 

Brian G. Short, Vice President 

Timothy P. Pastoor, Vice President-Elect 

David Jacobson Kram, Secretary/Treasurer 

Frank D. Sistare, Past President 

Cynthia A. Afshari, Councilor 

Nancy B. Beck, Councilor 


Thomas Simones, Student Representative 

Reproductive and Developmental Toxicology (321*) 

Mark E. Hurtt, President 

Alan Hoberman, Vice President 

Edward W. Carney, Vice President-Elect 

Susan L. Makris, Secretary/Treasurer 

Lori A. Dostal, Past President 

Janee B. Gelineau-van Waes, Councilor 

Jeffrey S. Moffit, Councilor 

Robert M. Parker, Councilor 

Yvonne Hoang, Postdoctoral Representative 

Nicholas Heger, Student Representative 

Risk Assessment (593*) 

Edward V. Ohanian, President 

Elaine M. Faustman, Vice President 

Robinan Gentry, Vice President-Elect 

Calvin C. Willhite, Secretary/Treasurer 

Harvey J. Clewell, Past President 

Rory B. Conolly, Councilor 

Laurie C. Haws, Councilor 

Anne Elizabeth Loccisano, Postdoctoral Representative 

David Taylor Szabo, Student Representative 

LeAdershIp 

Toxicologic and Exploratory Pathology (152*) 

Charles W. Qualls, President 

Glenn H. Cantor, Vice President 

Douglas C. Wolf, Vice President-Elect 

Sandra R. Eldridge, Secretary/Treasurer 

Karen S. Regan, Past President 

Norman J. Barlow, Councilor 

Brian J. Day, Councilor 

Chidozie Joshua Amuzie, Postdoctoral Representative 

Lu Wang, Student Representative 





Special Interest Group—Officers 

LeAdershIp 

American Association of Chinese in Toxicology (178*) 

Jia Sheng Wang, President 

Diana J. Auyeung-Kim, President-Elect 

Edward Chow, Secretary 

Yi Jin, Treasurer 

Y. James Kang, Past President 

Xueyan (Peter) Mu, Councilor 

Hanna Hongchin Ng, Councilor 

John C. Zhuang, Councilor 

Yu Janet Zang, Postdoctoral Representative 

Li (Susan) Xu, Student Representative 

Association of Scientists of Indian Origin (115*) 

Sanjay Chanda, President 

Binu K. Philip, Vice President 

Vinayak Srinivasan, Vice President-Elect 

S. Satheesh Anand, Secretary/Treasurer 

Gopala Krishna, Past President 

Des R. Kashyap, Councilor 

Brinda Mahadevan, Councilor 

Gunda Reddy, Councilor 

Rangaprasad Sarangarajan, Councilor 

Sudheer Beedanagari, Postdoctoral Representative 

Prasad Krishnan, Student Representative 

Hispanic Organization for Toxicologists (65*) 

Braulio D. Jimenez-Velez, President 

Pedro L. Del Valle, Vice President 

Ofelia A. Olivero, Secretary/Treasurer 

Mari S. Stavanja, Past President 

Javier Avalos, Councilor 

Ranulfo Lemus Olalde, Councilor 

Minerva Mercado Feliciano, Postdoctoral Representative 

Enrique Fuentes-Mattei, Student Representative 

Korean Toxicologists Association in America (38*) 

Woon-Gye Chung, President 

Sang-Tae Kim, Vice President 

James H. Kim, Secretary/Treasurer 

Ji-Eun Lee, Past President 

Jin Ho Chung, Councilor 


Narae Lee, Student Representative 

Toxicologists of African Origin (53*) 

Marquea D. King, President 

Claude McGowan, Vice President 

Anthony M. Ndifor, Secretary/Treasurer 

Bernard K. Gadagbui, Past President 

Elena K. Braithwaite, Councilor 

Abraham Dalu, Councilor 

Mildred M. Williams-Johnson, Councilor 

Antonio T. Baines, Councilor 



Women in Toxicology (418*) 

Laura Andrews, President 

Brinda Mahadevan, Vice President 

Suzanne Compton Fitzpatrick, President-Elect 

Frances G. Crofts, Secretary/Treasurer 

Stacie L. Wild, Past President 

Leigh Ann Burns Naas, Councilor 

Melissa C. Rhodes, Councilor 

Louisa A. Hooven, Postdoctoral Representative 

Courtney D. Kozul, Student Representative 



Introducing a new on-line SOT member resource… 


Go to the sot resource pavilion for on-site information. 


352 



Society of Toxicology Awards and Honors 

In recognition of distinguished toxicologists and students, 

SOT presents Honorary Membership and Awards each year. 

In addition to receiving a plaque, recipients are honored at a 

special Awards Ceremony at the SOT Annual Meeting and 

their names are listed in SOT publications. The deadline for 

2011 Honorary Membership and Award nominations is 

October 9, 2010. 

SOT Council reviews nominations for Honorary Membership 

and the Awards Committee reviews applications for SOT 

Awards and most Sponsored Awards. The Best Paper Awards 

are reviewed by the Board of Publications. The Education 

Committee selects the recipients of the Pfizer Undergraduate 

Travel Award and the Committee on Diversity Initiative selects 

the other undergraduate student travel recipients. 

Nominations for most awards must be submitted by a 

sponsor and a seconder who are Full members of SOT using 

the On-Line Award Nomination Form. The supporting 

documentation must indicate the candidate’s achievements 

in toxicology and is critical in the review of each application. 

See the award description for the additional requirements for 

some of the awards, including the Sponsored Awards. There 

are specific applications for Fellowships and Graduate Travel 

Support. 

Other graduate student and postdoctoral fellow awards are 

available through Regional Chapters, Specialty Sections, and 

Special Interest Groups. A student or postdoc may apply for 

any award for which he or she is eligible and may apply for 

and receive multiple awards, whether SOT, Regional Chapters, 

Specialty Sections, or Special Interest Groups, sponsor the 

awards. Policies related to travel support are determined by 

the sponsor (SOT, Regional Chapter, Special Interest Groups, 

or Specialty Section). Students may receive travel support 

from only one national SOT source. 

Full descriptions of all awards, awards no longer being 

offered, application procedures, and names of past recipients 

may be found on the SOT Web site at 


SOT Honor Descriptions 

Honorary Membership 

Awards Committee members are not eligible to receive any awards 

conferred by this Committee while serving on the Committee and 

for one subsequent year. 

The Society of Toxicology recognizes non-members who embody outstanding and sustained achievements in the field of toxicology 

with Honorary Membership. Candidates are nominated by two Full or Associate members of the Society. Seconding 

letters and information regarding career achievements in toxicology should accompany the nomination. A two-thirds vote of 

Council determines recipients, with not more than two Honorary Members elected during any one term of Council. Nominations 

should be sent to SOT Headquarters. 

Inductees 

1962 ....... Eugene M.K. Geiling* 

1962 ....... W. F. Von Oettingen* 

1962 ....... Torald H. Sollman* 

1963 ....... Ethel Browning* 

1966 ....... R. Tecwyn Williams* 

1976 ....... Norton Nelson* 

1982 ....... George H. Hitchings* 

1986 ....... Bernard B. Brodie* 

1986 ....... Herbert Remmer* 

1991 ....... Hyman J. Zimmerman* 

1994 ....... Ronald W. Estabrook 

1994 ....... Wendell W. Weber 

1995 ....... Gertrude B. Elion* 

1995 ....... Charles S. Lieber 

1996 ....... Sten G. Orrenius 

1996 ....... Dennis Parke* 

1997 ....... John E. Casida 

1997 ....... Roger W. Russell* 

1998 ....... Jud Coon 

1998 ....... Michel Mercier 

1999 ....... William O. Robertson 

1999 ....... Takashi Sugimura 

2000 ....... Findlay Russell 

2001 ....... Herbert Needleman 

2007 ....... Mario Molina 

2008 ....... Lee Hartwell 

2008 ....... H. Robert Horvitz 

2009 ....... Gilbert Omenn 

2009 ....... John E. Walker 

2010 ....... Philip Cohen 

2010 ....... Ferid Murad 

Indicates an SOT Sponsored Award 

*Deceased 

reFerenCe 



Society of Toxicology Awards and Honors (Continued) 

Awards Descriptions 



reFerenCe 

The Achievement Award is presented to a member of the 

Society of Toxicology who has less than 15 years experience 

since obtaining his/her highest earned degree (in the year of 

the Annual Meeting of the Society of Toxicology) and who 

has made significant contributions to toxicology. This award 

consists of a plaque and a cash stipend. 

Award Recipients 

1967 ....... Gabriel L. Plaa* 

1968 ....... Allan H. Conney 

1969 ....... Samuel S. Epstein 

1970 ....... Sheldon D. Murphy* 

1971 ....... Yves Alarie 

1972 ....... Robert L. Dixon* 

1973 ....... (No Award) 

1974 ....... Morris F. Cranmer 

1975 ....... Ian C. Munro 

1976 ....... Curtis D. Klaassen 

1977 ....... James E. Gibson 

1978 ....... Raymond D. Harbison 

1979 ....... Michael R. Boyd 

1980 ....... Philip G. Watanabe* 

1981 ....... (No Award) 

1982 ....... Frederick P. Guengerich 

1983 ....... (No Award) 

1984 ....... Melvin E. Andersen 

1985 ....... Alan R. Buckpitt 

1986 ....... Sam Kacew 

1987 ....... James S. Bus 

1988 ....... Jeanne M. Manson 

1989 ....... James P. Kehrer 

1990 ....... Michael P. Waalkes 

1991 ....... Debra Lynn Laskin 

1992 ....... Michael P. Holsapple 

1993 ....... David L. Eaton 

1994 ....... James L. Stevens 

1995 ....... Lucio G. Costa 

1996 ....... Kenneth S. Ramos 

1997 ....... Kevin E. Driscoll 

1998 ....... Rick G. Schnellmann 

1999 ....... Michel Charbonneau 

2000 ....... Christopher Bradfield 

2001 ....... Martin A. Philbert 

2002 ....... Ruth A. Roberts 

2003 ....... Lois D. Lehman-McKeeman 

2004 ....... David C. Dorman 

2005 ....... (No Award) 

2006 ....... Jose E. Manautou 

2007 ....... Jeffrey M. Peters 

2008 ....... Ivan Rusyn 

2009 ....... Russell S. Thomas 

2010 ....... Gary W. Miller 

354 

The Arnold J. Lehman Award is presented to recognize an 

individual who has made a major contribution to risk assessment 

and/or the regulation of chemical agents, including 

pharmaceuticals. The contribution may have resulted from the 

application of sound scientific principles to regulation and/ 

or from research activities that have significantly influenced 

the regulatory process. The nominee may be employed in 

academia, government, or industry and must be an SOT 

member. This award consists of a plaque and a cash stipend. 


1980 ....... Allan H. Conney 


1982 ....... Gary M. Williams 

1983 ....... David P. Rall* 

1984 ....... Tibor Balasz 

1985 ....... Frederick Coulston* 

1986 ....... Gerrit Johannes Van Esch 

1987 ....... John P. Frawley* 

1988 ....... Kundan S. Khera* 

1989 ....... Richard H. Adamson 

1990 ....... Harold C. Grice 

1991 ....... Bernard A. Schwetz 

1992 ....... Roger O. McClellan 

1993 ....... Thomas W. Clarkson 

1994 ....... Bruce Ames 

1995 ....... Emil A. Pfitzer* 

1996 ....... John F. Rosen 

1997 ....... (No Award) 

1998 ....... Helmut Alfred Greim 

1999 ....... (No Award) 

2000 ....... Carole A. Kimmel, Janardan K. Reddy 

2001 ....... Samuel M. Cohen 

2002 ....... Dennis Paustenbach 

2003 ....... Michael L. Dourson 

2004 ....... Melvin E. Andersen 

2005 ....... Rory B. Conolly 

2006 ....... Kathryn R. Mahaffey* 

2007 ....... Harvey J. Clewell 

2008 ....... Vicki Dellarco 

2009 ....... Michael Bolger 

2010 ....... Edward V. Ohanian 




Best Postdoctoral Publication 

Awards 

The Best Postdoctoral Publication Awards were created by 

the Postdoctoral Assembly to recognize talented postdoctoral 

researchers who have recently published exceptional papers 

in the field of toxicology. Applications are reviewed by the 

Postdoctoral Assembly Board and outside reviewers with 

appropriate scientific expertise. The review process follows 

NIH conflict of interest, confidentiality, and nondisclosure 

rules. 


2007 ....... Nadine Dragin, Kristen Mitchell, Drobna Zuzana 

2008 ....... Joshua P. Gray, Christie M. Sayes, 

Khristy J. Thompson 

2009 ....... Jeffrey W. Card, Kembra Howdeshell 

Lewis Zhichang Shi 

2010 ....... Bret F. Bessac, Manabu Nukaya, Nicolas Radio 

Board of Publications Best Paper in 

Toxicological Sciences Award 

The Board of Publications Award for the Best Paper in 

Toxicological Sciences is presented to the author(s) of 

the best paper published in this official SOT publication 

during a 12-month period, terminating with the June 

issue of the calendar year preceding the Annual Meeting at 

which the award is presented. The author(s) need not be a 

member of the Society of Toxicology. Submissions should 

include a one-page summary of the paper’s contribution 

to the science of toxicology and a copy of the article for 

which the nomination is being made. Any member of the 

Society may submit one title for consideration. In addition, 

the titles of no more than six papers to be considered 

are submitted by the editor of Toxicological Sciences. 

All papers submitted will be evaluated by the Board of 

Publications. This award consists of a plaque and a cash 

stipend. (This award was formerly known as the Frank R. 

Blood Award.) 

Best Paper in Toxicological Sciences 

(formerly published as Fundamental and Applied Toxicology) 


1995 ....... J. L. Larson, D. C. Wolf, B. E. Butterworth 

1995 ....... M. I. Luster, C. Portier, D. G. Pait, 

G. J. Rosenthal, D. R. Germolec, E. Corsini, 

B. L. Blaylock, P. Pollock, Y. Kouchi, W. Craig, 

K. L. White, A. E. Munson, C. E. Comment 

1996 ....... B. C. Allen, R. J. Kavlock, C. A. Kimmel, 

E. M. Faustman 

1997 ....... F. L. Fort, H. Ando, T. Suzuki, M. Yamamoto, 

T. Hamashima, S. Sato, T. Kitazaki, 

M. C. Matony, G. D. Hodgen 

1998 ....... D. D. Parrish, M. J. Schlosser, J. C. Kapeghian, 

V. M. Traina 

1999 ....... C. A. Franklin, M. J. Inskip, C. L. Baccanale, 

C. M. Edwards, W. I. Manton, E. Edwards, 

E. J. O’Flaherty 

2000 ....... H.A Boulares, C. Giardina, C.L. Navarro, 

E.A. Khairallah, S.D. Cohen 

2001 ....... Jinqiang Chen, Yunbo Li, Jackie A. Lavigne, 

Michael A. Trush, James D. Yager 

2002 ....... M. J. Bajt, J. A. Lawson, S. L. Vonderfecht, 

J. S. Gujral, H. Jaeschke 

2003 ....... S. Haddad, M. Beliveau, R. Tardif, K. Krishnan 

2004 ....... Abraham Nyska, Carolyn Moyer, Allen Ledbetter, 

David Christiani, Mette Schlasweiler, Daniel 

Costa, Russ Hauser, Urmila Kodavanti, 

2005 ....... Nicole V. Soucy, Michael A. Ihnat, Linda Hess, 

Chandrashekhar D. Kamat, Aaron Barchowsky, 

Mark J. Post, Linda R. Klei, Callie Clark, 

2006 ....... Hiroshi Sawada, Kenji Takami, Satoru Ashai 

2007 ....... Trevor Green, Robert Lee, Sara Lloyd, James 

Noakes, Timothy Pastoor, Richard Peffer, Mervyn 

Robinson, Patrick Rose, Alison Toghill, Felix 

Waechter, Edgar Weber 

2008 ....... Sarah Snykers, Tamara Vanhaecke, 

Peggy Papelue, Aernout Luttun, Yuehua Jiang, 

Yvan Vander Heyden, Catherine Verfaillie, Vera 

Rogiers 

2009 ....... Qian Yang, Tomokazu Nagano, Yatrik Shah, 

Connie Cheung, Shinji Ito, Frank J. Gonzalez 

2010 ....... Roy L.M. Dobson, Safa Motlagh, Mike Quijano, 

R. Thomas Cambron, Timothy R. Baker, Aletha 

M. Pullen, Brian T. Regg, Adrienne S. Bigalow- 

Kern, Thomas Vennard, Andrew Fix, Ranate 

Reimschuessel, Gary Overmann, Yuching Shan, 

George P. Daston 

Best Paper in Toxicology and Applied Pharmacology 


1995 ....... M. F. Denny, M. F. Ware, W. D. Atchison 

1996 ....... T. A. Slotkin, C. Lau, E. C. McCook, 

S. E. Lappi, F. J. Seidler 

1997 ....... P. R. S. Kodavanti, T. R. Ward, J. D. McKinney, 

C. L. Waller, H. A. Tilson 

1998 ....... J. S. Landin, S. D. Cohen, E. A. Khairallah 

1999 ....... S. K. Ramaiah, M G. Soni, T. J. Bucci, 

H. M. Mehendale, 

1999 ....... C. L. Zuch, D. J. O’Mara, D. A. Cory-Slechta 

2000 ....... J.E. Staples, N.C. Fiore, D.E. Frazier, Jr., 

T.A. Gasiewicz, A.E. Silverstone 

reFerenCe 




reFerenCe 

2001 ....... Barbara J. Mounho, Brian D. Thrall 

2002 ....... G.S. Ratra, S.G. Kamita, J.E. Casida 

2003 ....... J. Doorn, M. Schall, D. Gage, T. Talley, 

C. Thompson, R. Richardson 

Frank R. Blood Award 



1975 ....... Donald J. Ecobichon, G. J. Johnstone, 

O. Hutzinger 

1976 ....... Richard D. Brown 

1977 ....... J. Dedinas, George D. DiVincenzo, C. J. Kaplan 

1978 ....... Perry J. Gehring, E. O. Madrid, 

G. R. McGowan, Philip G. Watanabe 

1979 ....... R. Fradkin, E. J. Ritter, W. J. Scott, 

James G. Wilson 

1980 ....... Jerold A. Last, Peter F. Moore, Otto G. Raabe, 

Brian K. Tarkington 

1981 ....... Yves Alarie, Martin Brady, Christine Dixon, 

Meryl Karol 

1982 ....... Melvin E. Andersen, Michael L. Gargas, 

Lawrence J. Jenkins, Jr., Robert A. Jones 

1983 ....... Henry D. Heck 

1984 ....... Erik Dybing, Sidney Nelson, Erik Soderlund, 

Christer Von Bahr 

1985 ....... Nobumasa Imura, Masae Inokawa, 

Kyoko Miura 

1986 ....... Calvin C. Wilhite, M. I. Dawson, 

K. J. Williams 

1987 ....... John Kao, Frances K. Patterson, Jerry Hall 

1988 ....... Debra L. Laskin, Sungchul Ji, Anne M. Pilaro 

1989 ....... R. G. Cuddihy, W. C. Griffith, 

Rogene F. Henderson, Joe L. Mauderly, 

Roger O. McClellan, M. D. Snipes, 

Ronald K. Wolff 

1990 ....... William P. Beierschmitt, Joseph T. Brady, 

John B. Bartolone, D. Stuart Wyand, 

Edward A. Khairallah, Steven D. Cohen 

1991 ....... Jay Babcock Silkworth, Daryl Cutler, 

LuAnn Antrim, Don Houston, 

Casimir Tumasonis, Laurence S. Kaminsky 

1992 ....... Donald A. Fox, Steve D. Rubinstein, 

Pauline Hsu 

1993 ....... Thomas Mably, Robert W. Moore, 

Robert W. Goy, Richard E. Peterson 

1994 ....... Susan J. Borghoff, William H. Lagarde 

Contributions to Public Awareness 

of the Importance of Animals in 

Toxicology Research Award 

The Contributions to Public Awareness of the Importance of 

Animals in Toxicology Research Award is presented annually 

to an individual (or organization) in recognition of the 

contributions made to the public understanding of the role and 

importance of experimental animals in toxicological science. 

This award may be for either a single seminal piece of work 

or a longer-term contribution to public understanding of the 

necessity of the use of animals in toxicological research 

both to ensure and enhance the quality of human and animal 

health and the environment. The award consists of a plaque 

and a cash stipend. 


2000 ....... Allegheny-Erie Chapter 

2001 ....... Massachusetts Society for Medical Research 

2002 ....... George Nethercutt 

2003 ....... Michael Derelanko 

2004 ....... North Carolina Association for Biomedical 

Research (NCABR), Americans for Medical 

Progress (AMP) 

2005 ....... Orrin G. Hatch, Foundation for Biomedical 

Research (FBR) 

2006 ....... Jayne Mackta 

Distinguished Toxicology Scholar 

Award 

The Distinguished Toxicology Scholar Award is presented 

to a member of SOT who has made substantial and seminal 

scientific contributions to our understanding of the science of 

toxicology. Nominees should be active scientists involved in 

toxicological research. The prime consideration for this award 

is scientific accomplishments. This award consists of a plaque 

and a cash stipend. (This award was presented in 2001 as the 

Scientific Achievement Award.) 


2001 ....... James E. Troska 

2003 ....... Henry C. Pitot 

2004 ....... Gerald N. Wogan 

2005 ....... Daniel Nebert 

2006 ....... Sten G. Orrenius 

2007 ....... Stephen H. Safe 

2008 ....... Toshio Narahashi 

2009 ....... Lance R. Pohl 

2010 ....... Harihara M. Mehendale 

356 





Enhancement of Animal Welfare 

Award 

The Education Award is presented to an individual who is 

distinguished by the teaching and training of toxicologists 

and who has made significant contributions to education in 

the broad field of toxicology. This award consists of a plaque 

and a cash stipend. 


1975 ....... Harold C. Hodge* 

1976 ....... Ted A. Loomis 

1977 ....... Robert B. Forney* 


1980 ....... Herbert H. Cornish* 

1981 ....... Frederick Sperling* 

1982 ....... Lloyd W. Hazleton* 

1983 ....... Julius M. Coon* 

1984 ....... Frank Guthrie, Ernest Hodgson 

1985 ....... William B. Buck 

1986 ....... Robert I. Krieger 


1988 ....... John Autian 

1989 ....... Tom S. Miya 

1990 ....... Charles H. Hine 

1991 ....... Hanspeter R. Witschi 

1992 ....... Dean E. Carter 

1993 ....... Curtis D. Klaassen 

1994 ....... Robert A. Neal 

1995 ....... William Carlton 

1996 ....... Robert Snyder 

1997 ....... Albert E. Munson 

1998 ....... David J. Holbrook 

1999 ....... Jules Brodeur 

2000 ....... Gary Carlson 

2001 ....... Harihara Mehendale 

2002 ....... Joseph Borzelleca 

2003 ....... Frederick W. Oehme 

2004 ....... A. Jay Gandolfi 

2005 ....... Nobuyuki Ito 

2006 ....... Robert A. Schatz 

2007 ....... Torbjörn Malmfors 

2008 ....... Steven Cohen 

2009 ....... Janice E. Chambers, Serrine S. Lau 

2010 ....... Tetsuo Satoh 

The Enhancement of Animal Welfare Award is presented 

annually to a member of the Society in recognition of the 

contribution made to the advancement of toxicological 

science through the development and application of methods 

that replace, refine, or reduce the need for experimental 

animals. This award recognizes outstanding/significant 

contributions made by members of the Society of Toxicology 

to the sound and responsible use of animals in scientific 

research. The achievement recognized may be either a 

seminal piece of work or a long-term contribution to toxicological 

science and animal welfare. The award consists of a 

plaque and a cash stipend. 



2001 ....... Alan Goldberg 

2002 ....... Gary Williams 

2003 ....... G. Frank Gerberick, Ian Kimber 

2005 ....... Daniel Acosta 

2006 ....... William S. Stokes 

2007 ....... Thomas Hartung 

2009 ....... Sally Robinson 

2010 ....... Leonard M. Schechtman 


The SOT Founders Award is presented to a Full or Retired 

Full member of the Society of Toxicology who has demonstrated 

outstanding leadership in fostering the role of 

toxicological sciences in safety decision-making through the 

development and/or application of state-of-the-art approaches 

that elucidate, with a high degree of confidence, the distinctions 

for humans between safe and unsafe levels of exposures 

to chemical and physical agents. 


2008 ....... John Doull 

2009 ....... Roger O. McClellan 

2010 ....... James S. Bus 

reFerenCe 




Graduate Student Travel Support 

Graduate Student Travel Support defrays expenses for 

students presenting platform talks or posters at the SOT 

Annual Meeting. To be eligible, the student must be 

an SOT member (or have submitted a membership application) 

who has not previously received SOT Graduate Student 

Travel Support. 


The Leading Edge in Basic Science Award is presented to a 

scientist who, based on his/her research, has made a recent 

(within the last 5 years), seminal basic scientific contribution 

to understanding fundamental mechanisms of toxicity. 

The recipient may be a respected basic scientist, member or 

non-member, including toxicologists as well as other scientists 

who may not identify themselves with the discipline of 

toxicology but whose research findings are likely to have a 

pervasive impact on the field of toxicology. 


2009 ....... John Katzenellenbogen 

2010 ....... Richard S. Paules 

Merit Award 

1977 ....... Harry W. Hays* 

1978 ....... Julius M. Coon* 

1979 ....... David W. Fassett* 

1980 ....... Bernard L. Oser* 

1981 ....... John H. Weisburger 

1982 ....... Harold M. Peck* 

1983 ....... Perry J. Gehring* 

1984 ....... Tom S. Miya 

1985 ....... Carrol S. Weil* 

1986 ....... Ted A. Loomis 

1987 ....... Bo Holmstedt 

1988 ....... Seymour L. Friess* 

1989 ....... Wayland J. Hayes, Jr.* 


1991 ...... Toshio Narahashi 

1992 ....... W. Norman Aldridge 

1993 ....... John Doull 

1994 ....... Ernest Hodgson 

1995 ....... Robert A. Scala 


1997 ....... Mary O. Amdur* 

1998 ....... John A. Thomas 

1999 ....... Thomas Clarkson 

2000 ....... Philippe Shubik* 

2001 ....... Donald Reed 

2002 ....... Bernard Schwetz 

2003 ....... M.W. Anders 

2004 ....... Robert Goyer 

2005 ....... Roger McClellan 

2006 ....... A. Wallace Hayes 

2007 ....... James A. Swenberg 

2008 ....... Hanspeter Witschi 

2009 ....... Gary M. Williams 

2010 ....... Marion F. Ehrich 

reFerenCe 

The Merit Award is presented to a member of the Society 

of Toxicology in recognition of distinguished contributions 

to toxicology throughout an entire career in areas such as 

research, teaching, regulatory activities, consulting, and 

service to the Society. This award consists of a plaque and 

a cash stipend. The recipient delivers the Merit Awardee 

Lecture at the SOT Annual Meeting. 


1966 ....... Henry F. Smyth, Jr.* 

1967 ....... Arnold J. Lehman* 

1968 ....... R. T. Williams* 

1969 ....... Harold C. Hodge* 

1970 ....... Don D. Irish 

1971 ....... Kenneth P. DuBois 

1972 ....... O. Garth Fitzhugh* 

1973 ....... Herbert E. Stokinger* 

1974 ....... William B. Deichmann* 

1975 ....... Frederick Coulston* 

1976 ....... Verald K. Rowe* 

Minority Undergraduate Student 

and Advisor Awards 

The Minority Undergraduate Student and Advisor 

Awards provide support for awardees to participate in the 

Undergraduate Education Program at the SOT Annual 

Meeting. This program is an introduction to the discipline 

of toxicology for undergraduate science majors and includes 

an orientation, a special poster session with scientists, and 

activities with a SOT mentor. The travel awards are for those 

from races and ethnic groups underrepresented in the sciences 

(African American, American Indian, or Hispanic American) 

and for their advisors. The advisors are eligible regardless of 

racial or ethnic background. Meeting registration and support 

for travel, lodging, and meals are provided for students and 

advisors who are not local to the meeting site. Students and 

advisors from local institutions receive meeting and program 

registration and meals. In the past, the program has been 

358 




supported in part by NIH-MARC, Pfizer, Johnson & Johnson, 

Covance, and other supporters. The recipient list is available 

on the Web site. 



The Perry J. Gehring Diversity Student Award recognizes 

a student who was selected to participate in a previous SOT 

Undergraduate Program, is from an ethnic group underrepresented 

in toxicology (African American, Hispanic, Native 

American or Pacific Islander), and is presenting a paper at the 

upcoming SOT meeting. The award recipient is selected by 

the Committee on Diversity Initiatives. 

The Gehring Student Travel Award is provided through the 

Society of Toxicology Endowment Fund. This award recognizes 

Dr. Perry J. Gehring, who served as SOT President in 

1980–1981 and made important scientific contributions, especially 

in biological modeling and evidence-based assessment. 

Dr. Gehring had a strong interest in encouraging individuals 

from ethnic groups underrepresented in the sciences to enter 

biomedical sciences and toxicology. 


2009 ....... Vanessa De La Rosa 

2010 ....... Nygerma L. Dangleben 


The Public Communications Award is presented by the 

Society of Toxicology to recognize an individual who has 

made a major contribution to broadening the awareness of 

the general public on toxicological issues through any aspect 

of public communications. The award should reflect accomplishments 

made over a significant period of time. Examples 

of qualifying media in which the nominated communication 

may appear are as follows: books, brochures, continuing 

education courses, databases, extension bulletins, magazines, 

newspapers (local or national), outreach, public presentations, 

public forums, radio and television scripts, and workshops. 

The award consists of a plaque and a cash stipend. 


1994 ....... Michael A. Kamrin 

1995 ....... Philip Abelson* 

1996 ....... Bruce N. Ames 

1997 ....... Audrey Gotsch 

1999 ....... Ann de Peyster 

2001 ....... Anna Shvedova 

2002 ....... Sam Kacew 

2003 ....... Charlene A. McQueen 

2004 ....... Kenneth Olden 

2005 ....... Robert Kreiger 

2007 ....... Linda S. Birnbaum 

2010 ....... Philip Wexler 

SOT AstraZeneca IUTOX Fellowship 

AstraZeneca and SOT sponsor travel fellowship awards annually, 

which are administered by IUTOX. Awards are available 

to junior and senior scientists from a country where toxicology 

is underrepresented to assist with travel to attend the 

Society of Toxicology Annual Meeting. 


2002 ....... Christophor Dishovsky (Bulgaria), 

Zoltan Gregus (Hungary), 

Maritza Rojas Martini (Venezuela), 

Choon-Nam Ong (Singapore), 

W. Wasowicz (Poland), 

Ping-kun Zhou (China) 

2003 ....... Jian-Hui Liang (China), 

Marjan G. Vracko (Slovenia), 

Eman A. Seif (Egypt) 

2004 ....... Cristina Bolaton (Phillipines), 

P.K. Gupta (India), 

Salmaan Inayat-Hussain (Malaysia), 

Xianping Ying (China) 

2005 ....... Diana B. Apostolova (Bulgaria), 

Marite Arija Bake (Latvia), 

Teresa I. Fortuoul (Mexico), 

Mary Gulumian (South Africa), 

He Jiliang (China), 

Khalidya Khamidulina (Russia), 

L. Orish Orisakwe (Nigeria), 

Songsak Srianujata (Thailand), 

Sinan Suzen (Turkey) 

2006 ....... Olanike Adeyemo (Nigeria), 

Deepak Argwal (India), 

Carlos Colangelo (Argentina), 

Sandra Demichelis (Argentina), 

Mumtaz Iscan (Turkey), 

Karolina Lyubomirova (Bulgaria), 

Osman Aly Osman (Egypt), 

Shuang-Qing Peng (China), 

Julia Radenkova-Saeva (Bulgaria) 

reFerenCe 




reFerenCe 

2007 ....... Hatem Ahmed (Egypt), 

Jiri Bajgar (Czech Republic), 

Ismet Çok (Turkey), 

Carlos Garcia (Peru), 

Wenceslao Kiat (Philippines), 

Calivarathan Latchoumycandane (Singapore), 

Fateheya Metwally (Egypt), 

Hilmi Orhan (Turkey), 

Nwoha Umunna (Nigeria) 

2008 ....... Jin-Ho Chung (Korea), 

Lyndy McGaw (South Africa), 

Kemal Buyukguzel (Turkey), 

Hande Gurer-Orhan (Turkey), 

Phillip Burcham (Australia), 

Sayed Bakry (Egypt), 

Zdravko Paskalev (Bulgaria), 

Gafer Rageh Ahmed (Egypt) 

2009 ....... Sema Burgaz (Turkey) 

Estefania G. Moreira (Brazil) 

Kolawole V. Olorunshola (Nigeria) 

Kelly P.K. Olympio (Brazil) 

Betzabet Quintanilla-Vega (Mexico) 

Jalila Ben Salah (Tunisia) 

Suleeporn Sangrajang (Thailand) 

2010 ....... Asongalem Emmanuel Acha (Cameroon) 

Ayse Basak Engin (Turkey) 

Ronnie A. D. Frazer-Williams (Sierra Leone) 

Yan Li (China) 

Jesus Olivero-Verbel (Colombia) 

Suresh V.S. Rana (India) 

Ganna Shayakhmetova (Ukraine) 

Vanessa Steenkamp (South Africa) 

Marcelo Wolansky (Argentina) 

Motao Zhu (China) 

SOT Regional Chapter Awards 

Most SOT Regional Chapters provide awards to recognize 

outstanding students, postdoctoral fellows, or scientists 

throughout their career. Application requirements and deadlines 

vary. For more details refer to the award descriptions 

on the SOT Web site at www.toxicology.org, under 

Regional Chapters or the Awards and Fellowships section. 

SOT Special Interest Group Awards 

SOT Special Interest Groups provide awards to recognize 


throughout their career. Application requirements and deadlines 

vary. For more details refer to the award descriptions 

on the SOT Web site at www.toxicology.org, under Special 

Interest Groups or the Awards and Fellowships section. 

360 

SOT Specialty Section 

Student Awards 

Most SOT Specialty Sections provide awards to recognize 


throughout their career at the SOT Annual Meeting. 

Application requirements and deadlines vary. For more 

details refer to the award descriptions on the SOT Web site at 

www.toxicology.org, under Specialty Sections or the Awards 

and Fellowships section. 


The Translational Impact Award is presented to a scientist 

whose recent (in the last 10 years) outstanding clinical, 

environmental health, or translational research has improved 

human and/or public health in an area of toxicological 

concern. Scientists who are leaders in multidisciplinary 

team efforts who have contributed to alleviating toxicityrelated 

health problems are particularly attractive candidates. 

The nominee may be a member or non-member from any 

background (toxicologists, clinicians, basic scientists, epidemiologists, 

engineers, etc.). 


2009 ....... Thomas W. Kensler 

2010 ....... Kenneth E. McMartin 

Undergraduate Toxicology 

Education Awards 

The Undergraduate Toxicology Education Awards provide 

support for awardees to participate in the Undergraduate 

Education Program at the SOT Annual Meeting. This 

program is an introduction to the discipline of toxicology for 

undergraduate science majors and includes an orientation, 

a special poster session with scientists, and activities with a 

SOT mentor. The travel awards are for those from institutions 

that receive a limited amount of Federal funding in science 

and technology (list is available on the Web site). Preference 

in selection will be students who are first generation college 

attendees (that is, neither parent graduated from a four-year 

academic institution). 

Meeting registration and support for travel, lodging, and 

meals are provided for students who are not local to the 

meeting site. Students from local institutions receive registration, 

meeting materials, and an expense stipend. The recipient 

list is available on the Web site. 



Sponsored Award Descriptions 

AstraZeneca Traveling 

Lectureship Awards 

The AstraZeneca Traveling Lectureship Awards are 

presented through the Society of Toxicology to recognize 

excellence in research and service in toxicology. 

AstraZeneca, Ltd., provides one or two awards annually 

to promote greater collaboration between European and 

North American toxicologists and to enable North American 

toxicologists to undertake a three–four week lecture tour of 

Europe. The awards are intended to familiarize recipients 

with research and regulatory issues in Europe as well as 

bring a North American perspective to these issues. 

Candidates for these awards should be established, mid-career 

North American scientists who are members of the Society 

and who demonstrate the ability to develop collaborative 

relationships with European colleagues. The awards are given 

each year in the amount of $6,000 each. 


1990 ....... Robert I. Krieger, Joseph R. Landolph 

1991 ....... Sam Kacew 

1992 ....... Charles V. Smith, Jerold A. Last 

1993 ....... Terrence James Monks, Harihara H. Mehendale 

1995 ....... David L. Eaton, Hanspeter R. Witschi 

1996 ....... Rick G. Schnellmann, James P. Kehrer 

1997 ....... Lucio G. Costa, Durisala Desaiah 

1998 ....... Syed F. Ali, Curtis J. Omiecinski 

1999 ....... Alvaro Pugo 

2000 ....... Kenneth Ramos, Garold Yost 

2001 ....... Ronald Hines, Richard Seegal 

2003 ....... William D. Atchison 

2004 ....... Charlene A. McQueen 

2005 ....... Kevin M. Crofton 

2006 ....... Robert A. Roth 

2007 ....... Michael S. Denison 

2008 ....... José E. Manautou 

2009 ....... Kim Boekelheide 

2010 ....... J. Chris Corton 

Colgate-Palmolive Awards for Student 

Research Training in Alternative Methods 

The purpose of the Colgate-Palmolive Awards for Student 

Research Training in Alternative Methods is to enhance 

student research training using in vitro methods or alternative 

techniques to reduce, replace, or refine use of animals in 

toxicological research. The Awards Committee will present 

the awards to graduate students. Up to five awards, at $3,500 

each, are available. Deadlines for applications are February 

15, June 15, and October 9. 

The award is for expenses for training consistent with the 

goal of this award program. The training may include, but 

is not limited to, use of in vitro and ex vivo procedures, 

non-mammalian animal models, computer modeling, and 

structure-activity relationships. Graduate students may 

propose to develop expertise in relevant methodologies at 1) 

a laboratory away from their home institution; 2) a laboratory 

at their home institution that would not be available to 

them otherwise; or 3) approved workshops, symposia, or 

continuing education programs where hands-on training will 

be received. The training should help toxicology graduate 

students enhance their thesis or dissertation research. The 

overall goal is to support the replacement, reduction, or 

refinement of currently used animal models in toxicology 

research and testing. Awards of up to $3,500 per student will 

defray travel, per diem, and training expenses. 


2000 ....... Jason Gross 

2001 ....... Jason Biggs, Victoria Richards 

2002 ....... Kartik Shankar, Chad M. Vezina, 

Ryan L. Williams 

2003 ....... Sachin Devi, Midhun Korrapati, Pallavi Limaye 

2004 ....... Jaya Chilakapati, Marc A. Nascarella 

2005 ....... Vishaka Bhave, Ankur Dnyanmote, 

Jonathan Maher 

2006 ....... Mary Hassani, Prajakta Palkar 

2007 ....... Renee Gardner, Prajakta Palkar, Rohit Singhal, 

René Vinas 

2008 ....... Kimberly A. Hays, Haitian Lu 

2009 ....... Jennifer Cole, Katie Beth Paul, Samuel Peterson 

2010 ....... Maxwell C. K. Leung, David T. Szabo, 

Natalia M. VanDuyn 

reFerenCe 



Sponsored Award Descriptions (Continued) 

reFerenCe 

Colgate-Palmolive Grants for Alternative 

Research 

The Colgate-Palmolive Grants for Alternative Research will 

identify and support efforts that promote, develop, refine, or 

validate scientifically acceptable animal alternative methods 

to facilitate the safety assessment of new chemicals and 

formulations. Scientists at any stage of career progression 

may submit a proposal. 

High priority will be given to projects that use in vitro or nonanimal 

models, reproductive and developmental toxicology, 

neurotoxicology, systemic toxicology, sensitization, and acute 

toxicity. 

The maximum award is $40,000. Awards are made as 

a single lump payment. An expert panel from the SOT 

In Vitro and Alternative Methods Specialty Section will 

recommend a prioritized list of applicants for funding, with 

the final awards designated by the SOT Awards Committee. 

Awardees can apply again for funding. 


2006 ....... Rola Barhoumi, Abby Benninghoff, Jodie Flaws, 

Courtney Sulentic, Xiaouzhong Yu 

2007 ....... Rita L. Caruso, Daniel R. Cerven, 

Anne R. Greenlee, Glenn M. Walker 

2008 ....... Daniel R. Cerven, Duncan C. Ferguson, 

Shashi K. Ramaiah 

2009 ....... Qin M. Chen, Timothy Shafer, Mehmet Uzumcu 

2010 ....... Patrick Allard, Duncan C. Ferguson, 

Mehmet Uzumcu 

Colgate-Palmolive Postdoctoral Fellowship 


The Colgate-Palmolive Company sponsors the Colgate- 

Palmolive Postdoctoral Fellowship Award in In Vitro 

Toxicology through the Society of Toxicology to advance 

the development of alternatives to animal testing in toxicological 

research. The award is given in alternate years and 

includes stipend and research-related costs (up to $38,500) 

for one year. The award may be extended for an additional 

year upon agreement between Colgate-Palmolive and the 

postdoctoral fellow. The award is available to postdoctoral 

trainees employed by academic institutions, federal/national 

laboratories, or research institutes worldwide. Preference will 

be given to applicants in their first year of postdoctoral study. 

Applications are due in even calendar years and the fellowship 

is awarded for the following year. The next application 

deadline: October 9, 2010. 


1988 ....... Ernest Bloom 

1989 ....... Gin Hsieh 

1990 ....... Dennis E. Chapman 

1991 ....... Anne Walsh 

1992 ....... Qin Chen 

1993 ....... Erika Cretton 

1994 ....... William Chan 

1995 ....... Bob Van de Water 

1997 ....... Alan Parrish 

1999 ....... Russell Thomas 

2001 ....... Kevin Kerzee, Christopher Reilly 

2002 ....... Kevin Kerzee 

2003 ....... Kimberly Miller 

2004 ....... Kimberly Miller 

2005 ....... Francis Tukov 

2007 ....... Aaron Rowland 

2008 ....... Aaron Rowland 

2009 ....... Ankur Dnyanmote 

Colgate-Palmolive Traveling Lectureship in 

Alternative Methods in Toxicology Award 

The Colgate-Palmolive Company sponsors the Colgate- 

Palmolive Traveling Lectureship in Alternative Methods 

in Toxicology Award annually through the Society of 

Toxicology. This award covers expenses for an individual 

scholar to visit institution(s) for the dissemination of 

knowledge and for stimulating research that takes advantage 

of modern in vitro toxicology approaches. The overall 

goal of this program is to make scientists aware of the 

benefits of modern in vitro toxicology approaches and to stimulate 

research for the replacement, reduction, or refinement of 

currently used animal models. 

362 




Lecturing scholars should be established, mid-career through 

late-career scientists who are members of SOT and who are 

developing collaborative relationships with scientists at other 

institutions. 

Requests for funds can be made by the individual scholar 

or by a host from an academic institution, SOT Regional 

Chapter, SOT Special Interest Group, SOT Specialty Section, 

or another toxicology organization. Up to $15,000 is available 

for all the awards. The Awards Committee reviews the applications, 

which must be accompanied by a statement detailing 

the applicants expertise in alternative methods, a brief overview 

of the techniques to be discussed in the lecture, the 

budget request, and a letter from the host indicating interest 

in serving as host and the potential benefits to the institution. 


1996 ....... University of Mississippi Medical Center 

Visiting Professor: Tetsuo Satoh 

1996 ....... University of Illinois at Urbana 

Visiting Professor: Julio Davila 

1996 ....... Mississippi State University 

Visiting Professor: Michael Holsapple 

1996 ....... Washington State University 

Visiting Professor: Daniel Acosta 

1997 ....... Indiana University School of Medicine 

Visiting Professor: A. Jay Gandolfi 

1997 ....... University of Arizona Health Science Center 

Visiting Professor: Kevin E. Driscoll 

1997 ....... University of New Mexico Health 

Sciences Center 

Visiting Professor: Sam Kacew 

1997 ....... University of Illinois 

Visiting Professor: Michael Denison 

1998 ....... University of Washington 

Visiting Professor: Bruce Fowler 

1998 ....... San Diego State University 

Visiting Professor: Leigh Ann Burns-Naas 

1999 ....... San Diego State University 

Visiting Professor: Robert Chapin 

2000 ....... Yale University, School of Medicine 

Visiting Professor: Narendre Singh 

2001 ....... Medical College of Wisconsin 

Visiting Professor: Garold Yost 

2003 ....... Washington State University 

Visiting Professor: Marc W. Fariss 

2004 ....... Snorri S. Thorgeirsson 

Institution to be Visited: University of 

Louisiana at Monroe 

2008 ....... George Michalopoulos 

Institution to be Visited: University of 

Louisiana at Monroe 

Graduate Student Fellowship 

Award —Novartis 

The Graduate Student Fellowship—Novartis Award is available 

for Student members of the SOT engaged in full-time 

graduate study towards a Ph.D. degree in toxicology. The 

major professor must be an SOT member. The evaluation is 

based primarily on originality of the dissertation research, 

research productivity, relevance to toxicology, scholastic 

achievement, and letters of recommendation. Finalists are 

interviewed at the Annual Meeting and receive travel support. 


1989 ....... Timothy Zacharewski 

1990 ....... Mary Suzanne Stefaniak 

1991 ....... Donald Bjerke 

1992 ....... Lhanoo Gunawardhana 

1993 ....... Christopher Martenson 

1994 ....... Nyla Harper 

1995 ....... Heather E. Kleiner 

1996 ....... Russell Thomas 

1997 ....... Melva Rios-Blancos 

1998 ....... Kent Carlson 

1999 ....... Mark Hickman 

2000 ....... Jeffrey Moran 

2001 ....... Vishal Vaidya 

2002 ....... Kartik Shankar 

2003 ....... Sachin Devi 

2004 ....... James Luyendyk 

2005 ....... Andrea W. Wong 

2006 ....... Sheung P. Ng 

2007 ....... Atrayee Banerjee 

2008 ....... Helen J. Badham 

2009 ....... Yue Cui 

(Recipients of Graduate Fellowship Awards 

no longer offered may be found on the SOT Web site at 

www.toxicology.org.) 

reFerenCe 




Pfizer Undergraduate Student Travel Award 

Pfizer Undergraduate Student Travel Awards are presented 

through the Society of Toxicology to foster an interest in 

graduate studies in the field of toxicology by bringing promising 

undergraduate students to the SOT Annual Meetings. 

Pfizer, Inc. will provide up to five awards per year to undergraduate 

students presenting research at the Annual Meeting. 

Awardees will be selected by the Education Committee 

based on the quality of the submitted abstract and the advisor’s 

supporting recommendation. Those selected will receive 

travel assistance for the Annual Meeting, a plaque presented 

at the annual Awards Ceremony, and recognition at a special 

Pfizer function. Awardees will be matched with a graduate 

student and a Pfizer scientist to mentor them during the 

Annual Meeting, and will have the opportunity to attend the 

Society of Toxicology Undergraduate Education Program on 

the Sunday of the SOT Annual Meeting. 


2006 ...... Shawntay Chaney, Theresa M. Eagle, 

Natalie Malek, Adeliada Segarra, Ryan Vaughan 

2007 ....... Kay Gonsalves, Lisa Koselke, Basharat Sanni, 

Sonia Talathi, Anna Zimmerman 

2008 ....... Amy DeMicco, Tharu Fernando, Yamel Perdomo, 

Amy Yi Hsan Saik, Kelly Sullivan 

2009 ....... Sherine Crawford, Trish T. Hoang, 

Kelly Krcmarik, Cory M. Mathias, 

P. Sean McGrath 

2010 ....... Annie L. Carlton, Alisha Chitrakar, 

Megan E. Culbreth, Chang Woo Lee, 

Sharon Ochs 

reFerenCe 


Applications of New Technologies 

The Syngenta Fellowship Award in Human Health 

Applications of New Technologies is presented to either a 

third year (or later) graduate student or a postdoctoral trainee. 

The funding ($15,000) is to support mode-of-action research 

aimed at characterizing dose-dependent effects of xenobiotics 

on mammalian systems in such a way that the causal 

sequence of key events underlying toxicity is elucidated. The 

work should permit a quantitative basis for extrapolation of 

the results from animal bioassays or animal models (in silico, 

in vitro) to humans at relevant human doses. The awardee 

will receive funding to travel to the SOT Annual Meeting 

to accept the award and for travel to a Syngenta facility to 

present the results. 

Award Recipient 

2010 ...... Haitian Lu 

364 


_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 

Endowment Fund Donor Contribution Form 

SOT Endowment Family of Funds 

The individual Funds that make up the SOT Endowment Fund are briefly described below. All are, or intend to become, Permanently Restricted Net Asset 

Funds, with their assets invested so their Funds will be continued in perpetuity with proceeds used for the purpose(s) identified by their original donor or 

those who provided leadership for creating each specific Fund. 

General Purpose Funds 

• Educational Activities—Proceeds from this Fund support a margin of 

excellence in SOT Educational Activities. 

• International Activities—Proceeds from this Fund will be used to 

promote the involvement of the SOT in international activities such as 

those of the International Union of Toxicology. 

• Mary Amdur Student Award—Inhalation and Respiratory SS 

• Young Soo Choi Student Scholarship Award—Korean Toxicologists 

Association in America SIG 

• Laxman S. Desai ASIO Student Award—Association of Scientists of 

Indian Origin SIG 

• Diversity Initiatives—Committee on Diversity Initiatives 

• Founders Fund—Founders Award recipient selected by Awards 

Committee. 

• Angelo Furgiuele Young Investigator Technology Award— 

Reproductive and Developmental Toxicology SS 

• Perry J. Gehring Biological Modeling Student Award—Biological 

Modeling SS 

• Perry J. Gehring Diversity Student Travel Award—Committee on 

Diversity Initiatives 

• Perry J. Gehring Risk Assessment Student Award—Risk Assessment 

SS 

• Harry W. Hays Memorial Fund—SOT Education and/or Priority Needs 

Fund 

• Health and Environmental Science Institute Immunotoxicology 

Young Investigator Student Award—Immunotoxicology SS 

• Vera W. Hudson and Elizabeth K. Weisburger Scholarship—Women 

in Toxicology SIG 

• Frank C. Lu Food Safety Student Award—Food Safety SS 

Individual Recognition 

(Cumulative Contributions) 

• Benefactor—Cumulative contributions of 

$10,000 or more. 

• Paracelsus Circle Lifetime Member— 

Cumulative contribution of $5,000 or more. 

Alternatively, a contribution of $500 and 

statement of intent to contribute $5,000 

within 10 years. 


Recognition Levels 

Individual Recognition 

(Based on July–June Fiscal Year Giving) 

• Paracelsus Circle—$500 or more 

• Gold—$250–$499 or more 

• Silver—$100–$249 or more 

• Bronze—$40–$99 in a given year 

Corporate/Institutional Recognition 

(Based on July–June Fiscal Year Giving) 

• Diamond—Over $10,000 

• Platinum—$5,000–$9,999 

• Gold—$2,500–$4,999 

• Silver—$1,000–$2,499 

Donors who give $40 or more will be identified by name in the SOT Endowment Fund Annual Report and other Fund literature unless they wish to remain 

anonymous. In the case of couples who are both members of the SOT, the Recognition Level is based on the contribution of each individual. Thus, a $500 

joint contribution from a couple who are both members of the SOT is recognized at the Gold Level and a $1,000 joint contribution is recognized at the 

Paracelsus Circle Level. 

501(c)3 Charitable Organization 

• SOT Priorities—Proceeds from this Fund support the highest priority 

needs of the Society as determined by the SOT Council. 

• Student Travel—Proceeds from this Fund will be used to support student 

travel. 

Specific Purpose Funds 

These Funds match the interests of the donors with the future financial needs of SOT, its Regional Chapters (RC), Special Interest Groups (SIG), and its 

Specialty Sections (SS). 

• Jean Lu Student Scholarship Award—American Association of Chinese 

in Toxicology SIG 

• Roger O. McClellan Student Award—Comparative and Veterinary SS 

and Toxicologic and Exploratory Pathology SS 

• Harihara Mehendale ASIO Student Award—Association of Scientists 

of Indian Origin SIG 

• Metals Specialty Section Student Award—Metals SS 

• Molecular Biology Student Award—Molecular Biology SS 

• Pacific Northwest Toxicology Development Fund—Pacific Northwest 

RC 

• Emil A. Pfitzer Drug Discovery Student Award—Drug Discovery 

Toxicology SS 

• Gabriel L. Plaa Education Award—Mechanisms SS 

• Regulatory and Safety Evaluation Student Award—Regulatory and 

Safety Evaluation SS 

• Renal Toxicology Fellowship Award—Mechanisms SS 

• Robert J. Rubin Student Travel Award—Mechanisms SS and Risk 

Assessment SS 

• Dharm V. Singh ASIO Student Award—Association of Scientists of 

Indian Origin SIG 

• Dharm V. Singh Carcinogenesis Award—Carcinogenesis SS 

• Carl C. Smith Mechanisms Student Award—Mechanisms SS 

• Ronald G. Thurman Student Travel Award—Mechanisms SS 

Individuals who are interested in making a donation to create a specific purpose Fund or individuals from a Specialty Section or other formal/ 

informal group who are interested in providing leadership for creating a specific purpose Fund are encouraged to contact the SOT Endowment Fund Chair, 

Jacqueline H. Smith, by telephone: (410) 745-5771 or e-mail: jacquehs@aol.com or Clarissa Wilson at SOT Headquarters by telephone: (703) 438-3115 or 

e-mail: cwilson@aim-hq.com. 

The SOT Endowment Fund is part of the Society of Toxicology, a charitable, non-profit, 501(c)3 organization under the Internal Revenue Code. 

The SOT Tax Identification Number is 52-605-7050. Contributions to the SOT Endowment Fund typically will be considered tax-deductible contributions. 

The Society of Toxicology will provide written acknowledgement of all contributions made to the SOT Endowment Fund.

Contribution Information 

I wish to be identified by name as an 

Endowment Fund Donor by Recognition 

Level, as shown on the following page, in 

the SOT Endowment Fund Annual Report. 

Name for acknowledgement: 

_____________________________________ 

I do not want to be publicly identified 

as a Donor; I wish to remain anonymous. 

I am giving my gift: 

In memory of _________________________ 

In honor of __________________________ 

I intend to contribute $5,000 or more 

within ten years in order to be recognized as 

a Paracelsus Circle Lifetime Member. 

(For budget purpose only and is not legally enforceable.) 

My employer will match my contribution. 

(Please enclose your employer’s Matching Gift Form) 

Employer ____________________________ 

Please contact me concerning the following: 

To assist in arranging a Corporate Gift/ 

Stock or other assets. 

Naming the SOT Endowment Fund in my 

Will or Trust. 

Purchasing a Charitable Gift Annuity. 

Establishing a new Fund. 

Contributing securities, property, etc. 

Other ____________________________ 

Mail or Fax to: 

Society of Toxicology Endowment Fund 

1821 Michael Faraday Drive, Suite 300 

Reston, VA 20191 

Fax: (703) 438-3113 

366 

Donor Contribution Form 

The SOT Endowment Fund is a family of Funds created to match the interests 

of Donors with the future financial needs of the SOT, its Special Interest 

Groups, and its Specialty Sections. The individual Funds and Recognition Levels 

are briefly described on the following page. 

Name 

Affiliation 

Address 

City 

Country 

Telephone 

E-Mail 

Donor Information 

State/Region 

Fax 


Education $ 

International Activities $ 

SOT Priorities $ 

Student Travel $ 

Specific Purpose Funds 

(Listed on page 2) 

Payment 

Enclosed is a check for $ __________ 

Zip 


$ 

$ 

$ 

$ 

$ 

$ 

Check # __________ 

AMEX Discover Diners MasterCard Visa 

Credit Card # 

Name on Card 

Signature 

Date 

TOTAL $_______________ 

Exp Date 

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Tear out page _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _


NEW Endowment Funds Created in 2009 

For complete details on all the Endowment Funds visit www.toxicology.org. 

Laxman s. desai 

Association of scientists of Indian 

origin student Award Fund 

(Established January 2009) 

This Fund was initiated with a generous 

gift from Laxman S. Desai to provide 

support for awards that encourage graduate 

students and postdoctoral fellows, 

Laxman S. Desai 

who are of Indian origin, to pursue 

advanced studies in the field of toxicology. 

Proceeds from the Fund will be used to cover travel expenses 

to the SOT Annual Meeting or best paper awards based 

on abstracts accepted for presentation at the SOT Annual 

Meeting. Dr. Desai has had a distinguished career as a scientist 

and businessman. He was born in India and received his 

university training in toxicology/pharmacology in Belgium, 

and immigrated to the United States in 1967. 

diversity Initiatives Fund 

(Established January 2009) 

The Diversity Initiatives Fund was created 

to provide proceeds for enhancing the strategic 

growth initiatives of the SOT aimed 

at increasing and retaining individuals 

from groups under-represented in the field of toxicology. The 

initiatives may include, but will not be limited to: (a) Funding 

more students to attend the flagship annual Undergraduate 

Education Program for Minority Students; (b) Funding to 

allow students to extend their stay at the Annual Meeting 

longer than two nights, allowing them the opportunity to 

attend more scientific sessions; and (c) Broadening and 

deepening the institutional outreach to more institutions 

with significant enrollment of under-represented individuals. 

Award recipients will be selected by the Committee on 

Diversity Initiatives. 

harry W. hays 

Memorial Fund 

(Established May 2009) 

This Fund was established in the memory 

of Harry W. Hays (1909–2001), who was 

a founder of the Society of Toxicology 

and the Society’s fourth President 

(1964–1965). The fund was created with 

Harry W. Hays 

an initial generous gift from his nephew 

and SOT Legal Counsel, William C. 

Hays, Esq. Proceeds from the fund will be used annually to 

further the objectives of either or both the Society’s Education 

Fund or SOT Priority Needs Fund as determined by the SOT 

Council and, to the extent feasible, be identified as having 

been funded by the Harry W. Hays Memorial Fund. Dr. Hays 

played a vital role in documenting the history of the Society 

through its first 25 years. 

Metals specialty section 

student research Award 

Fund (Established October 2009) 

The Metals Specialty Section Student 

Research Award Fund was created by a 

group of SOT members who have actively conducted and 

communicated research on metals action and toxicity for 

many years. Proceeds of the fund will be used for research 

awards given to graduate students and postdoctoral fellows for 

excellence in mechanistic research of metals toxicity at the 

annual SOT meeting. 

pacific northwest 

toxicology development 

Fund (Established December 2009) 

This fund was created by a group of 

donors and the Pacific Northwest Chapter 

Executive Committee (PNCEC). Proceeds 

from this fund can be used to support three discrete objectives 

designed to provide development opportunities and 

professional recognition of toxicologists within the Pacific 

Northwest Chapter. The three objectives are 1) to foster 

student engagement, 2) to create special educational 

programs, and 3) to recognize outstanding achievement by 

Pacific Northwest regional toxicologists. The PNCEC will 

be responsible for identifying one or more objectives be 

supported each year and for developing detailed criteria for 

nomination and selection of the award recipients, including 

the organization of award selection committee(s). The 

PNCEC is not obligated to commit Fund proceeds to each of 

the stated objectives each year, nor is there a requirement to 

achieve a balance of expenditures between the three objectives 

on an annual basis or over time. 

reFerenCe 



NEW Endowment Funds Created in 2009 (Continued) 

For complete details on all the Endowment Funds visit www.toxicology.org. 

reFerenCe 

Gabriel L. plaa 

education Award Fund 

(Established December 2009) 

This Fund was created by his former 

student, Dr. Curt Klaassen, to memorialize 

Dr. Plaa’s contributions in 

toxicology, his leadership, mentorship, 

and friendship. Dr. Gabriel (Gabbie) L. 

Gabriel L. Plaa Plaa (1930–2009) played a significant 

role in the education of graduate and 

post-graduate students in toxicology and made outstanding 

contributions to applying mechanistic toxicology to the area 

chemical-induced liver injury during his career. Dr. Plaa 

was the SOT President (1983–1984), editor of Toxicology 

and Applied Pharmacology (1972–1980), and a recipient 

of numerous SOT Awards: Achievement (1967), Arnold J. 

Lehman (1981), Education (1987) and Merit (1996). His influence 

in training toxicologists was truly extraordinary as many 

of his former students also had leadership roles and received 

awards with the SOT. Proceeds from this Fund will be used 

to provide cash stipends to Award recipients selected on the 

basis of the scientific merit of papers proposed for presentation 

at the Annual Meeting by graduate or post-graduate 

students of toxicology. The Plaa Award will be aligned with 

the Mechanisms Specialty Section who will select Award 

Recipients based on the scientific quality of an abstract 

in mechanistic toxicology accepted for presentation at an 

Annual Meeting of the SOT. 

Endowment Fund 

2008–2009 Honor Roll of Contributors 

dharm V. singh 

Carcinogenesis Award Fund 

(Established April 2009) 

The Dharm V. Singh Carcinogenesis 

Award Fund was created with a generous 

contribution by Dharm Singh in memory 

of his wife, Sita Singh. Proceeds from this 

Fund will be used to encourage students 

Dharm V. Singh 

and postdoctoral fellows to pursue careers 

in research that will lead to a better understanding 

of the causes of cancer and improved diagnosis and 

treatment of this disease. 

ronald G. 

Thurman 

ronald G. thurman 

student travel Award Fund 

(Established August 2009) 

The Ronald G. Thurman Student 

Travel Award was established with an 

initial generous pledge of funds from 

former students of Dr. Thurman, who 

played a significant role in furthering 

the toxicology graduate program at the 

University of North Carolina at Chapel 

Hill. Proceeds from this Fund will be used to provide travel 

awards to one or more graduate students to participate in the 

SOT Annual Meeting. Dr. Thurman made important contributions 

to applying mechanistic toxicology to the areas of 

ethanol metabolism and toxicity, xenobiotic metabolism, liver 

transplantation, hepatocarcinogenesis, and hepatobiology. 

The award recipient(s) will be selected on the basis of the 

scientific quality of the abstract of a presentation that applies 

biochemical, pharmacological and/or toxicological techniques 

to questions of interest in mechanistic toxicology. 

Young Soo Choi 

Laxman Desai 

Barbara Gehring and Family 

Joe and Teri LeBeau 

John and Vera Doull 

William C. Hays 

Curtis and Cherry Klaassen 

LIFETIME CONTRIBUTION BENEFACTORS 

Cumulative contributions of $10,000 or more 

Frank C. Lu and Family 

Roger O. and Kathleen M. McClellan 

Harihara M. and Rekha Mehendale 

Mark R. Montgomery 

PArAceLSuS CIRCLE LIFETIME MEMBERS 

Cumulative contributions of $5,000 or more 

Jacqueline H. Smith 

Thomas R. Sutter 

James A. and Gloria Jean Popp 


Carl C. Smith and Family 

Elizabeth K. Weisburger 

Robert G. Tardiff 

James S. Woods 

368 



Endowment Fund (Continued) 

2008–2009 Contributions by Fund 


Amgen Foundation 

Barbara D. Beck 

Herman A. Birnbaum 

Matthew S. and Renee Bogdanffy 

Bristol-Myers Squibb Foundation 

Steven D. and Elly Cohen 

Paul W. and Grace Ferguson 

Donald A. Fox 

A. Jay Gandolfi 


George B. and Anna Karen Corcoran 

Michael L. Dourson 

Larry Fechter and Tom Stansbury 

eduCAtIon Fund ContrIButors 

Michael J. Graziano 

Carole A. Kimmel 

Elaine V. Knight 

Perry J. Kurtz in Memory of Dr. Jon Wetzel 

Gary L. Lage 

Merck Partnership for Giving 

Sharon A. Meyer 

InternAtIonAL ACtIVItIes Fund ContrIButors 

Bruce A. Fowler 

Michael and Mona Holsapple 

Jie Liu 

Jose E. Manautou 

Joyce K. Nelson 


Harry Salem 

William and Cristine Slikker 

SOT 50 th Anniversary Match 

Katie Sprugel 

Robert J. Staab 

Stacie L. Wild 

I. Glenn Sipes 



sot prIorIty needs Fund ContrIButors 

Daniel and Patricia Acosta 

Anonymous Donors 

Kim Boekelheide and Janet Austin 


Robert E. Chapin 


David L. and Janet Eaton 

Michael A. Gallo 


Russellyn Carruth and 

Bernard D. Goldstein 


Ronald N. Hines and D. Gail McCarver 

Jerry B. Hook 

Gary L. Lage 

Richard W. Pfeifer 

Catherine and Martin Philbert 


Donald and Caron Reed 

Charles F. Reinhardt 


Andrew M. Standeven in Honor of Roger 

P. Smith 

Andrew M. Standeven in Memory of Karen 

E. Watterhahn 


Clarissa and Tim Wilson 

Michael J. Winrow 

Morris S. Zedeck 


Janice E. Chambers 

Special Purpose Funds 

student trAVeL Fund ContrIButors 

Gary L. Lage 



reFerenCe 

Anonymous Donors 

Lung-Chi Chen 


Daniel L. Costa 

Gregory L. Finch 

Mike Foster 

MAry AMdur student AWArd Fund ContrIButors 

Nancy A. Gillett 

Joe Mauderly 

John B. Morris 

Annette C. Rohr 


Weiyi Su 

Peter A. Valberg 

James G. Wagner 

John E. Whalan 

Ronald K. and Mary Wolff 





reFerenCe 

Taehyeon M. Cho 

Young S. Choi in Memory of 

Mr. and Mrs. Jung Wook Choi 

Woon-Gye Chung 

James H. Kim 

younG soo ChoI student sChoLArshIp AWArd Fund ContrIButors 

Tae-Won Kim 

Ji-Eun Lee 

Roger O. and Kathleen M. McClellan in 

Honor of Young Soo Choi 

Betty C. Pyne 


Clarissa and Tim Wilson 

LAxMAn s. desAI AssoCIAtIon oF sCIentIsts oF IndIAn orIGIn student AWArd Fund ContrIButors 

Laxman S. Desai 


in Memory of Anasuya 

dIVersIty InItIAtIVes Fund ContrIButors 

Daniel and Patricia Acosta 

Michael and Lisa Aleo 

Tiffini K. Brabham 


Kimberly D. Daniel 

Marion F. Ehrich 

Betty J. Eidemiller 

Yvonne Frater 

Pamela L. Heard 

Johnson & Johnson Foundation 


Charles A. Miller 

Founders Fund ContrIButors 


Anthony M. Ndifor 

Pfizer Global R&D 

Denise Robinson Gravatt 


Mari S. Stavanja 

Myra L. Weiner 

James W. Newberne 

AnGeLo FurGIueLe younG InVestIGAtor teChnoLoGy AWArd Fund ContrIButors 


Angelo and Christine Furgiuele 


Andrew G. Ebert in Honor of 

Betty C. Pyne 

Dr. Joseph Borzelleca 

Jay I. Goodman 

Anonymous Donor in Honor of 

Bob and Diane Higginbotham 

perry J. GehrInG BIoLoGICAL ModeLInG student AWArd Fund ContrIButors 


perry J. GehrInG dIVersIty student trAVeL AWArd Fund ContrIButors 

Betty J. Eidemiller 

Sidney Green 

Robert I. Krieger 


perry J. GehrInG rIsK AssessMent student AWArd Fund ContrIButors 


Jay I. Goodman 


Harvey J. Clewell 


hArry W. hAys MeMorIAL Fund ContrIButors 

Eastman Charitable Foundation 


Shawn D. Lamb 

Robert A. Scala 


heALth And enVIronMentAL sCIenCe InstItute IMMunotoxICoLoGy younG InVestIGAtor 

student AWArd Fund ContrIButors 


Anonymous Donor 

Dennis J. and Leigh Ann Burns Naas 

Jeanine L. Bussiere 

ILSI Health and Environmental Sciences 

Institute 

Pfizer Foundation Matching 

Gifts Program 

Jean F. Regal 


370 






Philip H. Howard 

Sharon A. Meyer 




Frank C. Lu 

Norman J. and Valerie G. Barlow 

William E. Bechtold 

Arthur A. Bickford 

Brad Bolon 

Balbir S. Brar 

VerA W. hudson And eLIzABeth K. WeIsBurGer sChoLArshIp Fund ContrIButors 


Katie Sprugel 

Stacie L. Wild 

FrAnK C. Lu Food sAFety student AWArd Fund ContrIButors 


JeAn Lu student sChoLArshIp AWArd Fund ContrIButors 


roGer o. MCCLeLLAn student AWArd Fund ContrIButors 

Charles H. Hobbs 


Roger O. McClellan in Honor of My Fellow 

SOT Endowment Board Members 

Women in Toxicology Special Interest 

Group in Honor of Elizabeth K Weisburger 



Peter A. Valberg 

Ronald K. and Mary Wolff 

hArIhArA MehendALe AssoCIAtIon oF sCIentIsts oF IndIAn orIGIn student AWArd Fund ContrIButors 

Jaya Chilakapati 


Uday S. Devanaboyina 

Kimberly Clark Foundation 

Formaldehyde Council, Inc. 

General Electric 


Linda Malley in Honor of 

Harihara M. Mehendale 

MoLeCuLAr BIoLoGy student AWArd Fund ContrIButors 

Ronald N. Hines and D. Gail McCarver 

John H. and Joan E. Richburg 

Raja Mangipudy and Prathibha Rao 

in Honor of H. M. Mehendale 



Thomas R. Sutter 

eMIL A. pFItzer druG dIsCoVery student AWArd Fund ContrIButors 


Robert E. and Ursula Osterberg 


Jon C. and Judith R. Cook 


reGuLAtory And sAFety eVALuAtIon student AWArd Fund ContrIButors 



Robert E. and Ursula Osterberg 

Michael and Lisa Aleo 

Brian S. Cummings 

Jerry B. Hook in Memory of 

William O. Berndt 

Serrine S. Lau 

Lois D. Lehman-McKeeman 

Edward A. Lock 


Jin Ho Chung 

Richard A. Parent in Memory of 

Mildred Christian 

renAL toxICoLoGy FeLLoWshIp AWArd Fund ContrIButors 

Kenneth E. McMartin 

Terrence James Monks 

Pfizer Foundation Matching 

Gifts Program 


Rick G. Schnellmann 

roBert J. ruBIn student trAVeL AWArd Fund ContrIButors 

Hank and Sherry Gardner 

Rudolph J. Jaeger 


Jacqueline H. Smith in Memory of William 

O. Berndt 

Joan B. Tarloff 

Monica A. Valentovic and 

Gary O. Rankin 



Walter J. Kozumbo 


reFerenCe 





Balbir S. Brar 


dhArM V. sInGh AssoCIAtIon oF sCIentIsts oF IndIAn orIGIn student AWArd Fund ContrIButors 



A. Jay Gandolfi 


dhArM V. sInGh CArCInoGenesIs AWArd Fund ContrIButors 


CArL C. sMIth MeChAnIsMs student AWArd Fund ContrIButors 

Michael F. Hughes 


Donald and Caron Reed 

John H. and Joan E. Richburg 


Kendall B. Wallace 

other desIGnAtIons: toxICoLoGIsts oF AFrICAn orIGIn ContrIButors 

Edmond E. Creppy Michael L. Dourson SOT 50 th Anniversary Match 

RECOGNITION OF OTHERS 

In honor oF Joseph BorzeLLeCA 

Andrew G. Ebert 

In honor oF younG soo ChoI 

Roger O. and Kathleen M. McClellan 

In honor oF BoB And dIAne hIGGInBothAM 


In honor oF hArIhArA M. MehendALe 

Linda Malley 

Raja Mangipudy and Prathibha Rao 

In honor oF My FeLLoW sot 

endoWMent BoArd MeMBers 


In honor oF roBert J. ruBIn 

Mark R. Montgomery 

In honor oF roGer p. sMIth 

Andrew M. Standeven 

In honor oF eLIzABeth K. WeIsBurGer 


reFerenCe 

Desai Laxman 

In MeMory oF AnAsuyA 

In MeMory oF WILLIAM o. Berndt 

Jerry B. Hook 


In MeMory oF Mr. And Mrs. JunG WooK ChoI 

Young S. Choi 

In MeMory oF MILdred ChrIstIAn 

Richard A. Parent 

In MeMory oF KAren e. WAtterhAhn 

Andrew M. Standeven 

In MeMory oF Jon WetzeL 

Perry J. Kurtz 

372 



SOT Affiliates 

Abbott Laboratories 

Abbott Park, Illinois 

Chevron Corporation 

Richmond, California 

Metabolon, Inc. 

Research Triangle Park, North Carolina 

Absorption Systems 

Exton, Pennsylvania 

Alcon Research Ltd. 

Fort Worth, Texas 

American Chemistry Council 

Arlington, Virginia 

American Petroleum Institute 


Ani Lytics, Inc. 

Gaithersburg, Maryland 

AstraZeneca R&D 

Södertälje, Sweden 

BASi Evansville 

Mount Vernon, Indiana 

Battelle 

Columbus, Ohio 

Bayer HealthCare Pharmaceuticals 

Montville, New Jersey 

Biogen Idec, Inc. 

Cambridge, Massachusetts 

Boehringer Ingelheim 

Pharmaceuticals, Inc. 

Ridgefield, Connecticut 

Bristol-Myers Squibb Company 

Princeton, New Jersey 

CANTOX 

Mississauga, Ontario, Canada 

Celgene Corporation 

Summit, New Jersey 

Celsis In Vitro Technologies 

Baltimore, Maryland 

Charles River 

Wilmington, Massachusetts 

Colgate-Palmolive Company 

Piscataway, New Jersey 

Covance Laboratories Inc. 

Madison, Wisconsin 

Daiichi Sankyo Company Limited 

Shizuoka, Japan 

The Dial Corporation, 

A Henkel Company 

Scottsdale, Arizona 

Dow Chemical Company 

Midland, Michigan 

Dow Corning Corporation 

Midland, Michigan 

Eli Lilly and Company 

Indianapolis, Indiana 

ExxonMobil Biomedical Sciences, Inc. 

Annandale, New Jersey 

Genentech, Inc. 

South San Francisco, California 

GlaxoSmithKline 

King of Prussia, Pennsylvania 

The Hamner Institutes 

for Health Sciences 

Research Triangle Park, North Carolina 

Hoffmann-La Roche, Inc. 

Nutley, New Jersey 

Honeywell International, Inc. 

Morristown, New Jersey 

ISIS Services, LLC 

San Carlos, California 

J&J Pharma R&D Companies 

(Centocor, J&JPRD, Tibotec) 

Raritan, New Jersey 

Millennium: 

The Takeda Oncology Company 

Cambridge, Massachusetts 

MPI Research 

Mattawan, Michigan 

Novartis Pharmaceuticals Corporation 

East Hanover, New Jersey 

Pfizer, Inc. 

Groton, Connecticut 

Procter & Gamble Company 

Cincinnati, Ohio 

RTC Research Toxicology Centre S.P.A. 

Pomezia, Italy 

sanofi-aventis 

Bridgewater, New Jersey 

Schering-Plough Research Institute 

Summit, New Jersey 

Seguani, Ltd. 

Ledbury, Herefordshire, United Kingdom 

Suburban Surgical Company, Inc. 

Wheeling, Illinois 

Syngenta 

Greensboro, North Carolina 

WIL Research Laboratories, LLC. 

Ashland, Ohio 

Wyeth Research 

Collegeville, Pennsylvania 

If your organization is 

interested in participating in 

the SOT Affiliate program, 

please contact 

marcia@toxicology.org 

reFerenCe 



Headquarters Staff 

Society of Toxicology Headquarters 

1821 Michael Faraday Drive, Suite 300, Reston, Virgina 20190 

Tel: (703) 438-3115 • Fax: (703) 438-3113 • E-mail: sothq@toxicology.org • Web site: www.toxicology.org 

reFerenCe 

Staff Contact Extension E-mail Activity 

Shawn Douglas Lamb 1444 shawnl@toxicology.org Executive Director 

Clarissa Russell Wilson 1455 clarissa@toxicology.org Deputy Executive Director 

Rosibel Alvarenga 1432 rosibel@toxicology.org Membership Services 

Dylan Amerine 1438 dylan@toxicology.org Continuing Education, Graduate Committees, 


John Bae 1601 johnb@toxicology.org Membership Services 

Kim von Brook 1600 kimberly@toxicology.org Membership Services, Special Interest Groups, 

Specialty Sections 

Donna Breskin 1440 donna@toxicology.org Administration 

Chris Cerniglia 1445 chris@toxicology.org Publications, World Wide Web 

Krystle Correll 1436 krystle@toxicology.org Administration 

Sue Curran 1435 suec@toxicology.org Publications 

Jim Dailey 1428 jimd@toxicology.org Endowment, Registration 

Betty Eidemiller 1430 bettye@toxicology.org Committee on Diversity Initiatives, Data Task Force, 

Education Program, Postdoctoral Assembly, 


Veronica Fisher 1450 veronica@toxicology.org Financials 

Becca Isakower 1447 becca@toxicology.org Administration 

Ed Jennings 1453 ed@toxicology.org Financials 

Liz Kasabian 1454 liz@toxicology.org Exhibits 

Colleen Kelley-Vaquerano 1426 colleen@toxicology.org Publications, World Wide Web 

Maureen Kettering 1443 maureen@toxicology.org Exhibits, Meetings 

Marcia Lawson 1446 marcia@toxicology.org Board of Publications, Council Subcommittee for 

Non-SOT Annual Meeting and Regional Chapter Funding, 

Professional Needs Assessment Task Force, Scientific 

Liaison Task Force 

Martha Lindauer 1640 martha@toxicology.org Communications, Media and Congressional Relations 

Tonia Masson 1433 tonia@toxicology.org Administration 

Tim McKinney 1439 tim@toxicology.org Financials 

Kristen Meletti 1660 kristen@toxicology.org Career Resource and Development, Membership Services, 

Regional Chapters 

Tierre Miller 1451 tierre@toxicology.org Administration 

Katie Moore 1403 katie@toxicology.org Exhibits, Meetings 

Debbie O’Keefe 1441 debbie@toxicology.org Data Task Force, Publications, World Wide Web 

Christy Ours 1602 christy@toxicology.org Administration 

Sue Pitsch 1442 sue@toxicology.org Administration 

Heidi Prange 1424 heidi@toxicology.org Meetings 

Matthew Price 1429 matthew@toxicology.org Awards, Membership Services, Social Media 

Nichelle Sankey 1431 nichelle@toxicology.org Scientific Program Committee 

Stella Sasala 1650 stella@toxicology.org Financials 

Elisa Turner 1461 elisa@toxicology.org Publications 

Jennifer Ventura 1400 sot_admin@toxicology.org Administration 

Devin Yates 1434 devin@toxicology.org Publications, World Wide Web 

374 



Notes 



Sponsorship 

49 th Annual Society Meeting of Toxicology and ToxExpo 2010 


Sponsorship Opportunities 

Sponsorship Opportunities Are Still Available 

and Help To: 

• show your company’s commitment to 

advancing toxicology 

• Gain valuable exposure to 6,500 attendees 

• Keep meeting registration fees affordable to 

scientists, students, and all attendees, thereby 

bringing more participants together at this 

important event 

• reduce your bottom line—contributions are 

tax deductible under 501(c)3 provisions 

Sponsorship 

Levels: 

Diamond 

($10,000 or more) 

Platinum 

($5,000–$9,999) 

Gold 

($2,500–$4,999) 

Silver 

($1,000–$2,499) 

reFerenCe 

Sponsorship Gives You: 

• recognition in all Annual Meeting 

publications and promotional materials, 

ToxExpo Directory, the sot Web site, in postmeeting 

newsletters, and colorful signage 

and banners at the meeting 

• the right to host an exhibitor/sponsor hosted 

session at the Annual Meeting 

• Invitations to the president’s reception 

• And much more! 

For more information contact SOT Headquarters and ask for 

Liz Kasabian at (703) 438-3115 or e-mail liz@toxicology.org. 

376 


Annual Meeting Sponsors 

Platinum: ($5,000–$9,999) 

Abbott laboratories 

Affymetrix 

Allergan, inc. 

Ani lytics, inc. 

Biogen idec, inc. 

Burroughs wellcome fund 

Eli lilly and Company 

Exxon Mobil Corporation 

HistoTox labs, inc. 

Millennium 

Pharmaceuticals, inc. 

nCTr/fdA 

ToxServices llC 

gold: ($2,500–$4,999) 

Alcon research, inc. 

Bioreliance ® 

daiichi Sankyo Co., ltd. 

Eastman Charitable foundation 

gradient Corporation 

lAB research inc. 

rules-Based Medicine, inc. 

SafeBridge Consultants, inc. 

wil research laboratories, llC 

Silver: ($1,000–$2,499) 

Brock Scientific Consulting, llC 

Calvert laboratories, inc. 

Chevron Corporation 

Cosmetic ingredient review 

data Sciences international (dSi) 

Environmental Mutagen Society 

EPl, inc. (Experimental Pathology 

laboratories) 

research institute for fragrance 

Materials, inc. 

Safety Pharmacology Society 

Society of Toxicologic Pathology 

Teratology Society 

Toxicology Excellence for 

risk Assessment (TErA) 

(As of January 4, 2010)

Annual Meeting Sponsors 

(As of January 4, 2010) 

diamond: ($10,000 or more) 

AstraZeneca 

Pharmaceuticals lP 

Battelle 

Huntingdon life Sciences 

J&J Pharma r&d Companies 

(Centocor, J&JPrd, Tibotec) 

Boehringer ingelheim 

Pharmaceuticals, inc. 

Bristol-Myers Squibb 

Company 

MPi rESEArCH 

national Toxicology 

Program (nTP) 

Charles river 

niEHS 

Colgate-Palmolive 

Company 

Covance inc. 

forest research institute, 

inc., A Subsidiary of 

forest laboratories, inc. 

Hoffmann-laroche inc. 

niH-MArC 

Pfizer global research 

and development 

Purdue Pharma l.P. 

Thermo fisher Scientific 

49 th 


and ToxExpo TM 


1821 Michael faraday drive, Suite 300 • reston, vA 20190 

T: (703) 438-3115 • f: (703) 438-3113 • E-mail: sothq@toxicology.org 


we are proud to print this publication entirely on forest Stewardship Council certified paper. 

fSC certification ensures that the paper in this publication contains fiber from well-managed 

and responsibly harvested forests that meet strict environmental and socioeconomic standards. 

Cert no. XXX-XXX-XXXX 

SoT saved the following resources: XX trees preserved for the future • XX BTus energy not consumed • XX lbs net greenhouse gases prevented • XX 

gallons wastewater flow saved • XX lbs waterborne waste not created • XX lbs solid waste not generated

Annual Meeting Program - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?